Document PDF

NOW LICENSED
EUROPEAN SOCIETY OF CARDIOLOGY - ESC Congress 2015 - London

29 August – 2 September
Visit us at stand F100

Now licensed for:
Prevention of stroke and systemic embolism in adult patients with nonvalvular
atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart
failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient
ischaemic attack (TIA).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE),

and prevention of recurrent DVT and PE in adults.
Prescribers are recommended to consult the summary of product characteristics before prescribing LIXIANA.
Information about LIXIANA, including adverse reactions, precautions, contra-indications and method of use Final Programme
can be found at Lixiana.co.uk
Adverse events should be reported. Reporting forms and information

can be found at www.mhra.gov.uk/yellowcard. Adverse events
should also be reported to Daiichi Sankyo UK Medical Information
Legal classification: POM MA holder: Daiichi Sankyo Europe GmbH, Zielstattstrasse on 0800 028 5122, medinfo@daiichi-sankyo.co.uk
48, 81379 Munich, Germany. Job bag number: EDX/15/0074 Date of prep: July 2015.
www.escardio.org/ESC2015
www.lixiana.co.uk
220xxxxxx LXA UK ESC (UK) FP v10.indd 1 02/06/2015 12:01

Prince Regent
DLR Station
Prevention, Rehabilitation, Sports Cardiology,
ENTRANCE
(EAST)
MAIN
ESC MEETING
ROOMS
REGISTRATION
ESC HQ
Ischaemia, Coronary Artery Disease, Acute Cardiac Care, Acute Coronary Syndromes
Satellite Symposium
Basic Science
Coach Parking
SSC
Arrhythmias, Pacing, Resynchronisation
Nursing, Ageing
Industry
Management priorities and clinical
i
Hypertension, Pharma
Most scientific sessions, except satellite symposia, are arranged by topics in themed villages
Interventions, Peripheral Circulation, Stroke, Surgery
VILLAGE 1
outcomes in post-acute coronary syndrome
MAIN AUDITORIUM
LONDON
Congenital, Valvular Myopericardial Diseases, Pulmonary Circulation
(ACS) patients with type 2 diabetes (T2D)
VILLAGE 2
ESC PLAZA
Imaging, e-Technology
Delegate
Monday 31 August 2015; 12:45–13:45
Lounge
VILLAGE 3
Room: Oslo – Village 6
Workshops
VILLAGE 4
CPR
EXHIBITION
Chair:
2015
app
ESC
Taxi station
VILLAGE 5
Professor Faiez Zannad, Université de Lorraine and CHU, Vandoeuvre-lès-Nancy, France

Speakers:
Professor Peter Grant, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK
Heart Failure, LV dysfunction
i
VILLAGE 6
Medical Care
Dr Venugopal Menon, Cleveland Clinic, Cleveland, USA
THE HUB
Hyde
Park
VILLAGE 7
Agenda
Cloakroom & Left Luggage

VILLAGE 8
Time Presentation Speaker(s)
12:45–12:50 Welcome Faiez Zannad

EXHIBITION
VILLAGE 9
12:50–13:15 Management perspectives for the Venugopal Menon &

Information Point
post-ACS T2D patient: Peter Grant

PRESS
cardiologist vs diabetologist
i
Recording studio
13:15–13:40 Safety profile of DPP-4 inhibitors in All speakers, facilitated

post-ACS T2D patients: a debate by Faiez Zannad
ESC Fellows & VIP Lounge
i
POSTER AREA
Agora
13:40–13:45 Conclusions and close Faiez Zannad

ACCESS WITH
BADGE ONLY
MAIN AUDITORIUM
St James Park
POSTER AREA
Regents Park
Holland Park
Victoria Park
Green Park
Hyde Park
THE HUB
London
ESC Mobile App desk

Agora
Satellite Symposium − Takeda Booth

Speaker Service Centre
Experts-on-the-Spot Please also visit the Takeda Exhibition Booth for

Join the interactive Experts-on-the-Spot more information on our products. Location H500 in
2014
app
ESC
session entitled ‘Seeking improved the exhibition hall from 12:30 on Saturday 29 August
clinical outcomes in post-acute coronary
ESC Congress 365 desk
to 18:00 on Tuesday 1 September

syndrome (ACS) patients with type 2
San Marino
The Hague
Stockholm
VILLAGE 1
VILLAGE 2
VILLAGE 3
VILLAGE 4
VILLAGE 5
VILLAGE 6
VILLAGE 7
VILLAGE 8
VILLAGE 9
diabetes (T2D)’ on Tuesday 1 September

Damascus
Bucharest
Bratislava
Ljubljana
Belgrade
Chisinau
Moscow
Warsaw
ESC Stand
Madrid
Ankara
Algiers
Lisbon
Tirana
Rabat
Tunis
Bern
Oslo
Kiev
in Victoria Park (The Hub); 10:15–10:45 Job code: GLO/ALO/2015-00063 Date of preparation: June 2015
ESC Advert_170x240mm_01CB.indd 1 17/06/2015 10:27

DEAR CARDIOLOGY FRIENDS AND G1
COLLEAGUES FROM AROUND THE WORLD!
Welcome to ESC Congress 2015 in London, the largest gathering of the cardiovascular
community. We have a truly outstanding multinational congress for London and we look
forward to your participation!
ESC Congress is the largest international cardiology congress with faculty and abstracts
from over 110 countries, 40 joint sessions with sister societies and other specialties and
with participants from all parts of the world. ESC Congress is where communities meet,
exchange ideas and establish new friendships.
Outstanding and interactive: we continue to have an outstanding number of abstract

submissions (over 11 300), and introduced newly designed interactive sessions such as
Heart Team and Experts sessions. Interact with the panelists using your smartphone or
other mobile device! Please download the ESC 2015 Mobile App - you’ll need it!
Exciting: the spotlight of ESC Congress is “Environment and the Heart”.

Five important new ESC Guidelines will be presented. We also bring
you the latest clinical and scientific innovations with Hot Lines, Clinical Trial
Updates, Registries, Basic & Translational Science Hot Lines. The new Advances
in Science sessions will feature the best of the original research presented.
If you are in training or in research you cannot miss the ESC Cardiologists and Scientists
of Tomorrow sessions.
Live: key sessions will be shown live from London via the new ESC TV programme
on the ESC website. ESC Congress is designed to be a useful resource for the
whole year: log in to ESC Congress 365 to find all free congress resources!
Remember the exhibition, the satellites and new developments from industry
partners.
The Inaugural Session on Saturday 29 August is a key introduction to the congress.

We are honored to welcome for a keynote lecture Dr Elizabeth Blackburn, Nobel
Prize Laureate.
We are delighted that you have chosen to be part of ESC Congress and together we can
help shape the future of cardiology!
We know you will enjoy the hospitality of the City of London and being a part of a great
ESC Congress!
Fausto Pinto, FESC Geneviève Derumeaux, FESC

President 2014 - 2016 Chairperson 2014 - 2016
European Society of Cardiology Congress Programme Committee
and all ESC Members of the Congress

Programme Committee
G2 ESC CONGRESS COMMITTEES 2014-2016
The Scientific Programme has been prepared by the ESC Congress Programme
Committee in close collaboration with the ESC Working Groups, Associations,
Councils and ad hoc Members according to the nine following topic groups.
J F Pinto, FESC (Lisbon, PT)

G A Derumeaux, FESC (Creteil, FR)
Most scientific sessions, except satellite symposia, are arranged by topics in themed villages.
You will also find the scientific highlights of the 9 main topics of ESC Congress 2015 in The Hub.
VILLAGE 1 – BASIC SCIENCE

L Badimon FESC (Barcelona, ES) – Coordinator – Council on Basic Cardiovascular Science
J-L Balligand FESC (Brussels, BE)
C Basso FESC (Padua, IT) – WG Development, Anatomy & Pathology
P Ferdinandy FESC (Budapest, HU) – WG Cellular Biology of the Heart
S Hatem (Paris, FR)
I Hoefer FESC (Utrecht, NL) – WG Atherosclerosis & Vascular Biology
J D Pearson FESC (London, UK)
R F Ventura Clapier (Chatenay Malabry, FR)
VILLAGE 2 – PREVENTION - REHABILITATION

- SPORTS CARDIOLOGY - NURSING - AGEING
M C Deaton FESC (Cambridge, UK) – Coordinator
A Abreu (Lisboa, PT)
D Gaita FESC (Timisoara, RO) – World Heart Federation (WHF)
A O Nedoshivin FESC (St. Petersburg, RU)
E Prescott (Copenhagen, DK)
S Sharma FESC (London, UK) – EAPCR Representative
L Tokgozoglu FESC (Ankara, TR)
VILLAGE 3 – HYPERTENSION - PHARMA

B Williams FESC (London, UK) – Coordinator
M A Alonso FESC (London, UK)
D Atar FESC (Oslo, NO)
A Coca FESC (Barcelona, ES) – Hypertension Council
A G de Simone FESC (Napoli, IT)
F Mahfoud (Homburg/Saar, DE)
E Shlyakhto FESC (St. Petersburg, RU) – Russian Society of Cardiology (RSC)
G3
VILLAGE 4 – ARRHYTHMIAS - PACING - RESYNCHRONISATION

C Leclercq FESC (Rennes, FR) – Coordinator
M Brignole FESC (Lavagna, IT)
H Burri (Geneva, CH)
A De Paola FESC (Sao Paulo, BR) – Brazilian Society of Cardiology (BSC)
J Kautzner FESC (Prague, CZ)
K H Kuck FESC (Hamburg, DE) – EHRA Representative
C Linde FESC (Stockholm, SE)
P Volders FESC (Maastricht, NL)
VILLAGE 5 – CARDIAC IMAGING - E-TECHNOLOGY

P Lancellotti FESC (Liege, BE) – Coordinator – EACVI Representative
J Bax FESC (Leiden, NL) – ESC President Elect
C Bucciarelli FESC (Bristol, UK)
P Colonna FESC (Bari, IT)
L Ernande FESC (Paris, FR)
F A Flachskampf FESC (Uppsala, SE)
G Krstacic FESC (Zagreb, HR) – WG e-Cardiology
D Neglia FESC (Pisa, IT)
H Ukkonen (Turku, FI)
Z Vered FESC (Zerifin, IL)
VILLAGE 6 – INTERVENTIONS - PERIPHERAL CIRCULATION -

STROKE - SURGERY - CORONARY CIRCULATION
M Valgimigli FESC (Rotterdam, NL) – Coordinator
V Aboyans FESC (Limoges, FR)
Y D Chen FESC (Beijing, CN) – Chinese Society of Cardiology (CSC)
W Doehner FESC (Berlin, DE)
P H Kolh FESC (Liege, BE)
H K Najm FESC (Riyadh, SA) – Saudi Heart Association (SHA)
J-F Obadia (Lyon-Bron, FR)
Y Ozaki FESC (Toyoake, JP) – Japanese Circulation Society (JCS)
M Roffi FESC (Geneva, CH)
F Sellke (Providence, US) – American Heart Association (AHA)
K-H Sim FESC (Kuching, MY) – Asian Pacific Society of Cardiology (APSC)
S Windecker FESC (Bern, CH) – EAPCI Representative
VILLAGE 7 – ISCHAEMIA - CORONARY ARTERY DISEASE -

ACUTE CARDIAC CARE - ACUTE CORONARY SYNDROMES
J-P Collet FESC (Paris, FR) – Coordinator
D Erlinge FESC (Lund, SE)
A Koller (Budapest, HU) – WG Coronary Pathophysiology & Microcirculation
J Mehilli FESC (Munich, DE)
D Milicic FESC (Zagreb, HR)
J Morais FESC (Leiria, PT) – WG Thrombosis
S Price FESC (London, UK) – ACCA Representative
C J M Vrints FESC (Edegem, BE)
G4
VILLAGE 8 – VALVULAR DISEASE - PULMONARY CIRCULATION -
MYOCARDIAL - PERICARDIAL DISEASE - CONGENITAL HEART
DISEASE AND PAEDIATRIC CARDIOLOGY
R Rosenhek FESC (Vienna, AT) – Coordinator – WG Valvular Heart Disease
H Baumgartner FESC (Muenster, DE)
A L P Caforio FESC (Padua, IT) – WG Myocardial & Pericardial Diseases
M Delcroix (Leuven, BE)
E Jokinen (Helsinki, FI)
S Konstantinides FESC (Mainz, DE) – WG Pulmonary Circulation & Right Ventricular Dysfunction
A Linhart FESC (Prague, CZ)
JL Monin (Creteil, FR)
A Poppas (Providence, US) – American College of Cardiology (ACC)
VILLAGE 9 – HEART FAILURE -

LEFT VENTRICULAR DYSFUNCTION
S Anker FESC (Gottingen, DE) – Coordinator
J Bauersachs FESC (Hannover, DE)
D A Brito FESC (Lisbon, PT)
G Filippatos FESC (Athens, GR) – HFA Representative
A A Hagege FESC (Paris, FR)
J Lopez-Sendon FESC (Madrid, ES)
T McDonagh FESC (London, UK)
M F Piepoli FESC (Piacenza, IT)
O Smiseth FESC (Oslo, NO)
SPECIAL COORDINATORS
L M Goncalves FESC (Coimbra, PT) – Education
A Auricchio FESC (Lugano, CH) – EU Regulation and MEP Relation
A Keren FESC (Jerusalem, IL) – ESC 365 and My NCS@ESC
S Matskeplishvili (Moscow, RU) – ESC 365 and My NCS@ESC
S D Kristensen FESC (Aarhus, DK) – ESC TV
L Ernande FESC (Paris, FR) – My First ESC
J-L Zamorano FESC (Madrid, ES) – ESC Guidelines
M Boehm FESC (Homburg/Saar, DE) – Industry Programme
M Komajda FESC (Paris, FR) – Industry Programme
WITH SPECIAL THANKS TO OUR AD HOC MEMBERS

S Agewall FESC (Oslo, NO) – WG Cardiovascular Pharmacology & Drug Therapy
M Brodmann (Graz, AT) – WG Peripheral Circulation
M de Bonis (Milano, IT) – WG Cardiovascular Surgery
A Eicken FESC (Munich, DE) – WG Grown-up Congenital Heart Disease
R Asteggiano FESC (Turin, IT) – Council for Cardiology Practice
A W Hoes FESC (Utrecht, NL) – Council on Cardiovascular Primary Care
C S Jennings FESC (London, UK) – Council on Cardiovascular Nursing and Allied Professions
A N Kitsiou FESC (Athens, GR) – EACVI – Nuclear Cardiology and Cardiac CT section
S Plein (Leeds, UK) – EACVI – CMR section
G L Smith (Glasgow, UK) – WG Cardiac Cellular Electrophysiology
G Tarone (Turin, IT) – WG Myocardial Function
G5
ESC CARDIOLOGISTS OF TOMORROW NUCLEUS
R Fontes-Carvalho FESC (Porto, PT)
E A Jankowska FESC (Wrocław, PL)
S Muscli (Rome, IT)
M Pazdernik (Prague, CZ)
J Poess (Luebeck, DE)
RC Vidal Perez FESC (Santiago de Compostela, ES)
M Wallner (Graz, AT)
ESC SCIENTISTS OF TOMORROW NUCLEUS

C Antoniades (Oxford, UK)
J Fauconnier (Montpellier, FR)
S Ljubojevic (Graz, AT)
N Smart (Oxford, UK)
S Sossalla (Goettingen, DE)
G Vilahur FESC (Barcelona, ES)
GUIDELINES FOR INDUSTRY PARTICIPATION COMMITTEE

G A Derumeaux FESC (Creteil, FR)
S L Willemse (Best, NL)
I Marti (Allschwil, CH)
M Weimers (Mölndal, SE)
S Winter (Erlangen, DE)
ESC PRESS COMMITTEE

S D Kristensen FESC (Aarhus, DK) – Chairperson
L Badimon FESC (Barcelona, ES)
L Bolognese FESC (Arezzo, IT)
K A A Fox FESC (Edinburgh, UK)
J R Gonzalez Juanatey FESC (Santiago de Compostela, ES)
K Huber FESC (Vienna, AT)
J Perk FESC (Oskarshamn, SE)
S Price FESC (London, UK)
F Romeo FESC (Rome, IT)
F Schiele FESC (Besancon, FR)
M Valgimigli FESC (Rotterdam, NL)
F W A Verheugt FESC (Amsterdam, NL)
G6 CONTENTS
Welcome L etter ................................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1
E SC Co ng res s Com m ittee s / V illages & m ain top i cs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G2
Th e Eu rop ean Society of Cardiol og y, yo ur C o mmuni ty G9

E SC Boa rd .......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1 0
E SC Genera l As s em bly ...................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1 1
A bo ut the Euro pean Socie ty of Cardiolog y ........ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1 3
E uropea n Hea r t A ge ncy ...................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1 5
E SC Na tiona l Ca rdiac Societie s .......................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1 6
E SC Yo ung Community ....................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1 7
E SC Fellow s hip ................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G1 8
A cute Ca rd iova s cular Care Association (ACC A) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G2 2
E uropea n As s o ciation for Cardiovascular Preven t i on an d Reh ab i l i t at i on ( E AC P R) . . . G2 3
E uropea n As s o ciation of Cardiovascular Im aging ( E AC VI ) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G2 4
E uropea n As s o ciation of Pe rcutane ous Cardiova s cu l ar I n t er ven t i on s ( E A P C I ) . . . . . . . . G2 5
E uropea n Hea r t Rhythm Association (EHR A) .... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G2 6
H ea r t Fa ilure As sociation of the ESC (HFA) ..... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G2 7
E SC Wo rking Groups .......................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G2 8
E SC Co uncils ..................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G2 9
E SC Globa l Affa irs ............................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 1
E SC Journa l Fa mily ............................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 2
E SC Clinica l P ra ctice Guide line s ........................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 3
E SC Ed uca tion ................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 4
E SC EURObs er v ational Re search Program m e .... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 5
E SC TV ............................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 6
Gen er a l I n formation G37

S ched ule ............................................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 8
C o ntinuing M ed ical Education (CME) Cre dits ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 8
Ve nue / O pening Hours / Inaugural Se ssion / Aw ard s C erem ony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G3 9
R eg is tra tion / Ba dges ........................................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 0
P res s ................................................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 1
P u blic Tra ns por t ................................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 2
F ac ilities a nd lo cal inform ation .......................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 3
E SC Co ng res s resource s .................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 4
E SC initia tives : Histor y of Cardiolog y / CPR Wo r ks h op s . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 6
I nd us tr y P ro g ra m m e ........................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 7
A cknowled g ements ............................................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G4 8
E SC Co ng res s in R eview .................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G5 2
S ci en t i fi c Prog ramme G53

C o ng res s Spotlig ht / Congre ss H ighlight Se ssion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G5 4
B a s ic Sc ience Highlights / ESC Clinical Practice Gu i d el i n es Hi gh l i gh t s . . . . . . . . . . . . . . . . . . . . G5 5
My N CS@ ESC ................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G5 6
G e nera l Ca rd iolog y Tracks ................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G5 7
B a s ic Sc ience ...................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G5 8
S cientis ts o f Tom orrow ..................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G5 9
A Day with the Le ge nds .................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 0
E SC Ca rd iolog is ts of Tomorrow ........................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 1
Mo bile App Interactive sessions: interact and vo t e i n real t i m e! . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 2
E xper ts Ses s io ns : Mee t the Expe r ts / Case-Based / S ci en ce@ Breakf as t . . . . . . . . . . . . . . . . . . . G6 3
E SC Ca rd iolog y Quiz.......................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 4
E xper ts Ses s io ns : He ar t Te am / Cardiac Anatomy an d P at h ol og y Li ve S es s i on s . . . . . . . . G6 5
E SC Clinica l P ra ctice Guide line s / Mee t the Gu i d el i n es Tas k Force . . . . . . . . . . . . . . . . . . . . . . . . . G6 6
G7
G uid elines in Da ily Practice ............................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 7

Meet the Tria lis ts ............................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 8
H ot L ines , Clinic al Trial Updates and R egistries . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 9
B es t o f ESC Co ngre ss 2015, the online event .... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G7 0
Joint Ses s io ns ................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G7 1
E SC As s o cia tions Track ....................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G7 4
Journa ls Ses s ions ................................................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G7 5
A bs tra c t Ses s io ns .............................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G7 7
Po s ters Ses s ions ................................................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G7 8
S po ns o red Ses s ions ........................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G8 0
G uid elines fo r Speake rs ..................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G8 1
E SC Co ng res s 365 ............................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G8 2
S ci en t i fi c Prog ramme by Day and by V i l l age 1
Hands-On Tutorials .................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

Saturday 29 August
Morning ......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 9
Lunc h ............................................................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9
Afterno o n .................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 4
Po s ters .......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 5
Sunday 30 August
Morning ......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 1
Morning Po s ters ........................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 7
Lunc h ........................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 2 3
Afterno o n .................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 3 2
Afternoon Poste rs ........................................ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 5 8
Evening .......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 8 5
Monday 31 August
Morning ......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 8 9
Morning Po s ters ........................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 1 4
Lunc h ........................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4 0
Afterno o n .................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 4 7
Evening .......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 2 9 8
Tuesday 1 Se ptember
Morning ......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 0 1
Morning Po s ters ........................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 2 7
Lunc h ........................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5 2
Afterno o n .................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5 6
Wednesday 2 September
Morning ......................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 0 5
Ap p en d i ces
List of Cha irpersons, Spe akers and Authors ....... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 1 5
List of To pics ...................................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 2 3
List of Ac ro ny ms ............................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 3 5
List of Exhibitors ............................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 4 3
List of Countr y Code s ...................................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 6 3
D I SCOV ER A WO R L D O F
CARDIOLOGY RESOURCES
M A K E T H E M O S T O F W H AT T H E E S C C A N D O F O R Y O U
CONNECT WITH ESC TODAY

w w w.esc a rdio.org
EUROPEAN
SOCIETY
OF CARDIOLOGY
YOUR COMMUNITY
G10 ESC BOARD 2014 - 2016
The administration of the European Society of Cardiology (ESC) is conducted by a Board

and a management group of the Board. The Board is comprised of voting members (who
are elected by the General Assembly in even numbered years) and non-voting ex officio
members who are appointed by the Board. The Board of the ESC may establish committees
to attend to specific tasks.
Elected Members:
Management Group of the Board
FJ Pinto, FESC, Portugal President
JJ Bax, FESC, Netherlands President-Elect
F Cosentino, FESC, Sweden Secretary/Treasurer
Vice-Presidents
S Achenbach, FESC, Germany Global Affairs & Communication
D Atar, FESC, Norway National Affairs, Editors Network & Cardiologists of Tomorrow
B Casadei, FESC, United Kingdom Scientific Affairs & Research/Clinical Trials (also includes Working
Groups, Councils and Women in Cardiology)
Councillors
C Aguiar, FESC, Portugal Global Affairs/Communications
S Anker, FESC, Germany Scientific Affairs
C Erol, FESC, Turkey National Affairs
I Graham, FESC, Ireland Global Affairs
P Lancellotti, FESC, Belgium Scientific Affairs
B Merkely, FESC, Hungary National Affairs
Ex-Officio Voting Members

PE Vardas, FESC, Greece Past-President
H Bueno, FESC, Spain President Acute Cardiovascular Care Association

G Filippatos, FESC, Greece President Heart Failure Association of the ESC
G Habib, FESC, France President European Association of Cardiovascular Imaging
KH Kuck, FESC, Germany Past President European Heart Rhythm Association
A Pelliccia, FESC, Italy President European Association for Cardiovascular Prevention
and Rehabilitation
S Windecker, FESC, Switzerland President European Association of Percutaneous Cardiovascular
Interventions
Non-voting Members
GA Derumeaux, FESC, France Chairperson ESC Congress Programme Committee
R Ferrari, FESC, Italy Chairperson EURObservational Research Programme
T Lüscher, FESC, Switzerland Chairperson Publications Committee
A Vahanian, FESC, France Chairperson Education Committee
F Van de Werf, FESC, Belgium Chairperson European Affairs Committee
JL Zamorano, FESC, Spain Chairperson Committee for Practice Guidelines
L Badimon, FESC, Spain Representative Council on Basic Cardiovascular Science

D Fitzsimons, NFESC, United Kingdom Representative Council on Cardiovascular Nursing and
Allied Professions
N Clarke, United Kingdom Advisor and Management Group Member

G Olsson, Sweden Advisor and Management Group Member
I Bardinet, France Chief Executive Officer of the ESC

M Ximeris, France ESC Board Secretary
ESC GENERAL ASSEMBLY G11
Tuesday 1 September 2015, 10:00 - 11:00

Room San Marino - Village 2
ExCel Congress Centre, London
Open to all ESC Members*
AGENDA
Welcome address F Pinto, FESC, ESC President, 2014 – 2016
Report from the Vice President on Global Affairs

& Communication S Achenbach, FESC
Report from the Vice President on National Affairs,

Editors Network & Cardiologists of Tomorrow D Atar, FESC
Report from the Vice President on Scientific Affairs,

Research & Clinical Trials B Casadei, FESC
Financial & annual report F Cosentino, FESC, ESC Secretary/Treasurer, 2014 - 2016
Report from the Audit Committee S D’Isidoro, Chairman ESC Audit Committee
Resolutions and result of the vote F Pinto, FESC, ESC President, 2014 - 2016
* All members of the ESC National Cardiac Societies, ESC Associations, ESC Working Groups and ESC Councils. All Fellows
of the European Society of Cardiology (FESC).
You could be too!
Ask us about it on the ESC Stand.
www.escardio.org
ABOUT THE EUROPEAN SOCIETY G13
OF CARDIOLOGY
The European Society of Cardiology (ESC) represents over 87 000 cardiology professionals
world-wide. The ESC publishes guidelines and recommendations for clinical practice,
respected journals and other scientific and educational materials; runs major conferences and
educational programmes; and supports scientific endeavours across Europe and in all areas
of cardiology.
With the European Heart Agency in Brussels, the ESC advocates for the development of
strong policies for the prevention of cardiovascular disease in the European Union.
Not yet a member? Join us today!

Come to the ESC stand in the ESC Plaza and we’ll show you how.
FIND OUT WHAT THE ESC CAN DO FOR YOU

Congresses
ACCA Journals
Representation
Mobile apps ESC Congress in Review HFA My ESC Working Groups
eLearning
Guidelines
EACPR EACVI Global reach
escardio.org EAPCI
Young Community
Councils Textbooks National Cardiac Societies
EHRA ESC Congress 365 Networking Fellows of the ESC
Membership
Make sure to visit us for a sneak preview

of ESC Congress 2016 to be held
in Rome!
° Save 100 Euros on the registration fee (applies to

the first 100 healthcare professionals to register
on-site in London)
° Create your own personalised poster to take back

with you and help us spread the word to your
colleagues
° Come & tell us about your ESC Congress

experience and expectations
EUROPEAN HEART AGENCY G15
To achieve its mission “to reduce the burden of cardiovascular disease (CVD) in Europe”,
the European Society of Cardiology has set up in Brussels the European Heart Agency, a hub
for the pursuit of European endeavours with a specific policy, analysis and educational scope.
The European Heart Agency, which has three dimensions:
° European Affairs
The European Society of Cardiology is engaged in a constant dialogue with health
stakeholders in Europe, including EU and National policymakers, European advocacy
groups, including other professional medical associations, to secure a policy environment
favourable to cardiovascular health in Europe.
The main areas of European Affairs activities are prevention, research, regulatory
affairs and registries. Specific actions include ‘channelling’ the access to policymaking,
coordinating the actions of the ESC constituency, monitoring and exchanging information
and developing positions on EU legislation affecting cardiovascular health. The ESC also
provides the secretariat for the Members of the European Parliament (MEP) Heart Group
and is a founding member of two pan-European Alliances, the Alliance for Biomedical
Research in Europe (BioMed Alliance) and the European Chronic Diseases Alliance
(ECDA)
° The European Heart Health Institute is active in the new ESC initiatives, such
as medical innovation and healthcare economics. This expertise reinforces the policy
makers and engages the stakeholders by supporting future trends in European healthcare.
The ESC Atlas of Cardiology encompasses a wealth of CV data in the 56 ESC Member
Countries. This project will underline the cost of cardiovascular diseases and serve as a
European tool to identify the best practices and tackle new challenges.
° The European Heart Academy trains future leaders in cardiology. In collaboration

with selected excellent universities, the Academy provides the ultimate cardiovascular
degrees. The specialized programmes combine key opinion leaders, executive style
teaching formats with innovative, interactive and on-line learning tools.
For further information on ESC activities in Brussels, please speak to staff on the ESC or
European Heart Agency Stand in the ESC Plaza.
G16 ESC NATIONAL CARDIAC
SOCIETIES
National Cardiac Societies are the founders and backbone of the European Society of
Cardiology, actively participating in ESC activities including ESC Congress.
Did you know? By becoming a member of your National Cardiac Society, you also become a member
of the ESC. Come and meet your National Cardiac Society on the ESC Plaza - be part of the ESC
community!
ESC NATIONAL CARDIAC SOCIETY President Members Stand N°

Albanian Society of Cardiology A Goda, FESC 219 P135
Algerian Society of Cardiology M T Bouafia, FESC 288 P405
Armenian Cardiologists Association K G Adamyan, FESC 243 P390
Association of Cardiologists of Bosnia and Herzegovina Z Kusljugic, FESC 193 P130
Association of Cardiologists of Kazakhstan S Berkinbayev, FESC 685 P205
Austrian Society of Cardiology F Weidinger, FESC 800 P290
Azerbaijan Society of Cardiology F Ibrahimov, FESC 385 P125
Belgian Society of Cardiology A A Pasquet, FESC 513 P250
Belorussian Scientific Society of Cardiologists A Mrochek 82 P170
British Cardiovascular Society S Clarke, FESC 2364 P260
Bulgarian Society of Cardiology V Velchev 593 P185
Cardiological Society of Montenegro M Rabrenovic 43 -
Cardiology Society of Serbia Z Perisic, FESC 953 P175
Croatian Cardiac Society D Milicic, FESC 508 P120
Cyprus Society of Cardiology L Antoniades, FESC 143 P395
Czech Society of Cardiology M Taborsky, FESC 2317 P215
Danish Society of Cardiology C Gerdes, FESC 1329 P480
Egyptian Society of Cardiology A M K Etriby, FESC 1465 P295
Estonian Society of Cardiology P Laanmets, FESC 238 P480
Finnish Cardiac Society M J Pietila, FESC 815 P480
French Society of Cardiology Y Juilliere, FESC 5578 P305
Georgian Society of Cardiology A Aladashvili, FESC 240 P165
German Cardiac Society K H Kuck, FESC 8734 P280
Hellenic Cardiological Society S G Foussas, FESC 2252 P380
Hungarian Society of Cardiology R G Kiss, FESC 3855 P105
Icelandic Society of Cardiology TG Gudnason, FESC 71 P480
Irish Cardiac Society K McDonald 285 P255
Israel Heart Society M Glikson, FESC 726 P220
Italian Federation of Cardiology L Bolognese 5267 P245
Kosovo Society of Cardiology G Bajraktari, FESC 55 P150
Kyrgyz Society of Cardiology E Mirrakhimov, FESC 82 -
Latvian Society of Cardiology A Erglis, FESC 366 P480
Lebanese Society of Cardiology N Moussalem, FESC 385 P425
Libyan Cardiac Society K Ellafi, FESC 274 P415
Lithuanian Society of Cardiology G Marinskis, FESC 332 P480
Luxembourg Society of Cardiology J Beissel, FESC 97 P400
Macedonian FYR Society of Cardiology S Kedev, FESC 228 P155
Maltese Cardiac Society R G Xuereb, FESC 87 P145
Moldavian Society of Cardiology M Popovici 66 -
Moroccan Society of Cardiology S Abir-Khalil, FESC 647 P410
Netherlands Society of Cardiology B J Mulder, FESC 1649 P270
Norwegian Society of Cardiology T K Steigen, FESC 592 P480
Polish Cardiac Society Z Kalarus, FESC 4736 P200
Portuguese Society of Cardiology M F Mendes 1222 P100
Romanian Society of Cardiology G P Tatu-Chitoiu, FESC 1334 P300
Russian Society of Cardiology E V Shlyakhto, FESC 5500 P190
San Marino Society of Cardiology L Marinelli, FESC 70 P240
Slovak Society of Cardiology I Simkova, FESC 378 P195
Slovenian Society of Cardiology Z Fras, FESC 128 P160
Spanish Society of Cardiology J R Gonzalez Juanatey, FESC 4235 P230
Swedish Society of Cardiology F Braunschweig, FESC 1161 P480
Swiss Society of Cardiology U P Kaufmann, FESC 610 P420
Syrian Cardiovascular Association M Jokhadar 484 -
Tunisian Society of Cardiology and Cardio-Vascular Surgery M Mourali 412 P180
Turkish Society of Cardiology L Tokgozoglu, FESC 2703 P110
Ukrainian Association of Cardiology V Kovalenko, FESC 167 P140
Information about the ESC National Cardiac Societies is available on ESC website:
http://www.escardio.org/The-ESC/About/National-Cardiac-Societies/ESC-National-Cardiac-Societies
ESC YOUNG COMMUNITY G17
Setting out your career? Discover what the ESC Young Community can do for you at
ESC Congress 2015
Visit the Young Community Corner on the ESC Stand:

Discover the young group dedicated to your topic of interest
°° Meet the leaders and your peers
Get information on the 28 national young groups
°°Collect your Cardiologists of Tomorrow Pack, including your free copy of the latest ESC Clinical
Practice Pocket Guidelines and the Acute Cardiovascular Care Association Clinical Decision Making
Toolkit
Network with other young cardiologists and scientists
°°
Find out what the ESC can do for you all year round
Get the most out of ESC Congress and don’t miss:

How to session made for you
°°
How to shape your future, get the tips and tricks to find a job with international renowned
speakers: Prof. Martin Cowie, FESC (London) and Prof. Bela Merkely, FESC (Budapest)
Monday 31 August, 15:35 - 16:20, in the Agora (Poster Area)
Cardiologists of Tomorrow Track – more on page G61
°°
Scientists of Tomorrow Track – more on page G59
Stay connected and keep updated all year long!
My ESC Young Community Newsletter Network

Read the latest news for young Find your young ESC cardiology group
cardiologists and sign up through on LinkedIn
your My ESC account
Links and more at www.escardio.org/Young

G18 ESC FELLOWSHIP
ESC Fellowship
The ESC Fellowship community gathers international experts in the
cardiology field. Fellows and Nurse Fellows of the ESC have distinguished
themselves individually in clinical, educational, investigational, organisational
or professional aspects of Cardiology.
Launched in 1988, the ESC Fellowship Programme is now internationally
recognised as a prestigious title.
Exclusive Fellowship Privileges

Join the leading worldwide Community of more than 4 000 Fellows and take advantage of all
exclusive FESC and NFESC privileges included in the fee:
Preferential services and networking benefits at ESC Congress:
°° Entrance to ESC Congress

Advance priority hotel booking
° Exclusive access to the private “Fellows Lounge” including working facilities, Internet
connections, catering, free set of ESC Pocket Guidelines and more!
°°Distinctive FESC Gold congress badge

Fellowship Diploma
Subscriptions to:
°
ESC Journals: European Heart Journal (EHJ) or Cardiovascular Research (CVR) or
European Cardiovascular Nursing Journal (ECNJ) for Nurses
°My ESC Newsletter
Discounts on ESC Educational Products
Access to the online Fellowship Directory - network with your peers worldwide
JOIN THE PRESTIGIOUS FESC COMMUNITY
1. Review and collect all required documents

2. Apply online by connecting to: www.escardio.org/fellowship
3. Submit your application before the annual deadline: 30 September 2015
Please note that all applications are reviewed by the ESC Credentials Committee
More information on the ESC stand, ESC Plaza

Contact email: fellowship@escardio.org
G19
This year, ESC Credentials Committee is very pleased to welcome:
°° 367 newly elected Fellows of the ESC - FESC

5 newly elected Nurse Fellows of the ESC - NFESC
Congratulations and Welcome to the ESC newly elected Fellows!

Meet your peers during the Inaugural Session and be formally acknowledged.
You can collect your Fellowship Diploma in the Fellows Lounge from Sunday 30 August 2015
NEWLY ELECTED FELLOWS OF THE ESC
Argentina Canada Yan Xiaowei

Lobo Lorenzo Martin Kaul Padma Yan Hong Bing
Martinez Felipe Wood David Yang Yan-Zong
Tajer Carlos Yang Yanmin
China, People’s Republic of
Yu Zaixin
Armenia Cao Kejiang
Yuan Zuyi
Zelveian Parounak Chen Mao
Zeng Qiutang
Australia Chen Liang Long
Zeng YONG
Chew Derek Chen Yuanyuan
Zhang Li
Kilian Jens Guenter Du Zhimin
Zhang Yao-Jun
Lattimore Jo-Dee Gao ChuanYu
Zhao Shihua
Lim Han Sung Gao Pingjin
Zhou Jingmin
Sadick Norman Guo Jihong
Zhu Jun
Scott Adam Charles Guo Caixia
Zhu Zhiming
He Ben
Austria Zhu Yonghong
Huang Lianjun
Brodmann Marianne Zou Yunzeng
Ji Li Nong
Martinek Martin Kong Xiangqing Colombia
Niessner Alexander Li Yong Restrepo Gustavo
Plass Christian Andreas Li Hongwei
Scherr Daniel
Croatia
Li Xiao Dong Vrazic Hrvoje
Schukro Christoph Liang Chun
Steinwender Clemens Liu Shaowen Cyprus
Liu Xuebo Andreou Andreas
Azerbaijan
Liu Xiaoli Makrides Constantinos
Mustafayev Isakh
Lu Yongxin Czech Republic
Bangladesh Luo Jianfang Rokyta Richard
Afsar Nurul Nie Shao-Ping Snorek Michal
Khan Ranjit Chandra Pu Jun
Belarus Qiao Shubin Denmark
Ren Jingyi Dahl Jordi
Maroz-Vadalazhskaya Natalia
Shen Chengxing Gerdes Christian
Belgium Shi Hai-Ming Grove Erik Lerkevang
Debonnaire Philippe Larsen Torben Bjerregaard
Sun Yingxian
Dierckx Riet Mickley Hans Frederik
Tu Shengxian
Brazil Wang Lefeng Egypt
Nacruth Ricardo Wang Hongju Abdel Aziz Ahmed
Brunei Darussalam Wei Meng Etriby Adel Mohamad Kamal
Jaafar Isham Wu Yong Jian Girgis Hany Younan Azer
Wu Chun Shehata Mohamed
Cambodia Xu Ding-Li
Sok Chour Finland
Xu Bo Pietila Mikko Juhani
Xu Ya-Wei
G20 ESC FELLOWSHIP
France Kumar Ashutosh Luxembourg
Abi Nasr Imad Mardikar Harshawardhan Codreanu Andrei
Cattan Simon Mathavan Alagarsamy Wagner Kerstin
Czibik Gabor Mathew Rony
Malaysia
Ernande Laura Omana Soman Suman
Abdul Rahim Aizai Azan
Varenne Olivier P Manokar
Lam Kai Huat
Varghese Mithun Jacob
Germany Mohamed Yusof Ahmad K
Vijay Sudarshan Kumar
Almalla Mohammad Ong Samuel
Bigalke Boris Indonesia Liew Houng Bang
Blessing Erwin Alsagaff Mochamad Yusuf Bin Jamaluddin Ahmad Nizar
Christ Torsten Juzar Dafsah Quek David Kwang Leng
Hansmann Georg Tobing Daniel Rosli Mohd Ali
Hardt Stefan Israel Watson Timothy
Heer Tobias Gilon Dan Zainal Abidin Imran
Jaguszewski Milosz Jaroslaw Iakobishvili Zaza Zambahari Robaayah
Janosi Rolf Alexander Matetzky Shlomi Morocco
Kelle Sebastian Weisz Giora Abir-Khalil Saadia
Kleinbongard Petra Zafrir Barak
Kuhn Christian Myanmar
Lang Klaus Italy Aung Than Htike
Nitschke Thorsten Asteggiano Riccardo Kyaing Than Than
Ong Peter Emanuel Cadeddu Dessalvi Christian WIn Kyaw Soe
Pfeiffer Stefan Carluccio Erberto
Nepal
Pimenta Eduardo De Luca Leonardo
Karki Prahlad
Plicht Bjoern D’Onofrio Antonio
Pyxaras Stylianos Emdin Michele Netherlands
Rammos Christos Guerra Federico Akkerhuis Martijn
Sinning Jan-Malte Iacoviello Massimo Beijk Marcel
Theiss Hans Diogenes Luca’ Fabiana Brugts Jasper
Tiroch Klaus Maras Patrizia Elvan Arif
Tutarel Oktay Massucco Vicente Huisman Menno
Van Buuren Frank Navarese Eliano Pio Kavousi Maryam
Von Scheidt Wolfgang Perrino Cinzia Meuwissen Martijn
Von Zur Muhlen Constantin Saia Francesco Middeldorp Saskia
Wetzel Thomas Tondo Claudio Nijveldt Robin
Wieczorek Marcus Sluijter Joost
Japan
Greece Funabashi Nobusada New Zealand
Bourantas Christos Hao Hiroyuki Wong Selwyn
Deftereos Spyridon Hiroi Yukio Nigeria
Giannopoulos Georgios Ito Hiroshi Akintunde Adeseye
Ntatsios Antonios Kodama Takahide Karaye Kamilu
Papadopoulos Thomas Miura Shin-Ichiro Obasohan Austine
Stravopodis Petros Naganuma Toru Ojji Dike Bevis
Synetos Andreas Okayama Hideki
Ono Koh Norway
Hong Kong SAR, People’s Oyama Jun-ichi Brunvand Harald
Republic of China Sakata Yasushi Mjolstad Ole Christian
Wong Peter S C Sano Motoaki Pettersen Alf-Aage R
Hungary Sato Katsumasa Pakistan
Ferdinandy Peter Satoh Toru Mohammad Hafizullah
Shite Junya
India Sotomi Yohei Panama
Abdul Rahaman Muneer Morales Luis
Tada Hiroshi
Bhagwat Ajit
Tamita Koichi Peru
Chopra H
Tamura Yuichi Barreto Rodolfo
Dalal Jamshed
Tei Chuwa Bryce Alfonso
Dasbiswas Arup
Watanabe Masafumi Campos Alcantara Lourdes
Guha Santanu
Yamamoto Kazuhiro Gallardo Vallejo Segundo
Hiremath MS
Yoshizumi Masao Medina Palomino Felix Alvaro
G21
Murillo Jose Sudan United Kingdom

Obregon Vilches Heraclides Plinio Ziada Abdel Rahman Anderson Simon George
Revilla Hector Astin Felicity
Reyes Rocha Miguel Agustin
Sweden
Christersson Christina Babu-Narayan Sonya
Rospigliosi Benavides Maria Butts Jeremy
Hagstrom Emil
Angolina Collinson Paul
Johnston Nina
Salazar Pedro Di Angelantonio Emanuele
Naslund Ulf
Sanchez Palacios Miguel Evans Paul
Saha Samir Kanti
Sosa Jose Houghton Andrew Robert
Stahlberg Marcus
Vlasica Carlos Juan Antonio Hunter Ross
Varenhorst Christoph
Zegarra Ricardo Ingle Lee
Zubiate Talledo Mario Switzerland Kapetanakis Stam
Conen David Kaski Juan Pablo
Poland Greutmann Matthias
Dabrowski Rafal Keenan Niall
Hanssen Henner Kemah Frederick
Tycinska Agnieszka
Hellermann Jens Peter Kesavan Sujatha
Portugal Matter Christian M Lim Pitt
Baptista Sergio Mueller Dominic J Noman Awsan
Fontes Carvalho Ricardo Rickli Hans Nyktari Evangelia
Teles Rui Tobler Daniel Pugliese Francesca
Qatar Taiwan, ROC Punjabi Prakash
Abi Khalil Charbel Chan Kuei-Chuan Rahimi Kazem
Barman Manish Chang Kuan-Cheng Rajani Ronak
Charng Min-Ji Rittoo Dylmitr
Romania Rudd James
Floria Mariana Chen Wei-Jan
Chen Zhih Cherng Sharma Vishal
Frigy Attila Taggu Wasing
Statescu Cristian Cheng Shu-Meng
Chiu Chiung-Zuan Tzemos Nikolaos
Tepes Piser Ileana Vazir Ali
Hsieh I-Chang
Russian Federation Huang Po-Hsun Zeljko Hrvojka Marija
Ezhov Marat Ko Yu-Shien United States of America
Konnov Mikhail Kuo Jen-Yuan Butler Javed
Saudi Arabia Lin Tsung-Hsien Calkins Hugh
Al-Murayeh Mushabab Lin Yen-Hung Cheng Alan
Alnouri Fahad Tsai Wei-Chuan Costanzo Maria Rosa
Suliman Ihab Wang Chun-Chieh Ghazi Freidoon
Wang Chao-Hung Krasuski Richard
Serbia Wu Tsu-Juey
Popovic Dejana Scirica Benjamin Morgan
Vranic Ivana Tanzania, United Republic of Shetty A Nagesh Roy
Nyagori Harun
Singapore
Chin Calvin Trinidad & Tobago
Rampersad Risshi NURSE FELLOWS
Slovak Republic
Dubrava Juraj Turkey
Ates Ismail China, People’s Republic of
Slovenia Balbay Yucel Wu Ying
Brguljan Jana Demircan Sabri
Petrovic Danijel Denmark
Erdem Guliz Johansen Pernille Palm
Vokac Damijan Meric Murat
South Africa Sahin Mahmut Lebanon
Zuhlke Liesl Tulmac Murat Rihan Rashida
Spain Ulucam Melek Zekiye Sweden

Amat Santos Ignacio Jesus Yalcinkaya Emre Zughaft David
Yuksel Serkan
Brugaletta Salvatore United Kingdom
Estevez Loureiro Rodrigo United Arab Emirates Hill Loreena
Manzano Espinosa Luis Bartel Thomas
Montero Perez Barquero Manuel Jacobsen Alexander
Pascual Figal Domingo Andres Narayanan Sunil Roy
Vilahur Garcia Gemma
G22 ESC ASSOCIATIONS
Acute Cardiovascular Care Association (ACCA)

Encompassing the complete care of patients with acute cardiovascular
disorders from first medical contact in the pre-hospital phase up to the
end of the first week of hospitalisation.
Mission: To improve the quality of care and outcomes of patients with
acute cardiovascular diseases
Congress Journal
17-19 October 2015 EHJ-Acute Cardiovascular Care
Vienna - Austria
EUROPEAN
SOCIETY OF
CARDIOLOGY ®
Activities at ESC Congress 2015
° Visit Village 7, your area dedicated to Acute Cardiac Care

DON’T MISS
s ACCA Association Track: “Treatments for acute cardiac care: innovations or lost in translation?”
(Sunday 30 August 2015, 16:30-18:00, room Lisbon, Village 7)
° Come to the Membership Desk on the ESC Stand (ESC Plaza) to learn
more about ACCA and join our vibrant community!
s Pick-up your free ACCA Clinical Decision-Making Toolkit (also available online
and on mobile application for smartphones and Tablets)
ACUTE C ARDIOVASCUL AR C ARE
ASSOCIATION MEMBERSHIP 2015
Be part of a multi-disciplinary network
Access membership directory

Access database of CCU
s Access sample chapters of the new ACCA online educational platform

'SRXMFYXIXSPMZIWGMIRXM½GHMWGYWWMSR
Gain exclusive knowledge and expertise

JOIN US!
Access a unique portfolio of educational
resources at preferred prices
s Discover the new version of the IACC Textbook (a key reference for Apply for membership
www.escardio.org/ACCA
Build the future of your association
Get voting rights

Be eligible to sit for ACCA committees
Participate in ACCA’s life
training and certification in this specialty!) UNITED IN QUALITY CARE
Get your free sample chapter "the heart team"

s Get information on webinars programme
s Register now to the next IACC Certification Exam (19 October 2015 during
Acute Cardiovascular Care Congress in Vienna - Austria)
s As an ACCA Member, get preferred prices on
- Publications:
- EHJ- ACVC Journal (online or print annual subscriptions)
- NEW! IACC Textbook (lifelong online access or printed version)
- Registration to ACC Congress, the ACCA Annual Congress in October
s And many other opportunities
° Come to the ESC Young Community Corner in the ESC Plaza and meet the
Young ACCA !
° CPR Stand + Workshops jointly with ERC see more information on page G46
Find out more on www.escardio.org/ACCA

ESC ASSOCIATIONS G23
European Association for Cardiovascular Prevention

and Rehabilitation (EACPR)
Prevention, Epidemiology, Rehabilitation, Exercise Physiology, Sports
EACPR Cardiology.
European Association for
Cardiovascular Prevention
and Rehabilitation
A Registered Branch of the ESC Mission: To promote excellence in research, practice, education and policy
in cardiovascular health, primary and secondary prevention.
Congress Journal
July 2014 | Volume 21 | Issue 7
5-7 May 2016 M E M BE R O F T H E E S C J O U R N A L FA M ILY

European Journal of Preventive
Istanbul - Turkey Cardiology (EJPC)
Testing
Drug Testing
Treatment
Lipids
Li id
Prevention
Blood Pressure Prevention
Impact factor 2014: 3.319
Blood Pressure
Biomarkers Lipids
Treatment
European Journal of
Preventive Cardiology
Editor-in-Chief:
Diederick E Grobbee,
University Medical Center Utrecht,
The Netherlands
The official ESC journal for primary &

secondary cardiovascular prevention,
rehabilitation and sports cardiology
ISSN 2047-4873 | www.ejpc.sagepub.com
° Visit Village 2, your area dedicated to Prevention / Rehabilitation / Sports / Nursing / Ageing
DON’T MISS:
s EACPR Association Track: “The year in prevention: scientific highlights from EuroPRevent 2015
and beyond”
(Sunday 30 August, 16:30-18:00, room Bratislava, Village 2)
s EACPR General Assembly
(Sunday 30 August, 12:45-13:45, ESC Meeting Room 1, ESC Meeting Rooms, Level 3)
Check our website for the full schedule of open sections’ meetings
° Come to the ESC Stand (ESC Plaza) to learn more about EACPR and join us!
s Pick up your free European SCORE Risk Charts
s Learn more about the EACPR educational courses, eLearning programme and webinars
s Discover our CVD Prevention Tools
s As an EACPR member, get preferred prices on:
- Subscription to the European Journal of Preventive Cardiology (EJPC)
- Registration to EuroPRevent, the EACPR Annual Congress
s NEW! The ESC Textbook of Preventive Cardiology
Find out more on www.escardio.org/EACPR
European Association of Cardiovascular Imaging (EACVI)
Echocardiography, Cardiovascular Magnetic Resonance and Nuclear Cardiology
& Cardiac Computed Tomography.
Mission: To promote excellence in clinical diagnosis, research, technical
development, and education in cardiovascular imaging in Europe.
Congresses Journal
2-5 December 12-14 May 2016 11-13 Sept.2015 EHJ-
2012
ISSN 2047-2404 (Print) ISSN 2047-2412 (Online)
MEM BER OF THE ES C J OURN AL FAMI LY
2015 Florence, Italy Beijing, China European Heart Journal Cardiovascular

Cardiovascular
Seville, Spain World Summit of Imaging Imaging
Echocardiography Cardiovascular imaging including
echocardiography
Formerly European Journal of Echocardiography
Impact factor
2014: 4.105
Magnetic resonance
Computed tomography
Nuclear and invasive imaging
Editor-in-Chief: Gerald Maurer

Deputy Editors: Thomas Binder
Heinz Sochor
Senior Associate Editors: Juhani Knuuti
Luc Piérard
Sven Plein
See pp. XXX.
www.escardio.org/EACVI
www.ehjcimaging.oxfordjournals.org
D7343_Visuel_EuroCMR2016-Def.indd 1 30/01/2015 10:02
° Visit Village 5, your area dedicated to Cardiac Imaging

DON’T MISS:
s EACVI Association Track: “Multimodality Imaging as a help for decision-making, what’s new in 2015?”
(Sunday 30 August 2015, 16:30-18:00, room Damascus, Village 5)
s EACVI Club 35-COT joint track: “Recent advances in Cardiology: what does the busy cardiologist
need to know about…”
(Monday 31 August 2015, 11:00-12:30, Green Park, The Hub)
s EACVI General Assembly
(Tuesday 1 September 2015, 13:30-15:00, ESC Meeting Rooms 1, ESC Meeting Room, Level 3)
s EACVI Certification exams:
- in TTE (Wednesday 2 September 2015, 08:00-13:00, room Bratislava, Village 2)
- in CMR (2 sessions on Saturday 29 August 2015, 09:00-13:00 & 14:00-17:00, London Queen
Mary University, London city)
° Come to the ESC Stand in the ESC Plaza to learn more about EACVI and join us!
s Select your membership programme, subscribe on the stand to save time and access your benefits
immediately from London!
s Get information on our educational offer:
- EACVI grants in research & training for 2016 (application deadline: 30 September 2015)
- Tool boxes (on Contrast Echo, 3D and Valvular Disease)
- 10+ live webinars per year and on-demand recordings in your language
- Courses:
- EACVI Club 35 teaching courses on “Echocardiography for trainees”
24 October 2015, Antalya, Turkey – (Free for the EACVI Club 35 members)
- EACVI teaching course on “Magnetic Resonance in Cardiology”
1-3 October 2015, Lake Garda, Italy
- Online course on Pocket-size ultrasound devices
- NEW! Online Echo E-learning course (31 TTE tutorial videos)
- Online course on Basic Echocardiography Course (1,062 slides divided into chapters)
- Clinical Case Galleries
- Educational platforms: ESCeL and EduCAD
s On the ESC Shop (ESC Plaza), discover the EACVI products for sale: scientific posters, abridged
recommendations (NEW: also available in Portuguese, Chinese and French), Compendium, CMR
pocket guides and Imaging textbooks.
° Come to the ESC Young Community Corner, ESC Plaza, to learn about the EACVI Club 35
programme!
Find out more on www.escardio.org/EACVI

European Association of Percutaneous Cardiovascular

Interventions (EAPCI)
Coronary intervention, peripheral intervention, valve intervention, structural
heart intervention
Mission: To reduce the burden of cardiovascular disease in Europe through
percutaneous cardiovascular interventions.
Congress Journal
www.eurointervention.org Volume 10 - Number 1 - May 2014 - ISSN: 1774-024X
17 - 20 May 2016 EuroIntervention

Official Journal of EuroPCR and the European Association
of Percutaneous Cardiovascular Interventions (EAPCI)
EuroIntervention Journal (EIJ)
Paris-France Paclitaxel-coated balloon in bifurcations:
randomised BABILON trial
Penile artery angioplasty for erectile
dysfunction: FIM study
Out-of-hospital cardiac arrest:
EAPCI/Stent for Life consensus statement
Antiplatelet therapy management of stent
patients for cardiac/non-cardiac surgery:
Italian multidisciplinary consensus
Randomised DES vs. BMS in NSTE-ACS patients:
BASKET-PROVE 2-year results
Prognostic value of bleeding after PCI
in diabetic patients
DES characteristics influencing bifurcation
lesion stenting
Acute kidney injury after TAVI implantation
Renal denervation real-world registry: EDITOR-IN-CHIEF
ALSTER-BP results Patrick W. Serruys
CO-EDITORS
Pim de Feyter
Carlo Di Mario
Jean Marco
Marie-Claude Morice
Manel Sabaté
Horst Sievert
William Wijns
DEPUTY EDITORS
Nico Bruining
Pieter Kappetein
Pascal Vranckx
SUPPLEMENTS EDITORS
Jean Fajadet
Alec Vahanian
° Visit Village 6, your area dedicated to Interventions / Peripheral Circulation / Stroke /

Surgery with sessions designed to keep you up-to-date on how innovation changes daily
practice in intervention and also to present a collaborative 360º view of intervention and
surgery.
DON’T MISS
s EAPCI Association track: “Hot topics in interventional cardiology”
(Sunday 30 August 2015, 16:30-18:00, room Chisinau, Village 6)
s EAPCI Young-COT joint track: “Recent advances in cardiology: what does the busy
cardiologist need to know about..”
(Monday 31 August 2015, 11:00-12:30, Green Park, The Hub)
° Come to the Membership Desk on the ESC Stand (ESC Plaza) to learn more about EAPCI
and join us!
s Get information on the educational offer:
- Certificate of excellence in training in Interventional Cardiology ESC e-learning platform (ESCeL)
- Fellows Courses
- PCR Seminars
- Training and Research Grants in Interventional Cardiology (application deadline: 15 January 2016)
- List of European centres offering research and training positions
s Be informed on Valve for Life and Stent for Life initiatives
s Learn more on Congresses, Journals, PCR-EAPCI Textbook and Publications
s Discover the Young,Women and Nurses and Technicians communities and their projects
EAPCI Young!
Find out more on www.escardio.org/EAPCI

European Heart Rhythm Association (EHRA)
Arrhythmias, Cardiac Pacing, Electrophysiology, Heart Rhythm & AFIB.
Mission: To improve the quality of life of the European population by
reducing the impact of cardiac arrhythmias and reduce sudden cardiac
death.
Congress Journal
08-11 June 18-21 June EP Europace
Volume 16 Number 6 June 2014
ISSN 1099-5129 (Print) ISSN 1532-2092 (Online)
EUROPEAN
SOCIETY OF
CARDIOLOGY ®
2016 2017 MEMB ER OF THE ESC J OURNAL FAMI LY
EP
Nice - France Vienna - Austria
Europace
Journal of the European Heart Rhythm Association,
a Registered Branch of the ESC, and the ESC Working
Groups on Cardiac Cellular Electrophysiology
and e-Cardiology
Quality of life in patients with AF:

how to assess and improve it
QRS duration predicts death and
hospitalization in the AFFIRM study
Trends in mortality attributed to AF in England
Long-term results of duty-cycled
multi-electrode vs. conventional RF ablation
Cost-efficacy of atrial vs dual-chamber
pacing: DANPACE study
EP Wire – EHRA survey: trends in
ICD programming in Europe
Editor-in-Chief: John Camm

Deputy Editors: Luc Jordaens
Antonio Zaza
Areas of inflammation due to cardiac sarcoidosis correlate with low volt-

age maps associated with VT. See figure legend on page 907.
save the date.indd 1 29/05/2015 16:23 www.europace.oxfordjournals.org
° Visit Village 4, your area dedicated to Arrhythmias and Pacing

DON’T MISS
s EHRA Association Track: “Major breakthroughs in management of ventricular tachyarrhythmias,
atrial fibrillation, CRT & pacing and telemonitoring in 2014 – Take home messages”
(Sunday 30 August 2015, 16:30-18:00, room Madrid, Village 4)
° Come to the Membership Desk on the ESC stand (ESC Plaza) to learn more about
EHRA and join us!
s EHRA educational courses
- EHRA course on Basic and Advanced Invasive Cardiac Electrophysiology (Russian
language), 08-10 October 2015, St Petersburg, Russia
- EHRA EP Preparatory course (formerly Basic EP), 15-17 October 2015 – Sophia-Antipolis,
France.
- EHRA Advanced EP course, February 2016 – location to be defined
- EHRA Cardiac Pacing, ICD, and Cardiac Resynchronisation, Vienna, March 2016 Google Play Apple Store
The Mobile App is supported by Bayer HealthCare, Boehringer Ingelheim, Daiichi Sankyo
Europe GmbH and Medtronic in the form of an unrestricted educational grant.
(date to be defined) www.escardio.org/EHRA
s Monthly EHRA Webinars (e-learning) Albania . Algeria . Armenia . Austria . Azerbaijan . Belarus . Belgium . Bosnia & Herzegovina . Bulgaria . Croatia
Cyprus . Czech Republic . Denmark . Egypt . Estonia . Finland . France . Georgia . Germany . Greece . Hungary
Iceland . Ireland . Israel . Italy . Kazakhstan . Kosovo . Kyrgyzstan . Latvia . Lebanon . Libya . Lithuania . Luxembourg
Macedonia, FYR . Malta . Moldova . Montenegro . Morocco . Netherlands . Norway . Poland . Portugal . Romania
Russian Federation . San Marino . Serbia . Slovakia . Slovenia . Spain . Sweden . Switzerland . Syria . Tunisia . Turkey
Ukraine . United Kingdom
The EHRA White Book 2015
s EHRA Training Fellowships and a selection of EHRA Educational Content Online (for
The Current Status of Cardiac Electrophysiology
in ESC Member Countries
K.-H. Kuck, G. Hindricks, L. Padeletti, P. Raatikainen, D.O. Arnar
members only)
s Get a copy of the EHRA Key Messages booklet (available at the ESC Booth during the www.escardio.org/EHRA
ESC Annual Congress) and of the EHRA White Book

s Access to the ESC eLearning platform
s Discover the AfibMatters website for patients (Spanish, Italian, French and German
versions): www.afibmatters.org Women
s Download for free the application dedicated to the EHRA Key Messages in EP
s Learn more about our young, innovation and women communities!
s NEW! Don’t miss the EHRA book on “Pacemaker, ICD and CRT Troubleshooting”
s And many other opportunities
EHRA Young EP!
Find out more on www.escardio.org/EHRA

Heart Failure Association of the ESC (HFA)

Made up of basic and clinical sections, focused scientific committees and
study groups, embracing all aspects of heart failure.
Mission: To improve quality of life and longevity through better prevention,
diagnosis and treatment of heart failure, including the establishment of
networks, for its management, education and research.
Congress Journals
21-24 May 2016 European Journal on ESC Heart Failure
Florence - Italy Heart Failure (EJHF) HFA Open
Impact factor 2014: 6.526 Access Journal
Visuel HF2016 Def.indd 1 17/03/2015 16:38
° Visit Village 9, your area dedicated to Heart Failure

DON’T MISS:
s HFA Association Track: “Heart Failure 2015: update for the clinician"
(Sunday 30 August, 16:30-18:00, room Bern, Village 9)
° Come to the Membership Desk on the ESC Stand (ESC Plaza) to learn more about
HFA!
s Grants – Get information on available Clinical, basic research and Nurse grants
s Education – Discover the Post Graduate Course in heart failure and other educational
heart failure events
s Online education - How to gain CME credits while learning with the ESCeL HFA online
learning programme based on the latest ESC hear t failure Guidelines and the hear t
failure curriculum.
s Knowledge resources - How to access online the European Journal of Hear t Failure or
use our resources centre to visualize presentations from the heart failure congress.
s Leadership opportunities - How to apply to have the prestigious title of Fellow of the
HFA or serve on one of our Committees & Study Groups.
s The Voice of your profession - Discover the Global Heart Failure Awareness Programme
including the White Paper on Heart Failure to demonstrate the burden of the disease
with a clear Call to Action.
Heart Failure Specialists of Tomorrow! HEART FAILURE SPECIALISTS
OF TOMORROW
Find out more on www.escardio.org/HFA

G28 ESC WORKING GROUPS
15 ESC Working Groups for 15 areas of expertise in

Cardiology
Working Groups are the scientific backbone of the ESC and have been created to provide
scientific expertise by excellence in a specific field.
They contribute to the Mission of the ESC which is “To reduce the burden of cardiovascular
disease in Europe”.
Among many initiatives such as study groups, publications, registries, position papers and
ESC Clinical Practice Guidelines, the main function of a Working Group is to “contribute
scientifically to the ESC Congress and other educational and scientific initiatives”.
From research to clinical applications, ESC Working Groups stimulate and disseminate
scientific knowledge through various educational programmes. They encourage and ease
interactivity and exchange at a European level.
° Your Villages dedicated to the Working Groups specific field

tVillage 3: Pharma
tVillage 5: Imaging, e-Technology
tVillage 6: Peripheral Circulation, Stroke, Surgery
tVillage 7: Ischaemia, Coronary Artery Disease
tVillage 8: Congenital,Valvular Myopericardial Diseases, Pulmonary Circulation
tVillage 9: Left Ventricular dysfunction
DON’T MISS: the General Assemblies of the ESC Working Groups

Each ESC Working Group Chairperson presents the main achievements and the future
initiatives of his/her Working Group. This is a unique opportunity to discover, retrieve and get
involve in scientific projects.
Find the timetable and location on our website www.escardio.org/workinggroups
° Come to the Membership Desk on the ESC Stand (ESC Plaza) to join the ESC Working
Group of your sub-specialty and learn more about:
tScientific and educational activities
tSpecific initiatives
tAnnual meetings organised by each Working Group
tMembership is free of charge
° Come to the ESC Young Community Corner in the ESC Plaza and meet the Young
Thrombosis Researcher Group!
Find out more on www.escardio.org/workinggroups

ESC COUNCILS G29
UN
CO C
5 ESC Councils
C
IL
ES
The Councils bring together professionals with common interests in a particular field of
cardiovascular medicine.
The ESC Councils contribute to the scientific knowledge disseminated via the ESC
What’s going on at ESC Congress 2015?

> General Cardiology for Physicians,Technicians and General Practitioners (Saturday 29 August 2015)
> General Cardiology for Nurses and Allied Professionals (Saturday 29 August 2015)
Further your knowledge and improve your practice with these programmes organised by the ESC Council on
Cardiovascular Primary Care, the ESC Council for Cardiology Practice and the ESC Council on Cardiovascular
Nursing and Allied Professions in collaboration with British partner groups and associations.
Full details of the General Cardiology programme on page G57.
COUNCIL ON BASIC CARDIOVASCULAR SCIENCE (CBCS)

> Visit Village 1, your area dedicated to Basic Science
> Enjoy the Poster Reception, open to the Basic Science community and friends on Sunday 30 August at 18:30 in the Poster Area.
A relaxing moment to view posters and meet the awardees of this year’s Outstanding Achievement Awards.
> Find out more on the Council’s awards, grants, fellowship and its scientific meeting “Frontiers in CardioVascular
Biology” (08-10 July 2016, Florence, Italy) at the Membership Desk on the ESC Stand (ESC Plaza).
> Read more on the Basic Science programme on page G58.
COUNCIL ON CARDIOVASCULAR NURSING AND ALLIED PROFESSIONS (CCNAP)

> Visit Village 2, your area dedicated to Nursing
> At the ESC stand learn more about the Guidelines Implementation Programme for Nurses and Allied Professionals
and DON’T MISS
t "Guidance on the ESC Guidelines in Nursing Practice” (Saturday 29 August, 12:35-13:25,Victoria Park - The Hub)
> European Journal of Cardiovascular Nursing Reviewer of the Year Event and CCNAP Networking Reception
Nurses and allied professionals are welcome to this reception where the journal of CCNAP will honour its
collaborators. (Saturday 29 August, 20:00-22:00, Central London).
> Come to the Membership Desk on the ESC Stand (ESC Plaza) to learn more about the Council’s grants, awards, its
annual congress (EuroHeartCare) and the European Journal of Cardiovascular Nursing.
COUNCIL FOR CARDIOLOGY PRACTICE (CCP)

> "Clinic management problems in out-patients with atrial fibrillation"
(Monday 31 August, 12:40-13:50, Regents Park - The Hub)
> "Private Practice across Europe. What is the future?" Roundtable and networking event
(Tuesday 1 September, 12:15-13:15, ESC Meeting Room 1, ESC Meeting Rooms, level 3)
> "Council for Cardiology Practice Meeting"
(Tuesday 1 September, 13:30-16:00, ESC Meeting Room 10, ESC Meeting Rooms, Level 3)
> Subscribe to the E-journal of Cardiology Practice and participate in the Council’s surveys on clinical cardiology.
Find out more at the ESC Stand (ESC Plaza).
COUNCIL ON HYPERTENSION
> Visit Village 3, your area dedicated to Hypertension.
> Created in September 2014 the Council encourages research, teaching, communication of knowledge, and
participates in education, focusing on the cardiovascular aspects of hypertension. If you are a member, or would like
to become a member, of the Council on Hypertension, come along to the Council’s General Assembly where you
can find out what the Council is planning for the future and how you can participate.
> General Assembly of the Council on Hypertension
(Monday 31 August, 12:45 – 13: 45, ESC Meeting Room 1, ESC Meeting Rooms, Level 3)
> Come to the Membership Desk on the ESC Stand (ESC Plaza) to learn more about the Council’s activities
Find out more on www.escardio.org/councils
ESC GLOBAL AFFAIRS G31
European Roots - International Scope

Discover where the ESC is beyond Europe!
Living in an ESC Affiliated country?
Argentina China / Gulf States Korea Panama Taiwan

Australia Hong Kong India Malaysia Paraguay Thailand
Bangladesh Colombia Indonesia Macau Peru Uruguay
Brazil Costa Rica Iran Mexico Saudi Arabia Venezuela
Canada Cuba Iraq New Zealand Singapore Vietnam
Caribbean Ecuador Japan Oman South Africa
Chile Guatemala Jordan Pakistan Sudan
Come and discover what the ESC can do for you on the ‘ESC Global Affairs
Meeting Point’ (P560) on the ESC Plaza:
Meet the ESC Global Affairs Team, we will help you to get the ESC tools you need!
°° ESC on the road with the Global Scientific Activities programme - Discover when the
ESC will be coming to your region
We want to know what you need! Tell us what you need from the ESC – we’re here to
° listen and learn!
Leave with a special ESC INTERNATIONAL souvenir- take a ‘selfie’ and post
° on Twitter ‘#ESCpics #esccongress I was there!’
Don’t miss the International ESC Joint Sessions with our Global Partners!
Share views and perspectives on common or related issues - hot topics from the global community, for the
global community. Joint scientific sessions with:
American College of Cardiology Great Wall International Congress of Cardiology
American Heart Association InterAmerican Society of Cardiology
Argentine Society of Cardiology Japanese Circulation Society
Asian Pacific Society of Cardiology Korean Society of Cardiology
Brazilian Society of Cardiology Mexican Society of Cardiology
Canadian Cardiovascular Society South African Heart Association
Cardiological Society of India World Heart Federation
Chinese Society of Cardiology See page G71 for more details.
NEW! Don’t miss Joint Sessions with International Young Communities from Brazil and Japan!
ESC CLINICAL PRACTICE G33
GUIDELINES
Supporting the dissemination of knowledge on treatment of cardiovascular diseases is a major
responsibility of the European Society of Cardiology.
In order to improve clinical practice, the Committee for Practice Guidelines (CPG) brings
together groups of European experts with the task of developing recommendations and
guidelines for clinical practice.
These recommendations and guidelines clarify areas of consensus and disagreement, allowing
distribution of the best possible guidance to practicing physicians. Guidelines aim to present
all the relevant evidence on a particular clinical issue in order to help physicians to weigh the
benefits and risks of a particular diagnostic or therapeutic procedure.
They should be helpful in everyday medical decision-making.
ESC CLINICAL PRACTICE GUIDELINES at ESC CONGRESS 2015
Come and visit us on the ESC Stand (ESC Plaza).
° ESC Members: pick-up this year’s new printed Pocket Guidelines

2015 (while stocks last)
° ESC Pocket Guidelines Application for all users worldwide free of

charge
Access a whole range of ESC Pocket Guidelines directly on your mobile
device and experience the interactive tools (algorithms, calculators, charts,
scores...).
Search for “ESC Pocket Guidelines” in App Store / Google Play / Amazon
Don’t miss
° the ESC Clinical Practice Guidelines 2015 sessions in London Auditorium:

The Guidelines Overview, the dedicated sessions and the Meet the Task Force on:
> Ventricular Arrhythmias & Sudden Cardiac Death
> Pulmonary Hypertension (joint ESC/ERS)
> Acute Coronary Syndromes non-ST-Elevation
> Pericardial Diseases
> Infective Endocarditis
° NEW! the “My NCS@ESC” a series of Guidelines in daily practice sessions highlighting
the contribution of National Cardiac Societies to ESC Congress (see details on page G56)
°° the “Guidelines in Daily Practice” in other Villages.

the very popular ESC Cardiology Quiz (see details on page G64)
° NEW! ESC Guidelines Highlights, on Saturday, in room London - Main Auditorium

(see details on page G55)
For more information, visit: www.escardio.org/guidelines

EUROBSERVATIONAL RESEARCH G35
PROGRAMME
The EORP programme aims at providing a better understanding of medical
practice, based on the collection of observational/real life data, and to compare
this practice with the implementation of ESC guidelines.
Data is collected through a web-based eCRF from an extended network of
volunteer centres in Europe and around the world, collaborating with the 56 ESC
National and Affiliated Cardiac Societies members and affiliated members.
Thanks to the incredibly extensive and valuable data collection, large statistical analyses and sub-
group analyses are performed and results are published in specialist journals. In 2014, 11 articles
were published across a multiple variety of cardiology topics. Many more will be published in 2015.
You can consult the list of all the EORP publications to date at: www.escardio.org/EORP-publications.
Coordination, database management and analyses are managed by the EORP team of the ESC.
Sessions and presentations not to be missed during ESC Congress:

Sunday 30 August page
08:45 - 09:00 Improved outcomes with ESC guideline-adherent antithrombotic
treatment in high-risk patients with atrial fibrillation.
A report from the EORP-AF General Pilot Registry
G Y H Lip (Birmingham, GB) Hyde Park (The Hub) 73
09:00 - 09:15 Kidney function markedly influences the outcome of patients with atrial
fibrillation: real-world data from the EURObservational Research Programme -
Atrial Fibrillation General Registry Pilot Phase
G Boriani (Bologna, IT) Hyde Park (The Hub) 73
11:00 - 12:30 EUROASPIRE IV survey: how are we managing
cardiovascular risk in the primary care environment? Bratislava (Village 2) 91
Tuesday 1 September
09:15 - 09:30 ELECTRa (European Lead Extraction ConTRolled) registry: long-term results
on transvenous lead extraction in Europe
M G Bongiorni (Pisa, IT) St James Park (The Hub) 303
11:00 - 11:15 Clinical reality of primary prevention in people at high cardiovascular risk in
Europe: A comparison of EUROASPIRE III and IV surveys in general practice
K Kotseva (London, GB) Hyde Park (The Hub) 318
14:00 - 15:30 ESC registries, organised by EURObservational
Research Programme St James Park (The Hub) 356
- Heart Failure long-term registry: main results of the 1-year outcome
- Cardiomyopathy registry: main results of the pilot phase
- Chronic Ischemic Cardiovascular Disease registry: main results of the pilot phase
- Cardiac Oncology Toxicity Registry in Breast Cancer patient: rationale, study design,
and methodology
- European Lead Extraction ConTRolled Registry (ELECTRa): main results
MyNCS@ESC sessions will present some EORP national data.

More details can be found on page G56
Find out more on www.escardio.org/EORP

Hot news and analysis
from ESC Congress 2015
Tune into the Online TV Channel
on www.escardio.org/esctv
Scientific Sessions
Live the lecture room experience from your desktop
Late Breaking Science

Inside scope on Hot Lines, Trials and Registries
CAR
DIOT
ESC Guidelines ALK
Key messages from the ESC Clinical Practice Guidelines

CAR
DIOT
Experts Words ALK
Questions to faculties about their sessions

CAR
DIOT
ESC Initiatives ALK
ESC Board, Members and Affiliates discuss their activities
Young Researchers
A fresh review from cardiologists and scientists of the future
Congress by Day
Hot daily highlights in under 5 minutes
Congress by Topic
Top advances on main topics released after ESC Congress
Best of ESC Congress

The one hour online event on recent developments
that will affect your daily practice.
Save the date now and watch it live on
Thursday 3 September at 20:00 (CET)
ESC TV is supported by AstraZeneca and SERVIER

in the form of an unrestricted educational grant.
GENERAL
INFORMATION
G38 SCHEDULE
CONTINUING MEDICAL EDUCATION (CME) CREDITS

More CME credits this year! ESC Congress 2015 is accredited by the European Board for Accreditation in
Cardiology (EBAC) and by the European Accreditation Council in CME (EACCME) for 27 hours of external
CME credits. Each participant should claim only those hours of credit that have actually been spent in the
educational activity. EBAC works according to the quality standards of the European Accreditation Council for
Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists
(UEMS).
Attendance certificates for participants will be provided on-site upon request, in the Registration Area, as of
Monday 31 August in the afternoon.
EACCME/EBAC credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Detailed instructions for converting EACCME/EBAC Credits to AMA PRA Category 1 Credit are available on the AMA website:
www.ama-assn.org. If you have any questions, please contact the AMA Continuing Physician Professional Development at
pra@ama-assn.org.
In compliance with EBAC/EACCME guidelines, all speakers and chairpersons participating in this programme have disclosed or
indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee is responsible for
ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. For more
information on EBAC accreditation, please visit www.ebac-cme.org.
CONGRESS INFORMATION G39
Organisers Venue
ESC - European Society of Cardiology ExCeL London
The European Heart House One Western Gateway,
Les Templiers, 2035 Route des Colles, CS 80179 Biot Royal Victoria Dock,
06903 Sophia Antipolis Cedex - France London E16 1XL - United Kingdom
www.escardio.org ESC Congress is only accessible to certified healthcare
congress@escardio.org professionals in the science, management and prevention of
cardiovascular diseases.
CONGRESS OPENING HOURS

Main Entrance Registration Exhibition Sessions
Friday 28 August 08:00 - 19:00 10:00 - 18:30 CLOSED NO SESSIONS
Saturday 29 August 07:00 - 20:00 08:00 - 19:30 12:30 - 18:00 09:00 - 18:30
Sunday 30 August 07:00 - 21:00 07:00 - 18:30 09:00 - 18:00 07:30 - 20:00
Monday 31 August 07:00 - 21:00 07:00 - 18:30 09:00 - 18:00 07:30 - 20:00
Tuesday 1 September 07:00 - 20:00 07:00 - 18:30 09:00 - 18:00 07:30 - 19:45
Wednesday 2 September 07:00 - 13:00 08:00 - 13:00 CLOSED 08:30 - 12:30
The Inaugural Session will take place at the Congress Centre

on Saturday 29 August from 17:00 to 18:30, Room London (Main Auditorium)
Doors will open at 16:30.
Free access for registered participants with Congress badges (limited number of seats).
It will be followed by a networking reception in ESC Plaza.
The Awards Ceremony

will take place on Monday 31 August in The Hub at 18:00.
See you all there to congratulate winners througout the abstract programme.
European Heart for Children The European Heart for Children (EHC) will be present with a stand
located in the ESC Plaza where you can support our cause and help children with
congenital heart disease by purchasing our merchandise or making a donation. All
ited
profits raised will go directly to the children by means of medical missions.

n Lim
sig
De
er
tch
n Fle
Ala
©
The annual EHC Fundraising Dinner will take place on Sunday 30 August at 20:30 and will be hosted at Troxy
(490 Commercial Road, London E1 0HX). Guests will enjoy typical British food, local entertainment and a film
about the situation of congenital heart disease in different parts of the world. Prof. Hugo Saner, from the
European Association for Cardiovascular Prevention and Rehabilitation (EACPR), and his jazz band, will provide
the music. Tickets can be purchased by email at: info@europeanheartforchildren.org or at the EHC booth, stand
N100, on Saturday 29 and Sunday 30 August, if still available. The cost per ticket is GBP 150.
A Benefit Concert supporting European Heart for Children is being organised on Tuesday 1 September at 20:00
at the Cadogan Hall. While not exclusively for ESC Congress participants, delegates interested may purchase
tickets at the Benefit Concert Desk in the registration area.
During and after the Congress network, make contacts, discuss and debate!
#ESCcongress European Society of escardiodotorg
Cardiology
G40 REGISTRATION
Your personal Congress badge is your passport to the scientific sessions and exhibition.
Please wear your congress badge visibly at all times. Security guards can ask you to make your
badge more visible.
CONGRESS BADGE: WHERE SHOULD I GO?
° You received your badge voucher by email: please go to the Pre-Registration desks with your
voucher to print your badge and pick up your congress materials. If you have purchased in advance a
public transport ticket, you will also be able to retrieve your ticket in this area.
° You are not registered yet: please go to the “New Registration Self-Service” terminals where you can
register by yourself in an easy and straightforward manner.
Or you can also go to the “New Registration” desks where staff will be happy to process your
registration.
°° Exhibitors: please collect your badge from the “Exhibitors Registration” desk.
Press: please collect your badge or register onsite at the “Press Registration” desk.
°° For any other registration issues, please go to the “Registration Assistance” desk.
Public Transport Tickets
Delegates who have pre-booked and pre-paid transport tickets can retrieve them at the
appropriate counters located next to the Pre-Registration desks by scanning their congress badge.
Tickets are also sold onsite at the “Transport Ticket Sales” desk located in the Registration Hall.
More details on page G42.
What colour is your badge?

White Delegate Blue Scientific (Exhibitor) Purple Press
Green Exhibitor Red ESC Board Orange Staff
Silver Diamond Exhibitor Gold ESC Fellow
When should I go to the lecture rooms?

We recommend you go to the lecture room well before the session begins. Due to safety regulations,
we are required to close the access to the session if the room fills to capacity. Access is limited to
Delegates, Diamond Exhibitors, Scientific Exhibitors and ESC Fellows.
Have you selected your journal subscription?

All delegates paying a Standard, Nurse/Medical Technician or Emeritus FESC fee, are offered a complimentary
online journal subscription for 2016 to the European Heart Journal or Cardiovascular Research (CVR).
You can choose your journal on the ESC Stand (ESC Plaza). An upgrade to a paper version of either the
European Heart Journal or Cardiovascular Research can be purchased for a fixed price of € 149.
Raise your My ESC Profile

Have you been promoted this year?
Have you moved to a new institution/practice? Then do not forget to update your My ESC profile to
make sure it displays your most recent position and to ensure your publications/notifications are sent to
the correct address. Go to the Registration area to the Raise your My ESC Profile desk or to the ESC
stand at the ESC Plaza and receive a green smiley on your badge. Furthermore, you can update your
profile at any time by logging in to your My ESC account at the top of the page: www.escardio.org
Liability disclaimer: In the event of industrial disruption or other unforeseen circumstances, the ESC Congress accepts no
responsibility for any loss, damage, cost or expenses incurred by delegates. Delegates are strongly encouraged to make their
own arrangements with respect to personal insurance.
PRESS G41
The ESC provides a Press Centre and dedicated facilities for approximately 700 journalists
attending ESC Congress 2015. You can find all the details at www.escardio.org/press
Press registration
Press representatives can pre-register online or register on-site, free of charge, upon presentation of:
° A valid press identity card or appropriate letter of assignment with proof of three recent published
articles (cardiology or health-related, or referring to a previous ESC Congress).
° A filled in and signed embargo form that can either be found in the ESC Media Policy on
www.escardio.org or may be sent to you upon request. Once filled in, it is valid for one calendar year
(and therefore subsequent congresses up until 31 December).
The ESC Press Office will verify all documents and advise if the accreditation is validated.
If not, other fees will apply.
All decisions made by the ESC Press Office concerning press registration requests are final.
Press Representatives will have to pick up their access badge on-site at the Press Registration desk and
will be given a USB key containing a comprehensive press kit. No press badge will be sent by post. The
Press Registration desk is located in the Registration Area, Main Entrance, Level 0.
Press Facilities and Schedule
° The ESC provides a fully equipped Press Centre and dedicated facilities for approximately 700
journalists attending ESC Congress 2015. This includes a press Working Area, a Conference Room
and three Interview Rooms open to registered press.
° The Press Conference programme will begin on Saturday 29 August 2015 and continue throughout
the ESC Congress.
°Industry Press
ESC Press Conferences are held in the ESC Press Conference Room, Press Area, Level 3.
°° A Press Conference Room and two interview rooms are provided for Industry press activities.
Industry-organised press conferences and interviews are held in the Industry Press Conference
Room, Press Area, Level 2.
°°Industry officials and their communications agents are not eligible for press registration.
Access to the Industry Press Area is restricted to registered Press and Industry Exhibitors/Sponsors
with activities booked therein and during the booked periods.
Online ESC Press Office

Daily updates will include the latest press releases and any changes to the press conference schedule will
be available at www.escardio.org/press
Cardiology
G42 PUBLIC TRANSPORT
A variety of public and private ground transport is available to take you everywhere in and around
London, especially to the ESC Congress 2015 venue.
You have the choice of the extensive underground (Tube) network, London’s iconic red buses and
black taxis, trains, the docklands light railways (DLR), river boats and bikes.
The best way to get to ESC Congress at ExCel is by using the London underground (Tube) and the Docklands Light
Railway (DLR).
The Jubilee Line is the quickest route. Exit at Canning Town then change to the DLR (upstairs from the Jubilee
Line Level – trains normally depart from platform 3).
> Prince Regent is the Dockland Light Rail (DLR) station for ESC Congress 2015 main entrance – ExCel east entrance
> Custom House Station (DLR) is ExCel west entrance and accessible with your congress badge only
CONGRESS VENUE TO AND FROM AIRPORTS

London City Airport Journey time by car or taxi: 5 minutes (Approx £10)
Journey time by DLR: 15 minutes
Gatwick Journey time by car or taxi: 1 hour 15 minutes (Approx £100/120);
Journey time by public transport : 1 hour 20 minutes
Stansted Journey time by car or taxi: 40 minutes/1 hour (Approx £100/120);
Heathrow Journey time by car or taxi: 1 hour 20 minutes (Approx £80/100);
Luton Journey time by car or taxi: 1 hour (Approx £160);
Journey time by public transport: 1 hour 40 minutes
The above information for taxis are approximate journey times & costs which can vary depending on traffic.
You can also find estimations on the following website http://www.taxifarefinder.com/main.php?city=London
Transfers with Chauffeur Service companies:
To arrange and pre-book private transfers with a chauffeur-driven car or minicab from the various airports or
hotels to your destination, please contact:
ADDISON LEE – Standard car service: www.addl.ee/esc (account number: 503894 - account name: ESC then
ESC once more)
TRISTAR – Executive car service: https://esc.tristarworldwide.com/
YOUR ACCOMMODATION AND TRANSPORT PLANNER

An online interactive map to help you find your hotel and your detailed itinerary to the congress venue, including
stations, directions and journey time is available in the “Travel & City” section of www.escardio.org/ESC2015
Other useful links:
> On the web: http://www.tfl.gov.uk/plan-a-journey/
> On mobile devices: search for “London Official City Guide” in the App Store or Google Play
If you have questions, please contacts us at: transport-made-easy@escardio.org
SAVE TIME, MONEY AND GO GREEN:

PURCHASE YOUR CONGRESS PUBLIC TRANSPORT TICKET
The “Visitor Oyster Card” is the cheapest, greenest and quickest way to travel on public transport around London.
For ESC Congress it is a smartcard valid for 4 days of unlimited journeys on the Underground (known as the
“Tube”), buses, cable car and Docklands Light Railway (DLR) in zones 1-3 including the congress venue, ExCeL but
excluding airports and all other zones.
The cost of the 4 day card is 40 Euros, which is 20% off the visitor fare you could buy direct.
Tickets can be purchased onsite at the Transport Ticket desk in the Registration hall.
Visitor Oyster cards do not expire and can be reused on future visits by simply topping up credit at any station.
FACILITIES & LOCAL G43
INFORMATION
Access Delegate Lounge Medical Care
The building is fully accessible to The dedicated area to sit down A First Aid Point located in the
disabled people. and relax is located in ESC Plaza. middle of the venue, which is
Charging stations for mobile near the Central Boulevard
Banks & Currency devices are also available in the entry N4/ S4 down the stairs to
Exchange lounge. level 0.
There are four cash dispensers
ESC HQ There is also a secondary facility
(ATMs) located in main
The ESC Board, Leadership, and between the N10 and N11
corridor of the venue
Management Offices are located Central Boulevard entry.
(Central Boulevard).
on the second floor of the Main Tel: +44 (0)207 069 5556
The official currency in United
Entrance area.
Kingdom is the Pound Sterling No smoking
(£) commonly known simply ESC Information Points The ESC Congress is a non-
as the Pound. Payment in other Located throughout the venue smoking event. Smoking is strictly
currencies will not be accepted. (East and West Entrances & in prohibited in the building and its
the Central Boulevard), ESC staff close vicinity.
A Business Services Centre
is there to help you, so do not
which is situated downstairs hesitate to ask for assistance. Police and Safety
(level 0) in the middle of the Security guards are in direct
Central Boulevard entry N4/ Filming, Recording, and contact with the police. Please
S4 is able to exchange Euro to Photography do not hesitate to ask a security
Pounds. All visual or audio reproduction
guard or ESC staff member
is strictly prohibited. Out of
Charging Station should you require police
respect for presenters, and
You will be able to charge your to avoid possible copyright assistance. All bags are subject
devices in the Delegate Lounge infringement, you are kindly to inspection. Please take all
located in ESC Plaza. asked to respect this rule. personal effects with you upon
Most presentations, videos, leaving a lecture room.
Child Care Corner
slides, abstracts and reports
Children are not allowed in Silence/Prayer room
will be available on the ESC
the Congress area, however, Available next to the food
website via ESC Congress 365
there will be a childcare centre www.escardio.org/365. court vendor Wrapid, situated
during the Congress days, open between the S8/S9 Central
from 8:00 to 18:00. Childcare Language Boulevard entries.
professionals will look after your The official language at the
children, free of charge, while Congress is English. All lectures Restaurants in the Venue
you attend the sessions. See and presentations are in English Whether looking for a
conditions onsite. without translation. convenient seating area to eat or
meet with peers, or just wanting
City Info Left Luggage and a fast option on-the-go,
For information about London Cloakroom ESC Congress 2015 offers
and available restaurants Located at the Main Entrance
a wide choice of healthy
and other amenities, please Level 0 and in the middle of
and affordable food options,
visit the city desk at the the Venue, which is near to the
prepared and served quickly.
Information Points located at Central Boulevard entry N4/S4
the East and West Entrances. down the stairs to level 0.
The price is £1 per item. Wi-Fi
The ExCeL website (http://
www.excel-london.co.uk/) Lost and Found Within the Congress venue,
provides an excellent source of Lost and found items can there is a free Wi-Fi network
information for local services, i.e. be recovered at the Main accessible through:
supermarkets, dry cleaning and Information Point located at the Name: esc-congress
other services. Main Entrance (East) on Level 1. Password: esc-congress
G44 ESC CONGRESS RESOURCES
Ensure you make the most of your congress experience with a whole range of resources you
can use before, during and after the Congress
SP&P (SCIENTIFIC PROGRAMME & PLANNER)

The online version of the Scientific Programme allows you to prepare your Congress attendance and to
review abstracts online.
Search by topics, sessions or presenters and create your personalised programme.
ABSTRACTS ONLINE
All selected abstracts are available online one week before the Congress either on the ESC 2015 Mobile
App, SP&P or on ESC Congress 365
MOBILE APP
Download the free ESC 2015 Mobile App for the most up-to-date congress information:
> Access full programme, exhibitors, maps & practical information
> Search by Day, Village, Topic, Type or Track
> Create your personalised programme
> View video, slides, abstracts & reports with a direct access to ESC Congress 365
> Receive the latest news & follow #ESCcongress Twitter feed
> Ask questions and vote during “Mobile App interactive sessions” (Search in the “types & tracks”,
select a session and click on “Session information & interaction”)
Download the app at the dedicated desk in Central Boulevard and at the SERVIER stands B100, C100
and D100.
Or search for “ESC 2015” in the App Store/Google Play.
Don’t have a mobile device? Consult the ESC 2015 Mobile App available on the ESC 2015 Mobile App
Desk located in Central Boulevard.
ESC Congress 2015 Mobile App is supported by SERVIER in the form of an unrestricted educational grant.
ESC TV
Tune into the Online TV Channel on www.escardio.org/esctv for hot news and analysis live
from the Congress.
> Scientific Sessions: live the lecture room experience from your desktop. A selection of sessions
will be available online in realtime - these Sessions are indicated ‘‘Live from ESC Congress’’ in
the Scientific Programme & Planner and ESC 2015 Mobile App.
> Late Breaking Science: inside scope on Hot Lines, Trials and Registries
> ESC Guidelines - CardioTalk: key messages from the ESC Clinical Practice Guidelines
> Experts Words - CardioTalk: Questions to faculties about their sessions
> ESC Initiatives - CardioTalk: ESC Board, Members and Affiliates discuss their activities
> Young Researchers: a fresh inside review from cardiologists and scientists of the future
> Congress by Day: hot daily highlights in under 5 minutes
> Best of ESC Congress 2015: the one hour online event on recent developments that will affect your
daily practice - Save the date now and watch it live on Thursday 3 September at 20:00 (CET)
> Congress by Topic: top advances on main topics released after ESC Congress
ESC TV is supported by AstraZeneca and SERVIER in the form of an unrestricted educational grant
ESC CONGRESS 365 G45
Your digital library, available 24h a day 365 days a year on www.escardio.org/365
Browse through 10 main topics or use the improved search by keywords to review or view the sessions
you missed,
Select your favourite presentations for future reference and share content of interest with your
colleagues.
°° Abstract full text available 1 week before the congress

Slide presentations available 24 hours after the presentation.
° Videos from the scientific presentations available 24 hours after the presentation.
° Reports on key sessions and presentations provides unbiased scientific opinion from renowned experts.
ESC Congress 365 desk is located in Central Boulevard.
ESC Congress 365 is supported by AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, the Bristol-Myers Squibb and
Pfizer alliance, and SERVIER, in the form of an unrestricted educational grant
ESC CONGRESS NEWS
Your free daily newspaper of ESC Congress 2015.

Pick it up in the dedicated racks and share the key scientific highlights of the day, onsite reports from the
previous day, photographs from key events and useful information.
ESC CONGRESS IN REVIEW

ESC CONGRESS IN REVIEW - FOCUS ON ARRHYTHMIAS
Official peer review highlights from ESC Congress available in different languages.
The 2015 editions will be available after the Congress.
ESC Congress in Review is supported by SERVIER in the form of an unrestricted educational grant.
ESC Congress in Review - focus on Arrhythmias is supported by Daiichi-Sankyo in the form of an unrestricted educational grant.
BEST OF ESC CONGRESS 2015
Extend your ESC Congress experience with THE online event.

ON THURSDAY 3 SEPTEMBER AT 20:00 (CET)
ESC Congress 2015 provides you with the latest updates in cardiovascular science.
What does it really mean for you?
Watch the “Best of ESC Congress 2015” on ESC TV to see how recent developments will
affect your daily practice.
Save the date now to watch the 1 hour online event on www.escardio.org/bestofesc2015
This programme is accredited by the European Board for Accreditation in Cardiology (EBAC)
and by the European Accreditation Council in CME (EACCME)
Best of ESC Congress 2015 is supported by AstraZeneca and SERVIER in the form of an unrestricted educational grant
Cardiology
G46 ESC INITIATIVES
HISTORY OF CARDIOLOGY
Share the memories of advances that have been made in cardiovascular care over the years.
Soak up the past and discover the therapies, device and equipment developments achieved
by the profession.
Come and visit the History of Cardiology stand N200 in ESC Plaza.
It is a unique opportunity for everyone to express their interest and exchange with:
> Doctor Jean-Jacques Monsuez (Sevran, France)
> Professor Berndt Lüderitz (Bonn, Germany)
> Professor Dietrich Pfeiffer (Leipzig, Germany)
> Professor Otmar Pachinger (Innsbruck, Austria)
who are behind this valuable initiative supported by the ESC.
CPR (CARDIOPULMONARY RESUSCITATION) WORKSHOPS
Come and learn about the latest CPR guidelines and meet ERC qualified instructors on
Stand A900, Exhibition Area, next to ESC Plaza.
EUROPEAN
RESUSCITATION
Organised in partnership with ERC (European Resuscitation Council) COUNCIL
ESC and ERC have the pleasure to offer delegates 90 minutes refresher workshops on
CPR & AED and Advanced Skills, free of charge to delegates. The content of those refresher
workshops is based on in-hospital scenarios, on the latest ERC guidelines and a certificate of
attendance will be sent to participants by ERC after the congress.
Pre-register onsite and, as space is limited, please check in 5 minutes before start of session.
Saturday 29/08 Sunday 30/08 Monday 31/08 Tuesday 01/09
CPR & AED CPR & AED CPR & AED
09:00-10:30 refresher refresher refresher
workshop workshop workshop
10:30-11:30 Break Break Break
Advanced CPR Advanced CPR Advanced CPR
11:30-13:00
Skills workshop Skills workshop Skills workshop
13:00-14:00 Break Break Break
CPR & AED CPR & AED CPR & AED
14:00-15:30 Exhibition opens refresher refresher refresher
at 12:30 workshop workshop workshop
Pre register to
15:30-16:30 your workshops Break Break Break
Advanced CPR Advanced CPR Advanced CPR
16:30-18:00
Skills workshop Skills workshop Skills workshop
Resuscitate your life saving skills !

INDUSTRY PROGRAMME G47
Our industry partners offer a rich educational programme to delegates throughout the
congress. Discover the wide variety of activities from educational sessions to stand activities in
the Industry Programme booklet.
Invitations to Educational sessions

Invitations to EBAC Accredited Educational Programmes, Satellite Symposia, Experts on the Spot
sessions and Hands-On Tutorials are available in the Industry Programme booklet and also on display
racks located in a strategic location within the congress centre.
Exhibition
The extensive exhibition area accompanying ESC Congress 2015 is arranged around The Hub and
surrounded by the Poster area and Villages. We bring science to the very heart of the Exhibition to
foster necessary dialogue between healthcare professionals and the industry.
Innovation from industry is an essential part of the congress favouring debate, learning and exchange.
From pharmaceutical products to electronic devices, diagnostic tools to telemedicine, high tech imagery
to clinical management software, the exhibition area is a technical and scientific display of current and
future healthcare practices, goods and services relevant to the field of cardiology with a strong focus on
science and education.
Emerging Technologies Showcase Area (ETSA)

Once again the ESC is delighted to present an area in the Exhibition dedicated to the newest
cardiovascular developments from start-up companies at the forefront of research.
Publishers Area in Exhibition

The ESC is proud to work with a range of publishers who play an essential role in the global distribution
of cardiovascular related information.
To discover the latest publications available, visit the Publishers Area, where you can discover Oxford
University Press, SAGE and Wiley in the especially dedicated “ESC Publishers Row”.
Product Theatre - NEW THIS YEAR

Come to the Product Theatre located in the Exhibition, during coffee breaks and lunch breaks and
participate in 20-minute presentations on the latest products or services from our exhibitors. It will be
a time to exchange with exhibitors around informative presentations. Space is limited! Come 5 minutes
before the presentations start to ensure a seat!
Exhibition opening hours

Saturday 29 August 12.30 - 18.00
Sunday 30 August 09.00 - 18.00
Monday 31 August 09.00 - 18.00
Tuesday 1 September 09.00 - 18.00
Wednesday 2 September CLOSED
Important information: Please note that by scanning your badge on an Exhibition stand or at the entrance of a
Sponsored Session, you accept that the company may contact you, using your contact details as submitted to the ESC.
G48 ACKNOWLEDGEMENTS
Exhibiting Industry Partners Ferrer Internacional SA

(as of 17/06/2015) Fresenius Medical Care
FUKUDA DENSHI
For company information please refer to the full
listing at the end of this Programme, the Industry GE Healthcare
Programme and the Mobile App. Genzyme, a Sanofi company
Accriva Diagnostics Glenmark Pharmaceuticals Ltd
Actelion Pharmaceuticals Ltd GSK
Advanced Cooling Therapy Health in Code SL
Advanced Medical Education HITACHI Medical Systems Europe
Aegerion Pharmaceuticals SARL i-cor
Agfa HealthCare International Society on Thrombosis and Haemostasis
Ai Mediq S.A. ISA 2016 - Anitschkow Days, St. Petersburg
AMGEN (Europe) GmbH Itamar Medical Ltd
Aspen Europe Kaneka Pharma Europe N.V.
AstraZeneca Labtech Ltd.
AUM Cardiovascular, Inc. Lev EL Diagnostics of Heart Diseases
Bayer HealthCare Littmann / 3M Health Care
BePATIENT Maltron International Ltd
Biocare Co., Ltd McKesson Imaging & Workflow Solutions
BIOTRONIK MediMatic
Blueprint Genetics Oy Medis Medical Imaging Systems
BMS / Pfizer Alliance Meditek Ltd
Boehringer Ingelheim Medley Farmaceutica
BPLab Medscape Cardiology
British Journal of Cardiac Nursing Medtronic
British Society of Echocardiography Microlife AG
Cardiome AG MIDES GmbH
CardioSecur Mindray
Carewell Electronics Co., Ltd. Mortara Instrument Inc
CellAegis Devices Inc MSD
Charity Cardiac Risk in the Young (CRY) Mylan
China Qingdao Bright Medical Manufacturing Co Ltd NeuroVive Pharmaceutical AB
Circle Cardiovascular Imaging Inc. Norav Medical GmbH
Covance NorthEast Monitoring Inc
custo med GmbH Novartis Pharma AG
Daiichi Sankyo Europe GmbH Osaka University & JMC Corporation
DailyCare BioMedical Oxford University Press
Defibtech LLC Pfizer
DocCheck Medical Services GmbH Philips Healthcare
Dot Medical Ltd Physicians' Academy for Cardiovascular Education
DSM Nutritional Products Ltd Portola Pharmaceuticals Inc
Edan Instruments, Inc. PRS Neoscan
Edwards Lifesciences Radcliffe Cardiology
Eli Lilly and Company Limited Randox Laboratories
Elsevier ResMed
ERCULES Roche Diagnostics International Ltd
ESAOTE SADS UK
G49
SAGE Publications Ltd EBAC Accredited

Sanofi Regeneron Educational Programmes
Sanofi Regeneron Patient Advocacy Connection (as of 17/06/2015)
Schiller AG For further information, please refer to the
Schwarzer Cardiotek GmbH Scientific Programme daily sections, the Scientific
ScottCare Corporation Programme & Planner, the Industry Programme
SERVIER and the Mobile App.
Shire - Academic Medical Center Amsterdam
Siemens Healthcare GmbH Supported by an unrestricted educational grant from
Singulex Physicians' Academy for Cardiovascular Education
SOMNOmedics GmbH - Athens Medical School
St. Jude Medical Supported by an unrestricted educational
grant from SERVIER
STORZ MEDICAL AG
Sunshine Heart - Hôpital Européen Georges Pompidou
Supported by an unrestricted educational
Takeda Pharmaceuticals International GmbH grant from SERVIER
The Jama Network
- Leiden University Medical Center
The Lancet Supported by an unrestricted educational
THE MENARINI GROUP grant from AstraZeneca
The New England Journal of Medicine - The Sahlgrenska Academy - Göteborg University
Thrombosis Research Institute Supported by an unrestricted educational
TomTec Imaging Systems GmbH grant from AstraZeneca
Toshiba Medical Systems - Universitätsklinikum des Saarlandes
United Therapeutics Europe Ltd Supported by an unrestricted educational
grant from SERVIER
Vales and Hills Biomedical Tech.Ltd
- University College London
Vasomedical Inc
Supported by an unrestricted educational
VectraCor Inc. grant from Physicians' Academy for Cardiovascular Education
Wiley
- University Hospital, Umeå
Wisepress Online Bookshop Ltd Supported by an unrestricted educational
Wolters Kluwer Health grant from AstraZeneca
ZEUS Scientific - University Hospital Zurich
ZOLL Medical Corporation Supported by an unrestricted educational
grant from SERVIER
Product Theatre - University of Pisa
(as of 17/06/2015) Supported by an unrestricted educational
grant from SERVIER
For further information, please refer to the
Industry Programme, the Mobile App and the
dedicated flyer featuring the full programme
distributed at the Product Theatre area.
AMGEN (Europe) GmbH
Bayer HealthCare
Daiichi Sankyo Europe GmbH
Siemens Healthcare GmbH
Singulex
G50 ACKNOWLEDGEMENTS
Satellite Symposia Satellite Symposia – Experts on

(as of 17/06/2015) the Spot
For further information, please refer to the (as of 17/06/2015)
Scientific Programme daily sections, the Scientific For further information, please refer to the
Programme & Planner, the Industry Programme Scientific Programme daily sections, the Scientific
and the Mobile App. Programme & Planner, the Industry Programme
Abbott Vascular and the Mobile App.
Actelion Pharmaceuticals Ltd Boehringer Ingelheim
Aegerion BMS-Pfizer Alliance
AMGEN Cardiome International AG
Bayer Healthcare Daiichi Sankyo Europe GmbH
Boehringer Ingelheim MSD
Boston Scientific SANOFI and REGENERON
BMS-Pfizer Alliance Takeda Pharmaceuticals GmbH
Cardiome International AG
Charité Hands-On Tutorials
Cleveland Clinic (as of 17/06/2015)
Daiichi Sankyo Europe GmbH For further information, please refer to the
DSM Nutritional Products Scientific Programme daily sections, the Scientific
Edwards Lifesciences Programme & Planner, the Industry Programme
EPIC Alliance and the Mobile App.
Ferrer Philips Healthcare
Fukuda Denshi Co. Ltd. ResMed
GE Healthcare Shire
Genzyme, a Sanofi company Siemens AG Healthcare
GlaxoSmithKline Toshiba Medical Systems Europe BV
Lilly United Therapeutics Europe Limited and OMT GmbH
Medscape Cardiology / theheart.org
Medtronic Sponsorship
MSD (as of 17/06/2015)
Mylan The ESC gratefully acknowledges the following
NeuroVive Pharmaceutical organisations which have contributed to the
Novartis Pharmaceuticals success of ESC Congress 2015 via educational
grants, support of delegate services and delegate
Pfizer
materials, advertisements and other sponsorship
Philips Healthcare
opportunities.
ResMed
Actelion Pharmaceuticals Ltd
Roche Diagnostics
AMGEN (Europe) GmbH
SANOFI and REGENERON
AstraZeneca
SERVIER
Bayer HealthCare
Singulex, Inc.
Boehringer Ingelheim
Takeda Pharmaceuticals GmbH
Boston Scientific
The Menarini Group
Daiichi Sankyo Europe GmbH
theheart.org / Medscape Education
FUKUDA DENSHI
Thrombosis Research Institute London
MSD
Toshiba Medical Systems
Mylan
ZOLL
NeuroVive Pharmaceutical AB
ZS Pharma, Inc.
Novartis Pharma AG
G51
Pfizer Georgian Society of Cardiology

ResMed German Cardiac Society
Sanofi Regeneron Hellenic Cardiological Society
SERVIER Hungarian Society of Cardiology
Shire Interamerican Society of Cardiology
Siemens Healthcare GmbH International Society of Cardiovascular
Singulex Pharmacotherapy
Takeda Pharmaceuticals International GmbH Irish Cardiac Society
ZS Pharma, Inc. Israel Heart Society
Italian Federation of Cardiology
Exhibitors in ESC Plaza
Japanese Circulation Society
(as of 17/06/2015)
Kosovo Society of Cardiology
For further information, consult the pages
Lebanese Society of Cardiolgy
“European Society of Cardiology - Your
Community” of this Programme and the Libyan Cardiac Society
Mobile App Lithuanian Society of Cardiology
AEPC Luxembourg Society of Cardiology
Albanian Society of Cardiology Macedonian FYR Society of Cardiology
Algerian Society of Cardiology Maltese Cardiac Society
American College of Cardiology Mexican Society of Cardiology
American Heart Association Moroccan Society of Cardiology
American Society of Echocardiography Netherlands Society of Cardiology
Armenian Cardiologists Association PCR
Arrhythmia Alliance Polish Cardiac Society
Asian Pacific Society of Cardiology Congress Portuguese Society of Cardiology
Association of Cardiologists of Bosnia and Romanian Society of Cardiology
Herzegovina Russian Society of Cardiology
Association of Cardiologists of Kazakhstan San Marino Society of Cardiology
Austrian Society of Cardiology Saudi Heart Association
Azerbaijan Society of Cardiology Slovak Society of Cardiology
Belgian Society of Cardiology Slovenian Society of Cardiology
Belorussian Scientific Society of Cardiologists South African Heart Association
Brazilian Society of Cardiology Spanish Society of Cardiology
British Cardiovascular Society Swiss Society of Cardiology
Bulgarian Society of Cardiology The Great Wall International Congress of
Cardio Alex Cardiology (GW-ICC)
Cardiological Society of India Tunisian Society of Cardiology and Cardio-
Vascular Surgery
Cardiology Society of Serbia
Turkish Society of Cardiology
Cardiostim
UEMS Cardiology Section
Cardiovascular Society of India
Ukrainian Association of Cardiology
Chinese Society of Cardiology
World Heart Federation
Croatian Cardiac Society
Cyprus Society of Cardiology
Czech Society of Cardiology
Egyptian Society of Cardiology
European Association for the Study of Diabetes
European Heart for Children
French Society of Cardiology
ESC CONGRESS
IN REVIEW
Official peer-reviewed highlights
from ESC Congress
Check your mailing address

Check
C addres
in yyour
our “My ESC” account to
receive
receivive the 2015 edition
Learn mo
Le more on stand B802 or
on
o n EESC
S Sta
SC tand (ESC Plaza)
Stand
Read the official

ESC Congress
2014 highlights on
www.escardio.org/365
Help protect your patients with
non-valvular atrial fibrillation (NVAF)
against stroke / systemic embolism
SUPERIORITY SUPERIORITY
demonstrated on demonstrated on
STROKE OR MAJOR
SYSTEMIC BLEEDING
EMBOLISM vs. warfarin1†
vs. warfarin1*
ONLY ELIQUIS®
CONNECTS BOTH
Choose ELIQUIS®, the only factor Xa inhibitor
that demonstrated superior risk reduction in
stroke or systemic embolism with significantly
less major bleeding vs. warfarin.1
ELIQUIS ® (apixaban): An oral, direct factor Xa inhibitor indicated for prevention of stroke
and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF),
with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA);
age ≥75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥II).2
* 21% RRR; 0.33% ARR; p=0.01.

† 31% RRR; 0.96% ARR; p<0.001.
Prescribing information can be found overleaf

ELIQUIS® (apixaban) 2.5 mg & 5 mg Film-coated Tablets Prescribing Information
Consult summary of product characteristics (SmPC) prior to Carefully observe for signs of bleeding. Use with caution in conditions Interaction with Inducers of CYP3A4 and P-gp: No dose adjustment
prescribing and for full list of adverse events. PRESENTATION: Film- with increased risk of haemorrhage. Discontinue administration if for Eliquis is required during concomitant therapy with such agents,
coated tablets; 2.5mg and 5mg apixaban. INDICATION: Prevention of severe haemorrhage occurs. Interaction with other medicinal however in patients receiving concomitant systemic treatment with
stroke and systemic embolism in adult patients with non-valvular products affecting haemostasis: Concomitant treatment with any strong inducers of both CYP3A4 and P-gp Eliquis should be used with
atrial fibrillation (NVAF) with one or more risk factors, such as prior other anticoagulant is contraindicated (see contraindications). The caution for the prevention of VTE in elective hip or knee replacement
stroke or transient ischaemic attack (TIA), age ≥ 75 years, concomitant use of Eliquis with antiplatelet agents increases the risk surgery, for the prevention of stroke and systemic embolism in
hypertension, diabetes mellitus or symptomatic heart failure (NYHA of bleeding. Care is to be taken if patients are treated concomitantly patients with NVAF and for the prevention of recurrent DVT and PE.
Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary with non-steroidal anti-inflammatory drugs (NSAIDs), including Eliquis should not be used for the treatment of DVT and PE in
embolism (PE), and prevention of recurrent DVT and PE in adults (see acetylsalicylic acid. Following surgery, other platelet aggregation patients receiving concomitant systemic treatment with strong
Special warnings and precautions for information on inhibitors are not recommended concomitantly with Eliquis. In inducers of both CYP3A4 and P-gp since efficacy may be
haemodynamically unstable PE patients). Prevention of venous patients with atrial fibrillation and conditions that warrant mono or compromised. Hip fracture surgery (2.5mg only): Eliquis has not been
thromboembolic events (VTE) in adult patients who have undergone dual antiplatelet therapy, a careful assessment of the potential studied in clinical trials in patients undergoing hip fracture surgery to
elective hip or knee replacement surgery (2.5mg only). DOSAGE AND benefits against the potential risks should be made before combining evaluate efficacy and safety in these patients. Therefore, it is not
ADMINISTRATION: Oral. Prevention of stroke and systemic embolism this therapy with Eliquis. Use of thrombolytic agents for the recommended in these patients. Laboratory parameters: Clotting
in patients with NVAF: The recommended dose is 5mg taken twice a treatment of acute ischemic stroke: there is very limited experience tests (PT, INR, and aPTT) are affected as expected by the mechanism
day with water, with or without food. Patients who meet at least two with the use of thrombolytic agents for the treatment of acute of action of apixaban. Changes observed in these clotting tests at the
of the following criteria: serum creatinine ≥ 1.5 mg/dL ischemic stroke in patients administered Eliquis. Patients with expected therapeutic dose are small and subject to a high degree of
(133 micromole/l), age ≥ 80 years, or body weight ≤ 60 kg should prosthetic heart valves: safety and efficacy of Eliquis have not been variability (see SmPC). Information about excipients: Eliquis contains
receive the lower dose of Eliquis, 2.5 mg twice daily. All patients with studied in patients with prosthetic heart valves, with or without atrial lactose. Patients with galactose intolerance, the Lapp lactase
severe renal impairment (creatinine clearance 15-29 ml/min) should fibrillation. Therefore, the use of Eliquis is not recommended in this deficiency or glucose-galactose malabsorption should not take
receive the lower dose of Eliquis 2.5 mg twice daily. Therapy should setting. Surgery and invasive procedures: Eliquis should be Eliquis. DRUG INTERACTIONS: Agents associated with serious
be continued long term. Treatment of DVT, treatment of PE and discontinued at least 48 hours prior to elective surgery or invasive bleeding are not recommended concomitantly with Eliquis, such as:
prevention of recurrent DVT and PE (VTEt): The recommended dose procedures with a moderate or high risk of bleeding. This includes thrombolytic agents, GPIIb/IIIa receptor antagonists, thienopyridines
for the treatment of acute DVT and treatment of PE is 10 mg taken interventions for which the probability of clinically significant (e.g. clopidogrel), dipyridamole, dextran and sulfinpyrazone. Due to
orally twice daily for the first 7 days followed by 5 mg taken orally bleeding cannot be excluded or for which the risk of bleeding would an increased bleeding risk, concomitant treatment with any other
twice daily. As per available medical guidelines, short duration of be unacceptable. Eliquis should be discontinued at least 24 hours anticoagulants is contraindicated. Administration of activated
treatment (at least 3 months) should be based on transient risk prior to elective surgery or invasive procedures with a low risk of charcoal reduces Eliquis exposure. Also see contraindications and
factors (e.g. recent surgery, trauma, immobilisation). The bleeding. This includes interventions for which any bleeding that special warnings and precautions section; Consult SmPC
recommended dose for the prevention of recurrent DVT and PE is occurs is expected to be minimal, non-critical in its location or easily (contraindications, special warnings and precautions and drug
2.5 mg taken orally twice daily. When prevention of recurrent DVT controlled. If surgery or invasive procedures cannot be delayed, interactions) for full details on interactions. PREGNANCY AND
and PE is indicated, the 2.5 mg twice daily dose should be initiated appropriate caution should be exercised, taking into consideration an LACTATION: Pregnancy: Not recommended during pregnancy.
following completion of 6 months of treatment with Eliquis 5 mg increased risk of bleeding. This risk of bleeding should be weighed Breastfeeding: Discontinue breastfeeding or discontinue Eliquis
twice daily or with another anticoagulant. The duration of overall against the urgency of intervention. Eliquis should be restarted after therapy. UNDESIRABLE EFFECTS: Increased risk of occult or overt
therapy should be individualised after careful assessment of the the invasive procedure or surgical intervention as soon as possible bleeding from any tissue or organ, which may result in
treatment benefit against the risk for bleeding. Prevention of VTE provided the clinical situation allows and adequate haemostasis has posthaemorrhagic anaemia. The signs, symptoms, and severity will
(VTEp): elective hip or knee replacement surgery: The recommended been established (see SmPC). Temporary discontinuation: vary according to the location and degree or extent of the bleeding.
dose is 2.5mg taken twice a day with water, with or without food. The Discontinuing anticoagulants, including Eliquis, for active bleeding, Prevention of VTE in adult patients who have undergone elective hip
initial dose should be taken 12 to 24 hours after surgery. Physicians elective surgery, or invasive procedures places patients at an or knee replacement surgery (VTEp): Common (≥ 1/100 to < 1/10):
may consider the potential benefits of earlier anticoagulation for VTE increased risk of thrombosis. Lapses in therapy should be avoided and anaemia, haemorrhage, haematoma, nausea, contusion, Uncommon
prophylaxis as well as the risks of post-surgical bleeding in deciding if anticoagulation with Eliquis must be temporarily discontinued for (≥1/1,000 to < 1/100): gastrointestinal haemorrhage,
on the time of administration within this time window. In patients any reason, therapy should be restarted as soon as possible. Spinal/ haematochezia, post procedural haemorrhage Rare (≥1/10,000 to
undergoing hip replacement surgery, the recommended duration of epidural anaesthesia or puncture: When neuraxial anaesthesia < 1/1,000): hypersensitivity, allergic oedema and anaphylaxis.
treatment is 32 to 38 days. In patients undergoing knee replacement (spinal/epidural anaesthesia) or spinal/epidural puncture is Prevention of stroke and systemic embolism in adult patients with
surgery, the recommended duration of treatment is 10 to 14 days. employed, patients treated with antithrombotic agents for NVAF, with one or more risk factors (NVAF): Common (≥ 1/100 to
Missed Dose for All Indications: If a dose is missed, Eliquis should be prevention of thromboembolic complications are at risk of < 1/10): eye haemorrhage (including conjunctival haemorrhage),
taken immediately and then continue with twice daily dose as before. developing an epidural or spinal haematoma which can result in haemorrhage, haematoma, epistaxis, gastrointestinal haemorrhage,
Switching: switching treatment from parenteral anticoagulants to long-term or permanent paralysis. The risk of these events may be rectal haemorrhage, gingival bleeding, haematuria, contusion,
Eliquis (and vice versa) can be done at the next scheduled dose. increased by the post-operative use of indwelling epidural catheters Uncommon (≥1/1,000 to < 1/100): hypersensitivity, allergic oedema,
These agents should not be administered simultaneously. Switching or the concomitant use of medicinal products affecting haemostasis. anaphylaxis, brain haemorrhage, intra-abdominal haemorrhage,
treatment from VKA therapy to Eliquis: discontinue warfarin or other Indwelling epidural or intrathecal catheters must be removed at least haematochezia, abnormal vaginal haemorrhage, urogenital
VKA therapy and start Eliquis when the international normalized ratio 5 hours prior to the first dose of Eliquis. The risk may also be haemorrhage, traumatic haemorrhage, post procedural haemorrhage,
(INR) is < 2.0. Switching treatment from Eliquis to VKA therapy: increased by traumatic or repeated epidural or spinal puncture. incision site haemorrhage, Rare (≥1/10,000 to < 1/1,000): respiratory
continue administration of Eliquis for at least 2 days after beginning Patients are to be frequently monitored for signs and symptoms of tract haemorrhage. Treatment of DVT and PE, and prevention of
VKA therapy. After 2 days of co-administration of Eliquis with VKA neurological impairment (e.g., numbness or weakness of the legs, recurrent DVT and PE (VTEt): Common (≥ 1/100 to
therapy, obtain an INR prior to next scheduled dose of Eliquis. bowel or bladder dysfunction). If neurological compromise is noted, < 1/10): haemorrhage, haematoma, epistaxis, gastrointestinal
Continue co-administration of Eliquis and VKA therapy until the INR urgent diagnosis and treatment is necessary. Prior to neuraxial haemorrhage, rectal haemorrhage, gingival bleeding, haematuria,
is ≥2.0. Renal impairment: Not recommended in patients with intervention the physician should consider the potential benefit contusion, Uncommon (≥1/1,000 to < 1/100): haematochezia,
creatinine clearance < 15mL/min or in patients undergoing dialysis. versus the risk in anticoagulated patients or in patients to be abnormal vaginal haemorrhage, urogenital haemorrhage, traumatic
No dose adjustment in mild or moderate renal impairment. In severe anticoagulated for thromboprophylaxis. There is no clinical haemorrhage, post procedural haemorrhage, incision site
renal impairment (creatinine clearance 15- 29 mL/min) there may be experience with the use of Eliquis with indwelling intrathecal or haemorrhage Rare (≥1/10,000 to < 1/1,000): brain haemorrhage,
an increased risk of bleeding, the following recommendations apply: epidural catheters. In case there is such need and based on the respiratory tract haemorrhage Please refer to the SmPC for further
for the prevention of VTE in elective hip or knee replacement surgery general PK characteristics of Eliquis, a time interval of 20-30 hours details of adverse reactions including other types of haemorrhage.
(VTEp), for the treatment of DVT, treatment of PE and prevention of (i.e. 2 x half-life) between the last dose of Eliquis and catheter LEGAL CATEGORY: POM. PACKAGE QUANTITIES AND BASIC NHS
recurrent DVT and PE (VTEt), Eliquis is to be used with caution. For withdrawal should elapse, and at least one dose should be omitted PRICE: Carton of 10 film-coated tablets 2.5mg £10.98, 20 film-
the prevention of stroke and systemic embolism in patients with before catheter withdrawal. The next dose of Eliquis may be given at coated tablets 2.5mg £21.96, 60 film-coated tablets 2.5mg £65.90,
NVAF, patients should receive the lower dose of Eliquis 2.5 mg twice least 5 hours after catheter removal. As with all new anticoagulant 56 film-coated tablets 5mg £61.50, 28 film-coated tablets 5mg
daily. Patients with serum creatinine ≥ 1.5 mg/dL (133 micromole/L) drugs, experience with neuraxial blockade is limited and extreme £30.75. MARKETING AUTHORISATION NUMBERS:
associated with age ≥ 80 years or body weight ≤ 60 kg should also caution is therefore recommended when using Eliquis in the EU/1/11/691/001-3, EU/1/11/691/008, EU/1/11/691/014
receive the lower dose of Eliquis, 2.5 mg twice daily. In patients with presence of neuraxial blockade. Haemodynamically unstable PE MARKETING AUTHORISATION HOLDER: Bristol-Myers Squibb/Pfizer
creatinine clearance < 15 mL/min, or in patients undergoing dialysis, patients or patients who require thrombolysis or pulmonary EEIG, BMS House, Uxbridge Business Park, Sanderson Road, Uxbridge,
there is no clinical experience therefore Eliquis is not recommended. embolectomy: Eliquis is not recommended as an alternative to Middlesex, UB8 1DH. Telephone: 0800-731-1736. DATE OF PI
Hepatic impairment: Eliquis is contraindicated in patients with unfractionated heparin in patients with pulmonary embolism who PREPARATION: July 2014. 432UK14PR05940-01 ELQ578
hepatic disease associated with coagulopathy and clinically relevant are haemodynamically unstable or may receive thrombolysis or
bleeding risk. It is not recommended in patients with severe hepatic pulmonary embolectomy since the safety and efficacy of Eliquis have
impairment. It should be used with caution in patients with mild or not been established. Patients with active cancer: efficacy and safety Adverse events should be reported.
moderate hepatic impairment (Child Pugh A or B). No dose of Eliquis in the treatment of DVT, treatment of PE and prevention of
adjustment is required in patients with mild or moderate hepatic recurrent DVT and PE (VTEt) in patients with active cancer have not Reporting forms and information can be found
impairment. Eliquis should be used with caution in patients with been established. Renal impairment: see dosage and administration at www.mhra.gov.uk/yellowcard. Adverse events
elevated liver enzymes (ALT/AST >2 x ULN) or total bilirubin ≥1.5 x section. Elderly patients: increasing age may increase haemorrhagic should also be reported to Bristol-Myers Squibb
ULN. Prior to initiating Eliquis, liver function testing should be risk. Also, the co-administration of Eliquis with ASA in elderly patients
performed. Eliquis is not recommended in children and adolescents should be used cautiously because of a potentially higher bleeding Pharmaceuticals Ltd Medical Information on
below the age of 18. CONTRAINDICATIONS: Hypersensitivity to the risk. Body weight: low body weight (< 60 kg) may increase 0800 731 1736 or medical.information@bms.com
active substance or to any of the excipients listed in SmPC, active haemorrhagic risk. Hepatic impairment: see dosage and
clinically significant bleeding, hepatic disease associated with administration section. Interaction with Inhibitors of CYP3A4 and
coagulopathy and clinically relevant bleeding risk, lesion or condition P-gp: the use of Eliquis is not recommended in patients receiving ARR = Absolute Risk Reduction RRR = Relative Risk Reduction
if considered a significant risk factor for major bleeding (refer to concomitant systemic treatment with strong inhibitors of both References: 1. Granger CB et al. N Engl J Med 2011; 365: 981–992.
SmPC). Concomitant treatment with any other anticoagulant agent CYP3A4 and P-gp, such as azole-antimycotics (e.g., ketoconazole, 2. ELIQUIS ® (apixaban) Summary of Product Characteristics.
except under specific circumstances of switching anticoagulant itraconazole, voriconazole and posaconazole) and HIV protease 30th July 2014. Available at http://www.medicines.org.uk.
therapy or when unfractionated heparin is given at doses necessary inhibitors (e.g., ritonavir). These medicinal products may increase Last accessed 1st June 2015.
to maintain an open central venous or arterial catheter (refer to Eliquis exposure by 2-fold or greater in the presence of additional Date of preparation: June 2015 Job code: ELQ826
SmPC). SPECIAL WARNINGS AND PRECAUTIONS: Haemorrhage risk: factors that increase Eliquis exposure (e.g. severe renal impairment). www.eliquis.co.uk
SCIENTIFIC
PROGRAMME
G54 CONGRESS SPOTLIGHT:
“ENVIRONMENT AND THE HEART”
The Spotlight of the ESC Congress 2015 is “Environment and the Heart”.
It highlights the many different kinds of interactions between the Environment
and Cardiovascular Diseases.
Sessions related to the Spotlight of the Congress are highlighted with the
following icon in the programme.
CONGRESS HIGHLIGHTS
ire
The ent An overview by experts of all the new and exciting developments in
s
congres or clinical science presented at the Congress.
ise fd
summar t one All important take-home messages for you in under 2 hours.
s
you in ju !
ses s io n
10:30 - 12:30
London (Main Auditorium)
Chairpersons
G A Derumeaux (Paris, FR)
S G Priori (Pavia, IT)
10:30 ESC Congress 2015 Awards GA Derumeaux (Creteil, FR)

10:42 Arrhythmias C Linde (Stockholm, SE)
10:54 Heart failure and cardiomyopathies F Ruschitzka (Zurich, CH)
11:06 Acute coronary syndromes and acute cardiac care K Huber (Vienna, AT)
11:18 Interventional cardiology M Roffi (Geneva, CH)
11:30 Hypertension B Williams (London, UK)
11:42 Valvular heart disease and pulmonary circulation R Rosenhek (Vienna, AT)
11:54 Imaging V Delgado (Leiden, NL)
12:06 Preventive cardiology S Sharma (London, UK)
12:18 Best of ESC Congress Presentation
Sb BASIC
NEW!
SCIENCE HIGHLIGHTS G55
08:30 - 10:00
Hyde Park (The Hub)
Chairpersons
L Badimon (Barcelona, ES)
G A Derumeaux (Creteil, FR)
08:30 Development and cell - based new therapies:

stem cells and genes A Bayes Genis (Badalona, ES)
08:45 Integrative cardiovascular pathophysiology C De Wit (Luebeck, DE)
09:00 Cardiac function J L Balligand (Brussels, BE)
09:15 Ischaemic heart disease K Preissner (Giessen, DE)
09:30 Atherosclerosis and remodeling J Tunon Fernandez (Madrid, ES)
09:45 Inflammation and immunomodulation A C Newby (Bristol, UK)
ESC CLINICAL PRACTICE

GUIDELINES 2015 - HIGHLIGHT
NEW!
09:00 - 10:00
London (Main Auditorium)
Chairpersons
J L Zamorano Gomez (Madrid, ES)
A Vaz Carneiro (Lisboa, PT)
09:00 Pericardial Diseases S Achenbach (Erlangen, DE)

09:12 Ventricular Arrhythmias & Sudden Cardiac Death GYH Lip (Birmingham, UK)
09:24 ESC/ERS Pulmonary Hypertension V Aboyans (Limoges, FR)
09:36 Infective Endocarditis P Nihoyannopoulos (London, UK)
09:48 Acute Coronary Syndromes NSTE O Gaemperli (Zurich, CH)
My NCS@ESC In The Hub
Highlights the contribution of National Cardiac Societies to ESC Congress.
Seven societies have each designed their «My NCS@ESC» track.
A series of Guidelines in daily practice sessions based on 2013/2014
ESC Clinical Practice Guidelines and the new 2015 Guidelines.
GERMANY
Saturday 29 August, 13:30-15:00, Holland Park:
Atrial fibrillation *
Sunday 30 August, 16:30-18:00, Holland Park: SERBIA
Acute coronary syndromes NSTEMI
Saturday 29 August, 11:00-12:30, Holland Park:
Heart failure *
ISRAEL Tuesday 1 September, 11:00-12:30, Holland Park:
Saturday 29 August, 13:30-15:00, Green Park: Acute coronary syndromes NSTEMI
High-risk patients with aortic stenosis *
Monday 31 August, 11:00-12:30, Holland Park: TURKEY
Ventricular arrhythmias and sudden cardiac death
Saturday 29 August, 13:30-15:00, Regents Park:
Diabetes *
NORWAY Monday 31 August, 16:30-18:00, Holland Park:
Pulmonary hypertension
Saturday 29 August, 11:00-12:30, Regents Park:
Acute coronary syndrome *
Monday 31 August, 11:00-12:30,Victoria Park:
Sudden cardiac death UNITED KINGDOM
Saturday 29 August, 11:00-12:30, St James Park:
Hypertrophic cardiomyopathy *
RUSSIAN FEDERATION
Tuesday 1 September, 11:00-12:30,Victoria Park:
Saturday 29 August, 13:30-15:00, St James Park: Infective endocarditis
Aortic disease *
Monday 31 August, 14:00-15:30, Holland Park:
Ventricular arrhythmias
* Saturday sessions:
Implementation of multimodality imaging in
the current ESC Guidelines
SATURDAY SPECIAL TRACKS G57
A full day programme, designed to update healthcare professionals, will take place on Saturday 29 August.
The dedicated programmes cover the most relevant issues these professionals have to face on a
daily basis. A reduced fee for general practitioners, nurses and other allied professionals for these
tracks is available. It gives access to the below sessions, the saturday poster session, the inaugural
session and networking reception.
GENERAL CARDIOLOGY FOR PHYSICIANS, TECHNICIANS AND GENERAL PRACTITIONERS
A programme designed specifically for primary care physicians, general practitioners as well as general
cardiologists to further their knowledge and enhance practice.
The sessions address daily practice issues and offer a forum for discussions and exchange between
professionals and international experts.
Saturday 29 August in Hyde Park (The Hub) page

09:00 - 10:30 From start to finish of coronary artery disease 20
11:00 - 12:30 Atrial fibrillation - Update for the general practitioners 21
13:30 - 15:00 Primary care dilemmas 34
GENERAL CARDIOLOGY FOR NURSES AND ALLIED PROFESSIONALS
These programmes are organised in conjunction with the ESC Council for Cardiology Practice, the
ESC Council on Cardiovascular Primary Care & the ESC Council on Cardiovascular Nursing and Allied
Professions, in collaboration with British partner groups and associations.
The participants will be able to discuss and debate the latest developments and future prospects and how
nurse-led services contribute to improved evidence-based practice and outcomes, and effective strategies for
guideline implementation.
Saturday 29 August in Victoria Park (The Hub) page

09:00 - 10:30 Crossing boundaries - Nurse-led services across healthcare sectors 20
11:00 - 12:30 Cutting edge developments in cardiovascular interventions 22
13:30 - 15:00 Cardiovascular prevention at every level 35
Also, not to be missed on Saturday

Come and take part in a live training session on guidelines implementation challenges
presented in a dynamic interactive format.
12:35 - 13:25 Guidance on the ESC Guidelines in nursing practice 33
Other nursing sessions

Other sessions can be found under the track Nursing and Allied Professionals.
CARDIOPULMONARY RESUSCITATION (CPR WORKSHOPS)

Resuscitate your life saving skills! Come and learn about the latest CPR guidelines from ERC and meet
qualified instructors on Stand A900.
More information on page G46
G58 BASIC SCIENCE Sb
THE CORE BASIC SCIENCE PROGRAMME IS HELD IN VILLAGE 1
A few sessions not to be missed:

09:20 - 10:00 ESC William Harvey Lecture on Basic Science Regents Park (The Hub) 74
12:40 - 13:50 Young Investigators Awards Session: Basic Science Stockholm (Village 1) 124
T 14:00 - 15:30 Basic and Translational Science Hot Line I Stockholm (Village 1) 136
Monday 31 August
T 11:00 - 12:30 Basic and Translational Science Hot Line II Stockholm (Village 1) 208
NEW! A JOURNEY TO STOCKHOLM

This programme is complemented with exceptional participation of Nobel Prize Laureate
Doctor E Blackburn who will do us the honor to take part in the “Journey to Stockholm”
programme including an exceptional Young Investigators Award Session on the topic of
Ageing and Senescence.

11:00 - 12:30 Ageing and cardiovascular disease:
role of cellular senescence Regents Park (The Hub) 89
12:40 - 13:50 Young Investigators Awards Session: Ageing and
Senescence Regents Park (The Hub) 123
Also on Sunday
18:30 - 20:00 The Council on Basic Cardiovascular Science invites all basic scientists and friends
to the Poster Reception held in the Poster Area.
This is the opportunity for young scientists to meet experienced researchers in a
convivial atmosphere.
Don’t miss this year’s Outstanding A chievement Awards, presented to two early
career basic scientists for their significant contribution to their field of expertise.
THE ESC COUNCILS YOUNG COMMUNITY
SCIENTISTS OF TOMORROW G59
The “Scientists of Tomorrow” is a group of young proactive basic and clinical researchers,
who work closely with the Council on Basic Cardiovascular Science to fulfil its mission in
promoting and supporting basic science among young ESC members.
Members of the “Scientists of Tomorrow” contribute to the scientific, educational and

advocacy activities of the ESC paving the way of its future.
Sessions include key tips on the first successful grant application, the first paper published and
importantly, opportunities to develop the next career step.
The sessions will be held in Regents Park (The Hub)
Monday 31 August page

07:30 - 08:15 New technology: genome editing for modelling and correcting human disease 190
11:00 - 12:30 Sodium versus calcium in cardiac remodelling 206
14:00 - 15:30 Mechanisms of action of emerging therapeutics 248
16:30 - 18:00 How ischaemia regulates angiogenesis: new concepts 262
Tuesday 1 September
07:30 - 08:15 How to isolate human cardiomyocytes 302
08:30 - 10:00 Embryonic programming of congenital and adult cardiovascular disease 303
16:30 - 18:00 Gut microbiota: new players in cardiovascular medicine 373
Come, listen and interact with the young researchers.
NEW! INTERNATIONAL YOUNG COMMUNITY SESSIONS

The Scientists of Tomorrow have prepared sessions in collaboration with the Young
Community from Japan and the United Kingdom.
British Society for Cardiovascular Research

Saturday 29 August page
09:00 - 10:30 Cross-talk between cardiovascular and non-cardiovascular cells
in disease pathogenesis 20
Japanese Young Community

Sunday 30 August
07:30 - 08:15 Prospects for cell therapy in cardiac diseases 72
A DAY WITH Sunday 30 August
THE LEGENDS Regent’s Park (The Hub)
NAMED LECTURES
08:30 ESC Andreas Grüntzig Lecture on Interventional Cardiology

Interventional cardiology, where real life and science not necessarily meet.
B Meier, FESC (Bern, CH)
09:20 ESC William Harvey Lecture on Basic Science
Microcircular networks:The business end of the circulation.
AR Pries, FESC (Berlin, DE)
16:30 ESC Rene Laennec Lecture on Clinical Cardiology
The interaction of acute blood pressure change, pericardial restraint and acute
outflow tract stretch - A new paradigm underlying sudden cardiac death.
GR Sutherland (London, UK)
17:20 ESC Geoffrey Rose Lecture on Population Sciences
Optimising cardiovascular health: old and new challenges.
K-T Khaw (Cambridge, UK)
A JOURNEY TO STOCKHOLM
Special session with the exceptional participation of Nobel Prize Laureate.

11:00 Ageing and cardiovascular disease: role of cellular senescence
E Blackburn (San Francisco, US)
MEET THE LEGENDS
Hear about their professional journey & scientific experiences.

What made them do it? What lessons have they learned?
And what may inspire you!
10:00 M Haissaguerre (Pessac, FR)
14:00 RL Popp (Palo Alto, US)
14:50 KAA Fox, FESC (Edinburgh, UK)
A unique opportunity for interaction & discussion

with true Legends in cardiology.
ESC CARDIOLOGISTS OF G61
TOMORROW
The ESC Cardiologists of Tomorrow programme is a partnership between the ESC and its National
and Affiliated Cardiac Societies. It consists of a dynamic specific educational track throughout the
Congress that provides young cardiologists with some of the most relevant and up to date information
on key areas in Cardiovascular Medicine.
The programme also includes six highly interactive and educational clinical case sessions with seven
young clinicians presenting their cases and experts who moderate the sessions and facilitate interaction
with the audience.
All sessions will be held in Green Park (The Hub)

11:00 - 12:30 What would you like to have Madam/Sir: catheter or device? - Clinical Cases 21
Sunday 30 August
07:30 - 08:15 How to wake up your professional skills 72
08:30 - 10:00 Nightmare at the cath lab - Clinical Cases 74
11:00 - 12:30 Seeing the invisible - ECG and cardiac imaging quizzes 89
14:00 - 15:30 ICU shift - How to keep calm and carry on! 133
16:30 - 18:00 Treatment of coronary artery disease: from recent clinical trials to practice 150
Monday 31 August
08:30 - 10:00 Looking at the crystal ball: what will change the future of cardiology? 192
11:00 - 12:30 Recent advances in cardiology: what does the busy cardiologist need to know about... 207
14:00 - 15:30 Discussing the most challenging clinical cases - Clinical Cases
The four best cases in competition for an ESC award. The winner will receive a €2000 prize
and the three finalists €1000. 248
16:30 - 18:00 Expect the unexpected in the acute patients - Clinical Cases 263
Tuesday 1 September
07:30 - 08:15 Crazy versus serious ideas: researching can be fun and surprising! 302
08:30 - 10:00 Trials and statistics are easy! A guide for the clinical cardiologist 303
11:00 - 12:30 Rare, unusual and unexpected rhythm disturbances - That is what we like - Clinical Cases 320
14:00 - 15:30 Nothing is as it seems in interventional cardiology - Clinical Cases 357
16:30 - 18:00 Touching the valves: hazardous game - Clinical Cases 373
Also not to be missed:

Monday 31 August
15:35 - 16:20 How to shape your future - Tips and tricks for finding a job Agora (Poster Area) 260
NEW! INTERNATIONAL YOUNG COMMUNITY SESSIONS

The Cardiologists of Tomorrow have prepared sessions in collaboration with the Young Community
from Brazil and the United Kingdom.
Brazilian Young Community page

Monday 31 August
07:30 - 08:15 Artificial intelligence: smartphone applications to improve clinical practice 190
British Junior Cardiologists’ Association

Sunday 30 August
07:30 - 08:15 How to wake up your professional skills 72
09:00 - 10:30 Voting for the most game changing innovation of the year - The winner takes it all! 20
G62 MOBILE APP INTERACTIVE
SESSIONS
Some sessions, including all Guidelines in Daily Practice & Meet the Experts sessions have
been designed to actively involve the audience in the scientific exchange.
These sessions are held in their topic related villages as they address specific aspects of each
specialty.
For the session schedule look for the following icon in the programme:
You can also look on the online Scientific Programme & Planner and the ESC 2015 Mobile App.
Search under the types & tracks: “Mobile App Interactive sessions”
Interaction features:
Send directly your session/topic related question to the Chairperson during
Ask a Question the session: selection of questions will be answered during the session.
Answer questions when prompted by the speaker: Speaker will show a question
Voting slide with a choice of up to five possible answers (each referenced by a letter).
These letters will appear on your screen.
To vote, simply click on your answer’s letter. The answers of the vote will be
displayed on real time on the screen and discussed.
These features are only available during the sessions.
Make sure you have downloaded the ESC 2015

Mobile App to interact and vote during the
session
Search for “ESC 2015” in the App Store / Google Play
or scan the following QR Code.
° Your device must be connected to the free WI-FI

provided during the congress:
Login: esc-congress Password: esc-congress
° Open the ESC 2015 Mobile App
° Access the session you are attending
° Click on Session Information & Interaction

Session Information & Interaction
° During the session click on “Ask a question” or “Voting”

EXPERTS SESSIONS G63
These sessions are designed to allow for interaction amongst the experts themselves and the
participating audience. Be ready to hear the experts and to get involved!
MEET THE EXPERTS SESSIONS
Sessions focusing on the practical management of cardiovascular diseases in daily situations.

Each session is based on clinical cases which will be discussed by a panel of experts.
Discussion will conclude with essential take - home messages for practitioners.
Mobile App interactive sessions – Make sure you have downloaded the App to actively
participate.
These sessions are held in their topic related village.
CASE-BASED SYMPOSIA
Practical & interactive sessions specific to particular topics or themes. These are based upon
the presentation of clinical cases and designed to allow for panel discussions and interaction
with the audience.
participate.
These sessions are held in their topic related village.
NEW! - SCIENCE@BREAKFAST SESSIONS

What a great way to start the day! Wake up your brain with breakfast and discussion.
A unique opportunity for intense interaction between a small audience and two experts
addressing a specific current issue.
These sessions take place between 07:30 and 08:15 in The Hub

How to wake up your professional skills Green Park 72
Early morning an acute coronary syndrome patient comes in! How to manage? Holland Park 72
Prospects for cell therapy in cardiac diseases Regents Park 72
Challenges in surface ECG interpretation St James Park 72
Epigenetics Victoria Park 72
Monday 31 August
Artificial intelligence: smartphone applications to improve clinical practice Green Park 190
Chronic thromboembolic pulmonary hypertension: surgical or interventional treatment? Holland Park 190
New technology; genome editing for modelling and correcting human disease Regents Park 190
Exercise for heart failure in the morning St James Park 190
The beauty of imaging heart mechanics Victoria Park 190
Tuesday 1 September
Crazy versus serious ideas: researching can be fun and surprising! Green Park 302
Strategies to prevent smoking in vulnerable groups: women and children Holland Park 302
How to isolate human cardiomyocytes Regents Park 302
Issues and practical solutions for chronic total occlusion St James Park 302
How to evaluate the heart in hypertension Victoria Park 302
G64 ESC CARDIOLOGY QUIZ
Actively looking for participation and interaction with the audience.

The delegations from three different teams in competition will be submitted to a series of
questions and tests about different topics in ESC Clinical Practice Guidelines. GiP
Tuesday 1 September
16:30 - 18:00
Hyde Park (The Hub)
Chairpersons
J L Zamorano Gomez (Madrid, ES)
J L Gutierrez-Chico (Munich, DE)
Supreme court
P De Jaegere (Rotterdam, NL)
F Crea (Rome, IT)
U Rauch (Berlin, DE)
Score keepers
M Jaguszewski (Berlin, DE)
L Engel (Berlin, DE)
C Schwemmler (Berlin, DE)
GREEK TEAM
(DEFENDING CHAMPION 2014) INTERNATIONAL
BRAZILIAN TEAM
TEAM Represented by AHE-
PA University Hospital Led by S Matskeplishvili
Led by M Moreira Thessaloniki
Led by C Karvounis
Come and support a team and join in the educational game.
participate.
The organisers acknowledge the valuable contribution of the collaborators from Charite University Hospital in Berlin who
voluntarily helped in the development of this unique programme.
EXPERTS SESSIONS G65
HEART TEAM
Sessions presenting the essential interactions between all professionals involved in the management
of the incoming patient.This is a unique opportunity to witness the cardiovascular team in action
and how all specialties come together.
The Heart Team sessions are held in Hyde Park (The Hub)

16:30 - 18:00 Heart team for severe cardiac insufficiency
Hospital Louis Pradel, Lyon - FR 149
Monday 31 August
11:00 - 12:30 Emergency angioplasty for acute myocardial infarction: a “fly-on-the-wall”
Recording of catheter lab personnel interaction
The Royal Wolverhampton NHS Trust - UK 205
Tuesday 1 September
08:30 - 10:00 Survivor of out-of-hospital cardiac arrest - Acute and long-term management
Institute for Clinical and Experimental Medicine, Prague - CZ 303
CARDIAC ANATOMY AND PATHOLOGY LIVE SESSIONS
Live-video and hands-on demonstration on heart specimens showing congenital and acquired
heart disease. These sessions are organised jointly by the Working Group on Developmental
Anatomy and Pathology and the Association for European Cardiovascular Pathology
(AECVP), coordinated by Professor A Angelini, FESC.
The sessions are held in room Warsaw (Village 8)

11:00 - 13:00 Pathologic substrates of sudden death in the young 96
Monday 31 August
11:00 - 13:00 Cardiac anatomy for interventional cardiologists 212
Tuesday 1 September
11:00 - 13:00 Adult congenital heart diseases 325
ESC Clinical Practice
Guidelines 2015
2015 Guidelines sessions
Room London (Main auditorium)
Sunday 30 August
08:30 – 10:00 ESC Guidelines 2015 overview
14:00 – 15:30 ESC Guidelines - Acute Coronary Syndromes Non-ST-Elevation
Monday 31 August
08:30 – 10:00 ESC Guidelines - Ventricular Arrhythmias & Sudden Cardiac Death
14:00 – 15:30 ESC/ERS Guidelines - Pulmonary Hypertension
Tuesday 1 September
08:30 – 10:00 ESC Guidelines - Infective Endocarditis
14:00 – 15:30 ESC Guidelines - Pericardial Diseases
Ask your questions to

the ESC Guidelines Task Forces
Join the Task Force for an informal session in Hyde Park (The Hub)
from 15:40 to 16:20
Sunday 30 August: Ventricular Arrhythmias & Sudden Cardiac Death
Pulmonary Hypertension
Monday 31 August: Acute Coronary Syndromes Non-ST-Elevation
Tuesday 1 September: Infective Endocarditis
Pericardial Diseases
More on Guidelines? New this year:

ESC Clinical
Don’t miss the “Guidelines in Daily Practice” Practice Guidelines
GiP sessions in each Village: 2015 Highlights
What do the ESC Clinical Practice Guidelines Wednesday
2 September
really mean and how to implement these. 09:00 - 10:00
Did you know that all recent Pocket Guidelines & their interactive tools
are now available to download on your mobile device.
Search for “ESC Pocket Guidelines” in the App store / Google Play /
Amazon.
GiP GUIDELINES
PRACTICE
IN DAILY G67
Sessions designed to focus on the topic of ESC Clinical Practice Guidelines and their
implementation in daily clinical practice - These sessions are part of the Guidelines into
Practice Track.
Join the experts in each specialty to confront the guidelines and actual clinical cases and
discuss the implementation mode.
Mobile App Interactive Session - Audience is invited to participate via the Mobile App,
for votes and questions to be asked to the panel. Make sure you have downloaded the App.

08:30 - 10:00 Imaging guided management in recent ESC Guidelines Damascus (Village 5) 79
11:00 - 12:30 Mitral and tricuspid disease: keeping up with the Guidelines Ljubljana (Village 8) 95
16:30 - 18:00 Heart failure Bucharest (Village 9) 156
Monday 31 August
08:30 - 10:00 Are clinical guidelines the standard of care in real practice? Kiev (Village 3) 195
14:00 - 15:30 Hypertrophic cardiomyopathy Ljubljana (Village 8) 254
16:30 - 18:00 Acute aortic diseases Oslo (Village 6) 268
Tuesday 1 September
08:30 - 10:00 NSTEMI guidelines: helpful in the real world? Lisbon (Village 7) 309
08:30 - 10:00 Management of a patient with unexplained syncope and
of a patient with ventricular arrhythmias Madrid (Village 4) 307
14:00 - 15:30 Stroke and risk in atrial fibrillation: what do the Guidelines say? Moscow (Village 2) 360
14:00 - 15:30 2015 ESC Guidelines on NSTE-ACS: implementation in daily practice Oslo (Village 6) 362
NEW! - MY NCS@ESC SESSIONS

These sessions are held in The Hub from Saturday to Tuesday (see page G56)
This programme highlights the contribution of National Cardiac Societies to the
ESC Congress. Seven societies have each designed their “My NCS@ESC” track.
A series of Guidelines in Daily Practice GiP sessions based on 2013/2014 ESC Clinical
Practice Guidelines and the new 2015 Guidelines. In addition, a representative from each
society will take part in the ESC Cardiology Quiz to compose the international team.
These sessions are developed in collaboration with the ESC Clinical Practice Guidelines Task Force and ESC Education
department.
Mobile App Interactive Session - Audience is invited to participate via the Mobile App,
for votes and questions to be asked to the panel. Make sure you have downloaded the App.
Your chance to interact directly
MEET THE with the presenters of some of
TRIALISTS the best late-breaking trials!
ALBATROSS - Early aldosterone blockade in acute myocardial infarction: the

randomized trial.
Sunday 30 August
15:40-16:20 St James Park (The Hub)
LEADLESS - Safety and Efficacy of a Leadless Pacemaker.

Monday 31 August
10:10-10:50 Hyde Park (The Hub)
TECOS - Trial Evaluating Cardiovascular Outcomes with Sitagliptin in pa-

tients with type-2 Diabetes.
Monday 31 August
PATHWAY 2 - The principal results of the Prevention And Treatment of

Hypertension With Algorithm based therapY (PATHWAY) - Optimal treatment
of drug resistant hypertension.
Tuesday 1 September
10:10-10:50 Hyde Park (The Hub)
OPTILINK HF - Effect of implanted device-based impedance monitoring

with telemedicine alerts on mortality and morbidity in heart failure.
Tuesday 1 September
15:40-16:20 Regents Park (The Hub)
PLATFORM - Outcomes of an FFRCT diagnostic strategy versus usual care

in suspected coronary artery disease: results from the PLATFORM (Prospective
LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts) study.
Tuesday 1 September
HOT LINE SESSIONS G69
ESC Congress is the place to discuss the findings of the latest clinical trial results, clinical trial
updates and registries.
HOT LINES
These sessions take place in room London (Main Auditorium)

Every presentation is followed by an experts intervention to highlight the relevance of the
data presented, to provide clear take home messages and to place the recent trials into
perspective.

11:00 - 12:30 Acute myocardial infarction 88
16:30 - 18:00 Atrial fibrillation/pacing 148
Monday 31 August
11:00 - 12:30 Diabetes mellitus/pharmacology 205
16:30 - 18:00 Hypertension 261
Tuesday 1 September
11:00 - 12:30 Heart failure 318
16:30 - 18:00 Coronary artery disease 371
CLINICAL TRIAL UPDATE HOT LINES
These sessions take place in room Hyde Park (The Hub)

Sunday 30 August
14:00 - 15:30 Cardiovascular diseases: prevention, outcomes, quality 132
Monday 31 August
14:00 - 15:30 Antiplatelet therapy 247
Tuesday 1 September
14:00 - 15:30 Pharmacology & therapy 356
REGISTRY HOT LINES
Sunday 30 August
08:30 - 10:00 Atrial fibrillation Hyde Park (The Hub) 73
Tuesday 1 September
08:30 - 10:00 Interventions/acute cardiovascular care St James Park (The Hub) 303
11:00 - 12:30 Prevention Hyde Park (The Hub) 318
BASIC AND TRANSLATIONAL HOT LINES
These sessions take place in room Stockholm (Village 1)

Sunday 30 August
14:00 - 15:30 Inflammation and vascular disease 136
Monday 31 August
11:00 - 12:30 Ischaemia and cardiac function 208
EXTEND YOUR ESC CONGRESS
EXPERIENCE ON
Thursday 3 September 20:00 (CET)
ESC Congress 2015 provides you with

the latest updates in cardiovascular science
Watch the Best of ESC on ESC TV to see how
recent developments will affect your daily
practice
Moderated by
Geneviève A Derumeaux, FESC (FR)
Keith A A Fox, FESC (UK)
International Experts
V Delgado (NL) Imaging
C Linde, FESC (SE) Arrhythmias - Genetics and Basic Science
JJV McMurray, FESC (UK) Heart Failure
M Roffi, FESC (CH) Interventions - Valve Disease
S Sharma, FESC (UK) Cardiovascular Prevention
J Stepinska, FESC (PL) Acute Cardiac Care - Acute Coronary Artery Disease - Thrombosis
B Williams, FESC (UK) Hypertension
SAVE THE DATE NOW

TO WATCH THE 1 HOUR ONLINE EVENT
www.escardio.org/bestofesc2015
This programme is supported by AstraZeneca and SERVIER

This programme is accredited by the European Board for Accreditation

in Cardiology (EBAC) and by the European Accreditation
Council in CME (EACCME).
JOINT SESSIONS G71
These sessions, organised together with major cardiovascular and other specialty organisations from
around the world, give us the opportunity to share views and perspectives on common or related
issues.
The ESC takes this opportunity to thank all its partners for the fruitful collaboration.
This partnership broadens scientific knowledge thanks to the participation of professionals from
different specialised disciplines.
JOINT SESSIONS WITH AFFILIATED CARDIAC SOCIETIES & SISTER SOCIETIES

Strengthen relations between cardiologists and widen the scope of scientific exchange.
American College of Cardiology (ACC) page

Sunday 30 August
14:00 - 15:30 Cardiovascular diseases: it is not my fault... I have bad genes! Bratislava (Village 2) 250
Monday 31 August
08:30 - 10:00 The heart valve team: managing together Belgrade (Village 8) 309
American Heart Association (AHA)

Sunday 30 August
11:00 - 12:30 Optimising outcomes of coronary surgery, what the
cardiologist should know Chisinau (Village 6) 210
Monday 31 August
11:00 - 12:30 Challenges in the treatment of mitral disease Belgrade (Village 8) 363
Argentine Society of Cardiology (ASC)

Monday 31 August
11:00 - 12:30 Arrhythmias and emotional disorders
Electrophysiology meets psychiatry Madrid (Village 4) 209
Asian Pacific Society of Cardiology (APSC)

Saturday 29 August
13:30 - 15:00 Environmental effects on patients with pacemaker and ICD Algiers (Village 4) 37
Brazilian Society of Cardiology (BSC)

Sunday 30 August
11:00 - 12:30 Cardiac imaging and multimodality approach in
different clinical scenarios St James Park (The Hub) 89
Focus
on Monday 31 August
Brazil 08:30 - 10:00 Cardiovascular imaging in heart failure:
a global perspective The Hague (Village 5) 196
Additional joint sessions with the Young Communities (page G61)
Canadian Cardiovascular Society (CCS)

Sunday 30 August
11:00 - 12:30 Biomarkers for heart failure: state of the art Bern (Village 9) 96
Cardiological Society of India (CSI)

Saturday 29 August
13:30 - 15:00 Economic environment in cardiovascular outcome Bratislava (Village 2) 35
Chinese Society of Cardiology (CSC)

Sunday 30 August
08:30 - 10:00 STEMI treatment improvement in reperfusion and network
system in China Tunis (Village 7) 81
G72 Great Wall - International Congress of Cardiology (GW - ICC) page
Monday 31 August
11:00 - 12:30 Environment, hypertension and cardiovascular risk Tirana (Village 3) 209
InterAmerican Society of Cardiology (IASC)

Monday 31 August
08:30 - 10:00 Cardio - oncology Bern (Village 9) 198
InterAmerican Society of Cardiology (IASC)/Spanish Society

of Cardiology (SEC)
Sunday 30 August
14:00 - 15:30 Tropical cardiology Warsaw (Village 8) 141
Japanese Circulation Society (JCS)

Sunday 30 August
14:00 - 15:30 Impact of optical coherence tomography and
computed tomographic angiography on the
Focus management of acute coronary syndrome Chisinau (Village 6) 139
on Monday 31 August
Japan 14:00 - 15:30 Coronary spasm revisited: a message from
Europe (West) and Japan (East) Ankara (Village 7) 253
Additional joint sessions with the Young Communities (page G59)
Korean Society of Cardiology (KSC)

Sunday 30 August
14:00 - 15:30 Obesity and heart disease Bratislava (Village 2) 136
Mexican Society of Cardiology (MSC)

Sunday 30 August
14:00 - 15:30 Ischaemia and reperfusion Lisbon (Village 7) 140
Saudi Heart Association (SHA)

Sunday 30 August
08:30 - 10:00 Life - threatening ventricular arrhythmias:
where do we stand in 2015? Algiers (Village 4) 78
South African Heart Association (SAHeart)

Monday 31 August
13:30 - 15:00 HIV - related myocardial and pericardial diseases Belgrade (Village 8) 39
JOINT SESSIONS WITH OTHER MEDICAL ORGANISATIONS
Association for European Cardiovascular Pathology (AECVP)

Monday 31 August
11:00 - 12:30 Update on cardiovascular tumours Belgrade (Village 8) 212
Association for European Paediatric Cardiology (AEPC)

Sunday 30 August
08:30 - 10:00 Dilation of the aorta Warsaw (Village 8) 82
European Association for Cardio - Thoracic Surgery (EACTS)

Sunday 30 August
08:30 - 10:00 From pure revascularisation to concomitant mitral valve repair:
controversies and challenges Chisinau (Village 6) 80
European Association for the Study of Diabetes (EASD)

Tuesday 1 September
16:30 - 18:00 Mechanisms of thrombosis Stockholm (Village 1) 374
European Atheroclerosis Society (EAS) page G73
Tuesday 1 September
08:30 - 10:00 What is beyond statins in dyslipidaemia treatment? Moscow (Village 2) 306
European Renal Association - European Dialysis and

Transplant Association (ERA - EDTA)
Monday 31 August
14:00 - 15:30 Valvular heart disease in renal failure patients Belgrade (Village 8) 253
European Respiratory Society (ERS)

Sunday 30 August
16:30 - 18:00 Accelerating ageing links chronic obstructive pulmonary
disease and cardiovascular disease San Marino (Village 2) 152
European Resuscitation Council (ERC)

Sunday 30 August
14:00 - 15:30 Cardiac arrest in special environmental circumstances Ankara (Village 7) 140
European Society of Human Genetics (ESHG)

Tuesday 1 September
11:00 - 12:30 Genotype - environment interactions in cardiovascular diseases:
implications for pathogenesis and for management Stockholm (Village 1) 321
European Society of Hypertension (ESH)

Sunday 30 August
14:00 - 15:30 Difficult to treat hypertension Kiev (Village 3) 137
Monday 31 August
16:30 - 18:00 Clinical genomics of hypertension Tirana (Village 3) 266
European Stroke Conference (ESC)

Monday 31 August
16:30 - 18:00 Heart and brain: the concept of stress and emotions Chisinau (Village 6) 268
European Stroke Organisation (ESO)

Monday 31 August
11:00 - 12:30 Thrombectomy in heart and brain? What are the differences
and how to work together? Lisbon (Village 7) 211
International Society for Adult Congenital Heart Disease (ISACHD)

Saturday 29 August
13:30 - 15:00 The role of environment in adult congenital heart disease Ljubljana (Village 8) 40
International Society of Cardiovascular Pharmacotherapy (ISCP)

Saturday 29 August
13:30 - 15:00 Thyroid and the heart Tirana (Village 3) 37
International Society for Gender Medicine

Saturday 29 August
13:30 - 15:00 Mechanistic pathways of sex difference in
cardiovascular disease Stockholm (Village 1) 35
International Society for Heart Research (ISHR)

Tuesday 1 September
16:30 - 18:00 Translational aspects of remote ischaemic conditioning Rabat (Village 1) 374
International Society of Hypertension (ISH)

Tuesday 1 September
16:30 - 18:00 Hypertension highlights in 2015 Kiev (Village 3) 375
World Heart Federation (WHF)

Monday 31 August
14:00 - 15:30 How to reach 25% reduction in cardiovascular disease by
2025 (25 by 25) - Different countries, one roadmap! Moscow (Village 2) 250
G74
OTHER JOINTS SESSIONS
Cardiology Section of the Union of European Medical Specialists (UEMS)

11:00 - 12:30 From training to Continuing Professional Development
(CPD) - Frameworks and impact measurement Hyde Park (The Hub) 89
European Commission
Tuesday 1 September
12:45 - 13:45 European cardiovascular research and innovation -
EU funding and networking opportunities St James Park (The Hub) 352
ESC ASSOCIATIONS TRACK

Highlights from the ESC Associations’ Congresses or the major breakthrough in their sub -
specialty over the past twelve months.
ESC Associations Track are held on Sunday 30 August, 16:30 - 18:00
page
Acute Cardiovascular Care Association (ACCA)

Treatments for acute cardiac care: innovations or lost in translation? Lisbon (Village 7) 154
A Registered Branch of the ESC
European Association for Cardiovascular Prevention

EACPR
and Rehabilitation (EACPR)
The year in prevention: scientific highlights from EuroPRevent 2015
A Registered Branch of the ESC
and beyond Bratislava (Village 2) 152
European Association of Cardiovascular Imaging (EACVI)

Multimodality Imaging as a help for decision-making, what’s new
in 2015? Damascus (Village 5) 153
European Association of Percutaneous

Cardiovascular Interventions (EAPCI)
Hot topics in interventional cardiology 2015 Chisinau (Village 6) 154
European Heart Rhythm Association (EHRA)

Major breakthroughs in management of ventricular tachyarrhythmias,
atrial fibrillation, CRT and pacing and telemonitoring in 2014 -
Take home messages Madrid (Village 4) 153
Heart Failure Association of the ESC (HFA of the ESC)

Heart failure 2015: update for the clinician Bern (Village 9) 156
JOURNAL SESSIONS G75
CARDIOVASCULAR RESEARCH JOURNAL

13:30 - 15:00 Mechanistic pathways of sex difference in
cardiovascular disease Stockholm (Village 1) 35
EUROPEAN HEART JOURNAL
Sessions organised by Professor T Lüscher, Editor in Chief of EHJ, and his team.
The audience will be provided with the opportunity to get a closer look at the Journal,
including some of the best papers that were published over the last year. Touch base with the
editors and authors of some seminal papers and make suggestions to the editorial team.
Sunday 30 August
10:10 - 10:50 The European Heart Journal’s year in cardiology:
from prevention to intervention Hyde Park (The Hub) 88
Monday 31 August
12:40 - 13:40 The European Heart Journal’s year in cardiology:
heart failure and valvular heart diseases Hyde Park (The Hub) 240
Tuesday 1 September
10:10 - 10:50 What are the editor’s criteria for good scientific papers?
Meet the Editors of the European Heart Journal St James Park (The Hub) 316
THE LANCET
Monday 31 August
16:30 - 18:00 Stable angina Hyde Park (The Hub) 262
THE NEW ENGLAND JOURNAL OF MEDICINE
Monday 31 August
08:30 - 10:00 Highlights from the NEJM: editors’ choice Hyde Park (The Hub) 191
Original research
ABSTRACTS presentations
NEW! Advances in Science

Come and discover these new sessions in each village.
The best abstracts combined with key opinion leader perspectives on
the progress in science. Two lectures and three excellent abstracts.
Rapid Fire Abstract Sessions

Fast-paced and interactive sessions held in The Hub & Agora.
Key messages of ten abstracts followed by discussions on the research.
Award Sessions
Sunday 30 August from 12:40 to 13:55
Come and listen to the presenters in competition for an ESC Award.
Let’s meet in the Poster Area during

morning and afternoon breaks
Saturday from 12:30 to 13:30
Sunday to Tuesday from 10:00 to 11:00 and 15:30 to 16:30
Posters
On display for half a day by topic.
Moderated Posters
Presented on large plasma screens, moderated by experts in the field.
Presenters are in competition for an ESC Award.
Best Posters – New display!
4 Top score posters displayed on a large screen by topic.
Join the expert discussant during the coffee break.
See you all at the AWARDS CEREMONY on Monday 31 August at 18:00 in

St James Park (The Hub) to congratulate winners throughout the abstract programme.
ABSTRACT SESSIONS G77
11 306 abstracts were submitted for this year’s Congress.

Over 4 500 abstracts will be presented during the 5 days of the Congress.
Accepted abstracts will be presented as oral and poster presentations.
During and after the congress, abstracts will be published in:
°° The “ESC 2015” Mobile App available on the market stores

The Scienific Programme and Planner
° ESC Congress 365, your free access to ESC Congress content all year long (several formats available,
original abstract submission, presentation slides, e-poster)
° The European Heart Journal – Volume 36 – Abstract supplement 1 (Impact factor 2014 – 14,723)
NEW! - A DVANCES IN SCIENCE

Presenting the latest original findings in science in combination with expert lectures
on specific topics. These sessions bring you the best abstracts and key opinion leader
perspectives on the progress in science.
What do the experts say, what does novel research show us ...
Two lectures and three abstracts: these sessions are the pathways to the progress in science.
RAPID FIRE ABSTRACTS

These fast paced and interactive sessions present key messages of ten abstracts.
Each presentation is followed by Questions & Answers discussion with the experts’ chairs
and the audience.
YOUNG INVESTIGATORS AWARDS

Selected for the outstanding quality of their work, four young investigators will be competing in
each session for a prestigious ESC Award presenting their original research in front of a jury.
The awards will be focused on Basic Science, Clinical Science, Thrombosis, Population
Sciences, Coronary Pathophysiology and Microcirculation (Working Group award).
New this year! - Young Investigators Awards session on “Ageing and Senescence”, will be
part of "A journey to Stockholm" and will feature the Nobel Prize Laureate as guest of the
jury. The ESC will grant the winner with a prize of €2 000 and finalists will each receive a prize
of €1 000.
The six Young Investigators Awards Sessions are held

on Sunday 30 August from 12:40 to 13:50 page
Thrombosis St James Park (The Hub) 123
Basic Science Stockholm (Village 1) 124
Population Sciences Holland Park (The Hub) 124
Clinical Science Victoria Park (The Hub) 124
Coronary Pathophysiology and Microcirculation Green Park (The Hub) 123
Ageing and Senescence Regents Park (The Hub) 123
and
Nursing and Allied Professionals Investigators Award San Marino (Village 2) 125
G78 POSTERS SESSIONS
SCHEDULE
Saturday 30 August
Poster session 11:00 - 16:00
Meet the Poster Presenters 12:30 - 13:30
Best Poster viewing time 12:30 - 13:30
Moderated Poster session 12:30 - 13:30
From Sunday to Tuesday

Morning Afternoon
Poster session 08:30 - 12:30 14:00 - 18:00
Meet the Poster Presenters 10:00 - 11:00 15:30 - 16:30
Best Poster viewing time 10:00 - 11:00 15:30 - 16:30
Moderated Poster session 10:00 - 11:00 15:30 - 16:30
POSTERS
Seven different sessions from Saturday until Tuesday evening.
Visual display of the abstracts in a topic dedicated area. Presenters will be by their poster
during the dedicated viewing time to discuss their research with the visiting audience
NEW FORMAT! Best Posters

In recognition of the high scientific value of the abstracts presented as posters, each poster
session features four Best Posters displayed on a large plasma screen. A discussant visits the
presenters during the dedicated viewing time to animate discussions.
Make sure you stop by the Best Poster screens to view and exchange!
MODERATED POSTERS
These sessions are composed of seven original top rated abstracts. Each Moderated Poster
station features a large screen on which the abstracts will be presented in electronic format,
as well as additional screens on the border of the station, where they will be available for
consultation during the entire poster session (half day).
The research will be presented and discussed by the first author and two moderators
during the coffee breaks. The audience is welcome to join in the discussion. Presenters are
in competition for the “Best Moderated Poster” to win a free registration for next year’s
ESC Congress.
Don’t miss the Award Ceremony on Monday 31 August at 18:00 in The

Hub to congratulate the winners throughout the abstract programme
POSTER AREA FLOOR PLAN G79
A visual display of the abstracts in areas dedicated to each topic:
From VILLAGE 9 From VILLAGE 9
Ischaemia, Coronary Artery Arrhythmias, Pacing,

Cardiac Imaging
Basic Science Disease, Acute Cardiac Care, Resynchronisation
& e-Technology
Acute Coronary Syndromes
From
EXHIBITION
Valvular Disease, Pulmonary Circulation,

Myocardial-Pericardial Disease, Agora Posters
Congenital Heart Disease Desk
& Paediatric Cardiology
Interventions,
Prevention, Rehabilitation, From
Peripheral Circulation, Heart Failure , LV Dysfunction Hypertension, Pharma
Sports , Nursing, Ageing
Stroke / Surgery EXHIBITION
From FUNCTION SPACES SOUTH From FUNCTION SPACES SOUTH
Best Posters Moderated Posters

G80 SPONSORED SESSIONS
EBAC ACCREDITED EDUCATIONAL PROGRAMMES
The EBAC (European Board for Accreditation in Cardiology) accreditation,

granted by a board of specialists widely recognised in the field of cardiology,
confirms the scientific and educational quality of programmes proposed by
national and international scientific or academic organisations and institutions, such
as medical professional organisations, universities or teaching hospitals.
SATELLITE SYMPOSIA
Cooperation between clinicians, researchers and pharmaceutical and technical industries

has significantly contributed to a better understanding and management of patients with
cardiovascular diseases. This is reflected in a series of Industry Satellite Symposia that will offer
you an in-depth view of scientific progress and research in cardiovascular care.
These sessions are the perfect forum to learn and exchange on the latest scientific
information and developments from industry.
EXPERTS ON THE SPOT
These sessions provide delegates attending or interested in Satellite Symposia and EBAC
Accredited Educational Programmes with a further opportunity to question and exchange
with topic experts in a concise and interactive format on the session content. Experts on the
Spot sessions are arranged in The Hub, centrally located within the exhibition.
HANDS-ON TUTORIALS
Industry tutorials provide participants with an opportunity for hands-on learning from clinical
and/or technical experts on specific areas of expertise. Take home practical techniques and
advice from the experts on the application of the latest equipment, devices and therapies
relevant to your practice. Industry experts will provide you with educational sessions and
practical demonstrations in intimate classroom settings in the Hands-On Tutorials village
located in the exhibition.
For details on the session programmes, please refer to the Scientific

Programme daily sections, the Scientific Programme & Planner (SP&P)
online or the "ESC 2015" Mobile App.
GUIDELINES FOR SPEAKERS G81
All faculty members have to complete a Declaration Of Interest to allow the audience to take
into consideration potential conflict of interest when assessing the objectivity of the presentation.
DECLARATION OF INTEREST (DOI)
The existence of potential conflicts of interest does not necessarily indicate a bias. However it is our
ethical obligation to inform organisers and participants so that they are made aware of any relationship
that might cause unintentional bias.
A potential conflict of interest may arise from various relationships, past or present, such as employment,
consultancy, investments and stock ownership, funding for research, family relationship etc.
The Congress Programme Committee requests all persons to declare possible interest:
° Speakers/Abstract Presenters are requested to declare interest regarding their current presentation
on their first slide.
° Chairpersons/Discussants/Judges are requested to declare interest regarding the topics of the

presentations during the session on their first slide (if applicable) or orally at the beginning of the session.
° Poster Presenters are requested to disclose potential conflicts of interest regarding their current
poster presentation at the bottom of their poster.
Attention all speakers!

G HO URS
SSC OPENIN :00
14:00 - 19 0 Speaker Service Centre - Located next to Village 1
August 19:0
Friday 28 ugust 7:30 -
29 A - 19:00 Speakers must upload or validate their presentations -
Saturday st 7:00 19:00
30 Augu - at least 3 hours before the session starts
Sunday st 7: 00
31 Augu 7:00 - 19
:00
Monday tember 7:30 - 10:30 Speaker lounge and rehearsal room available
1 Se p
VILLAGE 1 Tuesday September
day 2
Rabat Wednes
Stockholm
VILLAGE 2 Heart
H
He
Hear
e Failure, LV dysfunction
ear
Bratislava
Moscow
San Marino
ACCESS WITH VILLAGE 9
BADGE ONLY
VILLAGE 3
Kiev i VILLAGE 8
Tirana
PRESS Interventions, Peripheral Circulation, Stroke, Surgery
VILLAGE 4
VILLAGE 7
Algiers
POSTER AREA Imaging, e-Technology
Madrid VILLAGE 6
Agora Arrhythmias, Pacing, Resynchronisation
VILLAGE 5
VILLAGE 5
Damascus
The Hague EXHIBITION Hypertension, Pharma
VILLAGE 4
VILLAGE 6 Prevention, Rehabilitation, Sports Cardiology,
Chisinau
Nursing, Ageing
Oslo i VILLAGE 3
THE HUB Basic Science
VILLAGE 7 ESC
2015
app
VILLAGE 2
Ankara THE HUB
Lisbon Green Park Hyde DLR Station
Tunis Holland Park Park VILLAGEE 1 Speaker
SSC Prince Regent
VILLAGE 8
Hyde Park
Regents Park
Service
Belgrade
St James Park EXHIBITION Centre EESC
SSC
C MEETING
ME
ROOMS
ROO
Victoria Park
Ljubljana
Warsaw POSTER AREA ESC H
HQ
Agora CPR
VILLAGE 9 Workshops
ESC PLAZA REGISTRATION
Bern MAIN AUDITORIUM
Bucharest London Delegate i
Lounge
LONDON
MAIN AUDITORIUM
ESC Stand Speaker Service Centre ESC Fellows & VIP Lounge i Information Point Cloakroom & Left Luggage Medical Care Taxi station MAIN
ENTRANCE
ESC Congress 365 desk ESC Mobile App desk Recording studio (EAST)
ESC
2014
app
Industry
Coach Parking
ESC CONGRESS 365
We remind you that slides and videos of presentations given during ESC Congress 2015(*) will be
available on ESC Congress 365 (www.escardio.org/365). (*) with copyrights given to the ESC.
With ESC Congress 365
t View the sessions you missed
t Review videos, slides, abstracts and reports
of your sessions of interest
FREE ACCESS
Save your favourite Share content

presentations for of interest with
future reference your colleagues
Convenient direct
access to 10 main
cardiovascular topics
Powerful search
by keywords
Your free access

to ESC Congress content all year long
Experience it yourself today! www.escardio.org/365
ESC Congress 365 is supported by AstraZeneca, Bayer HealthCare, Boehringer Ingelheim, the Bristol-Myers
Squibb and Pfizer alliance, and SERVIER, in the form of an unrestricted educational grant
SCIENTIFIC
PROGRAMME
BY DAY AND VILLAGE
Download the
ESC 2015 Mobile App
Browse sessions by Receive

Day,Village, Topic, the latest news
Type or Track &
view videos, slides,
abstracts & reports
Access exhibitors’
details and find
Follow onsite practical
#ESCcongress information
Twitter feed
Create & share Access Maps and

your personalised use the improved
programme Search Tool
(synchronised with
your online
Scientific Planner)
Ask questions and vote during “Mobile App Interactive Sessions”

Search in the “Types & Tracks”
select a session - click on “Session Information & Interaction”
“ESC 2015” in QR code for

iOS & Android
App Store / Google Play
Need help?
Find assistance at the dedicated desk, in the middle of the Central Boulevard
and at the SERVIER Stands B100, C100 and D100
ESC 2015 Mobile App is supported by SERVIER

TUTORIALS
HANDS-ON
HANDS-ON TUTORIALS
Devices, Imaging, Clinical Practice

Dedicated programmes from experts
on the practical application
of knowledge and skills
Sign up now in the Hands-On Tutorials room

or at the Sponsor’s Stand
3ODFHVDUHOLPLWHG¬
Egklk[a]flaÚ[k]kkagfk$]p[]hlkYl]ddal]kqehgkaY$Yj]YjjYf_]\Zqlgha[kafl`]e]\naddY_]k
VILLAGE 1
Rabat ACCESS WITH VILLAGE 9
BADGE ONLY
Stockholm
VILLAGE 2
i VILLAGE 8
Bratislava PRESS Interventions, Peripheral Circulation, Stroke, Surgery
Moscow VILLAGE 7
San Marino POSTER AREA Imaging, e-Technology
VILLAGE 3 VILLAGE 6
Agora Arrhythmias, Pacing, Resynchronisation
Kiev
Tirana VILLAGE 5
EXHIBITION Hypertension, Pharma
VILLAGE 4
Algiers
VILLAGE 4
Madrid
Nursing, Ageing
VILLAGE 5 i VILLAGE 3
THE HUB Basic Science
Damascus
ESC
2015 VILLAGE 2
The Hague 6 app
VILLAGE 6
5 Hyde DLR Station
4 Park VILLAGE 1
Chisinau Prince Regent
SSC
Oslo
EXHIBITION ESC MEETING

VILLAGE 7
3 ROOMS
Ankara THE HUB 2
Lisbon Green Park 1 ESC HQ
Holland Park
CPR
Tunis
Workshops REGISTRATION
Hyde Park ESC PLAZA
VILLAGE 8 Regents Park
St James Park Delegate i
Belgrade
Victoria Park Lounge
LONDON
Ljubljana
Warsaw POSTER AREA MAIN AUDITORIUM
Agora
VILLAGE 9 MAIN
Bern MAIN AUDITORIUM ENTRANCE
Bucharest London
Industry
(EAST)
Coach Parking
ESC Stand Speaker Service Centre ESC Fellows & VIP Lounge i Information Point Cloakroom & Left Luggage Medical Care Taxi station
ESC
2014
ESC Congress 365 desk app ESC Mobile App desk Recording studio
HANDS-ON TUTORIALS
SATURDAY 29 AUGUST 2015
Please note that places in Hands-On sessions are limited.

Registration is recommended on the sponsor booth or in front of the Hands-On Rooms.
13:00–14:00 | Hands-On Room 4

Computed Tomography (CT) myocardial perfusion in clinical practice
Sponsored by Toshiba Medical Systems Europe BV
Presenter: K.F. Kofoed (Copenhagen, DK)
Learning objectives:
Toshiba is offering a series of educational sessions for cardiologists throughout ESC 2015. Each mentored workshop is preceded
by a short lecture providing an overview on data acquisition, clinical use and image interpretation. Clinical cases will be analysed
and interpreted by participants on the workstations provided. Learning objectives are:
1. To understand the common clinical issues cardiologists and medical scientists are confronted with when dealing with cardiac
diseases
2. To learn to apply the latest methods in functional imaging covering both CT and ultrasound applications
3. To learn how to operate, analyze and interpret Ultrasound LV function using LV Volume, Global and segmental strain, based
on 2D and 3D ultrasound raw data
14:00–15:30 | Hands-On Room 3

Valves are to flow, as flow is to valves... clinical benefits of advancements in 3D TEE from
visualization to quantification
Sponsored by Siemens AG Healthcare
Presenter: S. Datta (Muzaffarpur, IN)
Cardiac imaging is rapidly developing, driven by the introduction of new imaging. In order to keep you updated in the field
of state-of-the-art cardiovascular imaging, Siemens Healthcare is providing a comprehensive set of Hands-on Tutorial (HOT)
sessions during this year’s ESC congress. You will have the opportunity to learn from renown clinical experts how to perform
and analyze real-time 3D echocardiography, comprehensive studies with Cardiac Computed Tomography, Cardiac Magnetic
Resonance Imaging and PET • Computed Tomography. Besides that, we also offer case-based learning sessions with detailed
discussions.
5
SATURDAY 29 AUGUST 2015
14:30–15:30 | Hands-On Room 4

Challenging cases in cardiac Computed Tomography (CT): arrhythmia
Presenter: O. Ghekiere (Liège, BE)
diseases
15:00–16:30 | Hands-On Room 2

Identifying rare diseases by their cardiac complications: interactive case studies of Fabry disease
Sponsored by Shire
Presenter: P.M. Elliott (London, UK)
15:00 Raising the profile of rare cardiovascular diseases in Europe.
– P.M. Elliott (London, UK)
15:15 Diagnosing rare diseases in cardiology: exploring the challenges through a case study.
15:30 The heart in Fabry disease.
– A. Linhart (Prague, CZ)
15:50 What might be achieved from long-term treatment of Fabry disease? Insights from a Fabry center
experience.
– C. Kampmann (Mainz, DE)
16:15 The role of the cardiologist in diagnosing patients with Fabry disease.
• To foster learning through an interactive session with delegate participation
• To raise awareness of Fabry disease and its associated cardiac manifestations in order to improve diagnosis
• To offer expert advice on strategies for the management of Fabry disease
16:00–17:30 | Hands-On Room 3

Molecular imaging – Benefits in coronary artery disease
Presenter: G.J.G. Platsch (Erlangen, DE)
discussions.
6
HANDS-ON TUTORIALS
SUNDAY 30 AUGUST 2015

09:00–10:30 | Hands-On Room 3

Cardiac magnetic resonance imaging in cardiomyopathies
Presenter: G. von der Recke (Bonn, DE)
discussions.
09:00–10:00 | Hands-On Room 6

TAVI CT: optimizing device selection through CT assessment
Sponsored by Philips Healthcare
Presenters: P. Donnelly (Belfast, UK) – M. Spence (Belfast, UK)
Cardiology informatics focused sessions will demonstrate how to efficiently manage information provided by different imaging
modalities and to plan interventional treatment.
10:00–11:00 | Hands-On Room 4

Challenging cases in cardiac Computed Tomography (CT): arrhythmia
Presenter: O. Ghekiere (Liège, BE)
diseases
10:00–11:00 | Hands-On Room 5

Sleep Apnea, from screening to therapy
Sponsored by ResMed
Presenter: C. Schoebel (Berlin, DE)
Through clinical cases, participants will learn about Sleep Disordered Breathing, their impact on patients with cardiovascular
diseases, the tools available for cardiologists to specifically screen for SDB in their patients, and finally the diagnosis and thera-
peutic options. They will have a chance to understand practicality of sleep testing solution for screening and diagnosis of SDB
through hands on.
10:30–11:30 | Hands-On Room 6

Fundamentals of physiological measurements in the interventional lab today and their clinical value
Presenter: J.E. Davies (London, UK)
Interventional cardiology oriented sessions will discuss the role of precision guided technologies in the interventional lab today.
7
11:00–12:30 | Hands-On Room 3

Molecular imaging – Benefits in coronary artery disease
Presenter: G.J.G. Platsch (Erlangen, DE)
discussions.
11:30–12:30 | Hands-On Room 4

Computed Tomography (CT) myocardial perfusion in clinical practice
Presenter: K.F. Kofoed (Copenhagen, DK)
diseases
12:00–13:00 | Hands-On Room 1

Novel implantable infusion pump to deliver prostanoids
Sponsored by United Therapeutics Europe Limited and OMT GmbH
Presenter: H.A. Ghofrani (Giessen, DE)
By attending these small group sessions, attendees will develop knowledge on current data and improve their skills in managing
PAH patients. In the first tutorial they will learn about how to use the new devices that are emerging to simplify the delivery of
parenteral prostanoids. The second tutorial will give insights into current research on the therapeutic management of prostanoids.
12:30–14:00 | Hands-On Room 2

Sponsored by Shire
experience.
8
HANDS-ON TUTORIALS
12:30–13:30 | Hands-On Room 6

Left ventricle failure. How new anatomical intelligence tools may improve echocardiographic
assessment of the failing left ventricle
Presenter: R. Hinojar (Madrid, ES)
During tutorials dedicated to Anatomical Intelligence of Ultrasound, participants will learn how the newly expanded set of Anatom-
ical Intelligence tools can help quickly and precisely assess left ventricle and left atrium function in the course of different medical
disorders.
13:00–14:30 | Hands-On Room 3

New possibilities in Computed Tomography (CT) cardiac imaging – Low dose in challenging
situations
Presenter: K. Nieman (Rotterdam, NL)
discussions.
14:00–15:00 | Hands-On Room 4

Coronary subtraction – Improving the evaluation of calcified coronary arteries on Computed
Tomography (CT)
Presenter: A. Fuchs (Copenhagen, DK)
diseases
14:00–15:00 | Hands-On Room 6

disorders.
15:00–16:30 | Hands-On Room 3

Cardiac magnetic resonance imaging in ischemic heart disease
discussions.
9
15:30–16:30 | Hands-On Room 4

2D wall motion tracking for the daily routine
Presenter: L. Perez De Isla (Madrid, ES)
diseases
15:30–16:30 | Hands-On Room 6

disorders.
16:00–17:00 | Hands-On Room 1

Therapeutic management of prostanoids – Insights into current research
Presenter: S. Rosenkranz (Cologne, DE)
17:00–18:00 | Hands-On Room 6

disorders.
10
HANDS-ON TUTORIALS
MONDAY 31 AUGUST 2015

09:00–10:30 | Hands-On Room 3

Computed Tomography (CT) cardiac imaging – CT dynamic myocardial perfusion
discussions.
09:00–10:00 | Hands-On Room 6

Why is global longitudinal strain important in patients with aortic stenosis?
Presenter: A. Apor (Budapest, HU)
disorders.
10:00–11:00 | Hands-On Room 4

Dedicated workflow for Computed Tomography (CT) TAVI planning
Presenter: J.E. Stirrup (London, UK)
diseases
10:00–11:00 | Hands-On Room 5

Sponsored by ResMed
through hands on.
11
10:30–12:00 | Hands-On Room 2

Sponsored by Shire
experience.
10:30–11:30 | Hands-On Room 6

disorders.
11:00–12:30 | Hands-On Room 3

discussions.
11:30–12:30 | Hands-On Room 4

Fusion of Computed Tomography (CT) and ultrasound in a hybrid viewer
Presenter: E. Casas Rojo (Madrid, ES)
diseases
12
HANDS-ON TUTORIALS
12:00–13:00 | Hands-On Room 1

Novel implantable infusion pump to deliver prostanoids
Presenter: H.A. Ghofrani (Giessen, DE)
12:00–13:00 | Hands-On Room 6

Cardyomyopathies and the left heart. How new anatomical intelligence tools may improve
echocardiographic assessment of the left heart
Presenter: A. Gonzalez Gomez (Madrid, ES)
disorders.
13:00–14:30 | Hands-On Room 3

Cardiac magnetic resonance imaging in cardiomyopathies
discussions.
13:00–14:00 | Hands-On Room 4

3D wall motion tracking for the daily routine
H.-J. Nesser (Linz, AT)
diseases
14:00–15:00 | Hands-On Room 6

TAVI CT: optimizing device selection through CT assessment
Presenters: P. Donnelly (Belfast, UK) – M. Spence (Belfast, UK)
13
15:00–16:30 | Hands-On Room 3

Computed Tomography (CT) TAVI planning – Precise and reproducible results
discussions.
15:30–16:30 | Hands-On Room 4

Wall motion tracking for monitoring the heart health of athletes
Presenter: G.E. Pieles (Bristol, UK)
diseases
15:30–16:30 | Hands-On Room 6

Advanced visualization analysis of cardiac cases in routine clinical practice. “ Out of clutter, find
simplicity”
Presenter: A. Wolak (Jerusalem, IL)
16:00–17:00 | Hands-On Room 1

Therapeutic management of prostanoids – Insights into current research
Presenter: S. Rosenkranz (Cologne, DE)
17:00–18:00 | Hands-On Room 6

Moving from justifying to guiding PCI: the role of physiological measurements in today’s
interventional lab
Presenter: J.E. Davies (London, UK)
Interventional cardiology oriented sessions will discuss the role of precision guided technologies in the interventional lab today.
14
HANDS-ON TUTORIALS
TUESDAY 1 SEPTEMBER 2015

09:00–10:30 | Hands-On Room 3

High accuracy in complex coronary lesions
discussions.
09:00–10:00 | Hands-On Room 6

disorders.
10:00–11:00 | Hands-On Room 5

Sponsored by ResMed
through hands on.
10:30–11:30 | Hands-On Room 6

disorders.
11:00–12:30 | Hands-On Room 3

Cardiac magnetic resonance imaging in ischemic heart disease
discussions.
15
12:00–13:00 | Hands-On Room 6

The impact of mitral valve insufficiency on the left heart. How new anatomical intelligence tools may
improve echocardiographic assessment of the left heart
Presenter: C. Fernandez-Golfin (Madrid, ES)
disorders.
13:00–14:30 | Hands-On Room 3

discussions.
14:00–15:00 | Hands-On Room 6

disorders.
15:15–16:45 | Hands-On Room 3

discussions.
15:30–17:00 | Hands-On Room 2

Sponsored by Shire
experience.
16
HANDS-ON TUTORIALS
15:30–16:30 | Hands-On Room 6

disorders.
17:00–18:00 | Hands-On Room 6

disorders.
17
NOTES
18
SATURDAY
SATURDAY
29 AUGUST
Browse the most up-to-date Scientific

Programme in the “ESC 2015” Mobile App.
Missed a session? Need to see it again?

Consult videos, slides, abstracts & reports
on ESC Congress 365, your free access to
ESC Congress content all year long.
Tweet about your favourite sessions: #ESCcongress

SATURDAY 29 AUGUST 2015 – MORNING SESSIONS
09:00–10:30 | Hyde Park - The Hub

FROM START TO FINISH OF CORONARY ARTERY DISEASE Symposium
Chairperson(s): K.F. Fox (London, UK); S. Alexander (Cambridge, UK)
09:00 Case presentation - Patient 10 yr risk low but lifetime high. 1
– S. Alexander (Cambridge, UK)
09:10 Joint British Societies guidelines for cardiovascular prevention 3. 2
– S. Connolly (London, UK)
09:30 Case presentation - Chest pain post myocardial infarction. 3
– C. Arden (Hants, UK)
09:40 Diagnosing post revascularisation (non cardiac) chest pain - How to assess, when to refer. 4
– R.A. Henderson (Nottingham, UK)
10:00 Case presentation - Refractory angina. 5
– M. Redwood (Cambridge, UK)
10:10 Refractory angina. 6
– R. De Silva (London, UK)
09:00–10:30 | Regents Park - The Hub

CROSS-TALK BETWEEN CARDIOVASCULAR AND NON-CARDIOVASCULAR CELLS IN DISEASE Symposium
PATHOGENESIS
ESC and the British Society for Cardiovascular Research
Chairperson(s): C. Antoniades (Oxford, UK); K.E. Porter (Leeds, UK)
09:00 Signalling and the control of the blood-brain barrier. 7
– P. Turowski (London, UK)
09:22 Cardiac fibroblasts, inflammation and heart failure. 8
– C. Tschoepe (Berlin, DE)
09:45 Crosstalk between neurons and cardiomyocytes. 9
– M. Mongillo (Padua, IT)
10:07 Communication between endothelium and vascular smooth muscle: implications for aneurysm 10
formation.
– K. Channon (Oxford, UK)
09:00–10:30 | Green Park - The Hub

VOTING FOR THE MOST GAME CHANGING INNOVATION OF THE YEAR – THE WINNER Special Session
TAKES IT ALL!
ESC and the British Junior Cardiologists’ Association
Chairperson(s): S.M.A. Sohaib (London, UK); M. Wallner (Graz, AT)
09:00 Introduction. 11
09:12 Electrophysiology. 12
– J. Brugada Terradellas (Barcelona, ES)
09:25 Coronary intervention. 13
– M.C. Morice (Massy, FR)
09:38 Cardiovascular imaging. 14
– L. Badano (Padua, IT)
09:51 Cardiovascular risk. 15
– J. Perk (Oskarshamn, SE)
10:04 Heart failure. 16
– C. Linde (Stockholm, SE)
10:17 Acute cardiac care. 17
– M. Lettino (Milan, IT)
09:00–10:30 | Victoria Park - The Hub

CROSSING BOUNDARIES – NURSE LED SERVICES ACROSS HEALTHCARE SECTORS Symposium
Chairperson(s): H. Waterhouse (Derby, UK); J. Hunt (Hove, UK)
09:00 Nurse prescribing in cardiovascular prevention and rehabilitation. 18
– M.A. Mooney (Belfast, UK)
09:22 Heart failure specialist services: Working across boundaries. 19
– J. Welstand (Wrexham, UK)
09:45 Community nurse-led management for complex multi-morbid patients. 20
– K. Berra (Menlo Park, US)
10:07 IV diuretics for heart failure in the home environment. 21
– L.M.J. Blue (Glasgow, UK)
20

ATRIAL FIBRILLATION – UPDATE FOR THE GENERAL PRACTITIONERS Symposium
Chairperson(s): C.J. Garratt (Manchester, UK); K.E. Griffith (York, UK)
11:00 Anticoagulant therapy in 2015. 22
– P. Heck (Cambridge, UK)
11:30 Slowing the racing heart - First steps for newly detected atrial fibrillation. 23
– N.J. Linker (Middlesbrough, UK)
SATURDAY – MORNING
12:00 Return to sinus rhythm - For who and how. 24
– P. Kanagaratnam (Four Oaks and Burningham, UK)
11:00–12:30 | St James Park - The Hub

IMPLEMENTATION OF MULTIMODALITY IMAGING IN THE CURRENT Guidelines in Daily Practice
ESC GUIDELINES IN THE UNITED KINGDOM – HYPERTROPHIC CARDIOMYOPATHY
Chairperson(s): H. Watkins (Oxford, UK); S. Sharma (London, UK)
11:00 Case presentation. 25
– J. Moon (London, UK)
11:22 What do the Guidelines say? 26
11:45 Clinical practice in the United Kingdom based on EORP registries or national registry. 27
– P.P. McKeown (Belfast, UK)
12:07 Gaps in the Guidelines. 28
– W.J. McKenna (London, UK)

ESC GUIDELINES IN NORWAY – ACUTE CORONARY SYNDROME
Chairperson(s): K.H. Haugaa (Oslo, NO); T.K. Steigen (Tromsø, NO)
– A. Opdahl (Oslo, NO)
– T. Edvardsen (Oslo, NO)
11:45 Clinical practice in Norway based on national registry. 31
– C. Risoe (Oslo, NO)
– O. Bleie (Bergen, NO)

WHAT WOULD YOU LIKE TO HAVE MADAM/SIR: CATHETER OR DEVICE? Clinical Cases
Chairperson(s): P. Neuzil (Prague, CZ); V. Kutyifa (Rochester, US)
11:00 Patient with Brugada pattern type I and atrial flutter with stroke. 33
– M. Kolios (Ioannina, GR)
11:12 Unusual cause of acquired long QT syndrome successfully treated with catheter ablation. 34
– V. Alcalde Martinez (Granada, ES)
11:25 A difficult ablation of recurrent ventricular arrhythmia. 35
– J.C. Duarte Rodrigues (Oporto, PT)
11:38 A difficult decision regarding defibrillator implantation. 36
– I. Mendez Fernandez (Madrid, ES)
11:51 A 74-year-old woman with disnea and a recent ICD implantation. 37
– V. Brunna (Madrid, ES)
12:04 Intra-isthmus reentry: hidden anatomic complexity of cavo-tricuspid isthmus and coronary sinus 38
ostium region.
– G. Zhou (Beijing, CN)
12:17 Cardiac resynchronisation alleviates chest pain due to exercise-induced left bundle branch block. 39
– D. Czuriga (Debrecen, HU)
21
11:00–12:30 | Holland Park - The Hub

IMPLEMENTATION OF MULTIMODALITY IMAGING IN THE CURRENT ESC Guidelines in Daily Practice
GUIDELINES IN SERBIA – HEART FAILURE
Chairperson(s): Z. Perisic (Nis̆, RS); M. Deljanin Ilic (Niska Banja, RS)
– A. Djordjevic-Dikic (Belgrade, RS)
– B. Beleslin (Belgrade, RS)
11:45 Clinical practice in Serbia based on EORP registries or national registry. 42
– I. Nedeljkovic (Belgrade, RS)
– M.V. Tomasevic (Belgrade, RS)

CUTTING EDGE DEVELOPMENTS IN CARDIOVASCULAR INTERVENTIONS Symposium
Chairperson(s): T.B. Hansen (Copenhagen, DK); J. Oliver (Tyne and Wear, UK)
11:00 TAVI: established benefits and remaining questions. 44
– M. Haude (Neuss, DE)
11:22 PPCI: implications in acute and community settings. 45
– F. Astin (Huddersfield, UK)
11:45 Women are from Venus: why gender issues in research and practice. 46
– V. Regitz-Zagrosek (Berlin, DE)
12:07 What’s New from the Cath Lab. 47
– L. Dullaghan (Belfast, UK)
11:00–12:30 | Rabat - Village 1

INDUCED PLURIPOTENT STEMS CELLS FOR CARDIOVASCULAR THERAPY Symposium
Chairperson(s): J. Dulak (Krakow, PL); R. Madonna (Chieti, IT)
11:00 Induced pluripotent stem cells: the new patient. 48
– A. Raya (Barcelona, ES)
11:22 Induced pluripotent stem cells and cardiomyocite differentiation. 49
– T. Eschenhagen (Hamburg, DE)
11:45 Pluripotent stem cells in vascular regeneration. 50
– J.-S. Silvestre (Paris, FR)
12:07 Reprogramming in cardiovascular medicine: chances and limitations. 51
– L. Gepstein (Haifa, IL)
11:00–12:30 | Stockholm - Village 1

TISSUE FACTOR AND ATHEROTHROMBOSIS: NEW FINDINGS Symposium
Chairperson(s): R.F. Storey (Sheffield, UK); T.W. Weiss (Vienna, AT)
11:00 Tissue factor as a signalling receptor: a new role for an old molecule. 52
– A. Siegbahn (Uppsala, SE)
11:22 Tissue factor encryption and decryption: facts and controversies. 53
– P. Hogg (Sydney, AU)
11:45 Tissue factor beyond coagulation: a role in vessel formation. 54
– G. Arderiu (Barcelona, ES)
12:07 AIternative spliced tissue factor and angiogenesis. 55
– H. Versteeg (Leiden, NL)
11:00–12:30 | Bratislava - Village 2

WOMEN’S CARDIOVASCULAR HEALTH: MEDICAL AND SOCIAL IMPLICATIONS Symposium
Chairperson(s): A.O. Nedoshivin (St. Petersburg, RU); F.M. Consolim-Colombo (São Paulo, BR)
11:00 Promotion of cardiovascular health in secondary prevention. 56
– M.C. Deaton (Cambridge, UK)
11:22 Effect of gender and exercise intensity on the outcome of rehabilitation. 57
– E. Van Craenenbroeck (Edegem, BE)
11:45 Lifetime impact of gestational diabetes. 58
– Y.M. Smulders (Amsterdam, NL)
12:07 Management of menopause. 59
– A. Abreu (Lisbon, PT)
22
11:00–12:30 | Moscow - Village 2

ATHLETE HEART: DETECTING THE FATALLY FLAWED AMONG THE FABULOUSLY Case-based Symposium
FIT
Chairperson(s): F. Carre (Rennes, FR); C. Schmied (Zurich, CH)
11:00 T wave inversion in an athlete: normal variant or harbinger of cardiac pathology. 60
– M. Papadakis (London, UK)
11:10 T wave inversion in an athlete: normal variant or harbinger of cardiac pathology - Panel 61
discussion and questions from the audience.
– M. Papadakis (London, UK), S. Gati (London, UK), A. La Gerche (Melbourne, AU)
11:20 Trabeculations of the left ventricle; novel cardiomyopathy or physiological adaptation to exercise? 62
– S. Gati (London, UK)
11:30 Trabeculations of the left ventricle; novel cardiomyopathy or physiological adaptation to exercise? 63
Panel discussion and questions from the audience.
– S. Gati (London, UK), A. La Gerche (Melbourne, AU), M. Papadakis (London, UK)
11:40 Right ventricle; the weak link in the athlete’s heart? 64
– A. La Gerche (Melbourne, AU)
11:50 Right ventricle; the weak link in the athlete’s heart? - Panel discussion and questions from the 65
audience.
– A. La Gerche (Melbourne, AU), S. Gati (London, UK), M. Papadakis (London, UK)
12:00 Differentiating athlete’s heart from cardiomyopathy; past, present and future - State of the Art 66
lecture.
– A. Pelliccia (Rome, IT)
11:00–12:30 | San Marino - Village 2

LOW-DENSITY LIPOPROTEIN CHOLESTEROL: HOW LOW AND HOW TO LOWER? Advances in Science
Chairperson(s): H.K. Chopra (New Delhi, IN); D.E. Grobbee (Utrecht, NL)
11:00 State of the Art in low-density lipoprotein lowering. 67
– P.P. Toth (Sterling, US)
11:20 Safety and efficacy of long-term very low achieved LDL-C in the IMPROVE IT trial. 68
– R.P. Giugliano, S.D. Wiviott, M.A. Blazing, S.A. Murphy, J. Zhou, J.A. White, T.A. Musliner,
A.J. Tershakovec, C.P. Cannon, E. Braunwald (Boston, Durham and Kenilworth, US)
11:37 Low LDL-cholesterol target achievement in statin-treated patients in clinical practice in China and 69
Europe: results of the Dyslipidemia International Study (DYSIS).
– A.K. Gitt, B.M. Ambegaonkar, M. Horack, P. Brudi, D. Lautsch, J. Ferrieres, D. Hu (Ludwigshafen am
Rhein, DE; Whitehouse Station, US; Vienna, AT; Toulouse, FR; Beijing, CN)
11:54 Comparing the expected benefit of plasma cholesterol reduction with or without LDL-C targets in 70
a high-risk, healthy population.
– F.H. Cesena, A.G. Laurinavicius, M.S. Bittencourt, R.D. Conceicao, R.D. Santos (São Paulo, BR)
12:11 Future direction for research in low-density lipoprotein lowering. 71
– L. Catapano (Milan, IT)
11:00–12:30 | Kiev - Village 3

ESC GUIDELINES TO RESOLVE DILEMMAS IN CLINICAL CARDIOLOGY Meet the Experts
Chairperson(s): M.A. Alonso Garcia (London, UK); S. Halvorsen (Oslo, NO)
11:00 ESC Guidelines to resolve dilemmas in clinical cardiology - Introduction to the session. 72
– S. Halvorsen (Oslo, NO)
11:05 A heart disease patient going to non-cardiac surgery. 73
– H.E. Botker (Aarhus, DK)
11:15 A heart disease patient going to non-cardiac surgery - Panel discussion and questions from the 74
audience.
– S.J. Pocock (London, UK), J. Steffel (Zurich, CH)
11:30 A patient with heart failure and cancer. 75
– M. Scherrer-Crosbie (Boston, US)
11:40 A patient with heart failure and cancer - Panel discussion and questions from the audience. 76
11:55 Recent previous stroke and STEMI. 77
– A. Cohen (Paris, FR)
12:05 Recent previous stroke and STEMI - Panel discussion and questions from the audience. 78
12:20 ESC Guidelines to resolve dilemmas in clinical cardiology - Take home message. 79
– M.A. Alonso Garcia (London, UK)
23
11:00–12:30 | Tirana - Village 3

CONTROVERSIES IN THE TREATMENT OF ATRIAL FIBRILLATION AND HYPERTENSION Debate Session
Chairperson(s): M. Dorobantu (Bucharest, RO); J.L. Tamargo (Madrid, ES)
11:00 Atrial fibrillation and PCI: always triple therapy! - PRO. 80
– D. Atar (Oslo, NO)
11:15 Atrial fibrillation and PCI: always triple therapy! - CONTRA. 81
– P.T. Buser (Basel, CH)
11:30 Atrial fibrillation and PCI: always triple therapy! - REBUTTAL PRO. 82
11:35 Atrial fibrillation and PCI: always triple therapy! - REBUTTAL CONTRA. 83
– P.T. Buser (Basel, CH)
11:40 Atrial fibrillation and PCI: always triple therapy! - CONCLUSION. 84
11:45 Refractory hypertension: optimize medical therapy - renal denervation is dead! - PRO. 85
– S.E. Kjeldsen (Oslo, NO)
12:00 Refractory hypertension: optimize medical therapy - renal denervation is dead! - CONTRA. 86
– F. Mahfoud (Homburg, DE)
12:15 Refractory hypertension: optimize medical therapy - renal denervation is dead! - REBUTTAL PRO. 87
12:20 Refractory hypertension: optimize medical therapy - renal denervation is dead! - REBUTTAL 88
CONTRA.
12:25 Refractory hypertension: optimize medical therapy - renal denervation is dead! - CONCLUSION. 89
11:00–12:30 | Algiers - Village 4

SUDDEN CARDIAC ARREST: PREPARING TO TREAT ATHLETES AND SPECTATORS Symposium
Chairperson(s): S. Timerman (São Paulo, BR); G. Steinbeck (Starnberg, DE)
11:00 Lessons learned in emergency medicine at the 2012 Olympic Games. 90
– D. Zideman (London, UK)
11:22 World Cup 2014 in Brazil, summary of emergency care. 91
– N. Ghorayeb (São Paulo, BR)
11:45 Current management of sudden cardiac arrest in football. 92
12:07 Post cardiac arrest syndrome - A review of therapeutic strategies. 93
– C.H. Hassager (Copenhagen, DK)
11:00–12:30 | Madrid - Village 4

CATHETER ABLATION OF ATRIAL FIBRILLATION: WHAT SHOULD THE CLINICIAN KNOW? Meet the Experts
Chairperson(s): D. Shah (Geneva, CH); S.-J. Yeh (Taoyuan, TW)
11:00 Catheter ablation of atrial fibrillation: what should the clinician know? Introduction to the session. 94
– D. Shah (Geneva, CH)
11:05 Catheter ablation in paroxymal atrial fibrillation as first line treatment. 95
– J.C. Nielsen (Aarhus, DK)
11:15 Catheter ablation in paroxymal atrial fibrillation as first line treatment - Panel discussion and 96
questions from the audience.
– G. Hindricks (Leipzig, DE), L. Mont (Barcelona, ES), J.C. Nielsen (Aarhus, DK)
11:30 Catheter ablation in long term persistent atrial fibrillation. 97
– P. Kirchhof (Birmingham, UK), L. Di Biase (New York, US)
11:40 Catheter ablation in long term persistent atrial fibrillation - Panel discussion and questions from 98
the audience.
– G. Hindricks (Leipzig, DE), L. Mont (Barcelona, ES), P. Kirchhof (Birmingham, UK)
11:55 Catheter ablation of atrial fibrillation in heart failure patients. 99
– P. Mabo (Rennes, FR)
12:05 Catheter ablation of atrial fibrillation in heart failure patients - Panel discussion and questions 100
from the audience.
– G. Hindricks (Leipzig, DE), L. Mont (Barcelona, ES), P. Mabo (Rennes, FR)
12:20 Catheter ablation of atrial fibrillation: what should the clinician know? Take home message. 101
– C. de Chillou (Vandoeuvre-lès-Nancy, FR)
24
11:00–12:30 | Damascus - Village 5

REMOTE PATIENT MONITORING: BETTER CARE AT LOWER COST. IS THIS A DREAM? Advances in Science
Chairperson(s): E.T. van der Velde (Leiden, NL); P. Guzik (Poznan, PL)
11:00 State of the Art in remote patient monitoring. 102
– H. Saner (Berne, CH)
11:20 A link to better care? The effect of remote monitoring on hospital admissions and mortality after 103
ICD implantation.
– G. Portugal, M. Oliveira, S. Almeida, P.S. Cunha, A. Lousinha, B. Valente, J. Feliciano, R. Pimenta,
A.S. Delgado, R. Ferreira (Lisbon and Vila Franca de Xira, PT)
11:37 Early detection and treatment of supraventricular arrhythmias with remote monitoring may 104
decrease atrial fibrillation burden in pacemaker patients: the randomized, multicenter setam trial.
– W. Amara, C. Montagnier, S. Cheggour, M. Boursier, C. Barnay, F. Georger, A. Deplagne, S. Fromentin,
M. Mlotek, J. Taeib (Montfermeil, Vannes, Avignon, Ars-Laquenexy, Aix-en-Provence, Béziers, Libourne,
Montbéliard and Saint-Étienne, FR)
11:54 Clinical and economic outcome of telemonitoring versus usual care among patients with severe 105
chronic heart failure.
– P. Dendale, I. Cleemput, R. Hoffmann, D. Vandijck (Hasselt and Brussels, BE)
12:11 Future direction for research in remote monitoring. 106
– M. Lange (Brussels, BE)
11:00–12:30 | The Hague - Village 5

NOVEL IMAGING TARGETS FOR CARDIAC DISEASE Symposium
Chairperson(s): L. Ernande (Paris, FR); L. Badano (Padua, IT)
11:00 The myocardial matrix as a diagnostic and therapeutic target. 107
– T.H. Marwick (Hobart, AU)
11:22 Imaging inflammatory atherosclerosis plaque. 108
– M. Dweck (Edinburgh, UK)
11:45 Imaging stem cell implantation. 109
– F.M. Bengel (Hannover, DE)
12:07 Molecular imaging with targeted contrast ultrasound. 110
– A. DeMaria (San Diego, US)
11:00–12:30 | Chisinau - Village 6

PREVENTION OF CARDIOEMBOLIC STROKE IN ATRIAL FIBRILLATION Symposium
Chairperson(s): B. Meier (Berne, CH); A.J. Camm (London, UK)
11:00 The enduring role of oral anticoagulation. 111
– M. Yamagishi (Kanazawa, JP)
11:22 The role of catheter ablation. 112
– E. Hoffmann (Munich, DE)
11:45 The role of lone surgical ablation. 113
– S. Salzberg (Zurich, CH)
12:07 LAA percutaneous closure: clinical results. 114
– S. Berti (Massa, IT)
11:00–12:30 | Oslo - Village 6

WAKING UP FROM NIGHTMARES IN INTERVENTIONAL CARDIOLOGY Case-based Symposium
Chairperson(s): A.S. Petronio (Pisa, IT); E. Eeckhout (Lausanne, CH)
11:00 That day, I took the wrong decision. 115
– R. Diletti (Rieti, IT)
11:15 That day, I took the wrong decision - Panel discussion and questions from the audience. 116
– R. Diletti (Rieti, IT), R.A. Byrne (Munich, DE), J.M. De La Torre Hernandez (Santander, ES)
11:30 The case from which I learnt the most. 117
– R.A. Byrne (Munich, DE)
11:45 The case from which I learnt the most - Panel discussion and questions from the audience. 118
– R. Diletti (Rieti, IT), R.A. Byrne (Munich, DE), J.M. De La Torre Hernandez (Santander, ES)
12:00 Nightmares in interventional cardiology - I would not do that again - State of the Art lecture. 119
– J.M. De La Torre Hernandez (Santander, ES)
25
11:00–12:30 | Ankara - Village 7

ANTITHROMBOTIC THERAPY IN PATIENTS WITH ATRIAL FIBRILLATION AND ACUTE CORONARY Symposium
SYNDROME
Chairperson(s): H. Rickli (St. Gallen, CH); M. Tubaro (Rome, IT)
11:00 Risk assessment: bleeding versus thrombosis. 120
– U. Zeymer (Ludwigshafen am Rhein, DE)
11:22 Dual therapy without aspirin. 121
– F. Andreotti (Rome, IT)
11:45 Choice of parenteral anticoagulation therapy. 122
– K. Huber (Vienna, AT)
12:07 Novel oral anticoagulant drugs, how effective and safe they are. 123
– R. De Caterina (Chieti, IT)
11:00–12:30 | Tunis - Village 7

TRIAGE OF CHEST PAIN IN THE EMERGENCY DEPARTMENT Advances in Science
Chairperson(s): E. Giannitsis (Heidelberg, DE); P. Goldstein (Lille, FR)
11:00 State of the Art in triage of patients with chest pain. 124
– F. Beygui (Caen, FR)
11:20 Copeptin supports early discharge in low- to intermediate-risk patients with suspected ACS: the 125
BIC-8 study update for 90-day outcomes.
– M. Mockel, A. Slagman, C. Hamm, J. Searle, K. Huber, C. Mueller, J. Vollert, S. Blankenberg, M. Vafaie,
E. Giannitsis (Berlin, Bad Nauheim, Hamburg and Heidelberg, DE; Vienna, AT; Basel, CH)
11:37 Direct comparison of the safety and efficacy of two rule-out strategies for acute myocardial 126
infarction.
– K.S. Wildi, R. Twerenbold, M. Rubini Gimenez, T. Reichlin, C. Puelacher, K. Grimm, T. Nestelberger,
J. Boeddinghaus, S. Osswald, C. Mueller (Basel, CH)
11:54 The 99th percentile of an updated heart fatty acid binding protein assay combines with high 127
sensitive troponin I to rule out acute myocardial infarction on presentation to the emergency
department.
– J.W. Pickering, J.M. Young, P. George, S. Aldous, R. Troughton, A.M. Richards, J. Wallace, M. Than
(Christchurch, NZ)
12:11 Future direction for research in chest pain assessment in the emergency department. 128
– C.E. Mueller (Basel, CH)
11:00–12:30 | Belgrade - Village 8

THE QUEST FOR NEW THERAPIES IN MYOCARDITIS Symposium
Chairperson(s): K. Klingel (Tübingen, DE); A.L.P. Caforio (Padua, IT)
11:00 Immune modulation and immunosuppression in myocarditis: current status. 129
– U. Eriksson (Wetzikon, CH)
11:22 Angiotensin II-mediated cardiac oxidative stress and inflammation. 130
– G. Oudit (Edmonton, CA)
11:45 Toll-like receptors as potential therapeutic targets. 131
– S. Frantz (Halle, DE)
12:07 Heart and liver: treating myocarditis by targeting hepatocytes. 132
– V. Poli (Turin, IT)
26
11:00–12:30 | Ljubljana - Village 8

DIFFICULT CASES IN VALVE DISEASE – LET’S CLEAR UP THE CONFUSION Meet the Experts
Chairperson(s): O. Alfieri (Brescia, IT); I. Simkova (Bratislava, SK)
11:00 Difficult cases in valve disease - Let’s clear up the confusion - Introduction to the session. 133
– D. Messika-Zeitoun (Paris, FR)
11:05 Low-flow/ low-gradient aortic stenosis. 134
– M.-A. Clavel (Quebec, CA)
11:15 Low-flow/ low-gradient aortic stenosis - Panel discussion and questions from the audience. 135
– M.-A. Clavel (Quebec, CA), A.A. Pasquet (Brussels, BE), A.P. Kappetein (Rotterdam, NL), J. Hung (Boston,
US)
11:30 Secondary mitral regurgitation. 136
– R. Beeri (Jerusalem, IL)
11:40 Secondary mitral regurgitation - Panel discussion and questions from the audience. 137
– A.A. Pasquet (Brussels, BE), A.P. Kappetein (Rotterdam, NL), M.-A. Clavel (Quebec, CA), R. Beeri
(Jerusalem, IL)
11:55 Which valve prosthesis for which patient. 138
– A.P. Kappetein (Rotterdam, NL)
12:05 Which valve prosthesis for which patient - Panel discussion and questions from the audience. 139
– A.P. Kappetein (Rotterdam, NL), A.A. Pasquet (Brussels, BE), M.-A. Clavel (Quebec, CA), R. Beeri
(Jerusalem, IL)
12:20 Difficult cases in valve disease - Let’s clear up the confusion - Take home message. 140
– O. Alfieri (Brescia, IT)
11:00–12:30 | Warsaw - Village 8

PREGNANCY AND HEART DISEASE – WHAT WE KNOW! WHERE TO GO? Advances in Science
Chairperson(s): C. Gohlke-Baerwolf (Ballrechten-Dottingen, DE); B.J.M. Mulder (Amsterdam, NL)
11:00 State of the Art in pregnancy and heart disease. 141
– F. Walker (London, UK)
11:20 Risk assessment in pregnant women with structural heart disease. 142
– I.M. Van Hagen, H. Boersma, M.R. Johnson, R. Hall, J.W. Roos-Hesselink (Rotterdam, NL; London and
Norwich, UK)
11:37 The risk of pregnancy in aortic stenosis: results from the ROPAC registry. 143
– S. Orwat, G.P. Diller, I.M. Van Hagen, R. Schmidt, D. Tobler, M. Greutmann, M.R. Johnson, R. Hall,
J.W. Roos-Hesselink, H. Baumgartner (Münster, DE; Rotterdam, NL; Basel and Zurich, CH; London and
Norwich, UK)
11:54 Pregnancy in patients with a Fontan circulation, results from a single centre. 144
– K.L. Von Klemperer, M. Cauldwell, P. Steer, L. Swan (London, UK)
12:11 Future direction for research in pregnancy and heart disease. 145
– C. Silversides (Toronto, CA)
11:00–12:30 | Bern - Village 9

AMBULATORY CARDIOGENIC SHOCK: CHALLENGES IN THE MANAGEMENT OF TRULY Symposium
ADVANCED HEART FAILURE
Chairperson(s): J.D. Parker (Toronto, CA); F.K. Triposkiadis (Larissa, GR)
11:00 Hemodynamic evaluation, traditional therapeutic approaches, approaches to decongestion. 146
– V.-P. Harjola (Helsinki, FI)
11:22 Advanced pharmacologic approaches - PDEVI? Roles for Serelaxin? Ularitide? Guanylate cyclase 147
agonists.
– M. Metra (Brescia, IT)
11:45 Device therapy - Novel pacing approaches, renal nerve ablation, aortic baroreceptor stimulation, 148
vagal stimulation etc....
– W.T. Abraham (Columbus, US)
12:07 Destination therapy - How to choose appropriate candidates. 149
– D. Milicic (Zagreb, HR)
11:00–12:30 | Bucharest - Village 9

CO-MORBIDITIES IN HEART FAILURE – AN OVERVIEW Symposium
Chairperson(s): J. Comin-Colet (Barcelona, ES); C.E. Angermann (Würzburg, DE)
11:00 Chronic lung disease. 150
– M. Lainscak (Celje, SI)
11:22 Hypertension and stroke. 151
– W. Doehner (Berlin, DE)
11:45 Diabetes. 152
– L. Ryden (Stockholm, SE)
12:07 Iron deficiency and anaemia in heart failure. 153
– E.A. Jankowska (Wroclaw, PL)
27
11:00–12:30 | Agora - Poster Area

ACUTE CARDIAC CARE IN THE EMERGENCY DEPARTMENT Rapid Fire Abstract
Chairperson(s): D. Logeart (Paris, FR); M. Moeckel (Berlin, DE)
11:00 Direct comparison of the safety and efficacy of two rule-out strategies for acute myocardial 154
infarction:2h-algorithm versus undetectable levels at presentation.
– M. Rubini Gimenez, R. Twerenbold, K. Wildi, T. Reichlin, J. Boeddinghaus, C. Puelacher, K. Grimm,
S. Osswald, C. Mueller (Basel, CH)
11:09 Refractory out-of-hospital cardiac arrest with ongoing cardiopulmonary resuscitation at hospital 155
arrival - survival and neurological outcome after conservative post-resuscitation care.
– H. Soeholm, J. Kjaergaard, F.K. Lippert, J.H. Thomsen, L. Kober, M. Wanscher, C. Hassager
(Copenhagen, DK)
11:18 When does ST depression predict coronary occlusion after an out-of-hospital cardiac arrest? 156
– K. Ramanathan, C. Cheung, B. Grunau, C.M. Taylor, M.W. Deyell, D. Barbic, K. Selvakumar, D. Lee,
J. Christenson, M.E. Farkouh (Vancouver and Toronto, CA)
11:27 Comparison of safety and efficacy of rule-out strategies in myocardial infarction: copeptin in 157
combination with troponin versus 2h algorithm.
– K.S. Wildi, R. Twerenbold, M. Rubini Gimenez, T. Reichlin, M. Wagener, J. Boeddinghaus, T. Nestelberger,
11:36 Acute heart failure as a clinical presentation of acute aortic syndromes: frequency, 158
pathophysiological mechanism, and prognostic effect.
– A. Corsini, F. Vagnarelli, M. Lorenzini, G. Norscini, L. Cinti, A. Foa’, S. Soflai Sohee, E. Biagini, G. Melandri,
C. Rapezzi (Bologna, IT)
11:45 Effects of hemolysis on the diagnostic accuracy of cardiac troponin I for the diagnosis of 159
myocardial infarction.
– C. Puelacher, R. Twerenbold, Z. Moreno-Weidmann, K. Wildi, J. Boeddinghaus, K. Grimm, T. Nestelberger,
C. Jaeger, K. Rentsch, C. Mueller (Basel, CH)
11:54 Copeptin for the prediction of adverse events in non-ST-elevation acute coronary syndrome. 160
– B. Morawiec, D. Kawecki, B. Przywara-Chowaniec, M. Opara, A. Gabrysiak, R. Szymanski, L.A.M. Ho,
O. Muller, E. Nowalany-Kozielska (Zabrze and Dabrowa, PL; Hong Kong, HK; Lausanne, CH)
12:03 Clinical characteristics of the ST segment patterns induced in patients with acute left circumflex 161
coronary artery occlusion.
– M. Vives Borras, A.H. Moustafa, J. Alvarez Garcia, A. Ferrero Gregori, A. Serra, J. Garcia-Picart, J. Balcells
Iranzo, J. Cinca (Barcelona and Manresa, ES)
12:12 High sensitivity troponin measurements in patients with acute non-cardiac and unknown origin 162
diagnoses: Results form the TRAPID-AMI trial.
– R.M. Nowak, J. McCord, R. Body, E. Giannitsis, M. Christ, F. Verschuren, R. Christenson, P. Dilba,
G. Bendig, C. Mueller (Detroit, Michigan and Baltimore, US; Manchester, UK; Heidelberg and Penzberg, DE;
Basel, CH; Brussels, BE)
12:21 Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in 163
emergency patients at high risk for acute coronary syndrome.
– F.H. Verbrugge, S. Kellens, M. Vanmechelen, L. Grieten, J. Van Lierde, J. Dens, M. Vrolix, P. Vandervoort
(Genk, BE)
28
SATURDAY 29 AUGUST 2015 – LUNCH TIME SESSIONS
Moderated Posters are on display from 11:00 to 16:00 on the plasma screen
of the topic related moderated poster station.
During the Moderated Poster session (12:30–13:30), from the large plasma screen, Presenters will summarise
their research within 3 minutes and then address questions from the Chairpersons and Audience.
12:30–13:30 | Moderated poster station - Poster Area
SATURDAY – LUNCH TIME

UPDATES ON ICD THERAPY Moderated Posters
Chairperson(s): A. McGavigan (Adelaide, AU); P. Neuzil (Prague, CZ)
12:30 Primary prevention indication for implantable cardioverter-defibrillator in post infarct patients: P164
the value of myocardial infarction scar characterization by magnetic resonance imaging.
– D. Voilliot, F. Odille, M. Andronache, I. Magnin-Poull, D. Mandry, P.-Y. Marie, J. Felblinger, E. Aliot,
N. Sadoul, C. De Chillou (Nancy, FR)
12:38 Risk stratification of ICD patients for appropriate shock and mortality in a multi-centre cohort. P165
The EU-TrigTreat study.
– L. Bergau, R. Willems, A.E. Tuinenburg, M.A. Vos, P. Flevari, C. Sohns, C. Roever, T. Friede, G. Hasenfuss,
M. Zabel (Göttingen, DE; Leuven, BE; Utrecht, NL; Athens, GR)
12:47 Use of primary prophylactic implantable cardioverter defibrillators in Europe - data from the P166
EU-CERT-ICD Registry.
– C. Sticherling, J. Hastrup Svendsen, S. Wijers, M. Scharfe, G. Schmidt, B. Vanderbeck, A. Lubinski,
B. Merkely, F. Braunschweig, M. Zabel (Basel, CH; Copenhagen, DK; Utrecht, NL; Munich and Göttingen,
DE; Leuven, BE; Lodz, PL; Budapest, HU; Stockholm, SE)
12:55 Identifying a population of patients suitable for the implantation of a subcutaneous defibrillator P167
(S-ICD) among patients implanted with a conventional transvenous device (TV-ICD).
– L. Zabala Diaz, J. Romero Roldan, J. Abad Vicente, L. Perez, X. Vinolas, J.B. Martinez, F. Perez, E. Garcia,
J. Alzueta, E. Diaz Infante (Pamplona, A Coruña, Barcelona, Vitoria/Gasteiz, Murcia, Vigo, Málaga and
Sevilla, ES)
13:04 Anti-tachycardia pacing is not associated with increased mortality. P168
– S. Sun, M.L. Brown, J.W. Johnson, V. Sharma, O.A. Obel (Dallas and Minneapolis, US)
13:12 Magnetic resonance imaging in patients with a subcutaneous implantable P169
cardioverter-defibrillator (S-ICD).
– P. Neuzil, M. Janotka, J. Keller, J. Vymazal, J. Weichet, J. Brada, M. Mudroch, J. Zacek, J. Petru (Prague,
CZ)
13:21 The role of implantable cardioverter defibrillators in patients with ventricular assist devices. P170
– A. Gkouziouta, A. Kostopoulou, D. Kalogerakis, A. Tsipis, G. Theodorakis, S. Adamopoulos (Athens, GR)

POST MYOCARDIAL INFARCTION OUTCOME Moderated Posters
Chairperson(s): M. Dalby (Harefield, UK); M.T. Bouafia (Blida, DZ)
12:30 Self-reported use of guideline-recommended medication 12 months after acute coronary P171
syndrome: a national longitudinal study.
– O.A. Alabas, K. Laut, T.B. Dondo, M. Van Laar, C.P. Gale (Leeds, UK)
12:38 Biomarker-based prediction model for recurrent ischemic events in revascularised patients with P172
acute coronary syndromes.
– D. Lindholm, J. Lindback, S.K. James, R.C. Becker, A. Himmelmann, A. Siegbahn, P.G. Steg, H.A. Katus,
C. Varenhorst, L. Wallentin (Uppsala and Mölndal, SE; Cincinnati, US; Paris, FR; Heidelberg, DE)
12:47 Impact of invasive strategies and sex on 5-year mortality after AMI. Insights From the French P173
ST-elevation and non-ST-elevation myocardial infarction (FAST-MI) 2005 registry.
– E. Puymirat, M. Donataccio, B. Parapid, G. Steg, H. Eltchaninoff, E. Ferreri, S. Charpentier,
J.E.A.N. Ferrieres, N. Danchin, T. Simon (Paris, Rouen, Nice and Toulouse, FR; Belgrade, RS)
12:55 Long term myocardial recovery after revascularization for ST-segment elevation myocardial P174
infarction as assessed by cardiac magnetic resonance imaging.
– R. Delewi, M.E.C.J. Hassell, A. Hirsch, R. Nijveldt, L. Robbers, J.G.P. Tijssen, A.C. Van Rossum, F. Zijlstra,
J.J. Piek (Amsterdam and Rotterdam, NL)
13:04 Galectin 3 is a powerful risk predictor for recurrent coronary events in acute coronary syndrome P175
patients.
– A. Schiopu, T. Yndigegn, H. Grufman, J. Nilsson, I. Goncalves (Malmö, SE)
13:12 Trajectories of quality of life after myocardial infarction: a national longitudinal study. P176
– O.A. Alabas, T.B. Dondo, K. Laut, M. Van Laar, C.P. Gale (Leeds, UK)
13:21 Prognostic impact of chronic total occlusions. A report from the Swedish Coronary Angiography P177
and Angioplasty Registry (SCAAR).
– E. Omerovic, T. Ramunddal, L. Hoebers, J. Henriques, C. Dworeck, G. Olivecrona, J. Harnek, U. Jensen,
M. Aasa, D. Ioanes (Gothenburg, Lund and Stockholm, SE; Amsterdam, NL)
29

DEVELOPMENTS IN NUCLEAR CARDIOLOGY, PROGNOSIS, RISK STRATIFICATION AND Moderated Posters
MANAGEMENT STRATEGIES
Chairperson(s): O. Gaemperli (Zurich, CH); A. Saraste (Turku, FI)
12:30 Effect of beta-blocking therapy on cardiac sympathetic nerve function in patients with idiopathic P178
pulmonary arterial hypertension.
– M.T. Rijnierse, J.S. Van Campen, K. De Boer, H.J. Harms, F.S. De Man, A.A. Lammertsma, P. Knaapen,
H.J. Bogaard, A. Vonk-Noordegraaf, C.P. Allaart (Amsterdam, NL)
12:38 Update on nuclear scan strategy to implement diagnosis in special populations of a large series P179
of patients with chest pain analyzed with the propensity score matching for cardiovascular risk
factors.
– A. Conti, S. Bianchi, D. Lazzeretti, A. Covelli, A.M. Lencioni, E. Angeli, R. Bonini, L. Vaggelli, C. Gallini,
E. Costanzo (Massa-Carrara and Florence, IT)
12:47 Measurement of left ventricular volumes and function with oxygen-15-labelled-water gated P180
positron emission tomography: comparison with cardiovascular magnetic resonance imaging.
– R.S. Driessen, J.E. Van Timmeren, W.J. Stuijfzand, M.T. Reinierse, P.G.H.M. Raijmakers,
A.A. Lammertsma, H.J. Harms, A.C. Van Rossum, M.C. Huisman, P. Knaapen (Amsterdam, NL)
12:55 Combination of fibrosis by cardiac magnetic resonance and late heart-to-mediastinum ratio by P181
cardiac 123-I MIBG imaging improves risk stratification in candidates for primary prevention
implantable car.
– P. Garcia-Gonzalez, P. Cozar-Santiago, O. Fabregat-Andres, J. Estornell-Erill, R. Sanchez-Jurado,
B. Bochard-Villanueva, A. Valle-Munoz, R. Paya-Serrano, J. Ferrer-Rebolleda, F. Ridocci-Soriano (Valencia
and Denia, ES)
13:04 Incremental prognostic value of SPECT imaging over renal function: a reclassification analysis. P182
– A. Ahmed, W. Qureshi, F. Khalid, M. Al-Mallah (Riyadh, SA; Winston-Salem, US)
13:12 18F-FDG-PET-CT assessed subclinical arterial inflammation is positively associated with P183
non-invasive markers of arterial stiffness in recently diagnosed type 2 diabetes patients.
– S.A. De Boer, M.C. Hovinga - De Boer, J.D. Lefrandt, A.M. Van Roon, P.W. Kamphuisen, H.L. Lutgers,
A.W.J.M. Glaudemans, H.J. Lambers Heersprink, R.H.J. Slart, D.J. Mulder (Groningen and Amersfoort, NL)
13:21 Diagnostic performance of the cadmium-zinc-telluride SPECT system with low-dose P184
technetium-99m as assessed by fractional flow reserve.
– S. Hida, T. Chikamori, N. Tanaka, J. Yamashita, Y. Igarashi, C. Shiba, T. Saitoh, K. Hirose, Y. Otaki,
A. Yamashina (Tokyo, JP)

NEWS IN CARDIAC ANATOMY Moderated Posters
Chairperson(s): S. Hatem (Paris, FR); C. Basso (Padua, IT)
12:30 Branch-related ruptures cause intramural hematoma and dissecting abdominal aortic aneurysm in P185
angiotensin II-infused ApoE−/− mice.
– B. Trachet, R.A. Fraga-Silva, A. Piersigilli, L. Aslanidou, A. Astolfo, M.F.M. Stampanoni, N. Stergiopulos,
P. Segers (Lausanne and Villigen, CH; Ghent, BE)
12:38 Quantification of focal lacerations in the tunica media that cause ascending aortic aneurysm in P186
angiotensin II-infused mice.
– B. Trachet, A. Piersigilli, R.A. Fraga-Silva, L. Aslanidou, A. Astolfo, M.F.M. Stampanoni, P. Segers,
N. Stergiopulos (Lausanne and Villigen, CH; Ghent, BE)
12:47 A comprehensive study of the human interatrial septum anatomy. P187
– M.K. Holda, M. Koziej, K. Piatek, J.P. Holda, W. Klimek-Piotrowska (Krakow, PL)
12:55 Anatomical model as a key for the cavo-tricuspid isthmus ablation. P188
13:04 An as yet unrecognised anatomic variant of intramural course of coronary arteries possibly P189
correlating with the mid-wall sign in cardiac magnetic resonance imaging.
– K. Wassilew, D. Messroghli (Berlin, DE)
13:12 The left atrial appendage morphology and its clinical significance. P190
13:21 Embryogenesis of myocardial trabeculae: insights from episcopic 3D imaging and fractal analysis P191 (W)
of notch noncompaction mouse models. (withdrawn)
– G.C. Captur, R.W. Wilson, W.J.M. McKenna, G.L. Luxan, J.L.P. De La Pompa, P.M.E. Elliott, T.J. Mohun,
J.C. Moon (London, UK; Madrid, ES)
30

PROGNOSIS IN PERICARDIAL DISEASE Moderated Posters
Chairperson(s): A.D. Ristic (Belgrade, RS); P. Seferovic (Belgrade, RS)
12:30 Recurrent pericarditis in children and adolescents.A multicentre cohort study. P192
– M. Imazio, A. Brucato, N. Pluymaekers, L. Breda, L. Cantarini, R. Cimaz, G. Limongelli, A. Valenti,
Y. Finkelstein, A. Martini (Turin, Bergamo, Chieti, Siena, Florence, Naples and Genoa, IT; Maastricht, NL;

Toronto, CA)
12:38 Predictors of adverse outcomes in pericardial diseases. P193
– T. Kudaiberdiev, G. Imanalieva, K. Tilemanbetova (Bishkek, KG)
12:47 Incremental value of cardiac magnetic resonance for the evaluation of cardiac tumors. P194
– S. Giusca, D. Mereles, A. Ochs, S. Buss, F. Andre, S. Seitz, J. Riffel, P. Fortner, H.A. Katus, G. Korosoglou
(Heidelberg, DE)
12:55 Percutaneous balloon pericardiotomy for severe malignant pericardial effusion. P195
– I. Ponz De Antonio, O. Gonzalez Fernandez, S. Rosillo, S. Jimenez Valero, R. Moreno, J.L. Lopez Sendon
(Madrid, ES)
13:04 Acute tuberculous pericarditis is associated with impaired left ventricular function. P196
– M.R. Matshela (Durban, ZA)
13:12 Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: The P197
FinPPS study.
– J. Lehto, J. Gunn, P.P. Karjalainen, J. Airaksinen, T.O. Kiviniemi (Turku and Satakunta, FI)
13:21 Improvement in functional capacity after pericardiectomy in patients with constrictive pericarditis. P198
– F. Fernandes, D.T.P. Melo, F.J.A. Ramires, F.R. Souza, A.L.C. Sayegh, M.J.N.N. Alves, C.E. Negrao,
R.R. Dias, V.M.C. Salemi, C. Mady (São Paulo, BR)

FROM PRE-DIABETES TO VASCULAR COMPLICATIONS Moderated Posters
Chairperson(s): N. Hancu (Cluj Napoca, RO); H. Saner (Berne, CH)
12:30 Impact of serum 1,5-anhydro-D-glucitol level on prediction of major adverse cardiac and P199
cerebrovascular events.
– N. Ikeda, H. Hara, Y. Hiroi (Tokyo, JP)
12:38 Rosuvastatin dose-dependently causes Insulin resistance and increases ambient glycemia In P200
hypercholesterolemic patients.
– K. Koh, S. Han, P. Oh, W.-J. Chung (Incheon, KR)
12:47 Lack of association between on-treatment low-density lipoprotein cholesterol levels and incident P201
diabetes in statin-treated coronary patients: the tnt and ideal studies.
– B. Arsenault, P. Kohli, D. Demicco, R. Laskey, M. Messig, J.J.P. Kastelein, D.D. Waters (Quebec, CA; San
Francisco, US; Amsterdam, NL)
12:55 Does uric acid predict future development of diabetes mellitus in the general population? P202
– T. Tanaka, H. Takase, T. Okado, K. Makino, S. Takayama, H. Hayashi, T. Sugiura, N. Ohte, Y. Dohi
(Hamamatsu and Nagoya, JP)
13:04 Relation of diabetes control, baseline risk and extent of coronary plaque to coronary and other P203
vascular outcomes over 7 years.
– D.A. Halon, M. Azencot, E. First, M.Y. Flugelman, R. Rubinshtein, B. Zafrir, B.S. Lewis (Haifa, IL)
13:12 Pre-diabetes augments the risk for target organ damage in newly diagnosed hypertensives. P204
– P. Xaplanteris, C. Vlachopoulos, D. Terentes-Printzios, P. Pietri, M. Abdelrasoul, N. Ioakeimidis,
G. Vyssoulis, D. Tousoulis (Athens, GR)
13:21 Are coronary arterial findings related to microvascular associated outcomes in asymptomatic P205
type 2 diabetics? A prospective CT angiographic 7 year outcomes study.
– D.A. Halon, M. Azencot, R. Rubinshtein, B. Zafrir, M.Y. Flugelman, B.S. Lewis (Haifa, IL)
31

PERCUTANEOUS NON-CORONARY TECHNIQUES FOR STROKE PREVENTION Moderated Posters
Chairperson(s): S. Berti (Massa, IT); A.K. Banerjee (Howrah, IN)
12:30 Indications for left atrial appendage occlusion and the impact on procedural safety and long-term P206
outcome: a report from the Amplatzer Cardiac Plug multicenter registry.
– A. Tzikas, X. Freixa, S. Gafoor, S. Shakir, H. Omran, S. Berti, W. Schillinger, B. Meier, J.W. Park,
H. Karvounis (Thessaloniki, GR; Barcelona, ES; Frankfurt am Main, Bonn, Göttingen and Hamburg, DE;
Berne, CH; Massa, IT)
12:38 Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation - a P207
systematic review and network meta-analysis of randomized controlled trials.
– H. Hanif, E. Belley-Cote, N. Dvirnik, B. Neupane, A. Alotaibi, D. Holmes, J. Eikelboom, R. Whitlock
(Hamilton, CA; Rochester, US)
12:47 Recurrent cerebral ischemia after patent foramen ovale percutaneous closure in older patients: a P208
two-centers registry study.
– P. Scacciatella, I. Meynet, P. Presbitero, M. Giorgi, C. Lucarelli, D. Zavalloni Parenti, L. Biava, S. Marra
(Turin and Rozzano, IT)
12:55 Does the percutaneous left atrium appendage closure influence left atrial performance? P209
– M. Madeira, R. Teixeira, C. Faustino, L. Paiva, L. Reis, I. Almeida, A. Quaresma, A. Botelho, M. Costa,
G. Lino (Coimbra, PT)
13:04 Percutaneous device closure of ruptured sinus of valsalva aneurysm: immediate and mid-term P210
follow-up results.
– M.J. Varghese, V.S. Thompson, O.K. George, P.V. George, G. Joseph (Vellore, IN)
13:12 Transcatheter very small patent ductus arteriosus closure without special implantable devices. P211
– D. Zverev, A. Pavlov, T. Makushkina, T. Tatarinova, V. Privorotsky, V. Gurev (St. Petersburg, RU)
13:21 Long term result of the left atrial appendage closure for stroke prevention in single high volume P212
center.
– Y. Matsuo, M. Sandri, G. Schuler, N. Mangner, M. Kurabayashi, S. Winkler (Maebashi, JP; Leipzig, DE)

HEART FAILURE THERAPY Moderated Posters
Chairperson(s): S. Solomon (Boston, US); A.P. Maggioni (Florence, IT)
12:30 Factors associated with dropout during the run-in period prior to randomization in PARADIGM-HF. P213
– A.S. Desai, B. Claggett, J.J.V. McMurray, M. Packer, J. Rouleau, K. Swedberg, M. Zile, M. Lefkowitz,
V. Shi, S. Solomon (Boston, Dallas, Charleston and East Hanover, US; Glasgow, UK; Montreal, CA;
Gothenburg, SE)
12:38 Elevated high sensitivity troponin is associated with poorer outcomes in patients with heart failure P214
and reduced by LCZ696.
– P. Jhund, B. Claggett, S. Solomon, A.A. Hagege, M.F. Prescott, J.L. Rouleau, K. Swedberg, M.R. Zile,
J.J.V. McMurray, M. Packer (Glasgow, UK; Boston, Hanover, Charleston and Dallas, US; Paris, FR;
Montreal, CA; Gothenburg, SE)
12:47 hSDF-1 over-expression to treat high risk ischemic heart failure patients - Phase II STOP-HF trial P215
1 year findings.
– M. Penn, L.W. Miller, R.D. Anderson, F. Mendelsohn, J. Shin, K.H. Silver, J. Pastore, R. Aras, A.N. Patel,
E.S. Chung (Akron, Tampa, Gainesville, Birmingham, New York, Cleveland, Salt Lake City and Cincinnati,
US)
12:55 The impact of digoxin on death and hospitalisation: unravelling the bias of prescription patterns. P216 (W)
(withdrawn)
– O.J. Ziff, M. Samra, M. Griffith, P. Kirchhof, D.A. Lane, G.Y.H. Lip, R.P. Steeds, J.N. Townend, D. Kotecha
(Birmingham and London, UK)
13:04 Novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. P217
– G. Savarese, G.M.C. Rosano, J. McMurray, R.P. Giugliano, B. Trimarco, P. Perrone-Filardi (Naples, IT;
London and Glasgow, UK; Boston, US)
13:12 Comparative associations between angiotensin converting enzyme inhibitors, angiotensin P218
receptor blockers and their combination, and outcomes in patients with heart failure and reduced
ejection fraction.
– G. Savarese, M. Edner, U. Dahlstrom, P. Perrone-Filardi, F. Cosentino, L.H. Lund (Stockholm and
Linköping, SE; Naples, IT)
13:21 Sitagliptin and the risk of hospitalization for heart failure in diabetic patients with chronic heart P219
failure.
– S.H. Sung, P.F. Hsu, H.M. Cheng, S.Y. Chuang (Taipei and Miaoli County, TW)
32

HYPERTENSION PATHOPHYSIOLOGY I Moderated Posters
Chairperson(s): R. Asmar (Paris, FR); M. Tomaszewski (Leicester, UK)
12:30 Interaction between alcohol habits and gene polymorphism of tumor necrosis factor receptor P220
superfamily, member 1B (TNFRSF1B) on the risk of essential hypertension.
– M. Eto, M. Okayama, T. Takeshima, M. Kumada, T. Aonuma, Y. Nakamura, E. Kajii (Wakuya, Kobe and

Shimotsuke, JP)
12:38 Natural history of patients with acute kidney injury and hypertensive urgency. P221
– S.-H. Wan, J.P. Slusser, D.O. Hodge, H.H. Chen (Rochester, US)
12:47 Hypertension awareness, treatment and control: does the risk factor profile matter? The Polish P222
Norwegian Study (PONS).
– G. Vaidean, M. Manczuk, K. Zatonska, A. Szuba (New York, US; Warsaw and Wroclaw, PL)
12:55 Potential association of circulatory level of endothelin-1 and hypertension in rural women in P223
bangladesh: evidences from a community based cross-sectional study.
– A. Rahman, S. Jesmin, A.K.M.A. Habib, A. Khan, F. Sohael, S. Kawano, M. Moroi, I. Iwashima, O. Sarwar
Hossain, T. Khatun (Bogra, Dhaka and Chapai Nawabgonj, BD; Tsukuba, Tokyo and Osaka, JP)
13:04 Hypertension control and medication burden in patients with additional risk factors in central and P224
eastern Europe.
– J. Vaclavik, S. Littnerova, Z. Zbozinkova, I. Schlegelmilch, J. Dlask (Olomouc, Brno and Prague, CZ; Vienna,
AT)
13:12 Serum uric acid in primary hypertension: cause or consequence? Data from SEPHAR II Survey. P225
– D. Lighezan, R. Buzas, O. Tautu, M. Dorobantu (Timisoara and Bucharest, RO)
13:21 Relationship of renal impairment and diastolic dysfunction to hypertension in minority ethnic P226
groups: ethnic-echocardiographic heart of England screening study (E-ECHOES).
– A. Shantsila, P.S. Gill, E. Shantsila, G.Y.H. Lip (Birmingham, UK)

GUIDANCE ON THE ESC GUIDELINES IN NURSING PRACTICE Special Session
Chairperson(s): I. Uchmanowicz (Wroclaw, PL); A. Stromberg (Linköping, SE)
12:35 Implementation of the Cardiovascular Diseases Prevention Guidelines - How do nurses see their 227
role?
– G. McKee (Dublin, IE)
12:47 Guidelines Implementation - A multidisciplinary affair! 228
– D. Fitzsimons (Belfast, UK)
13:00 ESC Clinical Practice Guidelines - Overcoming challenges to implementation in a live training 229
session.
– To be announced
13:12 Panel of experts. 230
– C.S. Jennings (London, UK)
33
SATURDAY 29 AUGUST 2015 – AFTERNOON SESSIONS

PRIMARY CARE DILEMMAS Symposium
Chairperson(s): S.C. Clarke (Cambridge, UK); J. Robson (London, UK)
13:30 ECG Quiz. 231
– S.P. Fynn (Cambridge, UK)
14:15 Dizziness and syncope - Case based diagnosis and management. 232
– P.B. Lim (London, UK)

ESC GUIDELINES IN THE RUSSIAN FEDERATION – AORTIC DISEASE
Chairperson(s): E.V. Shlyakhto (St. Petersburg, RU); A.V. Pokrovsky (Moscow, RU)
– V. Uspenskiy (St. Petersburg, RU)
– T. Chernyavskaya (Moscow, RU)
14:15 Clinical practice in the Russian Federation based on national registry. 235
– S. Abugov (Moscow, RU)
– R.S. Akchurin (Moscow, RU)

ESC GUIDELINES IN TURKEY – DIABETES
Chairperson(s): C. Erol (Ankara, TR); S. Aytekin (Istanbul, TR)
– M. Akcay (Samsun/Atakum, TR)
– N. Ozer (Ankara, TR)
14:15 Clinical practice in Turkey based on national registry. 239
– L.E. Sade (Ankara, TR)
– I. Dincer (Ankara, TR)

ESC GUIDELINES IN ISRAEL – HIGH-RISK PATIENTS WITH AORTIC STENOSIS
Chairperson(s): Y. Rozenman (Holon, IL); A. Finkelstein (Tel Aviv, IL)
– M. Merkin (Beer Sheva, IL)
– Y. Shapira (Reut, IL)
14:15 Clinical practice in Israel based on EORP registries or national registry. 243
– A. Segev (Tel Hashomer, IL)
– R. Rubinshtein (Haifa, IL)

ESC GUIDELINES IN GERMANY – ATRIAL FIBRILLATION
Chairperson(s): K.-H. Kuck (Hamburg, DE); U. Sechtem (Stuttgart, DE)
– C. Theis (Mainz, DE)
– S. Ernst (London, UK)
14:15 Clinical practice in Germany based on EORP registries or national registry. 247
– G. Hindricks (Leipzig, DE)
– O.A. Breithardt (Kassel, DE)
34

CARDIOVASCULAR PREVENTION AT EVERY LEVEL Symposium
Chairperson(s): G. McKee (Dublin, IE); J. Evans (London, UK)
13:30 Personalised medicine: towards earlier more effective cardiovascular risk communication. 249
– M. Kerins (Dublin, IE)
13:52 e-Cigarettes: friend or foe? 250
SATURDAY – AFTERNOON
– P. Hajek (London, UK)
14:15 Nurses taking the lead in prevention: The Global Nursing Leadership Forum. 251
– B. Fletcher (Jacksonville Beach, US)
14:37 On a global stage: the WHO 25 by 25 goals. 252
– S. Yusuf (Hamilton, CA)
13:30–15:00 | Rabat - Village 1

THE VULNERABLE PLAQUE: IMAGING AND STABILISATION Symposium
Chairperson(s): S. Yla-Herttuala (Kuopio, FI); S. Steffens (Munich, DE)
13:30 Pathophysiology of atherosclerotic plaque vulnerability. 253
– M. Daemen (Amsterdam, NL)
13:52 Can we see vulnerable plaques? 254
– F. Alfonso Manterola (Madrid, ES)
14:15 Plaque regression and stabilisation. 255
14:37 Novel therapeutic strategies for plaque stabilisation. 256
– E. Lutgens (Amsterdam, NL)

MECHANISTIC PATHWAYS OF SEX DIFFERENCE IN CARDIOVASCULAR DISEASE Symposium
ESC and the International Society for Gender Medicine
Chairperson(s): K.R. Sipido (Leuven, BE); R.F. Ventura-Clapier (Chatenay-Malabry, FR)
13:30 Sex differences in developmental origin of disease. 257
– C. Junien (Jouy-En-Josas, FR)
13:52 Human cardiac myocytes: calcium handling and sex differences. 258
– C.E. Molina (Essen, DE)
14:15 Sex differences in mitochondrial proteome and respiratory function. 259
– S. Menazza (Bethesda, US)
14:37 Sex differences in myocardial adaption to pressure overload. 260

ECONOMIC ENVIRONMENT IN CARDIOVASCULAR OUTCOME Symposium
ESC and the Cardiological Society of India
Chairperson(s): Y. Balbay (Ankara, TR); P.K. Deb (Kolkata, IN)
13:30 Cardiovascular disease burden in India: challenges ahead. 261
– S. Mishra (New Delhi, IN)
13:52 Cardiovascular disease prevention in developing countries - Contribution of nurses. 262
14:15 Metabolic syndrome in India: is it unique? 263
– A.K. Pancholia (Indore, IN)
14:37 Diabetes and cardiovascular disease - From EuroAspire to GlobalAspire? 264
35

IS OBESITY ALWAYS BAD? Debate Session
Chairperson(s): Z. Fras (Ljubljana, SI); E.A. Jankowska (Wroclaw, PL)
13:30 Obesity is always bad in cardiovascular diseases. PRO. 265
– D. Gaita (Timisoara, RO)
13:45 Obesity is always bad in cardiovascular diseases. CONTRA. 266
14:00 Obesity is always bad in cardiovascular diseases. REBUTTAL PRO. 267
14:05 Obesity is always bad in cardiovascular diseases. REBUTTAL CONTRA. 268
14:10 Obesity is always bad in cardiovascular diseases - CONCLUSION. 269
14:15 Are there metabolically healthy obese patients? PRO. 270
– N. Hancu (Cluj-Napoca, RO)
14:30 Are there metabolically healthy obese patients? CONTRA. 271
– L. Sperling (Atlanta, US)
14:45 Are there metabolically healthy obese patients? REBUTTAL PRO. 272
– N. Hancu (Cluj-Napoca, RO)
14:50 Are there metabolically healthy obese patients? REBUTTAL CONTRA. 273
14:55 Are there metabolically healthy obese patients? CONCLUSION. 274

SEX DIFFERENCES IN CARDIOVASCULAR DISEASE TRAJECTORIES Advances in Science
Chairperson(s): A. Rosengren (Gothenburg, SE); P.E. Ong (Stuttgart, DE)
13:30 State of the Art in sex differences in cardiovascular disease outcomes. 275
– A.H.E.M. Maas (Nijmegen, NL)
13:50 Sex differences in risk factor trajectories prior to coronary heart disease and stroke: the 276
Rotterdam Study.
– M. Kavousi, K. Dhana, D. Vistisen, A. Hofman, M.A. Ikram, O.H. Franco (Rotterdam, NL; Gentofte, DK)
14:07 Five-year clinical outcomes of patients with coronary artery spasm-induced acute myocardial 277
infarction.
– J.B. Kim, S.W. Rha, B.G. Choi, S.Y. Choi, J.K. Byun, J.J. Lee, S.K. Lee, C.G. Park, H.S. Seo, D.J. Oh
(Bucheon and Seoul, KR)
14:24 Trends in gender differences in cardiac care and outcome after acute myocardial infarction in 278
western Sweden.
– B. Redfors, O. Angeras, T. Ramunddal, P. Peturrson, I. Haraldsson, C. Dworeck, J. Odenstedt,
A. Ravn-Fischer, P. Albertsson, E. Omerovic (Gothenburg, SE)
14:41 Future direction for research in targeting gender disparities. 279
– N.C. Bairey Merz (Los Angeles, US)
13:30–15:00 | Kiev - Village 3

CHALLENGES IN HYPERTENSION Meet the Experts
Chairperson(s): B. Williams (London, UK); G. Parati (Milan, IT)
13:30 Challenges in hypertension - Introduction to the session. 280
– B. Williams (London, UK)
13:35 Masked hypertension. 281
– P. Verdecchia (Perugia, IT)
13:45 Masked hypertension - Panel discussion and questions from the audience. 282
– K. Kario (Shimotsuke, JP), A. Konradi (St. Petersburg, RU), R. McManus (Oxford, UK)
14:00 White coat hypertension. 283
– L.M. Ruilope (Madrid, ES)
14:10 White coat hypertension - Panel discussion and questions from the audience. 284
14:25 The “morning surge” in blood pressure. 285
– K. Kario (Shimotsuke, JP)
14:35 Postural hypotension - Panel discussion and questions from the audience. 286
14:50 Challenges in hypertension - Take home message. 287
– G. Parati (Milan, IT)
36

THYROID AND THE HEART Symposium
ESC and the International Society of Cardiovascular Pharmacotherapy
Chairperson(s): G.-A. Dan (Bucharest, RO); K.P. Kjeldsen (Copenhagen, DK)
13:30 Thyroid hormones in heart failure. 288
– F. Martinez (Córdoba, AR)
13:52 Thyroid hormone therapy and cardiac remodeling. 289
– D.V. Cokkinos (Athens, GR)
14:15 The thyronamines. A new player. 290
– I. Klein (Manhasset, US)
14:37 Cardioprotection and thyroid hormones. 291
– A. Pingitore (Pisa, IT)

ENVIRONMENTAL EFFECTS ON PATIENTS WITH PACEMAKER AND ICD Symposium
ESC and the Asian Pacific Society of Cardiology
Chairperson(s): B. Gorenek (Eskisehir, TR); K.-H. Sim (Kuching, MY)
13:30 Household appliances. 292
– C. Leclercq (Rennes, FR)
13:52 Cellular telephones. 293
– H. Burri (Geneva, CH)
14:15 Electromagnetic security systems. 294
– C.K. Ching (Singapore, SG)
14:37 Portable media players. 295
– M. Amin (Arad, BH)

ATRIAL FIBRILLATION POPULATION BASED STUDIES Advances in Science
Chairperson(s): A.P. Maggioni (Florence, IT); J. Brugada Terradellas (Barcelona, ES)
13:30 State of the Art in population impact of atrial fibrillation. 296
13:50 The association between influenza infection, vaccination and atrial fibrillation: a nationwide 297
case-control study.
– T.F. Chao, T.Y. Chang, S.A. Chen (Taipei, TW)
14:07 Comparative longitudinal outcomes of familial vs non-familial atrial fibrillation: results in 3608 298
matched cases.
– A. Gundlund, J.B. Olesen, J.P. Piccini, E.D. Peterson, L. Koeber, C. Torp-Pedersen, G.H. Gislason,
E.L. Fosboel (Gentofte, Copenhagen and Aalborg, DK; Durham, US)
14:24 Atrial fibrillation accelerates aging of the brain in the general elderly population. 299
– H. Stefansdottir, S. Sigurdsson, T. Aspelund, L.J. Launer, V. Gudnason, D.O. Arnar (Regensburg, DE;
Kopavogur and Reykjavik, IS; Bethesda, US)
14:41 Future direction for research in determinants of prognosis in patients with atrial fibrillation. 300
– L. Di Biase (New York, US)

CARDIAC IMAGING AND NON-CARDIAC CANCER Symposium
Chairperson(s): Z. Vered (Zerifin, IL); M. Vannan (Atlanta, US)
13:30 Cardiotoxicity of oncologic treatments: is there a uniform definition? 301
– M. Scherrer-Crosbie (Boston, US)
13:52 Detection of cardiac dysfunction and echo-monitoring of cardiotoxicity. 302
14:15 Coronary effects of chemotherapy: role of coronary flow reserve. 303
– A. Saraste (Turku, FI)
14:37 Early detection of cardiotoxicity using magnetic resonance. 304
– D.J. Pennell (London, UK)
37

HOW RELEVANT IS IMAGING-RELATED RISK Symposium
Chairperson(s): E. Picano (Astana, KZ); J. Schwitter (Lausanne, CH)
13:30 Radiation exposure: a known risk but does it matter? 305
– J.M. Knuuti (Turku, FI)
13:52 Potential biological effects of MRI imaging. 306
– S. Plein (Leeds, UK)
14:15 Contrast echocardiography: safe in the acute setting? 307
– B. Cosyns (Braine-l’Alleud, BE)
14:37 MRI in patients with implantable devices: what is the risk today? 308
– M.J.W. Gotte (The Hague, NL)

FUNCTIONAL MITRAL REGURGITATION: KNIFE AND/OR WIRES Symposium
Chairperson(s): J. Hung (Boston, US); H.K. Najm (Riyadh, SA)
13:30 Prevalence, risk factors and prognostic implication of functional mitral regurgitation. 309
– L.A. Pierard (Liège, BE)
13:52 Surgical mitral valve repair for functional mitral regurgitation is dead. 310
– M. Mack (Plano, US)
14:15 Why current randomised data keep mitral repair for functional mitral regurgitation still alive. 311
– R. Dion (Genk, BE)
14:37 Mitraclip registries: what do they tell and what are the limits? 312
– T. Feldman (Evanston, US)
13:30–15:00 | Oslo - Village 6

TAVI: A SOLUTION FOR ALL PATIENTS? Debate Session
Chairperson(s): M. Haude (Neuss, DE); H. Eltchaninoff (Rouen, FR)
13:30 Intermediate risk-patients: the answer is TAVI - PRO. 313
– M.B. Leon (New York, US)
13:45 Intermediate risk-patients: the answer is TAVI - CONTRA. 314
– T. Walther (Bad Nauheim, DE)
14:00 Intermediate risk-patients: the answer is TAVI - REBUTTAL PRO. 315
14:05 Intermediate risk-patients: the answer is TAVI - REBUTTAL CONTRA. 316
– T. Walther (Bad Nauheim, DE)
14:10 Intermediate risk-patients: the answer is TAVI - CONCLUSION. 317
14:15 TAVI should not be denied to very high risk patients - PRO. 318
– N.M.D.A. van Mieghem (Rotterdam, NL)
14:30 TAVI should not be denied to very high risk patients - CONTRA. 319
– F. Saia (Bologna, IT)
14:45 TAVI should not be denied to very high risk patients - REBUTTAL PRO. 320
– N.M.D.A. van Mieghem (Rotterdam, NL)
14:50 TAVI should not be denied to very high risk patients - REBUTTAL CONTRA. 321
– F. Saia (Bologna, IT)
14:55 TAVI should not be denied to very high risk patients - CONCLUSION. 322

WHICH IS THE BEST PARTNER FOR ASPIRIN IN TREATMENT OF ACUTE CORONARY Symposium
SYNDROMES?
Chairperson(s): K. Huber (Vienna, AT); E.L. Grove (Aarhus, DK)
13:30 Clopidogrel provides the greatest safety and efficacy. 323
– G. Parodi (Florence, IT)
13:52 Prasugrel is best suited with potent and irreversible P2Y12. 324
– J.-P. Collet (Paris, FR)
14:15 Reversible P2Y12 inhibition with ticagrelor is the best choice on top of aspirin. 325
– S. Husted (Herning, DK)
14:37 Aspirin needs an antithrombotic companion and rivaroxaban should be added as soon as 326
possible.
– J.M. Ten Berg (Nieuwegein, NL)
38
13:30–15:00 | Lisbon - Village 7

MECHANICAL CIRCULATORY SUPPORT – WHAT EVERY CARDIOLOGIST MAY NOT KNOW Meet the Experts
Chairperson(s): C.H. Hassager (Copenhagen, DK); P. Leprince (Paris, FR)
13:30 Mechanical circulatory support - What every cardiologist may not know - Introduction to the 327
session.
– P. Leprince (Paris, FR)
13:35 Mechanical circulatory support for PCI: high risky PCI without support – And what tools do you 328
have to determine what bail-out kit you might have and might need? What if you don’t have full
access to all the tools? What is the approach.
– P. Vranckx (Hasselt, BE)
13:45 Mechanical circulatory suppor for PCI - Panel discussion and questions from the audience. 329
– P. Vranckx (Hasselt, BE), A. Combes (Paris, FR), M.J.G. Morshuis (Bad Oeynhausen, DE)
14:00 When and who to refer for mechanical circulatory support for shock: centred around decisions 330
regarding referral for institution of support.
– A. Combes (Paris, FR)
14:10 When and who to refer for mechanical circulatory support for shock - Panel discussion and 331
14:25 Post-cardiotomy mechanical circulatory support – A collaborative approach. 332
– M.J.G. Morshuis (Bad Oeynhausen, DE)
14:35 Post cardiotomy mechanical circulatory support - A collaborative approach - Panel discussion 333
and questions from the audience.
14:50 Mechanical circulatory support - What every cardiologist may not know - Take home message. 334
13:30–15:00 | Tunis - Village 7

CARDIOPROTECTION AND POST MYOCARDIAL INFARCTION REMODELLING Advances in Science
Chairperson(s): N.D. Brunetti (Bari, IT); I. Goncalves (Malmö, SE)
13:30 State of the Art in inflammation and immunity. 335
– S. Massberg (Munich, DE)
13:50 The interleukin-6 receptor antagonist tocilizumab reduces inflammation and myocardial damage 336
in non-ST elevation myocardial infarction - a randomized, double-blind, placebo controlled study.
– O. Kleveland, G. Kunszt, M. Bratlie, T. Ueland, B. Amundsen, S. Aakhus, J.K. Damaas, P. Aukrust,
R. Wiseth, L. Gullestad (Trondheim and Oslo, NO)
14:07 Exosomes mediate activation of CD4+ T cells by dendritic cells after myocardial infarction. 337
– H. Liu, W. Gao, J. Yuan, C. Wu, K. Yao, J. Zhu, X. Guo, W. Yu, Y. Zou, J. Ge (Shanghai and Ningbo, CN)
14:24 Elevated circulating senescence-associated microRNAs reduce Sirt1 activity in patients with 338
coronary artery disease: Randomized Study of aggressive or moderate therapy with Pitavastatin.
– M. Satoh, Y. Takahashi, K. Takahashi, M. Tamada, T. Itoh, T. Nasu, Y. Morino, M. Nakamura (Morioka, JP)
14:41 Future direction for research in inflammation and immunity. 339
– P. Libby (Boston, US)

HIV-RELATED MYOCARDIAL AND PERICARDIAL DISEASES Symposium
ESC and the South African Heart Association
Chairperson(s): K. Sliwa-Hahnle (Cape Town, ZA); S. Pankuweit (Marburg, DE)
13:30 HIV-related myocardial and pericardial disease: viral or auto immune pathogenesis? 340
– K. Klingel (Tübingen, DE)
13:52 HIV and the heart in Sub-Saharan Africa. 341
– A.I. Sarkin (Pretoria, ZA)
14:15 HIV-related myocardial and pericardial disease. 342
– F. Boccara (Paris, FR)
14:37 An unusual presentation of HIV - related heart disease. 343
– A.I. Dzudie Tamdja (Douala, CM)
39

THE ROLE OF ENVIRONMENT IN ADULT CONGENITAL HEART DISEASE Symposium
ESC and the International Society for Adult Congenital Heart Disease
Chairperson(s): P. Khairy (Montreal, CA); B.J.M. Mulder (Amsterdam, NL)
13:30 Exercise: friend or foe. 344
– G.P. Diller (Münster, DE)
13:52 Socio-demographic variations in congenital heart disease worldwide. 345
– A. Kovacs (Toronto, CA)
14:15 Genetic environment as a cause of congenital heart disease. 346
– S. Mital (Toronto, CA)
14:37 Maternal lifestyle and pregnancy outcomes. 347
– S. Thorne (Birmingham, UK)

CATHETER INTERVENTION FOR MITRAL REGURGITATION – FROM INNOVATION TO Advances in Science
EVIDENCE
Chairperson(s): V. Falk (Berlin, DE); O. Alfieri (Brescia, IT)
13:30 State of the Art in catheter intervention for mitral regurgitation. 348
– A. Vahanian (Paris, FR)
13:50 One-year outcome after mitraclip implantation - Results from the German TRAMI registry. 349
– M. Puls, W. Schillinger, E. Lubos, P. Boekstegers, R.S. Von Bardeleben, C. Butter, C. Zuern, T. Ouarrak,
H. Eggebrecht, J. Senges (Göttingen, Hamburg, Siegburg, Mainz, Bernau bei Berlin, Tübingen,
Ludwigshafen am Rhein and Frankfurt am Main, DE)
14:07 Elevated residual pressure gradient at mitral valve after MitraClip implantation deteriorates long 350
term outcome in patients with severe mitral regurgitation and severe heart failure.
– T. Schau, A. Isotani, M. Pilz, M. Schoepp, M. Seifert, J. Weissenborn, M. Neuss, C. Butter (Bernau bei
Berlin, DE)
14:24 Transapical off-pump mitral valve repair with neochord implantation: 6-months clinical and 351
echocardiographic follow-up.
– A. Colli, F. Zucchetta, E. Manzan, E. Bizzotto, L. Besola, R. Bellu, D. Pittarello, G. Gerosa (Padua, IT)
14:41 Future direction for research in catheter intervention for mitral regurgitation. 352
– F. Maisano (Zurich, CH)
13:30–15:00 | Bern - Village 9

BIOMARKERS FOR HEART FAILURE – A REALITY CHECK Symposium
Chairperson(s): D.J. van Veldhuisen (Groningen, NL); S. Von Haehling (Berlin, DE)
13:30 New biomarkers: from prediction to action. 353
– A. Maisel (Solana Beach, US)
13:52 Biomarkers of kidney function - Useful or not? 354
– R.A. De Boer (Groningen, NL)
14:15 Tissue damage: troponins, copeptin and more. 355
– J. Lekakis (Haidari and Athens, GR)
14:37 Update on biomarkers: guided therapy. 356
– G.M. Felker (Durham, US)

COMORBIDITIES AND HEART FAILURE PROGNOSIS Advances in Science
Chairperson(s): S. Adamopoulos (Athens, GR); A. Cohen-Solal (Paris, FR)
13:30 State of the Art in heart failure and comorbidities. 357
– M. Senni (Bergamo, IT)
13:50 Prevalence of sleep-disordered breathing in heart failure patients: first results of the prospective 358
German SchlaHF-XT Registry.
– O. Oldenburg, M. Arzt, E. Erdmann, H. Teschler, B. Wellmann, K. Wegscheider, H. Woehrle (Bad
Oeynhausen, Regensburg, Cologne, Essen, Hamburg and Martinsried, DE)
14:07 Vascular disease as a risk factor of stroke or death in heart failure patients in sinus rhythm: a 359
nationwide cohort study.
– L. Melgaard, A. Gorst-Rasmussen, G. Lip, T.B. Larsen (Aalborg, DK; Birmingham, UK)
14:24 Heart failure patients hospitalised with bacterial infections: a U.S. nationwide analysis of 360
concomitant clostridium difficile infection rates and in-hospital mortality.
– P. Mamic, P. Heidenreich, L. Tennakoon, K. Staudenmayer (Palo Alto, US)
14:41 Future direction for research on impaired liver and gut function in heart failure. 361
– A. Sandek (Göttingen, DE)
40

STENT TECHNOLOGY AND CLINICAL OUTCOMES Rapid Fire Abstract
Chairperson(s): H. Aboul Einen (Cairo, EG); H.M. Mardikar (Nagpur, IN)
13:30 Comparative effectiveness and safety of new- versus early-generation drug-eluting stents 362
according to the complexity of coronary artery disease. A patient-level pooled analysis of 6,081
patients.
– R. Piccolo, D. Heg, J. Rat, A. Franzone, S. Silber, P.W.J.C. Serruys, T. Pigrim, P. Juni, S. Windecker
(Berne, CH; Munich, DE; Rotterdam, NL)
13:39 Clinical outcome of first vs second generation DES according to DAPT duration: Results of 363
ARCTIC-GENERATION.
– J.-P. Collet, J. Silvain, M. Kerneis, T. Cuisset, O. Barthelemy, G. Range, G. Cayla, E.R.I.C. Van Belle,
E.R.I.C. Vicaut, G. Montalescot (Paris, Marseille, Nîmes and Lille, FR)
13:48 Increased incidence of revascularization in higher risk patients treated with the absorb 364
everolimus-eluting bioresorbable scaffold: 12-months clinical results.
– R.P. Kraak, M.J.D. Grundeken, K.T. Koch, J.P.S. Henriques, J.J. Piek, J. Baan Jr, M.M. Vis, J.G.P. Tijssen,
R.J. De Winter, J.J. Wykrzykowska (Amsterdam, NL)
13:57 Bioresorbable vascular scaffold for the treatment of bifurcated coronary lesions. 365
– J. Suarez De Lezo Herreros De Tejada, P. Martin, M. Pan, S. Ojeda, M. Romero, J. Novoa, J. Garcia,
M. Mazuelos, A. Medina, J. Suarez De Lezo Cruz-Conde (Córdoba and Las Palmas de Gran Canaria, ES)
14:06 Prospective registry of bioresorbable coronary devices in clinical practice: immediate and 30-day 366
results of the REPARA registry.
– F. Hernandez, E. Pinar, E. Molina, J.F. Diaz, R. Lopez-Palop, J.C. Fernandez-Guerrero, F. Gimeno,
J. Zueco, F. Miranda, P. Canas Da Silva (Madrid, Murcia, Granada, Huelva, Alicante, Jaén, Valladolid,
Santander and Barcelona, ES; Lisbon, PT)
14:15 Chronic total occlusions in the UK: an unmet need for revascularization? an observational study 367 (W)
of 3,483 patients from the pan-London CTO cohort. (withdrawn)
– D.A. Jones, S.M. Gallagher, K.S. Rathod, J. Hill, C. Di Mario, A. Wragg, E.J. Smith (London, UK)
14:24 Attenuated coronary flow reserve early after implantation of a bioresorbable vascular scaffold: 368
one-month results of the vanish-trial.
– W. Stuijfzand, R.S. Driessen, P.G. Raijmakers, A.A. Lammertsma, A.C. Van Rossum, Y. Appelman,
J.S. Lemkes, M.A. Van Leeuwen, N. Van Royen, P. Knaapen (Amsterdam, NL)
14:33 QCA-Dmax as guidance for appropriate size selection and deployment of the Absorb scaffold(s) in 369
1232 patients from three study cohorts (ABSORB Cohort B, ABSORB EXTEND and ABSORB II):
Impact on the cli.
– Y. Ishibashi, S. Nakatani, P. Suwannasom, M. Grundeken, H. Garcia-Garcia, B. Chevalier, A. Abizaid,
Y. Onuma, P.W.J.C. Serruys (Kawasaki, JP; Rotterdam and Amsterdam, NL; Massy, FR; São Paulo, BR;
London, UK)
14:42 No more metal or one more: drug-coated balloons versus second-generation drug-eluting stents 370
for recurrent multi-metal-layered in-stent restenosis.
– H. Kawamoto, N. Ruparelia, A. Latib, T. Miyazaki, A. Mangieri, F. Figini, A. Chieffo, M. Montorfano,
A. Colombo (Milan, IT)
14:51 Comparison of clinical outcomes after transradial and transfemoral interventions in contemporary 371
antiplatelet era: a propensity score-matched analysis.
– J.C. Choe, K.S. Cha, J.H. Choi, B. Kim, J.S. Park, H.W. Lee, J.H. Oh, J.H. Choi, H.C. Lee, T.J. Hong
(Busan, KR)
15:30–16:30 | Rabat - Village 1

NEW PARADIGMS IN HEART FAILURE: RAAS INHIBITION AND THE MANAGEMENT OF Satellite Symposium
HYPERKALEMIA
Sponsored by ZS Pharma, Inc.
Chairperson(s): J.J.V. McMurray (Glasgow, UK)
15:30 Welcome and introductions - New paradigms in heart failure: RAAS inhibition and the 372
management of hyperkalemia.
– J.J.V. McMurray (Glasgow, UK)
15:35 Why aren’t we titrating optimal RAAS inhibitor life-saving therapy? 373
– F. Zannad (Vandoeuvre-lès-Nancy, FR)
15:50 New pharmacological options for heart failure. 374
– I. Pina (Bronx, US)
16:05 Paradigm shifts in the pharmacological management of heart failure. 375
16:10 Panel Discussion - New paradigms in heart failure: RAAS inhibition and the management of 376
hyperkalemia.
– J.J.V. McMurray (Glasgow, UK), F. Zannad (Vandoeuvre-lès-Nancy, FR), I. Pina (Bronx, US)
16:20 Questions and answers - New paradigms in heart failure: RAAS inhibition and the management of 377
hyperkalemia.
– J.J.V. McMurray (Glasgow, UK), F. Zannad (Vandoeuvre-lès-Nancy, FR), I. Pina (Bronx, US)
41

MANAGEMENT OF BLOOD PRESSURE CONTROL: AT THE CUTTING EDGE Satellite Symposium
Sponsored by The Menarini Group and Daiichi Sankyo Europe GmbH
Chairperson(s): B. Williams (London, UK); G. Parati (Milan, IT)
15:30 Chairperson’s introduction: what are the key barriers that are holding back improvements in 378
blood pressure control in 2015?
15:40 Blood pressure parameters today: has there been any change since 2008? 379
– T.W. Weiss (Vienna, AT)
16:00 How have initiatives implemented in France and Italy to achieve 70% blood pressure control 380
among treated hypertensives changed the situation?
– J.-J. Mourad (Bobigny, FR)
16:20 Has the introduction of single-pill fixed-dose combinations affected blood pressure management? 381
Presentation of two patient cases: The patient with chronic kidney disease and The elderly
patient.
– M. Volpe (Rome, IT)
16:40 The impact of new technology like home blood pressure monitoring and smartphone apps on 382
blood pressure control.
– G. Parati (Milan, IT)
16:50 Summary and Conclusions: management of blood pressure control: at the cutting edge. 383
– B. Williams (London, UK), G. Parati (Milan, IT)
Don’t miss the complimentary Experts on the Spot session scheduled on
Monday 31 August, 15:45–16:15 in Holland Park (The Hub)!

RESTORING HOPE TO HEART FAILURE PATIENTS EBAC Accredited Educational Programme
Organised by Universitätsklinikum des Saarlandes. Course Director: Michael Böhm
Chairperson(s): J.S. Borer (New York, US); M. Komajda (Paris, FR)
15:30 Introduction - Restoring hope to heart failure patients. 384
– M. Komajda (Paris, FR)
15:40 Strategy to optimize heart failure management. 385
– A.A. Voors (Groningen, NL)
15:50 Better cardiac efficiency for better outcomes. 386
– M. Böhm (Homburg, DE)
16:00 Panel discussion - “Need for action in a broad range of heart failure patients”. 387
– M.R. Cowie (London, UK), P. Ponikowski (Wroclaw, PL)
16:25 Conclusion - Restoring hope to heart failure patients. 388
– J.S. Borer (New York, US)
“This educational programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for one
hour of External CME credits. Each participant should claim only those hours of credit that have actually been spent
in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing
Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).”
Supported by an unrestricted educational grant from SERVIER
42

ANTICOAGULATION AND ATRIAL FIBRILLATION (AF): REAL LIFE DATA FROM THE Satellite Symposium
GARFIELD-AF REGISTRY
Sponsored by Thrombosis Research Institute London
Chairperson(s): A. Kakkar (London, UK); J.-P. Bassand (Thise, FR)
15:30 Global status of GARFIELD-AF. 389
– A. Kakkar (London, UK)
15:40 Regional differences in GARFIELD-AF. 390
– S. Goto (Isehara, JP)
15:50 First GARFIELD-AF Registry outcomes data. 391
– J.-P. Bassand (Thise, FR)
16:00 Gender and outcomes in GARFIELD-AF. 392
– A.J. Camm (London, UK)
16:10 GARFIELD-AF: a review of co-morbidities and their impact on outcomes. 393
– S.Z. Goldhaber (Boston, US)
16:20 Time in therapeutic range (TTR) and frequency in range (FIR) with outcomes in GARFIELD-AF. 394
– S. Haas (Munich, DE)
16:30 Securing quality in registries and a review of GARFIELD-AF data. 395
– K.A.A. Fox (Edinburgh, UK)
16:40 Discussion - Anticoagulation and AF: real life data from the GARFIELD-AF Registry. 396
– A.G.G. Turpie (Dundas, CA), D. Fitzmaurice (Birmingham, UK)
16:55 Closing remarks - Anticoagulation and AF: real life data from the GARFIELD-AF Registry. 397

PCSK9 INHIBITION IN LIPID MANAGEMENT: FINAL STEPS EBAC Accredited Educational Programme
TOWARDS IMPLEMENTATION INTO CLINICAL PRACTICE
Organised by Academic Medical Center Amsterdam. Course Director: John Kastelein
Chairperson(s): W. Koenig (Munich, DE); M. Farnier (Dijon, FR)
15:30 Introduction - PCSK9 inhibition: a renaissance in lipid management? 398
– M. Farnier (Dijon, FR)
15:35 Evolving scientific insights into the novel therapeutic target PCSK9: how does it all fit together? 399
– J.J.P. Kastelein (Amsterdam, NL)
15:50 Accumulating clinical data on PCSK9 inhibition: what are the key lessons? 400
– P.M. Ridker (Boston, US)
16:05 Lipid Management 2020: a glance at the future. 401
– K.K. Ray (London, UK)
16:20 Discussion - PCSK9 inhibition in lipid management: final steps towards implementation into 402
clinical practice.
– W. Koenig (Munich, DE)
Supported by an unrestricted educational grant Physicians’ Academy for Cardiovascular Education
43

DUAL ANTI-PLATELET THERAPY IN 2015 – REVIEWING THE EBAC Accredited Educational Programme
EVIDENCE
Organised by The Sahlgrenska Academy - Göteborg University. Course Director: Karl Swedberg
Chairperson(s): H. Bueno (Madrid, ES); P.G. Steg (Paris, FR)
15:30 Welcome and session objectives - Dual anti-platelet therapy in 2015 – Reviewing the evidence. 403
– P.G. Steg (Paris, FR)
15:35 Differentiating anti-platelet therapies: pharmacological evidence. Discussion. 404
– R.F. Storey (Sheffield, UK)
16:00 Optimal initiation of dual anti-platelet therapy – Reviewing the evidence. Discussion. 405
– S. James (Uppsala, SE)
16:25 Recent studies on duration of dual anti-platelet therapy – Future implications. Discussion. 406
– L. Mauri (Boston, US)
16:50 Summary and Close - Dual anti-platelet therapy in 2015 – Reviewing the evidence. 407
– H. Bueno (Madrid, ES)
Supported by an unrestricted educational grant from AstraZeneca
Sunday 30 August, 15:45–16:15 in Regents Park (The Hub)!

EDOXABAN – ENGAGING WITH THE REAL WORLD IN ATRIAL FIBRILLATION Satellite Symposium
Sponsored by Daiichi Sankyo Europe GmbH
Chairperson(s): C. Bode (Freiburg, DE); R. De Caterina (Chieti, IT)
15:30 Welcome and Introduction - Edoxaban – Engaging with the real world in atrial fibrillation. 408
– C. Bode (Freiburg, DE)
15:35 The pharmacology of edoxaban and the rationale for once daily anticoagulation. 409
– R. Kreutz (Berlin, DE)
15:50 Stroke prevention in atrial fibrillation - Balancing benefits and bleeding risks with edoxaban in the 410
ENGAGE AF-TIMI 48 trial.
– C.T. Ruff (Boston, US)
16:10 Sub analysis from ENGAGE AF-TIMI 48 and confirmation in clinical practice. 411
– J. Steffel (Zurich, CH)
16:30 Which non-vitamin K antagonist oral anticoagulant for which patient - Treatment algorithms for 412
anticoagulation in atrial fibrillation.
– G.Y.H. Lip (Birmingham, UK)
16:50 Panel Discussion and Closing - Edoxaban – Engaging with the real world in atrial fibrillation. 413
– C. Bode (Freiburg, DE), R. De Caterina (Chieti, IT), R. Kreutz (Berlin, DE), C.T. Ruff (Boston, US), J. Steffel
(Zurich, CH), G.Y.H. Lip (Birmingham, UK)
17:00–18:30 | London - Main Auditorium
INAUGURAL SESSION Special Event
We invite all delegates to join this Special Session which will be immediately followed by a networking
reception in the ESC Plaza.
44
SATURDAY 29 AUGUST 2015 – POSTER SESSION
11:00–16:00 | Best poster screen - Poster Area

BEST POSTERS SESSION 1 Best Posters
Discussant intervention 12:30–13:30
SATURDAY – POSTER SESSION

Best Posters are on display from 11:00 to 16:00 on the Best Poster plasma screen of the related topic.
During the viewing time (12:30–13:30), a discussant will visit the presenters to animate discussions, the screen will be
shared in 4 parts and each poster will take, in turns, full screen to allow time for Poster discussion.
BEST POSTERS IN GENETIC ASPECTS AND MECHANISMS OF ARRHYTHMIAS
Discussant: Best posters in genetic aspects and mechanisms of arrhythmias. P414

– C. Wolpert (Ludwigsburg, DE)
Molecular profiling of repolarization alternans recorded in the in-vivo human heart demonstrates changes P415
in Ca2+ handling proteins and repolarizing currents.
– P.D. Lambiase, J. Yanni, M. Orini, B. Hanson, M. Hayward, A. Smith, H. Zhang, H. Dobrzynski, M. Boyett,
P. Taggart (London and Manchester, UK)
Mechanisms for the frequency-dependence of triggered activity in catecholaminergic polymorphic P416
ventricular tachycardia.
– T.K. Danielsen, R. Manotheepan, M. Sadredini, K.H. Haugaa, S.E. Lehnart, O.M. Sejersted, I. Sjaastad,
M.K. Stokke (Oslo, NO; Göttingen, DE)
A novel KCNJ3 mutation as a susceptibility for ventricular arrhythmias in long-QT syndrome. P417
– T. Aiba, M. Ono, F. Toyoda, K. Ishibashi, Y. Miyamoto, A. Sekine, K. Kusano, H. Matsuura, T. Tanaka,
W. Shimizu (Suita, Otsu and Tokyo, JP)
Lamin A/C mutation prevalence and cardiac penetrance in Norway. P418
– N.E. Hasselberg, T.F. Haland, J. Saberniak, T. Edvardsen, K.E. Berge, K.H. Haugaa (Oslo, NO)
BEST POSTERS IN BIOMARKERS OF CORONARY ARTERY DISEASE
Discussant: Best posters in biomarkers of coronary artery disease. P419

– B. Lindahl (Uppsala, SE)
Impact of 18F-deoxyglucose positron emission tomography uptake in aorta on adverse vascular events. P420
– R. Iwatsuka, Y. Yonetsu, K. Yoshioka, Y. Matsuda, R. Ninomiya, M. Hoshino, Y. Sudo, A. Matsumura,
Y. Hashimoto, M. Isobe (Chiba and Tokyo, JP)
Predictive value of interleukin-6 in post-cardiac arrest patients treated with targeted temperature P421
management at 33 or 36 degrees.
– J. Bro-Jeppesen, D. Erlinge, Y. Devaux, H. Friberg, M. Kuiper, N. Nielsen, P. Stammet, M. Wise,
J. Kjaergaard, C. Hassager (Copenhagen, DK; Lund and Helsingborg, SE; Luxembourg, LU; Leeuwarden,
NL; Cardiff, UK)
Circulating levels of soluble IL-6 receptor in patients with ST-elevation myocardial infarction are P422
associated with later major adverse cardiac events.
– V.N. Ritschel, I. Seljeflot, H. Arnesen, S. Halvorsen, J. Eritsland, M. Fagerland, G.Ø. Andersen (Oslo, NO)
Association of serum galectin-3 levels with coronary atherosclerosis and plaque burden and structure in P423
patients with diabetes mellitus.
– D. Ozturk, O. Celik, M. Erturk, H.A. Cakmak, A.K. Kalkan, M. Gul (Istanbul, TR)
BEST POSTERS IN NUCLEAR CARDIOLOGY
Discussant: Best posters in nuclear cardiology. P424

– J.M. Knuuti (Turku, FI)
Phosphorylcholine antibody attenuates inflammation and preserves coronary vascular function in P425
atherosclerotic mice.
– M. Stahle, J.M. Silvola, S.E. Hellberg, H. Liljenback, P. Saukko, A. Roivainen, J. Knuuti, K. Pettersson,
A. Saraste (Turku, FI; Stockholm, SE)
Assessment of myocardial viability after acute myocardial infarction: a head-to-head comparison of the P426
perfusable tissue index by PET and delayed contrast enhanced CMR.
– P.F. Teunissen, S.A.J. Timmer, I. Danad, L.F.H.J. Robbers, P.G. Raijmakers, A.M. Beek, A.C. Van Rossum,
A.A. Lammertsma, N. Van Royen, P. Knaapen (Amsterdam, NL)
Clinical role of adrenergic septal activity as imaged by 123-I MIBG heart scan in HF patients. P427
– V. Frantellizzi, G. De Vincentis, A. Farcomeni, G.A. Follacchio, N. Rinvenuto, S. Sollaku, T. Garkavaya,
P. Scarparo, N. Salvi, F. Fedele (Rome, IT)
Which multiplexed images can be used to guide invasive electrophysiology procedures? P428
– S. Ernst, S. Babu-Narayan, J. Bomanji, S. Ben-Haim (London, UK)
45
BEST POSTERS IN VASCULAR HOMEOSTASIS

Discussant: Best posters in vascular homeostasis. P429
– S. Steffens (Munich, DE)
Shear stress pattern regulates aortic endothelial cell transcriptome: global gene expression profiles and P430
implications for aortic disease.
– C. Francis, M.B. Freidin, H. Gashaw, D. Reed, C.M. Potter, M. Paul-Clark, N.S. Kirkby, J.R. Pepper,
J.A. Mitchell (London, UK)
The activation of toll-like receptor 9 deteriorates blood flow recovery after hind-limb ischemia. P431
– S. Nishimoto, D. Fukuda, Y. Higashikuni, K. Tanaka, Y. Hirata, S. Yagi, T. Soeki, H. Sakaue,
M. Shimabukuro, M. Sata (Tokushima and Tokyo, JP)
Repairing and protective effects of rivaroxaban on vascular endothelium. P432
– B. Paradela-Dobarro, S. Raposeiras-Roubin, J.R. Gonzalez-Juanatey, E. Alvarez Castro (Santiago de
Compostela, ES)
Role of C1q/TNF-related protein 1 in preventing pathological vascular remodeling. P433
– N. Kanemura, R. Shibata, D. Yuasa, M. Ito, S. Hayakawa, T. Kambara, K. Matsuo, K. Ohashi, T. Murohara,
N. Ouchi (Nagoya, JP)
BEST POSTERS IN CONGENITAL HEART DISEASE

Discussant: Best posters in congenital heart disease. P434
– G.D. Webb (Cincinnati, US)
Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: 3-year results of P435
the TICAP trial.
– S. Ishigami, S. Tarui, T. Goto, D. Ousaka, M. Okuyama, K. Baba, S. Ohtsuki, S. Kasahara, S. Sano, H. Oh
(Okayama, JP)
Improvement of exercise capacity after transcatheter closure of atrial septal defect is impacted by the P436
tricuspid insufficiency.
– M. Komar, T. Przewlocki, B. Sobien, M. Olszowska, P. Wilkolek, L. Tomkiewicz-Pajak, G. Kopec,
P. Podolec (Krakow, PL)
Closed, not cured; continuing risk of pulmonary hypertension after shunt repair. P437
– A.C.M.J. Van Riel, I.M. Blok, E.M.C.J. Wajon, A.S.J.M. Sadee, M. Bakker-De Boo, A.P.J. Van Dijk,
E.S. Hoendermis, R.K. Riezebos, B.J.M. Mulder, B.J. Bouma (Amsterdam, Enschede, Almere, Apeldoorn,
Nijmegen and Groningen, NL)
Risk for ischemic stroke in 20,024 young adults with congenital heart disease. A case-control study. P438
– Z. Mandalenakis, A. Rosengren, G. Lappas, P. Eriksson, P.-O. Hansson, M. Dellborg (Gothenburg, SE)
BEST POSTERS IN NURSING

Discussant: Best posters in nursing. P439
Gender moderates the associations between perceived caregiving burden and outcomes in caregivers of P440
patients with heart failure.
– M.L. Chung, T.A. Lennie, D.K. Moser (Lexington, US)
Characteristics of responders to an integrated self-care intervention for persons with heart failure and P441
diabetes.
– S. Dunbar, C.M. Reilly, R.A. Gary, M.K. Higgins, J. Butler (Atlanta and Stony Brook, US)
Cognitive impairment in adolescents with congenital heart disease detected using the montreal cognitive P442
assessment screener.
– N.A. Pike, M.A. Woo, M.K. Poulsen, N.J. Halnon, A.B. Lewis, R. Kumar (Los Angeles, US)
Factors related to discussing prognosis by nurses at heart failure clinics in Sweden and the Netherlands. P443
– M.H.L. Van Der Wal, L. Hjelmfors, J. Martensson, A. Stromberg, T. Jaarsma (Linköping and Jönköping, SE)
BEST POSTERS ON MANAGEMENT OF PROCEDURAL RISKS

Discussant: Best posters on management of procedural risks. P444
– T. Kimura (Kyoto, JP)
Increased risk of contrast induced nephropathy in consecutive percuteneous coronary intervention after P445
multidetector computed tomography within short interval.
– J.H. Park, H.J. Yoon, K.B. Won, Y.K. Cho, H.S. Park, H.S. Kim, C.W. Nam, S.W. Han, S.H. Hur, Y.N. Kim
(Daegu, KR)
Impact of bleeding measured by Bleeding Academic Research Consortium (BARC) criteria on long term P446
mortality in STEMI patients undergoing primary PCI.
– D. Matic, D. Milasinovic, Z. Mehmedbegovic, J. Dobras, M. Marjanovic, I. Zivkovic, M. Zivkovic, M. Asanin,
V. Vukcevic, G. Stankovic (Belgrade, RS)
Acute kidney injury after primary angioplasty: is contrast-induced nephropathy the culprit? P447
– O. Caspi, M. Habib, M. Kapeliovich, W. Markiewicz, H. Hammerman, A. Rougin, R. Beyar, D. Aronson
(Haifa, IL)
Autologous clot injecton for the treatment of iatrogenic femoral arterio-venous fistula: a novel minimally P448
invasive method.
– J. Kurzawski, M. Sadowski, L. Zandecki, M. Janion (Kielce, PL)
46
BEST POSTERS IN CARDIAC SURGERY
Discussant: Best posters in cardiac surgery. P449

– D. Rittoo (Wirral, UK)

Melanocortin adrenocorticotropic anti-opioid peptide tetracosactide improves survival in high-risk P450
patients undergoing cardiac surgery: a single center, randomized, placebo-controlled, phase III study.
– G. Noera, C. Camerino, L. Ghetti, L. Carza, E. Picano, T. Bombardini (Cotignola, Lugo, Bologna and Pisa,
IT; Astana, KZ)
The novel cardiovascular biomarker secretoneurin provides valuable prognostic information in patients P451
with acute respiratory failure.
– P. Myhre, A.H. Ottesen, M. Okkonen, R. Linko, M. Stridsberg, S. Nygard, G. Christensen, V. Pettila,
T. Omland, H. Rosjo (Akershus and Oslo, NO; Helsinki, FI; Uppsala, SE)
Lack of right ventriculare remodeling after surgical ventricular restoration. P452
– A. Camporeale, S. Castelvecchio, F. Secchi, P.M. Cannao, C. Calvieri, L. Menicanti, G. Bonitta,
M. Lombardi (San Donato Milanese, IT)
Identifying preoperative predictive factors for the development of aortic valve insufficiency in patients P453
with continuous flow left ventricular assist devices.
– B. Gorodetski, A. Penkalla, T. Saito, V. Falk, T. Krabatsch, E. Potapov (Berlin, DE)
BEST POSTERS IN ANTITHROMBOTIC THERAPY: KEEP LEARNING
Discussant: Best posters in antithrombotic therapy: keep learning. P454

– J.L. Tamargo (Madrid, ES)
Genotyping, platelet reactivity and cardiovascular prognosis in patients after percutaneous coronary P455
intervention receiving dual antiplatelet therapy.
– G. Siasos, M. Zaromytidou, S. Kioufis, E. Oikonomou, K. Mourouzis, S. Tsalamandris, M. Anastasiou,
E. Dimitropoulos, M. Vavuranakis, D. Tousoulis (Athens, GR)
D-dimer level after one month of initial anticoagulant therapy determines the efficacy of long-term P456
warfarin therapy.
– N.M. Vorobyeva, A.B. Dobrovolsky, E.V. Titaeva, A.I. Kirienko, E.P. Panchenko (Moscow, RU)
Long term vitamin-K antagonist usage is associated with coronary artery calcification. P457
– S. Unlu, A. Sahinarslan, H.K. Kilic, G. Gokalp, G. Erbas, R. Yalcin, M. Arac (Ankara, TR)
International normalized ratio level after 2 initial doses of warfarin to predict the maintenance doses of P458
warfarin.
– P. Tanjararak, P. Sritara, S. Yamwong, T. Yingchoncharoen, P. Vathesatogkit (Bangkok, TH)
47
11:00–16:00 | Poster Area

POSTER SESSION 1 Poster Session
Posters are on display from 11:00 to 16:00. Presenters will be by their poster during the lunch break
between 12:30 and 13:30 for posters viewing time.
IMPLANTABLE CARDIOVERTER DEFIBRILLATORS I

Effects of digoxin on mortality in ICD-recipients: results of a 10 year follow-up study in 1020 patients. P459
– J.W. Erath, M. Vamos, H. Ackermann, S. Linzbach, A. Steidl, S.H. Hohnloser (Frankfurt am Main, DE)
Predictors of appropriate therapy from implantable cardioverter-defibrillators in Scandinavian P460
arrhythmogenic right ventricular cardiomyopathy patients.
– P.G. Platonov, K.H. Haugaa, H.K. Jensen, H.K. Bundgaard, A. Svensson, T. Gilljam, J. Hansen, O. Eschen,
T. Edvardsen, J.H. Svendsen (Lund, Linköping and Gothenburg, SE; Oslo, NO; Aarhus, Copenhagen and
Aalborg, DK)
Benefit of implantable cardioverter-defibrillator therapy after generator replacement in patients with P461
Brugada syndrome.
– S.H. Kim, J.Y. Kim, J.G. Cho, M.H. Lee, J.S. Kim, Y.H. Kim, Y.H. Kim, Y.S. Oh, M.Y. Lee, T.H. Rho (Seoul
and Gwangju, KR)
The impact of chronic renal disease on short- and long-term survival and risk of appropriate ICD therapy P462
in primary prevention ICD/CRT-D patients.
– A.C. Huth Ruwald, M. Vinther, G.H. Gislason, J.B. Johansen, J.C. Nielsen, H.H. Petersen,
O.D. Joergensen, S. Riahi, C. Jons (Gentofte, Odense, Aarhus, Copenhagen and Aalborg, DK)
Survival of patients with an implantable cardioverter defibrillator (ICD) relative to the age and sex P463
matched general population.
– J. Bashir, N.M. Hawkins, M. Grubisic, L. Ding, M. Gao (Vancouver, CA)
Geographic variation in utilization rates and determinants of access to pacemakers and implantable P464
cardioverter defibrillators in Austria, England, Germany, Italy and Slovenia, 2008-2012.
– H. Banks, G. Fattore, A. Torbica, C. Valzania, G. Boriani, T. Hunger, M. Arvandi, Y. Varabyova, V. Prevolnik
Rupel, R. Slabe-Erker (Milan and Bologna, IT; Hall in Tyrol, AT; Hamburg, DE; Ljubljana, SI)
Long-term clinical outcome after spinal cord stimulation for refractory stable angina pectoris in patients P465
with chronic pacemaker and ICD therapy.
– S. Eckert, K.J. Gutleben, D. Horstkotte (Bad Oeynhausen, DE)
Failure rate of prerequisite subcutaneous-ICD vector screening in patients with hypertrophic P466
cardiomyopathy.
– N. Maurizi, L. Oldenordkamp, T.F. Brouwer, K. Baldini, I. Olivotto, R.E. Knops, F. Cecchi (Pavia and
Florence, IT; Amsterdam, NL)
Unsustained ventricular tachycardias occurring early after ICD implant: prognostic significance among P467
patients with left ventricular dynsfunction.
– J. Jimenez-Candil, O. Duran, P. Perdiguero, E. Garcia-Piney, J. Hernandez, J. Morinigo, P.L. Sanchez
(Salamanca, ES)
Percutaneous mitral valve repair results in significant reduction of ventricular arrhythmias. P468
– C. Theis, T. Konrad, H. Mollnau, S. Sonnenschein, D. Kaempfner, B. Quesada Ocete, K. Bock,
E. Himmrich, T. Muenzel, T. Rostock (Mainz, DE)
10 years in managing high defibrillation threshold. P469
– M. Strauss, K. Kouraki, R. Zahn, T. Kleemann (Ludwigshafen am Rhein, DE)
IMPLANTABLE CARDIOVERTER DEFIBRILLATORS II

Dose patients whose left ventricular ejection fraction is more than 35% but with left ventricular P470
enlargment have indications for ICD and CRTD implantation?
– S. Zhao, S. Zhang, K.P. Chen, W. Hua, J.L. Pu, Y. Dai, Z.M. Liu, M. Tang, X.H. Fan (Beijing, CN)
Predictors of adequate and inadequate ICD interventions in patients with arrhythmogenic right ventricular P471
cardiomyopathy (ARVC).
– O. Wozniak, E.K. Biernacka, K. Poslednik, M. Konka, A. Przybylski, L. Szumowski, P. Hoffman (Warsaw, PL)
Implantable cardioverter defibrillator in patients with Brugada syndrome. P472
– J. Hernandez Ojeda, E. Arbelo, A. Gomez Juanatey, R. Borras, M. Matas, J.M. Tolosana, L. Mont,
J. Brugada (Barcelona, ES)
ICD implantation in adults with congenital heart disease is associated with high rates of both appropriate P473
and inappropriate shocks: a systematic review and meta-analysis.
– J.T. Vehmeijer, T.F. Brouwer, J. Limpens, R.E. Knops, B.J. Bouma, B.J.M. Mulder, J.R. De Groot
(Amsterdam, NL)
Primary and secondary prophylactic implantable cardioverter defibrillator implantation in patients with a P474
diagnosis of cancer - Insight from a nationwide Danish registry.
– A.C. Huth Ruwald, M. Vinther, G.H. Gislason, J.B. Johansen, J.C. Nielsen, H.H. Petersen,
O.D. Joergensen, S. Riahi, C. Jons (Gentofte, Odense, Aarhus, Copenhagen and Aalborg, DK)
R-wave amplitude during follow-up of implantable cardioverter defibrillators to predict under-sensing P475
upon spontaneous ventricular fibrillation.
– J.M. Lillo-Castellano, M. Marina-Breysse, J.B. Martinez-Ferrer, J. Alzueta, L. Perez-Alvarez, A. Alberola,
I. Fernandez Lozano, A. Rodriguez, R. Porro, D. Filgueiras-Rama (Madrid, Vitoria, Málaga, A Coruña,
Murcia, Santa Cruz de Tenerife and Caceres, ES)
48
Relationship between beta-blocker therapy and fast VT-related syncopes among ICD patients with left P476
ventricular dysfunction. Results from a multicenter study.
– J. Jimenez-Candil, I. Anguera, J. Fernandez-Portales, J. Hernandez, J. Morinigo, P. Dallaglio, A. Martin,
P.L. Sanchez (Salamanca, Barcelona and Caceres, ES)
Assessment of implantable cardioverter defibrillator leads with evidence of conductor externalisation: an P477

observational study.
– N. McKeag, E.C. Hodkinson, R.L. Noad, V.N. Kodoth, K. Ashfield, C.M. Wilson, D.J. McEneaney,
M.J.D. Roberts (Belfast and Craigavon, UK)
Dual versus single-coil implantable defibrillation leads. Current practice and rationale. P478
– I. Roy, N. Basterra, J. Martinez, L. Perez, J.B. Martinez, X. Vinolas, J. Fernandez, R. Villuendas, J. Alzueta,
A. Rodriguez (Pamplona, A Coruña, Vitoria, Barcelona, Badajoz, Badalona, Málaga and Santa Cruz de
Tenerife, ES)
Longevity of implantable cardioverter defibrillators: a comparison among manufactures and over time. P479
– B.A. Schaer, S. Von Gunten, M. Kuehne, C. Sticherling, S. Osswald, T. Szili-Torok, S. Yap,
D.A.M.J. Theuns (Basel, CH; Rotterdam, NL)
NON-INVASIVE STUDIES
Isolated late RV activation revealed by magnetocardiography predicts future lethal ventricular arrhythmic P480
events in patients with arrhythmogenic right ventricular cardiomyopathy.
– Y. Kimura, H. Takaki, K. Miyamoto, H. Okamura, T. Noda, T. Aiba, S. Kamakura, S. Yasuda, K. Kusano,
M. Sugimachi (Suita and Osaka, JP)
Left and biventricular pacing correct right ventricular pacing induced reduction in coronary flow. P481
– D. Sharif, N. Samniah, A. Yehia, Y. Sharif, U. Rosenschein (Haifa, IL)
Predictive value of ECG in arrhythmogenic right ventricular cardiomyopathy. P482
– K. Dubowski, K. Fejfer, O. Wozniak, M. Konka, E.K. Biernacka (Warsaw, PL)
Is right ventricular outflow tract pacing superior to right ventricular apex pacing?: long-term P483
echocardiographic follow-up results.
– X. Gong, X.H. Shu, Y.G. Su, Y.X. Liang, S.W. Chen, N.W. Zhou, S.W. Liu, J.B. Ge (Shanghai, CN)
The poor increase of inferior P-wave amplitude during treadmill exercise predicts sick sinus syndrome. P484
– J.K. Park, H.C. Lee, T.H. Kim, J.B. Park, J.S. Uhm, H.N. Pak, M.H. Lee, B.Y. Joung (Seoul, KR)
Mental stress unmasked new phenotype of sudden cardiac death related to adrenalin dependent P485
prolongation of the QT interval.
– J.B. Gourraud, A. Thollet, J. Barc, S. Le Scouarnec, S. Bezieau, J.J. Schott, R. Redon, H. Le Marec,
F. Kyndt, V. Probst (Nantes, FR)
Noninvasive evaluation of excitation abnormalities in patients with ischemic heart disease using P486
magnetocardiography.
– V.N. Sosnytskyy, T.V. Sosnytska, G.V. Miasnikov, L.A. Stadnyuk (Kiev, UA)
Multi-channel magnetocardiography can disclose left intraventricular disorganized conduction and can P487
predict cardiac events in non-ischemic dilated cardiomyopathy patients with narrow QRS.
– S. Kawakami, H. Takaki, S. Hashimoto, T. Aiba, K. Kusano, H. Ogawa, S. Yasuda, S. Kamakura,
Evaluation of QT dispersion and T peak to T end interval in patients with sarcoidosis. P488
– H.A. Kasapkara, H. Ayhan, E. Bilen, B. Duran Karaduman, A. Senturk, Z.S. Turinay, M.C. Guney,
T. Durmaz, T. Keles, E. Bozkurt (Ankara, TR)
Noninvasive electrocardiographic imaging for diagnosis and risk stratification in Brugada syndrome. P489
– M. Chaykovskaya, B. Rudic, A. Tsyganov, A. Shestak, E. Tulumen, V. Kalinin, H. Zaklyazminskaya,
R. Schimpf, M. Yakovleva, M. Borggrefe (Moscow, RU; Mannheim, DE; Yverdon-les-Bains, CH)
Prognostic value of very low frequency component of heart rate variability in takotsubo cardiomyopathy. P490
– M. Shimizu, H. Fujii, N. Yamawake, M. Nishizaki (Yokohama, JP)
RESYNCHRONISATION THERAPY I
T-wave area as biomarker of clinical response to cardiac resynchronization therapy. P491
– E.B. Engels, E.M. Vegh, C.J.M. Van Deursen, B. Merkely, K. Vernooy, J.P. Singh, F.W. Prinzen (Maastricht,
NL; Boston, US; Budapest, HU)
Does septal flash on echocardiography defines true left bundle branch block? P492
– B.F.J. Corteville, J. De Pooter, M. El Haddad, R. Stroobandt, F. Timmermans (Ghent, BE)
Randomized comparison of cardiac contractility modulation (CCM) delivered by one vs. two ventricular P493
leads in patients with heart failure.
– S. Roeger, S. Said, A. Kloppe, T. Lawo, U. Emig, B. Rousso, D. Gutterman, M. Borggrefe, J. Kuschyk
(Mannheim, Magdeburg, Bochum, Recklinghausen and Meiningen, DE; Hod Hasharon, IL; Milwaukee, US)
Medium and long-term results of triventricular pacing in patients with advanced heart failure: a P494
single-centre cohort study.
– R.A. Providencia, D. Rodgers, V. Cobb, P. Lambiase, S. Ahsan, O. Segal, M. Lowe, E. Rowland, F. Khan,
A.W. Chow (London, UK)
CRT Device left captuRe confirmation through an electrogram analysis model using a novel algorithm. P495
Results of the DREAM study.
– S. Baccillieri, D. Ambroso, P. Turrini, E. Dalla Vecchia, R. Verlato (Camposampiero and Marano Vicentino, IT)
Three-year experience of a multidisciplinary approach to cardiac resynchronisation therapy follow up at a P496
high volume centre.
– D.W.S. Chong, S.S. Din, S. Hughes, D.J. Wright, A. Rao (Manchester and Liverpool, UK)
49
Burden of scar and fibrosis: the strongest prognostic parameter for the need for ICD-therapies in patients P497
with primary prophylactic CRT-D?
– M. Grett, H.-J. Trappe (Herne, DE)
Reduction in total isovolumic time following cardiac resynchronisation therapy is a predictor of long term P498
risk of heart failure hospitalisation.
– K. Guha, J. Spiesshoefer, L. Mantziari, R. Sharma, A. Duncan (London, UK)
Elevated carbohydrate antigen 125 (CA-125) predicts poor prognosis in cardiac resynchronization therapy P499
of chronic heart failure patients.
– G. Szeplaki, P. Perge, A. Boros, V.K. Nagy, S.Z. Szilagyi, L. Molnar, T. Tahin, E. Zima, L. Geller, B. Merkely
(Budapest, HU)
Left ventricular endocardial pacing for CRT in patients with heart failure using puncture of interventricular P500
septum and apex of left ventricle.
– Y. Karpenko, A.A. Abramova, N.V. Naydenko, D.E. Volkov (Odessa and Kharkiv, UA)
Inflammatory and remodeling biomarkers response to CRT: is it related to echocardiographic or P501
functional exercise improvement?
– L. Almeida Morais, A. Abreu, H. Santa Clara, V. Santos, M. Mota Carmo, I. Rodrigues, G. Portugal, P. Silva
Cunha, M. Oliveira, R. Ferreira (Lisbon, PT)
RESYNCHRONISATION THERAPY II
Differences in interventricular electrical conduction delays and conduction pattern along a quadripolar P502
left ventricular lead during right ventricular paced vs. intrinsic ventricular rhythm.
– D. O’Donnell, C. Leclercq, M. Lunati, M. Landolina, P. Lercher, R. Rordorf, L. McSpadden, C. Jordan,
J. Singh, C. Pappone (Melbourne, AU; Rennes, FR; Milan, Crema, Pavia and Cotignola, IT; Graz, AT;
Sylmar and Boston, US)
Device longevity in a contemporary cohort of ICD/CRT-D patients undergoing device replacement. P503
– M. Biffi, E. Menardi, F. Zanon, G. Stabile, D. Potenza, C. La Rosa, D. Saporito, M. Bertini, F. Lissoni, P. De
Filippo (Bologna, Cuneo, Rovigo, Naples, San Giovanni Rotondo, Taranto, Rimini, Ferrara, Lodi and
Bergamo, IT)
Timing of ICD /CRT-D replacement in real-world practice: need for a behavioral change? P504
– M. Biffi, E. Ammendola, M. Santamaria, A. Campana, M. Iori, C. Baiocchi, M. Zoni Berisso, C. Tomasi,
M. Malacrida, M.L. Narducci (Bologna, Naples, Campobasso, Salerno, Reggio Emilia, Siena, Genoa-Sestri
Ponente, Ravenna, Milan and Rome, IT)
Differences in prevalence and degree of the abnormal early systolic contraction in left bundle branch P505
block with and without prolonged QRS duration (150 ms).
– H. Hara, T. Kaida, A. Horiguchi, N. Sato, H. Ito, S. Niwano, J. Ako (Sagamihara and Numazu, JP)
Predictive factors of echocardiographic response to cardiac resynchronization therapy: a prospective P506
cohort study.
– A. Abreu, H. Santa-Clara, M. Mota Carmo, V. Santos, L. Morais, G. Portugal, M. Alves, P. Cunha,
M. Oliveira, R. Ferreira (Lisbon, PT)
Septal contribution to stroke volume quantified with magnetic resonance imaging predicts clinical P507
outcome of cardiac resynchronization therapy in patients with heart failure.
– E. Ostenfeld, B. Ostensson, Z. Bakos, M. Kanski, E. Heiberg, H. Arheden, R. Borgquist, M. Carlsson (Lund,
SE)
Optimization of atrio-ventricular delay in resynchronization therapy guided by intraventricular flow P508
parameters: initial experience.
– D. Rodriguez Munoz, A. Carbonell San Roman, C. Lozano Granero, J.L. Moya Mur, J. Moreno Planas,
E. Franco Diez, R. Matia Frances, A. Hernandez-Madrid, C. Fernandez-Golfin, J.L. Zamorano Gomez
(Madrid, ES)
Pre-operatively elevated hepatocyte growth factor levels predicts 2-year mortality risk following cardiac P509
resynchronization therapy.
– P. Perge, A.M. Boros, S.Z. Szilagyi, I. Osztheimer, T. Tahin, L. Molnar, E. Zima, L. Geller, B. Merkely,
G. Szeplaki (Budapest, HU)
Does upgrade to tri-ventricular pacemaker improve long-term clinical response in non-responders to P510
biventricular cardiac resynchronization therapy?
– S.H. Man, M. Jeilan, S. Siddiqui, G.S. Chu, S.H. Chin, S.S. Varanasi, W.B. Nicolson, D. Chin, G.A. Ng
(Leicester, UK; Nairobi, KE)
Triple-site ventricular (TRIV) pacing: the new cardiac ressynchronization? P511
– M. Nobre Menezes, P. Marques, G. Lima Da Silva, A. Bernardes, A. Magalhaes, N. Cortez Dias,
L. Carpinteiro, J. De Sousa, F.J. Pinto (Lisbon, PT)
Maximal left ventricular pressure change analyzed in a time domain might reveal the missing link P512
between electrical dyssynchrony and left ventricular contractility in resynchronization therapy.
– S. Ross, E. Kongsgaard, T. Edvardsen, T. Haaland, L. Gammelsrud, R. Skaardal, H. Odland (Oslo, NO)
Importance of time-course assessment of left ventricular end-systolic volume to identify durable cardiac P513
resynchronization therapy responders.
– M. Ogano, Y. Iwasaki, J. Tanabe, K. Yodogawa, M. Hayashi, Y. Miyauchi, W. Shimizu (Shizuoka and Tokyo,
JP)
RESYNCHRONISATION THERAPY III

Functional capacity and neurocognitive profile: the effects of cardiac resynchronization therapy. P514
– M. Beltrami, L. Padeletti, M. Nesti, L. Pandolfini, S. Fumagalli (Florence, IT)
50
Prognostic value of liver function tests in heart failure patients with cardiac resynchronization therapy. P515
– J. Hosoda, T. Ishikawa, S. Umemura, K. Andoh, M. Nobuyoshi, S. Fujii, S. Shizuta, T. Kimura, T. Isshiki
(Yokohama, Kitakyushu, Kurashiki, Kyoto and Tokyo, JP)
Effect of cardiac resynchronisation therapy on the occurrence of ventricular arrhythmia in patients with P516
left ventricular assist device.

– E. Efimova, M. Doering, S. Richter, B. Dinov, P. Sommer, A. Bollmann, J. Fischer, J. Garbade, G. Hindricks,
A. Arya (Leipzig, DE)
Cardiac resynchronisation therapy reduces systemic inflammation in patients with asymptomatic left P517
ventricular systolic impairment.
– D.H. Elder, M. Mohan, S. Jagdeep, C.C. Lang, A.M. Choy (Dundee, UK)
Biventricular acute haemodynamic optimisation: comparing epicardial and endocardial pacing for optimal P518
left ventricular lead position in cardiac resynchronisation therapy.
– J.M. Behar, E. Hyde, T. Jackson, S. Claridge, M. Sohal, J. Webb, E. Sammut, S. Niederer, R. Razavi,
C.A. Rinaldi (London, UK)
Left atrial reverse remodeling in cardiac resynchronization therapy as assessed by computed P519
tomography.
– P.B. Hansen, A. Sommer, B.L. Noergaard, J.C. Nielsen (Aarhus, DK)
Decrease of microvolt T-wave alternation as antiarrhythmic predictor of effective cardiac P520
– T. Vaikhanskaya, T.M. Kaptsiukh, I.V. Sidorenko, T.V. Kurushka (Minsk, BY)
Association of super-response to cardiac resynchronisation therapy with biomarkers of inflammation and P521
myocardial fibrosis.
– V.A. Kuznetsov, T.N. Enina, L.A. Salamova, T.I. Petelina, D.V. Krinochkin, A.M. Soldatova, A.Y. Rychkov
(Tyumen, RU)
Effect of early post-implantation hemodynamic response to cardiac resynchronization therapy on stable P522
functional mitral regurgitation improvement in idiopathic dilated cardiomyopathy.
– D. Stolfo, E. Tonet, G. Barbati, M. Gigli, B. Pinamonti, M. Zecchin, F. Ramani, A. Pivetta, M. Merlo,
G. Sinagra (Trieste, IT)
Clinical presentation at first heart failure hospitalization does not predict recurrent heart failure events in P523
mild HF patients.
– A. Kosztin, J. Costa, B. Merkely, A.J. Moss, A. Kovacs, W. Zareba, S. McNitt, V. Kutyifa (Budapest, HU;
Rochester, US)
NEW ADVANCES IN STEMI AND NON STEMI
Direct Comparison of the Safety and Efficacy of two Rule-out Strategies for Acute Myocardial Infarction: P524
1h-algorithm versus 2h-accelerated diagnostic protocol.
– R. Twerenbold, K. Wildi, M. Rubini Gimenez, C. Puelacher, P. Hillinger, M. Wagener, J. Boeddinghaus,
K. Grimm, S. Osswald, C. Mueller (Basel, CH)
Direct comparison of the safety and efficacy of two rule-out strategies for acute myocardial infarction: P525
undetectable levels of troponin at presentation versus 2-hour accelerated diagnostic protocol.
– R. Twerenbold, K. Wildi, M. Rubini Gimenez, T. Reichlin, C. Puelacher, J. Boeddinghaus, K. Grimm,
M. Wagener, S. Osswald, C. Mueller (Basel, CH)
The effect of patient and centre characteristics on the outcome of a multi-faceted Quality Improvement P526
programme.
– D. Babalis, W. Banya, M.R. Cowie, M.D. Flather (London and Norwich, UK)
Previous statin medication as a prognostic marker of coronary artery disease severity at acute coronary P527
syndrome.
– R. Rodrigues, C. Sa, S. Goncalves, L. Rassi, F. Seixo (Setubal, PT)
Current use of evidence-based recommendations for the biochemical diagnosis of acute myocardial P528
infarction in routine clinical practice.
– P. Collinson, A. Hammerer-Lercher, K. Pulkki, J. Suvisaari, H. Baum, C. Duff, K.M. Aakre, M. Langlois,
S. Stankovic, P. Laitinen (London and Stoke-on-Trent, UK; Innsbruck, AT; Kuopio and Helsinki, FI;
Ludwigsburg, DE; Bergen, NO; Bruges, BE; Belgrade, RS)
Direct comparison of the safety and efficacy of two rule-out strategies for acute myocardial infarction:2h P529
accelerated diagnostic protocoll versus 2h-algorithm.
– M. Rubini Gimenez, R. Twerenbold, K. Wildi, T. Reichlin, C. Puelacher, P. Hillinger, S. Osswald, C. Mueller
(Basel, CH)
Diagnostic value of long non-coding RNA (LIPCAR) in patients with acute coronary syndrome and stable P530
coronary artery disease.
– M. Gyongyosi, G.A. Giurgea, A. Zimba, G. Goliasch, N. Pavo, J.C. Bergler-Klein, G. Maurer,
R. Kumarswamy, S. Batkai, T. Thum (Vienna, AT; Hannover, DE)
Exenatide does not improve myocardial salvage in patients with an acute myocardial infarction P531
successfully treated with primary percutaneous coronary intervention: the first results of the EXAMI trial.
– S.T. Roos, L. Timmers, P.S. Biesbroek, R. Nijveldt, M. Voskuil, P.R. Stella, B.K. Velthuis, N. Van Royen,
A.C. Van Rossum, Y.E.A. Appelman (Utrecht and Amsterdam, NL)
Treatment and outcome of patients with recurrent myocardial infarction. P532
– D. Radovanovic, L. Maurer, O. Bertel, J.-C. Stauffer, P. Erne (Zurich, Fribourg and Lucerne, CH)
Predictive factors of intrahospital mortality in patients with right ventricular myocardial infarction. P533
– M. Hassine, G. Chniti, D. Mlayeh, M. Boussada, M. Mahjoub, M. Ben Massoud, Z. Dridi, F. Betbout,
H. Gamra (Monastir, TN)
51
Who presents sudden cardiac arrest before hospital admission at the acute phase of STEMI? The P534
e-MUST study.
– N. Karam, S. Bataille, M. Tafflet, E. Marijon, F. Lapostolle, C. Spaulding, Y. Lambert, X. Jouven (Paris and
Versailles, FR)
INFARCTION ACUTE PHASE STEMI I

Relationship between total ischemic time and survival benefit of manual thrombus aspiration in patients P535
with STEMI undergoing primary percutaneous coronary intervervention.
– S. Hugelshofer, S. Fournier, S. Degrauwe, S. Puricel, P. Marques-Vidal, D. Radovanovic, P. Erne,
E. Eeckhout, O. Muller, J.F. Iglesias (Lausanne, Fribourg, Zurich and Lucerne, CH)
Onset-to-reperfusion time, but not door-to-reperfusion time, is associated with preserved left ventricular P536
function in patients with ST-elevation myocardial infarction.
– T. Takahashi, H. Okayama, M. Kinoshita, T. Miyoshi, K. Hara, A. Higaki, Y. Kawata, G. Hiasa, T. Yamada,
Y. Kazatani (Matsuyama, JP)
Prognostic impact of hyperglycemia in Japanese patients with acute myocardial infarction: a multi-center P537
cohort study of tokyo CCU network.
– M. Kishi (Tokyo, JP)
Determinants of medium-term relative necrotic mass reduction, assessed by cardiac magnetic P538
resonance, in STEACS revascularized by primary-PCI: Findings of the PROMISE randomized clinical trial.
– I. Ferreira Gonzalez, J. Rodriguez-Palomares, V. Pineda, B. Garcia-Del-Blanco, I. Otaegui, A. San-Roman,
F. Fernandez-Aviles, J. Elizaga, J. Barrabes, D. Garcia-Dorado (Barcelona, Valladolid and Madrid, ES)
Sex-specific trends in cardiovascular drugs use among STEMI patients in Poland from 2005 to 2011. P539
– L. Zandecki, M. Sadowski, M. Janion, M. Gierlotka, L. Polonski (Kielce and Zabrze, PL)
Cystatin C as an independent prognostic factor for in-hospital mortality in patients with acute myocardial P540
infarction with ST-segment elevation.
– J. Precek, M. Hutyra, F. Kovacik, M. Taborsky (Olomouc, CZ)
Periprocedural ventricular fibrillation in patients with ST-segment elevation myocardial infarction treated P541
with percutaneous coronary intervention determines higher in-hospital mortality.
– D. Pres, M. Hawranek, M. Gierlotka, M. Tajstra, G. Slonka, K. Wilczek, A. Lekston, M. Gasior (Zabrze, PL)
Which one should be treated in the setting of acute ST elevation myocardial infarction? Culprit lesion or P542
culprit vessel.
– U. Arslan, M. Yaman, I. Kocaoglu, O.E. Turan, H. Yucel, A. Aksakal, A.H. Ates (Samsun and Aydin, TR)
Fibrinolysis pre-PCI reduces the rate of cardiogenic shock when compared with primary PCI alone. P543
– M. Vanhaverbeke, L. Janssens, F. Van De Werf (Leuven and Bonheiden, BE)
Impact of pre-hospital pathways on use and timing of reperfusion therapy in STEMI patients. A P544
nationwide quality audit study by the French health authority.
– L. Banaei-Bouchareb, F. Capuano, N. Danchin, M. Gloanec, C. Grenier (Saint-Denis and Paris, FR)
INFARCTION ACUTE PHASE STEMI II
Right ventricular dysfunction and pulmonary hypertension: prevalence and prognosis in ST segment P545
elevation acute myocardial infarction.
– J. Reis Pires Martins, C. Arantes, G. Abreu, C. Rodrigues, A. Gaspar, P. Azevedo, C. Vieira, M. Pereira,
A. Rebelo, J. Marques (Braga, PT)
Cholesterol crystals and macrophage content decrease over coronary thrombus age in STEMI. P546
– A. Fernandez Cisnal, L. Fuentes-Castillo, M. Vila Sala, F. Fernandez, M. Gracida, J.L. Ferreiro,
J.L. Gomez-Lara, G. Roura, J.A. Gomez-Hospital, A. Cequier-Fillat (Barcelona, ES)
Significance of acute total coronary artery occlusion in patients with LCX-related STEMI and NSTEMI. P547
– J. Karwowski, L. Polonski, M. Gierlotka, M. Gasior, M. Beckowski, I. Kowalik, H. Szwed (Warsaw and
Zabrze, PL)
Heart type fatty acid binding protein as a diagnostic and a prognostic marker in patients presenting by P548
suspected ACS.
– A.F.R. Rizk, A.M.R. El Hadidi, O. Emad, N. Ismail, M. Hassan (Cairo, EG)
The acute myocardial infarction cost-of-illness study in Poland. P549
– A. Kozierkiewicz, K. Chlebus, M. Gierlotka, B. Wojtyniak, L. Polonski, M. Gasior, M. Zembala, Z. Kalarus,
G. Opolski, T. Zdrojewski (Warsaw, Gdansk and Zabrze, PL)
Benchmarking in the Myocardial Infarction Registry Rheinland-Pfalz (MIR-RLP) resulted in Increase in P550
Pre-hospital ECG-Recording and Reduction in Ischemic Time to Reperfusion in STEMI.
– A.K. Gitt, S. Schneider, J. Karcher, B.M. Schumacher, S. Heinemann, T. Muenzel, R. Zahn (Ludwigshafen
am Rhein, Kaiserslautern and Mainz, DE)
Worse short-term outcome for women with STEMI. Insights from the ATLANTIC study. P551
– E. Swahn, D. Venetsanos, S. Sederholm Lawesson, J. Alfredsson, M. Janzon, A. Cequier, M. Chettibi,
S. Goodman, A. Vant Hof, G. Montalescot (Linköping, SE; Barcelona, ES; Blida, DZ; Toronto, CA; Zwolle,
NL; Paris, FR)
Symptoms and pre-hospital delay times in relation to infarct related artery (IRA) in ST-elevation P552
myocardial infarction (STEMI) patients - a survey report from the SymTime study group.
– S. Sederholm Lawesson, J. Carlsson, R.M. Isaksson, K. Hellstrom Angerud, E. Logander, E. Swahn
(Linköping, Kalmar and Umeå, SE)
Comparison between thermodilution and Doppler flow velocity derived quantification of microvascular P553
function after acute myocardial infarction.
– G.A. De Waard, P.F. Teunissen, M.R. Hollander, I. Danad, P. Knaapen, N. Van Royen (Amsterdam, NL)
52
The impact of left ventricular hypertrophy on myocardial infarct size and myocardial salvage in patients P554
with ST-segment elevation myocardial infarction.
– L. Nepper-Christensen, J. Loenborg, K. Aleksov Ahtarovski, K. Kyhl Kristensen, N. Vejlstrup, H. Kelbaek,
M. Treiman, L. Koeber, L. Holmvang, T. Engstroem (Copenhagen, DK)

INFARCTION ACUTE PHASE STEMI III
Acute coronary syndromes in young (<45 years) patients. One-year cohort from Polish national PCI P555
registry.
– R.J. Gil, T. Pawlowski, Z. Siudak, A. Ochala, J. Legutko, D. Dudek (Warsaw, Krakow and Katowice, PL)
Pre-hospital ticagrelor in ST-segment elevation myocardial infarction: the French subgroup analysis of P556
the ATLANTIC study.
– G. Cayla, F. Lapostolle, C.J. Hammett, B. Merkely, J.F. Lassen, R.F. Storey, J.M. Ten Berg, C.W. Hamm,
A.W. Van ’T Hof, G. Montalescot (Nîmes, Bobigny and Paris, FR; Brisbane, AU; Budapest, HU; Aarhus, DK;
Sheffield, UK; Nieuwegein and Zwolle, NL; Bad Nauheim, DE)
Global and regional myocardial deformation mechanics of microvascular obstruction in acute myocardial P557
infarction a three dimensional speckle-tracking imaging study.
– O. Huttin, L. Zhang, S. Lemoine, J. Lemarie, D. Mandry, E. Micard, P.Y. Marie, N. Sadoul, N. Girerd,
C. Selton-Suty (Nancy and Vandoeuvre-lès-Nancy, FR)
Off-hours versus regular hours admission and its relation with long-term mortality of patients with acute P558
ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention.
– S. Dharma, R. Sukmawan, H. Andriantoro, I. Dakota, B.B. Siswanto, S.V. Rao (Jakarta, ID; Durham, US)
Shock index identifies more patients at risk than shock in STEMI treated with primary angioplasty. P559
– V. Hemradj, J.P. Ottervanger, M.J. De Boer, H. Suryapranata (Zwolle and Nijmegen, NL)
Implementation of a home-to-hospital dashboard for monitoring ischemic time in patients with P560
ST-elevated myocardial infarction.
– M. Hermans, M. Smeekes, O.S. Drexhage, T. Ytsma, M.J. Schalij, V.A.W.M. Umans (Leiden and Alkmaar,
NL)
Primary PCI is still beneficial later than 24 hours after STEMI. P561
– B. Ricci, E. Cenko, Z. Vasiljevic, S. Kedev, D. Trninic, B. Knezevic, D. Milicic, O. Manfrini, L. Badimon,
R. Bugiardini (Bologna, IT; Belgrade, RS; Skopje, MK; Banja Luka, BA; Podgorica, ME; Zagreb, HR;
Barcelona, ES)
Emergency surgical treatment of patients with acute myocardial infarction: analysis of registry data. P562
– R. Baretti, B. Maier, S. Behrens, R. Schoeller, H. Schuehlen, H. Theres, V. Falk (Berlin, DE)
Relationship between resolution of ST-segment elevation and microvascular obstruction in patients P563
treated with primary percutaneous coronary intervention.
– B.O. Kim, H.Y. Lee, Y.S. Byun, I.H. Chung, K.J. Rhee (Seoul, KR)
Lack of reperfusion therapy in patients with ST-segment elevation myocardial infarction in BLITZ 4 P564
registry: missed opportunity or well aware clinical choice?
– A. Chinaglia, L. Gonzini, G. Falsini, A. Pilleri, S. Valente, G. Gregori, R. Rollo, L. My, P. Scrimieri, Z. Olivari
(Turin, Florence, Arezzo, Cagliari, Ascoli Piceno, Brindisi, Taranto, Viterbo and Treviso, IT)
INFARCTION ACUTE PHASE STEMI IV
The Killip classification in prediction of laboratory efficacy Of P2Y12 receptor inhibitors in patients with P565
STE myocardial infarction.
– Z. Motovska, J. Knot, M. Ondrakova, J. Ulman, F. Bednar, M. Maly, P. Widimsky (Prague, CZ)
The relationship between the environmental factors and severity of clinical status and short-term P566
prognosis for the patients with non-ST elevation acute coronary syndromes.
– A. Cislak, P. Desperak, M. Hawranek, J. Wasilewski, M. Gierlotka, L. Pyka, A. Lekston, M. Zembala,
M. Gasior (Zabrze, PL)
Release kinetics of B-type natriuretic peptide signal peptide (BNPsp) in patients with acute myocardial P567
infarction.
– C. Liebetrau, O.D. Doerr, L.G. Gaede, A.B. Berkowitsch, C.T. Troidl, C.H. Hamm, H.N. Nef,
H.M. Moellmann, A.M.R. Richards, C.P. Pemberton (Bad Nauheim and Giessen, DE; Christchurch, NZ)
Contemporary troponin utilization in a large hospital system. P568
– J.B. Michel, R. Kowal (Dallas, US)
Conservative strategy in non ST elevation myocardial infarctio patients from the BLITZ 4 registry: which P569
patients for which reasons?
– A. Chinaglia, E. Picardi, L. Gonzini, T. Lanzillo, L. Corrado, M. Chiti, A.M. Paci, M. Catanzaro, N. Ciriello,
Z. Olivari (Turin, Florence, Avellino, Vercelli, Pistoia, Pisa, Caserta, Bari and Treviso, IT)
Frailty is associated with increased GRACE risk score in older patients with non-ST elevation acute P570
coronary syndrome.
– H. Sinclair, M. Veerasamy, X. Teoh, J.A. Coelho Lima Junior, W. Qiu, V. Kunadian (Newcastle-upon-Tyne,
UK; Boston, US)
Impact of a regional STEMI system of care implantation in clinical profile and prognosis of patients with P571
acute coronary syndrome admitted in the hospital of reference.
– A. Cordero, P. Carrillo, A. Frutos, R. Martinez, A. El Amrani, M. Garcia-Carrilero, C. Gunturiz,
V. Bertomeu-Martinez, R. Lopez-Palop (Alicante, ES)
Growth differentiation factor 15 is a prognostic parameter in patients with acute coronary syndrome P572
without history of diabetes mellitus.
– S. Farhan, M.K. Freynhofer, I. Brozovic, V. Bruno, B. Vogel, I. Tentzeris, S. Baumgartner-Parzer, K. Huber,
A. Kautzky-Willer (Vienna, AT)
53
Contrast-induced acute kidney injury in patients with non ST-segment elevation myocardial infarction P573
undergoing early versus delayed invasive strategy.
– B. Kocas, O. Abaci, G. Cetinkal, S. Arslan, Y. Dalgic, C. Kocas, A. Yildiz, M. Ersanli (Istanbul, TR)
Association between haptoglobin and intravascular ultrasound study in patients with non-ST elevation P574
– C.-C. Chiu, J.-P. Pan, S.-J. Lin (Taipei, TW)
High revascularization rates after clinical triage in patients with slightly elevated hs-troponin levels. P575
– M.M. Vorpahl, J. Szymanski, N. Karpettas, M. Seyfarth, K. Tiroch (Wuppertal, DE)
Early and long-term outcomes of patients with prior coronary artery bypass surgery presenting P576
non-ST-segment acute coronary syndromes treated with percutaneous coronary intervention.
– P. Desperak, M. Hawranek, A. Cislak, J. Wasilewski, M. Gierlotka, M. Tajstra, A. Lekston, M. Zembala,
M. Gasior (Zabrze, PL)
INFARCTION ACUTE PHASE STEMI V

Remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention in patients P577
with ST-elevation myocardial infarction is a cost-effective strategy.
– A.D. Sloth, M.R. Schmidt, K. Munk, M. Schmidt, L. Pedersen, H.T. Sorensen, H.E. Botker (Aarhus, DK)
The difficult task of reducing symptom-onset-to-balloon time among patients undergoing primary PCI. P578
– R. Montisci, R. Floris, M. Cadeddu, G.F. Decandia, G. Lai, R. Pirisi, M. Ruscazio, L. Meloni (Cagliari, IT)
Super-minimalist immediate mechanical intervention (super-MIMI) study. P579
– L. Belle, H. Madiot, H. Bouvaist, N. Delarche, F. Bouisset, P.Y. Petiteau, Z. Boueri, M. Abdellaoui, C. Durier,
O. Dubreuil (Annecy, Grenoble, Pau, Toulouse, Reims, Bastia, Argenteuil and Lyon, FR)
Comparison of the ability of TIMI, GRACE, CADILLAC and Zwolle risk scores to identify STEMI patients P580
with low risk of 5-year mortality after primary PCI.
– A. Novakovic, D. Milasinovic, Z. Mehmedbegovic, I. Mrkonjic, M. Glisic, A. Karadzic,
M. Radosavljevic-Radovanovic, M. Asanin, V. Vukcevic, G. Stankovic (Belgrade, RS)
Intra-aortic balloon pump use is not associated with reduced mortality in patients with cardiogenic shock P581
treated with primary percutaneous coronary intervention:.
– K.S. Rathod, D.A. Jones, M.B. Iqbal, M. Dalby, A. Wragg (London, UK)
Predictors of dual antiplatelet therapy non-adherence after PCI: insights from the PARIS registry. P582
– I. Mastoris, S. Sartori, M.W. Krucoff, P.G. Steg, C. Ariti, C. Antoniucci, I. Iakovou, S. Pocock, G. Dangas,
R. Mehran (New York and Durham, US; Paris, FR; London, UK; Florence, IT; Athens, GR)
Effect of erythropoietin administration on coronary circulation in patients after acute myocardial P583
infarction.
– M. Orii, K. Hirata, Y. Shiono, T. Yamano, Y. Matsuo, Y. Ino, T. Kubo, A. Tanaka, T. Hozumi, T. Akasaka
(Wakayama, JP)
Bivalirudin is not associated with lower mortality than heparin in real-world primary PCI. P584
– M. Hasun, J. Doerler, P. Jirak, C. Wegner, G. Grimm, P. Siostrzonek, D. Von Lewinski, F.X. Roithinger,
H. Alber, F. Weidinger (Vienna, Innsbruck, Klagenfurt, Linz, Graz and Mödling, AT)
INFARCTION ACUTE PHASE STEMI VI

Periprocedural hyperglicaemia worsens the short-term prognosis of patients with non-ST-segment P585
elevation acute coronary syndromes treated with percutaneous coronary intervention.
– M. Hawranek, A. Cislak, P. Desperak, D. Pres, J. Wasilewski, M. Gierlotka, M. Tajstra, A. Lekston,
L. Polonski, M. Gasior (Zabrze, PL)
Comparison between type 2 and type 1 myocardial infarction: clinical features, treatment strategies and P586
outcomes.
– P.J. Flores-Blanco, A.A. Lopez-Cuenca, M. Gomez-Molina, M.J. Sanchez-Galian, E. Guerrero-Perez,
F. Cambronero-Sanchez, M. Sanchez-Martinez, A. Garcia-Narbon, M. Valdes, S. Manzano Fernandez
(Murcia and Cieza, ES)
Comparison of early and long-term outcomes in patients with left versus right bundle branch block at P587
initial electrocardiogram in patients presenting with non-ST-segment acute coronary syndromes.
– P. Desperak, M. Hawranek, A. Cislak, L. Pyka, J. Wasilewski, M. Tajstra, A. Lekston, L. Polonski, M. Gasior
(Zabrze, PL)
Increased parathyroid hormone level is associated with increased arterial stiffness and endothelial P588
dysfunction in older patients with non-ST elevation acute coronary syndrome.
– J.A. Coelho Lima Junior, H. Sinclair, M. Veerasamy, J.J. Ang, W. Qiu, D. Neely, V. Kunadian
(Newcastle-upon-Tyne, UK; Boston, US)
Complete revascularization with percutaneous coronary intervention improves long-term outcomes in P589
patients with multivessel coronary artery disease presenting with NSTE-ACS.
– M. Hawranek, P. Desperak, A. Cislak, P. Gasior, J. Wasilewski, M. Gierlotka, L. Pyka, A. Lekston,
L. Polonski, M. Gasior (Zabrze, PL)
Interpretation of symptoms in chest pain patients is gender dependent: a prospective cohort study. P590
– M.G. Van Der Meer, Y. Van Der Graaf, H.M. Nathoe, P.A. Doevendans, B.E. Backus, A.J. Six, Y. Appelman
(Utrecht, Woerden and Amsterdam, NL)
Prognostic impact of iron metabolism change in patients with acute coronary syndrome. P591
– T. Duarte, S. Goncalves, R. Rodrigues, C. Sa, R. Marinheiro, L. Rassi, F. Seixo, R. Caria (Setubal, PT)
Non-ST elevation acute coronary syndrome and kidney failure: comparative study between 3 P592
mathematical estimators regarding in-hospital clinical outcome.
– M. Rodrigues Neto, R. Rodrigues, A. Correia, M. Gomes Serrao, N. Santos, S. Gomes, B. Silva, C. Alves,
A. Drumond Freitas, D. Pereira (Funchal, PT)
54
A single-sample algorithm applying high sensitivity troponin combined with heart-type fatty acid binding P593
protein to rule-out acute myocardial infarction in patients presenting with chest pain.
– S.C. Wiberg, M. Schoos, M. Schoenemann-Lund, K. Iversen, J. Thode, S.I. Hansen, P. Clemmensen,
R. Steffensen (Copenhagen, Hillerod and Nykøbing Falster, DK)
Benefit of early invasive therapy for diabetic patients with NSTE ACS. A landmark study from the P594

ISACS-TC registry.
– B. Ricci, E. Cenko, Z. Vasiljevic, M. Dorobantu, O. Gustiene, B. Knezevic, M. Dilic, O. Manfrini, L. Badimon,
R. Bugiardini (Bologna, IT; Belgrade, RS; Bucharest, RO; Kaunas, LT; Podgorica, ME; Sarajevo, BA;
Barcelona, ES)
Impact of sex-specific cut-off values of high-sensitivity troponin T on the prevalence of acute myocardial P595
infarction.
– M. Rubini Gimenez, R. Twerenbold, K. Wildi, T. Reichlin, T. Nestelberger, K. Grimm, P. Hillinger,
Influence of pre-infarction angina on the effect of remote ischemic conditioning in patients with P596
ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
– K. Pryds, A.D. Sloth, K. Munk, M.R. Schmidt, H.E. Botker (Aarhus, DK)
NUCLEAR CARDIOLOGY
Artificial neural network modelling enhances risk stratification for patients with suspected acute coronary P597
syndromes, negative cardiac biomarkers, and normal ECGs.
– P. Cremer, H. Ismaeel, G. Sakr, I. Elhajj, S. Khalaf, W. Jaber (Cleveland, US; Beirut, LB)
Serial 123-I MIBG imaging for assessing the progression of myocardial denervation in patients with P598
familial amyloid polyneuropathy.
– M.C. Azevedo Coutinho, N. Cortez Dias, G. Cantinho, R. Placido, G.L. Silva, A.R. Francisco, T. Guimaraes,
M.N. Menezes, I. Conceicao, F.J. Pinto (Lisbon, PT)
Myocardial perfusion imaging (MPI) is low yield to detect inducible ischemia in asymptomatic patients P599
with atrial fibrillation.
– P. Cremer, A. Mentias, W. Jaber (Cleveland, US)
Systematic review and meta-analysis of the relationship between inappropriate myocardial perfusion P600
imaging and cardiovascular outcomes.
– D. Winchester, I.Y. Elgendy, A. Mahmoud, J.B. Shuster (Gainesville, US)
Myocardial bridges functional significance identified by myocardial perfusional single photon emission P601
computed tomography.
– A. Ramirez Moreno, J.R. Siles Rubio, J. Munoz-Bellido, T. Velasco-Lajo, A. Valle-Alberca,
F. Bravo-Marques, A. Milan-Pinilla, E. Zambrano-Medina, L. Inigo-Garcia (Estepona and Marbella, ES)
Heart neuronal function assessed with I-123 MIBG after 3 months of exercise training in heart failure P602
patients.
– T. Valborgland, K. Isaksen, P.S. Munk, A.I. Larsen (Stavanger, NO)
Diagnostic performance of an ultrafast gamma camera system as studied by a multi-center registry. P603
– K. Goto, T. Chikamori, S. Hida, M. Miyagawa, H. Ishimura, K. Uchida, N. Fukuyama, T. Mochizuki,
A. Yamashina (Fukuyama, Tokyo, Toon and Fukuoka, JP)
Identification of unstable coronary artery plaques by intracoronary optical coherence tomography and P604
positron emission tomography.
– G. Locorotondo, M.L. Danza, F. Burzotta, I. Porto, G. Niccoli, A.M. Leone, L. Leccisotti, A. Giordano,
F. Crea, L. Galiuto (Rome, IT)
Imaging the kinetics of acute myocardial inflammation in the rat by nuclear methods (PET): expected P605
clinical implications.
– V. Jahns, R.A. Werner, Y. Maya, Y. Yanagisawa, T. Higuchi, R. Jahns (Würzburg, DE)
Exercise ammonia PET can guide management in patients with an anomalous interarterial course of a P606
right coronary artery from the left aortic sinus of Valsalva.
– A. Mentias, P. Cremer, G. Pettersson, R. Hobbs, W. Jaber (Cleveland, US)
[18F]FDG-PET: dual stem cell therapy improves cardiac regeneration and reduces adverse remodeling P607
after acute myocardial infarction.
– L. Gross, L. Paintmayer, S. Lehner, A. Todica, L. Brandl, C. Brenner, H. Theiss, W.-M. Franz, S. Massberg,
S. Brunner (Munich, DE; Innsbruck, AT)
Usefulness of PET-CT in the diagnostic strategy in infection of cardiac implantable electronic device. P608
– D. Klug, J. Meurice, C. Hossein-Foucher, C. Marquie, F. Brigadeau, D. Lacroix (Lille, FR)
MISCELLANEOUS I
Impact of routine manual thrombus aspiration on myocardial perfusion, myocardial salvage and infarct P609
size: nuclear substudy of PATA STEMI trial.
– D. Orlic, D. Sobic-Saranovic, N. Kozarevic, I. Grozdic, B. Beleslin, M. Tesic, D. Milasinovic, V. Dedovic,
M. Dikic, Z. Mehmedbegovic (Belgrade, RS)
Nuclear imaging to predict adverse events in heart failure patients. P610
– J. Limeres Freire, J. Rodriguez, G. Oristrell, X. Quiroga, M.N. Pizzi, J. Perez-Rodon, E. Galve, S. Aguade
(Barcelona, ES)
SPECT myocardial perfusion imaging findings in malignant coronary artery anomalies. P611
– C. Graeni, D.C. Benz, F. Mikulicic, J. Vontobel, R. Liga, B.A. Herzog, O. Gaemperli, P.A. Kaufmann,
R.R. Buechel (Zurich, CH)
55
Carotid artery stenosis does not predict local inflammatory activation: Implications from new imaging P612
modalities.
– I. Koutagiar, K. Toutouzas, G. Benetos, E. Athanasiadis, K. Filis, A. Georgakopoulos, G. Spyrou,
D.V. Cokkinos, D. Tousoulis, C.D. Anagnostopoulos (Athens, GR)
Serial evaluation of ascending and descending aortic distensibility by cardiac magnetic resonance P613
imaging to predict cardiovascular events in takayasu arteritis patients.
– N. Charoensri, C. Wuttichaipradit, S. Flamm, M. Bolen (Cleveland, US)
Differentiation of physiological sport adaptation from pathological left ventricular hypertophy with the P614
help of trabeculae quantification using cardiac magnetic resonance imaging.
– H. Vago, A. Toth, C.S. Czimbalmos, K. Kecskes, I. Csecs, F. Suhai, O. Kiss, N. Sydo, D. Becker,
B. Merkely (Budapest, HU)
The incremental impact of cardiovascular magnetic resonance on clinical decision-making. P615
– A. Rajwani, M.J. Stewart, J.D. Richardson, N.M. Child, N. Maredia (Middlesbrough and Stockton-on-Tees,
UK)
Arrythmogenic cardiomyopathy. Let’s have a closer look to the left ventricle. Report of our experience. P616
– R. Moscicki, E. Feliu, V. Climent, A. Garcia Fernandez, E. Galcera-Jornet (Alicante, ES)
Changes in remote extracellular volume and left ventricular ejection fraction during longitudinal follow-up P617
are inversely associated in survivors of acute STEMI.
– J. Carberry, D. Carrick, C. Haig, S.M. Rauhalammi, N. Ahmed, M. McEntegart, A. Mahrous, A. Radjenovic,
K.G. Oldroyd, C. Berry (Glasgow, UK)
Spleen signal attenuation as a marker of hyperemia in adenosine stress perfusion cardiac magnetic P618
resonance.
– C. Almeida, P. Fonseca, N. Almeida, D. Monteiro, R. Faria, N. Ferreira, R. Dourado, N. Bettencourt,
J. Ribeiro, V. Gama Ribeiro (Ponta Delgada and Vila Nova de Gaia, PT)
Acute safety of performing cardiac MRI scans in patients with the accent MR conditional pacemaker. P619
– M.P. Ainslie, C. Miller, A.B. Reid, D. Clark, G. Coutts, L. Francis, B. Brown, D.J. Fox, N. Davidson,
M. Schmitt (Manchester, UK)
Remote web-based lung ultrasound training for B-lines assessment. P620
– L. Gargani, R. Sicari, M. Raciti, C. Zoccali, E. Picano (Pisa and Reggio Calabria, IT; Astana, KZ)
One million electrocardiograms of primary care patients. P621
– M.S. Marcolino, E. Chazard, D. Palhares, C. Dumesnil, A. Caron, G. Ficheur, R. Beuscart, M.B. Alkmim,
P. MacFarlane, A.L. Ribeiro (Belo Horizonte, BR; Lille, FR; Glasgow, UK)
MISCELLANEOUS II
Impact of location of through-plane phase contrast velocity mapping. P622
– L. Bertelsen, J. Hastrup Svendsen, L. Koeber, C. Thomsen, S. Hoejberg, K. Haugan, N. Vejlstrup
(Copenhagen and Roskilde, DK)
Epicardial adipose tissue volume but not density is an independent predictor for myocardial ischemia. P623
– M. Hell, X. Ding, P. Slomka, D. Terzopoulos, S. Hayes, S. Achenbach, D.S. Berman, D. Dey (Erlangen, DE;
Los Angeles, US)
Non-invasive hybrid imaging in an ageing population. P624
– E.M. Engbers, J.R. Timmer, J.P. Ottervanger, M. Mouden, S. Knollema, P.L. Jager (Zwolle, NL)
Accuracy in precordial electrocardiogram (ECG) lead placement. P625
– S. Medani, N. Caples, M. Hensey, A. Hussaini, P. Owens (Waterford, IE)
Significance of left ventricular hypertrophy detected by electrocardiography in an era when P626
echocardiography is widely available.
– M. Okano, T. Kato, M. Funasako, E. Nakane, S. Miyamoto, T. Izumi, T. Haruna, M. Inoko (Osaka, JP)
Use of a wearable photoplethysmograph (PPG) to assess heart rate variability in response to stressful P627
stimuli.
– E. Simard, Z. Nichols, A. Conway, B. Wiederhold, M. Wiederhold, S. Steinhubl (New York and La Jolla, US)
Detection of vectorcardiographic P-wave alterations in patients with paroxysmal atrial fibrillation in sinus P628
rhythm - a novel diagnostic tool?
– N. Brasier, T. Kolbitsch, A. Tabord, J. Knobeloch, S. Engelter, M. Kuehne, D. Conen, J. Eckstein (Basel,
CH; Jena, DE)
Reliability of ST-segment shifts in the synthesized V3R to V5R leads. P629
– A. Tamura, K. Torigoe, Y. Goto, S. Naono, K. Shinozaki, H. Zaizen, N. Takahashi (Yufu, Oita and Beppu, JP)
High-frequency QRS analysis compared to conventional ST-segment analysis in patients with chest pain P630
after percutaneus coronary intervention referred for exercise tolerance test - a pilot study.
– D. Popovic, M.C. Ostojic, M. Banovic, M. Petrovic, B. Vujisic-Tesic, V. Vukcevic, M. Asanin, D. Orlic,
A. Ristic (Belgrade, RS)
Variability of automatic QRS duration measurement by commercially available ECG machines. P631
– V. Vancura, I. Ulc, D. Wichterle, M. Brabec, R. Rokyta (Plzen and Prague, CZ)
Improving evaluation of cardiac autonomic control and stroke volume during normal daily life activities P632
using impedance cardiography.
– I. Nederend, A.D.J. Ten Harkel, J.C.N. De Geus, N.A. Blom (Amsterdam and Leiden, NL)
Prognostic value of coronary artery calcium score in addition to single photon emission computed P633
tomography myocardial perfusion imaging in symptomatic patients.
– E.M. Engbers, J.R. Timmer, J.P. Ottervanger, M. Mouden, S. Knollema, P.L. Jager (Zwolle, NL)
Cardiovascular maladaptive changes during exertion in young hypertensive patients. P634
– M. Cusma-Piccione, C. Zito, M. D’Angelo, R. Manganaro, A. Oteri, L. Rivetti, A. Terrizzi, S. Quattrocchi,
A. Ioppolo, S. Carerj (Messina, IT)
56
Post-pacing cardiac T-wave memory is accompanied by homogeneous delay of left ventricular P635
mechanical activation that persists upon resolution of memory: a pilot echocardiographic study.
– M.C.B. Suran, A.D. Margulescu, R. Bruja, C. Siliste, D. Vinereanu (Bucharest, RO)
Mechanical and histological interfaces of a dilative ascending aorta. P636
– M. Bieseviciene, J.J. Vaskelyte, V. Lesauskaite, V. Mizariene, R. Karaliute, R. Verseckaite, R. Jonkaitiene

(Kaunas, LT)
MEDIATORS OF ATHEROSCLEROSIS
Carotid artery stenosis, cardiovascular risk factors and ischaemic stroke in the China Kadoorie Biobank P637
Study.
– S. Parish, L. Li, M. Arnold, R. Clarke, H. Du, Y. Guo, Z. Bian, Z. Chen (Oxford, UK; Beijing, CN)
Association of carotid plaque morphology and heart and brain-related miRNAs expression in patients P638
with ischemic stroke related to internal carotid artery stenosis.
– I. Karch, A. Kablak-Ziembicka, E. Stepien, R. Badacz, F.J. Enguita, J. Gacon, K. Zmudka, P. Podolec,
T. Przewlocki (Krakow and Tarnow, PL; Lisbon, PT)
Renin angiotensin aldosterone system antagonists improve endothelial glycocalyx and aortic stiffness P639
after 1 year successful treatment in untreated patients with essential hypertension. A pilot study.
– H. Triantafyllidi, L. Palaiodimos, I. Ikonomidis, M. Varoudi, A. Schoinas, P. Trivilou, G. Pavlidis, J. Lekakis
(Athens, GR)
Non-muscle myosin heavy chain II A is a new target protein of dysfunctional vascular endothelial cells P640
induced by disturbed flow.
– K.H. Kwon, J.H. Chung, K.C. Kim, H.B. Shim, W.J. Kim, D.H. Kang, S.W. Kang, H.J. Jo (Seoul and
Pohang, KR; Atlanta, US)
Activity of glutathione employing enzymes in aortic tissue from marfan syndrome patients. P641
– M.E. Soto, I. Perez-Torres, V. Guarner-Lans, E. Nunez-Garrido, V. Herrera-Alarcon, H.J. Martinez
Hernandez, B. Hernandez Mejia, R. Barragan-Garcia, E. Muruato-Ontiveros, A.M. Zuniga-Munoz (Distrito
Federal, MX)
Antagonism of protease-activated receptor 2 (PAR-2) rescues vascular endothelial dysfunction in diabetic P642
mice.
– R. Hashimoto, M. Shimabukuro, H.M. Salim, T. Hara, D. Fukuda, S. Yagi, T. Soeki, M. Sata (Tokushima, JP)
MiR-34a regulates DNA damage and repair on human umbilical vein endothelial cell after exposure to P643
tritiated water.
– L. Liu, Q. Chen, F.-M. Cui, Y.-M. He (Suzhou, CN)
Fibrinogen genetic variability and coagulation process mediate atherosclerosis manifestations and affect P644
the extent of the disease.
– N. Papageorgiou, A. Briasoulis, G. Hatzis, A. Miliou, M. Kozanitou, E. Androulakis, S. Papaioannou,
G. Latsios, Z. Pallantza, D. Tousoulis (Athens, GR)
Annexin A5-pHrodo: a new molecular hybrid probe to evaluate in-vivo efferocytosis. P645
– R. Stoehr, J. Tupiec, P. Leenders, N. Deckers, N. Marx, L.J. Schurgers, C.P. Reutelingsperger (Aachen,
DE; Maastricht, NL)
Annexin-A5 attenuates atherogenesis in ApoE−/− mice. P646
– R. Stoehr, J. Tupiec, J. Moellmann, N. Deckers, P. Leenders, N. Marx, L.J. Schurgers,
C.P. Reutelingsperger (Aachen, DE; Maastricht, NL)
ENVIRONMENTAL AND INTRINSIC FACTORS AFFECTING ENDOTHELIAL FUNCTION

Circulating microparticles from patients with acute coronary syndrome promote premature senescence P647
in endothelial cells associated with oxidative stress, down-regulation of eNOS and thrombogenicity.
– M. Abbas, L. Jesel, C. Auger, N. Messas, A.A. Constantinescu, A.J. Leon-Gonzalez, P. Ohlmann, F. Toti,
V.B. Schini-Kerth, O. Morel (Illkirch and Strasbourg, FR)
The effect of endothelin-1 and endothelin receptor blockade on the release of endothelial microparticles P648
in vitro and in vivo.
– C. Jung, M. Franz, M. Lichtenauer, M. Fritzenwanger, B. Goebel, A. Rafnsson, H.R. Figulla, J. Pernow
(Stockholm, SE; Jena, DE)
Lack of the antioxidant enzyme Glutathione Peroxidase-1 (GPx1) facilitates a pro-inflammatory and P649
activated vascular endothelium: implications for endothelial dysfunction and atherogenesis.
– A. Sharma, N. Stefanovic, D. Yuen, O. Huet, J. De Haan (Melbourne, AU; Brest, FR)
Intermittent hypoxia, endothelial dysfunction and increased coronary plaque burden in obstructive sleep P650
apnea: A fortuitous association?
– B. Shivalkar, J. Verabraecken, K. Wauters, R. Salgado, H. Heuten, D. Buys, C. Vrinst (Antwerp, BE)
Differences in the platelet proteome when comparing intracoronary and peripheral arterial blood from P651
ST-Elevation Myocardial Infarction patients: clues on platelet activation in the acute event.
– P. Velez, R. Ocaranza-Sanchez, D. Lopez-Otero, L. Grigorian-Shamagian, I. Rosa, J.R. Gonzalez-Juanatey,
A. Garcia (Santiago de Compostela, ES)
The effect of fresh versus old blood transfusion on endothelial function. P652
– Y. Parviz, C. Hsia, N. Abu-Romeh, M. Alemayehu, S. Wall, I. Chin-Yee, S. Lavi (London, CA)
Chronic air pollution exposure on atherosclerosis: CD36-dependent 7-ketocholesterol accumulation in P653
macrophages.
– Q. Sun, X. Rao, J. Zhong, A. Maiseyeu, B. Gopalakrishnan, F. Villamena, L.C. Chen, J.R. Harkema,
S. Rajagopalan (Columbus, Baltimore, New York and East Lansing, US)
57
Early effects of varenicline aided smoking cessation on endothelial glycocalyx and arterial wall properties. P654
– I. Ikonomidis, K. Kourea, G. Pavlidis, M. Marinou, E. Tsougos, I. Papadakis, H. Triantafyllidi,
L. Oikonomidou, K. Tympas, J. Lekakis (Athens, GR)
Rivaroxaban reduces circulating levels of osteopontin accompanied by improvement in vascular P655
endothelial function in atrial fibrillation patients.
– S. Namba, M. Yamaoka-Tojo, T. Hashikata, L. Kitasato, T. Hashimoto, R. Kameda, T. Shimohama, T. Tojo,
J. Ako (Sagamihara, JP)
Effects of dabigatran etexilate on endothelial dysfunction and vascular oxidative stress in a mouse model P656
of arterial hypertension.
– M. Knorr, M. Oelze, D. Minwegen, S. Karbach, S. Kossmann, A. Daiber, T. Muenzel (Mainz, DE)
IMMUNE RESPONSES AND THE VASCULATURE

Correlation between endothelial function, cardiac and respiratory function parameters in patients with P657
cystic fibrosis.
– M.M. Ciccone, P. Scicchitano, F. Cortese, G. Ricci, S. Carbonara, A. Zito, R. Carbonara, L. Mappa,
L. Cavallo, M. Gesualdo (Bari, IT)
Impact of periodontitis on endothelial function in patients with type 2 diabetes from different ethnic P658
groups.
– D.J. Bhowruth, T. Khan, N. Gkranias, M. Orlandi, J. Suvan, A. Hingorani, S. Hurel, N. Donos, J. Deanfield,
F. D’Aiuto (London, UK)
The effects of low dose interleukin-37 on arterial calcification in an animal model. P659
– M. Chai, Y.J. Zhou, Q.W. Ji, Y.Y. Liu, Y.X. Zhao, D.M. Shi (Beijing, CN)
Fibrinogen genetic variability accelerates atherogenesis by altering the inflammatory process and P660
coagulation in patients with diabetes mellitus type 2 and hypertension.
– N. Papageorgiou, A. Briasoulis, G. Hatzis, M. Kozanitou, A. Miliou, E. Androulakis, S. Tsalamandris,
G. Siasos, Z. Pallantza, D. Tousoulis (Athens, GR)
Toll-like receptor 9 in acute and chronic vascular injury. P661
– A.O. Krogmann, E. Luesebrink, C. Lahrmann, S. Zimmer, G. Nickenig (Bonn, DE)
EphrinB2/EphA4- mediated adhesion of monocytes to endothelial cells. P662
– G. Ende, D.M. Poitz, B. Stuetz, A. Augstein, J. Friedrichs, C. Werner, R.H. Strasser, S. Jellinghaus
(Dresden, DE)
Impact of Myeloperoxidase on atherogenesis and neointima formation in mice. P663
– V. Tiyerili, B. Camara, U. Becher, J. Schrickel, G. Nickenig, R. Andrie (Bonn, DE)
MDA-5 activation by cytoplasmic double-stranded RNA impairs endothelial function and aggravates P664
atherosclerosis.
– M. Steinmetz, T. Asdonk, A. Krogmann, C. Stroecker, C. Lahrmann, I. Motz, W. Barchet, G. Hartmann,
G. Nickenig, S. Zimmer (Bonn, DE)
Loss of endothelial ADAM10 augments atherosclerosis development in mice. P665
– E.P.C. Van Der Vorst, K. Theodorou, T. Rademakers, J.D. Van Buul, M. Lehrke, C. Lebherz, A. Ludwig,
J.F. Bentzon, E.A.L. Biessen, M.M.P.C. Donners (Maastricht and Amsterdam, NL; Aachen, DE; Aarhus, DK)
STA-21, a STAT3 inhibitor, limits atherosclerosis by reciprocal regulation of Th17 and Treg. P666
– E.H. Choo, K. Chang, E.H. Park, H.E. Park, S.H. Ihm, B.H. Hwang, E.M. Kim (Uijeongbu, Seoul and
Bucheon, KR)
DPP4-inhibition improves angiotensin II-induced vascular dysfunction and inflammation in mice. P667
– S. Steven, M. Hausding, M. Dib, S. Kroeller-Schoen, Y. Mikhed, S. Roohani, S. Agdauletova, M. Oelze,
T. Muenzel, A. Daiber (Mainz, DE)
AORTIC VALVE DISEASE
Clinical outcomes in patients requiring femoral covered stent graft during percutaneous transcatheter P668
aortic valve implantation.
– C. Tron, G. Cellier, E. Durand, N. Bouhzam, S. El Hatimi, M. Godin, G. Viart, H. Eltchaninoff (Rouen, FR)
Ischaemia in aortic stenosis: a story of opposing waves. P669
– M. Lumley, R. Williams, K.A. Asrress, B. Clapp, M. Marber, J. Piek, S. Redwood, J. Chambers, M. Siebes,
D. Perera (London, UK; Amsterdam, NL)
Clinical profiles and correlates of 30 day and 1 year mortality in patients older than 90 years old P670
undergoing transcatheter aortic valve replacement.
– R. Escarsega, N. Baker, S. Kiraijyan, M. Magalhaes, J. Gai, R. Torguson, A. Pichard, L. Satler, R. Waksman
(Washington, US)
Platelet activation is associated to the grade of aortic regurgitation after transfemoral aortic valve P671
implantation and is less enhanced in the newer Edward Sapien 3 valve than its predecessor valve.
– S. Fateh-Moghadam, S. Voesch, P. Htun, M. Droppa, R. Jorbenadze, T. Geisler, M. Gawaz, W. Bocksch
(Berlin, Tübingen and Augsburg, DE)
The effect of aortic stenosis and insufficiency on the mechanical properties of ascending thoracic aortic P672
aneurysms.
– D.P. Sokolis, E.P. Kritharis, K. Lampropoulos, D.C. Iliopoulos (Athens, GR)
Risk of Cerebral Embolization after Transfemoral Implantation of the Edwards SAPIEN Aortic Valve P673
without Compared to Implantation with prior Balloon Valvuloplasty.
– K. Bijuklic, T. Haselbach, J. Witt, K. Krause, L. Hansen, R. Gehrkens, J. Schofer (Hamburg, DE)
58
Clinically silent pseudoaneurysms after transcatheter aortic valve implantation (TAVI) using the ProStar P674
XL system-comparison between the CoreValve, the Edwards Sapien XT and the Edwards Sapien 3 Val.
– S. Fateh-Moghadam, R. Jorbenadze, A. Kilias, M. Droppa, P. Htun, M. Gawaz, W. Bocksch (Berlin,
Tübingen and Augsburg, DE)
The new balloon-expandable Edwards SAPIEN 3 valve effectively reduces paravalvular leakage compared P675

to its predecessor model SAPIEN XT in an all-comer TAVR-population.
– S. Fateh-Moghadam, B. Grossmann, T. Geisler, M. Gawaz, W. Bocksch (Tübingen, DE)
AORTIC VALVE INTERVENTIONS

Antiphospholipid antibodies as risk markers of embolism in infective endocarditis. P676
– C.H. Maigrat, J. Devignes, O. Huttin, F. Goehringer, T. Doco-Lecompte, P. Maureira, F. Alla, Y. Juilliere,
T. Lecompte, C. Selton-Suty (Vandoeuvre-lès-Nancy, FR; Geneva, CH)
Safety and efficacy of daptomycin in the treatment of patients with infective endocarditis: real world P677
clinical experience from a European registry.
– A. Guleri, R. Utili, P. Dohmen, N. Petrosillo, C. Piper, R. Pathan, K. Hamed (Lancashire, UK; Bianchi Napoli
and Rome, IT; Berlin and Bad Oeynhausen, DE; Hyderabad, IN; East Hanover, US)
Incremental use of three dimensional echocardiography in the assessment of the posterior leaflet P678
morphology in severe mitral regurgitation before interventional repair.
– A. Alfakhouri, K.M. Sveric, R.H. Strasser, S. Wiedemann (Dresden, DE)
The relationship between systemic lupus erythematosus disease activity index (SLEDAI) and cardiac P679
affection.
– M. Abdel Ghany, N. Nader, A. Youssef, Y. Kishk (Assuit, EG)
Akute kidney injury (AKI) and chronic kidney injury (CKI) and its relation to clinical outcome in patients P680
undergoing TAVI.
– S. Fateh-Moghadam, P. Htun, T. Geisler, M. Gawaz, W. Bocksch (Berlin, Augsburg and Tübingen, DE)
Parallel improvement in right heart function and pulmonary hypertension parameters following P681
Transcutaneous Aortic Valve Implantation (TAVI).
– N. Pareek, A. Constantine, R. Kanyal, P. Sawhney, S.W. Davies, C. Di Mario, A. Duncan, A.C. Lindsay,
N.E. Moat (London, UK)
Impact of access choice on outcome of patients undergoing transcatheter aortic valve implantation P682
(TAVI).
– J. Schewel, D. Schewel, T. Weiland, T. Thielsen, T. Schmidt, F. Kreidel, U. Schaefer, K.H. Kuck, C. Frerker
(Hamburg, DE)
Impact of prior CABG on complications and outcomes after transcatheter aortic valve implantation. P683
– R. Hoellriegel, N. Mangner, F. Woitek, S. Haussig, F. Schlotter, G. Stachel, D. Holzhey, F.W. Mohr,
G. Schuler, A. Linke (Leipzig, DE)
Significant reduction of paravalvular leakage with the new balloon expandable aortic valve prosthesis P684
independent of implantation height: Edwards Sapien 3 vs Sapien XT.
– G. Kaleschke, F. De Torres Alba, G.P. Diller, J. Vormbrock, S. Orwat, R. Radke, H. Reinecke, D. Fischer,
H. Baumgartner (Münster, DE)
Effect of gender on outcome of patients undergoing trans-catheter aortic valve implantation (TAVI). P685
– J. Schewel, D. Schewel, R. Sabielny, T. Thielsen, T. Schmidt, F. Kreidel, U. Schaefer, K.H. Kuck, C. Frerker
(Hamburg, DE)
CARDIOMYOPATHIES
Long-term natural history of right ventricular function in dilated cardiomyopathy: innocent bystander or P686
leading actor?
– P. Losurdo, M. Merlo, D. Stolfo, M. Gobbo, G. Barbati, B. Pinamonti, A. Pivetta, A. Di Lenarda, M. Anzini,
G.F. Sinagra (Trieste, IT)
N-terminal pro brain natriuretic peptide (Nt-proBNP) is a strong predictor of mortality in systemic P687
sclerosis.
– C. Meune, E. Hachulla, J. Avouac, J. Distler, N. Hunzelmann, S. Vettori, G. Valentini, C. Laszlo, A. Komocsi,
Y. Allanore (Bobigny, Lille and Paris, FR; Erlangen and Cologne, DE; Naples, IT; Pécs, HU)
Divergent clinical features of Takotsubo cardiomyopathy by the type of preceding stress. P688
– T. Murakami, T. Yoshikawa, Y. Maekawa, T. Yamaguchi, T. Ueda, T. Isogai, K. Sakata, K. Nagao,
T. Yamamoto, M. Takayama (Tokyo, JP)
Phenotypical expression of hypertrophic cardiomyopathy in a multi-ethnic society. P689
– H.C. Tang, L.L. Lazaro, G.R. Mercadal, M.N. Genuino, W.A. Tan, Z.P. Ding (Singapore, SG; Manila, PH)
Long-term outcome under clinical management of arrhythmogenic right ventricular cardiomyopathy P690
causing desmosomal-gene mutation carriers with no prior ventricular fibrillation or sustained ventricular.
– A. Zorzi, I. Rigato, K. Pilichou, M. Perazzolo Marra, G. Thiene, S. Iliceto, A. Rampazzo, B. Bauce, C. Basso,
D. Corrado (Padua, IT)
Long-term characterization and prognosis of dilated cardiomyopathy in children compared to adult P691
population: the trieste heart muscle disease registry experience.
– I. Puggia, M. Merlo, G. Barbati, D. Stolfo, M. Gigli, F. Ramani, A. Di Lenarda, G. Sinagra (Trieste, IT)
Doppler echocardiography underestimates the prevalence of mid-cavity obstruction in patients with P692
symptomatic hypertrophic cardiomyopathy.
– J.W. Malcolmson, A. Joshi, S. Hamshere, C. O’Mahony, N. Sekhri, S.A. Mohiddin (London, UK)
59
Fragmented QRS improves prediction ability of the Risk-SCD calculator for sudden cardiac death in P693
Japanese patients with hypertrophic cardiomyopathy.
– R. Teramoto, T. Konno, H. Tada, T. Tsuda, A. Hodatsu, K. Sakata, K. Hayashi, N. Fujino, M. Kawashiri,
M. Yamagishi (Kanazawa, JP)
The combination of diastolic filling and diastolic deformation predicts mortality in patients with cardiac P694
amyloidosis during serial echocardiography.
– K. Hu, D. Liu, S. Stoerk, S. Herrmann, M. Cikes, B. Kramer, P.D. Gaudron, G. Ertl, B. Bijnens,
F. Weidemann (Würzburg, DE; Zagreb, HR; Barcelona, ES)
Myocardial edema assessed with T2-weighted CMR imaging is associated with adverse clinical features P695
in hypertrophic cardiomypathy.
– D.H.F. Gommans, G.E. Cramer, J. Bakker, M. Michels, H.J. Dieker, M.A. Fouraux, C.L.M. Marcelis,
J. Timmermans, M.A. Brouwer, M.J.M. Kofflard (Nijmegen, Dordrecht and Rotterdam, NL)
PERICARDIAL AND MYOCARDIAL DISEASE, TUMOURS, OTHER

Resting heart rate is associated with prognosis in systemic sclerosis. P696
– L.E. Couperus, R.W.C. Scherptong, R.W. Treskes, J.K. De Vries, A.A. Schouffoer, J. Meijs, C.A. Swenne,
M.J. Schalij, H.W. Vliegen (Leiden, NL)
Dissection of the interventricular septum echocardiographic features. P697
– X. Gu, Y. He, S. Luan, Y. Zhao, L. Sun (Beijing, CN)
Impact of left ventricular wall hypertrophy relative to right ventricular wall thickness on pathological P698
remodeling and adverse cardiac events in hypertrophic cardiomyopathy.
– T. Konno, Y. Nagata, R. Teramoto, A. Hodatsu, E. Masuta, K. Hayashi, N. Fujino, M. Yamagishi (Kanazawa,
JP)
Cardiac tumors: clinical features, management strategies and outcomes. P699
– B. Hudzik, K. Miszalski-Jamnka, J. Glowacki, J. Szkodzinski, A. Lekston, M. Zembala, M. Gasior (Zabrze,
PL)
Functional capacity in patients with restrictive syndromes: endomyocardial fibrosis versus constrictive P700
pericarditis.
– A.L. Sayegh, D.T.P. Melo, F.R. De Souza, M.R. Dos Santos, A.C.B. Dutra-Marques, V.C. Salemi,
C.E. Negrao, C. Mady, M.J.N.N. Alves, F. Fernandes (São Paulo, BR)
Demographic characteristics and inhospital outcome of patients with pericardial diseases admitted to a P701
tertiary care hospital.
– M. Abdelhamid, S. Salama, K. Said, A. Elfol (Cairo, EG)
Left atrial remodeling and dysfunction occur early in patients with systemic sclerosis and normal left P702
ventricular function.
– D. Peluso, E. Pigatto, G. Romeo, U. Cucchini, D. Muraru, P. Aruta, F. Cozzi, L. Punzi, S. Iliceto,
L.P. Badano (Padua, IT)
Contemporary evaluation of non-surgical causes of cardiac tamponade: acute and long-term outcomes. P703
– A. Orbach, J. Schliamser, M.Y. Flugelman, B. Zafrir (Haifa, IL)
Tamponade among systemic lupus erythematosus patients. P704
– T. Larbi, Z. Meddeb, S. Hamzaoui, A. Elouni, K. Bouslema, S. M’rad (Tunis, TN)
CONGENITAL HEART DISEASE IMAGING
To be or not to be patent: the relationship between migraine and patent foramen ovale. P705
– N. Kahya Eren, N.G. Bulbul, S. Yakar Tuluce, C. Nazli, Y. Beckmann (Izmir, TR)
Spekle tracking in ALCAPA patients after surgical repair and normal ejection fractionas predictor of P706
residual coronary disease.
– B. Castaldi, V.L. Vida, E. Reffo, G. Stellin, O. Milanesi (Padua, IT)
Quantitative assessment of systolic left ventricular function with speckle-tracking echocardiography in P707
adult patients with repaired aortic coarctation.
– M.E. Menting, R.W.J. Van Grootel, A.E. Van Den Bosch, J.A. Eindhoven, J.S. McGhie, J.A.A.E. Cuypers,
M. Witsenburg, W.A. Helbing, J.W. Roos-Hesselink (Rotterdam, NL)
The value of dual source multidetector computed tomography in determining pulmonary blood supply in P708
patients with pulmonary atresia with ventricular septal defect.
– N. Chaosuwannakit, P. Makarawate (Khon Kaen, TH)
Comparison of left ventricular hypertrophy by electrocardiogram and echocardiography using novel data P709
analytics tool.
– J. Weinberg, P. Bhagat, S. Bieganski, A.S. Brown, M. Kanasseril, T. Lavers, K. Spencer, C. Sable
(Washington, Andover and Chicago, US; Sydney, AU)
Application of combined echocardiography STIC and computational fluid dynamics (CFD) technique in the P710
study of fetal aortic isthmus coarctation hemodynamics.
– Z. Chen, Y. Zhou, J.Y. Wang, Y.H. He, Y.N. Wang, W.M. Shi (Beijing, CN)
Association between fetal congenital heart defects and maternal risk of hypertensive disorders of P711
pregnancy.
– H. Boyd, S. Basit, I. Behrens, E. Leirgul, H. Bundgaard, J. Wohlfahrt, M. Melbye, N. Oyen (Copenhagen,
DK; Bergen, NO)
Aortic dissection in pregnancy in England: a retrospective incidence study using linked national P712
databases.
– A. Banerjee, I. Begaj, S. Thorne (Birmingham, UK)
60
Right ventricular function is associated with worse uteroplacental circulation in pregnant women with P713
Tetralogy of Fallot.
– M.A.M. Kampman, C.M. Bilardo, A. Balci, M.A. Oudijk, B.J.M. Mulder, J.W. Roos-Hesselink, M.W.M. De
Laat, K.M. Sollie-Szarynska, D.J. Van Veldhuisen, P.G. Pieper (Utrecht, Groningen, Zwolle, Amsterdam and
Rotterdam, NL)

Arrhythmogenic right ventriclar dysplasia during pregnancy: retrospective study of 21 patients. P714
– E. Varlet, J. Nizard, G. Duthoit, V. Fressart, N. Badenco, X. Waintraub, C. Maupain, T. Chastre,
F. Hidden-Lucet, E. Gandjbakhch (Paris, FR)
ADULT CONGENITAL HEART DISEASE

Dysrhythmia in patients with different types of atrial septal defects: a comparison of incidences. P715
– C.A. Houck, C.P. Teuwen, K. Kraaier, J.M. Van Opstal, J.W.J. Vriend, P.H. Van Der Voort, T.C. Konings,
J.W. Roos-Hesselink, A.J.J.C. Bogers, N.M.S. De Groot (Rotterdam, Enschede, The Hague, Eindhoven
and Amsterdam, NL)
Asthma-like dyspnoea in patients with a secundum atrial septal defect undergoing percutaneous closure. P716
– M. Nassif, C.B.B.C.M. Heuschen, H. Lu, B.J. Bouma, B.J.M. Mulder, R.J. De Winter (Amsterdam, NL)
Morbidity and Mortality Associated with Shones Complex in Adults. P717
– S.H. Aslam, P. Khairy, L.A. Mercier, A. Dore, F. Marcotte, R. Ibrahim, A. Asgar, J. Miro, N. Poirier,
F.P. Mongeon (Montreal, CA)
NT-proBNP and diastolic left ventricular function in patients with Marfan syndrome. P718
– P. Gehle, P.N. Robinson, M. Yigitbasi, F. Berger, V. Falk, B. Pieske, E. Wellnhofer (Berlin, DE)
Right atrial mechanics and P-wave indices long-term after biventricular repair of pulmonary atresia or P719
stenosis with intact ventricular septum.
– A.H.M. To, C.T.M. Lai, S.J. Wong, Y.F. Cheung (Hong Kong, HK)
Hypokalaemia in adults with atrial septal defect: prevalence and relation to arrhytmias. P720
– M. Komar, T. Przewlocki, B. Sobien, L. Tomkiewicz-Pajak, P. Wilkolek, J. Podolec, M. Olszowska,
M. Hlawaty, P. Podolec (Krakow, PL)
Representativeness of the German National Register for Congenital Heart Defects. A clinically oriented P721
analysis.
– P. Helm, M.-A. Koerten, H. Abdul-Khaliq, H. Baumgartner, D. Kececioglu, U.M.M. Bauer (Berlin, Homburg,
Münster and Bad Oeynhausen, DE)
Both systemic arterial and pulmonary artery stiffness predict ventricular recovery after successful P722
percutaneous closure of secundum atrial septal defects.
– A.O. Baykan, M. Gur, A. Acele, T. Seker, G.Y. Kalkan, D.Y. Sahin, M. Koc, A. Bulut, H. Harbalioglu, M. Cayli
(Adana, Kars and Diyarbakir, TR)
Scimitar syndrome in adults: not always a benign condition. P723
– A. Merola, C. Montanaro, A. Kempny, R. Alonso-Gonzalez, L. Swan, A. Uebing, M.A. Gatzoulis,
K. Dimopoulos (London, UK)
Cardiovascular risk factors in adults with congenital heart disease: recognized but not treated? P724
– M.-A. Koerten, G.P. Diller, H. Baumgartner, F. De Haan, P. Helm, J. Bauersachs, U.M.M. Bauer, O. Tutarel
(Berlin, Münster and Hannover, DE)
TO BE OR NOT TO BE OBESE: THIS IS THE CHALLENGE!

Chromatin changes by methyltransferase Set7 induce inflammatory adhesion molecules and endothelial P725
dysfunction in small visceral arteries from insulin resistant subjects.
– S. Costantino, F. Paneni, A. Virdis, M. Volpe, S. Taddei, F. Cosentino (Stockholm, SE; Pisa and Rome, IT)
Association of protein energy wasting and renal insufficiencies with cardiovascular outcomes in patients P726
with pre-dialysis chronic kidney disease.
– H. Takahashi, M. Hasegawa, H. Ishii, D. Kamoi, Y. Kumada, T. Murohara, Y. Yuzawa (Toyoake, Nagoya and
Kasamatsu, JP)
Adherence to mediterranean diet has a mediating effect on C-reactive protein and interleukin-6: the P727
10-year (2002-12) follow-up of Attica study.
– D.B. Panagiotakos, E. Georgousopoulou, C. Pitsavos, C. Chrysohoou, I. Skoumas, M. Ntertimani,
D. Tousoulis, C. Stefanadis (Athens, GR)
Epicardial adipose tissue is associated with insulin resistance and left atrial enlargment in young obese P728
women.
– K. Spahiu, E.S. Spahiu Eduard (Durres, AL)
Prevalence and trends of markers of sub-clinical coronary atherosclerosis in patients with abdominal P729
obesity.
– A.A.M. Farrag, S. Sorour, M.A. Salem, S. Bakhoum (Cairo, EG)
Long-term nutritional habits and four-year (2009-2013) all cause and cardiovascular disease mortality in P730
older adults: the ikaria study.
– C. Chrysohoou, J. Skoumas, G. Lazaros, K. Katte, S. Mazaris, E. Venieri, C. Zisimos, M. Kariori,
Temporal trends in all-cause mortality patients with acute myocardial infarction in regions with compared P731
to without desalinated drinking water from the Acute Coronary Syndrome Israeli Survey (ACSIS).
– M. Shechter, M. Shlezinger, Y. Amitay, I. Goldenberg (Tel Hashomer and Ramat Gan, IL)
The happy heart educational program randomized clinical trial: benefits for children with cardiovascular P732
risk factors and their caregivers are sustained after a year of follow-up.
– L.C. Pellanda, V. Minossi, R.F. Borges, S.P. Hattge Jr (Porto Alegre, BR)
61
Endothelial function in obese and overweight patients: the role of olive oil, fish and nuts. P733
– M.M. Ciccone, A. Zito, R. Carbonara, F. Cortese, M. Gesualdo, L. Ghiadoni, R. Lagioia, D. Scrutinio, G. De
Pergola, P. Scicchitano (Bari and Pisa, IT)
WASHOKU-modified DASH diet reduces blood pressure and improves cardiovascular risk factors P734
independently of body weight in subjects with untreated high normal blood pressure and stage 1
hypertension.
– A. Kawamura, S. Umemoto, J. Inagaki, H. Kishi, K. Kajiya, M. Mitarai, H. Oda, S. Kobayashi (Ube and
Tsukuba, JP)
Adipokines in metabolically healthy obese patients depending on the criteria of metabolic health and P735
gender.
– M. Boyarinova, A. Orlov, O. Rotar, A. Alieva, E. Moguchaya, E. Vasilieva, V. Yudina, V. Solntsev,
E. Baranova, A. Konradi (St. Petersburg, RU)
THE DARK SIDE OF SWEET!

New-onset diabetes mellitus and coronary artery spasm in patients underwent acetylcholine provocation P736
test.
– B.G. Choi, S.W. Rha, S.Y. Choi, J.K. Byun, J.J. Lee, J.B. Kim, E.J. Kim, C.G. Park, H.S. Seo, D.J. Oh
(Seoul, KR)
Previously unknown glucose disturbances are common among individuals with periodontitis, especially in P737
those with a previous myocardial infarction.
– A. Norhammar, B. Kjellstrom, N. Habib, P. Nasman, A. Gustafsson, L. Ryden (Stockholm, SE)
Diabetic cardiac autonomic dysfunction predicts adverse vascular function and clinical heart failure: P738
counter-physiological dissociation of resting heart rate with PR interval.
– Y.H. Chan, K.H. Yiu, K.K. Lau, S.W.L. Li, C.P. Lau, C.W. Siu, H.F. Tse (Hong Kong, HK)
The metabolic syndrome and coronaray heart disease: 40-years in the Seven Countries’ Study. P739
– B. Parapid, N. Danchin, A. Menotti, H. Blackburn, H. Adachi, D. Kromhout, D. Jacobs, A. Nissinen,
J. Moschandreas, M.C. Ostojic (Belgrade, RS; Paris, FR; Rome, IT; Minneapolis, US; Kurume, JP;
Wageningen, NL; Kuopio, FI; Heraklion, GR)
Impaired arterial stiffness and inflammatory status in patients with diabetic foot. P740
– T. Konsola, G. Siasos, N. Tentolouris, C. Kollia, E. Oikonomou, N. Gouliopoulos, M. Zaromitidou,
K. Mourouzis, E. Dimitropoulos, D. Tousoulis (Athens, GR)
Metabolically healthy obesity and risk of cardiovascular disease among the elderly: the rotterdam study. P741
– K. Dhana, M.A. Ikram, A. Hofman, M. Kavousi, O.H. Franco (Rotterdam, NL)
Insulin resistance and cardiovascular events in a general urban cohort: the Suita Study. P742
– Y. Kokubo, M. Watanabe, A. Higashiyama, Y.M. Nakao, T. Watanabe, Y. Miyamoto (Suita, JP)
Homeostatic model assessment derived insulin sensitivity predicts all-cause mortality independently of P743
traditional risk factors at long-term follow-up.
– M.L. Nielsen, M. Pareek, M. Leosdottir, P.M. Nilsson, M.H. Olsen (Odense, DK; Malmö, SE)
Usual blood pressure and risk of new onset diabetes: evidence from 4.1 million adults and a P744
meta-analysis of prospective studies.
– C.A. Emdin, S.G. Anderson, M. Woodward, K. Rahimi (Oxford, UK)
Epicardial adipose tissue as a marker of insulin resistance in patients with long-standing type 1 diabetes P745
mellitus.
– A. Moustafa, D. Vilades, C. Colom Comi, A. Perez-Perez, F. Carreras, R. Leta, G. Pons (Barcelona, ES)
Components of metabolic syndrome are associated with diastolic dysfunction. P746
– J.B. Lee, S.P. Hong, Y.S. Lee, R.Y.U. Jk, J.Y. Choi, K.S. Kim, J.H. Son, Y.W. Park, B.K. Kim, C.W. Lee
(Daegu, KR)
Associations of sex hormone-binding globulin, testosterone and estradiol with the risk of type 2 diabetes P747
among middle-aged men and women: the Rotterdam Study.
– T. Muka, C. Meun, L. Jaspers, A. Hofman, J.S.E. Laven, M. Kavousi, O.H. Franco (Rotterdam, NL)
OVERWEIGHT = “OVERDOSE” OF CARDIOVASCULAR RISK!
Left ventricular remodelling with increasing body fat: a 3D cardiac phenotyping study. P748
– B. Corden, A.S.M. De Marvao, T.J.W. Dawes, W. Shi, D. Rueckert, S.A. Cook, D.P. O’Regan (London, UK)
Timing and duration of overweight in association with metabolic health risk among middle-aged and P749
elderly.
– K. Dhana, A. Hofman, M. Kavousi, O.H. Franco (Rotterdam, NL)
Diastolic dysfunction and impaired cardiopulmonary performance in obesity: an analysis of the EURO-EX P750
trial.
– M. Pellegrino, G. Generati, F. Bandera, F. Carbone, V. Labate, E. Alfonzetti, M. Guazzi (San Donato
Milanese, IT)
Risks and advantages of body mass index on left ventricular function. P751
– M. Shimizu, H. Fujii, N. Yamawake, M. Nishizaki (Yokohama, JP)
Weight loss is also deleterious in obese patients with heart failure. P752
– C. Diez, E. Zamora, J. Lupon, M. De Antonio, M. Domingo, J. Santesmases, M. Troya, C. Diez-Quevedo,
S. Altimir, A. Bayes-Genis (Badalona, ES)
Heavy torso and narrow hip means high risk of myocardial infarction in elderly men: findings from a P753
population based case-control study on anthropometric measures.
– G. Nilsson, J. Leppert, P.O. Hedberg, A. Rosenblad, C.J.O. Ohrvik (Västerås and Stockholm, SE)
62
Differing effects of gender and obesity on nocturnal fluid displacement in patients with obstructive sleep P754
apnoea.
– M.K. Kobayashi, T.Y. Yamaguchi, Y.T. Takata, M.W. Watanabe, K.S. Shiina, Y.S. Usui, A.Y. Yamashina
(Tokyo, JP)
Validation of left ventricular hypertrophy cut-off values in morbidly and super-morbidly obese patients. P755

– J. Domienik, W. Lisik, B. Lichodziejewska, M. Ciurzynski, K. Kurnicka, Z. Rymarczyk, O. Dzikowska-Diduch,
A. Chmura, P. Pruszczyk (Warsaw, PL)
Mortality due to obesity and overweight: extending the obesity paradox to other ethnicities. P756
– S. Soderberg, M. Lilja, J.E. Shaw, P. Zimmet, B. Balkau, G. Alberti, J.E. Tuomilehto, D. Magliano (Umeå,
SE; Melbourne, AU; London, UK; Helsinki, FI)
Waist circumference and body mass index as complementary obesity parameters in cardiovascular risk P757
assessment in hypertensives with coronary heart disease.
– M. Wirtwein, D. Jarosz, E. Trybala, M. Gruchala, W. Sobiczewski (Gdansk and Chojnice, PL)
Are weight and BMI good predictors of in-hospital deaths in acute coronary syndromes? P758
– S. Jacob, J.B. Ruidavets, V. Bongard, C. Meisinger, D. Farmakis, U. Hakkinen, D. Fusco, A. Azevedo,
J. Marrugat, J. Ferrieres (Fontenay-aux-Roses and Toulouse, FR; Augsburg, DE; Athens, GR; Helsinki, FI;
Rome, IT; Porto, PT; Barcelona, ES)
The effects of one-night continuous positive airway pressure use for patients with obstructive sleep P759
apnoea on the whole body fluid redistribution.
– T. Yamaguchi, Y. Takata, R. Asanuma, K. Shiina, Y. Usui, A. Yamahina (Tokyo, JP)
DIABETES MELLITUS AND CARDIOVASCULAR DISEASE
Deterioration of glycemic control in South Asians vs. White Caucasians with diabetes and concomitant P760
coronary artery disease - analysis from the PRACTICE Registry.
– H. Bajaj, S. Sheikh, S. Gill-David, S. Hirjikaka, M. Tsigoulis, M. Gupta (Brampton and Hamilton, CA)
Metformin does not impair endothelial coverage of drug-eluting stents. P761
– M. Gracida, R. Romaguera, J. Gomez-Lara, J.L. Ferreiro, G. Roura, L. Teruel, A.L. Marcano, F. Jacobi,
J.A. Gomez-Hospital, A. Cequier (Barcelona, ES)
The impact of additional medical treatment on insulin resistance in cardiovascular patients: a propensity P762
score matched analysis.
– S.W. Rha, S. Xu, H.A. Ngow, J. Ali, B.G. Choi, S.Y. Choi, J.K. Byun, C.G. Park, H.S. Seo, D.J. Oh (Seoul,
KR)
Effect of haemoglobin A1c and peri-operative glucose levels on diabetic patients undergoing coronary P763
artery bypass grafting.
– T.K.M. Wang, A. Woodhead, J. Pemberton, T. Ramanathan (Auckland, NZ)
Influence of chronic kidney disease on vulnerability of coronary plaques in type 2 diabetes patients with P764
optimal medical therapy in Japan.
– M. Yano, A. Iwata, S. Imaizumi, S. Miura, K. Saku (Fukuoka, JP)
Effect of intensive glycemic control on indices of vascular function in patients with type 2 diabetes; P765
results at 6-12 month follow-up.
– S. Antoniou, A. Bechlioulis, S. Giannitsi, M. Bougiakli, K. Papathanassiou, A. Tsatsoulis, S. Tigas,
L.K. Michalis, K.K. Naka (Ioannina, GR)
TG/HDL ratio predicts incident diabetes and cardiovascular events in TNT and SPARCL. P766
– P. Kohli, J.W. Knowles, P. Amarenco, R. Fayyad, G. Reaven, D.A. Demicco, B. Arsenault, R. Laskey,
D.D. Waters (San Francisco, Palo Alto and New York, US; Paris, FR; Quebec, CA)
Association of diabetes mellitus with the incidence of adverse events in patients with atrial fibrillation: P767
The Fushimi AF Registry.
– M. Ishii, H. Ogawa, N. Masunaga, M. Iguchi, M. Esato, Y.H. Chun, H. Wada, K. Hasagawa, M. Abe,
M. Akao (Kyoto, JP)
Diabetes screening in patients with coronary artery disease: are the new guidelines a step backwards? P768
– S.B. Baptista, A. Ribeiro, M. Faustino, P. Alves, P. Farto E Abreu, V. Gil, C. Morais (Amadora, PT)
Acute hyperglycemia induces sympathetic overactivity and attenuates coronary microcirculation in P769
patients with impaired glucose tolerance.
– K. Murakawa, R. Yuyama, H. Yokoe, K. Matubara, I. Shiojima (Hirakata and Kyoto, JP)
Diabetes, admission blood glucose and time to death for acute myocardial infarction: a national cohort P770
study of 106,967 patients.
– M. Van Laar, C.P. Gale, T.B. Dondo, O.A. Alabas, I.B. Squire (Leeds and Leicester, UK)
Homeostatic model assessment derived insulin sensitivity only predicts incident myocardial infarction at P771
long-term follow-up.
– M. Pareek, M.L. Nielsen, M. Leosdottir, P.M. Nilsson, M.H. Olsen (Odense, DK; Malmö, SE)
IMPROVING CARE THROUGH ASSESSMENT, SUPPORT, SERVICES AND RESEARCH
How effective is non-medical prescribing in optimising secondary prevention medication post primary P772
percutaneous coronary intervention?
– A. Pottle, C. Hayes, S. Manning (Harefield, UK)
Utilization of team-resource management to tackle blood-stream infection in a cardiovascular intensive P773
care unit.
– H.T. Hsin (Taipei, TW)
Experiences of informed consent for percutaneous coronary intervention: an interview study. P774
– J.E. Probyn, J. Greenhalgh, D. Conway, A.C. Morton, J. Holt, K. Marshall, J. Wright, F. Astin (Salford,
Leeds, Wakefield, Sheffield and Huddersfield, UK)
63
Clinical nurses and nurse managers attitudes towards nursing research in Danish cardiovascular P775
departments.
– G. Ingwersen, C. Helmark, K. Johansen, T.B. Hansen (Roskilde, DK)
An exploration of cardiology patients and nurses perspectives of clinical research participation during P776
admission for an acute myocardial infarction.
– P. Rogers, P. Rogers, A. Pottle, J. Goodyer, S. Ali, A. Brown, S. Thiruthalil (London, UK)
Aligning the planets: the role of nurses in the care of patients with NSTEMI. P777
– C. Deaton, H. Cramer, R. Johnson, M. Evans, A. Timmis, J. Zaman, H. Hemingway, G. Feder (Cambridge,
Bristol, London and Norwich, UK)
A multiple regression analysis identifying the factors influencing attendance at a well attended Phase III P778
cardiac rehabilitation programme.
– C. Finn, G. McKee (Dublin, IE)
Implementation of WHO hypertension management protocol in community health care centers in China. P779
– X.H. Zhang, Y. Huo, L.S. Liu, T.R. Guan, Y. Zhang, X.Y. Liao, Y.M. Han, S.P. Ma, J.G. Zhao (Beijing,
Chengdu, Hangzhou, Shijiazhuang and Weihai, CN)
Mammillary body brain damage correlates with symptoms of sleep disturbances and depression in heart P780
failure.
– A.E.A. Louie, M.A. Woo, G.C. Fonarow, R. Kumar (Los Angeles, US)
Regional brain cortical thickness reduced in heart failure. P781
– M.A. Woo, R. Kumar, G.C. Fonarow (Los Angeles, US)
Self-care support by Internet for patients with heart failure: a qualitative interview study. P782
– C. Jansson, J. Westerlund, L. Klompstra, T. Jaarsma (Linköping, SE)
Impact of multiple symptoms on quality of life and event-free survival in chronic heart failure. P783
– S.E. Ivynian, C. Hwang, J. McDonagh, M. Digiacomo, S.C. Inglis, P.J. Newton (Sydney, AU)
UNDERSTANDING THE RISKS AND OPTIMISING OUTCOMES AFTER PCI I
Clustering of risk factors for insulin resistance plays an important role in plaque vulnerability in patients P784
with coronary artery disease.
– S.H. Han, Y.M. Park, P.C. Oh, K.K. Koh, K.H. Lee, S.Y. Suh, W.C. Kang, T.H. Ahn, E.K. Shin (Incheon, KR)
In patients with coronary artery disease women show higher carotid plaque temperatures. P785
– M. Drakopoulou, K. Toutouzas, G. Benetos, I. Koutagiar, K. Stathogiannis, A. Synetos, G. Latsios,
E. Tsiamis, E. Siores, D. Tousoulis (Athens, GR; Bolton, UK)
Lipoprotein(a) correlates with coronary plaque burden and thin cap fibroatheroma: an angiographic and P786
optical choherence tomography study.
– D. Chin, G. Niccoli, E. Reefat, N. Cosentino, G. Scalone, M. Volpe, F. Crea, L. De Biase (Rome, IT; Zagazig,
EG)
Are endothelial progenitor cells related to atherosclerotic plaque burden in coronary artery disease? An P787
OCT study 6 months after stent implantation.
– S. Otto, K. Nitsche, C. Jung, J.L. Gutierrez-Chico, F. Gassdorf, B. Goebel, D. Prochnau, H.R. Figulla,
T.C. Poerner (Jena and Berlin, DE)
Association of estimated glomerular filtration rate and dipstick proteinuria with lipid-rich plaque in P788
coronary artery disease patients.
– Y. Shimbo, S. Suzuki, H. Ishii, Y. Shibata, Y. Tatami, S. Harata, Y. Takayama, N. Osugi, T. Murohara
(Nagoya, JP)
Relationship between ambulatory high-sensitivity cardiac troponin I level and coronary artery stenosis in P789
patients with chest pain.
– T. Niida, T. Lee, T. Murai, Y. Kanaji, J. Matsuda, E. Usui, M. Araki, T. Kakuta (Tsuchiura, JP)
Enhanced inflammatory changes in the perivascular adipose tissue and coronary hyperconstricting P790
responses after drug-eluting stent implantation in pigs in vivo.
– K. Ohyama, Y. Matsumoto, H. Uzuka, K. Nishimiya, M. Hirano, M. Kumagai, J. Takahashi, K. Ito,
H. Shimokawa (Sendai, JP)
Efficacy and safety of radial access in patients with negative Allen test. P791
– C. Maniotis, C. Andreou, P. Dimitriou, E. Lazaris, D. Oikonomidis, M. Aggelaki, A. Antonakopoulos,
T. Zografos, M. Koutouzis, Z.S. Kyriakides (Athens, GR)
Registry-based comparison of clinical and safety events by catheterization access routes: radial versus P792
femoral outcomes.
– D.R. Dobies, K.R. Barber, A.L. Cohoon (Grand Blanc, US)
Peri-procedural myocardial infarction following PCI as defined by the universal definition predicts P793
increased mortality at 2 years.
– K. Liou, B. Ng, J. Isbister, P. Kellar, N. Jepson, S. Ooi (Sydney, AU)
UNDERSTANDING THE RISKS AND OPTIMISING OUTCOMES AFTER PCI II
The long-term impact of blood transfusion after percutaneous coronary intervention. P794
– G. Weisz, Y. Almagor, A. Butnaru, R. Farkash, S. Gotleib, M. Klutstein, A. Medina, D. Meerkin, M. Muriel,
D. Tzivoni (Jerusalem, IL)
Evaluation of the incidence of radial artery occlusion after TR band application with 11ml (reduced) P795
versus 15ml (standard) of air.
– S.W. Neoh, C. O’Callaghan, D. Mulcahy, B. Loo (Dublin, IE)
Incidence of radiation-induced skin lesions after percutaneous coronary intervention. P796
– A. Paziuc, L. Mangin, A. Ispas, M. Rata, B. Lafitte, H. Madiot, S. Vanwalleghem, C. Ricard, J.L. Georges,
L. Belle (Annecy and Versailles, FR)
64
Structural damage of the jailed wire in the treatment of coronary bifurcations: microscopic assessment. P797
– M. Pan Alvarez-Osorio, E. Villanueva, S. Ojeda, M. Romero, J. Suarez De Lezo Jr, F. Mazuelos, J. Segura,
P. Martin, A. Medina, J. Suarez De Lezo (Córdoba, ES)
Periprocedural myocardial injury and protection during elective stenting. P798
– M. Sokolov, V. Kobylyak, Y. Sokolov (Kiev, UA)

Angiographically visible distal embolization is not linked with culprit lesion but with clinical P799
characteristics.
– N.V. Yameogo, K. Stamboul, C. Richard, A. Gujoncik, I. L’Huillier, P. Buffet, L. Lorgis, Y. Cottin (Dijon, FR)
CHADS2 score predicts risk of contrast-induced nephropathy in patients with stable coronary artery P800
disease.
– R.H. Chou, P.S. Huang, C.Y. Hsu, H.B. Leu, C.C. Huang, J.W. Chen, S.J. Lin (Taipei, TW)
Urinary liver-type fatty acid-binding protein predict contrast-induced nephropathy and persistent renal P801
damage after percutaneous coronary intervention.
– S. Fukuzawa, S. Okino, J. Maekawa, S. Ichikawa, N. Kuroiwa, K. Yamanaka, T. Igarashi, M. Inagaki
(Funabashi, JP)
Transradial intervention versus transfemoral intervention accompanied with vascular closure device in P802
acute myocardial infarction.
– H.-J. Hwang, C.-B. Park, D.-H. Kim, J.-M. Cho, H.-Y. Park, E.-S. Jin, I.S. Sohn, C.-J. Kim (Seoul, KR)
Influence of the ratio between radial artery inner diameter and the introducer sheath outer diameter on P803
endothelial function in humans after transradial coronary procedures.
– S. Rathore, E. Dawson, T. Cable, J. Wright, J. Morris, D. Green (Camberley, Surrey, UK and Liverpool, UK)
Number of severe bleeding complications according to classification used: is unified classification of P804
bleeding complications really necessary?
– M. Doktorova, P. Vasko, S. Jirous, D. Vindis, R. Rokyta, L. Posch, Z. Motovska (Prague, Ostrava, Pilsen
and Olomouc, CZ)
EARLY AND LATE OUTCOMES AFTER PCI I

In-hospital death analysis of acute myocardial infarction after primary percutaneous coronary P805
intervention in Beijing from 2010-2013.
– L. Song, Y.J. Yang (Beijing, CN)
Clinical outcomes of percutaneous coronary intervention at centers with or without on-site surgical P806
back-up: an updated meta-analysis of 23 studies.
– D. Hwang, J.M. Lee, J. Park, K.J. Kim, B.K. Koo, H.S. Kim (Seoul, KR)
Prevalence and impact of chronic kidney disease in women undergoing percutaneous coronary P807
intervention with drug-eluting stents: a patient-Level pooled analysis of randomized controlled trials.
– U. Baber, G. Giustino, M. Aquino, S. Sartori, G.G. Stefanini, G.W. Mikhail, S. Windecker, D. Kandzari,
M.B. Leon, R. Mehran (New York and Atlanta, US; Milan, IT; London, UK; Berne, CH)
The lower the left ventricular ejection fraction, the more benefit from successful chronic total occlusion P808
intervention.
– S.W. Rha, B.G. Choi, S.Y. Choi, J.K. Byun, C.U. Choi, E.J. Kim, C.G. Park, H.S. Seo, D.J. Oh (Seoul, KR)
Impact of immature platelet fraction on antiplatelet response to various thienopyridine loading regimes in P809
patients undergoing elective percutaneous coronary intervention.
– C. Stratz, D. Trenk, T. Nuhrenberg, M. Amann, C. Valina, N. Loeffelhardt, M. Gick, H.J. Buettner,
F.J. Neumann, W. Hochholzer (Bad Krozingen, DE)
Mid-term cardiovascular outcomes of rosuvastatin pretreatment in patients with acute coronary P810
syndrome undergoing percutaneous coronary intervention: a meta-analysis of randomised controlled
trials.
– R. Sakurai (Tokyo, JP)
Clinical outcomes of percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) P811
between hospitals with and without onsite cardiac surgery backup.
– T. Akasaka, S. Hokimoto, N. Tabata, K. Sakamoto, K. Tsujita, E. Yamamoto, T. Tanaka, S. Kojima,
K. Kaikita, H. Ogawa (Kumamoto, JP)
Impact of a successful non-infarct related chronic total occlusion revascularization on clinical outcomes P812
in patients with acute myocardial infarction; from the Korean CTO (K-CTO) registry.
– J.Y. Park, S.W. Rha, B.G. Choi, J.W. Choi, S.K. Ryu, S.Y. Choi, J.B. Kim, C.U. Choi, H.S. Seo, D.J. Oh
(Seoul, KR)
Outcomes of percutaneous coronary intervention performed in off-site versus on-site surgical centres in P813
the United Kingdom.
– S.G. Anderson, C.A. Emdin, P.F. Ludman, M. Woodward, K. Rahimi, S. Garg (Manchester, Oxford,
Birmingham and Blackburn, UK)
Can we predict left ventricular dyssynchrony after anterior myocardial infarction by assessment of P814
circumflex artery motion during primary PCI?
– M. El Tahlawi, I. Mohammad, M. Aldaydamony, A. Shafie Ammar (Zagazig, EG)
The risk factors for complication of hemostasis after transradial coronary catheteriztion: The assessment P815
of protocol of hemostasis with TR band.
– T. Asano, M. Mizuno, M. Nakashima, T. Hashimoto, Y. Horiuchi, Y. Nishizaki, O. Takahashi (Tokyo and
Kanagawa, JP)
Impact of contrast-induced acute kidney injury and impaired left ventricular function on 5-year mortality P816
in STEMI patients undergoing primary PCI.
– S. Zaharijev, D. Milasinovic, P. Zlatanovic, Z. Mehmedbegovic, A. Petakov, A. Novakovic, V. Dedovic,
A. Janicijevic, M. Tesic, G. Stankovic (Belgrade, RS)
65
EARLY AND LATE OUTCOMES AFTER PCI II

SCAD management, controversies; in the stent era. P817
– A. Al-Hussaini, D.A. Adlam, N.S. Samani, G.M.C. McCann (Leicester, UK)
Outcome of patients with atrial fibrillation submitted to percutaneous coronary intervention: influence of P818
recommendations in new guidelines.
– A. Sambola Ayala, B. Miranda, B. Garcia Del Blanco, J. Limeres, M. Mutuberria, F. Alfonso, H. Bueno,
J.A. Barrabes, A. Cequier, D. Garcia-Dorado (Barcelona and Madrid, ES)
Predictors and clinical outcomes successful percutaneous coronary intervention in patients with chronic P819
total occlusion.
– M.H. Kim, C.D. Jin, L.Z. Guo, Y.R. Cho, J.S. Park, K.I. Park, T.H. Park, K.S. Cha, Y.D. Kim (Busan, KR)
Outcome of patients with acute myocardial infarction complicated by cardiogenic shock or arrest who P820
received extracorporeal membrane oxygenation assisted primary percutaneous coronary intervention.
– S.W. Cho, J.K. Jang, S.S. Kim, S.H. Kang (Jeju, KR)
Temporal trends and in-hospital outcomes of primary percutaneous coronary intervention in P821
nonagenarians with ST-segment elevation myocardial infarction.
– M.H. Jeong, J.Y. Kim, Y. Ahn, M.C. Cho, C.J. Kim, Y.J. Kim (Gwangju, KR)
Outcome for patients with ST-segment elevation myocardial infarction and spontaneous ST-segment P822
resolution before intervention.
– J. Loenborg, H. Kelbaek, L. Holmvang, S. Helqvist, N. Vejlstrup, E. Joergensen, K. Saunamaki, J.F. Lassen,
C.J. Terkelsen, T. Engstroem (Copenhagen and Aarhus, DK)
Are recommendations against multi-vessel intervention in ST-elevation myocardial infarction based on P823
current observational data accurate and valid?
– S. Chatterjee, P. Sardar, D. Mukherjee, R. Yeh, J. Giri (New York, El Paso, Boston and Philadelphia, US)
Impact of metabolic syndrome and obesity on clinical outcomes after primary percutaneous coronary P824
intervention for ST-segment elevation myocardial infarction.
– S.H. Lee, M.H. Jeong, J.H. Kim, H. Park, H.K. Kim, D.S. Sim, Y.J. Hong, Y. Ahn, J.G. Cho, J.C. Park
(Gwangju, KR)
Lymphocyte-to-monocyte ratio: a novel marker for predicting no-reflow phenomenon in patients P825
underwent primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
– A. Kurtul, S.N. Murat, M. Yarlioglues, M. Duran, A.H. Ocek, F. Oksuz, O. Aksoy (Ankara, TR)
The impact of diabetes mellitus on in-hospital bleeding in patients undergoing percutaneous coronary P826
intervention with drug-eluting stents.
Impact of cessation of dual antiplatelet therapy on mortality in STEMI patients with bleeding complicating P827
primary percutaneous coronary intervention.
– D. Matic, D. Milasinovic, Z. Mehmedbegovic, J. Dobras, I. Zivkovic, V. Pavlovic, M. Zivkovic, M. Asanin,
The reduction in door-to-balloon time improved in-hospital survival in patients with ST-elevation P828
myocardial infarction (report from Mie ACS registry).
– K.K. Konishi, T.K. Kitamura, R.Y. Yamauchi, A.T. Takasaki, T.O. Omura, S.O. Ota, T.M. Mori, K.D. Dohi,
J.M. Masuda, M.I. Ito (Suzuka and Tsu, JP)
EARLY AND LATE OUTCOMES AFTER PCI III

Coronariography after cardiac arrest, the reality of one centre. P829
– G.M. Rocha Rodrigues, M.S. Santos, A.T. Tralhao, P.F. Freitas, M.C. Castro, P.G. Goncalves, R.T. Teles,
M.A. Almeida, J.F. Ferreira, M.M. Mendes (Lisbon, PT)
Impact of leukocyte count at admission on short and long-term mortality in patients with ST-elevation P830
myocardial infarction undergoing primary PCI.
– D. Matic, D. Milasinovic, Z. Mehmedbegovic, J. Dobras, M. Marjanovic, I. Zivkovic, V. Pavlovic, V. Vukcevic,
M. Asanin, G. Stankovic (Belgrade, RS)
Causes of delay in door-to-balloon time in south-east Asian patients undergoing primary percutaneous P831
coronary intervention for ST-segment elevation myocardial infarction.
– H.H. Ho, S.W. Wong, K.H. Mok, M.C. Tan, W.J. Sim, A.S. Ang, K.H. Quah, D. Foo, P.J.L. Ong (Singapore,
SG)
Comparison of antithrombotic regimens for primary angioplasty in patients >75 years with ST elevated P832
myocardial infarction: the -ESTROFA MI+75 study.
– J.M. De La Torre Hernandez, J.A. Gomez Hospital, S. Brugaletta, A. Perez De Prado, R. Lopez Palop,
N. Salvatella, T. Garcia Camarero, J.R. Rumoroso, L. Andraka, M. Monteagudo (Santander, Barcelona,
Leon, Alicante, Galdacano, Bilbao and Valencia, ES)
Factors influencing no-reflow phenomenon in patients with ST-segment myocardial infarction treated P833
with primary percutaneous coronary intervention.
– B. Dzudovic, N. Djenic, R. Romanovic, S. Obradovic (Belgrade, RS)
Multicenter coronary chronic total occlusion intervention experience in Korean population; from the P834
Korean, nationwide, multicenter CTO (K-CTO) registry.
– S.W. Rha, B.G. Choi, S.Y. Choi, J.K. Byun, J.B. Kim, C.G. Park, H.S. Seo, D.J. Oh (Seoul, KR)
Should we recommend triple therapy in chronically anticoagulated patients undergoing PCI-stenting with P835
a HAS-BLED score of high risk of bleeding?
– B. Miranda Barrio, A. Sambola, A. Santos, J. Limeres, M. Mutuberria, B. Garcia Del Blanco, J.A. Barrabes,
D. Garcia-Dorado (Barcelona, ES)
Safety of drug-eluting stents in patients with an indication for chronic oral anticoagulation. P836
– A. Sambola Ayala, J. Limeres, A. Santos, B. Garcia Del Blanco, B. Miranda, M. Mutuberria, J.A. Barrabes,
F. Alfonso, H. Bueno, D. Garcia-Dorado (Barcelona and Madrid, ES)
66
TECHNICAL ASPECTS OF PCI

Results of radial versus femoral access during primary angioplasty for acute myocardial infarction: P837
problems with registry data.
– R. Zahn, M. Hochadel, H. Mudra, H. Darius, S. Kerber, K.E. Hauptmann, A. Elsaesser, S. Behrens,

T. Bauer, U. Zeymer (Ludwigshafen am Rhein, Munich, Berlin, Bad Neustadt an der Saale, Trier, Oldenburg
and Giessen, DE)
Aspiration thrombectomy in patients with ST-Segment elevation myocardial infarction: an updated P838
meta-analysis of 16 randomized trials.
– I.H. Tanboga, S. Topcu, E. Aksakal, A. Kaya, M. Kurt, U. Aksu, V. Oduncu, S. Sevimli (Erzurum, Ordu,
Hatay and Istanbul, TR)
SAFETY AND EFFICACY OF SECONDARY PREVENTION MEDICATIONS
Efficacy of tocilizumab for the treatment of patients with refractoryTakayasu arteritis. P839
– Y. Nakaoka, Y. Arita, T. Hashimoto-Kataoka, K. Higuchi, T. Yasui, T. Masaki, T. Ohtani,
K. Yamauchi-Takihara, Y. Sakata (Osaka, JP)
Is chromogenic anti-factor xa assay and therapeutic drug monitoring for rivaroxaban appropriate in P840
clinical practice?
– M.-D. Drici, F. Fischer, T. Lavrut, L. Startari, A. Appert, G. Bardy, B. Baldin (Nice, FR)
HEART FAILURE, PATHOPHYSIOLOGY AND DIAGNOSIS

Clinical profile and management of outpatients with non-ischaemic systolic heart failure: subanalysis of P841
the data-help study.
– J.M. Krzysztofik, W. Banasiak, B. Kurian, P. Ponikowski, E.A. Jankowska (Wroclaw and Warsaw, PL)
Prevalence and determinants of atrial dyssynchrony in heart failure patients. P842
– B. Assous, M. Baudet, N. Bihry, I. Corman, A. Cohen-Solal, D. Logeart (Paris, FR)
Usefulness of 99mTc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac P843
amyloidosis.
– A. Galat, J.R. Rosso, A.G. Guellich, A.V.D.G. Van Der Gucht, S.R. Rappeneau, D.B. Bodez, L.H. Hittinger,
J.L.D.B. Dubois-Rande, E.I. Itti, T.D. Damy (Créteil, FR)
Global longitudinal systolic strain is able to differentiate between non-ischemic and ischemic P844
cardiomyopathy among patients with systolic heart failure.
– M. Sengelov, T. Biering-Sorensen, P.G. Jorgensen, N.E. Bruun, F.J. Olsen, T. Fritz-Hansen, J.S. Jensen
(Gentofte, DK)
Impact of malignancies in the early and late time course of catecholamine induced myocardial stunning P845
(Tako-Tsubo cardiomyopathy).
– M. Girardey, L. Jesel, U. Campia, N. Messas, S. Hess, A. Trinh, A. Imperiale, H. Marzak, P. Ohlmann,
O. Morel (Strasbourg, FR; Washington, US)
Usefulness of a new proposed TNM- like classification for heart failure staging: comparison with the P846
classic NYHA.
– P. Severino, G. Calabrese, S. Calcagno, M.C. Gatto, M. Mancone, F. Fedele (Rome, IT)
Role of 123-iodine metaiodobenzylguanidine imaging in prediction of arrhythmic events in heart failure P847
patients candidate to ICD.
– P. Scarparo, P. Severino, N. Salvi, S. Calcagno, C. Calvieri, A. Ceccacci, V. Frantellizzi, G. De Vincentis,
M. Mancone, F. Fedele (Rome, IT)
Abnormal mitochondria in circulating blood monocytes of dogs with advanced heart failure. P848
– H.N. Sabbah, V. Sing-Gupta, R.C. Gupta (Detroit, US)
Neutrophil-to-lymphocyte ratio - an independent predictor of acute decompensated heart failure. P849
– C. Delcea, C.A. Buzea, A. Dima, I. Daha, M. Dobranici, R.A. Popescu, A.R. Dan, C. Baicus, G.A. Dan
(Bucharest, RO)
Detection of myocardial fibrosis in patients with hypertrophic cardiomyopathy evaluated by biological P850
markers.
– A. Zaroui, M. Asmi, C. Tejelbenet, R. Ben Said, N. Kaabachi, M.S. Mourali, R. Mechmeche (Tunis, TN)
Impact of serum ATX levels on cardiac prognosis in patients with heart failure. P851
– A. Funayama, T. Watanabe, Y. Otaki, S. Nishiyama, T. Arimoto, H. Takahashi, T. Shishido, T. Miyamoto,
I. Kubota (Yamagata, JP)
Prognostic significance of atrial arrhythmias in heart failure with preserved ejection function: insights P852
from karen.
– E. Donal (Rennes, FR)
CARDIOTOXICITY OF ANTINEOPLASTE DRUGS, DIAGNOSIS AND TREATMENTS
Can heart rate predict cardiotoxicity? P853

– C.A. Alvarez-Ortega, O. Gonzalez-Fernandez, S. Rosillo, T. Lopez-Fernandez, S. Valbuena-Lopez,
J. Caro-Codon, M. Canales-Albendea, J. Feliu-Batlle, A. Buno-Soto, J.L. Lopez-Sendon (Madrid, ES)
Baseline predictive models to identify high-risk patients for cardiotoxicity development: the possible role P854
of genetic polymorphisms.
– M. Triggiani, B.M. Cesana, G. Bonetti, D. Galli, S. Capellini, M. Fragni, V. Amoroso, E.L. Simoncini,
S. Sigala, S. Nodari (Brescia, IT)
67
Atrial function assessed by echocardiography in survivors of breast cancer treated with P855
anthracycline-containing therapy.
– Y.T. Yaylali, A. Saricopur, M. Yurtdas, H. Senol, G. Gokoz-Dogu (Denizli and Van, TR)
Relation of clinical and biochemical variables to conventional and speckle tracking echocardiography P856
imaging in patients with breast cancer on antineoplastic therapy.
– M.A. Nowakowska, L. Chrzanowski, K. Frynas, K. Wdowiak-Okrojek, E. Szymczyk, P. Wejner-Mik,
P. Lipiec, J.D. Kasprzak, M. Krakowska, P. Potemski (Lodz, PL)
Advanced 3D echocardiographic quantification in cardio-oncology patients: Is there an incremental P857
benefit to global strains beyond accurate assessment of ejection fraction?
– E. Bourni, A. Krommydas, R. Rajani, G. Carr-White, S. Kapetanakis (London, UK)
The importance of using strain derived criteria for detection of subclinical cardiotoxicity in breast cancer P858
patients undergoing anthracycline and trastuzumab.
– C. Santoro, R. Esposito, V. Schiano Lomoriello, R. Muscariello, M. Lembo, F. Ilardi, G. Arpino, S. De
Placido, G. De Simone, M. Galderisi (Naples, IT)
Cardioprotection induced by ranolazine after trastuzumab treatment: the reduction of cardiotoxicity in P859
vitro and in vivo study.
– N. Maurea, C. Coppola, G. Piscopo, F. Galletta, C. Maurea, D. Rea, G. Riccio, P. Maiolino, C. Arra, C. De
Lorenzo (Naples, IT)
Efficacy and safety of ACE-inhibitor and beta-blocker combination therapy in breast cancer patients with P860
chemotherapy-induced heart failure.
– F. Guerra, D. Contadini, A. Menditto, M. Marchesini, M. Morelli, E. Piccolo, N. Battelli, R. Berardi,
S. Cascinu, A. Capucci (Ancona, IT)
Cardioprotective effect of eplerenone in anthracyclines-induced cardiotoxicity. P861
– D. Martin, M. Metrich, R. Van Heeswijk, M. Stuber, R. Hullin (Lausanne, CH)
Percutaneous intramyocardial injection of amniotic membrane-derived mesenchymal stem cells improves P862
ventricular function and survival in non-ischaemic cardiomyopathy in rabbits.
– A. Giraldo, J. Talavera, M.J. Fernandez Del Palacio, C. Mico Valls, E. Garcia-Navarro, N. Marin Atucha,
G. Brooks, J.M. Moraleda (Reading, UK; Murcia, ES)
Protective effect of cilostazol on doxorubicin-induced cardiomyopathy mice. P863
– J.S. Koh, J.Y. Hwang, M.K. Kang, G.S. Roh, J.R. Park, J.W. Ahn (Jinju, KR)
Daunorubicine-induced downregulation of cardiac PPARs expression was prevented by ramipril. P864
– J. Klimas, H. Cernecka, G. Doka, J. Srankova, P. Ochodnicky, P. Krenek (Bratislava, SK)
CARDIOTOXICITY, DIFFERENT FORMS AND DIFFERENT MECHANISMS

Breast cancer chemotherapy related cardiotoxicity risk: from cardiovascular risk factors assessment a P865
strategy for its evaluation.
– I. Parrini, P. Modaffari, L. Fuso, A.M. Ferrero, E.M. Rebuffo, E. Piovano, P. Zola, R. Asteggiano, M.R. Conte
(Turin, IT)
Impaired myocardial function despite normal ejection fraction in patients on current cancer drug P866
therapies.
– L. Venneri, F. Calicchio, R. Manivarmane, A.J. Baksi, S.D. Rosen, R. Senior, A.R. Lyon, R.S. Khattar
(London, UK)
Preferential septal involvement in anthracycline-induced cardiotoxicity as assessed by speckle-tracking P867
and tissue Doppler analysis.
– G. Portugal, L. Branco, A. Galrinho, P. Pinto Teixeira, A.V. Monteiro, P. Rio, J. Abreu, A.T. Timoteo,
M. Mota Carmo, R. Ferreira (Lisbon, PT)
Clinical characteristics and outcome of heart failure and captagon amphetamine use: an observational P868
prospective study.
– A. Elasfar (Riyadh, SA)
Application of label-free autofluorescence lifetime in vivo to measure changes in myocardial fibrosis and P869
metabolism in a doxorubicin cardiomyopathy heart failure model.
– B.T. Dyer, J.M. Elder, J. Lagarto, S.E. Harding, P.M.W. French, N.S. Peters, C. Dunsby, A.R. Lyon (London,
UK)
Relationship between diastolic stiffness assessed by diastolic wall strain and cardiac toxicity from P870
anticancer agents.
– M. Arao, W. Shimizu (Tokyo, JP)
Incidence and clinical aspects of capecitabine cardiotoxicity: a prospective study in the real world. P871
– C. Lestuzzi, L. Tartuferi, A. De Paoli, E. Viel, S. Virdone, R. Innocente, G.M. Miolo, S. Spazzapan,
A. Banzato, A. Buonadonna (Aviano and Padua, IT)
SDF-1/CXCR4 axis downregulation in daunorubicin cardiomyopathy is partly restored by G-CSF and P872
DPP-4 inhibitor, but this is not associated with increased expression of stem cell markers.
– J. Srankova, L. Pivackova, G. Doka, J. Klimas, P. Krenek (Bratislava, SK)
Sympathoadrenergic activation induces sRAGE-downregulation. P873
– S.R. Selejan, A.M. Tatu, D. Linz, M. Hohl, S. Ewen, A. Kazakov, F. Mahfoud, M. Böhm, I. Kindermann
(Homburg, DE)
Potential role of epicardial adipose tissue in cardiac simpathetic denervation in heart failure. P874
– V. Parisi, G. Rengo, T. Pellegrino, R. Formisano, G. Pagano, G. Gambino, A. Cuocolo, P. Perrone Filardi,
D. Leosco, N. Ferrara (Naples, IT)
Increased levels of high sensitive troponin T after first dose of adriamycin therapy may predict brain-type P875
natriuretic rise after 6 months in patients with breast carcinoma.
– O. Sahin, C.E. Caglayan, S. Matyar, A.I. Celik, A. Cureoglu, O.S. Deveci, M. Demirtas, S. Paydas (Adana,
TR)
68
HEART FAILURE BIOMARKERS

Combined measurements of N-terminal pro-brain natriuretic peptide and D-dimer levels predict long-term P876
mortality in acute heart failure.
– K. Minami, M. Kurobe, S. Furudono, Y. Uchida, T. Nunohiro, S. Takeshita, H. Nakashima, K. Maemura

(Nagasaki, JP)
Transcriptome profiling of natriuretic peptide system in cardiac tissue of patients with idiopathic or P877
ischemic end-stage dilated cardiomyopathy.
– M. Cabiati, B. Svezia, M.M. Cesare, L. Botta, C. Caselli, M. Matteucci, V. Lionetti, S. Del Ry (Pisa and Milan,
IT)
B-type natriuretic peptide and amino terminal pro-B-type natriutec peptide is not released after acute P878
atrial injury.
– J. Pollock, R. Parik, T. Dickfeld, V. See, S. Seliger, C. Defilippi, R. Christenson (Baltimore, US)
NT-proBNP-guided treatment of high risk heart failure patients after acute decompensation. P879
– D. Koshkina, A. Skvortsov, O. Narusov, V. Protasov, S. Nasonova, V. Masenko, S. Tereschenko (Moscow,
RU)
Elevated ALT values predict mortality in cardiogenic shock: the CardShock study. P880
– T. Jantti, J. Lassus, J. Parissis, J. Tolonen, A. Sionis, J. Spinar, M. Banaszewski, K. Pulkki, A. Mebazaa,
V.-P. Harjola (Helsinki and Kuopio, FI; Athens, GR; Barcelona, ES; Brno, CZ; Warsaw, PL; Paris, FR)
Model for end-stage liver disease score excluding INR (MELD-XI) modified by serum direct bilirubin level P881
is useful for risk stratification in patients with acute heart failure.
– M. Yamamoto, T. Nagai, A. Okada, Y. Sugano, Y. Asaumi, T. Noguchi, K. Kusano, H. Ogawa, S. Yasuda,
T. Anzai (Suita and Osaka, JP)
Obesity and novel biomarkers in heart failure results from the Gutenberg Health Study. P882
– E. Zengin, C.R. Sinning, R.B. Schnabel, T. Munzel, P.S. Wild, K. Wollert, T. Kempf, S. Blankenberg,
D. Westermann, T. Zeller (Hamburg, Mainz and Hannover, DE)
Exhaled acetone concentration is a novel noninvasive biomarker related with disease severity in patients P883
with congestive heart failure.
– T. Yokokawa, Y. Sugano, A. Shimouchi, N. Jinno, M. Shirai, Y. Satoshi, H. Ogawa, T. Anzai (Osaka, JP)
Prognostic implications of autoantibodies against cardiac troponin I and myosin in peripartum P884
cardiomyopathy: a case-control study.
– A. Haghikia, K. Zaya, E. Podewski, J. Bauersachs, D. Hilfiker-Kleiner (Hannover and Heidelberg, DE)
Hypercapnia in patients with acute heart failure. P885
– M. Konishi, E. Akiyama, N. Iwahashi, N. Maejima, K. Tsukahara, K. Hibi, M. Kosuge, T. Ebina, K. Kimura
(Yokohama, JP)
PERIPHERAL CIRCULATION, METABOLISM AND OTHER IN HEART FAILURE

Physiopathological pattern in heart failure with reduced ejection fraction with increased or reduced P886
cardiac output vs oxygen uptake ratio during maximal exercise.
– G. Generati, F. Bandera, M. Pellegrino, V. Labate, F. Carbone, E. Alfonzetti, M. Guazzi (San Donato
Milanese, IT)
Intestinal congestion - a link with appetite loss, inflammation and cachexia in chronic heart failure. P887
– M. Valentova, S. Von Haehling, W. Doehner, N. Ebner, T. Bekfani, N. Scherbakov, J. Murin, J. Bauditz,
S.D. Anker, A. Sandek (Göttingen and Berlin, DE; Bratislava, SK)
The Association between Circulating Hemoglobin Level, Left Atrial Size and Pump Mechanics utilizing P888
Strain Measures in Asymptomatic Subjects.
– C.-L. Hung, K.T. Sung, C.I. Lo, W.R. Lan, T.C. Hung, J.Y. Kuo, J.Y. Hou, H.I. Yeh (Taipei, TW)
Determinants of plasma kidney injury molecule-1 and its prognostic utility in patients with acute heart P889
failure.
– M. Sokolski, R. Zymlinski, J. Biegus, P. Siwolowski, E.A. Jankowska, J. Todd, R. Yerramilli, J. Estis,
W. Banasiak, P. Ponikowski (Wroclaw, PL; Alameda, US)
Sympathetic overactivation predicts worsening renal function in patients with chronic heart failure. P890
– R. Ushijima, S. Joho, T. Akabane, H. Inoue (Toyama, JP)
Renal mechanisms of plasma kidney injury molecule-1 and clinical outcome in heart failure. P891
– J.E. Emmens, J.M. Ter Maaten, Y. Matsue, J.R. Teerlink, M.M. Givertz, D. Bloomfield, M. Metra,
K. Damman, P. Van Der Meer, A.A. Voors (Groningen, NL; San Francisco, Boston and Rahway, US;
Brescia, IT)
Influence of physical exercise on cardiac remodeling in spontaneously hypertensive rats. P892
– L. Urbano Pagan, R.L. Damatto, M.D.M. Cezar, D.H.S. Campos, A.R.R. Lima, C. Bonomo, M.J. Gomes,
Y.C. Moukbel, M.P. Okoshi, K. Okoshi (Botucatu, BR)
Sympathetic nerve activity in patients with secondary mitral regurgitation undergoing MitraClip P893
procedure.
– C. Hammerstingl, C. Oeztuerk, G. Nickenig, M. Weber, R. Schueler (Bonn, DE)
Circulating receptor for advanced glycation end products (RAGE) is a risk factor for developing heart P894
failure.
– T. Lancefield, M. Freeman, S.K. Patel, E. Velkoska, M. Horrigan, O. Farouque, L.M. Burrell (Melbourne, AU)
Effects of the mtp 493t variant on plasma lipids and cardiovascular outcomes in patients with chronic P895
heart failure.
– E. Omerovic, S. Shao, R. Liew, P. Dunselman, A. Hjalmarson, J. Kjekshus, J. McMurray, F. Waagstein,
H. Wedel, J. Wikstrand (Gothenburg, SE; Singapore, SG; Breda, NL; Oslo, NO; Glasgow, UK)
69
HYPERTENSION DIAGNOSIS & PATHOPHYSIOLOGY

Daily potassium intake and sodium-to-potassium ratio in the reduction of blood pressure: a meta-analysis P896
of randomized controlled trials.
– A. Binia, J. Jaeger, Y. Hu, A. Singh, D. Zimmermann (Lausanne, CH)
Prediction of future hypertension by electrocardiogram. P897
– T. Sugiura, H. Takase, S. Yamashita, N. Ohte, Y. Dohi (Nagoya and Hamamatsu, JP)
Linking white coat hypertension to subclinical organ damage: the possible role of cystatin-C. P898
– E. Androulakis, N. Papageorgiou, E. Chatzistamatiou, G. Latsios, C. Tsioufis, S. Papaioannou, S. Brili,
C. Antoniades, I. Kallikazaros, D. Tousoulis (Athens, GR)
Long term cardiovascular and metabolic effects of coffee consumption in young hypertensive subjects: P899
results from HARVEST study.
– L. Mos, O. Vriz, S. Martina, F. Saladini, C. Fania, G. Caravelli, M. Ruscio, E. Casiglia, P. Palatini (Udine,
Padua and Cremona, IT)
Novel biomarkers of kidney injury in hypertension. P900
– N. Zvartau, S. Mironova, E. Vasilieva, Y. Iudina, T. Makhmatova, M. Ionov, N. Avdonina, I. Emelyanov,
A. Konradi (St. Petersburg, RU)
The impact of pericardial fat volume, coronary and extracoronary calcification on coronary P901
atherosclerosis in patients with uncomplicated hypertension.
– A.A.M. Farrag, S. Sorour, M.A. Salem, S. Bakhoum (Cairo, EG)
Condition of plasma hemostasis in hypertensive patients with concomitant ischemic heart disease and P902
microalbuminuria.
– V.Z. Netiazhenko, A.I. Pastushyna, N.V. Netiazhenko, A.V. Liakhotska (Kiev, UA)
Effects of maternal cortisol during pregnancy and of birth weight on childrens blood pressure. P903
– F. Fan, Y. Zou, H. Tian, Y. Zhang, J. Zhang, X. Ma, Y. Liu, Y. Meng, Y. Yue, A. Dart (Xian, CN; Melbourne,
AU)
The cut-off point of vitamin D deficiency for hypertension among postmenopausal Korean women in the P904
general population: Korean National Health and Nutrition Examination Survey V.
– J.K. Park, H.T. Lee, Y.H. Lim, J.H. Shin, H.C. Park, S.I. Choi, K.S. Kim, S.G. Kim, J.H. Shin (Seoul and Guri,
KR)
Azilsartan reverses cardiac damages induced by activation of cardiac (pro)renin receptors caused by P905
high-salt intake in spontaneously hypertensive rats.
– H. Komaki, M. Iwasa, Y. Hayakawa, C. Okamoto, S. Minatoguchi, Y. Yamada, H. Kanamori, M. Kawasaki,
K. Nishigaki, S. Minatoguchi (Gifu, JP)
Association of mid-day naps occurrence and duration with bp levels in hypertensive patients. a P906
prospective observational study.
– M.S. Kallistratos, L.E. Poulimenos, A. Karamanou, N. Kouremenos, A. Koukouzeli, S. Vrakas,
E.F. Chamodraka, K. Tsoukanas, A. Martineos, A.J. Manolis (Athens, GR)
The increase in arterial stiffness may change in left ventricular geometry and lead to left ventricular P907
diastolic dysfunction.
– Y. Ohno, T. Miyoshi, T. Ono, K. Osawa, H. Oe, K. Nakamura, H. Ito (Okayama, JP)
70
SUNDAY
SUNDAY
30 AUGUST



SUNDAY 30 AUGUST 2015 – MORNING SESSIONS
Wake up your brain with breakfast and discussion.

addressing a specific current issue.
Come in early to enjoy the complimentary breakfast.

CHALLENGES IN SURFACE ECG INTERPRETATION Science@Breakfast
Chairperson(s): H. Burri (Geneva, CH); P. Mabo (Rennes, FR)
07:30 Atrial flutter: typical or atypical? 908
– E. Gandjbakhch (Paris, FR)
07:52 Patient with pacemaker: normal or abnormal device function? 909
– C.W. Israel (Bielefeld, DE)

PROSPECTS FOR CELL THERAPY IN CARDIAC DISEASES Science@Breakfast
ESC and the Japanese Circulation Society
Chairperson(s): N. Smart (Oxford, UK); D.S. Sawaki (Créteil, FR)
07:30 Modelling disease using patient iPS-derived cardiomyocytes. 910
– To be announced
07:52 Is there a future for cardiovascular stem cell therapy? 911
– G. Hasenfuss (Göttingen, DE)

HOW TO WAKE UP YOUR PROFESSIONAL SKILLS Science@Breakfast
ESC and the British Junior Cardiologists’ Association
Chairperson(s): C.E.P. Brough (Cheshire, UK); L. Chrzanowski (Lodz, PL)
07:30 Becoming tomorrow’s researcher and innovator. 912
– S. Westaby (Oxford, UK)
07:52 How to bring your research to the light. 913
– T.F. Luscher (Zurich, CH)

EARLY MORNING AN ACUTE CORONARY SYNDROME PATIENT COMES IN! Science@Breakfast
HOW TO MANAGE?
Chairperson(s): C.J.M. Vrints (Edegem, BE); J.A.C. Morais (Leiria, PT)
07:30 How to manage triple therapy after stenting. 914
– J.M. Ten Berg (Nieuwegein, NL)
07:52 How to manage very high-risk non-STEMI? 915
– L. Bonello (Marseille, FR)

EPIGENETICS Science@Breakfast
Chairperson(s): D. Hilfiker-Kleiner (Hannover, DE); J.D. Pearson (London, UK)
07:30 How to dissect epigenetics. 916
– S. Costantino (Stockholm, SE)
07:52 DNA methylation in the regulation of gene expression. 917
– J. Backs (Heidelberg, DE)
72

ESC GUIDELINES – OVERVIEW Main Session
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); S. Achenbach (Erlangen, DE)
08:30 Pericardial diseases - Part 1. 918
– Y. Adler (Rannana, IL)
08:39 Pericardial diseases - Part 2. 919
– P. Charron (Paris, FR)
08:48 Ventricular arrhythmias & sudden cardiac death - Part 1. 920
– C. Blomstrom-Lundqvist (Uppsala, SE)
08:57 Ventricular arrhythmias & sudden cardiac death - Part 2. 921
– S.G. Priori (Pavia, IT)
09:06 ESC/ERS pulmonary hypertension - Part 1. 922
– N. Galie (Bologna, IT)
09:15 ESC/ERS pulmonary hypertension - Part 2. 923
– M. Humbert (Le Kremlin-Bicêtre, FR)
09:24 Infective endocarditis - Part 1. 924
– G. Habib (Marseille, FR)
09:33 Infective endocarditis - Part 2. 925
– P. Lancellotti (Liège, BE)
09:42 Acute coronary syndromes NSTE - Part 1. 926
– M. Roffi (Geneva, CH)
09:51 Acute coronary syndromes NSTE - Part 2. 927
– C. Patrono (Rome, IT)
SUNDAY – MORNING
REGISTRY I – ATRIAL FIBRILLATION Registry Session
Chairperson(s): G. Breithardt (Münster, DE); K.-H. Sim (Kuching, MY)
08:30 Impact of atrial fibrillation on ischaemic stroke risk is eliminated with multiple risk factors: 928
a real-world analysis from 425,600 Chinese individuals without prior stroke.
– Y. Guo (Beijing, CN)
08:45 Improved outcomes with ESC guideline-adherent antithrombotic treatment in high-risk patients 929
with atrial fibrillation. A report from the EORP-AF General Pilot Registry.
09:00 Kidney function markedly influences the outcome of patients with atrial fibrillation: real-world data 930
from the EURObservational Research Programme - Atrial Fibrillation General Registry Pilot Phase.
– G. Boriani (Bologna, IT)
09:15 Global registry on long-term oral antithrombotic treatment in patients with atrial fibrillation: 931
final baseline characteristics of GLORIA-AF Phase II.
– M.V. Huisman (Leiden, NL)
09:30 The relationship between cold temperature and risk of ischaemic stroke in patients with atrial 932
fibrillation.
– T.F. Chao (Taipei, TW)
09:45 Beta-blockers in atrial fibrillation patients with or without heart failure: insights from a nationwide 933
cohort.
– P.B. Nielsen (Aalborg, DK)

EUROPEAN BIOBANKS: LARGE-SCALE EPIDEMIOLOGICAL RESEARCH AT YOUR DOORSTEP Special Session
Chairperson(s): A.P. Maggioni (Florence, IT); E. Prescott (Copenhagen, DK)
08:30 The Million Veterans study: lessons for the cardiology community. 934
– M. Gaziano (Boston, US)
08:52 UK Biobank: an open access resource for large scale epidemiological research in cardiovascular 935
disease.
– R.E. Collins (Oxford, UK)
09:15 German National Cohort: understanding the evolution of cardiovascular diseases. 936
– C.L. Schlett (Heidelberg, DE)
09:37 EPIC-Heart: unravelling genetic, biochemical, and lifestyle risk factors in coronary heart disease. 937
– A. Butterworth (Cambridge, UK)
73

ESC ANDREAS GRÜNTZIG LECTURE ON INTERVENTIONAL CARDIOLOGY Named Lecture
Chairperson(s): D. Atar (Oslo, NO); J. Marco (Martres Tolosane, FR)
08:32 Presentation of the awardee. 938
08:37 Interventional cardiology, where real life and science not necessarily meet. 939
– B. Meier (Berne, CH)
ESC WILLIAM HARVEY LECTURE ON BASIC SCIENCE Named Lecture

Chairperson(s): R. De Caterina (Chieti, IT); P. Kirchhof (Birmingham, UK)
09:27 Microcircular networks: the business end of the circulation. 941

– A.R. Pries (Berlin, DE)

NIGHTMARE AT THE CATH LAB Clinical Cases
Chairperson(s): D. Dudek (Krakow, PL); S. Muscoli (Rome, IT)
08:30 Entrapment of a rotablation burr in a freshly implanted stent - Highway to surgery. 942
– S. Fournier (Lausanne, CH)
08:42 A successful percutanous coronary intervention in an isolated single coronary artery: a very rare 943
coronary anomaly.
– S. Avunduk (Denizli, TR)
08:55 A 37 year-old woman with postpartum spontaneous dissection of the left main coronary artery: to 944
stent or not to stent? That is the question.
– S. Rodriguez Diego (Córdoba, ES)
09:08 Successful percutaneous management of iatrogenic type A aortic dissection following 945
intervention of the right coronary artery.
– B. Berta (Budapest, HU)
09:21 To stent or not to stent? 946
– C.E. Raphael (London, UK)
09:34 Enigma. 947
– A. Farag (Blackpool, UK)
09:47 We should have done it before... 948
– M. Boukantar (Créteil, FR)
74

PROGNOSIS AND MANAGEMENT IN ATRIAL FIBRILLATION Rapid Fire Abstract
Chairperson(s): J. Brachmann (Coburg, DE); T. Nair (Trivandrum, IN)
08:30 Prognostic value of excessive atrial ectopy in relation to atrial fibrillation and ischemic stroke in a 949
large pooled scandinavian holter cohort.
– B.S. Larsen, G.E. Engstrom, P.K. Kumarathurai, P.N. Nilsson, O.W. Wendelboe Nielsen, T.J. Juhlin,
L.J. Johnson, A.S. Sajadieh (Copenhagen, DK; Malmö, SE)
08:39 Prognosis in patients with atrial fibrillation with a presumed temporary cause in a community 950
based cohort study.
– L. Fauchier, N. Clementy, D. Angoulvant, D. Babuty, A. Bernard, G.Y.H. Lip (Tours, FR; Birmingham, UK)
08:48 Incidence of atrial fibrillation in different types of cancer: a Danish nationwide cohort study. 951
– C. Jakobsen, N. Carlson, M. Lamberts, M.L. Hansen, C. Torp-Pedersen, G.H. Gislason, M. Schou
(Hellerup, Herlev, Copenhagen and Aalborg, DK)
08:57 Improving AF detection in patients with cryptogenic stroke. Insights from a prospective cohort 952
with insertable cardiac monitor.
– B. Benito, E. Valles, E. Cuadrado, S. Cabrera, P. Ramos, A. Ois, A. Rodriguez-Campelo, J. Roque,
J. Marti-Almor (Barcelona, ES)
09:06 Atrial high rate episodes and silent ischemic brain lesions in patients with cardiac implantable 953
electronic devices: unmasking silent atrial fibrillation embolic risk.
– J. Benezet Mazuecos, J.A. Iglesias, M. Cortes, J.M. Rubio, J.J. De La Vieja, P.P. Perez, M.A. Quinones,
P. Sanchez-Borque, J. Farre (Madrid, ES)
09:15 Effect of early DC-cardioversion on recurrence of atrial fibrillation in patients with persistent atrial 954 (W)
SUNDAY – MORNING
fibrillation. (withdrawn)
– A. Osmanagic (Odense, DK)
09:24 Is TEE mandatory in patients undergoing ablation of AF with uninterrupted NOACs? Results from 955
a prospective multicenter registry.
– L. Di Biase, J.D. Burkhardt, C. Trivedi, S. Mohanty, P. Mohanty, D. Lakkireddy, J. Sanchez, J. Gallinghouse,
S. Beheiry, A. Natale (Austin, Kansas City and San Francisco, US)
09:33 Successful approaches in reduction of fluoroscopy time and radiation dose during catheter 956
ablation for atrial fibrillation.
– B. Aldhoon, D. Wichterle, P. Peichl, R. Cihak, J. Kautzner (Prague, CZ)
09:42 Long-term comparison of the number of supraventricular ectopic complexes after either 957
radiofrequency ablation or anti-arrhythmic drug therapy in patients with atrial fibrillation.
– C. Alhede, A. Johannessen, U. Dixen, J.S. Jensen, P. Raatikainen, G. Hindricks, H. Walfridsson,
P.S. Hansen, J.C. Nielsen, C. Joens (Gentofte, Hvidovre, Aarhus and Copenhagen, DK; Tampere, FI;
Leipzig, DE; Linköping, SE)
09:51 A dual-phase cardiac CT protocol for complete delineation of left atrial appendage (LAA) anatomy 958
and thrombus exclusion prior to AF ablation or LAA device exclusion.
– E. Nicol, C. Pavitt, O. Lazoura, A. Lindsay, M. Sriharan, M. Rubens, S. Padley, T. Wong (London, UK)
75

AGEING AND HEART DISEASE: IS 80 THE NEW 60? Rapid Fire Abstract
Chairperson(s): L. Ernande (Paris, FR); S. Masi (London, UK)
08:30 Multiple biomarkers for risk stratification of unselected older patients in the emergency 959
department.
– P. Bahrmann, A. Bahrmann, B. Hofner, M. Christ, S. Achenbach, C. Sieber, T. Bertsch (Nürnberg,
Heidelberg and Erlangen, DE)
08:39 Mechanisms of improvement in claudication after exercise training in peripheral arterial disease. 960
– J. Murrow, J. Brizendine, B. Djire, H.J. Young, K.R. Nilsson, K.K. McCully (Athens, US)
08:48 Clinical impact of complete revascularization in elderly patients with multivessel coronary artery 961
disease underwent percutaneous coronary intervention.
– M. Harada, T. Miura, H. Kobayashi, T. Kobayashi, M. Kobayashi, H. Kimura, H. Akanuma, S. Ebisawa,
Y. Miyashita, U. Ikeda (Nagano, JP)
08:57 Comorbidity and intervention in octogenarians with severe symptomatic aortic stenosis. 962
– M. Martinez-Selles, P. Diaz-Villanueva, D. Sanchez-Sendin, A. Carro Hevia, J.J. Gomez Doblas, B. Garcia
De La Villa, L. Cornide, A. Alonso Tello, R. Andion, R. Lopez-Palop (Madrid, ES)
09:06 Integration of frailty related blood biomarkers with standard frailty items to predict outcome after 963
acute coronary syndrome.
– C. Bonanad Lozano, V. Ruiz, E. Nunez, S. Garcia-Blas, J. Fernandez, J. Nunez, L. Mainar,
E. Rodriguez-Borja, F.J. Chorro, J. Sanchis (Valencia, ES)
09:15 Depressive symptoms at repeated study visits, non-fatal vascular events, and risk of death over 964
10 years in older adults. The Three-City Study.
– R. Pequignot, C. Dufouil, C. Prugger, K. Peres, S. Artero, C. Tzourio, J.P. Empana (Paris, Bordeaux and
Montpellier, FR)
09:24 Temporal trends in the treatment and outcomes of septua-, octo-, and nonagenarians with acute 965
coronary syndrome.
– D. Radovanovic, A.W. Schoenenberger, S. Windecker, J.F. Iglesias, G. Pedrazzini, A.E. Stuck, P. Erne
(Zurich, Berne, Lausanne, Lugano and Luzern, CH)
09:33 Do risk factors explain the sex/gender gap in mortality from coronary heart disease? 966
– J. Fritz, M. Edlinger, C.C. Kelleher, S. Strohmaier, G. Nagel, H. Concin, M. Hochleitner, E. Ruttmann,
H. Ulmer (Innsbruck and Bregenz, AT; Dublin, IE; Oslo, NO; Ulm, DE)
09:42 Quitting smoke ’hits a late break’ in acceleration of vascular aging. 967
– D. Terentes-Printzios, C. Vlachopoulos, P. Xaplanteris, N. Ioakeimidis, P. Pietri, D. Tousoulis (Athens, GR)
09:51 Beta-blocker therapy optimization in elderly patients with left ventricular systolic dysfunction. 968
– M. Cortes Garcia, A.M. Romero, J.A. Franco, J.A. Palfy, A. Garcia, M.L. Martin, M. Lopez, P. Avila, E. De La
Cruz, J. Farre (Madrid and Alcala de Henares, ES)
08:30–10:00 | Rabat - Village 1

OXIDATIVE STRESS AND VASCULAR DISEASE Symposium
Chairperson(s): L. Bertrand (Brussels, BE); I. Hoefer (Utrecht, NL)
08:30 Do microparticles play an active role in vascular disease? 969
– S. Leroyer (Saint-Germain-en-Laye, FR)
08:52 Transcriptional regulation of oxidant genes by epigenetic signatures. 970
– S. Costantino (Stockholm, SE)
09:15 Nox4 in ischaemic and inflammatory vascular disease. 971
– S. Sciarretta (Newark, US)
09:37 Regulation of oxidative stress in smooth muscle cells. 972
– S. George (Bristol, UK)

INFLAMMATION IN ISCHAEMIA AND REPERFUSION INJURY REVISITED Symposium
Chairperson(s): L. Badimon (Barcelona, ES); C. Weber (Munich, DE)
08:30 The innate immune response in reperfused myocardium. 973
– D. De Kleijn (Singapore, SG)
08:52 Role of AMPK in cardiovascular tissue remodelling. 974
– S. Horman (Brussels, BE)
09:15 Extracellular RNA as a therapeutic target for treating cardiovascular disease. 975
– K. Preissner (Giessen, DE)
09:37 Monocytes and heart function after acute myocardial infarction. 976
– Z. Mallat (Cambridge, UK)
76

SPORTS CARDIOLOGY IN PRACTICE: CHALLENGES IN THE EVALUATION OF ATHLETES Symposium
Chairperson(s): M. Borjesson (Vastra Frolunda, SE); H.K. Rasmusen (Copenhagen, DK)
08:30 Athletes with abnormal QT interval: the long and short of it. 977
– S. Sharma (London, UK)
08:52 Differentiating athlete’s hearts from hypertrophic cardiomyopathy. 978
– A. Boraita (Madrid, ES)
09:15 The athlete’s aorta: upper limits and markers of disease. 979
– P.E. Adami (Rome, IT)
09:37 Athletes with bradycardia: how slow is too slow? 980
– H. Raju (London, UK)

CARDIOVASCULAR RISK PREDICTION IN DAILY PRACTICE: TIME FOR A PARADIGM SHIFT? Meet the Experts
Chairperson(s): G. De Backer (St. Martens Latem, BE); J. Perk (Oskarshamn, SE)
08:30 Cardiovascular risk prediction in daily practice: time for a paradigm shift? Introduction to the 981
session.
– G. De Backer (St. Martens Latem, BE)
08:35 My patient has multiple cardiac risk factors: lifetime risk estimations? 982
– I.M. Graham (Dublin, IE)
08:45 My patient has multiple cardiac risk factors: lifetime risk estimations? - Panel discusssion and 983
SUNDAY – MORNING
– I.M. Graham (Dublin, IE), P.A. Sirnes (Moss, NO), R. Asteggiano (Turin, IT), G. Baron Esquivias (Sevilla, ES)
09:00 My patient does not understand risk: how can I explain? 984
– P. Donnelly (Belfast, UK)
09:10 My patient does not understand risk: how can I explain? Panel discussion and questions from the 985
audience.
– P. Donnelly (Belfast, UK), P.A. Sirnes (Moss, NO), R. Asteggiano (Turin, IT), G. Baron Esquivias (Sevilla, ES)
09:25 My patient is over age 55, should I prescribe a polypill? 986
– D.E. Grobbee (Utrecht, NL)
09:35 My patient is over age 55, should I prescribe a polypill? Panel discussion and questions from the 987
audience.
– D.E. Grobbee (Utrecht, NL), P.A. Sirnes (Moss, NO), R. Asteggiano (Turin, IT), G. Baron Esquivias (Sevilla,
ES)
09:50 Cardiovascular risk prediction in daily practice: time for a paradigm shift? Take home message. 988
– J. Perk (Oskarshamn, SE)

REPORTING ECONOMICAL ASPECTS IN OUTCOMES OF DISEASE MANAGEMENT Symposium
Chairperson(s): N. Kato (Norrköping, SE); T.M. Norekval (Bergen, NO)
08:30 Avoiding pitfalls in cost analysis in research in cardiac care. 989
– M. Sutton (Manchester, UK)
08:52 What variables to include in cost analysis in cardiovascular research: euros, QALYs or more? 990
– R.M. Califf (Silver Spring, US)
09:15 Cost effectiveness of heart failure programs, issues to consider. 991
– S. Stewart (Melbourne, AU)
09:37 How to use cost effectiveness data to influence policymaker and clinicians in cardiology. 992
– W.S. Weintraub (Newark, US)
77
08:30–10:00 | Kiev - Village 3

COMMON CLINICAL ISSUES IN CARDIOLOGY Meet the Experts
Chairperson(s): G.M.C. Rosano (Rome, IT); K. Node (Saga, JP)
08:30 Common clinical issues in cardiology - Introduction to the session. 993
– K. Node (Saga, JP)
08:35 Polypharmacy in heart failure and End Stage Renal Disease (ESRD). 994
– J.S. Borer (New York, US)
08:45 Polypharmacy in heart failure and ESRD - Panel discussion and questions from the audience. 995
– V. Fuster (New York, US), F. Zannad (Vandoeuvre-lès-Nancy, FR), A. Ungar (Florence, IT)
09:00 Heart failure with preserved ejection fraction in the elderly. 996
– T.G. Von Lueder (Oslo, NO)
09:10 Heart failure with preserved ejection fraction in the elderly - Panel discussion and questions from 997
the audience.
09:25 Syncope. 998
– A. Moya I Mitjans (Barcelona, ES)
09:35 Syncope - Panel discussion and questions from the audience. 999
09:50 Common clinical issues in cardiology - Take home message. 1000
– G.M.C. Rosano (Rome, IT)

NEW THERAPIES FOR HYPERTENSION Symposium
Chairperson(s): A. Coca (Barcelona, ES); B. Williams (London, UK)
08:30 Emerging drug therapies. 1001
– T. Unger (Maastricht, NL)
08:52 Baroreceptor stimulation. 1002
– M. Burnier (Lausanne, CH)
09:15 Arteriovenous fistula. 1003
– M. Lobo (London, UK)
09:37 Renal denervation. 1004

LIFE-THREATENING VENTRICULAR ARRHYTHMIAS: WHERE DO WE STAND IN 2015? Symposium
ESC and the Saudi Heart Association
Chairperson(s): A. Al Musaad (Riyadh, SA); B. Merkely (Budapest, HU)
08:30 Lessons from a cohort of sudden cardiac death victims to identify risk factors. 1005
– M. Malik (Purley, UK)
08:52 The role of revascularisation as the only intervention? 1006
– A. Hersi (Riyadh, SA)
09:15 Can catheter ablation of ventricular tachyarrhythmias prevent sudden cardiac death? 1007
– K.-H. Kuck (Hamburg, DE)
09:37 Subcutaneous ICD / Wearable defibrillator - A life saving device for a broader patient population? 1008
– F. Bokhari (Jeddah, SA)
78

CHALLENGES IN TREATING ARRHYTHMIAS IN ADULTS WITH CONGENITAL HEART Meet the Experts
DISEASE
Chairperson(s): E. Rosenthal (St. Albans, UK); M. Guenoun (Plan-de-Cuques, FR)
08:30 Challenges in treating arrhythmias in adults with congenital heart disease - Introduction to the 1009
session.
– E. Rosenthal (St. Albans, UK)
08:35 Ventricular tachycardia in repaired tetralogy of Fallot. 1010
– G. Hessling (Munich, DE)
08:45 Ventricular tachycardia in repaired tetralogy of Fallot - Panel discussion and questions from the 1011
audience.
– G. Hindricks (Leipzig, DE), G. Hessling (Munich, DE), P. Maury (Toulouse, FR)
09:00 Surgical ablation of ventricular arrhythmias in congenital heart disease. 1012
– A. Giamberti (San Donato Milanese, IT)
09:10 Surgical ablation of ventricular arrhythmias in congenital heart disease - Panel discussion and 1013
– G. Hindricks (Leipzig, DE), A. Giamberti (San Donato Milanese, IT), P. Maury (Toulouse, FR)
09:25 Treatment of atrial arrhythmias in congenital heart disease. 1014
– C. Berul (Washington, US)
09:35 Treatment of atrial arrhythmias in congenital heart disease - Panel discussion and questions from 1015
the audience.
– G. Hindricks (Leipzig, DE), C. Berul (Washington, US), P. Maury (Toulouse, FR)
SUNDAY – MORNING
09:50 Challenges in treating arrhythmias in adults with congenital heart disease - Take home message. 1016
– M. Guenoun (Plan-de-Cuques, FR)

IMAGING GUIDED MANAGEMENT IN RECENT ESC GUIDELINES Guidelines in Daily Practice
Chairperson(s): T. Edvardsen (Oslo, NO); H. Thiele (Lübeck, DE)
08:30 Stable coronary heart disease. 1017
08:45 Stable coronary heart disease - What do the Guidelines say? 1018
– U. Sechtem (Stuttgart, DE)
09:00 Stable coronary heart disease - Panel discussion on how to implement the Guidelines. 1019
– T.H. Marwick (Hobart, AU), U. Sechtem (Stuttgart, DE), H.J. Ukkonen (Turku, FI), C. Bucciarelli-Ducci
(Bristol, UK), K. Nieman (Rotterdam, NL)
09:10 Stable coronary heart disease - Conclusion and take home message. 1020
– H. Thiele (Lübeck, DE)
09:15 Hypertrophic cardiomyopathy. 1021
– J. Kuusisto (Kuopio, FI)
09:30 Hypertrophic cardiomyopathy - What do the Guidelines say? 1022
09:45 Hypertrophic cardiomyopathy - Panel discussion on how to implement the Guidelines. 1023
– J. Kuusisto (Kuopio, FI), P.M. Elliott (London, UK), E. Donal (Rennes, FR), G. Athanassopoulos (Piraeus, GR)
09:55 Hypertrophic cardiomyopathy - Conclusion and take home message. 1024

IMAGING ATHEROSCLEROSIS Symposium
Chairperson(s): F. Prati (Rome, IT); M.G. Sprynger (Liège, BE)
08:30 Vulnerable plaques and vulnerable patients. 1025
– J. Narula (New York, US)
08:52 Imaging non-obstructive coronary plaques. 1026
– H.M. Garcia-Garcia (Rotterdam, NL)
09:15 New imaging modalities for coronary disease. 1027
– R.M. Botnar (London, UK)
09:37 Imaging vascular inflammation. 1028
– A. Saraste (Turku, FI)
79

FROM PURE REVASCULARISATION TO CONCOMITANT MITRAL VALVE REPAIR: Debate Session
CONTROVERSIES AND CHALLENGES
ESC and the European Association for Cardio-Thoracic Surgery
Chairperson(s): R. Yadav (London, UK); M. De Bonis (Milan, IT)
08:30 Complex three-vessel disease and left main stenosis, Syntax II and EXCEL will change the 1029
landscape - PRO.
– G.W. Stone (New York, US)
landscape - CONTRA.
– C.H. Huber (Berne, CH)
landscape - REBUTTAL PRO.
landscape - REBUTTAL CONTRA.
– C.H. Huber (Berne, CH)
landscape - CONCLUSION.
09:15 Management of ischaemic mitral valve regurgitation. Repair/replace is needed - PRO. 1034
09:30 Management of ischaemic mitral valve regurgitation. Repair/replace is needed - CONTRA. 1035
– B.J. Gersh (Rochester, US)
09:45 Management of ischaemic mitral valve regurgitation. Repair/replace is needed - REBUTTAL PRO. 1036
09:50 Management of ischaemic mitral valve regurgitation. Repair/replace is needed - REBUTTAL 1037
CONTRA.
09:55 Management of ischaemic mitral valve regurgitation. Repair/replace is needed - CONCLUSION. 1038
08:30–10:00 | Oslo - Village 6

PRESSURE WIRE MEASUREMENT TO CHOOSE THE BEST TREATMENT FOR YOUR PATIENT: Symposium
WHAT THE GENERAL CARDIOLOGIST SHOULD KNOW
Chairperson(s): R. Trillo (Montouto-Teo, ES); H.M. Garcia-Garcia (Rotterdam, NL)
08:30 Appropriateness of care in patients with coronary artery disease: should we believe in 1039
non-invasive test?
– M. Patel (Durham, US)
08:52 Is routine pressure-wire measurement at time of diagnostic angiography ready for primetime? 1040
– E. Van Belle (Lille, FR)
09:15 Towards simplification and co-registration. 1041
– J.E. Davies (London, UK)
09:37 Ongoing studies and future directions. 1042
– J. Escaned (Madrid, ES)

ONGOING CHALLENGES IN ADP RECEPTOR BLOCKER THERAPY Symposium
Chairperson(s): B. Rocca (Rome, IT); P.G. Steg (Paris, FR)
08:30 To measure platelet function – Fact or fiction? 1043
– D. Aradi (Balatonfured, HU)
08:52 High on treatment platelet reactivity – Clinical implications. 1044
– D. Sibbing (Munich, DE)
09:15 Genetic profiling for patients under dual antiplatelet therapy: does it make sense? 1045
– J.M. Siller-Matula (Vienna, AT)
09:37 Pharmacology of Prasugrel and Ticagrelor – Impact on clinical use? 1046
– P. Capranzano (Catania, IT)
80

ECG IN THE EMERGENCY DEPARTMENT: ILLUSTRATED CASES Case-based Symposium
Chairperson(s): M. Lettino (Milan, IT); M. Pazdernik (Prague, CZ)
08:30 A patient with broad complex tachycardia. 1047
– A. Vischer (London, UK)
08:45 A patient with broad complex tachycardia - Panel discussion and questions from the audience. 1048
– A. Vischer (London, UK), J. Poess (Lübeck, DE), C.J.M. Vrints (Edegem, BE)
09:00 Differential diagnosis in a patient presenting after syncope. 1049
– J. Poess (Lübeck, DE)
09:15 Differential diagnosis in a patient presenting after syncope - Panel discussion and questions from 1050
the audience.
– A. Vischer (London, UK), J. Poess (Lübeck, DE), C.J.M. Vrints (Edegem, BE)
09:30 ECG in the emergency department - State of the Art lecture. 1051
– C.J.M. Vrints (Edegem, BE)
08:30–10:00 | Tunis - Village 7

STEMI TREATMENT IMPROVEMENT IN REPERFUSION AND NETWORK SYSTEM IN CHINA Symposium
ESC and the Chinese Society of Cardiology
Chairperson(s): J. Ge (Shanghai, CN); T.G. Gudnason (Reykjavik, IS)
08:30 Construction of national STEMI treatment network. 1052
– Y. Zhang (Beijing, CN)
SUNDAY – MORNING
08:52 Management of non-culprit lesions in primary PCI: ESC experience. 1053
– F.J. Neumann (Bad Krozingen, DE)
09:15 Reperfusion improvements of Chinese STEMI patients: thrombolysis and emergency PCI. 1054
– X.H. Fu (Shijiazhuang, CN)
09:37 Pre-hospital antithrombotic therapy and network system: ESC experience. 1055
– F. Weidinger (Vienna, AT)

AORTIC STENOSIS: NEW CHALLENGES Symposium
Chairperson(s): P. Pibarot (Quebec, CA); A. Cribier (Rouen, FR)
08:30 Basic and advanced echo parameters for aortic stenosis severity. 1056
– C.M. Otto (Seattle, US)
08:52 Other imaging modalities (CT, PET, CMR). 1057
09:15 Should we intervene in asymptomatic patients? 1058
– B. Iung (Paris, FR)
09:37 When should we use TAVI rather than surgery? 1059
– M. Gilard (Brest, FR)

OPTIMAL MANAGEMENT OF PULMONARY EMBOLISM Case-based Symposium
Chairperson(s): S.V. Konstantinides (Mainz, DE); G. Agnelli (Perugia, IT)
08:30 Does this patient have a pulmonary embolism? 1060
– J. Kline (Indianapolis, US)
08:45 Does this patient have a pulmonary embolism? Panel discussion and questions from the 1061
audience.
– M. Delcroix (Leuven, BE), S.Z. Goldhaber (Boston, US), N. Meneveau (Besançon, FR)
09:00 A patient with recurrent pulmonary embolism. 1062
– N. Meneveau (Besançon, FR)
09:15 A patient with recurrent pulmonary embolism - Panel discussion and questions from the audience. 1063
– M. Delcroix (Leuven, BE), S.Z. Goldhaber (Boston, US), N. Meneveau (Besançon, FR)
09:30 Systems of care: ideal management of pulmonary embolism - From emergency room to discharge 1064
- State of the Art lecture.
81

DILATION OF THE AORTA Symposium
ESC and the Association for European Paediatric Cardiology
Chairperson(s): J. Holm (Lund, SE); E.V.O. Jokinen (Helsinki, FI)
08:30 Morphology of dilated ascending aorta. 1065
– A.C. Gittenberger-De Groot (Leiden, NL)
08:52 Imaging of the aortic arch. 1066
– E.R. Valsangiacomo Buechel (Zurich, CH)
09:15 Bicuspid aortic valve and dilation of the ascending aorta. 1067
– To be announced
09:37 Conotruncal heart defects. 1068
– S. Di Filippo (Lyon, FR)
08:30–10:00 | Bern - Village 9

THE ESC/HFA GUIDELINES ON ACUTE AND CHRONIC HEART FAILURE Symposium
Chairperson(s): K. Dickstein (Stavanger, NO); Y.M. Lopatin (Volgograd, RU)
08:30 Diagnosis of heart failure. 1069
– M.F. Piepoli (Piacenza, IT)
08:52 Drugs for acute heart failure. 1070
09:15 Drugs for chronic heart failure. 1071
09:37 Devices for heart failure. 1072
– F. Ruschitzka (Zurich, CH)

HOW TO APPROACH SLEEP-DISORDERED BREATHING IN HEART FAILURE PATIENTS? Meet the Experts
Chairperson(s): W.T. Abraham (Columbus, US); M.-P. d’Ortho (Paris, FR)
08:30 How to approach sleep-disordered breathing in heart failure patients? Introduction to the session. 1073
– M.-P. d’Ortho (Paris, FR)
08:40 Current therapy. 1074
– M.R. Cowie (London, UK)
08:50 Current therapy - Panel discussion and questions from the audience. 1075
– M.R. Cowie (London, UK), J.L. Pepin (Grenoble, FR), J.L. Lopez-Sendon (Madrid, ES)
09:05 Future therapies. 1076
– P. Ponikowski (Wroclaw, PL)
09:15 Future therapies - Panel discussion and questions from the audience. 1077
– J.L. Pepin (Grenoble, FR), A.J.S. Coats (Coventry, UK), P. Ponikowski (Wroclaw, PL)
09:30 Sleep quality and snoring: what I need to know - State of the Art lecture. 1078
– S. Von Haehling (Berlin, DE)
09:55 How to approach sleep-disordered breathing in heart failure patients? - Take home message. 1079
82

NOVEL STRATEGIES FOR CARDIOPROTECTION Rapid Fire Abstract
Chairperson(s): D.J. Hausenloy (Singapore, SG); P. Ferdinandy (Budapest, HU)
08:30 The cardioprotection of miRNA-221 is due to direct targeting on DDIT4/mTORC1/p-4EBP1 1080
pathway.
– P.P.W. Wang, Q.Y. Chen, A.M. Richards (Singapore, SG; Shanghai, CN)
08:39 Exosomes from human cardiac progenitor cells, but not those from patient-matched bone marrow- 1081
derived mesenchymal stem cells, improve cardiac function after myocardial infarction in vivo.
– L. Barile, E. Cervio, M. Matteucci, T. Torre, T. Moccetti, V. Lionetti, G. Vassalli (Lugano, CH; Pisa, IT)
08:48 Bnip3 drives mitochondrial damage in the early phase of myocardial ischemia/reperfusion injury. 1082
– S. Ecken, U. Hendgen-Cotta, M. Kelm, T. Rassaf (Düsseldorf, DE)
08:57 Transvascular total left ventricular unloading in the acute phase of myocardial infarction markedly 1083
reduces infarct size and prevents heart failure in the long term.
– K. Saku, T. Kakino, T. Arimura, T. Akashi, K. Sunagawa (Fukuoka, JP)
09:06 The interplay of neutrophils and interferon gamma is critical for post-infarction survival in a 1084
murine model of myocardial infarction.
– M. Knorr, S. Finger, S. Karbach, S. Kossmann, M. Brandt, T. Muenzel, P. Wenzel (Mainz, DE)
09:15 Red blood cells impair post-ischemic cardiac function via arginase-dependent regulation of nitric 1085 (W)
oxide synthase and reactive oxygen species in type 2 diabetes. (withdrawn)
– J. Yang, X. Zheng, Y. Tratsiakovich, A. Kiss, K. Brismar, J. Pernow (Stockholm, SE)
09:24 Dysregulation of two phosphorylation sites in Akt, Thr308 and Ser473, upon reperfusion mediates 1086
enlargement of myocardial infarct size by chronic renal failure.
SUNDAY – MORNING
– T. Tobisawa, T. Yano, T. Miki, A. Kuno, M. Tanno, H. Kouzu, M. Ogasawara, S. Muratsubaki, K. Ohno,
T. Miura (Sapporo, JP)
09:33 Cardioprotective properties of matrix metalloproteinase inhibition: attenuation of nuclear protease 1087
activity, reduced DNA fragmentation and preserved OGG1.
– R.M. Bell, X. Rossello, R. Breckenridge, D.M. Yellon (London, UK)
09:42 Different pathways and additive effects of exenatide, glucose-insulin-potassium, and remote 1088
ischemic conditioning on infarct size in pigs.
– A. Rodriguez-Sinovas, J.J. Alburquerque-Bejar, I. Barba, J. Inserte, E. Miro-Casas, M. Ruiz-Meana,
M. Poncelas, U. Vilardosa, L. Valls-Lacalle, D. Garcia-Dorado (Barcelona, ES)
09:51 Distinct mechanisms of cardioprotection by different H2S donors. 1089
– A. Chatzianastasiou, S.I. Bibli, M.E. Wood, M. Whiteman, I. Andreadou, V.G. Manolopoulos,
A. Papapetropoulos (Athens, GR)
of the topic related Moderated poster station.

COMPLICATIONS IN DEVICES Moderated Posters
Chairperson(s): B. Hansky (Bad Oeynhausen, DE); C.E.H. Kennergren (Gothenburg, SE);
10:00 Is early reoperation after a CIED procedure associated with mortality after 6 months? Results P1090 (W)
from a complete, nationwide cohort. (withdrawn)
– R. Kirkfeldt, J.B. Johansen, O.D. Joergensen, E.A. Nohr, J.C. Nielsen (Aarhus and Odense, DK)
10:08 Analysis of efficacy and safety of transvenous leads extraction and long term mortality after P1091
procedures in women and men.
– A. Polewczyk, W. Jachec, G. Opolski, M. Grabowski, M. Janion, A. Kutarski (Kielce, Zabrze, Warsaw and
Lublin, PL)
10:17 Transvenous removal of pacing and ICD leads: single referral center experience. P1092
– M.G. Bongiorni, E. Soldati, L. Segreti, G. Zucchelli, A. Di Cori, S. Viani, L. Paperini, D. Levorato,
G. Branchitta, D. Andreini (Pisa, IT)
10:25 Managing periprocedural anticoagulation therapy in patients undergoing cardiac electronic device P1093
surgery: survey in Austria, Germany and Switzerland.
– F. Blaschke, P. Lacour, L.H. Boldt, A. Wutzler, A. Parwani, M. Huemer, P. Attanasio, W. Haverkamp (Berlin,
DE)
10:34 Transvenous coronary sinus and implantable cardioverter defibrillator lead extraction: different P1094
difficulties and complications.
– E.V. Dovellini, L. Giurlani, P. Corsi, A. Michelucci, G.P. Cerisano, R. Valenti, D. Antoniucci (Florence, IT)
10:42 Predictors of late complications in patients with ICD indicated for the complete system extraction. P1095
– M. Taborsky, M. Fedorco, T. Skala, D. Brecka, H. Grofkova, D. Klimes, P. Rohanek, J. Jarkovsky (Olomouc
and Brno, CZ)
10:51 Safety and effectiveness of lead extraction in octogenarians. P1096
– P. Defaye, H. Rekik, J.J. Ndjessan, A.M. Martin, P. Jacon (Grenoble, FR)
83

KNOWING MORE ABOUT STEMI AND NON-STEMI Moderated Posters
Chairperson(s): D. Capodanno (Catania, IT); G. Cayla (Nîmes, FR)
10:00 Direct Comparison of the Safety and Efficacy of two Rule-out Strategies for Acute Myocardial P1097
Infarction: 1h-Algorithm versus Combination of 1h-Algorithm and Undetectable Levels at
Presentation.
– R. Twerenbold, K. Wildi, M. Rubini Gimenez, C. Puelacher, P. Hillinger, J. Boeddinghaus, K. Grimm,
10:08 CRUSADE Risk Score for Predicting Major Bleeding based on BARC Standardized Definition in P1098
Patients with Acute Coronary Syndromes.
– P.J. Flores-Blanco, A.A. Lopez-Cuenca, M. Gomez-Molina, M. Sanchez-Martinez, M.J. Sanchez-Galian,
E. Guerrero-Perez, A. Garcia-Narbon, F. Cambronero-Sanchez, M. Valdes, S. Manzano Fernandez (Murcia
and Cieza, ES)
10:17 Direct comparison of safety and efficacy of 2 rule-out strategies for AMI: undetectable levels at P1099
presentation vs. combination of 1h-algorithm and undetectable levels at presentation.
– M. Rubini Gimenez, R. Twerenbold, K. Wildi, M. Wagener, C. Puelacher, P. Hillinger, S. Osswald, C. Mueller
(Basel, CH)
Infarction: undetectable levels of hs-troponin versus copeptin in combination with troponin.
– K.S. Wildi, R. Twerenbold, M. Rubini Gimenez, T. Reichlin, C. Puelacher, P. Hillinger, M. Wagener,
10:34 Comparison of 10-Year follow-up mortality rates in a randomized trial comparing routine invasive P1101
versus selective invasive management in patients with non ST-segment elevation acute coronary
syndrome.
– D.N. Kalkman, P. Woudstra, P. Damman, A. Hirsch, F. Windhausen, J.G. Tijssen, R.J. De Winter
(Amsterdam, NL)
10:42 Guideline recommended care and excess mortality for NSTEMI: a national cohort study. P1102
– T.B. Dondo, M. Van Laar, O.A. Alabas, M.S. Gilthorpe, P.D. Batin, A.D. Timmis, J.E. Deanfield,
H. Hemingway, C.P. Gale (Leeds, Wakefield and London, UK)
Infarction: 1h-algorithm using troponin versus a dual marker strategy combining copeptin and
troponin.
– R. Twerenbold, M. Rubini Gimenez, K. Wildi, K. Grimm, T. Reichlin, P. Hillinger, C. Puelacher,

WHAT’S NEW IN IMAGING FOR VALVULAR HEART DISEASE? Moderated Posters
Chairperson(s): V. Rigolin (Chicago, US); T. Masuyama (Nishinomiya, JP)
10:00 Novel method for determination of mitral regurgitation severity before and after percutaneous P1104
edge-to-edge mitral valve repair by contrast echocardiography.
– M. Huntgeburth, H. Ten Freyhaus, C. Sunderkamp, S. Baldus, V. Rudolph (Cologne, DE)
10:08 Is transnasal TEE imaging a viable alternative to conventional TEE during structural cardiac P1105
interventions? A comparison of image quality.
– D. Klettas, M. Monaghan (London, UK)
10:17 Does LAA sludge contraindicate early cardioversion of AF or PBMV? A TEE study. (withdrawn) P1106 (W)
– T. Bishay (Cairo, EG)
10:25 Echocardiographic predictors of new-onset atrial fibrillation in patients after transcatheter aortic P1107
valve implantation.
– Z. Rodriguez, L. Perez De Isla, C. Almeria, E. Garcia, A. Fernandez, P. Marcos-Alberca, F. Islas, J. Moreno,
J. Rodrigo, C. Macaya (Madrid, ES)
10:34 Predictive factors for echocardiographic overestimation of aortic valve area by continuity P1108
equation in patients with severe aortic stenosis.
– H. Inoue, H. Abe, K. Yasumura, H. Nishida, K. Shinouchi, H. Miura, M. Koide, M. Date, Y. Koretsune,
H. Kusuoka (Osaka, JP)
10:42 Medium term evolution of paravalvular leaks in the CoreValve percutaneous aortic valve P1109
prosthesis: echocardiographic assessment.
– M. Delgado Ortega, M. Puentes Chiachio, M. Ruiz Ortiz, D. Mesa Rubio, C. Ferreiro Quero, J.J. Sanchez
Fernandez, E. Duran Jimenez, M.C. Morenate Navio, M. Pan Alvarez Ossorio, J. Suarez De Lezo Cruz
Conde (Córdoba, ES)
10:51 A new method to measure aortic valve calcium by transthoracic echo. P1110
– M.L. Panelo, C. Fernandez-Palomeque, M. Ramis, F. Rotger, A. Bethencourt (Palma de Mallorca, ES)
84

CLINICAL IMPACT AND MODULATION OF ENDOTHELIAL (DYS)FUNCTION Moderated Posters
Chairperson(s): M. Shechter (Tel Hashomer, IL); P. Evans (Sheffield, UK)
10:00 Altered molecular signature of cardiac microvascular endothelium after chronic pressure overload P1111
and transition to heart failure.
– S. Trenson, A.S. Walravens, T. Petit, M. Vanhaverbeke, H. Gillijns, E. Caluwe, N. Vanden Driessche,
P. Herijgers, A. Luttun, S. Janssens (Leuven, BE)
10:08 Critical role of PTP1B in endoplasmic reticulum stress-induced endothelial dysfunction. P1112
– P.A. Thiebaut, D. Coquerel, E. Delile, F. Tamion, V. Richard (Rouen, FR)
10:17 SIRT3 deficiency induces endothelial insulin resistance and vascular dysfunction in obese mice P1113
and human subjects.
– L. Yang, J.L. Zhang, W.J. Xing, X. Zhang, J. Xu, X.N. Ning, H.F. Zhang, J. Li, F. Gao (Xi’an, CN)
10:25 Platelet endothelial aggregation receptor -1: a novel modifier of angiogenesis. P1114
– C. Vandenbriele, A. Kauskot, I. Vandersmissen, M. Criel, S. Craps, A. Luttun, S. Janssens, M. Hoylaerts,
P. Verhamme (Leuven, BE)
10:34 Dual Antithrombotic Effects of Ticagrelor in Arterial Thrombosis: an Antiplatelet Agent With P1115
Anticoagulant Properties.
– M.F. Reiner, A. Akhmedov, S. Stivala, S. Keller, G. Savarese, M. Glanzmann, T.F. Luescher, G.G. Camici,
J.H. Beer (Schlieren, Baden and Zurich, CH)
10:42 The impact of flavonoid supplementation on acute smoking-induced vascular dysfunction and P1116
fibrinolytic impairment.
– E. Kokkou, G. Siasos, E. Oikonomou, A. Verveniotis, N. Gouliopoulos, K. Zisimos, M. Zaromytidou,
SUNDAY – MORNING
A. Miliou, K. Mourouzis, D. Tousoulis (Athens, GR)
10:51 Transradial catheterisation: a clinical translational model of human arterial injury in vivo. P1117
– A. Mitchell, T. Fujisawa, N.L. Mills, D.E. Newby, N.L. Cruden (Edinburgh, UK)

ADVANCES IN CARDIOMYOPATHIES Moderated Posters
Chairperson(s): E. Biagini (Bologna, IT); P. Garcia-Pavia (Majadahonda, ES)
10:00 New sudden cardiac death risk score in hypertrophic cardiomyopathy - clinical application in a P1118
referral clinic and correlation with clinical, genetic and imaging data.
– A.C. Gomes, I. Cruz, L. Rocha Lopes, D. Caldeira, B. Stuart, G. Morgado, S. Almeida, R. Miranda,
L. Brandao, H. Pereira (Almada, PT)
10:08 Outcomes of hypertrophic cardiomyopathy patients undergoing non-cardiac surgery: A cohort P1119
study with matched non hypertrophic cardiomyopathy patients.
– A. Dhillon, A. Khanna, M. Randhawa, J. Cywinski, L. Saager, M. Thamilarasan, H.M. Lever, M.Y. Desai
(Cleveland, US)
10:17 Prognosis in dutch mybpc3 founder mutation carriers is defined by phenotype. P1120
– H.G. Van Velzen, A.F.L. Schinkel, R.A. Oldenburg, M.A. Van Slegtenhorst, I.M.E. Frohn - Mulder,
M. Michels (Rotterdam, NL)
10:25 Late gadolinium enhancement assessed by CMR in apical hypertrophic cardiomyopathy. A marker P1121
of ventricular arrhythmia and adverse events.
– A.M.G. Almeida, A. Bordalo, D. Brito, C. David, G. Lima Silva, R. Placido, A.R. Francisco, M.N. Menezes,
F.J. Pinto (Lisbon, PT)
10:34 Impact of liver transplantation on the natural history of familial amyloid polyneuropathy. P1122
– M.C. Azevedo Coutinho, N. Cortez-Dias, R. Placido, M.N. Menezes, A.R. Francisco, T. Guimaraes,
G.L. Silva, I. Conceicao, F.J. Pinto (Lisbon, PT)
10:42 Genetic spectrum of end stage idiopathic restrictive cardiomyopathy. P1123
– M. Gallego Delgado, L. Montserrat, M.J. Ruiz-Cano, V. Brossa-Loidi, J. Palomo, R. Marzoa-Rivas,
F. Perez-Villa, J. Salazar, L. Alonso-Pulpon, P. Garcia-Pavia (Madrid, A Coruña and Barcelona, ES)
10:51 Rest and exercise pulmonary hypertension in hypertrophic cardiomyopathy. P1124
– J. Abellard, J.N. Trochu, C. Cueff, A.S. Polge, C. Bauters, P. De Groote, A. Millaire, J.P. Gueffet, T. Le
Tourneau (Nantes and Lille, FR)
85

MANAGING LIPIDS – STATINS AND BEYOND Moderated Posters
Chairperson(s): R. Kausik (London, UK); R. Redberg (San Francisco, US)
10:00 Intensive intervention by specialised nurses after an acute coronary event improves lipid levels P1125
and reduces readmissions: a randomized controlled trial.
– S. Ruiz Bustillo, I. Ivern Diaz, N. Badosa Marce, J. Bruguera Cortada, O. Merono Duenas, D. Rodriguez
Anton, B.A. Perez, A. Fernandez Gasalla, E. Marco Navarro, J. Comin Colet (Barcelona, ES)
10:08 A combination of three specific Lactobacillus plantarum strains reduces low-density lipoprotein P1126
cholesterol and improves other cholesterol and lipid parameters in adults with
hypercholesterolemia.
– A. Ibarra, J. Cune, O. Hasselwander (Kantvik, FI; Barcelona, ES; Reigate, UK)
10:17 Impact of adding eicosapentaenoic acid to strong statin therapy on serum pentraxin X3 level: a P1127
six-month, randomized control study.
– S. Tani, A. Hirayama, W. Atsumi, T. Yagi, S. Niizuma, K. Kawauchi, K. Nagao (Tokyo, JP)
10:25 Predictive value of microparticle shedding in high cardiovascular risk subjects with and without P1128
future presentation of a major cardiovascular event.
– G. Chiva-Blanch, R. Suades, J. Crespo, R. Estruch, L. Badimon (Barcelona, ES)
10:34 Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs placebo in 1254 patients P1129 (W)
with heterozygous familial hypercholesterolaemia (HeFH): analyses up to 78 weeks from four
ODYSSEY trials. (withdrawn)
– J.J.P. Kastelein, M. Farnier, G.K. Hovingh, G. Langslet, M.T. Baccara-Dinet, D.A. Gipe, U. Chaudhari,
J. Zhao, C. Lorenzato, H.N. Ginsberg (Amsterdam, NL; Dijon, Montpellier and Paris, FR; Oslo, NO;
Tarrytown, Bridgewater, Basking Ridge and New York, US)
10:42 Usefulness of low-density lipoprotein cholesterol/ high-density lipoprotein cholesterol ratio on P1130
secondary prevention in the drug-eluting stent era.
– I. Matsumoto, S. Yokoyama, A. Misaki, M. Kurozumi, T. Nanba, Y. Takagi (Takamatsu, JP)
10:51 Prospectivev evaluation of cancer in 18,144 patients randomized to ezetimibe vs placebo: a P1131
prespecified analysis from the IMPROVE IT trial.
– R.P. Giugliano, S.D. Wiviott, C.S. Fuchs, A.J. Wagner, W. Goessling, J.A. White, T.A. Musliner,
A.M. Tershakovec, M.A. Blazing, E. Braunwald (Boston, Durham and Kenilworth, US)

ASSESSING PERCUTANEOUS TREATMENT OPTIONS FOR PAD Moderated Posters
Chairperson(s): H. Aboul Einen (Cairo, EG); I. Petrov (Sofia, BG)
10:00 How repeat endovascular therapy influence on outcomes of critical limb ischemia with tissue P1132
loss?
– N. Kobayashi, T. Muramatsu, R. Tsukahara, Y. Ito, H. Ishimori, K. Hirano, M. Nakano (Yokohama, JP)
10:08 Clinical impact of post-procedural fractional flow reserve on future restenosis in superficial P1133
femoral artery disease.
10:17 TP-trunk patency reduce TLR rate in patients treated EVT for femoro-popliteal lesions. P1134
– Y. Katoh, H. Taniguchi, T. Amano, M. Fujiwara, A. Higashimori, Y. Iwasaki (Osaka, Kyoto and Kishiwada, JP)
10:25 Predictors of 2-year mortality and risk stratification after surgical and endovascular P1135
revascularization for hemodialysis patients with critical limb ischemia due to infrainguinal artery
disease.
– T. Shiraki, O. Iida, M. Takahara, Y. Soga, T. Yamaoka, S. Mii, I. Kitano, M. Uematsu (Amagasaki, Osaka,
Fukuoka, Matsuyama, Kitakyushu and Kobe, JP)
10:34 Optimal revascularization strategy for in-stent occlusion after femoro-popliteal stenting. P1136
– Y. Tomoi, Y. Soga, Y. Kobayashi, S. Hiramori, K. Ando, M. Nobuyoshi (Kitakyushu, JP)
10:42 Relationship between primary patency and lesion length following bare nitinol stent placement for P1137
femoropopliteal artery disease.
– Y. Soga, M.T. Takahara, O.I. Iida, K.H. Hirano, K.S. Suzuki, K.A. Ando (Kitakyushu, Osaka, Amagasaki,
Yokohama and Sendai, JP)
10:51 Impact of patient’s activity on clinical outcome after femoropopliteal intervension. P1138
– H. Muranishi, Y. Soga (Kitakyushu, JP)
86

MYOCARDIAL FUNCTION Moderated Posters
Chairperson(s): N. Moussalem (Kesrouan, LB); I. Kanonidis (Thessaloniki, GR)
10:00 ST2-R2 score: degree of reverse remodelling and 4-year survival in patients with heart failure. A P1139
multicenter study.
– S. Sanders-Van Wijk, J. Lupon, J.L. Januzzi, M. De Antonio, H.P. Brunner-La Rocca, H. Gaggin, A. Galan,
R. Shah, M. Pfisterer, A. Bayes-Genis (Maastricht, NL; Badalona, ES; Boston, US; Basel, CH)
10:08 Right ventricle myocardial perfusion pressure and outcome in pulmonary hypertension due to left P1140
heart failure.
– R. Dragu, M. Habib, S. Rispler, H. Hammerman, D. Aronson (Haifa, IL)
10:17 The impact of left ventricular function and balloon aortic valvuloplasty on paravalvular leakage in P1141
patients undergoing TAVI.
– M. Drakopoulou, K. Toutouzas, G. Latsios, A. Synetos, K. Stathogiannis, A. Mastrokostopoulos, S. Yuecel,
U. Gerckens, E. Grube, D. Tousoulis (Athens, GR; Bonn, DE)
10:25 Mechanically independent ventricular beta2-adrenoceptor stimulation compensates for reduced P1142
contractile function in type-2 diabetes.
– R.F. Cook, G. Hughes, C.T. Bussey, P.A. Cragg, R.R. Lamberts (Dunedin, NZ)
10:34 Relationship of extracellular matrix regulation, collagen turnover and renin angiotensin system P1143
activity with myocardial function in patients with type 2 diabetes mellitus.
– J.H. Liu, Y. Chen, Z. Zhen, H.F. Tse, K.H. Yiu (Hong Kong, CN)
10:42 Comparative investigation of in vivo hemodynamics in rat models of physiological and P1144
pathological left ventricular hypertrophy.
SUNDAY – MORNING
– A. Olah, B.T. Nemeth, C. Matyas, A. Lux, M. Ruppert, D. Kellermayer, L. Szabo, M. Torok, B. Merkely,
T. Radovits (Budapest, HU)
10:51 Human iPSC-MSCs is superior to human ESC-CMs for improvement of left ventricular function in P1145
a porcine model of post-myocardial infarction heart failure.
– S.Y. Liao, Q.P. Ting, Z. Zhen, F. Luo, Z.Y. Zhu, Y. Liu, A. Chen, S. Oh, H.F. Tse (Hong Kong, HK;
Singapore, SG)

HYPERTENSION: DEVICES AND INTERVENTIONS Moderated Posters
Chairperson(s): N.V. Deshpande (Nagpur, IN); M. Mourali (Tunis, TN)
10:00 An ingestible sensor and wearable patch tracking adherence and activity patterns identified P1146
underlying factors leading of persistent hypertension: a real-world registry study.
– L. Dicarlo, R. Naik, N. Macey, R.J. West, P. Godbehere, S. Thurston, R. Fox, I. Singh, Y.A. Kim (Redwood
City, US; Sheffield, Suffolk, Cambridgeshire, Norfolk and Oxon, UK)
10:08 Renal sympathetic denervation in patients with treatment resistant hypertension: a meta-analysis P1147
– F. Fadl El Mula, Y. Jin, A.C. Larstorp, A. Persu, M. Sapoval, J. Rosa, J. Widimsky, M. Azizi, S. Kjeldsen,
J. Staessen (Oslo, NO; Leuven and Brussels, BE; Paris, FR; Prague, CZ)
10:17 Potential reduction in office and nocturnal blood pressure after renal denervation in patients with P1148
obstructive sleep apnea: a subgroup analysis of SYMPLICITY HTN-3.
– K. Kario, D. Bhatt, R. Townsend, J. Flack, M. Negoita, S. Oparil, G. Bakris (Tochigi, JP; Boston,
Philadelphia, Detroit, Santa Rosa, Birmingham and Chicago, US)
10:25 Effects of renal denervation on ADMA and sympathetic nerve activity in true resistant P1149
hypertensives.
– G. Seravalle, R. Dell’oro, D. Spaziani, C. Auguadro, P. Pizzini, G. Tripepi, F. Mallamaci, G. Mancia,
C. Zoccali, G. Grassi (Milan, Monza, Legnano and Reggio Calabria, IT)
10:34 Transforming the information highway for the clinical management of blood pressure using an P1150
ambulatory setting, objective assessment, and digital communication.
– L. Dicarlo, R. Weinstein, C. Morimoto, G. Moon, G. Savage, Y.A. Kim, T. Robertson, K.Y. Au-Yeung
(Redwood City and Walnut Creek, US)
10:42 Renal sympathetic denervation using MR guided high intensity focused ultrasound in a porcine P1151
model.
– M.K. Koopmann, J.S. Shea, E.K. Kholmovski, J.B. De Bever, E.M. Minalga, R.H. Hadley, O.T. Owan,
M.S. Salama, N.M. Marrouche, A.P. Payne (Salt Lake City, US)
10:51 Non-invasive coronary flow reserve in patients with resistant hypertension. P1152
– S. Voelz, S. Svedlund, B. Andersson, L.M. Gan, B. Rundqvist (Gothenburg, SE)
87

THE EUROPEAN HEART JOURNALS’ YEAR IN CARDIOLOGY: FROM PREVENTION TO Special Session
INTERVENTION
Chairperson(s): B.J. Gersh (Rochester, US); T.F. Luscher (Zurich, CH)
10:14 Managing lipids in 2015. 1154
10:22 Managing hypertension – Pill or ablation? 1155
10:30 Trends in interventional cardiology. 1156
– W. Wijns (Aalst, BE)
10:38 Acute coronary syndromes. 1157
– F. Van de Werf (Leuven, BE)
10:46 Summary. 1158

MEETH THE LEGENDS – KEITH FOX Meet the Legends
Chairperson(s): B. Casadei (Oxford, UK)
10:10 My scientific journey. 1159
10:30 Open forum discussion. 1160

HOT LINE I – ACUTE MYOCARDIAL INFARCTION Hot Line
Chairperson(s): F.J. Pinto (Lisbon, PT); K.A. Williams (Chicago, US)
11:00 Accurate and rapid diagnosis of myocardial infarction using a high sensitivity Troponin I 1-hour 1161
algorithm.
– D. Westermann (Hamburg, DE)
11:10 BACC: Discussant review. 1162
– J.S. Alpert (Tucson, US)
11:15 BACC: Panel discussion. 1163
11:18 Determining Optimal non-invasive Parameters for the Prediction of Left vEntricular morphologic 1164
and functional Remodeling in Chronic Ischemic Patients.
– F.E. Rademakers (Leuven, BE)
11:28 DOPPLER-CIP: Discussant review. 1165
– R. Bonow (Chicago, US)
11:33 DOPPLER-CIP: Panel discussion. 1166
11:36 Early aldosterone blockade in acute myocardial infarction: the randomized ALBATROSS Trial. 1167
– G.M. Montalescot (Paris, FR)
11:46 ALBATROSS: Discussant review. 1168
11:51 ALBATROSS: Panel discussion. 1169
11:54 Peri-infarct zone pacing to prevent adverse left ventricular remodeling in patients with very large 1170
12:04 PRomPT: Discussant review. 1171
12:09 PRomPT: Panel discussion. 1172
12:12 Does cyclosporine improve clinical outcomes in STEMI patients? The CIRCUS trial. 1173
– M. Ovize (Lyon, FR)
12:22 CIRCUS: Discussant review. 1174
– K. Przyklenk (Detroit, US)
12:27 CIRCUS: Panel discussion. 1175
88

FROM TRAINING TO CONTINUING PROFESSIONAL DEVELOPMENT (CPD) – FRAMEWORKS AND Symposium
IMPACT MEASUREMENT
ESC and the Section Cardiology of the Union of European Medical Specialists
Chairperson(s): R. Griebenow (Cologne, DE); A. Vahanian (Paris, FR)
11:00 How does the Professional Qualifications Directive EU 2013/55 impact on training in cardiology? 1176
– J.A. Hall (Middlesbrough, UK)
11:22 From need assessment to performance measurement. 1177
– S. Price (London, UK)
11:45 Continuing Professional Development (CPD) - Why is it different from CME? 1178
– L.K. Michalis (Ioannina, GR)
12:07 Live or online - The ESC portfolio for training and education in cardiology. 1179
– L.M. Goncalves (Coimbra, PT)

CARDIAC IMAGING AND MULTIMODALITY APPROACH IN DIFFERENT CLINICAL Case-based Symposium
SCENARIOS
ESC and the Brazilian Society of Cardiology
Chairperson(s): M.C. Moreira (Belo Horizonte, BR); G. Maurer (Vienna, AT)
11:00 A young patient with dyspnoea and syncope. 1180
– C.E. Rochitte (São Paulo, BR)
SUNDAY – MORNING
11:10 A young patient with dyspnoea and syncope - Panel discussion and questions from the audience. 1181
– C.E. Rochitte (São Paulo, BR), H.P. Schultheiss (Berlin, DE), W. Mathias Jr (São Paulo, BR), J.-L. Monin
(Créteil, FR)
11:22 Acute myocarditis - A difficult diagnosis. 1182
– H.P. Schultheiss (Berlin, DE)
11:32 Acute myocarditis - A difficult diagnosis - Panel discussion and questions from the audience. 1183
(Créteil, FR)
11:44 A challenging case of endocarditis. 1184
– W. Mathias Jr (São Paulo, BR)
11:54 A challenging case of endocarditis - Panel discussion and questions from the audience. 1185
(Créteil, FR)
12:06 A case for the multi-modality evaluation of severe aortic stenosis: the role of low flow gradient 1186
and diffuse myocardial fibrosis.
– J.-L. Monin (Créteil, FR)
12:16 A case for the multi-modality evaluation of severe aortic stenosis: the role of low flow gradient 1187
and diffuse myocardial fibrosis - Panel discussion and questions from the audience.
(Créteil, FR)

AGEING AND CARDIOVASCULAR DISEASE: ROLE OF CELLULAR SENESCENCE Special Session
A Journey to Stockholm
Chairperson(s): E.H.B. Blackburn (San Francisco, US)
11:00 Telomere dysfunction and aging – Recent insights into possible mechanisms. 1188
11:22 MicroRNA and cardiac ageing. 1189
11:45 Epigenetic and myocardial ageing. 1190
12:07 Cardiovascular disease and ageing: lessons from the English Longitudinal Study of Ageing. 1191

SEEING THE INVISIBLE – ECG AND CARDIAC IMAGING QUIZZES Symposium
Chairperson(s): J. Kautzner (Prague, CZ); J.J. Bax (Leiden, NL)
11:00 ECG in the Intensive Care Unit. 1192
– M. Pazdernik (Prague, CZ)
11:22 ECG in sudden cardiac death survivors. 1193
– B. Rudic (Mannheim, DE)
11:45 Challenging findings in cardiac imaging. 1194
– R. Fontes Carvalho (Porto, PT)
12:07 Cardiac imaging to solve mysteries. 1195
– R.C. Vidal Perez (Santiago de Compostela, ES)
89

ISSUES AND POTENTIAL SOLUTIONS IN PRIMARY PCI Rapid Fire Abstract
Chairperson(s): P. Widimsky (Prague, CZ); A. Erglis (Riga, LV)
11:00 Relative survival and excess mortality following Primary PCI for STEMI: Insights from a 97129 1196
patient national cohort study.
– R.A. Brogan, O.A. Alabas, T. Dondo, S. Almudarra, M. Van Laar, P.D. Batin, N. Curzen, P.F. Ludman,
M. De Belder, C.P. Gale (Leeds, Wakefield, Southampton, Birmingham and Middlesbrough, UK)
11:09 Symptom onset to reperfusion trends in patients with ST-elevation myocardial infarction across 1197
New York State from 2004 to 2010.
– P. McNair, S. Al’aref, B. Gosh, R. Swaminathan, H. Singh, L. Kim, D. Feldman, G. Bergman, S.C. Wong,
R. Minutello (New York, US)
11:18 Impact of national PCI network on prognosis after acute myocardial infarction in Estonia. 1198
– A. Saar, T. Marandi, T. Ainla, M. Blondal, K. Fischer, J. Eha (Tartu and Tallinn, EE)
11:27 Complete percutaneous coronary intervention versus culprit only percutaneous coronary 1199
intervention for acute ST elevation myocardial infarction with multivessel coronary artery disease:
a meta-analysis.
– L.G. Almelor, C. Fomaneg, A. Dayag (Quezon City, PH)
11:36 Impact of complete revascularization in a real world population of patients presenting with 1200
ST-elevation myocardial infarction.
– G.M. Rocha Rodrigues, S.M. Madeira, R.R. Rodrigues, M.S. Santos, P.F. Freitas, M.C. Castro, R.T. Teles,
M.A. Almeida, M.M. Mendes (Lisbon, PT)
11:45 Frequency, reasons and predictors of unplanned cardiac rehospitalizations following primary PCI 1201
in STEMI patients: results of the Comfortable AMI trial.
– E. Spitzer, L. Raeber, S. Zaugg, M. Frei, M. Magro, A. Baumbach, D. Tueller, V. Vukcevic, H. Kelbaek,
S. Windecker (Berne and Zurich, CH; Rotterdam, NL; Bristol, UK; Belgrade, RS; Copenhagen, DK)
11:54 Rarity of adverse events related to non-culprit coronary stenosis early after STEMI: implications 1202
for timing of additional revascularisation procedures.
– P. Rubartelli, D. Bartolini, S. Bellotti, A. Iannone, V. Fontana (Genoa, IT)
12:03 Improved outcome in patients treated with GP IIb/IIIa inhibitors undergoing primary PCI for 1203
STEMI. Results of the prospective ALKK-Registry.
– J.C. Karcher, R. Zahn, M. Hochadel, M. Brueck, T. Budde, S. Behrens, V. Schaechinger, H. Darius,
B. Zrenner, U. Zeymer (Ludwigshafen am Rhein, Wetzlar, Essen, Berlin, Fulda and Landshut-Achdorf, DE)
12:12 Role of contrast volume adjusted for weight and renal function as a predictor of contrast induced 1204
nephropathy and mortality in STEMI patients undergoing primary percutaneous coronary
intervention.
– G.M. De Ferrari, A. Somaschini, S. Cornara, G. Crimi, C. Pavesi, R. Camporotondo, A. Repetto, A. Potenza,
M. Gnecchi, M. Ferrario (Pavia, IT)
12:21 New generation drug-eluting stents vs. bare metal stents for primary angioplasty in patients >75 1205
years with ST elevated myocardial infarction: the ESTROFA MI+75 study.
– J.M. De La Torre Hernandez, S. Brugaletta, J.A. Gomez Hospital, A. Perez De Prado, R. Lopez Palop,
B. Cid, A. Diego, F. Gimeno De Carlos, J.A. Fernandez Diaz, J. Sanchis (Santander, Barcelona, Leon,
Alicante, Santiago de Compostela, Salamanca, Valladolid, Madrid and Valencia, ES)

BIG DATA – HOW DOES IT AFFECT CLINICAL PRACTICE? Special Session
Chairperson(s): G. Hindricks (Leipzig, DE); A.P. Maggioni (Florence, IT)
11:00 What is big data? 1206
– M. Ringel (Boston, US)
11:22 Who generates big data? 1207
11:45 Genome sequencing to advance health care. 1208
– K. Stefansson (Reykjavik, IS)
12:07 How big data affect clinical practice. 1209
11:00–12:30 | Rabat - Village 1

CARDIAC FIBROBLASTS AND CARDIOMYOCYTES IN MYOCARDIAL DAMAGE Symposium
Chairperson(s): F.A. van Nieuwenhoven (Maastricht, NL); R.F. Ventura-Clapier (Chatenay-Malabry, FR)
11:00 The cardiac fibroblast - Multiple sources, multiple roles. 1210
– S.B. Haudek (Houston, US)
11:22 The cardiac fibroblast - Inflammatory initiator post-myocardial infarction? 1211
– L. Liaudet (Lausanne, CH)
11:45 Myocite-fibroblast signalling in the myocardium. 1212
– P. Kohl (London, UK)
12:07 MicroRNA and cardiac repair. 1213
– C. Emanueli (Bristol, UK)
90

INFLAMMATION AND PLAQUE VULNERABILITY – ADVANCED INSIGHTS FROM MOUSE Advances in Science
AND MAN
Chairperson(s): M. Back (Stockholm, SE); C. Weber (Munich, DE)
11:00 State of the Art in atherosclerotic plaque destabilisation. 1214
– G. Pasterkamp (Utrecht, NL)
11:20 Dendritic cells are involved in hypercholesteralemia after myocardial infarction. 1215
– Z. Li, C. Wu, J. Yuan, H. Liu, W. Gao, A. Sun, Y. Zou, J. Ge (Shanghai, CN)
11:37 Serelaxin reduces oxidative stress in vitro and atherosclerosis in apoplipoprotein E deficient mice. 1216
– V. Tiyerili, H. Schatten, T. Beiert, J. Schrickel, G. Nickenig, R. Andrie (Bonn, DE)
11:54 Loss of hematopoietic DPP4 ameliorates atherosclerosis and vascular inflammation by 1217
non-catalytic mechanisms.
– J. Zhong, X. Rao, S. Oghumu, J. Deiuliis, A.R. Satoskar, M. Frieman, S. Rajagopalan (Baltimore and
Columbus, US)
12:11 Future direction for research in atherosclerosis: does the vulnerable plaque paradigm still hold? 1218
– V. Fuster (New York, US)

HOW ARE WE MANAGING CARDIOVASCULAR RISK IN THE PRIMARY CARE ENVIRONMENT? Symposium
EUROASPIRE IV SURVEY
Chairperson(s): D.E. Grobbee (Utrecht, NL); D.A. Wood (London, UK)
SUNDAY – MORNING
11:00 New challenges in a changing research environment. 1219
– K. Kotseva (London, UK)
11:22 Principal results. 1220
11:45 Identifying and managing dysglycaemia and diabetes. 1221
12:07 Implications for clinical practice. 1222
– C. Brotons (Barcelona, ES)

IS THERE REALLY STATIN INTOLERANCE AND HOW DO WE MANAGE IT? Case-based Symposium
Chairperson(s): J. Chapman (Paris, FR); J. Armitage (Oxford, UK)
11:00 My patient with muscle pain cannot get to goal with statins, what should I do? 1223
– E. Bruckert (Paris, FR)
11:15 My patient with muscle pain cannot get to goal with statins, what should I do? Panel discussion 1224
and questions from the audience.
– A. Corsini (Milan, IT), E. Bruckert (Paris, FR), E. Stroes (Amsterdam, NL)
11:30 How do I manage my patients with true statin intolerance? 1225
– E. Stroes (Amsterdam, NL)
11:45 How do I manage my patients with true statin intolerance? Panel discussion and questions from 1226
the audience.
– E. Bruckert (Paris, FR), A. Corsini (Milan, IT), E. Stroes (Amsterdam, NL)
12:00 Management of statin intolerance - State of the Art lecture. 1227
– J. Chapman (Paris, FR)

CHALLENGES IN TREATMENT ADHERENCE IN HEART FAILURE Symposium
Chairperson(s): J. Lupon Roses (Badalona, ES); M.H.L. Van Der Wal (Groningen, NL)
11:00 What’s for dinner? 1228
– S. Dunbar (Atlanta, US)
11:22 Physical activity - Sustainable? 1229
– K. Jolly (Birmingham, UK)
11:45 Cognitive impairment: a nursing challenge? 1230
– J. Boyne (Maastricht, NL)
12:07 Can technology help with adherence? 1231
– A. Stromberg (Linköping, SE)
91
11:00–12:30 | Kiev - Village 3

CARDIOTOXICITY OF ANTI-CANCER DRUGS Symposium
Chairperson(s): C. Funck-Brentano (Paris, FR); D. Cardinale (Milan, IT)
11:00 Cardiotoxicity of anthracycline. 1232
– A.R. Lyon (London, UK)
11:22 Cardiotoxicity of HER2 antagonists and tyrosine kinase inhibitors. 1233
– J. Bauersachs (Hannover, DE)
11:45 Detection and prevention of cardiotoxicity in clinical practice. 1234
– T. Lopez Fernandez (Madrid, ES)
12:07 Are anti-cancer drugs approved more easily than cardiovascular drugs? 1235

SYSTOLIC HYPERTENSION Advances in Science
Chairperson(s): A. Coca (Barcelona, ES); R. Cifkova (Prague, CZ)
11:00 State of the Art in systolic hypertension. 1236
– J. Staessen (Mechelen, BE)
11:20 Rising systolic blood pressure leads to a continuous progression towards hypertensive heart 1237
disease: a prospective population study.
– A. De Marvao, T. Dawes, W. Shi, D. Rueckert, S. Cook, D. O’Regan (London, UK; Singapore, SG)
11:37 Association of orthostatic hypertension with cardiovascular and all cause mortality in the systolic 1238
hypertension in the elderly program.
– J.B. Kostis, D. Sargsyan, W.J. Kostis (New Brunswick and Boston, US)
11:54 Serum MIG is a novel biomarker for increased arterial stiffness. 1239
– J. Oh, H.T. Yu, E.C. Shin, S. Park, S.H. Lee, S.M. Kang, D. Choi (Seoul and Daejeon, KR)
12:11 Future direction for research in treatment of systolic hypertension. 1240
– B. Trimarco (Naples, IT)

NEW APPROACHES TO PACING AND DEFIBRILLATION Symposium
Chairperson(s): C. Leclercq (Rennes, FR); R. Hatala (Bratislava, SK)
11:00 Leadless pacing. 1241
– P. Neuzil (Prague, CZ)
11:22 Subcutaneous defibrillators. 1242
– J. Poole (Seattle, US)
11:45 Novel approaches to left ventricular pacing. 1243
– V. Reddy (New York, US)
12:07 Wearable cardiac defibrillator. 1244
– H.U. Klein (Munich, DE)

MANAGEMENT OF ATRIAL FIBRILLATION IN SPECIFIC CONDITIONS Case-based Symposium
Chairperson(s): S. Ernst (London, UK); J.-Y. Le Heuzey (Paris, FR)
11:00 Athlete with atrial fibrillation. 1245
– H. Heidbuchel (Hasselt, BE)
11:15 Athlete with atrial fibrillation - Panel discussion and questions from the audience. 1246
– I.C. Van Gelder (Groningen, NL), J.L. Merino (Madrid, ES)
11:30 Obese patient with atrial fibrillation. 1247
– P.S. Sanders (Adelaide, AU)
11:45 Obese patient with atrial fibrillation - Panel discussion and questions from the audience. 1248
– I.C. Van Gelder (Groningen, NL), J.L. Merino (Madrid, ES)
12:00 Individualised treatment of atrial fibrillation in specific situations - State of the Art lecture. 1249
– J.-Y. Le Heuzey (Paris, FR)
92

DIFFICULT SCENARIOS IN PATIENTS WITH CHEST PAIN Meet the Experts
Chairperson(s): S. Achenbach (Erlangen, DE); A.N. Kitsiou (Athens, GR)
11:00 Difficult scenarios in patients with chest pain - Introduction to the session. 1250
– A.N. Kitsiou (Athens, GR)
11:05 A patient with hyperlipidemia and atypical chest pain. 1251
– K. Nieman (Rotterdam, NL)
11:15 A patient with hyperlipidemia and atypical chest pain - Panel discussion and questions from the 1252
audience.
– K. Nieman (Rotterdam, NL), S.R. Underwood (London, UK), S. Schroeder (Göppingen, DE), F. Rigo
(Mestre-Venice, IT)
11:30 A patient with renal failure, hypertension and chronic stable angina. 1253
– O. Gaemperli (Zurich, CH)
11:40 A patient with renal failure, hypertension and chronic stable angina - Panel discussion and 1254
– O. Gaemperli (Zurich, CH), S.R. Underwood (London, UK), S. Schroeder (Göppingen, DE), F. Rigo
(Mestre-Venice, IT)
11:55 A patient who went into cardiogenic shock. 1255
– M. Marwan (Erlangen, DE)
12:05 A patient who went into cardiogenic shock - Panel discussion and questions from the audience. 1256
– M. Marwan (Erlangen, DE), S.R. Underwood (London, UK), S. Schroeder (Göppingen, DE), F. Rigo
(Mestre-Venice, IT)
SUNDAY – MORNING
12:20 Difficult scenarios in patients with chest pain - Take home message. 1257
– S. Achenbach (Erlangen, DE)

SMART MOBILE – e-HEALTH SOLUTIONS FOR CARDIOLOGY Symposium
Chairperson(s): G. Krstacic (Zagreb, HR); C.E. Chronaki (Brookline, US)
11:00 Heart rate and blood pressure by mobile technology. 1258
– E.G. Caiani (Milan, IT)
11:22 Multi signal cardiovascular monitoring by mobile technology. 1259
– E.T. van der Velde (Leiden, NL)
11:45 Cardiovascular imaging by mobile technology. 1260
– N. Bruining (Rotterdam, NL)
12:07 3D heart model printing for preparation of percutaneous structural interventions. 1261
– A. Baszko (Poznan, PL)

CORONARY ARTERY DISEASE AND AORTIC STENOSIS Symposium
Chairperson(s): O. Goktekin (Istanbul, TR); M.C. Morice (Massy, FR)
11:00 Coronary artery disease and aortic stenosis: mechanisms of disease. 1262
– U. Landmesser (Berlin, DE)
11:22 Impact of coronary artery disease on clinical outcomes in patients with aortic stenosis. 1263
– G.G. Stefanini (Milan, IT)
11:45 Optimal management of coronary artery disease in patients undergoing surgical aortic valve 1264
replacement.
– M.J. Antunes (Coimbra, PT)
12:07 Optimal management of coronary artery disease in patients undergoing transcatheter aortic valve 1265
interventions.
– A. Chieffo (Milan, IT)
11:00–12:30 | Oslo - Village 6

PREVENTIVE INTERVENTIONAL CARDIOLOGY: A DREAM COMING TRUE? Symposium
Chairperson(s): K.A.A. Fox (Edinburgh, UK); G. Guagliumi (Bergamo, IT)
11:00 Vulnerable plaque: a moving target. 1266
– M. Joner (Gaithersburg, US)
11:22 Identification of vulnerable plaques in vivo: how close are we? 1267
– N. Gonzalo Lopez (Madrid, ES)
11:45 To stent or not to stent vulnerable lesions in stable coronary artery disease. 1268
– S. James (Uppsala, SE)
12:07 Management of non-culprit lesions in acute coronary syndromes. 1269
– C. Spaulding (Suresnes, FR)
93

CONTROVERSIES IN ANTIPLATELET MANAGEMENT IN PATIENTS UNDERGOING CORONARY Debate Session
INTERVENTIONS
Chairperson(s): F. Ibrahimov (Baku, AZ); N. Danchin (Paris, FR)
11:00 Antiplatelet management in patients undergoing coronary interventions - Pre-treatment is always 1270
better - PRO.
11:15 Antiplatelet management in patients undergoing coronary interventions - Pre-treatment is always 1271
better - CONTRA.
– L. Bolognese (Arezzo, IT)
11:30 Pre-treatment is always better - REBUTTAL PRO. 1272
11:35 Pre-treatment is always better - REBUTTAL CONTRA. 1273
– L. Bolognese (Arezzo, IT)
11:40 Pre-treatment is always better - CONCLUSION. 1274
11:45 Antiplatelet management in patients undergoing coronary interventions - DAPT beyond one year 1275
should be the standard - PRO.
12:00 Antiplatelet management in patients undergoing coronary interventions - DAPT beyond one year 1276
should be the standard - CONTRA.
– J. Mehilli (Munich, DE)
12:15 DAPT beyond one year should be the standard - REBUTTAL PRO. 1277
12:20 DAPT beyond one year should be the standard - REBUTTAL CONTRA. 1278
12:25 DAPT beyond one year should be the standard - CONCLUSION. 1279

ENVIRONMENTAL TRIGGERS OF MYOCARDIAL INFARCTION Meet the Experts
Chairperson(s): E. Omerovic (Gothenburg, SE); Y. Appelman (Amsterdam, NL)
11:00 Environmental triggers of myocardial infarction - Introduction to the session. 1280
– E. Omerovic (Gothenburg, SE)
11:05 Takotsubo stress cardiomyopathy. 1281
– A.S. Petronio (Pisa, IT)
11:15 Takotsubo stress cardiomyopathy - Panel discussion and questions from the audience. 1282
– M. Mendes (Carnaxide, PT), N. Mansencal (Boulogne-Billancourt, FR)
11:30 Spontaneous coronary dissection in pregnancy. 1283
– G. Mikhail (London, UK)
11:40 Spontaneous coronary dissection in pregnancy - Panel discussion and questions from the 1284
audience.
11:55 Climate change and atmospheric triggers. 1285
– M.J. Claeys (Edegem/Antwerpen, BE)
12:05 Climate change and atmospheric triggers - Panel discussion and questions from the audience. 1286
12:20 Environmental triggers of myocardial infarction - Take home message. 1287
– Y. Appelman (Amsterdam, NL)
94
11:00–12:30 | Tunis - Village 7

CORONARY MICROCIRCULATION, THE DARK SIDE OF THE MOON Debate Session
Chairperson(s): R. Bugiardini (Bologna, IT); M. Dorobantu (Bucharest, RO)
11:00 Acute coronary syndrome and microvascular dysfunction: the epicardial vessel is the only 1288
“culprit” - PRO.
– G. Rioufol (Bron, FR)
“culprit” - CONTRA.
– P.G. Camici (Milan, IT)
“culprit” - REBUTTAL PRO.
– G. Rioufol (Bron, FR)
“culprit” - REBUTTAL CONTRA.
“culprit” - CONCLUSION.
11:45 Microvascular dysfunction plays a minor role in ischaemic heart disease - PRO. 1293
– C. Piot (Montpellier, FR)
12:00 Microvascular dysfunction plays a minor role in ischaemic heart disease - CONTRA. 1294
– F. Crea (Rome, IT)
12:15 Microvascular dysfunction plays a minor role in ischaemic heart disease - REBUTTAL PRO. 1295
SUNDAY – MORNING
– C. Piot (Montpellier, FR)
12:20 Microvascular dysfunction plays a minor role in ischaemic heart disease - REBUTTAL CONTRA. 1296
12:25 Microvascular dysfunction plays a minor role in ischaemic heart disease - CONCLUSION. 1297

ADVANCED MANAGEMENT OF PULMONARY HYPERTENSION IN CONGENITAL HEART DISEASE Symposium
Chairperson(s): W. Budts (Leuven, BE); M.A. Gomez Sanchez (Madrid, ES)
11:00 Natural history and progression of pulmonary hypertension in congenital heart disease. 1298
– G.P. Diller (Münster, DE)
11:22 Predicting deterioration and need for escalation of treatment. 1299
– M. D’Alto (Naples, IT)
11:45 Experience with intravenous, subcutaneous and inhalative therapies. 1300
– R. Alonso Gonzalez (London, UK)
12:07 Pregnancy and contraception in pulmonary hypertension and congenital heart disease. 1301
– J.W. Roos-Hesselink (Rotterdam, NL)

MITRAL AND TRICUSPID DISEASE: KEEPING UP WITH THE GUIDELINES Guidelines in Daily Practice
Chairperson(s): D. Messika-Zeitoun (Paris, FR); L.D. Gillam (Morristown, US)
11:00 Asymptomatic young women with severe, primary mitral regurgitation. 1302
11:15 Asymptomatic young women with severe, primary mitral regurgitation - What do the Guidelines 1303
say?
– R. Rosenhek (Vienna, AT)
11:30 Asymptomatic young women with severe, primary mitral regurgitation - Panel discussion on how 1304
to implement the Guidelines.
– R. Rosenhek (Vienna, AT), O. Wendler (London, UK), L.A. Pierard (Liège, BE)
11:40 Asymptomatic young women with severe, primary mitral regurgitation - Conclusion and take 1305
home message.
– D. Messika-Zeitoun (Paris, FR)
11:45 Severe, secondary tricuspid regurgitation after the mitral valve surgery. 1306
– D. Muraru (Padua, IT)
12:00 Severe, secondary tricuspid regurgitation after the mitral valve surgery - What do the Guidelines 1307
say?
– M. De Bonis (Milan, IT)
12:15 Severe, secondary tricuspid regurgitation after the mitral valve surgery - Panel discussion on how 1308
– D. Muraru (Padua, IT), M. De Bonis (Milan, IT), O. Wendler (London, UK)
12:25 Severe, secondary tricuspid regurgitation after the mitral valve surgery - Conclusion and take 1309
home message.
– L.D. Gillam (Morristown, US)
95

PATHOLOGIC SUBSTRATES OF SUDDEN DEATH IN THE YOUNG Cardiac Anatomy and Pathology Live
Chairperson(s): T. Wichter (Osnabrück, DE); C. Basso (Padua, IT)
11:00 Live-video demonstration. 1310
– M.N. Sheppard (London, UK)
12:00 Hands-on specimen demonstration. 1311
11:00–12:30 | Bern - Village 9

BIOMARKERS FOR HEART FAILURE: STATE OF THE ART Symposium
ESC and the Canadian Cardiovascular Society
Chairperson(s): H. Ross (Toronto, CA); A. Mebazaa (Paris, FR)
11:00 Management of acute heart failure - The current and future role of biomarkers in management. 1312
– J.A. Ezekowitz (Edmonton, CA)
11:22 Biomarkers for the diagnosis in heart failure with preserved ejection fraction, what is their role? 1313
– E. O’Meara (Montreal, CA)
11:45 Biomarkers: guided therapy in chronic heart failure. 1314
– J. Januzzi (Boston, US)
12:07 Biomarkers for co-morbodity assessment in chronic heart failure. 1315

NATRIURETRIC PEPTIDES AS A THERAPEUTIC APPROACH IN CHRONIC AND ACUTE HEART Symposium
FAILURE
Chairperson(s): K. Swedberg (Gothenburg, SE); G.S. Filippatos (Athens, GR)
11:00 Pathophysiological basis of therapy with natriuretic peptides in heart failure. 1316
– T. Omland (Oslo, NO)
11:22 From candoxatril to omapatrilat and LCZ696. 1317
– M. Packer (Dallas, US)
11:45 ANP (carperitide), BNP (nesiritide). 1318
– C. O’Connor (Durham, US)
12:07 New natriuretric peptides in trials: ularitide & C/D-NP. 1319
– S.D. Anker (Göttingen, DE)

SYNCOPE AND SUDDEN DEATH Rapid Fire Abstract
Chairperson(s): L. Jordaens (Ghent, BE); B. Gorenek (Eskisehir, TR)
11:00 Management and outcomes of out of hospital cardiac arrest according to its time of occurrence: 1320
results from the paris sdec study.
– N. Karam, E. Marijon, L. Offredo, F. Beganton, L. Lamhaut, F. Dumas, C. Spaulding, A. Cariou, X. Jouven
(Paris, FR)
11:09 Duration of resuscitation efforts and survival after out-of-hospital cardiac arrest: an observational 1321
study.
– Y. Goto, T. Maeda, A. Funada, Y. Nakatsu-Goto (Kanazawa and Komatsu, JP)
11:18 Autopsy findings of victims with asystole or pulseless electrical activity vs. ventricular fibrillation 1322
at the time of cardiac arrest.
– A. Hantula, J. Junttila, E. Hookana, M.-L. Kortelainen, J. Perkiomaki, M. Martikainen, H.V. Huikuri (Oulu, FI)
11:27 German national experience with the wearable cardioverter-defibrillator (WCD). 1323
– N.K. Waessnig, U. Speiser, S. Quick, F.A. Rottstaedt, F.S.J. Szymkiewicz, S. Ringquist, R.H. Strasser,
M. Guenther (Dresden, DE)
11:36 Orthostatic- and postprandial hypotension in elderly patients with syncope. 1324
– J.F.H. Wold, E. Doejaaren, R.W.M.M. Jansen, J.H. Ruiter, J.H. Cornel (Alkmaar, NL)
11:45 Epileptic seizures are frequent in patients with long QT syndrome type 2. 1325
– I. Dahl, P.G. Larsson, K.H. Haugaa, E. Tauboll (Oslo, NO)
11:54 The effect of fluoxetine on recurrent vasovagal syncope with anxiety sensitivity. 1326
– P. Flevari, D. Leftheriotis, E. Repassos, D. Katsaras, J. Lekakis (Athens, GR)
12:03 Cumulative risk of symptoms in pediatric patients with long QT syndrome (LQTS) who were 1327
diagnosed by school-based screening programs in Japan.
– M. Yoshinaga, H. Ogata, H. Suzjuki, H. Ushinohama, N. Sumitomo, H. Horigome, S. Tateno, S. Sato,
N. Tauchi, M. Nagashima (Kagoshima, Wako, Niigata, Fukuoka, Saitama, Tsukuba, Chiba and Nagoya, JP)
12:12 Antiadrenergic autoimmunity in postural tachycardia syndrome and vasovagal syncope. 1328
– A. Fedorowski, R. Sutton, O. Melander, H. Li, X. Yu, D.C. Kem (Malmö, SE; London, UK; Oklahoma City,
US)
12:21 Increased risk of occupational accidents following syncope: a Danish nationwide study. 1329
– A. Nume, M.H. Ruwald, K. Kragholm Soerensen, D. Zahir, C. Torp-Pedersen, G. Gislason (Hellerup and
Aalborg, DK)
96
SUNDAY 30 AUGUST 2015 – MORNING POSTERS

BEST POSTERS IN SUDDEN DEATH
Discussant: Best posters in sudden death. P1330

– L. Mont (Barcelona, ES)
Long term outcomes of out of hospital cardiac arrest. P1331

– M. Shuvy, L.J. Morrison, F. Qiu, S. Cheskes, P. Dorian, D.C. Scales, P.R. Verbeek, H.C. Wijeysundera,
M. Koh, D.T. Ko (Toronto, CA)
Neurological outcomes in children transported to hospital without a prehospital return of spontaneous P1332
circulation after out-of-hospital cardiac arrest.
Survival improved for men but not women, despite increased bystander CPR and first resonder P1333
defibrillation for both: results form a statewide quality improvement initiative.
– C. Malta Hansen, K. Kragholm, D.A. Pearson, C. Tyson, L. Monk, D. Nelson, M.E. Dupre, J.G. Jollis,
B. McNally, C.B. Granger (Durham, Charlotte and Winston-Salem, US)
SUNDAY – MORNING
Very long-term follow-up of patients with out-of-hospital cardiac arrest due to idiopathic ventricular P1334
fibrillation: a single-centre experience.
– G. Conte, M. Caputo, F. Regoli, T. Moccetti, A. Auricchio (Lugano, CH)
BEST POSTERS IN POST MYOCARDIAL INFARCTION OUTCOMES
Discussant: Best posters in post myocardial infarction outcomes. P1335

– E. Omerovic (Gothenburg, SE)
Long-term mortality and risk of myocardial infarction associated with presence and extent of coronary P1336
artery disease in diabetic and non-diabetic patients.
– K.K.W. Olesen, M. Madsen, G. Egholm, T. Thim, L.O. Jensen, H.E. Boetker, H.T. Soerensen, M. Maeng
(Aarhus and Odense, DK)
Long-term risk of myocardial infarction and mortality in patients without obstructive coronary artery P1337
disease by coronary angiography.
Relation between rate of reperfusion decisions in the ambulance and STEMI case load. An analysis of the P1338
eMust registry in 18,063 patients managed by 41 mobile intensive care units.
– G. Lenoir, Y. Lambert, A. Loyeau, N. Danchin, T. Boche, F. Dupas, S. Bataille, F. Lapostolle (Bobigny, Le
Chesnay, Paris, Créteil and Pontoise, FR)
Acetylcholine-provoked coronary spasm at the site of significant organic stenosis is a potent predictor P1339
for cardiovascular events in patients with vasospastic angina.
– M. Ishii, K. Kaikita, K. Sato, T. Tanaka, K. Sakamoto, E. Yamamoto, K. Tsujita, S. Hokimoto, H. Ogawa
(Kumamoto, JP)
BEST POSTERS IN STRESS ECHOCARDIOGRAPHY
Discussant: Best posters in stress echocardiography. P1340

– G. Athanassopoulos (Pireas, GR)
The declining frequency of inducible myocardial ischemia during cardiac stress testing in the last 39 P1341
years (1970-2009).
– C. Carpeggiani, P. Landi, R. Sicari, E. Picano (Pisa, IT)
Dobutamine stress contrast echo in diabetic patients: the prognostic impact of appropriateness criteria P1342
indication.
– C. Aggeli, I. Felekos, V. Panagopoulou, S. Kastellanos, P. Koudounis, A. Aggelis, K. Zisimos, D. Tousoulis
(Athens, GR)
Should we perform exercise echocardiography on patients with left bundle branch block and suspected P1343
coronary disease?
– S. Moir, L. Dobson, I. Agahari, J. Cameron, P.M. Mottram (Melbourne, AU)
Objective criteria of LAD lesion during exercise stress echocardiography: coronary flow velocity reserve P1344
during exercise.
– A. Zagatina, N. Zhuravskaya (St. Petersburg, RU)
97
BEST POSTERS IN STEM CELLS AND CELL THERAPY
Discussant: Best posters in stem cells and cell therapy. P1345

– S. Janssens (Leuven, BE)
Optical action potential recordings in healthy and diseased induced pluripotent stem cell-derived P1346
cardiomyocytes.
– D. Sinnecker, Z. Chen, L. Dreizehnter, T. Dorn, A. Goedel, A. Moretti, K.L. Laugwitz (Munich, DE)
Soluble factors secreted by regulatory T cells promote cardiomyocyte proliferation during embryonic P1347
development and after myocardial infarction.
– S. Zacchigna, V. Martinelli, G. Colussi, M. Anzini, A. Nordio, S. Moimas, G. Sinagra, M. Giacca (Trieste, IT)
Improved vascularization and increased expression of contractile protein mediate beneficial effects of P1348
transplantation of adipose tissue mesenchymal cells expressing telomerase and myocardin in murine.
– R. Madonna, L. Petrov, M.A. Teberino, Y.J. Geng, P. Ferdinandy, M. Cabriera, E. Perin, D. Taylor, R. De
Caterina, J.T. Willerson (Chieti, IT; Kuopio, FI; Houston, US; Budapest, HU)
Prolyl hydroxylase inhibition induces SDF-1 and CXCR4 expression to increase CXCR4+ cell homing and P1349
myocardial repair.
– S.K. Ghadge, T.H. Pham, M. Messner, M. Doppelhammer, B. Husse, W.M. Franz, M.M. Zaruba (Innsbruck,
AT; Munich, DE)
BEST POSTERS IN CARDIOMYOPATHIES
Discussant: Best posters in cardiomyopathies. P1350

– A. Angelini (Padua, IT)
Lack of progression or regression of left ventricular hypertrophy in children with sarcomeric gene P1351
disease.
– G. Limongelli, R. Vastarella, M. Rubino, G. Frisso, D. Masarone, C. Mazzaccara, R. Gravino, F. Salvatore,
M.G. Russo, G. Pacileo (Naples, IT)
Myocardial involvement in patients with muscular dystrophies. P1352
– M. Gospodinova, T. Chamova, V. Guergelcheva, I. Tournev, S. Denchev (Sofia, BG)
Perforin is an independent risk factor for survival in patients with suspected inflammatory P1353
cardiomyopathy.
– F. Escher, U.K. Kuehl, D.L. Lassner, D. Westermann, W.C. Poller, C. Tschoepe, H.P. Schultheiss (Berlin
and Hamburg, DE)
Electroanatomic mapping guide increase diagnostic sensitivity of endomyocardial biopsy in patients with P1354
ventricular arrhythmias.
– M. Pieroni, P. Notarstefano, A. Camporeale, R. Guida, S. Grotti, T. Rio, C. Nucci, A. Fraticelli, A. Carnevali,
L. Bolognese (Arezzo and Rome, IT)
BEST POSTERS IN OBESITY
Discussant: Best posters in obesity. P1355

– R. Timar (Timisoara, RO)
Does childhood adiposity, or change in adiposity from childhood to adulthood, predict metabolically P1356
healthy obesity in adulthood?
– A. Venn, E. Bessell, C.G. Magnussen, T. Dwyer, K.J. Smith (Hobart, AU)
Association of body mass index with the incidence of stroke and death in real-world atrial fibrillation P1357
patients: The Fushimi AF Registry.
– Y. Hamatani, H. Ogawa, D. Takagi, Y. Yamashita, M. Esato, Y.H. Chun, H. Wada, K. Hasegawa, M. Abe,
M. Akao (Kyoto, JP)
Dairy intakes, erythrocyte membrane phospholipid fatty acids and cardiovascular risk. P1358
– V. Bongard, S. Huo Yung Kai, C. Simon, J. Dallongeville, D. Arveiler, J.B. Ruidavets, A. Wagner,
P. Amouyel, J.L. Sebedio, J. Ferrieres (Toulouse, Lyon, Lille, Strasbourg and Clermont-Ferrand, FR)
Fresh fruit consumption in relation to mortality from cardiovascular and non-cardiovascular diseases. P1359
– H. Du, L. Li, D. Bennett, Y.U. Guo, Z. Bian, J. Chen, T. Key, Z. Chen (Oxford, UK; Beijing, CN)
BEST POSTERS IN MORPHOLOGY VERSUS FUNCTIONAL ASSESSMENT... THE GREAT DEBATE

CONTINUES ON PAPERS
Discussant: Best posters in morphology versus functional assessment... the great debate continues on P1360
papers.
– Y. Kobayashi (Chiba, JP)
Comparison between physiological coronary artery stenosis severity assessed by fractional flow reserve P1361
and optical coherence tomography findings in stable angina pectoris.
– T. Lee, T. Murai, Y. Kanaji, J. Matsuda, E. Usui, M. Araki, T. Niida, T. Kakuta (Tsuchiura, JP)
The impact of target lesion characteristics assessed by optical coherence tomography on microvascular P1362
resistance in patients with non-ST-segment elevation acute coronary syndrome.
– T. Murai, T. Lee, Y. Kanaji, J. Matsuda, E. Usui, M. Araki, T. Niida, M. Isobe, T. Kakuta (Tsuchiura and
Tokyo, JP)
98
The impact of in-stent neoatherosclerosis on long-term clinical outcomes: an observational study from P1363
the optical coherence tomography registry.
– M. Kuroda, H. Otake, T. Shinke, T. Takaya, T. Osue, H. Kinutani, A. Konishi, H. Takahashi, D. Terashita,
K.I. Hirata (Kobe, JP)
FFR gray zone and clinical outcome. P1364
– J. Adjedj, B. De Bruyne, V. Flore, G. Di Gioia, A. Ferrara, M. Pellicano, J. Bartunek, M. Vanderheyden,
W. Wijns, E. Barbato (Aalst, BE)
BEST POSTERS IN BIOMARKERS
Discussant: Best posters in biomarkers. P1365

– M. Cicoira (Verona, IT)
Central apneas and chemoreflex activation influence on pulmonary hypertension in heart failure: role of P1366
adrenergic activation.
– V. Raglianti, A. Del Franco, G. Mirizzi, A. Aimo, C. Taddei, F. Bramanti, G. Iudice, C. Passino, M. Emdin,
A. Giannoni (Pisa, IT)
Resting heart rate and disease severity in chronic heart failure: results from INDICATE. P1367
– C. Zugck, P. Martinka, G. Stoeckl, C. Tschoepe, S. Stoerk (Straubing, Munich, Berlin and Würzburg, DE)
Impaired immune phenotype of circulating endothelial-derived microparticles in none-diabetic patients P1368
with chronic heart failure.
– A. Berezin, A. Kremzer (Zaporozhye, UA)
Lysyl oxidase overexpression impacts cardiovascular remodelling. P1369
– M. Galan, S. Varona, M. Orriols, S. Aguilo, A. De Diego, J. Osada, J. Martinez-Gonzalez, C. Rodriguez
SUNDAY – MORNING
(Barcelona and Zaragoza, ES)
BEST POSTERS IN TREATMENT OF HYPERTENSION
Discussant: Best posters in treatment of hypertension. P1370

– S. Manchanda (New Delhi, IN)
Effect of annual blood pressure control on major adverse cardiovascular events in patients with resistant P1371
hypertension - From Ibaraki hypertension assessment trial (I-HAT).
– T. Machino, A. Sato, T. Hoshi, N. Murakoshi, X. Dongzhu, T. Kimura, A. Nogami, K. Aonuma (Tsukuba, JP)
Arterial hypertension, endothelial microparticles, and endothelial dysfunction. P1372
– R. Sansone, M. Baaken, D. Schuler, P. Horn, M. Cortese-Krott, R. Westenfeld, M. Kelm, C. Heiss
(Düsseldorf, DE)
Guideline adherence and clinical outcomes in hypertensive crises. P1373
– J.K. De Vries, M.P.M. Harms (Groningen, NL)
Blood Pressure control, presence of depressive symptoms and clinical outcomes at 4 years in patients P1374
with cardiometabolic disease.
– B. Jani, S. Barry, J. Cavanagh, G. Der, N. Sattar, F. Mair (Glasgow, UK)
99

Posters are on display from 08:30 to 12:30. Presenters will be by their poster during the coffee break
MECHANISMS AND PREDICTORS OF SUDDEN CARDIAC DEATH

Novel Right-sided vectorcardiographic methods detect electrocardiographic defects in patients with P1375
arrhythmogenic right ventricular cardiomyopathy in the absence of conventional depolarization or repo.
– D. Cortez, J. Carlson, S. Graw, F. Brun, A. Spezzacatene, L. Mestroni, P. Platonov (Aurora, US; Lund, SE;
Trieste, IT)
Dispersion of T-wave area in left precordial leads predicts sudden cardiac death in standard 12-lead P1376
electrocardiogram.
– T. Kentta, B. Nearing, K. Porthan, J.T. Tikkanen, M. Viitasalo, M.S. Nieminen, V. Salomaa, L. Oikarinen,
R.L. Verrier, H.V. Huikuri (Oulu and Helsinki, FI; Boston, US)
QRS fragmentation induced by ventricular pacing predicts appropriate defibrillator therapies and total P1377
Mortality in subjects with cardiomyopathy.
– F. Del Carpio, S.M. Gharacholou, G.S. Scott, V.T. Nkomo, F. Lopez-Jimenez, S.J. Asirvatham (Rochester,
US)
Prediction of sudden death in patients with chronic heart failure by combination of early repolarization P1378
pattern and long runs of non-sustained ventricular tachycardia detected by serial Holter ECG.
– M. Ishimi, T. Yamada, T. Morita, Y. Furukawa, S. Tamaki, Y. Iwasaki, M. Kawasaki, A. Kikuchi, T. Kondo,
M. Fukunami (Osaka, JP)
Severe proarrhythmic potential of risperidone compared to quetiapine or citalopram. P1379
– G. Frommeyer, B. Bruecher, H. Von Der Ahe, S. Kaese, P. Milberg, L. Eckardt (Münster, DE)
Sudden death with structurally normal heart: results from the West of Scotland Familial Arrhythmia P1380
Network (FANS) and Inherited Cardiac Conditions Clinic.
– R. McIntyre, C. Brown, D. Connelly, A. Rankin, A. Rae, D. Oxnard, J. Anusis, V. Murday, I. Findlay (Dundee
and Glasgow, UK)
Sudden cardiac death and mitral valve prolapse: a single center experience. P1381
– A. Rafael, P. Bartko, R.A. Levine, E.I. Starobinska, S.A. Lubitz, D.J. Milan (Boston and Phoenix, US)
Initial prognosis and management of out-of-hospital cardiac arrest in women: the SDEC Paris study. P1382
– N. Karam, E. Marijon, F. Beganton, L. Lamhaut, F. Dumas, A. Cariou, C. Spaulding, X. Jouven (Paris, FR)
The Efficacy of electrical therapy using biphasic AEDs in the 2010 CPR guidelines for Patients with P1383
Out-of-Hospital Cardiac Arrest due to Ventricular Fibrillation.
– T. Yagi, K. Nagao, E. Tachibana, S. Tani, N. Yonemoto, S. Shirai, M. Takayama, H. Nonogi, K. Saku,
A. Hirayama (Kawaguchi, Tokyo, Kitakyushu, Shizuoka and Fukuoka, JP)
Comparison of biphasic and monophasic waveform defibrillations in out-of-hospital cardiac arrest: an P1384
observational cohort study.
ADRB2 Gln27Glu polymorphism impacts the timing of ventricular fibrillation during the acute phase of P1385
– B. Ankou, S. Chauveau, E. Morel, G. Morgan, B. London, P. Chevalier (Lyon, FR; Iowa City, US)
AKAP9 mutations identified in young patients with idiopathic ventricular fibrillation or polymorphic P1386
– K. Sonoda, S. Ohno, M. Ichikawa, Y. Fujii, Q. Wang, K. Kato, M. Fukuyama, H. Ito, H. Hayashi, M. Horie
(Niigata and Shiga, JP)
SUDDEN CARDIAC DEATH AND CHANNELOPATHIES AND CARDIOMYOPATHIES

Incidence and electrogram characteristic of non-sustained ventricular fibrillation in patients with primary P1387
electrical disorders.
– W.S. Lee, J. Kim, C.H. Kwon, U. Jo, J.H. Choi, Y.R. Kim, G.B. Nam, K.J. Choi, Y.H. Kim (Seoul, KR)
Prolonged right ventricular ejection delay identifies high risk patients and gender differences in Brugada P1388
syndrome.
– S.C.H. Van Malderen, D. Kerkhove, D.A.M.J. Theuns, C. Weytjens, S. Droogmans, D. Daneels, S. Van
Dooren, M. Meuwissen, P. Brugada, G. Van Camp (Rotterdam, NL; Brussels, BE)
Troponin T or I levels following ICD implantation with and without defibrillation testing and their P1389
predictive value for outcomes: Insights from the SIMPLE trial.
– M. Vamos, S.H. Hohnloser, S.J. Connolly, G. Duray, L. Vanerven, X. Vinolas, J. Neuzner, M. Glikson,
J. Wang, J.S. Healey (Frankfurt am Main and Kassel, DE; Hamilton, CA; Budapest, HU; Leiden, NL;
Barcelona, ES; Tel Hashomer, IL)
Increased myocardial expression of proapoptotic PERP, proadipogenic CPT1B and phospholamban in P1390
arrhythmogenic right ventricular cardiomyopathy/dysplasia compared to dilated cardiomyopathy and
controls.
– D. Akdis, A.M. Saguner, J. Kast, A. Medeiros-Domingo, F. Enseleit, P. Bode, A.C. Akdis, T.F. Luescher,
C. Brunckhorst, F. Duru (Zurich and Davos, CH)
ABCB1 gene variants, digoxin and risk of sudden cardiac death in a general population. P1391
– M.N. Niemeijer, M.E. Van Den Berg, J.W. Deckers, A.L.H.J. Aarnoudse, A. Hofman, O.H. Franco,
A.G. Uitterlinden, P.R. Rijnbeek, M. Eijgelsheim, B.H. Stricker (Rotterdam and Eindhoven, NL)
100
A novel cardiac ryanodine 2 receptor gene (RyR2) mutation as cause of sudden cardiac death by P1392
catecholaminergic polymorphic ventricular tachycardia.
– E. Diaz Pelaez, E. Zatarain Nicolas, J.M. Mena Latorre, E. Villacorta Arguelles, I. Mendez-Fernandez,
M.A. Espinosa-Castro, M. Centeno Jimenez, R. Yotti-Alvarez, F. Fernandez-Aviles (Madrid and Alcala de
Henares, ES)
S-wave angle identifies ARVD with normal ECGs compared to healthy family members. P1393
– D. Cortez, S. Graw, F. Brun, A. Spezzacatene, L. Mestroni (Aurora, US; Trieste, IT)
Prevalence of electrocardiographic findings associated to sudden cardiac death: spontaneous type 1 and P1394
type 2 Brugada patterns and QT disorders in Spanish population older than forty years.
– P. Awamleh Garcia, C. Graupner, R.M. Jimenez, P. Talavera, J.J. Gomez-Doblas, J. Muniz, J.J. Alonso,
E. Roig, A. Curcio, J. Serrano (Getafe, Fuenlabrada, Málaga, A Coruña and Barcelona, ES)
Differences in risk factors and outcome of cardiac arrest in southern Sweden depending on cardiac or P1395
non-cardiac origin.
– M.A. Ohlsson, L.M. Kennedy, T. Juhlin, O. Melander (Malmö, SE)
Potential role of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of P1396
sudden death risk in intermediate-risk patients with hypertrophic cardiomyopathy.
– R. Hinojar, C. Fernandez-Golfin, J.C. Portugal, A. Esteban, A. Megias, A. Gonzalez-Gomez, L.M. Rincon,
J.J. Jimenez Nacher, V. Puntmann, J.L. Zamorano (Madrid and Las Palmas de Gran Canaria, ES; Frankfurt
am Main, DE)
Nadolol is superior to metoprolol SR in protection from exercise induced arrhythmias in patients with P1397
catecholaminergic polymorphic ventricular tachycardia (CPVT).
– I.S. Leren, T.F. Haland, J. Saberniak, E. Majid, T. Edvardsen, K.H. Haugaa (Oslo, NO)
Deletion of SCN5A and SCN10A detected using NGS as a probable cause of Brugada syndrome. Results P1398
of a copy number variants cohort screening.
SUNDAY – MORNING
– A.J. Palomino Doza, A. Garcia Fernandez, J.G. Martinez Martinez, M.L. Pena Pena, J.P. Ochoa, D. Garcia,
D. De Una, C. Gayoso, V. Climent Paya, L. Monserrat Iglesias (A Coruña and Alicante, ES)
VENTRICULAR ARRHYTHMIAS
Monomorphic ventricular tachycardia conversion after ventricular fibrillation ablation in patients with P1399
ischemic heart disease.
– K. Masuda, A. Nogami, K. Kuroki, T. Machino, M. Igarashi, Y. Sekiguchi, K. Aonuma (Tsukuba, JP)
Early repolarization pattern: a marker of increased risk in patients with catecholaminergic polymorphic P1400
– E. Tulumen, E. Schulze-Bahr, S. Zumhagen, B. Stallmeyer, B.M. Beckmann, S. Kaab, C. Wolpert, B. Rudic,
C. Veltmann, M. Borggrefe (Mannheim, Münster, Munich, Ludwigsburg and Hannover, DE)
Electroanatomical scar characteristics of patients presenting with fast ventricular tachycardia after P1401
myocardial infarction: the impact on substrate based ablation approaches.
– M. De Riva Silva, G.F.L. Kapel, J. Venlet, S.R.D. Piers, M. Watanabe, M.J. Schalij, K. Zeppenfeld (Leiden,
NL)
Ventricular tachyarrhythmia during pregnancy in patients with structural heart disease: results from the P1402
ROPAC registry.
– E. Ertekin, A.M.F. Salam, I.M. Van Hagen, M.R. Johnson, R. Hall, J.W. Roos-Hesselink (Rotterdam, NL;
Doha, QA; London and Norwich, UK)
Ventricular arrhythmias induced by sodium channel blocker is a risk stratification tool in patients with P1403
Brugada syndrome.
– A. Ueoka, H. Morita, M. Kubo, K. Nakagawa, N. Nishii, S. Nagase, H. Ito (Okayama, JP)
Improvement in ventricular function and low incidence of ventricular arrhythmias in dilated P1404
cardiomyopathy.
– K. Broch, E. Kongsgaard, L. Gullestad, S. Aakhus (Oslo, NO)
Scar transmurality as a criterion for first-line endo-epicardial substrate-guided ventricular tachycardia P1405
ablation in ischemic cardiomyopathy.
– J. Acosta Martinez, J. Fernandez-Armenta, D. Penela, D. Andreu, R. Borras, F. Vassanelli, J. Brugada,
L. Mont, A. Berruezo (Barcelona, ES)
Subjects with suspected Brugada pattern: best electrocardiographic parameters in predicting positive P1406
sodium channel blocker test.
– C. Giustetto, N. Cerrato, C. Rolando, P. Carvalho, D. Castagno, M. Anselmino, R. Pozzi, L. Bergamasco,
F. Gaita (Turin and Orbassano, IT)
Implantable cardioverter-desfibrillator in hypertrophic cardiomyopathy patients: what can we expect with P1407
new guidelines?
– A.R. Godinho, M. Vasconcelos, I. Rangel, V. Araujo, C. Frutuoso, J.S. Cardoso, M.J. Maciel (Porto, PT)
N-terminal B-type natriuretic peptide is elevated and strongly associated with higher mortality in P1408
comatose out-of-hospital cardiac arrest patients - a TTM substudy.
– M. Frydland, D. Erlinge, Y. Devaux, H. Friberg, M. Kuiper, N. Nielsen, P. Stammet, M.P. Wise, J. Kjaergaard,
C. Hassager (Copenhagen, DK; Lund and Helsingborg, SE; Luxembourg, LU; Leeuwarden, NL; Cardiff, UK)
Genetic screening identifies a high proportion of mutations in patients with idiopathic ventricular P1409
fibrillation and sudden cardiac death.
– V. Probst, S. Le Scouarnec, F. Kyndt, J.J. Schott, J.B. Gourraud, F. Sacher, P. Mabo, E. Marijon,
R. Redon, X. Jouven (Nantes, Bordeaux-Pessac, Rennes and Paris, FR)
Novel camodulin 2 mutation causes unexplained cardiac arrest in two unrelated infants. P1410
– J. Jimenez Jaimez, M. Alvarez Lopez, A. Ortega, F. Perin, M.M. Rodriguez, R. Melgares Moreno,
L. Tercedor Sanchez (Granada, ES)
101
BASIC MECHANISMS OF ARRHYTHMIAS

Activation of normally quiescent Purkinje-myocardial junctions during acute myocardial ischaemia - an P1411
unexplored arrhythmogenic mechanism.
– F.S. Ng, E. Behradfar, M.T. Debney, A. Nygren, A. Hartley, A.R. Lyon, I.R. Efimov, E. Vigmond, N.S. Peters
(London, UK; Calgary, CA; St. Louis, US; Bordeaux, FR)
Attenuation of CLOCK-BMAL1 decreases the occurrence of ventricular arrhythmia in chronic heart P1412
failure.
– J. Zou, J. Yuan, Z. Qian, Y. Chen, Y. Wang, D. Zhu, P. Ge, X. Hou (Nanjing, CN)
Fibrillatory stress induces mitochondrial remodelling via mitofusin-2 in atrial cardiomyocytes. P1413
– L. Ishaq, M. Bou-Khalil, H. McBride, C. Redpath (Ottawa and Montreal, CA)
Melatonin protects against low potassium induced ventricular fibrillation by preventing dephosphorylation P1414
and redistribution of ventricular connexin-43 in isolated rat hearts.
– E.R. Diez, T. Benova, N.J. Prado, B. Liptak, C. Viczenczova, V. Knezl, R.M. Miatello, B. Becova,
N. Tribulova (Mendoza, AR; Bratislava, SK)
Reduced activity of dorsal vagal preganglionic neurones associated with synuclein pathology P1415
predisposes the heart to ventricular arrhythmia.
– A. Machhada, R. Ang, G. Ackland, N. Ninkina, V. Buchman, M.F. Lythgoe, S. Trapp, A. Tinker, N. Marina,
A.V. Gourine (London and Cardiff, UK)
Heterozygous plakoglobin deficiency results in increased biventricular beta-catenin expression. P1416
– J.K.C. Mak, F. Syeda, T.Y. Yu, E. Vloumidi, K. Gehmlich, P. Kirchhof, L. Fabritz (Birmingham and Oxford,
UK)
The connexin40A96S mutation is arrhythmogenic in mice after transaortic constriction operation. P1417
– J.W. Schrickel, F. Stoeckigt, R. Andrie, G. Nickenig, B. Tippaporn, M. Linhart, R. Meyer (Bonn, DE)
Orthogonal pacing reveals anisotropy in isolated rat atria and direction dependence of novel electrogram P1418
markers on a hitherto unprecedented scale.
– J.A.B. Zaman, S. Al-Aidarous, S. Alayoubi, P.M. Patel, J.D. Simonotto, C.M. Terracciano, N.S. Peters
(Stanford, US; London, UK)
Increased aldosterone-dependent Kv1.5 recycling causes atrial fibrillation in Kcne3−/− mice. P1419
– T.K. Roepke, C.K. Koehncke, B. Spallek, C. Gaertner, N. Lange, N. Wilck, A. Gaburro, U.L. Lisewski (Berlin,
DE)
Mechanisms of fever-induced QT prolongation in patients with KCNH2 mutations in the S5-pore region. P1420
– K. Hayashi, T. Nakajima, S. Tange, T. Tsuda, Y. Tanaka, M. Kawashiri, K. Ohta, Y. Kaneko, M. Kurabayashi,
M. Yamagishi (Kanazawa and Maebashi, JP)
A missense mutation of POPDC1 affecting cAMP-binding causes limb-girdle muscular dystrophy and P1421
cardiac arrhythmia.
– R.F. Schindler, C. Scotton, S.L. Simrick, C. Passarelli, S. Rinne, K.L. Poon, V.O. Nikolaev, N. Decher,
A. Ferlini, T. Brand (London, UK; Ferrara, IT; Marburg and Hamburg, DE)
Aliskiren suppresses extracellular matrix genes in atrial fibrillation - a global mRNA profiling in the canine P1422
experimental atrial fibrillation model.
– J. Kishihara, S. Niwano, H. Niwano, A. Satoh, T. Igarashi, N. Ishizue, T. Yoshizawa, M. Murakami,
H. Fukaya, J. Ako (Sagamihara, JP)
Diagnosis of arrhythmias in patients with unexplained palpitations using long term continuous monitoring. P1423
– T. Faber, K. Rybak, G. Rieger, L. Mangoni, S.H.K. The, G. Tjeerdsma, D. Lebedev, N. Franco, G. De Weerd
(Freiburg and Dessau, DE; Maastricht, Hoogeveen, Heerenveen and Sittard, NL; Rome, IT; St. Petersburg,
RU; Minneapolis, US)
MECHANISMS OF ARRHYTHMIAS AND CHANNELOPATHIES

Three-dimensional (3D) wavemapping of human persistent atrial fibrillation. P1424
– B. Pathik, T. Walters, G. Morris, J. Kalman, G. Lee (Melbourne, AU)
The risk variant rs13143308T on 4q25 predisposes to increased spontaneous calcium release and P1425
hypertrophy in human atrial myocytes.
– A. Herraiz, A. Llach, C. Tarifa, S.A. Serra, C. Munoz-Guijosa, A. Aranega, D. Franco, J. Cinca,
L. Hove-Madsen (Barcelona and Jaén, ES)
Stabilization of A78T-HERG that causes Long QT syndrome type 2 by heat shock protein family. P1426
– T. Kondo, J. Miake, K. Ogura, M. Kato, K. Iitsuka, K. Yamamoto, Y. Shirayoshi, I. Hisatome (Yonago, JP)
ST-segment elevation in Brugada syndrome patients is associated with late activation and fractionated P1427
epicardial electrograms in the right ventricular outflow tract.
– J.N. Ten Sande, R. Coronel, C.E. Conrath, A.H.G. Driessen, J.R. De Groot, H.L. Tan, K. Nademanee,
A.A.M. Wilde, J.M.T. De Bakker, P.F.H.M. Van Dessel (Amsterdam, NL; Los Angeles, US)
Current and expression of hERG mutation L539fs/47-*558W are regulated by chronic intracellular P1428
potassium concentration.
– Y. Lv, Z. Liu, C. Sun, A. Zhang, W. Han, G. Li, J. Wang, S. Pan, J. Pan (Xi’an, CN)
Phase contrast MRI reveals impaired diastolic relaxation and prolonged contraction duration in LQTS P1429
patients.
– J. Brado, M. Dechant, M. Menza, A. Komancsek, J. Geiger, B. Stiller, C. Bode, B.A. Jung, K.E. Odening
(Freiburg, DE; Zurich and Berne, CH)
Pathology and function of conduction tissue in Fabry disease cardiomyopathy. P1430
– A. Frustaci, E. Morgante, M.A. Russo, F. Scopelliti, C. Grande, R. Verardo, P. Franciosa, C. Chimenti
(Rome, IT)
Ranolazine prevents ventricular fibrillation in an experimental whole-heart model of short-QT-syndrome. P1431
– G. Frommeyer, C. Ellermann, S. Kaese, P. Milberg, L. Eckardt (Münster, DE)
102
A novel metric quantifies wavetail and wavefront interaction and identifies sites of potential reentrant P1432
activation.
– M.J. Bishop, N. Child, B. Hanson, R. Coronel, B. Boukens, R.D. Walton, I.R. Efimov, C.A. Rinaldi, J. Gill,
P. Taggart (London, UK; Amsterdam, NL; Washington, US; Bordeaux, FR)
Rare genetic variants previously associated with congenital forms of long QT syndrome have little or no P1433
effect on the QT interval.
– J. Ghouse, C. Theil Have, P. Weeke, J.B. Nielsen, S.P. Olesen, N. Grarup, A. Linneberg, O. Pedersen,
J.K. Kanters, M.S. Olesen (Copenhagen, DK)
Brugada syndrome: time-trend in incidence and prognosis. P1434
– E. Arbelo, J. Hernandez, A. Gomez-Juanatey, R. Borras, S. Vidorreta, J.M. Tolosana, L. Mont, J. Brugada
(Barcelona, ES)
DEVICE THERAPY
Preserved myocardial viability predicts response to cardiac resynchronization therapy better than P1435
targeted left ventricular placement.
– P. Murin, P. Spurny, P. Mitro, G. Valocik (Kosice, SK)
Electrical dyssynchrony in patients with left bundle branch block and factors related to its severity. P1436
– D. Duplyakov, Z. Vozhdaeva, E. Sysuenkova, V. Gluhova, S. Khokhlunov (Samara and Togliatti, RU)
Right ventricular pacing and newly occurrence of atrial fibrillation in patients paced with atrioventricular P1437
block.
– K. Hayashi, H. Abe, M. Fukunami, M. Takahashi, T. Watabe, H. Ohe, R. Kohno, Y. Oginosawa, Y. Otsuji
(Kitakyushu and Osaka, JP)
Involvement of left anterior fascicular block and clinical impact of the intra-ventricular mechanical P1438
SUNDAY – MORNING
dyssynchrony caused by right ventricular pacing among the patients with normal ejection fraction.
– M. Okada, K. Kashiwase, A. Hirata, K. Ueno, R. Amiya, Y. Ueda (Osaka, JP)
Unexpected malfunctions and viability loss with current co-radial pacemaker leads: two-year follow up P1439
study.
– M. Ishimura, M. Ueda, K. Miyazawa, T. Kajiyama, N. Hashiguchi, Y. Kobayashi (Chiba, JP)
Atrial lead characteristics, time from implantation and atrial high rate episodes compatible with silent P1440
atrial fibrillation: an unintentionally provoked situation?
– J. Benezet Mazuecos, J.A. Iglesias, A. Del Rio Lechuga, M. Cortes, J.J. De La Vieja, P.P. Perez,
J.M. Rubio, M.A. Quinones, P. Sanchez-Borque, J. Farre (Madrid and Jerez de la Frontera, ES)
Long lasting ventricular pacing in patients with SSS increases left ventricle diastolic dysfunction and P1441
myocardial fibrosis even after DDD pacing upgrade.
– L. Checinski, A. Slawuta, J. Moszczynska-Stulin, D. Zysko, J. Gajek (Wroclaw and Klodzko, PL)
Bachmann’s bundle pacing reduces the risk of chronic atrial fibrillation development. P1442
– M. Klis, A. Slawuta, P. Skoczynski, J. Moszczynska-Stulin, J. Gajek (Wroclaw and Klodzko, PL)
Puncture with care: as opposed to conventional wisdom, the course of the axillary vein is not reliably P1443
predicted by anatomical landmarks.
– M.O. Schrage, K. Krieger, C. Lenz, M. Walzer, L. Bruch, B. Keweloh (Berlin, DE)
Effectiveness of closed loop stimulation pacing in preventing disabling cardioinhibitory vasovagal P1444
syncope. A single-center experience.
– I. Anguera Camos, F. Rodriguez, A. Di Marco, P. Dallaglio, X. Sabate, A. Cequier (Barcelona, ES)
THROMBOSIS AND COAGULATION

Oxidative profile of intracoronary thrombi in STEMI patients increases with elapsed pain-to-PCI time. P1445
– T. Padro, I. Ramaiola, J. Cubedo, V. Martin-Yuste, M. Sabate, L. Badimon (Barcelona, ES)
In vitro generated high ploidy megakaryocytes show overexpression of genes involved in platelet activity P1446
and thrombosis.
– F.A. Choudry, S. Garcia, K. Downes, M. Kostadima, J. Martin, A. Mathur, M. Frontini, W.H. Ouwehand
(Cambridge and London, UK)
Altered fibrin clot properties affect the angiographic results of primary coronary intervention. P1447
– M. Sadowski, M. Zabczyk, L. Zandecki, A. Undas (Kielce and Krakow, PL)
No links between intracoronary thrombus components and slow reflow after primary coronary P1448
intervention.
– M. Sadowski, M. Zabczyk, L. Zandecki, A. Undas (Kielce and Krakow, PL)
Stent thrombosis in patients treated with bioresorbable vascular scaffolds: a meta-analysis of 7 studies P1449
and 2,568 patients.
– G. Quadri, C. Moretti, F. D’Ascenzo, P. Omede’, A. Montefusco, E. Cerrato, F. Conrotto, C. Templin,
T.F. Luscher, F. Gaita (Turin, Rivoli and Catania, IT; Zurich, CH)
Statin therapy reduces von Willebrand factor antigen levels: A systematic review and meta-analysis of P1450
randomized placebo-controlled trials.
– A. Sahebkar, C. Serban, S. Ursoniu, R. Mihaescu, D.P. Mikhailidis, P. Muntner, J. Rysz, A. Undas,
G.Y.H. Lip, M. Banach (Mashhad, IR; Timisoara, RO; London and Birmingham, UK; Birmingham, US; Lodz
and Krakow, PL)
The safety profile of new cationic dextran heparin antidotes. P1451
– E. Sokolowska, B. Kalaska, K. Kaminski, A. Lewandowska, I. Kasacka, K. Szczubialka, D. Pawlak,
M. Nowakowska, A. Mogielnicki (Bialystok and Krakow, PL)
103
Comparison of circadian laboratory measurements of coagulation assays between administrations of P1452

rivaroxaban and warfarin in patients with non-valvular atrial fibrillation.
– Y. Hitaka, M. Ogawa, S. Goto, Y. Nagata, J. Morii, S. Imaizumi, T. Yasuda, N. Matsumoto, A. Matsunaga,
K. Saku (Fukuoka, JP)
Potential clinical benefits and cost savings associated with inclusion of apixaban in the formulary for P1453
treatment of patients with venous thromboembolism.
– M. Hamilton, R. Leipold, D. Rublee, S. Stern, D. Gabriel, T. Gosden, A. Cohen (Princeton, Bethesda, New
York and Lexington, US; Surrey and London, UK)
PLATELETS, THROMBOSIS AND COAGULATION

TRAP induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran. P1454
– C.B. Olivier, P. Weik, M. Meyer, P. Diehl, Q. Zhou, U. Geisen, C. Bode, M. Moser (Freiburg, DE)
Platelets are permanently activated after splenectomy. P1455
– M. Gerges, C. Gerges, M.K. Frey, S. Panzer, I.M. Lang (Vienna, AT)
Microvascular obstruction in STEMI patients during pPCI is related to the size of the aspirated coronary P1456
artery thrombi and pre-PCI Neutrophil Extracellular Trap levels.
– A.S.A. Autar, M. Kurata, E. Regar, M. Valgimigli, F. Leebeek, F. Zijlstra, M. De Maat, H. Van Beusekom
(Rotterdam, NL)
Clinical determinants of arterial thrombus structure: ultrasctructural and immunohistochemical studies. P1457
– A. Kovacs, P. Sotonyi, A.I. Nagy, L. Szabo, B. Merkely, K. Kolev (Budapest, HU)
C-reactive protein gene variant modifies atherosclerosis in patients with advanced atherosclerosis: P1458
effects on endothelial function, inflammatory and coagulation processes.
– G. Hatzis, N. Papageorgiou, E. Oikonomou, G. Siasos, A. Miliou, S. Papaioannou, C. Antoniades,
S. Papaoikonomou, B. Schieffer, D. Tousoulis (Athens, GR; Marburg, DE)
Plateletcrit and platelet distribution width as predictors of ST elevation myocardial infarction in young P1459
patients.
– M.S. Cetin, E.H. Ozcan Cetin, S. Aydin, E. Kalender, S. Topaloglu, D. Aras, A. Temizhan, S. Aydogdu
(Ankara, TR)
Usefullness of platelet indices as predictors of stent thrombosis in ST elevation myocardial infarction. P1460
– M.S. Cetin, E.H. Ozcan Cetin, S. Aydin, E. Kalender, O. Ozeke, H.L. Kisacik, S. Topaloglu, D. Aras,
S. Aydogdu (Ankara, TR)
Identification of functional proteins related to Factor XIII in platelet lipid rafts. P1461
– V. Rabani, D. Montange, S. Gambert, N. Meneveau, S. Davani (Besançon and Dijon, FR)
Influence of morphine on the effect of clopidogrel and prasugrel in patients with ST elevation myocardial P1462
infarction. Results of the ETAMI trial.
– U. Zeymer, B. Mark, G. Montalescot, H. Thiele, R. Zahn (Ludwigshafen am Rhein and Lübeck, DE; Paris,
FR)
Patients receiving dual antiplatelet therapy and concomitant oral anticoagulation with dabigatran show P1463
increased platelet reactivity.
– M. Witkowski, D. Steffens, A. Chakraborty, A. Hassanein, U. Landmesser, U. Rauch (Berlin, DE)
Dual anti-platelet therapy after drug-eluting coronary stent implantation and risk of adverse cardiac P1464
events associated with surgery - a Danish registry study.
– G. Egholm, T. Thim, K.K.W. Olesen, M. Madsen, H.T. Soerensen, S.E. Jensen, L.O. Jensen,
S.D. Kristensen, H.E. Boetker, M. Maeng (Aarhus, Aalborg and Odense, DK)
PLATELETS AND ANTIPLATELETS THERAPY I
The relation between thrombelastography and long-term poststenting ischemic events: 2 years follow-up P1465
in East Asian patients after 600mg-dose clopidogrel loading.
– X. Hou (Shanghai, CN)
The vasculo-angiogenic and vaso-protective effects of cilostazol in patients with high risk for P1466
cardiovascular disease.
– T.-H. Chao, P.-Y. Liu, W.-C. Tsai, S.-Y. Tseng, Y.-H. Li (Tainan and Kaohsiung, TW)
The effect of PEAR1 genetic variants on antiplatelet therapy among acute coronary syndrome patients P1467
after percutaneous coronary intervention.
– Y. Yao, X.F. Tang, J. Wang, J.H. Zhang, Y.L. Ma, C. He, J.Q. Yuan (Beijing, CN)
A loading dose of aspirin plus clopidogrel is able to offset platelet reactivity in CAD patients carriers of P1468
Glu298Asp polymorphism undergoing elective PCI.
– T. Strisciuglio, G. Di Gioia, V. Legrand, C. De Biase, L. Delrue, J. Bartunek, M. Vanderheyden, B. Trimarco,
W. Wijns, E. Barbato (Naples, IT; Liège and Aalst, BE)
Oral crushed and dispersed ticagrelor 180mg compared to whole tablets of equal dose in STEMI patients P1469
undergoing primary PCI: a pharmacokinetic/pharmacodynamic study (the LIQUID study).
– I. Xanthopoulou, N. Barampoutis, V. Gkizas, C. Vogiatzi, P. Davlouros, G. Hahalis, G. Tsigkas, S. Nylander,
G. Parodi, D. Alexopoulos (Patras, GR; Mölndal, SE; Florence, IT)
High inter-individual variability on platelet inhibition with oral Aspirin compared with intravenous Lysine P1470
Acetylsalicylate in healthy volunteers.
– A.C. Martin Garcia, D. Vivas, E. Bernardo, A. Ortega-Pozzi, G. Tirado, C. Fernandez, I. Vilacosta,
I. Nunez-Gil, C. Macaya, A. Fernandez-Ortiz (Madrid, ES)
Comparative efficacy and safety of prasugrel and clopidogrel in patients with STEMI undergoing primary P1471
PCI in the prasugrel core population in clinical practice. Results of the prospective ALKK-Regist.
– P. Riedmaier, M. Hochadel, R. Zahn, S. Schuhmacher, S. Kerber, A. Elsaesserr, H. Schuehlen, U. Zeymer
(Ludwigshafen am Rhein, Kaiserslautern, Bad Neustadt an der Saale, Oldenburg and Berlin, DE)
104
Associations of plasma microRNAs with platelet proteins and platelet function. P1472
– D. Kaudewitz, P. Skroblin, K. Willeit, P. Willeit, T. Barwari, A. Zampetaki, A.C. Morton, S. Kiechl,
R.F. Storey, M. Mayr (London, Cambridge and Sheffield, UK; Innsbruck, AT)
The role of CYP2C19 and ABCB1 polymorphisms on platelet reactivity during dual antiplatelet therapy. P1473
– X. Hou (Shanghai, CN)
Contemporary antithrombotic strategies in patients with acute coronary syndromes managed without P1474
revascularization: insights from the eyeshot study.
– L. De Luca, S. Leonardi, I.M. Smecca, D. Formigli, D. Lucci, B. Tuccillo, Z. Olivari, M.M. Gulizia,
F.M. Bovenzi, S. De Servi (Rome, Pavia, Palermo, Benevento, Florence, Naples, Treviso, Catania and
Lucca, IT)
PLATELETS AND ANTIPLATELETS THERAPY II

Determinants of post-discharge bleeding events in ACS patients during antiplatelet therapy: insight from P1475
the A-MATCH trial.
– Y.H. Jeong, O.J.H. Oh, S.E.S. Shin, Y.H.J. Yoon, S.J. Suh, L.K.H. Lee, L.S.H. Lee, K.J.H. Kim (Jinju,
Changwon, Ulsan, Daegu, Bucheon, Incheon, Cheonan and Yangsan, KR)
Vitamin D levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with P1476
clopidogrel or ticagrelor.
– M. Verdoia, M. Nardin, C. Sartori, A. Schaffer, G. Di Giovine, P. Marino, H. Suryapranata, G. De Luca
(Novara, IT; Nijmegen, NL)
Real world evaluation of 1st and 2nd generation antiplatelet and anticoagulant therapy in patients P1477
following percutaneous coronary intervention (PCI).
– D.Z.J. Lee, F. Altaf, F. Virani, A. Malik, C. Elorz, A.B. Gopalamurugan, A. Marshall, K. Dickinson,
SUNDAY – MORNING
D.M. Walker, R.T. Gerber (Hastings, UK)
Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment. P1478
– I. Xanthopoulou, C. Vogiatzi, I. Pentara, K. Stavrou, N. Vlassopoulou, A. Perperis, A. Chasapi, I. Koniari,
N. Koutsogiannis, D. Alexopoulos (Patras, GR)
Factors affecting platelet reactivity shortly after P2Y12 receptor antagonist loading in STEMI patients P1479
undergoing primary PCI: the impact of pain-to-loading time.
– I. Xanthopoulou, P. Davlouros, G. Tsigkas, N. Koutsogiannis, I. Pentara, C. Vogiatzi, S. Deftereos,
S. Patsilinakos, G. Hahalis, D. Alexopoulos (Patras and Athens, GR)
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients. P1480
– M. Verdoia, M. Nardin, L. Barbieri, A. Schaffer, P. Marino, H. Suryapranata, G. De Luca (Novara, IT;
Nijmegen, NL)
Platelet alpha2B-adrenergic receptors in patients with coronary artery disease: The anti-aggreganting P1481
effect of their blockade.
– M. Marketou, G. Kochiadakis, N. Androulakis, K. Roufas, J. Kontaraki, J. Logakis, M. Alexandrakis,
I. Gavras, H. Gavras, P. Vardas (Heraklion, GR; Boston, US)
Efficacy and safety of triple therapy with novel oral anticoagulants for ischemic heart disease with atrial P1482
fibrillation in Japan.
– H. Amano, T. Ikeda, M. Toda, R. Okubo, T. Yabe, I. Watanabe, D. Saito (Tokyo, JP)
cMRP4 expression in platelet of patients under chronic aspirin treatment is influenced by microRNA P1483
modulation: a new mechanism for aspirin resistance?
– L.M. Biasucci, C. Mandolini, I. Massimi, G. Copponi, F. Pulcinelli, F. Crea (Rome, IT)
PLATELETS AND ANTIPLATELETS THERAPY III
Single nucleotide polymorphism in glycoprotein VI gene associated with platelet expression of the P1484
glycoprotein VI and risk of cardiovascular events.
– M. Droppa, D. Rath, K. Mueller, F. Stimpfle, A. Alboji, E. Schaeffeler, M. Schwab, M. Gawaz, T. Geisler
(Tübingen and Stuttgart, DE)
The impact of therapeutic hypothermia on on-treatment platelet reactivity and clinical outcome in P1485
cardiogenic shock patients undergoing primary PCI for acute myocardial infarction.
– M. Orban, K. Mayer, I. Bernlochner, T. Morath, S. Braun, S. Schulz-Schupke, H. Schunkert, K.-L. Laugwitz,
D. Sibbing, A. Kastrati (Munich, DE)
Short versus prolonged dual antiplatelet therapy (DAPT) duration after coronary stent implantation: a P1486
comparison between the DAPT trial and 9 other trials evaluating DAPT duration.
– T. Toyota, H. Shiomi, T. Morimoto, M. Natsuaki, T. Kimura (Kyoto, Nishinomiya and Fukuoka, JP)
Janus kinase 3 (JAK3) dependent signaling is critical to Ca2+-dependent platelet activation and thrombus P1487
formation.
– O. Borst, P. Muenzer, B. Walker, A. Fotinos, D. Rath, E. Schaeffeler, M. Schwab, T. Geisler, F. Lang,
M. Gawaz (Tübingen and Stuttgart, DE)
Use of oral anticoagulants in combination with antiplatelet therapy: insights from the GLORIA-AF registry. P1488
– G.Y.H. Lip, J. Halperin, H.C. Diener, S.J. Dubner, C.S. Ma, K.J. Rothman, K. Zint, A. Elsaesser, C. Teutsch,
M.V. Huisman (Birmingham, UK; New York and Research Triangle Park, US; Essen and Ingleheim, DE;
Buenos Aires, AR; Beijing, CN; Burlington, CA; Leiden, NL)
Short versus long term dual antiplatelet therapy after drug eluting stent implantation: systematic review P1489
and meta-analysis of randomized controlled trials.
– P. Villablanca Spinetto, P. Christia, D. Briceno, M. Salih, W. Gonzalez (New York and Chesterfield, US)
105
Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and P1490
clinical end points - International Clopidogrel Pharmacogenomics Consortium (ICPC) study design.
– T.O. Bergmeijer - For The International Clopidogrel Pharmacogenomics Consortium Investigators
(Nieuwegein, NL)
A systematic review and meta-analysis of optimal antiplatelet therapy for diabetic patients with acute P1491
coronary syndrome.
– J. Rossington, O.I. Brown, A. Hoye (Hull, UK)
High on-treatment platelet reactivity (HTPR) with Ticagrelor versus Prasugrel: a comprehensive P1492
meta-analysis.
– G. Lemesle, G. Schurtz, C. Bauters, M. Hamon (Lille and Caen, FR)
Antiplatelet effect of clopidogrel monotherapy in patients with oral anticoagulation with phenprocoumon P1493
undergoing coronary stent implantation.
– T. Boemicke, D. Trenk, C. Stratz, S. Leggewie, N. Loeffelhardt, C. Valina, M. Gick, H.J. Buettner,
F.J. Neumann, W. Hochholzer (Bad Krozingen, DE)
PLATELETS AND ANTIPLATELETS THERAPY IV
Platelet surface expression of TGF-beta1 is associated with platelet surface expression of SDF-1, CXCR4 P1494
and CXCR7.
– D. Rath, M. Chatterjee, O. Borst, K. Mueller, M. Gawaz, T. Geisler (Tübingen, DE)
Comparison of short-term clinical outcomes between new p2y12 receptor inhibitors and clopidogrel in P1495
patients with acute myocardial infarction: from the core cohort in Korea.
– K.-H. Park, M.-H. Jeong, H.-K. Kim, D.-S. Sim, Y.-J. Hong, J.-H. Kim, Y.-K. Ahn, S.-C. Cho, Y.-J. Kim,
H.-S. Kim (Gwangju, Daegu and Seoul, KR)
High on aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing P1496
PCI (RECLOSE2-ACS study).
– R. Marcucci, A.M. Gori, R. Paniccia, E. Grifoni, B. Giusti, R. Valenti, G. Parodi, G.F. Gensini, D. Antoniucci,
R. Abbate (Florence, IT)
Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. P1497
– R.F. Storey, D.L. Bhatt, P.G. Steg, G.W. Stone, H.D. White, C.M. Gibson, C.W. Hamm, J. Prats,
K.W. Mahaffey, R.A. Harrington (Sheffield, UK; Boston, New York, Parsippany and Stanford, US; Paris, FR;
Auckland, NZ; Bad Nauheim, DE)
Dual anti-platelet therapy after drug-eluting coronary stent implantation and risks associated with P1498
gastroscopy - a Danish registry study.
– G. Egholm, T. Thim, M. Madsen, H.T. Soerensen, S.E. Jensen, L.O. Jensen, S.D. Kristensen, H.E. Boetker,
M. Maeng (Aarhus, Aalborg and Odense, DK)
Effect on clinical outcomes of short or long duration of dual antiplatelet therapy after drug-eluting stents: P1499
a meta-analysis of randomized trials.
– G. Ferrante, P. Pagnotta, S. Ariotti, P. Calabro’, E. Moscarella, P. Presbitero, E. Corrada, M. Valgimigli
(Rozzano and Naples, IT; Rotterdam, NL)
Platelet function in the acute phase of stent thrombosis - the prestige registry. P1500
– T.C. Godschalk, W. Desmet, L. Feldman, G. Guagliumi, N. Malik, F.J. Neumann, R.A. Byrne, A.H. Goodall,
S. Massberg, J.M. Ten Berg (Nieuwegein, NL; Leuven, BE; Paris, FR; Bergamo, IT; Leicester, UK; Bad
Krozingen and Munich, DE)
Risk and benefits of triple therapy in patients undergoing percutaneous coronary stent implantation P1501
requiring chronic oral anticoagulation: a meta-analysis of 12 trials.
– L. Barbieri, M. Verdoia, P. Marino, H. Suryapranata, G. De Luca (Novara, IT; Nijmegen, NL)
Comparison of in-hospital clinical outcomes between ticagrelor versus clopiodogrel in patients with P1502
acute myocardial infarction undergoing successful revascularization.
– K.-H. Park, M.-H. Jeong, H.-K. Kim, D.-S. Sim, Y.-J. Hong, Y.-K. Ahn, S.-H. Kim, T.-H. Ahn, D.-J. Oh,
Y.-J. Kim (Gwangju, Suncheon, Incheon, Seoul and Daegu, KR)
Dual anti-platelet therapy after drug-eluting coronary stent implantation and risks associated with P1503
colonoscopic or rectoscopic polypectomy - a Danish registry study.
– S.B. Heintzelmann, G. Egholm, J.B. Pedersen, T. Thim, M. Madsen, H.T. Soerensen, L.O. Jensen,
S.D. Kristensen, H.E. Boetker, M. Maeng (Aarhus and Odense, DK)
Stent thrombosis after second generation drug-eluting stent implantation and duration of dual antiplatelet P1504
therapy.
– H. Amano, K. Kadota, S. Otsuru, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto,
K. Mitsudo (Kurashiki, JP)
MISCELLANEOUS
Access site versus non-access site bleeding in primary PCI: Incidence, impact on mortality and risk P1505
reduction according to antithrombin treatment. The EUROMAX trial.
– S. Kilic, A.W.J. Van ’T Hof, J.M. Ten Berg, A. Ayesta Lopez, U. Zeymer, M. Hamon, L. Soulat, D. Bernstein,
E.N. Deliargyris, P.G. Steg (Zwolle and Nieuwegein, NL; Madrid, ES; Ludwigshafen am Rhein, DE; Caen,
Chateauroux and Paris, FR; Parsippany, US)
Coronary index of microcirculatory resistance and echocardiographic parameters evolution in patients P1506
with ST-elevation acute myocardial infarction treated with primary angioplasty.
– M. Faustino, S. Bravo Baptista, A. Freitas, C. Monteiro, P. Leal, M. Nedio, C. Antunes, P. Farto E Abreu,
V.M. Gil, C. Morais (Amadora, PT)
106
Microvascular dysfunction following ST-segment elevation myocardial infarction is associated with short P1507
and long term cardiac function assessed by cardiac magnetic resonance imaging.
– M.E.C.J. Hassell, R. Delewi, M.A. Lavieren, R. Nijveldt, A. Hirsch, L. Robbers, K.M. Marques, F. Zijlstra,
A.C. Van Rossum, J.J. Piek (Amsterdam, NL)
Association of SDF-1 polymorphisms with differential platelet CXCR4 expression in patients with P1508
– D. Rath, M. Chatterjee, O. Borst, K. Mueller, S. Winter, M. Schwab, M. Gawaz, T. Geisler (Tübingen and
Stuttgart, DE)
Predictive factors of left ventricular thrombus after myocardial infarction using cardiovascular magnetic P1509
imaging.
– M. Audonnet (Angers, FR)
Risk-treatment paradox in anticoagulation therapy selection: Insights from a single center PCI registry. P1510
– I. Mastoris, M. Aquino, S. Roy, P. Krishnan, R. Mehran, G. Dangas, P. Moreno, J. Kovacic, A. Kini,
S. Sharma (New York, US)
Association of a reduced antiplatelet activity of CYP3A4-metabolized statin with clinical outcomes during P1511
dual antiplatelet therapy following percutaneous coronary intervention.
– J.S. Park, K.S. Cha, J.H. Choi, B. Kim, H.W. Lee, J.H. Oh, J.H. Choi, H.C. Lee, T.J. Hong, H.S. Kim (Busan
and Seoul, KR)
Discontinuation rates in patients with non-valvular atrial fibrillation treated with non-vitamin K antagonist P1512
oral anticoagulants are mainly related to drug specific side effects and bleeding.
– F. Al-Khalili, C. Lindstrom, A. Majeed (Stockholm, SE)
Patterns of uptake of non-vitamin K antagonist oral anticoagulants in Europe: an analysis from the P1513
GARFIELD-AF registry.
– A.J. Camm, G. Ambrosio, D. Atar, J.-P. Bassand, F. Cools, K.A.A. Fox, P. Jansky, M. Keltai, J.-Y. Le
SUNDAY – MORNING
Heuzey, A.K. Kakkar (London and Edinburgh, UK; Perugia, IT; Oslo, NO; Besançon and Paris, FR;
Brasschaat, BE; Prague, CZ; Budapest, HU)
Risk factors for major bleeding and efficacy of modified HAS-BLED score in patients on oral P1514
anticoagulation after coronary artery stenting.
– A. Kuwayama, K. Kadota, S. Habara, H. Tanaka, K. Maruo, Y. Fuku, H. Kato, S. Fujii, T. Goto, K. Mitsudo
(Kurashiki, JP)
D-dimer levels in patients with acute chest pain. P1515
– Y. Kotani, M. Toyofuku, T. Tamuta, T. Hamasaki, T. Tsujimoto, T. Chishiro (Wakayama, JP)
Use of antithrombotic therapy in patients with atrial fibrillation and prior stroke: insights from the global P1516
GLORIA-AF registry.
– G.Y.H. Lip, J.L. Halperin, H.C. Diener, S.J. Dubner, C.S. Ma, K.J. Rothman, K. Zint, A. Elsaesser,
M. Paquette, M.V. Huisman (Birmingham, UK; New York and Research Triangle Park, US; Essen and
Ingelheim am Rhein, DE; Buenos Aires, AR; Beijing, CN; Burlington, CA; Leiden, NL)
CARDIOVASCULAR MAGNETIC RESONANCE IN CLINICAL PRACTICE I

Detection and dynamics of ventricular thrombus by CMR after reperfused ST-segment elevation P1517
– C. Bonanad Lozano, J.V. Monmeneu, M.P. Lopez-Lereu, J. Gavara, A. Paya, D. Escribano, P. Racugno,
A. Hervas, F.J. Chorro, V. Bodi (Valencia, ES)
Prediction of reverse remodeling by cardiac mr imaging soon after a first ST-segment elevation P1518
myocardial infarction. Results of a large prospective registry.
– E. Cambronero Cortinas, C. Bonanad, J.V. Monmeneu, M.P. Lopez-Lereu, A. Paya, D. Escribano,
J.T. Ortiz, X. Bosch, F.J. Chorro, V. Bodi (Valencia and Barcelona, ES)
Natural history and clinical significance of infarct zone extracellular volume and remodelling in survivors P1519
of acute STEMI.
– J. Carberry, D. Carrick, C. Haig, S.M. Rauhalammi, N. Ahmed, M. McEntegart, A. Mahrous, A. Radjenovic,
The additive value of cardiovascular magnetic resonance first pass perfusion in diagnosis of P1520
microvascular disease in a population with chest pain and normal coronary arteries.
– C.E. Raphael, L.Y. Hsu, A. Greve, P. Gatehouse, C. Di Mario, J. Collinson, D.J. Pennell, A.E. Arai,
S.K. Prasad (London, UK; Washington, US)
Mitral annular plane excursion measured during routine cine-cardiac magnetic resonance imaging is a P1521
predictor of adverse cardiac events in patients with known or suspected coronary artery disease.
– S.J. Chacko, V. Rangarajan, N. Jariwala, S. Romano, J. Chung, S. McGraw, A. Farzaneh-Far (Chicago, US;
Verona, IT)
Temporal evolution and prognostic significance of infarct core pathology in ST-elevation myocardial P1522
infarction survivors revealed by serial quantitative T2-weighted cardiac magnetic resonance.
– D.J.A. Carrick, C. Haig, N. Ahmed, H. Eteiba, S. Hood, M. Petrie, M. Lindsay, A. Radjenovic, K.G. Oldroyd,
C. Berry (Glasgow, UK)
Cardiac magnetic resonance findings in active rheumatoid arthritis. P1523
– S. Kivisto, R. Koivuniemi, K. Korpi, T. Kaasalainen, M. Laine, M. Kupari, M. Leirisalo-Repo, M. Holmstrom
(Helsinki, FI)
1,5 T MRI in patients with classical cardiac implantable electronic devices: previous uncomplicated MRI P1524
study does not guarantee safety but increases the risk of adverse events.
– L. Hawryluk (Warsaw, PL)
Relationship of left atrial delayed enhancement magnetic resonance imaging with clinical parameters and P1525
outcome after ablation in lone atrial fibrillation.
– J. Ahn, D.H. Kim, S.Y. Roh, D.I. Lee, J.I. Choi, J. Shim, S.W. Park, Y.H. Kim (Seoul, KR)
107
CARDIOVASCULAR MAGNETIC RESONANCE IN CLINICAL PRACTICE II

The left ventricular apical aneurysms in Chinese hypertrophic cardiomyopathy. P1526
– C. Yan, H. Li, W. Fang, L. Li (Beijing, CN)
Clinical impact and usefulness of native T1 mapping in patients with idiopathic dilated cardiomyopathy. P1527
– E. Tateishi, T. Noguchi, Y. Morita, H. Ogawa, S. Yasuda (Suita, JP)
Substrates and predictors of acute and late myocardial dysfunction in acute myocarditis: a study P1528
performed by contrast enhancement cardiac magnetic resonance.
– M. De Lazzari, A. Susana, M.M. Marinato, F. Marin, A. Cipriani, B. Giorgi, L. Cacciavillani, D. Corrado,
M. Perazzolo Marra, S. Iliceto (Padua, IT)
Significant improvement of survival by T2* CMR in thalassemia major. P1529
– A. Pepe, A. Meloni, G.C. Del Vecchio, M.A. Romeo, M.R. Gamberini, F. Bonetti, M.G. Neri, G. Restaino,
V. Positano, C. Borgna-Pignatti (Pisa, Bari, Catania, Ferrara, Pavia and Campobasso, IT)
Combined high-resolution fibrosis and perfusion mapping by cardiac magnetic resonance in hypertrophic P1530
cardiomyopathy.
– A. Villa, E. Sammut, N. Zarinabad, G. Carr-White, N. Bettencourt, E. Nagel, R. Razavi, A. Chiribiri (London,
UK; Porto, PT)
Prospective changes of left ventricular iron and function by MR in pediatric thalassemia major patients P1531
treated with different chelators or not chelated.
– A. Meloni, L. Pitrolo, M.G. Neri, C. Salvatori, B. Pagano, P. Preziosi, M. Missere, G. Valeri, V. Positano,
A. Pepe (Pisa, Palermo, Locri, Rome, Campobasso and Ancona, IT)
Cardiac involvement in female Duchenne and Becker muscular dystrophy carriers in comparison to their P1532
first degree male relatives a CMR study.
– A.R. Florian, S. Roesch, M. Bietenbeck, U. Sechtem, A. Yilmaz (Münster and Stuttgart, DE)
A prospective CMR study of cardiac iron and function in non-trasfusion-dependent thalassemia P1533
intermedia patients treated with desferrioxamine.
– A. Meloni, M.P. Carta, C. Paci, S. Macchi, M.G. Neri, P. Preziosi, G. Restaino, V. Positano, D. De Marchi,
A. Pepe (Pisa, Cagliari, Montevarchi, Ravenna, Rome and Campobasso, IT)
Left ventricle myocardial edema as the substrate underlies transient T-wave inversion in acute P1534
myocarditis.
– M. De Lazzari, A. Baritussio, M. Siciliano, A. Zorzi, M.M. Marinato, F. Marin, B. Giorgi, S. Iliceto,
M. Perazzolo Marra, D. Corrado (Padua, IT)
Pre-contrast T1-mapping and extracellular volume mapping for the assessment of myocardial fibrosis: A P1535
validation with histologic sample.
– S. Nakamori, K. Dohi, M. Ishida, Y. Goto, T. Omori, N. Fujimoto, K. Kitagawa, N. Yamada, H. Sakuma,
M. Ito (Tsu, JP)
ECG, ARRHYTHMIA ANALYSIS, SIGNAL PROCESSING

Increased resting level of periodic repolarization dynamics predicts exercise-induced T-wave alternans. P1536
– A. Bauer, K.D. Rizas, W. Hamm, T. Nieminen (Munich, DE; Helsinki, FI)
Early repolarization pattern in patients with false tendons. P1537
– A.M. Ragab, Y. Yazeed, W. El-Naggar, A.M. Abdelwahab (Cairo, EG)
Sensitivity and specificity of an electrocardiogram in detecting left ventricular hypertrophy in a native P1538
tanzanian population.
– P. Chillo, J. Lwakatare, J. Lutale (Dar es Salaam, TZ)
Heart rate impact on heart rate variability prognostic value is different for different indices and outcomes. P1539
– J. Sacha, S. Barabach, G. Statkiewicz-Barabach, K. Sacha, A. Muller, P. Barthel, G. Schmidt (Opole,
Wroclaw and Krakow, PL; Munich, DE)
Combination of ECG electrical myocardial instability markers in patients with idiopathic ventricular P1540
arrhythmia.
– T.A. Kurilenko, E.V. Parmon, T.E. Tulintseva, M.S. Gordeeva, T.V. Treshkur, E.V. Shlyakhto (St. Petersburg,
RU)
Which QT correction formula should be implemented in a computer-based hospital-wide QT-monitoring P1541
system?
– B. Vandenberk, E. Vandael, I. Spriet, C. Garweg, J. Vandenberghe, B. Van Den Bosch, V. Foulon, J. Ector,
R. Willems (Leuven, BE)
ECG markers of electrical myocardial instability in patients with or without coronary artery disease. P1542
– T.A. Kurilenko, E.V. Parmon, T.E. Tulintseva, T.V. Treshkur, E.V. Shlyakhto, E.A. Ryngach, M.S. Gordeeva
(St. Petersburg, RU)
The electrocardiogram (ECG) is a poor diagnostic tool for the detection of left ventricular hypertrophy P1543
(LVH) in elderly patients with aortic stenosis.
– R. Kanyal, A. Constantine, P. Sawhney, A. Duncan, S.W. Davies, C. Di Mario, A.C. Lindsay, N.E. Moat
(London, UK)
Clinical significance of ventricular arrhythmias in patients with sickle cell disease. P1544
– J. Inamo, G. Loko, R. Ifrim, F. Demoniere, S. Alexis-Fardini, A. Inamo (Fort de France, FR; Lamentin, MQ)
Evaluation of changes in T-wave alternans induced by 21-days of bedridden immobilization by head-down P1545
bed-rest.
– A. Martin-Yebra, J.P. Martinez, V. Monasterio, P. Laguna, E.G. Caiani (Milan, IT; Zaragoza, ES)
108
E-CARDIOLOGY OTHER
Non-invasive acoustic detection of coronary artery disease. P1546
– S.E. Schmidt, S. Winther, N.R. Holm, H.E. Boetker, E. Toft, P. Clemmensen, J.J. Struijk, M. Boettcher
(Aalborg, Herning, Aarhus and Copenhagen, DK; Doha, QA)
Continuous monitoring with an implantable loop recorder improves outpatient heart failure care. P1547
– R. Tukkie, R. Tukkie, Y. Tuininga, H. Bosker, R. Kort, M. Janssen (Haarlem, Deventer and Arnhem, NL)
Heart failure telemonitoring in Japan and Sweden: the gap between research and practice. P1548
– N. Kato, P. Johansson, I. Okada, A.E. De Vries, K. Kinugawa, A. Stromberg, T. Jaarsma (Linköping, SE;
Tokyo, JP; Groningen, NL)
Body surface potential mapping in patients with arrhythmogenic rightventricular cardiomyopathy: spread P1549
of QRS notches and epsilon waves.
– D. Brala, A. Gapelyuk, U. Landmesser, O. Goeing, A. Schirdewan (Berlin, DE)
Mechanisms Enabling Limited Ablation to Terminate Human AF: In silico and clinical studies. P1550
– J.A.B. Zaman, G. Lalani, T. Baykaner, D.E. Krummen, P.J. Wang, S.M. Narayan, W.J. Rappel (Stanford and
San Diego, US)
Noninvasive measurement of stroke volume using impedance cardiography. P1551
– I. Nederend, A.D.J. Ten Harkel, J.C.N. De Geus, N.A. Blom (Amsterdam and Leiden, NL)
Artificial intelligence in cardiac imaging. Applications on hand held echo - preliminary data. P1552
– M. Mazzanti, F. Carlino (Ancona and Rome, IT)
Variability of minimal fibrous cap thickness measurement and reproducibility of categorization of P1553
fibroatheroma using a software based semiquantitative versus manual measurement.
– K. Yamaji, M.D. Radu, H.M. Garcia-Garcia, M. Taniwaki, P.W.J.C. Serruys, S. Windecker, J. Dijkstra,
L. Raber (Berne, CH; Copenhagen, DK; Rotterdam and Leiden, NL)
Interobserver and intraobserver validation of a novel echocardiographic 3D automated software for the P1554
SUNDAY – MORNING
assessment of mitral valve anatomy.
– I. Aquila, A. Gonzalez, C. Fernandez Golfin, L.M. Rincon, R. Hinojar, E. Casas, S. Ruiz, V. Barrios,
J.J. Jimenez Nacher, J.J. Zamorano (Madrid, ES)
Ritmo project (real time continuous web monitoring) a model of a multidisciplinary approach for safely P1555
managing of new therapies.
– S. Nodari, M. Triggiani, L. Lupi, A. Manerba, E. Rocco, C. Villa, N. Dasseni, G. Milesi, N. Berlinghieri,
F. Glisenti (Brescia, IT)
REGULATORS OF VASCULAR GROWTH AND FUNCTION
The neuropeptide catestatin influences cardiac vascular cell function and inhibits cardiomyocyte P1556
apoptosis in-vivo.
– M. Theurl, D. Lener, U. Stanzl, A. Beer, W.-M. Franz, R. Kirchmair (Innsbruck, AT)
Protein phosphatase 1 beta is modulated by chronic hypoxia and involved in the angiogenic endothelial P1557
cell migration.
– D. Iacobazzi, I. Garaeva, A. Albertario, M. Cherif, G. Angelini, M. Caputo, M.T. Ghorbel (Bristol, UK;
Chicago, US)
Glucagon-like peptide-1 (GLP-1) directly promotes angiogenesis via PKA/AMPK -dependent autophagy in P1558
endothelial cells.
– T.M. Mitsui, Y. Kureishi Bando, A.H. Monji, M. Aoyama, H.K. Kawase, H.K. Nishimura, T.M. Murohara
(Nagoya, JP)
Fenofibrate rescues diabetes-related impairment of ischaemia-mediated angiogenesis by ppar alpha P1559
independent modulation of thioredoxin interacting protein.
– J. Yuan, K. Rajamani, E. King, C. Bursill, L. Lecce, A. Jenkins, A. Keech, M. Ng (Sydney, AU)
Hedgehog signaling pathway in brain arteriovenous malformations. P1560
– R. Pola, I. Gatto, I. Giarretta, M. Marcantoni, C. Sturiale, A. Puca (Rome, IT)
Colchicine reduces plaque inflammation and fibrosis and prevents vascular remodelling in atherosclerotic P1561
rabbits.
– N. Merlet, F. Roubille, E. Rheaume, Y. Shi, T. Mihalache-Avram, D. Rivas, M. Mecteau, G. Brand,
D. Busseuil, J.C. Tardif (Montreal, CA)
Wars2 regulates cardiac angiogenesis. P1562
– M. Wang, P. Sips, E. Khin, M. Rotival, X. Sun, N. Hubner, M. Pravenec, E. Petretto, C. Macrae, S.A. Cook
(Singapore, SG; Boston, US; London, UK; Berlin, DE; Prague, CZ)
Circulating annexin A5 levels are related to carotid intima-media thickness but not coronary plaque P1563
composition.
– M. Burgmaier, S. Reith, L. Schurgers, N. Marx, C. Reutelingsperger (Aachen, DE; Maastricht, NL)
The comparison of flow-mediated dilatation and EndoPAT-reactive hyperemia index in patients with P1564
impaired glucose metabolism.
– H. Tsubata, T. Sawada, Y. Yasaka, H. Kawai, M. Yokoyama (Himeji, JP)
Usefulness of brachial flow-mediated dilation and platelet function to predicts long-term adverse clinical P1565
events in subjects without heart disease.
– M. Shechter, A. Shechter, H. Hod, R. Beigel, N. Koren-Morag, S. Matetzky (Tel Hashomer and Tel Aviv, IL)
109
RISK FACTORS FOR ENDOTHELIAL DYSFUNCTION

Tissue accumulation of Advanced Glycation Endproducts is increased in patients with an Abdominal P1566
Aortic Aneursym but does not predict all-cause mortality during 7 year follow-up.
– J. Boersema, L.C. De Vos, D.J. Mulder, R.P.F. Dullaart, A.J. Smit, C.J. Zeebregts, J.D. Lefrandt (Groningen,
NL)
Lower level of serum asymmetric dimethylarginine contributes to improving vascular endothelial function P1567
after short-term resistance training in healthy elderly people.
– R. Shimizu, M. Kato, Y. Kamada, S. Tanaka, N. Hamazaki, D. Kamekawa, A. Akiyama, T. Nakamura,
K. Yabu, T. Masuda (Sagamihara, JP)
Angiotensin ii downregulates mircrorna-145 to regulate kruppel-like factor 4 and myocardin expression in P1568
human coronary arterial smooth muscle cells under high glucose conditions.
– K.G. Shyu, W.P. Cheng, B.W. Wang (Taipei, TW)
Acute administration of dietary nitrate improves endothelial function and vascular stiffness in P1569
– S. Velmurugan, S.M. Ghosh, R.S. Khambata, S. Van Eijl, A. Robertson, T.A. Chowdhury, A. Ahluwalia
(London, UK)
Pharmacological effects of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha) - P1570
Controlling the plasma HDL-C and triglycerides, and prevention of atherosclerosis in experimental
animals.
– T. Takizawa, S. Goto, Y. Inokuchi, S. Miyata, Y. Yoshinaka, H. Yamazaki, K. Inoue, S. Tanabe
(Higashimurayama and Tokyo, JP)
Vascular ageing is apparent during an oral glucose challenge in healthy persons. P1571
– H. Dominguez, O. Bin Abdullah, J. Raunsoe, T.S. Hermann, T.J. Guterbaum, A.T. Major-Pedersen,
N. Ihlemann, C.T. Torp-Pedersen (Copenhagen, Herlev and Aalborg, DK)
Metabolic syndrome accelerates endothelial aging in younger subjects. P1572
– D. Terentes-Printzios, C. Vlachopoulos, P. Xaplanteris, N. Ioakeimidis, P. Pietri, K. Aznaouridis,
M. Abdelrasoul, I. Gourgouli, E. Paschalidis, D. Tousoulis (Athens, GR)
Role of metabolomics in interpreting the origin of pulmonary arterial hypertension in patients with P1573
systemic sclerosis.
– F. Ascedu, M. Deidda, C. Cadeddu, S. Orofino, S. Palmas, G. Giau, M. Mura, P.E. Manconi, G. Finco,
G. Mercuro (Monserrato, IT)
Increased endothelial activation is associated with impaired improvement of exercise capacity after P1574
exercise training in patients with type 2 diabetes and coronary artery disease.
– R. Byrkjeland, I.U. Njerve, H. Arnesen, S. Solheim, I. Seljeflot (Oslo, NO)
JNK inhibition mimics the beneficial effect of Roux-en-Y gastric bypass surgery on obesity-induced P1575
endothelial dysfunction.
– P. Doytcheva, E. Osto, T. Baechler, E. Tarasco, M. Bueter, C.M. Matter, T.A. Lutz, T.F. Luescher (Schlieren
and Zurich, CH)
Maternal cardiovascular effects of placental dysfunction in the 2nd trimester. P1576
– K. McLaughlin, R. D’Souza, M. Hladunewich, J. Parker, J. Kingdom (Toronto, CA)
Impaired endothelial function and arterial stiffness in patients with pseudoexfoliative glaucoma. P1577
– G. Siasou, G. Siasos, M. Moschos, N. Gouliopoulos, E. Oikonomou, T. Paraskevopoulos, M. Zaromytidou,
K. Mourouzis, S. Tsalamandris, D. Tousoulis (Athens, GR)
LIPIDS IN ATHEROSCLEROSIS
Modulation of cardiac structure by epicardial adipokines. P1578
– G. Conceicao, N. Goncalves, I. Falcao-Pires, D. Fontoura, S. Leite, A.P. Lourenco, A.F. Leite-Moreira
(Porto, PT)
Differentially expressed microRNAs in human peripheral blood mononuclear cells are potential markers P1579
for statin response.
– L. Salazar, T. Zambrano, M. Hirata, A. Cerda, R.D.C. Hirata (Temuco, CL; São Paulo, BR)
Novel mechanisms of modulating reverse cholesterol transport by heat shock protein 27. P1580
– E. O’Brien, A. Adijiang, C. Shi (Calgary, CA)
Vitamin D deficiency and VDR genotypes as nonclassic risk factors for dyslipidemia. P1581
– E. Tsvetkova (St. Petersburg, RU)
Local production of fatty acid-binding protein 4 in the epicardial/perivascular fat and macrophage leads P1582
to coronary atherosclerosis.
– M. Furuhashi, T. Fuseya, S. Ishimura, T. Mita, K. Hoshina, Y. Watanabe, A. Omori, M. Tanaka, H. Yoshida,
Expression level of fatty acid-binding protein 5 increased in pro-inflammatory macrophage with P1583
atherosclerotic lesion formation; evaluation as a potential biomarker for atherosclerosis imaging.
– Y. Shimizu, H. Hanzawa, Y. Zhao, S. Zhao, T. Sakamoto, N. Tamaki, Y. Kuge (Sapporo and Kokubunji, JP)
Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of P1584
virtual histology-intravascular ultrasound studies.
– M. Banach, C. Serban, A. Sahebkar, D.P. Mikhailidis, S. Ursoniu, S. Mosteoru, K.K. Ray, J. Rysz,
H.M. Garcia-Garcia, P.W.J.C. Serruys (Lodz, PL; Timisoara, RO; Mashhad, IR; London, UK; Rotterdam, NL)
RVX-208, an orally active BET inhibitor, lowers CVD risk by activities beyond raising ApoA-1/HDL. P1585
– E. Kulikowski, L. Tsujikawa, D. Gilham, S. Wasiak, C. Halliday, K. Lebioda, J. Johansson, M. Sweeney,
N. Wong (Calgary, CA; San Francisco, US)
110
Circulating soluble low density lipoprotein receptor-related protein 1 (sLRP1) is related to vascular lipid P1586
burden.
– D. De Gonzalo Calvo, A. Cenarro, M. Martinez-Bujidos, L. Badimon, A. Bayes-Genis, J. Ordonez-Llanos,
F. Civeira, V. Llorente-Cortes (Barcelona, Zaragoza and Badalona, ES)
Gold nano particles, conjugated to HDL Reduces Lp-PLA2 level in human macrophages. P1587
– E. Harari, D. Leshem-Lev, R. Ankri, D. Fixler, R. Kornowski, E.I. Lev (Petah Tikva and Ramat Gan, IL)
Reactive hyperaemia index and detection of endothelial dysfunction in children with familial P1588
hypercholesterolaemia.
– P. Jehlicka, M. Huml, A. Masopustova, L. Trefil, J. Kobr, J. Sykora (Pilsen, CZ)
MITRAL VALVE DISEASE

Release of interferon-gamma by activated CD8-positive T cells in human calcified aortic valves fosters P1589
formation of osteoclasts with impaired calcium resorptive potential.
– E. Nagy, Y. Lei, E. Martinez Martinez, S.C. Body, A. Assmann, P. Libby, G.K. Hansson, E. Aikawa (Boston,
US; Stockholm, SE)
Clinical use of the cardiovascular medicine heart failure (CVM-HF) index in mitraclip population. P1590
– V. Cammalleri, S. Muscoli, M. Macrini, A. Anceschi, G. Pascuzzo, E. Maio, F. De Persis, M. Marchei,
G.P. Ussia, F. Romeo (Rome, IT)
Differential effects of percutaneous edge-to-edge mitral valve repair on endothelial function based on left P1591
ventricular function.
– D. Duesing, E. Lubos, U. Schaefer, S. Blankenberg, S. Baldus, V. Rudolph (Hamburg and Cologne, DE)
Morphometric differences between primary and secondary mitral regurgitation evaluated by 3D P1592
transoesophageal echocardiography.
SUNDAY – MORNING
– E. Bourni, R. Rajani, V. Bapat, A. Krommydas, S. Kapetanakis (London, UK)
Mitral valve area obtained by the novel 3D PISA method has a statistically significant correlation with P1593
pulmonary artery systolic pressure in mitral stenosis.
– H. Mejia, J.A. De Agustin Loeches, D. Viliani, J.J. Gomez De Diego, C. Almeria, J.L. Rodrigo, P. Mahia,
M.A. Garcia-Fernandez, C. Macaya, L. Perez De Isla (Madrid, ES)
Impaired radial and circumferential myocardial contraction assessed by speckle tracking P1594
echocardiography accounts for ischemic mitral regurgitation in acute inferoposterior myocardial
infarction.
– Z. Valuckiene, J. Ovsianas, R. Ablonskyte-Dudoniene, V. Mizariene, R. Pranevicius, R. Jurkevicius (Kaunas,
LT)
Calcium-phosphate metabolism disturbances and physical activity in patients with significant mitral P1595
regurgitation.
– O. Mozenska, A. Segiet, D. Rabczenko, D.A. Kosior (Warsaw, PL)
Interventional paravalvular leakage closure after surgical and interventional heart valve replacement - P1596
midterm results.
– M. Weber, R. Schueler, D. Momcilovic, J.M. Sinning, N. Werner, E. Grube, F. Mellert, A. Welz, G. Nickenig,
C. Hammerstingl (Bonn, DE)
Importance of heart failure evaluation in patients undergoing mitraclip. P1597
– M. Neuss, H. Kaneko, T. Schau, J. Weissenborn, M. Schoepp, M. Seifert, C. Butter (Bernau bei Berlin, DE)
Survival and clinical outcome in functional mitral regurgitation: percutaneous mitral valve repair vs P1598
conservative treatment.
– M. Faggioni, F. Fiorelli, C. Giannini, M. De Carlo, A.S. Petronio, F. Guarracino (Pisa, IT)

Gender-related comparison in early and late outcomes after transcatheter aortic valve replacement. P1599
– M. Magalhaes, R. Torguson, S. Kiramijyan, E. Koifman, J. Gai, R. Escarsega, N. Baker, L. Satler,
A. Pichard, R. Waksman (Washington, US)
Concomitant mitral regurgitation increases mortality in high-risk patients with severe aortic stenosis P1600
treated with transcatheter aortic valve replacement.
– S. Haussig, N. Mangner, F. Woitek, J. Wilde, G. Stachel, S. Leontyev, D. Holzhey, F.W. Mohr, G. Schuler,
A. Linke (Leipzig, DE)
Peak aortic velocity correlates with serum leukotriene B4, metalloproteinase-2 and IFN gamma in P1601
calcified aortic valve disease.
– M. Springall, R. Bojalil, J. Cossio-Aranda, N. Espinola, J. Verdejo-Paris, S. Trevethan (Mexico City, MX)
When does the bicuspid aortopathy begin? P1602
– E.G. Milano, M.A. Prioli, L. Zanolla, M. Rebonato, C. Sandrini, G. Dolci, L. Rossetti, C. Vassanelli (Verona, IT)
The influence of endothelin-1, hs-CRP, coronary artery plaque burden and plaque morphology on calcific P1603
aortic valve disease.
– V. Appadurai, K. Nel, C.M. Anstey, R. Senior, C.D. Byrne, J.C. Kaski, R. Bull, C.J. Boos, E. Carlton,
K. Greaves (Nambour, AU; Dorset, London and Southampton, UK)
Transcatheter aortic valve replacement improves functional mitral regurgitation. P1604
– E. Ouzan, B. Kindya, Y. Ko, P. Block, C. Devireddy, B. Leshnower, V. Babaliaros, V. Thourani, S. Lerakis,
K. Mavromatis (Jerusalem, IL; Atlanta, US)
Prognostic Implications of fibrosis in low risk aortic stenosis patients. P1605
– C. Gavina, I. Falcao-Pires, B. Marinho, J. Rodrigues, J. Almeida, P. Pinho, F. Rocha-Gonacalves,
A. Leite-Moreira (Porto, PT)
111
Transfemoral Implantation of the Edwards SAPIEN 3 Aortic Valve without Predilation is Safe and Feasible P1606
in the Majority of Patients.
– K. Bijuklic, J. Witt, K. Krause, L. Hansen, J. Schofer (Hamburg, DE)
Incidence and predictors of late recurrence of left ventricular dysfunction after aortic valve replacement P1607
for chronic aortic regurgitation; long-term follow-up data.
– M. Amano, C. Izumi, M. Miyake, Y. Tamaki, S. Enomoto, T. Tamura, H. Kondo, K. Kaitani, Y. Nakagawa
(Nara, JP)
Transfemoral implantation of the direct flow medical (DFM) aortic valve for pure noncalcified aortic P1608
regurgitation.
– L. Hansen, K. Bijuklic, A. Latib, A. Colombo, F. Gatto, C. Oezbek, J. Schofer (Hamburg and Völklingen, DE;
Milan, IT)

Prediction of major cardioembolic events in adult Filipinos with endocarditis using the embolic risk P1609
French calculator.
– J. Aherrera, M.T. Abola, L. Abrahan, M.M. Balabagno, A. Faltado, P.F. Reganit, F.E. Punzalan (Manila, PH)
Assessment of operative mortality risk in patients with active infective endocarditis undergoing cardiac P1610
surgery: performance of the EuroScore I and II logistic models.
– S. Madeira, M. Santos, R. Rodrigues, A. Tralhao, J. Mesquita, J. Carmo, S. Guerreiro, P. Freitas,
M. Mendes, J. Neves (Lisbon, PT)
Evolution of 18F-FDG PET/CT findings under therapy in patients with infective endocarditis: first P1611
description.
– E. Ravis, L. Tessonnier, L. Saby, S. Hubert, C. Lavoute, E. Salaun, M. Sumian, J.P. Casalta, S. Camilleri,
G. Habib (Marseille, FR)
Factors associated with progression or regression of non-specific valvular changes detected during P1612
echocardiographic screening for rheumatic heart disease.
– M.G.W. Remond, D. Atkinson, A. White, A.D. Brown, J.R. Carapetis, B. Remenyi, K. Roberts, G.P. Maguire
(Cairns, Broome, Townsville, Adelaide, Perth, Darwin and Alice Springs, AU)
Rheumatic heart disease: factors associated with outcomes in a high-income country. P1613
– M. Mirabel, B. Noel, M. Tafflet, T. Parks, C. Braunstein, A.A. Hagege, E. Marijon, X. Jouven (Paris, FR;
Noumea, NC; Oxford, UK)
Adverse effect of aortic insufficiency after TAVI on short term outcome in patients with renal impairment. P1614
– M. Possner, J. Vontobel, C. Zindel, E.W. Holy, S.F. Staempfli, M. Zuber, F. Nietlispach, P.A. Kaufmann,
M. Niemann, F.C. Tanner (Zurich, CH)
Evaluation of the learning curve for transcatheter aortic valve implantation via the transfemoral approach. P1615
– T. Arai, T. Lefevre, T. Hovasse, H. Benamer, B. Cormier, E. Bouvier, M.C. Morice, B. Chevalier (Massy, FR)
Platelet size and bleeding following transcatheter aortic valve implantation. P1616
– M.K. Kowara, Z. Huczek, J. Kochman, R. Wilimski, P. Scislo, A. Scibisz, B. Rymuza, R. Andrzejewska,
K.J. Filipiak, G. Opolski (Warsaw, PL)
Balloon aortic valvuloplasty is not required for safe and effective transfemoral implantation of P1617
balloon-expandable transcatheter aortic valves.
– S.K. Aggarwal, N. Delahunty, M. Reinthaler, M.H. Cheang, E. Ako, J. Yap, M. Ozkor, M.J. Mullen (London,
UK)
Conventional vs. transapical vs. transfemoral aortic valve replacement - Real world comparison of 3751 P1618
patients in propensity score matched groups.
– J. Boergermann, E. Emmel, S. Scholtz, S. Ensminger, W. Scholtz, T. Becker, A. Zittermann, D. Horstkotte,
O. Kuss, J.F. Gummert (Bad Oeynhausen and Düsseldorf, DE)
CARDIOMYOPATHIES I
Elevation of serum high-sensitivity cardiac troponin T value is associated with progression of left P1619
ventricular remodeling in patients with hypertrophic cardiomyopathy.
– T. Kubo, Y. Baba, T. Hirota, K. Tanioka, N. Yamasaki, T. Sugiura, H. Kitaoka (Kochi, JP)
The course of cardiac sarcoidosis with delayed vs early steroid therapy in patients with atrioventricular P1620
block as the first clinical manifestation.
– R. Kandolin, J. Lehtonen, M. Kupari (Helsinki, FI)
Early arrhythmic events in idiopathic dilated cardiomyopathy. P1621
– P. Losurdo, D. Stolfo, G. Barbati, M. Gobbo, M. Gigli, B. Pinamonti, M. Zecchin, G. Finocchiaro, M. Merlo,
G.F. Sinagra (Trieste, IT; London, UK)
Secondary forms of Takotsubo Cardiomyopathy, a whole different prognosis. P1622
– I. Nunez-Gil, M. Almendro Delia, M. Andres, A. Sionis, A. Martin, T. Bastante, J.G. Cordoba Soriano,
J.A. Linares Vicence, S. Gonzalez Sucarrats, O. Fabregat Andres (Madrid, Sevilla, Barcelona, Salamanca,
Albacete, Zaragoza, Lleida and Valencia, ES)
High prevalence of N271I founder mutation in TNNT2 gene detected by NGS in a galician cohort cause P1623
hypertrophic cardiomyopathy associated with a benign course.
– J.P. Ochoa, R. Barriales Villa, M.L. Pena, J. Palomino Doza, M. Ortiz Genga, D. Alonso Garcia,
X. Fernandez Fernandez, L. Monserrat Iglesias (A Coruña, ES)
Arrhythmic risk assessment in family members with arrhythmogenic cardiomyopathy associated P1624
desmosomal mutations.
– A. Protonotarios, A. Anastasakis, C. Ritsatos, V. Vlagouli, P. Syrris, D. Tousoulis, L. Antoniades,
W.J. McKenna, A. Tsatsopoulou (Naxos and Athens, GR; London, UK; Nicosia, CY)
112
Expression of neural cell adhesion molecule (NCAM) in dilated cardiomyopathy is associated with P1625
inflammation and cardiomyocyte hypertrophy.
– M. Noutsias, H.P. Schultheiss, K. Ostermann (Jena and Berlin, DE)
Prognosis of left ventricular non-compaction cardiomyopathy - a multicentre study. P1626
– D.A. Moreira, J. Almeida, K. Domingues, N. Marques, I. Cruz, L. Teles, B. Picarra, S. Leao, R. Faria,
O. Azevedo (Viseu, Vila Nova de Gaia, Santarem, Faro, Almada, Évora, Vila-Real and Guimaraes, PT)
Predictors of left ventricular systolic function recovery in the first 15 days after hospital of admission in P1627
takotsubo cardiomyopathy - portuguese multicenter study.
– K. Domingues, C. Lourenco, O. Azevedo, S. Leao, B. Marmelo, I. Cruz, J. Almeida, L. Teles, B. Picarra,
N. Marques (Santarem, Penafiel, Guimaraes, Vila-Real, Viseu, Almada, Vila Nova de Gaia, Coimbra, Évora
and Faro, PT)
Ethnic variation in hypertrophic cardiomyopathy. P1628
– O. Watkinson, O. Guttman, C. O’Mahoney, M. Tome, P. Elliott (London, UK)
CARDIOMYOPATHIES II
Phenotypic variation of hypertrophic cardiomyopathy caused by the 3330+2T>G mutation in myosin P1629
binding protein-C in 303 Amish individuals.
– M. Muggenthaler, K. Zahka, H. Lever, M. Desai, B.A. Chioza, H. Cross, E.R. Behr, S. Sharma, A.H. Crosby
(London and Exeter, UK; Cleveland and Tucson, US)
Right ventricular wall thickness as a correlate of malignant ventricular arrhythmias in patients with P1630
hypertrophic cardiomyopathy.
– M. Rosca, A. Calin, A. Mateescu, P. Varga, C.C. Beladan, M. Gurzun, R. Enache, C. Baicus, C. Ginghina,
B.A. Popescu (Bucharest, RO)
SUNDAY – MORNING
Mid-regional pro-atrial natriuretic peptide for predicting mortality and heart failure in hypertrophic P1631
cardiomyopathy: a comparison with N-terminal pro-brain natriuretic peptide.
– C. Begue, E. Galve, J.L. Golmard, S. Morner, F. Imbert-Bismut, D. Brito, E. Arbustini, C. Hengstenberg,
M. Komajda, R. Isnard (Paris, FR; Barcelona, ES; Umeå, SE; Lisbon, PT; Pavia, IT; Regensburg, DE)
A comprehensive clinical evaluation of demosplakin ARVC carriers: does the type of mutation influence P1632
the phenotype?
– S. Castelletti, P. Syrris, A. Vischer, N. Kadoglou, W.J. McKenna, A. Pantazis (London, UK)
Predictive value of admission QRS duration for in-hospital clinical outcomes of patients with takotsubo P1633
cardiomyopathy.
– T. Yamaguchi, T. Yoshikawa, T. Ueda, Y. Maekawa, K. Sakata, T. Murakami, T. Isogai, K. Nagao,
T. Yamamoto, M. Takayama (Tokyo, JP)
Cardiovascular impact of tafamidis in familial amyloidotic polyneuropathy: experience of a center. P1634
– B. Brochado, P. Rodrigues, M.J. Sousa, I. Silveira, M. Santos, T. Coelho, V. Lagarto, H. Reis, H. Carvalho,
S. Torres (Porto, PT)
Comparative evaluation DDD pacing, alcohol ablation and surgical myotomy-myectomy in patients with P1635
– K. Rudenko, G. Knyshov, V. Lazoryshynets, B. Kravchuk, S. Siromakha, S. Fanta, O. Krykunov,
O. Trembovetska, N. Kolliakova, L. Nevmerzhytska (Kiev, UA)
Filamin C is a novel disease gene for familial restrictive cardiomyopathy. P1636
– A. Brodehl, R. Ferrier, S.C. Greenway, M.-A. Brundler, W. Yu, N. Alvarez, M. Giuffre, B. Gerull (Calgary, CA)
Ventricular Tachycardia is a Significant Prognostic Factor in Patients with Cardiac Sarcoidosis P1637
Regardless of Corticosteroid Therapy.
– N. Serizawa, A. Nomura, Y. Inagaki, A. Yoshida, H. Hattori, N. Kikuchi, A. Suzuki, T. Suzuki, T. Shiga,
N. Hagiwara (Tokyo, JP)
Apical ballooning type of stress-induced cardiomyopathy might be related to wrap-around LAD pattern. P1638
– H. Chung, S.W. Kwon, J.Y. Kim, P.K. Min, E.Y. Choi, Y.W. Yoon, B.K. Lee, S.J. Rim, H.M. Kwon,
B.K. Hong (Seoul and Incheon, KR)
CONGENITAL, FOETAL HEART DISEASE AND INTERVENTION

Percutaneous coronary arteries interventions in paediatric population: a 15-years experience. P1639
– Z. Jalal, J.F. Piechaud, S. Malekzadeh Milani, Y. Boudjemline (Paris and Massy, FR)
Selective propensity of bovine jugular vein to bacterial adhesion and impact of percutaneous pulmonary P1640
valve implantation procedural steps in genesis of infective endocarditis: an in-vitro study.
– Z. Jalal, L.G. Galmiche, D.L. Lebeaux, O. Villemain, G. Brugada, J.M. Ghigo, C. Beloin, Y. Boudjemline
(Paris, FR)
Cardiac troponin I release after transcatheter closure of the atrial septal defect are related with P1641
arrhythmias in the early follow-up.
– M. Komar, T. Przewlocki, B. Sobien, P. Wilkolek, L. Tomkiewicz-Pajak, P. Prochownik, U. Gancarczyk,
M. Olszowska, P. Podolec (Krakow, PL)
Percutaneous occlusion of vascular malformations in pediatric and adult patients: 20-year experience of P1642
a single center.
– T. Silva, J.D. Ferreira Martins, L. Sousa, A. Fiarresga, C. Trigo Pereira, R. Cruz Ferreira, F. Pinto (Lisbon, PT)
Controlled, uncontrolled, and zero antegrade pulmonary blood flow after bidirectional Glenn procedure: P1643
Real-world outcomes in a developing country.
– H. Zhang, T. Zhang, S.J. Li, S.S. Hu (Beijing, CN)
The fetal intracardiac echogenic foci debate: is it over? P1644
– A. Doronzo, R. Piazza, L. Neglia, E. Cervesato, G.L. Nicolosi, M. Cassin (Pordenone, IT)
113
Diagnosis and prognosis in nine fetuses with idiopathic constriction of the ductus arteriosus using fetal P1645
echocardiography.
– X. Gu, Y. He, Y.E. Zhang, X.W. Liu, J.C. Han (Beijing, CN)
Indications for fetal echocardiography: do they have a real predictive role? P1646
– A. Doronzo, R. Piazza, L. Neglia, E. Cervesato, G.L. Nicolosi, M. Cassin (Pordenone, IT)
Long-term outcome of ross procedure performed in childhood: a single centre cohort study in an adult P1647
congenital heart disease unit.
– M.O. Mohamed, P. Clift, F. Umar, D. Barron (Birmingham, UK)
Assessment of ventricular global longitudinal function in hypoplastic left heart syndrome using velocity P1648
vector imaging.
– X.U. Yang, Y. He, Y. Zhao, Y.E. Zhang, J.C. Han, X. Gu, L. Sun (Beijing, CN)
Follow-up of 316 molecularly defined pediatric long QT syndrome patients - clinical course, beta blocker P1649
treatment and side effects.
– M. Koponen, A. Marjamaa, A. Hiippala, J.M. Happonen, K. Kontula, H. Swan (Helsinki, FI)
Results and long-term follow-up for double-outlet right ventricle with biventricular repair. P1650
– O. Villemain, E. Belli, M. Ladouceur, L. Houyel, Z. Jalal, M. Ly, R. Roussin, P. Vouhe, D. Bonnet (Paris and
Le Plessis-Robinson, FR)
CLASSICAL AND NEW RISK FACTORS FOR CARDIOVASCULAR DISEASE
Temporal trends in the incidence of acute myocardial infarction and sudden cardiac death in the general P1651
population: a 10-year population based study.
– M. Honma, K. Tanaka, R. Komi, F. Tanaka, K. Sato, T. Sakai, M. Onodera, T. Onoda, K. Sakata,
M. Nakamura (Morioka, Ninohe and Kuji, JP)
Estimated glomerular filtration rate within the normal or mildly impaired range and incident non-valvular P1652
atrial fibrillation in the general population.
– A. Eisen, M. Haim, M. Hoshen, R. Balicer, O. Reges, Y. Rabi, M. Leibowitz, Z. Iakobishvili, D. Hasdai (Petah
Tikva and Tel Aviv, IL)
A cardiometabolic protective phenotype associated with the ANP genetic variant rs5068 in African P1653
Americans: the Multi-Ethnic Study of Atherosclerosis (MESA).
– V. Cannone, P.A. Decker, N.B. Larson, C.G. Scott, W. Palmas, K.D. Taylor, S.J. Bielinski, J.C. Burnett
(Rochester, New York and Torrance, US)
Unexpected High Prevalence of Possible and Probable FH in Clinical Practice - Results of DYSIS I. P1654
– A.K. Gitt, D. Lautsch, M. Horack, B.M. Ambegaonkar, P. Brudi, J. Ferrieres (Ludwigshafen am Rhein, DE;
Vienna, AT; Whitehouse Station, US; Toulouse, FR)
Lipoprotein(a) in familial hypercholesterolemia with proprotein convertase subtilisin kexin type 9 P1655
gain-of-function mutations: Implication of residual risk in statin-era.
– H. Tada, M. Kawashiri, A. Nohara, A. Inazu, H. Mabuchi, M. Yamagishi (Kanazawa, JP)
The association between serum apolipoprotein B and acute myocardial infarction is modified by plasma P1656
glycine.
– G.F.T. Svingen, E.K.R. Pedersen, Y. Ding, P.M. Ueland, H. Schartum-Hansen, R. Seifert, O.K. Nygaard
(Bergen, NO)
A variant in FLT1 is associated with long-term cardiovascular events in high risk patients: replication of P1657
genome-wide association data.
– C.J. Lee, J.-Y. Lee, S. Park, S.-M. Kang, D. Choi, Y. Jang, S.-H. Lee (Seoul, KR)
Ideal cardiovascular health and carotid stiffness. The Paris Prospective Study III. P1658
– J.P. Empana, B.G. Gaye, C.P. Prugger, M.P. Plichart, M.C.P. Perier, F.T. Thomas, B.P. Pannier,
P.B. Boutouyrie, X.J. Jouven (Paris, FR)
Twenty-five years trends in coronary artery disease in coronary artery disease in a population based P1659
study.
– B.L.M. Gerber, S. Kaddach, J.L. Vanoverschelde, M. Jeanjean (Brussels, BE)
The impact of single nucleotide polymorphism of superoxide dismutase on cardiovascular and all-cause P1660
mortality in the general population.
– Y. Otaki, T. Watanabe, G. Yamaura, H. Takahashi, T. Arimoto, T. Shishido, T. Miyamoto, I. Kubota
(Yamagata, JP)
Whole exome sequencing identifies deleterious variants in ABCA6 and ABCA10 genes possibly P1661
associated with hyper HDL-cholesterolemia.
Serum apoB level is superior to non-HDL-C and LDL-C in the severity prediction assessed by Gensini P1662
Score among un-treated patients undergoing coronary angiography.
– Y. Zhang, S. Li, Y.-L. Guo, C.-G. Zhu, N.-Q. Wu, G. Liu, Q. Dong, J.J. Li (Beijing, CN)
PSYCHO-SOCIAL STRESS: THE RISK FACTOR OF THE MODERN ERA

Validity and reliability of the HeartQoL questionnaire based on the EUROASPIRE IV study. P1663
– D. De Smedt, E. Clays, S. Hofer, N. Oldridge, K. Kotseva, D. De Bacquer (Ghent, BE; Innsbruck, AT;
Milwaukee, US; London, UK)
Prevalence, predictors and protective factors of job-related distress in a nationwide cardiologists sample. P1664
The IANUS- ItAliaN cardiologist’ Undetected distress Study-Survey.
– G. Russo, G. Majani, R. De Maria, A. Giardini, M. Marini, M. Milli, C. Raineri, R. Maestri, N. Aspromonte,
G. Di Tano (Trieste, Pavia, Milan, Ancona, Florence, Rome and Cremona, IT)
The association between somatization and health care utilization in patients with non-cardiac chest pain. P1665
– G. Mourad, A. Stromberg, T. Jaarsma (Norrköping and Linköping, SE)
114
Psychosocial consequences of venous thromboembolism in youth. Results from a mixed methods study. P1666
– A.A. Hojen, A. Gorst-Rasmussen, G.Y.H. Lip, D.A. Lane, L.H. Rasmussen, E.E. Sorensen, P. Dreyer,
T.B. Larsen (Aalborg and Aarhus, DK; Birmingham, UK)
Effect of combined occupational tasks on cardiovascular events: Prime study. P1667
– Y. Esquirol, J. Yarnell, J. Ferrieres, J.-B. Ruidavets, F. Kee (Toulouse, FR; Belfast, UK)
Sex differences in symptoms presentation and health care-seeking behaviour in patients with acute P1668
coronary syndrome.
– F. Melao, M. Viana, P. Dias, R. Almeida, C. Araujo, O. Laszczynska, V. Ribeiro, I. Moreira, M.J. Maciel,
A. Azevedo (Porto and Vila-Real, PT)
Comparative potential of the 2- and the 9-item patient health questionnaire to predict death or P1669
re-hospitalization in heart failure.
– S.M. Piepenburg, H. Faller, S. Stoerk, G. Gelbrich, B. Warrings, G. Ertl, C. Angermann (Würzburg, DE)
Abrupt changes in heart rate of supporters during FIFA world cups. P1670
– F. Demoniere, D. Choquet, J. Fabre, S. Hamouda, P.H. Cohen-Tenoudji, H. Lucron, D. Courcier, J. Inamo
(Fort de France, FR; Noumea, NC)
Spirituality and depression in patients with coronary artery disease. P1671
– F. Malafaia, G. Nishida, G. Barreto, V.L. Amato, A. Avezum (São Paulo, BR)
Influence of cognitive decline on 30-day outcomes in hospitalized patients with acute heart failure. P1672
– H. Kawanishi, M. Oguri, K. Yasuda, T. Katagiri, M. Shimano, H. Kamiya, H. Ishii, T. Murohara (Nagoya, JP)
TREATMENT STRATEGIES AND ADHERENCE: CAN WE DECREASE RISK?
Plant sterol supplementation on top of lipid-lowering therapies in familial hypercholesterolemia. P1673

– M.C. Izar, V.A. Machado, H.A. Fonseca, F.A. Fonseca (São Paulo, BR)
SUNDAY – MORNING
A Clinical Decision Support System can improves the quality of lipid-lowering therapy in coronary P1674
patients.
– A. Zamora, C. Carrion, G. Vazquez, A. Martin-Urda, M. Vilaseca, G. Paluzie, J.C. Sevilla, C. Soler, N. Plana,
R. Elosua (Girona, Blanes, Reus and Barcelona, ES)
Are coronary patients on lipid-lowering therapy in Europe achieving the recommended LDL-C target? P1675
Results from the Dyslipidemia International Study (DYSIS) II Europe.
– A.K. Gitt, J. Ferrieres, G. De Ferrari, M. Elisaf, M.P. Hermans, T. Kiernan, R. Oganov, D. Lautsch, V. Ashton,
B. Ambegaonkar (Ludwigshafen am Rhein, DE; Toulouse, FR; Pavia, IT; Ipiros, GR; Brussels, BE; Limerick,
IE; Moscow, RU; Kenilworth, US)
Tibolone can decrease lipoprotein(a) concentrations in postmenopausal women: a systematic review and P1676
meta-analysis of controlled trials.
– K. Kotani, A. Sahebkar, C. Serban, F. Andrica, P.P. Toth, S.R. Jones, K.M. Kostner, M.J. Blaha, S. Martin,
M. Banach (Shimotsuke, JP; Mashhad, IR; Timisoara, RO; Chicago and Baltimore, US; St. Lucia, AU; Lodz,
PL)
Identification and management of statin-intolerance: a survey of clinicians from 13 countries. P1677
– G.K. Hovingh, S.R. Gandra, J. McKendrick, R. Dent, H. Wieffer, A.L. Catapano, P. Oh, R.E. Rosenson,
E. Stroes (Amsterdam, NL; Thousand Oaks and New York, US; Fleet, UK; Milan, IT; Toronto, CA)
Real life adherence data to clinical practice guidelines for lipid management in chronic kidney disease: a P1678
multicenter cross-sectional survey.
– M. Arici (Ankara, TR)
Icosapent ethyl (eicosapentaenoic acid ethyl ester): effects on apolipoprotein C-III in patients from the P1679
MARINE and ANCHOR studies.
– C.M. Ballantyne, H.E. Bays, R.A. Braeckman, S. Philip, W.G. Stirtan, R.T. Doyle, P.N. Soni, R. Juliano
(Houston, Louisville, Doylestown, Bedminster and Mystic, US)
High prevalence of persistent lipid abnormalities among coronary patients: the Dyslipidemia International P1680
Study (DYSIS) II global results.
– A.K. Gitt, J. Ferrieres, V. Ashton, M. Horack, P. Brudi, B. Ambegaonkar (Ludwigshafen am Rhein, DE;
Toulouse, FR; Kenilworth, US)
Prevalence of lipid abnormalities among coronary patients remains high in the Middle East/Africa region: P1681
the Dyslipidemia International Study (DYSIS) II MEA results.
– S.N. Al Sifri, W. Al Mahmeed, R. Azar, M. Sobhy, A.K. Gitt, M. Horack, V. Ashton, P. Brudi,
B. Ambegaonkar, S. Wajih (Taif, SA; Abu Dhabi, AE; Beirut, LB; Alexandria, EG; Ludwigshafen am Rhein,
DE; Kenilworth, US)
Predictors of failure to use of a high potency statin regimen after an acute coronary syndrome: insights P1682
from the SOLID- TIMI 52 trial.
– A. Eisen, C.P. Cannon, E. Braunwald, D.L. Steen, J. Zhou, A.J. Dalby, J. Spinar, S. Daga, M.A. Lukas,
M.L. O’Donoghue (Boston, Cincinnati and Philadelphia, US; Johannesburg, ZA; Brno, CZ)
Statin utilization and low-density lipoprotein cholesterol goal attainment in patients at very high P1683
cardiovascular risk: insights from a French general practice population.
– J. Ferrieres, D.L. Steen, R. Sanchez, J. Chin, K. Gorcyca, I. Khan (Toulouse, FR; Cincinnati, Ohio,
Tarrytown, New York, Jersey City and Bridgewater, US)
LDL-C target attainment remains low among treated coronary patients in Asia-Pacific: the Dyslipidemia P1684
International Study (DYSIS) II AP results.
– J.P.S. Sawhney, F.T. Chiang, Y.S. Jang, P.N. Vinh, K.K. Poh, W. Buddhari, R. Sy, M. Munawar, B. Yan,
H.P. Balaji (New Delhi, IN; Taipei, TW; Seoul, KR; Ho Chi Minh City, VN; Singapore, SG; Bangkok, TH;
Manila, PH; Jakarta, ID; Hong Kong, HK)
115
HOW DOES STRESS AFFECT CARDIOVASCULAR RISK?

Troponin T and brain natriuretic peptide (BNP) in patients with psychosis. P1685
– S.V. Eriksson, E.O. Olsson, U.O. Osby (Stockholm and Solna, SE)
Clinical impact of psychological interventions to quality of life in Japanese patients with implantable P1686
cardioverter defibrillator.
– K. Miyazawa, M. Ueda, Y. Kondo, M. Ishimura, T. Kajiyama, N. Hashiguchi, T. Kurita, Y. Kobayashi (Chiba
and Osakasayama, JP; Bonn, DE)
Trigger and consequence of shock therapy in Japanese patients with implantable caradioverter P1687
defibrillator.
– Y. Kondo, M. Ueda, T. Kurita, T. Kanaeda, M. Nakano, N. Hashiguchi, T. Kajiyama, M. Ishimura,
K. Miyazawa, Y. Kobayashi (Bonn, DE; Chiba and Osaka, JP)
The effect of synthetic cannabinoids on P-wave dispersion: an observational study. P1688
– M. Sunbul, E.A. Sunbul, A. Terzi, S. Calli, E. Koca, R. Bilici, S. Citak (Istanbul, TR)
Prevalence of electrocardiographic abnormalities in a large sample of workers from several employment P1689
areas.
– J. Rodriguez Capitan, A. Fernandez-Meseguer, J.M. Garcia Pinilla, E. Calvo-Bonacho, M. Jimenez-Navarro,
J.C. Sainz, J.J. Gomez-Doblas, M.T. Garcia-Margallo, F. Cabrera-Bueno, E. De Teresa-Galvan (El Ejido,
Madrid and Málaga, ES)
A continuum in cocaine cardiotoxicity. From myocardial strain alteration to left ventricular dysfunction. A P1690
cardiovascular magnetic resonance strain/strain rate study.
– A.M. Maceira Gonzalez, L. Tuset, C. Ripoll, J. Cosin-Sales, B. Igual, J. Salazar, V. Belloch (Valencia, ES)
Factors associated with improvement of depression after acute coronary syndromes. P1691
– D. Nanchen, R. Auer, B. Gencer, O. Muller, P. Juni, C.M. Matter, S. Windecker, T.F. Luscher, F. Mach,
N. Rodondi (Lausanne, Geneva, Berne and Zurich, CH)
Electrophysiological features in chronic alcoholics in their relation to the echocardiographic and clinical P1692
data.
– A. Gorbunova, S.Y.U. Levashov (Chelyabinsk, RU)
Dramatic and specific differences in cardiovascular disease risk factors between homeless people and P1693
general population- a representative survey.
– E. Naszydlowska, T. Zdrojewski, S. Gluszek, A. Jegier (Kielce, Gdansk and Lodz, PL)
Entrance examination-related metabolic abnormalities in new university students: cross-sectional and P1694
follow-up analyses.
– T. Konno, M. Ikeda, M. Shimizu, T. Yoshimuta, H. Yoshikawa, J. Koizumi, T. Okada, A. Suzuki,
M. Yamagishi (Kanazawa, JP; Durham, US)
Marker of periodontitis as an independent predictor of cardiovascular outcome: a longitudinal P1695
population-based study.
– N. Kanjanahattakij, T. Yingchoncharoen, R. Mahanonda, O. Charatkulangkun, P. Vathesatogkit,
S. Yamwong, P. Sritara (Bangkok, TH)
EFFECT OF DIFFERENT RISK FACTORS ON THE CARDIOVASCULAR SYSTEM
Identifying familial hypercholesterolemia from registries of patients with acute myocardial infarction: an P1696
algorithm-based approach.
– M. Zeller, M. Farnier, C. Touzery, E. Puymirat, F. Schiele, J.C. Beer, J. Ferrieres, T. Simon, Y. Cottin,
N. Danchin (Dijon, Paris, Besançon and Toulouse, FR)
Remnant cholesterol predicts cardiovascular event risk in patients with type 2 diabetes independently P1697
from the baseline coronary artery disease state.
– C.H. Saely, D. Zanolin, P. Rein, A. Vonbank, A. Leiherer, A. Muendlein, H. Drexel (Feldkirch, AT; Triesen, LI;
Philadelphia, US)
Increased plant sterol deposition in vascular tissue characterizes patients with severe aortic stenosis and P1698
concomitant coronary artery disease.
– O. Weingaertner, A. Luister, H.F. Schott, C. Husche, H.J. Schaefers, M. Böhm, J. Plat, D. Luetjohann,
U. Laufs (Oldenburg, Homurg, Bonn and Homburg, DE; Maastricht, NL)
Post-prandial remnant-like particles formation in abetalipoproteinemia: prediction of the effectiveness of P1699
microsomal triglyceride transfer protein inhibitor on post-prandial remnant-like particles.
Random blood glucose and incidence of cardiovascular disease among adults without diabetes: findings P1700
of the China Kadoorie Biobank.
– F. Bragg, L. Li, D. Bennett, Y. Guo, L. Yang, Z. Bian, Y. Chen, R. Collins, R. Peto, Z. Chen (Oxford, UK;
Beijing, CN)
Clinical characteristics of the Japanese patients with severe hypertriglyceridemia: Implication of P1701
controversy of triglyceride as a causative risk factor of coronary artery disease.
Harnessing publicly available genetic data to prioritize therapeutic targets for cardiovascular prevention. P1702
– M.V. Holmes, V. Tragante, F.W. Asselbergs, D.I. Swerdlow, B.J. Keating (Oxford and London, UK; Utrecht,
NL; Philadelphia, US)
Determinants of 3-year mortality after an acute coronary syndrome - the French population MONICA P1703
registry.
– S. Blanco, A. Wagner, V. Bongard, D. Arveiler, B. Hass, J.-B. Ruidaverts, J. Ferrieres (Toulouse and
Strasbourg, FR)
116
Whole Exome Sequencing in Familial Hypobetalipoproteinemia. P1704

– H. Tada, A. Nomura, M. Kawashiri, A. Nohara, A. Inazu, H. Mabuchi, S. Kathiresan, M. Yamagishi
(Kanazawa, JP)
Association between epicardial fat and subclinical atherosclerosis assessed by coronary computed P1705
tomographic angiography in familial hypercholesterolaemia.
– L.C. Mangili, M.H. Miname, L.M. Lima, C.E. Rochitte, R. Prado, R. Kalil, R.D. Santos (São Paulo, BR)
Relationship of birth weight with body composition in young adulthood. P1706
– T. Kofler, M. Bossard, S. Aeschbacher, A. Tabord, J. Ruperti Repilado, S. Van Der Lely, S. Berger,
M. Risch, L. Risch, D. Conen (Basel, CH; Schaan, LI)
PHYSIOLOGY AND CORONARY CIRCULATION

Plasma levels of serotonin as a novel biomarker for coronary microvascular dysfunction in patient with P1707
vasospastic angina.
– Y. Odaka, J. Takahashi, R. Tuburaya, K. Nishimiya, K. Hao, Y. Matsumoto, Y. Hirowatari, H. Shimokawa
(Sendai and Kanagawa, JP)
Pressure-based baseline indices of functional stenosis severity are affected by changes in systemic P1708
hemodynamics.
– L. Casadonte, B.J. Verhoeff, J.J. Piek, J.A.E. Spaan, M. Siebes (Amsterdam, NL)
Direct quantitative assessment of the peripheral artery collateral circulation: validation of collateral flow P1709
index.
– M. Stoller, H. Steck, R. Grossenbacher, C. Seiler (Berne, CH)
The use of acute pd/pa drop after intracoronary nitroglycerin infusion to rule out significant FFR: CANICA P1710
(can intra-coronary nitroglycerin predict fractional flow reserve without adenosine?) study.
SUNDAY – MORNING
– R. Martin Reyes, J.A. Franco Pelaez, J.M. De La Torre, R. Lopez Palop, M. Larman, A. Sanchez Recalde,
I. Lozano, S. Brugaletta, F. Navarro, A. Farre (Madrid, Santander, Alicante, San Sebastian, Gijon and
Barcelona, ES)
Serial changes in microvascular resistance associated with elective percutaneous coronary intervention P1711
and their relationships with lesion characteristics assessed by optical coherence tomography.
– T. Murai, T. Lee, Y. Kanaji, J. Matsuda, E. Usui, T. Niida, M. Isobe, T. Kakuta (Tsuchiura and Tokyo, JP)
Distribution of pressure gradients along left anterior descending artery in patients with angiographically P1712
normal arteries.
– K. Fujii, M.F. Fukunaga, T.I. Imanaka, K.M. Miki, H.T. Tamaru, T.H. Horimatsu, T.S. Saita, M.N. Nishimura,
M.S. Shibuya, M.I. Ishihara (Nishinomiya, JP)
Improvement of left ventricular function: an additional benefit of percutaneous revascularization for P1713
occluded coronary artery.
– M. Chimura, S. Yamada, Y. Yasaka, H. Kawai (Himeji, JP)
Instantaneous wave-free ratio (iFR) provides the most robust measure of any resting physiological index: P1714
the effects of pressure drift and measurement variability on stenosis misclassification.
– C. Cook, Y. Ahmad, M. Shun-Shin, R. Petraco, S. Nijjer, R. Al-Lammee, D. Francis, S. Sen, J.E. Davies
(London, UK)
Prognostic value of the index of microcirculatory resistance after percutaneous coronary intervention in P1715
patients with non-ST-segment elevation acute coronary syndrome.
Tokyo, JP)
The randomized physiologic assessment of thrombus aspiration in patients with acute myocardial P1716
infarction with ST-segment elevation (PATA STEMI) trial: final results.
– D. Orlic, M. Ostojic, B. Beleslin, M. Tesic, M. Borovic, D. Sobic-Saranovic, D. Milasinovic, S. Stojkovic,
M. Nedeljkovic, G. Stankovic (Belgrade, RS)
Investigation of human coronary haemodynamics in normal and stenosed vessels to develop systems to P1717
quantify stenosis significance and predict the functional gain of intervention.
– S.S. Nijjer, S.S. Sen, R. Petraco, G. De Waard, T.P. Van De Hoef, M. Echavarria-Pinto, J. Escaned, J. Piek,
N. Van Royen, J.E.R. Davies (London, UK; Amsterdam, NL; Madrid, ES)
Impact of additional intracoronary nicorandil administration during fractional flow reserve Measurement P1718
with intravenous ATP infusion.
– H. Takami, S. Sonoda, M. Kitagawa, K. Kashiyama, Y. Muraoka, Y. Tsuda, M. Araki, Y. Otsuji (Kitakyushu,
JP)
Efficacy of pressure-derived indices by contrast medium induced submaximal hyperemia in comparison P1719
with fractional flow reserve and hyperemic end-diastolic Pd/Pa ratio.
– Y. Kanaji, T. Lee, T. Murai, J. Matsuda, E. Usui, M. Araki, T. Niida, T. Kakuta (Tsuchiura, JP)
The impact of elective percutaneous coronary intervention on coronary microvascular resistance. P1720
Tokyo, JP)
Influence of microvascular resistance on anatomical and functional severity of coronary artery stenosis. P1721
– K.W. Seo, M.H. Yoon, S.J. Tahk, S.Y. Choi, B.J. Choi, H.S. Lim, H.M. Yang, J.H. Shin, G.S. Hwang,
J.S. Park (Suwon, KR)
Diabetic hyperglycemia reduced store-operated calcium entry in vascular smooth muscle cells. P1722
– C. Schach, M. Goetz, M. Drzymalski, L. Maier, S. Wagner, D. Endemann (Regensburg, DE)
Impact of acute afterload reduction by transcatheter aortic valve implantation on the human coronary P1723
circulation.
– M. Stoller, S. Gloekler, R. Zbinden, K. Zuk, F. Praz, D. Tueller, S. Windecker, P. Wenaweser, C. Seiler
(Berne and Zurich, CH)
117
Influence of the side branch stenosis on the fractional flow reserve value of the main branch in a swine P1724
model.
– J.-H. Oh, J.S.K. Kim, J.H.C. Choi, B.W.K. Kim, J.S.P. Park, H.W.L. Lee, J.H.C. Choi, H.C.L. Lee,
K.S.C. Cha, T.J.H. Hong (Busan and Yangsan, KR)
Hyperemic flow velocity falls with worsening stenosis severity: the challenge for non-invasive predictors P1725
of coronary physiology.
– S.S. Nijjer, G. De Waard, S. Sen, R. Petraco, T.P. Van De Hoef, M. Echavarria-Pinto, J. Escaned, J. Piek,
J.E.R. Davies, N. Van Royen (London, UK; Amsterdam, NL; Madrid, ES)
INVASIVE AND NON-INVASIVE FUNCTIONAL CORONARY IMAGING

Reduction of radiation exposure in diagnostic cardiac catheterization and PCI - results of a German P1726
coronary angiography and angioplasty registry.
– B. Levenson, S. Goehring, W. Haerer, N. Reifart, G. Ringwald, A. Albrecht (Berlin, Weinheim, Ulm, Bad
Soden and Bruchsal, DE)
Comparison of first and second generation drug eluting stents (DES) in-stent restenosis assessed by P1727
optical coherence tomography (OCT).
– T. Kajiya, J. Takaoka, K. Fukunaga, R. Arima, A. Miyamura, N. Atsuchi, H. Yamaguchi, M. Kanmori,
M. Nakahara, Y. Atsuchi (Kagoshima, JP)
Clinical characteristics and angiographic features of optical coherence tomography verified spontaneous P1728
coronary artery dissection in patients with acute coronary syndrome.
– T. Nishiguchi, A. Tanaka, A. Taruya, Y. Matsuo, Y. Ino, K. Hirata, T. Kubo, T. Hozumi, T. Akasaka
(Wakayama, JP)
Fractional flow reserve-guided revascularization in patients with aortic stenosis: a propensity matched P1729
analysis.
– G. Di Gioia, M. Pellicano, G. Toth, F. Casselman, F. Van Praet, B. Stockman, I. Degrieck, B. Trimarco, B. De
Bruyne, E. Barbato (Naples, IT; Aalst, BE)
Features of coronary artery disease in 2776 type 1 diabetes patients undergoing coronary angiography. P1730
– V. Ritsinger, C. Hero, K. Eeg-Olofsson, A.M. Svensson, N. Saleh, B. Lagerqvist, A. Norhammar (Stockholm,
Gothenburg and Uppsala, SE)
Comparison of 1 year clinical outcomes of IVUS plus OCT guided PCI and IVUS guided PCI. P1731
– T. Kajiya, J. Takaoka, K. Fukunaga, R. Arima, A. Miyamura, N. Atsuchi, Y. Atsuchi (Kagoshima, JP)
Safety of elective transfemoral coronary angiography during uninterrupted warfarin therapy. P1732
– W. Wongcharoen, K. Pinyosamosorn (Chiang Mai, TH)
Rate and predictors of contrast-induced nephrotoxicity after coronary intervention depend on renal P1733
function at baseline.
– B. Guillon, M. Chatot, M. Badoz, B. Bonnet, N. Meneveau, F. Schiele (Besançon, FR)
Incidence and plaque characteristics of calcified nodules, plaque erosion and plaque rupture in diabetic P1734
patients with acute coronary syndrome - an optical coherence tomography study.
– S. Reith, S. Battermann, N. Marx, M. Burgmaier (Aachen, DE)
Impact of optical coherence tomography findings during percutaneous coronary intervention on 9-month P1735
follow-up outcomes.
– T. Sugiyama, S. Kimura, Y. Yamakami, K. Kojima, Y. Sagawa, H. Ohtani, K. Hishikari, H. Hikita,
A. Takahashi, M. Isobe (Yokosuka and Tokyo, JP)
Patient characteristics and prognosis of OCT verified calcified nodules in patients with acute coronary P1736
syndrome.
– T. Nishiguchi, A. Tanaka, A. Taruya, Y. Matsuo, Y. Ino, K. Hirata, T. Kubo, T. Hozumi, T. Akasaka
(Wakayama, JP)
Coronary plaque characteristics in patients impaired glucose tolerance. P1737
– K. Suzuki, Y. Kubota, D. Chinen, K. Inui, R. Aoyama, S. Nakamura, K. Murai, K. Katou, H. Takano,
W. Shimizu (Tokyo, JP)
Repeat coronary angiography in patients with previously normal coronary arteries. P1738
– V. Androshchuk, M. Protty, P. Freeman, N. Ossei-Gerning (Cardiff, UK)
Relationship between coronary artery compliance and vasospasm in patients with angiographically P1739
normal coronary arteries.
– H. Tamaru, K. Fujii, M. Shibuya, T. Imanaka, A. Sumiyoshi, T. Saita, M. Nishimura, T. Horimatsu,
M. Ishihara, T. Masuyama (Nishinomiya, JP)
Image-based FFR during coronary catheterization. P1740
– R. Kornowski, I. Lavi, M. Pellicano, B. De Bruyne (Petah Tikva, IL; Aalst, BE)
The role of optical coherence tomography in prediction of coronary ischemia assessed by fractional flow P1741
reserve: meta-analysis of diagnostic test accuracy.
– I.H. Tanboga, S. Topcu, E. Aksakal, U. Aksu, M. Kurt, A. Kaya, T. Isik, S. Sevimli (Erzurum, Hatay, Ordu and
Balikesir, TR)
Angioscopic comparison of coronary artery healing process through a decade after implantation of P1742
sirolimus-eluting stents and bare metal stents.
– M. Ichikawa, Y. Kijima (Higashi-Osaka, JP)
Distinct histopathological features of calcified nodule in coronary artery tree. P1743
– R. Kawakami, H. Hao, K. Fujii, M. Shibuya, K. Imanaka, T. Saita, A. Fujino, T. Masuyama, M. Ishihara,
S. Hirota (Hyogo, JP)
Association between necrotic plaque volume measured by iMAP and post procedural high sense P1744
troponin-T level elevation in patients underwent 2nd generation drug eluting stents implantation.
– K. Kitagawa, M. Sakakibara, Y. Jinno, S. Aoki, M. Takenaka, N. Iwakawa, T. Yokoi, S. Yamaguchi,
T. Amano, T. Murohara (Aichi, JP)
118
Comparison of vascular response to biolimus-eluting stent versus everolimus-eluting stent; two-year P1745
serial intravascular ultrasound observation from NEXT.
– A. Miyazawa, K. Kozuma, K. Hibi, M. Endo, N. Nakayama, T. Muramatsu, T. Akasaka, Y. Morino, T. Kimura
(Saitama, Tokyo, Yokohama, Wakayama, Iwate and Kyoto, JP)
Gender independent factor in atherosclerotic plaque characteristics. P1746
– M.E. Ten Haaf, M. Rijndertse, J. Cheng, S. De Boer, H. Garcia-Garcia, R. Geuns, E. Regar, M. Lenzen,
Y. Appelman, E. Boersma (Amsterdam and Rotterdam, NL)
Optical coherence tomography imaging of coronary saphenous vein graft lesions morphology, OCTOPUS P1747
registry.
– T.M. Roleder, E. Pociask, W. Wanha, P. Gasior, G. Smolka, M. Skowerski, D. Dudek, A. Ochala, Z. Gasior,
W. Wojakowski (Katowice and Krakow, PL)
Accuracy of IVUS and OCT in identifying functionally significant coronary stenosis according to vessel P1748
diameter: a meta-analysis of 2581 patients and 2807 lesions.
– F. D’Ascenzo, U. Barbero, E. Cerrato, A. Montefusco, S. Taha, J. Escaned, A. Colombo, T. Naganuma,
C. Moretti, F. Gaita (Turin and Milan, IT; Madrid, ES)
Angioscopic assessment of the culprit lesion plaque with intracoronary ultrasound signal attenuation in P1749
coronary heart disease.
– J. Matsuda, T. Kakuta, T. Lee, T. Murai, Y. Kanaji, H. Usui, T. Niida, M. Isobe (Tsuchiura and Tokyo, JP)
Older age is associated with overestimation of coronary artery stenoses. P1750
– N.M. Borren, J.P. Ottervanger, E.M. Engbers, A.W.J. Van ’T Hof (Zwolle, NL)
Transradial coronary angiography: registry data on the one-catheter-concept. P1751
– C. Langer, J. Riehle, S. Duerwald, N. Frey, M. Wiemer (Kiel and Minden, DE)
Density of stent struts is a risk factor for late acquired stent malappossition in second generation drug P1752
eluting stents - a prospective, randomized comparison using optical coherence tomography.
SUNDAY – MORNING
– C. Gangl, C. Roth, S. Scherzer, L. Krenn, D. Dalos, G. Delle-Karth, T. Neunteufl, J. Kastner, I. Lang,
R. Berger (Vienna, AT)
Clinical significance of echo-attenuated plaque on intravascular ultrasound in lesions with stable angina P1753
pectoris in comparison with other types of unstable plaque.
– S. Kimura, T. Sugiyama, Y. Yamakami, Y. Sagawa, K. Kojima, H. Ohtani, K. Hishikari, H. Hikita,
Global myocardial perfusion quantified in mild to severe systemic sclerosis; novel insights from MR P1754
stress imaging of coronary sinus flow.
– T. Gyllenhammar, M. Kanski, H. Engblom, D. Wuttge, M. Carlsson, R. Hesselstrand, H. Arheden (Lund, SE)
Non-invasive cardiac imaging in patients with myocardial injury after non cardiac surgery. P1755
– R.B. Grobben, J.A.R. Van Waes, T. Leiner, L.M. Peelen, G.J. De Borst, H.C. Vogely, D.E. Grobbee,
P.A.F.M. Doevendans, W.A. Van Klei, H.M. Nathoe (Utrecht, NL)
Clinical equivalence of evolocumab among patient subgroups in PROFICIO: a pooled analysis of 3146 P1756
patients from phase 3 studies.
– E. Stroes, J. Robinson, F. Raal, R. Dufour, D. Sullivan, M. Blagden, H. Kassahun, J. Yang, S. Wasserman,
M. Koren (Amsterdam, NL; Iowa City, Minneapolis, Thousand Oaks and Jacksonville, US; Johannesburg,
ZA; Montreal, CA; Camperdown, AU; Chesterfield, UK)
Optimal medical therapy may be a better initial strategy in patients with chronic total occlusion of a P1757
single coronary artery with low ischemic burden.
– J.-W. Hwang, J.-H. Yang, S.-H. Choi, W.-J. Jang, S.-H.W.A. Lee, J.-Y. Hahn, Y.-B. Song, J.-H. Choi,
S.-H. Lee, H.-C. Gwon (Seoul, KR)
Dabigatran vs. warfarin in venous thromboembolism: a meta-analysis. P1758
– I. Sipahi, C. Cuhadaroglu (Istanbul, TR)
Impact of ascorbic acid on post-cardiothoracic surgery atrial fibrillation and length of stay: a P1759
meta-analysis of randomized controlled trials.
– W. Baker, C. Coleman (Storrs, US)
Predictors of cardiovascular events from the 2-year follow-up data in patients with peripheral arterial P1760
disease treated with antiplatelet agents.
– Y. Higashi, T. Miyata, H. Shigematsu, H. Origasa, M. Fujita, H. Matsuo, H. Naritomi, H. Matsuda,
M. Nakajima (Hiroshima, Tokyo, Toyama, Kyoto and Osaka, JP)
A phase 1, randomized, placebo-controlled, single ascending and multiple dose study of subcutaneously P1761
administered ALN-PCSSC in subjects with elevated low density lipoprotein cholesterol.
– K. Fitzgerald, D. Kallend, S. White, A. Borodovsky, J. Sutherland, B. Bettencourt, V. Clausen, P. Wijngaard,
J. Horton, A. Simon (Cambridge, Parsippany and Dallas, US)
Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a P1762
randomized, prospective, placebo-controlled clinical trial.
– T.H. Tsai, S. Chua, P.H. Sung, Y.L. Chen, S. Leu, J.J. Sheu, H.K. Yip (Kaohsiung, TW)
HEART FAILURE: FROM BENCH TO BEDSIDE I

Assessment of intra- and inter-atrial asynchrony in patients with systolic and diastolic heart failure. P1763
– F.Q. Huang, L. Zhong, T.T. Le, J.I. Wong, R.S. Tan (Singapore, SG)
Resting heart rate shows an inverse correlation with left ventricular ejection fraction in patients with P1764
chronic heart failure: results from reality HF.
– Y. Cavusoglu, O. Kozan, S. Kucukoglu, A. Temizhan (Eskisehir, Izmir, Istanbul and Ankara, TR)
119
Endothelium-enriched microRNAs predict the presence of cardiac allograft vasculopathy. P1765

– N. Singh, W. Heggermont, S. Fieuws, J. Vanhaecke, J. Van Cleemput, B. De Geest (Leuven, BE)
Improved survival after heart transplantation in patients with cardiac amyloidosis. P1766
– M.A. Castel Lavilla, E. Santiago, M. Farrero, M. Cardona, A. Garcia-Alvarez, F. Perez-Villa (Barcelona, ES)
Novel PCR method for early detection of Chagas reactivation after heart transplantation in Chagas P1767
disease.
– L.E. Favaloro, M. Peradejordi, D. Absi, A. Schijman, C. Vigliano, C. Nagel, R. Ratto, M. Lopez Rosetti,
A. Bertolotti, R.R. Favaloro (Buenos Aires, AR)
Two-dimensional speckle tracking echocardiography in heart trasplant patients: mid-term follow up of P1768
right and left ventricular function.
– V. Monivas Palomero, S. Mingo Santos, E. Rodriguez Gonzalez, A. Restrepo Cordoba, J. Goirigolzarri
Artaza, D. Jimenez Sanchez, B. Rivero Arribas, M. Gomez Bueno, J. Segovia Cubero, L. Alonso Pulpon
(Madrid, ES)
Favorable medium-term outcome of transplanted hearts selected from marginal donors by P1769
pharmacological stress echocardiography.
– T. Bombardini, M. Cameli, R. Del Bene, M. Maccherini, L. Potena, E. Pilato, E. Picano (Pisa, Siena, Florence
and Bologna, IT; Astana, KZ)
Insulin resistance is a predictor of long term prognosis in chronic systolic heart failure. P1770
– L. Voronkov, M. Ilnytska, T. Gavrilenko, S. Potashev, P. Babich (Kiev, UA)
Change in relaxation pattern of the left and right ventricle after freedive training. P1771
– R. Pudil, M. Zajac (Hradec Králové and Prague, CZ)
Altered torsion mechanics in patients with hypertrophic cardiomyopathy: blame it on the P1772
LVOT-obstruction?
– L. Halmai, A. Kardos, T. Forster, A. Nemes, N. Banner, S. Neubauer (Milton Keynes, London and Oxford,
UK; Szeged, HU)
Diastolic dysfunction precedes overt systolic dysfunction in chemotherapy-induced cardiotoxicity. P1773
– G. Portugal, A. Galrinho, L. Branco, M. Mota Carmo, J. Feliciano, A.V. Monteiro, P. Pinto Teixeira, T. Pereira
Da Silva, M. Nogueira, R. Ferreira (Lisbon, PT)
Differences in sympathetic activity in chronic heart failure patients partially explain differences in P1774
prognosis between preserved and depressed ejection fraction.
– N. Farre, C. Enjuanes, G. Gonzalez-Robledo, P. Moliner-Borja, S. Ruiz, J.M. Verdu-Rotellar,
I. Rodriguez-Costoya, R. Olivero-Soldevila, J. Bruguera, J. Comin-Colet (Barcelona, ES)
HEART FAILURE: FROM BENCH TO BEDSIDE III

Left ventricular calcium-handling proteins in the type 2 diabetic human heart with preserved ejection P1775
fraction.
– R.R. Lamberts, G. Hughes, C.T. Bussey, P. Saxena, I.F. Galvin, M.K. Noye, S. Coffey, M.J.A. Williams,
J.C. Baldi, P.P. Jones (Dunedin, NZ; Oxford, UK)
The Relationship of Intima-Media Thickness in the Brachial Artery and Endothelial Function with Left P1776
Ventricular Diastolic Dysfunction.
– Y. Ohno, T. Miyoshi, T. Ono, H. Oe, K. Nakamura, H. Ito (Okayama, JP)
Association of arterial stiffness and elevated left atrial pressure in patients with and without diastolic P1777
dysfunction - a subgroup analysis from Diast-CHF.
– C. Luers, S. Seelaender, R. Wachter, G. Hasenfuss, B. Pieske, F. Edelmann (Oldenburg, Göttingen and
Berlin, DE)
Association of cystatin C with heart failure with preserved ejection fraction. Potential role of altered P1778
collagen metabolism.
– A. Gonzalez Miqueo, A. Huerta, B. Lopez, O. Beloqui, R. Querejeta, G. San Jose, S. Ravassa, E. Zublillaga,
G. Rabago, J. Diez (Pamplona and San Sebastian, ES)
Prognostic impact of the left atrial function in heart failure patients with preserved ejection fraction. P1779
– H. Okura, N. Matsusaki, M. Kanai, T. Fujimoto, Y. Sakamoto, T. Kataoka (Kurashiki and Sakai, JP)
Predictors of heart failure with preserved systolic function after ST-segment elevation myocardial P1780
infarction.
– J.-H. Ahn, J.R. Park, S.-J. Hwang, J.-S. Koh, Y.H. Jung, C.H. Kwak, J.-Y. Hwang (Jinju, KR)
Utility of sAxl and Lp-PLA2 biomarkers in early detection of cardiac allograft vasculopathy in heart P1781
transplantation patients.
– S. Mirabet Perez, P. Garcia De Frutos, J. Ordonez, V. Brossa, L. Lopez, C.H. Munoz Guijosa, A. Sionis,
E. Roig (Barcelona, ES)
S100/calgranulin mediated inflammation promotes FGF23 expression in cardiac fibroblasts and LVH. P1782
– M. Hofmann-Bowman, A. Daugherty, D. Rateri, L.Y. Yan (Chicago and Lexington, US)
Effect of alcohol intake on diastolic function: the Ethnic-Echocardiographic Heart of England Screening P1783
Study (E-ECHOES).
– E. Shantsila, A. Shantsila, P.S. Gill, G.Y.H. Lip (Birmingham, UK)
Heart rate as a diagnostic and prognostic marker in patients with heart failure with preserved ejection P1784
fraction.
– C.M. Stanescu, C. Gutu, G.A. Dan (Bucharest, RO)
Diastolic dyssynchrony has no impact on quality of life in patients with dialted cardiomyopathy. P1785
– A.A.M. Farrag, E. Fares, S. Bakhoum, W.A. El-Aroussy (Cairo, EG)
Riociguat treatment for patients with pulmonary hypertension due to heart failure with preserved ejection P1786
fraction.
– S. Aschauer, F. Duca, A. Bachmann, A. Kammerlander, C. Zotter-Tufaro, J. Mascherbauer, D. Bonderman
(Vienna, AT)
120
HEART FAILURE: FROM BENCH TO BEDSIDE IV

Comparison between in vivo and post mortem diagnoses in patients with heart failure. P1787
– L.F. Lipari Dinardi, T.V. Pereira, L.K.R. Almeida, L. Isper, T.S. Barbosa, V.S. Issa, S.M. Ayub-Ferreira,
L.A. Benvenuti, E.A. Bocchi (São Paulo, BR)
NGAL/MMP9 complex: from kidney injury to worsening of heart remodelling in cardiorenal syndrome type P1788
II.
– A. Angelini, C. Castellani, M.G. Virzi, M. Fedrigo, G. Thiene, M. Valente, C. Ronco, G. Vescovo (Padua and
Vicenza, IT)
Clinical applicability of different methods of baroreflex sensitivity assessment in patients with mild heart P1789
failure.
– B. Paleczny, M. Olesinska, A. Siennicka, P. Niewinski, E.A. Jankowska, B. Ponikowska, W. Banasiak,
S. Von Haehling, S.D. Anker, P. Ponikowski (Wroclaw, PL; Göttingen, DE)
Is hemoconcentration a reliable marker of decongestion in acute heart failure? P1790
– D. Aronson, A. Solomonica, S. Chirmicci, W. Darawsha, A. Azzam (Haifa, IL)
Diastolic but not systolic dysfunction is prevalent in long term breast cancer survivors. P1791
– G. Kunszt, K.H. Tjessem, H. Dalen, S.D. Fossaa, A. Fossaa, S. Aakhus (Oslo and Trondheim, NO)
Early changes in left atrial volume in patients with AMI and diastolic dysfunction - relation to invasive P1792
hemodynamics at rest and during exercise.
– R. Bakkestroem, M.J. Andersen, M. Ersboel, F. Gustafsson, L. Kober, C. Hassager, J. Bro-Jeppesen,
J.E. Moller (Odense and Copenhagen, DK)
Endomyocardial biopsy with a J-shaped sheath reduced the risk of tricuspid regurgitation after heart P1793
transplantation.
– Y. Tsukamoto, T. Ohtani, Y. Ichibori, K. Nakamoto, H. Kioka, O. Yamaguchi, K. Toda, N. Fukushima,
Y. Sawa, Y. Sakata (Osaka, JP)
SUNDAY – MORNING
Comparison of conventional measures to estimate right ventricular function in patients after heart P1794
transplantation using 3D and speckle-tracking echocardiography.
– A. Kosztin, A. Assabiny, M. Tokodi, S.Z. Braun, Z.S. Tarcza, A. Hajas, P. Takacs, B. Sax, B. Merkely,
A. Kovacs (Budapest, HU)
Evaluation of left ventricular myocardial mechanics and synchrony in heart transplant patients using P1795
three-dimensional echocardiography.
– A. Assabiny, A. Kosztin, B. Farkas, M. Tokodi, Z.S. Szelenyi, A. Hajas, P. Takacs, B. Sax, B. Merkely,
Time (not) to RELAX? P1796
– A. Matos, P. Mendes, P. Matos, L. Carneiro, R. Baptista, S. Costa, F. Franco (Coimbra, Penafiel and
Matosinhos, PT)
Urinary NGAL - troponin of the kidney? P1797
– M. Dankova, T. Pazmanova, V. Hricak, D. Svobodova, B. Zitny, J. Gergel, P. Pontuch (Bratislava, SK)
HEART FAILURE, OTHER

Prognostic differences among equations for estimated glomerular filtration ratio in acute heart failure P1798
syndrome.
– N. Kagiyama, Y. Matsue, T. Kume, H. Okura, M. Suzuki, A. Matsumura, K. Yamamoto, Y. Hashimoto,
K. Yoshida (Okayama, Kamogawa and Kurashiki, JP)
Patiromer reduced serum K+ in hyperkalaemic patients with HF and advanced CKD on RAAS inhibitors: P1799
Results from OPAL-HK and AMETHYST-DN.
– B. Pitt, M. Weir, D.A. Bushinsky, M. Mayo, D. Garza, Y. Stasiv, C. Du Mond, L. Berman, G. Bakris (Ann
Arbor, Baltimore, Rochester, Redwood City and Chicago, US)
The predictors of dyssynchrony deterioration in patients with left bundle branch block and normal EF. P1800
– D. Duplyakov, Z. Vozhdaeva, V. Gluhova, E. Sysuenkova (Samara and Togliatti, RU)
Incidence and long-term impact of progressive hyponatremia in heart failure patients with reduced and P1801
preserved ejection fraction.
– M. Yamazoe, A. Mizuno, S. Kosaka, Y. Shiraishi, T. Inohara, A. Goda, Y. Izumi, M. Yagawa, K. Mahara,
T. Yoshikawa (Tokyo, JP)
Visit-to-visit systolic blood pressure variability may predict adverse outcomes in stable heart failure with P1802
reduced ejection fraction.
– E. Troitskaya, Y. Kotovskaya, I. Merai, Z. Kobalava (Moscow, RU)
Right ventricular endomyocardial biopsy in a non-transplant population. A twenty-year single centre P1803
experience.
– A. Yahyai (Gothenburg, SE)
Predictors of acute heart failure after vascular surgery. P1804
– D.M. Gualandro, F.G. Marcondes-Braga, P.C. Yu, F.A.M. Cardozo, G.B. Llobet, D. Calderaro, E.S. Melo,
I.B. Casella, N. Luccia, B. Caramelli (São Paulo, BR)
Optimism and quality of life in patients with heart failure. P1805
– I.H. Kraai, K.M. Vermeulen, H.L. Hillege, T. Jaarsma, T. Hoekstra (Groningen, NL; Linköping, SE)
Ethnic disparity in the clinical characteristics of patients with heart failure. P1806
– I. Gotsman, S. Avishai-Eliner, R. Jabara, Z. Zemora, A. Shauer, C. Lotan, A. Keren (Jerusalem, IL)
Effect of newly developed left ventricular dysfunction on galectin-3 dynamics in patients with first P1807
episode of an acute coronary syndrome treated with percutaneous coronary intervention.
– M. Stachura, P.J. Kwasiborski, R. Ryczek, A. Krzesiak-Lodyga, E. Korzeniec, A. Karasek, A. Mikulska,
P. Kowalczyk, A. Cwetsch (Warsaw, PL)
121
HEART FAILURE: FROM BENCH TO BEDSIDE II

Fluid status predicts adverse outcome in patients with heart failure and preserved ejection fraction. P1808
– B. Koell, C. Zotter-Tufaro, J. Mascherbauer, F. Duca, S. Aschauer, A. Kammerlander, M. Antlanger,
M. Saemann, D. Bonderman (Vienna, AT)
Relationship between arterial stiffness and the degree of change in exercise induced left ventricular P1809
end-diastolic pressure in patients with preserved left ventricular ejection fraction.
– S.I. Choe, J.H. Shin, S.G. Kim, Y.H. Im, J.H. Shin (Guri and Seoul, KR)
Transgenic rat model overexpressing endothelial beta3-adrenoceptor: a new model for heart failure with P1810
– V. Prat, D. Roul, M. Ferron, N. Piriou, D. Guijarro, V. Aillerie, A. Grabherr, B. Rozec, B. Lauzier, C. Gauthier
(Nantes, FR)
Retained cardiac implantable electronic devices post orthotopic heart transplantation: prevalence and P1811
complications.
– A. Koshy, S. Nanayakkara, J. Martin, P. Bergin, J.A. Mariani (Melbourne, AU)
Prognostic relevance of the right heart catheter following heart transplantation. P1812
– J.P. Molkentin, I. Sudano, M. Frank, M. Naegele, F. Enseleit, F. Ruschitzka, A.J. Flammer (Zurich, CH)
Predictive value of PAPP-A, sCD40L, and anti-HLA antibodies in cardiac transplant recipients. P1813
– A. Shevchenko, T. Khalilulin, O. Shevchenko, B. Mironkov, V. Zakharevich, I. Muminov, S. Gautier (Moscow,
RU)
Diastolic adaptation as a central mechanism in the myocardial response to acute haemodynamic P1814
overload.
– A.M. Leite Moreira, J. Almeida-Coelho, I. Falcao-Pires, A.P. Lourenco, A.F. Leite-Moreira (Porto, PT)
Left atrial to left ventricular size ratio by 2D echocardiography can predict elevated left atrial pressures in P1815
heart failure patients with preserved ejection fraction.
– C. Katikireddy, B. Khatri, M. Singh, N. Shafi (Fresno, US)
Treating advanced heart failure with biventricular assist devices in a low organ donation environment. P1816
– A. Gkouziouta, G. Karavolias, L. Louca, S. Adamopoulos, P. Sfirakis (Athens, GR)
Cardiac progenitor cell infusion in patients with univentricular heart disease in heart failure with P1817
– T. Goto, D. Ousaka, S. Ishigami, S. Ohtsuki, S. Kasahara, S. Sano (Okayama, JP)
TREATMENTS OF HYPERTENSION
Impact of fixed-dose combination of perindopril/amlodipine on left ventricular myocardial deformation in P1818

patients with arterial hypertension.
– M.Y. Kolesnyk, G.V. Dzyak, Y.V. Didenko (Zaporizhzhya and Dnipropetrovsk, UA)
Combination with low-dose dextromethorphan improves the effect of amlodipine monotherapy in clinical P1819
hypertension.
– W.H. Yin, W.K. Tseng, H.I. Yeh, S.M. Cheng, T.C. Wu, M.H. Wen, Y.J. Hung, C.C. Wu, J.W. Chen (Taipei
and Kaohsiung, TW)
The blood pressure control predictors in hypertensive patients with and without ischemic heart disease. P1820
– G. Radchenko, L.O. Mushtenko, T.G. Salascheva (Kiev, UA)
Combination of optimal medical therapy is essential in management of patinents with coronary artery P1821
disease: pulse wave velocity long-term follow up Study.
– K. Shiina, H. Tomiyama, C. Matsumoto, M. Odaira, K. Kimura, A. Yamashina (Tokyo, JP)
Hypotensive effect of dinitrosyl iron complex with glutathione (DNIC): clinical trials on healthy volunteers P1822
and patients with stable hypertension and in case of hypertensive crisis.
– O. Rodnenkov, A. Zorin, A. Gosteev, A. Dragnev, E. Chazov (Moscow, RU)
Strong patient adherence and improved blood pressure control under treatment with a fixed dose P1823
combination (FDC) of bisoprolol and amlodipine.
– U. Hostalek, E.M.W. Koch, D. Czarnecka (Darmstadt and Alsbach, DE; Krakow, PL)
Persistence of initial antihypertensive therapy in patients of outpatient specialized cardiac clinic. P1824
– A. Kontsevaya, T. Romanenko (Moscow, RU)
Clinic and home blood pressure lowering effect of fimasartan in postmenopausal women with P1825
hypertension.
– S. Joo, K. Kim, D. Kim, S. Lee, K. Hwang, M. Kim, D. Kang, J. Park (Jeju, Seongnam, Busan, Wonju,
Cheongju, Seoul and Suwon, KR)
Can brain natriuretic peptide predict Prognosis in resistant hypertension? P1826
– A.O. Konradi, I. Emelyanov, V. Dorofeykov, P. Beltukov (St. Petersburg, RU)
Diuretics, having a tendency of more antihypertensive effect at a low temperature, reduce the seasonal P1827
variability of blood pressure.
– K. Nomoto, T. Mitsui, M. Miyagi, M. Kokubo, A. Shimizu, T. Murohara (Obu and Nagoya, JP)
Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. P1828
– M. Cengiz, S. Yavuzer, M. Yuruyen, H. Yavuzer, S.A. Dikici, B. Kilickiran Avci, O.F. Karatas, H. Uzun,
M. Ozen, Z. Ongen (Istanbul, TR)
Persistence of fixed and free combination of ramipril and amlodipine in hypertension. P1829
– G. Simonyi, T. Ferenci (Budapest, HU)
122
SUNDAY 30 AUGUST 2015 – LUNCH TIME SESSIONS

YOUNG INVESTIGATORS AWARDS SESSION: THROMBOSIS Young Investigators Awards Abstracts
Chairperson(s): K.A.A. Fox (Edinburgh, UK); J.A.C. Morais (Leiria, PT)
Judge(s): B. Rocca (Rome, IT); S. Halvorsen (Oslo, NO); A. Cohen (Paris, FR)
12:40 Assessment of a stroke risk stratification scheme in a heart failure population in sinus rhythm. 1830
– L. Melgaard, A. Gorst-Rasmussen, L.H. Rasmussen, G.Y. Lip, T.B. Larsen (Aalborg, DK; Birmingham, UK)
12:57 Risk of hemorrhagic and ischemic stroke for combined antiplatelet therapy and new generation 1831
oral anticoagulants in patients with acute coronary syndrome: Meta-analysis of 11 randomized
clinical trial.
– F. Gao, Y.J. Zhou, Z.J. Wang, H. Shen, S.W. Yang, X.L. Liu (Beijing, CN)
13:15 Stroke and recurrent haemorrhage associated with antithrombotic treatment following 1832
gastrointestinal bleeding in patients with atrial fibrillation: A Danish nationwide cohort study.
– L. Staerk, G.Y.H. Lip, J.B. Olesen, E.L. Fosbol, J.L. Pallisgaard, A. Gundlund, T.B. Lindhardt, M.L. Hansen,
C. Torp-Pedersen, G. Gislason (Hellerup, Hvidovre and Aalborg, DK; Birmingham, UK)
13:32 Dex40-GTMAC3, a new tool to reverse unfractionated heparin effects during intravascular or 1833
cardiac interventions.
– B. Kalaska, K. Kaminski, E. Sokolowska, D. Czaplicki, K. Stalinska, K. Szczubialka, J. Bereta, D. Pawlak,
M. Nowakowska, A. Mogielnicki (Bialystok and Krakow, PL)
Winners will be announced at the Awards Ceremony on Monday 31 August at 18:00 in the Hub.
SUNDAY – LUNCH TIME

YOUNG INVESTIGATORS AWARDS SESSION: AGEING AND Young Investigators Awards Abstracts
SENESCENCE
under the auspices of Nobel Prize Laureate
Chairperson(s): E.H.B. Blackburn (San Francisco, US); F. Cosentino (Stockholm, SE)
Judge(s): R.F. Ventura-Clapier (Chatenay-Malabry, FR); D. Garcia-Dorado (Barcelona, ES); K.R. Sipido (Leuven, BE)
12:40 Telomere length predicts clinical outcomes post-revascularization procedures: its role as a novel 1834
biomarker of systemic oxidative stress and cardiovascular ageing.
– M. Margaritis, G. Lazaros, S. Patel, L. Herdman, A.S. Antonopoulos, I. Akoumianakis, F. Sanna,
D. Tousoulis, K.M. Channon, C. Antoniades (Oxford, UK; Athens, GR)
12:57 Neureguline-1 attenuates stress-induced vascular senescence in vitro and in vivo. 1835
– H. Shakeri, D.M. Schrijvers, C.R. Van Hove, G.R. De Meyer, K. Lemmens (Antwerp, BE)
13:15 Matricellular protein CCN1-mediated premature senescence is a negative regulator of cardiac 1836
fibrosis.
– K. Meyer, B. Hodwin, S. Engelhardt, A. Sarikas (Munich, DE)
13:32 Vascular ageing, telomere biology, oxidative stress and chronic inflammation in patients with type 1837
2 diabetes mellitus.
– N. Brailova, E. Dudinskaya, I. Strazhesko, D. Akasheva, M. Pokrovskaya, O. Tkacheva, V. Pykhtina,
S. Boytsov, M. Shestakova (Moscow, RU)

YOUNG INVESTIGATORS AWARDS SESSION: CORONARY Young Investigators Awards Abstracts
PATHOPHYSIOLOGY AND MICROCIRCULATION
Chairperson(s): A. Koller (Budapest, HU); J.E. Davies (London, UK)
Judge(s): M. Ovize (Lyon, FR); T. Akasaka (Wakayama, JP); A.M. Caixeta (São Paulo, BR)
12:40 Spotty calcification as a marker of vulnerable plaque: novel findings from in vivo study in 1838
survivors of cardiac arrest and in vitro study in autopsied patients of sudden cardiac death.
– J. Pu, P. Zhang, G. Mintz, X. Ma, B. He (Shanghai, CN; Baltimore, New York and Philadelphia, US)
12:57 Enhanced platelet toll- like receptor- 2 and 4 expression in acute coronary syndrome. 1839
– K.M. Gurses, D. Kocyigit, M.U. Yalcin, H. Canpinar, E.B. Kaya, L. Tokgozoglu, M.A. Oto, D. Guc, N. Ozer,
K. Aytemir (Ankara, TR)
13:15 Impact of aortic valve stenosis on coronary hemodynamics and the instantaneous effect of 1840
transcatheter aortic valve implantation.
– E.M.A. Wiegerinck, T.P. Van De Hoef, M.C. Rolandi, Z.Y. Yong, F. Van Kesteren, K.T. Koch, M.M. Vis,
B.A.J.M. De Mol, J.J. Piek, J. Baan (Amsterdam, NL)
13:32 Incremental diagnostic value of combined non-invasive assessment of endothelial shear stress 1841
and molecular imaging of inflammation for the early identification of high-risk plaque.
– G. Gitsioudis, Y. Chatzizisis, A. Missiou, A. Antoniadis, D. Mitsouras, A. Giannopoulos, M. Stuber,
G. Giannoglou, H.A. Katus, G. Korosoglou (Heidelberg, DE; Boston, US; London, UK; Lausanne, CH;
Thessaloniki, GR)
123

YOUNG INVESTIGATORS AWARDS SESSION: POPULATION SCIENCES Young Investigators Awards Abstracts
Chairperson(s): E. Swahn (Linköping, SE)
Judge(s): T.C. Gillebert (Ghent, BE); S. Gielen (Halle, DE); A.N. Neskovic (Belgrade, RS)
12:40 30-year survival among patients with myocardial infarction before 50 years of age compared with 1842
the general population: a nationwide cohort study.
– M. Schmidt, S. Szepligeti, E. Hovath-Puho, H. Botker, H.T. Sorensen (Aarhus, DK)
12:57 A healthy lifestyle is strongly related to an increased heart rate variability in healthy adults. 1843
– S. Aeschbacher, T. Schoen, N. Good, N. Probst-Hensch, A. Schmidt-Trucksaess, M. Risch, L. Risch,
D. Conen (Basel, CH; Schaan, LI)
13:15 Threshold of ambient particulate matter level for increasing heart failure incidence may be lower 1844
than national standard.
– Q. Huynh, F. Johnston, C.L. Blizzard, T.H. Marwick, K. Negishi (Hobart, AU)
13:32 Dose and time dependent associations of smoking to incident subarachnoid hemorrhage in men 1845
and women.
– J.V. Lindbohm, J. Kaprio, V. Salomaa, M. Korja (Helsinki, FI)

YOUNG INVESTIGATORS AWARDS SESSION: CLINICAL SCIENCE Young Investigators Awards Abstracts
Chairperson(s): E.V. Shlyakhto (St. Petersburg, RU); P.E. Vardas (Heraklion, GR)
Judge(s): L.M. Goncalves (Coimbra, PT); G. de Simone (Naples, IT); J. Perk (Oskarshamn, SE)
12:40 Lower risk of mortality in angiotensin-converting enzyme inhibitor and angiotensin II receptor 1846
blocker treated patients with aortic stenosis. A nationwide propensity score matched study.
– M.J.D. Buron, K.E. Kristensen, G. Gislason (Hellerup, DK)
12:57 Low cardiorespiratory fitness predicts arrhythmia recurrence in patients with symptomatic atrial 1847
fibrillation.
– A. Elliott, R.K. Pathak, M.E. Middeldrop, M. Meredith, D. Lau, R. Mahajan, P. Sanders (Adelaide, AU)
13:15 Sudden death in sport: insights from a national pathology referral center. 1848
– G. Finocchiaro, M. Papadakis, J.L. Robertus, G. Mellor, E. Behr, S. Sharma, M. Sheppard (London, UK)
13:32 Subclinical left ventricular dysfunction is associated with reduced brain structure and function. 1849
– C.M. Park, E.D. Williams, T. Tillin, R. Stewart, N. Chaturvedi, A.D. Hughes (London, UK)

YOUNG INVESTIGATORS AWARDS SESSION: BASIC SCIENCE Young Investigators Awards Abstracts
Chairperson(s): L. Badimon (Barcelona, ES); J.L. Balligand (Brussels, BE)
Judge(s): L. Tokgozoglu (Ankara, TR); A. Angelini (Padua, IT); B. Ghaleh (Créteil, FR)
12:40 Platelet-derived growth factor-BB selectively augments non-canonical sonic hedgehog signaling 1850
in adventitial fibroblasts.
– J.-M. Daniel, J. Dutzmann, A. Koch, J. Bauersachs, D. Sedding (Hannover, DE)
12:57 CASK is an important regulator of cardiac excitation-contraction coupling. 1851
– J. Mustroph, S. Gupta, A. Dietz, F. Baehr, T. Islam, A. El-Armouche, L.S. Maier, S. Wagner (Göttingen,
Dresden and Regensburg, DE)
13:15 miR-218 and mi-R34a induce oxidative stress by orchestrating epigenetic remodelling of 1852
DNA/histone complexes in the diabetic heart.
– S. Costantino, F. Paneni, L. Berrino, M. Volpe, T.F. Luscher, F. Cosentino (Stockholm, SE; Naples and
Rome, IT; Zurich, CH)
13:32 Titin phosphorylation by PKG as a mechanism of acute adaptation to myocardial stretch. 1853
– A.M. Leite Moreira, J. Almeida-Coelho, J.S. Neves, M. Neiva-Sousa, R. Castro-Ferreira, N. Hamdani,
W.A. Linke, A.P. Lourenco, A.F. Leite-Moreira (Porto, PT; Bochum, DE)
124

NURSING AND ALLIED HEALTH PROFESSIONALS INVESTIGATOR AWARD Special Session
Chairperson(s): D. Fitzsimons (Belfast, UK); C.S. Jennings (London, UK)
Judge(s): Y. Juilliere (Vandoeuvre-lès-Nancy, FR); M. Dorobantu (Bucharest, RO); T. Jaarsma (Norrköping, SE)
12:40 Influence of childhood socioeconomic disadvantage in the incidence of cardiovascular disease in 1854
adults in Chile.
– C. Nazzal, P. Frenz, F. Cerecera, G. Cavada, J. Kaufmann (Santiago, CL; Montreal, CA)
12:55 Health care needs in adolescents into young adults with congenital heart disease: A Delphi survey 1855
of patients, parents and healthcare providers.
– C.W. Chen, W.J. Su, Y.T. Chiang, Y.M. Shu, P. Moons (Taipei and Tao-yuan, TW; Leuven, BE)
13:10 Antihypertensive treatment based on risk of cardiovascular disease or levels of risk factors? 1856
Findings from the Irish Longitudinal Study on Ageing (TILDA).
– C.M. Murphy, E. Shelley, R. Clarke, K. Bennett, T. Fahey, R.A. Kenny (Dublin, IE; Oxford, UK)
13:25 Can ambulance nurses adequately risk stratify patients with chest pain? A comparison between 1857
prehospital (ambulance) and hospital (ER) chest pain triage, using the HEART score.
– R.T. Tolsma, D. Ali, M.J. Fokkert, R.J. Slingerland, M. Ishak, F. Van Eenennaam, K. Bruheim, E.A. Badings,
J.M. Ten Berg, A.W.J. Van ’T Hof (Zwolle, Nieuwegein, Breukelen and Deventer, NL)

12:45–13:45 | Rabat - Village 1
HIGH-RISK AND CHALLENGING PATIENTS: EVOLVING STRATEGIES TO IMPROVE Satellite Symposium
CARDIOVASCULAR OUTCOMES
Sponsored by Pfizer, Inc.
Chairperson(s): K.K. Ray (London, UK)
12:45 Welcome & introduction - High-risk and challenging patients: evolving strategies to improve 1858
cardiovascular outcomes.
12:50 Aligning cardiovascular disease risk with appropriate treatment intensity. 1859
13:00 Statins and chronic kidney disease, friend or foe? 1860
– D. De Zeeuw (Groningen, NL)
13:15 Prognostic impact of variability in visit-to-visit blood pressure and low-density 1861
lipoprotein-cholesterol measurements.
– S. Bangalore (New York, US)
13:30 Q&A - High-risk and challenging patients: evolving strategies to improve cardiovascular 1862
outcomes.
– K.K. Ray (London, UK), D. De Zeeuw (Groningen, NL), S. Bangalore (New York, US)
13:40 Closing - High-risk and challenging patients: evolving strategies to improve cardiovascular 1863
outcomes.

TARGETING THE HIGH-RISK PATIENT: EVOLVING CONCEPTS ON EBAC Accredited Educational Programme
OPTIMALLY MODIFYING RISK BY LIPID-MODULATING THERAPIES
Organised by Leiden University Medical Center. Course Director: Wouter Jukema
Chairperson(s): C.M. Ballantyne (Houston, US)
12:45 Introduction - Targeting the high-risk patient: evolving concepts on optimally modifying risk by 1864
lipid-modulating therapies.
– C.M. Ballantyne (Houston, US)
12:50 Targeting LDL-c: commonalities and differences among major guidelines. 1865
13:05 Triglyceride-rich lipoproteins and remnants. 1866
– B.G. Nordestgaard (Herlev, DK)
13:20 Treatment of the high risk patient: what do we do after statin therapy? 1867
– J.W. Jukema (Leiden, NL)
13:40 Summary and close - Targeting the high-risk patient: evolving concepts on optimally modifying 1868
risk by lipid-modulating therapies.
125
12:45–13:45 | Kiev - Village 3

MANAGING DIABETES & CARDIOVASCULAR DISEASE (CVD): EBAC Accredited Educational Programme
EXPLORING NEW EVIDENCE AND OPPORTUNITIES
Organised by University College London. Course Director: John Deanfield
Chairperson(s): D.J. Betteridge (London, UK); J.E. Deanfield (London, UK)
12:45 Diabetes & cardiovascular disease: the risk factor to be challenged. 1869
– J.E. Deanfield (London, UK)
12:50 What is the story about diabetes & CVD: rationale for a multifactorial approach. 1870
– D.J. Betteridge (London, UK)
13:05 SGLT2 inhibition in the management of type 2 diabetes: potential impact on CVD risk. 1871
– S. Inzucchi (New Haven and Conn, US)
13:20 SGLT2 inhibitor outcome trials: future opportunities. 1872
– D. Fitchett (Toronto, CA)
13:35 Discussion - Managing diabetes & CVD: exploring new evidence and opportunities. 1873
– D.J. Betteridge (London, UK), J.E. Deanfield (London, UK), S. Inzucchi (New Haven and Conn, US),
D. Fitchett (Toronto, CA)
Supported by an unrestricted educational grant from Physicians’ Academy for Cardiovascular Education

TREATMENT INITIATION IN HYPERTENSIVE PATIENTS: A NEW EBAC Accredited Educational Programme
STRATEGY
Organised by Hopital Europeen Georges Pompidou. Course Director: Stephane Laurent
Chairperson(s): E. Agabiti-Rosei (Brescia, IT); R.E. Schmieder (Erlangen, DE)
12:45 Introduction - Treatment initiation in hypertensive patients: a new strategy. 1874
– R.E. Schmieder (Erlangen, DE)
12:48 Rationale for using a fixed-dose combination first-line in hypertension. 1875
– N.R. Poulter (London, UK)
13:03 A new antihypertensive strategy: optimized dosages right from the start. 1876
– S. Laurent (Paris, FR)
13:18 New combination therapy: the largest development program of the decade. 1877
– G. Bakris (Münster, US)
13:33 Discussion - Treatment initiation in hypertensive patients: a new strategy. 1878
– E. Agabiti-Rosei (Brescia, IT), R.E. Schmieder (Erlangen, DE), N.R. Poulter (London, UK), S. Laurent (Paris,
FR), G. Bakris (Münster, US)
13:43 Conclusion - Treatment initiation in hypertensive patients: a new strategy. 1879
– E. Agabiti-Rosei (Brescia, IT)
126

LESSONS LEARNED FROM THE TRIAL EVALUATING CARDIOVASCULAR OUTCOMES Satellite Symposium
WITH SITAGLIPTIN (TECOS) CARDIOVASCULAR (CV) SAFETY TRIAL AND THE EVOLVING
ROLE OF SITAGLIPTIN IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES AND
CARDIOVASCULAR DISEASE
Sponsored by MSD
Chairperson(s): N. Marx (Aachen, DE)
12:45 Welcome and introductions - Lessons learned from the Trial Evaluating Cardiovascular Outcomes 1880
with Sitagliptin (TECOS) Cardiovascular (CV) safety trial and the evolving role of sitagliptin in the
treatment of patients with type 2 diabetes and cardiovascul.
– N. Marx (Aachen, DE)
12:55 Building our understanding of the role dipeptidyl peptidase-4 (DPP-4) inhibitors play in the 1881
cardiovascular patient with type 2 diabetes.
– L. Leiter (Toronto, CA)
13:10 TECOS Cardiovascular (CV) safety trial: recent updates from the Cardiovascular (CV) safety trial 1882
for sitaglipton.
– E. Peterson (Durham, US)
13:40 Closing remarks - Lessons learned from the Trial Evaluating Cardiovascular Outcomes with 1883
Sitagliptin (TECOS) Cardiovascular (CV) safety trial and the evolving role of sitagliptin in the
treatment of patients with type 2 diabetes and cardiovascular disease.
– N. Marx (Aachen, DE)

Sunday 30 August, 15:45–16:15 in Green Park (The Hub)!

LATEST ADVANCES IN DIAGNOSTIC AND INTERVENTIONAL ECHO ILLUSTRATED BY Satellite Symposium
CLINICAL CASES
Chairperson(s): M.J. Monaghan (London, UK); R.M. Lang (Chicago, US)
12:45 Introduction to the session. Anatomical intelligence of ultrasound and periinterventional imaging. 1884
– M.J. Monaghan (London, UK)
12:50 Is anatomical intelligence of ultrasound ready for the next big step? - Lecture. 1885
– J.-L. Vanoverschelde (Brussels, BE)
13:06 Is anatomical intelligence of ultrasound ready for the next big step? - Case presentations. 1886
– C. Fernandez-Golfin (Madrid, ES)
13:23 Clinical cases illustrating how to improve interventions in structural heart disease. 1887
– J. Balzer (Düsseldorf, DE)
13:42 Anatomical intelligence of ultrasound and periinterventional imaging - Closing remarks. 1888
– R.M. Lang (Chicago, US)
12:45–13:45 | Oslo - Village 6

HYPERURICEMIA: NEW CRIMES FOR AN OLD FOE Satellite Symposium
Sponsored by The Menarini Group
Chairperson(s): A.J. Manolis (Voula, Athens, GR); C. Borghi (Bologna, IT)
12:45 Introduction - Hyperuricemia: new crimes for an old foe. 1889
– A.J. Manolis (Voula, Athens, GR)
12:50 Pivotal aspects of pathophysiology. 1890
– A.J. Manolis (Voula, Athens, GR)
13:05 Serum uric acid as main predictor of worse blood pressure (BP) control. 1891
– A. Cicero (Bologna, IT)
13:20 Management of hyperuricemia in clinical practice. 1892
– C. Borghi (Bologna, IT)
13:35 Discussion - Hyperuricemia: new crimes for an old foe. 1893
– A.J. Manolis (Voula, Athens, GR), A. Cicero (Bologna, IT), C. Borghi (Bologna, IT)
127

NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION – Satellite Symposium
TRANSLATING TRIAL DATA INTO CLINICAL PRACTICE
Sponsored by Daiichi Sankyo
Chairperson(s): A.J. Camm (London, UK); J. Weitz (Hamilton, CA)
12:45 Welcome and Introduction: non-vitamin K antagonist oral anticoagulants in atrial fibrillation – 1894
Translating trial data into clinical practice.
– J. Weitz (Hamilton, CA)
12:50 Practical considerations for treatment of atrial fibrillation patients with non-vitamin K antagonist 1895
oral anticoagulants.
13:05 ENGAGE-AF: translating trial results into clinical practice. 1896
– R.P. Giugliano (Boston, US)
13:20 Future perspectives on stroke prevention in atrial fibrillation. 1897
– P. Kirchhof (Birmingham, UK)
13:35 Panel Discussion: non-vitamin K antagonist oral anticoagulants in atrial fibrillation – Translating 1898
trial data into clinical practice.
– A.J. Camm (London, UK), J. Weitz (Hamilton, CA), H. Heidbuchel (Hasselt, BE), R.P. Giugliano (Boston,
US), P. Kirchhof (Birmingham, UK)
13:40 Closing remarks: non-vitamin K antagonist oral anticoagulants in atrial fibrillation – Translating 1899
trial data into clinical practice.
Monday 31 August, 10:15–10:45 in Regents Park (The Hub)!

HYBRID IMAGING AND ADVANCED QUANTIFICATION FOR ENHANCED DIAGNOSTIC Satellite Symposium
CONFIDENCE
Sponsored by Toshiba Medical Systems
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); J.E. Stirrup (London, UK)
12:45 Wall motion tracking for monitoring the heart health of athletes. 1900
– G.E. Pieles (Bristol, UK)
13:05 Fusion of CT and ultrasound images for improving the evaluation of calcified coronary arteries. 1901
– K.F. Kofoed (Copenhagen, DK)
13:25 A hybrid viewer for fusion of coronary CT and ultrasound 3D wall motion tracking. 1902
– J.L. Zamorano Gomez (Madrid, ES)

THE IMPORTANCE OF TIME IN CARDIOVERSION OF ATRIAL FIBRILLATION Satellite Symposium
Sponsored by Cardiome International AG
Chairperson(s): G.L. Botto (Como, IT); R. Schilling (London, UK)
12:45 Time is important in cardioversion of atrial fibrillation - Pro-con-discussion. 1903
– H. Domanovits (Vienna, AT)
12:55 Time is not important in cardioversion of atrial fibrillation - Pro-con-discussion. 1904
– F. Schiele (Besançon, FR)
13:05 Time is important in cardioversion of atrial fibrillation - Response - Pro-con-discussion. 1905
– H. Domanovits (Vienna, AT)
13:10 Time is not important in cardioversion of atrial fibrillation - Response - Pro-con-discussion. 1906
– F. Schiele (Besançon, FR)
13:15 Implementation of clinical pathways for rapid cardioversion of atrial fibrillation - Real-life 1907
experience with vernakalant.
– J. Cosin Sales (Valencia, ES)
13:35 Q&A - The importance of time in cardioversion of atrial fibrillation. 1908
– R. Schilling (London, UK), G.L. Botto (Como, IT)

Tuesday 1 September, 10:15–10:45 in Holland Park (The Hub)!
128
12:45–13:45 | Bern - Village 9

THE NEW WORLD OF ANTICOAGULATION: NOACS IN 2015 AND BEYOND Satellite Symposium
Sponsored by Boehringer Ingelheim
Chairperson(s): J. Eikelboom (Hamilton, CA); H.C. Diener (Essen, DE)
12:45 Welcome to the new world of anticoagulation. 1909
– J. Eikelboom (Hamilton, CA)
12:50 NOACs in clinical practice: step into my world. 1910
– H.C. Diener (Essen, DE)
13:00 The wider world: stroke prevention in practice. 1911
13:15 Management of bleeding and emergency procedures in anticoagulated patients. 1912
– C. Pollack (Philadelphia, US)
13:30 Panel discussion and Q&A - The new world of anticoagulation: NOACs in 2015 and beyond. 1913
– J. Eikelboom (Hamilton, CA; H.C. Diener (Essen, DE))
Don’t miss the complimentary Experts on the Spot sessions scheduled on:
– Sunday 30 August, 15:45–16:15 in Holland Park and Victoria Park (The Hub)!
– Monday 31 August, 10:15–10:55 in Holland Park and Victoria Park (The Hub)!

TRANSCATHETER MITRAL VALVE REPAIR (TMVR): HOW TO OPTIMIZE MITRAL Satellite Symposium
REGURGITATION TREATMENT
Sponsored by Abbott Vascular
Chairperson(s): A. Vahanian (Paris, FR); S. Kar (Los Angeles, US)
12:45 Introduction - Transcatheter Mitral Valve Repair (TMVR): how to optimize mitral regurgitation 1914
treatment.
– S. Kar (Los Angeles, US)
12:50 Mitral regurgitation kills: the urgency to diagnose and treat. 1915
– M. Senni (Bergamo, IT)
13:02 When should you treat or refer your Degenerative Mitral Regurgitation (DMR) patient for TMVR? 1916
– O. Alfieri (Brescia, IT)
13:14 When should you treat or refer your Functional Mitral Regurgitation (FMR) patient for TMVR? 1917
– R.S. Von Bardeleben (Mainz, DE)
13:27 Why should you treat or refer your patient to TMVR? 1918
13:40 Take home messages. 1919

ULTRA HIGH SENSITIVE BIOMARKERS: STRESS-TEST RULE OUT AND IDENTIFICATION Satellite Symposium
OF CARDIOVASCULAR RISK
Sponsored by Singulex, Inc.
Chairperson(s): P. Heseltine (Alameda, US)
13:00 Introduction - Ultra high sensitive biomarkers: stress-test rule out and identification of 1920
cardiovascular risk.
– P. Heseltine (Alameda, US)
13:05 Incremental value of a single high-sensitivity cardiac Troponin I measurement to rule-out 1921
myocardial ischemia.
– T. Reichlin (Basel, CH)
13:25 Cardiovascular biomarkers – Going from pathology to physiology. 1922
– D. Conen (Basel, CH)
13:40 Questions & conclusion - Ultra high sensitive biomarkers: stress-test rule out and identification 1923
of cardiovascular risk.
– P. Heseltine (Alameda, US)
129

AORTIC STENOSIS AND TAVI IN PRACTICE (BROUGHT TO BY THE COUNCIL ON Satellite Symposium
CARDIOLOGY PRACTICE AND THE VALVULAR HEART DISEASE WORKING GROUP)
Sponsored by Edwards Lifesciences
Chairperson(s): M. Guenoun (Plan-de-Cuques, FR); R. Rosenhek (Vienna, AT)
13:00 Indications for intervention in Aortic Stenosis. 1924
13:11 Patient Selection for TAVI. 1925
– J.J. Gomez-Doblas (Málaga, ES)
13:22 Technical aspects and outcomes of TAVI. 1926
– B.D. Prendergast (London, UK)
13:33 Follow-up management after aortic valve interventions. 1927
– R. Asteggiano (Turin, IT)

PRACTICAL DIMENSIONS OF NOAC-BASED MANAGEMENT OF STROKE PREVENTION IN Satellite Symposium
ATRIAL FIBRILLATION (AF) AND ACUTE CORONARY SYNDROME
Sponsored by Bayer Healthcare
Chairperson(s): S.Z. Goldhaber (Boston, US)
13:00 Program chair welcome and introduction -Practical dimensions of NOAC-based management of 1928
stroke prevention in Atrial Fibrillation (AF) and acute coronary syndrome.
13:05 Applying guidelines for management of AF to the front lines of cardiovascular practice: how are 1929
the guidelines directing us? How do we match specific patients with nonvalvular AF with specific
NOAC?
13:15 Practical issues for use of oral factor Xa inhibition following acute coronary syndrome: risk 1930
stratification, patient selection, timing of therapy, bleeding risk reduction, stented patients and
long-term management.
13:25 Practical dimensions of employing oral factor Xa inhibitors in patients with nonvalvular AF: the 1931
role of key clinical factors - Renal function, age, CHADS-VASc score, bleeding risk, previous
stroke, dosing, and regimen adherence - In selecting an evidence.
13:40 The foundation role of oral factor Xa inhibition for stroke prevention in AF and secondary 1932
prevention of acute coronary syndrome: from the registry and guidelines to the practical aspects
of cardiovascular care.

WHAT’S NEW IN CARDIAC COMPUTED TOMOGRAPHY (CT) & MAGNETIC RESONANCE Satellite Symposium
(MR)
Sponsored by GE Healthcare
Chairperson(s): G. Pontone (Milan, IT)
13:00 Update on MR coronary artery disease assessment. 1933
– G. Pilz (Hausham, DE)
13:22 Cardiac CT: from coronary assessment to myocardial perfusion. 1934
– L. Macron (Saint-Denis, FR)
13:00–13:45 | Tunis - Village 7

HOW TO USE HIGH-SENSITIVE CARDIAC TROPONIN T TO ACCELERATE THE Satellite Symposium
DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION: RESULTS FROM A PROSPECTIVE
MULTICENTER STUDY
Sponsored by Roche Diagnostics
Chairperson(s): H.A. Katus (Heidelberg, DE); B. Lindahl (Uppsala, SE)
13:00 Innovative approach to diagnose acute myocardial infarction in 1-hour with high-sensitive cardiac 1935
troponin T.
13:15 How to use low levels of high-sensitive cardiac troponin T to rule-out acute myocardial infarction 1936
with a single blood test.
– R. Body (Manchester, UK)
13:30 How markedly elevated initial high-sensitive cardiac troponin T value predicts acute myocardial 1937
infarction in patients with acute chest pain.
– E. Giannitsis (Heidelberg, DE)
130

THE PATIENT-CENTRIC APPROACH TO PULMONARY ARTERIAL HYPERTENSION Satellite Symposium
MANAGEMENT
Sponsored by Actelion Pharmaceuticals Ltd
Chairperson(s): N. Galie (Bologna, IT); J.G. Coghlan (London, UK)
13:00 Introduction - The patient-centric approach to pulmonary arterial hypertension management. 1938
– J.G. Coghlan (London, UK)
13:05 PAH management - Improving how PAH patients feel and function. 1939
– O. Sitbon (Le Kremlin-Bicêtre, FR)
13:20 PAH management - Improving patient outcomes. 1940
13:35 Discussion / closing remarks - The patient-centric approach to pulmonary arterial hypertension 1941
management.
– J.G. Coghlan (London, UK)
131
SUNDAY 30 AUGUST 2015 – AFTERNOON SESSIONS

ESC GUIDELINES – ACUTE CORONARY SYNDROMES NON-ST-ELEVATION Main Session
Chairperson(s): M. Roffi (Geneva, CH); C. Patrono (Rome, IT)
14:00 Diagnosis and risk assessment. 1942
14:22 Antithrombotic treatment. 1943
– J.-P. Collet (Paris, FR)
14:45 Invasive strategies and revascularisation. 1944
– M. Valgimigli (Rotterdam, NL)
15:07 Special populations and conditions. 1945

CLINICAL TRIAL UPDATE I – CARDIOVASCULAR DISEASES: PREVENTION, OUTCOMES, Clinical Trial Update
QUALITY
Chairperson(s): S. Achenbach (Erlangen, DE); M.L. Simoons (Rotterdam, NL)
14:00 The impact of digoxin on death and hospitalisation: unravelling the bias of prescription patterns. 1946
– D. Kotecha (Birmingham, UK)
14:15 Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients 1947
With vs Without Diabetes: the IMPROVE-IT Trial.
– R.P. Giugliano (Boston, US)
14:30 The Influence of Baseline Systolic Blood Pressure on Major Cardiovascular and Cerebrovascular 1948
Outcomes in the FREEDOM Trial: FREEDOM BP.
– M. Farkouh (New York, US)
14:45 Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in 1949
patients with multivessel coronary artery disease: 5-year clinical outcome of the FAME study.
– N.H.J. Pijls (Eindhoven, NL)
15:00 Prolonged event-free survival in more complex cases of heart disease: outcome data from 1,226 1950
patients from 3 randomised trials of nurse-led, multidisciplinary home-based intervention.
– S. Stewart (Melbourne, AU)
15:15 Persistent or Worsening Echocardiographic Dyssynchrony in Narrow QRS Heart Failure Patients 1951
Are Associated with Clinical Outcomes Unaffected by Cardiac Resynchronization Therapy:
an EchoCRT Substudy.
– J. Gorcsan (Pittsburgh, US)
132

MICROPARTICLES, VESICLES, EXOSOMES AND MIRNA: COMMUNICATION IN Rapid Fire Abstract
CARDIOVASCULAR PATHOLOGY
Chairperson(s): D. De Kleijn (Singapore, SG); J.P.G. Sluijter (Utrecht, NL)
14:00 Endothelial microparticles reduce neointimaformation and vascular smooth muscle cell 1952
proliferation in a microRNA-126-LRP6-dependent mechanism.
– F. Jansen, T. Stumpf, G. Nickenig, N. Werner (Bonn, DE)
14:09 MiR-223-3p post-transcriptionally regulates the expression of F3, the human tissue factor gene, 1953
and TF expression in acute coronary syndrome.
– A. Siegbahn, C. Christersson, J. Alfredsson (Uppsala, SE)
14:18 Differential effects of microparticles from patients with coronary artery disease as compared to 1954
healthy subjects on endothelial cell functions: critical role of miR-222.
– N. Kraenkel, S. Briand, E. Straessler, T.F. Luescher, U. Landmesser (Berlin, DE; Zurich, CH)
14:27 TGFb triggers miR-143/145 transfer from smooth muscle cells to endothelial cells through 1955
tunneling nanotubes.
– L. Elia, M. Climent Salarich, G. Condorelli, M. Quintavalle (Rozzano, IT)
14:36 MicroRNA-155 exerts cell-specific anti-angiogenic but pro-arteriogenic effects during adaptive 1956
neovascularization.
– F. Pankratz, X. Bemtgen, R. Zeiser, I. Hilgendorf, C. Smolka, T. Helbing, I. Hoefer, M. Moser, C. Bode,
S. Grundmann (Freiburg, DE; Utrecht, NL)
14:45 EMMPRIN is a major pro-angiogenic component of cardiac progenitor cell derived exosomes. 1957
SUNDAY – AFTERNOON
– J.A. Maring, K.R. Vrijsen, V. Verhage, P.A.F.M. Doevendans, S.A.J. Chamuleau, M.J. Goumans,
J.P.G. Sluijter (Leiden and Utrecht, NL)
14:54 Exosomes secreted from dendritic cells enhance tube formation in cardiac microvascular 1958
endothelial cells after myocardial infarction.
– H. Liu, J. Yuan, W. Gao, C. Wu, K. Yao, L. Zhang, X. Guo, W. Yu, Y. Zou, J. Ge (Shanghai and Ningbo, CN)
15:03 Endothelial microparticles reduce ICAM-1 expression in a microRNA-222-dependent mechanism. 1959
– F. Jansen, K. Baumann, G. Nickenig, N. Werner (Bonn, DE)
15:12 Inflammasome-induced intercellular signalling mechanisms via microparticles. 1960
– P. Pfeifer, F. Jansen, S. Zimmer, K. Baumann, E. Latz, B. Franklin, G. Nickenig, N. Werner (Bonn, DE)
15:21 MiR-33 antagonism increase cholesterol efflux and atheroma regression by increasing caveolin-1 1961
expression in hypercholesterolemia rabbits.
– W.W. Lin, M.F. Lee, W.T. Chao, K.Y. Wang (Taichung, TW)

MEET THE LEGENDS – RICHARD POPP Meet the Legends
Chairperson(s): F.J. Pinto (Lisbon, PT)
– R.L. Popp (Palo Alto, US)
– R.L. Popp (Palo Alto, US)
MEET THE LEGENDS – MICHEL HAISSAGUERRE Meet the Legends

Chairperson(s): G.A. Derumeaux (Créteil, FR)
– M. Haissaguerre (Pessac, FR)
– M. Haissaguerre (Pessac, FR)

ICU SHIFT – HOW TO KEEP CALM AND CARRY ON! Symposium
Chairperson(s): J. Poess (Lübeck, DE); S. Price (London, UK)
14:00 What should I know about hemodynamic monitoring? 1966
– I.C.C. van der Horst (Groningen, NL)
14:22 How to deal with mechanical assist devices? 1967
14:45 How to manage a septic patient? 1968
– M. Tubaro (Rome, IT)
15:07 How to deal with acute arrhythmias? 1969
– D. Scherr (Graz, AT)
133

IMPACT OF THE ENVIRONMENT ON ANTICOAGULATION IN NON-VALVULAR ATRIAL Rapid Fire Abstract
FIBRILLATION
Chairperson(s): M. Duytschaever (Ghent, BE); A. Oto (Ankara, TR)
14:00 Predicting intracranial bleeding risk in patients with atrial fibrillation using several bleeding risk 1970
scores.
– L. Fauchier, A. Banerjee, I. Lagrenade, N. Clementy, D. Angoulvant, A. Bernard, D. Babuty, G.Y.H. Lip
(Tours, FR; Birmingham, UK)
14:09 Major bleeding, hospitalisation rates and healthcare costs among non-valvular atrial fibrillation 1971
patients naive to oral anticoagulation and newly treated with novel oral anticoagulants.
– S. Deitelzweig, A. Bruno, N. Tate, A. Ogbonnaya, M. Shah, E. Farrelly, T. Lokhandwala, K. Gupta, M. Eaddy
(New Orleans, Plainsboro and Palm Harbor, US)
14:18 Time to cardioversion and risk complications with dabigatran versus warfarin A nationwide study. 1972
– J. Pallisgaard, T.B. Lindhardt, M.L. Hansen, A.M. Schjerning Olsen, J.B. Olesen, L. Staerk,
C. Torp-Pedersen, G.H. Gislasen (Gentofte, Copenhagen and Aalborg, DK)
14:27 Less non-major bleeding with apixaban versus warfarin among patients with atrial fibrillation: 1973
insights from the ARISTOTLE trial.
– M.C. Bahit, R.D. Lopes, D.M. Wojdyla, C. Held, M. Hanna, D. Vinereanu, S. Goto, J.H. Alexander,
L. Wallentin, C.B. Granger (Rosario and Santa Fe, AR; Durham and Princeton, US; Uppsala, SE; Bucharest,
RO; Isehara, JP)
14:36 Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in 1974
patients with atrial fibrillation: Insights from the ARISTOTLE trial.
– Z. Hijazi, S.H. Hohnloser, U. Andersson, J.H. Alexander, C.B. Granger, M. Hanna, R.D. Lopes, A. Siegbahn,
L. Wallentin (Uppsala, SE; Frankfurt am Main, DE; Durham and Princeton, US)
14:45 Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients on 1975
apixaban, dabigatran, rivaroxaban: cohorts comprising new initiators and/or switchers from
warfarin.
– P. Tepper, J. Mardekian, C. Masseria, H. Phatak, S. Kamble, Y. Abdulsattar, W. Petkun, G.Y.H. Lip
(Pittsburgh, New York and Princeton, US; Birmingham, UK)
14:54 Association between atrial fibrillation and risk of seizure disorder: the usefulness of CHADS2 1976
Score for risk stratification.
– C.-Y. Hsu, P.-H. Huang, H.-B. Leu, J.-W. Chen, S.-J. Lin (Taipei, TW)
15:03 Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for 1977
novel oral anticoagulant dose adjustment.
– N.M. Hawkins, P.S. Jhund, A. Pozzi, S.D. Solomon, C.B. Granger, S. Yusuf, M.A. Pfeffer, K. Swedberg,
S.A. Virani, J.J.V. McMurray (Vancouver and Hamilton, CA; Glasgow, UK; Boston and Durham, US;
Gothenburg, SE)
15:12 A telemedicine-based coagulation service versus regular medical care for oral anticoagulation of 1978
patients with atrial fibrillation - results from the thrombEVAL study.
– J. Prochaska, S. Gobel, K. Keller, M. Coldewey, C. Bickel, M. Lauterbach, C. Espinola-Klein, K.J. Lackner,
T. Munzel, P.S. Wild (Mainz, Koblenz and Trier, DE)
15:21 Risk vs. benefit of anticoagulation therapy in elderly patients with atrial fibrillation and 1979
documented ground-level falls.
– A. Bohm, P. Michalek, P. Slezak, J. Stevlik, P. Jackuliak, M. Stevove, T. Uher (Bratislava, SK)
134

WHAT IS NEW IN AORTIC VALVE DISEASE Rapid Fire Abstract
Chairperson(s): D. Gilon (Jerusalem, IL); M. Sobhy (Alexandria, EG)
14:00 Outcome of TAVI in Patients with Paradoxical Low-Gradient Aortic Stenosis: Results from a 1980
Multicenter Registry.
– A. Lauten, W.K. Kim, J.M. Sinning, M. Franz, W. Nikos, C. Hamm, G. Nickenig, H.R. Figulla, H. Moellmann
(Jena, Bad Nauheim and Bonn, DE)
14:09 Aortic valve gradient and clinical outcome in patients undergoing transcatheter aortic valve 1981
implantation for severe aortic stenosis.
– G. Witberg, R. Kornowski, H. Vaknin-Assa, A. Assali, Y. Shapira, T. Ben-Gal, A. Sagie, A. Barsheshet (Petah
Tikva, IL)
14:18 Impact of transcatheter aortic valve replacement (TAVI) on severity of concomitant mitral 1982
regurgitation, pulmonary artery pressure and tricuspid regurgitation.
– A. Lauten, A. Selle, M. Franz, A. Hamadanchi, B. Goebel, M. Ferrari, T. Sandhaus, T. Doenst, H.R. Figulla
(Jena and Wiesbaden, DE)
14:27 Impact of diabetes mellitus on short- and midterm mortality after transcatheter aortic valve 1983
implantation.
– F. Schlotter, N. Mangner, F. Woitek, G. Stachel, A. Lindner, J. Wilde, D. Holzhey, F.W. Mohr, G. Schuler,
A. Linke (Leipzig, DE)
14:36 Determinants and prognostic value of B-type natriuretic peptide in patients with aortic valve 1984
stenosis.
– V. Nguyen, C. Cimadevilla, D. Arangalage, M. Dehoux, J. Dreyfus, I. Codogno, X. Duval, V. Huart,
A. Vahanian, D. Messika-Zeitoun (Paris, FR)
14:45 Pre-existing and new-onset atrial fibrillation: a meta-analysis of mortality outcomes and 1985
cerebrovascular events in 13,795 patients undergoing transcatheter aortic valve implantation.
– A. Sannino, G. Gargiulo, G.G. Schiattarella, C. Perrino, E. Stabile, M.A. Losi, M.A. Galderisi, G.G. De
Simone, B. Trmarco, G. Esposito (Naples, IT)
14:54 Predictors of mortality in patients with aortic stenosis: the role of myocardial fibrosis. 1986
– V. Vassiliou, C.E. Raphael, A. Perperoglou, E. Nyktari, C.W.L. Chin, A. Ali, F. Alpendurada, D.J. Pennell,
M.R. Dweck, S.K. Prasad (London, Essex and Edinburgh, UK)
15:03 Overestimation of bicuspid aortic stenosis severity by echocardiography. 1987
– C.W.L. Chin, E. Luo, J. Hwan, A. White, D. Newby, M. Dweck (Edinburgh, UK)
15:12 Identification of peri-procedural myocardial infarction in patients undergoing transcatheter aortic 1988
valve implantation by using a high-sensitivity troponin I assay.
– C. Liebetrau, W.K. Kim, A.M. Meyer, L.G. Gaede, S.S. Schillinger, J.B. Blumenstein, H.N. Nef, C.H. Hamm,
T.W. Walther, H.M. Moellmann (Bad Nauheim and Giessen, DE)
15:21 Anticoagulation therapy of patients with atrial fibrillation after TAVI - Dresdner DOAK 1989
Register-TAVI (DDRT).
– G. Ende, L. Sichting, C. Pfluecke, S. Quick, L. Schoener, R.H. Strasser, K. Ibrahim (Dresden, DE)
14:00–15:30 | Rabat - Village 1

NEW STRATEGIES FOR REDUCING MYOCARDIAL ISCHAEMIA-REPERFUSION INJURY: HYPE OR Symposium
HOPE?
Chairperson(s): G. Heusch (Essen, DE); M. Ruiz-Meana (Barcelona, ES)
14:00 Can we directly act on the mitochondria transition permeability pore? 1990
14:22 Metabolic control of ischaemia reperfusion injury. 1991
– G. Vilahur Garcia (Barcelona, ES)
14:45 What is autophagy and what is its role in ischaemia-reperfusion? 1992
– J. Sadoshima (Newark, US)
15:07 Sphingosine-1 phosphate: from multiple sclerosis into cardioprotection, a long (and rewarding?) 1993
road.
– C. Garcia Santos-Gallego (New York, US)
135

BASIC AND TRANSLATIONAL SCIENCE HOT LINE ON Basic and Translational Science Hot Line
INFLAMMATION AND VASCULAR DISEASE
Chairperson(s): I. Hoefer (Utrecht, NL); A. Koller (Budapest, HU)
14:00 Lack of Dicer expression in smooth muscle cells promotes neointima formation. 1994
– F. Zahedi (Munich, DE)
14:15 Selenoprotein p promotes vascular smooth muscle cell proliferation and pulmonary hypertension 1995
- A possible novel therapeutic target.
– N. Kikuchi (Sendai, JP)
14:30 Results of histopathological thrombus evaluation in patients presenting with stent thrombosis 1996
across Europe: a report of the PRESTIGE consortium.
– J. Riegger (Munich, DE)
14:45 Novel reduction of PCSK9 expression: mechanistic insights into the anti-atherosclerotic & 1997
hypolipidemic effects of HSP27.
– E.R. O’Brien (Calgary, CA)
15:00 Aerobic and resistance exercise training prior to myocardial infarction prevents sympathetic 1998
overactivity and left ventricle inflammation in rats.
– C.A. Barboza (Sao Paulo, BR)
15:15 Disturbed TNFR2 expression and IL-6 secretion mediates a decreased proliferation of skeletal 1999
muscle myoblasts in CHF.
– T. Sente (Edegem, BE)

OBESITY AND HEART DISEASE Symposium
ESC and the Korean Society of Cardiology
Chairperson(s): B-H. Oh (Seoul, KR); D. Gaita (Timisoara, RO)
14:00 Current understanding of visceral obesity. 2000
– J.-P. Despres (Quebec, CA)
14:22 Perivascular adipose tissue in the pathogenesis of cardiovascular disease. 2001
– K. Koh (Incheon, KR)
14:45 Obesity paradox - Is it true? 2002
15:07 Metabolically healthy obesity from Korean cohort study - False or true? 2003
– S.H. Kim (Ansan, KR)

HOW TO EXERCISE PATIENTS WITH CARDIOVASCULAR DISEASE Meet the Experts
Chairperson(s): M.C. Deaton (Cambridge, UK); M. Mendes (Carnaxide, PT)
14:00 How to exercise patients with cardiovascular disease - Introduction to the session. 2004
– M.C. Deaton (Cambridge, UK)
14:05 60 y.o. woman, obese, dyslipidemia, sedentary after elective PCI. How to convince a patient to 2005
exercise and not to give up?
– K. Carver (Cambridge, UK)
14:15 60 y.o. woman, obese, dyslipidemia, sedentary after elective PCI. How to convince a patient to 2006
exercise and not to give up? Panel discussion and questions from the audience.
– A. Abreu (Lisbon, PT), B. Rauch (Freiburg Breisgau, DE), E. Garcia Porrero (Leon, ES), K. Carver
(Cambridge, UK)
14:30 55 y.o. man, CHF (NYHA III), dilated cardiomyopathy, non responder to CRT How much and what 2007
kind of exercise is necessary for good results?
– R.S. Taylor (Exeter, UK)
14:40 55 y.o. man, CHF (NYHA III), dilated cardiomyopathy, non responder to CRT How much and what 2008
kind of exercise is necessary for good results? Panel discussion and questions from the audience.
– A. Abreu (Lisbon, PT), B. Rauch (Freiburg Breisgau, DE), E. Garcia Porrero (Leon, ES), R.S. Taylor (Exeter,
UK)
14:55 75 y.o. woman, COPD, arthrosis, STEMI, incomplete revascularization How can we limit the 2009
negative effects of exercise?
– L.E.M. Vanhees (Leuven, BE)
15:05 75 y.o. woman, COPD, arthrosis, STEMI, incomplete revascularization How can we limit the 2010
negative effects of exercise? Panel discussion and questions from the audience.
– L.E.M. Vanhees (Leuven, BE), A. Abreu (Lisbon, PT), B. Rauch (Freiburg Breisgau, DE), E. Garcia Porrero
(Leon, ES)
15:20 How to exercise patients with cardiovascular disease - Take home message. 2011
– M. Mendes (Carnaxide, PT)
136

PREMATURE CARDIOVASCULAR AGEING Advances in Science
Chairperson(s): T.C. Gillebert (Ghent, BE); I. Spyridopoulos (Newcastle-upon-Tyne, UK)
14:00 State of the Art in cardiovascular premature ageing: new insights. 2012
– R. Belardinelli (Ancona, IT)
14:20 Glycemic excursions trigger senescence-associated pathways and vascular ageing features in 2013
patients with type 2 diabetes.
– F. Paneni, S. Costantino, R. Battista, G. Capretti, S. Chiandotto, M. Volpe, F. Cosentino (Stockholm, SE;
Sora and Rome, IT)
14:37 Assisted reproductive technologies-induced premature vascular ageing persists and evolves into 2014
arterial hypertension in adolescents.
– E. Rexhaj, R. Von Arx, D. Cerny, R. Soria, E. Bouillet, C. Sartori, U. Scherrer, S.F. Rimoldi (Berne and
Lausanne, CH)
14:54 Premature cardiac senescence in patients with lamin A/C mutations: at least 5 years gap from 2015
electrical to mechanical dysfunction.
– G. Peretto, C. Di Resta, S. Benedetti, S. Sala, M. Ferrari, P. Della Bella (Milan, IT)
15:11 Future directions for research in premature cardiovascular ageing. 2016
– E. Bacchi (Verona, IT)
14:00–15:30 | Kiev - Village 3
DIFFICULT TO TREAT HYPERTENSION Symposium
ESC / European Society of Hypertension
Chairperson(s): A. Coca (Barcelona, ES); A.F. Dominiczak (Glasgow, UK)
14:00 Cardiovascular imaging in hypertensive heart disease. 2017
– F.J. Pinto (Lisbon, PT)
14:18 Clinical diagnosis of resistant hypertension. 2018
14:36 Pharmacological treatment of resistant hypertension. 2019
14:54 Renal denervation: the way forward? 2020
– C. Tsioufis (Athens, GR)

HYPERTENSION POPULATION SCIENCE Advances in Science
Chairperson(s): C. Borghi (Bologna, IT); J. Wang (Shanghai, CN)
14:00 State of the Art in environmental determinants of blood pressure. 2021
– F.P. Cappuccio (Coventry, UK)
14:20 Risk of hypertension and chronic low grade inflammation amoung healthy young subjects living in 2022
the cities with different ambient air pollution.
– K.L. Bryniarski, G. Debski, R. Badacz, I. Gawlik, J. Marchewka, J. Konieczynski, N. Podolec, T. Przewlocki,
K. Zmudka, T. Guzik (Krakow, PL)
14:37 Could occupational determinants impact on changes in blood pressure over a five-year 2023
follow-up? Results from the VISAT study.
– S. Huo Yung Kai, Y. Esquirol, V. Bongard, J.-B. Ruidavets, J.-C. Marquie, J. Ferrieres (Toulouse, FR)
14:54 Hypertension prevalence, awareness, treatment and control in four states in india: the DISHA 2024
study baseline results.
– K. Kahol, P. Jeemon, D. Kondal, A. Purty, A. Bhardwaj, J. Sanghvi, P. Negi, S. Ladhani, G. Toteja,
D. Prabhakaran (New Delhi, Pondicherry, Tanda, Indore, Shimla and Mumbai, IN)
15:11 Future direction for research in preventing environmental impacts on blood pressure. 2025
– H. Schirmer (Tromsø, NO)

DO FEMALES BENEFIT MORE FROM CARDIAC RESYNCHRONISATION THERAPY (CRT)? Symposium
Chairperson(s): C. Linde (Stockholm, SE); J. Singh (Boston, US)
14:00 QRS duration and LBBB in relation with gender. 2026
– M. Malik (Purley, UK)
14:22 Should women have different ECG criteria for CRT than men? 2027
– U. Birgersdotter-Green (La Jolla, US)
14:45 Benefits from CRT - Findings from randomized clinical trials and meta-analyses. 2028
– F.Z. Khan (Stanmore, UK)
15:07 Do women get more complications from CRT? The Danish pacemaker and ICD registry. 2029
– R. Kirkfeldt (Aarhus, DK)
137

ANTICOAGULATION IN NON-VALVULAR ATRIAL FIBRILLATION Advances in Science
Chairperson(s): M.D. Ezekowitz (Villanova, US); M. Antz (Oldenburg, DE)
14:00 State of the Art in anticoagulation in non valvular atrial fibrillation. 2030
14:20 Rivaroxaban vs. warfarin with concomitant aspirin use in patients with atrial fibrillation: findings 2031
from the ROCKET AF trial.
– R. Shah, A.S. Hellkamp, S.D. Berkowitz, G. Breithardt, K.A.A. Fox, K.W. Mahaffey, C.C. Nessel,
J.P. Piccini, D.E. Singer, M.R. Patel (Durham, Whippany, Stanford, Raritan and Boston, US; Münster, DE;
Edinburgh, UK)
14:37 Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low 2032
body weight or high age receiving standard dose apixaban for stroke prevention in atrial
fibrillation.
– J. Alexander, U. Andersson, R.D. Lopes, Z. Hijazi, S.H. Hohnloser, J. Ezekowitz, S. Halvorsen, M. Hanna,
C.B. Granger, L. Wallentin (Durham and Princeton, US; Uppsala, SE; Frankfurt am Main, DE; Edmonton,
CA; Oslo, NO)
14:54 Level of kidney function predicts risk of stroke and bleeding in patients with atrial fibrillation. 2033
– A. Nissen Bonde, A.L. Kamper, N. Carlsson, E.L. Fosboel, L. Staerk, G.H. Gislason, J.B. Olesen (Gentofte,
Copenhagen and Hvidovre, DK)
15:11 Future direction for research in anticoagulation in non valvular atrial fibrillation. 2034

CARDIOVASCULAR IMAGING IN WOMEN Meet the Experts
Chairperson(s): B.L.M. Gerber (Woluwe-St. Lambert, BE); L.E. Sade (Ankara, TR)
14:00 Cardiovascular imaging in women - Introduction to the session. 2035
– B.L.M. Gerber (Woluwe-St. Lambert, BE)
14:05 Chest pain in a premenopausal woman. 2036
– L.J. Shaw (Atlanta, US)
14:15 Chest pain in a premenopausal woman - Panel discussion and questions from the audience. 2037
– L.J. Shaw (Atlanta, US), P.G. Camici (Milan, IT), S. Mavrogeni (Athens, GR), L.E. Sade (Ankara, TR)
14:30 Chest pain with normal coronaries in a female patient - Invasive and non-invasive assessment. 2038
14:40 Chest pain with normal coronaries in a female patient - Invasive and non-invasive assessment - 2039
– U. Sechtem (Stuttgart, DE), P.G. Camici (Milan, IT), A. Djordjevic-Dikic (Belgrade, RS), S. Mavrogeni
(Athens, GR)
14:55 A patient with a rheumatological disorder: risk of coronary artery disease. 2040
– C. Bucciarelli-Ducci (Bristol, UK)
15:05 A patient with a rheumatological disorder: risk of coronary artery disease - Panel discussion and 2041
– C. Bucciarelli-Ducci (Bristol, UK), P.G. Camici (Milan, IT), S. Mavrogeni (Athens, GR), L.E. Sade (Ankara, TR)
15:20 Cardiovascular imaging in women - Take home message. 2042
– L.E. Sade (Ankara, TR)
138

DEBATES IN ADVANCES IMAGING FOR PATIENT MANAGEMENT Debate Session
Chairperson(s): E. Plonska-Gosciniak (Szczecin, PL); A. Nchimi (Liège, BE)
14:00 Cardiac resonance is useful in diagnosis or rule-out of myocarditis - PRO. 2043
– M.G. Friedrich (Dorval, CA)
14:15 Cardiac resonance is useful in diagnosis or rule-out of myocarditis - CONTRA. 2044
14:30 Cardiac resonance is useful in diagnosis or rule-out of myocarditis - REBUTTAL PRO. 2045
– M.G. Friedrich (Dorval, CA)
14:35 Cardiac resonance is useful in diagnosis or rule-out of myocarditis - REBUTTAL CONTRA. 2046
14:40 Cardiac resonance is useful in diagnosis or rule-out of myocarditis - CONCLUSION. 2047
14:45 Stress imaging is the best choice in patients with intermediate pre-test probability for coronary 2048
artery disease - PRO.
– E. Nagel (Frankfurt am Main, DE)
15:00 Stress imaging is the best choice in patients with intermediate pre-test probability for disease - 2049
CONTRA.
– R. Sicari (Pisa, IT)
REBUTTAL PRO.
REBUTTAL CONTRA.
– R. Sicari (Pisa, IT)
CONCLUSION.

IMPACT OF OPTICAL COHERENCE TOMOGRAPHY AND COMPUTED TOMOGRAPHIC Symposium
ANGIOGRAPHY ON THE MANAGEMENT OF ACUTE CORONARY SYNDROME
Chairperson(s): F. Alfonso Manterola (Madrid, ES); T. Akasaka (Wakayama, JP)
14:00 Lesson from histopathology to imaging in vulnerable plaque. 2053
– E. Arbustini (Pavia, IT)
14:22 Detecting intact fibrous caps or ruptured fibrous caps by OCT and CTA. 2054
– Y. Ozaki (Toyoake, JP)
14:45 OCT-based management of AMI with intact fibrous cap and ruptured fibrous caps. 2055
– F. Prati (Rome, IT)
15:07 OCT-based management of stent thrombosis following DES. 2056
– M. Radu (Copenhagen, DK)
14:00–15:30 | Oslo - Village 6

ADVANCES IN BASIC SCIENCE: STATE OF THE ART ON PLAQUE VULNERABILITY Advances in Science
Chairperson(s): M. Joner (Gaithersburg, US); T. Amano (Nagakute, JP)
14:00 State of the Art in plaque vulnerability. 2057
– J. Narula (New York, US)
14:20 High-risk plaque features can be detected in non-stenotic carotid plaques of patients with 2058
ischemic stroke classified as cryptogenic using combined FDG-PET/MR imaging.
– F. Hyafil, A. Schindler, D. Sepp, T. Obenhuber, T. Boeckh-Behrens, S.G. Nekolla, M. Dichgans,
M. Schwaiger, T. Saam, H. Poppert (Munich, DE)
14:37 Impact of anti-oxidative capacity of high-density lipoprotein on vulnerability of coronary plaques 2059
in patients with type 2 diabetes mellitus.
– K. Takata, A. Iwata, S. Imaizumi, B. Zhang, S. Miura, K. Saku (Fukuoka, JP)
14:54 Pathological substrate for STEMI assessed by optical coherence tomography during primary PCI. 2060
– D.C.H.S. Neves, C. Biagioni, M. Echavarria Pinto, A. Quiros, M.J. Perez Vyzcaino, H. Mejia-Renteria,
A. Fernandez Ortiz, C. Macaya, N. Gonzalo, J. Escaned (Évora, PT; Madrid, ES)
15:11 Future direction for research in vulnerable plaque. 2061
– P.W.J.C. Serruys (Rotterdam, NL)
139

CARDIAC ARREST IN SPECIAL ENVIRONMENTAL CIRCUMSTANCES Symposium
ESC and the European Resuscitation Council
Chairperson(s): N. Nikolaou (Athens, GR); C. Spaulding (Suresnes, FR)
14:00 Cardiac arrest in drowning. 2062
– A.J. Handley (Cambridge, UK)
14:22 Unsuccessful CPR during out-of-hospital cardiac arrest: fast-track to the cath. lab? 2063
– R.W. Koster (Amsterdam, NL)
14:45 Cardiac arrest in sport. 2064
– F. Carre (Rennes, FR)
15:07 Cardiovascular effects of hypothermia. 2065
– J.P. Nolan (Bath, UK)

ISCHAEMIA AND REPERFUSION Symposium
ESC and the Mexican Society of Cardiology
Chairperson(s): M.A. Pena Duque (Mexico City, MX); R. Ferrari (Cona, IT)
14:00 Reperfusion: a double-edged sword. 2066
– D. Garcia-Dorado (Barcelona, ES)
14:22 Intramyocardial hemorrhage and cardiac rupture. 2067
– F.J. Roldan (Mexico City, MX)
14:45 Early perioperative myocardial reperfusion in cardiac surgery - Its impact on the long-term 2068
prognosis.
– F.M. Baranda (Mexico City, MX)
15:07 Strategy to prevent lethal reperfusion injury. 2069
14:00–15:30 | Tunis - Village 7

PATIENTS WITH ACUTE CORONARY SYNDROMES: BLEEDING AND BLOOD TRANSFUSION Symposium
Chairperson(s): C. Morgan (London, UK); E. Hylek (Boston, US)
14:00 Incidence of bleeding and outcomes in acute coronary syndromes. 2070
– S. Halvorsen (Oslo, NO)
14:22 Hemovigilance: the risks and benefits of red blood cell transfusion. 2071
– J. Silvain (Paris, FR)
14:45 How to prevent bleeding in acute coronary syndrome? 2072
– J.A.C. Morais (Leiria, PT)
15:07 How to prevent and manage brain hemorrhage? 2073
– P. Amarenco (Paris, FR)

SURGICAL CHALLENGES IN THE ADULT WITH CONGENITAL HEART DISEASE Symposium
Chairperson(s): A. Eicken (Munich, DE); E.V.O. Jokinen (Helsinki, FI)
14:00 The best surgical approach for the tricuspid valve. 2074
– A. Giamberti (San Donato Milanese, IT)
14:22 The dilated ascending aorta after repair of complex congenital heart disease. 2075
– H. Baumgartner (Münster, DE)
14:45 How to treat complex recoarctation of the aorta. 2076
– J. Hoerer (Bavaria, DE)
15:07 Reconstruction of the right ventricular outflow tract. 2077
– R. Pretre (Lausanne, CH)
140

RARE CARDIOMYOPATHIES: FROM ETIOLOGY TO TREATMENT Meet the Experts
Chairperson(s): F. Cecchi (Florence, IT); P. Charron (Paris, FR)
14:00 Rare cardiomyopathies: from etiology to treatment - Introduction to the session. 2078
– F. Cecchi (Florence, IT)
14:05 A patient with Danon disease. 2079
– C. Rapezzi (Bologna, IT)
14:15 A patient with Danon disease - Panel discussion and questions from the audience. 2080
– F. Cecchi (Florence, IT), C. Rapezzi (Bologna, IT), A.G. Rigopoulos (Schweinfurt, DE), A. Pantazis (London,
UK), H. Madeira (Lisbon, PT)
14:30 A patient with Friedreich’s ataxia. 2081
– D. Duboc (Paris, FR)
14:40 A patient with Friedreich’s ataxia - Panel discussion and questions from the audience. 2082
– D. Duboc (Paris, FR), A.G. Rigopoulos (Schweinfurt, DE), A. Pantazis (London, UK), H. Madeira (Lisbon, PT)
14:55 A patient with Fabry disease. 2083
15:05 A patient with Fabry disease - Panel discussion and questions from the audience. 2084
– A. Linhart (Prague, CZ), A.G. Rigopoulos (Schweinfurt, DE), H. Madeira (Lisbon, PT), A. Pantazis (London,
UK)
15:20 Rare cardiomyopathies: from etiology to treatment - Take home message. 2085
TROPICAL CARDIOLOGY Symposium
ESC, the InterAmerican Society of Cardiology and Spanish Society of Cardiology
Chairperson(s): M. Barbosa (Nova Lima, BR); J.R. Gonzalez Juanatey (Santiago de Compostela, ES)
14:00 Europe - Tropical heart diseases are here. 2086
– J.A. Marques Rodrigues (Mexico, MX)
14:22 Travelers’ exposure to tropical heart diseases. 2087
– K. Gonzalez (Barquisimeto, VE)
14:45 A new arrhythmic threat to Europe - Tropical heart diseases. 2088
– I. Mendoza (Caracas, VE)
15:07 Key imaging features in tropical cardiac diseases. 2089
– M.A. Garcia Fernandez (Madrid, ES)
14:00–15:30 | Bern - Village 9

PERCUTANEOUS VALVE INTERVENTION IN SEVERE HEART FAILURE Symposium
Chairperson(s): P. Ponikowski (Wroclaw, PL); H. Eltchaninoff (Rouen, FR)
14:00 New insights into mechanisms of heart failure in valve disease. 2090
– K. Toutouzas (Athens, GR)
14:22 Evaluation of LV function by multimodality imaging in valve disease. 2091
14:45 Intervention in functional mitral regurgitation: where is the evidence? 2092
– C. Tamburino (Catania, IT)
15:07 Is there a point of no return when percutaneous valve interventions should not be done? 2093

PREGNANCY AND HEART FAILURE Case-based Symposium
Chairperson(s): M.-E. Estensen (Oslo, NO); J.W. Roos-Hesselink (Rotterdam, NL)
14:00 PPCM case. 2094
– M. Petrie (Glasgow, UK)
14:15 PPCM case - Panel discussion and questions from the audience. 2095
– K. Sliwa-Hahnle (Cape Town, ZA), M. Petrie (Glasgow, UK)
14:30 A pregnant GUCH patient. 2096
– K. Sliwa-Hahnle (Cape Town, ZA)
14:45 A pregnant GUCH patient - Panel discussion and questions from the audience. 2097
– K. Sliwa-Hahnle (Cape Town, ZA), M. Petrie (Glasgow, UK)
15:00 How to diagnose and manage heart failure during pregnancy? State of the Art lecture. 2098
– K. Sliwa-Hahnle (Cape Town, ZA)
141

CURRENT AND FUTURE APPLICATIONS OF COMPUTED TOMOGRAPHY CORONARY Rapid Fire Abstract
IMAGING
Chairperson(s): P.A. Kaufmann (Zurich, CH); A.J.H.A. Scholte (Leiden, NL)
14:00 Combined score of clinical risk parameters and coronary CT angiography findings improves 2099
prediction of death: an analysis based on 15219 patients with 5.3 years of follow up from the
CONFIRM registry.
– S.D.C. Deseive, M. Hadamitzky, S. Massberg, J. Hausleiter (Munich, DE)
14:09 Characterization of coronary plaques in patients with acute coronary syndrome by multidetector 2100
computed tomography.
– N. Barysheva, I.N. Merkulova, M.S. Shabanova, S.A. Gaman, T.S. Sukhinina, T.N. Veselova, M.A. Shariya
(Moscow, RU)
14:18 Cardiac CT versus functional testing in suspected coronary artery disease - a randomised 2101
multicentre study.
– M.M. Lubbers, T.W. Galema, P. Musters, J.M. Akkerhuis, A. Liem, T. Bruning, B. Krenning, M. Ouhlous,
A. Niezen, K. Nieman (Rotterdam, NL)
14:27 Coronary atherosclerosis features for the prediction of ischemic events (CAFE-PIE study): a CT 2102
scan integrated score from a bi-center registry.
– A.I. Guaricci, N.D.B. Brunetti, F.D.R. De Rosa, S.M. Mushtaq, D.A. Andreini, M.P. Pepi, M.D.B. Di Biase,
G.P. Pontone (Foggia and Milan, IT)
14:36 Cardiac spectral CT scan to diagnose acute myocarditis. 2103
– G. Baudry, C. Bouleti, B. Iung, G. Ducrocq, C. Choquet, S. Zarka, J.P. Laissy, G. Steg, A. Vahanian, P. Ou
(Paris, FR)
14:45 Prevalence, distribution and predictive value on all-cause mortality of clinical relevant 2104
extracardiac findings from cardiac CT in the general population: The Heinz Nixdorf Recall Study.
– E. Tezgah, A.A. Mahabadi, K. Kara, N. Pundt, L. Eisele, A. Stang, S. Moebus, K.H. Joeckel, R. Erbel,
H. Kaelsch (Essen and Bochum, DE)
14:54 Does coronary CTA provide sufficient image quality in heart transplant recipients with suboptimal 2105
heart rate during scan?
– A. Bartykowszki, M. Kolossvary, B. Szilveszter, D. Horcsik, C. Celeng, A. Jermendy, M. Karolyi, Z. Bagyura,
B. Merkely, P. Maurovich-Horvat (Budapest, HU)
15:03 A direct comparison of coronary flow reserve as determined by dynamic myocardial CT perfusion 2106 (W)
imaging and radionuclide SPECT. (withdrawn)
– S. Seitun, C. Marini, S. Boccalini, M. Castiglione Morelli, I. Budaj, A. Galletto Pregliasco, C. Zawaideh,
G.P. Bezante, C. Ferro, G.M. Sambuceti (Genoa, IT)
15:12 Different effects of statin only or statin + ezetimibe on non-calcified coronary plaque (NCCP) 2107
assessed by computed tomography angiography (CTA) with and without metabolic syndrome
(MetS).
– K. Watanabe, K. Sekiya, Y. Suzuka, S. Shigemi, H. Saeki, T. Tachibana, T. Asami (Matsuyama, JP)
15:21 Effects of heart imaging radiation on dna double-strand break levels in blood lymphocytes: the 2108
heart-break study.
– M. Cheezum, C. Redon, A. Burrell, A. Kaviratne, J. Bindeman, D. Maeda, P. Wisniewski, P. Delacruz,
W. Bonner, T. Villines (Bethesda and San Antonio, US)
142

ANTIBRADYCARDIA PACING Moderated Posters
Chairperson(s): R. Vicuna (Quito, EC); P.E. Dilaveris (Athens, GR)
15:30 Temporary transvenous cardiac pacing: risk-benefit ratio. P2109
– A.R. Gaspar Lopes Francisco, N. Cortez-Dias, M.N. Menezes, G. Da Silva, T. Guimaraes, J. Agostinho,
I.S. Goncalves, A. Magalhaes, R. Placido, J. De Sousa (Lisbon, PT)
15:38 Bachmann’s bundle pacing prevents left atrial dyssynchrony and improves left ventricle filling. P2110
– A. Slawuta, M. Klis, P. Skoczynski, T. Bankowski, J. Moszczynska-Stulin, J. Gajek (Klodzko and Wroclaw,
PL)
15:47 Electromagnetic fields caused by smartphones as environmental risk for cardiac implantable P2111 (W)
electronic device malfunction. (withdrawn)
– C. Lennerz, H. Pavaci, H. Vrazic, C. Grebmer, M. Kottmaier, M. Kornmayer, V. Semmler, G. Von Olshausen,
I. Deisenhofer, C. Kolb (Munich and Landshut-Achdorf, DE; Zagreb, HR)
15:55 ECG criteria for right ventricular lead positioning. An analysis from the right pace study. P2112
– G.L. Botto, V. Calvi, G. Maglia, D. Pecora, G. Ciaramitaro, M. Canciello, F. Dettori, A. Lilli, M. Campari,
C. Muto (Como, Catania, Catanzaro, Brescia, Palermo, Naples, Oristano, Viareggio, Milan and Nola, IT)
16:04 MRI-induced lead heating of an MRI conditional pacemaker system. P2113
– G. Mouchawar, S. Sison, S. Chen, X. Min, J. Chen, J. Nyenhuis, R. Williamson (Sylmar, Houston and West
Lafayette, US)
16:12 Clinical impact of new-onset left bundle branch block after aortic CoreValve implantation: long P2114
term follow-up.
– J. Lopez Aguilera, J. Segura Saint-Gerons, F. Mazuelos Bellido, J.R. Suarez De Lezo Herreros De Tejada,
S. Ojeda Pineda, M. Romero Moreno, D. Pavlovic, M. Pan Alvarez-Osorio, M. Santisteban Sanchez De
Puerta, J. Suarez De Lezo Cruz Conde (Córdoba, ES)
16:21 Time course of detection of new atrial fibrillation (AF) and AF burden in patients with cardiac P2115
implanted electronic devices.
– G. Boriani, T.V. Glotzer, M. Santini, T.M. West, M. De Melis, M. Sepsi, M. Gasparini, T. Lewalter,
J.A. Camm, D. Singer (Bologna, Rome and Rozzano, IT; Hackensack and Boston, US; Maastricht, NL;
Brno, CZ; Munich, DE; London, UK)

IMPROVING ANTIPLATELETS REGIMEN AND CARDIOPROTECTION IN CORONARY Moderated Posters
PATIENTS
Chairperson(s): G. Parodi (Florence, IT); H. Ogawa (Kumamoto, JP)
15:30 Efficacy of antiplatelet agent usage for primary and secondary prevention in dialysis patients: P2116
a nation-wide data survey and propensity analysis.
– Y.H. Lin, C.K. Wu, Y.H. Yang, J.W. Huang, V.C. Wu, J.K. Lee, P.C. Chen, L.Y. Lin (Taipei and Chiayi City,
TW)
15:38 Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy P2117
with clopidogrel or ticagrelor.
– M. Verdoia, L. Barbieri, A. Schaffer, M. Nardin, P. Marino, H. Suryapranata, G. De Luca (Novara, IT;
Nijmegen, NL)
15:47 Whole blood viscosity predicts the definite stent thrombosis after primary percutaneous coronary P2118
– M.S. Cetin, E.H. Ozcan Cetin, O. Ozeke, D. Aras, S. Topaloglu, H.L. Kisacik, S. Aydogdu (Ankara, TR)
15:55 Impact of intravenous lysine acetylsalicylate versus oral aspirin on prasugrel inhibited platelets: P2119
results of a prospective, randomized, crossover study.
– D. Vivas, A. Martin, E. Bernardo, A. Ortega, G. Tirado, I. Nunez-Gil, I. Vilacosta, C. Macaya,
A. Fernandez-Ortiz (Madrid, ES)
16:04 Temporal trends in incidence of acute myocardial infarction and the effect of baseline P2120
cardioprotective therapy on initial clinical presentation: a nationwide study.
– L. Smedegaard, M.G. Charlot, G.H. Gislason, P.R. Hansen (Hellerup, DK)
16:12 Rac-1 as a new target to modulate endothelial function and platelet aggregation in diabetes P2121
mellitus.
– F. Ilardi, A. Carrizzo, G.G. Schiattarella, A. Damato, M.T. Ambrosio, V. Trimarco, C. Perrino, B. Trimarco,
C. Vecchione, G. Esposito (Naples and Pozzilli, IT)
16:21 Class effect of beta-blockers in survivors of ST-elevation myocardial infarction: a nationwide P2122
cohort study using insurance claims database.
– T.T. Lin, M.T. Liao, C.L. Lai (Hsin-Chu, TW)
143

CARDIOVASCULAR MAGNETIC RESONANCE – TRANSLATIONAL Moderated Posters
Chairperson(s): J.F. Rodriguez Palomares (Barcelona, ES); V.M. Ferreira (Oxford, UK)
15:30 Characterisation of the changes in cardiac structure and function in mice treated with P2123 (W)
anthracyclines using serial cardiac magnetic resonance imaging. (withdrawn)
– P.V. Staziaki, H. Farhad, O. Coelho-Filho, R.V. Shah, R.N. Mitchell, R.Y. Kwong, M. Scherrer-Crosbie,
U. Hoffmann, M. Jerosch-Herold, T.G. Neilan (Boston, US; Campinas, BR)
15:38 Rapid endovascular moderate hypothermia before reperfusion provides more cardioprotection P2124
than mild hypothermia in a porcine model of myocardial infarction.
– R. Dash, F. Dawoud, F. Ikeno, A. Tachibana, J. Lyons, Y. Mitsutake, W.B. Pyun, M. McConnell, U. Illindala,
A. Yeung (Stanford and San Jose, US)
15:47 P2Y12-receptor knockout leads to reduced myocardial ischemia/reperfusion injury in mice. P2125
– A. Maier, D. Duerschmied, D. Von Elverfeldt, M. Mauler, M. Moritz, T. Witsch, I. Neudorfer, K. Peter,
C. Bode, C. Von Zur Muehlen (Freiburg, DE; Melbourne, AU)
15:55 Presence of myocardial scar does not prevent improvement in myocardial perfusion and left P2126
ventricular function in refractory angina patients undergoing intramyocardial bone marrow cell
injection.
– I. Mann, S.F. Rodrigo, J. Van Ramshorst, S.L.M.A. Beeres, H.J. Lamb, H.M. Siebelink, R.J. Van Der Geest,
W.E. Fibbe, M.J. Schalij, D.E. Atsma (Leiden, NL)
16:04 Ultrasmall superparamagnetic particles of iron oxide-enhanced magnetic resonance imaging in P2127
the assessment of cellular inflammation after myocardial infarction.
– C. Stirrat, S.R. Alam, T.J. MacGillivray, C.D. Gray, M.R. Dweck, S. Mirsadraee, S. Semple, P.A. Henriksen,
D.E. Newby (Edinburgh, UK)
16:12 Non-invasive estimation of pulmonary vascular resistance by cardiovascular magnetic resonance P2128
in systolic heart failure: prognostic implications beyond late gadolinium enhancement.
– O. Fabregat Andres, J. Estornell-Erill, P. Garcia-Gonzalez, R. De La Espriella-Juan, B. Bochard-Villanueva,
A. Cubillos-Arango, C. Albiach, F. Ridocci-Soriano, S. Morell, J. Cortijo (Valencia, ES)
16:21 T1 mapping by cardiac magnetic resonance imaging: from histological validation to clinical P2129
implication.
– A. Kammerlander, S. Pfaffenberger, C. Zotter-Tufaro, A. Bachmann, S. Aschauer, F. Duca,
K. Knechtelsdorfer, M. Wiesinger, D. Bonderman, J. Mascherbauer (Vienna, AT)

DIET, LIPIDS AND THE VASCULATURE Moderated Posters
Chairperson(s): I. Komuro (Tokyo, JP); D.P. Mikhailidis (London, UK)
15:30 Dyslipidemia impairs high-density lipoprotein cardioprotective effects leading to larger infarcts. P2130
HDL-characterization by lipid analysis and differential proteomics.
– G. Vilahur, J. Cubedo, M. Gutierrez, L. Casani, A. Capdevila, G. Pons-Llado, F. Carreras, A. Hidalgo,
L. Badimon (Barcelona, ES)
15:38 Association between epicardial fat thickness and circulating endothelial progenitor cell levels in P2131
patients with coronary arterial disease.
– C.-C. Chiu, C.-Y. Hsu, P.-H. Huang, T.-C. Wu, H.-B. Leu, J.-W. Chen, S.-J. Lin (Taipei, TW)
15:47 ATF3 regulates high fat diet induced adipocytes hypertrophy and obesity in mice via repression of P2132
ChREBP signaling pathway.
– C.-F. Cheng, H.-C. Ku, T.-L. Tseng, H. Lin (Hualien and Taipei, TW)
15:55 Arginase inhibition improves endothelial function in patients with familial hypercholesterolemia. P2133
– O. Kovamees, A. Shemyakin, M. Eriksson, B. Angelin, J. Pernow (Stockholm, SE)
16:04 Vasculoprotective effects of dietary flavanols in hemodialysis patients: a double-blind, P2134
randomized, placebo-controlled trial.
– C. Rammos, U.B. Hendgen-Cotta, C. Heiss, G.R. Hetzel, W. Kleophas, F. Dellanna, J. Ottaviani,
H. Schroeter, M. Kelm, T. Rassaf (Düsseldorf, DE; Davis, US)
16:12 Occurrence of coronary lipid deposits and myocardial fatty dystrophy in dabigatran P2135
etexilate-treated diabetic rats.
– A. Scridon, D. Gheban, A. Marginean, M. Perian, R.C. Serban, D. Dobreanu (Tirgu Mures and Cluj-Napoca,
RO)
16:21 HDL functionality in children with type 1 diabetes. P2136
– C. Nguyen, E. Mcloughlin, T. Khan, M. Charakida, Y. Elia, E. Sochett, F. Mahmud, J. Deanfield (London,
UK; Toronto, CA)
144

CHALLENGES IN REPAIRED TETRALOGY OF FALLOT Moderated Posters
Chairperson(s): M. Jokhadar (Damascus, SY); W. Budts (Leuven, BE)
15:30 QRS fragmentation is superior to QRS duration in the prediction of death or ventricular P2137
tachycardia in adults with tetralogy of Fallot.
– J.P. Bokma, M.M. Winter, H.W. Vliegen, A.P. Van Dijk, P.G. Pieper, F.J. Meijboom, M.C. Post, B.J. Mulder,
B.J. Bouma (Amsterdam, Leiden, Nijmegen, Groningen, Utrecht and Nieuwegein, NL)
15:38 Left ventricular end-diastolic pressure is not related to right ventricular function and volume in P2138
adult patients with repaired Tetralogy of Fallot: A combined cardiac catheterization and cMRI
study.
– J. Vormbrock, G.P. Diller, G. Kaleschke, S. Orwat, P. Bauerschmitz, F. De Torres Alba, H. Baumgartner
(Münster, DE)
15:47 Relation between exercise capacity and skeletal muscle metabolism during exercise in patients P2139
with repaired tetralogy of Fallot.
– A. Frigiola, K. Bull, M. Papademetriou, A. Hoskote, G. Derrick, S. Cullen, F. Walker, A. Giardini (London, UK)
15:55 Ascending Aorta dilatation late after tetralogy of Fallot repair: an intrinsic aortopathy? P2140
– C. Cruz, T. Pinho, A. Lebreiro, C.C. Dias, J. Silva Cardoso, M. Julia Maciel (Porto, PT)
16:04 Infective endocarditis following pulmonary valve intervention in patients with repaired congenital P2141
heart disease; a comparison of surgical and percutaneous procedures.
– S. Cesna, M.I. Jones, F. Walker, S. Cullen, P. Bonhoeffer, V. Tsang, T.Y. Hsia, B. Pandya (Vilnius, LT;
London, UK)
16:12 Early cardiac remodelling post-pulmonary valve replacement in patients with repaired tetralogy of P2142
Fallot.
– E.L. Heng, M.A. Gatzoulis, G.C. Smith, D.F. Shore, B. Sethia, H. Uemura, G.P. Diller, S.Y. Ho, D.J. Pennell,
S.V. Babu-Narayan (London, UK; Münster, DE)
16:21 Age at intervention is the main risk factor for prosthetic pulmonary valve failure in patients with P2143
congenital heart disease.
– S. Del Prado Diaz, A. Gonzalez Garcia, D. Garcia Hamilton, J. Ruiz Cantador, A. Sanchez Recalde, L. Polo
Lopez, A. Aroca Peinado, J.M. Oliver Ruiz (Madrid, ES)

WHAT DOES EPIDEMIOLOGY TEACH US ABOUT CARDIOVASCULAR RISK? Moderated Posters
Chairperson(s): M. Dilic (Sarajevo, BA); M. Kayikcioglu (Izmir, TR)
15:30 LDL cholesterol remains an important predictor of coronary heart disease events even in the P2144
statin era.
– A.M. Navar-Boggan, E.D. Peterson, D.M. Wojdyla, J.E. Elassal, R.B. D’Agostino, R.J. Sanchez,
M.J. Pencina (Durham, Tarrytown and Boston, US)
15:38 Relationship between lipoprotein(a) level and mortality in 72766 Korean adults. P2145
– B.J. Kim, B.S. Kim, K.C. Sung, J.H. Kang, S.H. Lee, J.Y. Lee (Seoul, KR)
15:47 Prevalence and management of familial hypercholesterolaemia in the euroaspire iv project. P2146
– G. De Backer, J. Besseling, J. Chapman, G.K. Hovingh, J.J.P. Kastelein, K. Kotseva, K. Ray, Z. Reiner,
D. Wood, D. De Bacquer (Ghent, BE; Amsterdam, NL; Paris, FR; London, UK; Zagreb, HR)
15:55 Familial hypercholesterolemia is associated with poorer 5-year survival after acute myocardial P2147
infarction. The FAST-MI 2005 registry.
– N. Danchin, M. Farnier, M. Zeller, E. Puymirat, L. Belle, A. De Labriolle, Y. Cottin, F. Schiele, J. Ferrieres,
T. Simon (Paris, Dijon, Annecy, Montauban, Besançon and Toulouse, FR)
16:04 Impact of a major natural disaster on longitudinal changes in cardiovascular risk factors in the P2148
general population.
– S. Takahashi, K. Tanno, F. Tanaka, Y. Yonekura, K. Sakata, S. Kobayashi, M. Nakamura (Morioka, JP)
16:12 Lipoprotein(a): influence on cardiovascular manifestation. P2149
– K.-P. Mellwig, M. Schatton, B. Biermann, T. Kottmann, D. Horstkotte, F. Van Buuren (Bad Oeynhausen, DE)
16:21 Whole exome sequencing combined with integrated variant annotation prediction identifies P2150
asymptomatic Tangier disease with compound heterozygous mutations in ABCA1 gene.
145

CURRENT STATUS AND FUTURE DIRECTIONS OF CORONARY ARTERY BYPASS Moderated Posters
GRAFTING
Chairperson(s): Y. Sawa (Suita, JP); H.K. Najm (Riyadh, SA)
15:30 Long term follow-up following total arterial versus conventional and hybrid myocardial P2151
revascularisation: a propensity-match analysis.
– C. Muneretto, G. Bisleri, L. Di Bacco, A. Repossini, M. Tespili (Brescia and Seriate, IT)
15:38 An evaluation of the incidence and prognosis of post coronary artery bypass grafting myocardial P2152
infarction according to different definitions in the CORONARY trial.
– E.P. Belley-Cote, A. Lamy, G.I. Tagarakis, Y. Ou, J. Vincent, P. Kavsak, M. Zhang, P.J. Devereaux,
R.P. Whitlock (Hamilton, CA; Larissa, GR)
15:47 Impact of preexisting cerebral ischemia detected by magnetic resonance imaging on clinical P2153
outcomes after coronary artery bypass graft in patients without history of stroke.
– W.-J. Kim, Y.-M. Lim, S.-W. Lim, J.-Y. Moon, D. Min, S.-H. Kim, D.-H. Cha, S.-Y. Cho, W.-I. Yang, I.-J. Kim
(Seongnam and Gyeonggi-do, KR)
15:55 Colchicine treatment to reduce perioperative myocardial damage in patients undergoing on-pump P2154
coronary artery bypass grafting: a randomized study.
– G. Giannopoulos, C. Angelidis, V.K. Kouritas, P. Dedeilias, S. Fotakis, V. Panagopoulou, E. Toli,
D. Tousoulis, S. Deftereos (Athens, GR)
16:04 Long-term survival after off-pump coronary artery bypass graft surgery. P2155
– N.N. Patel, F. Fiorentino, M. Taghavi Azar Sharabiani, G.D. Angelini (London, UK)
16:12 Outcome after coronary artery bypass grafting and percutaneous coronary intervention in P2156
patients with stage 3B-5 chronic kidney disease.
– A.K. Lautamaki, T. Kiviniemi, F. Biancari, J.M. Gunn (Turku and Oulu, FI)
16:21 4-year mortality in 22,737 patients surviving 30 days after a first isolated coronary artery bypass P2157
graft procedure in 2002-2006, compared to the general population.
– S. Nielsen, L. Bjorck, A. Jeppsson, K.W. Giang, T. Zverkova Sandstrom, A. Rosengren (Gothenburg, SE)

BASIC MECHANISMS IN HEART FAILURE Moderated Posters
Chairperson(s): R.G. Kiss (Budapest, HU); B. Ghaleh (Créteil, FR)
15:30 Endothelial deletion of protein tyrosine phosphatase-1B promotes angiogenesis and improves P2158
survival and heart function after pressure overload-induced cardiac hypertrophy in mice.
– R. Gogiraju, M.R. Schroeter, M.L. Bochenek, K. Schaefer (Göttingen and Mainz, DE)
15:38 Ca-homeostasis in human cardiac hypertrophy and end stage heart failure is directly impacted by P2159
modulations of protein phosphatase 1 and -2a activity.
– J. Eiringhaus, T.H. Fischer, A.R. Saadatmand, S. Singh, M. Kohn, Y. Wang, L.S. Maier, G. Hasenfuss,
A. El-Armouche, S. Sossalla (Göttingen, Dresden, Heidelberg and Regensburg, DE)
15:47 Raf kinase inhibitor protein regulates interstitial and replacement cardiac fibrosis. P2160
– A. Kazakov, R. Hall, T. Meier, F. Lammert, M. Böhm, U. Laufs (Homburg, DE)
15:55 Contrasting effects of exercise training after myocardial infarction versus aortic stenosis depend P2161
critically on endothelial nitric oxide synthase.
– Y. Octavia, E.D. Van Deel, M.C. De Waard, M. De Boer, D.J. Duncker (Rotterdam, NL)
16:04 Regulation of fetal gene reprogramming by the early-onset myocardial infarction associated P2162
PHACTR1 gene in the heart.
– A. Kelloniemi, Z. Szabo, R. Serpi, J. Napankangas, P. Ohukainen, L. Kaikkonen, M. Leosdottir,
O. Melander, H. Ruskoaho, J. Rysa (Oulu, Helsinki and Kuopio, FI; Lund, SE)
16:12 Galectin-3: association with oxidative stress, inflammation and endotoxemia in patients with P2163
– E.A. Medvedeva, Y.V. Shchukin, V.A. Diachkov, E.A. Surkova (Samara, RU)
16:21 Impaired cardiac function in MMP13 knock out mice after myocardial infarction due to impaired P2164
remodeling.
– D. Westermann, D. Lindner, P.M. Becher, V. Lang, S. Hinrichs, S. Sosalla, S. Blankenberg (Hamburg and
Göttingen, DE)
146

HYPERTENSION AND HAEMODYNAMICS Moderated Posters
Chairperson(s): S. Laurent (Paris, FR); G. Schillaci (Perugia, IT)
15:30 Validation of noninvasive central blood pressure parameters attained with a brachial cuff-based P2165
oscillometric device among cardiovascular patients with cardiac dysfunction.
– T. Shoji, S. Okada, A. Nakagomi, Y. Kobayashi (Chiba, JP)
15:38 Association between resting heart rate and organ damage in high risk Japanese patients. P2166
– Y. Oba, S. Hoshide, K. Eguchi, K. Kario (Tochigi, JP)
15:47 Broad P-wave is associated with brain natriuretic peptide, left atrial dimension, length of P2167
hypertension history and hypertensive medication in hypertensive patients.
– T. Kabutoya, S. Hoshide, K. Kario (Tochigi, JP)
15:55 Aortic pulsatility assessed by a brachial cuff-based oscillometric method is a strong predictor for P2168
the presence of coronary artery disease.
– A. Nakagomi, S. Okada, T. Shoji, Y. Kobayashi (Chiba, JP)
16:04 Aorta-to-upper arm pulse wave transit time ratio can predict the risk of coronary artery disease P2169
and stroke better than pulse wave velocity.
– M.Y. Rhee, S.W. Jeong, C.H. Leem, Y.B. Lee (Goyang and Ulsan, KR)
16:12 Abdominal adiposity distribution quantified by ultrasound and incident hypertension in a general P2170
population.
– E. Seven, R.V. Fenger, L.L. Husemoen, A. Linneberg, J.L. Jeppesen (Copenhagen, DK)
16:21 Haemodynamic effects of adenosine adsorbed on silica nanoparticles. P2171
– I. Uskov (St. Petersburg, RU)

MEET THE GUIDELINES TASK FORCE I – VENTRICULAR ARRHYTHMIAS & SUDDEN CARDIAC Special Session
DEATH, PULMONARY HYPERTENSION
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); V. Aboyans (Limoges, FR)
15:40 Ventricular arrhythmias and sudden cardiac death. 2172
– C. Blomstrom-Lundqvist (Uppsala, SE), S.G. Priori (Pavia, IT)
15:59 Ventricular arrhythmias and sudden cardiac death - Panel discussion. 2173
– M. Borggrefe (Mannheim, DE), A.J. Camm (London, UK), P.M. Elliott (London, UK), G. Hindricks (Leipzig,
DE), P. Kirchhof (Birmingham, UK), A.H. Madrid (Madrid, ES), N. Nikolaou (Athens, GR), D.J. van Veldhuisen
(Groningen, NL)
16:00 Pulmonary hypertension. 2174
– N. Galie (Bologna, IT), M. Humbert (Le Kremlin-Bicêtre, FR)
16:19 Pulmonary hypertension - Panel discussion. 2175
– M.M. Hoeper (Hannover, DE), I.M. Lang (Vienna, AT), G. Simonneau (Clamart, FR)

MEET THE TRIALIST I: ALBATROSS Meet the Trialists
Chairperson(s): J.J.V. McMurray (Glasgow, UK)
15:40 Early aldosterone blockade in acute myocardial infarction: the randomized ALBATROSS Trial. 2176

DUAL ANTI-PLATELET THERAPY IN 2015 – EBAC Accredited Educational Programme - Experts on the Spot
REVIEWING THE EVIDENCE
Organised by The Sahlgrenska Academy - Goteborg University. Course Director: Karl Swedberg
Chairperson(s): H. Bueno (Madrid, ES)
15:45 Welcome and introduction - Dual anti-platelet therapy in 2015 – Reviewing the evidence. 2177
15:50 Clinical case study – When to initiate dual anti-platelet therapy? 2178
16:00 Open questions - Dual anti-platelet therapy in 2015 – Reviewing the evidence. 2179
– H. Bueno (Madrid, ES), L. Mauri (Boston, US)
16:13 Close - Dual anti-platelet therapy in 2015 – Reviewing the evidence. 2180
147

LESSONS LEARNED FROM THE TECOS CARDIOVASCULAR (CV) Satellite Symposium - Experts on the Spot
SAFETY TRIAL
Sponsored by MSD
Chairperson(s): E. Peterson (Durham, US)
15:45 The role of sitagliptin in the treatment of cardiovascular patients with type 2 diabetes. 2181

WORLD-WIDE CLINICAL USE OF NOACS: HOW ARE WE USING Satellite Symposium - Experts on the Spot
THEM?
Chairperson(s): J. Halperin (New York, US); S.Z. Goldhaber (Boston, US)
15:45 World-wide clinical use of NOACs: how are we using them? 2182
– J. Halperin (New York, US), S.Z. Goldhaber (Boston, US)

THE EVOLVING WORLD OF ANTICOAGULATION: MANAGING Satellite Symposium - Experts on the Spot
PATIENTS ON NOACS IN AN EMERGENCY
Chairperson(s): C. Pollack (Philadelphia, US); P. Verhamme (Leuven, BE)
15:45 The evolving world of anticoagulation: managing patients on NOACs in an emergency. 2183
– C. Pollack (Philadelphia, US), P. Verhamme (Leuven, BE)

HOT LINE II - ATRIAL FIBRILLATION/PACING Hot Line
Chairperson(s): E.M. Antman (Boston, US); J. Brugada Terradellas (Barcelona, ES)
16:30 Efficacy of Antiarrhythmic drugs Short-Term use after catheter ablation for Atrial Fibrillation 2184
(EAST-AF) Trial.
– K. Kaitani (Nara-Shi, JP)
16:36 Efficacy of adenosine triphosphate guided ablation for atrial fibrillation: UNmasking Dormant 2185
Electrical Reconduction by Adenosine TriPhosphate (UNDER-ATP) Trial.
– K. Kaitani (Nara-Shi, JP)
16:42 EAST-AF/UNDER-ATP: Discussant review. 2186
16:49 EAST-AF/UNDER-ATP: Panel discussion. 2187
16:53 Effect of empirical left atrial appendage isolation on long-term procedure outcome in patients 2188
with long-standing persistent atrial fibrillation undergoing catheter ablation: results from the
BELIEF.
– L. Di Biase (New York, US)
17:05 BELIEF: Discussant review. 2189
17:12 BELIEF: Panel discussion. 2190
17:16 Assessment of an education and guidance program for apixaban adherence in non-valvular atrial 2191
fibrillation: the randomized AEGEAN study.
17:28 AEGEAN: Discussant review. 2192
17:35 AEGEAN: Panel discussion. 2193
17:38 Safety and efficacy of a Leadless pacemaker: results from the LEADLESS II clinical trial. 2194
17:50 LEADLESS: Discussant review. 2195
17:57 LEADLESS: Panel discussion. 2196
148

HEART TEAM FOR SEVERE CARDIAC INSUFFICIENCY Special Session
The heart team. 2197
– J.F. Obadia (Lyon-Bron, FR), E. Bonnefoy-Cudraz (Bron, FR), H. Thibault (Bron, FR), L. Sebbag (Lyon, FR),
L. Juillard (Lyon, FR)
Brief presentation of the “advanced cardiac insufficiency heart team”. 2198
First severe decompensating cardiomyopathy. 2199
5 months later - New hospitalisation and new screening. 2200
Transiant improvement and severe decompensation at 18 months. 2201
Potential donor after 8 months on the waiting list. 2202
Chronic rejection 18 years after transplantation. 2203
Management of “end of life”. 2204

FROM BENCH TO SURGERY Rapid Fire Abstract
Chairperson(s): J.R. Gonzalez Juanatey (Santiago de Compostela, ES); A. Leite-Moreira (Porto, PT)
16:30 Lysyl oxidase-like-2 inhibition decreases cardiac fibrosis and improves diastolic dysfunction in 2205
experimental and clinical heart failure with preserved ejection fraction.
– K. Savvatis, J. Yang, M. Kasner, S. Van Linthout, P. Fan, L. Yao, C.P. Chang, C.P. Tschoepe (Berlin, DE;
Indianapolis and Foster City, US)
16:39 Chronic inhibition of Na+/Ca2+ exchanger (NCX) with SEA0400 improves cardiac function in a 2206
model of heart failure with preserved ejection fraction.
– U. Primessnig, T. Bracic, T. Glasnov, B. Pieske, F.R. Heinzel (Berlin, DE; Graz, AT)
16:48 Prophylactic epicardial left ventricular lead implantation in patients undergoing open heart 2207
surgery.
– D. Pecora, C. La Greca, U. Simoncelli, A. Sorgato, F. Morandi, M. Cirillo, C. Campana, C. Cuccia, G. Troise
(Brescia and Palermo, IT)
16:57 Myocardial and plasma matrix metalloproteinases and left ventricular remodeling: time-changes 2208
before and after surgical ventricular reconstruction in ischemic heart failure patients.
– S. Castelvecchio, G. Palladini, E. Baryshnikova, L. Menicanti, S. Perlini (Milan, Pavia and San Donato
Milanese, IT)
17:06 Primary graft failure after cardiac transplantation: prevalence, prognostic and risk factors. 2209
– P. Marques Correia, D. Prieto, M.C. Batista, M.J. Antunes (Coimbra, PT)
17:15 Combination of preoperative left and right ventricular echo parameters can predict right 2210
ventricular failure following left ventricular assist device implantation.
– T. Sugiyama- Kato, M. Daimon, K. Kimura, T. Kawada, S.L. Lee, A. Amano, P.C. Schulze, M. Farr,
S. Homma, D. Mancini (Tokyo, JP; New York, US)
17:24 Diastolic dysfunction is prognostic of long-term mortality in liver transplant recipients. 2211
– N. Naksuk, T. Peeraphadit, C. Thongprayoon, C. Krittanawong, V. Jaruvongvanich, P. Phatharacharukul,
R. Chaiteerakij, L.R. Roberts, K.W. Klarich (Rochester and Minneapolis, US; Bangkok, TH)
17:33 Clinical significance of elevated diastolic pressure gradient in heart failure with preserved ejection 2212
fraction.
– C. Zotter Tufaro, F. Duca, A.A. Kammerlander, S. Aschauer, A. Bachmann, B. Koell, D. Dalos,
J. Mascherbauer, D. Bonderman (Vienna, AT)
17:42 Heart failure in patients with reduced and preserved ejection fraction: are factors associated with 2213
all-cause and heart failure rehospitalization different?
– N. Farre, I. Rodriguez-Costoya, R. Olivero-Soldevila, P. Moliner-Borja, C. Enjuanes, S. Ruiz,
G. Gonzalez-Robledo, J.M. Verdu-Rotellar, J. Bruguera, J. Comin-Colet (Barcelona, ES)
17:51 The cardiac Protease-Activated Receptor 2 expression is crucial for the maintenance of the 2214
cardiac function in the aged heart.
– M. Witkowski, A. Weithauser, K. Savvatis, H.-P. Schultheiss, U.L.F. Landmesser, U. Rauch (Berlin, DE)
149

ESC RENE LAENNEC LECTURE ON CLINICAL CARDIOLOGY Named Lecture
Chairperson(s): G.A. Derumeaux (Créteil, FR); F.J. Pinto (Lisbon, PT)
– G.A. Derumeaux (Créteil, FR)
16:37 The interaction of acute blood pressure change, pericardial restraint and acute outflow tract 2216
stretch - A new paradigm underlying sudden cardiac death.
– G.R. Sutherland (London, UK)
ESC GEOFFREY ROSE LECTURE ON POPULATION SCIENCES Named Lecture

Chairperson(s): D.A. Wood (London, UK); I.A. Simpson (Southampton, UK)
– D.A. Wood (London, UK)
17:27 Optimising cardiovascular health: old and new challenges. 2218

– K.T. Khaw (Cambridge, UK)

TREATMENT OF CORONARY ARTERY DISEASE: FROM RECENT CLINICAL TRIALS TO PRACTICE Symposium
Chairperson(s): S. Muscoli (Rome, IT); M.E. Bertrand (Lambersart, FR)
16:30 CvLPRIT trial: is there room for ischaemia tests in the MI patient? 2219
– A.H. Gershlick (Leicester, UK)
16:52 BASKET-PROVE II: which stent in ischaemic heart disease? Metal, drug or biodegradable? 2220
– C.A. Kaiser (Basel, CH)
17:15 ISAR-SAFE: when to stop dual antiplatelet therapy after ACS? 2221
– S. Schupke (Munich, DE)
17:37 IMPROVE-IT: where is the ground in aggressive LDL lowering after ACS? 2222
– C.P. Cannon (Boston, US)

ACUTE CORONARY SYNDROMES NSTEMI IN GERMANY Guidelines in Daily Practice
Chairperson(s): C.W. Hamm (Bad Nauheim, DE); A. Kastrati (Munich, DE)
– T.K. Rudolph (Cologne, DE)
16:50 What do the “new” 2015 Guidelines tell us? 2224
– H. Moellmann (Bad Nauheim, DE)
17:10 How to manage the case according to the new recommendations? 2225
17:30 Mini quiz on 2014 ESC Guidelines. 2226
– H.M. Nef (Giessen, DE), S. Gielen (Halle, DE), J. Mehilli (Munich, DE), B. Vogel (Heidelberg, DE),
M. Neizel-Wittke (Düsseldorf, DE), T. Kempf (Hannover, DE), K.A. Hess (Aachen, DE)
150

OBESITY – THE GLOBAL THREAT! Rapid Fire Abstract
Chairperson(s): A. Badawi (New Cairo City, EG); N.D. Wong (Irvine, US)
16:30 The effects of excessive body mass on cardiac geometric remodeling, diastology and myocardial 2227
contractile mechanics in asymptomatic population.
– Y.H. Lai, K.T. Sung, J.Y. Kuo, T.C. Hung, H.I. Yeh, J.Y. Hou, C.L. Hung (Taipei, TW)
16:39 Impact of adipose tissue composition on cardiovascular risk assessment in patients with stable 2228
– A. Kunimura, T. Uetani, M. Takeshita, S. Okumura, N. Shinoda, K. Harada, B. Kato, H. Ishii, T. Amano,
T. Murohara (Nagoya, JP)
16:48 Effects of supplementation with green tea catechins on plasma C-reactive protein concentrations: 2229
A systematic review and meta-analysis of randomized controlled trials.
– C. Serban, A. Sahebkar, D. Antal, D.P. Mikhailidis, J. Rysz, M. Rizzo, S. Ursoniu, M. Banach (Timisoara,
RO; Mashhad, IR; London, UK; Lodz, PL; Palermo, IT)
16:57 QT interval prolongation in obesity and metabolic syndrome: myth or fact? 2230
– C. Strack, D. Fessmann, S. Fenk, M. Manka, J. Zeller, U. Hubauer, L. Maier, M. Fischer, A. Baessler
(Regensburg, DE)
17:06 Nutritional state predicts long-term survival in heart failure. 2231
– S. Sze, K.Y.K. Wong, S. Kazmi, D. Mellor, A. Rigby, A.L.C. Clark (Hull, UK)
17:15 Waist circumference versus other obesity indices as prognosticators of coronary artery disease in 2232
essential hypertension.
– K. Dimitriadis, C. Tsioufis, D. Tsiachris, K. Kintis, E. Andrikou, D. Syrseloudis, A. Kasiakogias, A. Kordalis,
I. Eleftheriadou, D. Tousoulis (Athens, GR)
17:24 Adherence to Mediterranean diet has an incremental protective effect over statin therapy against 2233
cardiovascular disease 10-year incidence: results of the ATTICA study.
– E. Georgousopoulou, D.B. Panagiotakos, C. Pitsavos, C. Chrysohoou, G. Georgiopoulos, I. Skoumas,
17:33 Genetic but not environmental factors have substantial influences on epicardial adipose tissue 2234
quantity: a classical twin study.
– A.L. Jermendy, D.V. Horcsik, T. Horvath, A. Bartykowszki, D.L. Tarnoki, A.D. Tarnoki, S. Voros, B. Merkely,
G. Jermendy, P. Maurovich-Horvat (Budapest, HU; Richmond, US)
17:42 Relations between parenting styles, parental feeding practices and the nutritional status of 2235
adolescents.
– L.C. Pellanda, A.B. Piccoli, C.P. Mosmann, L. Neiva-Silva (Porto Alegre, BR)
17:51 How we eat may be important as much as what we eat: eating behaviours and heart rate 2236
variability.
– M.E. Ozpelit, E. Ozpelit, N. Pekel, A. Yilmaz, S. Saygi, I. Tengiz, E. Ercan (Izmir, TR)
16:30–18:00 | Rabat - Village 1

REDEPLOYING DEVELOPMENTAL PROGRAMMES IN THE DAMAGED HEART Symposium
Chairperson(s): D.J. Henderson (Newcastle-upon-Tyne, UK); R. Kelly (Marseille, FR)
16:30 Regulators of myocardial repair. 2237
– N. Smart (Oxford, UK)
16:52 Controlling myocardial proliferation. 2238
– C. Jopling (Montpellier, FR)
17:15 Atrial fibrillation: insights from the embryo. 2239
– D. Franco (Jaén, ES)
17:37 Epicardial activation. 2240
– M. van den Hoff (Amsterdam, NL)

EXCITATION-CONTRACTION COUPLING ON THE ROAD OF TRANSLATION Advances in Science
Chairperson(s): C. Terracciano (London, UK); L.S. Maier (Regensburg, DE)
16:30 State of the Art in excitation and contraction coupling. 2241
– K.R. Sipido (Leuven, BE)
16:50 Unique regulation of cAMP signals at distinct excitation-contraction coupling (EEC) regulatory 2242
sites in adult cardiac myocytes.
– N.C. Surdo, M. Berrera, A. Koschinski, M. Zaccolo (Oxford, UK)
17:07 RyR2 stabilization by inhibiting aberrant Ca2+ release mediated by CaMKII signaling and Ca2+ 2243
buffering function suppresses arrhythmogenesis in Troponin T-related familial hypertrophic
cardiomyopathy.
– S. Okuda, T. Kato, M. Fukuda, S. Nishimura, S. Kobayashi, T. Oda, T. Yamamoto, M. Yano (Ube, JP)
17:24 Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium. 2244
– M. Wallner, E. Kolesnik, K. Ablasser, M. Khafaga, S. Ljubojevic, H. Sourij, M. Kapl, B. Kuzmiski, A. Griffith,
D. Von Lewinski (Graz, AT; Cambridge, US)
17:41 Future perspective and translation into clinic. 2245
151

THE YEAR IN PREVENTION: SCIENTIFIC HIGHLIGHTS FROM EUROPREVENT 2015 AND BEYOND Symposium
Chairperson(s): A. Pelliccia (Rome, IT); J.-P. Schmid (Berne, CH)
16:30 Scientific highlights in cardiac rehabilitation. 2246
– P. Doherty (York, UK)
16:52 Scientific highlights in exercise, basic and translational research. 2247
– M. Guazzi (San Donato Milanese, IT)
17:15 Scientific highlights in prevention, epidemiology and population science. 2248
– E. Prescott (Copenhagen, DK)
17:37 Scientific highlights in sports cardiology. 2249

WE ARE WHAT WE BREATHE: THE EFFECT OF POLLUTION Symposium
Chairperson(s): U. Nixdorff (Düsseldorf, DE); R.F. Storey (Sheffield, UK)
16:30 Pollution “pollutes” your vessels: the Heinz Nixdorf Recall study. 2250
– R. Erbel (Essen, DE)
16:52 Ambient air pollution and stroke: results from the ESCAPE study. 2251
– M. Stafoggia (Rome, IT)
17:15 Loud but not clear: the impact of noise and smoke on the cardiovascular diseases. 2252
– T. Munzel (Mainz, DE)
17:37 Mechanisms of the adverse cardiovascular effects of air pollution: lessons from controlled 2253
exposure studies.
– D.E. Newby (Edinburgh, UK)

ACCELERATING AGEING LINKS CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND Symposium
ESC and the European Respiratory Society
Chairperson(s): E.H. Bel (Amsterdam, NL); J.J. Bax (Leiden, NL)
16:30 Accelerated ageing in chronic obstructive pulmonary disease and cardiovascular disease: 2254
overview.
– P.J. Barnes (London, UK)
16:52 Cardiovascular disease as comorbidities of chronic obstructive pulmonary disease. 2255
– F. Mihaltan (Bucharest, RO)
17:15 Defective endothelial progenitor cells. 2256
– K. Paschalaki (London, UK)
17:37 Microparticles as mediators and biomarkers. 2257
– N. Werner (Bonn, DE)
16:30–18:00 | Kiev - Village 3

HYPERALDOSTERONISM: THE MAJOR UNDETECTED CAUSE OF HYPERTENSION? Case-based Symposium
Chairperson(s): J. Redon (Valencia, ES); E. Baranova (St. Petersburg, RU)
16:30 A case of resistent hypertension with normokalemia. 2258
– M. Stowasser (Woolloongabba, AU)
16:45 A case of resistent hypertension with normokalemia - Panel discussion and questions from the 2259
audience.
– M. Brown (Cambridge, UK), T.M. MacDonald (Dundee, UK), M. Stowasser (Woolloongabba, AU), F. Veglio
(Turin, IT)
17:00 A case of undetected microadenoma. 2260
– F. Veglio (Turin, IT)
17:15 A case of undetected microadenoma - Panel discussion and questions from the audience. 2261
– T. McDonald (Dundee, UK), M. Brown (Cambridge, UK), M. Stowasser (Woolloongabba, AU), F. Veglio
(Turin, IT)
17:30 Hyperaldosteronism - State of the Art lecture. 2262
– M. Brown (Cambridge, UK)
152

RESISTANT HYPERTENSION Advances in Science
Chairperson(s): R. Asmar (Paris, FR); S. Taddei (Pisa, IT)
16:30 State of the Art in resistant hypertension. 2263
16:50 Prevalence and comorbity of resistant hypertension in community practices. 2264
– C. Park, S. Lee, J. Lee, S. Park, E. Kim, C. Choi, J. Kim, S. Rha, H. Seo, D. Oh (Seoul, KR)
17:07 Cardiovascular morbidity of severe resistant hypertension among treated uncontrolled 2265
hypertensives: a 4-year follow-up study.
– A. Kasiakogias, C. Tsioufis, I. Bafakis, A. Kordalis, K. Dimitriadis, D. Tsiachris, E. Andrikou, K. Kintis,
I. Kallikazaros, D. Tousoulis (Athens, GR)
17:24 Resistant or pseudoresistant hypertension. Which is a true epidemic? Insights from renal 2266
denervation screening programme.
– M. Ojrzanowski, M.P. Plewka, J.D.K. Kasprzak (Lodz, PL)
17:41 Future direction for research in resistant hypertension. 2267

CARDIAC RESYNCHRONISATION THERAPY: STRATEGIES FOR IMPROVING RESPONSE Advances in Science
Chairperson(s): D. Gras (Nantes, FR); M. Lunati (Milan, IT)
16:30 State of the Art in avoiding non-responders to cardiac resynchronisation therapy. 2268
– J.C. Daubert (Rennes, FR)
16:50 Multimodality imaging-guided left ventricular lead placement improves clinical outcome in cardiac 2269
resynchronization therapy: a randomized controlled trial.
– A. Sommer, M.B. Kronborg, B.L. Norgaard, S.H. Poulsen, H.K. Jensen, J.M. Jensen, J. Kristensen,
C. Gerdes, P.T. Mortensen, J.C. Nielsen (Aarhus, DK)
17:07 Impact of multi-point left ventricular pacing on QRS duration and left ventricular ejection fraction. 2270
Preliminary results from a multicenter prospective study.
– L. Santini, D. Potenza, M. Giammaria, F. Zanon, G. Senatore, A. Curnis, D. Ricciardi, C. D’Agostino,
L. Calo’, G. Forleo (Rome, San Giovanni Rotondo, Turin, Rovigo, Ciriè, Brescia and Bari, IT)
17:24 Relation of QRS duration to clinical benefit of cardiac resynchronization therapy in mild heart 2271
failure patients without left bundle branch block MADIT-CRT sub-study.
– Y. Biton, V. Zareba, V. Kutyifa, H. Klein, S. McNitt, B. Polonsky, A.J. Moss, I. Goldenberg (Rochester, US)
17:41 Future direction for research in improving clinical outcome. 2272
– J. Singh (Boston, US)

MAJOR BREAKTHROUGHS IN MANAGEMENT OF VENTRICULAR TACHYARRHYTHMIAS, ATRIAL Symposium
FIBRILLATION, CRT AND PACING AND TELEMONITORING IN 2014 – TAKE HOME MESSAGES
Chairperson(s): S. Ernst (London, UK); C. Leclercq (Rennes, FR)
16:30 What is atrial fibrillation management and ablation? 2273
– L.V.A. Boersma (Nieuwegein, NL)
16:52 What is new in ablation VT/VF? 2274
– J. Kautzner (Prague, CZ)
17:15 News in CRT and pacing. 2275
– H. Burri (Geneva, CH)
17:37 News in syncope/ telemonitoring. 2276
– F. Braunschweig (Stockholm, SE)

MULTIMODALITY IMAGING AS A HELP FOR DECISION-MAKING, WHAT’S NEW IN 2015? Symposium
Chairperson(s): W.A. Zoghbi (Houston, US); B.A. Popescu (Bucharest, RO)
16:30 In hypertrophic cardiomyopathies. 2277
– M. Galderisi (Naples, IT)
16:52 In ischaemic heart disease. 2278
17:15 In valve diseases. 2279
– B. Cosyns (Braine-l’Alleud, BE)
17:37 In myocarditis/pericarditis. 2280
– S.E. Petersen (London, UK)
153

NEW ADVANCES IN CARDIAC IMAGING Advances in Science
Chairperson(s): M. Vannan (Atlanta, US); T. Kukulski (Zabrze, PL)
16:30 State of the Art in strain imaging to assess cardiac mechanics and physiology. 2281
– P.P. Sengupta (New York, US)
16:50 Validation of the pre-stretch/strain relationship as an non-invasive index of left-ventricular 2282
contractility.
– O. Mirea, C. Vallecilla, P. Claus, F.E. Rademakers, J. D’hooge (Leuven, BE)
17:07 Echocardiographic strain parameters assess early alterations of right ventricular contractility and 2283
cardiomyocyte excitation-contraction coupling: an experimental study in a large animal model.
– A. Hodzic, P. Bobin, F. Lefebvre, G. Vandecasteele, M. Ly, E. Gouadon, A. Capderou, J. Leroy,
C. Rucker-Martin, V. Lambert (Le Plessis-Robinson and Chatenay-Malabry, FR)
17:24 Strain and strain rate by speckle-tracking echocardiography reflect both the effects of exercise 2284
training and detraining in a rat model of athlete’s heart.
– A. Kovacs, A. Olah, A. Lux, C. Matyas, B.T. Nemeth, D. Kellermayer, L. Szabo, S. Braun, B. Merkely,
17:41 Future direction for research in cardiac mechanics. 2285
– J. D’hooge (Leuven, BE)

HOT TOPICS IN INTERVENTIONAL CARDIOLOGY 2015 Symposium
Chairperson(s): J.-P. Collet (Paris, FR); J. Fajadet (Toulouse, FR)
16:30 Transcatheter valve (aortic and mitral) interventions in 2015. 2286
16:52 Optimal DAPT duration after coronary stent implantation. 2287
17:15 Primary PCI in patients with multivessel CAD. 2288
– A. Baumbach (Bristol, UK)
17:37 Renal denervation update 2015. 2289
16:30–18:00 | Oslo - Village 6

MECHANICAL CIRCULATORY SUPPORT, FROM SHORT TO LONG TERM Case-based Symposium
Chairperson(s): M. Noc (Ljubljana, SI); V. Falk (Berlin, DE)
16:30 A case of ECMO for cardiogenic shock. 2290
– F. Pappalardo (Milan, IT)
16:45 A case of ECMO for cardiogenic shock - Panel discussion and questions from the audience. 2291
– S. Varnous (Paris, FR), F. Pappalardo (Milan, IT), J.D. Schmitto (Hannover, DE)
17:00 A case of implantable LVAD in end-stage heart failure. 2292
– S. Varnous (Paris, FR)
17:15 A case of implantable LVAD in end-stage heart failure - Panel discussion and questions from the 2293
audience.
– F. Pappalardo (Milan, IT), S. Varnous (Paris, FR), J.D. Schmitto (Hannover, DE)
17:30 Heart transplantation versus mechanical circulatory support - Is the gold standard changing? 2294
State of the Art lecture.
– J.D. Schmitto (Hannover, DE)

TREATMENTS FOR ACUTE CARDIAC CARE: INNOVATIONS OR LOST IN TRANSLATION? Symposium
Chairperson(s): H. Bueno (Madrid, ES); M. Lettino (Milan, IT)
16:30 Bivalirudin for ACS, end of story or bridge to the future? 2295
16:52 Fibrinolysis for acute pulmonary embolism, same future as for STEMI? 2296
– A. Torbicki (Otwock, PL)
17:15 Intra-aortic balloon pump will remain a nice concept. 2297
– D. Zahger (Beer Sheva, IL)
17:37 Cooling down, not so hot. 2298
154
16:30–18:00 | Tunis - Village 7

CONTROVERSIES IN POST-AMI CARDIOGENIC SHOCK Debate Session
Chairperson(s): T.M. Schiele (Munich, DE); J.S. Hochman (New York, US)
16:30 Inotropes should be forgotten - PRO. 2299
– M.S. Nieminen (Helsinki, FI)
16:45 Inotropes should be forgotten - CONTRA. 2300
17:00 Inotropes should be forgotten - REBUTTAL PRO. 2301
– M.S. Nieminen (Helsinki, FI)
17:05 Inotropes should be forgotten - REBUTTAL CONTRA. 2302
17:10 Inotropes should be forgotten - CONCLUSION. 2303
17:15 Intra-aortic balloon pump should be abandoned - PRO. 2304
17:30 Intra-aortic balloon pump should be abandoned - CONTRA. 2305
17:45 Intra-aortic balloon pump should be abandoned - REBUTTAL PRO. 2306
17:50 Intra-aortic balloon pump should be abandoned - REBUTTAL CONTRA. 2307
17:55 Intra-aortic balloon pump should be abandoned - CONCLUSION. 2308
LATE OUTCOME AFTER SHUNT CLOSURE: WHAT THE GENERAL CARDIOLOGIST Case-based Symposium
NEEDS TO KNOW
Chairperson(s): W. Budts (Leuven, BE); G.D. Webb (Cincinnati, US)
16:30 Device closed lesions: is systematic follow-up needed? 2309
– J. Pihkala (Helsinki, FI)
16:40 Device closed lesions: is systematic follow-up needed? Panel discussion and questions from the 2310
audience.
– J. Pihkala (Helsinki, FI), H. Baumgartner (Münster, DE), R.M.F. Berger (Groningen, NL), M. Schwerzmann
(Berne, CH)
16:52 Implication of late arrhythmia: how to detect and how to treat? 2311
17:02 Implication of late arrhythmia: how to detect and how to treat? Panel discussion and questions 2312
from the audience.
(Berne, CH)
17:14 Post closure pulmonary vascular disease: implications and treatment. 2313
– R.M.F. Berger (Groningen, NL)
17:24 Post closure pulmonary vascular disease: implications and treatment - Panel discussion and 2314
(Berne, CH)
17:36 Residual shunt lesions: prognosis and indication for reintervention. 2315
– M. Schwerzmann (Berne, CH)
17:46 Residual shunt lesions: prognosis and indication for reintervention - Panel discussion and 2316
(Berne, CH)
155

ENDOCARDITIS – EVALUATING RISK AND IMPROVING OUTCOME Advances in Science
Chairperson(s): C. Naber (Essen, DE); M.J. Antunes (Coimbra, PT)
16:30 State of the Art in endocarditis. 2317
– B.D. Prendergast (London, UK)
16:50 Development and validation of a risk score for cardiac surgery in infective endocarditis. 2318
– C. Olmos, I. Vilacosta, C. Fernandez, G. Tirado, A. Freitas-Ferraz, J. Lopez, C. Sarria, D. Vivas, L. Maroto,
J.A. San Roman (Madrid and Valladolid, ES)
17:07 Incidence, pathogenesis and outcome of patients developing infective endocarditis after 2319
transfemoral transcatheter aortic valve implantation.
– N. Mangner, F.J. Woitek, R. Hoellriegel, S. Haussig, F. Schlotter, G. Stachel, D. Holzhey, F.W. Mohr,
G. Schuler, A. Linke (Leipzig, DE)
17:24 Acute-onset infective endocarditis: the potentiality of early surgery. 2320
– C. Ferrera Duran, I. Vilacosta, C. Fernandez, C. Olmos, J. Lopez, C. Sarria, L. Maroto, D. Vivas,
C. Sanchez-Enrique, J.A. San Roman (Madrid and Valladolid, ES)
17:41 Future direction for research in endocarditis. 2321
– I. Vilacosta (Madrid, ES)
16:30–18:00 | Bern - Village 9

HEART FAILURE 2015: UPDATE FOR THE CLINICIAN Symposium
Chairperson(s): J.A. Goudevenos (Ioannina, GR); F. Ruschitzka (Zurich, CH)
16:30 Management of heart failure with chronic kidney disease. 2322
– C. Maack (Homburg, DE)
16:52 Heart failure and anticoagulation: for whom and when? 2323
– S. Homma (Manhattan, US)
17:15 New devices in the diagnosis and management of heart failure. 2324
– A.J.S. Coats (Coventry, UK)
17:37 Heart failure and diabetes. 2325
– P. Seferovic (Belgrade, RS)

HEART FAILURE Guidelines in Daily Practice
Chairperson(s): S.D. Anker (Göttingen, DE); A.A. Hagege (Paris, FR)
16:30 A case of chronic heart failure with high heart rate. 2326
16:45 A case of chronic heart failure with high heart rate - What do the Guidelines say? 2327
17:00 A case of chronic heart failure with high heart rate - Panel discussion on how to implement the 2328
Guidelines.
– J. Bauersachs (Hannover, DE), N. Aissaoui (Paris, FR)
17:10 A case of chronic heart failure with high heart rate - Conclusion and take home message. 2329
17:15 A case of HFpEF with EF 45% and its treatment. 2330
– B. Pitt (Ann Arbor, US)
17:30 A case of HFpEF with EF 45% and its treatment - What do the Guidelines say? 2331
17:45 A case of HFpEF with EF 45% and its treatment - Panel discussion on how to implement the 2332
Guidelines.
– J. Bauersachs (Hannover, DE), N. Aissaoui (Paris, FR)
17:55 A case of HFpEF with EF 45% and its treatment - Conclusion and take home message. 2333
– A.A. Hagege (Paris, FR)
156

VASCULAR BIOLOGY – NEW MOLECULAR AND GENETIC FINDINGS Rapid Fire Abstract
Chairperson(s): I. Hoefer (Utrecht, NL); A. Zampetaki (London, UK)
16:30 Inhibition of FGFR signaling with PD173074 ameliorates monocrotaline-induced pulmonary arterial 2334
hypertension and rescues BMPR-II expression.
– Y. Zheng, C.M. Xiong (Beijing, CN)
16:39 PI3Kalpha induced SMC migration and cell cycle progression is crucial for neointima formation 2335
following vascular injury.
– M. Vantler, J. Jesus, O. Leppaenen, X. Chen, M. Gerhardt, E. Berghausen, M. Zierden, S. Baldus,
J.J. Zhao, S. Rosenkranz (Köln, DE; Uppsala, SE; Boston, US)
16:48 Targeting the particulate guanylyl cyclase receptor b with a novel agonist, c-type natriuretic 2336
peptide-53, for selective vasorelaxation.
– S.J. Sangaralingham, B.K. Huntley, A. Buglioni, T. Ichiki, G.E. Harders, J.C. Burnett Jr (Rochester, US)
16:57 The role of macrophage STAT3 signaling in pathogenesis of aortic dissection. 2337
– S. Ohno, H. Aoki, M. Nishihara, A. Furusho, S. Hirakata, N. Nishida, S. Ito, M. Hayashi, H. Tanaka,
Y. Fukumoto (Kurume, JP)
17:06 Excessive sodium intake worsens aortic dissection via IL-17 pathway. 2338
– N. Nishida, H. Aoki, S. Ohno, M. Nishihara, A. Furusho, S. Hirakata, M. Hayashi, S. Ito, H. Yasukawa,
17:15 Endothelial mesenchymal transitions do not contribute to the development of pulmonary arterial 2339
hypertension caused by a VEGF receptor inhibitor in mice.
– R. Okamoto, I. Goto, Y. Ogihara, N. Yamada, H. Okada, M. Ito (Tsu and Saitama, JP)
17:24 Diastolic dysfunction in mice lacking nuclear factor (erythroid-derived 2)-like 2. 2340
– R. Erkens, C.M. Kramer, C. Panknin, L. Krause, M. Weidenbach, T. Krenz, E. Mergia, M. Kelm,
M.M. Cortese-Krott (Düsseldorf and Bochum, DE)
17:33 Casein kinase 2 beta is a critical player in platelet activation, arterial thrombosis and ischemic 2341
stroke.
– O. Borst, P. Muenzer, B. Walker, M. Chatterjee, F. Langhauser, R. Zahedi, A. Fotinos, C. Kleinschnitz,
F. Lang, M. Gawaz (Tübingen, Würzburg and Dortmund, DE)
17:42 RNA editing is essential for vascular homeostasis in vivo and controls gene expression in patients 2342
with cardiovascular disease.
– K. Stellos, A. Gatsiou, R. Boon, D. John, S. Uchida, T. Keller, W. Chen, H. Schwalbe, A.M. Zeiher,
S. Dimmeler (Frankfurt am Main and Berlin, DE)
17:51 Disruption of components of VEGF angiogenic signaling system in metabolic syndrome: Findings 2343
from a study conducted in rural Bangladeshi women.
– A. Rahman, S. Jesmin, S. Farzana, S. Ahmed, M.M. Islam, S.N. Sultana, O.F.S. Hossain, A.K.M.A. Habib,
N. Shimojo, S. Kawano (Bogra and Dhaka, BD; Tsukuba, JP)
157
SUNDAY 30 AUGUST 2015 – AFTERNOON POSTERS

BEST POSTERS IN CARDIOVERSION
Discussant: Best posters in cardioversion. P2344

– G. Baron Esquivias (Sevilla, ES)
Prevalence of auricular thrombosis before atrial flutter cardioversion: a 17-years transesophageal P2345
echocardiographic study.
– A. Cresti, M.A. Garcia Fernandez, F. De Sensi, G. Miracapillo, A. Picchi, F. Guerrini, S. Severi (Grosseto, IT;
Madrid, ES)
12-lead resting electrocardiogram reveals high-risk sources of cardioembolism in young adult stroke P2346
patients.
– J.R.R. Pirinen, J. Putaala, A.L. Aro, I. Surakka, A. Haapaniemi, M. Kaste, E. Haapaniemi, T. Tatlisumak,
M. Lehto (Helsinki, FI)
Dabigatran and rivaroxaban versus warfarin in patients with high risk of stroke and embolism undergoing P2347
electrical cardioversion with persistent and long-acting atrial fibrillation.
– O. Kalejs, A. Strelnieks, M. Kovalova, I. Sime, M. Vikmane, S. Sakne, I. Cgojeva, M. Zabunova, A. Lejnieks,
A. Erglis (Riga and Liepaja, LV)
Use of novel oral anticoagulants results in shorter waiting times for elective DC cardioversion. P2348
– D. Collison, S. Beecher, R. Walsh, Y. Smyth, J. Crowley (Galway, IE)
BEST POSTERS IN MYOCARDIAL ISCHAEMIA
Discussant: Best posters in myocardial ischaemia. P2349

– A. Koller (Budapest, HU)
Continuous erythropoietin receptor activation reverses increased myocardial susceptibility to P2350

ischemia/reperfusion injury in chronic renal failure.
– K. Nishizawa, T. Yano, T. Miki, M. Tanno, A. Kuno, H. Kouzu, T. Tobisawa, M. Mizuno, H. Sugawara,
High sensitivity cardiac troponin T significantly increases after a diagnostic stress test. P2351
– M.R. Ferraro, E. Orsini, P. Caravelli, L. Malloggi, F.L. Dini, M. Marzilli (Pisa, IT)
Long term outcome following remote ischemic postconditioning during percutaneous coronary P2352
interventions.
– S. Lavi, N. Abu-Romeh, S. Wall, M. Alemayehu, R. Lavi (London, CA)
Expression of SGLT1 in human hearts and impairment of cardiac energy metabolism by phlorizin during P2353
ischemia-reperfusion injury in mice.
– Y. Kashiwagi, T. Nagoshi, T. Yoshino, T. Tanaka, K. Ito, T. Harada, H. Takahashi, M. Ikegami, R. Anzawa,
M. Yoshimura (Tokyo, JP)
BEST POSTERS IN CARDIOVASCULAR MAGNETIC RESONANCE
Discussant: Best posters in cardiovascular magnetic resonance. P2354

– B.L.M. Gerber (Woluwe-St. Lambert, BE)
Left ventricular global function index and left lentricular mass volume ratio by CMR: association with P2355
heart failure in thalassemia major patients.
– A. Meloni, V. Positano, C. Tudisca, E. Chiodi, A. Vallone, M.G. Neri, G. Palazzi, D. Maddaloni, P. Keilberg,
A. Pepe (Pisa, Palermo, Ferrara, Catania, Modena and Fabriano, IT)
Troponin positive patients with unobstructed coronaries: incremental value of cardiovascular magnetic P2356
resonance.
– B. Raman, B. Pathik, N. Amin, D. Mahadevan, S. Rajendran, S. Khurana, J. Mazhar, C. Bridgman,
A. Ganesan, J.B. Selvanayagam (Adelaide, AU)
White-matter-lesions as detected by 3 Tesla MRI imaging of the brain demonstrate a high association P2357
with subclinical coronary artery calcification.
– H. Himpfen, S. Caspers, A.-A. Mahabadi, N. Pundt, U. Roggenbuck, K. Amunts, K. Zilles, S. Moebus,
K.-H. Joeckel, R. Erbel (Essen and Jülich, DE)
Stress-cardiac magnetic resonance imaging myocardial perfusion in chronic total occlusion patients. P2358
– A. Obedinsky, V. Kurbatov, E. Kretov, E. Pokushalov (Novosibirsk, RU)
158
BEST POSTERS IN METABOLISM AND THE HEART
Discussant: best posters in metabolism and the heart. P2359

– D. Hilfiker-Kleiner (Hannover, DE)
P21 deficiency is protective against high fat diet-induced metabolic disturbances and myocardial P2360
dysfunction.
– D. Sawaki, G. Czibik, F. Wan, J. Ternacle, M. Breau, A. Houssaini, S. Abid, L. Ernande, S. Adnot,
G. Derumeaux (Créteil, FR)
The SR influences mitochondrial ATP production via IP3 mediated Ca release. P2361
– L.K. Seidlmayer, J. Kuhn, O. Ritter (Würzburg, DE)
TIMP3 acts through apelin to maintain cardiac metabolic flexibility. P2362
– R. Stoehr, B.A. Kappel, M. Cavalera, M. Mavilio, R. Menghini, I. Arisi, N. Marx, M. Federici (Rome, IT;
Aachen, DE)
Identification of a glucose sensor in the heart. P2363
– A. Van Steenbergen, M. Balteau, H. Koepsell, G. Muccioli, J.L. Vanoverschelde, L. Hue, S. Horman,
L. Bertrand, C. Beauloye (Brussels, BE; Würzburg, DE)
BEST POSTERS IN PULMONARY HYPERTENSION TREATMENT STRATEGIES
Discussant: Best posters in pulmonary hypertension treatment strategies. P2364

Effect of selexipag on long-term outcomes in patients with pulmonary arterial hypertension (PAH) P2365
receiving one, two or no PAH therapies at baseline: results from the GRIPHON study.
– I. Lang, S. Gaine, N. Galie, H.A. Ghofrani, F.O. Le Brun, V. McLaughlin, L.J. Rubin, G. Simonneau,
O. Sitbon, M.M. Hoeper (Vienna, AT; Dublin, IE; Bologna, IT; Giessen and Hannover, DE; Allschwil, CH; Ann
Arbor and San Diego, US; Paris, FR)
Efficacy and safety of first-line oral triple upfront combination therapy in severe pulmonary arterial P2366
hypertension patients.
– H. Shigyo, T. Ogo, S. Fukui, J. Ueda, A. Tsuji, S. Yasuda, H. Ogawa, N. Nakanishi (Suita, JP)
Treating pulmonary hypertension in patients with heart failure and preserved ejection fraction: safety and P2367
efficacy in comparison to IPAH in COMPERA.
– C.F. Opitz, M.M. Hoeper, D. Huscher, D. Pittrow, S. Rosenkranz (Berlin, Hannover, Dresden and Cologne,
DE)
Safety and efficacy of cardiac rehabilitation initiated just after balloon pulmonary angioplasty in patients P2368
with inoperable chronic thromboembolic pulmonary hypertension.
– S. Fukui, Y. Goto, T. Ogo, A. Tsuji, R. Kumasaka, T. Arakawa, M. Nakanishi, H. Takaki, S. Yasuda,
N. Nakanishi (Osaka, JP)
BEST POSTERS IN EFFECTS OF EXERCISE ON THE CARDIOVASCULAR SYSTEM
Discussant: Best posters in effects of exercise on the cardiovascular system. P2369

– H.K. Rasmusen (Copenhagen, DK)
Differential effects of aerobic endurance, interval and strength endurance training on telomerase activity P2370
and senescence marker expression in circulating mononuclear cells.
– C. Werner, A. Hecksteden, J. Zundler, M. Böhm, T. Meyer, U. Laufs (Homburg and Saarbrücken, DE)
Perfect coronary arteries in sportsmen aged 45 years and older: the importance of lifelong exercise and P2371
ideal cardiovascular health. The MARC study.
– T. Braber, B.K. Velthuis, M.L. Bots, D.E. Grobbee, H.M. Nathoe, P.A. Doevendans, R. Rienks,
F.J.G. Backx, N.H.J. Prakken, A. Mosterd (Amersfoort, Utrecht and Groningen, NL)
Comparison of the cardioprotective effects of exercise training at early and late stages of experimental P2372
pulmonary arterial hypertension.
– D. Goncalves, R. Ferreira, H. Fonseca, A.I. Padrao, A.F. Silva, F. Vasques-Novoa, N. Goncalves, J. Alberto
Darte, A. Leite-Moreira, T. Henriques-Coelho (Porto and Aveiro, PT)
Screening for cardiac conditions predisposing to sudden cardiac death: the diagnostic yield and financial P2373
implications.
– H. Dhutia, A. Malhotra, S. Azizi, Z. Vinnicombe, F. Gill, K. Hughes, R. Narain, M. Papadakis, S. Sharma
(London, UK)
BEST POSTERS IN PCI: EXPOSING BASIC SCIENCE AND RADIATION... INTO CLINICS
Discussant: Best posters in PCI: exposing basic science and radiation... into clinics. P2374
– J. Aoki (Tokyo, JP)
Nanotechnology enabled rapid endothelialisation of stent-grafts. P2375

– B.J. Tefft, S. Uthamaraj, J.J. Harburn, D. Dragomir-Daescu, G.S. Sandhu (Rochester, US; Durham, UK)
Frontiers of plasmonic photothermal and stem cell therapy of atherosclerosis: nanotoxicity in P2376
NANOM-PCI trial.
– A. Kharlamov, J. Gabinsky, V. Shur (Rotterdam, NL; Yekaterinburg, RU)
159
Reduction of radiation exposure with a quality control system and influence of technological progress - P2377
comparison of a German coronary angiography and angioplasty registry and single centre data.
– A. Albrecht, B. Levenson, W. Haerer, N. Reifart, G. Ringwald, S. Goehring (Berlin, Ulm, Bad Soden,
Bruchsal and Weinheim, DE)
Radiation exposure of the operator during coronary interventions: comparison of right radial, left radial P2378
and right femoral approach.
– Z. Kallinikou, S. Puricel, M. Togni, N. Brugger, G. Baeriswyl, J.C. Stauffer, S. Cook, N. Ryckx, F. Verdun,
J.J. Goy (Fribourg, CH)
BEST POSTERS IN NEUROHORMONES
Discussant: Best Posters in neurohormones. P2379

– I.B. Squire (Leicester, UK)
Deletion of osteoprotegerin gene exacerbates cardiac hypertrophy and systolic dysfunction in aged-mice. P2380
– T. Tsuruda, I. Hao, S. Sakamoto, S. Kurogi, N. Udagawa, M. Nakamura, K. Hatakeyama, E. Chosa,
Y. Asada, K. Kitamura (Miyazaki and Matsumoto, JP)
Hypothyroidism predicts the mortality of idiopathic dilated cardiomyopathy. P2381
– J.R. Siles Rubio, C. Pera-Rojas, A. Ramirez Moreno, R. Bravo-Marques, M. Noureddine, L. Inigo-Garcia,
J. Munoz-Bellido, A. Milan-Pinilla, A. Valle-Alberca, E. Zambrano-Medina (Estepona and Marbella, ES)
Myocardial gene expression of osteopontin is higher in idiopathic than ischemic end-stage dilated P2382
cardiomyopathy.
– M. Cabiati, B. Svezia, L. Botta, C. Caselli, A. Pucci, V. Lionetti, S. Del Ry (Pisa and Milan, IT)
Pro-ADM is a strong prognostic biomarker in acute heart failure with preserved ejection fraction: data P2383
from the ACE 2 Study.
– M.O. Pervez, M.N. Lyngbakken, E.C. Langsjoen, A.D. Hoiseth, T. Omland, H. Rosjo (Akershus, NO)
BEST POSTERS IN SYMPATHETIC RENAL DENERVATION
Discussant: Best posters in sympathetic renal denervation. P2384

– E. Baranova (St. Petersburg, RU)
Renal norepinehrine periprocedural gradient and blood pressure response 6 months after renal P2385
denervation.
– K. Tiroch, A. Sause, J. Szymanski, I. Nover, R. Leischik, M. Vorpahl, M. Seyfarth (Wuppertal, DE)
Influence of renal sympathetic denervation on cardiac extracellular matrix turnover and cardiac fibrosis. P2386
– O. Doerr, C. Liebetrau, H. Moellmann, L. Gaede, C. Troidl, J. Wiebe, S. Voss, T. Bauer, C. Hamm, H. Nef
(Giessen and Bad Nauheim, DE)
Aortic pulse wave velocity as a marker for arterial stiffness predicts outcome of renal sympathetic P2387
denervation and remains unaffected by the intervention.
– P. Lurz, T.H. Okon, K. Roehnert, D. Heinemann, U. Mueller, K.-P. Rommel, T.H. Stiermaier, G. Schuler,
S. Desch (Leipzig and Lübeck, DE)
The effectivess of chemical renal denervation by vincristine depends on the flow rate of delivery. P2388
– A. Synetos, K. Toutouzas, M. Drakopoulou, A. Papanikolaou, G. Benetos, O. Kaitozis, G. Agrogiannis,
G. Latsios, C. Stefanadis, D. Tousoulis (Athens, GR)
160

RESYNCHRONISATION THERAPY IV
Triple site pacing improves LVdP/dtmax compared to conventional biventricular pacing. P2389
– F. Zanon, G. Pastore, E. Baracca, L. Marcantoni, D. Lanza, C. Picariello, L. Roncon, S. Aggio, F. Noventa,
F.W. Prinzen (Rovigo and Padua, IT; Maastricht, NL)
Features of a novel CRT Toolkit: an accurate algorithm for the measurement of ventricular conduction P2390
delays.
– F. Zanon, G. Forleo, L. Santini, R. Massaro, E. Menardi, E. Bertaglia, G. Ansalone, A. Locatelli, D. Spaziani,
M. Giammaria (Rovigo, Rome, San Giovanni Rotondo, Cuneo, Padua, Seriate, Magenta and Turin, IT)
Super-response to cardiac resynchronisation therapy in patients with congestive heart failure. P2391
– V.A. Kuznetsov, N.N. Melnikov, D.V. Krinochkin, A.M. Soldatova, T.N. Enina (Tyumen, RU)
The latest NICE guidelines on the use of cardiac resynchronisation therapy and implantable cardioverter P2392
defibrillator devices in heart failure may significantly increase implant rates.
– T. Mahendiran, O.E. Gosling, J. Newton, D. Giblett, D. McKenzie, M. Dayer (Taunton, UK)
ECG for cardiac resynchronization therapy optimization. P2393
– V. Lebedeva, T. Lubimceva, M. Trukshina, E. Lyasnikova, D. Lebedev (St. Petersburg, RU)
Cardiac resynchronization therapy: the importance of the interventricular depolarization time as a P2394
predictor of clinical response.
– R. Costa Rodrigues, M.S. Carvalho, S. Madeira, F.M. Costa, P.G. Santos, P. Carmo, D. Cavaco,
F. Morgado, P. Adragao (Funchal and Carnaxide, PT)
No association between cardiac resynchronization therapy response and left atrial size and function as P2395
assessed by computed tomography.
– P.B. Hansen, A. Sommer, B.L. Noergaard, J.C. Nielsen (Aarhus, DK)
The ratio of the neutrophil leukocytes to the lymphocytes predicts the outcome after cardiac P2396
– A.M. Boros, P. Perge, Z. Jenei, L. Molnar, E. Zima, L. Geller, Z. Prohaszka, B. Merkely, G. Szeplaki
(Budapest, HU)
Optimization of pacing parameters with 3D-echo increases response to CRT in paediatric patients. P2397
– M.S. Silvetti, A. Ammirati, R. Palmieri, L.M. Santucci, S. Placidi, M. Prosperi, L. Rava’, F. Drago (Rome, IT)
The effect of cardiac resynchronisation therapy on cognitive function in patients with moderate to severe P2398
heart failure.
– C.I. Freeman, R.A. McCarthy, L. Fletcher, L.A. Smith, D. Kelly, P.J. Cowburn (Southampton and
Basingstoke, UK)
Single center experience with transseptal endocardial left ventricular lead implantation using transseptal P2399
puncture via the subclavian vein.
– S.Z. Szilagyi, B. Merkely, L. Molnar, E. Zima, G. Szeplaki, I. Osztheimer, N. Szegedi, L. Geller (Budapest,
HU)
Service life of implantable cardioverter-defibrillators for cardiac resynchronization therapy: an analysis of P2400
determinants in current clinical practice.
– M. Landolina, A. Curnis, G. Morani, A. Vado, E. Ammendola, A. D’Onofrio, G. Stabile, M. Crosato,
M. Gasparini (Crema, Brescia, Verona, Cuneo, Naples, Treviso and Rozzano, IT)
ELECTROCARDIOGRAPHY – CARDIOVERSION – DEFIBRILLATION I
Difference of mean ventricular fibrillation zone cycle length between appropriate and inappropriate P2401
therapy in patients with BrS, ERS and IVF.
– W.S. Lee, J. Kim, C.H. Kwon, J.H. Choi, U. Jo, Y.R. Kim, G.B. Nam, K.J. Choi, Y.H. Kim (Seoul, KR)
Are wide complex tachycardia algorithms applicable in adults with congenital heart disease? P2402
– Z. Blazquez Bermejo, O. Salvador, J. Restrepo, P. Cepas, A. Vega, A. Gonzalez, J. Ruiz Cantador,
A. Sanchez Recalde, J.M. Oliver, R. Peinado (Madrid, ES)
Idiopathic ventricular fibrillation - electrocardiographic abnormalities do not predict recurrent P2403
arrhythmias.
– U. Chaudhry, R. Borgquist, A. Rubulis, L. Bergfeldt, S.M. Jensen, P.G. Platonov (Lund, Gothenburg and
Umeå, SE)
A low fibrillatory wave amplitude predicts sinus node dysfunction after catheter ablation in patients with P2404
persistent atrial fibrillation.
– A. Sunaga, M. Masuda, T. Kanda, Y. Matsuda, M. Fujita, O. Iida, S. Okamoto, T. Isihara, K. Nanto,
M. Uematsu (Amagasaki, JP)
Real world usage of direct oral anticoagulants in patients undergoing electrical cardioversion for atrial P2405
tachyarrhythmias.
– A.G. Carrizo, P. Lamelas, G. Amit, S.J. Divakara Menon, S.C. Ribas, J.S. Healey, S.J. Connolly, C.A. Morillo
(Hamilton, CA)
Transient QRS amplitude attenuation in patients with takotsubo cardiomyopathy. P2406
– F. Guerra, E. Rrapaj, I. Giannini, G. Pongetti, A. Fabbrizzioli, D. Aschieri, V. Pelizzoni, G.Q. Villani,
J.E. Madias, A. Capucci (Ancona and Piacenza, IT; Elmhurst, US)
161
Patients who revert to atrial fibrillation after cardioversion demonstrate impaired thrombotic status. P2407
– M. Farag, O. Okafor, M. Niespialowska-Steuden, B. Artman, V. Markides, D.A. Gorog (Hertfordshire and
London, UK)
Implantable cardioverter defibrillator shock does not immediately worsen left ventricular systolic and P2408
diastolic function.
– T. Mine, H. Kishima, K. Ashida, T. Masuyama (Nishinomiya, JP)
Early repolarization on electrocardiography in survivors after out of hospital cardic arrest;impact and P2409
short-term outcome.
– Y. Hori, K. Fukushima, H. Takahashi, N. Komiyama (Matsudo, JP)
Hyperkalemic induced Brugada phenocopy: clinical, electrocardiographic and arrhytmic caracterization. P2410
– A.R. Rivera Juarez, F. Atienza, I. Melgar Gonzalez, S. Zhang, B. Sanchez, A. Tejedor, A. Arenal,
F. Fernandez-Aviles (Madrid, ES; Guatemala, GT)
Can we monitor left atrial electrical remodelling with standard 12- lead ECG in patients with atrial P2411
fibrillation?
– M. Wojcik, R. Blaszczyk, A. Sochaj, E. Rychta, I. Leebe, K. Oleszczak, K. Poleszak, J. Baszak, A. Smolen,
A. Wysokinski (Lublin, PL)
QT-TQ dynamics in long QT patients during a supine-standing ECG test. P2412
– V.M.F. Meijborg, P.G. Posterma, H.J. Ritsema Van Eck, A.A.M. Wilde, R. Coronel (Amsterdam and
Rotterdam, NL)
ELECTROCARDIOGRAPHY – CARDIOVERSION – DEFIBRILLATION II

Electrocardiogram characteristics of verapamil-sensitive fascicular ventricular tachycardia. P2413
– G. Zhou, J. Ma, X. Guo, X. Liu, S. Zhang (Beijing, CN)
Association of right ventricular systolic function and conduction delay in patients with right bundle P2414
branch block.
– K.I. Cho, S.I. Im, H.S. Kim, J.H. Heo, T.J. Cha (Busan, KR)
Transient manifestation of J-waves during acute pericarditis: electrophysiological abnormalities in P2415
subepicardium are possibly associated with the genesis of J-waves.
– I. Abe, M. Nakagawa, Y. Ikebe, S. Saito, H. Kondo, T. Shinohara, Y. Teshima, K. Yufu, N. Takahashi (Oita,
JP)
Evaluation of Tp–e interval and Tp–e/QT ratio in patients with coronary slow flow. P2416
– K. Karaman, F. Altunkas, M. Karayakali, A. Arisoy, M. Cetin, I. Akar, C. Zencir, B. Ayguc, A. Celik,
K. Ceyhan (Tokat, Adiyaman and Aydin, TR)
Electrocardiographic characteristics of the painful left bundle branch block syndrome. P2417
– A. Shvilkin, M.E. Josephson (Boston, US)
Is ECG a reliable means of preexcitation syndrome diagnosis? P2418
– B. Brembilla-Perrot, A. Olivier, J.M. Sellal, V. Manenti, T. Villemin, D. Beurrier, C. De Chillou, J. Vincent,
N. Girerd (Vandoeuvre-lès-Nancy, FR)
Frontal QRS-T angle as a predictor of appropriate implantable cardioverter-defibrillator therapy in P2419
ischemic and non-ischemic cardiomyopathy.
– S. Chandrachamnong, W. Wiwatworapan, T. Yingchoncharoen, T. Ngernsritrakul, S. Apiyasawat, O. See,
P. Sritara (Bangkok, TH)
The effect of percutaneous closure of atrial septal defects on the P-wave dispersion. P2420
– O. Ozturk, U. Ozturk (Diyarbakir, TR)
Prevalence of early repolarization pattern in 12-lead electrocardiogram: a population-based study. P2421
– M.G. Matta, P.E. Gulayin, S. Garcia Zamora, R. Poggio, L. Gutierrez, V.E. Irazola, J. Gonzalez-Zuelgaray,
A.L. Rubinstein (Buenos Aires, AR)
A novel formula to predict the QT interval during intrinsic atrioventricular conduction from the ventricular P2422
paced electrocardiogram.
– R. Sriwattanakomen, A. Shvilkin (Boston, US)
Identification of the anatomic location of focal atrial tachycardias using synthesized 18 lead P2423
electrocardiography.
– M. Ishimura, M. Ueda, K. Miyazawa, T. Kajiyama, N. Hashiguchi, Y. Kobayashi (Chiba, JP)
Association of initial and terminal ventricular activation velocity ratio on 12-leads electrocardiography P2424
with myocardial scar presence.
– S. Priyantoro, Y. Yuniadi, M. Kasim (Jakarta, ID)
ANTIBRADYCARDIA PACING
Reduction in unnecessary ventricular pacing fails to affect hard clinical outcomes: A meta-analysis. P2425
– M. Shurrab, G. Botto, S. Connolly, B. Arouny, D. Newman, G. Boriani, L. Padeletti, J. Healey, E. Crystal
(Toronto and Hamilton, CA; Como, Bologna and Florence, IT)
Health-related quality of life improvement following transcatheter pacing system implantation. P2426
– R.E. Knops, F.V.Y. Tjong, J.R. De Groot, C. Waweru, K. Stromberg, D. Reynolds, P. Ritter (Amsterdam, NL;
Mounds View and Oklahoma City, US; Bordeaux, FR)
Using the CHADS2 and CHA2DS2-VASc Scores for prediction of long-term outcome in patients with P2427
atrioventricular block undergoing permanent pacemaker implantation.
– J.-N. Liao, T.F. Chao, T.C. Tuan, S.A. Chen (Taipei, TW)
Progression of cardiac conduction abnormalities in patients with familial amyloid polyneuropathy after P2428
liver transplantation.
– A.R. Gaspar Lopes Francisco, N. Cortez-Dias, T. Guimaraes, G. Da Silva, M.N. Menezes, R. Placido,
P. Marques, J. De Sousa, F.J. Pinto, C. Azevedo Coutinho (Lisbon, PT)
162
Independent predictors of permanent atrioventricular block after transcatheter aortic valve replacement. P2429
– N. Badenco, R. Frank, C. Maupain, C. Nguyen, G. Duthoit, P. Leprince, G. Lebreton, O. Barthelemy,
E. Gandjbakhch, J.P. Collet (Paris, FR)
Left ventricular only pacing is a feasible and safe way to avoid tricuspid valve injury in patients with P2430
pre-existent tricuspid valve disease or surgery.
– T.W. Lim, W.T. Yeo, D. Singh, S.C. Seow, P. Kojodjojo (Singapore, SG)
Eight years experience in permanent pacemaker implantation after open heart surgery. P2431
– K.O. Yazdani, A. Yaminisharif, A. Shafiee, A. Kazemisaeed, H.A. Tafti (Tehran, IR)
Longitudinal strain and twist calculated by Cardiac MRI differs between apical and rvot pacing sites. P2432
– M.P. Ainslie, C. Miller, A.B. Reid, D. Clark, L. Francis, B. Brown, D.J. Fox, N. Davidson, A. Trafford,
M. Schmitt (Manchester, UK)
Minimum invasive hemodynamic assessment of right ventricular outflow tract septal wall pacing versus P2433
conventional right ventricular apex pacing.
– G. Lima Da Silva, P. Marques, M. Nobre Menezes, A. Bernardes, A. Magalhaes, N. Cortez-Dias,
L. Carpinteiro, J. De Sousa, F.J. Pinto (Lisbon, PT)
Procedural safety and long-term follow-up after pacemaker implantation in nonagenarians. P2434
– A. Loirat, D. Feneon, A. Behaghel, N. Behar, A. Le Helloco, P. Mabo, J.C. Daubert, C. Leclercq,
R.P. Martins (Rennes, FR)
Standardised patient referral pathway improves outpatient waiting times for elective brady pacemaker P2435
implants in a tertiary care hospital.
– M. Jawad Ul Qamar (Birmingham, UK)
DEVICE COMPLICATIONS
Impact of catheter ablation for atrial tachyarrhythmias on inappropriate shocks in patients with P2436
implantable cardioverter defibrillator and cardiac resynchronization therapy-defibrillator.
– K. Minami, K. Nakamura, S. Naito, T. Sasaki, K. Kumagai, S. Oshima (Maebashi, JP)
Ambulatory pacemaker Implant and ablation procedures: A risk worth taking? P2437
– G. Vanerio (Montevideo, UY)
Lead dependent infective endocarditis. How significant the size of right heart vegetations is? P2438
– A. Polewczyk, W. Jachec, A. Tomaszewski, W. Brzozowski, G. Opolski, M. Grabowski, M. Janion,
A. Kutarski (Kielce, Zabrze, Lublin and Warsaw, PL)
High recurrence rate of device-related adverse events following transvenous lead extraction procedure in P2439
CRT patients.
– F. Regoli, M.G. Bongiorni, R. Rordorf, M. Santamaria, L. Segreti, T. Moccetti, G. Conte, M.L. Caputo,
C. Klersy, A. Auricchio (Lugano, CH; Pisa, Pavia and Campobasso, IT)
Major complications of transvenous lead extraction. Risk factors are still ephemeral. An analysis of 1767 P2440
procedures.
– A. Kutarski, M. Polewczyk, M. Czajkowski, A.M. Polewczyk, A. Polewczyk, S. Targonska, J. Stazka (Lublin
and Kielce, PL)
Exteranalization of ICD leads, not only riata problem. P2441
– A. Maciag, P. Syska, M. Sterlinski, A. Kolodzinska, A. Przybylski, K. Kusmierski, A. Oreziak, H. Szwed
(Warsaw and Rzeszow, PL)
Clinical features and changes in epidemiology of infective endocarditis on pacemaker devices over a P2442
27-year period (1987-2013).
– F.C.A. Carrasco, M.A.S. Anguita, M.R.O. Ruiz, J.C.D. Castillo, F.C.B. Castillo, D.M. Mesa, M.D. Delgado,
E.R. Romo, M.P. Pan, J.S.L. Suarez De Lezo (Córdoba, ES)
Detection of Cardiovascular Implantable Electronic Device Infections with Sonication Following Lead P2443
Extraction and Generator Change.
– B.L. Nguyen, A. Oliva, A.L. Di Giamberardino, M.T. Mascellino, A. Cipolla, N. Alessandri, C. Gaudio,
A. Ciccaglioni, C.M. Mastroianni, V. Vullo (Rome and Latina, IT)
Risk factors, presentation, treatment and consequences of cardiac device infections; a retrospective P2444
analysis.
– A. Eksi, S. Yuksel, S. Demircan, A. Erbay, H. Zengin, K. Soylu, O. Yilmaz, M. Sahin (Kurupelit-Samsun, TR)
Transvenous leads extraction- analysis of factors influencing long-term mortality after procedures. P2445
Lublin, PL)
Adverse consequences of inappropriate antitachycardia pacing delivered with implantable cardioverter P2446
defibrillators: life threatening proarrhythmic effects.
– I. Morishima, T. Sone, H. Tsuboi, Y. Morita, R. Yoshida, T. Tomomatsu, Y. Ikai, K. Terada, Y. Tsuji,
T. Koyama (Ogaki, JP)
Five-years microbiologic characteristic of patients with complications of electrotherapy. P2447
– R. Mlynarski, A. Mlynarska, R. Kaczkowski, E. Pilat, J. Wilczek, J. Biernat, M. Sosnowski, K.S. Golba
(Katowice, PL)
NON-INVASIVE STUDIES
A novel 3-directional magnetocardiographic approach can disclose left ventricular intraventricular P2448
conduction delay in dilated cardiomyopathy patients with narrow QRS.
– S. Kawakami, H. Takaki, S. Hashimoto, T. Aiba, K. Kusano, H. Ogawa, S. Yasuda, S. Kamakura,
163
The relationship between the repolarization parameters and serum electrolyte levels in patients with P2449
J-wave syndrome.
– N. Sato, R. Sasaki, M. Imahashi, K. Saito, A. Talib, N. Sakamoto, K. Akasaka, S. Fujii, Y. Kawamura,
N. Hasebe (Asahikawa, JP)
Noninvasive epi-endocardial imaging of cardiac arrhythmias. P2450
– M.S. Khlynin, S.V. Popov, R.E. Batalov, S.N. Krivolapov (Tomsk, RU)
T-wave deformation in non-aberrant premature atrial contractions: A novel indicator associated with P2451
T-wave alternans and a history of life-threatening arrhythmias in patients with long QT syndromes.
– N. Takasugi, H. Goto, T. Kuwahara, M. Takasugi, H. Toyoshi, T. Nakashima, T. Kubota, M. Kawasaki,
K. Nishigaki, S. Minatoguchi (Gifu, JP)
Relationship between the sinoatrial conduction time and the occurrence of Mobitz II sinoatrial exit block. P2452
– K. Makowski, E. Kramarz (Warsaw, PL)
Arrhythmogenic region of premature ventricular contraction relates early left ventricular systolic P2453
dysfunction.
– H. Yamamoto, H. Katoh, M. Kunishige, M. Kosugi, Y. Mizukami, S. Beppu (Osaka, JP)
P-wave signal-averaged electrocardiography analysis in acute exacerbation of chronic obstructive P2454
pulmonary disease.
– C.A. Buzea, A.R. Dan, G.A. Dan, C. Delcea, M.I. Balea, D. Gologanu, R.A. Popescu, A. Iernici (Bucharest,
RO)
Electrophysiological study frequently is negative in patients <40 suspected of supraventricular P2455
tachycardia but also complaining of chest pain and or syncope.
– B. Brembilla-Perrot, V. Manenti, A. Olivier, J.M. Sellal, T. Villemin, D. Beurrier, J. Rizk, A. Moulin Zinsch,
F. Marcon, N. Girerd (Vandoeuvre-lès-Nancy, FR)
Positive Late Potentials are not explained by cardiac MRI findings in patients with ventricular arrhythmias. P2456
– P. Marstrand, J.J. Thune, N. Vejlstrup, H. Bundgaard, J. Theilade (Copenhagen, DK)
Rapid diagnosis and management of symptomatic arrhythmia - the role of telemedicine. P2457
– A. Roth, Y. Shacham, M. Golovner (Tel Aviv, IL)
STEMI I
Is there any benefit with beta-blocker therapy in patients with myocardial infarction with left ventricular P2458
systolic dysfunction and atrial fibrillation?
– R. Gonzalez Ferreiro, S. Raposeiras Roubin, E. Abu-Assi, A. Redondo Dieguez, A. Lopez Lopez, B. Alvarez
Alvarez, V. Gonzalez Salvado, R.R. Abumuaileq, J.M. Garcia Acuna, J.R. Gonzalez Juanatey (Santiago de
Compostela, ES)
Beta-blocker therapy and short-term outcome in acute heart failure caused by acute coronary P2459
syndromes: a propensity-score matching secondary analysis of the ALARM-HF registry.
– P. Simitsis, J. Parissis, D.T. Farmakis, V. Bistola, I. Ikonomidis, A. Mebazaa, G. Filippatos, J. Lekakis,
F. Follath (Athens, GR; Paris, FR; Zurich, CH)
A risk score for predicting cardiac arrest requiring defibrillation or cardiopulmonary resuscitation for P2460
patients admitted with suspected non-ST-elevation acute coronary syndromes.
– J. Faxen, T. Jernberg, J. Sundstrom, B. Lindahl, K. Szummer (Stockholm and Uppsala, SE)
Safety and efficacy of the esc 0h/3h-protocol for rapid rule-out of myocardial infarction among women P2461
and men.
– M. Rubini Gimenez, R. Twerenbold, K. Wildi, T. Reichlin, C. Puelacher, P. Hillinger, M. Wagener,
J. Boeddinghaus, S. Osswald (Basel, CH)
Hyponatremia at discharge as a predictor of 12-month clinical outcomes in hospital survivors after acute P2462
– M.H. Bae, N.K. Kim, C.Y. Kim, S.Y. Jang, J.H. Kim, J.H. Lee, D.H. Yang, H.S. Park, Y. Cho, S.C. Chae
(Daegu, KR)
High event rate in patients with acute coronary syndromes and atrial fibrillation: Results from the P2463
prospective EPICOR Registry.
– U. Zeymer, L. Annemans, N. Danchin, S. Pocock, F. Van De Werf, J. Medina, H. Bueno (Ludwigshafen am
Rhein, DE; Ghent and Leuven, BE; Paris, FR; London, UK; Madrid, ES)
Clinical and angiographic characteristics of patients with acute coronary syndromes without P2464
cardiovascular risk factors.
– A. Correia, R. Rodrigues, B. Silva, M. Neto, S. Gomes, A. Drumond, D. Pereira (Funchal, PT)
Clinical impact of multivessel disease with or without chronic total occlusion in non-infarct-related artery P2465
on five-year outcomes in patients with STEMI undergoing primary PCI.
– H. Watanabe, H.S. Shiomi, T.K. Kimura (Kyoto, JP)
Incidence rates and predictors of major adverse cardiovascular outcomes occurring before vs. after P2466
1-year following discharge after acute coronary syndrome.
– D. Iglesias, E. Abu-Assi, S. Raposeiras-Roubin, A. Martinez-Gomez, R. Gonzalez-Ferreiro, A. Lopez-Lopez,
R. Fandino-Vaquero, R.R.Y. Yousef-Abumuaileq, J.M. Garcia-Acuna, J.R. Gonzalez-Juanatey (Santiago de
Compostela, ES)
Cardiovascular risk in post-myocardial infarction patients: Nationwide real-world data on distribution and P2467
impact of combination of risk factors in a real-life setting.
– T. Jernberg, L.P. Hasvold, H. Hjelm, M. Thuresson, M. Janzon (Stockholm, Södertälje, Nyköping and
Linköping, SE)
164
STEMI II
Zowlle risk score: the missed opportunity for early discharge after primary percutaneous intervention. P2468
– A. Arabi, J. Alsuwaidi, A. Gehani, S. Arafa, A. Alqahtani, A. Alnabti, S. Aboujalala, I. Rafie, O. Altameemi,
M. Yacoub (Doha, QA)
Postinfarct left ventricular remodeling in male STEMI patients. Contribution from periinfarct activation of P2469
TNF-related apoptosis inducing ligand and osteoprotegerin.
– M. Przewlocka-Kosmala, B. Karolko (Wroclaw, PL)
TIMI score versus CHA2DS2-VASc: which one does a better job predicting long term mortality in an acute P2470
coronary syndrome population?
– F. Soares, H. Martins, N. Moreira, R. Ferreira, J.M. Ferreira, R. Baptista, F. Goncalves, S. Monteiro,
P. Monteiro, M. Pego (Coimbra and Guarda, PT)
Age and gender differences in place and causes of deaths of acute myocardial infarction in-patients in a P2471
3-year observation after discharge (from nationwide AMI-PL study).
– M. Gierlotka, B. Wojtyniak, T. Zdrojewski, M. Gasior, L. Polonski, L. Wierucki, M. Zembala, Z. Kalarus,
M. Wysocki, G. Opolski (Zabrze, Warsaw and Gdansk, PL)
Primary angioplasty in multivessel disease: what to do after PRAMI results? P2472
– M. Madeira, F. Caetano, I. Almeida, M. Costa, L. Goncalves (Coimbra, PT)
Validation of the ProACS risk stratification score for acute coronary syndromes. P2473
– A.T. Timoteo, S. Aguiar Rosa, M. Afonso Nogueira, T. Pereira Silva, P. Rio, R. Carvalho, M.L. Ferreira,
R. Cruz Ferreira (Lisbon, PT)
The effect of PCI strategy on 1-year mortality in STEMI patients with multi-vessel CAD who present P2474
without cardiogenic shock.
– G.W. Witberg, S. Matetzky, I. Goldenberg, N. Shlomo, D. Hasdai, R. Kornowski, Z. Iakobishvili (Petah Tikva
and Tel Hashomer, IL)
The impact of high D-dimer levels on in-hospital mortality in patients with ST-segment elevation P2475
myocardial infarction treated with primary percutaneous coronary intervention.
– K. Minami, M. Kurobe, S. Furudono, Y. Uchida, T. Nunohiro, S. Takeshita, H. Nakashima, K. Maemura
(Nagasaki, JP)
Mechanical chest compressions during prolonged resuscitation for reperfusion ventricular fibrillation that P2476
complicated coronary intervention for ST-elevation myocardial infarction.
– M.M. Demidova, H. Wagner, D. Erlinge, P.G. Platonov (Lund, SE)
Clinical and angiographic predictors of microvasulcar dysfunction In ST-Segment elevation myocardial P2477
infarction.
– S.D. Park, M.D. Lee, M.J. Lee, S.W. Kwoun, S.H. Shin, S.I. Woo, D.H. Kim, J.U.N. Kwan, K.S. Park
(Incheon, KR)
STEMI III
Prognostic implication of creatinine clearance and hemoglobin composite index in patients with P2478
ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
– T.-H. Yang, H.-C. Shin, Y.-M. Lee, H.-S. Jung, H.-Y. Jin, J.-S. Seo, J.-S. Jang, D.-K. Kim, D.-S. Kim
(Busan, KR)
Circadian rhythms in patients with ST-elevation myocardial infarction. P2479
– D.J. Severino, B.S. Santos, D.D. Durao (Santarem, PT)
Morphine and reperfusion success in ST-elevation myocardial infarction - insights from cardiac magnetic P2480
resonance imaging.
– S. De Waha, I. Eitel, S. Desch, G. Fuernau, P. Lurz, G. Schuler, H. Thiele (Lübeck and Leipzig, DE)
Independent association of longitudinal strain of left anterior ascending artery territory and TIMI frame P2481
count after acute anterior STEMI.
– T. Niglio, M. Galderisi, C. Santoro, E. Stabile, A. Rapacciuolo, P. Cirillo, G. Galasso, G. De Simone,
G. Esposito, B. Trimarco (Naples, IT)
Prognostic impact of female gender on a contemporary cohort of Spanish patients with acute myocardial P2482
infarction.
– B. Diaz Fernandez, S. Raposeiras Roubin, E. Abu Assi, D. Iglesias Alvarez, V. Gonzalez Salvado, A. Lopez
Lopez, A. Redondo Dieguez, R.R. Abumuaileq, J.M. Garcia Acuna, J.R. Gonzalez-Juanatey (Santiago de
Compostela, ES)
Serial improvement of early mortality of acute myocardial infarction in the whole Tokyo metropolitan P2483
area: progress of direct CCU network system.
– M. Takayama, J. Yamashita, M. Yamasaki, M. Miura, H. Miyachi, M. Suzuki, H. Tanaka, K. Miyauchi,
T. Yamamoto, K. Nagao (Tokyo, JP)
Physical activity as a trigger of myocardial infarction and long-term survival following primary P2484
percutaneous coronary intervention.
– Z. Mehmedbegovic, V. Dedovic, M. Zivkovic, D. Milasinovic, M. Tesic, I. Mrkonjic, M. Glisic, S. Juricic,
AAcute coronary syndrome with normal or near normal coronary angiography: prevalence and long term P2485
outcome.
– D. Grosseto, D. Santoro, A. Santarelli, S. Carigi, F. Baldazzi, N. Franco, M. Menozzi, M. Marconi,
G. Piovaccari (Rimini and Riccione, IT)
Time window for clinical benefit from manual thrombus aspiration during percutaneous coronary P2486
intervention for acute ST-elevation myocardial infarction.
– D.S. Sim, M.H. Jeong, Y.K. Ahn, Y.J. Kim, S.C. Chae, J.K. Chae, C.J. Kim, M.C. Cho, S.W. Rha,
K.B. Seung (Gwangju, Daegu, Jeonju, Seoul and Cheongju, KR)
165
Association between hyperglycemia at admission and microvascular obstruction in patients with P2487
ST-segment elevation myocardial infarction.
– S. Ota, M. Yokoyama, H. Kataiwa, K. Komukai, T. Imanishi (Gobo, JP)
STEMI IV
Early versus late diagnosis in patients with ST-elevation-myocardial infarction: clinical characteristics and P2488
long-term-survival.
– B. Jaeger, S. Farhan, G. Christ, W. Schreiber, A. Podczeck-Schweighofer, F. Weidinger, T. Stefenelli,
G. Delle-Karth, G. Maurer, K. Huber (Vienna, AT)
Is the predictive ability of GRACE risk score for mid-term mortality identical in all age groups? P2489
– A.T. Timoteo, S. Aguiar Rosa, M. Afonso Nogueira, P. Rio, R. Carvalho, M.L. Ferreira, R. Ferreira (Lisbon,
PT)
The association of epicardial fat thickness with stress hyperglycemia in patients with ST elevation P2490
– E.H. Ozcan Cetin, M.S. Cetin, O. Ozeke, D. Aras, S. Topaloglu, H. Kisacik, A. Temizhan, S. Aydogdu
(Ankara, TR)
Intravascular ultrasound guidance versus angiographic guidance in primary percutaneous coronary P2491
– K. Nakatsuma, H. Shiomi, T. Morimoto, K. Ando, K. Kadota, T. Yamamoto, Y. Furukawa, Y. Nakagawa,
M. Horie, T. Kimura (Kyoto, Hyogo, Fukuoka, Kurashiki, Otsu, Kobe and Nara, JP)
Bioresorbable vascular scaffolds for ST-segment elevation myocardial infarction treatment. P2492
– A.V. Khripun, M.V. Malevannyi, Y. Kulikovskikh (Rostov-on-Don, RU)
Abnormal oscillations of circadian gene expression in peripheral blood mononuclear cells among acute P2493
myocardial infarct patients as a possible cause for increased thrombosis risk.
– C. Liang, Q.X. Jiang, F. Wu, Z.Q. He, Z.G. Huang, J.Y. Zhang, Z.G. Wu (Shanghai, CN)
Long term prognosis in transradial primary PCI versus femoral approach in elderly patients (>80 years P2494
old).
– S. Gestal Romani, B. Cid Alvarez, B. Alvarez Alvarez, R. Ocaranza Sanchez, D. Lopez Otero, N. Bouzas
Cruz, A. Lopez Lopez, M. Castineira Busto, R. Trillo Nouche, J.R. Gonzalez Juanatey (Santiago de
Compostela, ES)
Shock index, as a predictor of myocardial injury in patients with ST-segment elevation myocardial P2495
infarction: a cardiac magnetic resonance imaging study.
– J.K. Hwang, W.J. Jang, Y.B. Song, E.K. Kim, J.H. Yang, J.Y. Hahn, S.H. Choi, S.C. Lee, J.H. Choi,
H.C. Gwon (Seoul, KR)
Absence of chest pain and long-term mortality in patients with ST-elevation myocardial infarction P2496
(STEMI).
– L. Bjorck, S. Nielsen, T. Jernberg, W.K. Kok, T. Sandstrom, A. Rosengren (Gothenburg and Uppsala, SE)
Development of invasively measured coronary flow reserve before and after reperfusion for acute P2497
myocardial infarction: results from an experimental porcine model and the human situation.
– G.A. De Waard, M.R. Hollander, P.F. Teunissen, M. Jansen, L.F. Robbers, E. Eerenberg, A. Beek, N. Van
Royen (Amsterdam, NL)
STEMI V
Total bilirubin on admission predicts in-hospital clinical outcomes in patients with ST segment elevation P2498
myocardial infarction undergoing primary percutaneous coronary intervention.
– T.-H. Yang, H.-C. Shin, Y.-M. Lee, H.-Y. Jin, J.-S. Seo, J.-S. Jang, D.-K. Kim, D.-S. Kim (Busan, KR)
Acute improvement of vascular function and oxidative stress by remote ischemic-conditioning in patients P2499
with acute myocardial infarction.
– I. Ikonomidis, E. Iliodromitis, M. Varoudi, I. Andreadou, G. Pavlidis, N. Liarakos, L. Palaiodimos, A. Zoga,
H. Triantafyllidi, J. Lekakis (Athens, GR)
Crucial components of the characteristics for ST-segment elevation myocardial infarction in acute P2500
coronary syndrome.
– A. Nakano, O. Seguchi, T. Washio, H. Daida, M. Kitakaze (Osaka and Tokyo, JP)
Does hospitalization for acute coronary heart disease events occur more frequently in Ramadan: a P2501
population-based study (2009-2014)?
– I. Bensahi, I. Nouamou, N. Fikal, A. Assaidi, R. Habbal (Casablanca, MA)
ProACS score: an early and simple score for risk stratification of patients with Acute Coronary P2502
Syndromes.
– A.T. Timoteo, S. Aguiar Rosa, M. Afonso Nogueira, R. Cruz Ferreira (Lisbon, PT)
Chronic pre-treatment of statin is associated with low incidence of mechanical complications after acute P2503
– R. Shutta, M. Hara, M. Nishino, T. Yoshimura, N. Makino, Y. Egami, J. Tanouchi, Y. Sakata, Y. Sakata,
I. Komuro (Sakai, Osaka, Suita, Sendai and Tokyo, JP)
Long-term prognostic significance of complete revascularisation at the acute stage of myocardial P2504
infarction. The FAST-MI 2005 registry.
– E. Puymirat, L. Bonello, E. Bonnefoy-Cudraz, J. Silvain, P. Bazin, P. Druelles, J. Ferrieres, F. Schiele,
T. Simon, N. Danchin (Paris, Marseille, Lyon, Dinan, Rennes, Toulouse and Besançon, FR)
Determinants and clinical relevance of polyhedrocyte content in intracoronary thrombus formed during P2505
– J. Zalewski, M. Zabczyk, J. Nessler, A. Undas (Krakow, PL)
166
Early discharge of low-risk patients after successful PCI treatment of ST-segment elevation myocardial P2506
infarction - 12 month clinical follow-up data (analysis from PL-ACS and AMI-PL registries).
– D. Pres, M. Gierlotka, M. Gasior, M. Hawranek, M. Tajstra, L. Pyka, T. Osadnik, A. Lekston, M. Zembala,
L. Polonski (Zabrze, PL)
Short-term exposure to fine particulate air pollution and risk of ST elevation myocardial infarction, P2507
ventricular arrhythmias and mortality.
– J. Baneras Rius, I. Ferreira-Gonzalez, J.A. Barrabes Riu, J.R. Marsal Mora, A. Ribera Sole, R.M. Lidon
Corbi, E. Domingo Ribas, G. Marti Aguasca, D. Garcia-Dorado (Barcelona, ES)
STEMI VI
Survival advantage of overweight and obesity in patients with acute myocardial infarction. P2508
– D.Y. Nah, J.W. Chung, J.H. Bae, J.H. Kim, Y.S. Kim, M.Y. Rhee, Y.K. Kim, M.M. Lee, Y.J. Kim (Gyeongju,
Goyang and Daegu, KR)
Using landiolol during primary percutaneous coronary intervention attenuates myocardial reperfusion P2509
injury in patients with ST-segment elevation acute myocardial infarction.
– M. Kiyokuni, T.M. Mitsuhashi, T.S. Sugano, T.I. Ishigami, T.I. Ishikawa, T.E. Endo, K.K. Kimura,
S.U. Umemura (Yokohama, JP)
Acute coronary syndrome in elderly - what is the place for invasive strategy? P2510
– S. Aguiar Rosa, A.T. Timoteo, M. Afonso Nogueira, R. Cruz Ferreira (Lisbon, PT)
Prognostic impact of anemia on admission in Japanese patients with acute myocardial infarction: a P2511
multi-center study of Tokyo CCU network.
– M. Kishi (Tokyo, JP)
The diagnostic value of intracoronary pressure-velocity loops during primary intervention in ST segment P2512
elevation myocardial infarction to predict subsequent development of microvascular injury.
– G.A. De Waard, P.F. Teunissen, M.R. Hollander, M. Echavarria-Pinto, A. Quiros, C. Broyd, P. Knaapen,
J. Escaned, N. Van Royen (Amsterdam, NL; Madrid, ES)
Patient’s delay in seeking care do not affect one-year post-discharge mortality in STEMI treated with P2513
primary coronary angioplasty.
– D.T. Placzkiewicz, M. Puzniak, A. Kleinrok (Zamosc, PL)
The relationship between post procedural ST-segment resolution and long term clinical events in patients P2514
who underwent primary percutaneous coronary intervention.
– E. Turkyilmaz, A. Kalayci, V. Oduncu, O. Ozveren, C.Y. Karabay, T. Akgun, A. Bitigen, N. Tefik, C. Kirma
(Istanbul, TR)
Comparison of the in-hospital complications and mortality in patients with Takotsubo cardiomyopathy P2515
and ST segment elevation myocardial infarction.
– M. Budnik, R. Piatkowski, J. Kochanowski, K. Wojtera, K. Jablkowska-Gorecka, G. Opolski (Warsaw, PL)
Prognostic value of hs-TnT compared with cardiac magnetic resonance imaging based infarct P2516
characteristics following reperfused acute myocardial infarction.
– T.L. Nguyen, J. Phan, J. Xiong, L. Hee, C. Juergens, R. Rajaratnam, H. Dimitri, J. French, D. Richards,
L. Thomas (Liverpool and Sydney, AU)
Primary angioplasty in acute myocardial infarction due to occluded, unprotected left main coronary P2517
artery.
– J. Palacios Rubio, P. Jimenez-Quevedo, C. Sanchez-Enrique, M.J. Perez-Vizcayno,
J.P. Vilchez-Tschischke, A. Cecconi, I.J. Nunez-Gil, L. Nombela-Franco, J. Escaned, A. Fernandez-Ortiz
(Madrid, ES)
Impact of new-onset atrial fibrillation on 30-day and one-year mortality in STEMI patients undergoing P2518
primary PCI.
– I. Zivkovic, D. Milasinovic, A.D. Ristic, Z. Mehmedbegovic, V. Pavlovic, D. Matic, V. Vukcevic,
P.M. Seferovic, M. Asanin, G. Stankovic (Belgrade, RS)
Can syntax score predict angiographically visible distal embolization during primary percutaneous P2519
coronary intervention?
– I. Biyik, I.F. Akturk, D. Ozturk, C. Sarikamis, O. Celik, F. Uzun, A.A. Yalcin, G. Yildiz, A. Ayaz, M.K. Erol
(Usak and Istanbul, TR)
STEMI VII
Risk factors of contrast-induced nephropathy development in patients with ST-elevated myocardial P2520
infarction while performing percutaneous coronary intervention.
– V.N. Karetnikova, A.V. Osokina, M.V. Evseeva, V.V. Kalaeva, O.V. Gruzdeva, O.L. Barbarash (Kemerovo,
RU)
All-cause in-hospital death analysis of patients with acute myocardial infarction from China acute P2521
myocardial infarction registry (CAMI).
– L. Song, Y.J. Yang, J.G. Yang, X.J. Gao, W. Li, H.Y. Xu (Beijing, CN)
Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients after P2522
stent implantation.
– M. Attanasio, R. Marcucci, A.M. Gori, R. Paniccia, R. Priora, S. Valente, D. Balzi, A. Barchielli, R. Abbate,
G.F. Gensini (Florence, IT)
Patient characteristics and organisational factors associated with delayed primary intervention in STEMI. P2523
– P. Rubartelli, A. Iannone, D. Bartolini, S. Bellotti, V. Fontana (Genoa, IT)
Relative survival potential of platelets is differentially associated with CXCR4-CXCR7 and modulates P2524
clinical outcome following STEMI.
– D. Rath, P. Krumm, T. Zitzelsberger, M. Chatterjee, O. Borst, M. Gawaz, T. Geisler (Tübingen, DE)
167
Relationship between infarct artery location, acute total coronary occlusion and mortality in STEMI and P2525
NSTEMI patients.
– J. Karwowski, M. Gierlotka, L. Polonski, M. Gasior, M. Beckowski, I. Kowalik, H. Szwed (Warsaw and
Zabrze, PL)
Do women with st segment elevation myocardial infarction submitted to primary angioplasty have a P2526
worse prognosis than man?
– J.M. Amado, D. Bento, D. Silva, J. Guedes, N. Marques, W. Santos, P. Gago, J. Mimoso, I. Jesus (Faro, PT)
Factors influencing the patient delay in STEMI. P2527
– A. Kleinrok, M. Puzniak, D. Placzkiewicz, T. Jastrzebski (Zamosc, PL)
Diabetes Mellitus type 2 is an important risk factor for sudden cardiac arrest in patients with STEMI. P2528
– P. Trzcinski, M. Jaskowski, L. Figiel, J.D. Kasprzak (Lodz, PL)
Kidney lesion in ST-elevation myocardial infarction- how to evaluate it? P2529
– A. Correia, B. Silva, M. Neto, R. Rodrigues, S. Gomes, A. Pereira, N. Santos, A.C. Alves, D. Pereira
(Funchal, PT)
Infarct size in staged versus immediate complete revascularisation for multivessel disease in the P2530
complete versus lesion-only PRImary PCI trial cardiovascular magnetic resonance substudy
(CvLPRIT-CMR).
– J.N. Khan, J.P. Greenwood, S.A. Nazir, D.J. Kelly, C. Peebles, J. Wong, A.H. Gershlick, G.P. McCann
(Leicester, Leeds, Derby, Southampton and Middlesex, UK)
Transradial vs. Transfemoral Coronary Intervention for ST Elevation Myocardial Infarction. P2531
– O. Kalpak, S. Antov, H. Pejkov, I. Spiroski, J. Kostov, S. Kedev (Skopje, MK)
NEW TECHNOLOGY ADDRESSING UNSOLVED CLINICAL PROBLEMS

Diagnostic accuracy of focused cardiac ultrasound performed by emergency physicians for the P2532
assessment of ascending aorta dilatation and aneurysm.
– O. Ottaviani, P. Nazerian, C. Tozzetti, C. Catini, A. Nencioni, F. Morello, P.F. Ticali, S. Grifoni, M. Vittorini,
S. Vanni (Florence and Turin, IT)
Inferior vena cava compression maneuver as a novel technique to detect patent foramen ovale: P2533
transesophageal echocardiographic study.
– E. Yamashita, T. Murata, E. Goto, N. Suzuki, T. Sasaki, K. Nakamura, K. Kumagai, S. Naito, H. Hoshizaki,
S. Oshima (Maebashi, JP)
Tissue Doppler imaging of pulmonary arteries - a novel technique for detecting pulmonary hypertension? P2534
– S. Ozturk, M. Yilmaztepe, F. Ozkalayci, M. Aktoz, B. Geyik, G. Ekuklu, H.Y. Gurlertop (Edirne, TR)
A novel echocardiographic method for assessing arterial stiffness in obstructive sleep apnea syndrome. P2535
– S. Akdag, A. Akyol, H.A. Cakmak, H. Gunbatar, M. Asker, N. Babat, A.R. Tosu, M. Yaman,
H.A. Gumrukcuoglu (Van, Rize, Istanbul and Samsun, TR)
Comparison of right ventricular volumes, ejection fraction and mechanical indices derived automatically P2536
from 3D speckle tracking to cardiac magnetic resonance imaging.
– A.S. Gopal, R.S. Toole, S.K. Saha, N. Reichek (Roslyn, US; Sundsvall, SE)
Usefulness of aortic valve area measurement obtained by single-beat recording of double-envelope P2537
technique in patients with aortic stenosis and atrial fibrillation.
– N. Watanabe, H. Oe, Y. Ohno, Y. Sakatani, A. Ueoka, T. Miyoshi, N. Nishii, K. Nakamura, H. Morita, H. Ito
(Okayama, JP)
Quantification of valve dimensions by transesophageal 3D echocardiography in patients with functional P2538
and degenerative mitral regurgitation.
– B. Goebel, R. Heck, A. Hamadanchi, S. Otto, C. Jung, A. Lauten, H.R. Figulla, T.C. Poerner (Jena, DE)
Validation of novel vendor-independent software algorithm for left ventricular volumes and ejection P2539
fraction by three-dimensional echocardiography: impact of manual correction versus automated tracking.
– A. Cecchetto, D. Muraru, V. Spadotto, G. Romeo, P. Aruta, S. Mihaila, S. Onciul, U. Cucchini, S. Iliceto,
L.P. Badano (Padua, IT; Bucharest, RO)
Assessment of left ventricular layer torsion in hypertensive patients using novel one-beat P2540
three-dimensional speckle tracking echocardiography with high volume rates.
– M. Ishiguro, M. Kawasaki, R. Tanaka, M. Nagaya, S. Minatoguchi, H. Miwa, H. Sato, T. Noda, S. Watanabe,
S. Minatoguchi (Gifu, JP)
Impact of vendor-independent versus vendor-specific software packages on left ventricular volume P2541
measurements performed on 3D echo data sets obtained from different echo systems.
– A. Cecchetto, D. Muraru, D. Ermacora, G. Romeo, A. Maddalozzo, S. Onciul, U. Cucchini, S. Iliceto,
L.P. Badano (Padua, IT; Bucharest, RO)
NEW INSIGHTS INTO VALVULAR HEART DISEASE
Prediction of pulmonary regurge in asymptomatic repaired tetralogy of Fallot patients: a comparison to P2542
cardiac magnetic resonance imaging.
– H.M. Agha, D. Mahgoub, F. Moustafa, A. Kharabish, Y. Hussein, G. Hussein, L. El Zambely, H. El Kiky,
M. Abd El Raouf, M. Abd El Rahman (Cairo, EG)
Dynamics of mitral valve annulus in patients with mitral regurgitation due to fibro-elastic deficiency or P2543
barlow’s disease.
– S.E. Van Wijngaarden, I. A.L. Amri, V. Kamperidis, M.V. Regeer, P.J. Van Rosendael, M.J. Schalij,
R.J. Klautz, J.J. Bax, N. Ajmone Marsan, V. Delgado (Leiden, NL)
Automatic quantification of aortic regurgitation using 3D full volume color Doppler echocardiography: a P2544
validation study with cardiac magnetic resonance imaging.
– J.H. Choi, G.R. Hong, H.J. Chang, I.J. Cho, C.Y. Shim, J.W. Ha, N. Chung (Seoul, KR)
168
In patients with functional tricuspid regurgitation, tricuspid annulus size by three-dimensional P2545
echocardiography is related to right heart chamber volumes.
– G. Romeo, P. Aruta, D. Muraru, G. Cavalli, M.H. Miglioranza, C. Jenei, K. Addetia, F. Veronesi, R.M. Lang,
L.P. Badano (Padua and Bologna, IT; Porto Alegre, BR; Debrecen, HU; Chicago, US)
Determinants of normal tricuspid annulus area in healthy volunteers: a three-dimensional P2546
echocardiographic study.
– C. Jenei, D. Muraru, K. Addetia, F. Veronesi, G. Cavalli, P. Aruta, S. Iliceto, R.M. Lang, L.P. Badano
(Debrecen, HU; Padua and Bologna, IT; Chicago, US)
Accuracy in aortic annulus measurements: New automatic quantitative 3D method vs manual 3D P2547
transesophageal echocardiography using multidetector computed tomography as reference.
– A. Garcia Martin, C. Lazaro Rivera, C. Fernandez Golfin Loban, L. Salido Tahoces, J.L. Moya Mur,
A. Gonzalez Gomez, I. Aquila, L.M. Rincon Diaz, J.J. Jimenez Nacher, J.L. Zamorano Gomez (Madrid, ES)
Color Flow Quantification: a new method to assess mitral regurgitation severity. P2548
– C. Vieira, F. Islas, J.A. De Agustin, G. Feltes, J.J. Gomez De Diego, P. Marcos-Alberca, C. Almeria,
J.L. Rodrigo, M.A. Garcia Fernandez, L. Perez De Isla (Braga, PT; Madrid, ES)
Three-dimensional dynamic assessment of tricuspid annulus in patients with functional tricuspid P2549
regurgitation in rheumatic left heart valve disease.
– P. Mahia, M.T. Nogales-Romo, F. Islas, A. De Agustin, J.J. Gomez De Diego, C. Almeria, J.L. Rodrigo,
Three-dimensional printing of tricuspid valve using transthoracic echocardiography. P2550
– D. Muraru, F. Veronesi, D. Dequal, A. Maddalozzo, C. Jenei, K. Addetia, R. Lang, G. Romeo, S. Iliceto,
L.P. Badano (Padua and Bologna, IT; Debrecen, HU; Chicago, US)
LEFT AND RIGHT ATRIAL MORPHOLOGY AND FUNCTION
Early detection of left atrial functional and stiffness abnormalities in chronic kidney disease patients with P2551
preserved left ventricular ejection fraction and normal left atrial size.
– Y. Ohara, Y. Tsuda, Y. Fukuoka, Y. Hosogi, K. Yamamoto (Kochi, JP)
Prognostic value of right atrial function and dimensions in patients with pulmonary hypertension. P2552
– R. Placido, N. Cortez-Dias, S. Robalo Martins, A.R. Francisco, M. Nobre E Menezes, E. Infante De Oliveira,
S. Goncalves, L. Santos, A.G. Almeida, F. Pinto (Lisbon, PT)
Use of transthoracic echocardiography in patients implanted with Amplatz atrial appendage plugs. P2553
– M. Kubala, S. Traulle, S. Quenum, O. Buiciuc, J.S. Hermida (Amiens, FR)
Left atrial mechanics after successful surgical ablation of atrial fibrillation during valvular heart disease P2554
surgery.
– N. Lorenzo, I. Mendez, G.F. Martinis, M. Taibo, R. Montes De Oca, S. Badia, G. Reyes, F. Alfonso,
R. Aguilar (Madrid, ES)
The application of a novel three-dimensional transesophageal echocardiographic technique for the P2555
assessment of left atrial appendage anatomy in transcatheter LAA closure.
– Q. Zhou, Y.-J. Wang, H.-N. Song, L. Zhang, B. Hu, R.-Q. Guo (Wuhan, CN)
Which is better for assessing recurrence risk of atrial fibrillation after catheter ablation, 2D- or P2556
3D-speckle tracking echocardiography?
– A. Mochizuki, S. Yuda, T. Fujito, M. Kawamukai, J. Nishida, A. Muranaka, S. Shimoshige, A. Hashimoto,
K. Tsuchihashi, T. Miura (Sapporo, JP)
Left atrial global longitudinal strain, a new and early cardiotoxicity marker? P2557
– L. Perez De Isla, J. Moreno, F. Moreno, J.A. Garcia Saenz, M. Clavero, G. Serrano, F. Islas, P.M. Alberca,
J.A. De Agustin, J.J. Gomez De Diego (Madrid, ES)
Measurement of maximal and minimal left and right atrial volumes: comparison of different P2558
semi-automatic algorithms of real-time 3D echocardiography.
– H. Mueller, S. Reverdin, G. Ehret, L. Conti, S. Dos Santos (Geneva, CH)
Normative study of left atrium phasic volumetric changes by 3D echocardiography in 225 healthy P2559
volunteers.
– M.H. Miglioranza, D. Muraru, S. Mihaila, U. Cucchini, D. Peluso, D. Ermacora, A. Maddalozzo, C. Palermo,
S. Iliceto, L.P. Badano (Porto Alegre, BR; Padua, IT; Bucharest, RO)
Left atrial volumes are larger when measured with 3D than 2D echocardiography: implications for the P2560
definition of normality.
– D. Muraru, M.H. Miglioranza, D. Ermacora, S. Mihaila, U. Cucchini, D. Peluso, P. Aruta, G. Romeo,
S. Iliceto, L.P. Badano (Padua, IT; Porto Alegre, BR; Bucharest, RO)
NEW TECHNIQUES IN CORONARY, CAROTID AND HYPERTENSIVE DISEASE

Clinical value of right atrial strain in predicting early hemodynamic deterioration in patients with P2561
pulmonary hypertension.
– L. Ferrarotti, C. Piccinino, D. Sola, A. Giubertoni, J. Zanaboni, P. Marino (Novara, IT)
Carotid plaque neovascularization is independently associated with asymptomatic South Asians vs P2562
Europeans: A possible mechanism underlying the greater cardiovascular disease burden in South Asians.
– B.N. Shah, N.S. Chahal, B. Anantharam, J.S. Kooner, R. Senior (London and Harrow, UK)
Echolucent carotid plaque is useful for assessment of residual risk in patients with history of myocardial P2563
infarction on statin therapy.
– M. Uematsu, T. Nakamura, T. Mochida, J. Nakamura, D. Fujioka, Y. Saito, K. Nakamura, K. Kawabata,
J. Obata, K. Kugiyama (Shimokato, Chuo and Yamanashi, JP)
Right ventricular function: the neglected issue in systemic hypertension. P2564
– I. Eweda, A.E. Mostafa, O. Awad, P. Demian (Cairo, EG)
169
3-year outcomes after test with measuring coronary artery flow velocity reserve at the peak of exercise. P2565
– A. Zagatina, N. Zhuravskaya (St. Petersburg, RU)
Resting myocardial deformation by 2D speckle tracking echocardiography predicts left ventricular P2566
functional improvement 12 months after myocardial infarction.
– E. Szymczyk, P. Lipiec, B. Michalski, K. Szymczyk, J.D. Kasprzak (Lodz, PL)
Prognostic value of transthoracic coronary flow reserve in medically treated patients with remaining P2567
non-culprit stenosis of intermediate severity after primary percutaneous intervention.
– M. Tesic, A. Djordjevic-Dikic, G. Stankovic, D. Milasinovic, Z. Mehmedbegovic, M. Zivkovic, V. Dedovic,
I. Jovanovic, J. Stepanovic, B. Beleslin (Belgrade, RS)
Value of detecting severe multi-vessel coronary artery stenosis using three-dimensional speckle tracking P2568
echocardiography.
– Y. Mu, Y.H. Li, X.P. Gong, Z.S. Wu (Urmuqi, CN)
Three-dimensional speckle tracking echocardiography in ischemic and non-ischemic cardiomyopathy: P2569
correlation with myocardial scar imaging using cardiac magnetic resonance.
– M.F.A. Aly, S.A.K. Kleijn, R.F.M. Menken-Negroiu, L.F.R. Robbers, A.M.B. Beek, O.K. Kamp (Beni-Suef,
EG; Amsterdam, NL)
3D myocardial strain measurement after reperfusion therapy is useful to predict future clinical events in P2570
patients with ST-segment elevation myocardial infarction.
– C.H. Kim, G.Y. Cho, Y.E. Yoon, J.J. Park, T.J. Youn, I.H. Chae (Seongnam, KR)
VASCULAR BIOLOGY
Translational potential of cardiac regeneration: from fish & mice to men? P2571
– R. S.M. Gomes, P. Skroblin, X. Yin, A.B. Munster, M. Chong, H. Tomlins, S. Langley, A. Zampetaki,
F. Wardle, M. Mayr (London and Cambridge, UK)
ADMA and arginine derivatives in relation to non-invasive vascular function in the general population. P2572
– C. Baum, S.S. Johannsen, T. Zeller, D. Atzler, P.S. Wild, E. Schwedhelm, R.H. Boeger, S. Blankenberg,
T. Munzel, R.B. Schnabel (Hamburg and Mainz, DE)
Dysfunction of skeletal muscle pericytes from type 2 diabetic patients with critical limb ischemia is P2573
associated with altered oxidative status.
– R. Vono, G. Spinetti, C. Gargioli, E. Sangalli, D. Maselli, A. Gotti, S. Losa, P. Madeddu (Milan and Rome, IT;
Bristol, UK)
Determinants of accelerated vascular aging: results from the Cardiovascular Risk factors Affecting P2574
Vascular agE (CRAVE) study.
– D. Terentes-Printzios, C. Vlachopoulos, P. Xaplanteris, N. Ioakeimidis, K. Aznaouridis, P. Pietri,
M. Abdelrasoul, E. Paschalidis, D. Tousoulis (Athens, GR)
Folic acid administration has a modest anti-inflammatory effect in apoE deficient mice. P2575
– P. Kourkouti, G. Siasos, A. Briasoulis, A. Valatsou, G. Vogiatzi, C. Antoniades, E. Oikonomou,
M. Zaromytidou, D. Perrea, D. Tousoulis (Athens, GR)
Metformin and vildagliptin: from blood glucose lowering to nephroprotection. P2576
– V. Bayrasheva, E.N. Grineva, A.Y.U. Babenko, Y.V. Dmitriev, S.G. Chefu, I. Shatalov, A.N. Ivanova (St.
Petersburg, RU)
Evidence of protozoan biofilm communities in atheromatous debris: a metagenomic analysis. P2577
– R. Heuser, S.E.F. Stephen Fry, J.E.E. Ellis, R.S. Schwartz, D.L.M. Martinez, M.A.S. Shabilla,
A.M.H. Heninburg, B.S. Schwartz (Phoenix and Scottsdale, US)
Microparticle-induced thrombin formation predicts severity of coronary artery calcification in patients P2578
with severe aortic valve stenosis.
– P. Horn, G. Erkilet, P. Kroepil, L. Schurgers, T. Zeus, C. Heiss, M. Kelm, R. Westenfeld (Düsseldorf, DE;
Maastricht, NL)
Establishing a model for intravital imaging of the beating murine heart. P2579
– D. Kavanagh, N. Kalia (Birmingham, UK)
Evaluation of the immunomodulatory properties of cardiac adipose tissue progenitor cells: a step towards P2580
their use in cell-based cardiac regeneration.
– I. Perea Gil, M. Monguio-Tortajada, C. Galvez-Monton, A. Bayes-Genis, F.E. Borras, S. Roura (Badalona,
ES)
Glucagon-like peptide 1 (GLP1) improves disseminated intravasal coagulation (DIC) and vascular function P2581
in LPS-induced endotoxemia.
– S. Steven, M. Kopp, Y. Mikhed, M. Oelze, K. Schwierzek, K. Jurk, S. Dankwardt, S. Strand, T. Muenzel,
A. Daiber (Mainz, DE)
Patients with stable and acute coronary artery disease show a different inflammatory mRNA and miRNA P2582
expression pattern in their monocyte subpopulations than healthy subjects.
– A. Kratzer, H. Giral, N. Kraenkel, M.F. Mueller, R. Klingenberg, P. Jakob, T.F. Luescher, U. Landmesser
(Berlin, DE; Zurich, CH)
Premature vascular aging in aldosterone-associated hypertension: role of Nox1. P2583
– A. Harvey, A.C. Montezano, D. Graham, Y. He, G. Ceravolo, C. Yabe-Nishimura, K. Griendling, R.M. Touyz
(Glasgow, UK; Ottawa, CA; Kyoto, JP; Atlanta, US)
VASCULAR REMODELLING
Effect of dilated ascending aorta on LV deformation mechanics. A 2D speckle tracking echocardiography P2584
study.
– K.K. Keramida, N.K. Kouris, V.K. Kostopoulos, V.G. Giannaris, C.D.O. Olympios (London, UK; Athens, GR)
170
CMR assessment of arterial stiffness in patients with large vessel vasculitis. P2585
– C. Wuttichaipradit, T. Yingchoncharoen, A. Clifford, G. Hoffman, S. Flamm, M. Bolen (Cleveland, US)
Role of sildenafil in the recruitment of hematopoietic progenitor cells in hypoxia-induced pulmonary P2586
hypertension.
– S. Favre, P. Bianciardi, L.K. Von Segesser, G. Pompilio, M. Samaja, G. Milano (Lausanne, CH; Milan, IT)
Vascular aldosterone synthase contributes to phosphate-induced osteogenic transformation of vascular P2587
smooth muscle cells.
– I. Alesutan, J.G.J. Voelkl, M. Feger, T. Castor, S. Mia, R. Viereck, M. Sacherer, M. Kuro-O, C. Wagner,
F. Lang (Tübingen, DE; Graz, AT; Dallas, US; Zurich, CH)
MicroRNA-216a induces a premature senescent-like phenotype and regulates angiogenic activity in P2588
human vascular endothelial cells.
– S.J. Yang, X.N. Mi, Y.X. Wang, Y. Chen, R.T. Hui, W.L. Zhang (Beijing, CN)
Deregulation of thioredoxin system contributes to monocyte dysfunction in diabetes mellitus: Implications P2589
for impaired arteriogenesis in type2 diabetic patients.
– R. Godfrey, H.M. Schulten, S.K. Shanmuganathan, I. Loeffler, N. Mueller, G. Wolf, U.A. Mueller,
F.D. Boehmer, J. Waltenberger (Münster and Jena, DE)
Inhibition of BET bromodomains attenuates smooth muscle cell proliferation and prevents neointima P2590
formation.
– J. Dutzmann, M. Haertle, J.M. Daniel, K. Donde, J. Bauersachs, S. Weisheit, D.G. Sedding (Hannover, DE)
Selective PPAR alpha agonist, K-877 suppresses macrophage activation and experimental arterial lesion P2591
formation.
– H. Iwata, K. Murakami, P. Ricchiuto, S. Singh, A. Mojcher, P. Libby, E. Aikawa, M. Aikawa (Boston, US)
Inhibition of collateral formation by activated protein c in murine hindlimb ischemia model. P2592
– C. Deffge, M. Wagner, S. Weinert, J. Lauf, B. Isermann, R.C. Braun-Dullaeus, J. Herold (Magdeburg, DE)
A comparative quantitative histopathological study in aneurysms of the ascending aorta with special P2593
emphasis on Marfan’s syndrome.
– K. Wassilew, J. Kremmin, R. Hammerschmidt, V. Falk, P. Gehle (Berlin, DE)
VASCULAR INFLAMMATION
Total antioxidant capacity of diet and plasma markers of oxidant-antioxidant status are associated with P2594
low-grade chronic inflammation: the rotterdam study.
– T. Muka, N. Stringa, A. Brahimaj, A. Zaciragic, B. Kraja, A. Dehghan, A. Hofman, J.C. Kiefte-De Jong,
O.H. Franco (Rotterdam, NL)
Exploring the obesity paradox in secondary prevention: A new biological role of femoral adipose tissue in P2595
humans.
– A. Antonopoulos, M. Margaritis, L. Herdman, F. Sanna, I. Akoumianakis, G. Krasopoulos, M. Petrou,
D. Tousoulis, K.M. Channon, C. Antoniades (Oxford, UK; Athens, GR)
Antimicrobial peptide LL37/ RNA complexes stimulate Toll-like receptor 3 upon shock wave therapy of P2596
ischemic muscle.
– C. Tepekoylu, M. Graber, D. Lobenwein, E. Kirchmair, M. Grimm, J. Holfeld (Innsbruck, AT)
Expression of sVEGFR3 decoy receptor alters lipid accumulation and changes cardiac lymphatic vessel P2597
organization.
– T. Vuorio, J.P. Laakkonen, H. Hakkarainen, S. Yla-Herttuala (Kuopio, FI)
IL-6 modulates angiogenesis through bone marrow dereived cells activation. P2598
– M. Shoji, F. Fumiaki, S. Koba, Y. Kobayashi (Tokyo, JP)
Delayed overexpression of vascular endothelial growth factor in the right ventricular myocardium P2599
accelerates irreversible cardiac remodeling in pulmonary arterial hypertension.
– E. Woo, S. Hosako, J. Kawakami, R. Kato, Y. Ijiri, T. Yamaguchi, Y. Izumi, M. Yoshiyama, T. Katsumata,
T. Hayashi (Osaka, JP)
miRNA126 regulates the Tissue Factor isoform expression in endothelial cells under inflammatory P2600
conditions.
– M. Witkowski, A. Weithauser, T. Tabaraie, U. Landmesser, U. Rauch (Berlin, DE)
CD14+CD16+ patrolling monocytes expressing LRP5 are internalized in advanced coronary P2601
atherosclerosis.
– M. Borrell-Pages, J.C. Romero, O. Juan-Babot, J. Crespo, L. Badimon (Barcelona, ES)
TGFbeta signalling as modulator of endothelial-to-mesenchymal transition during chronic P2602
thromboembolic pulmonary hypertension.
– M.L. Bochenek, N.S. Rosinus, M. Lankeit, M. Bosmann, S. Horke, E. Mayer, T. Muenzel, S. Konstantinides,
K. Schaefer (Mainz and Bad Nauheim, DE)
Fish oils, eicosapentaenoic acid and docosahexaenoic acid, attenuate oxidative stress-induced DNA P2603
damage in vascular endothelial cells.
– C. Sakai, M. Ishida, Y. Kihara, M. Yoshizumi, T. Ishida (Hiroshima, JP)
Transcription factor Runx2 promotes aortic fibrosis and stiffness in type 2 diabetes. P2604
– U. Raaz, I.N. Schellinger, F.C. Emrich, J.K. Hennigs, S. Eken, E. Chernogubova, M. Adam,
L. Maegdefessel, J.M. Spin, P.S. Tsao (Stanford, US; Stockholm, SE)
A DPP4 inhibitor, vildagliptin, attenuates monocyte inflammatory response through suppression of MAP P2605
kinase pathways and ameliorates CaCl2-induced vascular remodeling in mice.
– Y. Noda, T. Miyoshi, T. Yonezawa, M. Yoshida, K. Nakamura, H. Morita, H. Ito (Okayama, JP)
171

Induction of aortic valve interstitial cell transformation and calcification via angiotensin II type 1 receptor P2606
(ATR1).
– P. Kapusta, P. Mazur, J. Natorska, E. Wypasek, J. Sadowski, A. Undas (Krakow, PL)
Low gradient severe aortic stenosis with preserved ejection fraction: reclassification of severity by fusion P2607
of Doppler and computed tomographic data.
– V. Kamperidis, P. Van Rosendael, S. Katsanos, F. Van Der Kley, M. Regeer, I. Al Amri, G. Sianos,
N. Ajmone Marsan, V. Delgado, J.J. Bax (Leiden, NL; Thessaloniki, GR)
Transcatheter mitral valve-in-ring implantation with the direct flow medical valve. P2608
– A. Latib, F. Gatto, K. Bijuklic, C. Oezbek, A. Colombo, J. Schofer (Milan, IT; Völklingen and Hamburg, DE)
Functional outcomes in patients with symptomatic mitral regurgitation treated with transcatheter P2609
edge-to-edge mitral valve repair.
– R. De Palma, P. Jacobsen, R. Winter, M. Settergren (Stockholm, SE)
Size of mitral valve leaflet and predominant tethering of posterior leaflet determine degree of residual P2610
functional mitral regurgitation following isolated coronary artery bypass grafting.
– S. Yoshida, K. Toda, T. Nakamura, S. Miyagawa, Y. Yoshikawa, S. Fukushima, S. Saito, D. Yoshioka,
S. Yajima, Y. Sawa (Osaka, JP)
Cutoff mitral gradient and systolic pulmonary artery pressure predictive of dyspnea on Doppler stress in P2611
mitral stenosis.
– S. Lehachi (Algiers, DZ)
Impact of atrial fibrillation on mitral annular morphology in severe degenerative mitral regurgitation: P2612
implication in repair strategy.
– C.N. Jin, K.K. Kam, J.L. Looi, X.S. Yang, J.P. Sun, A.P. Lee (Hong Kong, HK)
Comparison of transoesophageal and transthoracic echocardiographic measurements of mechanism and P2613
severity of mitral regurgitation in ischemic cardiomyopathy.
– P.A. Grayburn, L. She, K. Golba, K. Mokrzycki, J. Drozdz, A. Cherniavsky, R. Przybylski, K. Wrobel,
H. Haddad, G. Maurer (Dallas and Durham, US; Katowice, Szczecin, Lodz, Zabrze and Krakow, PL;
Novosibirsk, RU; Ottawa, CA; Vienna, AT)
Mitraclip versus heartport mitral valve annuloplasty in very severe heart failure. P2614
– T. Ondrus, J. Bartunek, M. Vanderheyden, B. Stockman, C. Mirica, M. Kotrc, F. Van Praet, M. Penicka
(Aalst, BE)
Long term outcome of balloon mitral valvotomy in patients with atrial fibrillation. P2615
– G. Cheniti, I. Mechri, M. Mahjoub, M. Hassine, M. Ben Messoud, Z. Dridi, F. Betbout, H. Gamra (Monastir,
TN)

Impact of pre-operative moderate/severe functional tricuspid regurgitation in TAVI population and its P2616
post-procedural modifications.
– S. Miyazaki, M. Barletta, I. Rosa, C. Marini, A. Chieffo, M. Montorfano, A. Latib, A. Margonato, A. Colombo,
E. Agricola (Milan, IT)
Transcatheter aortic valve implantation in patients with reduced ejection fraction and low transvalvular P2617
gradient: the rule of 40.
– F. Conrotto, F. D’Ascenzo, G. Tarantini, P.F. Agostoni, A. Marzocchi, P. Presbitero, F. Bedogni,
M. D’Amico, F. Gaita, S. Marra (Turin, Padua, Bologna and Milan, IT; Utrecht, NL)
Determinants of functional capacity in aortic stenosis patients. P2618
– F. Bandera, G. Generati, M. Pellegrino, F. Carbone, V. Labate, E. Alfonzetti, M. Guazzi (San Donato
Milanese, IT)
Left ventricular deformation analysis by two-dimensional speckle-tracking echocardiography for P2619
prediction of cardiovascular outcomes in asymptomatic severe aortic valve stenosis.
– A. Malagoli, L. Rossi, C. Sticozzi, A. Zanni, G.Q. Villani (Piacenza, IT)
Serial NT-pro-B-type natriuretic peptide measurements after transcatheter aortic valve replacement: P2620
diagnostic and prognostic value for mortality, cardiac decompensation and cardiac rehospitalisation?
– L.S.E. Gaede, C. Liebetrau, W.K. Kim, J. Blumenstein, O. Doerr, A. Berkowitsch, T. Walther, C. Hamm,
H. Nef, H. Moellmann (Bad Nauheim and Giessen, DE)
Controlled release metoprolol for aortic regurgitation: a double blind, randomised controlled trial of P2621
efficacy and safety.
– K. Broch, S. Urheim, M.T. Lonnebakken, W. Stueflotten, R. Massey, K. Fossaa, E. Hopp, S. Aakhus,
L. Gullestad (Oslo and Bergen, NO)
Change in stent size at each inflation volume of SAPIEN XT: bench test vs. post-procedural stent sizes. P2622
– K. Miyake, K. Kadota, Y. Hyodo, S. Otsuru, D. Hasegawa, S. Habara, T. Maruo, Y. Fuku, T. Goto,
Rapid deployment balloon-expandable aortic valve replacement: rates of major paravalvular leak and new P2623
permanent pacemaker implantation.
– T. Wahlers, G. Laufer, M. Borger, M. Shrestha, A. Kocher, T. Walther, F. Mohr, C. Schmitz, F. Duhay,
A. Haverich (Cologne, Hannover, Bad Nauheim, Leipzig and Munich, DE; Vienna, AT; New York and Irvine,
US)
Incidence, predictive factors and impact of delirium after transcatheter aortic valve implantation. P2624
– M. Abawi (Utrecht, NL)
172

Value-Based approach in re-designing the care pathway for patients with infective endocarditis. P2625
– R. Dworakowski, A. Fife, J. Byrne, D. Whittaker, F. Matcham, M. Gunning, S. Block, P. MacCarthy,
O. Wendler (London, UK)
Ross procedure as a treatment of aortic valve endocarditis. P2626
– A. Ringle, M. Richardson, F. Juthier, N. Rousse, A.S. Polge, A. Coisne, A. Duva-Pentiah, A. Vincentelli,
D. Montaigne, A. Prat (Lille, FR)
Current clinical presentation, management and long-term outcome of infectious endocarditis: results P2627
from a contemporary registry in 2 referral centers.
– H. Schaubroeck, A.M. Willems, B. Vande Kerckhove, T. De Corte, T. De Backer, J. De Sutter (Ghent, BE)
Regulatory T cell subsets in patients with rheumatic heart Disease: relation to disease severity. P2628
– M.I. Salama, H.M. Hassoba, A.F. Abdelhai, H.M. Kamal, S.E. Younis (Ismailia, EG)
Role of reversibility assessment of pulmonary vascular resistance index (PVRI) and echocardiography in P2629
management of valvular heart disease (VHD).
– K.B. Khokhar, G. Devlin, R. Fisher, M.A. El-Gamel, P. Jogia (Waikato, NZ)
Impact of patient blood management on the incidence of acute kidney injury in patients undergoing P2630
– T. Tesorio, A. Cioppa, L. Salemme, A. Pucciarelli, E. Stabile, C. Bancone, S.M. Caparrotti, L.S. De Santo
(Mercogliano, Naples and Foggia, IT)
Soluble ST2 for risk stratification and the prediction of mortality in patients undergoing transcatheter P2631
– A. Stundl, F. Courtz, P.J. Leimkuehler, M. Weber, S. Pingel, A. Sedaghat, R. Schueler, E. Grube,
G. Nickenig, J.M. Sinning (Bonn, DE)
Transfemoral transcatheter aortic valve implantation in lower risk patients: 30-day and long-term P2632
outcomes.
– C. Rodriguez, E. Durand, M. Godin, C. Tron, A. Cribier, H. Eltchaninoff (Rouen, FR)
Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve P2633
replacement.
– J.M. Sinning, K.C. Wollert, A. Sedaghat, C. Widera, C. Hammerstingl, M. Vasa-Nicotera, E. Grube,
G. Nickenig, N. Werner, T. Kempf (Bonn and Hannover, DE)
CARDIOMYOPATHIES
Selumetinib, an oral anti-neoplastic drug, may prevent cardiac hypertrophy via targeting the ERK P2634
pathway.
– Z.X. Chen, C. Li, F.B. Luo, H. Yang, Y.J. Li, L.H. Chen, H.W. Cai, D. Long, Q.P. Zhang, L. Rao (Chengdu,
CN; London, UK)
Clinical profile and outcomes of peripartum cardiomyopathy in a southeast Asian tertiary centre: the P2635
PERIPHIL study.
– L.R.C. Cuenza, N.C. Manapat, J.R. Jalique (Manila, PH)
Effect of tafamidis on the progression of cardiac involvement in patients with familial amyloid P2636
polyneuropathy.
– M.C. Azevedo Coutinho, N. Cortez-Dias, I. Conceicao, G. Cantinho, A.R. Francisco, T. Guimaraes,
G.L. Silva, M.N. Menezes, R. Placido, F.J. Pinto (Lisbon, PT)
Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic P2637
cardiomyopathy.
– L. Fang, A. Ellims, X.-L. Moore, D. White, A. Taylor, J. Chin-Dusting, A. Dart (Melbourne, AU)
Gradient reduction after percutaneous septal ablation modifies the risk profile in hypertrophic obstructive P2638
cardiomyopathy.
– L. Faber, A. Burghardt, H. Seggewiss, F. Van Buuren, D. Horstkotte (Bad Oeynhausen and Schweinfurt, DE)
Predictive value of tei index for patients with cardiac amyloidosis. P2639
– D. Liu, K. Hu, P. Nordbeck, S. Herrmann, M. Cikes, B. Kramer, G. Ertl, S. Stoerk, F. Weidemann (Würzburg
and Unna, DE; Zagreb, HR)
Coexistence of degenerative aortic stenosis and wild type transthyretin-related cardiac amyloidosis: a P2640
potentially dangerous association that can be non-invasively identified.
– S. Longhi, M. Lorenzini, C. Gagliardi, A. Milandri, E. Biagini, P.L. Guidalotti, R. Bonfiglioli, F. Saia,
A. Marzocchi, C. Rapezzi (Bologna, IT)
First arrhythmic event-associated clinical disease profile in arrhythmogenic cardiomyopathy associated P2641
desmosomal mutation carriers.
– A. Protonotarios, A. Anastasakis, D.B. Panagiotakos, C. Ritsatos, V. Vlagouli, P. Syrris, D. Tousoulis,
L. Antoniades, W.J. McKenna, A. Tsatsopoulou (Naxos and Athens, GR; London, UK; Nicosia, CY)
The ability of serum markers of fibrosis to predict future shocks in ICD recipients with dilated P2642
cardiomyopathy?
– E. Kanoupakis, J. Fanourgiakis, E. Kallergis, H. Mavrakis, M. Vernardos, K. Roufas, M. Touloupaki,
A. Daskalakis, P. Vardas (Heraklion, GR)
Novel epsilon wave characteristics in arrhythmogenic cardiomyopathy. P2643
– A. Protonotarios, A. Anastasakis, E. Prappa, C. Ritsatos, V. Vlagouli, D. Tousoulis, L. Antoniades,
A. Tsatsopoulou (Naxos and Athens, GR; Nicosia, CY)
173
CHRONIC PULMONARY HYPERTENSION

Beneficial effect of combined therapy with macitentan and sildenafil in a rat model of pulmonary arterial P2644
hypertension.
– K.H. Kim, H.K. Kim (Bucheon and Seoul, KR)
Lack of pharmacokinetic interaction between the dual endothelin receptor antagonist macitentan and the P2645
combined oral contraceptive, norethisterone and ethinyl estradiol.
– N. Hurst, M. Pellek, P.N. Sidharta, J. Dingemanse (Allschwil, CH; Cologne, DE)
Audit of prostanoid use in a nationally designated PH centre. P2646
– W. Gin-Sing, S. Gibbs, L. Howard, M. Lau-Walker, G. Lee, G. Villa (London, UK)
Comparison of caveolin-1 isoforms expression in the right ventricle and lungs of monocrotaline induced P2647
– E. Malikova, K. Galkova, D. Vavrincova, P. Vavrinec, P. Krenek, J. Klimas (Bratislava, SK)
Evaluating hemodynamics at rest and exercise capacity by echocardiographic parameters in patients P2648
with pulmonary hypertension.
– Y. Nakano, T. Kondo, Y. Kamimura, S. Adachi, S. Shimazu, A. Hirashiki, T. Murohara (Nagoya, JP)
Involvement of angiotensin converting enzyme 2 in pulmonary hypertension. P2649
– A. Darago, M. Fagyas, T. Vincze, A. Peter, I. Manyine Siket, I. Edes, Z. Papp, A. Toth (Debrecen, HU)
Comparison of the effects of bosentan on endothelial function in patients with pulmonary arterial P2650
hypertension or chronic thromboembolic pulmonary hypertension.
– A. Hirashiki, Y. Kamimura, Y. Nakano, S. Adachi, K. Takeshita, T. Murohara, T. Kondo (Nagoya, JP)
Baseline characteristics and outcome of adult patients with pulmonary hypertension in Africa: results P2651
from the Pan-African Pulmonary Hypertension Cohort (PAPUCO) study.
– F. Thienemann, A. Dzudie, A.O. Mocumbi, L. Blauwet, M.U. Sani, K.M. Karaye, I. Mbanze, K. Tibazarwa,
A. Damasceno, K. Sliwa (Cape Town, ZA; Douala, CM; Maputo, MZ; Rochester, US; Kano, NG)
Results in chronic thromboembolic pulmonary hypertension from the Spanish registry: a nationwide P2652
perspective.
– R. Del Pozo, I. Blanco, F. Martinez Garcia, A. Lara Padron, P. Gallego, M.E. Barrios Garrido, T. Elias
Hernandez, S. Cadenas Menendez, J. Cortina, P. Escribano (Madrid, Barcelona, Murcia, Santa Cruz de
Tenerife, Sevilla and Salamanca, ES)
Sleep-disordered breathing in pulmonary arterial hypertension PAH and in pulmonary hypertension due to P2653
left ventricular dysfunction - comparison of clinical characteristics.
– K. Wiklo, B. Uznanska-Loch, K. Len, A. Dydula, E. Trzos, D. Miskowiec, J.D. Kasprzak, M. Kurpesa (Lodz,
PL)
GROWN-UP CONGENITAL HEART DISEASE AND SURGERY
Survival into adulthood of patients with congenital heart disease in Sweden. P2654
– M. Dellborg, A. Rosengren, G. Lappas, P. Eriksson, Z. Mandalenakis (Gothenburg, SE)
High incidence of endocarditis in adults with congenital ventricular septal defect. P2655
– E. Berglund, U. Thilen, M. Delborg, C. Christersson, P. Sorensson, N.-E. Nielsen, B. Johansson (Umeå,
Lund, Gothenburg, Uppsala, Stockholm and Linköping, SE)
The unnatural history of valvular pulmonary stenosis: outcome up to 40 years after surgical repair. P2656
– J.A.A.E. Cuypers, M.E. Menting, E.M.W.J. Utens, W.A. Helbing, M. Witsenburg, A.E. Van Den Bosch,
R.T. Van Domburg, F.J. Meijboom, A.J.J.C. Bogers, J.W. Roos-Hesselink (Rotterdam and Utrecht, NL)
Risk of hemorrhagic stroke in children and young adults with congenital heart disease. P2657
– A. Rosengren, Z. Mandalenakis, G. Lappas, P. Eriksson, P.-O. Hansson, M. Dellborg (Gothenburg, SE)
Macitentan superior to bosentan in pulmonary arterial hypertension due to congenital heart disease? P2658
– I.M. Blok, A.C.M.J. Van Riel, M.J. Schuuring, R.H.A.C.M. De Bruin-Bon, A.P.J. Van Dijk, A.H. Zwinderman,
B.J.M. Mulder, B.J. Bouma (Amsterdam and Nijmegen, NL)
Increased endurance capacity in adults with complex congenital heart disease after home-based interval P2659
exercise training on ergometer cycle.
– C. Sandberg, M. Hedstrom, M. Dellborg, A. Magnusson, A.-K. Zetterstom, K. Wadell, B. Johansson (Umeå
and Gothenburg, SE)
Comparative outcomes after acute aortic dissection in genetic aortopathy syndromes. P2660
– D. Van Der Linde, L. Davies, A.G. Sherrah, P.G. Bannon, M. Vallely, M. Wilson, L. Turner, A. Keech,
R.W. Jeremy (Sydney, AU)
Functional parameters or biomarkers: which best predicts prognosis in adults with pulmonary arterial P2661
hypertension due to congenital heart disease?
– I.M. Blok, A.C.M.J. Van Riel, M.J. Schuuring, R.H.A.C.M. De Bruin-Bon, A.P.J. Van Dijk, E.S. Hoendermis,
A.H. Zwinderman, B.J.M. Mulder, B.J. Bouma (Amsterdam, Nijmegen and Groningen, NL)
Evaluation of transition services for adolescents with congenital heart disease: attendance at first adult P2662
congenital clinic appointment.
– H. Habibi, N.A.Y. Chung (London, UK)
Global and regional systolic left ventricular function after arterial switch operation: a speckle tracking P2663
echocardiography study.
– G. Di Salvo, Z. Bulbul, N. Moiduddin, Z. Issa, S. Al Oufi, M. Fayyadh (Riyadh, SA)
Chronological changes in mitral regurgitation after atrial septal defect closure in adults; predictors of P2664
aggravation of mitral regurgitation.
– S. Nishimura, C. Izumi, M. Amano, M. Miyake, H. Kondo, T. Tamura, K. Kaitani, Y. Nakagawa (Tenri, JP)
Decreased diastolic ventricular kinetic energy in young Fontan patients demonstrated on P2665
four-dimensional cardiac magnetic resonance imaging.
– P. Sjoberg, E. Heiberg, H. Arheden, P. Liuba, M. Carlsson (Lund, SE)
174
EXERCISE IS THERAPY IN HEART DISEASE

Effects of functional electrical stimulation of lower limb muscles on circulating endothelial progenitor P2666
cells, CD34+ monocytes and VEGF-A in heart failure with reduced ejection fraction.
– N. Magoutis, J. Parissis, A. Karavidas, D.T. Farmakis, V. Mantzaraki, M. Peppa, I. Ikonomidis, G. Filippatos,
V. Pyrgakis, J. Lekakis (Athens, GR)
Gender differences in morphological and functional aspects of athletes heart in a rat model. P2667
– A. Olah, A. Lux, C. Matyas, B.T. Nemeth, D. Kellermayer, L. Szabo, M. Ruppert, M. Torok, B. Merkely,
Hyperinsulinemia and overweight in obese Zucker rats effectively suppressed by exercise training with P2668
hypoxia recovery.
– W.S. Hu (New Taipei City, TW)
Exercise training leads to an increase of the proangiogenic TIE2 monocyte/ EPC ratio in patients with P2669
peripheral arterial disease over 6 months.
– J.F. Dopheide, J. Rubrech, A. Trumpp, P. Geissler, T. Gori, M.P. Radsak, T. Muenzel, C. Espinola-Klein
(Mainz, DE)
Exaggerated exercise blood pressure response is related to increased arterial stiffness, asymmetric P2670
dimethylarginine and osteoprotegerin in essential hypertension.
– K. Dimitriadis, C. Tsioufis, T. Kalos, S. Galanakos, K. Kyriazopoulos, F. Lagiou, L. Nikolopoulou,
D. Tousoulis (Athens, GR)
Long-term change of physical activity towards a physically active lifestyle is associated with reduced P2671
arterial stiffness in elderly males: results of the SAPALDIA 3 cohort study.
– S. Endes, E. Schaffner, S. Caviezel, J. Dratva, M. Wanner, B. Martin, C. Schindler, N. Kuenzli,
N. Probst-Hensch, A. Schmidt-Trucksaess (Basel and Zurich, CH)
Increased activity of renin-angiotensin-aldosterone system induces vascular endothelial damage causing P2672
the excessive blood pressure elevation even during moderate exercise in hypertensive patients.
– K. Yabu, T. Masuda, M. Ogura, R. Shimizu, D. Kamekawa, Y. Kamada, S. Tanaka, A. Aoyama,
M. Yamaoka-Tojo, J. Ako (Sagamihara, JP)
High intensity interval training effects in patients with heart failure submitted to cardiac resynchronization P2673
therapy.
– A. Abreu, H. Santa Clara, V. Santos, L. Morais, L. Oliveira, G. Portugal, P. Cunha, M. Oliveira, M. Mota
Carmo, R. Ferreira (Lisbon, PT)
Effects of exercise training on cardiac autonomic activity in heart transplant and left ventricular assist P2674
device patients- assessment of heart rate profile.
– K. Fan, J. Ng, G. Yip, C. Ko, M. Wong, K. Chan, K. Cheng, C. Tsui (Hong Kong, HK)
Results from a French multicenter study on the combination of exercise training + electrical P2675
myostimulation treatment in chronic heart failure (HF-CREMS study).
– B. Verges, M.-C. Iliou, B. Pavy, J.P. Mabire, C. Bosse Pilon, Y. Morvan, E. Kessler, M. Ghannem (Dijon,
Paris, Machecoul, Cricqueboeuf, Rennes, Joigny, Abreschviller and Tracy-Le-Mont, FR)
Changes in cardiorespiratory fitness predict incident hypertension: a population-based long-term study. P2676
– S.Y. Jae, S. Kurl, B. Franklin, J. Laukkanen (Seoul, KR; Kuopio, FI; Royal Oak, US)
Physical inactivity increases endostatin and osteopontin in patients with coronary artery disease. P2677
– M. Sponder, M.F.S. Fritzer-Szekeres, R.M. Marculescu, B.L. Litschauer, J.S.J. Strametz-Juranek (Vienna,
AT)
CARDIOVASCULAR ADAPTATION TO EXERCISE

Left ventricular contractility of athlete’s heart: assessment by speckle tracking echocardiography and P2678
invasive pressure-volume analysis in rats.
– T. Radovits, A. Olah, A. Kovacs, A. Lux, C. Matyas, B.T. Nemeth, D. Kellermayer, L. Szabo, A. Meltzer,
ExerciseTraining prevents diastolic dysfunction induced by fructose overload in old female P2679
ovariectomized rats.
– J.F. Machi, N. Bernares, D.S. Dias, P. Cruz, I.C. Moraes-Silva, M. Barbosa, A. Nascimento, K. De Angelis,
M.C. Irigoyen (São Paulo, BR)
Ventricular ectopy in young athletes: an innocent bystander or a harbinger of structural heart disease? P2680
– K. Prakash, H. Dhutia, E. San Damaso, A. Malhotra, G. Mellor, A. Meghani, R. Narain, L. Millar,
M. Papadakis, S. Sharma (London, UK)
Dynamic coupling between atrio-ventricular duration and RR-interval in phase-rectification analysis P2681
shows rate-dependent intranodal conduction facilitation related to physical conditioning status.
– P.R. Benchimol Barbosa, O. Nasario-Junior, J. Nadal (Rio de Janeiro, BR)
Left atrial morphological and electrical remodeling in athletes: a prospective, longitudinal combined ECG P2682
and speckle-tracking study.
– F. D’Ascenzi, M. Solari, M. Focardi, M. Cameli, M. Biagi, F. Cassano, D. Corrado, M. Bonifazi, S. Mondillo,
M. Henein (Siena and Padua, IT; Umeå, SE)
Right precordial T-wave inversion in healthy endurance athletes can be explained by lateral displacement P2683
of the cardiac apex.
– M. Brosnan, G. Claessen, H. Heidbuchel, D.L. Prior, A. La Gerche (Melbourne, AU; Leuven and Hasselt, BE)
Circulatory power and exercise ventilatory power during exercise over time during sequential P2684
combination therapy in pulmonary arterial hypertension.
– A. Hirashiki, Y. Kamimura, Y. Nakano, S. Adachi, T. Okumura, K. Takeshita, T. Murohara, T. Kondo
(Nagoya, JP)
175
Influence of cardiorespiratory fitness, body composition and blood pressure on retinal vessel diameters P2685
in swiss primary school children - the sportcheck study.
– H. Hanssen, K. Imhof, L. Zahner, O. Faude, A. Schmidt-Trucksass (Basel, CH)
Watching television and mortality from pulmonary embolism among middle-aged Japanese men and P2686
women: the JACC study.
– T. Shirakawa, H. Iso, S. Ikehara, K. Yamagishi, A. Tamakoshi (Osaka, Takatsuki, Tsukuba and Sapporo, JP)
Changes in cardiac troponins, natriuretic peptides, D-dimer, and cardiac hemodynamics after strenuous P2687
exercise_ a meta-analysis.
– F. Sedaghat-Hamedani, E. Kayvanpour, L. Frankenstein, D. Mereles, S. Buss, E. Giannitsis, K. Jensen,
H.A. Katus, B. Meder (Heidelberg, DE)
Physical activity and the incidence of major cardiovascular diseases: Evidence from the China Kadoorie P2688
Biobank Study.
– D. Bennett, L. Li, H. Du, Y. Guo, Z. Bian, J. Chen, Z. Chen (Oxford, UK; Beijing, CN)
The impact of different types of aerobic exercise on vascular function. P2689
– D. Athanasiou, G. Siasos, G. Terzis, A. Stasinaki, E. Dimitropoulos, E. Oikonomou, M. Zaromytidou,
K. Mourouzis, S. Tsalamandris, D. Tousoulis (Athens, GR)
EXERCISE, PHYSICAL ACTIVITY AND SPORT IN HEALTH

Suppressed middle-acidosis by oral bicarbonate ingestion affected stroke volume responses during an P2690
all-out long sprint cycling event.
– P.M. Lepretre, C. Hanon, C. Thomas, S. Dorel, R. Delfour-Peyrethon, S. Perrey, D. Bishop (Amiens, Paris,
Evry, Nantes and Montpellier, FR; Melbourne, AU)
Usefulness of chest pain units as fast-track screening for ACS in low-intermediate risk patients. P2691
– A. Carbonell San Roman, C. Fraile Sanz, P. Catalan Sanz, T. Segura De La Cal, L.M. Rincon Diaz, P. Pastor
Pueyo, C. Fernandez-Golfin, J.L. Zamorano Gomez (Madrid, ES)
Exertional oscillatory ventilation as a long-term prognostic factor for patients with post-acute coronary P2692
syndrome.
– K. Yamashita, T. Kawashima, S. Chiba, C. Nago, K. Nakamura, N. Miyagi, M. Shimajiri, T. Kuniyoshi,
H. Uehara (Urasoe, JP)
Heart rate variability detects psychophysiological stress induced by realistic force-on-force training of P2693
police personnel.
– D. Brisinda, F. Fioravanti, A.R. Sorbo, A. Venuti, R. Fenici (Rome, IT)
Impaired beta cell function attenuates training effects by reducing the increase in heart rate reserve and P2694
heart rate recovery in patients with myocardial infarction.
– K. Omiya, C. Itoh, M. Kasahara, M. Takai, A. Hayashi, H. Matsuda, M. Yamauchi, S. Watanabe (Yokohama
and Kawasaki, JP)
Diagnostic value of automatically measured ST-segment changes in individual ECG leads to detect P2695
myocardial ischemia during exercise ECG.
– C. Puelacher, T. Reichlin, R. Abaecherli, R. Twerenbold, M. Wagener, U. Honegger, N. Schaerli, G. Pretre,
M. Zellweger, C. Mueller (Basel, CH)
Stage 3 or 4 chronic kidney disease disrupts the improvement in exercise capacity after hospital P2696
discharge in patients with ischemic heart disease.
– R. Matsuzawa, T. Masuda, K. Kamiya, N. Hamazaki, K. Nozaki, S. Tanaka, E. Maekawa, J. Ako
(Sagamihara, JP)
Regular trainings in patients with advanced heart failure (NYHA III) after ICD and CRT-D implantations: P2697
good or bad in terms of QoL and depression symptoms.
– E. Smolis-Bak, R. Dabrowski, I. Kowalik, H. Rymuza, H. Szwed (Warsaw, PL)
Carotid intima-media thickness and arterial functional properties in young high level and recreational long P2698
distance runners and weight lifters -A pilot study.
– P. Sotiriou, E. Kouidi, A. Karagiannis, N. Koutlianos, P. Geleris, V. Vassilikos, A. Deligiannis (Thessaloniki,
GR)
Chronotropic Incompetence and dynamic post-exercise autonomic dysfunction are associated with the P2699
presence and severity of erectile dysfunction.
– A. Samentzas, C. Vlachopoulos, D. Terentes-Printzios, A. Angelis, P. Xaplanteris, N. Ioakeimidis, P. Pietri,
A. Trikas, D. Tousoulis (Athens, GR)
Neighbourhood environmental attributes associated with walking in South Australian adults: differences P2700
between urban and rural areas.
– N. Berry, T. Sugiyama, R. Nolan, J. Dollman, N. Coffee (Adelaide, AU)
Does moderate but regular exercise alter the baroreceptor response in pregnancy? P2701
– R.E. Carpenter, O. Uzun, S.J. Emery, D. Rassi, M.J. Lewis (Swansea and Cardiff, UK)
EXERCISE TRAINING AND PHYSICAL ACTIVITY

Changes in Cardiorespiratory fitness and Incidence of Myocardial perfusion defects and Major Adverse P2702
Cardiac Events.
– M. Al-Mallah, A. Ahmed, W. Qureshi (Riyadh, SA; Winston-Salem, US)
Screen time is a risk factor for higher exercise blood ressure independent of moderate-to-vigorous P2703
physical activity or fitness in adolescents.
– B. Weisser, C. Hacke (Kiel and Hamburg, DE)
176
Improvement aerobic capacity leads to cognitive function benefits in patients with chronic kidney disease P2704
on hemodialysis.
– F. Stringuetta-Belik, V.R.O. Silva, R.S. Goncalves, R. Bazan, G.P. Braga, P. Barretti, J.C.T. Caramori,
L.C. Martin, R.J.S. Franco (Botucatu, BR)
Endothelium-dependent relaxation in cardiac patients referred for cardiac rehabilitation. P2705
– R. Belardinelli, L.T. Tiano, M.L. Lacquaniti, O.R. Ruga, A.M. Moraca, F.G. Guazzarotti, G.P.P. Perna
(Ancona, IT)
Inspiratory muscle weakness is associated with exercise intolerance in patients with heart failure with P2706
– Y. Kinugasa, K. Yamada, T. Sota, M. Miyagi, S. Sugihara, M. Kato, K. Yamamoto (Yonago, JP)
Determinants of exercise capacity in patients with preserved left ventricular ejection fraction and reduced P2707
left ventricular ejection fraction.
– S. Kikuchi, N. Ikehara, T. Goto, K. Wakami, N. Ohte (Nagoya, JP)
Usefulness of exercise testing in prediction of short-term outcome among patients with stable coronary P2708
artery disease.
– A.M. Kiviniemi, T.V. Kentta, M.J. Junttila, J.S. Perkiomaki, O.-P. Piira, S. Lepojarvi, O. Ukkola, A.J. Hautala,
M.P. Tulppo, H.V. Huikuri (Oulu, FI)
A 6-minute stepper test (6-MST) is a feasible protocol for assessing exercise capacity in older adults P2709
which also allows physiological changes to be accurately monitored throughout exercise.
– S. Jones, T. Tillin, D. Key, N. Chaturvedi, A.D. Hughes (London, UK)
Prognostic value of double product reserve during cardiopulmonary exercise test in patient with P2710
idiopathic dilated cardiomyopathy.
– D. Han, J.C. Youn, S. Park, S.H. Lee, D. Choi, S.M. Kang (Seoul, KR)
Physically active lifestyle does not protect overweight and obese subjects from developing fatal or P2711
non-fatal cardiovascular event: The 10-year (2002-12) Follow-up of Attica Study.
– C. Chrysohoou, D. Panagiotakos, E. Georgousopoulou, C. Pitsavos, J. Skoumas, C. Chatzinikolaou,
N. Skourlis, V. Metaxa, C. Stefanadis, D. Tousoulis (Athens, GR)
Aerobic exercise improves vascular insulin sensitivity by upregulating cholinergic anti-inflammatory P2712
pathway in spontaneously hypertensive rats.
– Z.X. Hou, Y. Zhang, C.J. Mi, W.J. Xing, L. Yang, L. Tao, F. Gao (Xi’an, CN)
The influence of short-term exercise training on QT dispersion and double product in diabetic patients P2713
after coronary artery bypass graft surgery.
– V. Stoickov, M. Deljanin Ilic, S. Ilic, M. Stoickov, D. Petrovic, S. Saric, S. Andonov, J. Cvetkovic, V. Mitic (Nis̆
and Niska Banja, RS)
DECREASING CARDIOVASCULAR RISK IN VULNERABLE POPULATIONS
The association of statin adherence and in-stent restenosis. P2714

– C. Kocas, O. Abaci, B.B. Kocas, G. Cetinkal, S. Arslan, A. Yildiz, M. Ersanli (Istanbul, TR)
A community pharmacy-based cardiovascular risk screening service implemented in a resource-limited P2715
country.
– Z. Jahangard-Rafsanjani, N. Hakimzadeh, K.H. Gholami, A. Sarayani (Tehran, IR)
Liraglutide is more effective than lifestyle changes in modulating subcutaneous and visceral fat P2716
distribution, liver steatosis, insulin sensitivity and beta-cell function after comparable weight loss.
– F. Santilli, M.T. Guagnano, A. Tartaro, E. Angelucci, P.G. Simeone, G. Laronga, M.T. Maccarone,
V. Federico, G. Davi, A. Consoli (Chieti, IT)
Adherence to evidence-based therapies and incidence of clinical outcomes among high cardiovascular P2717
risk patients: the react registry.
– E.L. Figueiredo, G.F. Werner, M.A. Cavalcante, J.M.M. Dantas, S.B. Pereira, L.A.P. Matos, J.P. Andrade,
F.M.C. Colombo, O. Berwanger, A.A.V. De Paola (Belo Horizonte, Presidente Prudente, Espírito Santo, São
Paulo and Rio de Janeiro, BR)
A retrospective analysis of the relationship between cardio-respiratory fitness (CRF) and depression in P2718
high risk individuals who attend a preventive cardiology programme.
– J. Windle, I. Gibson, K. Cunningham, C. Kerins, A.M. Walsh, J. Jones, S. Connolly, A. Mead, G. Flaherty,
T. Grove (Galway, IE; London, UK)
Long-term administration of eicosapentaenoic acid prevents the progress of left ventricular hypertrophy P2719
via reducing oxidative stress and advanced glycation end-products in patients with hypertension.
– A. Aoyama, T. Masuda, M. Ogura, Y. Kamada, S. Tanaka, K. Kamiya, K. Nozaki, E. Maekawa,
M. Yamaoka-Tojo, J. Ako (Sagamihara, JP)
Effects of exercise-based cardiac rehabilitation on HDLl function in patients with coronary artery P2720
diseases, independently of lipid-lowering medication.
– S. Koba, F. Furuyama, Y. Yokota, M. Shoji, M. Ayaori, K. Ikewaki, Y. Kobayashi (Tokyo and Tokorozawa, JP)
Adherence to Mediterranean diet protects against cardiovascular disease independently of creatinine P2721
clearance rate: the 10-year (2002-12) Follow-up of Attica study.
– C. Chrysohoou, D. Panagiotakos, E. Georgousopoulou, C. Pitsavos, J. Skoumas, A. Christou, T. Grekas,
M. Kambaxis, C. Stefanadis, D. Tousoulis (Athens, GR)
Obese hypogonadal men with a history of cardiovascular diseases (CVD) benefit from long-term P2722
treatment with testosterone undecanoate (TU): observational, real-life data from a registry study.
– F. Saad, A. Haider, K.S. Haider, G. Doros, A. Traish (Berlin and Bremerhaven, DE; Boston, US)
Adherence to Mediterranean diet reduces the risk for 10-year type 2 diabetes development. The role of P2723
TNF-a and homocystein as possible mediators.
– D.B. Panagiotakos, E. Koloverou, C. Pitsavos, C. Chrysohoou, E. Georgousopoulou, N. Skourlis,
I. Skoumas, D. Tousoulis, C. Stefanadis (Athens, GR)
177
Effectiveness of the EUROACTION PLUS (EA+) preventive cardiology programme for high CVD risk P2724
smokers in modifying dietary habits and anthropometric indices.
– E. Thompson, C. Jennings, K. Kotseva, D. De Bacquer, A. Hoes, J. De Velasco, S. Brusaferro, A. Atrey,
J. Jones, D. Wood (London, UK; Ghent, BE; Utrecht, NL; Valencia, ES; Udine, IT)
Olive oil consumption can favorably affect cardiovascular prognosis in patients after percutaneous P2725
coronary intervention.
– E. Oikonomou, G. Siasos, M. Zaromytidou, S. Tsalamandris, K. Mourouzis, M. Anastasiou,
E. Dimitropoulos, K. Zisimos, K. Maniatis, D. Tousoulis (Athens, GR)
FROM TECHNICALITIES TO PROGNOSIS IN PCI

Comparison of long term clinical outcomes between bare metal stent versus different types of drug P2726
eluting stents for treatment of acute myocardial infarction.
– H.W. Lee, T.J. Hong, J.H. Choi, B.W. Kim, J.S. Park, J.H. Oh, J.H. Choi, H.C. Lee, K.S. Cha, I.S. Han
(Busan, KR)
Comparative outcomes of zotarolimus-eluting stents in British Columbia: a real world analysis of 17,747 P2727
patients using propensity score and instrumental variable methods.
– M.B. Iqbal, I.J. Nadra, J.N. Din, C. Hendry, A. Fung, E. Aymong, A.W. Chan, S. Hodge, S.D. Robinson,
A. Della Siega (Victoria, Vancouver and Kelowna, CA)
Quantification and management of thrombus burden during primary PCI: limitations of angiography P2728
demonstrated with optical coherence tomography imaging.
– C. Biagioni, D. Neves, M. Echavarria Pinto, A. Quiros, M.J. Perez Vizcayno, L. Nombela, A. Fernandez Ortiz,
C. Macaya, N. Gonzalo, J. Escaned (Madrid, ES)
Single string technique for complex coronary bifurcation stenting. P2729
– G.G. Toth, S. Pyxaras, P. Mortier, G. Di Gioia, J. Adjedj, M. Pellicano, E. Barbato, B. De Bruyne, M. De
Beule, W. Wijns (Graz, AT; Coburg, DE; Ghent and Aalst, BE; Naples, IT)
Evaluating vascular healing of polymer-free sirolimus-eluting stents on native coronary vessels: a serial P2730
follow-up of 3- and 6-month optical coherence tomography imaging study.
– P. Suwannasom, E. Benit, O. Gach, C. Von Birgelen, S. Hofma, B. Xu, Y. Onuma, H. Garcia-Garcia,
R. Gao, P.W.J.C. Serruys (Rotterdam, Enschede and Leeuwarden, NL; Hasselt and Liège, BE; Beijing, CN;
London, UK)
Predictors for crossover from one stent to 2 stent techniques while treating coronary bifurcation lesions. P2731
– G. Greenberg, R.K. Kornowski, H.V. Vaknin Assa, T.B. Bental, E.L. Lev, A.A. Assali (Petah Tikva, IL)
Comparative study with optical coherence tomography at 6 and 12 months between drug-eluting stents P2732
with resorbable polymer and drug-eluting scaffolds with full bioresorbable platform.
– J.M. De La Torre Hernandez, G. Marti, J.R. Rumoroso, H. Gutierrez, S. Brugaletta, J.F. Diaz, F. Hernandez,
B. Cid, N. Gonzalo, R. Lopez Palop (Santander, Barcelona, Galdacano, Valladolid, Huelva, Madrid,
Santiago de Compostela and Alicante, ES)
The paradigm shift of peri-contrast staining (PSS) in first generation DES era to second generation DES P2733
era.
– T. Tokuda, T. Muramatsu, R. Tsukahara, Y. Ito, H. Ishimori, K. Hirano, M. Nakano, M. Yamawaki, M. Araki
(Yokohama, JP)
Long-term outcomes in NANOM-FIM trial: 5-year analysis. P2734
– A. Kharlamov, J. Gabinsky (Rotterdam, NL; Yekaterinburg, RU)
Evaluation of efficacy and safety of biolimus A9™-eluting stent in patients with acute coronary syndrome; P2735
a multicenter, observational study (BEAUTY study).
– K.-H. Park, M.-H. Jeong, Y.-J. Hong, Y.-K. Ahn (Gwangju, KR)
Long-term outcomes for first generation versus second generation drug-eluting stents in the P2736
contemporary era: a propensity-matched analysis from the British Columbia Cardiac Registry.
– M.B. Iqbal, I.J. Nadra, J.N. Din, C. Hendry, A. Fung, E. Aymong, A.W. Chan, S. Hodge, S.D. Robinson,
A. Della Siega (Victoria, Vancouver and Kelowna, CA)
Simple versus complex drug-eluting stenting for coronary bifurcation lesions: an updated meta-analysis P2737
– J.-S. Jang, H.-C. Shin, H.-Y. Jin, J.-S. Seo, T.-H. Yang, D.-K. Kim, D.-S. Kim (Busan, KR)
Is correlation of incidence of stent fracture after drug-eluting stent implantation with strut thickness P2738
different between de novo and in-stent restenosis lesions?
– M. Ohya, K. Kadota, S. Otsuru, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto, K. Mitsudo
(Kurashiki, JP)
Predictors of late restenosis following paclitaxel-coated balloon angioplasty in patients with in-stent P2739
restenosis.
– S. Habara, K. Kadota, D. Hasegawa, T. Tada, H. Tanaka, Y. Fuku, T. Goto, K. Mitsudo (Kurashiki, JP)
Impact of a dedicated chronic ootal occlusion (CTO) programme on procedural success among specialist P2740
and non-specialist operators: a single centre experience.
– A.N. Pavlidis, A. Kalogeropoulos, R. Weerackody, D. Perera, D. Jones, A. Archbold, A. Wragg, A. Sirker,
A. Mathur, E.J. Smith (London, UK)
Does optimal lesion preparation reduce the amount of acute recoil of the Absorbe BVS? P2741
– G.B. Danzi, M. Sesana, M. Arieti, G. Villa, S. Rutigliano, A. Aprile, A. Nicolino, S. Moshiri, R. Valenti (Pietra
Ligure, Desenzano del Garda and Florence, IT)
Early experience implanting a polymer-free biolimus A9 drug coated stent in complex real world patients P2742
from two United Kingdom centers.
– T. Kinnaird, M. Uddin, M. Butt, A. Hailan, N. Ossei-Gerning, A. Chase, A. Choudhury, D. Smith,
R. Anderson (Cardiff and Swansea, UK)
178
First-in-man (FIM) evaluation of a novel balloon delivery system for the self-apposing coronary artery P2743
stent.
– H. Lu, A. Ijsselmuiden, M. Nassif, M. Grundeken, A. De Vries, A. Weevers, M. Scholte, J. Wykrzykowska,
R. De Winter, K. Koch (Amsterdam and Dordrecht, NL)
Simplified vascular closure device deployment without an arteriogram: single center experience in over P2744
2000 consecutive patients.
– A.S. Manolis, S. Koulouris, D. Stalikas (Athens, GR)
Three-year outcome after biolimus-eluting versus sirolimus-eluting coronary stent implantation in P2745
diabetic and non-diabetic patients - a SORT OUT V substudy.
– K.K.W. Olesen, M. Maeng, L.O. Jensen, S.D. Kristensen, H.E. Boetker, J. Aaroe, M. Madsen, J. Ravkilde,
J.F. Lassen, E.H. Christiansen (Aarhus, Odense and Aalborg, DK)
Serial observation of everolimus-eluting stent incomplete stent apposition by frequency domain optical P2746
coherence tomography.
– N. Suzuki, T. Kubo, J. Shite, S. Uemura, Y. Bo, M. Habara, T. Shinke, Y. Saito, K. Kozuma, T. Akasaka
(Tokyo, Wakayama, Osaka, Kurashiki, Toyohashi, Kobe and Nara, JP; Harbin, CN)
Incidence and clinical impact of longitudinal stent deformation after the PROMUS element platinum P2747
chromium-everolimus eluting stent implantation.
– T. Hiromasa, S. Kuramitsu, T. Domei, M. Hyodo, Y. Soga, S. Shirai, K. Ando, M. Nobuyoshi (Kitakyushu, JP)
The incidence of stent fracture after drug-eluting stent implantation: comparison between de novo lesion P2748
and in-stent restenosis lesion.
– T. Kanazawa, K. Kadota, S. Otsuru, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto,
Impact of stent overlap on 2-year clinical outcomes in patients treated with biolimus-eluting stent and P2749
cobalt chromium everolimus-eluting stent.
– T. Hiromasa, S. Kuramitsu, H. Jinnouchi, T. Morinaga, Y. Kobayashi, T. Domei, M. Hyodo, Y. Soga,
S. Shirai, K. Ando (Kitakyushu, JP)
Clinical outcome of aorto-ostial lesions treated with first or second generation drug-eluting stents. P2750
– S. Kono (Himeji, JP)
Transradial versus transfemoral approach for chronic total occlusions of coronary arteries: feasibility and P2751
predictors of success.
– F. Soares, V.A. Jimenez Diaz, F. Saraiva, A. Ortiz Saez, A. De Miguel Castro, G. Bastos Fernandez,
J.L.M. Ortiz, J. Andrade, J.A. Baz Alonso, A. Iniguez Romo (Coimbra and Leiria, PT; Vigo, ES)
Bioabsorbable vascular scaffold radial expansion and conformation compared to a metallic platform. P2752
– N. Foin, D.R. Lee, C. Bourantas, A. Mattesini, G. Caiazzo, E. Fabris, D. Kilic, C. Di Mario, P. Wong,
P.W.J.C. Serruys (Singapore, SG; London, UK; Florence, IT)
A novel tram stent method in treatment of coronary bifurcation lesions. P2753
– M.A.R.K. Arokiaraj (Pondicherry, IN)
Fractional flow reserve assessed by pressure wire could predict proper stent deployment. P2754
– A.A. Elasfar, H.A. Remah, O.S. Elshahawy (Tanta, EG)
Impact of transradial approach on clinical outcomes and bleeding complications in high risk ACS patients P2755
undergoing PCI with GP IIb/IIIa inhibitor: from the CAP registry.
– S.Y. Choi, Y.W. Choi, S.J. Tahk, H.S. Kim, W.H. Kim, C.W. Yu, C.W. Lee, S.W. Rha, J.O. Jeong, B.J. Choi
(Suwon, Seoul, Daejeon and Pucheon, KR)
Effect of a novel peptide and sirolimus-coated stent on re-endothelialization and anti-restenosis. P2756
– M.H. Jeong, E.J. Jang, I.H. Bae, D.S. Park, K.S. Lim, J.K. Park, D.S. Sim (Gwangju, KR)
Study with optical coherence tomography of everolimus-eluting stents with abluminal bioabsorbable P2757
polymer at 3, 6 and 12 months after implantation.
– J.M. De La Torre Hernandez, P. Tejedor, D.H. Lee, J.M. Duran Hernandez, T. Garcia Camarero,
J. Monedero Campo, F. Sainz Laso, M. Alvarez Calderon, G. Veiga Fernandez, J. Zueco (Santander and
Burgos, ES)
Influence of three-dimensional bifurcation angle on immediate and long term outcomes in patients with P2758
bifurcation lesions treated by simple approach.
– M. Pan Alvarez-Osorio, M.C. Morenate, S. Ojeda, M. Romero, M. Blanco, P. Martin, J. Suarez De Lezo
Herreros De Tejada, J. Segura, A. Medina, J. Suarez De Lezo Cruz-Conde (Córdoba and Las Palmas de
Gran Canaria, ES)
The multicentre LONGPRIME registry: everolimus DES in long lesions. P2759
– J.F. Diaz Fernandez, J.C. Fernandez Guerrero, N. Delarche, C. Bretelle, J.C. Zueco Gil, R. Lopez Palop,
B. Garcia Del Blanco, V. Mainar, R. Albert, A. Albarran (Huelva, Jaén, Santander, Alicante, Barcelona and
Madrid, ES; Pau, Valence and Chartres, FR)
Rotational atherectomy through the radial artery: procedural success and long term clinical outcomes. P2760
– J. Delgado Silva, L. Paiva, R. Cacao, R. Ramos, S. Margalho, R. Fernandes, H. Oliveira, M. Costa,
L. Goncalves (Coimbra, PT)
Provisional versus planned double-stenting strategy in coronary bifurcation lesions treated with P2761
bioresorbable scaffold.
– H. Kawamoto, A. Latib, N. Ruparelia, T. Miyazaki, A. Sticchi, F. Figini, A. Chieffo, M. Carlino, M. Montorfano,
A. Colombo (Milan, IT)
Associations between stent length and clinical outcomes in women undergoing PCI with new generation P2762
drug eluting stents.
– J. Chandrasekhar, G. Stefanini, S. Sartori, M. Aquino, W. Wijns, L. Mehta, D. Itchhaporria, T. Kimura,
D. Kandzari, R. Mehran (New York, Columbus, Newport Beach and Atlanta, US; Berne, CH; Aalst, BE;
Kyoto, JP)
179
Computed tomography scan assessment at follow-up in patients with chronic total occlusion treated with P2763
bioresorbable vascular scaffolding.
– S. Ojeda, M. Pan Alvarez-Osorio, M. Romero, P. Martin, J. Novoa, J. Segura, F. Mazuelos, J. Suarez De
Lezo Herreros De Tejada, A. Medina, J. Suarez De Lezo Cruz-Conde (Córdoba and Las Palmas de Gran
Canaria, ES)
Optical coherence tomography guidance for bvs implantation in complex lesions. P2764
– G. Caiazzo, A. Mattesini, I.D. Kilic, E. Fabris, R. Serdoz, C. Indolfi, C. Di Mario (Catanzaro and Florence, IT;
London, UK)
Clinical and angiographic one year outcome of mini-crush stenting for the treatment of true coronary P2765
bifurcation lesions.
– A. Nicolino, S. Moshiri, L. Olivotti, A. Baselice, K. Paonessa, G.B. Danzi (Pietra Ligure, IT)
Impact of different drug-eluting kinetics on 3-year clinical outcomes following first- or second-generation P2766
zotarolimus-eluting stent implantation; a propensity score-matched analysis.
Procedure related platelet activation in long lesions treated with bioresorbable vascular scaffold versus P2767
xience xpedition implantation (proactive trial).
– M. Pellicano, G. Di Gioia, G. Toth, A. Ferrara, J. Adjedj, L. Delrue, J. Bartunek, W. Wijns, B. De Bruyne,
E. Barbato (Aalst, BE; Naples, IT)
Acute performance of second generation everolimus-eluting bioresorbable vascular scaffolds for P2768
percutaneous treatment of chronic total coronary occlusions.
– A. La Manna, A. Chisari, G. Giacchi, D. Capodanno, G. Longo, M. Di Silvestro, C. Tamburino (Catania, IT)
Clinical and angiographic outcome of excimer laser coronary angioplasty (ELCA) + paclitaxel coated P2769
balloon for patients with second generation drug-eluting stent restenosis.
– A. Hirohata, K. Yamamoto, M. Ohara, Y. Miyake, A. Hayashida, N. Kagiyama, R. Yoshioka, T. Yoshida,
T. Ohe (Okayama, JP)
Temporal trend in the incidence of stent thrombosis-is it the impact of improved antiplatelet regimen and P2770
evolving coronary stent technology?
– P. Kansara, W. Qureshi, U. Choudhry, J. Hopkins, C. Jurkovitz, J. Laughery, P. Kolm, E. Rahman, S. Weiss,
W.S. Weintraub (Newark, US)
Anatomical and functional assessment of Tryton bifurcation stent before and after final kissing balloon P2771
dilatation: evaluations by three-dimensional coronary angiography, optical coherence tomography.
– S. Pyxaras, G.G. Toth, G. Di-Gioia, G.J. Ughi, S. Tu, D. Rusinaru, T. Adriaenssens, J.H.C. Reiber,
M.B. Leon, W. Wijns (Coburg, DE; Graz, AT; Aalst and Leuven, BE; Leiden, NL; New York, US)
ECMO in high-risk percutaneous interventions in the catheterization laboratory. P2772
– S. Merchan, J. Martin-Moreiras, A. Uribarri, M.J. Dalmau, F. Martin, A. Diego, J. Rodriguez-Collado,
I. Cruz-Gonzalez, C. Rubio, P.L. Sanchez (Salamanca, ES)
Percutaneous coronary intervention during extracorporeal membrane oxygenation versus coronary artery P2773
bypass graft surgery in high-risk patients.
– N. Kochergin, V. Ganyukov, D. Shukevich (Kemerovo, RU)
Predictor of persistent slow/no-reflow after percutaneous coronary intervention with thrombus aspiration P2774
and distal protection for ST-elevation myocardial infarction.
– Y. Hyodo, K. Kadota, S. Otsuru, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto,
The effect of drug-eluting stent on mid-term epicardial and microvascular endothelial function: a P2775
coronary blood flow assessment with acetylcholine test.
– H. Tamaru, K. Fujii, M. Shibuya, T. Imanaka, A. Sumiyoshi, T. Saita, M. Nishimura, T. Horimatsu,
M. Ishihara, T. Masuyama (Nishinomiya, JP)
Modified stent platform favorably affects longitudinal stent strength and stent deformation of the P2776
platinum chromium everolimus-eluting stent: an in vivo frequency domain optical coherence tomography.
– H. Okura, R. Yamada, K. Yoshida (Kurashiki and Okayama, JP)
Use of protective ballooning technique with provisional stenting for treatment of non-left main coronary P2777
bifurcation lesions.
– A. Ramirez Moreno, J.R. Siles Rubio, L. Inigo-Garcia, J. Munoz-Bellido, A. Milan-Pinilla, R. Bravo-Marques,
M. Pombo-Jimenez, A. Valle-Alberca, E. Zambrano-Medina, M. Noureddine (Estepona and Marbella, ES)
A rabbit iliac model for testing the acute thrombogenicity and longterm biocompatibility of novel coronary P2778
stents and scaffolds.
– N. Malik, C.S. Shah, A.H. Goodall, A.H. Gershlick (Basildon and Leicester, UK)
Efficacy and safety of transradial multi-vessel coronary artery disease intervention as compared with P2779
single vessel disease intervention.
– W.G. Choi, S.W. Rha, S.H. Kim, D.J. Oh, B.G. Choi, S.Y. Choi (Chungju and Seoul, KR)
Longitudinal neointimal distribution after drug-eluting stent implantation: an optical coherence P2780
tomography study.
– S. Otsuki, S. Brugaletta, Y. Shiratori, G. Scalone, O. Gomez-Monterrosas, S. Romero-Villafane, X. Freixa,
V. Martin-Yuste, M. Masotti, M. Sabate (Barcelona, ES)
Dedicated side branch stent versus mini-crushing stenting: comparison between two techniques in the P2781
treatment of true coronary bifurcation. The procedural outcome.
– A. Nicolino, R. Rosso, S. Moshiri, A. Rognoni, A. Lupi, A.S. Bongo, G.B. Danzi (Pietra Ligure and Novara, IT)
Favorable clinical long-term follow-up of mini-crushing technique for treatment of true bifurcations. P2782
– A. Nicolino, S. Moshiri, L. Olivotti, K. Paonessa, A. Baselice, G.B. Danzi (Pietra Ligure, IT)
Anti-CD34 capturing in coronary stenting leads to improved endothelial coverage: COMBO vs. Xience P2783
Prime.
– G.H.J.M. Ellenbroek, E. Ligtenberg, S. Rowland, J.A. Post, G. Pasterkamp, I.E. Hoefer (Utrecht and
Hoevelaken, NL)
180
CHANGES IN HEART FAILURE, EPIDEMIOLOGY AND MANAGEMENT

Takotsubo cardiomyopathy in regional Australia. P2784
– R.J. MacFadyen, S. Lovibond, K. Rajah, A. Antonov, J. Martin, A. Sharma, C. Hengel, F. Charchar,
E. Oqueli (Ballarat, Geelong and Melbourne, AU)
Demographic and clinical characteristics of male and female patients with preserved ejection fraction in P2785
a large health organization.
– L. Bash, D. Weitzman, O. Sharon, M. Aviram-Paz, G. Chodick, V. Shalev (Rahway, US; Tel Aviv and Hod
Hasharon, IL)
The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic P2786
heart failure.
– N. Ebner, E.A. Jankowska, V. Sliziuk, S. Elsner, L. Steinbeck, J. Kube, A. Sandek, W. Doehner, S.D. Anker,
S. Von Haehling (Berlin, DE; Wroclaw, PL)
Determinants and temporal trends of in-hospital and late onset heart failure (HF) after acute myocardial P2787
infarction (AMI): a study of 230,408 AMI patients between1996-2010.
– L.A. Desta, T. Jernberg, C. Hofman-Bang, J. Spaak, H. Persson (Stockholm, SE)
Heart failure mortality: evolution from 2003 to 2012. P2788
– V. Bertomeu-Gonzalez, A. Lopez-Pineda, F.J. Elola, J.V. Segura-Heras, L. Rodriguez-Padial,
C. Fernandez-Perez, J.L. Bernal-Sobrino, V. Bertomeu-Martinez (San Juan de Alicante, Madrid and Toledo,
ES)
Comorbidities and factors associated with reduced (≤40%) left ventricle ejection fraction at discharge P2789
from acute myocardial infarction (results from the PL-ACS registry).
– M. Gierlotka, M. Hawranek, M. Tajstra, K. Wilczek, M. Janion, B. Sredniawa, A. Lekston, M. Zembala,
L. Polonski, M. Gasior (Zabrze and Kielce, PL)
Outpatient consultation supporting post-discharge heart failure patients reduces 30-day P2790
re-hospitalization rate.
– C. Pacho, M. Domingo, R. Nunez, M. Rodriguez, R. Cabanes, B. Gonzalez, C. Rios, P. Barroso, J. Lupon,
A. Bayes-Genis (Badalona, ES)
Incidence and prognostic impact of acute respiratory distress as a trigger for takotsubo cardiomyopathy P2791
- Results from the International Takotsubo Registry (InterTAKRegistry).
– L.C. Napp, V.L. Cammann, J. Diekmann, J.R. Ghadri, T.F. Luescher, J. Bauersachs, C. Templin (Hannover,
DE; Zurich, CH)
Telephone access to a heart failure unit: a useful health resource to prevent clinical decompensation and P2792
hospital readmissions in high-risk heart failure outpatients.
– S. Lopez-Fernandez, M. Puga-Martinez, M. Molina-Jimenez, M. Gonzalez-Molina Espinar,
D. Rodriguez-Torres, R. Rivera-Lopez, M. Verdugo, R. Melgares-Moreno (Granada, ES)
Pathological monitoring after heart transplantation: 10-year-experience from single heart transplantation P2793
center.
– L. Li, H.Y. Wang, L.F. Song, X.J. Duan, Y. Sun, Y. Tang, Q.Z. Wang, Y. Chu, H. Zhao, J. Huang (Beijing, CN)
Is noninvasive ventilation effective and safe in cardiogenic pulmonary edema in very old patients? P2794
– M. Poli, P. Trambaiolo, V. Basso, M. Penco, G. Ferraiuolo (Rome and L’Aquila, IT)
Effect of sleep position on cardiac arrhythmias in patients with heart failure and obstructive sleep apnea P2795
syndrome.
– C. Gurgun, O. Kacmaz Basoglu, B. Keskin, M.S. Tasbakan, A. Gurgun (Izmir, TR)
Ferric carboxymaltose in iron deficient heart failure patients: a meta-analysis on individual patient data. P2796
– S.D. Anker, J. Comin-Colet, G. Filippatos, F. Ruschitzka, G.P. Arutyunov, M. Motro, C. Mori, S.J. Pocock,
D.J. Van Veldhuisen, P. Ponikowski (Göttingen, DE; Barcelona, ES; Athens, GR; Zurich and Glattbrugg, CH;
Moscow, RU; Tel Hashomer, IL; London, UK; Groningen, NL; Wroclaw, PL)
NON-PHARMACOLOGICAL THERAPY IN HEART FAILURE EXERCISE, VENTILATION
Effects of positive airway pressure therapy on nocturnal oxygen saturation in heart failure patients with P2797
sleep-disordered breathing.
– A. Tueroff, H. Fox, T. Bitter, B. Wellmann, D. Horstkotte, O. Oldenburg (Bad Oeynhausen, DE)
Exercise cardiac power and the risk of heart failure in men. P2798
– S. Kurl, S.Y. Jae, F. Zaccardi, J. Kauhanen, K. Ronkainen, J.A. Laukkanen (Kuopio, FI; Seoul, KR; Rome, IT)
Impact of sleep-disordered breathing and its treatment on post-discharge outcomes in hospitalized P2799
patients with left ventricular systolic dysfunction following acute decompensated heart failure.
– S. Suda, T. Kasai, H. Matsumoto, A. Murata, S. Yatsu, T. Kato, M. Hiki, H. Daida (Tokyo, JP)
The impact of decompensated heart failure requiring hospitalization on pulmonary diffusing capacity of P2800
carbon monoxide.
– K. Moriuchi, K. Nakamura, H. Kanzaki, K. Kusano, T. Noguchi, S. Yasuda, H. Ogawa, T. Anzai (Osaka, JP)
Exercise therapy in heart failure with reduced ejection fraction is safe but did not improve mortality, P2801
cardiac death or hospitalisation - a meta-analysis.
– S. Sze, V. Allgar, K.Y.K. Wong (Hull, UK)
The inverse correlation of sympathetic activity and daytime sleepiness in patients with heart failure and P2802
sleep apnea.
– H. Itaya, J.A. Joh, M.N. Nakamura (Tokyo, JP)
Impact of adaptive servo ventilation therapy on cardiovascular event free survival in feart failure patients. P2803
– T. Kato, N. Takama, K. Aihara, Y. Sugito, Y. Seta, K. Kaneko, M. Kurabayashi (Tomioka and Maebashi, JP)
181
Rapid introduction of adaptive servo-ventilation in the emergency room reduces the rate of endotracheal P2804
intubation and hospitalization in patients with acute cardiogenic pulmonary edema.
– M. Kinoshita, H. Okayama, T. Miyoshi, A. Higaki, K. Hara, Y. Kawata, G. Hiasa, T. Yamada, Y. Kazatani
(Matsuyama, JP)
Device-measured rapid shallow breathing with exertion worsens prior to heart failure decompensation. P2805
– S. Rials, B. Merkely, R. Gardner, V. Averina, R. Sweeney, Y. Zhang, Q. An, J. Boehmer (Columbus, St. Paul
and Hershey, US; Budapest, HU; Glasgow, UK)
Is 3D interchangeable with 2D echocardiography for the initiation of device therapy in patients with heart P2806
failure with reduced ejection fraction?
– S. Mihaila, A. Velcea, A.A. Andronic, S.I. Calin, L.L. Matei, R.C. Rimbas, D. Muraru, L.P. Badano,
D. Vinereanu (Bucharest, RO; Padua, IT)
Effect of heart rate on the response to cardiac resynchronization therapy. P2807
– H. Mohamed Fereig Hamed, A.M. Hamdy, M.A. Nabih, N.A. Agiba (Cairo, EG)
BASIC MECHANISMS IN HEART FAILURE
Apocynin attenuates systolic dysfunction and decreases superoxide generation in soleus muscle of heart P2808
failure rats.
– C. Bonomo, P.F. Martinez, M.J. Gomes, A.R.R. Lima, L.U. Pagan, R.L. Damatto, D.C. Fernandes,
F.R.M. Laurindo, K. Okoshi, M.P. Okoshi (Botucatu, Campo Grande and São Paulo, BR)
Unveiling the potential benefit of adenosine a2b receptor blockage to counteract right cardiac overload in P2809
rat pulmonary arterial hypertension.
– B. Braganca, T. Rodrigues, M. Goncalves, F. Ferreirinha, P. Correia De Sa, A.P. Fontes Sousa (Porto, PT)
Endoglin is required to maintain normal cardiac function in adult life. P2810
– S. Tual-Chalot, B.J. Davison, Y. Jin, R.E. Redgrave, L. Jakobsson, M.J. Taggart, H.M. Arthur
(Newcastle-upon-Tyne, UK; Stockholm, SE)
Clinical correlates of soluble neprilysin concentrations in patients with acute heart failure. P2811
– M. Navarro Penalver, M.T. Perez Martinez, J. Sanchez Mas, M.R. Gracia-Rodenas, J. Barallat, A. Galan,
J. Lupon, A. Bayes Genis, J. Nunez, D. Pascual Figal (Murcia, Barcelona and Valencia, ES)
Distribution of leukocyte populations is affected by cardiac resynchronisation therapy. P2812
– K. Kaminski, K. Ptaszynska Kopczynska, M. Marcinkiewicz Siemion, P. Singh, U. Radzikowska, M. Rusak,
A. Lisowska, M. Witkowski, W.J. Musial, M. Moniuszko (Bialystok, PL)
Hepatocyte growth factor in patients with acute heart failure. P2813
– D.A. Pascual Figal, M.C. Asensio-Lopez, M.T. Perez-Martinez, M.R. Gracia-Rodenas, J. Sanchez-Mas,
J.L. Morales-Rull, J.A. Gimeno-Orna, J.J. Puente-Lanzarote, P. Bettencourt, J.I. Perez-Calvo (Murcia,
Lleida and Zaragoza, ES; Porto, PT)
Excessive extracellular water accumulation in patients with sarcopaenia with acute decompensated heart P2814
failure.
– S. Saigo, M. Endo, T. Suzuki, J. Kirigaya, F. Otomo, M. Inoue, H. Nakahashi, H. Himeno, S. Umemura,
K. Kimura (Fujisawashi and Yokohama, JP)
Procalcitonin is a marker of infection in patients with heart failure and a strong predictor of mortality: a P2815
systematic review and meta-analysis.
– C. Meune, L. Aissou, E. Sorbets, F.X. Goudot, N. Pop, L. Benouda (Bobigny, FR)
The influence of gender on epidemiology, precipitating Factors, management and prognosis of the P2816
patients with acute decompensated heart failure: insights from KorHF Registry.
– J.-H. Lee, S.M. Kim, S.Y. Lee, J.W. Bae, K.K. Hwang, D.W. Kim, M.C. Cho (Cheongju, KR)
Three-dimensional growth of cardiac stem cells to form biosynthetic cardiac tissues. P2817
– Y. Bai, W. Bian, J. Wu, Y. Zhang, J. Qian, Y. Zou, J. Ge (Shanghai, CN; Durham, US)
Factors associated with increased levels of serum cardiac troponin during the peripartum period. P2818
– M. Okano, T. Kato, A. Miyata, T. Nagano, M. Inoko (Osaka, JP)
LONG TERM MONITORING & PROGNOSIS IN HEART FAILURE

Does the inclusion of depression and cognitive screening to frailty assessment improve prediction of P2819
outcomes in heart transplant-eligible patients?
– S.R. Jha, H.K. Hannu, P. Newton, K. Wilhelm, C. Hayward, A. Jabbour, M. Harkess, P. Tunnicilff, S. Shaw,
P. Macdonald (Sydney, AU)
A cost-effective inpatient heart failure service can save lives and reduce admissions. P2820
– L.T.M. Yung, R. Horne, R. Gilbert, L. Watkins, C.J. Burrell (Plymouth, UK)
Re-admission patterns in patients following first admission for heart failure: heart failure with preserved P2821
ejection fraction as compared with heart failure with reduced ejection fraction.
– G. O’Carroll, D. Waterhouse, E. O’Connell, R. O’Hanlon, C. Kenny, K. Mc Donald (Dublin, IE)
Necropsy findings in patients with heart failure. P2822
– L.F. Lipari Dinardi, V.S. Issa, T.V. Pereira, L.K.R. Almeida, L. Isper, T.S. Barbosa, S.M. Ayub-Ferreira,
L.A. Benvenuti, E.A. Bocchi (São Paulo, BR)
Chikungunya virus induced myocarditis. P2823
– I. Mendoza, I. Morr, I. Mendoza, K. Gonzalez, I. Villalobos, Y. Meza, C. Morr, C. Morr, J. Marques (Caracas,
VE; Miami, US)
Graft rejection requiring treatment within the 1st year after heart transplantation significantly affects P2824
survival, as opposed to later rejection episodes.
– I. Planinc, D. Fabijanovic, J. Ljubas-Macek, B. Skoric, Z. Baricevic, H. Jurin, J. Samardzic, H. Gasparovic,
M. Cikes, D. Milicic (Zagreb, HR)
182
Current situation of management of systolic heart failure in Russia: Russian hospital heart failure registry P2825
(RUS-HFR) results.
– A. Yurchenko, M. Sitnikova, E. Lyasnikova, M. Trukshina, E. Shlyakhto, D. Duplyakov, R. Libis (St.
Petersburg, Samara and Orenburg, RU)
High burden of primary care contacts in patients with left ventricular systolic dysfunction- findings from P2826
the heart failure and optimal outcomes from pharmacy study.
– P. Forsyth, R. Lowrie, P.S. Jhund, N. Greenlaw, J.J.V. McMurray, F.S. Mair (Glasgow, UK)
Sudden cardiac death risk assessment after septal alcohol ablation in patients with hypertrophic P2827
cardiomyopathy according to the new ESC 2014 guidelines.
– M. Jensen, F. Van Buuren, A. Axelsson, Z. Dimitriadis, S. Helqvist, S. Scholtz, L. Faber, H. Bundgaard
(Copenhagen, DK; Bad Oeynhausen, DE)
IMAGING ON DIAGNOSIS & PROGNOSIS IN HEART FAILURE

Comparing the efficasy of Tadalafil versus Placebo on pulmonary artery systolic pressure and right P2828
ventricular function in patients with beta-thalassemia intermedia.
– R. Jalalian, A. Tammadoni, M. Iranian, M. Saravi, A. Mohgadamnia, S. Khafi (Sari and Babol, IR)
Deterioration of left ventricular function in patients caused by right ventricular stimulation: can it be P2829
predicted by LV-function at the time of implant?
– M. Ebert, S. Richter, M. Doering, G. Hindricks, T. Arentz, D. Kalusche (Leipzig and Freiburg, DE)
Noninvasive estimation of the feature of hypertensive heart failure using novel one-beat P2830
three-dimensional speckle tracking echocardiography with high volume rates.
– S. Minatoguchi, M. Kawasaki, R. Tanaka, M. Ishiguro, T. Yoshizane, M. Iwama, T. Hirose, K. Ono, T. Noda,
Takotsubo cardiomyopathy and its clinical associations: differentiating acute anterior ST-segment P2831
myocardial infarction with electrocardiographic findings.
– J. Orme, M. Najib, A. Loli (Phoenix, US)
Clinical and echocardiographic correlation of plasma transforming growth factor (TGF)-beta levels in P2832
patients with heart failure.
– A. Malodiya, S.A. Hamid, S. Khan, M.T. Saltzberg, T. Tsuda (Newark and Wilmington, US)
Subclinical impairment of left ventricular function in patients with end stage renal failure detected by P2833
three-dimensional speckle tracking echocardiography.
– M.M. Sun, X.H. Shu, Y. Kang, C.Z. Pan, X.S. Cao, J.B. Ge (Shanghai, CN)
Adding brain natriuretic peptide, ultrasound lung comets or tissue Doppler to clinical guidance in P2834
reducing heart failure hospitalization.
– M. Saraya, H. Kassem, H. Salah Eldin (Cairo, EG)
Ascending aorta distensibility support for failing left ventricle: an evidence from coronary CT angiography. P2835
– M. Sosnowski, A. Czekaj, A. Mlynarski, J. Skrzypek-Wanha, J. Brzoska, W. Wojakowski (Katowice, PL)
Predicting left ventricular reverse remodeling as well as outcome after cardiac resynchronization therapy P2836
with a score combining clinical, electrocardiographic, and echocardiographic parameters.
– A. Bernard, S. Marechaux, L. Fauchier, A. Menet, M. Fournet, F. Schnell, C. Leclercq, P. Mabo, E. Donal
(Tours, Lille and Rennes, FR)
DEVICES & INTERVENTIONS IN HYPERTENSION

Optical coherence tomography imaging long term follow-up of renal arteries after radio-frequency P2837
catheter-based renal denervation.
– T.M. Roleder, M. Skowerski, W. Wanha, T. Jadczyk, L. Partyka, G. Smolka, A. Ochala, M. Tendera,
Z. Gasior, W. Wojakowski (Katowice and Krakow, PL)
Comparative study measuring the optic nerve sheat diameter with transorbital ultrasound in healthy P2838
women, pregnant women and pregnant with preeclampsia/eclampsia.
– E.G. Urias, J. Ortega, C.B. Arteaga (Culiacan, MX)
Catheter based renal denervation for resistant hypertension. 24 month results of the EnligHTN I Study P2839
using a multielectrode ablation system.
– C. Tsioufis, V. Papademetriou, K. Dimitriadis, A. Kasiakogias, M. Worthley, A. Sinhal, D. Chew,
Y. Malaiapan, D. Tousoulis, S. Worthley (Athens, GR)
Challenges facing renal denervation: insight from real world experience at two UK centres. P2840
– A.E. Burchell, K. Chan, E.C. Hart, M. Saxena, A.K. Jain, D.J. Collier, J.F.R. Paton, A.K. Nightingale,
M.D. Lobo, A. Baumbach (Bristol and London, UK)
Effect on heart rate following renal denervation: Insights from the Global SYMPLICITY Registry. P2841
– M. Böhm, G. Mancia, F. Mahfoud (Homburg, DE; Milan, IT)
Triple versus dual antiplatelet therapy in patients undergoing unprotected left main percutaneous P2842
– S.W. Rha, B.G. Choi, S.Y. Choi, J.K. Byun, J.B. Kim, S. Xu, E.J. Kim, C.G. Park, H.S. Seo, D.J. Oh (Seoul,
KR)
Blood pressure reductions following catheter-based renal denervation are not related to improvements in P2843
adherence to antihypertensive drugs measured by urine/plasma toxicological analysis.
– S. Ewen, M.R. Meyer, B. Cremers, U. Laufs, D. Linz, I. Kindermann, C. Ukena, H.H. Maurer, M. Böhm,
F. Mahfoud (Homburg, DE)
Sustained beneficial effects of multi-electrode renal sympathetic denervation on cardiac adaptations in P2844
resistant hypertension: A 24-months follow-up study.
– C. Tsioufis, V. Papademetriou, K. Dimitriadis, A. Kasiakogias, D. Tsiachris, C. Thomopoulos, I. Liatakis,
D. Tousoulis (Athens, GR; Washington, US)
183
Agreement between automatic and manual measurement of heart rate in patients with atrial fibrillation. P2845
– T.T. Lin, C.L. Wang, C.L. Lai (Hsin-Chu, TW)
Quality of life after renal denervation: EuroQoL 5 dimensions (EQ-5D) outcomes at 12 months in the P2846
Global SYMPLICITY Registry.
– J. Weil, I. Kindermann, G. Mancia, F. Mahfoud, M. Böhm (Lübeck and Homburg, DE; Milan, IT)
The effect of low sodium dialysate on ambulatory blood pressure measurement parameters in patients P2847
undergoing hemodialysis.
– S. Akdag, A. Akyol, H.A. Cakmak, A.R. Tosu, M. Asker, M. Yaman, Y. Soyoral, B. Yegin, A.K. Gor,
H.A. Gumrukcuoglu (Van, Rize, Istanbul and Samsun, TR)
Obstructive sleep apnea using watch-pat 200 is independently associated with an increase in the morning P2848
blood pressure surge in never-treated hypertensive patients.
– J.S. Cho, S.H. Her, S.H. Ihm, C.J. Kim, M.W. Park, G.M. Park, T.S. Kim (Seoul, KR)
184
SUNDAY 30 AUGUST 2015 – EVENING SESSIONS
18:30–19:30 | Rabat - Village 1

CLINICAL USEFULNESS OF POLYPILL IN DEVELOPED COUNTRIES: FROM THE Satellite Symposium
CONCEPT TO THE REALITY
Sponsored by Ferrer
Chairperson(s): V. Fuster (New York, US)
18:30 How to cope with secondary prevention after a cardiovascular event. A worldwide problem. 2849
– A. Wood (Vancouver, CA)
18:45 Importance of adherence in improving outcomes in secondary cardiovascular prevention. 2850
– M. Castellano (New York, US)
19:05 The Polypill: a reality in cardiovascular disease prevention and treatment. 2851
18:30–20:00 | Bratislava & San Marino - Village 2

LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) MANAGEMENT – CAN WE Satellite Symposium
REDEFINE WHAT IS POSSIBLE?
Sponsored by SANOFI and REGENERON
Chairperson(s): K.K. Ray (London, UK); J.J.P. Kastelein (Amsterdam, NL)
18:30 Treat-to-target: concept or reality? 2852
19:00 Reaching new levels of low LDL-C: where is the limit? 2853
SUNDAY – EVENING
19:30 Can future therapies redefine what is possible for patients? 2854
– R.H. Eckel (Denver, US)
Monday 31 August, 10:15–10:45 in Green Park (The Hub)!
18:30–19:30 | Kiev - Village 3

DUAL ANTIPLATELET TREATMENT DURATION IN ACUTE CORONARY SYNDROME (ACS) Satellite Symposium
– PERCUTANEOUS CORONARY INTERVENTION (PCI): ONE FOR ALL OR ALL FOR ONE?
Chairperson(s): G.M. Montalescot (Paris, FR)
18:30 Introduction - Acute Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one 2855
for all or all for one?
18:35 Messages from the Dual Antiplatelet Therapy (DAPT) Study - What do I need to know? 2856
– K. Garratt (Rochester, US)
18:55 Finding the right balance between ischemic event and bleeding risk in patients after ACS-PCI. 2857
– M. Nakamura (Tokyo, JP)
19:15 Discussion - Summary and closing remarks - Dual antiplatelet treatment duration in Acute 2858
Coronary Syndrome (ACS) - Percutaneous Coronary Intervention (PCI): one for all or all for one?

APPRAISAL OF THERAPIES IN ANGINA MANAGEMENT EBAC Accredited Educational Programme
Organised by University Hospital Zurich. Course Director: Thomas Luscher
Chairperson(s): K.M. Fox (London, UK); T.F. Luscher (Zurich, CH)
18:30 Introduction - Appraisal of therapies in angina management. 2859
18:37 Multiple approaches in angina management. 2860
– K.M. Fox (London, UK)
19:02 Breaking the disabling ischemia cycle. 2861
19:27 What still needs to be clarified in stable angina management? 2862
19:52 Conclusion - Appraisal of therapies in angina management. 2863
– K.M. Fox (London, UK)
185
18:30–19:15 | Oslo - Village 6

FINDING THE HOLY GRAIL OF ATRIAL FIBRILLATION (AF) ABLATION Satellite Symposium
Sponsored by Medtronic
Chairperson(s): D.L. Packer (Rochester, US); E. Hoffmann (Munich, DE)
18:30 What have we learned after 10 years and 120,000 cryoballoon procedures. 2864
– R. Schilling (London, UK)
18:45 A new era for atrial fibrillation ablation: rationale of the FIRE and ICE study. 2865
19:00 What does the future hold for AF patients? 2866
– P. Brugada Terradellas (Brussels, BE)

EXPLORING THE UNIVERSE OF ORAL ANTICOAGULATION IN PATIENTS WITH Satellite Symposium
NON-VALVULAR ATRIAL FIBRILLATION: CONTINUING THE JOURNEY
Sponsored by BMS-Pfizer Alliance
Chairperson(s): G.Y.H. Lip (Birmingham, UK); S.H. Hohnloser (Frankfurt am Main, DE)
18:30 What have we learned and how can we advance antithrombotic treatment further? 2867
18:35 Improving patient outcomes: how has the treatment landscape evolved? 2868
18:50 Overcoming the dilema of stroke vs bleeding risk. 2869
– S.H. Hohnloser (Frankfurt am Main, DE)
19:10 Exploring real-world evidence for oral anticoagulation. 2870
19:30 Optimising oral anticoagulation in routine clinical practice. 2871
19:50 The journey continues: future perspectives on improving patient care. 2872

TRANSLATING EUROPEAN SOCIETY OF CARDIOLOGY (ESC) ACUTE PULMONARY Satellite Symposium
EMBOLISM (PE) GUIDELINES INTO CLINICAL PRACTICE
Sponsored by Bayer HealthCare
Chairperson(s): A.G.G. Turpie (Dundas, CA); S.V. Konstantinides (Mainz, DE)
18:30 Welcome and Introduction - Translating European Society of Cardiology (ESC) Acute Pulmonary 2873
Embolism (PE) Guidelines into clinical practice.
– A.G.G. Turpie (Dundas, CA)
18:35 Assessing the severity of Acute PE. 2874
– D. Jimenez (Madrid, ES)
18:50 Facilitating the outpatient management of Acute PE patients. 2875
– L. Howard (London, UK)
19:05 Multidisciplinary management and follow-up of Acute PE patients. 2876
– S.V. Konstantinides (Mainz, DE)
19:20 Panel Discussion, Q&A and Closing - Translating European Society of Cardiology (ESC) Acute 2877
Pulmonary Embolism (PE) Guidelines into clinical practice.
– A.G.G. Turpie (Dundas, CA)
186
18:30–20:00 | Bern - Village 9

STABLE CORONARY ARTERY DISEASE (SCAD) MANAGEMENT: IS THE HEMODYNAMIC Satellite Symposium
APPROACH STILL VALID?
Sponsored by The Menarini Group
Chairperson(s): A.J. Camm (London, UK); J.L. Lopez-Sendon (Madrid, ES)
18:30 Introduction - Stable Coronary Artery Disease (SCAD) management: is the hemodynamic 2878
approach still valid?
18:35 SCAD: where we are? 2879
– J.L. Lopez-Sendon (Madrid, ES)
19:00 HR reduction and clinical outcomes. 2880
– S. Bangalore (New York, US)
19:25 The advantage of being hemodinamically independent. 2881
19:50 Final discussion and conclusion - Stable Coronary Artery Disease (SCAD) management: is the 2882
hemodynamic approach still valid?

TREATMENT OF HYPERTENSION IN NEW FRONTIERS Satellite Symposium
Sponsored by Novartis Pharmaceuticals
SUNDAY – EVENING
Chairperson(s): B. Williams (London, UK); G.T. McInnes (Glasgow, UK)
18:30 Introduction - Treatment of hypertension in new frontiers. 2883
18:40 Hypertension management across borders. 2884
– G.T. McInnes (Glasgow, UK)
19:00 Challenges of treating hypertension in China. 2885
– J. Wang (Shanghai, CN)
19:20 Reaching blood pressure control in Asia and the Middle East-real world data. 2886
– J. Sison (Makati City, PH)
19:40 Closing remarks and Q&A - Treatment of hypertension in new frontiers. 2887
– B. Williams (London, UK), G.T. McInnes (Glasgow, UK)
187
NOTES
188
MONDAY
31 AUGUST
MONDAY



MONDAY 31 AUGUST 2015 – MORNING SESSIONS


EXERCISE FOR HEART FAILURE IN THE MORNING Science@Breakfast
Chairperson(s): T. Jaarsma (Norrköping, SE); M.C. Deaton (Cambridge, UK)
07:30 Is there an ideal exercise modality? 2888
– M. Halle (Munich, DE)
07:52 Exercise prescription for the frail, elderly and unstable patients? 2889

NEW TECHNOLOGY: GENOME EDITING FOR MODELLING AND CORRECTING HUMAN Science@Breakfast
DISEASE
Chairperson(s): S.E. Harding (London, UK)
07:30 New technology; genome editing for modelling and correcting human disease. 2890
– T.R. Webb (Leicester, UK)

ARTIFICIAL INTELLIGENCE: SMARTPHONE APPLICATIONS TO IMPROVE CLINICAL Science@Breakfast
PRACTICE
Chairperson(s): L. Correia (Rio de Janeiro, BR); M. Wallner (Graz, AT)
07:30 Useful applications for the cardiologist. 2891
– J.J. Gomez de Diego (Madrid, ES)
07:52 Which applications to “prescribe” to my patients? 2892

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION: SURGICAL OR Science@Breakfast
INTERVENTIONAL TREATMENT?
Chairperson(s): I.M. Lang (Vienna, AT); M. Delcroix (Leuven, BE)
07:30 Pulmonary endarterectomy is the best option for most patients. 2893
– D. Jenkins (Cambridge, UK)
07:52 Balloon pulmonary angioplasty – A smart solution for non-operable patients? 2894
– A.K. Andreassen (Oslo, NO)

THE BEAUTY OF IMAGING HEART MECHANICS Science@Breakfast
Chairperson(s): H.J. Ukkonen (Turku, FI); A.A. Pasquet (Brussels, BE)
07:30 Imaging assessment of the left ventricule. 2895
– J.U. Voigt (Leuven, BE)
07:52 Imaging assessment of the right ventricule. 2896
– P. Nihoyannopoulos (London, UK)

ESC GUIDELINES – VENTRICULAR ARRHYTHMIAS & SUDDEN CARDIAC DEATH Main Session
Chairperson(s): S.G. Priori (Pavia, IT); C. Blomstrom-Lundqvist (Uppsala, SE)
08:30 Coronary artery disease. 2897
08:52 Left ventricular dysfunction. 2898
– D.J. van Veldhuisen (Groningen, NL)
09:15 Genetic arrhythmias. 2899
09:37 Ventricular tachycardias and ventricular fibrillation in structurally normal hearts. 2900
190

HIGHLIGHTS FROM THE NEW ENGLAND JOURNAL OF MEDICINE: EDITORS’ CHOICE Symposium
ESC and the NEJM
Chairperson(s): J. Jarcho (Boston, US); F. Van de Werf (Leuven, BE)
08:30 Angiotensin/Neprolysin Inhibition in heart failure – Represented in NEJM by the PARADIGM-HF 2901
trial.
08:42 PCSK9 Inhibitors for Hyperlipidemia – Represented in NEJM by the OSLER and ODYSSEY trials. 2902
– E. Stein (Chicago, US)
08:55 Dual Antiplatelet Therapy – Represented in NEJM by the DAPT and PEGASUS trials. 2903
09:21 Radiofrequency Ablation for Atrial Fibrillation – Represented in NEJM by the MANTRA-PAF trial. 2904
09:34 Primary Prevention of Cardiovascular Disease with the Mediterranean Diet – Represented in 2905
NEJM by the PREDIMED trial.
– R. Estruch (Barcelona, ES)
09:47 Novel Oral Anticoagulants for Atrial Fibrillation – Represented in NEJM by the ENGAGA, 2906
ARISTOTLE, ROCKET and RE-LY trials.
– L.C. Wallentin (Uppsala, SE)

LONG-TERM OUTCOME AFTER PCI Rapid Fire Abstract
Chairperson(s): K. Kozuma (Tokyo, JP); U.P. Kaufmann (Berne, CH)
08:30 Predictors of long-term outcomes following saphenous vein graft intervention: an observational 2907
analysis of 1,310 patients from the British Columbia cardiac registry.
– M.B. Iqbal, I.J. Nadra, D. Ayers, A. Fung, E. Aymong, A.W. Chan, S. Hodge, A. Della Siega, S.D. Robinson
(Victoria, Vancouver and Kelowna, CA)
08:39 Very long-term (10 to 14 years) outcomes after implantation of bare-metal stent. 2908
– K. Yamaji, H. Shiomi, T. Morimoto, T. Kimura (Kitakyushu, Kyoto and Nishinomiya, JP)
08:48 Long-term clinical outcomes of STEMI patients treated with BVS. 2909
– C.M. Felix, J.M. Fam, Y. Ishibashi, R. Diletti, Y. Onuma, B. Everaert, E. Regar, N.M.D.A. Van Mieghem,
F. Zijlstra, R.J.M. Van Geuns (Rotterdam, NL)
08:57 Long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial 2910
infarction.
MONDAY – MORNING
– K. Kyhl, J. Lonborg, N. Vejlstrup, H. Kelbaek, H.E. Botker, L. Kober, M. Treiman, T. Engstrom (Copenhagen
and Aarhus, DK)
09:06 The longest available clinical follow-up of a cohort of real-world patients treated exclusively with 2911
drug-eluting stents.
– J.R. Costa Jr, A.G.M.R.S. Sousa, A.C.M. Moreira, R.A.C. Costa Jr, M.N.C. Cano, G.A.M. Maldonado,
J.E.S. Sousa (São Paulo, BR)
09:15 Differential prognostic impact between 1st and 2nd generation drug-eluting stents in coronary 2912
bifurcation lesions: pooled analysis of the COBIS II, Excellent, and Resolute-Korea registies.
– K.J. Kim, J.M. Lee, J.Y. Hahn, K.W. Park, W.J. Chun, S.W. Rha, C.W. Yu, J.O. Jeong, B.K. Koo, H.S. Kim
(Seoul, Changwon and Daejeon, KR)
09:24 Predictors of late coronary thrombotic events after percutaneous coronary intervention: insights 2913
from the PARIS registry.
– G. Giustino, S. Sartori, C. Ariti, J.B. Hermiller, D.J. Cohen, S. Pocock, R. Waksmann, A. Kini, A. Colombo,
R. Mehran (New York, Indianapolis, Boston and Washington, US; London, UK; Milan, IT)
09:33 Relative survival and excess mortality following unprotected left main stem percutaneous 2914
coronary intervention: a national cohort study of 11079 emergent and elective cases.
– O.A. Alabas, S. Almudarra, R.A. Brogan, M.J. Rutherford, T.B. Dondo, M. Van Laar, N. Curzen, M. De
Belder, P. Ludman, C.P. Gale (Leeds, Leicester, Southampton, Middlesbrough and Birmingham, UK)
09:42 The optimal duration of dual antiplatelet therapy in patients receiving percutaneous coronary 2915
intervention with drug-eluting stents.
– O. Sheyin, X. Perez, B. Pierre-Louis, D. Kurian (New York, US)
09:51 1-year angiographic and 5-year clinical outcome of cobalt-chromium everolimus-eluting versus 2916
zotarolimus-eluting coronary stents in patients with multivessel CAD.
– I. Pershukov, A. Omarov, T. Batyraliev, J. Ramazanov, Z. Karben, B. Sidorenko (Voronezh and Moscow,
RU; Almaty, KZ; Gaziantep, TR; Baku, AZ)
191

MOBILE HEALTH AND TECHNOLOGY: THE FUTURE TECHNICAL ENVIRONMENT FOR Symposium
PREVENTION?
Chairperson(s): K. Berra (Menlo Park, US); C.S. Jennings (London, UK)
08:30 Mobile technology and rural primary care: the SMART trial. 2917
– D. Heaney (Edinburg, UK)
08:52 Informatic oriented exercise training in cardiovascular disease: the EXPERT flowchart. 2918
– D.R.M.J. Hansen (Hasselt, BE)
09:15 Mobile phone diabetes care program: improves glycemic control and saves costs. 2919
– M. Peek (Chicago, US)
09:37 Heart failure and ageing: “isolation” telemonitoring. 2920
– S. Winkler (Berlin, DE)

LOOKING AT THE CRYSTAL BALL: WHAT WILL CHANGE THE FUTURE OF CARDIOLOGY? Symposium
Chairperson(s): J. Stepinska (Warsaw, PL); J. Gorcsan (Pittsburgh, US)
08:30 Arrhythmias. 2921
08:52 Coronary artery disease. 2922
09:15 Valvular heart disease. 2923
– A. Cribier (Rouen, FR)
09:37 Environment and cardiovascular disease. 2924

HOT TOPICS IN CONGENITAL HEART DISEASE Rapid Fire Abstract
Chairperson(s): A. Eicken (Munich, DE); G.D. Webb (Cincinnati, US)
08:30 Mortality risk in children and young adults with congenital heart disease in Sweden. 2925
– Z. Mandalenakis, A. Rosengren, G. Lappas, P. Eriksson, K. Skoglund, M. Dellborg (Gothenburg, SE)
08:39 Down syndrome and congenital heart disease: surgical therapy, development of eisenmenger 2926
syndrome and survival in 1,549 patients from the German national register for congenital heart
defects.
– M.-A. Koerten, P. Helm, H. Abdul-Khaliq, H. Baumgartner, D. Kececioglu, C. Schlensak, U.M.M. Bauer,
G.P. Diller (Berlin, Homburg, Münster, Bad Oeynhausen and Tübingen, DE)
08:48 NOACs, Are they safe in congenital heart disease? First results of an international multicenter 2927
registry.
– H. Yang, G.T.J. Sieswerda, M. Ladouceur, D. Tobler, M. Schwerzmann, T. Rutz, M. Greutmann,
G. Scognamiglio, B.J. Bouma, B.J.M. Mulder (Amsterdam and Utrecht, NL; Paris, FR; Basel, Berne,
Lausanne and Zurich, CH; Naples, IT)
08:57 Prognostic value of NT-proBNP after atrial redirection surgery. 2928
– M. Westhoff-Bleck, E. Podewski, O. Tutarel, D. Wenzel, C. Capello, H. Bertram, J. Bauersachs, J. Widder
(Hannover and Munich, DE)
09:06 Cardiopulmonary adaptation to short-term high altitude exposure in adult Fontan patients. 2929
– M. Schwerzmann, R. Staempfli, M. Trovato, P. Eser, L. Trachsel, C. Thomet, K. Wustmann, C. Deluigi,
M. Wilhelm, J.P. Schmid (Berne, CH)
09:15 Does fontan circulation engender progressive liver dysfunction? 2930
– G. Ferraro, D. Marini, R. Bordese, S. Gala, P.L. Calvo, C. Pace Napoleone, G. Agnoletti (Turin, IT)
09:24 Left ventricular function as a predictor for long-term outcomes in marfan syndrome. 2931
– D. Van Der Linde, F. Loeper, P.G. Bannon, M. Vallely, M. Wilson, R.W. Jeremy (Sydney, AU)
09:33 Super flexible replicas of complicated congenital heart disease employing with stereolithography 2932
and vacuum casting -a reliable simulator for surgical operation.
– I. Shiraishi, K. Kurosaki, S. Kanzaki, T. Hoashi, K. Kagizaki, H. Ichikawa (Suita and Osaka, JP)
09:42 Right atrial flow patterns in the normal heart - a new clue in the patent foramen ovale and 2933
cryptogenic stroke story.
– J. Kakarla, J.D. Parikh, K.G. Hollingsworth, B. Keavney, G.A. Ford, J.J. O’Sullivan, A.M. Blamire, L. Coats
(Newcastle-upon-Tyne, Manchester and Oxford, UK)
09:51 Lifelong endocarditis prophylaxis for congenital heart disease patients with prosthetic material? 2934
– J.M. Kuijpers, F.J. Meijboom, P.G. Pieper, H.W. Vliegen, E.O.F. Van Gorselen, M.S. Hulsbergen-Zwarts,
B.J.M. Mulder, B.J. Bouma (Amsterdam, Utrecht, Groningen, Leiden, Doetinchem and Tilburg, NL)
192

THE INCREASING EVIDENCE FOR CARDIAC REHABILITATION Rapid Fire Abstract
Chairperson(s): M.C. Deaton (Cambridge, UK); J. Niebauer (Salzburg, AT)
08:30 Is cardiac rehabilitation (CR) safe and useful in octogenarians after transcatheter aortic valve 2935
implantation (TAVI) compared to surgical aortic valve replacement (sAVR) for aortic stenosis?
– F. Tarro Genta, E. Eleuteri, F. Bertolin, Z. Bouslenko, C. Taglieri, M. Tidu, P. Giannuzzi (Turin and Veruno, IT)
08:39 Secondary prevention after myocardial infarction widens health disparities between Swedish and 2936
immigrant patients.
– K. Bragason, S. Zdravkovic, P. Tyden, M. Leosdottir (Malmö, SE)
08:48 Optimizing patient benefit from CRT response with the addition of high intensity interval training - 2937
a randomized controlled trial.
– R. Pinto, A. Abreu, V. Santos, X. Melo, P. Cunha, M. Oliveira, R. Soares, R. Ferreira, B. Fernhall,
H. Santa-Clara (Lisbon, PT; Chicago, US)
08:57 Comprehensive rehabilitation for patients treated for atrial fibrillation with ablation; Results from 2938
the CopenHeartRFA randomized trial.
– S.S. Risom, A.D.Z. Zwisler, J.H.S. Svendsen, T.B.R. Rasmussen, K.L.S. Sibilitz, T.L.S.M. Madsen,
C.G. Gluud, J.L. Lindschou, P.W. Winkel, S.K.B. Berg (Copenhagen and Odense, DK)
09:06 Exercise-based cardiac rehabilitation after heart valve surgery: cost analysis of health care use 2939
and sick leave.
– T.B. Hansen, A.D. Zwisler, S.K. Berg, K.L. Sibilitz, L.C. Thygesen, P. Doherty, R. Soegaard (Roskilde,
Odense, Copenhagen and Aarhus, DK; York, UK)
09:15 Effectiveness of cardiac rehabilitation in patients with type 2 diabetes mellitus after percutaneous 2940
– M.J. Romero Reyes, N. Cobo Gomez, P. Escane Duarte, R. Picon Heras, R. Guerola Segura, F.J. Molano
Casimiro, L. Pastor Torres (Seville, ES)
09:24 Women’s risk factor control by cardiac rehabilitation program model: a randomized controlled 2941 (W)
trial. (withdrawn)
– S.L. Grace, L. Midence, H.M. Arthur, P. Oh (Toronto and Hamilton, CA)
09:33 Sleep disordered breathing in cardiac rehabilitation: prevalence, predictors and influence on 2942
six-minute walk test.
– G. Loo, A.P. Chua, H.Y. Tay, R. Poh, B.C. Tai, C.H. Lee (Singapore, SG)
09:42 Clinical predictors of exercise-induced regression of coronary atherosclerosis: a serial 2943
intravascular ultrasonography study.
– E. Madssen, V. Videm, T. Moholdt, U. Wisloff, K. Hegbom, R. Wiseth (Trondheim, NO)
09:51 Effect of exercise training on functional capacity and oxygen uptake kinetics in patients with 2944
MONDAY – MORNING
restrictive cardiomyopathy.
– A.L. Sayegh, M.R. Dos Santos, F.R. De Souza, I.R.P. Amorim, V.C. Salem, E. Rondon, C.E. Negrao,
C. Mady, M.J.N.N. Alves (São Paulo, BR)
08:30–10:00 | Rabat - Village 1

OLIGONUCLEOTIDE AND MIRNAS THERAPEUTICS FOR CARDIOVASCULAR REPAIR Symposium
Chairperson(s): M. Mayr (London, UK); P. Ferdinandy (Budapest, HU)
08:30 Non coding RNA as therapy for heart failure. 2945
– L.J. De Windt (Maastricht, NL)
08:52 miRNAs in cardiac function and survival. 2946
– E. Van Rooij (Utrecht, NL)
09:15 miRNAs in vascular cell therapy. 2947
– L. Maegdefessel (Stockholm, SE)
09:37 miRNAs inducing cardiac regeneration. 2948
– M. Giacca (Trieste, IT)

NOVEL GENETIC PATHWAYS INVOLVED IN CARDIAC ARRHYTHMIAS Symposium
Chairperson(s): B. Casadei (Oxford, UK); S. Hatem (Paris, FR)
08:30 Genetic, transcriptional and functional analyses to identify genes for atrial fibrillation. 2949
– M.F. Sinner (Munich, DE)
08:52 Genetic basis of cardiac fibrosis. 2950
– J. Diez Martinez (Pamplona, ES)
09:15 Novel genes linked to Brugada syndrome. 2951
– P. Brugada Terradellas (Brussels, BE)
09:37 Insights from GWAS in cardac arrhythmias. 2952
– X. Jouven (Paris, FR)
193

MANAGING THE MIND FOR IMPROVED CARDIOVASCULAR OUTCOMES Symposium
Chairperson(s): M.E. Cupples (Belfast, UK); S. Gielen (Halle, DE)
08:30 Uncovering depression: reading patients’ minds. 2953
– M.M.N. Abreu (Lisbon, PT)
08:52 Stress: what does it mean to our patients? 2954
– C. Albus (Cologne, DE)
09:15 Is happiness good for the heart? 2955
– N. Rebelo da silva (Lisbon, PT)
09:37 Behavioural cardiology - Its time has come. 2956
– D.L. Hare (Melbourne, AU)

MEDICATION IN CARDIOVASCULAR PATIENTS -THE ASSUMED RISK... Meet the Experts
Chairperson(s): N.D. Wong (Irvine, US); E. Agabiti-Rosei (Brescia, IT)
08:30 Medication in cardiovascular patients -The assumed risk... - Introduction to the session. 2957
– N.D. Wong (Irvine, US)
08:35 Antidiabetic drugs and cardiovascular risk. 2958
– E. Standl (Munich, DE)
08:45 Antidiabetic drugs and cardiovascular risk - Panel discussion and questions from the audience. 2959
– E. Standl (Munich, DE), C.M. Yu (Hong Kong, HK), N. Sattar (Glasgow, UK), D. Gaita (Timisoara, RO)
09:00 Statin - Still the best preventive drug? 2960
09:10 Statin - Still the best preventive drug? Panel discussion and questions from the audience. 2961
– L. Sperling (Atlanta, US), G.P. Tatu-Chitoiu (Bucharest, RO), M. Livingston (Abingdon, UK), C.M. Yu (Hong
Kong, HK)
09:25 Antihypertensive drugs and their metabolic disturbances. 2962
– S.E. Erdine (Istanbul, TR)
09:35 Antihypertensive drugs and their metabolic disturbances - Panel discussion and questions from 2963
the audience.
– S.E. Erdine (Istanbul, TR), G.P. Tatu-Chitoiu (Bucharest, RO), C.M. Yu (Hong Kong, HK), J. Redon
(Valencia, ES)
09:50 Medication in cardiovascular patients - The assumed risk... - Take home message. 2964
– E. Agabiti-Rosei (Brescia, IT)

SPORTS CARDIOLOGY IN DEVELOPMENT Advances in Science
Chairperson(s): F. Carre (Rennes, FR); H. Heidbuchel (Hasselt, BE)
08:30 State of the Art in electrocardiogram interpretation of the young athlete’s electrocardiogram: 2965
journey to perfection.
08:50 High aerobic capacity is associated with increased survival. A 44 years follow-up of the study of 2966
men born in 1913.
– P. Ladenvall, C. Persson, Z. Mandalenakis, L. Wilhelmsen, G. Grimby, K. Svardsudd, P.-O. Hansson
(Gothenburg and Uppsala, SE)
09:07 Effect of gender and sporting discipline on left ventricular adaptation to exercise. 2967
– G. Finocchiaro, M. Papadakis, H. Dhutia, A.K. Steriotis, A. D’Silva, A. Malhotra, S. Sharma (London, UK)
09:24 The relationship between the dose of exercise and coronary artery calcification in veteran 2968
athletes.
– A. Merghani, K. Alfakih, K. Patel, V. Maestrini, S. Rosmini, A. Cox, H. Dhutia, R. Narain, J. Moon, S. Sharma
(London, UK)
09:41 Future direction for research in life long endurance sport and the heart: back to the future. 2969
– A. La Gerche (Melbourne, AU)
194
08:30–10:00 | Kiev - Village 3

ARE CLINICAL GUIDELINES THE STANDARD OF CARE IN REAL PRACTICE? Guidelines in Daily Practice
Chairperson(s): C.W. Hamm (Bad Nauheim, DE); K.F. Fox (London, UK)
08:30 Young sportsman with mild hypertension and sudden cardiac death. 2970
– L. Monserrat (A Coruña, ES)
08:45 Young sportsman with mild hypertension and sudden cardiac death - What do the Guidelines say 2971
about evaluating such patients and preventing SCD?
– P.G. Pieper (Groningen, NL)
09:00 Young sportsman with mild hypertension and sudden cardiac death - Panel discussion on how to 2972
implement the Guidelines to prevent sudden death.
– M.A. Losi (Naples, IT), P.M. Elliott (London, UK)
09:10 Young sportsman with mild hypertension and sudden cardiac death - Conclusion and take home 2973
message.
– K.F. Fox (London, UK)
09:15 A case of severe angina non suitable for revascularisation. 2974
– R. Fontes Carvalho (Porto, PT)
09:30 A case of severe angina non suitable for revascularisation - What do the Guidelines say? 2975
09:45 A case of severe angina non suitable for revascularisation - Panel discussion on how to 2976
implement the Guidelines.
– J.L. Lopez-Sendon (Madrid, ES), R. Mehran (New York, US)
09:55 A case of severe angina non suitable for revascularisation - Conclusion and take home message. 2977
– To be announced

THE HEART IN HYPERTENSION Symposium
Chairperson(s): T. Kahan (Stockholm, SE); T.M. MacDonald (Dundee, UK)
08:30 Pathophysiology of the hypertensive heart. 2978
08:52 Hypertensive heart disease in women and men. 2979
– E. Gerdts (Bergen, NO)
09:15 Impact of obesity on hypertensive heart disease. 2980
– G. de Simone (Naples, IT)
09:37 Atrial fibrillation - Risk factor or trigger for HFpEF. 2981
MONDAY – MORNING
– K. Wachtell (Oslo, NO)

CRT/ICD – TO IMPLANT OR NOT TO IMPLANT? THAT IS THE QUESTION Symposium
Chairperson(s): J.C. Daubert (Rennes, FR); C. Linde (Stockholm, SE)
08:30 CRT or right ventricular in patients with high degree AV block? 2982
– J.-J. Blanc (Brest, FR)
08:52 CRT or RV pacing in the patient with sinus node disease, AV block I and RBBB? 2983
– M. Glikson (Ramat Gan, IL)
09:15 To replace or not an ICD at time of battery depletion? 2984
– M. Gasparini (Rozzano, IT)
09:37 The heart failure CRT responder with CRT-D: CRT or CRT-D at the time of replacement. 2985
– J. Singh (Boston, US)

GENETICS ASPECTS OF ARRHYTHMIAS Advances in Science
Chairperson(s): A.A.M. Wilde (Amsterdam, NL); C. Gerdes (Aarhus, DK)
08:30 State of the Art in therapy of channelopathies. 2986
– C. Wolpert (Ludwigsburg, DE)
08:50 Role of electrophysiological study for risk stratification of asymptomatic patients with Brugada 2987
syndrome: a meta-analysis.
– S. Stavrakis, R. Lazzara (Oklahoma City, US)
09:07 Worldwide experience with the S-ICD in patients with congenital long QT. 2988
– R. Weiss, B. Knight, S. Kaab, P. Neuzil, P. Sheridan, L. Eckhardt, S. Doshi, H. Mead, M. Hood (Columbus,
Chicago, Santa Monica and Redwood City, US; Munich and Münster, DE; Prague, CZ; Sheffield, UK;
Auckland, NZ)
09:24 ICD in Catecholaminergic Polymorphic Ventricular Tachycardia. (withdrawn) 2989 (W)
– F. Wanguemert Perez, P.M. Ruiz Hernandez, C. Bosch Calero, O. Campuzano Larrea, G.J. Perez,
P. Berne, R. Brugada, J. Brugada (Las Palmas de Gran Canaria, Girona and Barcelona, ES)
09:41 Future direction for research in improving therapy. 2990
195

DISCREPANCIES AMONGST TECHNIQUES IN ASSESSING THE SEVERITY OF VALVULAR Meet the Experts
HEART DISEASE
Chairperson(s): B. Chambers (London, UK); G. Van Camp (Aalst, BE)
08:30 Discrepancies amongst techniques in assessing the severity of valvular heart disease - 2991
Introduction to the session.
– B. Chambers (London, UK)
08:35 A patient with aortic stenosis (AVA 0.7 cm2 ), low gradient and preserved LV function. 2992
– P. Pibarot (Quebec, CA)
08:45 A patient with aortic stenosis (AVA 0.7 cm2 ), low gradient and preserved LV function - Panel 2993
– P. Pibarot (Quebec, CA), G. Maurer (Vienna, AT), M. Garbi (London, UK), L.A. Pierard (Liège, BE)
09:00 A patient with rheumatic mitral and aortic valve disease. 2994
– P. Unger (Brussels, BE)
09:10 A patient with rheumatic mitral and aortic valve disease - Panel discussion and questions from 2995
the audience.
– P. Unger (Brussels, BE), G. Maurer (Vienna, AT), M. Garbi (London, UK), L.A. Pierard (Liège, BE)
09:25 A patient with moderate mitral regurgitation and left ventricular dilatation. 2996
– J. Magne (Limoges, FR)
09:35 A patient with moderate mitral regurgitation and left ventricular dilatation - Panel discussion and 2997
– M. Garbi (London, UK), G. Maurer (Vienna, AT), L.A. Pierard (Liège, BE), J. Magne (Limoges, FR)
09:50 Discrepancies amongst techniques in assessing the severity of valvular heart disease - Take 2998
home message.
– G. Van Camp (Aalst, BE)

CARDIOVASCULAR IMAGING IN HEART FAILURE: A GLOBAL PERSPECTIVE Symposium
Chairperson(s): A. de Paola (São Paulo, BR); F.J. Pinto (Lisbon, PT)
08:30 Heart failure worldwide: a global perspective. 2999
08:52 Advances in echocardiography for heart failure: diagnosis and risk stratification. 3000
– W. Mathias Jr (São Paulo, BR)
09:15 CMR in the differential diagnosis of cardiomyopathies. 3001
– C.E. Rochitte (São Paulo, BR)
09:37 CMR for risk stratification in heart failure. 3002
– C. Bucciarelli-Ducci (Bristol, UK)

TAVI IN 2015: WHERE ARE WE GOING? Symposium
Chairperson(s): C. Tamburino (Catania, IT); C. Naber (Essen, DE)
08:30 The state of TAVI in Europe. 3003
08:52 Safety of TAVI procedures. 3004
– P. Wenaweser (Berne, CH)
09:15 Antithrombotic therapy in TAVI. 3005
– G. Dangas (New York, US)
09:37 Unmet needs and future solutions. 3006
– N. Piazza (Dollard-des-Ormaux, CA)
08:30–10:00 | Oslo - Village 6

HYBRID CORONARY REVASCULARISATION AND LAA EXCLUSION PROCEDURES: A TEAM Symposium
EFFORT!
Chairperson(s): P. Suwalski (Warsaw, PL); E. Teiger (Créteil, FR)
08:30 Hybrid coronary revascularisation, when surgeon and interventional cardiologist have to work 3007
together.
– V. Falk (Berlin, DE)
08:52 Catheter-based systems of left atrial appendage exclusion. 3008
09:15 Modern minimally invasive approaches to left atrial appendage exclusion. 3009
– S. Salzberg (Zurich, CH)
09:37 Hybrid exclusion of the left atrial appendage. 3010
– K. Bartus (Krakow, PL)
196

IMAGING AND MANAGEMENT IN LOW- RISK ACUTE CORONARY SYNDROME Debate Session
Chairperson(s): S. Plein (Leeds, UK); R. Sicari (Pisa, IT)
08:30 Low risk ACS should undergo CT angiography - PRO. 3011
– B. Shivalkar (Edegem, BE)
08:45 Low risk ACS should undergo CT angiography - CONTRA. 3012
– R. Senior (London, UK)
09:00 Low risk ACS should undergo CT angiography - REBUTTAL PRO. 3013
– B. Shivalkar (Edegem, BE)
09:05 Low risk ACS should undergo CT angiography - REBUTTAL CONTRA. 3014
– R. Senior (London, UK)
09:10 Low risk ACS should undergo CT angiography - CONCLUSION. 3015
09:15 Ischaemia versus plaque burden as determinants of prognosis - PRO. 3016
09:30 Ischaemia versus plaque burden as determinants of prognosis - CONTRA. 3017
– T.H. Schindler (Baltimore, US)
09:45 Ischaemia versus plaque burden as determinants of prognosis - REBUTTAL PRO. 3018
09:50 Ischaemia versus plaque burden as determinants of prognosis - REBUTTAL CONTRA. 3019
– T.H. Schindler (Baltimore, US)
09:55 Ischaemia versus plaque burden as determinants of prognosis - CONCLUSION. 3020

DIFFICULT CASES IN ACUTE CORONARY SYNDROMES: REVASCULARISATION IN CLINICAL Meet the Experts
PRACTICE
Chairperson(s): D. Erlinge (Lund, SE); P.H. Kolh (Liège, BE)
08:30 Difficult cases in acute coronary syndromes revascularisation in clinical practice - Introduction to 3021
the session.
– D. Erlinge (Lund, SE)
08:35 NSTEMI case with three vessel disease. 3022
– L. Holmvang (Copenhagen, DK)
08:45 NSTEMI case with three vessel disease - Panel discussion and questions from the audience. 3023
– A. Kastrati (Munich, DE), E. Puymirat (Paris, FR), M. Sousa Uva (Lisbon, PT)
09:00 STEMI case with three vessel disease. 3024
MONDAY – MORNING
– B. Skoric (Zagreb, HR)
09:10 STEMI case with three vessel disease - Panel discussion and questions from the audience. 3025
09:25 STEMI with cardiogenic shock. 3026
– M. Dalby (Harefield, UK)
09:35 STEMI with cardiogenic shock - Panel discussion and questions from the audience. 3027
09:50 Difficult cases in acute coronary syndromes: “revascularisation in clinical practice” - Take home 3028
message.
– P.H. Kolh (Liège, BE)
08:30–10:00 | Tunis - Village 7

ANTITHROMBOTIC DRUGS – AN ONGOING RESEARCH Advances in Science
Chairperson(s): J. Samardzic (Zagreb, HR); J. Silvain (Paris, FR)
08:30 State of the Art in use of antithrombotics in acute coronary syndromes. 3029
08:50 Effect of time to interventional treatment on NSTE-ACS outcomes in PLATO. 3030
– C. Pollack, D. Diercks, S. Husted, S.K. James, P.J. Schulte, S. Sheng, P.G. Steg, L. Wallentin,
A. Himmelmann, C.P. Cannon (Philadelphia, Dallas, Durham and Boston, US; Herning/Holstebro, DK;
Uppsala and Mölndal, SE; Paris, FR)
09:07 Treatment and long-term results of acute coronary syndrome (ACS) in patients on chronic oral 3031
anticoagulants (OAC): data from the EPICOR (NCT01171404) study.
– J. Stepinska, I. Wojtkowska, L. Annemans, N. Danchin, S. Pocock, F. Van De Werf, J. Medina, H. Bueno
(Warsaw, PL; Vub and Leuven, BE; Paris, FR; London, UK; Madrid, ES)
09:24 Efficacy and Safety of Ticagrelor for Long-Term Secondary Prevention of Atherothrombotic 3032
Events in Relation to Renal Function: Insights from the PEGASUS-TIMI 54 trial.
– G. Magnani, M.S. Sabatine, D.L. Bhatt, M. Choen, G. Steg, R. Storey, J. Kuder, S. Murphy, E. Braunwald,
M.P. Bonaca (Boston and Newark, US; Paris, FR; Sheffield, UK)
09:41 Future direction for research in antithrombotics. 3033
197

UPDATE IN MITRAL REGURGITATION Symposium
Chairperson(s): R. Rosenhek (Vienna, AT); A. Poppas (Providence, US)
08:30 Grading of mitral regurgitation by echo. 3034
08:52 Asymptomatic severe mitral regurgitation: should we intervene? 3035
– L.D. Gillam (Morristown, US)
09:15 Percutaneous intervention in mitral regurgitation. 3036
09:37 When to intervene: what do the Guidelines tell us. 3037

ACUTE PULMONARY EMBOLISM: PERSISTING AND NEW CONTROVERSIES Debate Session
Chairperson(s): I.M. Lang (Vienna, AT); N. Meneveau (Besançon, FR)
08:30 Echocardiography and biomarker testing are mandatory in normotensive patients. PRO. 3038
08:45 Echocardiography and biomarker testing are mandatory in normotensive patients. CONTRA. 3039
09:00 Echocardiography and biomarker testing are mandatory in normotensive patients. REBUTTAL 3040
PRO.
09:05 Echocardiography and biomarker testing are mandatory in normotensive patients. REBUTTAL 3041
CONTRA.
09:10 Echocardiography and biomarker testing are mandatory in normotensive patients - CONCLUSION. 3042
09:15 New oral anticoagulants are the new standard of care. PRO. 3043
– H. Buller (Amsterdam, NL)
09:30 New oral anticoagulants are the new standard of care. CONTRA. 3044
– M.D. Ezekowitz (Villanova, US)
09:45 New oral anticoagulants are the new standard of care. REBUTTAL PRO. 3045
– H. Buller (Amsterdam, NL)
09:50 New oral anticoagulants are the new standard of care. REBUTTAL CONTRA. 3046
– S. Schellong (Dresden, DE)
09:55 New oral anticoagulants are the new standard of care - CONCLUSION. 3047

BICUSPID AORTIC VALVE DISEASE – NEW KNOWLEDGE AND OPEN QUESTIONS Advances in Science
Chairperson(s): E. Brochet (Paris, FR); P. Tornos Mas (Barcelona, ES)
08:30 State of the Art in bicuspid aortic valve disease. 3048
– C.M. Otto (Seattle, US)
08:50 Gender differences in the clinical history of adult patients with bicuspid aortic valves. 3049
– H. Michelena, R.M. Suri, O. Katan, M.F. Eleid, M.A. Clavel, M.J. Maurer, P.A. Pellikka, D. Mahoney,
M. Enriquez-Sarano (Rochester, US)
09:07 BAV morphology in relation to coronary vessel dominance and outcome. 3050
– W.M.C. Koenraadt, G. Tokmaji, H.W. Vliegen, A.J.H.A. Scholte, H.M. Siebelink, A.C. Gittenberger-De
Groot, B.J. Mulder, B.J. Bouma, M.J. Schalij, M.R.M. Jongbloed (Leiden and Amsterdam, NL)
09:24 NOTCH1 polymorphisms as a predictor of aortic insufficiency in patients with bicuspid aortic 3051
valve.
– T. Tatarinova, N. Alexeyeva, E. Grekhov, O. Freylikhman, A. Kostareva, O. Moiseeva (St. Petersburg, RU)
09:41 Future direction for research in bicuspid aortic valve disease. 3052
– A. Della Corte (Naples, IT)
08:30–10:00 | Bern - Village 9

CARDIO-ONCOLOGY Symposium
ESC and the InterAmerican Society of Cardiology
Chairperson(s): M. Barbosa (Nova Lima, BR); T. Lopez Fernandez (Madrid, ES)
08:30 A cancer patient on chemotherapy wth LVEF dropping to 40-45%. 3053
– J.A. Lax (Buenos Aires, AR)
08:52 Left ventricular dysfunction and heart failure. 3054
– J.C. Plana (Houston, US)
09:15 Cancer and venous thromboembolic disease. 3055
– G. Agnelli (Perugia, IT)
09:37 Cardiac arrhythmias. 3056
– E. Arbelo (Barcelona, ES)
198

TIPS & TRICKS ON HOW TO TREAT ACUTE HEART FAILURE Meet the Experts
Chairperson(s): A. Mebazaa (Paris, FR); M. Gheorghiade (Chicago, US)
08:30 Tips & tricks on how to treat acute heart failure - Introduction to the session. 3057
– A. Mebazaa (Paris, FR)
08:35 Focus on diuretics. 3058
– D. Brito (Lisbon, PT)
08:45 Focus on diuretics - Panel discussion and questions from the audience. 3059
– D. Brito (Lisbon, PT), J.R. Teerlink (San Francisco, US), H. Thiele (Lübeck, DE), M. Jessup (Philadelphia, US)
09:00 Focus on vasodilators. 3060
– J. Masip (Barcelona, ES)
09:10 Focus on vasodilators - Panel discussion and questions from the audience. 3061
– J. Masip (Barcelona, ES), J.R. Teerlink (San Francisco, US), H. Thiele (Lübeck, DE), M. Jessup (Philadelphia,
US)
09:25 Focus on inotropes. 3062
– J.T. Parissis (Athens, GR)
09:35 Focus on inotropes - Panel discussion and questions from the audience. 3063
– J.T. Parissis (Athens, GR), J.R. Teerlink (San Francisco, US), H. Thiele (Lübeck, DE), M. Jessup
(Philadelphia, US)
09:50 Tips & tricks on how to treat acute heart failure - Take home message. 3064

DETECT TO REPAIR DEFICIENT CARDIAC GENES Rapid Fire Abstract
Chairperson(s): J. Hall (Minneapolis, US); S.A. Cook (London, UK)
08:30 Proximal titin A-band truncation causes dilated cardiomyopathy in response to increased 3065
afterload in mice.
– I.G. Lunde, H. Wakimoto, M.A. Burke, V. Soukoulis, W.A. Linke, J. Gorham, D. Conner, G. Christensen,
J.G. Seidman, C.E. Seidman (Boston, US; Bochum, DE; Oslo, NO)
08:39 AAV9-mediated gene transfer of desmin restores cytoskeletal integrity and attenuates 3066
development of cardiomyopathy in desmin-deficient mice.
– M.B. Heckmann, R. Bauer, L. Winter, K.H. Strucksberg, A. Jungmann, R. Schroeder, H.A. Katus,
O.J. Mueller (Heidelberg and Erlangen, DE)
08:48 Performance of the copy number variant (CNV) screening using next generation sequencing in a 3067
MONDAY – MORNING
cohort of inherited cardiac disease patients.
– J. Palomino Doza, D. De Una, C. Gayoso, M.L. Pena Pena, J.P. Ochoa, M. Ortiz, D. Garcia, A. Grana,
O. Martinez De Ilarduya, L. Monserrat (A Coruña, ES)
08:57 The Eya4/Six1 signalling cascade is activated in acquired heart disease. 3068
– T. Williams, D. Oppelt, P. Nordbeck, J. Schoenberger, O. Ritter (Würzburg, DE)
09:06 Immunomodulatory microRNAs expressed in the myocardium predict individual antiviral capacity 3069
in human enteroviral heart disease.
– W. Poller, M. Gast, X. Wang, U. Kuehl, A. Stroux, M. Rohde, C. Skurk, H. Schultheiss, U. Landmesser
(Berlin, DE)
09:15 Can differences in genetic background explain differences in extent of clinical expression of a 3070
disease causing mutation?
– J.A. Jansweijer, K.Y. Van Spaendonck, J.P. Van Tintelen, M.W. Tanck, A.A. Wilde, Y.M. Pinto (Amsterdam
and Groningen, NL)
09:24 Genotype impacts survival in marfan syndrome. 3071
– R. Franken, M. Groenink, V. De Waard, H. Feenstra, A.J. Scholte, M. Van Den Berg, G. Pals,
A.H. Zwinderman, J. Timmermans, B.J.M. Mulder (Amsterdam, Leiden, Groningen and Nijmegen, NL)
09:33 Comprehensive sequencing of dilated cardiomyopathy genes reveals additive effects of multiple 3072
genes on disease risk and severity.
– F. Mazzarotto, R. Walsh, R.J. Buchan, S. John, E.C. Edwards, U. Tayal, S.K. Prasad, P.J.R. Barton,
J.S. Ware, S.A. Cook (London, UK)
09:42 Truncating titin mutations cause a mild and treatable form of dilated cardiomyopathy. 3073
– J.A. Jansweijer, K. Nieuwhof, F. Russo, M.P. Van Den Berg, A.A.M. Wilde, R.A. De Boer, K.Y. Van
Spaendonck, J.P. Van Tintelen, Y.M. Pinto (Amsterdam and Groningen, NL)
09:51 Genetics of noncompaction cardiomyopathy (NCCM). 3074
– J.I. Van Waning, K. Caliskan, M. Michels, A.F.M. Schinkel, M.A. Slegtenhorst, D.F. Majoor-Krakauer
(Rotterdam, NL)
199

DIFFERENT ASPECTS IN MANAGEMENT OF ATRIAL FIBRILLATION Moderated Posters
Chairperson(s): P. Kulakowski (Warsaw, PL); H. Kottkamp (Zurich, CH)
10:00 Invasive treatment strategies of iatrogenic pulmonary vein stenosis in patients after atrial P3075
fibrillation ablation.
– L.A. Geller, G. Szeplaki, V.K. Nagy, T. Tahin, S.Z. Szilagyi, I. Osztheimer, N. Szegedi, E.E. Ozcan,
P. Maurovich-Horvath, B. Merkely (Budapest, HU)
10:08 How common is normal renal function among patients with atrial fibrillation? P3076
– S.D. Pokorney, P. Shrader, J. Ansell, G.C. Fonarow, B. Gersh, P.R. Kowey, R.G. Blanco, K.W. Mahaffey,
J.P. Piccini, E.D. Peterson (Durham, New York, Los Angeles, Rochester, Wynnewood and Palo Alto, US)
10:17 Association between permanent atrial fibrillation and cognitive impairment: insights from a cohort P3077
of 902 patients with chronic heart failure.
– B. Benito, C. Enjuanes, E. Valles, A. Perez, P. Poveda, D. Bas, A. Garcia-Elias, M. Tajes, J. Marti-Almor,
J. Comin-Colet (Barcelona, ES)
10:25 Progression to asymptomatic atrial fibrillation as a prognostic index: the Euro Heart Study. P3078
– F. Guerra, M. Brambatti, E. Dudink, R. Nieuwlaat, H.J. Crijns, A. Capucci (Ancona, IT; Maastricht, NL;
Hamilton, CA)
10:34 Relationship between reduced left atrial function and electro-anatomical remodeling in patients P3079
undergoing atrial fibrillation ablation.
– A.S. Parwani, D.A. Morris, M. Huemer, A. Wutzler, P. Attanasio, F. Blaschke, B. Pieske, W. Haverkamp,
L.H. Boldt (Berlin, DE)
10:42 CHA2DS2-VASc score predicts in-hospital mortality beyond GRACE score after acute myocardial P3080
infarction.
– K. Stamboul, L. Fauchier, V. Yameogo, G. Cartigny, A. Gudjoncik, L. Lorgis, J.C. Beer, C. Touzery,
M. Zeller, Y. Cottin (Dijon and Tours, FR)
10:51 Atrial fibrillation after coronary artery bypass surgery: can ivabradine reduce its occurrence? P3081
– Z. Abdel-Salam, W. Nammas (Cairo, EG)

EXPERIMENTAL AND CLINICAL RESEARCH IN MYOCARDIAL ISCHAEMIA Moderated Posters
Chairperson(s): Y. Huo (Beijing, CN); T.W. Weiss (Vienna, AT)
10:00 Pharmacological evaluation of novel adenine-hydrogen sulfide slow release hybrids designed as P3082
multi-target cardioprotective agents.
– N. Lougiakis, A. Papapetropoulos, S. Toumpas, A. Zoga, Z. Zhou, N. Pouli, P. Marakos, E. Gikas,
E.K. Iliodromitis, I. Andreadou (Athens, GR)
10:08 Tenascin-C regulates inflammatory response and aggravate ventricular remodeling after P3083
myocardial infarction in mice model.
– T. Kimura, A. Sato, S. Sakai, K. Tajiri, M. Hiroe, K. Imanaka, T. Yoshida, K. Aonuma (Tsukuba, Tokyo and
Tsu, JP)
10:17 Endothelial nitric oxide synthase activation as a novel mechanism for nitroglycerin-induced P3084
cardioprotection.
– S.I. Bibli, A. Papapetropoulos, A. Daiber, S. Steven, P. Brouckaert, E.K. Iliodromitis, I. Andreadou (Athens,
GR; Mainz, DE; Ghent, BE)
10:25 Arginase inhibition protects from myocardial ischemia-reperfusion injury in rats with type 1 P3085
diabetes.
– Y. Tratsiakovich, A. Kiss, J. Yang, A.T. Gonon, P.O. Sjoquist, J. Pernow (Stockholm, SE)
10:34 Inflammatory activity of pericoronary adipose tissue in prediabetic patients with NSTE-ACS. P3086
– T. Mazurek, M. Kobylecka, R. Wilimski, J. Kochman, K.J. Filipiak, L. Krolicki, G. Opolski (Warsaw, PL)
10:42 Gamma-Glutamyltransferase Stimulates Tissue Factor Expression Independent of its Enzymatic P3087
Activity in Human Mononuclear Cells.
– V. Scalise, C. Balia, S. Cianchetti, M. Franzini, V. Carnicelli, T. Neri, R. Zucchi, A. Celi, A. Corti, R. Pedrinelli
(Pisa, IT)
10:51 Andexanet alfa reverses edoxaban-induced anticoagulation in a rabbit liver laceration model of P3088
acute bleeding.
– P.R. Pine, S.J. Hollenbach, S. Tan, F. Deguzman, J. Malinowski, P. Pratikhya, G. Lu, J.T. Curnutte,
P.B. Conley (South San Francisco, US)
200

CARDIOVASCULAR MAGNETIC RESONANCE – ISCHAEMIC HEART DISEASE Moderated Posters
Chairperson(s): E. Mc Alindon (Wes Midlands, UK); P. Pedrotti (Milan, IT)
10:00 Impact of sleep apnea on severe microvascular dysfunction assessed by cardiovascular magnetic P3089
resonance after primary angioplasty in patients with acute myocardial infarction.
– K. Tamita, A. Yamamuro, E. Hyodo, T. Iwamura, M. Maeda, T. Tokuda, K. Moribayashi, T. Nagaura
(Nishinomiya, JP)
10:08 Safety of anticoagulation withdrawal guided by magnetic resonance in STEMI patients with left P3090
ventricular thrombus.
– G. Caldentey, T. Lopez, R. San Antonio, J. Rodriguez, X. Bosch, S. Prat, M. Sitges, T.M. De Caralt,
R.J. Perea, J.T. Ortiz (Barcelona, ES)
10:17 Prognostic significance of global myocardial perfusion reserve measured using coronary sinus P3091
flow during stress cardiovascular magnetic resonance imaging.
– N. Jariwala, M. Bauml, S. Romano, V. Rangarajan, S. Chacko, J. Chung, A. Farzaneh-Far (Chicago, US;
Verona, IT)
10:25 ST-segment depression resolution: correlation with myocardial damage and prognostic value in P3092
patients with STEMI.
– S. Reinstadler, K. Rommel, S. Desch, J. Poess, H. Thiele, I. Eitel (Innsbruck, AT; Leipzig and Lübeck, DE)
10:34 Subendocardial stress perfusion defects on cardiovascular magnetic resonance in patients with P3093
angina and unobstructed coronaries are frequently related to functional coronary vasomotor
abnormalities.
– P.E. Ong, G. Pirozzolo, K. Bentz, A. Athanasiadis, S. Hill, T. Schaeufele, A. Yilmaz, H. Mahrholdt,
U. Sechtem (Stuttgart and Münster, DE)
10:42 Left ventricular thrombus formation in patients with acute reperfused ST-elevation myocardial P3094
infarction - insights from cardiac magnetic resonance.
– J.P. Poess, S.D. Desch, S.D.W. De Waha, H.T. Thiele, I.E. Eitel (Lübeck and Bad Segeberg, DE)
10:51 Long term effect of pulmonary endarterectomy on right ventricular loading conditions in patients P3095
with chronic thromboembolic hypertension by cardiac MRI.
– A. Rolf, W. Kim, S. Stein, J. Rixe, C. Liebetrau, H. Moellmann, H.M. Nef, S. Guth, E. Mayer, C. Hamm (Bad
Nauheim and Giessen, DE)

NEW ADVANCES IN CARDIOVASCULAR GENETICS AND GENE THERAPY Moderated Posters
Chairperson(s): J. Hall (Minneapolis, US); G. Condorelli (Rozzano, IT)
MONDAY – MORNING
10:00 PRKG1 mutations and thoracic aortic disease: another candidate gene to consider during genetic P3096
diagnosis approach to non-syndromic cases.
– M. Gago-Diaz, A. Blanco-Verea, G. Teixido, F. Huguet, A. Carracedo, A. Evangelista, M. Brion (Santiago de
Compostela and Barcelona, ES)
10:08 Impact of diabetes mellitus on Thymosin B4 mediated therapeutic neovascularization. P3097
– R. Hinkel, A. Howe, S. Straub, W. Husada, S. Lee, S. Renner, E. Wolf, C. Kupatt (Munich, DE)
10:17 Major histocompatibility complex risk haplotype predisposes to acute coronary syndrome. P3098
– J. Sinisalo, E. Vlachopoulou, M.I. Mayranpaa, T.P. Arstila, M. Perola, H. Huikuri, P.J. Karhunen,
P.T. Kovanen, R. Elosua, M. Lokki (Helsinki, Oulu and Tampere, FI; Barcelona, ES)
10:25 Gene transduction efficiencies, left ventricular function and fibrosis formation in mouse heart P3099
after direct intramyocardial gene transfers with adeno-, adeno-associated- and lentiviral vectors.
– M. Merentie, L. Lottonen-Raikaslehto, V. Parviainen, J. Huusko, M. Hedman, S. Yla-Herttuala (Kuopio, FI)
10:34 A deep phenotype and exome-sequencing based characterization of patients with P3100
non-compaction cardiomyopathy (NCCM).
– J.H. Haas, Z.F. Zhu, C.G. Geier, R.P.W. Pribe-Wolferts, K.S.F. Frese, E.K. Kayvanpour,
F.S.H. Sedaghat-Hamedani, A.K. Keller, H.A.K. Katus, B.M. Meder (Heidelberg, Berlin and Saarbrücken,
DE; Wuhan, CN)
10:42 Targeted capture sequencing identifies a mutation in a substantial amount of prior genotype P3101
negative - phenotype positive patients with inherited primary arrhythmia syndrome or
cardiomyopathy.
– T. Robyns, C. Kuiperi, T. De Ravel, K. Devriendt, J. Van Cleemput, R. Willems, D. Nuyens, G. Matthijs,
A. Corveleyn (Leuven and Genk, BE)
10:51 Targeted versus whole exome re-sequencing for clinical diagnostic application in inherited P3102
cardiac conditions.
– C.J. Pua, K. Miao, J. Bhalshankar, R. Walsh, S. John, S.Q. Lim, K. Chow, E. Edwards, J.S. Ware,
S.A. Cook (Singapore, SG; London, UK)
201

ADVANCES IN ENDOCARDITIS Moderated Posters
Chairperson(s): C. Izgi (Istanbul, TR); B. Hoen (Pointe-á-Pitre, GP)
10:00 Isolated right-sided infective endocarditis in cardiac device carriers: clinical profile and prognosis. P3103
– C. Ortiz-Bautista, P.E. Garcia, J. Lopez, T. Sevilla, C. Olmos, C. Ferrera, C. Saez, I. Vilacosta, A. Puerto,
J.A. San Roman (Valladolid and Madrid, ES)
10:08 Streptococcus bovis endocarditis revisited. A not so virulent microorganism. P3104
– C. Olmos, I. Vilacosta, C. Sarria, C. Sanchez-Enrique, J. Lopez, D. Vivas, C. Ferrera, C. Saez,
P.E. Garcia-Granja, J.A. San Roman (Madrid and Valladolid, ES)
10:17 Dramatic decrease in Staphylococcus aureus infective endocarditis early mortality using a new P3105
strictly applied protocol.
– L. Oliver, M. Jamme, J.P. Casalta, F. Gouriet, L. Saby, S. Hubert, E. Salaun, C. Lavoute, G. Habib,
D. Raoult (Marseille, FR)
10:25 External validation of a risk score for symptomatic embolisms in infective endocarditis. P3106
– C. Olmos, I. Vilacosta, C. Fernandez, C. Ferrera, J. Lopez, C. Sarria, C. Sanchez-Enrique, A. Freitas-Ferraz,
G. Tirado, J.A. San Roman (Madrid and Valladolid, ES)
10:34 The influence of radiological lesions on neurological outcome in endocarditis patients with P3107
preoperative stroke.
– M. Diab, A. Guenther, P. Scheffel, C. Sponholz, T. Lehmann, M. Franz, G. Faerber, T. Doenst (Jena, DE)
10:42 Socioeconomic status and risk of staphylococcus aureus bacteremia - a Danish nationwide P3108
cohort study.
– L.E. Bruun, M.D. Schmiegelow, P.S. Andersen, A. Petersen, G.H. Gislason, R.L. Skov, C. Torp-Pedersen
(Hellerup, Copenhagen and Aalborg, DK)
10:51 Clinical characteristics and outcomes of nosocomial infective endocarditis in Asia. P3109
– J.-W. Hwang, E.-J. Cho, G.-Y. Lee, E.-K. Kim, S.-A. Chang, S.-J. Park, S.-C. Lee, S.-W. Park (Seoul, KR)

IMPACT OF SMOKING CESSATION ON CARDIOVASCULAR PROGNOSIS: MYTHS AND Moderated Posters
REALITY
Chairperson(s): M. Amanullah (Dhaka, BD); S. Jaber (Aden, YE)
10:00 Time course changes of atherosclerotic LDL complexes after smoking cessation. P3110
– S. Shimada, M. Komiyama, H. Wada, S. Ura, S. Terashima, H. Yamakage, M. Akao, A. Shimatsu,
Y. Takahashi, K. Hasegawa (Kyoto and Nara, JP)
10:08 Effect of smoking cessation on metabolic factors and the incidence of metabolic syndrome. P3111
– S. Takayama, H. Takase, T. Okado, T. Tanaka, K. Makino, H. Hayashi, T. Sugiura, N. Ohte, Y. Dohi
10:17 Exposure to cigarette smoke and the morphology of atherosclerotic plaques in the extracranial P3112
arteries assessed by computed tomography angiography in patients with essential hypertension.
– P. Gac, M. Jurdziak, P. Jazwiec, G. Mazur, R. Poreba (Wroclaw, PL)
10:25 Prognostic influence of smoking in patients with an acute myocardial infarction: paradox or P3113
confusion? A propensity-score matched analysis.
– A. Cid Menendez, S. Raposeiras-Roubin, E. Abu-Assi, R.A. Abellas-Sequeiros, R. Gonzalez-Ferreiro,
M. Castineira-Busto, B. Alvarez-Alvarez, R.R. Abumuaileq, J.M. Garcia-Acuna, J.R. Gonzalez-Juanatey
(Santiago de Compostela, ES)
10:34 Association between tobacco smoking and pro-inflammatory humoral signalling in human P3114
epicardial adipose tissue; A prospective cohort study in patients undergoing major cardiac
surgery.
– M. Orban, L. Mach, M. Tretina, H. Bedanova, M. Soucek, P. Nemec (Brno, CZ)
10:42 The combined effect of the 3872 A/G polymorphism on C-Reactive Protein gene with tobacco P3115
smoking on endothelial function, on inflammatory, thrombotic processes and the risk for coronary
artery disease.
– G. Hatzis, N. Papageorgiou, E. Oikonomou, G. Latsios, A. Synetos, A. Miliou, S. Papaioannou,
C. Antoniades, B. Schieffer, D. Tousoulis (Athens, GR; Marburg, DE)
10:51 Smoking versus healthy diet impact on left ventricular mass and diastolic performance in P3116
essential hypertension patients.
– A. Angelis, C. Vlachopoulos, N. Ioakimidis, K. Aggeli, C. Chrysochoou, K. Aznaouridis, M. Abdelrasoul,
I. Felekos, C. Georgakopoulos, D. Tousoulis (Athens, GR)
202

MANAGEMENT OF PROCEDURAL RISKS Moderated Posters
Chairperson(s): M. Nakamura (Tokyo, JP); A. Bhagwat (Aurangabad, IN)
10:00 Transradial access for percutaneous coronary intervention (PCI) in British Columbia, Canada from P3117
1999 to 2013: consistently lower mortality and transfusion rates in a large unselected patient
cohort.
– W.T. Roberts, J. Shin, L. Ding, C.H. Ng, B. Berry, I.J. Nadra, A. Della Siega, S.D. Robinson (Victoria and
Vancouver, CA)
10:08 The European and Chinese cardiac and renal remote ischemic preconditioning study P3118
(EURO-CRIPS): a randomized controlled trial.
– C.M. Moretti, E.C. Cerrato, E.C. Cavallero, U.L. Limbruno, P.O. Omede, M.B. Bertaina, T.L. Lefevre,
A.P. Palazzuoli, S.L.C. Chen, F.G. Gaita (Turin, Orbassano, Grosseto and Siena, IT; Massy, FR; Nanjing,
CN)
10:17 Contrast volume to creatinine clearance ratio for the prediction of contrast induced nephropathy P3119
in patients undergoing coronary angiography or percutaneous intervention.
– L. Barbieri, M. Verdoia, P. Marino, H. Suryapranata, G. De Luca (Novara, IT; Nijmegen, NL)
10:25 Disaster in the cath lab - cardiogenic shock induced by procedure: results from the EHS PCI P3120
registry.
– T. Bauer, H. Nef, M. Hochadel, H. Moellmann, U. Zeymer, A. Gitt, F. Weidinger, J. Marco, C. Hamm
(Giessen, Ludwigshafen am Rhein and Bad Nauheim, DE; Vienna, AT; Monaco, MC)
10:34 Complications of percutaneous thrombin injection in patients with post-catheterization femoral P3121
pseudoaneurysm.
– J. Kurzawski, M. Sadowski, L. Zandecki, A. Janion-Sadowska (Kielce, PL)
10:42 Radiation dose reduction in the cardiac catheterization laboratory utilising a novel protocol. P3122
– A. Jurado Roman, I. Sanchez Perez, F. Lozano Ruiz-Poveda, M.T. Lopez Lluva, J.M. Benitez, N. Pinilla,
P. Agudo Quilez, A. Moreno Arciniegas, M.T. Marina Breysse, J. Piqueras (Ciudad Real and Madrid, ES)
10:51 On- and off-label use of vascular closure device in Japan. P3123
– T. Kuno, S. Kohsaka, Y. Numasawa, M. Sawano, S. Takagi, S. Noma, K. Negishi, Y. Maekawa,
A. Kawamura, K. Fukuda (Ashikaga City, Tokyo, Hiratsuka, Utsunomiya and Yokohama, JP)

DIASTOLIC DYSFUNCTION Moderated Posters
Chairperson(s): J. Silva-Cardoso (Porto, PT); B. Pieske (Berlin, DE)
10:00 Differences in prognosis between heart failure with preserved and depressed ejection fraction P3124
MONDAY – MORNING
can be partially explained by differences in renin-angiotensin-aldosterone system (RAAS).
– N. Farre, R. Olivero-Soldevila, I. Rodriguez-Costoya, C. Enjuanes, P. Moliner-Borja, G. Gonzalez-Robledo,
S. Ruiz, A. Garcia-Elias, J. Bruguera, J. Comin-Colet (Barcelona, ES)
10:08 Predictors of development of diastolic dysfunction in the middle-aged subjects: a prospective P3125
follow-up study.
– J. Perkiomaki, M. Mottonen, J. Lumme, Y.A. Kesaniemi, O. Ukkola, H.V. Huikuri (Oulu, FI)
10:17 Unmasking the prevalence of silent myocardial infarction, ischaemia and microvascular P3126
dysfunction in HFPEF with CMR.
– P. Kanagala, A.S. Cheng, J.N. Khan, A.S. Singh, S.A. Nazir, I.B. Squire, L.L. Ng, G.P. McCann (Leicester
and Kettering, UK)
10:25 Acute chamber stiffening is responsible for high filling pressures during exercise in HFNEF. A P3127
dynamic pressure-volume and histological study.
– C. Perez Del Villar, J. Bermejo, K. Savvatis, P. Martinez-Legazpi, B. Lopez, R. Yotti, A. Gonzalez-Mansilla,
F. Spillmann, F. Fernandez-Aviles, C. Tschoepe (Madrid and Navarra, ES; Berlin, DE)
10:34 Differences in prevalence and severity of sleep-disordered breathing in HF-REF and HF-PEF: first P3128
results of the prosprective German SchlaHF-XT Registry.
– O. Oldenburg, M. Arzt, E. Erdmann, H. Teschler, B. Wellmann, K. Wegscheider, H. Woehrle (Bad
Oeynhausen, Regensburg, Cologne, Essen, Hamburg and Martinsried, DE)
10:42 Inflammatory biomarkers predict HF severity and prognosis in patients with heart failure with P3129
– C. Hage, E. Michaelsson, C. Linde, E. Donal, J.C. Daubert, L.M. Gan, L.H. Lund (Stockholm and Mölndal,
SE; Rennes, FR)
10:51 Insulin resistance is an independent predictor of left ventricle diastolic dysfunction across the P3130
diabetic continuum.
– R. Ladeiras-Lopes, R. Fontes-Carvalho, P. Bettencourt, A.F. Leite-Moreira, A. Azevedo (Vila Nova de Gaia
and Porto, PT)
203

HYPERTENSION TREATMENT Moderated Posters
Chairperson(s): S. Bangalore (New York, US); T. Kahan (Stockholm, SE)
10:00 The impact of overt vascular disease in patients with comorbid type-2 diabetes and hypertension: P3131
data from the Dialogue registry.
– A.K. Gitt, D. Tschoepe, P. Bramlage, C. Koch, T. Ouarrak, R.E. Schmieder (Ludwigshafen am Rhein, Bad
Oeynhausen, Mahlow, Nuremberg and Erlangen, DE)
10:08 Achievement of individualized blood pressure and HbA1c targets in patients with hypertension P3132
and type-2 diabetes.
– R.E. Schmieder, D. Tschoepe, C. Koch, P. Bramlage, T. Ouarrak, A.K. Gitt (Erlangen, Bad Oeynhausen,
Nürnberg, Mahlow and Ludwigshafen am Rhein, DE)
10:17 Phosphodiesterase 5 inhibitor prevents hypoxia-induced cardiopulmonary remodeling through an P3133
antiproliferative mechanism.
– S. Favre, S. Puttini, L.K. Von Segesser, G. Pompilio, G. Vassalli, M. Samaja, G. Milano (Lausanne and
Lugano, CH; Milan, IT)
10:25 First quality assessment of cardiovascular drugs in 10 sub-saharan African countries: the seven P3134
study.
– M. Antignac, I.B. Diop, B. Do, M.S. Ikama, R. N’guetta, D.M. Balde, Y. Tchabi, A. Sidi Aly, E. Marijon,
X. Jouven (Paris, FR; Dakar, SN; Brazaville, CG; Abidjan, CI; Conakry, GN; Cotonou, BJ; Nouakchott, MR)
10:34 Quality of cardiovascular drugs in street markets and pharmacies in 10 sub-saharan African P3135
countries: the seven study.
– M. Antignac, I.B. Diop, M. Bernard, D. De Terline, J.L. Takombe, I. Toure, P. Zabsonre, J.M.F. Damorou,
M. Mirabel, X. Jouven (Paris, FR; Dakar, SN; Kinshasa, ZR; Niamey, NE; Ouagadougou, BF; Lomé, TG)
10:42 Heart rate as a predictor of cardiovascular outcomes: new evidence from the “ACTION” database. P3136 (W)
(withdrawn)
– P. Meredith, H.L. Elliott (Glasgow, UK)
10:51 Effect of renal sympathetic denervation on the expression of miRNA-133a, an indicator for reverse P3137
remodeling processes in hypertensive heart disease.
– O. Doerr, C. Liebetrau, H. Moellmann, L. Gaede, C. Troidl, S. Lankes, S. Voss, T. Bauer, C. Hamm, H. Nef

MEET THE TRIALIST II: LEADLESS Meet the Trialists
Chairperson(s): A. Auricchio (Lugano, CH)
10:10 Safety and Efficacy of a Leadless Pacemaker: results from the LEADLESS II clinical trial. 3138

NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN ATRIAL Satellite Symposium - Experts on the Spot
FIBRILLATION – HOW TO APPLY EVIDENCE FROM RANDOMISED
CLINICAL TRIALS IN DAILY PRACTICE
Chairperson(s): R. De Caterina (Chieti, IT)
10:15 Which patient subgroups benefit most from treatment with non-vitamin K antagonist oral 3139
anticoagulants?
10:25 What do we need to take into account when selecting among the various non-vitamin K 3140
antagonist oral anticoagulants?
– A. Goette (Paderborn, DE)
10:30 Fitting the non-vitamin K antagonist oral anticoagulant to the patient. 3141
10:35 Panel Discussion: non-vitamin K antagonist oral anticoagulants in atrial fibrillation - How to apply 3142
evidence from randomised clinical trials in daily practice.
– R. De Caterina (Chieti, IT), C.T. Ruff (Boston, US), A. Goette (Paderborn, DE)

LOW DENSITY LIPOPROTEIN-CHOLESTEROL (LDL-C) Satellite Symposium - Experts on the Spot
MANAGEMENT – CAN WE REDEFINE WHAT IS POSSIBLE?
Sponsored by SANOFI and REGENERON
Chairperson(s): C.P. Cannon (Boston, US)
10:15 Treat to target or reaching new lower levels of LDL-C - Which approach for which patient. 3143
10:30 Can future therapies redefine what is possible for patients? 3144
– R.H. Eckel (Denver, US)
204

STATE-OF-THE-ART: ATRIAL FIBRILLATION (AF) ABLATION IN Satellite Symposium - Experts on the Spot
PATIENTS ON NOACS
Chairperson(s): S.H. Hohnloser (Frankfurt am Main, DE); H. Calkins (Baltimore, US)
10:15 State-of-the-art: AF ablation in patients on NOACs. 3145
– S.H. Hohnloser (Frankfurt am Main, DE), H. Calkins (Baltimore, US)

STATE-OF-THE-ART: PERCUTANEOUS CORONARY INTERVENTION Satellite Symposium - Experts on the Spot
(PCI) IN PATIENTS ON NOACS
Chairperson(s): G.Y.H. Lip (Birmingham, UK); G. Nickenig (Bonn, DE)
10:15 State-of-the-art: PCI in patients on NOACs. 3146
– G.Y.H. Lip (Birmingham, UK), G. Nickenig (Bonn, DE)

HOT LINE III – DIABETES MELLITUS/PHARMACOLOGY Hot Line
Chairperson(s): F. Cosentino (Stockholm, SE); R. Chazal (Fort Myers, US)
11:00 Trial Evaluating Cardiovascular Outcomes with Sitagliptin in patients with type-2 Diabetes: 3147
TECOS.
11:10 TECOS: Discussant review. 3148
– J. Tuomilehto (Helsinki, FI)
11:15 TECOS: Panel discussion. 3149
11:18 Finerenone versus eplerenone in patients with worsening chronic heart failure with type 2 3150
diabetes mellitus and/or chronic kidney disease: main results of the ARTS-HF trial.
– G.S. Filippatos (Athens, GR)
11:28 ARTS-HF: Discussant review. 3151
– S. Solomon (Boston, US)
11:33 ARTS-HF: Panel discussion. 3152
11:36 The evaluation of Lixisenatide in acute coronary syndromes (ELIXA). 3153
MONDAY – MORNING
– E.F. Lewis (Boston, US)
11:46 ELIXA: Discussant review. 3154
11:51 ELIXA: Panel discussion. 3155
11:54 The Standard care versus Celecoxib Outcome Trial (SCOT); a randomised, trial comparing the 3156
cardiovascular safety of celecoxib versus traditional non-steroidal anti-inflammatory drugs.
– T.M. MacDonald (Dundee, UK)
12:04 SCOT: Discussant review. 3157
12:09 SCOT: Panel discussion. 3158
12:12 The OPTIDUAL trial: 12 vs 48 months of clopidogrel after drug-eluting stent placement. 3159
– G. Helft (Paris, FR)
12:22 OPTIDUAL: Discussant review. 3160
12:27 OPTIDUAL: Panel discussion. 3161

EMERGENCY ANGIOPLASTY FOR ACUTE MYOCARDIAL INFARCTION: A Special Session
“FLY-ON-THE-WALL” RECORDING OF CATHETER LAB PERSONNEL INTERACTION
Chairperson(s): M.S. Norell (Wolverhampton, UK); S.C. Clarke (Cambridge, UK)
The heart team. 3162
– T. Franks (Wolverhampton, UK), T. Hazelwood (Wolverhampton, UK), M.S. Norell (Wolverhampton, UK),
A. Scarrott (Wolverhampton, UK), S. Ubaid (Coventry, UK)
Introduction. 3163
– S.C. Clarke (Cambridge, UK)
Background. 3164
– M.S. Norell (Wolverhampton, UK)
Live case recording. 3165
11:45 Discussion and debrief of the catheter lab team. 3166
– S.C. Clarke (Cambridge, UK)
205

NEW CONCEPTS IN ECHOCARDIOGRAPHY Rapid Fire Abstract
Chairperson(s): J. Separovic Hanzevacki (Zagreb, HR); L.L. Rodriguez (Cleveland, US)
11:00 Vena contracta area for severity grading in functional and degenerative mitral regurgitation: A 3167
study based on transesophageal 3D colour Doppler in 419 patients.
– B. Goebel, R. Heck, A. Hamadanchi, S. Otto, C. Jung, A. Lauten, H.R. Figulla, T.C. Poerner (Jena, DE)
11:09 Left atrial function across the spectrum of cardiovascular disease in the elderly- the ARIC study. 3168
– A. Goncalves, H.U.N.G. Chung-Lieh, B. Claggett, K. Nochioka, A.M. Shah, S. Cheng, D.W. Kitzman,
S.D. Solomon (Boston and Winston-Salem, US)
11:18 Ultrasonic relative pressure imaging as a new and noninvasive method to visualize intracardiac 3169
pressure distribution: a validation study.
– M. Stugaard, T. Kamimukai, K. Masuda, T. Hirano, T. Tanaka, T. Okada, T. Asanuma, S. Nakatani (Suita
and Tokyo, JP)
11:27 Comparative usefulness of a novel echocardiographic measurement of pulmonary vascular 3170
resistance based on a theoretical formula among non-invasive methods.
– T. Kanda, M. Fujita, O. Iida, M. Masuda, S. Okamoto, T. Ishihara, K. Nanto, T. Shiraki, M. Uematsu
(Amagasaki, JP)
11:36 The difference of relationship between epicardial fat thickness and coronary artery calcification in 3171 (W)
patients with and without metabolic syndrome: from the CAESAR study. (withdrawn)
– B.J. Kim, J.G. Kang, E.S. Jung (Seoul, KR)
11:45 Different behaviour of left atrial external work between acute left ventricular anterior and 3172
posterior ischaemia.
– K. Inoue, T. Asanuma, K. Masuda, D. Sakurai, J. Higaki, S. Nakatani (Osaka and Toon, JP)
11:54 Vortex-mediated flow redirection towards the left ventricular outflow tract: influence of variations 3173
in atrio-ventricular delay.
– D. Rodriguez Munoz, C. Lozano Granero, A. Carbonell San Roman, J.L. Moya Mur, C. Fernandez-Golfin,
E. Casas Rojo, C. Lazaro Rivera, A. Hernandez-Madrid, J. Moreno Planas, J.L. Zamorano Gomez (Madrid,
ES)
12:03 Long-term antihypertensive treatment improves left ventricular twisting and untwisting in 3174
hypertensives: a 3 year follow-up study.
– I. Ikonomidis, H. Triantafyllidi, P. Trivilou, S. Tzortzis, C. Papadopoulos, G. Pavlidis, J. Paraskevaidis,
L. Palaiodimos, D. Vlastos, J. Lekakis (Athens, GR)
12:12 Combined analysis of speckle-tracking echocardiography and late gadolinium enhancement 3175
cardiac magnetic resonance improves prediction of functional recovery after acute myocardial
infarction.
– E. Altiok, R. Hoffmann, M. Frick, S. Hamada, A. Kirschfink, J. Schroeder, N. Marx, M. Becker (Aachen and
Lingen, DE)
12:21 Combined assessment of carotid intima-media thickness and left ventricular concentric 3176 (W)
hypertrophy predict cardiovascular death in hemodialysis patients. (withdrawn)
– H. Yoshikawa, M. Suzuki, M. Nakamura, K. Sugi, M. Yoshikawa (Tokyo, JP)

SODIUM VERSUS CALCIUM IN CARDIAC REMODELLING Symposium
Chairperson(s): J. Fauconnier (Montpellier, FR); G. Antoons (Maastricht, NL)
11:00 Proteins kinases: key regulators of Na+ & Ca2 homeostasis in atrial fibrillation. 3177
– N. Voigt (Essen, DE)
11:22 Diastolic ion equilibrium in the failing heart. 3178
– W. Louch (Oslo, NO)
11:45 Non-specific cationic channels in ventricular remodelling. 3179
– To be announced
12:07 Is intracellular sodium the real driver for cardiac hypertrophy and dysfunction? 3180
– M. Shattock (London, UK)
206

RECENT ADVANCES IN CARDIOLOGY: WHAT DOES THE BUSY CARDIOLOGIST NEED TO Special Session
KNOW ABOUT...
In association with EACVI Club 35, Young EAPCI, Young ACCA, EHRA, Young Committee, HOT
Chairperson(s): R.C. Vidal Perez (Santiago de Compostela, ES); D. Atar (Oslo, NO)
11:00 Fractional flow reserve and beyond (iFR, CT-FFR). 3181
– G.G. Toth (Graz, AT)
11:09 Fractional flow reserve and beyond (iFR, CT-FFR) - Discussion. 3182
– A. Baumbach (Bristol, UK)
11:18 Why should you look to the right heart? 3183
– J. Grapsa (London, UK)
11:27 Why should you look to the right heart? - Discussion. 3184
– F. Schnell (Rennes, FR)
11:36 Therapeutic hypothermia - The end of an era? 3185
– A. Viana Tejedor (Madrid, ES)
11:45 Therapeutic hypothermia - The end of an era? - Discussion. 3186
– M. Lettino (Milan, IT)
11:54 Sudden death. 3187
– T.J.R. De Potter (Aalst, BE)
12:03 Sudden death - Discussion. 3188
12:12 Novel devices for heart failure. 3189
12:21 Novel devices for heart failure - Discussion. 3190

VENTRICULAR ARRHYTHMIAS AND SUDDEN CARDIAC DEATH IN ISRAEL Guidelines in Daily Practice
Chairperson(s): M. Glikson (Ramat Gan, IL); R. Beinart (Ramat Gan, IL)
– I. Dobrecky-Mery (Nahariyya, IL)
– M. Haim (Beer Sheva, IL)
– M. Haim (Beer Sheva, IL)
MONDAY – MORNING
12:00 Mini-Quiz on 2014 ESC Guidelines. 3194
– D. Hasdai (Petah Tikva, IL), E. Lev (Ramat Hasharon, IL), E. Nikolsky (Haifa, IL), D. Zahger (Beer Sheva, IL),
R. Beeri (Jerusalem, IL), I. Dobrecky-Mery (Nahariyya, IL), H. Danenberg (Jerusalem, IL)

SUDDEN CARDIAC DEATH IN NORWAY Guidelines in Daily Practice
Chairperson(s): K.H. Haugaa (Oslo, NO); G. Vollan (Bergen, NO)
– H. Bjornstad (Bodo, NO)
– P.M. Tande (Tomso, NO)
– P.M. Tande (Tomso, NO)
– P.M. Tande (Tomso, NO), H. Bjornstad (Bodo, NO), A.I. Larsen (Stavanger, NO), T. Steen (Oslo, NO),
M.-E. Estensen (Oslo, NO), S.O. Samstad (Trondheim, NO), E. Gerdts (Bergen, NO)
11:00–12:30 | Rabat - Village 1

NEW TARGETS TO REDUCE ATHEROSCLEROSIS BURDEN Symposium
Chairperson(s): R. De Caterina (Chieti, IT); C. Monaco (Oxford, UK)
11:00 Adaptive immunity and atherogenesis. 3199
– G.K. Hansson (Stockholm, SE)
11:22 Vaccination with apoB100 peptides recognized by autoantibodies. 3200
– J. Nilsson (Malmö, SE)
11:45 Vaccination with oxLDL and the role of B1 cells. 3201
– J. Kuiper (Leiden, NL)
12:07 LRP1-Domain CR9 as target to inhibit atherosclerosis. 3202
– V. Llorente-Cortes (Barcelona, ES)
207

BASIC AND TRANSLATIONAL SCIENCE HOT LINE ON ISCHAEMIA Basic and Translational Science Hot Line
AND CARDIAC FUNCTION
Chairperson(s): D. Garcia-Dorado (Barcelona, ES); A.R. Pries (Berlin, DE)
11:00 Molecular mechanisms of ischemic damage: protective effects of alpha-crystallin-B. 3203
– J. Cubedo (Barcelona, ES)
11:15 Red blood cells impair post-ischemic cardiac function via arginase-dependent regulation of nitric 3204
oxide synthase and reactive oxygen species in type 2 diabetes.
– J.N. Yang (Stockholm, SE)
11:30 Characterization of cardiac stress (Takotsubo Syndrome)-related miRNAs ex vivo. 3205
– A. Derda (Hildesheim, DE)
11:45 Anti-inflammatory peptide SP16 reduces infarct size after myocardial ischemia and reperfusion in 3206
the mouse.
– S. Toldo (Richmond, US)
12:00 Polymorphism in the GNAS gene predicts ventricular tachyarrhythmias and sudden cardiac death: 3207
results from the DISCOVERY trial and Oregon Sudden Death Study.
– H. Wieneke (Essen, DE)
12:15 Evidence for Circulating Stem Cells Derived from the Human Heart and Their Therapeutic 3208
Potential.
– H.-M. Yang (Seoul, KR)

WHAT SHOULD YOU EAT TO LIVE A HEART HEALTHY LIFE? Symposium
Chairperson(s): O. Barna (Kiev, UA); M. Verschuren (Bilthoven, NL)
11:00 The complexity and limitations of interpreting dietary epidemiologic studies. 3209
– G.N. Thomas (Birmingham, UK)
11:22 Transfats: time to get tough with the food industry? 3210
– S. Stender (Hellerup, DK)
11:45 Carbs against cardio: more evidence of the threat to the heart. 3211
– S. Poole (Cambridge, UK)
12:07 High protein and low glycemic index: the Diogenes trial. 3212
– T. Meinert Larsen (Frederiksberg, DK)

HOW TO RETURN TO “NORMAL” LIFE AFTER CARDIAC EVENT Case-based Symposium
Chairperson(s): M.E. Cupples (Belfast, UK); J.-P. Schmid (Berne, CH)
11:00 48 y.o. male, plane pilot, tennis player, incomplete revascularization. 3213
– H. Voller (Rudersdorf, DE)
11:15 48 y.o. male, plane pilot, tennis player, incomplete revascularization - Panel discussion and 3214
– L.M. Patricio (Sesimbra, PT), A.M.K. Etriby (Cairo, EG), J. Niebauer (Salzburg, AT)
11:30 67 y.o. female, NSTEMI-ACS, 3-vessel disease, LV dysfunction. 3215
– L.M. Patricio (Sesimbra, PT)
11:45 67 y.o. female, NSTEMI-ACS, 3-vessel disease, LV dysfunction - Panel discussion and questions 3216
from the audience.
– H. Voller (Rudersdorf, DE), L.M. Patricio (Sesimbra, PT), J. Niebauer (Salzburg, AT)
12:00 How to return to “normal” life after cardiac even - State of the Art lecture. 3217
– M.E. Cupples (Belfast, UK)

FAT AND CARDIOVASCULAR TISSUES: FRIEND OR FOE? Symposium
Chairperson(s): U. Lendeckel (Greifswald, DE); U. Schotten (Maastricht, NL)
11:00 Epicardial adipose tissue: a major biological tissue. 3218
– A. Dutour (Marseille, FR)
11:22 Epicardial adipose tissue and coronary artery disease. 3219
– T. Mazurek (Warsaw, PL)
11:45 Epicardial adipose tissue, diabetes and cardiovascular diseases. 3220
– J. Eckel (Düsseldorf, DE)
12:07 Cross talk between adipose tissue and atrial myocardium. 3221
– S. Hatem (Paris, FR)
208
11:00–12:30 | Kiev - Village 3

OUR CARDIOTOXIC ENVIRONMENT: STRESS, OBESITY AND THE DEVELOPMENT OF Symposium
Chairperson(s): G. Parati (Milan, IT); E.V. Shlyakhto (St. Petersburg, RU)
11:00 Is environmental stress a cardiovascular risk factor? How does it influence other cardiovascular 3222
risks?
– A. Steptoe (London, UK)
11:22 Obesity and the selfish brain – A link between stress and cardiovascular disease? 3223
– A. Peters (Lübeck, DE)
11:45 Autonomic nervous system activity, stress and cardiovascular disease – Potential mechanisms. 3224
– A. Flaa (Oslo, NO)
12:07 Are human physiological adaptations to stress fit for purpose in the modern world? Possible 3225
impact on obesity and cardiovascular disease.
– A. Jones (London, UK)

ENVIRONMENT, HYPERTENSION AND CARDIOVASCULAR RISK Symposium
ESC and the CHF / Great Wall ICC
Chairperson(s): C.S. Ma (Beijing, CN); P. van de Borne (Brussels, BE)
11:00 An overview of hypertension in Asia. 3226
11:22 Diet and lifestyle influences on hypertension in China. 3227
– Y.Q. Zhang (Beijing, CN)
11:45 The effects of environmental noise exposure on hypertension and CV risk. 3228
– T. Munzel (Mainz, DE)
12:07 Long-term exposure to air pollution and hypertension. 3229
– K.B. Fuks (Düsseldorf, DE)

CONTROVERSIES IN INNOVATIVE DEVICE THERAPY Debate Session
Chairperson(s): P.E. Vardas (Heraklion, GR); K. Okumura (Hirosaki, JP)
11:00 Leadless pacemakers are ready to start - PRO. 3230
MONDAY – MORNING
– P. Ritter (Pessac, FR)
11:15 Leadless pacemakers are ready to start - CONTRA. 3231
11:30 Leadless pacemakers are ready to start - REBUTTAL PRO. 3232
– P. Ritter (Pessac, FR)
11:35 Leadless pacemakers are ready to start - REBUTTAL CONTRA. 3233
11:40 Leadless pacemakers are ready to start - CONCLUSION. 3234
11:45 Subcutaneous ICD is the new standard - PRO. 3235
– G. Bardy (Carnation, US)
12:00 Subcutaneous ICD is the new standard - CONTRA. 3236
12:15 Subcutaneous ICD is the new standard - REBUTTAL PRO. 3237
– G. Bardy (Carnation, US)
12:20 Subcutaneous ICD is the new standard - REBUTTAL CONTRA. 3238
12:25 Subcutaneous ICD is the new standard - CONCLUSION. 3239

ARRHYTHMIAS AND EMOTIONAL DISORDERS – ELECTROPHYSIOLOGY MEETS PSYCHIATRY Symposium
ESC and the Argentine Society of Cardiology
Chairperson(s): E. Arbelo (Barcelona, ES); O. Oseroff (Buenos Aires, AR)
11:00 Panic attacks or arrhythmia or both? 3240
– A. Sarkozy (Edegem, BE)
11:22 Emotional distress and inherited arrhythmia disorders. 3241
– J. Gonzalez-Zuelgaray (Buenos Aires, AR)
11:45 Anger and ventricular arrhythmias - What about the ICD patient? 3242
12:07 Psychiatric patients and the challenge for arrhythmias invasive treatment when needed. 3243
– A. Bochoeyer (Buenos Aires, AR)
209

DIFFICULT TRANSOESOPHAGEAL ECHO CASES Case-based Symposium
Chairperson(s): F. Flachskampf (Uppsala, SE); B.A. Popescu (Bucharest, RO)
11:00 Embolic sourse in atrial fibrillation. 3244
– P. Colonna (Bari, IT)
11:10 Embolic sourse in atrial fibrillation - Panel discussion and questions from the audience. 3245
– P. Colonna (Bari, IT), R.E. Dulgheru (Liège, BE), E. Brochet (Paris, FR), F. Flachskampf (Uppsala, SE)
11:20 Suspicion of valvular prosthesis dysfuntion. 3246
– R.E. Dulgheru (Liège, BE)
11:30 Suspicion of valvular prosthesis dysfuntion - Panel discussion and questions from the audience. 3247
11:40 Is the mitral valve repairable? 3248
– E. Brochet (Paris, FR)
11:50 Is the mitral valve repairable? Panel discussion and questions from the audience. 3249
12:00 Transoesophageal echocardiography - State of the Art lecture. 3250
– F. Flachskampf (Uppsala, SE)

CARDIOVASCULAR MAGNETIC RESONANCE IMAGING IN 2015: MORE IMPACT IN Advances in Science
MANAGING PATIENTS
Chairperson(s): C. Bucciarelli-Ducci (Bristol, UK); M. Al-Mallah (Riyadh, SA)
11:00 State of the Art in the prognostic role of cardiovascular magnetic resonance. 3251
– I. Eitel (Leipzig, DE)
11:20 Prediction of long-term major events soon after a first ST-segment elevation myocardial infarction 3252
by cardiovascular magnetic resonance.
– P. Racugno, C. Bonanad Lozano, D. Escribano, A. Paya, J. Nunez, M.P. Lopez-Lereu, J.V. Monmeneu,
E. Cambronero, F.J. Chorro, V. Bodi (Valencia, ES)
11:37 Utility of cardiac MRI in detecting myocardial involvement and predicting adverse events in 3253
sarcoidosis: A study in 330 patients.
– V. Kouranos, G.E. Tzelepis, A. Rapti, S. Mavrogeni, K. Aggeli, M. Ntouskou, R. Sharma, P.P. Sfikakis,
A.U. Wells, E. Gialafos (London, UK; Athens, GR)
11:54 Prognostic impact of unrecognized myocardial scar in the myocardium perfused by non-culprit 3254
artery detected by late gadolinium enhanced CMR in patients with acute myocardial infarction.
– T. Omori, T. Kurita, K. Dohi, T. Nakata, S. Nakamori, K. Kitagawa, K. Hoshino, H. Sakuma, M. Ito (Tsu, JP)
12:11 Future direction for research in CMR to impact patients management. 3255
– V. Ferrari (Philadelphia, US)

OPTIMISING OUTCOMES OF CORONARY SURGERY, WHAT THE CARDIOLOGIST SHOULD KNOW Symposium
ESC and the American Heart Association
Chairperson(s): M. Sousa Uva (Lisbon, PT); M.A. Creager (Boston, US)
11:00 Timing and management of antithrombotics in patients with acute coronary syndrome. 3256
– M.A. Borger (New York, US)
11:22 Prevention and management of perioperative atrial fibrillation. 3257
– F. Sellke (Providence, US)
11:45 Prevention and management of acute kidney injury. 3258
– M. Ranucci (Milan, IT)
12:07 Optimal secondary prevention of coronary surgery. 3259
210
11:00–12:30 | Oslo - Village 6

CAROTID ARTERY DISEASE AND STROKE IN DAILY PRACTICE Meet the Experts
Chairperson(s): D. Krieger (Copenhagen, DK); P. Amarenco (Paris, FR)
11:00 Carotid artery disease and stroke in daily practice - Introduction to the session. 3260
– P. Amarenco (Paris, FR)
11:05 Symptomatic carotid artery disease in an octogerian. 3261
– R.S. von Allmen (St. Gallen, CH)
11:15 Symptomatic carotid artery disease in an octogerian - Panel discussion and questions from the 3262
audience.
– I. Ikonomidis (Athens, GR), P.H. Kolh (Liège, BE), R.S. von Allmen (St. Gallen, CH)
11:30 Carotid artery stenosis in a patient undergoing CABG. 3263
– V. Aboyans (Limoges, FR)
11:40 Carotid artery stenosis in a patient undergoing CABG - Panel discussion and questions from the 3264
audience.
– I. Ikonomidis (Athens, GR), V. Aboyans (Limoges, FR), P.H. Kolh (Liège, BE)
11:55 Cryptogenic stroke: how far should we look for the cause? 3265
12:05 Cryptogenic stroke: how far should we look for the cause?Panel discussion and questions from 3266
the audience.
– I. Ikonomidis (Athens, GR), W. Doehner (Berlin, DE), P.H. Kolh (Liège, BE)
12:20 Carotid artery disease and stroke in daily practice - Take home message. 3267
– D. Krieger (Copenhagen, DK)

THE PUZZLE OF THE UNSTABLE PLAQUE Symposium
Chairperson(s): E. Braunwald (Boston, US); G. Guagliumi (Bergamo, IT)
11:00 Lessons from the grave. 3268
11:22 How to detect vulnerable plaque in clinical practice? 3269
– M. Radu (Copenhagen, DK)
11:45 Haemodynamic forces and plaque vulnerability. 3270
– P. Motreff (Clermont-Ferrand, FR)
12:07 Plaque sealing of non-flow limiting vulnerable plaque - Worth the risk? 3271
MONDAY – MORNING
THROMBECTOMY IN HEART AND BRAIN? WHAT ARE THE DIFFERENCES AND HOW TO WORK Symposium
TOGETHER?
ESC and the European Stroke Organisation
Chairperson(s): A. Davalos (Badalona, ES); S.G. Foussas (Athens, GR)
11:00 Treating heart or brain, any difference? Views from an interventional cardiologist. 3272
– P. Widimsky (Prague, CZ)
11:22 How to select the best candidate for thrombectomy in acute stroke patients? Views from an 3273
interventional neuroradiologist.
– J. Fiehler (Hamburg, DE)
11:45 What can Strokologists learn from more than 20 years of advantage in endovascular pathways? 3274
– M. Mazighi (Paris, FR)
12:07 Hyperacute stroke pathways: recognize, triage and diagnose stroke efficiently. 3275
– A. Davalos (Badalona, ES)
211
11:00–12:30 | Tunis - Village 7

ORAL ANTICOAGULANTS STILL IN THE FOCUS Advances in Science
Chairperson(s): D. Milicic (Zagreb, HR); E.L. Grove (Aarhus, DK)
11:00 State of the Art in current status clinical use of anticoagulants. 3276
11:20 Lower risk of myocardial infarction in atrial fibrillation patients treated with vitamin K antagonist 3277
than in combination with acetylsalicylic acid (ASA) or ASA alone.
– C.J. Lee, J.L. Pallisgaard, G.H. Gislason, C. Torp-Pedersen, A. Brandes, S. Husted, S.P. Johnsen,
M.L. Hansen (Copenhagen, Aalborg, Odense and Aarhus, DK)
11:37 Vitamin K antagonist control in Eastern and Southeastern Asia. 3278
– S. Oh, S. Goto, P. Angchaisuksiri, A.J. Camm, F. Cools, S. Haas, Y. Koretsune, T.W. Lim, G. Accetta,
A.K. Kakkar (Seoul, KR; Kanagawa and Osaka, JP; Bangkok, TH; London, UK; Brasschaat, BE; Munich,
DE; Singapore, SG)
11:54 Adherence to anticoagulant treatment with apixaban and rivaroxaban in a real-world setting. 3279
– F. Al-Khalili, C. Lindstrom, S. Schulman, A. Majeed (Stockholm, SE; Hamilton, CA)
12:11 Future direction for research in anticoagulation therapy. 3280

UPDATE ON CARDIOVASCULAR TUMOURS Symposium
ESC and the Association for European CardioVascular Pathology
Chairperson(s): M.N. Sheppard (London, UK); J.R. Gimeno Blanes (Murcia, ES)
11:00 2015 WHO classification of cardiac tumours. 3281
– C. Basso (Padua, IT)
11:22 Primary cardiac sarcomas. 3282
– P. Bruneval (Paris, FR)
11:45 Advances in clinical imaging. 3283
– A.D. Ristic (Belgrade, RS)
12:07 Current perspective on cardiac malignancies and chemotherapy. 3284
– C. Lestuzzi (Aviano, IT)

EVERYTHING YOU NEED TO KNOW ABOUT BICUSPID AORTIC VALVES Symposium
Chairperson(s): J.-L. Monin (Créteil, FR); D.T. Kremastinos (Athens, GR)
11:00 Diagnosis and classification by echo: what the clinician needs to know. 3285
– A. Evangelista Masip (Barcelona, ES)
11:22 Serial follow-up: how often and which imaging techniques? 3286
– V. Delgado (Leiden, NL)
11:45 Natural history and the rationale for familial screening. 3287
– H. Michelena (Rochester, US)
12:07 When and how to intervene? 3288

CARDIAC ANATOMY FOR INTERVENTIONAL CARDIOLOGISTS Cardiac Anatomy and Pathology Live
Chairperson(s): G. Thiene (Padua, IT); S. Ernst (London, UK)
11:00 Live video demonstration. 3289
– S.Y. Ho (London, UK)
11:00–12:30 | Bern - Village 9

DEVICES FOR HEART FAILURE: THE PIPELINE Symposium
Chairperson(s): P. Seferovic (Belgrade, RS); A.J.S. Coats (Coventry, UK)
11:00 Cardiac contractility modulation. 3291
11:22 Vagal and spinal cord denervation and renal denervation. Autonomic nervous system modulation. 3292
11:45 LV reconstruction. 3293
12:07 Bio-artificial heart. 3294
– A. Carpentier (Paris, FR)
212

NUTRITIONAL DEFICIENCIES AND EXCESSES IN HEART FAILURE Case-based Symposium
Chairperson(s): G. Ertl (Würzburg, DE); A. Stromberg (Linköping, SE)
11:00 How to assess and to correct specific nutritional deficiencies? 3295
– A.L. Clark (Kingston-upon-Hull, UK)
11:15 How to assess and to correct specific nutritional deficiencies? Panel discussion and questions 3296
from the audience.
– A.L. Clark (Kingston-upon-Hull, UK), T. Jaarsma (Norrköping, SE), C.E. Angermann (Würzburg, DE)
11:30 Managing cachexia and muscle wasting in heart failure: from appetite stimulants to antibolics. 3297
11:45 Managing cachexia and muscle wasting in heart failure: from appetite stimulants to antibolic - 3298
– M. Lainscak (Celje, SI), T. Jaarsma (Norrköping, SE), C.E. Angermann (Würzburg, DE)
12:00 Managing obesity in heart failure: from behavioural therapy to surgery. 3299
12:15 Managing obesity in heart failure: from behavioural therapy to surgery - Panel discussion and 3300
– G.M.C. Rosano (Rome, IT), T. Jaarsma (Norrköping, SE), C.E. Angermann (Würzburg, DE)

ADVANCES IN HEART FAILURE THERAPY Rapid Fire Abstract
Chairperson(s): J.A. Vlasica Carlos (Lima, PE); H.N. Sabbah (Detroit, US)
11:00 Angiotensin receptor neprilysin inhibition and renal function and in heart failure: results from 3301
PARADIGM-HF.
– K. Damman, K. Andersen, J. Belohlavek, M.P. Lefkowitz, J.L. Rouleau, S.D. Solomon, K. Swedberg,
M. Zile, M. Packer, J.J.V. McMurray (Glasgow, UK; Reykjavik, IS; Prague, CZ; Hanover, Boston, Charleston
and Dallas, US; Montreal, CA; Gothenburg, SE)
11:09 Effect of LCZ696 on urinary albumin excretion and relation to outcomes in patients with heart 3302
failure.
– M. Gori, M. Senni, B. Claggett, J. Rouleau, K. Swedberg, M. Zile, M. Lefkowitz, M. Packer, J. Mc Murray,
S.D. Solomon (Bergamo, IT; Boston, Charleston, East Hanover and Dallas, US; Montreal, CA; Gothenburg,
SE; Glasgow, UK)
11:18 Beta-blocker therapy and in-hospital outcome in acute heart failure: a propensity-score matching 3303
secondary analysis of the ALARM-HF registry.
MONDAY – MORNING
– D.T. Farmakis, J. Parissis, P. Simitsis, V. Bistola, I. Ikonomidis, G. Papingiotis, G. Filippatos, A. Mebazaa,
J. Lekakis, F. Follath (Athens, GR)
11:27 Hydrophilic versus lipophilic statin therapy on outcomes in patients with heart failure: a 3304
systematic review and an adjusted indirect comparison meta-analysis of randomised trials.
– K. Osei Bonsu, D.D. Reidpath, A. Kadirvelu (Bandar Sunway, MY)
11:36 Carperitide versus nitroglycerin as a first-line therapy in patients with acute heart failure: a 3305
propensity-matched comparison.
– N. Iwakami, T. Nagai, Y. Sugano, T. Shibata, Y. Asaumi, T. Noguchi, K. Kusano, H. Ogawa, S. Yasuda,
11:45 ONO-4232, an EP4-selective agonist, improves left ventricular diastolic dysfunction in chronic 3306
heart failure model.
– M. Takahashi, T. Kanaji, K. Sato, Y. Hirota (Osaka, JP)
11:54 Bendavia, a novel mitochondria-targeting peptide, improves contraction and relaxation of failing 3307
cardiomyocytes isolated from dogs with chronic heart failure.
– H.N. Sabbah, R.C. Gupta, P. Mohyi (Detroit, US)
12:03 Hepato-renal dysfunction on admission predicts the outcome in acute heart failure. 3308
– J. Biegus, R. Zymlinski, P. Siwolowski, M. Sokolski, E.A. Jankowska, W. Banasiak, P. Ponikowski
(Wroclaw, PL)
12:12 Predictors, treatment and long-term course of iron deficiency in unselected patients with heart 3309
failure: The RAID-HF registry.
– H. Wienbergen, M. Hochadel, S. Michel, A. Fach, W. Von Scheidt, M. Pauschinger, J. Senges,
R. Hambrecht (Bremen, Ludwigshafen am Rhein, Augsburg and Nuremberg, DE)
12:21 RA123456, a novel potent and selective CaMKII inhibitor reduces diastolic Ca2+ leak and 3310
enhances SR Ca2+ content in human cardiomyocytes.
– M. Dryzmalski, B. Floerchinger, L. Rupprecht, C. Schmid, Y. Zausig, A.J. Muslin, P. Janiak, P. Beauverger,
L.S. Maier, S. Wagner (Regensburg, DE; Cambridge, US; Chilly-Mazarin, FR)
213
MONDAY 31 AUGUST 2015 – MORNING POSTERS

BEST POSTERS IN SYNCOPE MANAGEMENT
Discussant: Best posters in syncope management. P3311

– C. Podoleanu (Targu Mures, RO)
Family history of syncope is associated with increased risk of adverse cardiovascular events and P3312
mortality - a Danish nationwide study.
– D. Zahir, M.H. Ruwald, L.E. Bruun, A.K. Nume, C. Torp-Pedersen, G.H. Gislason (Hellerup and Aalborg, DK)
Miniaturized reveal LINQ insertable cardiac monitoring performance in different body types. P3313
– L.R.C. Dekker, P.H. Sanders, M. Di Bacco, T.A. Bergemann, E. Pokushalov, H. Purerfellner (Eindhoven and
Maastricht, NL; Adelaide, AU; Novosibirsk, RU; Linz, AT)
Application of syncope guidelines in the emergency department do not reduce admission rates: a P3314
retrospective cohort study.
– B. Deif, S.J. Kang, A. Ismail, T. Vanniyasingam, J.C. Guzman, C.A. Morillo (Hamilton, CA)
3 years experience of diagnosing and managing postural tachycardia (PoTS) from a UK regional syncope P3315
service.
– Y. Zheng, C. Moyles, Y. Blackburn, E. Joy, K. Mohee, C. Morley (Bradford, UK)
BEST POSTERS IN ANTITHROMBOTICS
Discussant: Best posters in antithrombotics. P3316

– A. MacIsaac (Melbourne, AU)
The efficacy and safety of ticagrelor in women versus men with a prior myocardial infarction: insights P3317
from the PEGASUS-TIMI 54 trial.
– M.L. O’Donoghue, M.P. Bonaca, G. Magnani, D.L. Bhatt, M. Cohen, P.G. Steg, R.F. Storey, S.M. Murphy,
E. Braunwald, M.S. Sabatine (Boston and West Orange, US; Paris, FR; Sheffield, UK)
Ticagrelor 60 mg twice-daily provides effective platelet inhibition in patients with prior myocardial P3318
infarction: the PEGASUS-TIMI 54 platelet function substudy.
– R.F. Storey, D.J. Angiolillo, M.P. Bonaca, M.R. Thomas, D.L. Bhatt, P.G. Steg, A.J. Ahsan, J. Kuder,
E. Braunwald, M.S. Sabatine (Sheffield and Nottingham, UK; Jacksonville and Boston, US; Paris, FR)
Differences in dual antiplatelet treatment for acute coronary syndrome patients undergoing PCI or not: a P3319
Danish nationwide population-based cohort study.
– G. Gislason, L.P. Hasvold, T. Diness, A. Pottegaard, A. Broe, M. Emneus, A. Green (Copenhagen and
Odense, DK; Södertälje, SE)
New users of low-dose acetylsalicylic acid and risk of colorectal cancer: results using three different P3320
study designs.
– L.A. Garcia Rodriguez, L. Cea Soriano, M. Soriano-Gabarro (Madrid, ES; Berlin, DE)
BEST POSTERS IN E-CARDIOLOGY
Discussant: Best posters in e-cardiology. P3321

– G. Krstacic (Zagreb, HR)
Continuous monitoring of day by day variations in biventricular pacing percentage, rather than its mean P3322
values, is a better predictor of clinical outcomes regardless of rhythm type.
– M. Mazurek, E. Jedrzejczyk-Patej, R. Lenarczyk, A. Liberska, J. Boidol, S. Morawski, T. Podolecki,
P. Pruszkowska, O. Kowalski, Z. Kalarus (Zabrze, PL)
Mobile echo acquisition and transfer for donor organ assessment. P3323
– N. Al-Attar, H. Alhaideri, P. Curry, S. Haj Yahia (Glasgow, UK)
Relationship between Serum Electrolytes and Electrocardiographic Intervals. P3324
– C. Krittanawong, C. Thongprayoon, S. Sharma, M.R. Bell, P.A. Brady, V. Herasevich, S. Kapa,
S.J. Asirvatham, N. Naksuk (Rochester, US)
Impact of motion correction algorithm on the image quality and diagnostic utility in patients undergoing P3325
CT angiography: a randomized controlled trial.
– H. Sheta, K. Egstrup, M. Husic, L. Heinsen, K. Niemann, J. Lambrechtsen (Svendborg, DK; Rotterdam, NL)
BEST POSTERS IN CARDIAC BIOLOGY AND SENESCENCE
Discussant: Best posters in cardiac biology and senescence. P3326

– P. Ferdinandy (Budapest, HU)
P53-induced inflammation exacerbates cardiac dysfunction during pressure overload. P3327

– Y. Yoshida, I. Shimizu, G. Katsuumi, M. Suda, Y. Hayashi, S. Jiao, T. Minamino (Niigata, JP)
214
Testosterone antagonizes doxorubicin-induced senescence of cardiomyocytes. P3328

– P. Altieri, S. Bollini, C. Barisione, E. Lazzarini, M. Canepa, C.G. Tocchetti, G.P. Bezante, P. Spallarossa,
C. Brunelli, P. Ameri (Genoa and Naples, IT)
Rho-dependent kinases ROCK1 and ROCK2 and their contribution to the myofibroblast phenotype of P3329
cardiac fibroblasts.
– S. Hartmann, A. Jatho, W.H. Zimmermann, S. Lutz (Göttingen, DE)
Phosphodiesterase 3A1 protects the heart against isoproterenol-induced cardiac injury via anti-oxidative P3330
mechanism.
– M. Oikawa, S. Iwaya, S. Saitoh, C. Yan, Y. Takeishi (Fukushima, JP; Rochester, US)
BEST POSTERS IN AORTIC AND BICUSPID AORTIC VALVE DISEASE
Discussant: Best posters in aortic and bicuspid aortic valve disease. P3331
– M. Czerny (Freiburg, DE)
Circulating endothelial microparticles are elevated in bicuspid aortic valve disease and are associated to P3332
aortic root dilatation.
– J.M. Alegret, N. Martinez-Micaelo, J.M. Vernis, C. Ligero, O. Palazon, P. Valdovinos, H. Tajes,
R. Beltran-Debon (Reus, ES)
Association of bicuspid aortic valve morphology with ascending aortic dimensions and growth. P3333
– F.E.C.M. Peeters, N. Van Der Linden, A.L.L. Thomassen, H.J.G.M. Crijns, S.J.R. Meex, B.L.J.H. Kietselaer
(Maastricht, NL)
Detachment of commissure is a major cause of aortic regurgitation in acute type A aortic dissection. P3334
– K. Mahara, M. Ota, K. Kishiki, Y. Izumi, R. Fukumoto, T. Fukui, J. Umemura, T. Sumiyoshi, S. Takanashi
(Tokyo, JP)
Predictors of aortic complications in patients with bicuspid aortic valve. P3335
– L. Neglia, R. Piazza, V. Leonelli, M. Morosin, A. Doronzo, E. Leiballi, R. Pecoraro, M. Cinello, C. Lutman,
M. Cassin (Palermo, Pordenone and Trieste, IT)
BEST POSTERS IN ENVIRONMENT AND CARDIOVASCULAR DISEASES
Discuassant: Best posters in environment and cardiovascular diseases. P3336

– G. Hoek (Utrecht, NL)
Yellow dust and particle pollution are independently associated with increased risk of hospital admission P3337
for ischemic heart disease in South Korea.
– S.C. You, I.S. Kim, J.S. Uhm, H.N. Pak, M.H. Lee, C.S. Kim, B.Y. Joung (Seoul, KR)
Air pollutants and acute myocardial infarction in a heavily industrialised region. Is there any relationship? P3338
– O. Polikutina, O. Barbarash, Y. Slepynina, E. Bazdyrev (Kemerovo, RU)
MONDAY – MORNING
Particular matter and hemorrhagic stroke: a systematic review and meta-analysis. P3339
– B. Zhang, Y.I. Zhong, Z. Lu (Guangzhou, CN)
Ambient particulate matter air pollution and temperature levels: impact on blood pressure in high-risk P3340
cardiac patients.
– P. Giorgini, M. Rubenfire, R. Das, T. Gracik, L. Wang, M. Morishita, R.L. Bard, E.A. Jackson, C. Ferri,
R.D. Brook (L’Aquila, IT; Ann Arbor, US)
BEST POSTERS IN PCI: LONG-TERM OUTCOME
Discussant: Best Posters in PCI: long-term outcome. P3341

– K. Tanabe (Tokyo, JP)
Predictors of late bleeding after percutaneous coronary intervention: insights from the PARIS registry. P3342
– G. Giustino, S. Sartori, C. Ariti, G. Weisz, T. Stuckey, S. Pocock, F. Shawl, C.M. Gibson, A. Chieffo,
R. Mehran (New York, Greensboro, Tacoma Park and Boston, US; London, UK; Milan, IT)
Mortality after coronary angiography in 2776 type 1 diabetes patients undergoing coronary angiography. P3343
– V. Ritsinger, C. Hero, K. Eeg-Olofsson, A.M. Svensson, N. Saleh, B. Lagerqvist, A. Norhammar (Stockholm,
Gothenburg and Uppsala, SE)
Antiplatelet drugs regimen in patients with stent thrombosis: insights from the national PESTO French P3344
OCT registry.
– N. Amabile, C. Trouillet, G. Cayla, G. Range, O. Dubreuil, E. Vautrin, L. Mangin, N. Meneveau, P. Motreff,
G. Souteyrand (Paris, La Rochelle, Nîmes, Chartres, Lyon, Grenoble, Annecy, Besançon and
Clermont-Ferrand, FR)
Association between progressive peri-stent contrast staining, major adverse cardiac events, and very late P3345
stent thrombosis: a comparison between 1st and 2nd generation drug-eluting stent.
– T. Tada, K. Kadota, D. Hasegawa, S. Habara, H. Tanaka, Y. Fuku, H. Katoh, T. Goto, K. Mitsudo (Kurashiki,
JP)
215
BEST POSTERS IN NEW TREATMENT MODALITIES AND TREATMENT IMPLEMENTATION
Discussant: Best posters in new treatment modalities and treatment implementation. P3346
– V. Pyrgakis (Athens, GR)
Efficacy of short courses of low-frequency electric myostimulation in patients hospitalized for P3347
decompensated chronic heart failure (CHF) in early terms of hospital treatment.
– V. Sviridenko, M. Poltavskaya, A. Syrkin, A. Doletsky, I. Giverts, O. Dikur (Moscow, RU)
The effect of treatment optimization on the suitability of ARNI among patients followed at a heart failure P3348
outpatient clinic.
– B. Muk, B. Szabo, M. Dekany, P. Bogyi, D. Vagany, Z.S. Majoros, T. Borsanyi, K. Bozo, R.G. Kiss,
N. Nyolczas (Budapest, HU; Örebro, SE)
Impact of standardised medication titration forms and incentive payments on medication titration in heart P3349
failure: should we pay for more?
– J.J. Atherton, J. Suna, A. Hickey, L. Marquart, G. Javorsky, A. Munns, C. Denaro, A. Mudge (Brisbane, AU)
Preventable death in elderly versus younger patients admitted with decompensated heart failure by P3350
targeting pre-discharge NT-proBNP levels: importance of attainability of targets.
– S. Stienen, K. Salah, L. Eurlings, P. Bettencourt, A. Bayes-Genis, M. Metra, V. Verdiani, J. Tijssen, Y. Pinto,
W.E. Kok (Amsterdam and Maastricht, NL; Porto, PT; Badalona, ES; Brescia and Florence, IT)
BEST POSTERS IN HYPERTENSION MONITORING AND TREATMENT
Discussant: Best Posters in hypertension monitoring and treatment. P3351

– S. Abir-Khalil (Rabat, MA)
Accuracy of different types of blood pressure measuring devices at high altitude. Data from P3352
HIGHCARE-ALPS.
– G. Bilo, A. Faini, X. Liu, S. Hoshide, S. Salerno, A. Giuliano, M. Lang, D. Soranna, C. Lombardi, G. Parati
(Milan, IT; Tochigi, JP)
Control rate of hypertension by ambulatory 24-h-blood-pressure in hypertensive type 2 diabetic patients- P3353
results of the German T2Target registry in primary care.
– T. Mengden, U. Ligges, P. Bramlage, W. Sehnert (Bad Nauheim, Dortmund and Cloppenburg, DE)
Cardiovascular diseases registry (RECVASA): focus on antihypertensive treatment and outcomes in P3354
hypertensive patients with cardiac comorbidities.
– M. Lukiyanov, S.A. Boytsov, S.Y.U. Martsevich, S.S. Yakushin, A.N. Vorobyev, A.V. Zagrebelnyy,
A.D. Deev, A.N. Kozminsky, K.G. Pereverseva, E.A. Pravkina (Moscow and Ryazan, RU)
The anti-hypertrophic microRNAs miR-1, miR-133a and miR-26b and their relationship to left ventricular P3355
hypertrophy in patients with essential hypertension.
– J.E. Kontaraki, M.E. Marketou, F.I. Parthenakis, S. Maragkoudakis, E.A. Zacharis, G.E. Kochiadakis,
P.E. Vardas (Heraklion, GR)
216

CATHETER ABLATION AND SUPRAVENTRICULAR ARRHYTHMIAS

Long-term natural history of adult Wolff-Parkinson-White syndrome patients treated with and without P3356
catheter ablation.
– T. Bunch, H.T. May, T.L. Bair, J.L. Anderson, B.G. Crandall, M.J. Cutler, V. Jacobs, J.P. Weiss,
J.B. Muhlestein, J.D. Day (Murray, US)
Management of refractory atrial appendage tachycardia: repetitive catheter ablation or thoracoscopic P3357
atrial appendectomy?
– Z. Liu, Y.H. Jia (Beijing, CN)
Serum levels of YKL-40 before and after therapy in patients with supraventricular arrhythmias. P3358
– D.T. Farmakis, N. Michelakakis, G. Neroutsos, A. Perpinia, E. Voukouti, A. Karavidas, M. Georgiakaki,
V. Pyrgakis (Athens, GR)
Characterization and significance of accessory pathway dormant conduction in patients with WPW P3359
syndrome.
– D. Kaempfner, C. Theis, T. Konrad, S. Sonnenschein, H. Mollnau, K. Bock, B. Quesada Ocete,
E. Himmrich, T. Muenzel, T. Rostock (Mainz, DE)
Noncoronary cusp could be the first-choice ablation site for para-Hisian atrial tachycardia. P3360
– Y. Yamauchi, S. Inaba, S. Yamashita, M. Sekigawa, T. Hirao, K. Aonuma, K. Hirao, K. Okishige (Yokohama,
Musashino, Tsukuba and Tokyo, JP)
Safety, efficacy and learning curve of no-X-ray catheter ablation of atrioventricular nodal reentry P3361
tachycardia.
– S. Stec, K.D. Deutsch, D.K. Karbarz, M.K. Klank-Szafran, J.S. Sledz, M.M. Mazij, B.L. Ludwik,
A. Chruszcz-Chrabaszcz, M. Chrabaszcz, L.S. Spikowski (Rzeszow, Skarzysko-Kamienna, Radom and
Wroclaw, PL)
Anatomical features determining the difficulty of ablation in atrioventricular nodal reentrant tachycardia. P3362
– C. Garweg, R. Willems, S. De Buck, R. Louw, J. Ector (Leuven, BE)
Clinical course of paroxysmal atrioventricular nodal reentrant tachycardia in children. P3363
– T. Kruchina, I. Vinogradova, D. Egorov, O. Laur, G. Novik, B. Tatarsky (St. Petersburg, RU)
Feasibility and accuracy of non-invasive mapping and ablation of different atrial tachycardias. P3364
– T. Neumann, H. Greiss, N. Deubner, A. Berkowitsch, E. Akkaya, J. Sperzel, M. Kuniss (Bad Nauheim, DE)
Comparisons of natural follow-up of supraventricular tachycardia related-adverse events with P3365
MONDAY – MORNING
supraventricular tachycardia ablation-related adverse events.
– B. Brembilla-Perrot, J.M. Sellal, V. Manenti, A. Olivier, T. Villemin, M. Benichou, S. Dorlet, C. De Chillou,
N. Girerd (Vandoeuvre-lès-Nancy, FR)
Use of remote magnetic navigation and 3D image integration to avoid transbaffle access in patients after P3366
total cavopulmonary connection surgery: a single centre experience.
– K. Roy, A. Ueda, F. Gomez, I. Suman-Horduna, S. Babu-Narayan, S. Ernst (London, UK)
The use of a new rapid high resolution mapping system in the validation of linear lesions. P3367
– L. Mantziari, C. Butcher, A. Kontogeorgis, S. Panikker, K. Roy, V. Markides, T. Wong (London, UK)
Short PQ interval on ECG in children: etiology of the phenomenon and its clinical significance. P3368
– E. Oleichuk, T. Kruchina, I. Vinogradova, O. Laur, G. Novik, D. Egorov (St. Petersburg, RU)
Performance of the SA-VA difference to differentiate atrioventricular nodal reentrant tachycardia from P3369
orthodromic reentrant tachycardia in a large cohort of patients.
– F. Akerstrom, M.A. Arias, D.J. Garcia-Fernandez, M. Pachon, R. Salgado, A. Puchol, L. Rodriguez-Padial
(Toledo and Burgos, ES)
CATHETER ABLATION OF SUPRAVENTRICULAR AND VENTRICULAR ARRHYTHMIAS

Novel method of alcohol ablation using endovascular intramyocardial injections. P3370
– E. Kretov, A. Strelnikov, R. Naydenov, D. Sergeevichev, I. Zaykov, A. Romanov, E. Pokushalov (Novosibirsk,
RU)
Ablation of frequent PVC in primary prevention patients meeting criteria for ICD implant. Safety and P3371
appropriateness of withholding the implant.
– D. Penela, J. Acosta, L. Aguinaga, L. Tercedor, J. Fernandez-Armenta, P. Sanchez, J. Brugada, L. Mont,
A. Berruezo (Barcelona and Granada, ES; CITY MISSING, AR)
Isolated epicardial RVOT scar: a typical substrate for VT in endurance athletes without evidence for P3372
inherited cardiomyopathy.
– J. Venlet, S.R.D. Piers, G.F.L. Kapel, M. De Riva Silva, M.J. Schalij, K. Zeppenfeld (Leiden, NL)
Ventricular scar area identified by intracardiac echocardiography improves characterization of substrate P3373
during ventricular tachycardia ablation in structural heart disease.
– S. Kapa, D. Padmanabhan, A. Deshmukh, S. Mulpuru, D. Packer (Rochester, US)
Catheter Ablation of ventricular tachycardia in patients with arrhythmogenic right ventricular P3374
cardiomyopathy: insights from a French monocentric registry.
– Z. Souissi, S. Boule, F. Brigadeau, C. Marquie, L. Guedon-Moreau, C. Kouakam, W. Escande, D. Klug,
S. Kacet, D. Lacroix (Lille, FR)
217
Totally nonfluoroscopic approach for supravenrticular and ventricular tachycardias ablation. Experience P3375
on more than 350 cases.
– E. Kropotkin, E.A. Ivanitskiy (Krasnoyarsk, RU)
The transseptal or transaortic approach for pediatric left sided accessory pathway ablation in era of P3376
NavX/Ensite? Comparison of four apporaches.
– A. Baszko, K. Czyz, S. Stec, A. Lazniak, K. Deutch, J. Sledz, W. Bobkowski (Poznan, Rzeszow and Kielce,
PL)
Electroanatomic mapping system allows zero fluoroscopy in cryo and radiofrequency ablation of P3377
accessory pathways in children.
– C. Raimondo, E. Ebrille, R. De Vito, F. Di Clemente, D. Caponi, P. Di Donna, F. Gabbarini, M. Morosato,
F. Gaita, M. Scaglione (Asti, Turin, Siena and Verona, IT)
Mechanism and catheter ablation of post-cardiac surgery atrial tachycardias. P3378
– G. Zhou, J. Ma, X. Guo, X. Liu, Q. Sun, S. Zhang (Beijing, CN)
Electrocardiographic estimation of successful ablation site in patients with manifest posteroseptal P3379
accessory pathway.
– T. Ulus, H.K. Kabul, C. Barcin, M. Unlu, S. Samedli, S. Kose (Eskisehir and Ankara, TR)
Long-term outcome of intra-atrial reentrant tachycardia catheter ablation in adults with congenital heart P3380
disease.
– R. Peinado, O. Salvador, D. Filgueiras-Rama, A.E. Gonzalez, J. Ruiz-Cantador, A. Vega, J.L. Merino,
M. Gonzalez Vasserot, A. Sanchez Recalde, J.M. Oliver (Madrid, ES)
Real-time magnetic resonance-guided ablation of typical right atrial flutter using a combination of active P3381
catheter tracking and passive catheter visualization in man.
– S. Hilbert, P. Sommer, M. Gutberlet, T. Gaspar, B. Foldyna, C. Piorkowski, M. Grothoff, G. Hindricks
(Leipzig and Dresden, DE)
ABLATION OF ATRIAL FIBRILLATION I
The Historic - AF Trial: European, prospective multicenter study of hybrid thoracoscopic and P3382
transcatheter ablation of persistent atrial fibrillation.
– C. Muneretto, G. Bisleri, G.L. Polvani, A. Curnis, F. Rosati, E. Merati, G. Fassini, M. Moltrasio, C. Tondo,
R. Krakor (Brescia and Milan, IT; Dortmund, DE)
Feasibility and safety of uninterrupted peri-procedural apixaban administration in patients undergoing P3383
radiofrequency catheter ablation for atrial fibrillation: results from a multicenter study.
– L. Di Biase, D. Lakkireddy, C. Trivedi, T. Deneke, M. Martinek, S. Mohanty, P. Mohanty, J. Sanchez,
J.D. Burkhardt, A. Natale (Austin and Kansas City, US; Bad Neustadt an der Saale, DE; Linz, AT)
Rivaroxaban a new alternative to warfarin for atrial fibrillation ablation: a meta-analysis of embolic and P3384
bleeding complications.
– D. Musat, N. Garikipati, M.W. Preminger, T. Sichrovsky, S. Mittal, J.S. Steinberg (Ridgewood and Dayton,
US)
Radiation exposure during pulmonary vein isolation can be dramatically reduced in German EP labs: P3385
comparison of optimized versus non-optimized fluoroscopy.
– T. Kleemann, J. Brachmann, T. Lewalter, K. Kuck, S. Willems, E. Hoffmann, L. Eckardt, M. Hochadel,
J. Senges, R. Zahn (Ludwigshafen am Rhein, Coburg, Munich, Hamburg and Münster, DE)
Sites of atrial fibrillation rotors may overlay ganglionated plexi in left atrium. P3386
– T. Baykaner, J. Zaman, T. Zografos, I. Pantos, D.E. Krummen, S.M. Narayan, D.G. Katritsis (San Diego and
Stanford, US; Athens, GR)
Ipsilateral pulmonary vein isolation using a new force-power-time formula reduces PV reconnection and P3387
improves outcomes in atrial fibrillation patients.
– P. Taghji, M. Duytschaever, Y. Vandekerckhove, T. Phlips, R. Choudhury, R. Tavernier, H. Nakagawa
(Bruges, BE; Oklahoma City, US)
Intra-operative mapping procedure for diagnosis of the substrate of atrial fibrillation. P3388
– N.M.S. De Groot, A. Yaksh, C. Kik, F. Oei, P. Woestijne, J. Hofland, M. Allessie, A. Bogers (Rotterdam, NL)
Reduction of fluoroscopy exposure during atrial fibrillation ablation using a novel fluoroscopy image P3389
integrated 3-dimensional electroanatomical mapping system.
– Y. Huo, M. Christoph, M. Forkmann, M. Pohl, J. Mayer, J. Salmas, J. Sitzy, C. Wunderlich, C. Piorkowski,
T. Gaspar (Dresden, DE)
Catheter ablation of atrial fibrillation: long-term outcome of radiofrequency catheter ablation for redo P3390
procedures after pulmonary vein isolation with the cryoballoon technique.
– K. Kettering, F. Gramley (Frankfurt am Main, DE)
Cryoballoon ablation vs RF-catheterablation of persistent atrial fibrillation: influence of LA area on P3391
succesrate.
– H. Greiss, A. Berkowitsch, N. Duebner, S. Zaltsberg, E. Akkaya, C.W. Hamm, T. Neumann, M. Kuniss (Bad
Nauheim, DE)
Catheter ablation of atrial fibrillation - Lessons from redo procedures. P3392
– S. Rolf, M. Kreuzhuber, S. Kircher, P. Sommer, A. Arya, A. Bollmann, S. Richter, S. Nedios, J. Kosiuk,
G. Hindricks (Leipzig, DE)
Periprocedural complication rates in respect of anticoagulation strategies in patients undergoing catheter P3393
ablation for persistent atrial fibrillation.
– M. Gunawardene, D. Steven, A. Sultan, B. Schaeffer, D. Schreiber, J. Moser, R.Ö. Akbulak, H. Servatius,
B.A. Hoffmann, S. Willems (Hamburg and Cologne, DE; Berne, CH)
218
ABLATION OF ATRIAL FIBRILLATION II

May a clinical assessment predict left atrial appendage thrombi presence in patients undergoing atrial P3394
fibrillation transcatheter ablation? A large retrospective experience.
– M. Anselmino, L. Garberoglio, S. Gili, A. Battaglia, W. Grosso Marra, S. Frea, M. Morello, D. Castagno,
M. Scaglione, F. Gaita (Turin and Asti, IT)
A novel, safe and effective modality of treating persistent atrial fibrillation: concomitant left atrial P3395
appendage electrical isolation and device occlusion.
– S. Panikker, J.W.E. Jarman, L. Mantziari, E. Nicol, S.K. Haldar, W. Hussain, J.P. Foran, V. Markides,
T. Wong (London, UK)
Feasibility and safety of pulmonary vein and coronary sinus isolation in patients with atrial fibrillation and P3396
CRTD: results from a prospective database.
– L. Di Biase, J.D. Burkhardt, C. Trivedi, P. Mohanty, S. Mohanty, R. Horton, J. Sanchez, P. Santangeli,
D. Lakkireddy, A. Natale (Austin and Kansas City, US)
Meta-analysis of Outcome of Catheter Ablation of Persistent Atrial Fibrillation Using Termination Mode as P3397
a Procedural Endpoint.
– C. Pizzi, B. Xhyhery, G.M. Costa, M. Faustino, L. Manzoli (Bologna, Pescara and Chieti, IT)
Anatomical and functional determinants of preferential rotor locations and stability in atrial fibrillation. P3398
– F.S. Ng, C.H. Roney, M.T. Debney, C. Eichhorn, A. Nachiappan, N. Qureshi, R.A. Chowdhury,
P. Kanagaratnam, A.R. Lyon, N.S. Peters (London, UK)
One Shot technologies TO Pulmonary vein isolation (1STOP) project: the standard clinical practice. P3399
– M. Lunati, G. Arena, C. Tondo, L. Padeletti, P. De Filippo, S. Porcellini, L. Leoni, D. Catanzariti, R. Verlato,
A. Curnis (Milan, Massa, Florence, Bergamo, Paderno Dugnano, Padua, Rovereto, Camposampiero and
Brescia, IT)
Impact of continuous monitoring of the pulmonary venous pressure on the acute results of cryoablation P3400
in atrial fibrillation.
– K. Hisazaki, K. Kaseno, N. Amaya, K. Hasegawa, Y. Fukuoka, T. Morishita, K. Ishida, H. Uzui, H. Tada
(Fukui, JP)
Phased array pulmonary vein isolation vs radiofrequency catheter ablation for atrial fibrillation: a P3401
non-inferiority systematic review and meta-analysis.
– A.G. Carrizo, P. Lamelas, N. Pinilla Echeverri, P. Gal, A.G. Elvan, C.A. Morillo (Hamilton, CA; Zwolle, NL)
Prevention of phrenic nerve palsy during cryoballoon ablation in patients with atrial fibrillation - P3402
comparison between percutaneous and endovascular electromyographic monitoring technique.
– H.-H. Minden, M. Koenig-Gorsleben, T. Schau (Henningsdorf and Bernau bei Berlin, DE)
Acute procedural and clinical outcome comparison using the first and second-generation cryoballoon: P3403
inside a large cohort of data derived from real world multicentric experience.
– G. Arena, C. Tondo, A. Curnis, C. Ardito, S. Porcellini, D. Catanzariti, L. Sciarra, L. Leoni, G. Senatore,
L. Padeletti (Massa, Milan, Brescia, Paderno Dugnano, Rovereto, Rome, Padua, Ciriè and Florence, IT)
MONDAY – MORNING
Voltage guided pulmonary vein isolation; preliminary results of short term outcome. P3404
– U. Boles, A. Enriquez, A. Baranchuk, D. Redfearn, C. Simpson, H. Abd Allah, K. Michael (Kingston, CA)
The anticoagulant effect of heparin during radiofrequency ablation (RFA) in patients taking apixaban and P3405
rivaroxaban.
– L.C. Brendel, F. Dobler, G. Hessling, S.L. Braun, A.L. Steinsiek, B.M. Kaess, R. Eckl, I. Deisenhofer, I. Ott
(Munich, DE)
ABLATION OF ATRIAL FIBRILLATION III

Relationship of lungs to left atrium in patients undergoing atrial fibrillation ablation. P3406
– K.A. Walsh, D. Keane, G.J. Fahy (Cork and Dublin, IE)
Loss of pace capture on the ablation line for pulmonary vein isolation can improve the clinical outcome of P3407
catheter ablation for atrial fibrillation.
– I. Koichi, N. Tanaka, K. Tanaka, Y. Toyoshima, T. Oka, Y. Orihara, Y. Koyama, A. Okamura, K. Iwakura,
K. Fujii (Osaka, JP)
Comparison of pulmonary vein isolation guided by remote magnetic navigation in patients with P3408
paroxysmal atrial fibrillation using an irrigated gold-tip and a classical irrigated catheter.
– R. Prisecaru, L. Riahi, D. Stockman, Y. De Greef, P. Van Den Heuvel, B. Schwagten (Antwerp, BE)
A combination of epicardial and endocardial catheter ablation approaches to atrial arrhythmias after P3409
multiple failed atrial fibrillation ablations.
– Y. Huo, T. Gaspar, M. Christoph, M. Forkmann, M. Pohl, J. Mayer, J. Salmas, J. Sitzy, C. Wunderlich,
C. Piorkowski (Dresden, DE)
Chronic hemodialysis is a predictor of periprocedural bleeding complications and ischemic stroke in P3410
patients undergoing catheter ablation of atrial fibrillation.
– Y. Murakawa, A. Nogami, M. Shoda, K. Inoue, S. Naito, K. Kumagai, Y. Miyauchi, T. Yamane, N. Morita,
K. Okumura (Kawasaki, Tsukuba, Tokyo, Osaka, Maebashi, Fukuoka, Hachioji and Hirosaki, JP)
Immediate and medium-term outcomes of cryoballoon in patients with paroxysmal and persistent atrial P3411
fibrillation: a large cohort of data derived from real world multicentric experience.
– C. Tondo, G. Arena, L. Padeletti, G. Cattafi, S. Porcellini, L. Sciarra, L. Leoni, R. Verlato, D. Catanzariti,
A. Curnis (Milan, Massa, Florence, Paderno Dugnano, Rome, Padua, Camposampiero, Rovereto and
Brescia, IT)
Comparison between multi electrodes mapping with the flower catheter and point-by-point technique for P3412
multiple atrial tachycardias in the context of atrial fibrillation ablation.
– T. Delassi, S.S. Bun, D.G. Latcu, M. El Jamili, N. Saoudi (Monaco, MC)
219
Remote magnetic catheter navigation versus conventional ablation in atrial fibrillation ablation: P3413
comparing efficacy, safety and fluoroscopic time.
– P. Lim, J.K. Loh, K. Chua, E. Lim, D. Chong, B.Y. Tan, K.L. Ho, C.K. Ching, W.S. Teo (Singapore, SG)
Monitoring of sedation depth with bispectral index during ablation of atrial fibrillation - are we sedating P3414
too deep?
– J. Moser, M. Lemoine, D. Schreiber, B. Schaeffer, R. Ö. Akbulak, M. Jularic, C.H. Eickholt, C.H. Meyer,
S. Willems, B.A. Hoffmann (Hamburg, DE)
Randomized comparison of catheter ablation of atrial fibrillation with or without non-fluoroscopic P3415
sensor-based catheter navigation.
– S. Rolf, K. Schoene, S. Richter, A. Arya, A. Bollmann, P. Sommer, G. Hindricks (Leipzig, DE)
Catheter ablation of persistent AF: anatomically-based circumferential PV ablation in combination with a P3416
potential-guided segmental approach to achieve PV isolation - long-term FU results (6 years).
– K. Kettering, F. Gramley (Frankfurt am Main, DE)
Safety and feasibility of atrial fibrillation ablation in biological valve patients while on uninterrupted novel P3417
oral anticoagulant.
– L. Di Biase, C. Trivedi, P. Mohanty, S. Mohanty, J. Sanchez, D. Lakkireddy, S. Beheiry, R. Hortom,
J.D. Burkhardt, A. Natale (Austin, Kansas City and San Francisco, US)
ABLATION OF ATRIAL FIBRILLATION IV

Stepwise approach ablation versus pulmonary vein isolation in patients with paroxysmal atrial fibrillation: P3418
randomized controlled trial.
– M. Faustino, T. Agricola, B. Xhyheri, G.M. Costa, L. Leonzio, E. Di Girolamo, C. Pizzi (Pescara, Bologna,
Lanciano and Chieti, IT)
Mitral isthmus ablation with a circular mapping catheter positioned in the left atrial appendage as a P3419
reference for complete conduction block.
– T. Nishiyama, S. Kashimura, Y. Katsumata, T. Kimura, N. Nishiyama, Y. Tanimoto, Y. Aizawa, K. Fukuda,
S. Takatsuki (Tokyo, JP)
Esophageal temperature monitoring during atrial fibrillation ablation: sensitivity of a conventional probe P3420
to detect significant temperature increases.
– R. Delgado, J.L. Merino, E.C. Falconi, A. Burgos, R. Olivares, M. Arceluz, P.F. Cruz, O. Salvador, J. Caro,
J.L. Lopez Sendon (Madrid, ES)
Echocardiographic assessment of atrial and ventricular remodelling after hybrid epicardial P3421
transdiaphragmatic and percutaneous endocardial radiofrequency ablation of persistent atrial fibrillation.
– J. Toplisek, A. Pernat, B. Gersak, N. Ruzic Medvescek, B. Robic, M. Sinkovec (Ljubljana, SI)
The impact of CT image integration using CartoSound image directly acquired from the left atrium in P3422
atrial fibrillation ablation.
– K. Kaseno, K. Hisazaki, N. Amaya, K. Nakamura, D. Aoyama, Y. Shiomi, K. Hasegawa, M. Yokokawa,
H. Uzui, H. Tada (Fukui and Maebashi, JP)
Atrial rhythm and atrial electrogram amplitude. P3423
– S. Havranek, Z. Fingrova, T. Boucek, J. Simek, V. Bulkova (Prague, CZ)
The impact of anterior mitral block on left atrial appendage activation time. P3424
– S. Havranek, J. Simek, D. Wichterle (Prague, CZ)
Loss of contact force affects outcomes in atrial fibrillation ablation. P3425
– K. Morrice, G. Bardhaj, P. Petychev, P. Geelen, T.J.R. De Potter (Aalst, BE)
Characterization of reconduction of pulmonary veins after pulmonary vein isolation using a P3426
multi-electrode duty cycled radiofrequency ablation catheter.
– A. Langbein, L. Karolyi, T. Weinmann, F. Scharfe, S.G. Spitzer (Dresden, DE)
Early redo procedure of atrial fibrillation ablation: the energy source does have a role? P3427
– A. Dello Russo, L. Cipolletta, G.M. Fassini, M. Moltrasio, M. Casella, S. Conti, G. Del Giorno, G. Vettor,
S. Riva, C. Tondo (Milan, IT)
ACUTE CARDIAC CARE IN THE EMERGENCY DEPARTMENT I

Role of atrial fibrillation in patients with acute coronary syndrome and elevated high-sensitive troponin T P3428
levels.
– A.S. Parwani, M. Borschert, B. Kherad, L.H. Boldt, W. Haverkamp, B. Pieske, F. Krackhardt (Berlin, DE)
Inflammatory mediator TIMP-1 is a prognostic marker for mortality in acute coronary syndrome (ACS). P3429
– M.T. Nieminen, P. Vesterinen, O. Parkkonen, T. Tervahartiala, T. Sorsa, J. Sinisalo, P.J. Pussinen (Helsinki,
FI)
Acute heart failure complicating acute myocardial infarction in the contemporary era of modern P3430
treatment.
– J. Krzysztofik, M. Sokolski, M. Proniak, A. Lis, M. Kosowski, W. Zimoch, K. Reczuch, W. Banasiak,
P. Ponikowski, E.A. Jankowska (Wroclaw, PL)
Patients with acute coronary syndrome without chest pain: in-hospital and 1-year prognosis. P3431
– M. Rodrigues Neto, R. Rodrigues, A. Correia, S. Gomes, B. Silva, M. Gomes Serrao, G. Caires,
M. Rodrigues, A. Drumond Freitas, D. Pereira (Funchal, PT)
Myocardial injury in patients without suspected acute coronary syndrome attending the emergency P3432
department.
– A.R. Chapman, A.S. Shah, A. Vaswani, A. Noaman, F. Strachan, D.E. Newby, S. Walker, D.A. McAllister,
A. Gray, N.L. Mills (Edinburgh, UK)
220
Impact of renal dysfunction at admission on survival in mechanically ventilated ST-elevation myocardial P3433
infarction patients after cardiopulmonary resuscitation.
– V. Kanic, M. Vollrath, R. Ekart, S. Bevc, B. Dvorsak, Z. Kanic, R. Hojs (Maribor, SI; Leipzig, DE)
Patients with moderate cerebral perfusion deficit upon hospital arrival may be good candidates for P3434
therapeutic hypothermia following out-of-hospital cardiac arrest.
– T. Unoki, K. Nishiyama, N. Ito, Y. Tsujimura, M. Abe, S. Beppu, T. Endo, H. Anan, T. Nakayama, K. Nagao
(Kyoto, Kawasaki, Sendai, Fujisawashi and Tokyo, JP)
Angiographic findings and survival in patients undergoing coronary angiography due to sudden cardiac P3435
arrest in Western Sweden.
– B. Redfors, T. Ramunddal, O. Angeras, C. Dworeck, P. Petursson, B. Libugan, J. Odenstedt,
P. Albertsson, J. Herlitz, E. Omerovic (Gothenburg, SE)
Optimal blood pressure for favourable neurological outcome in adult patients following in-hospital P3436
cardiac arrest.
– C.H. Wang, C.H. Huang, W.T. Chang, M.S. Tsai, P.H. Yu, A.Y. Wang, N.C. Chen, W.J. Chen (Taipei, New
Taipei City, Taoyuan and Yilan, TW)
Clinical profile, treatment, and outcomes of patients with type B acute aortic syndromes: findings from a P3437
large multicenter Italian registry.
– F. Vagnarelli, M. Marini, A. Corsini, I. Battistoni, S. Soflai Sohee, G. Norscini, T. Piva, G. Melandri,
C. Rapezzi, G.P. Perna (Bologna and Ancona, IT)
Efficacy and safety of intensive statin treatment in Chinese old patients with acute coronary syndrome P3438
undergoing percutaneous coronary intervention.
– W. Liu, Z.Y.X. Zhao, Z.Y.J. Zhou (Beijing, CN)
ISCHAEMIA, EXPERIMENTAL STUDIES I

Two-year clinical outcome of biolimus-eluting stent in coronary bifurcation lesions compared with P3439
everolimus-eluting stent.
– H. Masuda, S. Kuramitu, H. Jinnouchi, T. Hiromasa, Y. Kobayashi, T. Morinaga, S. Shirai, K. Ando,
M. Nobuyoshi (Kitakyushu, JP)
Sex-based differences in 2-year clinical outcome after percutaneous coronary intervention with new P3440
generation drug eluting stent.
– H. Jinnouchi, S. Kuramitsu, Y. Kobayashi, T. Hiromasa, T. Morinaga, H. Masuda, S. Shirai, K. Ando,
M. Nobuyoshi (Kitakyushu, JP)
Investigating the molecular signaling pathway of perconditioning: focused on STAT5 and eNOS inhibition. P3441
– I. Andreadou, S.I. Bibli, A. Zoga, D. Farmakis, P. Efentakis, E. Mastromanolis, D.T.H. Kremastinos,
E.K. Iliodromitis (Athens, GR)
Post-infarction adverse remodeling in rats is attenuated by local growth hormone administration via an P3442
alginate-scaffold.
MONDAY – MORNING
– E.P. Daskalopoulos, A.D. Vilaeti, E. Barka, P. Mantzouratou, M. Kontonika, A. Papalois, C. Pantos,
W.M. Blankesteijn, S. Agathopoulos, T.M. Kolettis (Maastricht, NL; Ioannina and Athens, GR)
Vasonatrin peptide inhibits endoplasmic reticulum stress and attenuates myocardial ischemia/reperfusion P3443
injury in diabetic rats.
– H. Zhang, W. Wang, Z. Shi, F. Fu, X. Liang (Xi’an, CN)
Hyperglycaemic exacerbation of myocardial ischaemia/reperfusion injury is mitigated by SGLT inhibition. P3444
– I. Harding, M. O’Keeffe, D.M. Yellon, R.M. Bell (London, UK)
Kinetics of cardioprotection by plasma dialysate from healthy volunteers undergoing remote ischemic P3445
preconditioning.
– H. Hildebrandt, P. Kahlert, G. Heusch, P. Kleinbongard (Essen, DE)
Oxidative DNA damage in acute myocardial infarction. P3446
– J. Bis, P. Fikrova, R. Stetina, J. Stasek, J. Dusek, Z. Zadak (Hradec Králové and Brno, CZ)
Endothelial progenitor cell-conditioned medium delivery by polymer nanoparticles in an ischemic P3447
hindlimb model.
– M.C. Barsotti, L. Botta, T. Santoni, F. Felice, S. Burchielli, A. Pucci, A.M. Piras, F. Chiellini, R. Solaro, R. Di
Stefano (Pisa, IT)
Circulating microRNAs as potential novel biomarkers for clinical outcome in patients with acute coronary P3448
syndrome.
– P. Jakob, D. Heg, R. Klingenberg, N. Rodondi, P. Vogt, F. Mach, S. Windecker, C.M. Matter, T.F. Luescher,
U. Landmesser (Zurich, Berne, Lausanne and Geneva, CH)
The difference in rates of postprocedural ischemia in side branch and main branch after coronary P3449
bifurcation stenting detected with intracoronary electrocardiography.
– D.V. Vassilev, K. Karamfiloff, R.G. Gil, G.R. Rigatelli (Sofia, BG; Warsaw, PL; Rovigo, IT)
The effects of serum klotho levels on endothelial function and early atherosclerosis predictors in healty P3450
population:.
– N. Keles, M. Caliskan, B. Dogan, N.N. Keles, F. Aksu, O. Kostek, B. Isbilen, A. Oguz (Istanbul and Erzurum,
TR)
ACUTE INTENSIVE CARDIOVASCULAR CARE I

Incremental value of copeptin with high sensitivity cardiac troponin T for exclusion of severe coronary P3451
stenosis in patients with preexisting coronary artery disease.
– A. Iemmi, A.M. Dupuy, N. Kuster, J.P. Cristol, F. Roubille, J.C. Macia, B. Lattuca, M. Akodad, D. Belardi,
F. Leclercq (Montpellier, FR)
221
High-grade atrioventricular block in ST-segment elevation myocardial infarction patients: insights of a P3452
terciary centre.
– G. Abreu, C. Braga, C. Arantes, J. Martins, C. Quina-Rodrigues, C. Vieira, A. Salgado, P. Azevedo,
J. Marques (Braga, PT)
Factors associated with subacute or late cardiac tamponade in the postoperative period of cardiac P3453
surgery. A case-control study.
– E. Hernandez Leiva, M. Carreno Jaimes, R. Dennis Verano, D. Isaza Restrepo, F. Rada Bucheli, A. Cadena
Bonifante, J.P. Umana Mallarino (Bogota, CO)
Non-occlusive mesenteric ischemia (NOMI) after out of hospital cardiac arrest: incidence and outcome of P3454
an underappreciated phenomenon.
– R. Wurm, A. Cho, H. Arfsten, K.A. Tendl, R. Van Tulder, C. Wallmueller, F. Sterz, C.A. Adlbrecht, G. Heinz
(Vienna, AT)
Effective heart rate control by ivabradine in patients with acute heart failure. P3455
– J. Treptau, O. Jeske, L.C. Napp, A. Menon, B. Schieffer, A. Schaefer, J. Bauersachs, J. Tongers (Hannover
and Marburg, DE)
A single centre contemporary retrospective review of intra aortic balloon pump use. P3456
– F. Choudhary, R. Parasa, S. Brown, A. Harcombe (Nottingham, UK)
Acute coronary syndromes without chest pain: a high risk group? P3457
– P. Magalhaes, S. Leao, F. Cordeiro, P. Mateus, S. Carvalho, J.I. Moreira (Vila-Real, PT)
ISCHAEMIA, EXPERIMENTAL STUDIES II
Circulating endothelial progenitor cells are actively involved in the reparative mechanisms of stable P3458
ischemic myocardium.
– D. Morrone, F. Felice, C. Scatena, A. De Martino, M.L.E. Picoi, R. Di Stefano, G. Bevilacqua, U. Bortolotti,
A.G. Naccarato, A. Balbarini (Pisa, IT)
Inhibition of Rap1 enhances mesenchymal stem cells-mediated heart protection following myocardial P3459
infarction.
– Y. Zhang, S. Chiu, X. Liang, F. Gao, S. Liao, H. Tse, Q. Lian (Hong Kong, HK)
Selective inhibition of receptor activator of NFkB ligand (RANKL) in hematopoietic cells improves P3460
outcome after experimental myocardial infarction in mice.
– S. Slavic, O. Andrukhova, U. Zeitz, K. Ford, M. Kleiter, S. Handschuh, P.J. Kostenuik, R.G. Erben (Vienna,
AT; Newbury Park, US)
Intracoronary adenosine: dose-response relationship with hyperemia. P3461
– J.A. Adjedj, G.T. Toth, N.P.J. Johnson, M.P. Pellicano, A.F. Ferrara, V.F. Flore, G.D.G. Di Gioia,
E.B. Barbato, O.M. Muller, B.D.B. De Bruyne (Aalst, BE; Houston, US; Lausanne, CH)
Early detection of low-grade myocardial ischemia by miniaturized 3-axis accelerometer. P3462
– S. Hyler, S. Pischke, O.J. Grymyr, A. Espinoza, H. Skulstad, J. Bergsland, E. Fosse, P.S. Halvorsen (Oslo,
NO)
Low molecular weight dextran usage in intracoronary imaging guided percutaneous coronary intervention P3463
was associated with high incidence of filter no re-flow phenomenon.
– M. Nozoe, Y. Yamamoto (Fukuoka, JP)
Human mesenchymal stem cell (hMSC)-derived exosomes upregulate Bcl-2, a cross talk between P3464
apoptosis and autophagy, reducing ischemia / reperfusion injury.
– P. Wang, X.F. Jiang, K.S. Lew, Q.Y. Chen, A.M. Richards (Singapore, SG; Shanghai, CN)
Activation of orphan nuclear receptor ROR-alpha, but not ROR-beta and ROR-gamma, protects against P3465
myocardial ischemia/reperfusion injury.
– J. Pu, P. Zhang, E. Gao, X. Ma, B. He (Shanghai, CN; Baltimore and Philadelphia, US)
The investigation of the dynamic thiol-disulfide homeostasis in acute coronary syndrome. P3466
– M.E. Erkus, I.H. Altiparmak, R. Demirbag, O. Gunebakmaz, Z. Kaya, A. Taskin, S. Neselioglu, O. Erel
(Sanliurfa and Ankara, TR)
The effect of high loading dose of atorvastatin in ST elevation myocardial infarction patients undergoing P3467
primary percutaneous coronary intervention on microvascular perfusion.
– S. Indriani, D. Firman, A. Santoso, A.M. Soesanto (Jakarta, ID)
ACUTE INTENSIVE CARDIOVASCULAR CARE II

Does the timing of the initiation of intraaortic balloon pump therapy affect mortality in patients with acute P3468
coronary syndrome complicated by cardiogenic shock?
– G.T. Szabo, I. Bojti, I. Racz, I. Edes, Z.S. Koszegi (Debrecen, HU)
Impact of intra-aortic balloon pump in prognosis of patients with acute myocardial infarction complicated P3469
by cardiogenic shock after primary percutaneous coronary intervention: nationwide cohort study.
– S. Chimed, H.Y. Liang, W.H. Hsu (Taichung, TW)
Mortality and the effect of of target temperature management (33 vs. 36) in comatose patients P3470
resuscitated from cardiac arrest does not differ between males and females.
– M. Winther-Jensen, C. Hassager, M. Wanscher, N. Nielsen, A. Aneman, H. Friberg, Y. Gasche, J. Horn,
J. Hovdenes, J. Kjaergaard (Copenhagen, DK; Helsingborg and Lund, SE; Sydney, AU; Geneva, CH;
Amsterdam, NL; Oslo, NO)
Effect of temperature on the relationship between cardiac power output and mixed venous oxygen P3471
saturation in healthy pigs: comparison to dobutamine.
– A. Alogna, M. Manninger-Wuenscher, M. Schwarzl, B. Zirngast, J. Verderber, D. Zweiker, P. Steendijk,
H. Maechler, B. Pieske, H. Post (Graz, AT; Hamburg and Berlin, DE; Leiden, NL)
222
Mehran contrast nephropathy risk score: is still useful ten years later? P3472
– R. Abellas Sequeiros, S. Raposeiras-Roubin, E. Abu-Assi, D. Iglesias-Alvarez, A. Redondo-Dieguez,
R. Gonzalez-Ferreiro, R. Ocaranza-Sanchez, C. Pena-Gil, J.M. Garcia-Acuna, J.R. Gonzalez-Juanatey
Acute coronary syndrome and atrial fibrillation a world of many questions. P3473
– M. Cassandra, A. Fernandes, M. Madeira, L. Teles, I. Almeida, F. Caetano, M. Costa, L. Goncalves
(Coimbra, PT)
Is there clinical benefit with thrombus aspiration in patients with ST-segment elevation myocardial P3474
infarction? Results from real-life data.
– R.A. Abellas Sequeiros, S. Raposeiras-Roubin, E. Abu-Assi, M. Castineira-Busto, R. Fandino-Vaquero,
A. Cid-Menendez, M.C. Gonzalez-Cambeiro, A. Lopez-Lopez, J.M. Garcia-Acuna, J.R. Gonzalez-Juanatey
Tissue Doppler estimation of hemodynamic status of cardiogenic shock due to acute coronary syndrome P3475
or acute decompensation of chronic heart failure.
– M. Chmielecki, M. Fijalkowski, R. Galaska, A. Rynkiewicz, I. Stopczynska, M. Gruchala (Gdansk, PL)
Mini-invasive circulatory support systems and extracorporeal membrane oxygenation in the management P3476
of cardiogenic shock and refractory cardiac arrest: results from a prospective registry.
– P. Ostadal, A. Kruger, D. Vondrakova, P. Kmonicek, M. Mates, M. Janotka, K. Kopriva, P. Jehlicka,
D. Doubek, P. Neuzil (Prague, CZ)
Impact of acute heart failure in patients with non-ST elevation acute coronary syndrome by their P3477
functional classification and the application of early invasive strategy.
– Y. Shiraishi, S. Kohsaka, M. Sawano, T. Inohara, K. Fukuda (Tokyo, JP)
ACUTE CARDIAC CARE IN THE EMERGENCY DEPARTMENT II

Tissue inhibitor of matrix metalloproteinase 1 (TIMP-1) as a novel marker to distinguish acute coronary P3478
syndrome (ACS) from other acute cardiac conditions.
– P. Vesterinen, M.T. Nieminen, T. Tervahartiala, T. Sorsa, P. Pussinen, J. Sinisalo (Helsinki, FI)
Different clinical findings at the chest pain unit: do women spend more time seeking emergency room? P3479
– M.B. Rivas, E.T. Mesquita, A. Volschan, M.I. Garcia, M.V.R.S. Martins, A.V. Meireles, R. Lobo, K. Mocarzel,
R. Lameira, I. Starling (Rio de Janeiro, BR)
Copeptin and high-sensitive troponin T for the rapid diagnosis of non-ST-elevation acute coronary P3480
syndrome.
– B. Morawiec, D. Kawecki, B. Przywara-Chowaniec, M. Opara, A. Gabrysiak, L.A.M. Ho, O. Muller,
E. Nowalany-Kozielska (Zabrze, PL; Hong Kong, HK; Lausanne, CH)
1h-algorithm versus 2h-algorithm.
– R. Twerenbold, M. Rubini Gimenez, K. Wildi, T. Reichlin, C. Puelacher, P. Hillinger, M. Wagener,
MONDAY – MORNING
Neurologic status as a predictor of short-term outcome in patients with cardiogenic shock. P3482
– Y. Ueki, H. Imamura, M. Mohri, T. Matoba, Y. Tsujita, M. Yamasaki, K. Nagao, E. Tachibana, N. Yonemoto
(Tokyo, JP)
An updated heart fatty acid binding protein assay facilitates improved rule-out of acute myocardial P3483
infarction within 2 hours of entry to the emergency department: threshold derivation and validation.
– J.W. Pickering, J.M. Young, P. George, J. Wallace, S. Aldous, R. Troughton, A.M. Richards, M.P. Martin
(Christchurch, NZ)
Direct comparison of the safety and efficacy of two rule-out strategies for acute myocardial infarction: P3484
undetectable levels of cardiac troponin at presentation versus 1h-algorithm.
– R. Twerenbold, M. Rubini Gimenez, K. Wildi, C. Puelacher, K. Grimm, M. Wagener, J. Boeddinghaus,
T. Reichlin, S. Osswald, C. Mueller (Basel, CH)
Heart score with and without a single troponin testing to rule-out acute coronary syndrome. P3485
– T. Moumneh, V. Richard-Jourjon, E. Friou, B. Mazet-Guillaume, J. Choukroun, A. Penaloza, F. Prunier,
P.M. Roy (Angers, Poitiers and Le Mans, FR; Brussels, BE)
High sensitivity troponin T in the rule-out of acute coronary syndrome at the emergency department: the P3486
age matters.
– R. Martin Asenjo, B. Diaz Anton, J. Nuche Berenguer, E.A. Lopez Jimenez, L. Castro Arias, J.J. Parra
Fuertes, C. Iborra Cuevas, R. Tello De Meneses, F. Arribas Ynsaurriaga (Madrid, ES)
Underlying cause for pre hospital cardiac arrest - incidence of culprit lesions after successful P3487
resuscitation and their predictability by ECG recordings.
– H.-C. Mochmann, S. Strauss, B. Windorfer, H.R. Arntz, U. Landmesser (Berlin, DE)
ACUTE INTENSIVE CARDIOVASCULAR CARE III
Therapeutic hypothermia in patients resuscitated from out-of-hospital cardiac arrest: a meta-analysis of P3488
randomized controlled trials.
– P. Villablanca Spinetto, P. Christia, M. Makkiya, D. Briceno, E. Einsenberg, M. Salih, W. Gonzalez,
M. Menegus, M. Garcia, D. Sims (New York and Chesterfield, US)
Peak systolic velocity by tissue Doppler detects changes in myocardial contraction related to inotropic P3489
effects of levosimendan in patients with acute heart failure complicating myocardial infarction.
– T. Husebye, J. Eritsland, I. Seljeflot, H. Arnesen, R. Bjoernerheim, G.O. Andersen (Oslo, NO)
Role of copeptin in the postoperative management of patients after on-pump cardiac surgery. P3490
– E. Angeloni, G. Melina, S. Refice, A. Roscitano, F. Capuano, C. Comito, R. Sinatra (Rome, IT)
223
Ventricular conduction defects - prevalence and impact on survival in cardiogenic shock. P3491
– H.E.V. Tolppanen, R. Jurkko, J. Lassus, J. Spinar, M. Ventila, T. Nieminen, T. Tarvasmaki, M. Banaszewski,
A. Sionis, V.-P. Harjola (Helsinki, FI; Brno, CZ; Warsaw, PL; Barcelona, ES)
Effects of hyperthermia and mild hypothermia on myocardial function in pigs: comparison to dobutamine. P3492
– A. Alogna, M. Manninger-Wuenscher, M. Schwarzl, B. Zirngast, J. Verderber, D. Zweiker, P. Steendijk,
H. Maechler, B. Pieske, H. Post (Graz, AT; Hamburg and Berlin, DE; Leiden, NL)
Culprit-only or complete revascularization in patients with non-ST segment elevation acute coronary P3493
syndromes and multivessel coronary artery disease: a propensity score matching-based analysis.
– R. Baptista, S. Monteiro, P. Monteiro, F. Goncalves, M. Pego (Coimbra, PT)
Long-term outcome after extracorporeal membrane oxygenation due to refractory cardiogenic shock. P3494
– S. De Waha, S. Desch, I. Eitel, J. Poess, G. Fuernau, G. Schuler, H. Thiele (Lübeck and Leipzig, DE)
The immediate percutaneous intervention after bypass surgery complicated by periprocedural myocardial P3495
infarction may improve clinical outcomes.
– J. Zalewski, K. Krawczyk, K. Janowiec, A. Flis, J. Nessler (Krakow, PL)
ECHOCARDIOGRAPHIC MODIFICATIONS IN EVOLUTION AND TREATMENT OF VALVULAR HEART

DISEASE
Differences in left ventricle mass regression in patients with aortic valve stenosis treated with P3496
transcatheter or surgical aortic valve replacement: an echocardiographic study.
– A.T. Ngo, C. Hassager, H.G.H. Thyregod, D. Steinbruchel, L. Sondergaard, N. Ihlemann (Copenhagen, DK)
Left ventricular mechanical dispersion predicts clinical outcome in patients with moderate to severe P3497
aortic stenosis.
– L.G. Klaeboe, T.F. Haland, I.S. Leren, R.M.A. Ter Bekke, H. Rosjo, T. Omland, K.H. Haugaa, T. Edvardsen
(Oslo and Akershus, NO; Maastricht, NL)
Dynamic 3-dimensional echocardiographic assessment of mitral valve in patients with functional mitral P3498
regurgitation caused by lone atrial fibrillation.
– T. Machino, Y. Seo, K. Sato, A. Sugano, M. Yamamoto, Y. Harimura, T. Ishizu, K. Aonuma (Tsukuba, JP)
Predictive factors of left ventricular outflow tract obstruction after aortic surgery in patients with severe P3499
aortic stenosis.
– G. Hashimoto, M. Suzuki, H. Yoshikawa, T. Otsuka, K. Makino, Y. Isekame, S. Ozaki, M. Moroi,
M. Nakamura, K. Sugi (Tokyo, JP)
A cross-sectional study of endocardial lead-related tricuspid regurgitation: towards proposing a new P3500
practical 2D/3D echocardiographic approach for better risk stratification.
– A. Hamdanchi, Y. Asadi, S. Otto, M. Hoyme, C. Jung, A. Lauten, T. Doenst, H.R. Figulla, T.C. Poerner,
B. Goebel (Jena, DE)
Echocardiographic changes in TAVI: Comparison of direct versus non-direct TAVI with a self-expanding P3501
bioprosthesis.
– K. Stathogiannis, K. Toutouzas, G. Latsios, A. Synetos, E. Sanidas, M. Drakopoulou, S. Yuecel,
U. Gerckens, E. Grube, D. Tousoulis (Athens, GR; Bonn, DE)
Left atrial volume changes and left atrial 2D strain measurements for diagnostic and prognostic P3502
evaluation of heart failure patients with MR undergoing mitraclip procedure.
– O.M. Galuszka, M. Reinthaler, S. Rutschow, M. Gross, U. Landmesser, M. Kasner (Berlin, DE)
Assessing aortic regurgitation after TAVI: overcoming diagnostic pitfalls. P3503
– A. Goncalves, C. Nyman, D.R. Okada, A. Singh, J. Swanson, S.D. Solomon, P.B. Shah, D.L. Bhatt,
D. Shook, R. Blankstein (Boston, US)
Impact of aortic valve repair and valve-sparing procedures on the mitral annular geometry assessed by P3504
3-dimensional transesophageal echocardiography.
– M. Page, M. Laflamme, C. De Meester, M. Amzulescu, M. Van Dyck, C. Watremez, L. De Kerchove,
G. El-Khoury, A. Pasquet, J.L. Vanoverschelde (Brussels, BE)
Mitral/Aortic Velocity flow Integral Ratio as a simple and useful index to evaluate residual mitral P3505
regurgitation after MitraClip implantation.
– G. Palmiero, L. Ascione, C. Sordelli, V. Monda, R. Ascione, A. D’Andrea, G. Bonzani, P. Caso (Naples, IT)
THE GREAT DIAGNOSTIC POWER OF STRESS ECHOCARDIOGRAPHY
Diagnostic and prognostic features in patients with a positive exercise ECG testing but normal exercise P3506
echocardiography.
– G. Sanchez-Fernandez, J. Peteiro, L. Perez-Cebey, A. Bouzas-Mosquera, J. Broullon,
J.M. Vazquez-Rodriguez (A Coruña, ES)
Outcome by treadmill exercise echocardiography in patients with low pre-test probability of coronary P3507
artery disease.
– J. Peteiro, L. Perez-Cebey, A. Bouzas-Mosquera, J. Broullon, G. Sanchez-Fernandez,
J.M. Vazquez-Rodriguez (A Coruña, ES)
Usefulness of negative supine bicycle exercise stress echocardiography in patients with end stage renal P3508
disease evaluated for renal transplantation.
– F. Mantovani, L. Bertelli, R. Lugli, F. Bursi, M.G. Modena, V. Chiarini, S.S. Abdelmoneim, E. Rubbiani,
G. Cappelli, A. Barbieri (Modena, IT; Rochester, US)
Blunted stress upregulation of stroke volume index is related to impaired end-diastolic volume P3509
recruitment.
– T. Bombardini, M.C. Scali, S. Salvadori, E. Picano (Pisa, IT; Astana, KZ)
224
End-systolic volume and end-diastolic volume reserve predict cardiac events in patients with negative P3510
stress echocardiography.
– T. Bombardini, E. Picano (Pisa, IT; Astana, KZ)
Impact of pre-operative dobutamine stress echocardiography on outcomes in patients undergoing P3511
orthotopic liver transplantation.
– K. Patel, L. Rodriguez, R.A. Grimm, B.P. Griffin, M.Y. Desai (Cleveland, US)
Is ischemic cascade reproduced during dipyridamole-induced myocardial ischemia? P3512
– A. Di Franco, A. Villano, F. Bruno, G. Russo, P. Lamendola, C. Lauria, A. Sestito, F. Pennestri’, G.A. Lanza,
F. Crea (Rome, IT)
Dobutamine-induced changes of longitundinal strain predicts longterm mortality in severe heart failure. P3513
– I. Ikonomidis, I. Paraskevaidis, C. Papadopoulos, V. Stasinos, J. Parissis, J. Lekakis (Athens, GR)
Value of additional diastolic strain rate analysis at rest, during dobutamine stress and recovery in P3514
detecting significant coronary stenosis.
– E. Rumbinaite, J.J. Vaskelyte, I. Ceponiene, M. Viezelis, T. Lapinskas, J. Vencloviene, M. Kinderyte,
E. Ruzgyte, I. Jonauskiene, R. Slapikas (Kaunas, LT)
Prognostic utility of stress testing and novel cardiac biomarkers in post-menopausal women at low to P3515
intermediate risk for coronary ARTery disease (SMART study): 5 year outcome.
– S.S. Abdel Moneim, C. Ball, S.J. Eifert Rain, M. Garcia, F. Mantovani, C. Orlandi, S.L. Mulvagh (Rochester,
US)
NOVEL IMAGING TECHNIQUES IN CARDIAC DIAGNOSIS AND THERAPY

Contribution of ultrasound contrast in predicting conduction disturbances during percutaneous alcohol P3516
septal ablation.
– J. Ternacle, P. Boiron, R. Gallet, S. Champagne, C. Antoine, L. Krapf, H.-L. Doan, J.-L. Dubois-Rande,
E. Teiger, P. Lim (Créteil, FR)
The early impact of breast cancer radiotherapy on myocardial tissue properties in 2D echocardiography P3517
with increased echodensity of the myocardial walls, an ultrasound tissue characterization study.
– S. Tuohinen, T. Skytta, V. Virtanen, M. Virtanen, T. Luukkaala, P. Kellokumpu-Lehtinen, P. Raatikainen
(Tampere and Jyvaskyla, FI)
Acute changes in right atrial function after iloprost inhalation in patients with pulmonary arterial P3518
hypertension: an echocardiographic deformation imaging study.
– L. Gabrielli, A. Kanacri, J. Vega, R. Saavedra, S. Cordova, P. Sepulveda, P. Castro (Santiago, CL)
Myocardial scar evaluation by 2D contrast echocardiography. P3519
– R. Murzilli, L.A. Leo, S. Muzzarelli, E. Pasotti, T. Moccetti, F.F. Faletra (Lugano, CH)
Development of an echocardiographic model to predict significant perivalvular regurgitation after TAVI. P3520
– F. Islas, C. Olmos, C. Almeria, E. Garcia, L. Nombela-Franco, A. Fernandez-Ortiz, P. Marcos-Alberca,
P. Mahia, C. Macaya, L. Perez De Isla (Madrid, ES)
MONDAY – MORNING
A new echocardiographic evaluation of ascending aorta elasticity in patients with bicuspid aortic valve. P3521
– C. Zito, L. Longobardo, M.C. Cusma-Piccione, M. Zucco, M. D’Angelo, M.L. Carerj, M. Meschisi,
R. Manganaro, M.C. Todaro, S. Carerj (Messina, IT)
Accuracy af adenosine 2D strain stress echocardiography in the detection of coronary artery disease in P3522
– J.A. Ejlersen, S.H. Poulsen, J. Mortensen, O. May (Herning and Aarhus, DK)
Stress speckle tracking; an underestimated tool in detecting myocardial viability. P3523
– A.M. Saleh, K. Zintl, A. Elamin, M. Elbaz, H. Negm, B. Bluem, H. Pless, J. Brachmann (Coburg, DE; Cairo,
EG)
The quantitative assessment of the rotation and twist of the left ventricle during dobutamine stress P3524
echocardiography- comparison between patients with and without significant coronary artery stenosis.
– A.J. Mielczarek, J.D. Kasprzak, P. Lipiec, K. Wierzbowska-Drabik (Lodz, PL)
Value of peak cardiac power output-to-left ventricular mass to risk stratify patients with chronic systolic P3525
heart failure.
– C. Cucco, G.E. Mandoli, M.C. Scali, G. Guarini, A. Simioniuc, V. Di Bello, F.L. Dini, M. Marzilli, E. Picano
(Pisa, IT; Astana, KZ)
CARDIAC MECHANICS AND VALVULAR HEART DISEASE
Edge-to-edge-repair in patients with secondary mitral regurgitation: effect myocardial function as P3526
assessed by echocardiographic speckle tracking analysis.
– L. Faber, W. Scholtz, N. Bogunovic, S. Scholtz, Z. Dimitriadis, J. Boergermann, J. Gummert, D. Horstkotte
(Bad Oeynhausen, DE)
Back to the future: head to head comparison of hemodynamically re-validated Doppler end-diastolic P3527
pulmonary regurgitant gradient and ASE-EACVI algorithm for the estimation of pulmonary wedge
pressure.
– P. Barbier, M. Guglielmo, M.C. Scali, A. Simioniuc, C. Cucco, L. Fusini, G. Savioli, C. Cefalu, F. Dini (Milan,
Pisa and Pavia, IT)
Determination of the compensatory mechanism in HCM and severe aortic stenosis patients with P3528
preserved LV ejection fraction by 2D myocardial multi-layer speckle tracking strain echocardiography.
– K. Ozawa, N. Funabashi, H. Takaoka, Y. Kobayashi (Chiba, JP)
The impact of significant tricuspid regurgitation on echocardiographic assessment of right ventricular P3529
performance.
– R. Takemoto, H. Oe, Y. Ohno, N. Watanabe, S. Takahashi, T. Kimura, T. Miyoshi, K. Nakamura, H. Morita,
H. Ito (Okayama, JP)
225
Impact of global and segmental hypertrophy on 2D and 3D strain in hypertrophic cardiomyopathy: P3530
comparison with healthy subjects.
– D. Voilliot, O. Huttin, N. Hammache, L. Filippetti, T. Vaugrenard, E. Aliot, N. Sadoul, Y. Juilliere,
C. Selton-Suty (Nancy and Aix-en-Provence, FR)
Global myocardial mechanics with 3-Dimensional speckle tracking echocardiography in hypertrophic P3531
cardiomyopathy.
– R. Hinojar, E. Casas, J.C. Portugal, A. Gonzalez-Gomez, L.M. Rincon, A. Garcia Martin, S. Ruiz,
J.J. Jimenez Nacher, C. Fernandez-Golfin, J.L. Zamorano (Madrid and Las Palmas de Gran Canaria, ES)
Novel vendor independent software for right ventricular quantification by 3D echocardiography shows P3532
good reproducibility and improved accuracy in comparison with cardiac magnetic resonance.
– V. Spadotto, D. Muraru, A. Cecchetto, G. Romeo, P. Aruta, A. Maddalozzo, M.H. Miglioranza, D. Peluso,
S. Iliceto, L.P. Badano (Padua, IT; Porto Alegre, BR)
Reduction in left atrial early diastolic strain rate evaluated by two-dimensional speckle tracking reflects P3533
left atrial appendage dysfunction in acute ischemic stroke patients with sinus rhythm.
– G. Yamaura, T. Watanabe, M. Wanezaki, S. Sasaki, S. Nishiyama, T. Arimoto, H. Takahashi, T. Shishido,
T. Miyamoto, I. Kubota (Yamagata, JP)
Age- and Gender-related Differences on Left Ventricular Systolic Mechanics in Asymptomatic Asian P3534
Population: Special Focus on Torsion.
– K.T. Sung, Y.H. Lai, C.I. Lo, W.R. Lan, T.C. Hung, J.Y. Kuo, J.Y. Hou, H.I. Yeh, C.L. Hung (Taipei, TW)
GENETICS AND GENE THERAPY
The long noncoding RNA MALAT1-derived mascRNA is highly enriched in immune cells and regulates P3535
monocyte-macrophage functions.
– W. Poller, M. Gast, B. Schroen, X. Wang, C. Skurk, M. Loebel, C. Scheibenbogen, H. Schultheiss,
U. Landmesser, S. Dimmeler (Berlin and Frankfurt am Main, DE; Maastricht, NL)
A novel locus on chromosome 19p13.3 linked to arrhythmogenic cardiomyopathy. P3536
– G. Poloni, I.E.A. Li Mura, B. Bauce, I. Rigato, M. Calore, A. Lorenzon, M. De Bortoli, D. Corrado, C. Basso,
A. Rampazzo (Padua, IT)
Constitutively active phosphatase inhibitor-1 improves cardiac contractility in unchallenged mice but is P3537
deleterious in a model of pressure-overload.
– D.M. Schwab, R. Bauer, L. Tilemann, M. Heckmann, A. Jungmann, C. Vettel, H.A. Katus, A. El-Armouche,
O.J. Mueller (Heidelberg and Dresden, DE)
Translational regulation shapes the molecular landscape of complex disease phenotypes. P3538
– S. Schafer, E. Adami, M. Heinig, K.E. Costa Rodrigues, F. Kreuchwig, E. Cuppen, M. Pravenec, M. Vingron,
S.A. Cook, N. Hubner (Singapore, SG; Berlin, DE; Utrecht, NL; Prague, CZ)
Mice with cardiac specific overexpression of hDSC2 develop a biventricular cardiomyopathy associated P3539
with severe fibrosis and calcification.
– A. Brodehl, C. Diao, K. Martens, D.D. Belke, B. Gerull (Calgary, CA)
Next generation sequencing in thoracic aortic aneurysms and dissections - eight novel mutations in P3540
known genes (ACTA2, FBN1, MYH11, SKI, SMAD3, and TGFBR1).
– J.K. Poninska, Z.T. Bilinska, M. Rydzanicz, E. Michalak, M. Franaszczyk, E. Szpakowski, A. Pollak,
P. Chmielewski, M. Kusmierczyk, R. Ploski (Warsaw, PL)
Gene expression in myocardial tissue and peripheral blood cells: potential RNA-biomarkers for P3541
myocarditis identification.
– A. Runov, D. Khaschevskaya, E. Kurchakova, O. Moiseeva, M. Vonsky (St. Petersburg, RU)
Strategies to normalize zebrafish specific cardiac phenotypes resembling different human myosin binding P3542
protein C3 mutations using RNA approach.
– S. Da’as, E.A. Mohamed, J. Yu, J. Butcher, J. Al Suwaidi, M. Yacoub (Doha, QA; London, UK; Ithaca, US)
Detection of novel TTN truncating variants in patients with unexplained left ventricular systolic P3543
dysfunction and genotype-phenotype correlations.
– M. Franaszczyk, R. Ploski, P. Chmielewski, J. Kosinska, E. Michalak, P. Stawinski, M. Kusmierczyk,
T. Zielinski, G. Truszkowska, Z.T. Bilinska (Warsaw, PL)
STEM CELLS AND CELL THERAPY I

Teratocarcinoma arising from induced pluripotent stem cell-derived cardiac tissue constructs can be P3544
diagnosed by FDG-PET to induce alloimmune rejection by cessation of immunosuppression.
– A. Kawamura, S. Miyagawa, S. Fukushima, T. Kawamura, E. Ito, T. Watabe, S. Masuda, J. Hatazawa,
E. Morii, Y. Sawa (Osaka, JP)
Improved endothelialisation of synthetic dual peptide-conjugated vascular graft seeded with human P3545
pericytes.
– P. Campagnolo, A.J. Gormley, L.W. Chow, P. Madeddu, M.M. Stevens (London and Bristol, UK)
Neoinnervation and neovascularization in decellularized pericardial implants after myocardial infarction in P3546
swine.
– C. Galvez-Monton, M.T. Fernandez Figueras, M.T. Marti, C. Soler-Botija, S. Roura, I. Perea-Gil,
C. Prat-Vidal, A. Llucia-Valldeperas, A. Raya, A. Bayes-Genis (Badalona and Barcelona, ES)
Intracoronary transplantation of MSCs with overexpressed integrin-linked kinase improves cardiac P3547
function in porcine myocardial infarction.
– B. Xu, M.U. Dan, J.U.N. Xie (Nanjing, CN)
226
The longevity gene SIRT6 switches macrophages into an anti-inflammatory phenotype and improves P3548
cardiac function after myocardial infarction in mice.
– L. Levin-Kotler, U. Amit, T. Ben-Mordechai, D. Palevski, N. Molotski, D. Kain, R. Holbova, Y. Kanfi,
H.Y. Cohen, J. Leor (Tel Hashomer and Ramat Gan, IL)
Cardiac tissue sheet including human iPS cell-derived cardiomyocytes and vascular cells restores P3549
impaired left ventricular systolic function of infarcted porcine hearts: a preclinical study.
– H. Masumoto, M. Ishigami, T. Aoki, F. Takai, T. Ikuno, M. Kawatoh, K. Minakata, T. Ikeda, R. Sakata,
J. Yamashita (Kyoto, JP)
Human amniotic fluid stem cell secretome protects cardiomyocytes against doxorubicin toxicity. P3550
– E. Lazzarini, P. Altieri, P. Spallarossa, M. Canepa, L. Varesio, G.P. Bezante, R. Cancedda, C. Brunelli,
S. Bollini, P. Ameri (Genoa, IT)
Transplantation of cardiac progenitor cells with three-dimensional thick scaffold into the pericardial P3551
space improves cardiac function and graftability after myocardial infarction in mice.
– N. Kondo, T. Nagai, M. Liu, T. Takahashi, M. Kanda, K. Matsuura, I. Komuro, Y. Kobayashi (Chiba and
Tokyo, JP)
A model of anthracycline-induced cardiotoxicity using induced pluripotent stem cell-derived P3552
cardiomyocytes.
– K. Streckfuss-Boemeke, L. Haupt, A. Fomin, S. Wagner, S. Sossalla, L. Cyganek, W. Linke, L.S. Maier,
K. Guan, G. Hasenfuss (Göttingen, Bochum and Regensburg, DE)
Physiologically trained cardiac adipose tissue derived progenitor cells within fibrin scaffolds to improve P3553
cardiac function.
– A. Llucia-Valldeperas, C. Soler-Botija, C. Galvez-Monton, C. Prat-Vidal, S. Roura, I. Perea-Gil, B. Sanchez,
J. Rosell-Ferrer, R. Bragos, A. Bayes-Genis (Badalona and Barcelona, ES; Boston, US)
Allogeneic cardio-reparative cell therapy for acute myocardial infarction. Preliminary results of the P3554
CAREMI clinical trial.
– R. Sanz Ruiz, J.L. Abad, L. Corcostegui, C. Suberbielle, J. Bogard, R. Yotti, R. Al-Daccak, S. Janssens,
F. Fernandez-Aviles, L. R-Borlado (Madrid, ES; Paris, FR; Leuven, BE)
Post MI environment switches resident and transplanted mesenchymal stromal cells toward a P3555
pro-inflammatory phenotype and impairs their reparative properties via toll like receptor-4.
– N. Naftali-Shani, L. Levin-Kotler, D. Palevski, U. Amit, D. Kain, N. Landa, E. Hochhauser, J. Leor (Tel
Hashomer and Petah Tikva, IL)
STEM CELLS AND CELL THERAPY II

Improvement in ADMA and oxidative stress after stem cell therapy in patients with critical limb ischemia. P3556
– J. Madaric, M. Valachovicova, J. Pribojova, R. Mateova, T. Madaricova, M. Mistrik, K. Sebekova, I. Vulev
(Bratislava, SK)
Granulocyte colony-stimulating factor promotes the proliferation of cardiac side population cells by P3557
MONDAY – MORNING
AKT-GATA4 pathway.
– H. Gong, Z. Chen, B. Zhou, G. Zhang, J. Jia, Y. Li, C. Yang, Y. Zou (Shanghai, CN)
Analysis of secretion profiles of pro-angiogenic paracrine factors in clinical trials of stem cell therapy for P3558
– M. Lichtenauer, A. Anker, B. Wernly, M. Leisch, C. Schreiber, A. Arrer, R. Wodnar, C. Jung, U.C. Hoppe
(Salzburg, AT; Jena, DE)
In vivo implantation of tissue engineered vascular graft using newborn piglet thymus derived stem cells: a P3559
proof of concept study.
– M. Swim, D. Iacobazzi, C. Zebele, D. Holopherne-Doran, A.L. Duncun, G. Pieles, G. Chanoit, A. Upex,
M. Caputo, M.T. Ghorbel (Bristol, UK)
The adult myocardium has a robust endogenous cardiomyocyte turnover potential. P3560
– F. Marino, I. Aquila, T. Mancuso, E. Cianflone, C. Carresi, V. Mollace, C. Indolfi, G.M. Ellison,
B. Nadal-Ginard, D. Torella (Catanzaro, IT; London, UK)
c-kit/CreERT2 knock-in allele minimally tags c-kit positive resident endogenous cardiac stem cells and P3561
its cardiomyocyte progeny in the adult life.
– E. Cianflone, C. Vicinanza, I. Aquila, M. Scalise, F. Marino, T. Mancuso, E.D. Giovannone, G.M. Ellison,
B. Nadal-Ginard, D. Torella (Catanzaro, IT; London, UK)
An integrated approach using patient-specific induced pluripotent stem cells and protein biochemistry to P3562
study Vici syndrome associated cardiomyopathy.
– J. Qi, M. Gautel, K. Guan (Göttingen, DE; London, UK)
In situ activation of endogenous cardiac stem cells alters their secretome, miRnome, potentiating their P3563
regenerative capacity on the injured heart.
– A.J. Smith, I. Aquila, F. Marino, M. Scalise, B.J. Henning, B. Nadal-Ginard, G.M. Ellison, D. Torella (London,
UK; Catanzaro, IT)
Combined therapy with shock wave and autologous bone marrow-derived mesenchymal stem cells P3564
lessen left ventricular dysfunction through inhibiting oxidative stress in swine myocardial infarction
model.
– J.J. Sheu, S. Chua, T.H. Tsai, S. Leu, Y.L. Chen, P.H. Sung, H.K. Yip (Kaohsiung, TW)
Therapeutic potential of induced pluripotent stem cells in monocrotaline-induced pulmonary arterial P3565
hypertension.
– M.W. Ke, W.C. Huang, C.C. Cheng, S.H. Chiou, S.R. Wann, C.W. Shu, K.R. Chiou, C.J. Tseng, G.Y. Mar,
C.P. Liu (Kaohsiung and Taipei, TW; Bristol, UK)
227
Human cardiac stem cells and saphenous vein-derived pericytes show a molecular interaction involving P3566
DPP-4/SDF-1 turnover and additively promote the healing of mouse infarcted hearts.
– E. Avolio, M. Meloni, H.L. Spencer, F. Riu, R. Katare, G. Mangialardi, A. Oikawa, I. Rodriguez-Arabaolaza,
A.P. Beltrami, P. Madeddu (Bristol, UK; Udine, IT)
Quantitative analysis of cardiomyocyte contractile kinetics and force generation using automated P3567
morphologic similarity measure.
– J.D. Kijlstra, D. Hu, N.V. Mittal, P. Van Der Meer, A. Garakani, I.J. Domian (Boston and Saratoga, US;
Singapore, SG; Groningen, NL)

Echocardiographic and clinical long-term outcome of real world patients undergoing percutaneous P3568
edge-to-edge mitral valve repair.
– M. Orban, C. Sonne, M.W. Orban, H. Lesevic, D. Braun, H. Schunkert, S. Massberg, A. Kastrati,
J. Hausleiter, I. Ott (Munich, DE)
Prevalence of severe mitral regurgitation eligible for transcatheter edge-to-edge mitral valve repair. P3569
– J. Wallenborn, S. Stoerk, S. Herrmann, O. Kukuy, G. Fette, F. Puppe, K. Hu, W. Voelker, G. Ertl,
F. Weidemann (Würzburg, DE)
Influence of ischemic and nonischemic cardiomyopathy on mortality and regurgitation after MitraClip P3570
results from the Dresdner MitraClip-registry.
– S. Wiedemann, D. Ebert, F.M. Heidrich, C. Melz, M. Buechau, M. Ledinko, B. Alzoubi, A. Alfakouri,
K.M. Sveric, R.H. Strasser (Dresden, DE)
New cutoffs are needed for the assessment of functional mitral regurgitation severity using P3571
three-dimensional echocardiography.
– S. Mihaila, D. Muraru, P. Aruta, M.H. Miglioranza, S. Iliceto, D. Vinereanu, L.P. Badano (Bucharest, RO;
Padua, IT)
Comparing the clinical characteristics and long-term outcomes of patients undergoing MitraClip with P3572
degenerative versus functional mitral regurgitation.
– M. Neuss, H. Kaneko, T. Schau, A. Isotani, J. Weissenborn, M. Schoepp, M. Seifert, C. Butter (Bernau bei
Berlin, DE)
Transfemoral closure of mitral paravalvular leak in the presence of metalic aortic valve. P3573
– P. Jimenez-Quevedo, C. Almeria, L. Nombela, C. Biagioni, G. Morrison, B. Das Neves, E. Garcia (Madrid,
ES)
Non invasive ultrasonic chordal cutting. P3574
– O. Villemain, M. Pernot, W. Kwiecinski, A. Bel, M. Tanter, A. Hagege, E. Messas (Paris, FR)
AORTIC VALVE INTERVENTION

Blood culture-negative infective endocarditis due to Tropheryma whipplei - biomarker suggest intestinal P3575
barrier dysfunction and systemic immune activation.
– J. Friebel, V. Moos, K. Weigt, D. Steffens, U. Landmesser, T. Schneider (Berlin, DE)
Profile and outcome of patients with left-sided infective endocarditis with surgical indication who did not P3576
undergo surgery.
– P.E. Garcia Granja, C. Ortiz Bautista, J. Lopez, T. Sevilla, I. Vilacosta, C. Olmos, C. Ferrera, C. Sarria,
I. Gomez, J.A. San Roman (Valladolid and Madrid, ES)
In vivo long-term serial tracking of living mesenchymal stem cells seeded on bioengineered artificial P3577
pulmonary valve scaffold in sheeps.
– M. Gyongyosi, K. Zlabinger, H. Spriersterbach, L. Balkay, G. Trencsenyi, I. Kertesz, M. Emmert, S.G. Ong,
J.C. Wu, S. Hoerstrup (Vienna, AT; Berlin, DE; Debrecen, HU; Zurich, CH; Stanford, US)
Predictive value of plasma osteopontin level as a new biomarker in patients with rheumatic heart disease. P3578
– H. Hasoba, H.M. Kamal, H. Elbahaie, F. Elashry (Ismailia, EG)
Metabolic syndrome affects outcomes of heart valve surgery. P3579
– E. Angeloni, G. Melina, S. Refice, A. Roscitano, F. Capuano, C. Comito, R. Sinatra (Rome, IT)
Impact of a per procedure electrophysiological study during ttranscatheter aortic valve implantation. P3580
– C. Potelle, F. Brigadeau, A. Sudre, C. Delhaye, T. Modine, D. Koussa, D. Klug, D. Lacroix (Lille, FR)
Evaluation of conventional surgery risk scores and the TAVI2-SCORe to predict 1-year mortality after P3581
transcatheter aortic valve implantation with a self-expandable prosthesis.
– C.M. Van De Heyning, V.M. Collas, T.E. Philipsen, I.E. Rodrigus, C.J. Vrints, J.M. Bosmans (Antwerp, BE)
Impact of mitral regurgitation in mortality of patients undergoing transcather aortic valve implantation. P3582
– M. Drakopoulou, K. Toutouzas, N. Anousakis-Vlachochristou, G. Latsios, A. Synetos,
A. Mastrokostopoulos, S. Brili, S. Sideris, E. Tsiamis, D. Tousoulis (Athens, GR)
Post-operative first degree atrio-ventricular block as a new predictor of complete atrio-ventricular block P3583
or sudden death after balloon-expandable transcatheter aortic valve implantation.
– G. Viart, F. Anselme, E. Durand, A. Savoure, C. Tron, N. Auquier, N. Bouhzam, H. Eltchaninoff (Rouen, FR)
Impact of diabetes mellitus and hemoglobin a1c on patient outcomes following transcatheter aortic valve P3584
implantation.
– E. Chorin, A. Finkelstein, S. Banai, L. Barak, G. Keren, A. Steinvil (Tel Aviv, IL)

Rapid progression of mild to moderate aortic stenosis in patients with end stage renal disease. P3585
– D. Kim, J.Y. Shim, I.J. Cho, H.J. Chang, G.R. Hong, J.W. Ha, N.S. Chung (Seoul, KR)
228
Significance of aortic regurgitation pre-transcatheter aortic valve implantation. P3586

– S. Madeira, J. Abecasis, R. Teles, R. Ribeiras, M. Castro, J. Brito, M. Almeida, M. Andrade, J. Neves,
M. Mendes (Lisbon, PT)
Effect of statins on tissue factor expression and calcification in human aortic valve interstitial cells. P3587
– E. Wypasek, P. Kapusta, P. Mazur, J. Natorska, J. Sadowski, A. Undas (Krakow, PL)
His bundle recording during and after TAVR to predict early and late atrio-ventricular block. P3588
– C. Nguyen, N. Badenco, C. Maupain, M. Laali, R. Choussat, X. Waintraub, T. Chastre, F. Hidden-Lucet,
J.P. Collet, R. Frank (Paris, FR)
Increased levels of NT-proBNP are associated with reduced exercise capacity and peak oxygen P3589
consumption in asymptomatic patients with chronic aortic regurgitation.
– K. Broch, S. Urheim, R. Massey, W. Stueflotten, K. Fossaa, E. Hopp, S. Aakhus, L. Gullestad (Oslo, NO)
Bisphosphonates inhibit calcification of aortic valve in an experimental model of aortic valve stenosis. P3590
– A. Synetos, K. Toutouzas, M. Drakopoulou, K. Stathogiannis, G. Benetos, G. Agrogiannis,
C. Anagnostopoulos, A. Papalois, D. Cokkinos, D. Tousoulis (Athens, GR)
Screening of GATA family reveals genetic variants in GATA5 gene in individuals with bicuspid aortic valve. P3591
– M. Martin Fernandez, C. Alonso -Montes, A. Barral Varela, J. Rozado Castano, R. Padron Encalada,
L. Martinez-Arias, M. Naves, J.B. Cannata -Andia, C. Moris, I. Rodriguez (Oviedo, ES)
Pulmonary hypertension in patients undergoing transcatheter aortic valve replacement: incidence, clinical P3592
impact and evolution.
– L. Testa, A. Latib, F. De Marco, M. De Carlo, A.S. Petronio, F. Ettori, C. Fiorina, C. Tamburino, N. Brambilla,
F. Bedogni (Milan, Pisa, Brescia and Catania, IT)
Baseline Mitral Regurgitation in Transcatheter Aortic Valve Replacement Patients: Does it impact 1 Year P3593
Mortality?
– S. Kiramijyan, M. Magalhaes, E. Koifman, R. Escarsega, R. Torguson, J. Gai, L. Satler, A. Pichard, F. Asch,
R. Waksman (Washington, US)
Association of myocardial fibrosis and clinical outcomes in aortic stenosis patients treated by P3594
transcatheter aortic valve replacement.
– L. Green, N. Mewton, G. Rioufol, J.F. Obadia, M. Pozzi, M. Viallon, P. Croisille, G. Finet (Lyon and
Saint-Étienne, FR)
MYOCARDITIS
The myeloid derived suppressor cell- determined innate immunity is decisive for the chronic course of P3595
viral myocarditis.
– K. Klingel, L. Holz, M. Sauter, N. Ettischer, R. Kandolf (Tübingen, DE)
NOD2 knock down induces cardiobeneficial effects in murine Coxsackievirus B3-induced myocarditis. P3596
– C. Tschoepe, I. Mueller, Y. Xia, K. Savvatis, S. Van Linthout (Berlin, DE)
Pentaglobin treatment in viral myocarditis - An update. P3597
MONDAY – MORNING
– B. Maisch, S. Pankuweit, H. Haake, N. Schlotmann, R. Funck (Marburg and Bad Hersfeld, DE)
Cardioprotective effect of calpastatin-overexpression in coxsackievirus B3-induced myocarditis. P3598
– M.H. Li, Y.I.N.G. Yu, Y.Q. Xie, Y. Yu, Y.Z. Zou, R.Z. Chen, J.B. Ge (Shanghai, CN)
Patients with acute myocarditis more often develop beta1-receptor autoantibodies than patients with P3599
post-infarction myocardial inflammation: first results from the prospective ETiCS-study.
– V. Boivin, C. Zechmeister, J. Ullrich, D. Leyh, W. Bauer, S. Stoerk, G. Ertl, M.J. Lohse, R. Jahns (Würzburg,
DE)
Myocardial gene expression profiling as novel diagnostic tool for eosinophilic myocarditis. P3600
– D. Lassner, M. Rohde, U. Kuhl, R. Kurucz, C.S. Siegismund, U.M. Gross, F. Escher, C. Tschope,
H.-P. Schultheiss (Berlin, DE)
Acute myocarditis: correlation between myocardial necrosis biomarkers and delayed enhancement mass P3601
evaluated by cardiac magnetic resonance.
– A.R. Gaspar Lopes Francisco, M.N. Menezes, G. Da Silva, T. Guimaraes, P. Costa, J.S. Marques, M. Fiuza,
C. David, F.J. Pinto, A.G. Almeida (Lisbon, PT)
Fingolimod affects NK cells and CTLs migration and ameliorates coxsackievirus B3-induced myocarditis P3602
via restraining virus replication through perforin-mediated cardiomyocytes apoptosis.
– X.G. Wang, M.H. Li, Y.I.N.G. Yu, Y.Q. Xie, Y. Yu, Y.Z. Zou, R.Z. Chen, J.B. Ge (Shanghai, CN)
Short and mid-term survival and left ventricular function changes in fulminant versus non-fulminant acute P3603
myocarditis.
– E. Ammirati, M. Lilliu, M. Cipriani, A. Garascia, M. Brambatti, S. Nonnini, P. Pedrotti, F. Oliva, C.F. Russo,
M. Frigerio (Milan, IT)
Short and long-term outcome of acute myocarditis: what can we expect? P3604
– F. Melao, T. Pinho, M. Vasconcelos, V. Ribeiro, E. Martins, A. Madureira, I. Ramos, F. Macedo, M.J. Maciel
(Porto, PT)
Identification of potential pathogenic epitopes in various cardiac pathologies. P3605
– A.-M. Mueller, R. Oettl, C. Weiss, A. Fischer, M. Bockstahler, G. Hristov, E. Giannitsis, H. Katus, Z. Kaya
(Heidelberg and Mannheim, DE)
The role of TWEAK and FN14 in autoimmune myocarditis. P3606
– A. Fischer, A.-M. Mueller, A. Bangert, M. Bockstahler, R. Oettl, H. Katus, Z. Kaya (Heidelberg, DE)
229

Shrinkage of defect size after the catheter ablation for atrial fibrillation in patients with unclosed atrial P3607
septal defect.
– K. Nakagawa, S. Nagase, T. Akagi, Y. Takaya, M. Kubo, H. Oe, N. Nishii, K. Nakamura, H. Morita, H. Ito
(Okayama, JP)
Life expectancy of adults with congenital heart disease. P3608
– P. Gallego Garcia De Vinuesa, A. Gonzalez Garcia, D. Hamilton Garcia, J. Ruiz Cantador, A. Sanchez
Recalde, L. Polo Lopez, A. Aroca Peinado, I. Ferreira Gonzalez, R. Yotti, J.M. Oliver Ruiz (Sevilla, Madrid
and Barcelona, ES)
Population health science approaches to cardiovascular disease in Marfan syndrome. P3609
– A. Pitcher, J.C. Forfar, S. Neubauer, M.J. Goldacre, R. Goldacre (Oxford, UK)
Psychiatric disorders in adults with congenital heart disease (PsyConHeart): unmet needs and impact on P3610
quality of life.
– M. Westhoff-Bleck, J. Briest, D. Fraccarollo, D. Hilfiker-Kleiner, L. Winter, U.E. Maske, M.A. Busch,
J. Bauersachs, S. Bleich, K.G. Kahl (Hannover and Berlin, DE)
Atrial septal defect device closure in the elderly, symptomatic benefits except for arrhythmia. P3611
– M. Thilen, C. Christersson, M. Dellborg, E. Mattsson, A. Trzebiatowska-Krzynska, U. Thilen (Uppsala,
Gothenburg, Stockholm, Linköping and Lund, SE)
Cardiac outcomes and prevalence of coronary stenosis in adult patients after arterial switch operation for P3612
transposition of the great arteries.
– M. Noris Mora, A. Pijuan Domenech, M.T. Subirana Domenech, Q. Ferrer Menduina, S. Pie Raventos,
R. Abella, M.A. Castro Alba, H. Cuellar Calabria, D. Garcia-Dorado Garcia, L. Dos Subira (Palma de
Mallorca and Barcelona, ES)
Late outcomes in adults following anatomic repair of congenitally corrected transposition of the great P3613
arteries.
– S. Arif, S.E. Bowater, P.F. Clift, S.A. Thorne, L.E. Hudsmith (Birmingham, UK)
Risk of cardiovascular events in children and young adults with congenital heart disease. P3614
– M. Fedchenko, Z. Mandalenakis, A. Rosengren, G. Lappas, P. Eriksson, M. Dellborg (Gothenburg, SE)
Outcome of adult survivors of congenital heart lesions after 25 years follow-up.estimates of the P3615
standardized mortality ratio.
– A. Gonzalez-Garcia, D. Garcia Hamilton, P. Gallego-G De Vinuesa, J. Ruiz-Cantador, A. Sanchez-Recalde,
L. Polo-Lopez, A. Aroca, I. Ferreira-Gonzalez, R. Yotti, J.M. Oliver Ruiz (Madrid, Sevilla and Barcelona, ES)
ACUTE PULMONARY EMBOLISM

The influence of age on the prognostic value of the clinical prediction rules in patients with pulmonary P3616
embolism.
– I. Kiluk, U. Kosacka, R. Milewski, B. Sobkowicz (Bialystok, PL)
Accuracy of a clinical-ultrasonographic score for the diagnostic stratification of patients with suspected P3617
pulmonary embolism.
– P. Nazerian, C. Gigli, G.F. Sferrazza Papa, V. Salvatori, E. Gambetta, F. Nava, M. Vittorini, C. Becattini,
S. Grifoni, S. Vanni (Florence, Milan, Perugia and Turin, IT)
Prognostic impact of cardiovascular risk in pulmonary embolism. P3618
– J. Neiva, S. Almeida, R. Duarte, A. Rocha Almeida, C. Rabacal (Vila Franca de Xira, PT)
Time trends and case fatality rates of pulmonary embolism during 11 years of observation in P3619
northwestern Italy.
– F. Dentali, W. Ageno, F. Pomero, L. Fenoglio, A. Squizzato, M. Bonzini (Varese and Cuneo, IT)
Low dose prolonged infusion of tissue type plasminogen activator therapy in massive pulmonary P3620
embolism.
– A.C. Aykan, T. Gokdeniz, I. Gul, E. Kalaycioglu, F. Boyaci, E. Hatem, I. Dursun, D. Altintas Aykan, T. Turan,
S. Celik (Trabzon, TR)
Withholding anticoagulation after negative CTPA is safe in patients with a likely clinical probability of PE. P3621
– F.A. Klok, T. Vd Hulle, N. Van Es, P.L. Den Exter, J. Van Es, I.C.M. Mos, R.A. Douma, P.W. Kamphuisen,
H.R. Buller, M.V. Huisman (Leiden, Amsterdam and Groningen, NL)
CT-proET1 predicts survival in scleroderma-associated pulmonary hypertension. P3622
– H. Ten Freyhaus, D. Dumitrescu, S. Schnorbach, K. Kappert, T. Viethen, M. Hellmich, S. Baldus,
N. Hunuzelmann, S. Rosenkranz (Cologne and Berlin, DE)
Homoarginine predicts mortality in treatment-naive patients with pulmonary arterial hypertension. P3623
– D. Atzler, J.-L. Cracowski, K. Cordts, R.H. Boeger, M. Humbert, E. Schwedhelm (Oxford, UK; Grenoble and
Le Kremlin-Bicêtre, FR; Hamburg, DE)
Survival based on the transpulmonary and diastolic pressure gradient in end-stage COPD post-capillary P3624
– K.H. Andersen, F. Gustafsson, M. Iversen, J. Carlsen (Copenhagen, DK)
Factors associated with operability of chronic thromboembolic pulmonary hypertension: insights of P3625
Spanish registry (REHAP).
– R. Del Pozo, I. Blanco, C.A. Quezada, R. Lopez Reyes, V. Egurbide Arberas, D. Cremer Luengos,
F.J. Garcia Hernandez, J. Segovia Cubero, M. Lopez Meseguer, P. Escribano (Madrid, Barcelona, Valencia,
Bilbao, Palma de Mallorca and Sevilla, ES)
230
CARDIOVASCULAR PREVENTION: INTERVENTIONS AND OUTCOMES

Mortality trends from cardiovascular diseases in southern Brazil. P3626
– J.C. Schneider, D.G. Schneider, I.J.C. Schneider, F.R.S. Ramos, M.A.O. Vargas (Florianópolis, BR)
Stable prevalence of coronary heart disease according to electrocardiographic findings in Mauritius P3627
between 1987 and 2009.
– S. Soderberg, D. Magliano, J.E. Shaw, A. Tamosiunas, R. Reklaitiene, S. Kowlessur, V. Pauvaday,
G. Alberti, P. Zimmet, J.E. Tuomilehto (Umeå, SE; Melbourne, AU; Kaunas, LT; Port Louis, MU; London,
UK; Helsinki, FI)
Analysis of drugs stored at home by elderly patients undergoing myocardial infarction. P3628
– S.E. Ushakova, T.S. Polyatykina, M.V. Aleksandrov, N.V. Budnikova, E.A. Novichkova, A.V. Paykova
(Ivanovo, RU)
Factors associated with grade 1 hypertension: a cross-sectional assessment and implications for P3629
hypertension care based on the Dietary Approaches to Stop Hypertension (DASH) approach in primary
care.
– H.H.X. Wang, M.C.S. Wong, R.Y. Mok, M.W.M. Kwan, W.M. Chan, C.K.M. Fan, C.L.S. Lee, J.J. Wang,
S.M. Griffiths (Shatin and Hong Kong, HK; Guangzhou, CN)
Sub-specialization in cardiology care and outcome: Should clinical services be redesigned, again? P3630
– B. Pathik, C. De Pasquale, A. McGavigan, A. Sinhal, J. Vaile, P. Tideman, C. Bridgman, J. Selvanayagam,
W. Heddle, D. Chew (Adelaide, AU)
The weekend effect among patients presenting with acute coronary syndrome in the philippine general P3631
hospital.
– J.D. Ramos, J.A. Aherrera, F.E. Punzalan (Manila, PH)
Functional capacity recovery after myocardial infarction in patients with multivessel disease. P3632
– R.A. Mori Junco, R. Dalmau Gallarza, A. Castro Conde, O. Gonzalez Fernandez, C. Alvarez Ortega, V. Rial
Baston, P. Meras Colunga, J. Irazusta, J.L. Lopez Sendon (Madrid, ES)
An exploratory study to determine if younger patients’ with implantable cardioverter defibrillators have an P3633
improved quality of life following cardiac rehabilitation.
– A.G. Grieger (London, UK)
Effects of rehabilitation on endothelial function assessed through changes in nitric oxide metabolism and P3634
hypertensive response to exercise in patients with stable coronary artery disease.
– D. Simonovic, M. Deljanin Ilic, S. Ilic, G. Kocic, R. Pavlovic, V. Mitic, S. Saric (Nis̆, RS)
Avoiding unplanned admissions for patients with chronic pain of cardiac origin: analysis of the impact of P3635
the liverpool angina management programme.
– J.D. Bridson, R.J. Houghton, M. Fisher, H.K. Tsang, A. Leach, A. Eleuteri, D.G. Groves (Liverpool, UK)
Seasonal difference in angina attacks in patients with vasospastic angina. P3636
– T. Shoji, Y. Saito, S. Tokimasa, T. Nakayama, Y. Fujimoto, Y. Kobayashi (Chiba, JP)
Eastern European immigrants with ischemic heart disease in southern Europe: Cardiovascular profile and P3637
MONDAY – MORNING
risk of events.
– P.E. Garcia-Granja, I.J. Amat Santos, H.D. Ayala, J. Lopez, H.D. Cubero, D. Diez, L. Vera, F. Gimeno,
I. Gomez, A. San Roman (Valladolid, ES)
CARDIOVASCULAR REHABILITATION: INTERVENTIONS AND OUTCOMES I
Twelve weeks of successful smoking cessation therapy with varenicline improves spirometric lung age. P3638
– M. Iwaoka, S. Ishibashi, S. Onodera, T. Katayama, H. Shimamura, T. Tsuji (Tokyo, JP)
Intensive aerobic exercise training on 3 days/week compared to 5 days/week in patients with coronary P3639
artery disease: Is less more?
– M. Uhlemann, S. Moebius-Winkler, J. Adam, V. Adams, U. Mueller, N. Mangner, S. Erbs, A. Linke,
G. Schuler (Leipzig and Weissenfels, DE)
A contemporary model of cardiac rehabilitation improves accessibility and uptake. P3640
– J. Smith, T. Briffa, A. Bremner, J. Garton-Smith, J. Redfern, D. Hendrie, J. Rankin, L. Dimer, A. Maiorana
(Perth and Sydney, AU)
The role of the individual hospital in adherence to medical guidelines after acute myocardial infarction. P3641
– A.J. Tybjerg, M.T. Svendsen, R.N. Mortensen, B.J. Nielsen, L. Kober, G.H. Gislarson, C. Torp-Pedersen,
H. Boggild (Aalborg, Hjorring, Copenhagen and Hellerup, DK)
Comparison between moderate-high exercise and continuous exercise in a real-life cardiac rehabilitation P3642
setting - nine months follow-up.
– Y. Pernick, I. Zyssman, H.P. Kubis, J.P. Moore, Z. Vered (Zerifin, IL; Bangor, UK)
Short term inspiratory muscle training associated with combined aerobic and resistance training is P3643
benefic in patients undergoing cabg surgery in phase II cardiac rehabilitation program.
– I.M. Albuquerque, B.M. Hermes, D.M. Cardoso, M.S. Vicente, T.N. Gomes, S.N. Pereira, T.D. Santos,
V.A. Barbosa (Santa Maria and Santa Cruz do Sul, BR)
Effects of inspiratory muscle training in patients with atrial fibrillation. P3644
– M. Zeren, R. Demir, Z. Yigit, H.N. Gurses (Istanbul, TR)
Effects of home-based training with telemonitoring guidance in low to moderate risk patients entering P3645
cardiac rehabilitation.
– J.J. Kraal, N. Peek, M.E. Van Den Akker-Van Marle, H.M.C. Kemps (Amsterdam, Leiden and Veldhoven,
NL; Manchester, UK)
A multidimensional score: a way to predict the success of cardiac rehabilitation. P3646
– P. Maras, S. Doimo, A. Altinier, A. Della Mattia, C. Klersy, L. Scudeller, G. Sinagra (Trieste and Pavia, IT)
231
Home-based walking training and adherence to medical therapy in patients undergoing coronary artery P3647
bypass grafting.
– S. Pomeshkina, E. Loktionova, N. Arkhipova, O. Barbarash (Kemerovo, RU)
Inspiratory muscle training and aerobic training present similar effects on blood pressure and P3648
cardiovascular autonomic control in hypertensive patients.
– J. Ferreira, K.B. Scapini, F. Santos, O. Coelho, S.B. Souza, P. Dal Lago, F.M. Consolim-Colombo,
M.C. Irigoyen (São Paulo and Porto Alegre, BR)
Five-repetition sit-to-stand test in heart failure patients. Reliability and correlation with the Six Minutes P3649
Walking Test.
– F. Maslowsky, M. Pribetich, G. Lo Bello, E. Milani, S. Sarzi Braga, R.F. Pedretti (Tradate, IT)
CARDIOVASCULAR REHABILITATION: INTERVENTIONS AND OUTCOMES II

Impact of a cardiac rehabilitation programme on mortality and cardiovascular events after a P3650
percutaneous coronary intervention in patients with multivessel disease and incomplete revascularization.
– N. Cobo Gomez, M.J. Romero Reyes, R. Picon Heras, P. Escane Duarte, J.A. Mora Pardo, M.J. Gonzalez
Correa, F.J. Molano Casimiro, L. Pastor Torres (Sevilla, ES)
Importance of in-hospital remote telemetry in cardiac rehabilitation units. Our centre experience. P3651
– I. Burazor, M. Lazovic (Belgrade, RS)
Case management in patients after TAVI: are frailty and exercise capacitiy predictors for decision making P3652
process?
– H. Voller, S. Eichler, A. Harnath, W. Kamke, C. Butter, M. Kraehe, M. Schikora, J. Jachczyk, A. Salzwedel
(Potsdam, Cottbus, Burg and Bernau bei Berlin, DE)
Cardiopulmonary exercise testing is predictive of return to work in cardiac patients after multicomponent P3653
rehabilitation.
– H. Voller, A. Salzwedel, R. Reibis, S. Eichler, H. Buhlert, S. Kamniski, K. Wegscheider (Potsdam,
Rüdersdorf and Hamburg, DE)
Cardiac rehabilitation versus usual care increases physical capacity but not mental health after heart P3654
valve surgery: results of the randomized CopenHeartVR trial.
– K. Laerum Sibilitz, S.K. Berg, L.C. Thygesen, C. Gluud, J. Lindschou, J.P. Schmid, C. Hassager,
L.V. Kober, R.S. Taylor, A.D. Zwisler (Copenhagen, DK; Berne, CH; Exeter, UK)
A web-based social-cognitive sexual counseling intervention for nurses: A pilot study. P3655
– E. Steinke, S. Barnason, T.J. Hill, V. Mosack (Wichita and Omaha, US)
Beneficial effect of cardiac rehabilitation on endothelial function in patients who received coronary P3656
revascularization.
– I.H. Jung, B.O. Kim, H.Y. Lee, Y.S. Byun, G.J. Rhee, C. Kim (Seoul, KR)
Multidisciplinary rehabilitation program in patients with advanced heart failure after cardiac P3657
– J.R. Siles Rubio, A. Ramirez Moreno, E. Zambrano-Medina, M. Noureddine, R. Bravo-Marques,
A. Milan-Pinilla, L. Inigo-Garcia, A. Valle-Alberca, J. Munoz-Bellido, M. Pombo-Jimenez (Estepona and
Marbella, ES)
Loaded breathing exercise increases cardiovascular sympathetic modulation acutely in patients with P3658
essential hypertension.
– J. Ferreira, K.B. Scapini, F. Santos, P. Dal Lago, F.M. Consolim-Colombo, M.C. Irigoyen (Porto Alegre and
São Paulo, BR)
Effect of long-term home based cardiac rehabilitation programme on readmission rate and mortality risk P3659
after coronary revascularization.
– E.B. Vataman, A.A. Grivenco, S.S. Filimon, D.M. Lisii, L.G. Morcov (Chisinau, MD)
Implementation of Jacobson’s progressive relaxation in coronary bypass surgery patients before chest P3660
tube removal.
– M.R. Rupar, S. Kostic (Belgrade, RS)
Prognostic value of endothelial parameters changes during cardiac rehabilitation on recurrent chest pain P3661
in patients with coronary artery disease: 30 months follow up.
– M. Deljanin Ilic, S. Ilic, D. Simonovic, G. Kocic, R. Pavlovic, V. Stoickov (Niska Banja and Nis̆, RS)
IMPROVEMENT OF MEDICAL CARE IN CARDIOVASCULAR PATIENTS: SOCIAL AND ECONOMIC ISSUES

Long-term healthcare costs after myocardial infarction in a clinical practice setting in Sweden; results P3662
from a contemporary nationwide registry study.
– M. Janzon, M. Henriksson, L.P. Hasvold, H. Hjelm, M. Thuresson, T. Jernberg (Linköping, Stockholm,
Södertälje and Nyköping, SE)
Deterioration in quality of care after acute myocardial infarction in 2012: results from 5 consecutive years P3663
of French nation-wide assessment of quality of discharge prescription after AMI.
– F. Schiele, L. Banaei-Bouchareb, F. Capuano, J.F. Thebaut, N. Danchin, M. Gloanec, C. Grenier
(Besançon, La Plaine Saint Denis and Paris, FR)
Weekend and out of hours admission to hospital with acute coronary syndrome confers poorer mortality P3664
and longer length of hospital stay.
– R. Potluri, H. Uppal, D. Lavu, S. Chandran (Birmingham and Manchester, UK)
Improvement in one-year survival after acute myocardial infarction according to socioeconomic position P3665
in Chile: analysis of the period 2002-2011.
– C. Nazzal, F. Alonso, F. Cerecera, J. Ojeda (Santiago, CL)
Trends in social inequalities in the prevalence of major cardiovascular disease among adults in Germany. P3666
– M.A. Busch, A. Schienkiewitz, L.E. Kroll, A. Goesswald, T. Lampert (Berlin, DE)
232
Burden of cardiovascular hospitalizations following myocardial infarction among older adults. P3667
– E. Levitan, P. Muntner, L. Chen, K.L. Monda, R.S. Rosenson (Birmingham, Thousand Oaks and New York,
US)
Acute coronary syndrome perception: determinants and impact on medical care seeking. P3668
– V. Ribeiro, F. Melao, O. Laszczynska, C. Araujo, M. Viana, J.I. Moreira, M.J. Maciel, P. Dias, A. Azevedo
(Porto and Vila-Real, PT)
ST-segment Elevation Myocardial Infarction and primary angioplasy: the predictors of patient delay. P3669
– H. Pereira, R. Cale, E. Pereira, D. Caldeira, S. Vitorino, S. Mello, F.J. Pinto (Almada and Lisbon, PT)
Gender differences in predictors of left ventricular myocardial relaxation in non-obese, healthy P3670
individuals.
– H. Sekiguchi, M. Kimura, Y. Takahashi, F. Tatsumi, E. Watanabe, N. Ishizuka, K. Shimamoto, M. Kawana
(Tokyo, JP)
Trends in adolescents lifestyle in post-communist country following the accession to the European Union P3671
(EU).
– A. Fijalkowska, P. Jankowski, M. Jodkowska, A. Oblacinska, B. Woynarowska, T. Maciejewski,
E. Szczerba, J. Mazur (Warsaw and Krakow, PL)
Delayed hospital discharge in an italian cardiology department: causes and features of the phenomenon. P3672
– D. Santoro, D. Grosseto, S. Amati, D. Calabrese, S. Carigi, L. Farneti, P. Venturi, I. Panzini, E. Fabbri,
G. Piovaccari (Rimini, IT)
Cost effectiveness analysis of oral anticoagulant therapy with rivaroxaban for nonvalvular atrial fibrillation P3673
in a secondary hospital in Spain.
– R. Andion Ogando, J.M. Martin Antoran, E.M. Arias Valdes, E. Laherran Rodriguez, J.M. Asin Guillen,
J.A. San Roman Calvar (Palencia, Medina del Campo and Valladolid, ES)
DELETERIOUS EFFECTS OF OBESITY AND DIABETES

Obesity is associated with subclinical myocardial injury independently of a dysmetabolic state. P3674
– M.N. Lyngbakken, H. Rosjo, O.L. Holmen, H. Dalen, K. Hveem, T. Omland (Oslo, Levanger and Trondheim,
NO)
Impact of low serum levels of 1,5-anhydroglucitol on cardiovascular events in patients after first-time P3675
elective percutaneous coronary intervention.
– S. Takahashi, K. Shimada, K. Miyauchi, E. Sai, T. Miyazaki, T. Shiozawa, H. Tamura, S. Okazaki, K. Isoda,
H. Daida (Tokyo, JP)
Exercise intolerance in elderly asymptomatic type 2 diabetes: left ventricular dysfunction, diabetes P3676
control, therapy or insulin resistance?
– Y. Wang, H. Yang, L. Wright, M. Nolan, M. Saito, T. Marwick, K. Negishi (Hobart, AU)
Effects of renin-angiotensin-aldosterone system blockers on contrast-induced nephropathy and its P3677
association with NGAL levels in diabetic patients undergoing coronary angiography.
MONDAY – MORNING
– H. Goksuluk, N. Kerimli, Y. Atmaca, O.U. Ozcan, M. Gerede, C.T. Kaya, C. Erol (Ankara, TR)
Concordance of glucose based and of HbA1c based diagnoses of diabetes in patients with established P3678
coronary atherosclerosis: a comparison between men and women.
– C.H. Saely, D. Zanolin, P. Rein, A. Vonbank, A. Leiherer, G. Naerr, A. Muendlein, H. Drexel (Feldkirch, AT;
Triesen, LI; Philadelphia, US)
Divergent association of obesity with aortic stiffness and wave reflections in patients with metabolic P3679
syndrome: the obesity paradox.
– P. Pietri, C. Vlachopoulos, N. Ioakeimidis, M. Abdelrasoul, I. Gourgouli, E. Paschalidis,
D. Terentes-Printzios, C. Stefanadis, D. Tousoulis (Athens, GR)
Role of intereleukin-6 in the visual impairment of diabetic patients. P3680
– N. Gouliopoulos, G. Siasos, M. Moschos, E. Oikonomou, G. Siasou, T. Paraskevopoulos, T. Konsola,
M. Zaromytidou, E. Dimitropoulos, D. Tousoulis (Athens, GR)
Metabolic syndrome and the contributory predictive role of inflammatory or renal markers on P3681
cardiovascular disease: 10 year (2001-2011) follow-up of the ATTICA Study.
– C.M. Kastorini, D.B. Panagiotakos, E. Georgousopoulou, L. Papadimitriou, C. Chrysohoou, P.E. Puddu,
J. Skoumas, D. Tousoulis, C. Pitsavos, C. Stefanadis (Athens, GR; Rome, IT)
Decreased insulin sensitivity and abdominal obesity promote coronary atherosclerosis’ extent and P3682
severity in non-diabetic patients.
– B. Parapid, B. Obrenovic-Kircanski, K. Lalic, J. Saponjski, V. Vukcevic, S. Stojkovic, N. Milic, N.M. Lalic,
M.C. Ostojic (Belgrade, RS)
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all cause P3683
mortality in patients with coronary artery disease.
– S.G. Anderson, D.C. Hutchings, K. Rahimi, M. Woodward, A.H. Heald (Oxford, Manchester and Crewe, UK)
Mobilization of endothelial progenitor cells after endovascular interventions in patients with type 2 P3684
diabetes mellitus.
– M. Michurova, V. Kalashnikov, O. Smirnova, O. Ivanova, S. Terekhin, I. Kononenko (Moscow, RU)
The optimal interval of screening to detect type2 diabetes for pre-diabetic patients with coronary artery P3685
disease.
– T. Asano, S. Ohde, M. Yamazoe, I. Komatsu, T. Adachi, Y. Nishihata, H. Mitsuhashi, Y. Yokoyama,
H. Niinuma, Y. Nishi (Tokyo, JP)
233
SHORT AND LONG-TERM OUTCOMES AFTER PCI AND NON-CORONARY INTERVENTION

Intracoronary electrocardiogram changes are associated with postprocedural myonecrosis after coronary P3686
bifurcation percutaneous coronary interventions.
– D.V. Vassilev, K. Karamfiloff, R.G. Gil, G.R. Rigatelli (Sofia, BG; Warsaw, PL; Rovigo, IT)
Comparisons of the outcomes of the two drug eluting stents in diabetic patients: abluminal P3687
biolimus-eluting biodegradable polymer stents and zotalimus-eluting permanent polymer stents.
– Y.W. Yoon, B.K. Hong, B.K. Lee, S.J. Rim, H.M. Kwon, J.Y. Kim, E.Y. Choi (Seoul, KR)
Long-term clinical outcome of periprocedural myocardial injury in patients undergoing percutaneous P3688
coronary intervention for chronic total occlusion lesions.
– H. Tanaka, S. Habara, Y. Fuku, T. Goto, K. Kadota, K. Mitsudo (Kurashiki, JP)
Real-world comparison between 1st and 2nd generation drug-eluting stents: Insights from the DESIRE P3689
Registry.
– J.R. Costa Jr, A.G.M.R.S. Sousa, A.C.M. Moreira, G.A.M. Maldonado, R.A.C. Costa, J.E.S. Sousa (São
Paulo, BR)
Serum vascular endothelial growth factor-C levels inversely associated with the risk of atherosclerotic P3690
cardiovascular events following drug-eluting stent implantation.
– T. Unoki, H. Wada, M. Akao, S. Ura, A. Yamada, N. Masunaga, M. Ishii, M. Abe, D. Takagi, K. Hasegawa
(Kyoto, JP)
Independent predictors of the recurrent restenosis after paclitaxel-coated balloon angioplasty for in-stent P3691
restenosis; importance of initial ballooning and balloon positioning during procedure.
– H. Koiwaya, N. Watanabe, N. Kuriyama, T. Kimura, T. Nakama, M. Furugen, K. Ashikaga, T. Ueno,
Y. Fukumoto, Y. Shibata (Miyazaki and Fukuoka, JP)
Improvement of left ventricular function assessment by global longitudinal strain after successful P3692
percutaneous coronary intervention for chronic total occlusions.
– M. Chimura, S. Yamada, H. Kawai, Y. Yasaka (Himeji, JP)
Timing, patterns and long term prognosis of recurrent myocardial infarction after primary angioplasty - P3693
stent thrombosis versus non-stent-related reinfarction.
– A. Monteiro, R. Ramos, A. Fiarresga, L. Sousa, D. Cacela, L. Patricio, L. Bernardes, T. Pereira Da Silva,
C. Soares, R.C. Ferreira (Lisbon, PT)
Influence of side branch predilation on long-term follow-up in patients with bifurcation lesions treated by P3694
provisional stenting.
– S. Ojeda, M.C. Morenate, M. Pan Alvarez-Osorio, M. Romero, D. Valeron, M. Blanco, F. Mazuelos,
J. Suarez De Lezo Herreros De Tejada, A. Medina, J. Suarez De Lezo Cruz-Conde (Córdoba and Las
Palmas de Gran Canaria, ES)
Drug eluting stent versus bare metal stent in saphenous vein graft lesions: a comprehensive P3695
meta-analysis of 14,000 patients.
– I.H. Tanboga, S. Topcu, E. Aksakal, M. Kurt, A. Kaya, U. Aksu, T. Isik, V. Oduncu, S. Sevimli (Erzurum,
Hatay, Ordu, Balikesir and Istanbul, TR)
The safety and efficacy of ultra-long 2nd generation drug eluting stent implantation. P3696
– Y. Honda (Yokohama, JP)
Growth differentiation factor-15 predicts bleedings in patients with STEMI after PCI. P3697
– J.H. Zhang, J.Q. Yuan, X.M. Meng, X.F. Tang, J. Wang, Y. Yao, B. Xu, Y.J. Yang, R.L. Gao (Beijing, CN)
The prognostic impact of variation in left ventricular ejection fraction following elective percutaneous P3698
– A. Levi, T. Bental, A.R. Assali, E.I. Levi, H. Vaknin-Assa, M. Vaturi, Y. Shapira, A. Sagie, R. Kornowski
(Petah Tikva, IL)
Prognostic significance of whole blood viscosity in patients with ST elevation myocardial infarction P3699
undergoing primary coronary intervention.
– E.H. Ozcan Cetin, M.S. Cetin, U. Canpolat, O. Ozeke, S. Topaloglu, D. Aras, H.L. Kisacik, S. Aydogdu
(Ankara, TR)
Impact of successful revascularization of chronic total occlusion on long-term clinical outcome: P3700
comparison of clinical factors between successful and failed procedures.
– T. Teramoto, E. Tsuchikane, M. Yamamoto, S. Kano, H. Matsuo, Y. Kawase, Y. Suzuki, T. Suzuki
(Toyohashi, Nagoya and Gifu, JP)
Clinical outcome of paclitaxel-coated balloon angioplasty for the treatment of coronary in-stent P3701
restenosis in hemodialysis patients.
– M. Hayashi, S. Kuramitsu, T. Domei, M. Hyodo, Y. Soga, S. Shirai, K. Ando (Fukuoka, JP)
“Very” long-term clinical outcomes after sirolimus-eluting stent implantation. P3702
– H. Matsuda, S. Kuramitsu, T. Domei, M. Hyodo, Y. Soga, S. Shirai, K. Ando (Fukuoka, JP)
Are there different outcomes following diffuse long lesion intervention between chronic total occlusion P3703
and non-chronic total occlusion lesions?
– J.H. Ahn, S.W. Rha, B.G. Choi, S.Y. Choi, J.K. Byun, H.O. Lee, D.H. Kim, C.G. Park, H.S. Seo, D.J. Oh
(Gumi and Seoul, KR)
Bioresorbable vascular scaffolding for the percutaneous treatment of long diffuse coronary lesions. P3704
– M. Romero, J. Suarez De Lezo, P. Martin, J. Garcia, M. Pan, F. Mazuelos, S. Ojeda, J. Segura, A. Medina,
J. Suarez De Lezo Cruz-Conde (Córdoba and Las Palmas de Gran Canaria, ES)
Long term prognostic value of risk scores after drug-eluting stent implantation for unprotected left main P3705
coronary artery disease - a pooled analysis of the isar left main and isar left main 2 trials.
– E. Xhepa, T. Tada, R.A. Byrne, K. Tiroch, S. Cassese, M. Fusaro, S. Kufner, K.L. Laugwitz, J. Mehilli,
A. Kastrati (Munich and Wuppertal, DE)
234
Two-year outcomes of successful recanalization for chronic total occlusion between antegrade and P3706
retrograde approach: propensity matched analysis.
Predictors of early and late bleeding events after drug-eluting stent implantation. P3707
– Y. Honda (Yokohama, JP)
Long-term clinical results after first generation drug-eluting stent implantation. P3708
– M. Yokoi, K. Nasu, M. Habara, Y. Kinoshita, A. Kodama, M. Yamamoto, Y. Ochiumi, E. Tsuchikane,
M. Terashima, T. Suzuki (Toyohashi, JP)
Clinical predictors of mortality following rotational atherectomy and stent implantation in high risk P3709
patients.
– I.F. Edes, Z. Ruzsa, G.Y. Szabo, S. Nardai, D. Becker, K. Benke, B. Szilveszter, B. Merkely (Budapest, HU)
Impact of angiographically visible stent malapposition (Peri-stent contrast staining: PSS) and stent P3710
fracture on five-year clinical outcome after drug-eluting stent implantation.
– Y. Ozaki, T.F. Ismail, T. Kawai, M. Ohota, M. Okumura, H. Takahashi, H. Umeda, T. Muramatsu,
T. Murohara (Toyoake, Toyota and Nagoya, JP; London, UK)
Implications of pre-procedural TIMI flow in patients with acute coronary syndromes: undergoing P3711
percutaneous coronary intervention: A study of 21,024 patients from the London Heart Attack group.
– D.A. Jones, K.S. Rathod, S.M. Gallagher, A. Wragg, A. Mathur (London, UK)
An observational study of real world clinical outcomes from 1999-2013 following percutaneous coronary P3712
intervention (PCI) among older patients in British Columbia, Canada.
– W.T. Roberts, J. Shin, L. Ding, C.H. Ng, I.J. Nadra, A. Della Siega, S.D. Robinson (Victoria and Vancouver,
CA)
Long-term angiographic outcomes of recurrent restenosis in patients with drug-eluting stent implantation P3713
for in-sent restenosis of drug-eluting stent.
– T. Kanazawa, K. Kadota, S. Otsuru, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto,
Long-term outcomes with 3rd versus 2nd generation coronary drug eluting stents - a meta-analysis. P3714
– B.N. Mukete, V.Q. Nguyen, K.Y. Singh, R. Samson, Q.A. Saleh, K.C. Atianzar, O. Mogabgab, A.A. Alonso,
T.H. Le Jemtel, N.N. Abi Rafeh (New Orleans, US)
Impact of SYNTAX Score-II on very long-term mortality in STEMI patients undergoing primary PCI. P3715
– D. Milasinovic, M. Zivkovic, A. Novakovic, Z. Mehmedbegovic, V. Dedovic, I. Zivkovic, O. Ninkovic,
Acute coronary syndrome in octogenarians, association between percutaneous coronary intervention and P3716
long-term mortality.
– S. Barywani, M. Petzold, M. Fu (Gothenburg, SE)
Patterns of dual anti platelet therapy cessation in left main and proximal left anterior descending artery P3717
PCI: Results from the PARIS registry.
– J. Chandrasekhar, S. Sartori, C. Ariti, S. Pocock, M. Aquino, D. Cohen, D. Moliterno, T. Henry, G. Steg,
MONDAY – MORNING
R. Mehran (New York, Kansas City, Lexington and Minneapolis, US; London, UK; Paris, FR)
Results of percutaneous coronary intervention of de novo lesions with sequent please paclitaxel eluting P3718
balloon catheter at a very long-term follow-up.
– I. Sanchez Perez, A. Jurado Roman, F. Lozano Ruiz-Poveda, N. Pinilla Echevarri, M.T. Lopez Lluva,
M. Marina Breysse, A. Moreno Arciniegas, J. Benitez Peyrat, J. Piqueras Flores (Ciudad Real, ES)
Long-term clinical outcomes after combined drug-coated balloon/bare metal stent angioplasty compared P3719
with everolimus-eluting stents.
– T.C. Poerner, S. Otto, J. Gassdorf, K. Nitsche, H.R. Figulla (Jena, DE)
The SYNTAX-II score predicts clinical outcomes after percutaneous coronary intervention for patients P3720
with left main and/or 3 vessel diseases.
– M. Zhao, T. Nuehrenberg, M. Gick, M. Ferenc, C.M. Valina, R.P. Kienzle, H.J. Buettner, F.J. Neumann (Bad
Krozingen, DE)
Gender differences in 5-year clinical outcomes following percutaneous coronary intervention. P3721
– R. Naito, K. Miyauchi, H. Konishi, S. Tsuboi, M. Ogita, T. Kasai, H. Tamura, S. Okazaki, K. Isoda, H. Daida
(Tokyo, JP)
Impact of first generation drug-eluting stents on the long-term clinical results compared with bare-metal P3722
stent.
– M. Yokoi, K. Nasu, M. Habara, Y. Kinoshita, A. Kodama, M. Yamamoto, Y. Ochiumi, E. Tsuchikane,
M. Terashima, T. Suzuki (Toyohashi, JP)
The influence of aortic root calcium volume and distribution on the risk of paravalvular regurgitation after P3723
transcatheter aortic valve replacement.
– N.C. Hansson, J. Leipsic, A. Rossi, D. Dvir, M. Simonato, S. Kennon, H.R. Andersen, J. Webb, F. Pugliese,
B.L. Norgaard (Aarhus, DK; Vancouver, CA; London, UK)
Clopidogrel not indicated before TAVI, after TAVI with caution and under platelet reactivity assessment. P3724
– K. Czerwinska, A. Witkowski, M. Dabrowski, J. Stepinska (Warsaw, PL)
Pressure half-time by echocardiography in comparison with cardiac magnetic resonance for P3725
quantification of paravalvular regurgitation after transcatheter aortic valve implantation.
– E. Altiok, M. Frick, R. Hoffmann, J. Schroeder, N. Marx, M. Becker (Aachen and Lingen, DE)
3-D Echocardiographic measurement of aortic annulus using area or circumference for TAVI. Does it P3726
make a difference?
– A. Papachristidis, D. Roper, R. Dworakowski, J. Byrne, O. Wendler, P. MacCarthy, M.J. Monaghan
(London, UK)
Clinical impact of left atrial appendage closure on the incidence of stroke, bleeding and on quality of life P3727
in patients with atrial fibrillation: a standardized single center registry.
– T.C. Poerner, S. Wieg, B. Goebel, S. Otto, H.R. Figulla (Jena, DE)
235
Learning curve of percutaneous left atrial appendage closure for stroke prevention in single high volume P3728
center.
– Y. Matsuo, M. Sandri, N. Mangner, G. Schuler, M. Kurabayashi, S. Winkler (Maebashi, JP; Leipzig, DE)
Ruptured sinus of Valsalva aneurysm closure with new types PDA devices. P3729
– M. Szkutnik, R. Fiszer, J. Bialkowski (Zabrze, PL)
Impact of complex septal anatomy on clinical events in long term follow up after percutaneous closure of P3730
patent formamen ovale.
– M. Ruiz Ortiz, M. Delgado, D. Mesa, F. Baeza, M.C. Morenate, M. Santisteban, F. Mazuelos, J. Suarez De
Lezo Herreros De Tejada, M. Pan, J. Suarez De Lezo (Córdoba, ES)
Transfemoral tricuspid valve-in-valve and valve-in-ring implantation using the Edwards SAPIEN XT valve: P3731
one-year follow-up.
– C. Bouleti, D. Himbert, E. Brochet, P. Ou, B. Iung, M. Urena, G. Ghodbane, A.A. Fassa, P. Nataf,
A. Vahanian (Paris, FR)
Clinical outcomes of the intra-aortic balloon pump for resuscitated patients with acute myocardial P3732
infarction complicated by cardiac arrest.
– H. Park, H.K. Kim, M.H. Jeong, Y.G. Ahn, D.S. Sim, S.C. Chae, J.G. Cho, Y.J. Kim, S.H. Hur, I.W. Seong
(Gwangju, Daegu and Daejeon, KR)
A multi-modality intra-arterial imaging comparison of renal artery trauma induced by balloon-based and P3733
non-balloon-based renal denervation devices.
– A. Karanasos, N. Van Mieghem, M. Bergmann, E. Hartman, J. Ligthart, E. Van Der Heide, C.H. Heeger,
F. Zijlstra, E. Regar, J. Daemen (Rotterdam, NL; Hamburg, DE)
One-shot circumferential renal artery denervation with relative sparing of the arterial wall may be P3734
possible using a novel microwave catheter.
– P. Qian, T. Barry, S. Al Raisi, P. Kovoor, A. McEwan, A. Thiagalingam, S. Thomas (Sydney, AU)
Effects of renal denervation on cardiac sympathetic activity and innervation. P3735
– L. Donazzan, F. Mahfoud, S. Ewen, C. Ukena, C.M. Kirsch, D. Hellwig, E. Samer, M. Esler, M. Bohm
(Homburg, DE; Melbourne, AU)
Assessment of efficacy and renal hemodynamics with renal function after catheter-based renal P3736
denervation in patients with resistant hypertension.
– L. Plashchinskaya, D. Goncharik, A. Chasnoits, V. Barsukevich, N. Semenova, A. Savchenko,
V. Golenischa, A. Mrochek (Minsk, BY)
The proximity of abdominal structures to the renal artery: a study to assess the potential risks of renal P3737
denervation.
– H.C. Patel, J.B. Moser, S. Otero, C. Hayward, S.D. Rosen, A.R. Lyon, R. Mohiaddin, C. Di Mario, S. Padley
(London, UK)
Effects of renal sympathetic denervation on cardiac sympathetic activity and function in patients with P3738
therapy resistant hypertension.
– P.M. Van Brussel, D.W. Eeftinck Schattenkerk, L.C. Dobrowolski, R.J. De Winter, J.A. Reekers,
H.J. Verberne, L. Vogt, B.J.H. Van Den Born (Amsterdam, NL)
Multi-electrode versus single-electrode renal denervation devices: can we improve safety and efficacy? P3739
– A. Trivisonno, C. Olivieri, G.L. Magri, F. Caranci, M. Scappaticci, G. Luciani, N. Bruno, E. Assante Di
Panzillo, S. Crispo, F. Versaci (Campobasso and Isernia, IT)
Left atrial appendage closure followed by a single anti platelet therapy: a single center experience. P3740
– M. Dinet, Z. Jalal, X. Iriart, P. Renou, L. Sibon, N. Tafer, J.B. Thambo (Bordeaux-Pessac, FR)
Multi-centre European experience of left atrial appendage closure using a new generation percutaneous P3741
epicardial suture device in non-valvular atrial fibrillation.
– J.P. Foran, S. Panikker, R. Tilz, K. Bartus, S. Gafoor, J. Myc, R. Lee, H. Sievert, K.-H. Kuck, T. Wong
(London, UK; Hamburg and Frankfurt am Main, DE; Krakow, PL; San Francisco, US)
HEART FAILURE THERAPY, VARIOUS I

Effect of additive tolvaptan versus increased furosemide on refractory heart failure with renal impairment: P3742
results from the K-STAR study.
– T. Inomata, Y. Ikeda, H. Shinagawa, K. Kida, Y. Shibagaki, N. Sato, Y. Kumagai, J. Ako, T. Izumi
(Sagamihara, Kawasaki and Tokyo, JP)
Strategies for diuretic management of acute heart failure: data from a web-survey of the Italian P3743
Association of Hospital Cardiologists (ANMCO).
– G. Di Tano, R. De Maria, M. Marini, M. Milli, C. Raineri, G. Russo, M. Parolini, N. Aspromonte (Florence and
Milan, IT)
Is the therapeutic efficacy of coenzyme Q10 replicated in a geographical subgroup of the Q-SYMBIO P3744
study?
– S.A. Mortensen, P. Dolliner, K.J. Filipiak, U. Alehagen, D. Pella, G. Steurer, G.P. Littarru, A. Kumar,
F. Rosenfeldt (Copenhagen, DK; Vienna, AT; Warsaw, PL; Linköping, SE; Kosice, SK; Ancona, IT; Amritsar,
IN; Melbourne, AU)
UM206, a peptide fragment of wnt5a, attenuates post-infarct remodeling. P3745
– K.C.M. Hermans, A. Uitterdijk, D.P.M. De Wijs-Meijler, E.P. Daskalopoulos, A. Verzijl, I.K. Reiss,
D.J. Duncker, W.M. Blankesteijn, D. Merkus (Maastricht and Rotterdam, NL)
The adoption and application of ivabradine treatment along with beta blocker therapy in real life clinical P3746
practice: Results from REALITY HF Study.
– Y. Cavusoglu, O. Kozan, A. Temizhan, S. Kucukoglu (Eskisehir, Izmir, Ankara and Istanbul, TR)
High use of statins in heart failure patients also after trials that failed to show a benefit: a Danish P3747
nationwide study.
– N. Al-Hussainy, G. Gislason, S. Bisgaard Christensen, C. Torp-Pedersen (Copenhagen, DK)
236
STAT3 is indispensable for cardioprotective effects of DPP-4 inhibitor on heart failure after myocardial P3748
infarction.
– M. Hirose, H. Takano, A. Kubota, H. Wang, Y. Kobara, T. Inagawa, H. Tadokoro, H. Hasegawa,
Y. Kobayashi (Chiba and Numazu, JP)
LCZ696, the angiotensin-receptor neprilysin inhibitor, attenuates cardiac fibrosis and improves its P3749
function in the heart failure model of diabetes mellitus in mice.
– Y. Suematsu, S. Miura, M. Goto, E. Yahiro, Y. Uehara, K. Saku (Fukuoka, JP)
The angiotensin receptor neprilysin inhibitor LCZ696 improves systolic cardiac function compared to P3750
angiotensin converting enzyme inhibition in a rat model of myocardial infarction.
– A.R. Kompa, T.J. Weller, T. Von Lueder, B.H. Wang, H. Krum (Melbourne, AU)
Exogenous extracellular heat shock protein HSC70 protects against experimental septic cardiomyopathy. P3751
– J.H. Hsu, J.R. Wu, Z.K. Dai, R.C. Yang, J.L. Yeh (Kaohsiung, TW)
RELAX-AHF-EU: a prospective, multicenter, randomised, open-label study assessing the efficacy and P3752
safety of serelaxin in patients hospitalised for acute heart failure in Europe.
– A.P. Maggioni, O. Chioncel, S. Janssens, J. Lopez-Sendon, O.W. Nielsen, R. Sabia, C. Serban, Z. Yousef,
G. Ertl (Florence, IT; Bucharest, RO; Leuven, BE; Madrid, ES; Copenhagen, DK; Basel, CH; Cardiff, UK;
Würzburg, DE)
Administration of eicosapentaenoic acid reduces cardiovascular and all-cause mortality in chronic P3753
hemodialysis patients.
– N. Umemoto, H. Ishii, T. Sakakibara, D. Kamoi, T. Aoyama, H. Takahashi, T. Murohara (Nagoya, JP)
HEART FAILURE THERAPY, VARIOUS II
Angiotensin II Receptor-Neprilysin Inhibitor, LCZ696 Blocked Aldosterone Synthesis in Human P3754

Adrenocortical Cell Line.
– S. Miura, Y. Suematsu, Y. Matsuo, S. Tomita, A. Nakayama, M. Goto, E. Yahiro, Y. Uehara, K. Saku
(Fukuoka, JP)
Adherence to optimal medical treatment is associated with a reduction of all-cause mortality in P3755
ambulatory patients with heart failure.
– J. Alvarez-Garcia, A. Ferrero-Gregori, M. Vives-Borras, M.T. Puig, R. Vazquez, J. Delgado,
D.A. Pascual-Figal, L. Alonso-Pulpon, J.R. Gonzalez-Juanatey, J. Cinca (Barcelona, Cadiz, Madrid, Murcia
and Santiago de Compostela, ES)
Incidence and predictors of doubling of serum creatinine during treatment of heart failure and preserved P3756
ejection fraction with spironolactone.
– A.S. Desai, J. Liu, B. Claggett, M. Bristow, J. Fleg, E.F. Lewis, S. McKinlay, B. Pitt, S.D. Solomon,
M.A. Pfeffer (Boston, Denver, Bethesda, Watertown and Ann Arbor, US)
Pharmacological inhibition of galectin-3 and aldosterone pathways prevents isoproterenol-induced left P3757
ventricular dysfunction and fibrosis in mice.
MONDAY – MORNING
– G. Vergaro, M. Prud’homme, R. Merval, C. Passino, M. Emdin, J.L. Samuel, A. Cohen Solal, C. Delcayre
(Pisa, IT; Paris, FR)
Heart rate control and beta-blockade are not optimal in patients with systolic heart failure and chronic P3758
obstructive pulmonary disease.
– M. Tkaczyszyn, M. Drozd, B. Kurian, W. Banasiak, P. Ponikowski, E.A. Jankowska (Wroclaw and Warsaw,
PL)
The influence of metformin on mortality and hospitalization in patients with heart failure and type 2 P3759
diabetes.
– A. Retwinski, M. Kosmalski, M. Crespo-Leiro, A. Maggioni, G. Opolski, P. Ponikowski, L. Polonski,
E. Jankowska, J. Drzewoski, J. Drozdz (Lodz, Warsaw, Wroclaw and Katowice, PL; A Coruña, ES;
Florence, IT)
Negative effect of right ventricular systolic failure on time in therapeutic range (TTR) of patients with P3760
warfarin treatment.
– O. Beton, L.D. Asarcikli, T. Efe, M. Yaman, T. Sen, E.G. Ipek, H. Kafes, A. Temizhan, M.B. Yilmaz (Sivas,
Ankara, Samsun, Kutahya and Kayseri, TR)
Clinical efficacy and safety of tiotropium and indacaterol administration in patient with chronic heart P3761
failure due to coronary artery disease combined with chronic obstructive pulmonary disease.
– V. Evdokimov, A. Evdokimova, E. Kovalenko, K. Tebloev, O. Zolotova (Moscow, RU)
Comparative temporal effects of nitrate-centred and diuretic-centered treatment of acute P3762
decompensated heart failure on congestion and renal function injury as well as tubular damage
biomarkers.
– K.M. Amosova, A.B. Bezrodnyi, I.I. Gorda, I.Y. Katsytadze, A.V. Sablin, N.V. Melnychenko, S.Z. Bogdan,
E.V. Hodakovska, P.O. Lazarev, A.V. Soloschenko (Kiev, UA)
Characterising patients with chronic heart failure in community care after hospitalisation: a potential role P3763
for Ivabradine.
– C.C. Lang, M. Mohan, L. Cochrane, H. Charles, D.H. Elder (Dundee, UK)
Early administration of tolvaptan can improve in-hospital clinical outcomes in patients with acute heart P3764
failure: a dual center experience.
– H. Niikura, R. Iijima, Y. Yazaki, T. Ono, H. Hara, H. Annzai, N. Kobayashi, M. Moroi, M. Nakamura, K. Sugi
(Tokyo and Gunma, JP)
Prevalence of hospitalised patients with heart failure eligible for treatment with ivabradine. P3765
– P. Wheeler, S. Soar, A. Al-Mohammad (Sheffield, UK)
237
HEART FAILURE THERAPY, VARIOUS III

Tight heart rate control and pulsatile hemodynamics in patients with heart failure of ischemic etiology. P3766
– Y.M. Lopatin, T.H. Temirsultanova (Volgograd, RU)
Vitamin d supplementation improves the size and function of the left ventricle in patients with heart P3767
failure.
– J. Lowry, J. Gierula, R. Byrom, S. Barnes, H.A. Jamil, L.C. Kearney, R.M. Cubbon, M.T. Kearney, K.K. Witte
(Leeds, UK)
Impact of digoxin use in patients with atrial fibrillation and heart failure: data from the Korean Heart P3768
Failure (KorHF) Registry.
– S.-W. Choi, S.W. Han, Y.K. Ahn, D.J. Choi, J.J. Kim, E.S. Jeon, M.C. Cho, S.C. Chae, M.M. Lee, K.H. Ryu
(Hwaseong, Gwangju, Seongnam, Seoul, Cheongju, Daegu and Goyang, KR)
Treatment with ranolazine attenuates cardiac hypertrophy and contractile dysfunction in a murine model P3769
of heart failure induced by chronic beta1-adrenergic stimulation.
– U. Primessnig, P. Schoenleitner, A. Schmidt, A. Hoell, P. Wakula, S. Engelhardt, G. Antoons, B. Pieske,
F.R. Heinzel (Berlin and Munich, DE; Maastricht, NL; Graz, AT)
Efficacy of long-term ivabradine therapy on prognosis, left and right heart functional parameters in P3770
patients with chronic heart failure and preserved left ventricular systolic function.
– K.G. Adamyan, L.R. Tumasyan, A.L. Chilingaryan, L.G. Tunyan (Yerevan, AM)
Individualized treatment in patients with comorbid type-2 diabetes and heart failure: insights from the P3771
DIALOGUE registry.
– A.K. Gitt, D. Tschoepe, P. Bramlage, C. Koch, T. Ouarrak, R. Schmieder (Ludwigshafen am Rhein, Bad
Oeynhausen, Mahlow, Nürnberg and Erlangen, DE)
Acute phase efficacy of sodium zirconium cyclosilicate (zs-9) in patients with severe hyperkalaemia: P3772
analysis from two phase 3 studies.
– M. Kosiborod, W.F. Peacock, E. Lerma, H.S. Rasmussen, P.T. Lavin, B. Singh, A. Yang, D. Packham
(Kansas City, Houston, Chicago, Coppell and Framingham, US; Reservoir, AU)
Does higher stimulation dosage in cardiac contractility modulation increase patient outcome? Data from P3773
the FIX HF 13 Trial.
– A. Kloppe, D. Mijic, F. Schiedat, H. Bogossian, M. Zarse, A. Muegge, B. Lemke (Düsseldorf, Ludenscheid
and Bochum, DE)
Safety and efficacy of G-CSF and autologous bone marrow-derived cells in ischaemic cardiomyopathy: P3774
Results of the REGENERATE-IHD Phase II trial.
– S. Hamshere, T. Choudhury, A. Mozid, S. Agarwal, D.A. Jones, J. Martin, A. Mathur (London, UK)
Chronic vagus nerve stimulation reduces cardiac electrical instability assessed by quantitative T-wave P3775
alternans analysis and suppresses ventricular tachycardia in heart failure patients.
– I. Libbus, B.D. Nearing, B. Amurthur, B.H. Kenknight, R.L. Verrier (Houston and Boston, US)
Effects of beta blocker therapy on resting heart rate in real life clinical practice in patients with chronic P3776
heart failure and reduced ejection fraction: results from reality HF study.
– Y. Cavusoglu, O. Kozan, A. Temizhan, S. Kucukoglu (Eskisehir, Izmir, Ankara and Istanbul, TR)
HEART FAILURE THERAPY, VARIOUS IV

Tolvaptan in patients with acute decompensated heart failure, could reduce renal worsening from P3777
randomized controlled trial two.
– Y. Katoh, T. Hirosa, T. Uchida, H. Taniguchi, J. Okuda, S. Enomoto, I. Kouchi (Osaka, JP)
Effects on beta-blockers on heart failure with preserved ejection fraction; from the Korean Acute Heart P3778
Failure (KorAHF) registry.
– S.H. Kim, S.H. Baek, S.C. Yun, E.S. Jeon, J.J. Kim, S.M. Kang, B.H. Oh (Seoul, KR)
Long-term advantages of HR control with ivabradin-bisoprolol combination versus bisoprolol uptitration P3779
on exercise capacity, chronotropic reserve and pulsatile arterial hemodynamics in CAD patients.
– K.M. Amosova, I. Katsytadze, A. Bezrodniy, Y.U. Rudenko, A. Andreev, Y.O. Sychenko, I.I. Gorda,
N. Shishkina (Kiev, UA)
Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated P3780
heart failure: importance of preserved kidney size.
– H. Toda, K.N. Nakamura, K.N. Nakagawa, N.N. Nishii, S.N. Nagase, H.M. Morita, H.I. Ito (Okayama, JP)
Dipeptidyl peptidase-4 inhibitor exerts better cardioprotection than enalapril against late-phase left P3781
ventricular remodeling after myocardial infarction in obese-insulin resistant rats.
– N. Apaijai, S. Lekawanvijit, S. Chattipakorn, N. Chattipakorn (Chiang Mai, TH)
Resveratrol ameliorates dystrophic cardiomyopathy by activating FoxO transcription factors. P3782
– A. Kuno, T. Miura, Y. Horio (Sapporo, JP)
Bendavia (MTP-131), a novel mitochondria-targeting peptide, improves mitochondrial respiration in P3783
isolated failing dog cardiomyocytes.
– H.N. Sabbah, R.C. Gupta (Detroit, US)
Difference in efficacy of vasodilators for acute heart failure syndrome between female and male. P3784
– N. Kagiyama, Y. Matsue, T. Kume, H. Okura, A. Matsumura, M. Suzuki, Y. Hashimoto, K. Yamamoto,
K. Yoshida (Okayama, Kamogawa and Kurashiki, JP)
Furosemide dose response curve after hypersaline in heart failure. P3785
– G. Parrinello, F. Di Gaudio, P. Di Pasquale, D. Torres, F. Balistreri, S. Indelicato, U. Lupo, F. Cuttitta,
J. Butler, S. Paterna (Palermo, IT; New York, US)
Head to head comparison of therapeutic efficacy among three iron chelators on cardiac function in P3786
iron-overloaded rats.
– S. Wongjaikam, S. Kumfu, S. Chattipakorn, S. Fucharoen, N. Chattipakorn (Chiang Mai and Nakhon
Pathom, TH)
238
HEART FAILURE THERAPY, VARIOUS V

Different impacts of statin therapy on clinical outcomes in acute decompensated heart failure patients P3787
with or without ischemic etiology.
– J.Y. Cho, K.H. Kim, Y. Ahn, E.S. Jeon, J.J. Kim, S.C. Chae, S.H. Baek, S.M. Kang, M.C. Cho, B.H. Oh
(Gwangju, Seoul, Daegu and Cheongju, KR)
GH differentially modulates skeletal muscle proteins in rats with aortic stenosis-induced heart failure. P3788
– A.R.R. Lima, R.L. Damatto, L.U. Pagan, M.J. Gomes, C. Bonomo, M.D.M. Cezar, F.C. Damatto,
P.S.A. Gaiolla, K. Okoshi, M.P. Okoshi (Botucatu, BR)
Clinical, biochemical and echocardiographic phenotyping of patients with cardiac dysfunction stratified P3789
according to prescription of loop diuretics.
– P. Pellicori, L. Monzo, P. Costanzo, P. Putzu, A. Bennett, C. Gaudio, J. Zhang, A.L. Clark, J.G. Cleland
(Hull, UK; Rome, IT)
Early diuretic response is a long-term prognostic marker in patients hospitalized for acute heart failure. P3790
– V. Carubelli, V. Lazzarini, M.C. Simoncioni, F. Ziliani, A.I. Castrini, C. Lombardi, M. Metra (Brescia, IT)
Impact of loop diuretic infusion modalities on congestion signs and outcomes in patients with acute heart P3791
failure.
– A. Palazzuoli, G. Ruocco, M. Pellegrini, B. Franci, M.S. Campagna, R. Nuti, C. Ronco, P.A. McCullough
(Siena and Vicenza, IT; Dallas, US)
Efficacy of addition of ivabradine to bisoprolol in patients with essential hypertension, coronary artery P3792
disease and reduced left ventricular systolic function.
– S. Vatinian, S. Gurgenyan, K. Nikoghosyan (Yerevan, AM)
Sodium zirconium cyclosilicate (zs-9) for hyperkalaemia treatment: efficacy and tolerability in heart failure P3793
patients on renin-angiotensin-aldosterone system inhibitors (RAASI) from a phase 3 study.
– S.D. Anker, A. Mebazaa, F. Zannad, H.S. Rasmussen, P.T. Lavin, S. Bhupinder, A. Yang, M. Kosiborod
(Göttingen, DE; Paris and Vandoeuvre-lès-Nancy, FR; Coppell, Framingham and Kansas City, US)
Right ventricular function is associated with survival in patients undergoing surgical left ventricular P3794
reconstruction.
– L.E. Couperus, V. Delgado, H.F. Verwey, L.F. Tops, M.E. Van Vessem, M. Palmen, R.J.M. Klautz,
M.J. Schalij, S.L.M.A. Beeres (Leiden, NL)
Impact of pulmonary hypertension on mortality in patients treated with nitric oxide for failure to wean P3795
following cardiothoracic surgery.
– M.J. Zdradzinski, M. Ahmad, J. Cheng, R.A. Krasuski (Cleveland, US)
BLOOD PRESSURE, MONITORING VARIABILITY AND ARTERIAL STIFFNESS

Classification of blood pressure by office and ambulatory readings in hypertensive type 2 diabetic P3796
patients- results of the German T2Target registry in primary care.
– T. Mengden, U. Ligges, P. Bramlage, W. Sehnert (Bad Nauheim, Dortmund and Cloppenburg, DE)
MONDAY – MORNING
Greater night-time blood pressure variability in acute coronary syndrome patients with more impaired P3797
reactive hyperemia index.
– Y. Saito, T. Nakayama, Y. Fujimoto, Y. Kobayashi (Chiba, JP)
Ambulatory blood pressure monitoring in adolescent girls, reproductive-age women and postmenopausal P3798
women with obesity.
– A. Starodubova, O. Kislyak, G. Storozhakov (Moscow, RU)
Multiple office blood pressure measurement is not inferior to home blood pressure monitoring compared P3799
with 24-hour ambulatory blood pressure monitoring: a prospective multicenter study.
– T.Y. Choi, M.Y. Rhee, H.B. Park, J.H. Kim, J. Namgung, S.Y. Lee, D.K. Cho, S.Y. Kim, J.Y. Kim, J.S. Park
(Goyang, Ilsan, Seoul, Wonju and Suwon, KR)
Ambulatory monitoring derived blood pressure variability is associated with cerebral white matter lesions P3800
in elderly hypertensive patients.
– M. Kokubo, A. Shimizu, K. Nomoto, M. Miyagi, T. Mitsui, T. Sakurai, K. Toba (Obu, JP)
How do vitamin D and PTH affect diurnal blood pressure rhythm in newly diagnosed hypertensive P3801
patients and normotensives.
– M. Kutlu Karadag, O. Secen (Elazig, TR)
Role of ambulatory blood pressure monitoring in long-term follow-up of gestational hypertension. P3802
– A.M. Maresca, C. Mongiardi, L. Robustelli Test, S. Moretti, M. Agostinis, N. Tandurella, A.M. Bertolini,
G.V. Gaudio, A.M. Grandi, L. Guasti (Varese and Somma Lombardo, IT)
Serum cystatin-C as a marker for left ventricular hypertrophy in isolated nocturnal hypertension. P3803
– E. Androulakis, N. Papageorgiou, E. Chatzistamatiou, G. Latsios, C. Tsioufis, S. Papaioannou, S. Brili,
C. Antoniades, I. Kallikazaros, D. Tousoulis (Athens, GR)
Effect of liver transplant in circadian variation of blood pressure in patients with familial amyloid P3804
polyneuropathy.
– T. Guimaraes, N. Cortez-Dias, A.R.G. Francisco, R. Placido, G.L. Silva, M. Menezes, I. Neves, I. Conceicao,
F.J. Pinto, C. Azevedo Coutinho (Lisbon, PT)
Correlation central blood pressure with intima-media thickness, office and ambulatory blood pressure on P3805
combination therapy with lercanidipin and diltiazem in patients with arterial hypertension.
– O. Rekovets, Y.U. Sirenko, O. Torbas, A. Dobrokhod, G. Primak, V. Granich, P. Sidorenko, S. Polischuk,
A. Vaschilko, S. Kushnir (Kiev, UA)
Reversing the clock of vascular aging: the effect of antihypertensive treatment. P3806
– D. Terentes-Printzios, C. Vlachopoulos, N. Ioakeimidis, P. Xaplanteris, K. Aznaouridis, P. Pietri,
E. Paschalidis, D. Tousoulis (Athens, GR)
The influence of antihypertensive treatment on arterial stiffness, shear stress and activity of chosen P3807
matrix metalloproteinases.
– T. Pizon, M. Rajzer, D. Czarnecka (Krakow, PL)
239
MONDAY 31 AUGUST 2015 – LUNCH TIME SESSIONS

THE EUROPEAN HEART JOURNAL’S YEAR IN CARDIOLOGY: HEART FAILURE AND Special Session
VALVULAR HEART DISEASE
Chairperson(s): M. Metra (Brescia, IT); F. Ruschitzka (Zurich, CH)
12:44 Imaging in valvular heart disease and heart failure. 3809
– J.J. Bax (Leiden, NL)
12:57 Heart Failure 2015 – New drugs on the horizon. 3810
13:10 Aortic stenosis: natural history, TAVI and surgery. 3811
13:23 Mitral tricuspid regurgitation: from catheter based clipping to valve replacement. 3812
13:36 Summary. 3813

CLINIC MANAGEMENT PROBLEMS IN OUT-PATIENTS WITH ATRIAL FIBRILLATION Special Session
organised by the Council for Cardiology Practice
12:40 Anticoagulation: better with novel oral anticoagulants. 3814
– M. Guenoun (Plan-de-Cuques, FR)
12:54 Atrial fibrillation and heart failure: the egg and the chicken. 3815
– D.J. Richter (Athens, GR)
13:08 Heart control and rate control in clinical practice. 3816
13:22 What optimal candidate to radiofrequency ablation? The point of view of a clinician. 3817
– R. Asteggiano (Turin, IT)
13:36 Panel discussion. 3818
– R. Asteggiano (Turin, IT), G. Baron Esquivias (Sevilla, ES), M. Guenoun (Plan-de-Cuques, FR), D.J. Richter
(Athens, GR)

NAVIGATING THE UNIVERSE OF ANTICOAGULATION IN STROKE PREVENTION AND Satellite Symposium
VENOUS THROMBOEMBOLISM
Chairperson(s): A.J. Camm (London, UK)
12:45 Exploring the patient’s perspective on anticoagulation in stroke prevention and venous 3819
thromboembolism.
12:55 Overcoming challenges with oral anticoagulation. 3820
– M. Alings (Breda, NL)
13:15 Enhancing patient care with oral anticoagulation. 3821
– J. Eikelboom (Hamilton, CA)
13:35 Improving patient care: the voyage continues. 3822

RENAL DENERVATION (RDN) FOR UNCONTROLLED HYPERTENSION: INTRODUCING Satellite Symposium
THE SPYRAL HTN GLOBAL CLINICAL TRIAL PROGRAM
Chairperson(s): M. Böhm (Homburg, DE)
12:45 Brief history of RDN. 3823
12:51 Anatomical Optimization of renal denervation: Have we found the “sweet spot”? 3824
– J.E. Davies (London, UK)
13:01 Addressing the confounding effect of dynamic drug therapy adherence in clinical trial design. 3825
– P.J. Blankenstijn (Utrecht, NL)
13:11 Population variability: have we identified the correct population for renal denervation therapy? 3826
13:21 Blood pressure measurement: how does the decline translate to CV risk reduction? 3827
– G. Mancia (Milan, IT)
13:31 Introducing the SPYRAL HTN global clinical program and audience Q&A. 3828
240

EVIDENCE AND EVOLUTION IN PULMONARY ARTERIAL HYPERTENSION (PAH) Satellite Symposium
Sponsored by GlaxoSmithKline
Chairperson(s): N. Galie (Bologna, IT)
12:45 Introduction - Evidence and evolution in Pulmonary Arterial Hypertension (PAH). 3829
12:50 Evolution of primary endpoints. 3830
– J.L. Vachiery (Brussels, BE)
13:05 Treat to goal... What has changed? 3831
– M.M. Hoeper (Hannover, DE)
13:20 Evolution of Combination Therapy in PAH. 3832
13:35 Discussion and conclusions - Evidence and evolution in Pulmonary Arterial Hypertension (PAH). 3833
12:45–13:45 | Kiev - Village 3

SLEEP DISORDERED BREATHING IN HEART FAILURE (HF), SERVE HF RESULTS AND Satellite Symposium
BEYOND
Sponsored by ResMed
Chairperson(s): C.S.P. Lam (Singapore, SG); D.J. van Veldhuisen (Groningen, NL)
12:45 SERVE HF results. 3834
13:05 Implication and perspectives. 3835
– C. O’Connor (Durham, US)
13:20 Panel discussion – Sleep disordered breathing in Heart Failure (HF), SERVE HF results and 3836
beyond.
– M.R. Cowie (London, UK), C. O’Connor (Durham, US), K. Wegscheider (Berlin, DE), H. Woehrle (Ulm, DE),
C.S.P. Lam (Singapore, SG), D.J. van Veldhuisen (Groningen, NL)

ARTERIAL STIFFNESS – THE CARDIO-ANKLE VASCULAR INDEX (CAVI) FROM Satellite Symposium
RESEARCH TO CLINICAL PRACTICE
MONDAY – LUNCH TIME

Sponsored by Fukuda Denshi Co. Ltd.
Chairperson(s): R. Asmar (Paris, FR); G. Mancia (Milan, IT)
12:45 Introduction - Arterial stiffness – The Cardio-Ankle Vascular Index (CAVI) from research to clinical 3837
practice.
– R. Asmar (Paris, FR), G. Parati (Milan, IT)
12:49 Assessing large artery function beyond blood pressure. 3838
13:02 CAVI and aortic stiffness; a new insight into cardiovascular risk. 3839
– G. Schillaci (Perugia, IT)
13:15 Arterial stiffness and metabolic syndrome; preliminary results of the triple A study. 3840
– R. Asmar (Paris, FR)
13:28 Assessment of arterial stiffness by CAVI and Magnetic Resonance (MR). 3841
– P. Leeson (Oxford, UK)
13:41 Conclusion - Arterial stiffness – The Cardio-Ankle Vascular Index (CAVI) from research to clinical 3842
practice.
– R. Asmar (Paris, FR), G. Parati (Milan, IT)
241

ENERGY AT THE HEART OF ISCHEMIC HEART DISEASE PATIENTS EBAC Accredited Educational Programme
Organised by University of Pisa. Course Director: Mario Marzilli
Chairperson(s): R. Ferrari (Cona, IT); M. Marzilli (Pisa, IT)
12:45 Introduction - Energy at the heart of ischemic heart disease patients. 3843
– R. Ferrari (Cona, IT)
12:52 Heart disease: a story of cardiac energy deficiency. 3844
– D.J. Hausenloy (Singapore, SG)
13:07 Antianginal drugs to overcome energy deficiency. 3845
– L.H. Wolff Gowdak (São Paulo, BR)
13:22 Persistant angina: clinical relevance and therapeutic approach. 3846
13:37 Conclusion - Energy at the heart of ischemic heart disease patients. 3847
– M. Marzilli (Pisa, IT)

CHANGING CONVENTIONS – INTRAVENOUS IRON IN HEART FAILURE Satellite Symposium
Sponsored by Charité
Chairperson(s): G.S. Filippatos (Athens, GR); J.G.F. Cleland (London, UK)
12:45 Introduction - Changing conventions - Intravenous iron in heart failure. 3848
– G.S. Filippatos (Athens, GR)
12:50 Iron deficiency - Prevalence, the burden, pathophysiology and diagnosis. 3849
13:10 Now what? Treatment of intravenous iron improves patients’ outcome. 3850
13:35 Panel discussion - Changing conventions - Intravenous iron in heart failure. 3851
– S.D. Anker (Göttingen, DE), P. Ponikowski (Wroclaw, PL), G.S. Filippatos (Athens, GR)

CYTOKINES AND CARDIOVASCULAR DISEASE: EXPLORING EBAC Accredited Educational Programme
INFLAMMATION & CLINICAL OUTCOMES
Organised by Academic Medical Center Amsterdam. Course Director: John Kastelein
Chairperson(s): P. Libby (Boston, US); T.F. Luscher (Zurich, CH)
12:45 Introduction - Cytokines and cardiovascular disease: exploring inflammation & clinical outcomes. 3852
– P. Libby (Boston, US)
12:55 Inflammation in acute myocardial infarction & ventricular remodelling. 3853
– M. Nahrendorf (Boston, US)
13:10 Inflammation and thrombosis. 3854
13:25 Inflammation as target for therapy in atherothrombosis. 3855
– P.M. Ridker (Boston, US)
13:40 Discussion - Cytokines and cardiovascular disease: exploring inflammation & clinical outcomes. 3856
Supported by an unrestricted educational grant from Physicians’ Academy for Cardiovascular Education
242

CURRENT AND FUTURE THERAPEUTIC OPTIONS TARGETING RESIDUAL Satellite Symposium
CARDIOVASCULAR DISEASE (CVD) RISK: EMERGING THERAPIES FOR THE TREATMENT
OF DYSLIPIDEMIA
Sponsored by Cleveland Clinic
Chairperson(s): S.E. Nissen (Cleveland, US)
12:45 Introduction - Current and future therapeutic options targeting residual Cardiovascular Disease 3857
(CVD) risk: emerging therapies for the treatment of dyslipidemia.
– S.E. Nissen (Cleveland, US)
12:50 Management of statin-intolerant high-risk patients: what are the current options? 3858
– L. Cho (Cleveland, US)
13:05 Cholesteryl Ester Transfer Protein (CETP) Inhibition in CVD risk management: a critical and 3859
contemporary appraisal.
– S.J. Nicholls (Adelaide, AU)
13:20 The next generation of novel low-density lipoprotein cholesterol-lowering agents: PCSK9 3860
inhibitors.
13:35 Commentary and discussion - Current and future therapeutic options targeting residual 3861
Cardiovascular Disease (CVD) risk: emerging therapies for the treatment of dyslipidemia.

WHY REDUCING LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL MATTERS: AN Satellite Symposium
EVIDENCE BASED DISCUSSION
Sponsored by MSD
Chairperson(s): C.P. Cannon (Boston, US); U. Laufs (Homburg, DE)
12:45 Opening by the chairs - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an 3862
evidence based discussion.
– C.P. Cannon (Boston, US), U. Laufs (Homburg, DE)
12:50 What do recent trial results add to the legacy of lowering LDL cholesterol? Putting recent clinical 3863
study results in the context of pervious trials.

13:00 What mendelian studies can teach: using naturally randomized genetic data to fill evidence gaps. 3864
– B.A. Ference (Detroit, US)
13:10 Addressing the clinical treatment gap 2015. 3865
– A.K. Gitt (Ludwigshafen am Rhein, DE)
13:20 Putting the evidence and treatment standards in the perspective of lifetime benefit. 3866
– P.P. Toth (Sterling, US)
13:30 Panel discussion & Q&A - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an 3867
evidence based discussion.
– C.P. Cannon (Boston, US), U. Laufs (Homburg, DE), B.A. Ference (Detroit, US), A.K. Gitt (Ludwigshafen am
Rhein, DE), P.P. Toth (Sterling, US)
13:40 Closing - Why reducing Low-Density Lipoprotein (LDL) cholesterol matters: an evidence based 3868
discussion.
– C.P. Cannon (Boston, US), U. Laufs (Homburg, DE)

Monday 31 August, 15:45–16:15 in Green Park (The Hub)!
243
12:45–13:45 | Oslo - Village 6

MANAGEMENT PRIORITIES AND CLINICAL OUTCOMES IN POST-ACUTE CORONARY Satellite Symposium
SYNDROME (ACS) PATIENTS WITH TYPE 2 DIABETES (T2D)
Sponsored by Takeda Pharmaceuticals GmbH
Chairperson(s): F. Zannad (Vandoeuvre-lès-Nancy, FR)
12:45 Welcome - Management priorities and clinical outcomes in post-acute coronary syndrome (ACS) 3869
patients with type 2 diabetes (T2D).
12:50 Management perspectives for the post-ACS T2D patient: cardiologist vs diabetologist (Part 1 & 3870
Part 2).
– V. Menon (Cleveland, US), P.J. Grant (Leeds, UK)
13:15 Safety profile of DPP-4 inhibitors in post-ACS T2D patients. 3871
13:25 Debate: what can we conclude about the safety profile of DPP-4 inhibitors in post-ACS T2D 3872
patients?
– F. Zannad (Vandoeuvre-lès-Nancy, FR), V. Menon (Cleveland, US), P.J. Grant (Leeds, UK)
13:40 Conclusions and close - Management priorities and clinical outcomes in post-acute coronary 3873
syndrome (ACS) patients with type 2 diabetes (T2D).
Tuesday 1 September, 10:15–10:45 in Victoria Park (The Hub)!

DUAL ANTI-PLATELET THERAPY IN ATHEROTHROMBOSIS IN 2015: EBAC Accredited Educational Programme
DEBATING THE EVIDENCE
Organised by University Hospital of Umeå. Course Director: Ulf Naslund
Chairperson(s): K.A.A. Fox (Edinburgh, UK); C.W. Hamm (Bad Nauheim, DE)
12:45 Welcome and session objectives - Dual anti-platelet therapy in atherothrombosis in 2015: 3874
debating the evidence.
12:50 Dual anti-platelet therapy after acute coronary syndromes – should we continue beyond 12 3875
months? Pro.
– M. Sabatine (Boston, US)
13:05 Dual anti-platelet therapy after acute coronary syndromes – should we continue beyond 12 3876
months? Contra.
– N. Danchin (Paris, FR)
13:20 Discussion - Dual anti-platelet therapy in atherothrombosis in 2015: debating the evidence. 3877
– K.A.A. Fox (Edinburgh, UK), C.W. Hamm (Bad Nauheim, DE), M. Sabatine (Boston, US), N. Danchin (Paris,
FR)
13:35 Summary and close - Dual anti-platelet therapy in atherothrombosis in 2015: debating the 3878
evidence.
– C.W. Hamm (Bad Nauheim, DE)
Tuesday 1 September, 10:15–10:45 in Regents Park (The Hub)!
244

A CONSENSUS ON ATHEROGENIC DYSLIPIDAEMIA Satellite Symposium
Sponsored by MYLAN
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); L. Catapano (Milan, IT)
12:45 Introduction - A consensus on atherogenic dyslipidaemia. 3879
– J.L. Zamorano Gomez (Madrid, ES)
12:50 What is it? 3880
– Z. Reiner (Zagreb, HR)
13:00 What causes it? 3881
– M. Farnier (Dijon, FR)
13:15 How does it impact cardiovascular risk? 3882
– A. Zambon (Padua, IT)
13:25 How can we treat it? 3883
– M.T. Tavares Aguiar (Lisbon, PT)
13:40 Conclusion - A consensus on atherogenic dyslipidaemia. 3884
12:45–13:45 | Bern - Village 9

YOUR PATIENTS, YOUR PRACTICE, YOUR CHOICE: NOACS IN THE CLINIC Satellite Symposium
Chairperson(s): S. Connolly (Hamilton, CA); E. Hylek (Boston, US)
12:45 Beyond the trials: NOACs in practice. 3885
– S.J. Connolly (Hamilton, CA)
12:50 Your patient requires Atrial Fibrillation (AF) ablation: what would you do? 3886
13:05 Your patient with Non-Valvular Atrial Fibrillation (NVAF) requires a coronary stent: what would you 3887
do?
– S.H. Hohnloser (Frankfurt am Main, DE)
13:20 Your patient requires surgery: what would you do? 3888
– J. Weitz (Hamilton, CA)
13:35 Panel discussion and Q&A - Your patients, your practice, your choice: Novel Oral AntiCoagulants 3889
(NOACs) in the clinic.
– E. Hylek (Boston, US)

Monday 31 August, 15:45–16:15 in Victoria Park (The Hub)!

A ROYAL PROGRESSION OF NOACS Satellite Symposium
Sponsored by theheart.org / Medscape Education
Chairperson(s): A. Kakkar (London, UK)
12:45 Introductions - A royal progression of Novel Oral Anticoagulants (NOACs). 3890
12:50 What registries with oral anticoagulants are telling us. 3891
13:05 How to overcome the fear of bleeding. 3892
13:20 Factors to consider when choosing an oral anticoagulant. 3893
13:35 Question and Answer Session - A royal progression of Novel Oral Anticoagulants (NOACs). 3894

NUTRITIONAL INGREDIENTS FOR CARDIOVASCULAR DISEASE REDUCTION Satellite Symposium
Sponsored by DSM Nutritional Products
Chairperson(s): M. Eggersdorfer (Stein, CH); R. Winwood (Haverhill, UK)
13:00 Marine fatty acids for primary and secondary Cardiovascular Disease (CVD) risk reduction. 3895
– P.C. Calder (Southampton, UK)
13:22 The potential of lycopene free tomato extracts in primary prevention of cardiovascular disease. 3896
– N. O’Kennedy (Aberdeen, UK)
245

A PRACTICAL GUIDE TO THE MANAGEMENT OF FABRY DISEASE CARDIOMYOPATHIES Satellite Symposium
Sponsored by Genzyme, a Sanofi company
Chairperson(s): A. Linhart (Prague, CZ)
13:00 Management of atrial fibrillation. 3897
– M. Namdar (Geneva, CH)
13:15 Prevention of sudden cardiac death. 3898
13:30 Heart failure and enzyme replacement therapy. 3899
13:00–13:45 | Tunis - Village 7

REMOTE PATIENT MANAGEMENT – PROTECTING PATIENTS WITH THE WEARABLE Satellite Symposium
CARDIOVERTER DEFIBRILLATOR (WCD)
Sponsored by ZOLL
Chairperson(s): G. Hindricks (Leipzig, DE); H.P. Brunner-La Rocca (Maastricht, NL)
13:00 Introduction - Remote patient management – Protecting patients with the Wearable Cardioverter 3900
Defibrillator (WCD).
13:05 Discussion of the utility of remotely managed patient clinical and diagnostic markers to effect 3901
better outcomes.
13:20 Overview of the online patient management system and clinical case scenarios for its use in 3902
managing WCD patients.
– D. Thomas (Heidelberg, DE)
13:35 Panel Discussion/Q&A -Remote patient data management - Protecting patients with the wearable 3903
cardioverter defibrillator.
– D. Thomas (Heidelberg, DE), P. Mabo (Rennes, FR), G. Hindricks (Leipzig, DE), H.P. Brunner-La Rocca
(Maastricht, NL)

EXPECT THE UNEXPECTED IN THE PULMONARY ARTERIAL HYPERTENSION CLINIC Satellite Symposium
Sponsored by Actelion Pharmaceuticals Ltd
Chairperson(s): S. Rosenkranz (Cologne, DE); I.M. Lang (Vienna, AT)
13:00 Introduction - Expect the unexpected in the pulmonary arterial hypertension clinic. 3904
– I.M. Lang (Vienna, AT)
13:05 Challenges in PAH - Interactive patient case I. 3905
– J.S.R. Gibbs (London, UK)
13:20 Interactive patient case - Interim discussion. 3906
– S. Rosenkranz (Cologne, DE)
13:30 Challenges in PAH - Interactive patient case II. 3907
13:40 Closing remarks - Expect the unexpected in the pulmonary arterial hypertension clinic. 3908
– I.M. Lang (Vienna, AT)
246
MONDAY 31 AUGUST 2015 – AFTERNOON SESSIONS

ESC/ERS GUIDELINES – PULMONARY HYPERTENSION Main Session
Chairperson(s): N. Galie (Bologna, IT); M. Humbert (Le Kremlin-Bicêtre, FR)
14:00 Definition, classification, diagnosis and screening. 3909
14:22 Risk stratification and therapy of pulmonary arterial hypertension. 3910
– M.M. Hoeper (Hannover, DE)
14:45 Pulmonary arterial hypertension subgroups. 3911
15:07 Pulmonary hypertension due to lung disease, to left heart disease and CTEPH. 3912
– J.L. Vachiery (Brussels, BE)

CLINICAL TRIAL UPDATE II – ANTIPLATELET THERAPY Clinical Trial Update
Chairperson(s): D. Atar (Oslo, NO); P. O’Gara (Boston, US)
14:00 Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in patients 3913
with previous myocardial infarction: a collaborative meta-analysis of randomised trials.
– J. Udell (Toronto, CA)
14:15 Effect of pre-hospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: the 3914
ATLANTIC-H24 analysis.
14:30 Bleeding risk of prasugrel-based dual antiplatelet therapy after stent implantation in stable 3915
– R. Jeger (Basel, CH)
14:45 Mortality related to bleeding is uncommon with continued thienopyridine use beyond one year. 3916
15:00 Comparison of four bleeding risk scores to identify rivaroxaban-treated venous thromboembolism 3917
patients at low risk for major bleeding.
– J. Kline (Indianapolis, US)
15:15 Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal. 3918
– M. Bonaca (Boston, US)
MONDAY – AFTERNOON
SHOULD THE SAME RULES APPLY FOR DRUG AND DEVICE APPROVAL? EU VS. US Special Session
PERSPECTIVE
Chairperson(s): A.G. Fraser (Cardiff, UK); F.J. Pinto (Lisbon, PT)
14:00 Should the same rules apply for drug and device approval? EU - Regulator. 3919
– H. Hillege (Groningen, NL)
14:05 Should the same rules apply for drug and device approval? US - Regulator. 3920
– R.M. Califf (Silver Spring, US)
14:10 Should the same rules apply for drug and device approval? EU - Industry. 3921
– R. ten Hoedt (Tolochenaz, CH)
14:15 Should the same rules apply for drug and device approval? US - Industry. 3922
– R.A.D. Scott (Thousand Oaks, US)
14:20 Should the same rules apply for drug and device approval? EU - Physicians. 3923
14:25 Should the same rules apply for drug and device approval? US - Physicians. 3924
14:30 Should the same rules apply for drug and device approval? EU - Physicians. 3925
– A.G. Fraser (Cardiff, UK)
14:35 Should the same rules apply for drug and device approval? US - Physicians. 3926
14:40 Should the same rules apply for drug and device approval? Panel discussion and questions from 3927
the audience.
– M. Roffi (Geneva, CH), L. Cho (Cleveland, US)
247

MECHANISMS OF ACTION OF EMERGING THERAPEUTICS Symposium
Chairperson(s): S. Ljubojevic (Graz, AT); S. Sossalla (Göttingen, DE)
14:00 Mechanisms of action of the vasoactive hormone peptide serelaxin. 3928
– T.B. Dschietzig (Berlin, DE)
14:22 Runx1 and cardiac remodeling after acute myocardial infarction. 3929
– C. Loughrey (Glasgow, UK)
14:45 Signalling “PARADIGM” for treating heart failure. 3930
– J.L. Tamargo (Madrid, ES)
15:07 Ryanodine receptor modulators for the treatment of arrhythmias. 3931
– S.E. Lehnart (Göttingen, DE)

DISCUSSING THE MOST CHALLENGING CLINICAL CASES Clinical Cases
Chairperson(s): B. Merkely (Budapest, HU); L.M. Goncalves (Coimbra, PT)
14:00 How to treat a febrile systemic lupus erythematosus patient with right ventricular outflow tract 3932
mass: antibiotics versus anticoagulation.
– A.E.H. Amin (Cairo, EG)
14:15 Management of a giant left main coronary pseudoaneurysm: a step-by-step hybrid approach. 3933
– A.F. Ispas (Cluj-Napoca, RO)
– E.A. Jankowska (Wroclaw, PL), S. Muscoli (Rome, IT)
14:45 Purkinje-related idiopathic ventricular fibrillation treated by catheter ablation. 3935
– C.A. Martin (Cambridge, UK)
15:00 Cardiac tamponade and circulatory shock due to eosinophilic myocarditis unmasking a 3936
pulmonary adenocarcinoma.
– E. Ammirati (Milan, IT)
– M. Pazdernik (Prague, CZ), J. Poess (Lübeck, DE)
Learn with the four most challenging case reports. A panel will discuss all cases in a lively and interactive way.
The winner will be selected by the Chairpersons, panelists and audience of the session on the following criteria:
Originality, scientific content, presentation, answers to questions.
Audience will be asked to participate in the selection of the winner, voting online using the Mobile App
voting functionality at the end of the session.
Prizes will be awarded to all finalists and grand prize to the best clinical case. Results will be announced at
the Awards Ceremony on Monday 31 August at 18:00 in The Hub.

VENTRICULAR ARRHYTHMIAS IN THE RUSSIAN FEDERATION Guidelines in Daily Practice
Chairperson(s): S. Matskeplishvili (Moscow, RU); A. Romanov (Novosibirsk, RU)
– E. Mikhaylov (St. Petersburg, RU)
14:20 What do the “new” 2015 Guideline tell us? 3939
– A.S. Revishvili (Moscow, RU)
– A.S. Revishvili (Moscow, RU)
– E. Baranova (St. Petersburg, RU), D. Duplyakov (Samara, RU), A. Kontsevaya (Moscow, RU), Y.M. Lopatin
(Volgograd, RU), S. Gilyarevsky (Moscow, RU), A. Konradi (St. Petersburg, RU), Y. Kotovskaya (Moscow,
RU)
248

INFLAMMATION AND IMMUNITY Rapid Fire Abstract
Chairperson(s): I. Goncalves (Malmö, SE); S. Massberg (Munich, DE)
14:00 Increased risk of abdominal aortic aneurysm in patients with psoriasis: A nationwide study. 3942
– U. Khalid, A. Egeberg, L. Smedegaard, O. Ahlehoff, L. Skov, G. Gislason, P.R. Hansen (Hellerup and
Copenhagen, DK)
14:09 Oxidized LDL induce tissue factor expression in CD3+ T-lymphocytes: a possible link between 3943
immunity, inflammation and thrombosis.
– G. Cimmino, G. Ciccarelli, G. Barra, S. Conte, G. Pellegrino, L. Insabato, G. Cali’, P. Cirillo, R. De Palma,
P. Golino (Naples, IT)
14:18 Indoleamine 2,3-dioxygenase (IDO) enzyme: linking innate immunity and altered T-cell 3944
differentiation in acute coronary syndromes.
– C. Zara, M. Manchi, A. Severino, D. Flego, S. Ucci, F. Trotta, D. Pedicino, L.M. Biasucci, G. Liuzzo, F. Crea
(Rome, IT)
14:27 Macrophage degradation in coronary atherosclerotic plaques by statin therapy: an optical 3945
coherence tomography study.
– T. Nishiguchi, T. Kubo, K. Komukai, Y. Matsuo, Y. Ino, K. Hitrata, A. Tanaka, T. Hozumi, T. Akasaka
(Wakayama, JP)
14:36 Long-term cardiovascular outcomes in patients with collagen disease who underwent 3946
– S. Maruta (Ibaraki, JP)
14:45 OxLDL upregulates microRNA-155 in dendritic cells by binding transcription factor YY1/MYB 3947
through the JAK1/2 signaling pathway.
– H. Yan (Hangzhou, CN)
14:54 The neutrophil-lymphocyte ratio predicts mortality in acute coronary syndrome: a metaanalysis. 3948
– E.W. Timbol, J.D.R. Ramos, J.A.M. Aherrera, L.O. Chiong (Manila, PH)
15:03 IL-17 plays a major inflammatory mediator in ischemic heart failure. 3949
– S.L. Chang, Y.W. Hsiao, Y.N. Tsai, S.A. Chen (Taipei, TW)
15:12 Selective inhibition of the NLRP3 inflammasome dose-dependently reduces infarct size and 3950
preserves cardiac function in a porcine model of myocardial infarction.
– G.P.J. Van Hout, L. Bosch, G.H.J.M. Ellenbroek, M. Cooper, W.W. Van Solinge, S.C.A. De Jager,
A. Robertson, G. Pasterkamp, I.E. Hoefer (Utrecht, NL; Brisbane, AU)
15:21 Effects of paediatric HIV infection on childhood vasculature. 3951
– N.S. Idris, D.E. Grobbee, D. Burgner, M.M.H. Cheung, N. Kurniati, S. Sastroasmoro, C.S.P.M. Uiterwaal
(Jakarta, ID; Utrecht, NL; Melbourne, AU)
14:00–15:30 | Rabat - Village 1

NEW INSIGHTS IN THROMBOSIS: FROM MOLECULAR BASIS TO CLINICAL MANIFESTATIONS Symposium
Science in Practice
Chairperson(s): J.A.C. Morais (Leiria, PT); A. Siegbahn (Uppsala, SE)
14:00 Evolving concepts in thrombus morphology and composition in acute coronary events. 3952
– L. Badimon (Barcelona, ES)
14:22 Microparticles contribution to thrombus formation and progression. 3953
– A. Siegbahn (Uppsala, SE)
14:45 New players in haemostasis and thrombosis. 3954
15:07 Pathophysiological relevance of platelet immune functions. 3955
– F. Cognasse (Saint-Étienne, FR)

EARLY WOUND HEALING AFTER MYOCARDIAL INFARCTION: NEW CONCEPTS Symposium
Chairperson(s): J.L. Balligand (Brussels, BE); S. Frantz (Halle, DE)
14:00 Epigenetic regulation of inflammation. 3956
– B. Schroen (Maastricht, NL)
14:22 How do miRNAs regulate healing? 3957
– T. Thum (Hannover, DE)
14:45 Does metabolism contribute to healing? 3958
– P. Rouet (Toulouse, FR)
15:07 Imaging of healing. 3959
249

CARDIOVASCULAR DISEASES: IT IS NOT MY FAULT... I HAVE BAD GENES! Symposium
ESC and the American College of Cardiology
Chairperson(s): K.A. Williams (Chicago, US); L. Tokgozoglu (Ankara, TR)
14:00 Nature or nurture: one or both? 3960
– C. Macrae (Boston, US)
14:22 Cardiovascular diseases - It’s not my fault. 3961
– S. Blankenberg (Hamburg, DE)
14:45 What lifestyle changes should we recommend our patients? 3962
– D. Polk (Boston, US)
15:07 Stress: the new player in the field. 3963
– C. Albus (Cologne, DE)

HOW TO REACH 25% REDUCTION IN CARDIOVASCULAR DISEASE BY 2025 (25 BY 25) – Symposium
DIFFERENT COUNTRIES, ONE ROADMAP!
ESC and the World Heart Federation
Chairperson(s): D.A. Wood (London, UK); P.E. Vardas (Heraklion, GR)
14:00 Taking the global view on cardiovascular disease prevention. 3964
– S. Yusuf (Hamilton, CA)
14:22 Asia Pacific - Threatened by cardiovascular disease? 3965
– C.M. Yu (Hong Kong, HK)
14:45 Europe - One region, different approaches. 3966
15:07 From advocacy to implementation: World Heart Day to Emerging Leaders programme. 3967
– J. Ralston (Geneva, CH)
14:00–15:30 | Kiev - Village 3

RENOVASCULAR HYPERTENSION: HOW, WHEN AND IF TO INTERVENE Case-based Symposium
Chairperson(s): M. Viigimaa (Tallinn, EE); M. Volpe (Rome, IT)
14:00 A case of fibromuscular dysplasia. 3968
– P.W. De Leeuw (Maastricht, NL)
14:15 A case of fibromuscular dysplasia - Panel discussion and questions from the audience. 3969
– R. Cifkova (Prague, CZ), T. Zeller (Bad Krozingen, DE), P.W. De Leeuw (Maastricht, NL)
14:30 A case of atherosclerotic renovascular hypertension. 3970
– T. Zeller (Bad Krozingen, DE)
14:45 A case of atherosclerotic renovascular hypertension - Panel discussion and questions from the 3971
audience.
– T. Zeller (Bad Krozingen, DE), R. Cifkova (Prague, CZ), P.W. De Leeuw (Maastricht, NL)
15:00 Renovascular hypertension - State of the Art lecture. 3972
– C.J. Cooper (Toledo, US)

MICROCIRCULATORY DAMAGE IN HYPERTENSION Symposium
Chairperson(s): M. Brodmann (Graz, AT); G. de Simone (Naples, IT)
14:00 Arterial stiffness can be considered a marker of microvascular damage. 3973
– M.H. Olsen (Odense, DK)
14:22 The role of hypertension on diabetic microcirculatory damage. 3974
14:45 Microvascular injury and the kidney in hypertension. 3975
15:07 New methods of evaluation of microvascular structural alterations in hypertension. 3976
– D. Rizzoni (Brescia, IT)
250

REFLEX SYNCOPE: AN UPDATE Symposium
Chairperson(s): R.A. Kenny (Dublin, IE); P. Alboni (Ferrara, IT)
14:00 Carotid sinus syndrome revisited: new insights. 3977
– M. Brignole (Lavagna, IT)
14:22 Tilt table testing: new insights. 3978
– R. Sutton (Monte Carlo, MC)
14:45 Atypical presentations: the role of adenosine. 3979
– J.-C. Deharo (Marseille, FR)
15:07 How to improve the benefit of cardiac pacing. 3980
– A. Moya I Mitjans (Barcelona, ES)

CARDIAC ARREST/SUDDEN CARDIAC DEATH IN THE YOUNG Case-based Symposium
Chairperson(s): T.J.R. De Potter (Aalst, BE); A.C. Van Der Wal (Amsterdam, NL)
14:00 A young patient with cardiac arrest and a channelopathy. 3981
– F. Sacher (Bordeaux-Pessac, FR)
14:15 A young patient with cardiac arrest and a channelopathy - Panel discussion and questions from 3982
the audience.
– R. Tilz (Hamburg, DE), E. Marijon (Paris, FR), F. Sacher (Bordeaux-Pessac, FR)
14:30 A young patient with cardiac arrest without any evidence of heart disease. 3983
– R. Tilz (Hamburg, DE)
14:45 A young patient with cardiac arrest without any evidence of heart disease - Panel discussion and 3984
– R. Tilz (Hamburg, DE), E. Marijon (Paris, FR), F. Sacher (Bordeaux-Pessac, FR)
15:00 Sudden cardiac death in the young in Europe - State of the Art lecture. 3985
– A.A.M. Wilde (Amsterdam, NL)

IMAGING IN INTERVENTIONAL CARDIOLOGY Case-based Symposium
Chairperson(s): M. Garbi (London, UK); F.E. Rademakers (Leuven, BE)
14:00 Closure of atrial septal defect. 3986
– L. Perez De Isla (Madrid, ES)
14:10 Closure of atrial septal defect - Panel discusion and questions from the audience. 3987
– L. Perez De Isla (Madrid, ES), R.S. Von Bardeleben (Mainz, DE), M.J. Monaghan (London, UK), G. Marinskis
(Vilnius, LT)
14:22 Clipping mitral valve for Mitral Regurgitation. 3988
14:32 Clipping mitral valve for Mitral Regurgitation - Panel discussion and questions from the audience. 3989
– R.S. Von Bardeleben (Mainz, DE), M.J. Monaghan (London, UK), P. Caso (Naples, IT), L. Perez De Isla
(Madrid, ES)
14:44 Complications of TAVI. 3990
– M.J. Monaghan (London, UK)
14:54 Complications of TAVI - Panel discussion and questions from the audience. 3991
– L. Perez De Isla (Madrid, ES), R.S. Von Bardeleben (Mainz, DE), M.J. Monaghan (London, UK), P. Caso
(Naples, IT)
15:06 Closure of left atrial appendage. 3992
– P. Caso (Naples, IT)
15:16 Closure of left atrial appendage - Panel discussion and questions from the audience. 3993
– L. Perez De Isla (Madrid, ES), R.S. Von Bardeleben (Mainz, DE), M.J. Monaghan (London, UK), P. Caso
(Naples, IT)
251

COMPUTED TOMOGRAPHY AND CORONARY RISK Advances in Science
Chairperson(s): J.M. Knuuti (Turku, FI); D. Neglia (Pisa, IT)
14:00 State of the Art in coronary computed tomography. 3994
14:20 Can cardiac CT angiography identify asymptomatic type 2 diabetics at high risk for adverse 3995
coronary events? A prospective 7 year outcomes study.
14:37 5 year prognostic value of coronary computed tomographic angiography using machine learning: 3996
results from the CONFIRM Registry.
– M. Motwani, P. Slomka, D.S. Berman, J.K. Min (Los Angeles and New York, US)
14:54 Relationship between non-calcified coronary plaque volumes by coronary CT angiography and 3997
fractional flow reserve.
– S. Gaur, K.A. Oevrehus, D. Dey, J.A. Leipsic, J.M. Jensen, J.F. Lassen, H.E. Boetker, E.H. Christiansen,
A.K. Kaltoft, B.L. Norgaard (Aarhus and Vejle, DK; Los Angeles, US; Vancouver, CA)
15:11 Future direction for research in coronary computed tomography. 3998
– A.J.H.A. Scholte (Leiden, NL)

BLEEDING AND ISCHAEMIC EVENTS IN PCI PATIENTS: PREDICTION, PREVENTION AND Advances in Science
MANAGEMENT
Chairperson(s): S. Leonardi (Pavia, IT); F. Weidinger (Vienna, AT)
14:00 State of the Art in bleeding prediction, prevention and management in ACS patients treated with 3999
PCI.
14:20 Relationship between platelet count, platelet reactivity and ischemic and bleeding risk in patients 4000
undergoing PCI with DES: Insights from the ADAPT-DES registry.
– G. Giustino, U. Baber, R. Mehran, C. Litherland, B. Witzenbichler, G. Weisz, M.J. Rinaldi, B.R. Brodie,
A.J. Kirtane, G.W. Stone (New York, Charlotte and Greensboro, US; Dachau, DE; Jerusalem, IL)
14:37 Bleeding episodes in “complete, staged” versus “culprit only” revascularization in patients with 4001
multivessel disease and ST-segment elevation myocardial infarction. - A DANAMI-3-Primulti
substudy.
– G. Sadjadieh, T. Engstroem, S. Helqvist, D.E. Hoefsten, L. Koeber, F. Pedersen, H.H. Tilsted, H. Kelbaek,
L. Holmvang (Copenhagen, Aalborg and Roskilde, DK)
14:54 The effect of cangrelor and access site on ischemic and bleeding events: insights from 4002
CHAMPION-PHOENIX.
– J.A. Gutierrez, R.A. Harrington, G.W. Stone, P.G. Steg, C.M. Gibson, C.W. Hamm, M.J. Price,
K.W. Mahaffey, H.D. White, D.L. Bhatt (Boston, Stanford, New York and La Jolla, US; Paris, FR; Bad
Nauheim, DE; Auckland, NZ)
15:11 Future direction for research in bleeding prediction, prevention and management. 4003
14:00–15:30 | Oslo - Village 6

INDICATIONS FOR MITRAL VALVE REPAIR Meet the Experts
Chairperson(s): J.F. Obadia (Lyon-Bron, FR); B.A. Popescu (Bucharest, RO)
14:00 Indications for mitral valve repair - Introduction to the session. 4004
– B.A. Popescu (Bucharest, RO)
14:05 A dystrophy in a patient over 80 year old. 4005
– T.A.F. Folliguet (Vandoeuvre-lès-Nancy, FR)
14:15 A dystrophy in a patient over 80 year old - Panel discussion and questions from the audience. 4006
– S. Benyoussef (La Marsa, TN), N. Cardim (Lisbon, PT), C. Selton-Suty (Nancy, FR)
14:30 A moderate secondary MR with indication to myocardial revascularisation. 4007
– P. Punjabi (London, UK)
14:40 A moderate secondary MR with indication to myocardial revascularisation - Panel discussion and 4008
14:55 A severe secondary MR with poor LV function, AF and no option for revascularisation. 4009
15:05 A severe secondary MR with poor LV function, AF and no option for revascularisation - Panel 4010
15:20 Indications for mitral valve repair - Take home message. 4011
– J.F. Obadia (Lyon-Bron, FR)
252

CORONARY SPASM REVISITED: A MESSAGE FROM EUROPE (WEST) AND JAPAN (EAST) Symposium
Chairperson(s): T. Murohara (Nagoya, JP); P.G. Camici (Milano, IT)
14:00 Incidence of vasospastic angina: German perspective. 4012
– P.E. Ong (Stuttgart, DE)
14:22 Significance of coronary spasm after PCI: Japanese perspective. 4013
– H. Ogawa (Kumamoto, JP)
14:45 Relationship of microcirculation injury to coronary spasm: Italian perspective. 4014
15:07 Role of coronary spasm in ischaemic heart disease: Japanese perspectives. 4015
– H. Shimokawa (Sendai, JP)

HOW TO DIAGNOSE, MANAGE AND TREAT TYPE 2 MYOCARDIAL INFARCTION? Case-based Symposium
Chairperson(s): R. Kornowski (Petah Tikva, IL); P. Vranckx (Hasselt, BE)
14:00 Type 2 myocardial infarction associated with tachyarrhythmia. 4016
– D. Dudek (Krakow, PL)
14:15 Type 2 myocardial infarction associated with tachyarrhythmia - Panel discussion and questions 4017
from the audience.
– A. Witkowski (Warsaw, PL), D. Dudek (Krakow, PL), D. Zahger (Beer Sheva, IL), M. Gilard (Brest, FR)
14:30 Type 2 myocardial infarction following a massive bleeding event. 4018
– D. Zahger (Beer Sheva, IL)
14:45 Type 2 myocardial infarction following a massive bleeding event - Panel discussion and questions 4019
from the audience.
– D. Dudek (Krakow, PL), A. Witkowski (Warsaw, PL), D. Zahger (Beer Sheva, IL), M. Gilard (Brest, FR)
15:00 How to diagnose, manage and treat type 2 myocardial infarction? State of the Art lecture. 4020
– K. Thygesen (Aarhus, DK)
14:00–15:30 | Tunis - Village 7

WHAT’S NEW IN MICROCIRCULATION AND COLLATERALS Advances in Science
Chairperson(s): J.E. Davies (London, UK); R. Sicari (Pisa, IT)
14:00 State of the Art in microcirculation and collaterals. 4021
– A. Lerman (Rochester, US)
14:20 Index of microvascular resistance in real-world practice in patients with stable ischemic heart 4022
disease: insight from the international imr registry.
– J.M. Lee, A.S. Yong, J.H. Doh, C.W. Nam, E.S. Shin, B.K. Koo, M.K. Ng, J. Escaned, W. Fearon,
K. Oldroyd (Seoul, Goyang, Daegu and Ulsan, KR; Stanford, US; Sydney, AU; Madrid, ES; Clydebank, UK)
14:37 Effects of prasugrel versus clopidogrel on coronary microvascular function in patients undergoing 4023
elective percutaneous coronary intervention: a randomized double-blind study.
– F. Mangiacapra, M. Pellicano, L. Di Serafino, E. Bressi, A. Peace, G. Di Gioia, J. Bartunek, W. Wijns, B. De
Bruyne, E. Barbato (Aalst, BE)
14:54 The comparative clinical utility of the index of microvascular resistance versus coronary flow 4024
reserve for acute risk assessment in reperfused ST-elevation myocardial infarction patients.
– D.J.A. Carrick, C. Haig, J. Layland, M. Petrie, M. McEntegart, S. Hood, N. Ahmed, A. Radjenovic,
15:11 Future direction for research in microcirculation. 4025
– G. Niccoli (Rome, IT)

VALVULAR HEART DISEASE IN RENAL FAILURE PATIENTS Symposium
ESC and the European Renal Association - European Dialysis and Transplant Association
Chairperson(s): P. Tornos Mas (Barcelona, ES); A. Wiecek (Katowice, PL)
14:00 Natural history of aortic stenosis in Chronic Kidney Disease. 4026
14:22 TAVI procedure in CKD. 4027
– W.R. Davies (Cambridge, UK)
14:45 Valvular calcification in CKD patients. 4028
– A. Bellasi (S. Fermo, IT)
15:07 The problem of anticoagulation in CKD patients with valvular disease. 4029
– J. Floege (Aachen, DE)
253

HYPERTROPHIC CARDIOMYOPATHY Guidelines in Daily Practice
Chairperson(s): P.M. Elliott (London, UK); A. Keren (Jerusalem, IL)
14:00 A hypertrophic cardiomyopathy patient with intermediate sudden cardiac death risk. 4030
– I. Olivotto (Florence, IT)
14:15 A hypertrophic cardiomyopathy patient with intermediate sudden cardiac death risk - What do the 4031
Guidelines say?
– M. Borggrefe (Mannheim, DE)
14:30 A hypertrophic cardiomyopathy patient with intermediate sudden cardiac death risk - Panel 4032
discussion on how to implement the Guidelines.
– I. Olivotto (Florence, IT), M. Borggrefe (Mannheim, DE), P. Spirito (Genoa, IT), A. Anastasakis (Athens, GR)
14:40 A hypertrophic cardiomyopathy patient with intermediate sudden cardiac death risk. Conclusion 4033
and take home message.
14:45 A hypertrophic cardiomyopathy patient with skeletal muscle weakness and visual impairment. 4034
– M. Arad (Ramat Gan, IL)
15:00 A hypertrophic cardiomyopathy patient with skeletal muscle weakness and visual impairment - 4035
What do the Guidelines say?
– J. Mogensen (Odense, DK)
Panel discussion on how to implement the Guidelines.
– M. Arad (Ramat Gan, IL), J. Mogensen (Odense, DK), P. Spirito (Genoa, IT), A. Anastasakis (Athens, GR)
Conclusion and take home message.
– A. Keren (Jerusalem, IL)

CONGENITAL ANOMALIES OF THE CORONARY ARTERIES Symposium
Chairperson(s): E.V.O. Jokinen (Helsinki, FI); L. Swan (London, UK)
14:00 Normal and abnormal course of coronary arteries. 4038
– L. Houyel (Le Plessis-Robinson, FR)
14:22 Multimodality imaging of coronary arteries. 4039
– A. Bozio (Lyon, FR)
14:45 ALCAPA (Bland-White-Garland) syndrome. 4040
– L. Swan (London, UK)
15:07 Risk of sudden cardiac death. 4041
– S. Di Filippo (Lyon, FR)
14:00–15:30 | Bern - Village 9

HEART FAILURE WITH PRESERVED EJECTION FRACTION – WHAT WE KNOW, WHAT WE DON’T Symposium
KNOW, AND WHERE WE ARE GOING
Chairperson(s): O.A. Smiseth (Oslo, NO); S.D. Anker (Göttingen, DE)
14:00 Epidemiology and pathophysiology. 4042
– W.J. Paulus (Amsterdam, NL)
14:22 Diagnosis. 4043
14:45 Current management. 4044
– W.C. Little (Jackson, US)
15:07 The future. 4045
– B. Pieske (Berlin, DE)
254

CARDIO-ONCOLOGY – WHERE HEART FAILURE EXPERTS MEET CANCER Advances in Science
Chairperson(s): J. Springer (Berlin, DE); A.L. Clark (Kingston-upon-Hull, UK)
14:00 State of the Art in Cardio-Oncology. 4046
– S. Von Haehling (Berlin, DE)
14:20 Heart failure mortality following cancer treatment: a linked health data analysis of blood, 4047
lymphatic and breast cancer patients (1996-2009).
– M. Chowdhury, N. Berry, B. Koczwara, A. McCarthy, S. Ullah, J. Atherton, D. Roder, R. Clark (Adelaide and
Brisbane, AU)
14:37 Preserved exercise capacity in lymphoma survivors with asymptomatic left ventricular systolic 4048
dysfunction.
– K. Murbraech, K. Broch, M.B. Lund, C.E. Kiserud, S. Aakhus (Oslo, NO)
14:54 High-sensitivity T troponin for early detection of cardiotoxicity among patients on chemotherapy. 4049
– C.A. Alvarez-Ortega, O. Rodriguez-Fraga, O. Gonzalez-Fernandez, S. Rosillo, T. Lopez-Fernandez,
Z. Blazquez-Bermejo, S. Valbuena-Lopez, M. Moreno-Yanguela, A. Buno-Soto, J.L. Lopez-Sendon
(Madrid, ES)
15:11 Future direction for research in treatment and biomarker development for cardiotoxicity. 4050

CARDIOVASCULAR MAGNETIC RESONANCE FOR CLINICAL DIAGNOSIS AND Rapid Fire Abstract
PROGNOSTICATION
Chairperson(s): C. Deluigi (Berne, CH); F. Noohi Bezanjani (Teheran, IR)
14:00 Computed tomography coronary angiography versus stress cardiac magnetic resonance for the 4051
management of symptomatic revascularized patients: a cost effectiveness study.
– G. Pontone, D. Andreini, C. Rota, M. Guglielmo, S. Mushtaq, A. Baggiano, V. Beltrama, A. Solbiati,
A.I. Guaricci, M. Pepi (Milan and Foggia, IT)
14:09 Coronary high-intensity plaque on t1-weighted magnetic resonance imaging and its association 4052
with percutaneous coronary intervention related myocardial injury.
– T. Hoshi, A. Sato, D. Akiyama, D. Hiraya, S. Sakai, K. Aonuma (Tsukuba, JP)
14:18 Impact of weight reduction on pericardial fat volume and cardiac structure: Implications for atrial 4053
fibrillation in a randomized clinical trial.
– H.S. Abed, A.J. Nelson, J.D. Richardson, S.G. Worthley, A. Vincent, G.A. Wittert, D.P. Leong (Sydney and
Adelaide, AU; Hamilton, CA)
14:27 Impact of long-term steroid therapy on epi- and pericardial fat deposition - a cardiac MRI study. 4054
– S. Greulich, D. Kitterer, J. Latus, S. Birkmeier, N. Braun, U. Sechtem, D. Alscher, H. Mahrholdt (Stuttgart,
DE)
14:36 Myocardial haemorrhage after acute reperfused ST-elevation myocardial infarction: temporal 4055
evolution, relation to microvascular obstruction and prognostic significance.
– D.J.A. Carrick, C. Haig, N. Ahmed, H. Eteiba, M. McEntegart, S. Watkins, M. Lindsay, A. Radjenovic,
14:45 Comparison of transthoracic echocardiography versus cardiac magnetic for implantable 4056
cardioverter defibrillator therapy in primary prevention strategy dilated cardiomyopathy patients.
– G. Pontone, D. Andreini, A. Solbiati, M. Guglielmo, S. Mushtaq, A. Baggiano, V. Beltrama, C. Rota,
A.I. Guaricci, M. Pepi (Milan and Foggia, IT)
14:54 Cardiac magnetic resonance can predict appropriate primary prevention ICD-therapy in ischemic 4057
and dilated cardiomyopathy patients using late gadolinium enhancement heterogeneity.
– R. Jablonowski, U. Chaudhry, J. Van Der Pals, H. Engblom, H. Arheden, E. Heiberg, K.C. Wu, R. Borgquist,
M. Carlsson (Lund, SE; Baltimore, US)
15:03 Cardiac progenitor cell therapy reduces myocardial fibrosis and stiffness to improve cardiac 4058
function in patients with univentricular heart disease.
– S. Ishigami, S. Tarui, T. Goto, D. Ousaka, M. Okuyama, K. Baba, S. Kasahara, S. Ohtsuki, S. Sano, H. Oh
(Okayama, JP)
15:12 Myocardial extracellular matrix remodeling is associated with diffuse myocardial fibrosis and 4059
collateral function in coronary chronic total occlusion.
– J.Y. Qian, Y.Y. Chen, D. Ren, J.F. Xu, Z.W. Chen, Y.N. Song, H.B. Yang, Y. Lou, J.B. Ge (Shanghai, CN)
15:21 Prognostic value of peri-infarct tissue heterogeneity in reperfused STEMI. 4060
– C. Eitel, F. Bode, S. Desch, H. Thiele, I. Eitel (Lübeck, DE)
255

ATRIAL FIBRILLATION IN REAL WORLD Moderated Posters
Chairperson(s): J. Dalal (Mumbai, IN); A. de Paola (São Paulo, BR)
15:30 Female sex, age and time delay to cardioversion as risk factors in the cardioversion of acute atrial P4061
fibrillation. The FinCV Study.
– A. Bah, I. Nuotio, T. Groenberg, A. Ylitalo, M. Nikkinen, K. Ruuhijarvi, J. Airaksinen, J. Hartikainen (Kuopio,
Turku and Rovaniemi, FI)
15:38 Atrial fibrillation and hypertrophic cardiomyopathy: a propensity score analysis from a multicenter P4062
Portuguese study.
– R. Teixeira, N. Maques, L. Lopes, E. Correia, J. Almeida, C. Lourenco, R. Faria, P. Magalhaes,
K. Domingues, O. Azevedo (Coimbra, Faro, Almada, Viseu, Vila Nova de Gaia, Penafiel, Famalicão,
Vila-Real, Santarem and Guimaraes, PT)
15:47 Atrial fibrillation in patients admitted to coronary care units in western Sweden. Focus on obesity P4063
and lipotoxicity.
– E. Omerovic, S. Gizurarson, M. Stahlman, A. Jeppsson, Y. Shao, B. Redfors, L. Bergfeldt, J. Boren
(Gothenburg, SE)
15:55 Clinical implication of atrial fibrillation in patients with apical hypertrophic cardiomyopathy. P4064
– S.E. Lee, J.K. Park, J.S. Uhm, J.Y. Kim, H.N. Pak, M.H. Lee, B.Y. Joung (Seoul, KR)
16:04 Evaluation of safety and efficacy of perioperative use of rivaroxaban and apixaban in catheter P4065
ablation for atrial fibrillation.
– Y. Iriki, H. Ichiki, N. Oketani, A. Yoshimura, H. Okui, R. Maenosono, F. Namino, M. Miyata, M. Ohishi
(Kagoshima, JP)
16:12 Major bleeding in a post-marketing assessment of 39,052 non-valvular atrial fibrillation patients P4066
on rivaroxaban.
– W.F. Peacock, M. Patel, S. Tamayo, N. Sicignano, K. Hopf, Z. Yuan (Houston, Durham, Portsmouth,
Trevose and Titusville, US)
16:21 Clinical evaluation of laboratory methods to monitor rivaroxaban treatment in patients with atrial P4067
fibrillation.
– M. Skeppholm, M. Berndtsson, F. Al-Khalili, Y. Ronquist-Nii, A. Pohanka, J. Antovic, R.E. Malmstrom
(Stockholm, SE)

PRE-HOSPITAL PHASE OF STEMI Moderated Posters
Chairperson(s): M.J. Pietila (Turku, FI); U. Zeymer (Ludwigshafen am Rhein, DE)
15:30 Does prehospital ECG transmission reduce false activations of the cardiac catheterization lab P4068
compared to paramedic ECG interpretation in a primary PCI program?
– R. Colleran, J. Crowley, B.D. Mac Neill, P. Nash, F. Sharif, B. Hynes, D. Mylotte, Y. Smyth, K. Daly
(Galway, IE)
15:38 Pre-hospital trans-satellite wireless 12 lead ECG transmission from the ambulance to primary PCI P4069
centre.
– A.A. Gehani, J.M. Al Suwaidi, O. Tamimi, A.R. Arabi, A. Al Qahtani, S.O. Arafa, A.R. Nabti, I. Rafie,
S. Abujalala, M. Yacoub (Doha, QA)
15:47 The importance of a qualified pre-hospital ECG and subsequent triage of patients with STEMI to P4070
the catheterization laboratory to minimize the door-to-balloon time.
– W. Rutsch, H. Schuehlen, M. Stockburger, H. Theres, S. Poloczek, G. Plock, B. Maier (Berlin, DE)
15:55 Feasibility of pre-hospital chest pain triage in the ambulance by paramedics using a the heart P4071
score based upon a single high-sensitive troponin T analysis. Results from phase 1 of the
FAMOUS triage.
– D. Ali, M.J. Fokkert, R.J. Slingerland, R. Tolsma, M. Ishak, F. Van Eenennaam, K. Bruheim, E. Badings,
J.M. Ten Berg, A.W.J. Hof (Zwolle, Nieuwegein, Amsterdam and Deventer, NL)
16:04 Increased dissemination of registered AEDs is associated with higher rate of bystander P4072
defibrillation in public locations but not in residential areas - a nationwide study.
– S.M. Hansen, C.M. Hansen, S. Rajan, F. Folke, G. Gislason, L. Kober, F. Lippert, C. Torp-Pedersen,
M. Wissenberg (Aalborg, Gentofte and Copenhagen, DK)
16:12 Epidemiology and outcomes of poisoning-induced out-of-hospital cardiac arrest. P4073
– P. Jabre, B. Dahan, F. Beganton, E. Marijon, F. Dumas, W. Bougouin, D. Jost, J.P. Empana, P. Carli,
X. Jouven (Paris, FR)
16:21 GDF-15 is a predictor of cardiovascular events in patients presenting with suspicion of acute P4074
coronary syndrome.
– S. Tzikas, L. Palapies, T. Zeller, S. Baldus, C. Bickel, V. Vassilikos, K.J. Lackner, T. Munzel, T. Keller
(Thessaloniki, GR; Frankfurt am Main, Hamburg, Cologne, Koblenz and Mainz, DE)
256

INFORMATION TECHNOLOGY APPLICATIONS IN CARDIOLOGY Moderated Posters
Chairperson(s): N. Kachenoura (Paris, FR); T. Nieminen (Lahti, FI)
15:30 Monitoring of day by day fluctuations of different cardiac resynchronization therapy parameters P4075
allows to predict device interventions.
– A. Liberska, M. Mazurek, E. Jedrzejczyk-Patej, K. Przybylska-Siedlecka, M. Koziel, S. Morawski,
J. Kowalczyk, R. Lenarczyk, O. Kowalski, Z. Kalarus (Zabrze, PL)
15:38 The Utilization and Clinical Feasibility of 24-Hour Hand-Carry Remote ECG Recording Device in P4076
Cardiac Arrhythmias and Atrial Fibrillation: A Pilot Study.
– C.-L. Hung, W.L. Chang, S.P. Wei, J.P. Tsai, Y.J. Chen, J.Y. Kuo, H.I. Yeh, J.Y. Hou, S.C. Shih (Taipei, TW)
15:47 Value of the frontal plane QRS-t angle for diagnosis and prognosis in patients with symptoms P4077
suggestive of acute myocardial infarction.
– T. Reichlin, R. Twerenbold, M. Rubini, K. Wildi, J. Boeddinghaus, R. Abaecherli, S. Osswald, C. Mueller
(Basel, CH)
15:55 Diagnostic accuracy of 12 lead ECG Q-waves as a marker of myocardial scar and as a predictor P4078
of infarcted artery: validation with CMR.
– A. Ghosh Dastidar, A. Carpenter, C. Wilson, J. Rodrigues, A. Baritussio, N. Ahmed, A. Palazzuoli,
A. Baumbach, A. Nightingale, C. Bucciarelli-Ducci (Bristol, UK; Padua, IT)
16:04 Assessment of deceleration capacity from short-term recordings predicts mortality after P4079
– A. Bauer, K.D. Rizas, W. Hamm, G. Schmidt (Munich, DE)
16:12 How low can we go? Performing EP-Procedures at a low radiation dose level. P4080
– C. Kowalewski, D. Vukajlovic, F. Heissenhuber, K. Kurzidim (Regensburg, DE)
16:21 Deriving actionable clinical knowledge from large retrospective set of cardiac echo reports: P4081
evaluation of machine learning-based discovery of rules for detecting conflicts between report
statements.
– D.H. Liang, M. Sevenster, S. Bieganski, P. Bhagat, T. Forsberg, Y. Jia, M. Kanasseril, K. Spencer (Stanford,
Briarcliff Manor, Andover and Chicago, US; Suresnes, FR)

EXTRACELLULAR MATRIX, REMODELLING AND INFLAMMATION Moderated Posters
Chairperson(s): C. Monaco (Oxford, UK); A.C. Newby (Bristol, UK)
15:30 Glycoproteomics analysis of cardiac extracellular matrix reveals the presence of decorin P4082
fragments with anti-myostatin and anti-fibrotic activity.
– J. Barallobre-Barreiro, S.K. Gupta, X. Yin, M. Chong, M. Jahangiri, R. Viner, A. Kichler, T. Thum, J. Heineke,
M. Mayr (London, UK; Hannover, DE; Strasbourg, FR)
15:38 Inhibition of Myofibroblast Differentiation by FOXO3a - Implications for acute myocardial P4083
infarction and cardiac Remodeling.
– L. Holzhauser, A. Jenke, M. Grueger, K. Savvatis, R. Schur, U. Landmesser, C. Skurk (New York, US;
Berlin, DE)
15:47 Targeting the nuclear receptor PPARdelta as novel strategy to prevent in-stent restenosis and P4084
stent thrombosis.
– J. Hytoenen, O. Leppaenen, M. Jastroch, A. Heuser, J.-D. Drenckhahn, D. Mueller, W.-H. Schunck,
F. Jung, S. Ylae-Herttuala, F. Blaschke (Kuopio, FI; Munich, Berlin and Teltow, DE)
15:55 Role of Rac1 GTPase for the mineralocorticoid receptor mediated structural remodelling in atrial P4085
fibrillation.
– D. Lavall, N. Jacobs, P. Schuster, M. Böhm, U. Laufs (Homburg, DE)
16:04 A CD31-derived peptide favors M2 macrophage polarization and arterial repair following P4086
Angiotensin II-induced dissection.
– K. Guedj, M. Clement, J. Khallou-Laschet, M. Morvan, A.T. Gaston, F. Andreata, G. Even, B. Escoubet,
A. Nicoletti, G. Caligiuri (Paris, FR)
16:12 Interleukin-1 receptor antagonist contributes to the suppression of both angiotensin ii-induced P4087
hypertension and organ damage.
– K. Akita, K. Isoda, H. Daida (Tokyo, JP)
16:21 The synergistic effect of -174G/C polymorphism on interleukin-6 gene promoter with tobacco P4088
smoking on endothelial function, inflammatory and thrombotic processes in coronary artery
disease patients.
– G. Hatzis, N. Papageorgiou, G. Siasos, E. Oikonomou, S. Papaioannou, A. Miliou, A. Kalampogias,
A. Antonopoulos, B. Schieffer, D. Tousoulis (Athens, GR)
257

AORTIC STENOSIS – FROM BASICS TO PROGNOSIS Moderated Posters
Chairperson(s): J. Bergler-Klein (Vienna, AT); A. Nobre (Lisbon, PT)
15:30 Calcification of aortic valve and coronary atherosclerosis: differences in bicuspid and tricuspid P4089
valves.
– P.J. Van Rosendael, V. Kamperidis, M. Regeer, N. Ajmone Marsan, J.J. Bax, V. Delgado (Leiden, NL)
15:38 Shorter leukocyte telomere length is associated with the risk of calcific aortic stenosis. P4090
– M.D. Musameh, M.J. Denniff, C.P. Nelson, D. Sprigings, V. Codd, N.J. Samani (Leicester and
Northampton, UK)
15:47 Myocardial fibrosis and microRNA-21 expression in patients with severe aortic valve stenosis and P4091
preserved ejection fraction: a 2D speckle tracking echocardiography, tissutal and plasmatic study.
– I. Fabiani, L. Conte, C. Scatena, N.R. Pugliese, C.M. Mazzanti, I. Nicastro, A. De Martino, U. Bortolotti,
A.G. Naccarato, V. Di Bello (Pisa, IT)
15:55 Combining tumor marker carbohydrate antigen 125 and the logistic EuroSCORE improves risk P4092
stratification in patients undergoing transcatheter aortic valve implantation.
– O. Husser, J. Nunez, T. Kessler, A. Holzamer, C. Templin, T.F. Luescher, A. Kastrati, H. Schunkert,
M. Hilker, C. Hengstenberg (Munich and Regensburg, DE; Valencia, ES; Zurich, CH)
16:04 New-onset midwall dysfunction predicts impaired prognosis in aortic valve stenosis with normal P4093
ejection fraction (the SEAS study).
– D. Cramariuc, M.T. Lonnebakken, C. Gohlke-Barwolf, T.R. Pedersen, S. Ray, Y.A. Kesaniemi, K. Boman,
E. Gerdts (Bergen and Oslo, NO; Bad Krozingen, DE; Manchester, UK; Oulu, FI; Skelleftea, SE)
16:12 SuPAR is associated with cardiovascular events and mortality in patients with asymptomatic P4094
aortic stenosis.
– G. Hodges, C.N. Bang, J. Jeppesen, J. Eugen-Olsen, K. Wachtell (Copenhagen, DK; Örebro, SE)
16:21 Prognostic value of left atrial reservoir function in patients with severe aortic stenosis. P4095
– E. Galli, M. Fournet, C. Chabanne, E. Flecher, A. Leguerrier, P. Mabo, E. Donal (Rennes, FR)

DIFFERENTIATING PHYSIOLOGICAL ADAPTATION FROM CARDIAC PATHOLOGY IN Moderated Posters
ATHLETES
Chairperson(s): M. Papadakis (London, UK); S. Caselli (Rome, IT)
15:30 Athletic cardiac adaptation is secondary to increased myocyte mass. P4096
– A.K. McDiarmid, P.P. Swoboda, B. Erhayiem, R.E. Lancaster, G.K. Lyall, J.P. Greenwood, C. Ferguson,
S. Plein (Leeds, UK)
15:38 Impact of matrix metalloproteases and their inhibitors in the athlete’s heart. P4097
– B. Lakatos, B. Sax, G. Szeplaki, H. Vago, A. Toth, A. Assabiny, A. Hajas, T. Radovits, B. Merkely,
15:47 Impact of exaggerated blood pressure response on parameters of cardiac remodelling in amateur P4098
endurance athletes.
– L.D. Trachsel, N. Brugger, P. Eser, M. Wilhelm (Berne and Fribourg, CH)
15:55 Differentiation of arrhythmogenic right ventricular cardiomyopathy and athlete’s heart using P4099
cardiac magnetic resonance imaging.
– C.S. Czimbalmos, H. Vago, A. Toth, F. Suhai, I. Csecs, O. Kiss, N. Sydo, T. Simor, D. Becker, B. Merkely
(Budapest and Pécs, HU)
16:04 Brugada ECG-pattern in athletes: prevalence and predisposing factors. P4100
– M. Di Valentino, C. Limoni, A.P. Porretta, M. Cattaneo, P. Foglia, G. Moschovitis, A. Gallino, A. Menafoglio
(Bellinzona and Lugano, CH)
16:12 Automatic use of seattle criteria led to less than ten percentage of abnormal electrocardiograms P4101
when applying to a general population of young swiss males.
– R.A. Abaecherli, R.L. Leber, R.S. Schmid, R.K. Kobza, C.S. Schmied, F.F. Frey, J.J.S. Schmid (Basel, Baar,
Lucerne, Zurich and Ittigen, CH)
16:21 Exercise stress testing in 73,000 patients: safety with abnormalities of serum potassium. P4102
– J. Bird, P. Pellikka, T. Allison, R. McCully, G. Kane (Rochester, US)
258

PREDICTION MODELS IN CLINICAL PRACTICE Moderated Posters
Chairperson(s): P. Juni (Berne, CH); Y. Ikari (Kanagawa, JP)
15:30 Graz CLI Score: a risk score for critical limb ischemia in peripheral arterial occlusive disease P4103
patients.
– P. Rief, F. Hafner, P. Eller, G. Hackl, M. Brodmann, T. Gary (Graz, AT)
15:38 Usefulness of the Platelet- to- lymphocyte ratio in predicting long term cardiovascular mortality in P4104
patients with peripheral arterial occlusive disease.
– F. Uzun, M. Erturk, H.A. Cakmak, A.K. Kalkan, M. Gurdogan, I.F. Akturk, A.A. Yalcin, O.F. Baycan,
B. Uygur, U. Bulut (Istanbul, Rize and Edirne, TR)
15:47 Implications of different criteria for percutaneous coronary intervention-related myocardial P4105
infarction on study results of three large phase III clinical trials: the CHAMPION experience.
– S. Leonardi, R.D. Lopes, F. Abnousi, S. Mangum, J. Prats, M. Wilson, M. Todd, R.A. Harrington, D.L. Bhatt,
K.W. Mahaffey (Pavia, IT; Durham, Stanford, Parsippany and Boston, US)
15:55 Gender-related differences in carotid inflammation in patients with coronary artery disease. P4106
– G. Benetos, K. Toutouzas, M. Drakopoulou, I. Koutagiar, A. Papanikolaou, A. Synetos, G. Latsios,
E. Tsiamis, E. Siores, D. Tousoulis (Athens, GR; Bolton, UK)
16:04 The peak rate of arterial dilatation during measurement of flow-mediated dilatation. P4107
– A. Dykun, T. Gori, T. Munzel, J.D. Parker (Toronto, CA; Mainz, DE)
16:12 Ankle brachial index predicts two year mortality in sub-saharan older adults. P4108
– H. Samba, M. Guerchet, B. Ndamba Bandzouzi, P. Mbelesso, I. Desormais, J.F. Dartigues, P.M. Preux,
V. Aboyans, P.M. Lacroix (Limoges and Bordeaux, FR; Brazzaville, CG; Bangui, CF)
16:21 Protein energy wasting is associated with poor outcome after lower extremity revascularization in P4109
chronic haemodialysis patients with peripheral artery disease.
– Y. Kumada, H. Ishii, T. Aoyama, D. Kamoi, T. Sakakibara, N. Umemoto, H. Takahashi, T. Murohara
(Kasamatsu, Nagoya and Toyoake, JP)

HEART FAILURE: DIVERSITY OF PHENOTYPING Moderated Posters
Chairperson(s): C. Whelan (London, UK); A. Santoso (Jakarta Barat, ID)
15:30 The relationship between hemoconcentration and renal function variability in patients with acute P4110
heart failure syndrome: data from the Korean Acute Heart Failure (KorAHF) registry.
– J. Oh, S.M. Kang, E.S. Jeon, J.J. Kim, S.H. Baek, M.C. Cho, S.C. Chae, D.J. Choi, B.S. Yoo, B.H. Oh
(Seoul, Cheongju, Daegu, Seongnam and Wonju, KR)
15:38 Prevalence of hereditary transthyretin cardiac amyloidosis in patients with Hypertrophic P4111
Cardiomyopathy. A multicenter study.
– T. Damy, B. Costes, A.A. Hagege, E. Donal, M. Slama, J.P. Gueffet, D. Logeart, C. Selton-Suty,
F. Canoui-Poitrine, M. Goossens (Créteil, Paris, Rennes, Clamart, Nantes and Vandoeuvre-lès-Nancy, FR)
15:47 Clinical impact of quantitative and qualitative alterations in the extracellular matrix (ECM) in P4112
human cardiomyopathy.
– N. Takahashi, K. Nagao, K. Fukuchi, F. Sano, H. Ito, F. Hayashi, T. Inada, T. Makita, M. Tanaka (Osaka, JP)
15:55 PCR proof of parvovirus B19 genomes in endomyocardial biopsies of patients presenting with P4113
myocarditis or dilated cardiomyopathy - Meta-Analysis confirms a possible bioportfolio.
– M. Noutsias, P. Schlattmann, C. Konstas, K. Haentze, S.E. Ludwig, V. Kechagias, H.R. Figulla, B. Klutt
(Jena, DE)
16:04 A novel method for the quantitative evaluation of diurnal respiratory instability in patients with P4114
heart failure.
– N. Kumagai, K. Dohi, S. Miyahara, M. Tanimura, Y. Sato, E. Sugiura, S. Nakamori, N. Fujimoto, N. Yamada,
M. Ito (Tsu, JP)
16:12 MicroRNAs as a quantitative and prognostic biomarker of interstitial cardiac fibrosis in pressure P4115
overloaded mice.
– S. De Jong, B. Kok, M.C.A. Van Wijk, M.S.C. Fontes, M.A.D. Brans, J.M.T. De Bakker, M.A.D. Vos,
H.V.M. Van Rijen, M.F.A. Bierhuizen (Utrecht, NL)
16:21 Renal congestion assessed by intra-renal Doppler profile associates with the clinical courses in P4116
congestive heart failure.
– Y. Seo, T. Ishizu, N. Iida, M. Yamamoto, T. Machino-Ohtsuka, K. Aonuma (Ibaraki, JP)
259

HYPERTENSION PATHOPHYSIOLOGY II Moderated Posters
Chairperson(s): S. Abir-Khalil (Rabat, MA); H.I. Kandil (Cairo, EG)
15:30 Hemodynamic correlates of abnormal aortic root dimensionin in an adult population: the strong P4117
heart study.
– G. De Simone, M.J. Roman, M. De Marco, J.N. Bella, R. Izzo, E.T. Lee, R.B. Devereux (Naples, IT; New
York, Bronx and Oklahoma City, US)
15:38 Association of plasma testosterone with central haemodynamics in hypertensive men. P4118
– P. Pietri, C. Vlachopoulos, N. Ioakeimidis, A. Aggelis, D. Terentes-Printzios, M. Abdelrasoul, I. Gourgouli,
E. Paschalidis, C. Stefanadis, D. Tousoulis (Athens, GR)
15:47 Relationship between cognitive dysfunction, clinic and 24-h blood pressure, and blood pressure P4119
variability.
– G. Seravalle, F. Quarti, M. Bombelli, S. Buzzi, R. Facchetti, C. Cuspidi, G. Grassi, G. Mancia (Milan and
Monza, IT)
15:55 The risk factors that predict the occurrence or progression of chronic hypertension in postpartum P4120 (W)
period in women with a history of hypertensive disorders of pregnancy. (withdrawn)
– J.-W. Hwang, S.-J. Park, S.-Y. Oh, S.C. Lee, S.W. Park, D.-K. Kim (Seoul, KR)
16:04 Association of hypertension with the incidence of adverse events in patients with atrial fibrillation: P4121
The Fushimi AF Registry.
– M. Ishii, H. Ogawa, N. Masunaga, M. Iguchi, M. Esato, Y.H. Chun, H. Wada, K. Hasegawa, M. Abe,
M. Akao (Kyoto, JP)
16:12 Non-invasive central systolic blood pressure not peripheral systolic blood pressure associated P4122
with kidney function decline in a Chinese community-based population.
– F. Fan, J. Jia, X. Xu, X. Qin, Y. Yang, J. Li, D. Chen, Y. Zhang, Y. Huo (Beijing and Guangzhou, CN)
16:21 Associations between serum uric acid levels and the incidence of hypertension and atrial P4123
fibrillation.
– A. Karamanou, M.S. Kallistratos, L.E. Poulimenos, K. Vergis, A. Martinaios, N. Kouremenos, S. Vrakas,
A. Koukouzeli, S. Pagoni, A.J. Manolis (Athens, GR)

HOW TO SHAPE YOUR FUTURE – TIPS AND TRICKS FOR FINDING A JOB Special Session
Chairperson(s): B. Merkely (Budapest, HU)
15:35 How to shape your future - Tips and tricks for finding a job. 4124
15:57 How to shape your future - Tips and tricks for finding a job - Discussion. 4125

MEET THE GUIDELINES TASK FORCE II – ACUTE CORONARY SYNDROMES Special Session
NON-ST-ELEVATION
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); H. Baumgartner (Münster, DE)
15:40 Acute coronary syndromes. 4126
– M. Roffi (Geneva, CH), C. Patrono (Rome, IT)
16:19 Acute coronary syndromes - Panel discussion. 4127
– F. Andreotti (Rome, IT), D. Chew (Adelaide, AU), J.-P. Collet (Paris, FR), C.E. Mueller (Basel, CH),
R.F. Storey (Sheffield, UK), M. Valgimigli (Rotterdam, NL)

MEET THE TRIALIST III: TECOS Meet the Trialists
Chairperson(s): J. Tuomilehto (Helsinki, FI)
15:40 Trial Evaluating Cardiovascular Outcomes with Sitagliptin in patients with type-2 Diabetes. 4128

CLINICAL CHALLENGES IN ORAL ANTICOAGULATION: YOUR Satellite Symposium - Experts on the Spot
QUESTIONS DISCUSSED
Chairperson(s): G.Y.H. Lip (Birmingham, UK)
15:45 Clinical challenges in oral anticoagulation: your questions discussed. 4129
– G.Y.H. Lip (Birmingham, UK), H. Darius (Berlin, DE), A.T. Cohen (London, UK)
260

WHAT DO CLINICAL OUTCOME TRIALS TELL US? Satellite Symposium - Experts on the Spot
Sponsored by MSD
Chairperson(s): C.P. Cannon (Boston, US)
15:45 What do clinical outcome trials tell us? Lessons learned from IMPROVE-IT. 4130

THE FUTURE OF ANTICOAGULATION MANAGEMENT IN ATRIAL Satellite Symposium - Experts on the Spot
FIBRILLATION (AF) IN EUROPE – AN ASSESSMENT OF TODAY’S
CHALLENGES WITH RECOMMENDATIONS FOR THE FUTURE
Chairperson(s): A.J. Camm (London, UK)
15:45 The current landscape of AF therapy in Europe, latest research findings and recommendations 4131
from an international steering committee.
16:00 AF-related stroke prevention: Todays and future challenges from a patients perspective. 4132
– T. Lobban (Shipston-on-Stour, UK)

VENOUS THROMBOEMBOLISM: WHAT’S NEW? Satellite Symposium - Experts on the Spot
Chairperson(s): S.V. Konstantinides (Mainz, DE); W. Ageno (Varese, IT)
15:45 Venous thromboembolism: what’s new? 4133
– S.V. Konstantinides (Mainz, DE), W. Ageno (Varese, IT)

HOT LINE IV – HYPERTENSION Hot Line
Chairperson(s): G.A. Derumeaux (Creteil, FR); I. Komuro (Tokyo, JP)
16:30 A trial of Telmisartan prevention of cardiovascular diseases (ATTEMPT-CVD): the large 4134
biomarkers study with 1228 patients.
– H. Ogawa (Kumamoto, JP)
16:42 ATTEMPT-CVD: Discussant review. 4135
– T.C. Gillebert (Ghent, BE)
16:49 ATTEMPT-CVD: Panel discussion. 4136
16:53 The principal results of the Prevention And Treatment of Hypertension With Algorithm based 4137
therapY (PATHWAY) - Optimal treatment of drug resistant hypertension - PATHWAY 2.
17:05 PATHWAY 2: Discussant review. 4138
– G. Mancia (Milan, IT)
17:12 PATHWAY 2: Panel discussion. 4139
17:16 Principal results from Prevention And Treatment of Hypertension With Algorithm based therapY 4140
(PATHWAY): comparison of single and combination diuretics in essential hypertension -
PATHWAY-3.
17:28 PATHWAY 3: Discussant review. 4141
– A. Coca (Barcelona, ES)
17:35 PATHWAY 3: Panel discussion. 4142
17:38 Principal results of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with 4143
Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly - PARAMETER study.
17:50 PARAMETER: Discussant review. 4144
– M. Packer (Dallas, US)
17:57 PARAMETER: Panel discussion. 4145
261

STABLE ANGINA Symposium
ESC and the Lancet
Chairperson(s): S. Spencer (London, UK); F. Van de Werf (Leuven, BE)
16:30 Prognosis and diagnosis. 4146
– D.E. Newby (Edinburgh, UK)
17:00 Pharmacological therapies. 4147
– M. Ohman (Durham, US)
17:30 Revascularisation and invasive strategies. 4148
– R. Mehran (New York, US)

KILLING THE HEART Rapid Fire Abstract
Chairperson(s): T.M. Suter (Berne, CH); C.J. Plummer (Newcastle-upon-Tyne, UK)
16:30 Can we predict which patients are at risk of fluoropyrimidines cardiotoxicity? 4149
– C. Lestuzzi, L. Tartuferi, E. Viel, S. Virdone, E. Vaccher, S. Spazzapan, A. De Paoli, A. Buonadonna,
A. Lleshi, E. Bidoli (Aviano, IT)
16:39 Trimetazidine prevents doxorubicine cardiotoxicity: echo and biomarker study. 4150
– E. Shkolnik, Y. Vasyuk, V. Nesvetov, M. Scherbak, L. Shkolnik, G. Varlan (Moscow, RU)
16:48 Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide 4151
synthase and mitochondrial integrity.
– Y. Octavia, G. Kararigas, M. De Boer, R. Kietadisorn, M. Swinnen, H. Duimel, F.K. Verheyen, S. Janssens,
D.J. Duncker, A.L. Moens (Rotterdam and Maastricht, NL; Berlin, DE; Leuven, BE)
16:57 Cardio-0ncology: the cardioprotective role of NACA in reducing oxidative stress due to 4152
doxorubicin and trastuzumab.
– D. Jassal, V. Goyal, K. Bordun, S. Premecz, D. Cheung, R. Fandrich, S. Mandal, E. Kardami, P.K. Singal,
S. Niraula (Winnipeg, CA)
17:06 Cardioprotective effects of Ecklonia cava polyphenol on doxorubicin-induced cardiomyopathy in 4153
rats.
– H.K. Jeon, H.S. Ahn, K.T. Kim (Uijeonbu, KR)
17:15 Galectin-3 and longitudinal global strain predict drug-related cardiotoxicity in patients with breast 4154
cancer.
– A. Magalhaes, M. Menezes, N. Cortez-Dias, M. Saraiva, D. Silva, L. Santos, C. Calisto, L. Costa, F. Pinto,
M. Fiuza (Lisbon, PT)
17:24 Are all heart failure risk factors equal? Comparison of myocardial dysfunction late after 4155
chemotherapy with other stage A heart failure in community patients.
– M.T. Nolan, Y. Wang, H. Yang, T.H. Marwick (Hobart, AU)
17:33 Global longitudinal strain to detect cardiotoxicity in adult survivors of childhood leukemia. 4156
– J. Christiansen, R. Massey, H. Dalen, A. Kanellopoulos, E. Ruud, S. Aakhus (Oslo and Trondheim, NO)
17:42 New mechanisms of taxanes-related cardiotoxicity in women with breast cancer. 4157
– M. Florescu, D.J. Mihalcea, L.S. Magda, D. Jinga, E. Radu, A. Chirca, A.M. Acasandrei, O.A. Enescu,
R.C. Rimbas, D. Vinereanu (Bucharest and Magurele, RO)
17:51 Detection of early and late left and right ventricular dysfunction in patients treated with 4158
anthracyclines.
– A.C. Gomes, A. Ferreira, L. Rocha Lopes, H. Mansinho, H. Pereira (Almada, PT)

HOW ISCHAEMIA REGULATES ANGIOGENESIS: NEW CONCEPTS Symposium
Chairperson(s): J.D. Pearson (London, UK); G. Vilahur Garcia (Barcelona, ES)
16:30 Generating and regenerating coronary arteries. 4159
– L. Miquerol (Marseille, FR)
16:52 Vessel growth and maturation. 4160
– C. Kupatt (Munich, DE)
17:15 Blood vessel growth: the synergy of VEGF- and extracellular matrix-dependent neuropilin 4161
signalling in postnatal blood vessel growth.
– C. Ruhrberg (London, UK)
17:37 Novel regulators of vessel growth and maturation. 4162
– S. Germain (Paris, FR)
262

EXPECT THE UNEXPECTED IN THE ACUTE PATIENTS Clinical Cases
Chairperson(s): K. Huber (Vienna, AT); K.A. Krychtiuk (Vienna, AT)
16:30 Loeys-Dietz type III syndrome: tips and tricks for the favourable outcome of a rare disease, in 4163
spite of misdiagnosis.
– A. Fontana (Monza, IT)
16:42 Tako-tsubo cardiomyopathy during a thyroid storm; a critical intersection. 4164
– A.M. Saleh (Coburg, DE)
16:55 Typical STEMI - or not: embolic LAD occlusion and fulminant pulmonary embolism with in-transit 4165
thrombus in a patent foramen ovale.
– P.P. Rainer (Graz, AT)
17:08 Metastatic squamous cell carcinoma of unknown origin to right atrium. 4166
– E. Pllaha (Msida, MT)
17:21 New myocardial involvement detected by PET/MRI in a Vandetanib-treated patient with medullary 4167
thyroid cancer.
– J. Kloth (Essen, DE)
17:34 Syncope in a patient with congenital heart disease. 4168
– A. Doronzo (Bari, IT)
17:47 Acute coronary syndrome associated with a congenital triatrial heart disease. 4169
– M. Berous (Montpellier, FR)

PULMONARY HYPERTENSION IN TURKEY Guidelines in Daily Practice
Chairperson(s): L. Tokgozoglu (Ankara, TR); M.S. Kucukoglu (Istanbul, TR)
– E.B. Kaya (Sihhiye, TR)
16:50 What do the “new” Guidelines tell us? 4171
– C. Kaymaz (Istanbul, TR)
– C. Kaymaz (Istanbul, TR)
17:30 Mini quiz on ESC Guidelines 2014. 4173
– D. Ural (Kocaeli, TR), A. Yildirir (Ankara, TR), A.K. Kepez (Istanbul, TR), T.K. Keles (Ankara, TR), M.B. Yilmaz
(Sivas, TR), H.M. Ozdemir (Ankara, TR), U. Canpolat (Ankara, TR)
263

RISK STRATIFICATION IN PULMONARY EMBOLISM AND IN PULMONARY HYPERTENSION Rapid Fire Abstract
Chairperson(s): O. Sitbon (Le Kremlin-Bicêtre, FR); A. MacIsaac (Melbourne, AU)
16:30 Acute pulmonary embolism: external validation of the 2014 risk stratification model of the 4174
European Society of Cardiology.
– C. Becattini, G. Agnelli, M. Lankeit, L. Masotti, P. Pruszczyk, S. Vanni, P.W. Kamphuisen, M.C. Vedovati,
M.G. De Natale, S. Konstantinides (Perugia and Florence, IT; Mainz, DE; Warsaw, PL; Groningen, NL)
16:39 BNP testing performed after triaging patients with acute PE by standard Hestia decision rule is 4175
not needed - a randomised trial.
– M.V. Huisman, W. Zondag, P.L. Den Exter, F.A. Klok (Leiden, NL)
16:48 Effectiveness of a clinical score, cardiac troponin, and echocardiography testing algorithm for 4176
risk stratification of normotensive patients with acute symptomatic pulmonary embolism.
– D. Jimenez, J.L. Lobo, C. Fernandez-Golfin, J.J. Jimenez-Nacher, A.K. Portillo, R. Nieto, M. Lankeit,
S. Konstantinides, R.D. Yusen (Madrid and Vitoria, ES; Mainz, DE; St. Louis, US)
16:57 Acute not-high-risk pulmonary embolism: a comparison of risk assessment strategies. 4177
– L. Hobohm, C. Niemann, J. Schwung, V. Seeber, G. Hasenfuss, T. Muenzel, S. Konstantinides, M. Lankeit
(Mainz and Göttingen, DE)
17:06 Investigation of a new pathophysiological axis for risk stratification of normotensive pulmonary 4178
embolism: prognostic impact of copeptin.
– K. Hellenkamp, J. Schwung, H. Rossmann, A. Kaeberich, G. Hasenfuss, R. Wachter, S. Konstantinides,
M. Lankeit (Göttingen and Mainz, DE)
17:15 Derivation of a new score to predict chronic thromboembolic pulmonary hypertension after acute 4179
pulmonary embolism.
– F.A. Klok, O. Dzikowska-Diduc, M. Kostrubiec, H.W. Vliegen, P. Pruszczyk, G. Hasenfuss, M.V. Huisman,
S. Konstantinides, M. Lankeit (Leiden, NL; Warsaw, PL; Göttingen and Mainz, DE)
17:24 RV dyssynchrony predicts clinical outcomes after balloon pulmonary angioplasty in patients with 4180
chronic thromboembolic pulmonary hypertension.
– T. Tsugu, M. Murata, T. Kawakami, R. Yasuda, H. Tokuda, Y. Minakata, M. Kataoka, H. Tsuruta,
H. Kanazawa, K. Fukuda (Tokyo, JP)
17:33 Reduction in NT-proBNP and its correlation with survival in patients with PAH treated with 4181
riociguat: 2-year results from the PATENT-2 long-term extension study.
– M.M. Hoeper, N. Galie, H.-A. Ghofrani, J. He, Y. Huang, D. Langleben, D. Zhou, S. Nikkho, A. Fritsch,
A. Torbicki (Hannover, Giessen, Berlin and Wuppertal, DE; Bologna, IT; Beijing, Guangzhou and Shanghai,
CN; Montreal, CA; Otwock, PL)
17:42 Outcome comparison of patients with idiopathic/heritable pulmonary arterial hypertension, 4182
pulmonary hypertension due to left heart disease and pulmonary hypertension due to lung
disease.
– A. Rinaldi, A. Manes, F. Dardi, M. Palazzini, C. Bachetti, G. Mazzanti, A. Albini, E. Gotti, E. Monti, N. Galie’
(Bologna, IT)
17:51 Prognostic value of right heart adaptation to pulmonary arterial hypertension: a prospective 4183
cohort study.
– T. Dawes, A. De Marvao, W. Shi, D. Rueckert, G. Watson, L. Howard, S. Gibbs, S. Cook, M. Wilkins,
D. O’Regan (London, UK; Singapore, SG)
16:30–18:00 | Rabat - Village 1

ION CHANNEL MOLECULAR COMPLEXES: BEYOND THEIR CANONICAL FUNCTIONS Symposium
Chairperson(s): P.G.A. Volders (Maastricht, NL); J. Gorelik (London, UK)
16:30 Connexins and the cardiac connexome. 4184
– M. Delmar (New York, US)
16:52 Non-canonical functions of sodium channel proteins. 4185
– C.A. Remme (Amsterdam, NL)
17:15 Dynamics of potassium channels expression in cardiac myocytes. 4186
– E. Balse (Paris, FR)
17:37 Excitation-transcription coupling in the heart. 4187
– S. Ljubojevic (Graz, AT)
264

ADVANCES IN CARDIAC REGENERATION Advances in Science
Chairperson(s): T. Eschenhagen (Hamburg, DE); S. Janssens (Leuven, BE)
16:30 State of the Art in cardiac regeneration. 4188
– W.-H. Zimmermann (Göttingen, DE)
16:50 Leukemia inhibitory factor enhances cardiomyocyte regeneration after myocardial infarction from 4189
endogenous stem cells and not from circulating bone marrow-derived cells.
– M. Kanda, T. Nagai, T. Takahashi, N. Kondou, A.T. Naito, H. Akazawa, G. Sashida, A. Iwama, I. Komuro,
Y. Kobayashi (Chiba and Tokyo, JP)
17:07 Epigenetic modulation of cardiac progenitor cells through miR-29a/Dnmt3a axis promotes their 4190
cardiac differentiation.
– A. De Pauw, B. Sekkali, A. Loriot, C. De Smet, D. Catalucci, D. Hilfiker-Kleiner, J.-L. Balligand (Brussels,
BE; Milan, IT; Hannover, DE)
17:24 Arrhythmic risk after transplantation of induced pluripotent stem cell derived cardiomyocytes into 4191
infarcted mouse hearts.
– G. Peinkofer, A. Klinke, M. Maass, K. Urban, M. Lange, T. Saric, J. Mueller-Ehmsen, S. Baldus,
J. Hescheler, M. Halbach (Cologne and Hamburg, DE)
17:41 Future direction for research in cardiac regeneration. 4192
– A. Bayes Genis (Badalona, ES)

UNCOVERING ENVIRONMENTAL IMPACTS ON CARDIOVASCULAR HEALTH Advances in Science
Chairperson(s): P. Puska (Helsinki, FI); A. Konradi (St. Petersburg, RU)
16:30 State of the Art in the environment and cardiovascular health. 4193
– S. Smith (Chapel Hill, US)
16:50 How cold is too cold: the effect of seasonal temperature variation on risk of STEMI. 4194
– S. Liu, R.A. Ducas, B. Hiebert, L. Olien, R. Philipp, J.W. Tam (Winnipeg, CA)
17:07 Particulate matter and NO2 air pollution trigger ST-elevation myocardial infarction: a case cross 4195
over study of the Belgian STEMI registry.
– J.-F. Argacha, P. Collart, P. Kayaert, D. Schoors, T. De Vos, A. Wauters, C. Bauloye, P. Evrard,
P. Sinnaeve, M.J. Claeys (Brussels, Brussel, Mont Godinne, Leuven and Antwerp, BE)
17:24 Environmental exposure to beta-hexachlorocyclohexane is associated with higher systolic blood 4196
pressure among people living close to an industrial area.
– R.M. Bruno, N. Di Lascio, F. Faita, R. Sicari, F. Fantini, F. Blasetti, D. Porta, S. Narduzzi, F. Forastiere (Pisa,
Colleferro and Rome, IT)
17:41 Future direction for research on the environment and cardiovascular health. 4197
– B. Brunekreef (Utrecht, NL)

MEDITERRANEAN DIETS, POLYPHENOLS AND CARDIOVASCULAR DISEASE Symposium
Chairperson(s): I.M. Graham (Dublin, IE); P.G. Hugenholtz (Wageningen, NL)
16:30 Regulation of vascular endothelial function by red wine procyanidins: implications for 4198
cardiovascular health.
– R. Corder (London, UK)
16:52 Regulation of vascular function by olive oil polyphenols. 4199
17:15 Meta analysis on vegetable/fruit consumption (including their natural polyphenols) and 4200
cardiovascular mortality.
– F.B. Hu (Boston, US)
– R. Corder (London, UK), R. De Caterina (Chieti, IT), F.B. Hu (Boston, US)
265

PREDICTING THE FUTURE: THE ACCURACY OF RISK SCORES Advances in Science
Chairperson(s): J. Hippisley-Cox (Nottingham, UK); M. Sobhy (Alexandria, EG)
16:30 State of the Art in predicting risk. 4202
16:50 External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation. 4203
– Z. Hijazi, J. Lindback, O. Ostlund, A. Siegbahn, J.H. Alexander, C.B. Granger, C. Held, R.A.H. Stewart,
H.D. White, L. Wallentin (Uppsala, SE; Durham, US; Auckland, NZ)
17:07 Exercise capacity can significantly improve SCORE risk prediction model in low risk 4204
asymptomatic adults.
– A. Israel, S. Kivity, Y. Sidi, S. Segev, B. Lavi, I. Goldenberg, E. Maor (Jerusalem and Tel Hashomer, IL)
17:24 Overestimation of incident ASCVD events by the ACC/AHA risk score in the German population: 4205
The KORA and the Heinz Nixdorf Recall Studies.
– T. De Las Heras Gala, A. Mahabadi, A. Peters, J. Baumert, H. Geisel, K.H. Joeckel, S. Moebus, R. Erbel,
C. Meisinger, W. Koenig (Munich, Essen, Augsburg and Ulm, DE)
17:41 Future direction for research in risk scores. 4206
– M.T. Cooney (Dublin, IE)
16:30–18:00 | Kiev - Village 3

WHEN TO STOP GIVING A DRUG? Case-based Symposium
Chairperson(s): V. Fuster (New York, US); U.P. Kaufmann (Bern, CH)
16:30 A case illustrating when we can stop giving a beta blocker. 4207
– A. Castro Conde (Madrid, ES)
16:45 A case illustrating when we can stop giving a beta blocker - Panel discussion and questions from 4208
the audience.
– A. Castro Conde (Madrid, ES), G. Dangas (New York, US)
17:00 A case illustrating how long to give dual antiplatelet therapy after PCI. 4209
– G. Dangas (New York, US)
17:15 A case illustrating how long to give dual antiplatelet therapy after PCI - Panel discussion and 4210
– A. Castro Conde (Madrid, ES), G. Dangas (New York, US)
17:30 When to stop giving a drug? State of the Art lecture. 4211

CLINICAL GENOMICS OF HYPERTENSION Symposium
ESC and the European Society of Hypertension
Chairperson(s): A.F. Dominiczak (Glasgow, UK); I. Hoefer (Utrecht, NL)
16:30 Genetic dissection of primary hyper aldosteronism. 4212
16:52 Genetic testing in modern management of phaeochromocytoma. 4213
– A. Januszewicz (Warsaw, PL)
17:15 Epigenetic modification in arterial hypertension. 4214
– B.C. Kone (Gainesville, US)
17:37 Next generation sequencing and clinical medicine. 4215
– M. Caulfield (London, UK)

ATRIAL FIBRILLATION AND SUDDEN DEATH – AN UNRECOGNISED ASSOCIATION? Symposium
Chairperson(s): X. Jouven (Paris, FR); Z. Kalarus (Zabrze, PL)
16:30 Epidemiological data. 4216
– H. Tan (Amsterdam, NL)
16:52 Can atrial fibrillation increase the propensity to ventricular fibrillation? 4217
– M. Borggrefe (Mannheim, DE)
17:15 Atrial fibrillation and impaired coronary blood flow - The mechanism? 4218
– G. Heusch (Essen, DE)
17:37 Atrial fibrillation in channelopathy. 4219
– L. Fabritz (Birmingham, UK)
266

QRS MORPHOLOGY IN CARDIAC RESYNCHRONISATION THERAPY Meet the Experts
Chairperson(s): B. Merkely (Budapest, HU); F. Hidden Lucet (Paris, FR)
16:30 QRS morphology in cardiac resynchronisation therapy - Introduction to the session. 4220
– B. Merkely (Budapest, HU)
16:35 Left bundle branch block or QRS duration. 4221
– M.R. Gold (Charleston, US)
16:45 Left bundle branch block or QRS duration - Panel discussion and questions from the audience. 4222
– M. Gasparini (Rozzano, IT), M.R. Gold (Charleston, US), F. Leyva-Leon (Sutton Coldfield, UK)
17:00 Non left bundle branch block. 4223
– V. Kutyifa (Rochester, US)
17:10 Non left bundle branch block - Panel discussion and questions from the audience. 4224
– M. Gasparini (Rozzano, IT), V. Kutyifa (Rochester, US), F. Leyva-Leon (Sutton Coldfield, UK)
17:25 Rate-dependent left bundle branch block. 4225
– C. Leclercq (Rennes, FR)
17:35 Rate-dependent left bundle branch block - Panel discussion and questions from the audience. 4226
– M. Gasparini (Rozzano, IT), C. Leclercq (Rennes, FR), F. Leyva-Leon (Sutton Coldfield, UK)
17:50 QRS morphology in cardiac resynchronisation therapy - Take home message. 4227
– F. Hidden Lucet (Paris, FR)

SAME PHENOTYPE, DIFFERENT DISEASE? Case-based Symposium
Chairperson(s): C. Basso (Padua, IT); J.-W. Ha (Seoul, KR)
16:30 A patient with left ventricular hypertrophy. 4228
– F. Alpendurada (London, UK)
16:40 A patient with left ventricular hypertrophy - Panel discussion and questions from the audience. 4229
– F. Alpendurada (London, UK), A. D’Andrea (Naples, IT), S.E. Petersen (London, UK), O. Bruder (Essen, DE)
16:52 An athlete with a big heart. 4230
– A. D’Andrea (Naples, IT)
17:02 An athlete with a big heart - Panel discussion and questions from the audience. 4231
17:14 Does this patient have non-compaction or just a lot of trabeculation? 4232
– S.E. Petersen (London, UK)
17:24 Does this patient have non-compaction or just a lot of trabeculation? Panel discussion and 4233
17:36 Dilated heart with reduced ejection fraction. 4234
– O. Bruder (Essen, DE)
17:46 Dilated heart with reduced ejection fraction - Panel discussion and questions from the audience. 4235

ECHO STRAIN IMAGING: WHAT DOES IT TELL EARLY AFTER MYOCARDIAL Advances in Science
INFARCTION?
Chairperson(s): S. Nakatani (Takarazuka, JP); A.N. Neskovic (Belgrade, RS)
16:30 State of the Art in strain imaging after myocardial infarction. 4236
– Z.B. Popovic (Cleveland, US)
16:50 Two-dimensional diastolic speckle tracking echocardiography in the triage of patients with acute 4237
chest pain at emergency department.
– S. Sasaki, S. Ito, G.C. Kane, J.P. Bois, N.S. Anavekar, K.J. Olson, V.R. Bellamkonda, E.P. Hess,
P.A. Smars, J.K. Oh (Rochester, US)
17:07 The timeline of changes in regional systolic and diastolic function in patients with stunned 4238
myocardium.
– K. Wdowiak-Okrojek, A. Shim, P. Wejner-Mik, J.D. Kasprzak, P. Lipiec (Lodz, PL)
17:24 Difference in the prognostic impact of left ventricular global longitudinal strain between anterior 4239 (W)
myocardial infarction and non-anterior myocardial infarction. (withdrawn)
– S.Y. Jang, N.K. Kim, C.Y. Kim, J.H. Kim, M.H. Bae, J.H. Lee, D.H. Yang, H.S. Park, Y. Cho, S.C. Chae
(Daegu, KR)
17:41 Future direction for research in strain imaging after myocardial infarction. 4240
267

HEART AND BRAIN: THE CONCEPT OF STRESS AND EMOTIONS Symposium
ESC and the European Stroke Conference
Chairperson(s): K. Spengos (Athens, GR); P. Taggart (London, UK)
16:30 Takotsubo cardiomyopathy. 4241
– To be announced
16:52 Anger, emotion and arrhythmias. 4242
– P. Lambiase (London, UK)
17:15 The role of stress in neurological disorders. 4243
– K. Szabo (Mannheim, DE)
17:37 How does the brain adapt to stress? 4244
– To be announced
16:30–18:00 | Oslo - Village 6

ACUTE AORTIC DISEASES Guidelines in Daily Practice
Chairperson(s): C.J.M. Vrints (Edegem, BE); M. Tendera (Katowice, PL)
16:30 How not to miss a type A dissection? 4245
– M. Cikes (Zagreb, HR)
16:45 How not to miss a type A dissection? What do the Guidelines say? 4246
17:00 How not to miss a type A dissection? Panel discussion on how to implement the Guidelines. 4247
– J. Elefteriades (New Haven, US), R. Erbel (Essen, DE), V. Falk (Berlin, DE), A. Evangelista Masip (Barcelona,
ES), M. Cikes (Zagreb, HR)
17:10 How not to miss a type A dissection? Conclusion and take home message. 4248
17:15 Management of complicated type B dissection (apparent type B). 4249
– J. Poess (Lübeck, DE)
17:30 Management of complicated type B dissection (apparent type B) - What do the Guidelines say? 4250
– M. Grabenwoeger (Vienna, AT)
17:45 Management of complicated type B dissection (apparent type B) - Panel discussion on how to 4251
implement the Guidelines.
– J. Poess (Lübeck, DE), M. Grabenwoeger (Vienna, AT), R. Erbel (Essen, DE), J. Elefteriades (New Haven,
US), V. Falk (Berlin, DE)
17:55 Management of complicated type B dissection (apparent type B) - Conclusion and take home 4252
message.

MANAGEMENT OF CARDIOGENIC SHOCK Advances in Science
Chairperson(s): M. Tubaro (Rome, IT); P. Vranckx (Hasselt, BE)
16:30 State of the Art in the management of cardiogenic shock. 4253
– J.L. Van Herck (Wilrijk, BE)
16:50 Temporal trends in the epidemiology, management and outcome of patients with cardiogenic 4254
shock complicating acute coronary syndromes.
– L. De Luca, Z. Olivari, A. Farina, L. Gonzini, F. Chiarella, A. Boccanelli, G. Di Pasquale, S. De Servi,
M. Gulizia, S. Savonitto (Rome, Treviso, Lecco, Florence, Genoa, Bologna, Pavia and Catania, IT)
17:07 Modified shock index - a strong preditor of outcome among patients presenting with ST-segment 4255
elevation myocardial infarction.
– G. Abreu, C. Braga, C. Arantes, C. Quina-Rodrigues, J. Martins, C. Vieira, M. Alvares Pereira, P. Azevedo,
17:24 Aetiology of shock or cardiac arrest in patients treated with venoarterial extramembrane 4256
oxygenation.
– E. Kagawa, K. Dote, M. Kato, S. Sasaki, N. Oda, Y. Nakano, Y. Kihara (Hiroshima, JP)
17:41 Future direction for research on the management of cardiogenic shock. 4257
– C. Spaulding (Suresnes, FR)
268
16:30–18:00 | Tunis - Village 7

UNDERSTANDING POST INFARCTION RISK FOR A BETTER LONG TERM SURVIVAL Advances in Science
Chairperson(s): D. Milicic (Zagreb, HR); P. Motreff (Clermont-Ferrand, FR)
16:30 State of the Art in risk assessment of patients post myocardial infarction. 4258
– F. Alfonso Manterola (Madrid, ES)
16:50 A new risk scoring system to assess 1-year all-cause death or myocardial infarction in patients 4259 (W)
treated with contemporary guideline-adherent optimal therapies after acute myocardial infarction.
(withdrawn)
– P.S. Song, D.R. Ryu, H.J. Jeong, G.W. Seo, D.K. Kim, K.H. Kim, S.H. Seol, M.H. Jeong, S.H. Choi,
D.I. Kim (Busan, Chuncheon, Gwangju and Seoul, KR)
17:07 Chronology of events after hospital discharge following acute myocardial infarction is not 4260
uniform. Five-year follow-up of the FAST-MI 2005 registry.
– N. Danchin, E. Puymirat, F. Carrat, N. Lapidus, P. Motreff, M. Pansieri, J. Fajadet, J. Ferrieres, F. Schiele,
T. Simon (Paris, Clermont-Ferrand, Avignon, Toulouse and Besançon, FR)
17:24 Long term relative survival and excess mortality after acute myocardial infarction, 2003-2010: a 4261
national cohort study.
– O.A. Alabas, M. Rutherford, M. Van Laar, T.B. Dondo, J.E. Deanfield, A.D. Timmis, C.P. Gale (Leeds,
Leicester and London, UK)
17:41 Future direction for research in predicting post infarction outcomes. 4262
– N. Danchin (Paris, FR)

UPDATE IN DILATED CARDIOMYOPATHY Symposium
Chairperson(s): A. Linhart (Prague, CZ); W.J. McKenna (London, UK)
16:30 New definition and classification of dilated cardiomyopathy, a working group statement. 4263
– Y. Pinto (Amsterdam, NL)
16:52 Individualised diagnostic work-up. 4264
– G. Limongelli (Naples, IT)
17:15 Rationale for genetic testing. 4265
17:37 Etiology based management. 4266
– A.L.P. Caforio (Padua, IT)
TAVI – CURRENT STATUS AND FUTURE PERSPECTIVES Advances in Science
Chairperson(s): A. Cribier (Rouen, FR); O. Wendler (London, UK)
16:30 State of the Art in TAVI. 4267
– H. Eltchaninoff (Rouen, FR)
16:50 Five-year haemodynamic outcomes of the first-generation balloon-expandable transcatheter 4268
heart valve.
– T. Lefevre, H. Eltchaninoff, G. Wimmer-Greinecker, V. Schaechinger, D. Himbert, M. Romano, M. Thielman,
F. Mohr, T. Walther (Massy, Rouen and Paris, FR; Bad Bevensen, Fulda, Essen, Leipzig and Bad Nauheim,
DE)
17:07 Comparative survival after trans-apical, direct aortic, and subclavian transcatheter aortic valve 4269
implantation.
– G.M. Froehlich, P.B. Baxter, C.M. Malkin, J.S. Scott, N.M. Moat, D.H.S. Hildick-Smith, P.M.C. MacCarthy,
M.B. De Belder, P.L. Ludman, D.B. Blackman (Leeds, London, Brighton, Middlesborough and Birmingham,
UK)
17:24 TAVI in local anesthesia without general anesthesia or deep sedation, a single center comparison 4270
of 30-day clinical outcome between balloon-expandable and self-expandable valves.
– S. Fateh-Moghadam, A. Prinz, B. Grossmann, M. Droppa, T. Geisler, M. Gawaz, W. Bocksch (Tübingen,
DE)
17:41 Future direction for research in TAVI. 4271
269

CONTEMPORARY APPROACH TO MARFAN SYNDROME AND RELATED INHERITED THORACIC Symposium
AORTIC DISEASE
Chairperson(s): Y. Von Kodolitsch (Hamburg, DE); C. Boileau (Paris, FR)
16:30 Diagnosis and differential diagnosis - When should we consider genetic testing? 4272
– J. De Backer (Ghent, BE)
16:52 Who needs more extensive cardiovascular imaging? 4273
– E.R. Valsangiacomo Buechel (Zurich, CH)
17:15 Medical treatment - Which drug at what age? 4274
– G. Jondeau (Paris, FR)
17:37 Surgical or interventional approach - When and how to intervene? 4275
– D. Cameron (Baltimore, US)
16:30–18:00 | Bern - Village 9

BIOMARKERS: PRESENT AND FUTURE Advances in Science
Chairperson(s): M. Emdin (Pisa, IT); J.L. Lopez-Sendon (Madrid, ES)
16:30 State of the Art in biomarkers. 4276
16:50 Soluble Neprilysin compared to NTproBNP for heart failure risk stratification in ambulatory 4277
patients.
– A. Bayes-Genis, J. Barallat, A. Galan, J. Penafiel, J. Vila, M. De Antonio, M. Domingo, E. Zamora,
J. Santesmases, J. Lupon (Badalona and Barcelona, ES)
17:07 Cardiac injury in neoplasia and association with cardiovascular hormones. 4278
– N. Pavo, M. Huelsmann, M. Raderer, C. Adlbrecht, G. Strunk, G. Goliasch, H. Gisslinger, C. Marosi,
C. Zielinski, R. Pacher (Vienna, AT)
17:24 Soluble neprilysin in acute heart failure: prognostic value and kinetics. A pilot study. 4279
– A. Bayes-Genis, J. Barallat, D. Pascual, J. Nunez, G. Minana, J. Sanchez-Mas, A. Galan, J. Sanchis,
M.T. Perez-Martinez, J. Lupon (Badalona, Murcia and Valencia, ES)
17:41 Future direction for research - using biomarker in the context of telemdicine. 4280
– F. Koehler (Berlin, DE)

MODERN DRUG THERAPY IN HEART FAILURE Advances in Science
Chairperson(s): A. Mebazaa (Paris, FR); E.A. Jankowska (Wroclaw, PL)
16:30 State of the Art in heart failure therapy. 4281
16:50 One-year mortality in diuretic treated patients with heart failure. A report from the Swedish Heart 4282
Failure registry based on a cohort of 27,374 patients.
– P. Paren, M. Edner, U. Dahlstrom, A. Rosengren, M. Schaufelberger (Mölndal, Stockholm, Linköping and
Gothenburg, SE)
17:07 Low-dose aspirin therapy is not associated with reduced cardiovascular morbidity or mortality in 4283
heart failure with sinus rhythm: a nationwide propensity score matched study.
– C. Madelaire, G. Gislason, S.L. Kristensen, C. Torp-Pedersen, F. Gustafsson, L. Kober, M. Schou
(Copenhagen, Aalborg and Herlev, DK)
17:24 Use of digoxin is safe in patients with atrial fibrillation and heart failure: a nationwide propensity 4284
matched study.
– C. Madelaire, M. Schou, K.E. Kristensen, M. Schmiegelow, C. Torp-Pedersen, F. Gustafsson, L. Kober,
G. Gislason (Copenhagen, Herlev and Aalborg, DK)
17:41 Future direction for research in acute heart failure. 4285
270

MICROCIRCULATION AND COLLATERALS Rapid Fire Abstract
Chairperson(s): R. Bugiardini (Bologna, IT); S. Hiremath (Pune, IN)
16:30 How to make a diagnosis of microvascular angina; the diagnostic potency of rest-stress 4286
myocardial perfusion magnetic resonance imaging.
– T. Warisawa, T. Naganuma, Y. Fujino, H. Ishiguro, S. Tahara, N. Kurita, K. Hozawa, S. Nakamura,
S. Nakamura (Matsudo and Chiba, JP)
16:39 Effect of pre-procedural antiplatelet and anticoagulant therapy on myocardial no-reflow following 4287
percutaneus coronary intervention.
– E. Cenko, B. Ricci, S. Kedev, Z. Vasiljevic, B. Knezevic, D. Trninic, D. Milicic, O. Manfrini, L. Badimon,
R. Bugiardini (Bologna, IT; Skopje, MK; Belgrade, RS; Podgorica, ME; Banja Luka, BA; Zagreb, HR;
Barcelona, ES)
16:48 Diabetes mellitus and coronary microvascular function in asymptomatic patients with severe 4288
aortic stenosis and nonobstruced coronary arteries.
– M. Banovic, B. Vujisic-Tesic, V. Brkovic, I. Nedeljkovic, M. Jaukovic, D. Trifunovic, D. Popovic, A. Ristic
(Belgrade, RS)
16:57 The association between coronary artery calcium & coronary flow reserve assessed by integrated 4289
rubidium positron emission tomography/CT in women with angina and no obstructive coronary
artery disease.
– N.D. Mygind, M.M. Michelsen, A. Pena, D. Frestad, T. Christensen, A.A. Ghotbi, P. Hasbak, A. Kjaer,
J. Kastrup, E. Prescott (Copenhagen, DK)
17:06 Decreased shear stress affects vascular clinical outcome in Kawasaki disease patients with 4290
coronary artery lesions.
– M. Watanabe, R. Fukazawa, Y. Katsube, M. Kamisago, T. Ohkubo, M. Abe, N. Suzuki, K. Hashimoto,
Y. Hashimoto, S. Ogawa (Tokyo, JP)
17:15 In-hospital outcomes associated with radial versus femoral access and intervention in acute 4291
coronary syndromes: results from the ISACS-TC registry.
– E. Cenko, B. Ricci, S. Kedev, Z. Vasiljevic, B. Knezevic, O. Manfrini, D. Milicic, A. Koller, L. Badimon,
R. Bugiardini (Bologna, IT; Skopje, MK; Belgrade, RS; Podgorica, ME; Zagreb, HR; Pécs, HU; Barcelona,
ES)
17:24 The effects of nicorandil on microvascular function in patients with STEMI undergoing primary 4292
PCI.
– J. Kostic, M. Dobric, D. Milasinovic, A. Djordjevic Dikic, M. Tesic, S. Stojkovic, J. Stepanovic,
M. Nedeljkovic, Z. Trifunovic, B. Beleslin (Belgrade, RS)
17:33 The Resistive Reserve Ratio is Associated with Acute Infarct Characteristics in Patients with 4293
Acute STEMI.
– J. Layland, D. Carrick, N. Ahmed, N. Nerlekar, S. Watkins, M. Petrie, S. Hood, H. Eteiba, K.G. Oldroyd,
C. Berry (Fitzroy and Melbourne, AU; Glasgow, UK)
17:42 The index of microvascular resistance is a novel biomarker for myocardial haemorrhage and risk 4294
stratification in acute reperfused ST-elevation myocardial infarction patients.
– D.J.A. Carrick, C. Haig, J. Layland, H. Eteiba, M. McEntegart, S. Watkins, M. Lindsay, A. Radjenovic,
17:51 Prognostic values of coronary microvascular function in patients with angina symptoms and 4295
impact of impaired glucose homeostasis.
– H. Westergren, J. Blomster, S. Svedlund, L.-M. Gan (Gothenburg, SE)
271
MONDAY 31 AUGUST 2015 – AFTERNOON POSTERS

BEST POSTERS IN IMPLANTABLE AND SUBCUTANEOUS DEFIBRILLATOR THERAPY
Discussant: Best posters in implantable and subcutaneous defibrillator therapy. P4296

– E. Aliot (Vandoeuvre-lès-Nancy, FR)
The evolution of ICD programming practice: What is the relative impact of clinical evidence on clinical P4297
practice?
– M.L. Brown, L.D. Sterns, M. Silver, F.M. Merchant, J.P. Piccini, J.W. Johnson, J. Coles (Mounds View,
Raleigh, Atlanta and Durham, US; Victoria, CA)
Efficacy and safety of the implantable cardioverter defibrillator in pediatric patients with channelopathies. P4298
– A. Mazzanti, M. Facin, V. Jorat, F. Esposito, R. Bloise, M. Memmi, V. Novelli, M. Morini, C. Napolitano,
S.G. Priori (Pavia and Naples, IT; São Paulo, BR; Shiraz, IR)
Learning curve associated with inappropriate shocks of the subcutaneous implantable defibrillator: P4299
results from a pooled analysis of 882 patients from the IDE study and EFFORTLESS Registry.
– T.F. Brouwer, R.E. Knops, C.S. Barr, D.A. Theuns, R. Weiss, P.D. Lambiase, A.R. Leon, P. Jones,
N. Carter, M.C. Burke (Amsterdam and Rotterdam, NL; Dudley and London, UK; Columbus, Atlanta, Arden
Hills and Chicago, US)
BEST POSTERS IN CORONARY ARTERY DISEASE AND COMORBIDITIES
Discussant: Best posters in coronary artery disease and comorbidities. P4300

– A. Goda (Tirana, AL)
Depression is the strongest predictor of angina and is independent of underlying coronary artery disease P4301
severity in patients with cardiovascular disease.
– S. Hayek, A. Del Mar Soto, M. Awad, N. Ghasemzadeh, M. Khayata, B. Harfoush, A. Yadalam, A. Shah,
V. Vaccarino, A. Quyyumi (Atlanta, US)
Role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation (AF) undergoing percutaneous P4302
coronary intervention (PCI).
– M. Freeman, N. Andrianopoulos, L. Roberts, A.L. Brennan, D.J. Clark, S.J. Duffy, A.E. Ajani, C.M. Reid,
G. New, A.W. Teh (Melbourne, AU)
Non-ST-elevation acute coronary syndromes with renal impairment - which formula serves better? P4303
– A. Correia, R. Rodrigues, B. Silva, M. Neto, S. Gomes, A. Drumond, D. Pereira (Funchal, PT)
Persistence to secondary prevention drugs in ACS patients with reduced renal function and long-term P4304
outcome.
– M. Khedri, K. Szummer, J.J. Carrero-Roig, T. Jernberg, M. Evans, S.H. Jacobson, J. Spaak (Stockholm,
SE)
BEST POSTERS IN EARLY DETECTION OF CARDIAC DISEASE
Discussant: Best posters in early detection of cardiac disease. P4305

– J.U. Voigt (Leuven, BE)
Subclinical left ventricular systolic dysfunction by strain imaging in chronic kidney disease subjects with P4306
preserved ejection fraction: The prospective CASCADE study.
– Q.Z. Cai, A.Y.M. Wang (Hong Kong, HK)
Normal range of LV global longitudinal strain in asymptomatic lymphoma survivors. P4307
– K. Murbraech, K. Broch, H. Dalen, C.E. Kiserud, S. Aakhus (Oslo and Levanger, NO)
Usefulness of 2D strain parameters to rule out acute rejection after heart transplantation. P4308
– D. Jimenez Sanchez, V. Monivas Palomero, J. Goirigolzarri Artaza, S. Mingo Santos, A. Restrepo Cordoba,
E. Rodriguez Gonzalez, B. Rivero Arribas, M. Gomez Bueno, I. Sayago Silva, J. Segovia Cubero (Madrid,
ES)
Early detection of abnormal left atrial and left ventricular coupling using two-dimensional speckle P4309
tracking echocardiography in patients with preserved left ventricular ejection fraction.
– Y. Ohara, Y. Tsuda, Y. Fukuoka, S. Hosogi, K. Yamamoto (Kochi, JP)
BEST POSTERS IN ENDOTHELIAL FUNCTION
Discussant: Best posters in endothelial function. P4310

– P. Evans (Sheffield, UK)
Evaluation of cardiovascular risk in OSA patients in cPAP therapy over four years of follow-up. P4311
– M.M. Ciccone, R. Carbonara, F. Devito, G. Bulzis, F. Giardinelli, A. Dachille, V. Quaranta, P. Carratu’,
O. Resta, A. Zito (Bari, IT)
272
The impact of different types of exercise on endothelial function and arterial stiffness. P4312
– D. Athanasiou, G. Siasos, G. Terzis, A. Stasinaki, E. Dimitropoulos, N. Gouliopoulos, E. Oikonomou,
M. Zaromytidou, K. Mourouzis, D. Tousoulis (Athens, GR)
Inhibition of ROCK1 activity by calcium channel blocker suppresses angiotensin II-induced endothelial P4313
dysfunction.
– A. Cai, R.L. Xu, L.W. Li, W.Y. Mai, Y.L. Zhou, J.Y. Chen (Guangzhou, CN)
Endothelial p53 is crucially involved in regulating vascular function. P4314
– H. Kayamori, I. Shimizu, M. Yokoyama, Y. Yoshida, M. Suda, G. Katsuumi, T. Minamino (Niigata and Chiba,
JP)
BEST POSTERS IN PROSTHETIC VALVE DISEASE
Discussant: Best posters in prosthetic valve disease. P4315

– H. Al Alfarhan (Baghdad, IQ)
Antithrombotic strategy after bioprosthetic aortic valve replacement in patients with sinus rhythm: P4316
evaluation of guideline implementation.
– S.J. Van Der Wall, V.A.W.M. Umans, J. Schotten, M. Keijzers, R. Wolterbeek, E.K. Jansen, M.V. Huisman,
A.B.A. Vonk (Leiden, Alkmaar, Zaandam, Haarlem and Amsterdam, NL)
Postoperative lipids management among patients with bioprosthetic heart valves: mid-term follow-up P4317
analysis.
– E. Angeloni, G. Melina, S. Refice, F. Capuano, A. Roscitano, C. Comito, R. Sinatra (Rome, IT)
Thrombolytic therapy for left side prosthetic valve thrombosis short and long term follow up study. P4318
– S. Gupta (Jaipur, IN)
Thrombolysis versus unfractionated heparin as firstline strategy for non-obstructive prosthetic valve P4319
thrombosis.
– S. Gunduz, M. Yesin, M. Kalcik, M.O. Gursoy, A.C. Aykan, M.A. Astarcioglu, S. Karakoyun, A. Kilicgedik,
C. Toprak, M. Ozkan (Istanbul, TR)
BEST POSTERS IN CARDIOVASCULAR RISK FACTORS
Discussant: Best posters in cardiovascular risk factors. P4320

Diabetes and cause-specific mortality: evidence from 55 000 deaths in 700 000 adults in 44 prospective P4321
studies.
– L. Gnatiuc, J. Halsey, J. Emberson, S. Lewington (Oxford, UK)
Dietary intake of alpha-linolenic acid and risk of myocardial infarction: a Danish cohort study. P4322
– C.S. Bork, M.U. Jakobsen, S. Lundbye-Christensen, E.B. Schmidt, K. Overvad (Aalborg and Aarhus, DK)
Association between persistent psychological distress and 12 year cardiovascular and total mortality in P4323
patients with stable coronary artery disease.
– R.A.H. Stewart, D.M. Colquhoun, S.L. Marshner, J. Simes, A.C. Kirby, P.J. Nestel, N. Glozier, A. O’Neil,
A.M. Tonkin, H.D. White (Auckland, NZ; Brisbane, Sydney and Melbourne, AU)
European HeartQoL reference values in patients with coronary heart disease. P4324
– D. De Smedt, E. Clays, S. Hofer, N. Oldridge, K. Kotseva, D. De Bacquer (Ghent, BE; Innsbruck, AT;
Wisconsin, US; London, UK)
BEST POSTERS IN RISK FACTORS AND OUTCOMES AFTER PCI
Discussant: Best posters in risk factors and outcomes after PCI. P4325
– E. Barbato (Aalst, BE)
Differential impact of diabetes on platelet reactivity and stent thrombosis in women and men: insights P4326
from the ADAPT-DES study.
– G. Giustino, U. Baber, R. Mehran, C. Litherland, B. Witzenbichler, M.J. Rinaldi, F.J. Neumann, T.D. Stuckey,
A.J. Kirtane, G.W. Stone (New York, Charlotte and Greensboro, US; Dachau and Bad Krozingen, DE)
Mortality trends after unprotected left main stem PCI in England and Wales, 2005-2014: Analysis of 10,825 P4327
cases from the British Cardiovascular Intervention Society (BCIS) national registry.
– S. Almudarra, N. Curzen, P. Baxter, S. Fleming, I. Pearson, P. Ludman, M. De Belder, C. Gale (Leeds,
Southampton, Birmingham and Middlesbrough, UK)
Impact of platelet reactivity in anemic and non-anemic patients with coronary artery disease undergoing P4328
percutaneous coronary intervention: insights from the adapt-des study.
– G. Giustino, U. Baber, R. Mehran, C. Litherland, B. Witzenbichler, G. Weisz, F.J. Neumann, D.C. Metzger,
A.J. Kirtane, G.W. Stone (New York and Kingsport, US; Dachau and Bad Krozingen, DE; Jerusalem, IL)
Randomized comparison of 9-month stent struts coverage of biolimus and everolimus drug-eluting stents P4329
asssessed by OCT in patients with STEMI.
– P. Cervinka, P.K. Kala, M.J. Jakl, J.K. Kanovsky, A.K. Kupec, R.S. Spacek, M.K. Kvasnak,
M.C. Cervinkova, H.B. Bezzera, K.T. Tanaka (Ústí nad Labem, Brno and Hradec Králové, CZ; Cleveland,
US)
273
BEST POSTERS IN VENTRICULAR FUNCTION / HAEMODYNAMICS
Discussant: Best posters in ventricular function / haemodynamics. P4330

– L.S. Maier (Regensburg, DE)
Effect of High-Intensity Interval training combined with Strength exercise on aorto-ventricular coupling in P4331
patients with chronic heart failure. A randomized phase III clinical trial.
– C. Chrysohoou, A. Angelis, G. Tsitsinakis, E. Herouvim, D. Tsiachris, P. Rapakoulias, C. Pitsavos,
I. Vogiatzis, N. Koulouris, D. Tousoulis (Athens, GR)
Lung function in relation to cardiac dysfunction and heart failure in the general population. P4332
– C. Baum, F.M. Ojeda, P.S. Wild, N. Rzayeva, T. Zeller, C.R. Sinning, S. Blankenberg, T. Munzel, K.F. Rabe,
R.B. Schnabel (Hamburg, Mainz and Großhansdorf, DE)
A single-centre experience in the hemodynamic improvement and prognosis of heart transplantation P4333
candidates with group 2 reactive pulmonary hypertension treated with sildenafil.
– M. Oliveira-Santos, R. Ramalho, R. Baptista, S. Leao, S. Costa, A. Marinho-Da-Silva, R. Martins, F. Franco,
M. Pego (Coimbra and Vila-Real, PT)
Percutaneous ventricular restoration (PVR) therapy using the parachute device in subjects with ischemic P4334
heart failure: one year meta-analysis and bad nauheim experience.
BEST POSTERS IN AUTONOMIC NERVOUS SYSTEM IN HYPERTENSION
Discussant: Best posters in autonomic nervous system in hypertension. P4335

– J.F.R. Paton (Bristol, UK)
Cardiac pacemaker stimulates the brain as well as the heart in humans - A PET functional study. P4336
– H. Suzuki, K. Satoh, S. Tatebe, Y. Matsumoto, M. Kondo, M. Nakano, K. Fukuda, K. Hiraoka, M. Tashiro,
Increased cardiovascular sympathetic modulation as a predictor of death in patients with amyotrophic P4337
lateral sclerosis.
– L. Dalla Vecchia, B. De Maria, K. Marinou, G. Mora, A. Porta (Milan, IT)
Sympathetic nerve activity and arterial baroreflex function in rheumatoid arthritis. P4338
– A.M. Adlan, J.F.R. Paton, G.Y.H. Lip, G.D. Kitas, J.P. Fisher (Birmingham, Bristol and Dudley, UK)
Cerebral blood flow to the brain stem is reduced in humans with hypertension. P4339
– S.B. Neumann, E.A. Warnert, L.E. Ratcliffe, A.E. Burchell, A.K. Nightingale, R.G. Wise, J.F.R. Paton,
E.C. Hart (Bristol and Cardiff, UK)
274

ABLATION OF ATRIAL FIBRILLATION I

Initial results of a second-generation multielectrode mapping and ablation catheter for pulmonary vein P4340
isolation (PVAC GOLD).
– S. Weber, M. Hoeher, D. Schultes (Regensburg and Bayreuth, DE)
First in man evaluation of a new ablation catheter thermocool smarttouch sf in atrial fibrillation ablation. P4341
– M. Christoph, C. Wunderlich, Y. Huo, M. Forkmann, J. Mayer, J. Salmas, M. Pohl, T. Gaspar, C. Piorkowski
(Dresden, DE)
Superior efficacy of pulmonary vein isolation with online contact force measurement persists after the P4342
learning period: a prospective case control study.
– M. Wolf, J.B. Saenen, H. Miljoen, W. Bories, C. Vrints, A. Sarkozy (Antwerp, BE)
Pulmonary vein isolation for paroxysmal atrial fibrillation using a novel gold multi-electrode duty cycled P4343
radiofrequency ablation catheter. First results.
– S.G. Spitzer, L. Karolyi, C. Raemmler, F. Scharfe, T. Weinmann, T. Otto, A. Langbein (Dresden, DE)
Do patients and doctors differ in their perception of the patients symptom relief after ablation of atrial P4344
fibrillation?
– A. Bjorkenheim, A. Brandes, L. Svedberg, A. Chemnitz, N. Edvardsson, D. Poci (Örebro and Gothenburg,
SE; Odense, DK)
Pulmonary vein isolation for persistent atrial fibrillation using a novel gold multi-electrode duty cycled P4345
radiofrequency ablation catheter, first results.
– S.G. Spitzer, A. Langbein, C. Raemmler, F. Scharfe, T. Weinmann, T. Otto, L. Karolyi (Dresden, DE)
Comparison in Long-Term Efficacy between First and Second Generation Cryoballoon Ablation Catheter. P4346
– M. Moltrasio, G. Fassini, F. Tundo, A. Dello Russo, S. Riva, B. Majocchi, M. Casella, V. Marino, S. Conti,
C. Tondo (Milan, IT)
Acute recovery of pulmonary vein conduction in contact force-optimized circumferential pulmonary vein P4347
isolation is associated with minor catheter tissue contact angles.
– Y.U. Celikyurt, P. Seizer, M. Gramlich, M. Gawaz, J. Schreieck (Tübingen, DE)
Risk factors of recurrence of paroxysmal atrial fibrillation after radiofrequency catheter ablation. P4348
– X.L. Zhang, H. Fu, X. Wei, Y.J. Liang, H. Tang (Chengdu, CN)
Low flow velocities in the left atrial appendage can predict atrial fibrillation recurrence in patients P4349
undergoing ablation?
– S. Guerreiro, R. Ribeiras, J. Abecasis, P. Adragao, F.B. Morgado, D. Cavaco, M.J. Andrade, M. Mendes
(Lisbon, PT)
Pulmonary vein reconnection: is contact force more important than stability? P4350
– P. Adragao, F. Moscoso Costa, D. Cavaco, L. Parreira, P. Santos, P. Carmo, S. Carvalho, T. Teixeira,
A. Soares, M. Abecasis (Lisbon, PT)
ABLATION OF ATRIAL FIBRILLATION II

Effect of type of monitoring on verification of atrial fibrillation recurrence after catheter ablation: P4351
Comparison of the 7 day Holter monitoring and implantable monitor with remote control.
– M. Taborsky, T. Skala, M. Fedorco, H. Grofkova, J. Jarkovsky (Olomouc and Brno, CZ)
Left atrial surface area that remains not isolated after ablation of persistent atrial fibrillation predicts long P4352
term outcomes.
– C.J. Nalliah, T.W. Lim, P. Qian, A. Bhaskaran, R. Kurup, E. Kizana, P. Kovoor, D.L. Ross, S.P. Thomas
(Sydney, AU; Singapore, SG)
Low amplitude of fibrillatory waves on surface ecg predicts non-responder for ablation in patients with P4353
long-standing persistent atrial fibrillation.
– Y. Hama, Y. Matsudo, T. Kuwahara, N. Eguchi, Y. Fujimoto, M. Yamamoto, T. Himi (Kisarazu and
Yokosuka, JP)
Apnea-hypopnea index evaluated by type-3 portable monitoring predicts outcome following initial P4354
pulmonary vein isolation in patients with paroxysmal atrial fibrillation.
– H. Kawakami, T. Nagai, A. Fujii, T. Uetani, K. Nishimura, K. Inoue, J. Suzuki, A. Ogimoto, T. Okura, J. Higaki
(Toon, JP)
Different right atrial conduction pattern between paroxysmal and persistent atrial fibrillation. P4355
– H.S. Mun, M.K. Kang, J.S. Uhm, J.Y. Kim, J.R. Cho, N.H. Lee, H.N. Pak, M.H. Lee, H.M. Kwon, B. Joung
(Seoul, KR)
Acute changes during atrial fibrillation ablation targeting rotor sources. P4356
– L. Vitali Serdoz, P. Halbfass, C. Mahnkopf, J. Brachmann (Coburg, DE)
Baroreflex, heart rate and blood pressure variability after circumferential pulmonary vein ablation: a P4357
2-year follow-up pilot study.
– S. Chauveau, A. Cividjian, N. Girerd, M.M. Arisha, C. Julien, C. Barres, L. Quintin, P. Chevalier (Lyon and
Nancy, FR)
275
Long-term outcome and predictors of atrial tachycardia recurrence following catheter ablation of left P4358
atrial flutter.
– H. Salih, S. Combes, R. Providencia, R. Cassagneau, P. Sousa, T. Pambrun, K. Nader, N. Combes,
S. Boveda, J.P. Albenque (Toulouse, FR)
LA fibrosis predicts LVEF improvement in HF patients undergoing AF ablation. P4359
– J. Sitzy, T. Gaspar, Y. Huo, M. Christoph, M. Forkmann, J. Mayer, M. Pohl, J. Salmas, C. Wunderlich,
C. Piorkowski (Dresden, DE)
An increased sympathetic tone after ablation predicts recurrence of atrial fibrillation in patients P4360
undergoing catheter ablation of atrial fibrillation: Investigation using cardiac iodine-123-metaiodo.
– M. Masuda, H. Mizuno, H. Minamiguchi, S. Konishi, T. Ohtani, O. Yamaguchi, Y. Okuyama, M. Uematsu,
Y. Sakata (Amagasaki and Suita, JP)
Pulmonary vein isolation suffices for the first session but not for the second in ablation of persistent atrial P4361
fibrillation.
– K. Tanimoto, K. Inagawa, T. Nishiyama, Y. Ikegami, T. Kimura, N. Nishiyama, Y. Aizawa, Y. Momiyama,
K. Fukuda, S. Takatsuki (Tokyo, JP)
ABLATION OF ATRIAL FIBRILLATION III

Significant reduction of radiation exposure during catheter ablation of paroxysmal atrial fibrillation using P4362
a new image integration module:.
– R.O. Akbulak, M.J. Jularic, B.S. Schaeffer, D.S. Schreiber, J.M. Moser, C.E. Eickholt, C.M. Meyer,
B.H. Hoffmann, S.W. Willems (Hamburg, DE)
Clinical characteristics and outcomes of adenosine induced atrial fibrillation after pulmonary vein P4363
isolation.
– D.H. Kim, Y.H. Kim, S.W. Park, D.I. Lee, S.Y. Roh, J.H. Ahn, J.M. Shim (Seoul, KR)
Long-term results of a surgical treatment of stand-alone atrial fibrillation with the use of right P4364
thoracoscopic approach and a microwave or monopolar radiofrequency energy source.
– P. Budera, P. Osmancik, D. Herman, Z. Straka (Prague, CZ)
A phantom study to assess the accuracy of a new electromagnetic catheter guidance technology P4365
(MediGuide).
– F. Bourier, T.R. Reents, S. Ammar, A. Buiatti, V. Semmler, B. Kaess, C. Kolb, M. Telishevska, G. Hessling,
I. Deisenhofer (Munich, DE)
Differences in X-ray dose in patient and physician during pulmonary vein isolation. P4366
– M. Seifert, V. Moeller, S. Fehrendt, B. Ettert, C. Butter (Bernau bei Berlin, DE)
Treatment of atrial fibrillation using second-generation cryo balloon: characteristics of recurrences and P4367
periprocedural findings during re-do procedures.
– D.E. Pajitnev, T. Neumann, H. Greiss, N. Deubner, E. Akkaya, A. Berkowitsch, J. Sperzel, C.W. Hamm,
M. Kuniss (Offenbach am Main and Bad Nauheim, DE)
Left atrial size as the strongest predictor of mid-term outcome after ablation of atrial fibrillation using P4368
second-generation cryoballoon.
– E. Akkaya, A. Berkowitsch, H. Greiss, D. Pajitnev, N. Deubner, S. Zaltsberg, C.W. Hamm, T.H. Neumann,
M. Kuniss (Bad Nauheim, DE)
Long-term outcome and the mechanisms of pulmonary antrum radial-linear ablation in patients with P4369
paroxysmal atrial fibrillation.
– X. Zhao, Y.X. Zhu, J.Y. Zhang, D.N. Liao, J.Q. Hu, W.L. Lu, Y. Huang, Y.Z. Zhang, H. Gong, Z.G. Liu
(Shanghai, CN; Columbus, US)
Impact of left atrial epicardial adiposity on recurrence of atrial fibrillation after catheter ablation. P4370
– S.L. Zhang, Y. Sun, L.J. Gao, Y.L. Xia, Y.X. Dong, X.M. Yin, D. Chang, T. Cong, Y.Z. Yang, D.D. Miao
(Dalian, CN)
Impact of right atrial lines on eight-year rhythm outcome following bipolar radiofrequency maze. P4371
– F. Luca’, S. Gelsomino, C. Puntrello, P. Lozekoot, R. Lorusso, C. Rostagno, G.M. Francese, M.M. Gulizia,
M. La Meir, J.G. Maessen (Marsala, Florence and Catania, IT; Maastricht, NL; Brussels, BE)
Internet-based evaluation with the arrhythmia-specific questionnaire ASTA before and after treatment P4372
with catheter ablation for atrial fibrillation.
– U. Walfridsson, A. Jonsson, L. Karlsson, I. Liuba, K. Safstrom, H. Walfridsson (Linköping, SE)
ABLATION OF ATRIAL FIBRILLATION IV

Improved procedural efficiency using the new technology in cryotherapy for paroxysmal atrial fibrillation: P4373
a prospective randomized trial.
– Y. Gang, H. Gonna, G. Domenichini, M. Sampson, N.M.K. Aryan, M. Norman, Z. Zuberi, P. Dhillon,
E.R. Behr, M.M. Gallagher (London, UK)
Body mass index and recurrent atrial fibrillation following catheter ablation: a meta-analysis. P4374
– C.X. Wong, T. Sullivan, M.T. Sun, R. Mahajan, R.K. Pathak, M. Middeldorp, D. Twomey,
K.C. Roberts-Thomson, D.H. Lau, P. Sanders (Adelaide, AU)
Comparison of substrate ablation with or without anatomical ablation for atrial fibrillation: does P4375
pulmonary vein isolation prior to substrate ablation improve the outcome?
– A. Yoshimura, H. Ichiki, N. Oketani, Y. Iriki, H. Okui, R. Maenosono, F. Namino, M. Miyata, M. Ohishi
(Kagoshima, JP)
The impact of time delay after atrial fibrillation diagnosis and ablation on age-based 5-year outcomes P4376
after atrial fibrillation catheter ablation.
– T. Bunch, T.L. Bair, H.T. May, V. Jacobs, B.G. Crandall, M. Cutler, J.P. Weiss, C. Mallender, J.L. Anderson,
J.D. Day (Murray, US)
276
Plasma von Willebrand factor activity: a novel predictor of recurrence after catheter ablation for atrial P4377
fibrillation.
– Y. Wada, M. Wada, I. Nakajima, K. Ishibashi, K. Miyamoto, H. Okamura, T. Noda, T. Aiba, S. Kamakura,
K.F. Kusano (Osaka, JP)
Ablation of fibrillatory rotors and autonomic denervation in atrial fibrillation. P4378
– T. Zografos, T. Baykaner, J.A. Zaman, I. Pantos, D.E. Krummen, D.G. Katritsis, S.M. Narayan (Athens, GR;
San Diego, US; London, UK)
Monocyte toll- like receptor- 4 expression is associated with atrial fibrillation recurrence following P4379
cryoablation.
– K.M. Gurses, D. Kocyigit, M.U. Yalcin, H. Canpinar, H. Yorgun, L. Tokgozoglu, M.A. Oto, D. Guc, N. Ozer,
Adenosine in atrial firillation ablation: does it improve the outcome? P4380
– F. Moscoso Costa, D. Cavaco, P. Santos, P. Carmo, S. Carvalho, T. Teixeira, A. Soares, M. Marques,
L. Parreira, P. Adragao (Lisbon, PT)
Leptin levels are associated with atrial fibrillation recurrence after pulmonary vein isolation. P4381
– F. Soucek, N. Covassin, P. Singh, L. Ruzek, T. Kara, M. Suleiman, A. Lerman, P.A. Friedman, V.K. Somers
(Brno, CZ; Rochester, US)
Radiofrequency ablation of atrial fibrillation: comparison of success rate of circular ablation vs P4382
point-by-point ablation with contact force in paroxysmal and persistent atrial fibrillation.
– R. Rosso, Y.L. Levi, S.V. Viskin (Tel Aviv, IL)
Impact of reduced freezing times on mid-term outcome: a single center study evaluating an improved P4383
version of the cryoballoon in ablation of paroxysmal atrial fibrillation.
– G. Noelker, S. Molatta, F. Koch, B. Koerber, D. Horstkotte, K.J. Gutleben (Bad Oeynhausen, DE)
Impact of complex-fractionated atrial electrograms and low voltage areas on identification of atrial P4384
fibrillation sources.
– Y. Hama, Y. Matsudo, T. Kuwahara, N. Eguchi, Y. Fujimoto, M. Yamamoto, T. Himi (Kisarazu and
Yokosuka, JP)
ABLATION OF ATRIAL FIBRILLATION V

Circumferential pulmonary vein isolation in patients with atrial fibrillation: comparison of contact force P4385
versus pace ad ablate approach during ablation.
– A.S. Parwani, M. Huemer, A. Wutzler, P. Attanasio, F. Blaschke, B. Pieske, W. Haverkamp, L.H. Boldt
(Berlin, DE)
Percutaneous left appendage closure: a very low rate of perioperative complications during initial P4386
experience in a dedicated electrophysiology team.
– P. Defaye, H. Rekik, A. Martin, J.J. Ndjessan, F. Dugenet, P. Jacon (Grenoble, FR)
Visually guided laser ablation: a single centre long term experience. P4387
– L. Sediva, J. Petru, J. Skoda, M. Janotka, M. Chovanec, P. Neuzil (Prague, CZ)
Can left atrial fibrosis be non-invasively assessed by echocardiography - correlation with P4388
electroanatomical mapping in patients undergoing ablation for atrial fibrillation.
– E. Pilichowska, B. Zaborska, J. Baran, S. Stec, P. Kulakowski (Warsaw, PL)
Comparison of mid-term success rate between single-shot technologies for paroxysmal atrial fibrillation P4389
ablation.
– S. Conti, A. Dello Russo, G. Fassini, S. Riva, M. Moltrasio, F. Tundo, L. Cipolletta, G. Vettor, G. Del Giorno,
C. Tondo (Milan, IT)
Optimal ablation strategies in long standing persistent atrial fibrillation. P4390
– S.K. Haldar, D.G. Jones, T. Bahrami, A. Desouza, J. Jarman, S.K. Panikker, W. Hussain, T. Salukhe,
V. Markides, T. Wong (London, UK)
Spatial relationship of focal impulses, rotors and low voltage zones in patients with persistent atrial P4391
fibrillation.
– A. Schade, P. Halbfass, L. Costello-Boerrigter, P. Mueller, K. Nentwich, M. Roos, G.A. Szoelloesi,
F. Steinborn, H. Lapp, T. Deneke (Erfurt and Bad Neustadt an der Saale, DE)
Direct evidence of endo-epicardial dissociation of the atrial wall in patients with longstanding persistent P4392
atrial fibrillation.
– N.M.S. De Groot, L. Van Der Does, A. Yaksh, P. Knops, P. Vd Woestijne, C. Kik, A. Bogers, M.A. Allessie
(Rotterdam, NL)
Peri-operative atrial fibrillation (POAF) complicating non-cardiac surgery: a case-control pilot study. P4393
– J.B. Wenner, G.L. Bryson, C.J. Redpath (Ottawa, CA)
Less than two minutes, second generation cryoballoon applications achieves acute PVI in 78% without P4394
phrenic nerve palsy: preliminary results of the 1-2-3 study.
– M.M.D. Molenaar, M.F. Scholten, T. Hesselink, Y.J. Stevenhagen, J.M. Van Opstal (Enschede, NL)
Having sinus rhythm definitely pays off. PRAGUE-12 randomized study sub-analysis. P4395
– P. Budera, P. Osmancik, Z. Straka (Prague, CZ)
High incidence of low esophageal temperatures during second generation cryoballoon therapy for atrial P4396
fibrillation.
– M.M.D. Molenaar, M.F. Scholten, T. Hesselink, Y.J. Stevenhagen, J.M. Van Opstal (Enschede, NL)
277
ATRIAL FIBRILLATION AND ANTICOAGULATION

A simulated head to head comparison of stroke and major bleeding with apixaban versus rivaroxaban in P4397
high-risk NVAF Patients.
– K.J. Ishak, H. Phatak, M. Rael, T. Lanitis, M. Hoog, S. Kamble, C. Masseria (Montreal, CA; Princeton, San
Francisco and New York, US; London, UK)
Outcomes of rivaroxaban versus warfarin in women and men with nonvalvular atrial fibrillation: results P4398
from the ROCKET AF trial.
– B. Dixon, A.S. Hellkamp, Y. Lokhnygina, J.P. Piccini, S.D. Berkowitz, K.W. Mahaffey, R.C. Becker,
G. Breithardt, K.A.A. Fox, M.R. Patel (Durham, Whippany, Stanford and Cincinnati, US; Münster, DE;
Edinburgh, UK)
Predictive value of CHA2DS2-VASc score for thromboembolic events in non selected outpatients without P4399
– C. Mazzone, G. Barbati, C. Carriere, S. Poli, E. Grande, G. Russo, G. Cioffi, L. Tarantini, G. Sinagra, A. Di
Lenarda (Trieste, Trento and Belluno, IT)
Effect of rivaroxaban and warfarin on fibrin clot structure. P4400
– Y.C. Lau, Q. Xiong, A. Blann, G.Y.H. Lip (Birmingham, UK; Nanchang, CN)
Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical P4401
Practice Research Datalink.
– A.F. Macedo, J. Bell, C. Mc Carron, R. Conroy, J. Richardson, A. Scowcroft, T. Sunderland, N. Rotheram
(Bracknell and Berkshire, UK)
The patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants also need the P4402
transesophageal echocardiography for the prevention of systemic embolization.
– Y. Ito, M. Igarashi, A. Kimata, K. Yoshida, M. Misaki, K. Aonuma, N. Takeyasu (Ibaraki and Kasama, JP)
Importance of fluctuations of kidney function on non-vitamin K oral anticoagulant dosing adjustment in P4403
patients with atrial fibrillation and recent acute decompensated heart failure.
– J.M. Andreu Cayuelas, F.J. Pastor-Perez, C.M. Puche, A. Mateo-Martinez, A. Garcia-Alberola,
P.J. Flores-Blanco, F. Marin, M. Valdes, V. Roldan, S. Manzano-Fernandez (Murcia, ES)
Evolving antithrombotic treatment patterns in patients with newly diagnosed atrial fibrillation in P4404
GARFIELD-AF.
– A.J. Camm, G. Ambrosio, D. Atar, E. Berge, F. Cools, S.Z. Goldhaber, G. Kayani, Y. Koretsune,
A.G.G. Turpie, A.K. Kakkar (London, UK; Perugia, IT; Oslo, NO; Brasschaat, BE; Boston, US; Osaka, JP;
Hamilton, CA)
Anticoagulation and outcomes of dialysis patients with atrial fibrillation: 9-year cohort study. P4405
– T.K.M. Wang, J. Sathananthan, C. Hood, M. Marshall, A. Kerr (Auckland, NZ)
HAS-BLED versus ATRIA at predicting the risk of major bleeding in a real world cohort of patients with P4406
non-valvular atrial fibrillation on vitamin K antagonists.
– R. Riziq-Yousef Abumuaileq, E. Abu-Assi, S. Raposeiras-Roubin, A. Lopez-Lopez, N. Bouzas-Cruz,
M. Castiniera-Busto, V. Gonzalez-Salvado, R. Gonzalez-Ferreiro, C. Pena-Gil, J.R. Gonzalez-Juanatey
INFARCTION ACUTE PHASE STEMI

Adherence to performance measures and in-hospital outcomes for myocardial infarction in China: P4407
findings from China Acute Myocardial Infarction (CAMI) registry.
– J.G. Yang, Y.J. Yang, H.Y. Xu, X.R. Tang, W. Li, X.J. Gao, W. Zhao, S.L. Song, Y. Wang, Y. Sun (Beijing,
CN)
Lead aVR, the new armamentarium for culprit artery localization in acute inferior wall myocardial P4408
infarction; will it be the first point for artery localization?
– P. Kumar, S.K. Dwivedi, R.K. Saran, S. Chandra, V.S. Narain, R. Sethi, A. Pradhan, S. Saraf, G. Chaudhary,
A. Sharma (Lucknow, IN)
Acute phase Glycemic Variability by continuous glucose monitoring system (CGMS) is associated with P4409
endothelial dysfunction in patients with ST-Elevation Myocardial Infarction.
– T. Masahide, H. Hara, F. Hayashi, R. Iijima, K. Sugi, M. Nakmura (Tokyo, JP)
Pharmaco invasive strategy for ST elevation myocardial infarction (STEMI) is able to significantly reduce P4410
mortality with a low NNT in a very populated city.
– P.I.M. Moraes, D.G. Peternelli, A.R. Nunes, E.V.S. Santos, S. Reggi, J.M.A. Sousa, A.C. Moreno,
H. Soufen, C.M.R. Alves, A.C. Carvalho (São Paulo, BR)
Circulating corin concentrations are related to infarct size in patients after ST-segment elevation P4411
– H.-J. Feistritzer, G. Klug, S.J. Reinstadler, J. Mair, A. Mayr, G. Goebel, W.M. Franz, B. Metzler (Innsbruck,
AT)
Outcome in patients with STEMI undergoing interhospital transfer: similar baseline characteristics and P4412
outcome despite a longer treatment delay.
– P. Rubartelli, S. Bellotti, A. Iannone, D. Bartolini, V. Fontana (Genoa, IT)
Electrocardiographic findings leading to false ST elevation myocardial infarction activations at a P4413
percutaneous coronary intervention capable center.
– C. Dookhan, A. Ghatak, C. Mendoza, E. De Marchena, A. Ferreira (Miami, US)
An admission clinical index score for risk stratification of New-onset atrial fibrillation in STEMI patients P4414
undergoing primary PCI.
– A. Mazzone, M. Scalese, U. Paradossi, N. Botto, K. Chatzianagnostou, A. Taddei, S. Molinaro, R. De
Caterina, S. Berti (Massa, Pisa and Chieti, IT)
278
Patterns of coronary dominance and long-term prognosis in a contemporary cohort of patients with P4415
ST-elevation myocardial infarction.
– N. Bouzas Cruz, E. Abu Assi, S. Raposeiras Roubin, R. Ocaranza, A. Lopez Lopez, R. Gonzalez Ferreiro,
A. Redondo Dieguez, M. Castineira Busto, J.M. Garcia Acuna, J.R. Gonzalez Juanatey (Santiago de
Compostela, ES)
High-sensitivity troponin T for prediction of left ventricular function and infarct size one year following P4416
STEMI.
– S. Reinstadler, H.J. Feistritzer, G. Klug, J. Mair, A. Tu, A. Mayr, W.M. Franz, B. Metzler (Innsbruck, AT)
POST INFRACTION PERIOD I
Patterns of left ventricular remodeling during the first year after a reperfused myocardial infarction: a P4417
prospective MRI study.
– H. Delagarde, L. Biere, G. Clerfond, M. Audonnet, S. Willoteaux, F. Prunier, A. Furber (Angers, FR)
The association between adherence to the mediterranean diet and diabetes mellitus on the 10-year P4418
(2004-2014) acute coronary syndrome (ACS) prognosis; the Greecs study.
– D.B. Panagiotakos, V. Notara, M. Kouvari, M. Michalopoulou, Y. Kogias, P. Stravopodis, S. Zombolos,
I. Stergiouli, Y. Mantas, C. Pitsavos (Athens, Karditsa, Zakynthos, Kalamata and Chalkida, GR)
Is GRACE Score risk useful for predicting long term prognosis in NSTEMI patients with normal or P4419
near-normal coronary angiography?
– A. Redondo Dieguez, E. Emad Abu-Assi, R. Rocio Gonzalez Ferreiro, B. Belen Alvarez Alvarez, A. Adrian
Cid Menendez, A. Andrea Lopez Lopez, V. Violeta Gonzalez Salvado, D. Diego Iglesias Alvarez, S. Sergio
Raposeiras Roubin, J.R. Jose Ramon Gonzalez-Juanatey (Santiago de Compostela, ES)
Impact and cost effectiveness of stress imaging as gatekeeper to complete revascularisation in STEMI P4420
patients with moderate-severe bystander disease at primary percutaneous coronary intervention.
– A. Baritussio, A. Ghosh Dastidar, J. Rodrigues, E. McAlindon, D. Augustine, T. Johnson, J. Strange,
A. Nightingale, A. Baumbach, C. Bucciarelli-Ducci (Bristol, UK)
The personalized assessment of severity of st-segment elevation myocardial infarction: clinical P4421
application of genetic polymorphisms, associated with lipid disorders and hypertension.
– V. Kashtalap (Kemerovo, RU)
Glycosylated Apo J levels in acute myocardial infarction: implications in prognosis. P4422
– J. Cubedo, T. Padro, A. Sionis, J. Sans, L. Badimon (Barcelona, ES)
Influence of face cooling (diving reflex) on heart rate variability and double product in patients after P4423
– V. Stoickov, M. Deljanin Ilic, S. Ilic, M. Stoickov, I. Milovanovic, D. Petrovic, S. Saric, J. Cvetkovic, V. Mitic
(Nis̆ and Niska Banja, RS)
The influence of pre-hypertension on long-term major adverse cardiac events in patients with acute P4424
myocardial infarction and preserved left ventricular systolic function.
– H.W. Lee, T.J. Hong, J.H. Choi, B.W. Kim, J.S. Park, I.S. Han, J.H. Oh, J.H. Choi, H.C. Lee, K.S. Cha
(Busan, KR)
POST INFRACTION PERIOD II

Prognosis of patients with acute myocardial infarction after previous coronary artery bypass surgery; P4425
26-year experience of the POP study.
– P. Mitrovic, B. Stefanovic, M. Radovanovic, N. Radovanovic, G. Matic, D. Rajic, R. Lasica, A. Novakovic,
N. Mijic, Z. Vasiljevic (Belgrade, RS)
Clinical impact of left ventricular spontaneous echo contrast in patients with acute anterior wall P4426
– S. Lee, S.K. Song, J.Y. Yoon, L.Y. Jung, Y.S. Kim, S.R. Lee, K.S. Rhee, J.K. Chae, W.H. Kim, J.K. Ko
(Jeonju, KR)
Predictive value of plasma galectin-3 levels for in-hospital and long-term complications of patients with P4427
right ventricular myocardial infarction.
– T.A. Lozova, V. Tseluyko (Sumy and Kharkov, UA)
Clinical Impacts of High-Sensitivity C-Reactive Protein Reduction for Secondary Prevention in Asian P4428
Patients with One-year Survivor after Acute Myocardial Infarction.
– H.K. Kim, H.J. Park, S.S. Kim, M.H. Jeong, H.S. Kim, J.K. Chae (Gwangju, Seoul and Jeonju, KR)
Long term prognostic value of worsening renal function and uric acid in-hospital changes in patients with P4429
– G. Lazaros, D. Tsiachris, C. Tsioufis, C. Vlachopoulos, C. Chrysohoou, G. Georgiopoulos, A. Kordalis,
The role of unprocessed meat consumption on the 10-year (2004-2014) acute coronary syndrome (ACS) P4430
prognosis.
– D.B. Panagiotakos, V. Notara, M. Kouvari, D. Tzanoglou, Y. Kogias, P. Stravopodis, G. Papanagnou,
S. Zombolos, Y. Mantas, C. Pitsavos (Athens, Karditsa, Zakynthos, Lamia, Kalamata and Chalkida, GR)
The long-term prognosis of patients diagnosed as type 2 myocardial infarction does not differ from that P4431
of patients with myocardial injury.
– L. Sarkisian, L. Saaby, T.S. Poulsen, A.C.P. Diederichsen, N. Jangaard, O. Gerke, M. Nybo, S. Hosbond,
K. Thygesen, H. Mickley (Odense and Aarhus, DK)
Spot urine albumin to creatinine ratio outperforms novel acute kidney injury biomarkers in patients with P4432
– G. Chalikias, D. Kareli, C. Tsigalou, P. Kikas, D. Makrygiannis, S. Chatzikyriakou, G. Kampouromiti,
D. Symeonidis, S. Konstantinides, D. Tziakas (Alexandroupolis, Kavala and Athens, GR)
279
Statin non-prescribtion at discharge and long-term mortality in patients with ST-elevation myocardial P4433
infarction undergoing primary percutaneous coronary interventions.
– Z. Mehmedbegovic, M. Zivkovic, V. Dedovic, D. Milasinovic, M. Tesic, V. Pavlovic, I. Zivkovic, D. Orlic,
Strong predictive value of left ventricular global longitudinal strain on mortality and heart failure P4434
admissions following ST segment myocardial infarction.
– P. Pinto-Teixeira, P. Rio, L. Branco, A. Galrinho, G. Portugal, A. Monteiro, L. Ferreira, J. Abreu, A. Timoteo,
R. Ferreira (Lisbon, PT)
CPR CARDIOPULMONARY RESUSCITATION

Improved survival after out-of-hospital cardiac arrest most substantial in younger patients - results from P4435
a statewide quality improvement initiative in North Carolina during 2010-2013.
– K. Kragholm, C.M. Hansen, D.A. Pearson, C. Tyson, L. Monk, D. Nelson, M. Dupre, J. Jollis, B. McNally,
C. Granger (Durham, Charlotte, Winston-Salem and Atlanta, US)
CPR quality in out-of-hospital cardiac arrest patients treated with basic- versus advances life support P4436
with and without mechanical chest compressions.
– T. Tranberg, J.F. Lassen, A.K. Kaltoft, T.M. Hansen, C. Stengaard, L. Knudsen, L. Rognaas, S. Trautner,
C.J. Terkelsen (Aarhus and Copenhagen, DK)
Does hyperglycaemia predict the prognosis in patients after cardiac arrest? The higher the glucose level, P4437
the worsen the outcome?
– E. Kagawa, K. Dote, M. Kato, S. Sasaki, N. Oda, Y. Nakano, Y. Kihara (Hiroshima, JP)
Out-of-hospital cardiac arrest with no obvious extra cardiac cause: impact of coronary angiogram on P4438
early survival.
– V. Maurin, C. Saint-Andre, W. Picard, E. Gerbaud, L. Leroux, P. Dos Santos, P. Coste (Bordeaux-Pessac
and Pau, FR)
Using of LUCAS II device for CPR by regional no-urban Medical Emergency Service. P4439
– J. Karasek, R. Polasek, A. Rechova, F. Klein, J. Polach, P. Ostadal (Liberec and Prague, CZ)
Vitamin D deficiency is associated with severe shock in patients with sudden cardiac arrest. P4440
– J. Wi, J.S. Uhm, H.N. Pak, M.H. Lee, B. Joung (Seoul, KR)
Deoxyribonucleic acid damage in humans successfully resuscitated from cardiac arrest. P4441
– R. Hazukova, J. Koci, M. Rezacova, E. Cermakova, I. McColl, M. Pleskot (Hradec Králové, CZ)
POST INFARCTION PERIOD III

Results of stem cell therapy in anterior STEMI patients with severe systolic disfunction. Pilot study. P4442
Romanian experience.
– N. Oprescu, M. Micheu, A. Scarlatescu, D. Pitic, L. Calmac, M. Dorobantu (Bucharest, RO)
Could pulmonary hemodynamic impact diffusion lung capacity in patients with ST elevation myocardial P4443
infarction?
– S. Altarev, M. Katsyuba, O. Polikutina, Y. Slepynina, V. Karetnikova (Kemerovo, RU)
Renal dysfunction strongly predicts adverse short and long term survival in patients undergoing P4444
reperfusion for STEMI.
– R.S. Wright, G.S. Sandhu, J.H. Herrmann, G.B. Barsness, J.H. Holmen, R.L. Lennon, J.G.M. Murphy
(Rochester, US)
In hospital mortality for prehospital STEMI patients directly admitted to cath-lab beyond 120 min. P4445
– L. Rebillard, N. Danchin, A. Loyeau, L. Lamhaut, J.-M. Juliard, S. Bataille, F. Lapostolle, Y. Lambert (Melun,
Paris, Bobigny and Versailles, FR)
Infarct size assessment after spontaneous, guide wire or angioplasty induced reperfusion in acute P4446
– B. Lattuca, A. Micheau, F. Roubille, G. Cayla, N. Nagot, E. Nogue, J.C. Macia, T.T. Cung, R. Gervasoni,
F. Leclercq (Montpellier and Nîmes, FR)
The Zwolle risk score as a guide to early discharge. P4447
– A.M. Fawzy, S. George, P. Calvert, P.F. Ludman, S.N. Doshi, J.N. Townend, S.Q. Khan (Birmingham, UK)
The role of myeloperoxidase and monocyte chemoattractant protein-1 in the improvement of left P4448
ventricular function after ST-segment elevation myocardial infarction.
– K. Kupczynska, B.W. Michalski, M. Krzeminska-Pakula, E. Szymczyk, L. Peczek, P. Lipiec, J.D. Kasprzak
(Lodz, PL)
Prediction of mortality by strain echocardiography compared to CMR. P4449
– M.-M. Becker, S. Hamada, J. Schroeder, R. Hoffmann, T. Rubeau, E. Altiok, C. Lente, N. Marx (Aachen
and Lingen, DE)
Gender differences on the 10 year (2004-2014) acute coronary syndrome (ACS) incidence rates, among P4450
cardiac patients: a classification analysis.
– D.B. Panagiotakos, V. Notara, E. Papataxiarchis, E. Tsompanaki, Y. Kogias, P. Stravopodis,
G. Papanagnou, S. Zombolos, Y. Mantas, C. Pitsavos (Athens, Karditsa, Zakynthos, Lamia, Kalamata and
Chalkida, GR)
Impact of proportion of rapid eye movement sleep on all-cause mortality and stroke in patients with P4451
– H. Nakashima, S. Kaibara, M. Kurobe, K. Minami, S. Furudono, Y. Uchida, T. Nunohiro, S. Takeshita,
K. Maemura (Nagasaki, JP)
Influence of music therapy in patients with early post-infarction angina. P4452
– P. Mitrovic, B. Stefanovic, A. Paladin, M. Radovanovic, N. Radovanovic, G. Matic, D. Rajic, R. Lasica,
A. Novakovic, Z. Vasiljevic (Belgrade, RS)
280
Effects of chronic beta-blocker treatment on admission haemodynamics in STEMI patients treated with P4453
Primary Angioplasty.
– V. Roolvink, V. Hemradj, J.P. Ottervanger, A.W.J. Hof Van ’T, J.H.E. Dambrink, M. Gosselink, E. Kedhi,
H. Suryapranata (Zwolle, NL)
ACUTE CARDIAC CARE IN THE EMERGENCY DEPARTMENT

Direct comparison of the safety and efficacy of two rule-out strategies for acute myocardial P4454
infarction:2h-algorithm versus combination of 1h-algorithm and undetectable levels at presentation.
– M. Rubini Gimenez, R. Twerenbold, K. Wildi, C. Puelacher, S. Osswald, C. Mueller (Basel, CH; Bad
Krozingen, DE)
Can we utilize pharmaco invasive strategy in patients with chest pain needle time over 3 hours? P4455
– E. Jesus, G.M. Ferreira, D.G. Peternelli, P.I.M. Moraes, A.H.P. Barbosa, I.G. Jr, J.M.A. Sousa,
C.M.R. Alves, A.C.C. Carvalho (São Paulo, BR)
Troponin T elevation in acute aortic syndromes: frequency and impact on diagnostic delay and P4456
misdiagnosis.
– F. Vagnarelli, A. Corsini, M. Lorenzini, S. Soflai Sohee, M.L. Bacchi Reggiani, G. Norscini, L. Cinti,
G. Melandri, G. Ambrosio, C. Rapezzi (Bologna and Perugia, IT)
Combined cardiac and lung ultrasound protocol for differential diagnosis of acute dyspnea in the P4457
emergency department.
– J. Oehman, V.P. Harjola, J.O. Lassus, V.P. Karjalainen (Pori and Helsinki, FI)
Risk stratification in patients with acute chest pain with normal high-sensitivity cardiac troponin levels P4458
and need for downstream testing.
– M.W. Smulders, S.C.A.M. Bekkers, A. Liefhebber, J. Vervuurt, M.P. Van Dieijen-Visser, A.M.A. Mingels,
H.P. Brunner-La Rocca, P.C. Dagnelie, H.J.G.M. Crijns, B.L.J.H. Kietselaer (Maastricht, NL)
combination of copeptin and hs-cTn versus undetectable levels of hs-cTn and 1h-algorithm.
– K.S. Wildi, R. Twerenbold, M. Rubin Gimenez, T. Reichlin, T. Nestelberger, M. Wagener, S. Osswald,
C. Mueller (Basel, CH)
Differential diagnosis at admission between tako-tsubo cardiomyopathy and acute apical-anterior P4460
myocardial infarction in postmenopausal women.
– A. Zorzi, A. Baritussio, M. Elmaghawry, M. Siciliano, F. Migliore, M. Perazzolo Marra, S. Iliceto, D. Corrado
(Padua, IT)
High-sensitivity cardiac troponin on presentation to rule out acute myocardial infarction. P4461
– A.S. Shah, A. Anand, K.K. Lee, P. Adamson, A. Chapman, T. Langdon, F. Strachan, D. McAllister,
D.E. Newby, N.L. Mills (Edinburgh, UK)
Myocardial deformation by strain echocardiography identify patients with acute coronary syndrome and P4462
non-diagnostic ecg presenting in a chest pain unit.
– M.-M. Becker, J. Schroeder, S. Hamada, T. Rubeau, E. Altiok, C. Lente, N. Marx (Aachen, DE)
The ability of five established risk scores, used in conjunction with two high-sensitivity troponin assays, P4463
to identify chest pain patients suitable for early discharge after a single blood draw.
– E. Carlton, K. Greaves (Bristol, UK; Sunshine Coast, AU)
CAD AND COMORBIDITIES
Hybrid coronary revascularization in 100 patients with multivessel disease: what can we expect? P4464
– J.C. Duarte Rodrigues, M. Vasconcelos, R. Rodrigues, M.J. Amorim, M. Campelo, J.C. Silva, P. Pinho,
M.J. Maciel (Porto, PT)
The impact of risk factors on predicting significant stenosis in the presence and absence of coronary P4465
calcification: results from the Euro-CCAD study.
– R. Nicoll, H. Mickley, K. Overhus, A. Diederichsen, P. Gueret, F. Cademartini, A. Schmermund,
P. Zamorano, M. Budoff, M.Y. Henein (Umeå, SE; Odense, DK; Créteil, FR; Florence, IT; Frankfurt am Main,
DE; Madrid, ES; CITY MISSING, US)
Prognostic impact of contrast volume on the basis of renal function and CHA2DS2-VASc score in patients P4466
– D. Abe, A. Sato, K. Tateishi, T. Harunari, M. Kaneko, N. Kuroki, T. Yuba, K. Suzuki, T. Iwama, K. Aonuma
(Tokyo and Tsukuba, JP)
Risk stratification using the CHADS2 score in patients with coronary heart disease undergoing P4467
– H. Hioki, T. Miura, Y. Miyashita, H. Motoki, K. Shimada, M. Kobayashi, H. Kimura, E. Mawatari, S. Ebisawa,
U. Ikeda (Matsumoto, Nagano and Saku, JP)
Predictors of longterm outcomes in spontaneous coronary artery dissection. P4468
– L.L. Gheorghe, S.J. Camacho Freire, J. Roa Garrido, A.E. Gomez Menchero, R. Cardenal Piris,
A.M. Ramzy, M. Sancho Jaldon, G. Calle Perez, R. Del Pozo Contreras, J.F. Diaz Fernandez (Cadiz and
Huelva, ES; Benha, EG)
Lower burden of coronary disease in treated patients with HIV. A retrospective single centre study. P4469
– E.J. O’Dwyer, P. Bhamra-Ariza, S. Rao, S. Emmanuel, C.J. Holloway (Sydney, AU)
Novel association factor in spontaneous coronary artery dissection and recurrences. P4470
– S.J. Camacho Freire, L. Gheorghe, A.E. Gomez Menchero, J. Roa Garrido, R. Cardenal Piris, J. Morgado
Polavieja, A.M. Ramzy, A. Lopez Suarez, M. Sancho Jaldon, J.F. Diaz Fernandez (Huelva and Cadiz, ES;
Benha, EG)
281
Clinical characteristics and outcomes of acute myocardial infarction in young Korean adults. P4471
– S.H. Lee, J.H. Kim, M.H. Jeong, H. Park, H.K. Kim, D.S. Sim, Y.J. Hong, Y. Ahn, J.G. Cho, J.C. Park
(Gwangju, KR)
Clinical impact of beta-blocker on long-term clinical outcomes in patients with coronary chronic total P4472
occlusion.
– J.K. Hwang, J.H. Yang, S.H. Choi, Y.B. Song, J.Y. Hahn, J.H. Choi, S.H. Lee, H.C. Gwon (Seoul, KR)
High triglycerides, low HDL cholesterol and a low LDL cholesterol per apolipoprotein B ratio predict P4473
incident diabetes in patients with established coronary artery disease.
– C.H. Saely, P. Rein, A. Vonbank, D. Zanolin, G. Naerr, A. Leiherer, A. Muendlein, H. Drexel (Feldkirch, AT;
Triesen, LI; Philadelphia, US)
Impact of diabetes on 2-year clinical outcomes in patients with acute myocardial infarction: Korean P4474
registry of DIAMOND (diabetic acute myocardial infarction disease).
– I.C. Kim, S.H. Hur, Y.K. Cho, H.J. Yoon, C.W. Nam, J.W. Bae, W. Jang, K.B. Kim, H.S. Kim (Daegu,
Cheongju and Seoul, KR)
Middle Eastern patients undergoing percutaneous coronary intervention: factors that impact in-hospital P4475
and one year outcome. Results from the first Jordanian PCI Registry (JoPCR 1).
– I. Alhaddad, A. Hammoudeh, E. Al Mousa, M. Jarrah, A. Saleh, Z. Qaqa, H. Janabi, H. Kharabsheh,
L. Hazaimeh, Y. Khader (Amman and Irbid, JO)
New onset diabetes mellitus at mid-term follow-up after acute myocardial infarction is related to P4476
increased prevalence of decreased renal function.
– J. Kowalczyk, P. Francuz, K. Przybylska, M. Koziel, J. Obrebska, E. Jedrzejczyk-Patej, T. Podolecki,
R. Lenarczyk, B. Sredniawa, Z. Kalarus (Zabrze, PL)
Temporal trends in clinical features and outcomes in the elderly following percutaneous coronary P4477
intervention.
– R. Naito, K. Miyauchi, H. Konishi, S. Tsuboi, M. Ogita, T. Kasai, H. Tamura, S. Okazaki, K. Isoda, H. Daida
(Tokyo, JP)
CLINICAL ADVANCES IN COMPUTED TOMOGRAPHY ANGIOGRAPHY

Circulating monocytes are strongly associated with coronary artery calcification (CAC) density in a P4478
population of asymptomatic subjects.
– A. Mazzone, S. Sbrana, A. Clemente, D. Della Latta, A. Ripoli, S. Storti, N. Botto, C. Susini, S. Berti (Massa
and Pisa, IT)
Coronary CT angiography in patients with a zero agatston score: results from the German cardiac CT P4479
registry.
– M. Marwan, S. Achenbach, S. Schneider, A. Schmermund, G. Korosoglou, J. Hausleiter, S. Schroeder,
T. Limbourg, A. Leber, O. Buder (Erlangen, Ludwigshafen am Rhein, Frankfurt am Main, Heidelberg,
Munich, Tübingen and Essen, DE)
Machine learning applied to clinical and coronary CT angiography variables for prediction of MACE. P4480
– M. Motwani, P. Slomka, D.S. Berman, J.K. Min (Los Angeles and New York, US)
Long-term prognostic performance of low-dose 64-slice coronary CT angiography with prospective ecg P4481
triggering.
– O. Clerc, B. Kaufmann, M. Possner, R. Liga, J. Vontobel, F. Mikulicic, C. Graeni, D. Benz, P. Kaufmann,
R. Buechel (Zurich, CH)
Relation between quantitative coronary CTA and myocardial ischemia by adenosine stress CT myocardial P4482
perfusion.
– A. Van Rosendael, L.J. Kroft, M.A. De Graaf, A. Broersen, J.J. Bax, A.J. Scholte (Leiden, NL)
Diagnostic accuracy of first-pass myocardial perfusion imaging without stress in comparison with P4483
invasive FFR.
– K. Osawa, T. Miyoshi, S. Fujii, K. Yamauchi, Y. Ootsuka, A. Kurozumi, Y. Koyama, M. Tachibana,
K. Nakamura, H. Ito (Okayama and Osaka, JP)
Carotid plaque predicts severity of coronary atherosclerosis in asymptomatic diabetics: a prospective P4484
study.
– A. Jeevarethinam, S. Venuraju, S. Ruano, A. Dumo, M. Rosenthal, D. Nair, M. Cohen, D. Darko, R. Rakhit,
A. Lahiri (London, UK)
Duration of diabetes is a major determinant of optimal time to initiate cardiovascular screening in P4485
asymptomatic type-2 diabetic subjects: results from the proceed study.
– S. Venuraju, A. Jeevarethinam, D. Darko, M. Rosenthal, M. Cohen, D. Nair, A. Lahiri, R. Rakhit (London, UK)
The number of circulating CD34 positive cell is an independent predictor of the annual progression of P4486
coronary calcium score determined by MDCT: Results from the PEACH trial.
– M. Tachibana, T. Miyoshi, K. Nakamura, K. Kohno, Y. Koyama, H. Asonuma, S. Sakuragi, M. Doi,
N. Yamada, H. Ito (Okayama, Osaka, Kasaoka, Iwakuni, Takamatsu and Ibara, JP)
Non-invasive assessment of coronary everolimus-eluting bioresorbable vascular scaffolds using multi P4487
detector-computed tomography - comparison to invasive coronary angiography.
– F.K. Schneck, M. Renker, A. Rolf, H.M. Nef, O. Doerr, T. Bauer, H. Moellmann, C. Liebetrau, C.W. Hamm,
J. Rixe (Giessen and Bad Nauheim, DE)
TECHNICAL DEVELOPMENTS IN COMPUTED TOMOGRAPHY ANGIOGRAPHY

Bail out intravenous esmolol for heart rate control in cardiac computed tomography angiography. P4488
– S. Aguiar Rosa, R. Ramos, H. Marques, R. Santos, C. Leal, T. Pereira Silva, H. Casado, M. Saraiva,
L. Figueiredo, R. Cruz Ferreira (Lisbon, PT)
282
Ethnicity and coronary artery calcification: normal reference range for different ethnic groups. P4489
– S. Sze, K.Y.K. Wong, G. Koulaouzidis, J. Zhang, P. Lynas, T. McArthur, M. Tighe, P.J. Jenkins (Hull, UK)
Coronary artery calcium quantification in the optimization of a comprehensive cardiac CT protocol for the P4490
diagnosis of hemodynamically significant coronary artery disease.
– R. Ladeiras-Lopes, N. Bettencourt, N. Ferreira, F. Sampaio, G. Pires-Morais, L. Santos, B. Melica,
A. Rodrigues, P. Braga, V. Gama (Vila Nova de Gaia, PT)
Predictive value of coronary artery lumen area quantification for hemodynamically relevant coronary P4491
stenoses by computed tomography angiography.
– F. Plank, G. Friedrich, W. Dichtl, M. Kummann, A. Klauser, W. Jaschke, G. Feuchtner (Innsbruck, AT)
Impact of calcium distribution for predicting successful revascularization of chronic total occlusion: P4492
assessed by multi-detector computed tomography.
– S. Mori, T. Muramatsu, R. Tsukahara, Y. Ito, T. Sakai, K. Hirano, M. Nakano, M. Yamawaki, M. Araki,
N. Kobayashi (Yokohama, JP)
Lesion-specific myocardial mass: a new index for diagnosis and treatment of coronary artery disease. P4493
– H.Y. Kim, E.K. Kim, S.J. Park, J.O. Choi, S.C. Lee, J.K. Oh, S.W. Park, Y.H. Choe, S.A. Chang, J.H. Choi
(Seoul, KR; Rochester, US)
Feasibility of coronary computed tomography angiography using automated attenuation-based selections P4494
of tube parameters in low radiation dose turbo flash mode in third generation 192-slice dual-source.
– U. Speiser, M. Campan, S. Quick, D. Danowski, I. Platzek, M. Laniado, R.H. Strasser (Dresden, DE)
Epicardial fat density evaluated with MDCT is associated with cardio-metabolic risk factors. P4495
– M. Tachibana, T. Miyoshi, K. Tokioka, K. Nakamura, T. Masai, Y. Koyama, K. Ohsawa, H. Morita, H. Ito
(Okayama and Osaka, JP)
Improved visualization of the coronary arteries using model-based iterative reconstruction for cardiac CT. P4496
– M. Karolyi, B. Szilveszter, A.L. Jermendy, A. Panajotu, A. Bartykowszki, C. Celeng, R. Raaijmakers,
W. Giepmans, B. Merkely, P. Maurovich-Horvat (Budapest, HU; Best, NL)
COMPUTED TOMOGRAPHY USE IN STRUCTURAL HEART DISEASE

Left atrial antral wall thickness around pulmonary veins is associated with stroke and the reconnection of P4497
pulmonary venous potential after catheter ablation on atrial fibrillation.
– J. Park, C.H. Park, J.S. Uhm, H.J. Lee, J.Y. Kim, H.N. Pak, M.H. Lee, Y.J. Kim, B.Y. Joung (Seoul, KR)
Paced QRS morphology is closely correlated with the right ventricular pacing lead position: a study by P4498
cardiac computed tomography.
– A. Sunaga, M. Masuda, T. Kanda, Y. Matsuda, M. Fujita, O. Iida, S. Okamoto, T. Isihara, K. Nanto,
Assessment of the coronary sinus vein with multi-detector computed tomography angiography - P4499
implications for mitral valve reshaping in patients with functional mitral valve regurgitation.
– J. Rixe, M. Renker, F.K. Schneck, A. Rolf, H. Moellmann, T. Bauer, O. Doerr, C. Liebetrau, C.W. Hamm,
H.M. Nef (Giessen and Bad Nauheim, DE)
Computed tomography angiography compared to transesophageal echocardiography for assessing mitral P4500
valve parameters prior to percutaneous edge-to-edge mitral valve repair.
– M. Renker, J. Rixe, F. Schneck, S. Moellmann, C. Walther, A. Rolf, O. Doerr, H. Nef, C. Hamm,
H. Moellmann (Giessen and Bad Nauheim, DE)
Detection of right ventricular myocardial fibrosis using quantitative CT attenuation of the right ventricular P4501
myocardium in the late phase on 320 slice CT in subjects with pulmonary hypertension.
– K. Ozawa, N. Funabashi, H. Takaoka, N. Tanabe, K. Tatsumi, Y. Kobayashi (Chiba, JP)
Aortic valve orientation and root angles are associated with aortic dilatation pattern and acute aortic P4502
event risk.
– A.A. Hardikar, A. Iannaccone, T.H. Marwick (Hobart, AU)
Novel Cardiac Fusion Imaging with Multi-detector Computed Tomography and Doppler Echocardiography P4503
In the assessment of Adult Congenital Heart Disease: Integrated anatomical and functional multi-modali.
– N. Watanabe, H. Oe, T. Miyoshi, K. Osawa, H. Sakamoto, Y. Ohno, M. Tachibana, Y. Takaya, T. Akagi,
Left atrial appendage sizing for percutaneous occlusion with amplatzer cardiac plug: a multumodality P4504
imaging approach.
– X. Iriart, W. Selmi, Z. Jalal, J.B. Thambo (Bordeaux-Pessac, FR)
A novel mechanism to explain the discrepancy between anatomical aortic valve area and haemodynamic P4505
echocardiographic parameters, a pilot computational flow dynamics study.
– T.K. Mittal, S. Bozikis, L. Reichmuth, A. Baltabaeva, S. Rahman Haley, M. Dalby, Q. Long (London, UK)
COMPUTED TOMOGRAPHY ANGIOGRAPHY IN CLINICAL USE

Usefulness of myocardial imaging by 64 multidetector-row computed tomography using stress test to P4506
assess myocardial ischemia and stenotic coronary artery.
– T. Okimoto, N. Shiode, Y. Masaoka, M. Otsuka, M. Tamekiyo, T. Kawase, K. Yamane, Y. Kagawa,
Y. Hayashi (Hiroshima, JP)
Clinical utility of stress dynamic myocardial perfusion imaging using 256-slice computed tomography P4507
detecting myocardial ischemia: comparison with echocardiographic assessment of coronary flow
reserve.
– T. Kono, T. Uetani, K. Nishimura, K. Inoue, J. Suzuki, T. Kido, T. Okura, T. Mochizuki, J. Higaki, A. Ogimoto
(Toon, JP)
283
First real-world clinical experience with non-invasive fractional flow reserve derived from coronary P4508
computed tomography angiography.
– S. Gaur, J.M. Jensen, H.E. Boetker, L.C. Gormsen, E.H. Christiansen, A.K. Kaltoft, J.F. Lassen,
B.L. Norgaard (Aarhus, DK)
Appropriate and inappropriate use of cardiac computed tomography in a large volume centre. P4509
– A.M. Ferreira, P. Goncalves, L. Marta, A. Tralhao, S. Madeira, F.P. Machado, N. Cardim, H. Marques
(Lisbon, PT)
Coronary CT angiography in patients with low-risk acute chest pain: quantitative analysis of plaque P4510
parameters.
– M. Hell, A. Schuhbaeck, G. Muschiol, D. Dey, M. Marwan, S. Achenbach (Erlangen, DE; Los Angeles, US)
Impact of coronary plaque characteristics assessed by 320-detector row computed tomography on P4511
myocardial injury associated with percutaneous coronary intervention for chronic total occlusion.
– E. Usui, T. Niida, J. Matsuda, Y. Kanaji, T. Murai, T. Lee, T. Kakuta, Y. Iesaka (Tsuchiura, JP)
Significance of epicardial adipose tissue thickness ratio as a predictor for coronary plaque vulnerability P4512
measured by multidetector computed tomography.
– R. Okubo, T. Yabe, I. Watanabe, D. Saitoh, H. Amano, M. Toda, T. Ikeda, M. Harada (Tokyo and Takasaki,
JP)
Role of coronary artery calcium scoring in detection of coronary artery disease according to framingham P4513
risk score in populations with low to intermediate risks.
– W.-J. Kim, Y.-M. Lim, S.-W. Lim, I.-J. Kim, D.-H. Cha, W.-I. Yang, S.-H. Kim, S.-Y. Cho, J.-Y. Moon, D. Min
(Seongnam and Gyeonggi-do, KR)
Noninvasive prediction of functional significance of coronary artery stenosis by coronary computed P4514
tomography measurements.
– M. Mizusawa, S. Kimura, Y. Yamakami, K. Kojima, Y. Sagawa, H. Otani, K. Hishikari, T. Sugiyama,
H. Hikita, A. Takahashi (Yokosuka, JP)
EXCITATION-CONTRACTION COUPLING AND CONTRACTILE REMODELLING

Rosuvastatin attenuates the tgf-beta1-induced proliferation and differentiation of cardiac fibroblast P4515
through RUNX3 activation.
– J.Y. Qian, D.Y. Ren, J.F. Xu, Y.Y. Chen, P. Yu, M.Q. Fu, Y.N. Song, Y. Lou, J.B. Ge (Shanghai, CN)
Mitochondria play an important role in the regulation of the nuclear Ca concentration. P4516
– L.K. Seidlmayer, A. Leucht, A. Berbner, O. Ritter (Würzburg, DE)
The role of nitric oxide synthase (NOS) and its essential cofactor tetrahydrobiopterin (BH4) in diabetic P4517
cardiomyopathy.
– D. Duglan, R.C. Carnicer, J.N. Simon, A. Recalde, S. Chuaiphichai, A. Hale, H. Whittington, C. Lygate,
K.M. Channon, B. Casadei (Oxford, UK)
BMP7 ameliorate cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition in viral P4518
cardiomyopathy.
– Y. Xie, Y. Yu, M.H. Li, R.Z. Chen (Shanghai, CN)
Human cardiac fibroblasts increase SR-dependency of induced pluripotent stem cell-derived P4519
cardiomyocyte calcium handling by manipulating SR uptake and SERCA2a expression via direct physical
contact.
– C. Kane, P. Dias, J. Gorelik, C. M.N. Terracciano (London, UK)
ISCHAEMIA AND PROTECTION

Reparative fibrosis is impeded in MK5 deficient mice following myocardial infarction. P4520
– S.A. Nawaito, P. Pouliot, M.-E. Clavet-Lanthier, Y. Shi, M.A. Gillis, M. Gaestel, F. Lesage, J.C. Tardif,
B.G. Allen (Montreal, CA; Hannover, DE)
VCP746: a cardioprotective adenosine receptor agonist with minimal haemodynamic effects. P4521
– C.H. Chuo, L.T. May, P. Scammells, B.H. Wang, H. Krum, A.R. Kompa, P.J. White (Melbourne, AU)
Effect of remote ischemic preconditioning on platelet activation and reactivity induced by percutaneous P4522
– A. Stazi, F. Torrini, M. Laurito, M. Milo, G. Russo, A. Villano, L. Barone, D. Flego, G.A. Lanza, F. Crea
(Rome, IT)
Cardioprotective effects of dipeptidyl peptidase-4 (DPP-4) inhibitors independently of DPP-4. P4523
– T. Yamaguchi, I. Yasukatsu, T. Yamazaki, Y. Nakamura, K. Shimada, M. Yoshiyama, H. Iwao (Osaka, Sakai,
Izumi and Habikino, JP)
High-density lipoproteins increase myocardial salvage and attenuate microvascular obstruction by P4524
modulating toll-like receptor innate immune signaling.
– G. Vilahur, M. Gutierrez, L. Casani, J. Cubedo, A. Capdevila, G. Pons-Llado, F. Carreras, A. Hidalgo,
L. Badimon (Barcelona, ES)
Calpastatin Overexpression Impairs Post-infarct Scar Healing in Mice by Compromising Reparative P4525
Immune Cell Recruitment and Activation.
– F. Wan, E. Letavernier, C. Le Saux, L. Baud, A. Houssaini, E. Marcos, J.-L. Dubois-Rande, S. Adnot,
G. Derumeaux, B. Gellen (Créteil and Paris, FR; San antonio, US)
Cardioprotective effect of cgmp induction by sgc activator, bay60-2770, in ischemia-reperfusion injured P4526
rat heart.
– W. Kim, K.H. Lee, J.H. Cho, J.Y. Rhew, J.S. Woo (Seoul, Suncheon and Jeonju, KR)
Cardioprotective effects of inorganic phosphate in an ischemia-reperfusion model. P4527
– F.J. Roldan, N. Pavon, I. Rojas, S. Tejeida, J. Rodriguez-Zavala, E. Chavez, J. Vargas-Barron (Mexico City,
MX)
284
Urocortin-1 preserve XIAP and CD40-ligand to reduce ischemia/reperfusion-induced cardiac myocyte P4528
apoptosis via the activation of ERK1/2 through EPAC.
– T. Smani, I. Diaz, E. Calderon-Snachez, A. Ordonez (Sevilla, ES)
The damaging nature of extracellular RNA in cardiac ischemia/reperfusion injury: prevention of P4529
cardiomyocyte death and heart failure by RNase1.
– H.A. Cabrera-Fuentes, M. Ruiz-Meana, S. Kostin, A. Boening, S. Lecour, E.A. Liehn, D.J. Hausenloy,
D. Garcia-Dorado, K.D. Schlueter, K.T. Preissner (Giessen, Bad Nauheim and Aachen, DE; Barcelona, ES;
Cape Town, ZA; London, UK)
Physical exercise exerts beneficial effects on walking capacity and polarization state of circulating P4530
monocytes and muscular macrophages in a mouse model of intermittent claudication.
– M. Pellegrin, M. Mayer, K. Bouzourene, J.-F. Aubert, L. Mazzolai (Lausanne, CH)
METABOLISM AND METABOLIC SYNDROMES

NADPH oxidase 4 promotes adaptive cardiac remodelling through enhancing fatty acid oxidation in the P4531
murine heart.
– A. Nabeebaccus, A. Hafstad, A. Zoccarato, T. Eykyn, X. Yin, A. Brewer, M. Zhang, E. Aasum, M. Mayr,
A.M. Shah (London, UK; Tromsø, NO)
Cystatin C is not causally associated with diabetes or the metabolic syndrome. P4532
– M. Magnusson, J. Molvin, G. Engstrom, M. Persson, P. Nilsson, A. Christensson, O. Melander (Malmö and
Lund, SE)
Platelet to lymphocyte ratio as a novel indicator of inflammation is associated with the presence and P4533
severity of metabolic syndrome.
– M. Akboga, U. Canpolat, M. Yuksel, C. Yayla, O. Turak, O. Ozeke, S. Topaloglu, D. Aras (Ankara and
Diyarbakir, TR)
Increased serum YKL-40 is a novel marker of metabolic syndrome in adult patients. P4534
– M. Akboga, R. Yalcin, A. Sahinarslan, C. Demirtas, U. Canpolat, H. Pasaoglu, D. Aras, Y. Tavil, A. Abaci
(Ankara, TR)
FactorXa inhibits brown adipose tissue function and induces systemic metabolic dysfunction in obesity. P4535
– Y. Hayashi, I. Shimizu, Y. Yoshida, M. Suda, R. Ikegami, G. Katsuumi, H. Kayamori, S. Jiao, T. Minamino
(Niigata, JP)
The phosphodiesterase-5 inhibitor vardenafil protects against diabetic cardiomyopathy in type-2 diabetes P4536
mellitus.
– C. Matyas, B.T. Nemeth, A. Olah, M. Ruppert, D. Kellermayer, M. Torok, L. Szabo, G. Szabo, B. Merkely,
T. Radovits (Budapest, HU; Heidelberg, DE)
Peripheral gamma-aminobutyric acid (GABA) signaling in brown adipose tissue induces metabolic P4537
dysfunction in obesity.
– T. Sato, I. Shimizu, Y. Yoshida, M. Suda, Y. Hayashi, G. Katsuumi, H. Kayamori, T. Minamino (Niigata, JP)
Chronic vagus nerve stimulation exerts glycemic control and cardioprotection via preventing cardiac P4538
mitochondrial dysfunction in obese-insulin resistant rats.
– B. Samniang, T. Chanchai, S. Kumfu, K. Shinlapawittayatorn, S. Chattipakorn, N. Chattipakorn (Chiang Mai,
TH)
Interplay between chromatin modifying enzymes SUV39H1, SRC-1 and JMJD2C triggers redox signalling P4539
and vascular dysfunction in obesity.
– F. Paneni, S. Costantino, A. Virdis, A.J. Pospisilik, T. Jenuwein, M. Volpe, S. Taddei, F. Cosentino
(Stockholm, SE; Pisa and Rome, IT; Freiburg, DE)
The incretin hormone GIP is modulated by inflammatory stimuli and downregulated in critically ill ICU P4540
patients: central relevance of interleukin 1 beta.
– F. Kahles, C. Meyer, S. Diebold, J. Moellmann, C. Lebherz, H.M. Findeisen, A. Koch, F. Tacke, N. Marx,
M. Lehrke (Aachen and Münster, DE)
The absence of Two-pore channels induce metabolic alterations at cardiac level. P4541
– V. Garcia-Rua, S. Bravo, J. Parrington, S. Feijoo-Bandin, D. Rodriguez-Penas, A. Mosquera-Leal,
M. Portoles, M. Rivera, J.R. Gonzalez-Juanatey, F. Lago (Santiago de Compostela and Valencia, ES;
Oxford, UK)
CARDIAC BIOLOGY AND SENESCENCE

Teneligliptin ameliorates hypertensive cardiac remodeling via angiotensin-II-mediated cardiac P4542
sodium-proton exchanger1 pathway.
– H.K. Kawase, Y. Kureishi Bando, M.A. Aoyama, T.M. Mitsui, T.M. Murohara (Nagoya and Obu, JP)
The effects of age on ovine atrial conduction. P4543
– C.M. Pearman, D.A. Eisner, A.W. Trafford, K.M. Dibb (Manchester, UK)
VASCULAR REMODELLING
HDL-raising gene transfer antagonizes pro-fibrogenic effects of the vasculosplenic axis in a murine P4544
model of type 2 diabetes mellitus.
– S. Van Linthout, F. Spillmann, K. Miteva, N. Singh, B. De Geest, C. Tschoepe (Berlin, DE; Leuven, BE)
285

A role for tenascin-C in the development of pulmonary arterial hypertension? P4545
– M.-P. Winter, F. Dragschitz, A. Alimohammadi, F. Nagel, D. Santer, A. Panzenboeck, V. Seidl, B. Podesser,
I.M. Lang (Vienna, AT)
Response to fluid challenge test in normal subjects and in a heterogeneous population with pulmonary P4546
hypertension.
– M. D’Alto, E. Romeo, P. Argiento, G.M. Di Marco, A. Correra, G. Di Nardo, B. Sarubbi, M.G. Russo,
R. Naeije (Naples, IT; Brussels, BE)
The trigger of pulmonary injury after balloon pulmonary angioplasty in patients with chronic P4547
thromboembolic pulmonary hypertension.
– K. Ejiri, S. Fujii, A. Ogawa, H. Matsubara, H. Ito (Okayama, JP)
Clinical and echocardiographic characteristics of patients with pulmonary hypertension associated with P4548
heart failure with preserved ejection fraction or with pre-capillary pulmonary hypertension.
– E. Berthelot, D. Montani, X. Jais, C. Dreyfuss, R. Rifai, A. Bouchachi, M. Humbert, G. Simonneau,
O. Sitbon, P. Assayag (Le Kremlin-Bicêtre, FR)
Percutaneous treatment of carbon dioxide mist attenuates the development of right ventricular P4549
dysfunction in monocrotaline-induced pulmonary hypertensive rats.
– T. Yamaguchi, Y. Izumi, T. Yamazaki, Y. Nakamura, K. Shimada, M. Yoshiyama, H. Iwao (Osaka, Sakai,
Izumi and Habikino, JP)
Genetics of pulmonary arterial hypertension in a Spanish cohort. Preliminary results of the Spanish P4550
multicentric study of genetics of HPAH/IPAH.
– P. Navas Tejedor, J. Tenorio, C.A. Quezada Loaiza, M. Lopez Meseguer, E. Barrios Garrido, C. Alvarez,
M.T. Velazquez Martin, J.F. Delgado Jimenez, P. Lapunzina Abadia, P. Escribano Subias (Madrid,
Barcelona and Oviedo, ES)
The assessment of exercise tolerance and oxygenation after balloon pulmonary angioplasty for patients P4551
with inoperable chronic thromboembolic pulmonary hypertension.
– Y. Taniguchi, N. Emoto, Y. Shinkura, H. Kinutani, K. Nakayama, T. Shinke, K. Hirata (Kobe, JP)
Pulmonary hypertension in patients with dialysis: epidemiology and clinical impact. P4552
– A. Yoshida, N. Serizawa, K. Sugiyama, N. Kato, T. Suzuki, J. Yamaguchi, T. Shiga, N. Hagiwara (Tokyo, JP)
Echocardiography of right ventricular reserve in healthy subjects. P4553
– M. D’Alto, A. Pavelescu, P. Argiento, E. Romeo, A. Correra, G.M. Di Marco, G. Scognamiglio, B. Sarubbi,
M.G. Russo, R. Naeije (Naples, IT; Brussels, BE)
Common pitfalls in pulmonary hypertension diagnosis: the real-world application of ESC guidelines P4554
algorythm.
– F. Guerra, A. Barbarossa, M. Serenelli, F. Guazzarotti, G.P. Perna, A. Capucci (Ancona, IT)
AORTIC VALVE DISEASE I
Comparing bone turnover biomarkers levels in aortic stenosis of bicuspid and tricuspid valve. P4555
– E. Zhiduleva, O. Irtyuga, T. Karonova, E. Kazakova, O. Moiseeva (St. Petersburg, RU)
Causes of death, mortality and evaluation of prognostic factors in patients with severe aortic stenosis in P4556
an aging society.
– S. Miura (Kitakyushu, JP)
What is the prognostic significance of tricuspid regurgitation in moderate aortic stenosis? P4557
– J.G. Murphy, N. Sydo, V. Nkomo, G. Kane, M. Sarano, B. Merkely, T.G. Allison (Rochester, US; Budapest,
HU)
Impact of pulmonary arterial pressure on long-term survival in patients with aortic stenosis and preserved P4558
left ventricular ejection fraction.
– J. Magne, C. Boulogne, M. Deltreuil, V. Petitalot, N. Echahidi, C. Cassat, P. Virot, M. Laskar, V. Aboyans,
D. Mohty (Limoges, FR)
Assessment of myocardial deformation: predicting left ventricular dysfunction after surgery in patients P4559
with chronic mitral regurgitation.
– E.J. Cho, J.W. Hwang, S.J. Park, H.R. Yun, S.A. Chang, S.C. Lee, S.W. Park (Seoul, KR)
Asymptomatic, severe degenerative mitral regurgitation: a step towards earlier detection of myocardial P4560
dysfunction.
– K.K. Keramida, N.K. Kouris, V.K. Kostopoulos, P.K. Kostakou, C.D.O. Olympios (London, UK; Athens, GR)
Whole blood viscosity as an overlooked predictor of spontaneous echo contrast in patients with mitral P4561
stenosis.
– E.H. Ozcan Cetin, M.S. Cetin, S. Kuyumcu, Y. Akin, A. Temizhan, S. Aydogdu (Ankara, TR)
The overlooked parameter of shear stress in mitral annular calcification: Whole blood viscosity. P4562
– E.H. Ozcan Cetin, M.S. Cetin, E. Kalender, O. Ozeke, D. Aras, A. Temizhan, S. Topaloglu, S. Aydogdu
(Ankara, TR)
Impact of leaflet tear/partial clip detachment on outcomes of repeat MitraClip therapy in high P4563
surgical-risk patients.
– F. Kreidel, M. Schlueter, H. Alessandrini, C. Frerker, T. Thielsen, S. Geidel, U. Schaefer, K.-H. Kuck
(Hamburg, DE)
The prognostic significance of post-MitraClip vena contracta area in heart failure patients with functional P4564
mitral regurgitation.
– H. Alessandrini, F. Kreidel, M. Schlueter, C. Frerker, T. Thielsen, P. Wohlmuth, U. Schaefer, K.-H. Kuck
(Hamburg, DE)
286
AORTIC VALVE DISEASE II

Impact of computed tomography aortic annulus measurements during systole and diastole on prosthesis P4565
choice in patients undergoing transcatheter aortic valve implantation.
– U. Fischer-Rasokat, W.K. Kim, C. Liebetrau, S. Moellmann, J. Blumenstein, L. Gaede, T. Walther, H. Nef,
C. Hamm, H. Moellmann (Bad Nauheim and Giessen, DE)
Change in frailty status in octogenarians with severe symptomatic aortic stenosis after aortic valve P4566
replacement.
– A. Frantzen, B. Fridlund, L.S.P. Eide, R. Haaverstad, K.O. Hufthammer, K.K.J. Kuiper, A. Ranhoff,
T.M. Norekval (Bergen, NO; Jönköping, SE)
The opening of aortic valve during exercise is a key to prevent development of aortic insufficiency among P4567
those with closed aortic valve at rest during ventricular assist device support.
– T. Imamura, K. Kinugawa, H. Maki, M. Hatano, O. Kinoshita, K. Nawata, S. Kyo, M. Ono (Tokyo, JP)
Long term survival after aortic valve replacement: role of European and American guidelines adherence. P4568
– A. Colli, L. Besola, E. Bizzotto, D. Gregori, E. Manzan, F. Zucchetta, G. Gerosa (Padua, IT)
Exercise hemodynamics in symptomatic patients with low gradient aortic stenosis with normal ejection P4569
fraction. A simultaneous right-heart catheterization and Doppler-echocardiographic study.
– C. Perez Del Villar, R. Yotti, M.A. Espinosa, E. Gutierrez, A. Barrio, M.J. Lorenzo, P.L. Sanchez,
P. Martinez-Legazpi, F. Fernandez-Aviles, J. Bermejo (Madrid and Salamanca, ES)
Echocardiographic and MRI assessment of myocardial strain and strain rates using speckle tracking and P4570
feature tracking in asymptomatic aortic stenosis.
– J. McAdam, A. Singh, A.M. Marsh, F. Lai, J.P. Greenwood, G.P. McCann (Leicester and Leeds, UK)
The relationship between aortic valve weight and hydraulic vascular load in patients with severe isolated P4571
aortic stenosis who underwent surgical aortic valve replacement.
– E. Barasch, D. Alexandru, J.M. Conroy, F. Petillo, S. Pollack, N. Reichek, A. Anagnostopoulos (Roslyn, US)
Pre-procedural dual antiplatelet therapy and bleeding events following transcatheter aortic valve P4572
implantation (TAVI).
– Z. Huczek, J. Kochman, M. Grygier, R. Parma, R. Wilimski, P. Scislo, A. Ochala, M. Lesiak, K.J. Filipiak,
G. Opolski (Warsaw, Poznan and Katowice, PL)
Anatomical parameters do not predict procedural success in patients undergoing transcatheter aortic P4573
valve implantation.
– S. Pingel, M. Weber, A. Stundl, A. Sedaghat, E. Grube, F. Mellert, M. Vasa-Nicotera, N. Werner,
G. Nickenig, J.M. Sinning (Bonn, DE)
Additional value of exercise-stress echocardiography in asymptomatic patients with aortic valve stenosis. P4574
– C. Goublaire, M. Melissopoulou, V. Nguyen, E. Brochet, C. Cimadevilla, I. Codogno, A. Vahanian,
D. Messika-Zeitoun (Paris, FR)
Improved management of left-sided infective endocarditis not accompanied by lower mortality. P4575
– T. Sevilla, P.E. Garcia Granja, J. Lopez Diaz, I. Vilacosta, C. Ortiz Bautista, C. Olmos, C. Ferrera, I. Gomez,
J.A. San Roman (Valladolid and Madrid, ES)
Changes in clinical, epidemiological and prognostic profiles in native left-sided infective endocarditis P4576
without underlying heart disease.
– F.J. Castillo Bernal, M. Anguita, J.C. Castillo, F. Carrasco, M. Ruiz, G. Gutierrez, C. Aristizabal,
J. Fernandez, D. Mesa, J. Suarez De Lezo (Córdoba, ES)
A new gatekeeper for prevention of in-hospital mortality in infective endocarditis: platelet to lymphocyte P4577
ratio.
– M. Akboga, O. Turak, U. Canpolat, C. Yayla, M. Suleymanoglu, F. Oksuz, M. Mendi, F. Ozcan (Ankara, TR)
The impact of a second mitral valve surgery after repairing a rheumatic mitral valve. P4578
– G.F. Freitas Coutinho, P.M. Correia, C.F. Branco, M.J. Antunes (Coimbra, PT)
Inter-rater variability in reporting screening echocardiograms for rheumatic heart disease in high risk P4579
populations.
– G.P. Maguire, D. Atkinson, A. White, A.D. Brown, J.R. Carapetis, B. Remenyi, K. Roberts, M.G.W. Remond
(Alice Springs, Broome, Townsville, Adelaide, Perth, Darwin and Cairns, AU)
How accurate are cardiologists at detecting aortic and mitral murmurs? a reality check on auscultation P4580
skills in the era of transcatheter interventions.
– M. Barrett, M.W. Martinez, M. Scott, P. O’Gara (Allentown and Boston, US)
Aortic valve replacement with or without concurrent coronary artery bypass grafting in octogenarians: P4581
8-year cohort study.
– T.K.M. Wang, D.H. Choi, T. Ramanathan, P. Ruygrok (Auckland, NZ)
Impact of direct transcatheter aortic valve implantation on final device position and paravalvular leak. Is it P4582
beneficial?
– M. Vavuranakis, M. Lavda, T. Papaioannou, D. Vrachatis, K. Kalogeras, G. Siasos, C. Moldovan,
A.M. Kolokathis, M. Kariori, D. Tousoulis (Athens, GR)
Treatment of post procedural aortic regurgitation in transcatheter aortic valve replacement patients. P4583
– E. Koifman, S. Kiramijyan, S. Negi, M. Magalhaes, R. Didier, J. Gai, R. Torguson, A. Pichard, L. Satler,
Safety of transcatheter aortic valve implantation in patients with pure native aortic valve regurgitation. P4584
– E. Munoz-Garcia, M. Munoz-Garcia, A.J. Munoz Garcia, A.J. Dominguez-Franco, M.F. Jimenez-Navarro,
J.H. Alonso-Briales, J.J. Gomez-Doblas, J.M. Hernandez-Garcia, E. De Teresa-Galvan (Málaga and Jaén,
ES)
287
PERICARDIAL AND MYCOCARDIAL DISEASE, TUMOURS, OTHER

Layer-specific strain in diabetic patients with normal ejection fraction using speckle tracing imaging. P4585
– Y.M. Xue, X.H. Shu, C.Z. Pan, J. Shi, Z. Li, J.B. Ge (Shanghai, CN)
Anakinra: an emerging option for refractory idiopathic recurrent pericarditis: a systematic review of P4586
published evidence.
– G. Lazaros, M. Imazio, A. Brucato, D. Vassilopoulos, P. Vasileiou, M. Gattorno, D. Tousoulis, A. Martini
(Athens, GR; Turin, Bergamo and Genoa, IT)
Lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular inflammation marker, is frequently P4587
increased in patients presenting with acute pericarditis.
– A. Izhaki, M. Boaz, T. Chaimy, Y. Abuhav, J. Roitelman, Y. Rozenman (Holon and Tel Hashomer, IL)
Intravenous human immunoglobulins for refractory recurrent pericarditis: a systematic review of all P4588
published cases.
– M. Imazio, G. Lazaros, E. Picardi, P. Vasileiou, M. Carraro, D. Tousoulis, R. Belli, F. Gaita (Turin, IT; Athens,
GR)
Cardiac assessment of patients with familial amyloid polyneuropathy. P4589
– M. Gospodinova, S. Sarafov, T. Chamova, V. Guergelcheva, I. Tournev, S. Denchev (Sofia, BG)
Comparative assessment of right ventricular outflow tract (RVOT) dimensions by echocardiography and P4590
magnetic resonance tomography in arrhythmogenic right ventricular cardiomyopathy (ARVC).
– A. Gotschy, A.M. Saguner, M. Niemann, C. Brunckhorst, F. Duru, F.C. Tanner, R. Manka (Zurich, CH)
Fragmented QRS complexes in patients with hypertrophic cardiomyopathy: a marker of myocardial P4591
fibrosis detected by cardiac magnetic resonance imaging with gadolinium enhancement.
– E. Tulumen, P. Ehlermann, C. Doesch, B. Rudic, V. Liebe, S. Roeger, J. Kuschyk, H.A. Katus,
T. Papavassiliu, M. Borggrefe (Mannheim and Heidelberg, DE)
Prognostic significance of non-dilated left ventricular size and mitral regurgitation in patients with P4592
end-stage phase of hypertrophic cardiomyopathy.
– T. Kubo, Y. Baba, K. Tanioka, T. Hirota, N. Yamasaki, H. Kitaoka (Kochi, JP)
HsTNFalpha activity and the severity of inflammation, hypertrophy and fibrosis in pts with inflammatory P4593
cardiomyopathy.
– A. Shchedrina, A.A. Skvortsov, K.A. Zykov, O.Y. Narusov, A.A. Safiullina, S.N. Tereschenko (Moscow, RU)
Cardiac MRI characterization of phospholamban R14del-related cardiomyopathy. P4594
– W.P. Te Rijdt, J.N. Ten Sande, T.M. Gorter, P.A. Van Der Zwaag, P.L. Van Haelst, R.A. De Boer,
S.M. Boekholdt, T.P. Willems, M.P. Van Den Berg, P.F. Van Dessel (Groningen, Amsterdam and Sneek, NL)
PAEDIATRIC CARDIOLOGY, OTHER

Long term outcome and survival of neonates with total abnormal pulmonary venous return. P4595
– A. Lemaire, O. Metton, J. Mitchell, M. Veyrier, C. Ducreux, R. Henaine, M. Bakloul, J. Ninet, S. Di Filippo
(Lyon, FR)
The natural history of hypervagotonic binodal dysfunction in children. Comparison of different variants of P4596
the binodal dysfunction.
– E.S. Vasichkina, D.S. Lebedev, D.F. Egorov (St. Petersburg, RU)
Clinical and echocardiographic predictors for the recurrence of subaortic stenosis. P4597
– P. Theocharis, N.D. Papamichael, T. Bharucha (Southampton and London, UK)
Relation between soluble suppression of tumorigenicity 2 (sST2) and brain natriuretic peptide (BNP) in P4598
healthy pediatric subjects: from birth through adulthood.
– C. Caselli, R.R. Ragusa, C.M. Cantinotti, D.A.A. D’Amico, S.S. Storti, C.M. Cabiati, A. Clerico, G. Federico,
M.G. Trivella, S. Del Ry (Pisa, IT)
It is the time to reconsider the evolution of preexcitation syndrome in children? P4599
– B. Brembilla-Perrot, J.M. Sellal, A. Olivier, V. Manenti, T. Villemin, A. Tisserand, F. Marcon, J.L. Cloez,
J.P. Lethor, A. Moulin-Zinsch (Vandoeuvre-lès-Nancy, FR)
Follow-up of children and teenagers with paroxysmal supraventricular tachycardia but without P4600
preexcitation syndrome.
– B. Brembilla-Perrot, A. Olivier, J.M. Sellal, V. Manenti, T. Villemin, A. Moulin-Zinsch, J.P. Lethor, F. Marcon,
C. De Chillou, N. Girerd (Vandoeuvre-lès-Nancy, FR)
Soluble suppression of tumorigenicity 2 (sST2) time-course in pediatric patients with heart failure P4601
supported by ventricular assist device implant.
– C. Caselli, A. Di Molfetta, R. Ragusa, A. D’Amico, M. Cabiati, M. Cantinotti, G. Federico, S. Del Ry,
A. Amodeo, M.G. Trivella (Pisa, Rome and Massa, IT)
Double outlet right ventricle with non-committed ventricular septal defect. P4602
– O. Villemain, D. Bonnet, M. Vergnat, M. Ladouceur, V. Lambert, Z. Jalal, P. Vouhe, E. Belli (Paris and Le
Plessis-Robinson, FR)
Risk stratification and outcome in patients with coronary artery lesions caused by kawasaki disease. P4603
– E. Tsuda, N.T. Tsujii, Y.H. Hayama, O.Y. Yamada (Osaka, JP)
Possible mechanism of coronary calcification in chronic-phase Kawasaki disease. P4604
– T. Yahata, C. Suzuki, K. Ikeda, K. Hamaoka (Kyoto, JP)
New concept for left ventricular training in corrected transposition of the great arteries to allow double P4605
switch operation.
– P.A. Zartner, V. Hraska, C. Haun, B. Asfour, M.B. Schneider (Sankt Augustin, DE)
Outcome of blalock taussig shunt placement without patent ductus arteriosus ligation in neonates with P4606
pulmonary atresia.
– K. Odumusi, S. Ghaleb, U. Abbas, J. Brownlee (Corpus Christi, US)
288
BIOMARKERS: INSIGHTS INTO THE HEALTH OF PATIENTS AND POPULATIONS

Prognostic value of profound iron deficiency in patients with Coronary Artery Disease - establishment of P4607
a new functional definition of iron deficiency in the AtheroGene Study.
– M. Karakas, C. Waldeyer, S. Appelbaum, A. Altay, P.S. Wild, K.J. Lackner, T. Munzel, D. Westermann,
S. Blankenberg, T. Zeller (Hamburg and Mainz, DE)
Association between plaque vulnerability and omega-3 polyunsaturated fatty acids in normal P4608
low-density-lipoprotein cholesterol patients with coronary artery disease.
– M. Habara, K. Nasu, Y. Kinoshita, E. Tsuchikane, M. Terashima, T. Matsubara, T. Suzuki (Toyohashi, JP)
Relations of estradiol, total testosterone and sex-hormone binding globulin to 11-year cardio-metabolic P4609
risk factors changes in postmenopausal women: the Rotterdam Study.
– T. Muka, N.S. Erler, L. Jaspers, C. Meun, A. Hofman, J.C. Kiefte-De Jong, J.S.E. Laven, M. Kavousi,
O.H. Franco (Rotterdam, NL)
Can copeptin assist the diagnosis of acute kidney injury in breathless patients? P4610
– C.J. Pemberton, J. Lee, M. Than, J.W. Pickering, R.W. Troughton, M. Richards (Christchurch, NZ)
Relationships between possible novel biomarkers related to angiogenesis or oxidative stress and the P4611
angiographic severity of coronary artery disease: baseline data from the ANOX study.
– T. Unoki, D. Takagi, M. Suzuki, M. Matsuda, Y. Ajiro, T. Shinozaki, M. Abe, M. Akao, K. Hasegawa,
H. Wada (Kyoto, Saitama, Kure, Yokohama and Sendai, JP)
Combining B-type natriuretic peptide and high-sensitivity cardiac troponin I in the evaluation of patients P4612
with suspected inducible myocardial ischemia.
– C. Puelacher, M. Wagener, G. Lee, Y. Tanglay, N. Schaerli, U. Honegger, G. Pretre, M. Zellweger,
Lack of effect of higher dose vitamin D supplements on systolic blood pressure and arterial stiffness P4613
measure in older people after 12 months of treatment. Results of BEST-D trial.
– J. Tomson, H. Hin, R. Kurien, J. Cox, M. Lay, J. Sayer, J. Emberson, C. Newman, J. Armitage, R. Clarke
(Oxford and Banbury, UK; New York, US)
Impact of exercise training on dipeptidyl peptidase 4 and its relation to endothelial biomarkers in patients P4614
with stable coronary artery disease.
– M. Deljanin Ilic, S. Ilic, G. Kocic, B. Djordjevic, D. Simonovic, S. Saric, V. Mitic (Niska Banja and Nis̆, RS)
Determination of the 99th percentile value for high-sensitivity cardiac troponin T and I. P4615
– D.M. Kimenai, R.M. Henry, C.J.H. Van Der Kallen, P.C. Dagnelie, M.T. Schram, C.D. Stehouwer, J.D. Van
Suijlen, O. Bekers, M.P. Van Dieijen-Visser, S.J.R. Meex (Maastricht and Apeldoorn, NL)
Red cell distribution width as a novel predictor for the clinical outcomes in patients with paroxysmal atrial P4616
fibrillation.
– K.H. Lee, H.W. Park, N.S. Yoon, J.G. Cho, S.S. Kim, Y.K. Ahn, M.H. Jeong, J.C. Park (Gwangju, KR)
Macrophage migration inhibitory factor (MIF) levels in the blood rise in response to myocardial ischaemia P4617
evoked by an exercise stress test.
– F.L. Fan, L. Fang, X.L. Moore, J. O’Brien, H. Thomson, A. Ellims, H. Schneider, X.J. Du, T. Barber, A. Dart
(Xian, CN; Melbourne, AU)
Long-term mortality in hospitalized patients with cardiac troponin values below the 99th percentile. P4618
– L. Sarkisian, L. Saaby, T.S. Poulsen, N. Jangaard, S. Hosbond, A.C.P. Diederichsen, O. Gerke, M. Nybo,
K. Thygesen, H. Mickley (Odense and Aarhus, DK)
IMPROVING RISK SCORES IN THE REAL WORLD
Paroxysmal versus non-paroxysmal atrial fibrillation in Europe: the EORP-AF General Pilot Registry. P4619
– G. Boriani, C. Laroche, I. Diemberger, M.I. Popescu, L.H. Rasmussen, G.A. Dan, Z. Kalarus, L. Tavazzi,
A.P. Maggioni, G.Y.H. Lip (Bologna and Cotignola, IT; Sophia Antipolis, FR; Oradea and Bucharest, RO;
Aalborg, DK; Zabrze, PL; Birmingham, UK)
Beyond Framingham risk equations: how can cardiovascular risk be estimated when treatment changes P4620
over time?
– K.K. Poppe, R.D. Pylypchuk, R.T. Jackson, R.J. Stevens (Auckland, NZ; Oxford, UK)
The added value of a combined genetic score as cardiovascular risk predictor in a Portuguese population P4621
with intermediate risk according to the European score.
– A. Pereira, R. Palma Dos Reis, R. Rodrigues, S. Gomes, A.C. Sousa, E. Henriques, G. Guerra, C. Freitas,
D. Pereira, M.I. Mendonca (Funchal and Lisbon, PT)
Validation of SAME-TT2R2 score for predicting poor anticoagulation in a prospective real world cohort of P4622
atrial fibrillation patients initiating Vitamin K antagonists.
– V. Roldan-Schilling, F. Marin, S. Cancio, J. Galvez, M. Valdes, V. Vicente, G.Y.H. Lip (Murcia, ES;
Birmingham, UK)
External validation of prediction models for the diagnosis of coronary artery disease. P4623
– S. Altintas, I.A. Joosen, M.G.M. Hunink, K. Nieman, P.J. Nelemans, J.E. Wildberger, H.J. Crijns,
A.M.A. Mingels, M. Das, B.L. Kietselaer (Maastricht and Rotterdam, NL)
Accuracy of statin assignment according to the European vs. American guidelines - a coronary CT P4624
correlation study.
– A. Tralhao, A.M. Ferreira, P.A. Goncalves, S. Madeira, R. Rodrigues, M. Castro, H. Marques (Lisbon, PT)
Genetic multifactorial and multilocus study in a Portuguese population with coronary disease. P4625
– A. Pereira, R. Palma Dos Reis, S. Gomes, R. Rodrigues, A.C. Sousa, E. Henriques, G. Guerra, C. Freitas,
D. Pereira, M.I. Mendonca (Funchal and Lisbon, PT)
289
Predictors and risk model for stroke and death in non-anticoagulated patients with atrial fibrillation: The P4626
Fushimi AF Registry.
– Y. Hamatani, Y. Yamashita, H. Ogawa, M. Esato, Y.H. Chun, H. Wada, K. Hasegawa, M. Abe, G.Y. Lip,
M. Akao (Kyoto, JP; Birmingham, UK)
Accuracy of 10 year-risk calculation for first atherosclerotic cardiovascular event from new pooled cohort P4627
equations and WHO risk calculation in EGAT population.
– K. Vilaiwatanakorn, P. Vathesatogkit, T. Yingchoncharoen, S. Yamwong, P. Sritara (Bangkok, TH)
CAIDE risk score predicts atherosclerosis and vascular events in HIV patients. Preliminary data from the P4628
Italian multicentre cohort of CARdiovascular and late-life Dementia risk in HIV (CARDH) Study.
– F. Vadini, E. Mazzotta, F. Sozio, M. Tontodonati, G. Madeddu, T. Ursini, E. Polilli, G. Calella, F. Santilli,
G. Parruti (Pescara, Sassari and Chieti, IT)
Predicting, at admission for non ST ACS, patients who will not undergo PCI: a score from the Euro Heart P4629
Survey- ACS III registry.
– F. Schiele, H. Bueno, M. Tubaro, K.A.A. Fox, A.K. Gitt, N. Meneveau, E. Puymirat, T. Simon, N. Danchin
(Besançon and Paris, FR; Madrid, ES; Rome, IT; Edinburgh, UK; Ludwigshafen am Rhein, DE)
CLINICAL PARAMETERS TO IMPROVE RISK PREDICTION

Heritability of coronary calcium quantity and total plaque burden: a classical twin study. P4630
– P. Maurovich-Horvat, Z.D. Drobni, M. Kolossvary, T. Horvath, L. Littvay, A.D. Tarnoki, D.L. Tarnoki,
G. Jermendy, B. Merkely (Budapest, HU)
No contribution of ankle brachial index as a risk reclassification tool for statin prescription according to P4631
the new ACC/AHA cholesterol guideline.
– V. Kramer, G. Valentino, L. Orellana, M. Fernandez, C. Navarrete, M.J. Bustamante, M. Adasme, A. Salazar,
M. Acevedo (Santiago and La Serena, CL)
Cardiac function-specific risk factors for one-year mortality in patients admitted with acute coronary P4632
syndromes.
– O.P. Perelshtein, I. Goldenberg, R. Klempfner, R. Kuperstein (Ramat Gan, IL)
Relative performance of three different estimated glomerular filtration rates on clinical outcomes in P4633
patients with acute myocardial infarction undergoing percutaneous coronary intervention.
– K.H. Lee, H.W. Park, N.S. Yoon, S.S. Kim, J.G. Cho, Y.K. Ahn, M.H. Jeong, J.C. Park (Gwangju, KR)
Predictive value of apoB/apoA1 ratio on the risk of myocardial infarction in different ethnic groups. P4634
– M. Berteotti, M. Magnoni, L.R. Limite, G. Peretto, G.D. Norata, D. Cianflone (Milan, IT)
Association of creatinine clearance with clinical outcomes in patients with atrial fibrillation: The Fushimi P4635
AF Registry.
– M. Abe, H. Ogawa, T. Unoki, M. Ishii, N. Masunaga, M. Esato, Y. Chun, H. Wada, K. Hasegawa, M. Akao
(Kyoto, JP)
The relation of ambulatory heart rate with all-cause mortality among middle-aged men: a prospective P4636
cohort study.
– E. Clays, M. Lidegaard, F. Kittel, K. Van Herck, G. De Backer, D. De Bacquer, A. Holtermann, M. Korshoj
(Ghent and Brussels, BE; Copenhagen, DK)
Combined ECG-based risk stratification for sudden cardiac death in patients after myocardial infarction: P4637
5-year data.
– E. Okisheva, V. Sulimov, D. Tsaregorodtsev (Moscow, RU)
Respiratory sinus arrhythmia: a surrogate of vagal tone independently predicts mortality after myocardial P4638
infarction.
– D. Sinnecker, A. Steger, M. Dommasch, A. Mueller, J. Gebhardt, K.L. Laugwitz, P. Barthel, G. Schmidt
(Munich, DE)
Relationship between cardiac autonomic dysfunction measured by heart rate recovery after exercise and P4639
coronary artery calcification.
– Y.S. Kwon, J. Park, J.H. Kim (Busan, KR)
New scoring using serum albumin and body mass index can predict driveline infection during long-term P4640
left ventricular assist device treatment.
– T. Imamura, K. Kinugawa, M. Hatano, O. Kinoshita, K. Nawata, S. Kyo, M. Ono (Tokyo, JP)
Ultrasound fat indexes and coronary artery disease: improved risk stratification in obese patients with P4641
high and very high cardiovascular risk.
– M. Haberka, J. Stanisz-Kempa, Z. Gasior (Katowice, PL)
UNDERSTANDING RISK ACROSS DIFFERENT GROUPS: NEW INSIGHTS

Exploration of risk factors for major bleeding in Japanese patients with atrial fibrillation: The Fushimi AF P4642
Registry.
– M. Ishii, H. Ogawa, N. Masunaga, M. Iguchi, M. Esato, Y.H. Chun, H. Wada, K. Hasegawa, M. Abe,
M. Akao (Kyoto, JP)
Multilocus genome-wide study with variants associated with cardiovascular risk factors and coronary P4643
artery disease in a Southern European population.
– A. Pereira, M.I. Mendonca, S. Gomes, R. Rodrigues, A.C. Sousa, S. Freitas, G. Guerra, S. Borges,
D. Pereira, R. Palma Dos Reis (Funchal, PT)
Take a look at the colon: cardiovascular risk scores predict colorectal advanced adenoma and carcinoma P4644
in a large asymptomatic screening cohort.
– D. Niederseer, A. Stadlmayr, U. Huber-Schoenauer, M. Ploederl, D. Lederer, W. Patsch, E. Aigner, C. Datz
(Oberndorf and Salzburg, AT)
290
What is the best genetic score to predict the risk coronary disease? P4645
– A. Pereira, M.I. Mendonca, S. Gomes, R. Rodrigues, A.C. Sousa, E. Henriques, G. Guerra, C. Freitas,
D. Pereira, R. Palmas Dos Reis (Funchal and Lisbon, PT)
Genetic polymorphisms and coronary disease - multivariate study including traditional risk factors. P4646
– A. Pereira, M.I. Mendonca, S. Gomes, R. Rodrigues, A.C. Sousa, S. Freitas, G. Guerra, I. Ornelas,
D. Pereira, R. Palma Dos Reis (Funchal, PT)
Can we characterize the risk of stroke and death in patients with non-valvular atrial fibrillation based on P4647
the parameter defining a CHA2DS2-VASc score equal to 1?
– C. El Asri, S. Lang, L. Soulat-Dufour, L. Boyer-Chatenet, S. Ederhy, C. Van Der Vynckt, M. Charbonnier,
N. Haddour, F. Boccara, A. Cohen (CITY MISSING, FR)
Central obesity modifies the role of triglycerides in the risk of fatal and non-fatal cardiovascular event: P4648
10-year follow-up (2002-12) of the ATTICA study.
– E. Georgousopoulou, D.B. Panagiotakos, C. Pitsavos, C. Chrysohoou, I. Skoumas, M. Chatzigeorgiou,
E. Pitaraki, D. Tousoulis, C. Stefanadis (Athens, GR)
Lipoprotein-associated phospholipase A2 as independent predictor of atherosclerosis among patients P4649
with zero coronary artery calcium score.
– E. Kaczmarska, Z. Dzielinska, C. Kepka, J. Janas, P. Kunicki, K. Kryczka, R. Pracon, M. Kruk,
J. Pregowski, M. Demkow (Warsaw, PL)
Can we refine the risk stratification of cardiovascular events in patients with non-valvular atrial fibrillation P4650
with a CHA2DS2-VASc score equal to 1 by using the CRP level at admission?
– C. Van Der Vynckt, S. Lang, L. Soulat-Dufour, L. Boyer-Chatenet, S. Ederhy, M. Charbonnier, N. Haddour,
S. Adavane, F. Boccara, A. Cohen (Paris, FR)
Comparison of contemporary risk models for predicting mortality and morbidity after combined aortic P4651
valve replacement and coronary artery bypass grafting.
– T.K.M. Wang, D.H. Choi, G.D. Gamble, T. Ramanathan, P. Ruygrok (Auckland, NZ)
Sleep duration and risk of incident of ischaemic heart disease: a 7-year prospective study of 0.5 million P4652
Chinese adults.
– Y. Chen, L. Li, J. Wang, H. Gao, R. Clarke, Y. Guo, Z. Bian, R. Peto, J. Chen, Z. Chen (Oxford, UK; Beijing,
CN)
UNDERSTANDING RISK AND OUTCOMES THROUGH BIOMARKERS

Elevated brain natriuretic peptide plasma level as a marker of increased maternal complications in P4653
pregnant ladies with preeclampsia/eclampsia syndrome.
– G. Youssef, N. Haroon, R. Diab, E. Baligh (Cairo, EG)
Lipoprotein associated phospholipase A2 does not improve mortality prediction. P4654
– M. Benderly, B. Sapir, O. Kalter-Leibovici, R. Zimlichman (Ramat-Gan, Tel Aviv and Holon, IL)
Relation between high-density lipoprotein efflux capacity and coronary plaque progression in type 2 P4655
diabetes patients with intensive lipid-lowering therapy.
– S. Imaizumi, A. Iwata, K. Takata, B. Zhang, S. Miura, K. Saku (Fukuoka, JP)
Cardioprotective role of fetuin-A in patients with end-stage renal disease on regular hemodialysis. P4656
– A.E. Mostafa, E. Khedr, A. Shaban, M. Behairy, M.T. Hamza, A.M. Sabry, A. Donia (Cairo, EG)
Plasma hydroxyanthranilic acid and incident type 2 diabetes in patients with stable angina pectoris. P4657
– E.R. Pedersen, E. Strand, G.F.T. Svingen, Ø. Midttun, P.M. Ueland, R. Seifert, O.K. Nygard (Bergen, NO)
The arachidonate 15-lipoxygenase enzyme product present in heart tissue from patients with ischaemic P4658
heart disease induces hypercoagulability.
– A. Lundqvist, G.I. Hansson, A. Jeppsson, L. Mattsson Hulten (Gothenburg and Mölndal, SE)
Relationship between serum beta-2-microglobulin and cardiovascular risk factors. P4659
– B.M.Y. Cheung, C.L. Cheung (Hong Kong, HK)
Postoperative myocardial injury assessed by high-sensitivity cardiac troponin T and revised cardiac risk P4660
index in patients undergoing non-cardiac surgery.
– H. Toda, K.N. Nakamura, K.N. Nakagawa, N.N. Nishii, S.N. Nagase, H.M. Morita, H.I. Ito (Okayama, JP)
Asymmetric dimethylarginine (ADMA) - intermediate phenotypes and atrial fibrillation in the general P4661
population.
– M. Ramuschkat, S. Appelbaum, D. Atzler, T. Zeller, R.H. Boeger, P.S. Wild, T. Muenzel, S. Blankenberg,
E. Schwedhelm, R.B. Schnabel (Hamburg and Mainz, DE)
Neutrophil/lymphocyte ratio predicts cardiovascular risk. The PREDIMED trial. P4662
– J. Rodriguez Capitan, E. Gomez-Gracia, M. Jimenez-Navarro, M.A. Martinez-Gonzalez, J. Salas-Salvado,
M. Fito, F. Aros, L. Serra-Majem, J.R. Alvero-Cruz, J. Warnberg (El Ejido, Madrid, Málaga, Navarra, Reus,
Barcelona, Vitoria and Las Palmas de Gran Canaria, ES)
Relationships of QTc interval with cardiac biomarkers in young adults. P4663
– T. Kofler, M. Bossard, S. Aeschbacher, A. Maseli, S. Blum, J. Todd, J. Estis, M. Risch, L. Risch, D. Conen
(Basel, CH; Alameda, US; Schaan, LI)
Correlation between plasma pentraxin-3, endothelial function and arterial stiffness in hemodialysis P4664
patients.
– M.M. Ciccone, M. Gesualdo, G. Ricci, S. Carbonara, R. Carbonara, F. Giardinelli, A. Zito, G. Pertosa,
G. Loreto, P. Scicchitano (Bari, IT)
RISK FACTORS IN CLINICAL PRACTICE

Seasonal variation of the critical limb ischemic events in the whole Hungarian population. P4665
– E. Kolossvary, T. Ferenci, L. Kovats, T. Kovats, Z. Jarai, K. Farkas (Budapest, HU)
291
Relationship between traditional cardiovascular risk factors and specific coronary angiographic findings: P4666
data from a large cohort of catheterized patients.
– E. Sanidas, D. Papadopoulos, N. Dalianis, G. Anastasiadis, G. Tzanis, G. Kelepesis, M. Bonou,
J. Barbetseas (Athens, GR)
Atrial fibrillation and impaired renal function predict cardiovascular outcome in mostly hypertensive P4667
patients with symptomatic peripheral artery disease and preserved ejection fraction.
– M. Vrsalovic, K. Vucur, B. Jelakovic (Zagreb, HR)
Are intermediate ankle-brachial index values related to circulating inflammatory, thrombotic and lipid P4668
markers in hypertension? Insights from a large cohort of never treated hypertensives.
– P. Xaplanteris, C. Vlachopoulos, D. Terentes-Printzios, M. Abdelrasoul, P. Pietri, A. Aggelakas, G. Vyssoulis,
IMAGING FOR PERIPHERAL DISEASE

Near-infrared spectroscopic hand imaging: a new tool to assess microcirculatory impairment in systemic P4669
sclerosis.
– L. Gargani, T. Barskova, V. Hartwig, M. Marinelli, S. Guiducci, S. Bellando Randone, Y. Blagojevic,
M.G. Trivella, M. Matucci Cerinic, A. L’Abbate (Pisa and Florence, IT)
Ultrasound evaluation of the forearm arteries anomalies in patients undergoing percutaneous coronary P4670
intervention via radial artery access.
– M. Plewka, J.P. Peruga, J.Z. Peruga, J.D. Kasprzak (Lodz and Kalisz, PL)
Faces of hypertension and renal microcirculation. P4671
– G. Moustakas, D. Konstantinidis, E. Chatzistamatiou, I. Babatseva Vagena, C. Trachanas, G. Memo,
A. Feretou, A. Androulakis, A. Avgeropoulou, I. Kallikazaros (Athens, GR)
Correlation between arterial stiffness as measured by progression of cardiac ankle vascular index and P4672
long term hypertension control status.
– S. Pibalyart, P. Vathesatogkit, T. Yingchoncharoen, S. Yamwong, P. Sritara (Bangkok, TH)
Magnetic resonance angiographic follow-up of denervation-induced renal artery dissections. P4673
– J. Daemen, A. Karanasos, M. Van Kranenburg, N. Van Mieghem, J. Ligthart, E. Van Der Heide, M. Ouhlous,
F. Zijlstra, E. Regar (Rotterdam, NL)
Impacts of age on coronary atherosclerosis and vascular response to statin therapy. P4674
– T. Nozue, S. Yamamoto, S. Tohyama, K. Fukui, S. Umezawa, Y. Onishi, T. Kunishima, K. Hibi,
M. Terashima, I. Michishita (Yokohama, Hiratsuka, Kawasaki and Toyohashi, JP)
Clinical presentation and outcome of bleeding in patients on treatment with new oral anticoagulants or P4675
vitamin K antagonists in real-life.
– L. Franco, C. Becattini, L. Masotti, C. Nitti, S. Cattinelli, R. Cappelli, G. Manina, R. Sbrojavacca, F. Pomero,
G. Agnelli (Perugia, Florence, Ancona, Trieste, Siena, Milan, Udine and Cuneo, IT)
Is it necessary to use new antiplatelet agents in patients who are treated with a bioresorbable vascular P4676
scaffold?
– J. Novoa Medina, D. Pavlovic, P. Martin Lorenzo, J. Suarez De Lezo Herreros De Tejada, M. Blanco,
S. Ojeda, D. Valeron, M. Pan, J. Suarez De Lezo Cruz Conde, A. Medina (Las Palmas de Gran Canaria and
Córdoba, ES)
Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its P4677
association with coronary atherosclerosis.
– T. Nozue, S. Yamagishi, M. Takeuchi, T. Hirano, S. Yamamoto, S. Tohyama, K. Fukui, S. Umezawa,
Y. Onishi, I. Michishita (Yokohama, Kurume, Ishikawa, Tokyo and Hiratsuka, JP)
SAME-TT2R2 score and the time in therapeutic range in anticoagulated elderly with atrial fibrillation. P4678
– J. Jaspers Focks, S.P.G. Van Vugt, M.T.H. Albers - Akkers, R. Joustra, L. Bloem - De Vries,
F.W.A. Verheugt, M.A. Brouwer (Nijmegen, NL)
Antiplatelet drug resistance in Asian population. P4679
– S. Ambalath (Trivandrum and Kerala, IN)
The assessment of anti-coagulant activity to predict bleeding outcome in atrial fibrillation patients P4680
receiving dabigatran etexilate.
– Y. Hu, Y.B.Y. Yu, S.A.C. Chen (Taipei, TW)
PERCUTANEOUS/ENDOVASCULAR TREATMENT
Outcome of transcatheter closure using the amplatzer devices in largest series of patients with isolated P4681
aorto-pulmonary window (APW) defect.
– A. Phatarpekar, M. Phadke, C. Lanjewar, P. Kerkar (Mumbai, IN)
Comparison of hybrid endovascular and open surgical repair for thoracic aortic disease involving arch. P4682
– W.C. Kang, M.G. Kim, P.C. Oh, E.K. Shin, C.H. Park, J.Y. Lee, Y.G. Ko, D. Choi (Incheon and Seoul, KR)
Percutaneous repair of prosthetic paravalvular leaks: acute and short-term outcomes. P4683
– G. Scognamiglio, G. Santoro, C. Capogrosso, C. Iacono, G. Gaio, F. D’Aiello, P. Coppolino, M.T. Palladino,
B. Sarubbi, M.G. Russo (Naples, IT)
Deficiency of endothelial progenitor cells is associated with subacute thrombosis after angioplasty in P4684
hemodialysis patients.
– C.-C. Wu, M.-Y. Hsieh, P.-H. Huang, J.-W. Chen, S.-J. Lin (Hsin-Chu and Taipei, TW)
292
The outcome of renal artery stenting in angiographically borderline renal artery stenosis, assessed as P4685
functionally significant by IVUS and rest and hyperemic pressure gradients.
– T. Przewlocki, A. Kablak-Ziembicka, D. Rzeznik, P. Musialek, A. Roslawiecka, M. Trystula, P. Podolec,
P. Pieniazek, K. Zmudka (Krakow, PL)
Impact of age on the long-term clinical outcomes after carotid artery stenting: a single centre registry. P4686
– J. Delgado Silva, L. Paiva, R. Cacao, R. Fernandes, S. Margalho, R. Ramos, H. Oliveira, M. Costa,
L. Goncalves (Coimbra, PT)
Balloon pulmonary angioplasty as treatment option for patients with unoperable chronic thromboembolic P4687
– C. Liebetrau, C.W. Wiedenroth, A.B. Breithecker, J.B. Blumenstein, A.G. Ghofrani, S.G. Guth, C.H. Hamm,
G.K. Krombach, H.M. Moellmann, E.M. Mayer (Bad Nauheim and Giessen, DE)
Early release kinetics of N-terminal pro-B-type natriuretic peptide in patients after percutaneous P4688
transluminal septal myocardial ablation.
– T. Fresz, E. Nagy, J. Tomcsanyi, R. Sepp (Budapest and Szeged, HU)
Stent implantation jailing deep femoral artery does not worsen clinical outcomes 6 months after P4689
endovascular treatment in patients with peripheral artery disease.
– Y. Iwata, K. Jujo, N. Kaneko, T. Umemoto, M. Utsunomiya, D. Ueshima, T. Doijiri, Y. Kobayashi (Ichihara,
Tokyo, Yamato and Chiba, JP)
Initial experience with the Tightrail rotating mechanical dilator sheath for transvenous lead extraction: P4690
safety and efficacy.
– K. Aytemir, H. Yorgun, U. Canpolat, M.L. Sahiner, E.B. Kaya, B. Evranos, N. Ozer (Ankara, TR)
Endovascular treatment for subacute deep vein thrombosis. P4691
– T. Senoo, S. Umemura, S. Tsujimoto, M. Motohiro, H. Kamihata, I. Shiojima (Hirakata, JP)
Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu P4692
arteritis: two-year results.
– X.J. Jiang (Beijing, CN)
Endovascular treatment of aortic coarctation. P4693
– M. Slim, Y. Messaoudi, E. Boughzela, R. Gribaa, E. Neffati, S. Ouali, G. Cheniti, S. Kacem, H. Ben Salem,
F. Remadi (Sousse, TN)
Prognosis and its predictors after endovascular therapy in hemodialysis patients with critical limb P4694
ischemia in contemporary practice.
– M. Nakao, J. Yamaguchi, S. Kataoka, S. Hatakeyama, H. Ohtsuki, K. Kamishima, K. Jujo, H. Arashi,
Y. Minami, N. Hagiwara (Tokyo, JP)
TECHNICAL ASPECTS OF PCI

Acute coronary syndromes in women undergoing percutaneous coronary intervention with drug-eluting P4695
stents: a patient-level pooled analysis of randomized controlled trials.
– G. Giustino, G.G. Stefanini, M. Aquino, S. Sartori, G.W. Stone, P.W.J.C. Serruys, E. Camenzind,
P.C. Smits, H.S. Kim, R. Mehran (New York, US; Milan, IT; Rotterdam, NL; Geneva, CH; Seoul, KR)
Comparison of biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting P4696
stent in terms of clinical outcome in patient with acute myocardial infarction.
– J.Y. Rhew, W. Kim, J.H. Cho, J.S. Woo, H.S. Kim (Jeonju, Seoul and Suncheon, KR)
Impact of the American College of Cardiology/American Heart Association lesion classification for P4697
outcomes in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
– P.S. Song, G.W. Seo, D.K. Kim, K.H. Kim, S.H. Seol, H.Y. Jin, T.H. Yang, Y.K. Ahn, M.H. Jeong, D.I. Kim
(Busan and Gwangju, KR)
Gender differences on short term outcomes after contemporary percutaneous coronary intervention. P4698
– E. Cenko, B. Ricci, Z. Vasiljevic, B. Knezevic, D. Trninic, D. Milicic, S. Kedev, O. Manfrini, L. Badimon,
R. Bugiardini (Bologna, IT; Belgrade, RS; Podgorica, ME; Banja Luka, BA; Zagreb, HR; Skopje, MK;
Barcelona, ES)
Old- versus new-generation drug-eluting stents in women with chronic kidney disease: a patient-level P4699
pooled analysis of randomized controlled trials.
– U. Baber, G. Giustino, G.G. Stefanini, M. Aquino, S. Sartori, G. Weisz, M. Valgimigli, A. Kastrati, A. Chieffo,
R. Mehran (New York, US; Milan, IT; Rotterdam, NL; Munich, DE)
Impact of successful recanalization of chronic total occlusions using coronary stents on long-term P4700
clinical outcomes: a meta-analysis.
– J.-S. Jang, H.-C. Shin, T.-H. Yang, H.-Y. Jin, J.-S. Seo, D.-K. Kim, D.-S. Kim (Busan, KR)
The hybrid toolkit for Chronic total occlusions: materials used in the RECHARGE Registry (REgistry of P4701
Crossboss and Hybrid procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom).
– J. Maeremans, A. Avran, P. Knaapen, S. Walsh, C. Hanratty, B. Faurie, P. Agostoni, J. Spratt, P. Kayaert,
J. Dens (Hasselt, Brussels and Genk, BE; Marignane and Grenoble, FR; Amsterdam and Utrecht, NL;
Belfast and Edinburgh, UK)
Adjunctive balloon post-dilatation in patients with ST-segment elevation myocardial infarction undergoing P4702
primary percutaneous coronary intervention.
– P.S. Song, J.Y. Hahn, E.K. Kim, Y.B. Song, S.H. Choi, J.H. Choi, H.C. Gwon (Busan and Seoul, KR)
Feasibility and safety of percutaneously inserted emergency VA-ECMO in cardiac catheterisation P4703
laboratory in acute MI with sever cardiogenic shock.
– A.E. Ghabashi, M.A. Alghamdi, A. Allan, S.R. Halawa (Hofuf, SA)
A comparison of baseline and residual SYNTAX scores in prediction of mortality after primary P4704
percutaneous coronary intervention for STEMI.
– Y. Singbal, L. Hogan, J.K. Haladyn, M. Fryer, P. Garrahy, R. Lim (Brisbane, AU)
293
Multivessel disease diagnosed at the time of primary PCI for STEMI: complete revascularization versus P4705
conservative strategy.
– O. Hlinomaz, L. Groch, L. Polokova, F. Lehar, T. Vekov, M. Griva, J. Sitar, M. Rezek, B. Gersh, P. Widimsky
(Brno, Zlin and Prague, CZ; Sofia, BG; Rochester, US)
Beneficial effects of an old drug - intracoronary verapamil improves left ventricular function in acute P4706
anterior STEMI.
– L. Pascalau, V. Turi, M. Badalica-Petrescu, M. Valcovici, R. Christodorescu, S.R. Dragan (Timisoara, RO)
Natural history of stent malapposition in patients treated by primary percutaneous coronary intervention: P4707
Subanalysis of ROBUST trial.
– M. Jakl, P. Cervinka, P. Kala, J. Kanovsky, A. Kupec, J. Vanek, K. Tanaka, S. Nishino, A. Schnell,
H.G. Bezerra (Hradec Králové, Ústí nad Labem and Brno, CZ; Cleveland, US)
Intracoronary nitroprusside versus verapamil for the prevention of no/slow reflow phenomenon in P4708
patients undergoing primary percutanous coronary intervention.
– H. Abdelaziz, S. Khaled, T. Khairy, S. Thabet, W. Elkelany, T. Rashid (Cairo, EG)
Effect of guidewire passage and mechanical thrombus aspiration on ST segment displacement in primary P4709
percutaneous coronary intervention for STEMI.
– P. Russhard, F. Al-Janabi, M. Parker, G.J. Clesham (Basildon and Chelmsford, UK)
Safety and effectiveness of deferring definitive treatment of the culprit lesion in ST-elevation myocardial P4710
infarction.
– C. Granda Nistal, B. Rubio Alonso, A. Jurado Roman, J. Garcia Tejada, S. Mayordomo Gomez, A. Miguel
Gutierrez, E.P. Garcia Martin, M.T. Velazquez Martin, F. Hernandez Hernandez, A. Albarran
Gonzalez-Trevilla (Madrid and Ciudad Real, ES)
In-hospital, thirty-day and six-month result of biodegradable polymer coated sirolimus eluting stent in P4711
coronary artery lesions (i-TRIAL study).
– R.S. Polavarapu, J. Prajapati, A. Raheem, K. Thakkar, V. Pamidimukkala, A. Polavarapu, N. Polavarapu,
S. Chinta, S. Kothari, A. Thakkar (Guntur, Andhra Pradesh, Gandhinagar, Gujarat, Navsari, Mehsana and
Surat, IN)
The role of thrombus aspiration for primary angioplasty in patients >75 years with ST elevated myocardial P4712
infarction: the ESTROFA MI+75 study.
– J.M. De La Torre Hernandez, S. Brugaletta, J.A. Gomez Hospital, J. Botas, J. Navarro Cuartero, J. Elizaga,
J.A. Linares, F. Hernandez, A. Arrebola, A. Gomez Jaume (Santander, Barcelona, Alcorcon, Albacete,
Madrid, Zaragoza, Granada and Palma de Mallorca, ES)
Real-world experience with ultra-thin biodegradable polymer coated sirolimus-eluting coronary stent: P4713
Six-month clinical outcomes of FLEX-Registry.
– A. Abhyankar, P. Chandwani, S. Saxena, P. Kumar, P. Verma, M.S. Sandhu, N. Parikh, A. Bhupali, S. Jain,
J. Prajapati (Surat, Gujarat, Jaipur, Rajasthan, Mohali, Punjab, Manipal, Karnataka, Gurgaon, Haryana,
Kolhapur, Maharashtra and Gandhinagar, IN)
Safety and efficacy of angio-seal vs exo-seal in patients undergoing primary percutaneous coronary P4714
intervention for ST-elevation myocardial infarction.
– N. Pinilla Echeverri, I. Sanchez Perez, A. Jurado Roman, M.T. Lopez Lluva, J. Benitez Peyrat, M. Marina
Breysse, J. Piqueras Flores, A. Moreno Arciniegas, P. Agudo Quilez, F. Lozano Ruiz-Poveda (Hamilton, CA;
Ciudad Real and Madrid, ES)
ST-elevation myocardial infarction and multivessel disease: predictors of non-culprit lesion P4715
revascularization.
– C. De Biase, G. Di Gioia, T. Strisciuglio, M. Esposito, D. Franco, R. Izzo, E. Stabile, G. Esposito,
B. Trimarco, E. Barbato (Naples, IT)
The impact of operator fatigue and sleep deprivation on primary percutaneous intervention procedure P4716
technique and outcomes.
– A. Arabi, J. Alsuwaidi, A. Gehani, A. Alqahtani, S. Arafa, A. Alnabti, I. Rafie, O. Alameemi, M. Yacoub (Doha,
QA)
Clinical outcomes of successful percutaneous coronary intervention for chronic total occlusion treated P4717
with sirolimus-eluting stent: results from the multicenter CTO registry.
– R.S. Polavarapu, J. Prajapati, K. Thakkar, A. Raheem, V. Pamidimukkala, A. Polavarapu, N. Polavarapu,
M. Noronha, B. Khambhati, A. Thakkar (Guntur, Andhra Pradesh, Gandhinagar, Gujarat, Mehsana, Navsari
and Surat, IN)
Clinical outcomes of first and second generation drug-eluting stent implantation for unprotected left main P4718
coronary artery bifurcation.
– M. Tsutsumi, T. Muramatsu, Y. Ito, K. Hirano, M. Yamawaki, M. Araki, N. Kobayashi, H. Takimura, S. Mori,
Y. Sakamoto (Yokohama, JP)
Influence of screen display in percutaneous coronary intervention: size does not matter. P4719
– J. Rondan Murillo, I. Lozano, J.M. Vegas, B. Samaniego, E. Hernandez, D. Leon, B. Vega, T. Gonzalez,
I. Valverde, E. Segovia (Gijon, ES)
NON-CORONARY CARDIAC INTERVENTIONS

Catheter substrate mapping to guide left ventricle aneurysm exclusion in patients post myocardial P4720
infarction.
– P. Neuzil, J. Petru, J. Skoda, L. Sediva, M. Janotka, M. Chovanec, S. Kralovec, I. Skalsky, S. Cerny,
P. Pavel (Prague, CZ)
A randomized comparison of subcutaneous “Z” stitch versus manual compression to achieve hemostasis P4721
after large caliber femoral venous sheaths’ removal.
– R. Pracon, J. Henzel, I. Cendrowska-Demkow, B. Pregowska-Chwala, A. Tarnowska, M. Demkow
(Warsaw, PL)
294
BASIC MECHANISMS, VENTRICULAR FUNCTION, PROGNOSIS III

Cytotoxic serum activity is independent mortality predictor of patients with chronic heart failure. P4722
– M. Klosinska, M. Stasiak, J. Drozdz, C. Cierniewski, M. Krzeminska-Pakula, J.D. Kasprzak (Lodz, PL)
The utility of biomarker risk prediction score in patients with chronic heart failure. P4723
– A. Berezin, A. Kremzer, T. Samura, T. Berezina (Zaporozhye, UA)
Prognostic value of cystatin C-derived estimated glomerular filtration rate in the patients with acute P4724
decompensated heart failure.
– S.Y. Jang, N.K. Kim, C.Y. Kim, J.H. Kim, M.H. Bae, J.H. Lee, D.H. Yang, H.S. Park, Y. Cho, S.C. Chae
(Daegu, KR)
Right ventricular function is a powerful independent predictor of adverse heart failure outcomes. P4725
– L.W. Wang, A.M. Keogh, P.S. Macdonald, A. Jabbour, E. Kotlyar, M.P. Feneley, D. Fatkin, C.S. Hayward
(Sydney, AU)
Heart rate / systolic blood pressure ratio at discharge as a simple prognostic factor for adverse clinical P4726
outcomes in patients with acute heart failure.
– J.Y. Cho, K.H. Kim, Y. Ahn, E.S. Jeon, J.J. Kim, S.C. Chae, S.H. Baek, S.M. Kang, M.C. Cho, B.H. Oh
(Gwangju, Seoul, Daegu and Cheongju, KR)
The presence of metabolic syndrome predicts long-term outcome in heart failure patients. P4727
– G. Bajraktari, G. Berisha, I. Bytyci, E. Haliti, P. Ibrahimi, A. Ahmeti, A. Poniku, M.Y. Henein (Prishtina, XK;
Umeå, SE)
Outcome of cardiac sarcoidosis patients treated with cardiac resynchronization therapy- comparison P4728
with other non-ischemic cardiomyopathy patients.
– K. Motoki, S. Nagase, N. Nishii, K. Nakagawa, K. Nakamura, H. Morita, H. Ito (Okayama, JP)
Transient systolic hypotension worsens the 2-year prognosis of chronic heart failure with preserved left P4729
ventricular ejection fraction.
– D. Serova, V. Serov, A. Shutov, I. Savinova, E. Shmelkova (Ulyanovsk, RU)
KIM-1 and NAG: new renal biomarkers for prognosis in acutely decompensated heart failure. P4730
– C. Jungbauer, S. Stadler, L. Maier, A. Luchner (Regensburg, DE)
BASIC MECHANISMS
Octadecatrienal and phosphatidylcholine as a potential new biomarkers in heart failure - novel insights P4731
from the analysis of serum metabolome in chronic heart failure patients.
– M. Marcinkiewicz-Siemion, K. Ptaszynska-Kopczynska, M. Ciborowski, A. Lisowska, M. Jasiewicz,
A. Szpakowicz, P. Miklasz, A. Kretowski, W.J. Musial, K.A. Kaminski (Bialystok, PL)
Angiotensin II activates MCP-1 through the infiltration of monocytes and macrophages into the heart and P4732
induces cardiac hypertrophy and dysfunction via Toll-like receptor 4.
– S. Umemoto, S. Matsuda, K. Yoshimura, T. Murata, T. Fukai, M. Matsuzak (Ube, JP; Chicago, US)
Adrenergic signaling-induced bone marrow and endothelial cell senescence promotes cardiac P4733
remodeling in heart failure.
– G. Katsuumi, I. Shimizu, Y. Yoshida, M. Suda, Y. Hayashi, S. Jiao, T. Minamino (Niigata, JP)
Differentiation of fibroblasts into myofibroblasts during hypertensive-derived cardiac fibrosis is promoted P4734
by alpha-v beta-5 integrin-mediated activation of TGF-beta1.
– G.L. Perrucci, D. Tosi, P. Nigro, G. Bulfamante, F. Magrini, G. Pompilio, F. Lombardi (Milan, IT)
IL-6 signaling in patients with chronic heart failure treated with cardiac resynchronization therapy. P4735
– K. Ptaszynska-Kopczynska, M. Marcinkiewicz-Siemion, A. Lisowska, A. Szpakowicz, M. Witkowski,
E. Waszkiewicz, P. Jakim, W.J. Musial, K.A. Kaminski (Bialystok, PL)
Wnt-signaling plays a critical role in cardiac hypertrophy and heart failure progression in mice. P4736
– A. Benkner, J. Ruedebusch, A. Poesch, M. Doerr, U. Voelker, S.B. Felix, K. Grube (Greifswald, DE)
Klotho and FGF receptor are concomitantly expressed in human individuals with heart failure. P4737
– G. Poelzl, S. Ghadge, M. Messner, E.M. Stocker, C. Ensinger, B.E. Husse, M.M. Zaruba (Innsbruck, AT)
Changes in cardiac cytoarchitecture in human dilated cardiomyopathy. P4738
– E. Ehler, M. Pluess, T. Randall, J. Dwyer, T. Iskratsch, C. Dos Remedios, P. Bennett (London, UK; Sydney,
AU)
Hepcidin and its regulator molecule hemojuvelin in systolic heart failure. P4739
– J. Banach, M. Grochowska, J. Blazejewski, D. Karasek, L. Gackowska, W. Sinkiewicz (Bydgoszcz, PL)
Fish oils may promote lusitropy by reducing phospholamban expression in human heart. P4740
– P. Saravanan, S. O’Neill, P.C. Calder, A. Trafford, N.C. Davidson (Wirral, Manchester and Southampton, UK)
BASIC MECHANISMS VENTRICULAR FUNCTION

Left ventricular deformation accurately predicts the extent of myocardial fibrosis in patients with P4741
advanced heart failure requiring transplantation.
– M. Cameli, S. Mondillo, F.M. Righini, M. Lisi, S. Sparla, C. Di Tommaso, F. Marino, C. Tsioulpas,
M. Maccherini, M. Henein (Siena, IT; Umeå, SE)
Ventricular-vascular coupling is altered in marfan syndrome but preserved in TAAD. P4742
– F. Loeper, J. Oosterhuis, M. Van Dorpel, D. Van Der Linde, R.W. Jeremy (Sydney, AU)
Clinical features of microvascular dysfunction and the relation to exercise hemodynamics in heart P4743
transplanted patients.
– T.S. Clemmensen, H. Eiskjaer, B.B. Loegstrup, J. Froekiaer, L.P. Tolbod, K. Bouchelouche, S.H. Poulsen
(Aarhus, DK)
295
Advanced heart failure with reduced ejection fraction and severe mitral insufficiency is associated with a P4744
reduced cardiac output vs oxygen uptake response to maximal exercise.
– G. Generati, F. Bandera, M. Pellegrino, F. Carbone, V. Labate, E. Alfonzetti, M. Guazzi (San Donato
Milanese, IT)
Multipoint pacing acutely induces better hemodynamics and QRS narrowing compared to conventional P4745
biventricular pacing.
– F. Zanon, E. Baracca, G. Pastore, L. Marcantoni, D. Lanza, C. Picariello, S. Aggio, L. Roncon, F. Noventa,
Strain pressure product- an afterload corrected myocardial strain measure and its association with P4746
features of preclinical heart failure and outcomes.
– H. Yang, K. Negishi, M. Nolan, Y. Wang, M. Saito, T. Marwick (Hobart, AU)
A novel and practical method to quantify mitral annulus motion and tricuspid annulus motion from P4747
cardiac magnetic resonance.
– L. Zhong, S. Leng, X.D. Zhao, J.I. Wong, F.Q. Huang, T.T. Le, R.S. Tan (Singapore, SG)
Rapid improvement of symptoms, filling pressures and pulmonary congestion estimated by combined P4748
echo and lung ultrasound protocol during early course of AHF treatment.
– J. Oehman, V.P. Harjola, J.O. Lassus, P. Karjalainen (Pori and Helsinki, FI)
Microvascular function as a link to left ventricular longitudinal deformation capacity in heart transplanted P4749
patients.
– T.S. Clemmensen, H. Eiskjaer, B.B. Loegstrup, S.H. Poulsen (Aarhus, DK)
Right to left ventricular interdependence evaluated by the ratio between pulmonary systolic to diastolic P4750
time at rest and during exercise in heart failure reduced ejection fraction: clinical insights.
– G. Generati, F. Bandera, M. Pellegrino, F. Carbone, V. Labate, E. Alfonzetti, M. Guazzi (San Donato
Milanese, IT)
Impact of persistent pulmonary hypertension on patients with severe aortic valve stenosis following TAVI. P4751
– M. Drakopoulou, K. Toutouzas, K. Stathogiannis, G. Latsios, A. Synetos, A. Michelongona,
A. Mastrokostopoulos, G. Trantalis, O. Kaitozis, D. Tousoulis (Athens, GR)
Statin effects on clinical outcomes in patients with acute myocardial infarction with acute severe systolic P4752
heart failure.
– W. Kim, J.H. Cho, J.Y. Rhew, J.S. Woo (Seoul, Suncheon and Jeonju, KR)
BASIC MECHANISMS, VENTRICULAR FUNCTION, PROGNOSIS I

Preserved ventricular-arterial coupling but more myocardial oxygen consumption and less mechanical P4753
efficiency in haemodialysis patients.
– M. Obokata, K. Negishi, K. Kurosawa, K. Ito, T. Ogawa, Y. Ando, M. Kurabayashi (Maebashi and Takasaki,
JP; Hobart, AU)
Left bundle branch block and resynchronisation therapy have major effects on right ventricular work load. P4754
– P. Storsten, E. Boe, E.W. Remme, M. Eriksen, E. Kongsgaard, O. Gjesdal, O.A. Smiseth, H. Skulstad (Oslo,
NO)
Kinetic energy patterns: towards quantitative non-invasive measurement of heart failure using magnetic P4755
resonance 4-dimensional flow.
– M. Kanski, P.M. Arvidsson, J. Toger, R. Borgquist, E. Heiberg, M. Carlsson, H. Arheden (Lund, SE)
Computer-controlled infusion system of cardiovascular drugs to automatically optimize hemodynamics in P4756
– K. Uemura, T. Kawada, M. Sugimachi (Suita, JP)
Baseline and change in QRS morphology with biventricular pacing is associated changes in biventricular P4757
function and clinical outcomes in advanced heart failure.
– Y.T. Tan, D. Wan, K. Al-Lawati, H.S. Lim (Birmingham, UK)
Acute hemodynamic comparison of biventricular, LV only and multipoint pacing in CRT patients. P4758
– F. Zanon, E. Baracca, G. Pastore, L. Marcantoni, D. Lanza, C. Picariello, S. Aggio, L. Roncon, F. Noventa,
Increased galectin-3 was closely associated with arterial wave reflections and provided incremental P4759
prognostic value upon natriuretic peptide in patients with acute heart failure.
– H.M. Cheng, S.H. Sung, W.C. Yu, S.Y. Chuang, C.H. Chen (Taipei and Miaoli County, TW)
Model of end-stage liver Disease excluding INR (MELD-XI) scoring system provides the additional P4760
prognostic information to hyponatremia in patients admitted with acute decompensated heart failure.
– T. Yamada, S. Tamaki, Y. Iwasaki, M. Ishimi, H. Hakui, M. Seo, Y. Sato, T. Ozaki, M. Fukunami (Osaka, JP)
Prognostic impact of plasma phospholipid fatty acid composition and dihomo-gamma-linoleic acid level P4761
in patients with acute heart failure.
– T. Nagai, N. Iwakami, Y. Sugano, T. Shibata, Y. Asaumi, T. Noguchi, K.F. Kusano, H. Ogawa, S. Yasuda,
Prognostic role of growth differentiation factor 15 (GDF-15) in obese patients with systolic heart failure P4762
(HF).
– J. Benes, M. Kotrc, V. Melenovsky, J. Kautzner, P. Jarolim (Prague, CZ; Boston, US)
Impact of elevated end-diastolic pulmonary regurgitation gradient on worse clinical outcome in patients P4763
with acute heart failure.
– Y. Honda, T. Nagai, Y. Sugano, T. Shibata, Y. Asaumi, T. Noguchi, K. Kusano, H. Ogawa, S. Yasuda,
T. Anzai (Osaka, JP)
296
BASIC MECHANISMS, VENTRICULAR FUNCTION, PROGNOSIS II

Defining prognosis in patients with advanced heart failure. P4764
– A. Ramalho, M. Santos, S. Leao, R. Baptista, S. Costa, A. Marinho Da Silva, R. Martins, F. Franco, M. Pego
(Coimbra and Vila-Real, PT)
Elderly heart failure with preserved ejection fraction patients showed different predictors for P4765
cardiovascular mortality than younger counterparts.
– J.J. Hai, P.H. Chan, H.F. Tse, C.W. Siu (Hong Kong, HK)
Regression of sokolow-lyon voltage is associated with higher incidence of cardiac events in patients with P4766
– D. Kinoshita, T. Shishido, T. Takahashi, M. Yokoyama, T. Narumi, S. Kadowaki, Y. Honda, T. Watanabe,
I. Kubota (Yamagata, JP)
Soluble ST2 predicts cardiovascular events, infectious and all-cause mortality in diabetic hemodialysis P4767
patients.
– F. Hammer, B. Dieplinger, C. Drechsler, B. Genser, M. Egger, T. Mueller, V. Krane, W. Maerz, S. Stoerk,
C. Wanner (Würzburg and Mannheim, DE; Linz, AT)
Low plasma albumin at admission is associated with worse outcomes in cardiogenic shock. P4768
– T. Jantti, J. Lassus, J. Parissis, J. Tolonen, A. Sionis, J. Spinar, M. Banaszewski, K. Pulkki, A. Mebazaa,
V.-P. Harjola (Helsinki and Kuopio, FI; Athens, GR; Barcelona, ES; Brno, CZ; Warsaw, PL; Paris, FR)
Is the combination BNP- Six-minute walking test a simple and reliable strategy to define prognosis of P4769
patients with chronic heart failure?
– A.B. Scardovi, S. Ghio, P.L. Temporelli, P. Faggiano, A. Rossi, A. Simioniuc, A. Ferraironi, G.G. Galeotti,
R. Ricci, F.L. Dini (Rome, Pavia, Veruno, Brescia, Verona and Pisa, IT)
Slovak acute heart failure survey II - predictors of in-hospital mortality. P4770
– P. Lesny, I. Varga, M. Luknar, P. Solik, E. Goncalvesova (Bratislava, SK)
Comparison of characteristics and outcomes in patients with HFpEF and HFrEF: result from KorAHF P4771
registry.
– W.S. Choe, H.J. Cho, H.Y. Lee, S.E. Lee, B.H. Oh (Seoul, KR)
Hepatic dysfunction - an important prognostic indicator for mortality in heart failure; a population based P4772
study.
– S. Jagdeep, D. Levin, M. Mohan, M. Francis, C.C. Lang (Dundee, UK)
Pre-operative serum sodium and atrial fibrillation predict improvement in cognitive function following left P4773
ventricular assist device implantation.
– G. Bhat, G. Yost, E. Mahoney (Oak Lawn, US)
HAEMODYNAMICS AND AUTONOMIC NERVOUS SYSTEMS IN HYPERTENSION
Impact of hypertension on myocardial salvage assessed by cardiac magnetic resonance in patients with P4774
reperfused acute myocardial infarction.
– T. Omori, S. Nakamori, K. Dohi, M. Ishida, N. Fujimoto, Y. Ichikawa, K. Kitagawa, N. Yamada, H. Sakuma,
M. Ito (Tsu, JP)
Association between diffuse myocardial fibrosis and decreased myocardial strain in hypertensives with P4775
preserved ejection fraction. A pilot study with cardiovascular magnetic resonance.
– A.M. Maceira Gonzalez, L. Tuset, F. Martinez, G. Pichler, B. Igual, E. Solaz, J. Redon (Valencia, ES)
Comparison of methodology to evaluate arterial stiffness in elderly males. P4776
– K.E. Smith, E.A. Ellins, L.T. Lennon, O. Papacosta, S.G. Wannamethee, P.H. Whincup, J.P. Halcox
(Swansea and London, UK)
An increase in peak excess pressure accounts for the rise in systolic blood pressure along the aorta. P4777
– O. Narayan, J.E. Davies, A.D. Hughes, K.H. Parker, S.A. Hope, I.T. Meredith, J. Cameron (Melbourne, AU;
London, UK)
The relationship between right ventricular mechanics and different geometric patterns according to the P4778
updated criteria: findings from the hypertensive population.
– M. Tadic, A.M. Majstorovic, B.I. Ivanovic, V.C. Celic (Belgrade, RS)
Relationship between left ventricular systolic stress and systolic strain or strain rate in hypertension P4779
assessed by one-beat 3-dimensional speckle tracking echocardiography with high volume rate.
– M. Ishiguro, M. Kawasaki, R. Tanaka, S. Minatoguchi, K. Ono, M. Saeki, H. Miwa, T. Yoshizane, T. Noda,
Myocardial fibrosis correlated with sub-endocardial but not global circumferential strain in hypertension. P4780
– W.-C. Tsai, L.-T. Yang, Y.-W. Liu, W.-H. Lee (Tainan, TW)
Effects of iron overload on sympathetic nervous system in essential hypertensive patients. P4781
– G. Seravalle, R. Dell’oro, F. Quarti, I. Boggioni, S. Buzzi, G. Mancia, G. Grassi (Milan and Monza, IT)
Prolonged heart rate recovery as predictor of incidental hypertension and survival. P4782
– C. Hjalmarsson, L. Holmqvist, B. Andersson, K. Manhem, L. Bergfeldt (Gothenburg, SE)
Reduced baseline heart rate and increased exercise-induced heart rate response as characteristic P4783
features in patients with orthostatic hypotension.
– M. Noda, S. Watanabe, T. Murakami, T. Nakamura, T. Ikenouchi, Y. Yamamoto, K. Ichikawa, M. Usui
(Tokyo, JP)
High sodium enhances non-neuronal acetylcholine release in the renal cortex. P4784
– S. Shimizu, T. Kawada, T. Akiyama, M. Fukumitsu, A. Kamiya, T. Shishido, M. Sugimachi (Osaka, JP)
Blood pressure and sympathetic activity markers are associated with monocyte chemoattractant protein P4785
1 (MCP1) levels.
– H. Lopes, R.F. Dominguez, J.G. Santos, V. Costa-Hong, L.A. Bortolotto, F. Consolim-Colombo (São Paulo,
BR)
297
MONDAY 31 AUGUST 2015 – EVENING SESSIONS
AWARDS CEREMONY Special Event
Chairperson(s): F.J. Pinto (Lisbon, PT); G.A. Derumeaux (Créteil, FR)

An opportunity to congratulate the winners throughout the Abstract Programme and for further exchange
with Members of the jury as well as Congress Programme Committee Members.
18:30–20:00 | Rabat - Village 1

PCSK9 INHIBITORS AND EVIDENCE-BASED OUTCOMES – WHAT DOES THE FUTURE Satellite Symposium
HOLD?
Sponsored by Pfizer
Chairperson(s): P.J. Barter (Sydney, AU); C.M. Ballantyne (Houston, US)
18:30 Current unmet needs and evidence-based approaches for Cardiovascular risk reduction among 4786
high-risk patients.
18:50 PCSK9 inhibition: from proof of concept to clinical application. 4787
– G. Lambert (Le Kremlin-Bicêtre, FR)
19:10 Cardiovascular risk reduction with PCSK9 inhibition: insight and long-term Cardiovascular 4788
outcomes.
– J.-C. Tardif (Montreal, CA)
19:30 Panel discussion and Q&A - PCSK9 inhibitors and evidence-based outcomes - What does the 4789
future hold?
– P.J. Barter (Sydney, AU), C.M. Ballantyne (Houston, US)

CYCLOPHILIN D INHIBITORS IN REPERFUSION INJURY Satellite Symposium
Sponsored by NeuroVive Pharmaceutical
Chairperson(s): M. Ovize (Lyon, FR); D. Garcia-Dorado (Barcelona, ES)
18:30 Welcome and introduction - Cyclophilin D inhibitors in reperfusion injury. 4790
– D. Garcia-Dorado (Barcelona, ES)
18:35 Mitochondrial permeability transition in reperfusion injury. 4791
18:45 Reducing reperfusion injury in STEMI patients: Cyclosporine to ImpRove Clinical oUtcomes in ST 4792
elevation myocardial infarction patients (the CIRCUS trial).
18:55 Clinical perspectives for cyclophilin D inhibitors. 4793
19:05 Panel discussion and conclusion - Cyclophilin D inhibitors in reperfusion injury. 4794

SHERLOCK HOLMES AND THE ASSESSMENT OF PREMATURE HEART DISEASE Satellite Symposium
Sponsored by Aegerion
Chairperson(s): J.J.P. Kastelein (Amsterdam, NL); J.E. Deanfield (London, UK)
18:30 Welcome and introduction - Sherlock Holmes and the assessment of premature heart disease. 4795
– J.J.P. Kastelein (Amsterdam, NL), J.E. Deanfield (London, UK)
18:35 Homozygous Familial Hypercholesterolaemia (HoFH) – isolated incidents or serial cases? 4796
& Questions.
– S. Kathiresan (Boston, US)
19:00 Improved detection and interrogation of HoFH & Questions. 4797
– D. Blom (Cape Town, ZA)
19:25 A matter of proof – what constitutes evidence? & Questions. 4798
– Z.A. Fayad (New York, US)
19:50 Discussion and closing - Sherlock Holmes and the assessment of premature heart disease. 4799
– J.J.P. Kastelein (Amsterdam, NL), J.E. Deanfield (London, UK)
298

PREVENTING ATRIAL FIBRILLATION-RELATED STROKES AND RECURRENT ACUTE Satellite Symposium
CORONARY SYNDROMES: COMBINING EVIDENCE FROM CLINICAL TRIALS AND REAL
LIFE
Chairperson(s): A.J. Camm (London, UK); C. Bode (Freiburg, DE)
18:30 Welcome and Introduction - Preventing atrial fibrillation-related strokes and recurrent acute 4800
coronary syndromes: combining evidence from clinical trials and real life.
18:35 Stroke prevention in high-risk patients with atrial fibrillation in clinical trials. 4801
18:55 The latest insights from real-life settings on the prevention of atrial fibrillation-related stroke. 4802
19:10 Extending the scope of novel oral anticoagulants: what’s new from the studies? 4803
– R. Cappato (Rozzano, IT)
19:25 Novel oral anticoagulant use for secondary prevention of acute coronary syndromes: where are 4804
we now?
– C. Gibson (Boston, US)
19:40 Q&As and practical considerations: clinical scenarios - Preventing atrial fibrillation-related strokes 4805
and recurrent acute coronary syndromes: combining evidence from clinical trials and real life.
19:55 Conclusion - Preventing atrial fibrillation-related strokes and recurrent acute coronary 4806
syndromes: combining evidence from clinical trials and real life.

WHERE ARE WE WITH CURRENT HEART FAILURE (HF) MANAGEMENT SYSTEMS, Satellite Symposium
STRUCTURE AND SCIENCE?
Sponsored by Medscape Cardiology / theheart.org
Chairperson(s): M. Jessup (Philadelphia, US); J.J.V. McMurray (Glasgow, UK)
18:30 Introduction - Where are we with current Heart Failure (HF) management systems, structure and 4807
science?
– M. Jessup (Philadelphia, US)
18:35 A call to action in HF: what have we achieved and where are we going? 4808
MONDAY – EVENING
18:45 Dual action molecules in HF: from bench to bedside. 4809
– J.C. Burnett Jr (Rochester, US)
19:00 A case of HF management today: can we do better for our patients? 4810
19:20 Q & A Session - Where are we with current Heart Failure (HF) management systems, structure 4811
and science?
19:29 Wrap up and closing remarks - Where are we with current Heart Failure (HF) management 4812
systems, structure and science?
18:30–19:15 | Tunis - Village 7

CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) – CHOOSING THE Satellite Symposium
RIGHT PATH TO SUCCESSFUL PATIENT OUTCOMES
Chairperson(s): J.S.R. Gibbs (London, UK)
18:30 Opening and introduction - Chronic Thromboembolic Pulmonary Hypertension (CTEPH) – 4813
Choosing the right path to successful patient outcomes.
18:35 Making the right choices: from diagnosis to surgery. 4814
– E. Mayer (Bad Nauheim, DE)
18:50 Making the right choices: from diagnosis to medical treatment. 4815
– D. Langleben (Montreal, CA)
19:05 Q and A - Chronic Thromboembolic Pulmonary Hypertension (CTEPH) – Choosing the right path 4816
to successful patient outcomes.
299

ADVANCES IN THE MANAGEMENT OF VALVULAR HEART DISEASE: THE HEART TEAM Satellite Symposium
APPROACH
Sponsored by Cleveland Clinic
Chairperson(s): W. Jaber (Cleveland, US); V. Menon (Cleveland, US)
18:30 Recognizing complications of Transcatheter Aortic Valve Replacements (TAVRs): 4817
echocardiographic lessons from around the globe.
– W. Jaber (Cleveland, US)
18:45 Is there a right valve for the right patient: impact of valve design on candidacy? 4818
– E.M. Tuzcu (Cleveland, US)
19:00 Should all patients with asymptomatic aortic stenosis be offered aortic valve replacement? The 4819
crucial role for pre-procedure evaluation.
– B. Griffin (Cleveland, US)
19:15 Future challenges in the adoption of TAVR. 4820
– L. Svensson (Cleveland, US)
300
TUESDAY
1 SEPTEMBER
TUESDAY



TUESDAY 1 SEPTEMBER 2015 – MORNING SESSIONS


ISSUES AND PRACTICAL SOLUTIONS FOR CHRONIC TOTAL OCCLUSION Science@Breakfast
Chairperson(s): C. Di Mario (London, UK); Y. Kobayashi (Chiba, JP)
07:30 Coronary computed tomography guided PCI of chronic total occlusion. 4821
– Y. Chen (Beijing, CN)
07:52 Complex CTO, step by step case based scenario for a successful retrograde approach. 4822
– G.S. Werner (Darmstadt, DE)

HOW TO ISOLATE HUMAN CARDIOMYOCYTES Science@Breakfast
Chairperson(s): S. Sossalla (Göttingen, DE)
07:30 How to isolate atrial cardiomyocytes. 4823
– C.E. Molina (Essen, DE)
07:52 How to isolate ventricular cardiomyocytes. 4824
– R. Coppini (Florence, IT)

CRAZY VERSUS SERIOUS IDEAS: RESEARCHING CAN BE FUN AND SURPRISING! Science@Breakfast
Chairperson(s): M.T. Tavares Aguiar (Lisbon, PT)
07:30 Crazy ideas producing highly cited papers. 4825
07:52 Plausible hypotheses leading to unexpected results. 4826
– S.D. Kristensen (Aarhus, DK)

STRATEGIES TO PREVENT SMOKING IN VULNERABLE GROUPS: WOMEN AND CHILDREN Science@Breakfast
Chairperson(s): J. Perk (Oskarshamn, SE); C. Radu-Loghin (Brussels, BE)
07:30 Preventing: can we do it? 4827
– E. Dagli (Istanbul, TR)
07:52 Combating: do we have the right approaches? 4828
– S. Michie (London, UK)

HOW TO EVALUATE THE HEART IN HYPERTENSION Science@Breakfast
Chairperson(s): G. de Simone (Naples, IT); S. Matskeplishvili (Moscow, RU)
07:30 Echocardiography. 4829
– R.B. Devereux (New York, US)
07:52 MRI. 4830
– V. Muthurangu (London, UK)

ESC GUIDELINES – INFECTIVE ENDOCARDITIS Main Session
Chairperson(s): G. Habib (Marseille, FR); P. Lancellotti (Liège, BE)
08:30 Prevention, prophylaxis. 4831
08:52 Diagnosis. 4832
– P. Tornos Mas (Barcelona, ES)
09:15 When to operate? 4833
09:37 Specific situations. 4834
– U. Snygg-Martin (Gothenburg, SE)
302

SURVIVOR OF OUT-OF-HOSPITAL CARDIAC ARREST – ACUTE AND LONG-TERM Special Session
MANAGEMENT
Chairperson(s): J. Kautzner (Prague, CZ); To be announced
08:30 The heart team. 4835
– J. Kettner (Prague, CZ), R. Kockova (Prague, CZ), K. Sedlacek (Prague, CZ), A. Krebsova (Prague, CZ)
08:38 Brief presentation of the heart team. 4836
08:47 Patient admission and initial ICU management. 4837
08:55 The role of cardiac imaging for diagnosis. 4838
09:04 ICD implantation and programming. 4839
09:12 Genetic evaluation of the family. 4840
09:21 Follow up, admission for recurrent CT, catheter ablation and long term follow up. 4841

REGISTRY II – INTERVENTIONS / ACUTE CARDIOVASCULAR CARE Registry Session
Chairperson(s): P. Widimsky (Prague, CZ); M.E. Bertrand (Lambersart, FR)
08:30 Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic 4842
cardiomyopathy: results from the Euro-ASA registry.
– J. Veselka (Prague, CZ)
08:45 Carbonated beverages are associated with out-of-hospital cardiac arrests of cardiac origin: from 4843
the All-Japan Utstein Registry.
– K. Saku (Fukuoka, JP)
09:00 CRT-P or CRT-D? The CeRtiTuDe Cohort Study. 4844
09:15 ELECTRa (European Lead Extraction ConTRolled) registry: long-term results on transvenous lead 4845
extraction in europe.
– M.G. Bongiorni (Pisa, IT)
09:30 CABG-related bleeding complications in patients treated with ticagrelor or clopidogrel: analysis 4846
from a nationwide registry.
– A. Jeppsson (Gothenburg, SE)
09:45 Percutaneous coronary intervention centre volume and 30-day mortality: A contemporary national 4847
cohort study of 427,467 cases.
– D. O’Neill (London, UK)

EMBRYONIC PROGRAMMING OF CONGENITAL AND ADULT CARDIOVASCULAR DISEASE Symposium
Chairperson(s): N. Smart (Oxford, UK); D. Hilfiker-Kleiner (Hannover, DE)
08:30 Developmental origins of adult disease. 4848
– S. Langley Evans (Nottingham, UK)
08:52 Congenital heart disease in pregnancies complicated by maternal diabetes mellitus. 4849
– E.J. Meijboom (Enschede, NL)
09:15 Developmental origins of adult cardiovascular health and disease. 4850
– C. Fall (Southampton, UK) TUESDAY – MORNING
09:37 Developmental programming of cardiovascular disease by prenatal hypoxia. 4851
– S. Ozanne (Cambridge, UK)

TRIALS AND STATISTICS ARE EASY! A GUIDE FOR THE CLINICAL CARDIOLOGIST Symposium
Chairperson(s): R. Fontes Carvalho (Porto, PT); M.A. Alonso Garcia (London, UK)
08:30 Intention-to-treat versus on-treatment analysis - What to choose? 4852
08:52 Superiority versus non-inferiority - What is the difference? 4853
09:15 Time to first event versus repeated event analysis - Who wins the game? 4854
09:37 Pitfalls in major clinical trials. 4855
– S.J. Pocock (London, UK)
303

NOVELTIES IN CARDIAC RESYNCHRONISATION THERAPY Rapid Fire Abstract
Chairperson(s): F. Leyva-Leon (Sutton Coldfield, UK); E. Simantirakis (Heraklion, GR)
08:30 Transseptal endocardial left ventricular lead implantation after failed CRT implantation- long term 4856
results.
– L.A. Geller, L. Molnar, S.Z. Szilagyi, E. Zima, G. Szeplaki, V.K. Nagy, E.E. Ozcan, A. Apor, Z. Sallo,
08:39 Cardiac resynchronization therapy improves left ventricular volumes in patients with ejection 4857
fraction between 36 and 50% with left bundle branch block: MIRACLE EF study.
– E.S. Chung, G. Egnaczyk, A. Curtis, G. Fonarow, A. Tang, M. Cowie, F. Levya, C. Manrodt, N. Patel,
C. Linde (Cincinnati, Buffalo, Los Angeles and Minneapolis, US; Malahat, CA; London and Birmingham, UK;
Stockholm, SE)
08:48 Cardiac resynchronization therapy in the elderly - is there an indication for a defibrillator? 4858
– M. Doering, J. Lucas, K. Bode, A. Muessigbrodt, T. Heine, H. Knopp, G. Hindricks, S. Richter (Leipzig, DE)
08:57 Relationship between indices of left ventricular lead electrical position in spontaneous rhythm and 4859
right ventricular pacing: implications for optimization of cardiac resynchronization therapy.
– D. Wichterle, K. Sedlacek, H. Jansova, L. Kryze, V. Vancura, R. Cihak, J. Kautzner (Prague, CZ)
09:06 Prognostic role of right ventricular function in patients with heart failure undergoing cardiac 4860
– G.L. Botto, S. Maffe’, G. Stabile, E. Bertaglia, A. D’Onofrio, U. Parravicini, F. Esposito, L. Padeletti,
M. Malacrida, A. Rapacciuolo (Como, Borgomanero, Naples, Padua, Florence and Milan, IT)
09:15 Different long-term outcome depending on cardiac rhythm in heart failure patients undergoing 4861
cardiac resynchronization therapy.
– E. Jedrzejczyk-Patej, M. Mazurek, R. Lenarczyk, A. Liberska, K. Przybylska-Siedlecka, T. Podolecki,
P. Pruszkowska, A. Sokal, O. Kowalski, Z. Kalarus (Zabrze, PL)
09:24 Effect of apical and non-apical right ventricular lead position on cardiac resynchronization 4862
therapy outcome.
– T. Zografos, K.C. Siontis, M. Jastrzebski, V. Kutyifa, H.U. Klein, W. Zareba, D.G. Katritsis (Athens, GR;
Rochester, US; Krakow, PL)
09:33 Targeting the LV pacing site by means of electrical delay and LVdP/dtmax may predict the long 4863
term clinical outcome in CRT patients.
– F. Zanon, L. Marcantoni, D. Lanza, C. Fraccaro, E. Baracca, G. Pastore, C. Picariello, L. Roncon, S. Aggio,
F.W. Prinzen (Rovigo, IT; Maastricht, NL)
09:42 Impact of collagen turnover markers on echocardiographic response and mortality after CRT-D 4864
implantation in TRUST-CRT study population.
– A. Sokal, R. Lenarczyk, O. Kowalski, K. Mitrega, S. Pluta, J. Stabryla-Deska, Z. Kalarus (Zabrze, PL)
09:51 Ventricular antitachycardia pacing therapy in heart failure patients with cardiac resynchronization 4865
therapy defibrillator: efficacy, safety and impact on heart failure hospitalizations and mortality.
– G. Boriani, M. Landolina, R. Ricci, M. Lunati, E. Daleffe, R. Rordorf, G. Morani, G. Gasparini, A. Proclemer,
M. Gasparini (Bologna, Crema, Rome, Milan, Udine, Pavia, Verona, Mestre-Venice and Rozzano, IT)
304

HAEMODYNAMICS IN HYPERTENSION Rapid Fire Abstract
Chairperson(s): G.E. Fabregues (Buenos Aires, AR); G. Mancia (Milan, IT)
08:30 The VKORC1 (-1639) G>A promoter polymorphism is associated with elevated systemic arterial 4866
blood pressure.
– A. Panzenboeck, C. Gerges, S. Zehetmayer, G. Endler, V. Leibetseder, T.R. Bader, C. Mannhalter,
I.M. Lang (Vienna, AT)
08:39 Lack of regression of left ventricular hypertrophy is accompanied by increased incidence of 4867
stroke and combined cardiovascular disease in essential hypertensives.
– D. Tsiachris, C. Tsioufis, V. Antonakis, K. Dimitriadis, D. Flessas, F. Lagiou, S. Galanakos, A. Milkas,
D. Roussos, D. Tousoulis (Athens, GR)
08:48 Prognostic implications of left ventricular strain and strain risk score in patients with hypertensive 4868
heart disease.
– M. Saito, F. Khan, T. Stoklosa, A. Iannaccone, K. Negishi, T. Marwick (Hobart, AU)
08:57 Predictive role of hypertension related organ damage and blood pressure control patterns for the 4869
incidence of new-onset atrial fibrillation in essential hypertensives.
– D. Tsiachris, C. Tsioufis, V. Antonakis, K. Dimitriadis, D. Flessas, E. Andrikou, D. Aragiannis, A. Kefala,
C. Stefanadis, D. Tousoulis (Athens, GR)
09:06 Hypertensive left ventricular geometry and myocardial mechano-energetic efficiency: refining 4870
cardiovascular risk profile in arterial hypertension.
– M. De Marco, G. De Simone, R. Izzo, V. Trimarco, E. Stabile, M. Lembo, M.-V. Manzi, B. Trimarco, N. De
Luca (Naples, IT)
09:15 Aortic stiffness and essential hypertension phenotypes. 4871
– E. Chatzistamatiou, G. Moustakas, C. Trachanas, D. Konstantinidis, I. Babatseva Vagena, A. Feretou,
G. Memo, A. Androulaks, A. Avgeropoulou, I. Kallikazaros (Athens, GR)
09:24 An increase in left ventricular wall thickness augments ejection fraction in hypertensive heart 4872
disease through changes in absolute wall thickening: a cardiac magnetic resonance imaging
study.
– J.C.L. Rodrigues, S. Rohan, A. Ghosh Dastidar, M.C.K. Hamilton, C. Bucciarelli-Ducci, A.K. Nightingale,
J.R.F. Paton, N.E. Manghat, D.H. MacIver (Bristol and Taunton, UK)
09:33 Associations of hemodynamic load with impaired myocardial flow reserve: role of sex and 4873
hypertension.
– T. Coutinho, K. Srivaratharajah, R. Beanlands, R. Dekemp, L. Mielniczuk (Ottawa, CA)
09:42 Left ventricular mass versus pulse wave velocity as predictors of coronary artery disease in 4874
patients with essential hypertension: Data from a Greek 6-year-follow-up study.
– K. Dimitriadis, C. Tsioufis, E. Andrikou, T. Milkas, A. Kasiakogias, A. Papanikolaou, D. Syrseloudis,
D. Roussos, D. Tousoulis (Athens, GR)
09:51 Electrocardiographic detection of hypertensive left ventricular hypertrophy in the presence of 4875
obesity and left ventricular remodeling: re-calibration against cardiac magnetic resonance.
– J.C.L. Rodrigues, B. McIntyre, A. Ghosh Dastidar, S.M. Lyen, L.E.K. Ratcliffe, A.E. Burchell,
M.C.K. Hamilton, C. Bucciarelli-Ducci, A.K. Nightingale, N.E. Manghat (Bristol, UK)
08:30–10:00 | Rabat - Village 1

CORONARY MICROVASCULAR REMODELLING AND CARDIAC DYSFUNCTION Symposium
Science in practice
Chairperson(s): A.R. Pries (Berlin, DE); P. Libby (Boston, US)
08:30 Coronary microvascular remodelling: the integrative picture. 4876 TUESDAY – MORNING
– C. De Wit (Lübeck, DE)
08:52 The pathophysiology of remodelling and microvascular function. 4877
– D.J. Duncker (Rotterdam, NL)
09:15 Clinical assessment and characterisation of coronary microvascular dysfunction. 4878
09:37 Microvascular obstruction and large vessel dysfunction: what is the connection? 4879
305

IN-DEPTH CHARACTERISATION OF THROMBOSIS IN MYOCARDIAL INFARCTION Symposium
Science in practice
Chairperson(s): A. Siegbahn (Uppsala, SE); T.W. Weiss (Vienna, AT)
08:30 The evolving acute coronary thrombus; a role for erythrocytes? 4880
08:52 Gene expression polymorphisms and risk of coronary thrombosis. 4881
– I. Seljeflot (Oslo, NO)
09:15 The role of leukocytes/granulocytes microparcticles in evolving coronary thrombosis. 4882
– R. Suades Soler (Barcelona, ES)
09:37 Time-course of circulating biomarkers of acute coronary thrombosis. 4883
– W. Koenig (Munich, DE)

REDUCING CARDIOVASCULAR RISK IN DIABETES: ONE SIZE DOES NOT FIT ALL Advances in Science
Chairperson(s): O. Barna (Kyiv, UA); M. Volpe (Rome, IT)
08:30 State of the Art in reducing cardiovascular risk in diabetes. 4884
– N. Sattar (Glasgow, UK)
08:50 Improved cardiovascular risk factors control associated with a large-scale risk reduction program 4885
among diabetes population.
– J. Rana, A. Karter, J. Liu, H. Moffet, M. Jaffe (Oakland and South San Francisco, US)
09:07 Resting heart rate and measures of effort related cardiac autonomic dysfunction predicts 4886
cardiovascular events in asymptomatic type 2 diabetics.
– B. Zafrir, M. Azencot, B.S. Lewis, M.Y. Flugelman, D.A. Halon (Haifa, IL)
09:24 Impact of stress testing for coronary artery disease screening in asymptomatic patients with 4887
diabetes mellitus: a community-based study.
– M. Omer, R. Bates, S. Abdelmoneim, A. Arruda-Olson, C. Scott, K. Bailey, R. McCully, P. Pellikka
(Rochester, US)
09:41 Future direction for research in reducing cardiovascular disease risk in type 2 diabetes. 4888
– J. Tuomilehto (Helsinki, FI)

WHAT IS BEYOND STATINS IN DYSLIPIDAEMIA TREATMENT? Symposium
ESC and the European Atherosclerosis Society
Chairperson(s): Z. Reiner (Zagreb, HR); L. Tokgozoglu (Ankara, TR)
08:30 Should we still use niacin, ezetimibe or fibrates? 4889
– M.-R. Taskinen (Helsinki, FI)
08:52 PCSK9 inhibitors: are they the new statins? 4890
09:15 Mipomersen and lomitapide: hope or hype? 4891
09:37 What else can we offer our patients? 4892
– O. Wiklund (Gothenburg, SE)
08:30–10:00 | Kiev - Village 3

THE BRAIN IN HYPERTENSION Symposium
Chairperson(s): R. Touyz (Glasgow, UK); M.H. Olsen (Odense, DK)
08:30 Pathophysiology of stroke and cognitive decline in hypertension. 4893
– M. Galagoudza (St. Petersburg, RU)
08:52 How to treat blood pressure in acute stroke. 4894
– P. Bath (Nottingham, UK)
09:15 Chronic treatment of blood pressure after stroke. 4895
– E.V. Shlyakhto (St. Petersburg, RU)
09:37 Treatment of high blood pressure: impact on cognitive decline. 4896
– A. Coca (Barcelona, ES)
306

LEFT VENTRICULAR HYPERTROPHY Advances in Science
Chairperson(s): M. Foppa (Porto Alegre, BR); G. de Simone (Naples, IT)
08:30 State of the Art in hypertensive left ventricular hypertrophy. 4897
– R.B. Devereux (New York, US)
08:50 Urinary albumin predicts future hypertension and increases in blood pressure in the general 4898
population.
– S. Murai, H. Takase, T. Sugiura, S. Yamashita, N. Ohte, Y. Dohi (Nagoya and Hamamatsu, JP)
09:07 The hypertrophic microRNAs miR-208b, miR-499 and miR-21 are related to left ventricular 4899
hypertrophy in patients with essential hypertension.
– J.E. Kontaraki, M.E. Marketou, F.I. Parthenakis, S. Maragkoudakis, E.A. Zacharis, G.E. Kochiadakis,
P.E. Vardas (Heraklion, GR)
09:24 Probability of echocardiographic left ventricular hypertrophy regression during antihypertensive 4900
treatment in a real-word context: The Campania Salute Network.
– M.T. Lonnebakken, R. Izzo, C. Mancusi, M. De Marco, M.A. Losi, G. Canciello, V. Trimarco, N. De Luca,
E. Gerdts, G. De Simone (Bergen, NO; Naples, IT)
09:41 Future direction for research in left ventricular hypertrophy. 4901
– V. Muthurangu (London, UK)

MANAGEMENT OF A PATIENT WITH UNEXPLAINED SYNCOPE AND OF A PATIENT Guidelines in Daily Practice
WITH VENTRICULAR ARRHYTHMIAS
Chairperson(s): M. Brignole (Lavagna, IT); C. Torp-Pedersen (Aalborg, DK)
08:30 Management of a patient with unexplained syncope and normal heart. 4902
– T.J.R. De Potter (Aalst, BE)
08:45 Management of a patient with unexplained syncope and normal heart - What do the Guidelines 4903
say?
09:00 Management of a patient with unexplained syncope and normal heart - Panel discussion on how 4904
– M. Lunati (Milan, IT), N. Edvardsson (Pixbo, SE)
09:10 Management of a patient with unexplained syncope and normal heart - Conclusion and take home 4905
message.
– M. Brignole (Lavagna, IT)
09:15 Management of a patient with non sustained ventricular tachycardia and structural heart disease. 4906
– R.P. Martins (Rennes, FR)
09:30 Management of a patient with non sustained ventricular tachycardia and structural heart disease 4907
- What do the Guidelines say?
– J. Beissel (Luxembourg, LU)
- Panel discussion on how to implement the Guidelines.
– H.V. Huikuri (Oulu, FI), T. Yamada (Birmingham, US)
- Conclusion and take home message.
– C. Torp-Pedersen (Aalborg, DK)
TUESDAY – MORNING
NEW ERA IN MYOCARDIAL PERFUSION IMAGING Advances in Science
Chairperson(s): D. Neglia (Pisa, IT); H.J. Ukkonen (Turku, FI)
08:30 State of the Art in diagnostic and prognostic value of nuclear MPI: decades of experience. 4910
08:50 Myocardial perfusion imaging predicts mortality in patients evaluated for kidney transplantation. 4911
– S. Helve, M. Laine, I. Helantera, J. Sinisalo, O. Lammintausta, J. Lehtonen, H. Hanninen, P. Finne,
T. Nieminen (Helsinki, FI)
09:07 Incremental Prognostic Value of Noninvasive Coronary Flow Reserve. 4912
– M. Al-Mallah, A. Ahmed, A. Aljizeeri, I. Suleiman (Riyadh, SA)
09:24 Comparison of coronary flow reserve detected by positron emission tomography (PET) in patients 4913
with hypertrophic cardiomyopathy and hypertrophic cardiomyopathy with hypertension.
– F. Yalcin, H. Yalcin, I. Pozios, R. Abraham, T.P. Abraham (Baltimore, US)
09:41 Future direction for research in myocardial perfusion imaging. 4914
– P.A. Kaufmann (Zurich, CH)
307

MULTIMODALITY CARDIAC IMAGING IN ATRIAL FIBRILLATION Symposium
Chairperson(s): M. Vannan (Atlanta, US); A. Nchimi (Liège, BE)
08:30 Echo for left atrial morphology and function. 4915
– E. Donal (Rennes, FR)
08:52 Nuclear cardiology in the evaluation of arrhythmic substrate. 4916
– A. Gimelli (Pisa, IT)
09:15 Added value of CMR fibrosis imaging in atrial fibrillation: present and future. 4917
09:37 Relevant morphology by cardiac computed tomography. 4918
– F. Pugliese (London, UK)

DEBATES IN PERIPHERAL ARTERIAL DISEASE (PAD) Debate Session
Chairperson(s): E. Messas (Paris, FR); C. Espinola-Klein (Mainz, DE)
08:30 Should we screen for PAD? - PRO. 4919
– K.K. Naka (Ioannina, GR)
08:45 Should we screen for PAD? - CONTRA. 4920
– C. Vlachopoulos (Athens, GR)
09:00 Should we screen for PAD? - REBUTTAL PRO. 4921
– K.K. Naka (Ioannina, GR)
09:05 Should we screen for PAD? - REBUTTAL CONTRA. 4922
09:10 Should we screen for PAD? - CONCLUSION. 4923
09:15 Should we revascularise claudicants? - PRO. 4924
– M. De Carlo (Pisa, IT)
09:30 Should we revascularise claudicants? - CONTRA. 4925
– M. Brodmann (Graz, AT)
09:45 Should we revascularise claudicants? - REBUTTAL PRO. 4926
– M. De Carlo (Pisa, IT)
09:50 Should we revascularise claudicants? - REBUTTAL CONTRA. 4927
– M. Brodmann (Graz, AT)
09:55 Should we revascularise claudicants? - CONCLUSION. 4928
08:30–10:00 | Oslo - Village 6

STATE OF THE ART IN INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT Advances in Science
Chairperson(s): F. Alfonso Manterola (Madrid, ES); Y. Ozaki (Toyoake, JP)
08:30 State of the Art in invasive imaging and functional assessment. 4929
– T. Akasaka (Wakayama, JP)
08:50 Wave intensity analysis reflects microcirculatory capillary density: a combined histological and 4930
intracoronary physiology study.
– C.J. Broyd, M. Echavarria-Pinto, A. Quiros, J. Sergovia, N. Gonzalo, P. Garcia-Pavia, A. Fernandez-Ortiz,
C. Macaya, J.E. Davies, J. Escaned (Madrid, ES; London, UK)
09:07 Performance of two novel invasive indices of coronary microvascular resistance using invasive 4931
and non-invasive reference standards: superiority of Doppler derived hyperaemic microvascular
resistance.
– R.P.C. Williams, K. De Silva, M. Lumley, K.N. Asrress, B. Clapp, M. Marber, A. Chiribiri, S. Plein,
S. Redwood, D. Perera (London and Leeds, UK)
09:24 Accounting for right atrial pressure in the calculation of fractional flow reserve (FFR) significantly 4932
increases the number of physiologically significant stenoses suitable for PCI.
– C.M. Cook, R. Petraco, S. Nijjer, J. Tarkin, R.A. Al-Lammee, C. Di Mario, J. Escaned, S. Sen, J. Davies
(London, UK; Madrid, ES)
09:41 Future direction for research in invasive imaging and functional assessment. 4933
– H.M. Garcia-Garcia (Rotterdam, NL)
308

NSTEMI GUIDELINES: HELPFUL IN THE REAL WORLD? Guidelines in Daily Practice
Chairperson(s): M. Sousa Uva (Lisbon, PT); F.J. Neumann (Bad Krozingen, DE)
08:30 NSTEMI and atrial fibrillation. 4934
– V. Kunadian (Newcastle-upon-Tyne, UK)
08:45 NSTEMI and atrial fibrillation - What do the Guidelines say? 4935
09:00 NSTEMI and atrial fibrillation - Panel discussion on how to implement the Guidelines. 4936
– V. Kunadian (Newcastle-upon-Tyne, UK), M. Valgimigli (Rotterdam, NL), J.-P. Collet (Paris, FR)
09:10 NSTEMI and atrial fibrillation - Conclusion and take home message. 4937
– M. Sousa Uva (Lisbon, PT)
09:15 Pre treatment in NSTEMI. 4938
– A. Bellemain-Appaix (Biot, FR)
09:30 Pre treatment in NSTEMI - What do the Guidelines say? 4939
– D. Chew (Adelaide, AU)
09:45 Pre treatment in NSTEMI - Panel discussion on how to implement the Guidelines. 4940
– J. Mehilli (Munich, DE), D. Chew (Adelaide, AU), A. Bellemain-Appaix (Biot, FR)
09:55 Pre treatment in NSTEMI - Conclusion and take home message. 4941
08:30–10:00 | Tunis - Village 7

HYPOTHERMIA AND CARDIOPROTECTION Symposium
Chairperson(s): D. Angoulvant (Tours, FR); A. Berdeaux (Créteil, FR)
08:30 Mechanisms involved in cardioprotection by hypothermic ischaemia and hypothermic 4942
preconditioning.
– A.P. Halestrap (Bristol, UK)
08:52 What have we learned from the experimental data on cooling in animals? 4943
– R. Tissier (Maison Alfort, FR)
09:15 Myocardial ischaemia and myocardial function. 4944
– H. Post (Berlin, DE)
09:37 Where do we stand regarding the clinical translation of cooling during STEMI? 4945

THE HEART VALVE TEAM: MANAGING TOGETHER Symposium
ESC and the American College of Cardiology
Chairperson(s): F.J. Pinto (Lisbon, PT); R. Chazal (Fort Myers, US)
08:30 TAVI or surgery: the cardiologist’s perspective. 4946
– P. O’Gara (Boston, US)
08:52 Surgery or TAVI: the surgeon’s perspective. 4947
– M. Mack (Plano, US)
09:15 Multi modality imaging of the aortic valve and aorta. 4948
09:37 Aortic insufficiency and valve repair: techniques and results. 4949
– G. El Khoury (Brussels, BE)
TUESDAY – MORNING
309

CHALLENGING CASES IN ADULT CONGENITAL HEART DISEASE Meet the Experts
Chairperson(s): H. Baumgartner (Münster, DE); F. Walker (London, UK)
08:30 Challenging cases in congenital heart disease - Introduction to the session. 4950
08:35 An adult with classical Fontan – Conversion yes or no. 4951
– A. Eicken (Munich, DE)
08:45 An adult with classical Fontan – Conversion yes or no - Panel discussion and questions from the 4952
audience.
– A. Eicken (Munich, DE), D. Bonnet (Paris, FR), G.P. Diller (Münster, DE)
09:00 A pregnant patient with newly diagnosed congenital heart disease. 4953
– J.W. Roos-Hesselink (Rotterdam, NL)
09:10 A pregnant patient with newly diagnosed congenital heart disease - Panel discussion and 4954
– D. Bonnet (Paris, FR), G.P. Diller (Münster, DE), J.W. Roos-Hesselink (Rotterdam, NL)
09:25 A patient with corrected Tetralogy of Fallot and non sustained VT. 4955
– P.J. Holm (Lund, SE)
09:35 A patient with corrected Tetralogy of Fallot and non sustained VT - Panel discussion and 4956
– P.J. Holm (Lund, SE), D. Bonnet (Paris, FR), G.P. Diller (Münster, DE)
09:50 Challenging cases in congenital heart disease - Take home message. 4957
– F. Walker (London, UK)

SUDDEN CARDIAC DEATH IN THE CARDIOMYOPATHIES Advances in Science
Chairperson(s): J. Mogensen (Odense, DK); Y. Pinto (Amsterdam, NL)
08:30 State of the Art in risk stratification for sudden cardiac death. 4958
– W.J. McKenna (London, UK)
08:50 Clinical profile and predictors of arrhythmia-related symptoms in scandinavian arrhythmogenic 4959
right ventricular cardiomyopathy patients.
– P.G. Platonov, K.H. Haugaa, A. Svensson, H.K. Jensen, T. Gilljam, H. Bundgaard, O. Eschen, J.H. Hansen,
T. Edvardsen, J.H. Svendsen (Lund, Linköping and Gothenburg, SE; Oslo, NO; Aarhus, Copenhagen,
Aalborg and Gentofte, DK)
09:07 Heterogeneous myocardial contraction is related to cardiac fibrosis and predict ventricular 4960
arrhythmias in patients with hypertrophic cardiomyopathy.
– T.F. Haland, V.M. Almaas, N.E. Hasselberg, J. Saberniak, I.S. Leren, S. Aakhus, E. Hopp, T. Edvardsen,
K.H. Haugaa (Oslo, NO)
09:24 A validation study of the 2014 ESC sudden cardiac death risk prediction model in a population 4961
with hypertrophic cardiomyopathy.
– A. Fernandez, A. Quiroga, M. Mysuta, J.H. Casabe, M. Biagetti, E. Guevara, L. Favaloro, J.P. Ochoa,
A. Fava, N. Galizio (Buenos Aires, AR)
09:41 Future direction for research in sudden cardiac death risk stratification. 4962
– I. Olivotto (Florence, IT)
08:30–10:00 | Bern - Village 9

DEVICES FOR HEART FAILURE TODAY Symposium
Chairperson(s): A.S. Manolis (Glyfada-Athens, GR); G. Hasenfuss (Göttingen, DE)
08:30 CRT and ICD. 4963
– J.G.F. Cleland (London, UK)
08:52 Remote monitoring devices. 4964
09:15 Renal replacement therapies. 4965
– M.R. Costanzo (Naperville, US)
09:37 Ventricular Assist Devices. 4966
310

GENE AND STEM CELL THERAPY IN HEART FAILURE: FACT OR FICTION? Symposium
Chairperson(s): P. Menasche (Paris, FR); G.S. Filippatos (Athens, GR)
08:30 Update in stem cell therapy. 4967
– A.M. Zeiher (Frankfurt am Main, DE)
08:52 Advances in gene therapy. 4968
– R.J. Hajjar (New York, US)
09:15 Tissue bioengineering. 4969
– J. Leor (Tel Hashomer, IL)
09:37 Regenerative therapy: what the cardiologist should know. 4970
– A. Terzic (Rochester, US)

FLASH NEWS ON ANTITHROMBOTICS Rapid Fire Abstract
Chairperson(s): S. Halvorsen (Oslo, NO); G. Vilahur Garcia (Barcelona, ES)
08:30 PER977 (ciraparantag) reverses edoxaban anticoagulation at steady state and has no effect on 4971
re-anticoagulation at the next scheduled dose.
– B. Laulicht, S. Bakhru, S. Steiner, K. Brown, M. Grosso, H. Lanz, M. Mercuri, J. Costin (Danbury and
Edison, US)
08:39 Treatment pattern of dual antiplatelet therapy in 104,012 patients with acute coronary syndrome: 4972
a Swedish nationwide population-based cohort study.
– O. Angeras, P. Hasvold, M. Thuresson, A. Deleskog, O.Ö. Braun (Gothenburg, Södertälje, Uppsala and
Lund, SE)
08:48 A new strategy to reverse the platelet inhibitory effect of ticagrelor. 4973
– L. Schoener, B. Richter, C. Pfluecke, M. Christoph, S. Quick, D. Poitz, R.H. Strasser, K. Ibrahim (Dresden,
DE)
08:57 Ticagrelor treatment after myocardial infarction improves adverse remodeling. (withdrawn) 4974 (W)
– Y. Birnbaum, J.R. Perez-Polo, S. Nylander, Y. Ye (Houston and Galveston, US; Mölndal, SE)
09:06 Balancing the risk of ischaemic and bleeding events in ACS. 4975
– G. Ducrocq, P.J. Schulte, A. Budaj, J.H. Cornel, C. Held, A. Himmelmann, S. Husted, R.F. Storey,
L. Wallentin, P.G. Steg (Paris, FR; Durham, US; Warsaw, PL; Alkmaar, NL; Uppsala and Mölndal, SE;
Holstebro, DK; Sheffield, UK)
09:15 Rivaroxaban and vitamin K antagonists are equally effective in preventing recurrent venous 4976
thromboembolism - a Danish nationwide study.
– C. Sindet-Pedersen, J.L. Pallisgaard, G.H. Gislason, L.C. Arevalo, J.B. Olesen (Hellerup and Copenhagen,
DK)
09:24 Clinical outcome of patients with venous thromboembolism under oral anticoagulation in regular 4977
medical care versus a telemedicine-based anticoagulation clinic.
– K. Keller, J. Prochaska, M. Coldewey, S. Gobel, C. Bickel, C. Junger, K. Lackner, C. Espinola-Klein,
T. Munzel, P. Wild (Mainz and Koblenz, DE)
09:33 Prothrombin complex concentrate or Idarucizumab in combination with fibrinogen plus 4978
tranexamic acid are equally effective in a dabigatran anticoagulation experimental polytrauma
model.
– M. Honickel, T. Braunschweig, R. Rossaint, O. Grottke (Aachen, DE)
09:42 Management and clinical consequences of major bleeding in high-risk patients following an acute 4979
coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial.
– E. Hagstrom, D. Wojdyla, M.L. Neely, S.R. Stevens, R.A. Harrington, L. Wallentin, J.H. Alexander, TUESDAY – MORNING
S.G. Goodman, R.D. Lopes (Uppsala, SE; Durham and Stanford, US; Toronto, CA)
09:51 Clinical outcomes of atrial fibrillation patients receiving NSAIDs in the RE-LY trial. 4980
– M.D. Ezekowitz, S.J. Connolly, M. Fraessdorf, M. Brueckmann, J. Kreuzer, J. Oldgren, P. Reilly, S. Yusuf,
L. Wallentin (Philadelphia and Ridgefield, US; Hamilton, CA; Ingelheim am Rhein, DE; Uppsala, SE)
ESC GENERAL ASSEMBLY Special Event
Open to all ESC Members (Members of ESC Associations, ESC National Cardiac Societies,
ESC Working Groups, ESC Councils and all Fellows of the European Society of Cardiology (FESC).
311

ANTITHROMBOTIC PROPHYLAXIS IN ATRIAL FIBRILLATION Moderated Posters
Chairperson(s): S. Themistoclakis (Venice-Mestre, IT); M. Taborsky (Olomouc, CZ)
10:00 High burden of potentially avoidable stroke from discontinuation of warfarin therapy in P4981
non-valvular atrial fibrillation.
– S.B. Freedman, C. Martinez, C. Wallenhorst, A. Katholing (Sydney, AU; Frankfurt am Main, DE)
10:08 Precipitated non valvular atrial fibrillation (NVAF): can we apply the CHA2DS2-VASc score in the P4982
determination of the risk of stroke and death?
– S. Lang, L. Soulat-Dufour, L. Boyer-Chatenet, S. Ederhy, C. Van Der Vynckt, N. Benyounes, C. El Asri,
S. Adavane, F. Boccara, A. Cohen ( and Paris, FR)
10:17 Ablation of atrial fibrillation with uninterrupted NOAC treatment is not associated with severe P4983
peri- and postprocedural complications.
– C. Wunderlich, M. Christoph, T. Gaspar, J. Salmas, Y. Huo, M. Forkmann, M. Pohl, J. Mayer, C. Piorkowski
(Dresden, DE)
10:25 Warfarin therapy is associated with lower risk of dementia in patients with incident atrial P4984
fibrillation in a community based cohort.
– T. Hu, M. Madhavan, B.J. Gersh, V.L. Roger, J. Killian, S.A. Weston, S.J. Asirvatham, A.M. Chamberlain
(Rochester, US)
10:34 Prognosis in patients with atrial fibrillation and CHA2DS2-VASc score = 1 in a community based P4985
cohort study.
– L. Fauchier, C. Lecoq, N. Clementy, D. Angoulvant, D. Babuty, G.Y.H. Lip (Tours, FR; Birmingham, UK)
10:42 5-year real world experience using three LAA-closure devices. P4986
– A. Sedaghat, F. Hauptmann, J.W. Schrickel, R. Schueler, N. Werner, G. Nickenig, C. Hammerstingl (Bonn,
DE)
10:51 Comparative cost-effectiveness of oral anticoagulants for stroke prevention in non-valvular atrial P4987
fibrillation patients in the UK.
– G.Y.H. Lip, T. Lanitis, T. Kongnakorn, H. Phatak, L. Liu, J. Lawrence, P. Dorian (Birmingham and London,
UK; Bangkok, TH; Princeton and New York, US; Toronto, CA)

ACUTE PHASE OF STEMI Moderated Posters
Chairperson(s): B.J.M. Mulder (Amsterdam, NL); H.M. Mardikar (Nagpur, IN)
10:00 Impact of ESC guidelines system delays on myocardial salvage in STEMI. P4988
– G. Caldentey, T. Lopez, J. Rodriguez, G. Caixal, X. Bosch, M. Masotti, V. Martin, M. Sabate, J.T. Ortiz
(Barcelona, ES)
10:08 High mortality in patients with ST elevations undergoing emergency coronary angiography not P4989
treated with primary PCI or CABG.
– U. Zeymer, M. Hochadel, A. Elsaesser, H. Darius, R. Zahn (Ludwigshafen am Rhein, Oldenburg and Berlin,
DE)
10:17 Cerebral and renal impact in 5,040 patients with acute myocardial infarction wth cardiogenic P4990
shock combined coronary revascularization and intra-aortic balloon pump support: implications
from populati.
– T.H. Chen, Y.Y. Chen, C.T. Mao (Taipei, TW)
10:25 Gender differences in cardiogenic shock after acute myocardial infarction. The FAST-MI P4991
programme.
– N. Aissaoui, E. Puymirat, D. Angoulvant, P. Goldstein, P. Gueret, D. Blanchard, F. Schiele, J. Ferrieres,
T. Simon, N. Danchin (Paris, Tours, Lille, Créteil, Besançon and Toulouse, FR)
10:34 30 day clinical outcomes of bivalirudin vs heparin in the elderly patients with ST-segment P4992
elevation myocardial infarction undergoing percutaneous coronary intervention, a pooled analysis.
– K. Qaderdan, G.J.A. Vos, P.G. Steg, G.W. Stone, C.W. Hamm, A. Van ’T Hof, R. Mehran, E.N. Deliargyris,
D. Bernstein, J.M. Ten Berg (Nieuwegein and Zwolle, NL; Paris, FR; New York, US; Bad Nauheim, DE)
10:42 Revascularization strategies in patients with ST-segment elevation myocardial infarction and P4993
multivessel disease in a real world population.
– J. Reis Pires Martins, C. Arantes, G. Abreu, C. Rodrigues, C. Braga, J. Costa, M. Pereira, A. Rebelo,
10:51 Comparative effectiveness of primary percutaneous coronary intervention versus fibrinolytic P4994
therapy for ST-elevation myocardial infarction by time to treatment. A national cohort study.
– C.P. Gale, W.R. Long, P.D. Baxter, M.S. Gilthorpe, R.M. West, P.D. Batin, H. Hemingway, A.D. Timmis,
K.A.A. Fox, M.A. Debelder (Leeds, Wakefield, London, Edinburgh and Middlesborough, UK)
312

ADVANCES IN CARDIAC COMPUTED TOMOGRAPHY IMAGING Moderated Posters
Chairperson(s): O. Gaemperli (Zurich, CH); G. Pontone (Milan, IT)
10:00 Aortic valve calcium volume predicts paravalvular regurgitation and the need for balloon P4995
post-dilatation after transcatheter aortic valve implantation.
– P. Fonseca, C. Almeida, J. Almeida, N. Bettencourt, F. Sampaio, N. Ferreira, D. Caeiro, H. Goncalves,
P. Braga, V. Gama (Vila Nova de Gaia and Ponta Delgada, PT)
10:08 Coronary artery calcium and metal stent subtraction by 320-row cardiac-CT: fact or fiction? P4996
– D. Vilades Medel, R. Leta Petracca, F. Carreras Costa, X. Alomar Serrallach, G. Pons Llado (Barcelona, ES)
10:17 Diagnostic Accuracy of Rapid Kilovolt Peak-Switching Dual-Energy CT Coronary Angiography in P4997
Patients with High Calcium Score.
– S. Mushtaq, G. Pontone, A. Annoni, E. Conte, A. Baggiano, C. Segurini, V. Volpato, M. Pepi, C. Fiorentini,
D. Andreini (Milan, IT)
10:25 Relationship between adverse coronary plaque characteristics, coronary CT angiography and P4998
fractional flow reserve: comparison of proximal and total vessel based analyses.
– K.A. Oevrehus, S. Gaur, D. Dey, J. Leipsic, H.E. Botker, J.M. Jensen, J.F. Lassen, B.L. Norgaard (Aarhus,
DK; Los Angeles, US; Vancouver, CA)
10:34 Gender differences in computed tomography measurements before transcatheter aortic valve P4999
implantation.
– E. Shaviv, O. Goitein, K. Konen, E. Shwammenthal, A. Segev, I. Barabash, F. Fefer, E. Hay, V. Guetta,
A. Hamdan (Tel Hashomer, IL)
10:42 Epicardial adipose tissue expansion and differentiation status predict myocardial redox state and P5000
coronary calcification.
– A. Antonopoulos, L. Herdman, N. Sabharwal, C. Shirodaria, S. Thomas, A. Kelion, R. Sayeed, S. Neubauer,
K.M. Channon, C. Antoniades (Oxford, UK)
10:51 German cardiac CT registry: Indications, procedural data and clinical results of cardiac computed P5001
tomography in 7061 patients.
– S. Achenbach, A. Schmermund, G. Korosoglou, J. Hausleiter, S. Schroeder, A. Leber, T. Limbourg, J. Rixe,
J. Senges, O. Bruder (Erlangen, Frankfurt am Main, Heidelberg, Munich, Göppingen, Ludwigshafen am
Rhein, Giessen and Essen, DE)

CARDIOVASCULAR DYSFUNCTION AND REPAIR – ROLES OF INFLAMMATION AND Moderated Posters
IMMUNE CELLS
Chairperson(s): R. Nagai (Tochigi, JP); D. Greaves (Oxford, UK)
10:00 Sphigosine-mono-phosphate (S1P) induces the migration of Muse cells but not non-Muse cells P5002
toward the rabbit post-infarct heart and contributes to the improvement of cardiac function and
remodeling.
– Y. Yamada, S. Minatoguchi, H. Kanamori, K. Higashi, M. Kawasaki, K. Nishigaki, A. Mikami, S. Wakao,
M. Dezawa, S. Minatoguchi (Gifu and Sendai, JP)
10:08 Perivascular accumulation of M1 macrophages elicits the development of immature vascular P5003
formation.
– K. Soma, N. Takeda, T. Isagawa, H. Abe, H. Semba, K. Koyama, M. Wake, I. Manabe, R. Nagai, I. Komuro
(Tokyo and Tochigi, JP)
10:17 Animal experimental evaluation of growth adaptation in in vivo tissue-engineered “biotube” P5004
vascular grafts.
– M. Furukoshi, R. Iwai, T. Moriwaki, Y. Nakayama (Osaka, JP) TUESDAY – MORNING
10:25 Chronic cardiac allograft rejection after heterotopic rat heart transplantation: effects of P5005
antibody-based targeted delivery of interleukin-10 in a preventive and a therapeutic approach.
– M. Franz, F. Doll, K. Gruen, N. Koese, H. Schubert, C. Jung, J. Gummert, A. Renner, A. Berndt, H.R. Figulla
(Jena and Bad Oeynhausen, DE; Zurich, CH)
10:34 In vivo inhibition of microRNA-155 attenuates experimental septic cardiomyopathy. P5006
– F. Vasques-Novoa, C. Quina-Rodrigues, R. Cerqueira, L. Mendonca, F. Baganha, R. Soares-Dos-Reis,
C. Reguenga, P. Castro-Chaves, A.F. Leite-Moreira, R. Roncon-Albuquerque Jr (Porto, PT)
10:42 Whole blood omega-3 fatty acid content predicts recurrent venous thromboembolism and death P5007
in elderly patients with acute venous thromboembolism.
– M.F. Reiner, S. Stivala, A. Limacher, M. Mean, N. Rodondi, D. Aujesky, C. Von Schacky, T.F. Luescher,
G.G. Camici, J.H. Beer (Schlieren, Baden, Berne and Zurich, CH; Munich, DE)
10:51 Periodontal bacteria promote systemic immune responses and persistence of intramural P5008
hematoma in experimental abdominal aortic dissection/aneurysm.
– S. Delbosc, K. Guedj, A.T. Gaston, B. Escoubet, A.T. Nicoletti, J.B. Michel, G. Caligiuri (Paris, FR)
313

OUTCOMES AFTER TAVI Moderated Posters
Chairperson(s): J. Fernandes E Fernandes (Lisbon, PT); K.T. Chan (Hong Kong, HK)
10:00 Aortic stiffening is a strong determinant of heart failure after transcutaneous valve replacement. P5009
– B. Harbaoui, P.Y. Courand, P. Charles, M. Montoy, R. Dauphin, O. Jegaden, P. Lantelme (Lyon, FR)
10:08 Incidence and predictors of coronary obstruction following transcatheter aortic valve implantation P5010
in the real world.
– T. Arai, T. Lefevre, T. Hovasse, M.C. Morice, H. Benamer, P. Garot, T. Unterseeh, E. Bouvier, B. Cormier,
B. Chevalier (Massy, FR)
10:17 Pre- and postprocedural mitral regurgitation and mortality following transcatheter aortic valve P5011
replacement for severe aortic stenosis - an interaction with aortic regurgitation (POL-TAVI
registry).
– P. Szymanski, T. Hryniewiecki, M. Dabrowski, J. Jastrzebski, J. Kochman, D. Sorysz, T. Kukulski,
M. Zembala (Warsaw, Krakow and Zabrze, PL)
10:25 Transcarotid transcatheter aortic valve replacement: feasibility and safety. P5012 (W)
– T. Modine, D.M. Mylote, A.S. Sudre, E.T. Teiger, N.D. Debry, J.F.O. Obadia, M.K. Koussa (Lille, Paris and
Lyon, FR; Galway, IE)
10:34 Type of atrial fibrillation and clinical outcomes in patients undergoing transcatheter aortic valve P5013
implantation.
– A.A. Shaul, R. Kornowski, H. Vaknin Assa, A. Assali, B. Strasberg, E. Kadmon, G. Golovchiner, K. Orvin,
A. Barsheshet (Petah Tikva, IL)
10:42 Seven-year outcome after TAVI. P5014
– C. Bouleti, B. Alos, D. Himbert, B. Iung, M. Urena, C. Kerneis, E. Brochet, P. Ou, P. Nataf, A. Vahanian
(Paris, FR)
10:51 Changes in the pacemaker rate after transition from Edwards Sapien XT to Sapien 3 transcatheter P5015
aortic valve implantation are primarily related to the implantation height.
– F. De Torres-Alba, G. Kaleschke, G.P. Diller, J. Vormbrock, S. Orwat, R. Radke, F. Reinke, D. Fischer,
H. Reinecke, H. Baumgartner (Münster, DE)

ADVANCING THE CLINICAL APPLICATION OF BIOMARKERS Moderated Posters
Chairperson(s): K. Thygesen (Aarhus, DK); C.E. Mueller (Basel, CH)
10:00 Prognostic value of circulating MicroRNAs in patients with coronary artery disease - results from P5016
the AtheroGene study.
– M. Karakas, S. Appelbaum, C. Schulte, P.S. Wild, K.J. Lackner, T. Munzel, D. Westermann,
S. Blankenberg, T. Zeller (Hamburg and Mainz, DE)
10:08 Association between high-sensitive troponin I and coronary artery calcification in a healthy P5017
Danish background population.
– F. Olson, J. Engborg, M.H. Sorensen, N.P. Sand, J. Lambrechtsen, F.H. Steffensen, M. Nybo, O. Gerke,
H. Mickley, A.C. Diederichsen (Odense, Esbjerg, Svendborg and Vejle, DK)
10:17 Circulating aldosterone predicts future cardiorenal and metabolic disease in the general P5018
community.
– A. Buglioni, V. Cannone, S.J. Sangaralingham, C.G. Scott, K.R. Bailey, R.J. Rodeheffer, R. Sarzani,
J.C. Burnett (Rochester, US)
10:25 Cardiac biomarkers and the prediction of primary CVD events in two cohort studies: results from P5019
the BRHS and MIDSPAN family study.
– P. Welsh, A. McConnachie, C. Hart, O. Papacosta, M. Upton, G. Watt, G. Wannamethee, N. Sattar
(Glasgow, London and Stockton-on-Tees, UK)
10:34 Effects of combined cognitive and physical training on telomere length in patients with mild P5020
cognitive impairment.
– A. Borghini, A. Mercuri, S. Turchi, M.R. Bruno, R. Sicari, E. Picano, M.G. Andreassi (Pisa, IT; Astana, KZ)
10:42 Associations of estradiol, sex hormone-binding globulin and testosterone with circulating levels of P5021
amino-terminal pro-B-type natriuretic peptide in postmenopausal women: The Rotterdam Study.
– K.G. Vargas, T. Muka, A. Hofman, J.S.E. Laven, M. Kavousi, O.H. Franco (Rotterdam, NL)
10:51 Homoarginine predicts outcome in patients with acute chest pain and coronary syndrome. P5022
– D. Atzler, C. Baum, F. Ojeda, K. Cordts, T. Keller, R.B. Schnabel, R.H. Boeger, S. Blankenberg,
E. Schwedhelm, T. Zeller (Oxford, UK; Hamburg and Frankfurt am Main, DE)
314

UNDERSTANDING PATHOPHYSIOLOGY FROM IMAGING AND FUNCTIONAL ASSESSMENT Moderated Posters
Chairperson(s): A. Martinez (Santiago, CL); T. Tomaru (Chiba, JP)
10:00 Demonstration of the functional consequences of the coronary stenosis on the basis of the P5023
flow-pressure relations using 3D-QCA morphological data.
– B. Tar, F. Molnar, P. Polgar, C.S. Jenei, C.S. Bujaki, J. Falukozy, C.S.A. Dezsi, Z.S. Koszegi (Nyíregyháza,
Debrecen, Balatonfured and Gyor, HU)
10:08 Change in characteristics of the population receiving angiography in an era with decreasing P5024
cardiovascular incidence and mortality.
– H. Schirmer, J. Mannsverk, T. Steigen, A. Iqbal, T. Trovik (Tromsø, NO)
10:17 The impact of exercise therapy on coronary plaque. P5025
– T. Noto, K. Ositani, D. Harada, J. Takagawa, H. Ishise, T. Kameyama, H. Asanoi, K. Iuti, H. Inoue (Imizu,
Toyama and Niikawa, JP)
10:25 Association between serum levels of C-reactive protein and changes of plaque composition in P5026
non-infarct-related coronary arteries following high-intensity statin therapy. Results of the IBIS-4
Study.
– K.C. Koskinas, L. Raeber, M. Taniwaki, H.M. Garcia-Grcia, P. Juni, A. Moschovitis, C.M. Matter, S. Zaugg,
S. Windecker (Berne and Zurich, CH; Rotterdam, NL)
10:34 Contrast medium induced Pd/Pa ratio (CMR) versus FFR and adenosine-free indexes in the P5027
evaluation of intermediate coronary stenosis.
– A.M. Leone, P. Cialdella, G.L. De Maria, E. Basile, L. Paraggio, D. D’Amario, C. Trani, F. Burzotta,
A.G. Rebuzzi, F. Crea (Rome, IT)
10:42 Influence of optical coherence tomography on PCI strategy during bioresorbable scaffold P5028
implantation.
– N.F. Boeder, J. Wiebe, O. Doerr, T. Bauer, A. Elsaesser, H. Moellmann, S. Achenbach, C.W. Hamm,
H.M. Nef (Giessen, Oldenburg, Bad Nauheim and Erlangen, DE)
10:51 Usefulness of optical coherence tomography in determining the mechanisms of myocardial P5029
infarction in patients without angiographically demonstrable coronary artery disease.
– T. Takahashi, H. Okayama, M. Kinoshita, T. Miyoshi, K. Hara, A. Higaki, Y. Kawata, G. Hiasa, T. Yamada,
Y. Kazatani (Matsuyama, JP)

OMINOUS SIGNS IN HEART FAILURE Moderated Posters
Chairperson(s): D. Brito (Lisbon, PT); G.Q. Villani (Piacenza, IT)
10:00 Overexpression of phosphodiesterase-2 in mice reduces CaMKII-dependent enhancement of late P5030
sodium current through impared beta-adrenergic response.
– N. Dybkova, F. Mason, A. El-Armouche, S. Sossalla (Göttingen and Dresden, DE)
10:08 Risk related to diabetes and pre-diabetes in heart failure with reduced ejection fraction: Insights P5031
from PARADIGM-HF.
– S. Kristensen, I. Squire, R.C. Starling, V. Shi, J.L. Rouleau, S.D. Solomon, K. Swedberg, M. Zile, M. Packer,
J.J.V. McMurray (Glasgow and Leicester, UK; Cleveland, Hanover, Boston, Charleston and Dallas, US;
Montreal, CA; Gothenburg, SE)
10:17 Respiratory syncytial virus infection is associated with acute decompensated heart in adult P5032
patients with congestive heart failure.
– N. Bellei, L.P. Moreira, H.L. Godoy, D.R. Almeida, A.A. De Paola (São Paulo, BR)
10:25 Development of major types of cancer in patients with heart failure. P5033
– A. Banke, M. Schou, L. Videbaek, J. Moeller, F. Gustafsson, J. Dahl, C. Torp-Pedersen, L. Koeber, TUESDAY – MORNING
P. Hildebrandt, G. Gislason (Odense, Copenhagen, Aalborg and Frederiksberg, DK)
10:34 High prevalence of iron deficiency in heart failure with preserved ejection fraction. P5034
– S. Fitzsimons, R. Troughton, G.D. Gamble, G.D. Devlin, M. Lund, M. Richards, R.N. Doughty (Auckland,
Christchurch and Hamilton, NZ)
10:42 Time-related cumulative incidence of congestive heart failure after childhood cancer treatment; a P5035
DCOG LATER study.
– E.A.M. Feijen, W.E.M. Kok, A. Font-Gonzalez, H.J.H. Van Der Pal, C.M. Ronckers, N. Hollema, H.N. Caron,
W.J.E. Tissing, L.C.M. Kremer (Amsterdam, The Hague and Groningen, NL)
10:51 Impact of diabetes mellitus on heart failure with reduced ejection fraction - a Swedish registry P5036
based analysis.
– I. Johansson, M. Edner, P. Nasman, U. Dahlstrom, L. Ryden, A. Norhammar (Stockholm and Linköping, SE)
315

HYPERTENSION AND COMORBIDITIES: A CHALLENGE OF TREATMENT Moderated Posters
Chairperson(s): C. Borghi (Bologna, IT); Z. Kusljugic (Tuzla, BA)
10:00 Effect of Diosmin treatment on left ventricular systolic function in hypertensive patients with P5037
chronic venous insufficiency.
– R. Al Namat, C. Ghiciuc, C.E. Lupusoru, M.M. Leon, O. Mitu, S. Rusu, N.L. Rascanu, F. Mitu (Iasi, RO)
10:08 Sitagliptin and risk of hypertension in patients with type 2 diabetes mellitus: meta-analysis of P5038
randomized trials.
– B. Zhang, Y.I. Zhong, Z. Lu (Guangzhou, CN)
10:17 The effect of mineralocorticoid receptor antagonists in patients with hypertension and diabetes P5039
mellitus: a systematic review and meta-analyses.
– S. Takahashi, J. Katada, F. Kitamura, K. Yokoyama (Tokyo, JP)
10:25 Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative P5040
stress parameters in patients with hypertension and type 2 diabetes mellitus.
– G. Derosa, F. Querci, I. Franzetti, P.D. Ragonesi, A. D’Angelo, P. Maffioli (Pavia, Alzano Lombardo,
Gallarate and Milan, IT)
10:34 Vascular function and atherosclerosis are similar in patient with idiopathic hyperaldosteronism P5041
and essential hypetension.
– Y. Fujii, T.U. Ueda, H.T. Teragawa (Hiroshima, JP)
10:42 Diverge responses of cardiac autonomic function to beta-blocker therapy depending on chronic P5042
kidney disease.
– H. Makimoto, K. Fujiu, K. Shimizu, E. Amiya, T. Kojima, M. Daimon, C. Meyer, I. Komuro (Tokyo, JP;
Düsseldorf, DE)
10:51 Implementation of hypertension guidelines recommendations in primary care improves detection P5043
of silent renal damage.
– E. Ardeleanu, M. Dorobantu, R. Darabont, D. Lighezan, R. Lighezan, D. Gurgus, A. Deleanu, P. Nicola,
S. Baaj (Timisoara and Bucharest, RO)

MEET THE TRIALIST IV: PATHWAY 2 Meet the Trialists
Chairperson(s): G. Mancia (Milan, IT)
10:10 The principal results of the Prevention And Treatment of Hypertension With Algorithm based 5044
therapY (PATHWAY) - Optimal treatment of drug resistant hypertension - PATHWAY 2.

WHAT ARE THE EDITOR’S CRITERIA FOR GOOD SCIENTIFIC PAPERS? Special Session
MEET THE EDITORS OF THE EUROPEAN HEART JOURNAL
Chairperson(s): T.F. Luscher (Zurich, CH); K.R. Sipido (Leuven, BE)
10:10 How do Editors select the best manuscripts? 5045
– J. Jarcho (Boston, US)
10:23 How to convince successfully your peers? 5046
10:36 Appropriate statistics and their implementation. 5047
– R.E. Carter (Rochester, US)
316

DUAL ANTI-PLATELET THERAPY IN EBAC Accredited Educational Programme - Experts on the Spot
ATHEROTHROMBOSIS IN 2015: DEBATING
THE EVIDENCE
Organised by University Hospital of Umeå. Course Director: Ulf Naslund
Chairperson(s): K.A.A. Fox (Edinburgh, UK)
10:15 Welcome and introduction - Dual anti-platelet therapy in atherothrombosis in 2015: debating the 5048
evidence.
10:20 Clinical case study – Optimal duration of dual antiplatelet therapy. 5049
10:30 Open questions - Dual anti-platelet therapy in atherothrombosis in 2015: debating the evidence. 5050
– K.A.A. Fox (Edinburgh, UK), C.W. Hamm (Bad Nauheim, DE)
10:43 Close - Dual anti-platelet therapy in atherothrombosis in 2015: debating the evidence. 5051

TREATMENT OF ATRIAL FIBRILLATION (AF) IN SPECIAL PATIENT Satellite Symposium - Experts on the Spot
POPULATIONS
Sponsored by Cardiome International AG
Chairperson(s): H. Heidbuchel (Hasselt, BE)
10:15 Cardioversion of AF in EP-setting. 5052
– J. Hartikainen (Kuopio, FI)
10:30 Cardioversion of AF in patients after cardiac surgery. 5053
– B. Korbmacher (Düsseldorf, DE)

SEEKING IMPROVED CLINICAL OUTCOMES IN POST-ACUTE Satellite Symposium - Experts on the Spot
CORONARY SYNDROME (ACS) PATIENTS WITH TYPE 2 DIABETES
(T2D)
Sponsored by Takeda Pharmaceuticals GmbH
Chairperson(s): K.K. Ray (London, UK); S. Genovese (Milan, IT)
10:15 The cardiologist’s perspective. 5054
10:25 The diabetologist’s perspective. 5055
– S. Genovese (Milan, IT)
10:35 Questions from the audience - Seeking improved clinical outcomes in post-acute coronary 5056
syndrome (ACS) patients with type 2 diabetes (T2D).
– K.K. Ray (London, UK), S. Genovese (Milan, IT)
TUESDAY – MORNING
317

HOT LINE V – HEART FAILURE Hot Line
Chairperson(s): J.J. Bax (Leiden, NL); S. Yusuf (Hamilton, CA)
11:00 Effect of implanted device-based impedance monitoring with telemedicine alerts on mortality and 5057
morbidity in heart failure: results from the OptiLink HF study.
11:12 OptiLink HF: Discussant review. 5058
– K. Swedberg (Gothenburg, SE)
11:19 OptiLink HF: Panel discussion. 5059
11:23 CUPID 2: a phase 2b trial investigating the efficacy and safety of the intracoronary administration 5060
of AAV1/SERCA2a in patients with advanced heart failure.
– B.H. Greenberg (La Jolla, US)
11:35 CUPID 2: Discussant review. 5061
11:42 CUPID 2: Panel discussion. 5062
11:46 Treatment of sleep-disordered breathing with predominant central sleep apnoea with adaptive 5063
servo-ventilation in patients with chronic heart failure: SERVE-HF study results.
11:58 SERVE-HF: Discussant review. 5064
– A. Poppas (Providence, US)
12:05 SERVE-HF: Panel discussion. 5065
12:08 The BENznidazole Evaluation For Interrupting Trypanosomiasis trial. 5066
– C.A. Morillo (Hamilton, CA)
12:20 BENEFIT: Discussant review. 5067
– To be announced
12:27 BENEFIT: Panel discussion. 5068

REGISTRY III – PREVENTION Registry Session
Chairperson(s): M. Yamagishi (Kanazawa, JP); A. Pelliccia (Rome, IT)
11:00 Clinical reality of primary prevention in people at high cardiovascular risk in Europe: a comparison 5069
of EUROASPIRE III and IV surveys in general practice.
– K. Kotseva (London, UK)
11:15 Differences in outcomes in stable CAD patients managed by cardiologists vs non-cardiologists. 5070
Data from the international prospective CLARIFY registry in 32,468 patients.
– M. Tendera (Katowice, PL)
11:30 Association between pre-operative statin use and major cardiovascular events among patients 5071
undergoing noncardiac surgery: the VISION study.
– O. Berwanger (Sao Paulo, BR)
11:45 XANTUS. 5072
12:00 The real world evidence of chronic heart failure: findings from 41,413 patients of the ARNO 5073
database.
– A.P. Maggioni (Florence, IT)
12:15 Consequences of the implementation of a high-sensitivity cardiac troponin assay at Swedish 5074
coronary care units.
– K.M. Eggers (Uppsala, SE)
318

HYPERTENSION TREATMENT Rapid Fire Abstract
Chairperson(s): L.M. Ruilope (Madrid, ES); A.M. Heagerty (Manchester, UK)
11:00 Effects of antihypertensive therapies on primary and secondary prevention of stroke: systematic 5075
review and network meta-analysis.
– H.M. Cheng, W.T. Wang, C.E. Chiang, S.S. Sung, L.K. You, S.Y. Chuang, C.H. Chen (Taipei and Miaoli
County, TW)
11:09 A novel blood pressure lowering and renal enhancing designer peptide: acute MANP in 5076
experimental hypertension.
– A. Buglioni, S.J. Sangaralingham, G.E. Harders, J.C. Burnett (Rochester, US)
11:18 Impact of a custom-made mandibular repositioning device (MRD) on blood pressure in 5077
obstructive sleep apnea (OSA) patients noncompliant with continuous positive airway pressure
(CPAP).
– M.P. D’Ortho, V. Attali, D. Leger, C. Monaca, P.J. Monteyrol, L. Morin, E. Mullens, B. Pigearias,
J.C. Meurice, M.F. Vecchierini (Paris, Lille, Bordeaux, Saint-Priest, Albi, Nice and Poitiers, FR)
11:27 Lack of evidence that frailty modifies the positive impact of antihypertensive treatment in very 5078
elderly people.
– J. Warwick, E. Falaschetti, K. Rockwood, A. Mitnitski, L. Thijs, N. Beckett, C. Bulpitt, R. Peters (London,
UK; Halifax, CA; Leuven, BE)
11:36 Effect of a short term antihypertensive treatment on retinal arterioles evaluated with adaptive 5079
optics camera.
– D. Rosenbaum, A. Mattina, C. Kanagasabapathy, E. Koch, M. Paques, N. Chateau, B. Lamaury Bardet,
X. Girerd (Paris and Orsay, FR)
11:45 Effect of allopurinol on serum uric acid and endothelial function in patients with essential arterial 5080
hypertension optimally treated.
– A.S. Hodorogea, A. Campeanu, A.M. Iliesiu, I.T. Nanea (Bucharest, RO)
11:54 Effects of angiotensin-II receptor blocker or calcium channel blocker on abdominal aortic 5081
aneurysm growth at presurgical stage.
– T.M. Murohara, Y. Kureishi Bando, K.N. Nishigami, A.H. Hirakawa, E.T. Taguchi, M.I. Iida, M. Nanasato,
H.K. Kamiya, K.N. Komori (Nagoya and Kumamoto, JP)
12:03 Chronic treatment with orally active angiotensin-(1-7) formulation decrease oxidative damage and 5082
improve hemodynamic parameters in spontaneously hypertensive rats.
– D. Ravizzoni Dartora, P. Rohr, M. Bertagnolli, A. Nascimento, D. Dias, K.R. Casalli, K. De Angelis,
M.C. Irigoyen, R.A. Santos (Porto Alegre and São Paulo, BR; Montreal, CA)
12:12 The influence of antihypertensive therapy with amlodipine and telmisartan on serum adiponectin 5083
level in the metabolic syndrome.
– A. Karimova, S. Mammaev, V. Petrosova (Makhachkala, RU)
12:21 Predicting prognosis in patients with hypertensive left ventricular hypertrophy during thirteen 5084
years.
– D. Djordjevic, I. Tasic, S. Kostic, B. Stamenkovic, M. Lovic, D. Lovic (Nis̆, RS)
TUESDAY – MORNING
319

ACUTE INTENSIVE CARDIOVASCULAR CARE Rapid Fire Abstract
Chairperson(s): E. Bonnefoy-Cudraz (Bron, FR); D. Sibbing (Munich, DE)
11:00 Direct comparison of the safety and efficacy of two rule-out strategies for AMI: combination of 5085
1h-algorithm and undetectable levels at presentation versus 2h-accelerated diagnostic protocol.
– M. Rubini Gimenez, R. Twerenbold, K. Wildi, T. Reichlin, M. Wagener, C. Puelacher, S. Osswald, C. Mueller
(Basel, CH)
11:09 Inaccurate treatment and poor outcome in patients with ACS and atypical symptoms. 5086
– E. Cenko, R. Ricci, Z. Vasiljevic, D. Trninic, B. Knezevic, O. Gustiene, D. Milicic, O. Manfrini, L. Badimon,
R. Bugiardini (Bologna, IT; Belgrade, RS; Banja Luka, BA; Podgorica, ME; Kaunas, LT; Zagreb, HR;
Barcelona, ES)
11:18 A comparison of biomarkers and risk scores on risk stratification for patients with acute coronary 5087
syndrome.
– T. Onda, K. Inoue, S. Suwa, J. Matsuoka, Y. Nishizaki, M. Sumiyoshi, H. Daida (Tokyo and Shizuoka, JP)
11:27 Kinetics of high-sensitive cardiac troponin T and I differ in patients with ST-segment elevation 5088
myocardial infarction treated by primary coronary intervention.
– G. Laugaudin, N. Kuster, K. Solecki, J.P. Cristol, A.M. Dupuy, F. Leclercq, R. Gervasoni, J.C. Macia,
T.T. Cung, F. Roubille (Montpellier, FR)
11:36 Epidemiology of cardiogenic shock in French reanimations: incidence, etiologies, outcome and 5089
evolution on 15 years (a report from the CubRea database).
– E.P. Puymirat, J.Y.F. Fagon, P.A. Aegerter, C.H.B. Hauw-Berlemont, C.B. Bailleul, J.L.D. Diehl,
B.D. Guidet, G.C. Chatellier, N.D. Danchin, N. Aissaoui (Paris, FR)
11:45 Iron metabolism in acute myocardial infarction complicated by cardiogenic shock - a biomarker 5090
substudy of the IABP-SHOCK II-trial.
– G. Fuernau, F. Traeder, S.S. Lele, M.M. Rajapurkar, B.N. Mukhopadhyay, S. Desch, I. Eitel, G. Schuler,
V. Adams, H. Thiele (Leipzig and Lübeck, DE; Baroda, Gujarat and Nadiad, IN)
11:54 Blood hyperosmolarity and mortality in patients after an acute coronary syndrome: how does 5091
dehydration affect prognosis?
– S. Fernandez Santos, M. Pascual Izco, S. Briongos Figuero, T. Segura De La Cal, G. Alonso Salinas,
A. Camino Lopez, M. Jimenez Mena, M. Sanmartin Fernandez, J.L. Zamorano Gomez (Madrid, ES)
12:03 Urinary output predicts survival in patients undergoing extracorporeal membrane oxygenation 5092
following cardiovascular surgery.
– G. Goliasch, C. Roth, L. Schrutka, C. Binder, M.P. Winter, G. Heinz, I.M. Lang, G. Maurer, A. Niessner,
K. Distelmaier (Vienna, AT)
12:12 Clinical impact of delirium and antipsychotic therapy on patients admitted to the coronary care 5093
unit.
– N. Naksuk, C. Thongprayoon, J.Y. Park, S. Sharma, P. Gaba, A.N. Rosenbaum, T. Peeraphatdit,
P.A. Brady, S. Kapa, S.J. Asirvatham (Rochester and Minneapolis, US)
12:21 The impact of multidisciplinary team approach with critical care specialist and cardiologist 5094
co-management style on the clinical outcomes of cardiac intensive care unit patients.
– Z. Fanari, A. Barekatain, R. Kerzner, S. Hammami, W.S. Weintraub, V. Maheshwari (Newark, US)

RARE, UNUSUAL AND UNEXPECTED RHYTHM DISTURBANCES – THAT IS WHAT WE LIKE Clinical Cases
Chairperson(s): M. Taborsky (Olomouc, CZ); M. Pazdernik (Prague, CZ)
11:00 End stage heart failure related to tachycardia-induced cardiomyopathy in a 8 years old girl. 5095
– A.G. Negru (Timisoara, RO)
11:12 Wolff-Parkinson-White syndrome with hypertrophic left ventricule diagnosed as danon disease by 5096
gene analysis in a young adult.
– J. Hao (Beijing, CN)
11:25 Noninvasive ECG imaging revealed Brugada syndrome in patient with normal surface ECG. 5097
– M. Chaykovskaya (Moscow, RU)
11:38 A rare but distinctive malignant ventricular arrhythmia. 5098
– J.K. Loh (Singapore, SG)
11:51 Are nonselective sodium-channel blockers also helpful in patients with long QT due to potassium 5099
channel mutations and recurrent episodes of ventricular polymorphic tachycardia and ICD
shocks?
– N. Shcherbakova (Moscow, RU)
12:04 A heart within the heart. 5100
– T.F. Benito Gonzalez (Leon, ES)
12:17 The complexity of a “simple” syncope. 5101
– B. Garcia-Aranda Dominguez (Toledo, ES)
320

ACUTE CORONARY SYNDROMES NSTEMI IN SERBIA Guidelines in Daily Practice
Chairperson(s): M. Nedeljkovic (Belgrade, RS); S. Stojkovic (Belgrade, RS)
– D. Orlic (Belgrade, RS)
11:20 What do the “new” 2015 ESC Guidelines tell us? 5103
– M. Radosavljevic-Radovanovic (Beograd, RS)
11:40 How to manage the case according to th new recommandations? 5104
– M. Radosavljevic-Radovanovic (Beograd, RS)
– B. Vujisic-Tesic (Belgrade, RS), J. Stepanovic (Belgrade, RS), S. Apostolovic (Nis̆, RS), S. Obradovic
(Belgrade, RS), M. Pavlovic (Nis̆, RS), V. Mitov (Zajecar, RS), Z. Mehmedbegovic (Belgrade, RS)

INFECTIVE ENDOCARDITIS IN THE UNITED KINGDOM Guidelines in Daily Practice
Chairperson(s): B.D. Prendergast (London, UK); B. Chambers (London, UK)
– M. Dayer (Taunton, UK)
– R. Watkin (Birmingham, UK)
– R. Watkin (Birmingham, UK)
– P.M. Elliott (London, UK), S. Price (London, UK), R.A. Henderson (Nottingham, UK), P. Nihoyannopoulos
(London, UK), L.J. Freeman (Norwich, UK), R.J.C. Hall (Holt, UK), P. Kirchhof (Birmingham, UK)
11:00–12:30 | Rabat - Village 1

INTEGRATIVE BIOLOGY – FOCUS ON OMICS Meet the Experts
Chairperson(s): I. Hoefer (Utrecht, NL); A.R. Pries (Berlin, DE)
11:00 Integrative biology - Focused on OMICS - Introduction to the session. 5110
– I. Hoefer (Utrecht, NL)
11:05 Metabolomics. 5111
– M. Mayr (London, UK)
11:15 Metabolomics - Panel discussion and questions from the audience. 5112
– K. Clarke (Oxford, UK), M. Mayr (London, UK), P. Evans (Sheffield, UK), F. Vivanco (Madrid, ES),
L. Monserrat (A Coruña, ES)
11:30 Genomics and transcriptomics. 5113
– L. Monserrat (A Coruña, ES)
11:40 Genomics and transcriptomics - Panel discussion and questions from the audience. 5114
– M. Mayr (London, UK), M. Kitakaze (Suita, JP), P. Evans (Sheffield, UK), F. Vivanco (Madrid, ES),
11:55 Proteomics. 5115
– F. Vivanco (Madrid, ES)
12:05 Proteomics - Panel discussion and questions from the audience. 5116
– M. Mayr (London, UK), M. Kitakaze (Suita, JP), P. Evans (Sheffield, UK), F. Vivanco (Madrid, ES),
12:20 Integrative Biology - Focused on OMICS - Take home message. 5117
TUESDAY – MORNING
– A.R. Pries (Berlin, DE)

GENOTYPE-ENVIRONMENT INTERACTIONS IN CARDIOVASCULAR DISEASES: IMPLICATIONS Symposium
FOR PATHOGENESIS AND FOR MANAGEMENT
ESC and the European Society of Human Genetics
Chairperson(s): C. Basso (Padua, IT); J. Schmidtke (Hannover, DE)
11:00 Exercise-induced arrhythmias. 5118
– R. Brugada Terradellas (Girona, ES)
11:22 Aortopathies. 5119
– Y. Von Kodolitsch (Hamburg, DE)
11:45 Nutrigenomics. 5120
– D. Corella (Valencia, ES)
12:07 Heart rate variability. 5121
– N. Probst-Hensch (Basel, CH)
321

DIABETES MANAGEMENT: THE WAY TO CONTROL ATHEROSCLEROSIS Advances in Science
Chairperson(s): P.J. Grant (Leeds, UK); L. Sperling (Atlanta, US)
11:00 State of the Art in diabetes management. 5122
11:20 Fresh fruit consumption in relation to mortality and incidence of vascular events among 26,000 5123
individuals with diabetes: a 7-year prospective study.
– H. Du, L. Li, D. Bennett, Y. Guo, Z. Bian, J. Chen, T. Key, Z. Chen (Oxford, UK; Beijing, CN)
11:37 The different impact of different statins on insulin resistance in Asian population: a propensity 5124
score matched analysis.
– S.W. Rha, S. Xu, H.A. Ngow, J. Ali, B.G. Choi, S.Y. Choi, J.K. Byun, C.G. Park, H.S. Seo, D.J. Oh (Seoul,
KR)
11:54 Insulin and acute myocardial infarction in diabetic patients with chronic kidney disease and 5125
end-stage renal disease undergoing dialysis: a national cohort study.
– T.T. Lin, M.T. Liao, L.Y. Lin (Hsin-Chu and Taipei, TW)
12:11 Future direction for research in diabetes management. 5126
– Z. Fras (Ljubljana, SI)

CAN WE ADDRESS THE CHALLENGES OF AGEING AND FRAILTY? Symposium
Chairperson(s): A. Abreu (Lisbon, PT); A. Stromberg (Linköping, SE)
11:00 Frailty - How can we measure it and what is the clinical relevance? 5127
– C. Vigorito (Naples, IT)
11:22 Cardiac rehabilitation - How should it be tailored for old, frail patients? 5128
– P. Doherty (York, UK)
11:45 Comorbidities - How can we manage? 5129
– O. Hanon (Paris, FR)
12:07 Biological ageing - How old is too old for cardiac devices? 5130
– K. Dickstein (Stavanger, NO)
11:00–12:30 | Kiev - Village 3

CLINICAL CHALLENGES IN USE OF ANTICOAGULANTS Case-based Symposium
Chairperson(s): C. Torp-Pedersen (Aalborg, DK); J.C. Kaski (London, UK)
11:00 My patient on oral anticoagulation has a high stroke and bleeding risk – What to do? 5131
– A. Niessner (Vienna, AT)
11:15 My patient on oral anticoagulation has a high stroke and bleeding risk – What to do? Panel 5132
– A. Niessner (Vienna, AT), L.C. Wallentin (Uppsala, SE), E.A. Lopez De Sa Y Areses (Madrid, ES)
11:30 My patient needs to be on anticoagulation: NOACS or warfarin? 5133
– To be announced
11:45 My patient needs to be on anticoagulation: NOACS or warfarin? Panel discussion and questions 5134
from the audience.
– A. Niessner (Vienna, AT), L.C. Wallentin (Uppsala, SE)
12:00 Clinical challenges in use of anticoagulants - State of the Art lecture. 5135

DO CURRENT CLINICAL TRIALS MEET SOCIETY NEEDS? Symposium
Chairperson(s): C. Ceconi (Cona, IT); K.M. Fox (London, UK)
11:00 Industry sponsored trials: pressures and conflicts. 5136
– M. Sabatine (Boston, US)
11:22 A statistical perspective: what improvements are needed? 5137
– S.J. Pocock (London, UK)
11:45 Do global trials really meet global needs? 5138
– M. Pfeffer (Boston, US)
12:07 Do current clinical trials meet society needs? A journal perspective. 5139
322

ASYMPTOMATIC ATRIAL FIBRILLATION AND RISK OF STROKE Symposium
Chairperson(s): G. Breithardt (Münster, DE); T. Potpara (Belgrade, RS)
11:00 How to detect asymptomatic atrial fibrillation. 5140
– J. Brachmann (Coburg, DE)
11:22 How much does atrial fibrillation duration increase the risk of stroke and justify anticoagulation? 5141
11:45 Cryptogenic stroke - The neurologist’s view. 5142
– D. Krieger (Copenhagen, DK)
12:07 Cryptogenic stroke - Oral anticoagulants even without documented atrial fibrillation? 5143

LEADS EXTRACTION Advances in Science
Chairperson(s): C. Alonso (St. Cloud, FR); C.E.H. Kennergren (Gothenburg, SE)
11:00 State of the Art in leads extraction. 5144
– J.-C. Deharo (Marseille, FR)
11:20 Major transvenous lead extraction complications - occurrence and outcomes. An analysis of 1767 5145
procedures.
– A. Kutarski, M. Polewczyk, M. Czajkowski, A. Polewczyk, A. Polewczyk, S. Targonska, J. Stazka (Lublin
and Kielce, PL)
11:37 Chronic venous obstruction during cardiac device revision: incidence, predictors and efficacy of 5146
percutaneous techniques.
– G. Morani, M. Morosato, L. Tomasi, B. Bolzan, C. Vassanelli (Verona, IT)
11:54 Cardiac device infections- survival after transvenous leads extractions procedure. 5147
Lublin, PL)
12:11 Future direction for research in leads extraction. 5148

FAMILY SCREENING FOR CARDIAC DISEASE Case-based Symposium
Chairperson(s): B. Bauce (Padua, IT); A.M.G. Almeida (Lisbon, PT)
– N. Cardim (Lisbon, PT)
11:10 Hypertrophic cardiomyopathy - Panel discussion and questions from the audience. 5150
– N. Cardim (Lisbon, PT), K.H. Haugaa (Oslo, NO), A. Evangelista Masip (Barcelona, ES), J. Moon (London, UK)
11:22 Arrhythmogenic ventricular cardiomyopathy. 5151
– K.H. Haugaa (Oslo, NO)
11:32 Arrhythmogenic ventricular cardiomyopathy - Panel discussion and questions from the audience. 5152
– N. Cardim (Lisbon, PT), K.H. Haugaa (Oslo, NO), A. Evangelista Masip (Barcelona, ES), J. Moon (London, UK)
11:44 Bicuspid aortic valve and aortopathy. 5153
11:54 Bicuspid aortic valve and aortopathy - Panel discussion and questions from the audience. 5154
– N. Cardim (Lisbon, PT), K.H. Haugaa (Oslo, NO), S. Achenbach (Erlangen, DE), J. Moon (London, UK)
12:06 Early coronary artery disease. 5155 TUESDAY – MORNING
12:16 Early coronary artery disease Panel discussion and questions from the audience. 5156
– N. Cardim (Lisbon, PT), K.H. Haugaa (Oslo, NO), A. Evangelista Masip (Barcelona, ES),
S. Achenbach (Erlangen, DE)

NON-INVASIVE IMAGING IN ISCHAEMIC HEART DISEASE: COMPARATIVE EFFECTIVENESS Symposium
STUDIES
Chairperson(s): S.R. Underwood (London, UK); A. DeMaria (San Diego, US)
11:00 CMR and SPECT: the CE-MARC study. 5157
– J. Greenwood (Leeds, UK)
11:22 SPECT, PET and CTA: the SPARC study. 5158
– K. Nieman (Rotterdam, NL)
11:45 Stress imaging and CTA: the EVINCI study. 5159
– D. Neglia (Pisa, IT)
12:07 Unmet needs in comparative effectiveness research in imaging: the on-going ISCHAEMIA trial. 5160
323

ABDOMINAL AORTIC ANEURYSM: PILL, STENT OR KNIFE? Symposium
Chairperson(s): A. Bura-Riviere (Toulouse, FR); A.F. Gallino (Bellinzona, CH)
11:00 Medical therapy in AAA. 5161
11:22 Unruptured AAA: stent or knife? 5162
– E. Stabile (Salerno, IT)
11:45 AAA repair: does sex matter? 5163
– R.S. von Allmen (St. Gallen, CH)
12:07 Ruptured AAA: knife or stent? 5164
– E. Allaire (Créteil, FR)
11:00–12:30 | Oslo - Village 6

BIORESORBABLE SCAFFOLD IN CORONARY INTERVENTION IN DAILY PRACTICE Meet the Experts
Chairperson(s): H.C. Tan (Singapore, SG); P.W.J.C. Serruys (Rotterdam, NL)
11:00 Bioresorbable scaffold in coronary intervention in daily practice - Introduction to the session. 5165
– H.C. Tan (Singapore, SG)
11:05 Scaffold implantation for the treatment of a bifurcated lesion. 5166
– J. Ge (Shanghai, CN)
11:15 Scaffold implantation for the treatment of a bifurcated lesion - Panel discussion and questions 5167
from the audience.
– J. Ge (Shanghai, CN), A. Colombo (Milan, IT), J.J. Wykrzykowska (Abcoude, NL)
11:30 The unforeseens during scaffold implantation. 5168
– A. Colombo (Milan, IT)
11:40 The unforeseens during scaffold implantation - Panel discussion and questions from the 5169
audience.
11:55 Managing scaffold thrombosis, a new version of an old issue. 5170
– J.J. Wykrzykowska (Abcoude, NL)
12:05 Managing scaffold thrombosis, a new version of an old issue - Panel discussion and questions 5171
from the audience.
12:20 Bioresorbable scaffold in coronary intervention in daily practice - Take home message. 5172

OPTIMISING MANAGEMENT OF ACUTE CORONARY SYNDROMES IN DIFFERENT PATIENT Symposium
SUBGROUPS
Chairperson(s): S.D. Kristensen (Aarhus, DK); S.C. Clarke (Cambridge, UK)
11:00 The elderly. 5173
11:22 Women. 5174
11:45 Diabetics. 5175
– To be announced
12:07 Atrial fibrillation patients. 5176

CHALLENGES IN TROPONIN INTERPRETATION Case-based Symposium
Chairperson(s): K. Thygesen (Aarhus, DK); F. Crea (Rome, IT)
11:00 Acute pulmonary oedema and atrial fibrillation with elevated troponin. 5177
– D. Milicic (Zagreb, HR)
11:15 Acute pulmonary oedema and atrial fibrillation with elevated troponin - Panel discussion and 5178
– H.A. Katus (Heidelberg, DE), D.J. Richter (Athens, GR)
11:30 Positive troponin after cardiac surgery. 5179
– C. Gavina (Matosinhos, PT)
11:45 Positive troponin after cardiac surgery - Panel discussion and questions from the audience. 5180
– H.A. Katus (Heidelberg, DE), D.J. Richter (Athens, GR)
12:00 Challenges in troponin interpretation. State of the Art lecture. 5181
324
11:00–12:30 | Tunis - Village 7

INTERNATIONAL COMPARISONS OF ACUTE CARDIOVASCULAR CARE AND OUTCOMES Symposium
Chairperson(s): D. Brieger (Concord, AU); I.A. Simpson (Southampton, UK)
11:00 International comparisons of STEMI care and outcomes. 5182
– H. Hemingway (London, UK)
11:22 Lessons from SWEDE HEART. 5183
– T. Jernberg (Stockholm, SE)
11:45 STEMI in China, can we learn from the past? 5184
– L. Jiang (Beijing, CN)
12:07 Quality of life after STEMI: lessons from the USA. 5185
– V. Kunadian (Newcastle-upon-Tyne, UK)

INTEGRATED CARDIOVASCULAR IMAGING FOR PERICARDIAL DISEASES Symposium
Chairperson(s): Y. Adler (Rannana, IL); H. Frank (Tulln, AT)
11:00 Role of echocardiography. 5186
– G. Di Salvo (Naples, IT)
11:22 Role of computed tomography and cardiac magnetic resonance. 5187
– J. Bogaert (Leuven, BE)
11:45 Cardiac catheterization: when is it necessary? 5188
12:07 Integrated cardiovascular imaging for pericardial diseases - What do the Guidelines tell us? 5189
– M. Imazio (Turin, IT)

ACUTE PULMONARY EMBOLISM – WHEN GUIDELINES DO NOT HELP Symposium
Chairperson(s): A. Torbicki (Otwock, PL); J.S.R. Gibbs (London, UK)
11:00 Subsegmental pulmonary embolism. 5190
– G. Meyer (Paris, FR)
11:22 Deep venous thrombosis in patients with pulmonary embolism. 5191
– L. Mazzolai (Lausanne, CH)
11:45 Pulmonary embolism in pregnancy. 5192
– S. Middeldorp (Amsterdam, NL)
12:07 Indefinite anticoagulation: who are the candidates? 5193
– S.V. Konstantinides (Mainz, DE)

ADULT CONGENITAL HEART DISEASES Cardiac Anatomy and Pathology Live
Chairperson(s): S.Y. Ho (London, UK); K. Dimopoulos (London, UK)
11:00 Live-video demonstration. 5194
– A. Angelini (Padua, IT)
11:00–12:30 | Bern - Village 9 TUESDAY – MORNING

MANAGEMENT AND PREVENTION OF CARDIOTOXICITY SECONDARY TO CANCER DRUGS Symposium
Chairperson(s): T.M. Suter (Berne, CH); D. Tousoulis (Athens, GR)
11:00 Detection of cardiotoxicity: an imaging overview. 5196
11:22 Prevention of cardiotoxicity secondary to chemotherapy. 5197
– D. Cardinale (Milan, IT)
11:45 Cancer and atrial fibrillation. 5198
– D.T. Farmakis (Piraeus, GR)
12:07 End-Stage cancer as cardio-vascular disease. 5199
– J. Springer (Berlin, DE)
325

DEBATES IN HEART FAILURE Debate Session
Chairperson(s): J.G.F. Cleland (London, UK); J.R. Gonzalez Juanatey (Santiago de Compostela, ES)
11:00 I only need ECG and ejection fraction to select patients for CRT. PRO. 5200
11:15 I only need ECG and ejection fraction to select patients for CRT. CONTRA. 5201
– O.A. Smiseth (Oslo, NO)
11:30 I only need ECG and ejection fraction to select patients for CRT. REBUTTAL PRO. 5202
11:35 I only need ECG and ejection fraction to select patients for CRT. REBUTTAL CONTRA. 5203
– O.A. Smiseth (Oslo, NO)
11:40 I only need ECG and ejection fraction to select patients for CRT - CONCLUSION. 5204
11:45 To eliminate atrial fibrillation in heart failure. PRO. 5205
12:00 To eliminate atrial fibrillation in heart failure. CONTRA. 5206
– W. Haverkamp (Berlin, DE)
12:15 To eliminate atrial fibrillation in heart failure. REBUTTAL PRO. 5207
12:20 To eliminate atrial fibrillation in heart failure. REBUTTAL CONTRA. 5208
12:25 To eliminate atrial fibrillation in heart failure - CONCLUSION. 5209

WHAT IS NEW IN MITRAL VALVE DISEASE Rapid Fire Abstract
Chairperson(s): A.J. Berrebi (Issy-les-Moulineaux, FR); R.P. Martin (Atlanta, US)
11:00 The Relationship Between Mitral Annular Calcification and Red Cell Distribution Width: A Cross 5210
Sectional Study.
– C. Yayla, M. Akboga, U. Canpolat, K. Gayretli Yayla, F. Bayraktar, M. Suleymanoglu, S. Kuyumcu, A. Eyiol,
S. Aydogdu (Ankara and Konya, TR)
11:09 The pan-inflammatory process may cause mitral valve deterioration in systemic autoimmune 5211
disorder patients: a transthoracic echocardiography study.
– A. Sugiura, N. Funabashi, K. Ozawa, H. Takaoka, Y. Koabayashi (Chiba, JP)
11:18 Appropriation of current recommendations for the optimal timing of surgery in patients with 5212
degenerative severe mitral regurgitation.
– S. Lazam, M.P. Montant, C.F. Chenot, C.H.D.M. De Meester, B.J. Boulif, P.A. Pasquet, G.B. Gerber,
V.D. Vancrayenest, A.-C.P. Pouleur, J.L.V.O. Vanoverschelde (Brussels, BE)
11:27 Evolution of functional mitral regurgitation and prognosis in medically managed heart failure 5213
patients with reduced ejection fraction.
– R. Nasser, L. Van Assche, A. Vorlat, T. Vermeulen, E. Van Craenenbroeck, V. Conraads, C. Vrints,
M.J. Claeys (Antwerp, BE)
11:36 Differential impact of mitral valve surgery on outcome of coronary artery bypass grafting with or 5214
without surgical ventricular reconstruction in the surgical treatment for ischemic heart failure trial.
– M.Y.C. Tsang, L. She, F.A. Miller, J.O. Choi, M.A. Deja, S. Castelvecchio, V. Rao, T. Kukulski, D. Prior,
J.K. Oh (Vancouver and Toronto, CA; Durham and Rochester, US; Seoul, KR; Katowice and Zabrze, PL;
San Donato Milanese, IT; Melbourne, AU)
11:45 The EVEREST II REALISM Continued Access Study - 1 Year Outcomes in Patients with Primary 5215
Mitral Regurgitation.
– S. Kar, D.S. Lim, P.A. Grayburn, A. Wang, E. Foster, N.J. Weissman, A. Trento, G. Ailawadi, M. Mack,
T. Feldman (Los Angeles, Charlottesville, Dallas, Durham, San Francisco, Washington and Evanston, US)
11:54 Successful MitraClip implantation beyond EVEREST II criteria and German consensus 5216
recommendations.
– A. Isotani, T. Schau, M. Neuss, M. Schoepp, C. Butter (Bernau bei Berlin, DE)
12:03 Transcatheter mitral valve implantation in high-risk patients. 5217
– C. Bouleti, D. Himbert, B. Iung, M. Urena, A.A. Fassa, E. Brochet, P. Ou, P. Nataf, A. Vahanian (Paris, FR)
12:12 Initial results of fully percutaneous transcatheter mitral valve implantation for native mitral valve 5218
disease in patients with extensive annular calcification.
– M. Urena, D. Himbert, C. Bouleti, E. Brochet, B. Iung, P. Ou, M.P. Dilly, W. Ghodhbane, P. Nataf,
A. Vahanian (Paris, FR)
12:21 Should we reconsider the role of anticoagulation in moderate mitral stenosis? 5219
– K. Leemasawat, A. Phrommintikul, R. Kanjanavanit (Chiang Mai, TH)
326
TUESDAY 1 SEPTEMBER 2015 – MORNING POSTERS

BEST POSTERS IN RESYNCHRONISATION THERAPY
Discussant: Best posters in Resynchronisation therapy. P5220

– J.C. Daubert (Rennes, FR)
Differentiating the electromechanical substrate responsive to cardiac resynchronisation therapy from P5221
non-electrical dyssynchrony substrates by computer-assisted regional strain analysis.
– J. Lumens, B. Tayal, J. Walmsley, A. Delgado-Montero, P.R. Huntjens, S. Saba, T. Delhaas, F.W. Prinzen,
J. Gorcsan (Maastricht, NL; Pittsburgh, US)
Anatomical and electrical interlead distance predict outcome in cardiac resynchronization therapy P5222
patients.
– G.L. Botto, A. D’Onofrio, P. Pepi, A. De Simone, M. Santamaria, S.I. Caico, D. Pecora, E. Bertaglia,
M. Malacrida, G. Stabile (Como, Naples, Mantova, Maddaloni, Campobasso, Gallarate, Brescia, Padua and
Milan, IT)
Good relation between left ventricular electrical activation and contraction in patients undergoing cardiac P5223
– M. Mafi Rad, J. Van T Sant, Y. Blaauw, F.J. Meijboom, P.A. Doevendans, H.J. Crijns, F.W. Prinzen,
M. Meine, K. Vernooy (Maastricht and Utrecht, NL)
Metabolic scintigraphy with radiolabeled fatty acid in prognosis of cardiac resynchronization therapy in P5224
patients with dilated cardiomyopathy.
– Y. Lishmanov, M. Gulya, K. Zavadovsky, S. Sazonova, D. Lebedev (Tomsk, RU)
BEST POSTERS IN ACUTE CORONARY SYNDROMES
Discussant: Best posters in acute coronary syndromes. P5225

Troponin positive acute coronary syndrome with unobstructed coronary arteries: improved diagnostic P5226
accuracy of early cardiovascular magnetic resonance investigation, and implication for patients.
– A. Ghosh Dastidar, P. Singhal, J. Rodrigues, N. Ahmed, M. Townsend, A. Nightingale, J. Strange,
T. Johnson, A. Baumbach, C. Bucciarelli-Ducci (Bristol, UK)
Dynamic enhancement pattern of unstable coronary plaque: analysis by 320-row area detector computed P5227
tomography.
– T. Kameyama, H. Ihori, K. Ohara, M. Nonomura, T. Misaki, H. Inoue (Toyama, JP)
Age dependent association of body mass index with coronary artery calcification: true or false? P5228
– S. Van Workum, S. Altintas, M. Kok, P.J. Nelemans, J.E. Wildberger, H.J. Crijns, M. Das, B.L. Kietselaer
(Maastricht, NL)
Association of big endothelin-1 with coronary artery calcification. P5229
– P. Qing, X.-L. Li, R.-X. Xu, Y.-L. Guo, J. Sun, Q. Dong, C.-G. Zhu, N.-Q. Wu, J.J. Li (Beijing, CN)
BEST POSTERS IN CARDIAC COMPUTED TOMOGRAPHY
Discussant: Best posters in cardiac computed tomography. P5230 TUESDAY – MORNING

– A.J.H.A. Scholte (Leiden, NL)
Association of quantitative global plaque volume and Agatston score with major cardiovascular events on P5231
long-term follow-up of patients referred for coronary CT angiography.
– M. Marwan, A. Schuhbaeck, J. Kilger, M. Jaeger-Beitinger, M. Deser, A. Atzinger, M. Timm,
C. Schmidkonz, J. Kuribara, S. Achenbach (Erlangen, DE)
Independent prognostic value of coronary artery calcium score and coronary computed tomography P5232
angiography in an outpatient cohort of low to intermediate risk chest patients.
– M.J. Bom, P.M. Van Der Zee, F.M. Van Der Zant, R.J.J. Knol, J.H. Cornel (Alkmaar, NL)
Characteristics of atherosclerotic plaques evaluated at coronary computed tomography angiography P5233
associated with higher risk of future acute coronary syndrome: a long-term follow-up study.
– E. Conte, S. Mushtaq, C. Segurini, M. Guglielmo, A. Baggiano, V. Volpato, A. Annoni, G. Pontone, M. Pepi,
D. Andreini (Milan, IT)
Coronary CT angiography anatomic assessment and lesion-specific ischemia: impact of integrating P5234
coronary plaque volume and CT derived fractional flow reserve.
– S. Gaur, K.A. Oevrehus, D. Dey, J.A. Leipsic, J.M. Jensen, J.F. Lassen, H.E. Boetker, E.H. Christiansen,
A.K. Kaltoft, B.L. Norgaard (Aarhus and Vejle, DK; Los Angeles, US; Vancouver, CA)
327
BEST POSTERS IN VASCULAR BIOLOGY

Discussant: Best posters in vascular biology. P5235
– R. Krams (London, UK)
Nicotinamide-streptozotocin-induced type 2 diabetes in uninephrectomized high-fat-fed rats: a novel P5236
non-genetic rat model of diabetic nephropathy.
– V.K. Bayrasheva, E.N. Grineva, A.Y. Babenko, I. Shatalov, Y.V. Dmitriev, S.G. Chefu, A.N. Ivanova (St.
Petersburg, RU)
Characterization of hemodynamics in great arteries of wild-type mouse using CFD based on ultrasound P5237
images.
– Z. Chen, Y. Zhou, Y.C. Ma, J.Y. Wang, Y.A.H. He, Z.A. Li (Beijing, CN)
Modeling Marfan syndrome with induced pluripotent stem cell-derived vascular smooth muscle cells. P5238
– Y. Saito, K. Nakamura, T. Miyoshi, M. Yoshida, H. Sugiyama, H. Ito (Okayama, JP)
Resveratrol inhibits aortic root dilatation in marfan mice. P5239
– S. Hibender, R. Franken, I. Van Der Made, E.E. Schermer, Y.M. Pinto, M. Groenink, A.H. Zwinderman,
B.J.M. Mulder, C.J.M. De Vries, V. De Waard (Amsterdam, NL)
BEST POSTERS IN TRICUSPID DISEASE

Discussant: Best posters in tricuspid disease. P5240
– C.C. Keong (Singapore, SG)
Outcomes of tricuspid valve replacement: a meta-analysis. P5241
– E. Angeloni, G. Melina, S. Refice, F. Capuano, A. Roscitano, C. Comito, R. Sinatra (Rome, IT)
Rigid annuloplasty ring or flexible band for treating functional tricuspid regurgitation? Insights from a P5242
clinical and echocardiographic study.
– L. Dell’angela, G. Gatti, M. Morosin, B. Pinamonti, M. Cassin, R. Piazza, B. Benussi, G.L. Nicolosi,
A. Pappalardo, G. Sinagra (Trieste and Pordenone, IT)
Is two-dimensional measurement of tricuspid annulus the most appropriate criteria for selecting P5243
candidates for surgery? Insights from 3D echocardiography.
– P. Mahia, R. Aguilar-Torres, G. Tirado, M.T. Nogales-Romo, P. Marcos-Alberca, C. Almeria, J.L. Rodrigo,
Tricuspid valve annuloplasty for functional tricuspid regurgitation: immediate outcomes and risk factors P5244
for late failure.
– L. Dell’angela, G. Gatti, M. Morosin, B. Pinamonti, M. Bollini, A. Poletti, B. Benussi, G.L. Nicolosi,
A. Pappalardo, G. Sinagra (Trieste and Pordenone, IT)
BEST POSTERS IN ELDERLY AND CARDIOVASCULAR DISEASES

Discussant: Best posters in elderly and cardiovascular diseases. P5245
– H. Voller (Rudersdorf, DE)
Hypertensive target organ damage and longitudinal changes in brain structure and function in older P5246
patients with manifest cardiovascular disease: The SMART-MR study.
– M. Muller, P.H. Van Der Veen, F.L.J. Visseren, H.M. Nathoe, W.P.T.M. Mali, Y. Van Der Graaf,
M.I. Geerlings (Leiden and Utrecht, NL)
Results of the cardiac surgery in octogenarians. P5247
– J. Kunstyr, M. Porizka, T. Vanek, M. Nejedly, P. Jehlicka, J. Buckova, J. Mokrejs, F. Mosna (Prague and
Plzen, CZ)
Transcatheter aortic valve implantation in very elderly patients: immediate results and medium term P5248
follow-up.
– I. Pascual Calleja, P. Avanzas, A.J. Munoz Navarro, D. Lopez Otero, R. Del Valle, M.F. Jimenez Navarro,
B. Cid Alvarez, J.M. Hernandez, R. Trillo-Nouche, C. Moris (Oviedo, Málaga and Santiago de Compostela,
ES)
Impact of low diastolic blood pressure on risk of cardiovascular death in elderly and late-elderly patients P5249
with coronary artery disease after coronary revascularization: the CREDO-Kyoto Registry.
– H. Kai, T. Kimura, Y. Furukawa, Y. Fukumoto, T. Kita (Kurume, Kyoto and Kobe, JP)
BEST POSTERS IN KNOWN AND EMERGING RISK FACTORS AFTER CARDIAC SURGERY
Discussant: Best posters in known and emerging risk factors after cardiac surgery. P5250
– R.G. Xuereb (Ta’ Xbiex, MT)
Blood transfusion and increased hospital morbidity and mortality in patients undergoing coronary artery P5251
bypass grafting.
– V. Tanganelli, I.C. Campos, P.S. Farsky, J.G.T. Egito, H.P. Maues, M.C.C. Mousinho, F.A. Martins,
G. Munhoz (São Paulo, BR)
Smokers undergoing coronary surgery are at a greater risk for perioperative complications. P5252
– F. Leite, P. Antunes, M.J. Antunes (Coimbra, PT)
Genetic variant in glycoprotein receptor Ia is associated with major adverse cardiac and cerebrovascular P5253
events after coronary artery bypass graft surgery.
– H.N. Liu, H.Y. Gu, Z. Zhou, S.S. Hu, Z. Zheng (Beijing and Zhenjiang, CN)
Troponin T value and hospital mortality after cardiac surgery. P5254
– L.N. Maia, M.N. Machado, M.A. Nakazone, O.L. Silva Jr, I.H. Grigolo, D.F. Martin, F.B. Rodrigues,
M.G.L. Oliveira (Sao Jose do Rio Preto, BR)
328
BEST POSTERS IN BASIC CARDIO-ONCOLOGY RESEARCH
Discussant: Best posters in basic cardio-oncology research. P5255

– G. Bajraktari (Prishtina, XK)
A selective angiotensin-II type 2 receptor agonist reduced cancer cachexia-induced cardiomyopathy. P5256
– M. Konishi, C. Drescher, A. Tschirner, A.J. Coats, S.D. Anker, J. Springer (Göttingen, DE; Melbourne, AU)
Plasma levels of tumor necrosis factor in relation to intramuscular gene expression of TNF, metabolic P5257
related enzymes and skeletal muscle pathology in heart failure.
– A.I. Larsen, T. Valborgland, S. Lindal, J.T. Kvaloy, P. Aukrust, P.S. Munk, A. Yndestad (Stavanger, Tromsø
and Oslo, NO)
Effects of late exercise on cardiac remodeling and myocardial calcium handling proteins in rats with P5258
moderate and large myocardial infarction size.
– M.P. Okoshi, D.M. Guizoni, S.A. Oliveira-Jr, L.U. Pagan, S.L.R. Noor, A.R.R. Lima, R.L. Damatto,
L.A.M. Zornoff, P.F. Martinez, K. Okoshi (Botucatu and Campo Grande, BR)
Myofilament changes in doxorubicin-induced cardiotoxicity. P5259
– P. Goncalves Rodrigues, D. Miranda-Silva, C. Barros, N. Hamdani, W. Linke, A.F. Leite-Moreira,
I. Falcao-Pires (Porto, PT; Bochum, DE)
BEST POSTERS IN HYPERTENSION IN SPECIFIC POPULATIONS
Discussant: Best posters in hypertension in specific populations. P5260

– S. Jaber (Aden, YE)
Nationwide prevalence, awareness, treatment and control of hypertension among the adult population in P5261
Bangladesh.
– S. Jesmin, Y. Iwashima, M.A. Rahman, A.K.M.A. Habib, N. Shimojo, M. Moroi, N. Yamaguchi, O. Okazaki,
S. Kawano, Y. Kawano (Tsukuba, Suita, Tokyo and Ami, JP; Bogra, BD)
Age-related change of blood pressure and brachial-ankle pulse wave velocity in native Papuan P5262
populations.
– A. Ishida, M. Fujisawa, E. Garcia Del Saz, K. Okumiya, Y. Kimura, I. Manuaba, Y. Ohya, K. Matsubayashi
(Okinawa, Kyoto and Kochi, JP; Papua, ID)
Prevalence of hypertension and other cardiovascular risk factors in participants in the 2014 Hypertension P5263
World Day campaign in Italy.
– C. Torlasco, C. Calvanese, A. Faini, F. Santini, C. Borghi, G. Parati (Milan and Bologna, IT)
Association between CXCL13 gene polymorphism and essential hypertension in Tatars from Russia. P5264
– Y. Timasheva, T.R. Nasibullin, A.N. Zakirova, O.E. Mustafina (Ufa, RU)
TUESDAY – MORNING
329

ATRIAL FIBRILLATION I
Prognostic impact of resting heart rate in atrial fibrillation in octogenarians with systolic heart failure. P5265
– S.B. Barywani, M. Fu (Gothenburg, SE)
Left atrium size further stratify the risk of left atrial thrombus in patients with non-valvular persistent P5266
– R.-B. Tang, J.-Z. Dong, M.-S. Shang, X. Du, D.-Y. Long, R.-H. Yu, R. Bai, C.-S. Ma (Beijing, CN)
Effect of digoxin on all-cause mortality in patients with atrial fibrillation: a population-based cohort study. P5267
– L. Fauchier, G. Laborie, N. Clementy, A. Bernard, D. Angoulvant, G.Y.H. Lip, D. Babuty (Tours, FR;
Birmingham, UK)
Increased levels of both NT-proBNP and MR-proANP after initiation of atrial fibrillation: results from an P5268
invasive electrophysiological study.
– E. Charitakis, H. Walfridsson, U. Alehagen (Linköping, SE)
Atrial fibrillation as an independent risk factor for depression in elderly population. P5269
– K. Rewiuk, B. Wizner, A. Klich-Raczka, A. Wiecek, M. Mosakowska, P. Slusarczyk, K. Broczek, T. Grodzicki
(Kraków, Katowice and Warsaw, PL)
Prevalence of erectile dysfunction in atrial fibrillation patients - cross-sectional, epidemiological study. P5270
– A.E. Platek, F.M. Szymanski, K.J. Filipiak, M. Kotkowski, G. Opolski (Warsaw, PL)
The association of non-0 blood groups with spontaneous echo contrast. Is there a place for “A” blood P5271
group at thromboembolic risk scores in atrial fibrillation.
– E.H. Ozcan Cetin, M.S. Cetin, S. Kuyumcu, F. Ozcan, D. Aras, S. Topaloglu, S. Aydogdu (Ankara, TR)
Sex-related differences in epidemiologic and clinical presentation of atrial fibrillation in the Balkan P5272
countries - insights from the BALKAN AF Snap Shot Survey.
– M. Polovina, E. Goshev, Z. Kusljugic, L.J. Music, H. Gjergo, G.A. Dan, V. Paparisto, E. Trendafilova,
T. Potpara, G.Y.H. Lip (Belgrade, RS; Sofia, BG; Tuzla, BA; Podgorica, ME; Tirana, AL; Bucharest, RO;
Birmingham, UK)
Do all AF patients with a CHA2DS2-VASc score of 2 (males) or 3 (females) have the same risk of ischemic P5273
stroke? A nationwide population-based cohort study.
– J.-N. Liao, T.F. Chao, G.Y. Lip, S.A. Chen (Taipei, TW; Birmingham, UK)
CHA2DS2-VASc score predicted extensive substrate and poor outcome of catheter ablation of persistent P5274
– R.-B. Tang, J.-Z. Dong, X.-H. Liu, R.-H. Yu, D.-Y. Long, C.-H. Sang, M. Ning, C.-X. Jiang, R.O.N.G. Bai,
C.-S. Ma (Beijing, CN)
ATRIAL FIBRILLATION II
Diastolic electrocardiographic parameters and diastolic index predict postoperative atrial fibrillation. P5275
– A.I. Tekkesin, E. Bozbeyoglu, Y. Cakilli, C. Turkkan, M.I. Hayiroglu, O. Yildirimturk, V.O. Tanik, A. Kaya,
N.S. Yelgec, A.T. Alper (Istanbul, TR)
Risk prediction in atrial fibrillation. Comparison between the CHADS2, CHA2DS2-VASc score in a large P5276
contemporary cohort of patients with incident non-valvular atrial fibrillation.
– M. Haim, M. Hoshen, O. Reges, Y. Rabi, R. Balicer (Beer Sheva and Tel Aviv, IL)
Effectiveness of structured hospital based nurse-led atrial fibrillation clinics: A comparison of a P5277
real-world population versus a clinical trial population.
– I. Qvist, J.M.L. Hendriks, D.S. Moeller, A.E. Albertsen, H.M. Mogensen, G.D. Oddershede, A. Odgaard,
L.S. Mortensen, S.P. Johnsen, L. Frost (Silkeborg, Viborg, Lystrup and Aarhus, DK; Maastricht, NL)
Left atrial thrombosis in patients with atrial fibrillation undergoing cardioversion. P5278
– K. Golubic, I. Ivanac Vranesic, A. Smalcelj, D. Milicic (Zagreb, HR)
Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in atrial P5279
fibrillation patients.
– D. Pastori, P.P. Pignatelli, R.C. Cangemi, W.R.H. Hiatt, A.F. Farcomeni, T.V. Vicario, T.B. Bucci,
R.C. Carnevale, G.Y.H.L. Lip, F.V. Violi (Rome, IT; Denver, US; Birmingham, UK)
Rate control or rhythm control - what do we choose more often in patients with higher thromboembolic P5280
risk? Data from a multicenter real-life registry.
– A.E. Platek, F.M. Szymanski, K.J. Filipiak, A. Hrynkiewicz-Szymanska, J. Syska-Suminska, A. Klos-Szadryn,
M. Strojek, M. Kotkowski, M. Dluzniewski, G. Opolski (Warsaw, PL)
Being diagnosed with atrial fibrillation/flutter is associated with lower perceived physical health - a P5281
Danish cross sectional study.
– V. Hoegh, S. Lundbye-Christensen, C. Delmar, K. Frederiksen, S. Riahi, K. Overvad (Aalborg and Aarhus,
DK)
Atrial fibrillation is underdiagnosed in general practice: the PROFIL FA awareness campaign results in P5282
patients above 80y.
– J.M. Davy, M. Trancart, V. Donio, Y. Briand, N. Spiess (Montpellier, Bourg-la-Reine and Paris, FR)
330
Stroke history as predictive criteria for further atrial fibrillation diagnostic: French screening campaign of P5283
atrial fibrillation (PROFIL FA) in general practice.
– J.M. Davy, M. Trancart, V. Donio, Y. Briand, N. Spiess (Montpellier, Bourg-la-Reine and Paris, FR)
Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide P5284
cohort study.
– C. Benn Christiansen, C. Torp-Pedersen, J.B. Olesen, G. Gislason, M. Lamberts, N. Carlson, M. Buron,
N. Juul, G.Y.H. Lip (Aalborg and Copenhagen, DK; Birimingham, UK)
Prevalence and predictors of subclinical atrial tachyarrythmias in high risk patients detected by P5285
prolonged continuous Holter monitoring.
– R. Rossini, A. Calabrese, P. Ferrero, G. Musumeci, D. Capodanno, C. Vittori, E. Collaku, P. Canova,
O. Valsecchi, M. Senni (Bergamo and Catania, IT)
The relationship between the frequency of paroxysmal episodes of atrial fibrillation and left atrial function P5286
as measured by strain imaging.
– K.G. Adamyan, A.L. Chilingaryan, L.G. Tunyan, L.R. Tumasyan (Yerevan, AM)
ATRIAL FIBRILLATION III

Predictors of rheumatic atrial fibrillation: Late Gadolinium Enhancement MRI study to assess atrial P5287
fibrosis.
– A.S.H. Shehata, Y.B. Baghdady, A.M.A. Abdel Wahab, M.A.S. Salem (Cairo, EG)
Predictors for atrial fibrillation in patients with coronary artery disease: a cross-sectional analysis of P5288
BOREAS registry data.
– N. Kokubu, H. Akasaka, J. Nishida, N. Nagano, N. Murakami, S. Muratsubaki, M. Tanno, A. Hashimoto,
T. Miki, T. Miura (Sapporo, JP)
Prevalence of non valvular atrial fibrillation in a large cohort of ambulatory patients. A survey from a large P5289
data base of a GP group.
– G. Casolo, G. Cavirani, A. Bonci, G. Catelani, P.L. Dal Torrione, D. Maggi, A. Pellizzari, E. Salvatori,
E. Santarelli, M. Tomei (Lido di Camaiore, IT)
Critical coronary atherosclerosis in patients with recent onset atrial fibrillation and troponin rise. P5290
– A. Conti, E. Angeli, C. Grifoni, F. Trausi, D. Lazzeretti, S. Bianchi, S. Catarzi, A. Covelli, M.E. Perrotta,
N. Renzi (Massa-Carrara and Florence, IT)
Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation: a single centre, P5291
randomized, double blind, placebo controlled study.
– M. Farkowski, A. Maciag, T. Chwyczko, M. Beckowski, P. Syska, I. Kowalik, M. Pytkowski, J. Wozniak,
R. Dabrowski, H. Szwed (Warsaw, PL)
Patient profile in non-valvular atrial fibrillation (NVAF) and stroke: findings from a real-world setting in P5292
Spain.
– C. Lefevre, H. Benhaddi, L. Lacoin, H. Diaz Cuervo, Y.-C. Lee, D. Evans, D. Budd (Rueil-Malmaison, FR;
Oviedo, ES; New York, US)
Does renal function affect clinical course and management in patients with atrial fibrillation? P5293
– P. Lopatowska, A. Tomaszuk-Kazberuk, E. Mlodawska, H. Bachorzewska-Gajewska, J. Malyszko,
S. Dorzycki, W.J. Musial (Bialystok, PL)
The impact of new onset atrial fibrillation on mortality and morbidity in patients with acute coronary P5294
syndrome.
– K. Golinska Grzybala, A. Furman-Niedziejko, M. Wilczynska-Golonka, M. Matoga, I. Palka, R. Rychlak,
I. Chrzan, J. Zalewski, J. Nessler (Krakow and Tarnow, PL)
Lone atrial fibrillation: work up and predictors of recurrences. P5295
– A. Buiatti, S.B. Busch, T.R. Reents, B.K. Kaess, F.B. Bourier, M.T. Telishveska, M.K. Kottmaier,
G.H. Hessling, I.D. Deisenhofer (Munich, DE)
More advanced electroanatomical remodeling of left atrium and contractile dysfunction of left atrial P5296
appendage increase the risk of stroke for women in comparison to men in atrial fibrillation.
– J.S. Lee, T.H. Kim, J.S. Uhm, C.Y. Shim, B.Y. Joung, G.R. Hong, M.H. Lee, H.N. Pak (Seoul, KR) TUESDAY – MORNING
Atrial fibrillation with or without valvular disease: is the prognosis different? P5297
– C. Mazzone, G. Barbati, C. Carriere, A. Cherubini, G. Faganello, G. Cioffi, L. Tarantini, S. Poli, G. Sinagra,
A. Di Lenarda (Trieste, Trento and Belluno, IT)
Guideline adherence for stroke prevention and risk of mortality in patients with atrial fibrillation. P5298
– T.F. Chao, G. Y.H. Lip, S.A. Chen (Taipei, TW; Birmingham, UK)
ATRIAL FIBRILLATION IV
Combination of bilevel positive airway pressure and oral airway insertion is an effective strategy during P5299
atrial fibrillation ablation.
– Y. Yamaguchi, K. Kumagai, M. Nakano, D. Kutsuzawa, K. Minami, S. Shimizu, T. Yano, T. Sasaki,
K. Nakamura, S. Naito (Maebashi, JP)
Which components of the CHA2DS2-VASc score are the most important in obstructive sleep apnea P5300
patients with atrial fibrillation?
– F.M. Szymanski, K.J. Filipiak, A.E. Platek, M. Kotkowski, G. Karpinski, G. Opolski (Warsaw, PL)
Twenty-four hours holter monitoring and clinical predictors for new onset atrial fibrillation in a P5301
non-selected population.
– S. Cabrera Gomez, E. Valles, B. Benito, P. Ramos, J. Bruguera, J. Marti-Almor (Barcelona, ES)
Opportunistic screening for atrial fibrillation in hospitalized geriatric patients. P5302
– R. Tavernier, Y. Vandekerckhove, R. Van Hoeyweghen, R. Houben, M. Duytschaever (Bruges, BE;
Maastricht, NL)
331
The clinical impact of atrial fibrillation complicating ST-segment elevation myocardial infarction depends P5303
on location of infarction and timing of arrhythmia - data from a 10-year prospective study.
– T. Podolecki, R. Lenarczyk, J. Kowalczyk, E. Jedrzejczyk-Patej, P. Francuz, A. Swiatkowski, P. Chodor,
M. Mazurek, T. Zielinska, Z. Kalarus (Zabrze, PL)
Prognostic usefulness of the glomerular filtration rate estimation equations in patients with non-valvular P5304
atrial fibrillation on vitamin K antagonists: the new CKD-EPI versus the re-expressed MDRD-4.
– R. Riziq-Yousef Abumuaileq, E. Abu-Assi, A. Lopez-Lopez, S. Raposeiras-Roubin, V. Gonzalez-Salvado,
J. Garcia-Seara, X.A. Fernandez-Lopez, L. Martinez-Sande, J.R. Gonzalez-Juanatey (Santiago de
Compostela, ES)
Atrial ectopy and NT-proBNP as predictors of atrial fibrillation. P5305
– P. Kumarathurai, M.R. Mouridsen, N. Mattsson, B. Larsen, O.W. Nielsen, T.A. Gerds, A. Sajadieh
(Copenhagen, DK)
Anthropometric measures and risk of atrial fibrillation - a cohort study of 1.2 million young men. P5306
– K. Andersen, F. Rasmussen, M. Neovius, P. Tynelius, J. Sundstrom (Uppsala and Stockholm, SE)
The incidence of atrial fibrillation increased significantly among men in their sixties and seventies. P5307
– K. Tamaki, M. Koshiyama, M. Ohta (Morioka, JP)
Duration of diabetes mellitus and thromboembolic events in atrial fibrillation: a nationwide cohort study. P5308
– T.F. Overvad, F. Skjoeth, G.Y.H. Lip, D.A. Lane, I.E. Albertsen, L.H. Rasmussen, T.B. Larsen (Aalborg, DK;
Birmingham, UK)
Acute ranolazine plus amiodarone vs amiodarone alone for conversion of recent-onset atrial fibrillation: a P5309
prospective clinical study.
– N. Tsanaxidis, I. Aidonidis, A. Hatziefthimiou, F. Triposkiadis, I. Skoularigis (Larissa, GR)
A multidisciplinary atrial fibrillation clinic is superior to standard outpatient treatment. P5310
– A.E. Albertsen, E. Moenning, R. Nielsen, D. Moeller (Viborg, DK)
ATRIAL FIBRILLATION V
Stroke severity in relation to duration of atrial fibrillation and supraventricular runs in patients with P5311
cerebral ischemia.
– M. Weber-Krueger, J. Liman, G. Gelbrich, R. Stahrenberg, K. Wasser, J. Witzenhausen, P. Kermer,
J. Seegers, K. Groschel, R. Wachter (Göttingen, Würzburg, Northeim, Sande, Regensburg and Mainz, DE)
A severity of sleep-disordered breathing with atrial fibrillation ablation candidates is associated with the P5312
long-term outcome after pulmonary vein antrum isolation.
– K. Kaitani, H. Kondo, N. Onishi, Y. Hayama, C. Izumi, Y. Nakagawa (Tenri, JP)
Causes of death and influencing factors in a cohort study of patients with atrial fibrillation. P5313
– L. Fauchier, O. Villejoubert, N. Clementy, B. Pierre, A. Bernard, D. Angoulvant, D. Babuty (Tours, FR)
Time course of atrial fibrillation in patients with a congenital heart defects. P5314
– C. Teuwen, T.T.K. Ramdjan, M. Gotte, R. Evertz, B. Brundel, J.W.J. Vriend, S.G. Molhoek, J.K. Triedman,
A.J.J.C. Bogers, N.M.S. De Groot (Rotterdam, The Hague, Nijmegen, Groningen and Breda, NL; Boston,
US)
Does renal dysfunction predict new onset of atrial fibrillation in the Japanese general population? P5315
– H. Takase, T. Okado, T. Tanaka, K. Makino, S. Takayama, H. Hayashi, T. Sugiura, N. Ohte, Y. Dohi
Impact of non-rheumatic valvular heart disease on mortality in patients with atrial fibrillation: Results P5316
from the German AFNET registry.
– A. Gerth, M. Nabauer, M. Oeff, K.G. Haeusler, A. Buchholz, K. Wegscheider, P. Kirchhof, G. Steinbeck,
G. Breithardt (Munich, Brandenburg, Berlin, Hamburg, Starnberg and Münster, DE; Birmingham, UK)
Chronic osteomyelitis as a new risk factor for incident atrial fibrillation: evidence from a nationwide P5317
cohort of 23 million people.
– K.C. Chang, L.C. Hsiao, C.H. Muo, C.Y. Chou, C.H. Tseng (Taichung, TW)
Presentation, treatment, and outcome of patients with Atrial Fibrillation and Chronic Kidney Disease. A P5318
prospective national study.
– Y. Arnson, H. Weinberg, M. Hoshen, O. Reges, R. Balicer, M. Leibowitz, M. Haim (Kfar Saba, Tel Aviv and
Beer Sheva, IL)
Comparison of emerging blood biomarkers, NTproBNP and the CHA2DS2-VASc score in the prediction of P5319
paroxysmal atrial fibrillation in patients with continuous rhythm monitoring.
– P. Wakula, B. Neumann, J. Kienemund, E. Thon-Gutschi, T. Stojakovic, H. Scharnagl, B. Pieske, M. Kapl,
F.R. Heinzel (Berlin, DE; Graz, AT)
Increasing incidence of non-valvular atrial fibrillation (AF) between 2001-2013 in the UK: largely due to P5320
non-primary AF hospital diagnosis in the elderly.
– C. Martinez, A. Katholing, C. Wallenhorst, S.B. Freedman (Frankfurt am Main, DE; Sydney, AU)
Ventricular rate is not related to survival in patients with heart failure and atrial fibrillation. P5321
– S. Hawkey, D. Levin, M. Mohan, F. Baig, L. Rutherford, C.C. Lang, A.M. Choy (Dundee, UK)
Usual blood pressure, atrial fibrillation and vascular risk: evidence from 4.3 million adults. P5322
– C.A. Emdin, S.G. Anderson, G. Salimi-Khorshidi, M. Woodward, K. Rahimi (Oxford, UK)
ATRIAL FIBRILLATION VI
Accessory pathway ablation is enough to suppress atrial fibrillation in patients without elevated B-type P5323
natriuretic peptide level among those with WPW syndrome and atrial fibrillation (WPW-AF study).
– M. Kawabata, M. Gohya, Y. Takahashi, Y. Yamauchi, K. Ohtomo, J. Nitta, K. Okishige, M. Nishizaki,
Y. Iesaka, K. Hirao (Tokyo, Saitama, Yokohama and Tsuchiura, JP)
332
Increased cardiovascular risk after treatment for hyperthyroidism. P5324

– P. Giesecke, O. Torring, V. Frykman, J. Hoijer, M. Rosenqvist (Stockholm, SE)
Effect of colchiciNe on the inciDence of Atrial Fibrillation in open heart surgery patients: end-AF Trial. P5325
– R.A. Tabbalat, N.M. Hamad, I.A. Alhaddad, A.J. Hammoudeh, B.F. Akasheh, Y.S. Khader (Amman and
Irbid, JO)
Ectopies with a short coupling interval may trigger atrial fibrillation. P5326
– T. Kanda, M. Masuda, M. Fujita, O. Iida, S. Okamoto, T. Ishihara, K. Nanto, T. Shiraki, A. Sunaga,
Comparisons of the effect of anticoagulation therapies on the coagulation systemincluding the tissue P5327
factor pathway between vitamin K antagonist and the factor Xa inhibitors.
– S. Otuki, I. Daisuke, A. Sato, T. Takano, Y. Hasegawa, N. Yagihara, H. Watanabe, T. Minamino (Niigata, JP)
The prevalence and risk factors for atrial fibrillation in beta-thalassemia major: a cross-sectional study in P5328
a UK specialist cardio-haematology clinic.
– R.M. Bell, S. Mohamed, E.A. Ako, R. Chatterjee, R. Bajoria, J. Porter, J.M. Walker (London, UK)
Electrocardiographic differences between symptomatic and asymptomatic paroxysmal atrial fibrillation. P5329
– P. Papakonstantinou, E. Arkolaki, S. Chrysostomakis, E. Kanoupakis, E. Simantirakis, P. Vardas (Heraklion,
GR)
Relationship between inflammatory markers and coagulation cascade in patients with atrial fibrillation. P5330
– S. Grigoryan, L.G. Hazarapetyan, K.G. Adamyan (Yerevan, AM)
Comparison among CHADS2, CHA2DS2-VASc and R2CHADS2 score in Japanese patients with P5331
paroxysmal non-valvular atrial fibrillation without receiving anticoagulant therapy.
– R. Yoshizawa, T. Komatsu, Y. Satoh, M. Ozawa, F. Kunugita, Y. Morino, M. Nakamura (Morioka, JP)
The prevalence of left atrial enlargement in unselected atrial fibrillation patients. P5332
– A. Szymanska, M. Dluzniewski, A.E. Platek, F.M. Szymanski, J. Syska-Suminska, A. Klos-Szadryn,
M. Glinka, M. Strojek, A. Kuciej, M. Tomaszewska-Kiecana (Warsaw, PL)
CORONARY ARTERY DISEASE AND COMORBIDITIES I

Relationship between abdominal aortic and coronary artery calcification as detected by computed P5333
tomography in chronic kidney disease patients.
– S. Suzuki, H. Ishii, Y. Shibata, Y. Tatami, S. Harata, Y. Takayama, N. Osugi, Y. Shimbo, T. Ota, T. Murohara
(Nagoya, JP)
Obesity paradox in patients with coronary artery disease treated with percutaneous coronary P5334
intervention.
– Y.J. Youn, J.W. Lee, S.G. Ahn, M.S. Ahn, J.Y. Kim, B.S. Yoo, S.H. Lee, J. Yoon (Wonju, KR)
Predictors of chronic total occlusion in a non-culprit artery in patients undergoing coronary angiography P5335
for acute coronary syndrome: mean platelet volume and serum uric acid.
– A. Kurtul, M. Yarlioglues, S.N. Murat, I.E. Celik, M.B. Demircelik, A.H. Ocek, M. Duran, G. Ergun, M. Cetin,
E. Ornek (Ankara, TR)
The impact of subclinical hypothyroidism or thyroid autoimmunity on coronary vasospasm in patients P5336
without associated cardiovascular risk factors.
– H.S. Kim, K.I. Cho, J.H. Heo, T.J. Cha (Busan, KR)
Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation. P5337
– E. Munoz-Garcia, M. Munoz-Garcia, A.J. Munoz Garcia, A.J. Dominguez-Franco, M.F. Jimenez-Navarro,
J.J. Gomez-Doblas, J.H. Alonso-Briales, J.M. Hernandez-Garcia, E. De Teresa-Galvan (Málaga and Jaén,
ES)
Acute coronary syndrome in patients with pre-existing severe aortic stenosis. P5338
– J. Reis Pires Martins, C. Arantes, G. Abreu, C. Rodrigues, A. Gaspar, P. Azevedo, A. Salgado, M. Pereira,
Lipid profile and paraoxonase 1 enzyme activity in patients with type 2 diabetes mellitus and different P5339
genotypes of paraoxonase 1 gene.
– E. Bazhenova, V. Stepanova, M. Badmaeva, O. Belyaeva, O. Berkovich, S. Pchelina, E. Baranova (St.
Petersburg, RU)
TUESDAY – MORNING
Prognostic value of elevated high-sensitivity cardiac troponin T levels in patients with stable coronary P5340
artery disease.
– M. Biener, E. Giannitsis, J. Lamerz, M. Mueller-Hennessen, M. Vafaie, H.A. Katus (Heidelberg, DE)
Circulating miRNAs as potential biomarkers of coronary artery calcification and their roles of predicting P5341
– W. Liu, L.S.K. Lin, L.Y.X. Li, J.Y.J. Zhou (Beijing and Bei Jing, CN)
Lack of association between HbA1c and cardiovascular outcome in Japanese type 2 diabetic patients P5342
– S. Ueda, T. Morimoto, K. Node (Okinawa, Nishinomiya and Saga, JP)
CORONARY ARTERY DISEASE AND COMORBIDITIES II

Myocardial revascularization using exclusive skeletonized internal thoracic artery grafting in diabetic P5343
multivessel-disease patients.
– H. Aznag, R.T. Tarhbalouti, N.T. Tazi (Agadir, MA)
Increased circulating betatrophin concentrations in patients with coronary heart disease. P5344
– Y. Qin, Y. Wang (Beijing, CN)
Does iron deficiency have any prognostic impact in acute coronary syndromes? P5345
– J. Reis Pires Martins, C. Arantes, G. Abreu, C. Rodrigues, C. Vieira, A. Gaspar, P. Azevedo, M. Pereira,
333
Prognostic value of the product between creatinine and urea nitrogen in the admission of patients with P5346
– A. Fernandes, L. Teles, M. Madeira, M. Cassandra, I. Almeida, F. Caetano, M. Costa, L. Goncalves
(Coimbra, PT)
Non-invasive identification of impaired coronary flow reserve in coronary artery disease patients with P5347
intermediate coronary stenosis by assessment of digital reactive hyperemia.
– I. Ikonomidis, V. Tritakis, G. Pavlidis, S. Tzortzis, N. Kadoglou, P. Trivilou, J. Papadakis, J. Paraskevaidis,
D. Vlastos, J. Lekakis (Athens, GR)
Accuracy of the GRACE score for the estimation of hospital and 1-year mortality of elderly patients with P5348
acute coronary syndromes.
– A. Cordero, R. Lopez-Palop, P. Carrillo, A. Frutos, A. El Amrani, R. Martinez Abellan, C. Gunturiz,
M. Garcia-Carrilero, V. Bertomeu-Martinez (Alicante, ES)
The role of acute kidney injury in acute myocardial infarction. P5349
– E. Scorodumova, V. Kostenko, L. Pivovarova, M. Malyshev, O. Ariskina, I. Osipova, A. Fedorov, A. Siverina
(St. Petersburg, RU)
Impaired glucose tolerance and coronary artery spasm in non-diabetic patients underwent acetylcholine P5350
provocation test.
– B.G. Choi, S.W. Rha, S.Y. Choi, J.K. Byun, J.J. Lee, J.B. Kim, E.J. Kim, C.G. Park, H.S. Seo, D.J. Oh
(Seoul, KR)
Long term mortality and risk of myocardial infarction associated with presence and extent of coronary P5351
artery disease.
Are there differences on prognosis among patients with previous ischemic heart disease versus P5352
cerebrovascular disease admitted with acute coronary syndrome?
– G. Abreu, C. Arantes, C. Braga, J. Martins, C. Quina-Rodrigues, C. Vieira, M. Alvares Pereira Pereira,
P. Azevedo, J. Marques (Braga, PT)
Major adverse cardiac and cerebrovascular events in chronic kidney disease patients undergoing cardiac P5353
catheterization: a 7-year follow-up.
– T. Usmiani, C. Budano, A. Andreis, C. Calcagnile, P.L. Sbarra, M. Andriani, A.L. Fanelli, S. Marra (Turin, IT)
Prognostic impact of chronic total coronary occlusion on implantable cardioverter-defibrillator recipients P5354
with ischemic heart diseases.
– T. Nishikawa, M. Fujino, I. Nakajima, K. Kusano, T. Anzai, Y. Goto, T. Noguchi, H. Ogawa, S. Yasuda
(Osaka, JP)
CORONARY ARTERY DISEASE AND COMORBIDITIES III
Impact of drug-eluting stent-associated coronary artery spasm on 3-year clinical outcomes: a propensity P5355
score matching analysis.
Impact of acute hyperglycemia after angioplasty for acute myocardial infarction. P5356
– M. Hassine, M. Boussada, D. Mlayeh, M. Mahjoub, M. Ben Massoud, Z. Dridi, F. Betbout, H. Gamra
(Monastir, TN)
Relation of resistin to PCSK9 levels in CAD patients with varying degree of obesity. P5357
– S. Li, R.-X. Xu, Y. Zhang, Y.-L. Guo, C.-G. Zhu, G. Liu, Q. Dong, J.J. Li (Beijing, CN)
Prevalence of coronary artery disease in end-stage liver disease transplantation candidates. P5358
– L. Mircoli, B. Antonelli, L. Dihel, A. Pernigotti, P. Perolo, F. Sozzi, C. Vecchiato, F. Lombardi (Milan, IT)
The influence of comorbidity on the prognosis following coronary computed tomography angiography in P5359
patients suspected of coronary artery disease.
– L. Huche Nielsen, H.E. Boetker, H.T. Sorensen, M. Schmidt, N.P.R. Sand, J.M. Jensen, F.H. Steffensen,
B.L. Norgaard (Vejle, Aarhus and Esbjerg, DK)
Triglycerides-to-HDL-cholesterol ratio predicts atherosclerosis severity and major adverse cardiovascular P5360
events after acute coronary syndrome.
– E. Almeida-Gutierrez, K.M. Cruz-Madrigal, G. Borrayo-Sanchez, M.A. Madrid-Miller, R.C. Garcia-Mendez
(Mexico City, MX)
In-Hospital impact of anemia at admission in patients with acute coronary syndromes. P5361
– D.J. Severino, B.S. Santos, D.D. Durao (Santarem, PT)
Association of vitamin D receptor genetic polymorphisms with coronary artery disease in Russian P5362
population.
– E.G. Sergeeva, M.I. Zaraisky, J.I. Ionova, O.V. Galkina, A.V. Gorbach (St. Petersburg, RU)
Association of carotid wall shear stress, carotid atherosclerosis, and coronary artery disease in patients P5363
with chest pain.
– K.I. Cho, B.H. Kim, H.S. Kim, J.H. Heo (Busan and Pusan, KR)
Evolution of high sensitivity troponin-T in patients undergoing high efficiency on-line hemodiafiltration P5364
versus conventional low-flux hemodialysis.
– I. Ethier, H. Cardinal, M. Beaulieu, M.P.C. Grooteman, M.J. Nube, R. Levesque, D. Auger (Montreal, CA;
Amsterdam, NL)
334
CORONARY ARTERY DISEASE AND COMORBIDITIES IV

Analysis of new score of risk in a population of diabetic patients with acute coronary syndrome P5365
undergoing coronary revascularization by percutaneous angioplasty.
– M. Crisci, G. Di Palma, R.M. Bianchi, V. Diana, D. Tartaglione, M. Cappelli Bigazzi, I. Pariggiano, R. Calabro,
M.G. Russo, P. Calabro (Naples, IT)
Association between serum thyroid stimulating hormone (TSH) levels and coronary collateral P5366
development.
– E.E. Ustun, A. Ongun, O.U. Ozcan, H. Goksuluk, S. Gulec, C. Erol (Ankara, TR)
Admission hemoglobin levels and Killip class in acute coronary syndrome patients: insights from the P5367
cohort EPIHeart.
– J.C. Duarte Rodrigues, S. Machado Leite, P. Dias, R. Almeida, O. Laszczynska, C. Araujo, I. Moreira,
M.J. Maciel, A. Azevedo (Porto and Vila-Real, PT)
Fibrinogen high levels, but not fibrinogen genetic variability is a risk factor coronary artery disease in P5368
patients with essential hypertension and diabetes mellitus type 2.
– N. Papageorgiou, A. Briasoulis, G. Hatzis, M. Kozanitou, A. Miliou, E. Androulakis, G. Latsios,
S. Papaioannou, Z. Pallantza, D. Tousoulis (Athens, GR)
miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic P5369
– C. Schulte, S. Molz, S. Appelbaum, M. Karakas, P.S. Wild, K.J. Lackner, R.B. Schnabel, S. Blankenberg,
T. Muenzel, T. Zeller (Hamburg and Mainz, DE)
Association between sex hormone-binding globulin and coronary artery disease in males. P5370
– C.M. Wickramatilake, M.R. Mohideen, C. Pathirana (Galle, LK; Batu Pahat Johor, MY)
Differential adipose tissue bradykinin receptors gene expression profiles in obese patients with and P5371
without coronary artery disease.
– M. Marketou, G. Kochiadakis, J. Kontaraki, E. Zacharis, K. Roufas, F. Maragoudakis, D. Vougia, J. Logakis,
S. Petousis, P. Vardas (Heraklion, GR)
A prognostic value of aortic annulus displacement assessed by contrast left ventriculography in cardiac P5372
catheter laboratory.
– S. Kuwata, K. Yoneyama, K. Kongoji, T. Mitarai, K. Mizukoshi, R. Kamijima, M. Izumo, Y. Tanabe,
T. Harada, Y. Akashi (Kawasaki, JP)
Background characteristics and prognosis in non-invasively treated patients with type 1 and type 2 P5373
myocardial infarction. Data from the SWEDEHEART registry.
– T. Baron, K. Hambraeus, D. Erlinge, T. Jernberg, B. Lindahl (Uppsala, Falun, Lund and Stockholm, SE)
Identification and characterization of heterozygous familial hypercholesterolemia patients using the P5374
Vanderbilt University Medical Center Synthetic Derivative database.
– L. Lipworth, J. Shirey-Rice, W.-Q. Wei, J. Hardin, G. Shi, K. Monda, J.P. Fryzek, S. Fazio, S.S. Cohen,
J.C. Denny (Nashville, Thousand Oaks, Baltimore, Ann Arbor and Portland, US)
Impact of coronary calcification in female patients undergoing PCI: Results from a pooled analysis of 26 P5375
randomized trials.
– I. Mastoris, M. Aquino, S. Sartori, G.G. Stefanini, G.W. Mikhail, P.G. Steg, M.C. Morice, R.V. Jeger,
G.W. Stone, R. Mehran (New York, US; Milan, IT; London, UK; Paris, FR; Basel, CH)
Prognostic value of coronary artery calcium score for major perioperative cardiovascular complications P5376
in type 2 diabetic patients undergoing trans-femoral amputation.
– E. Shalaeva, H. Saner, B. Babadjanov, U. Pulatov, Q. Matmurotov, A. Shalaeva (Tashkent, UZ; Berne, CH)
CORONARY ARTERY DISEASE AND COMORBIDITIES V
Acute coronary syndrome in patients without cardiovascular risk factors: in-hospital morbidity and P5377
mortality.
– M. Rodrigues Neto, A. Correia, R. Rodrigues, M. Gomes Serrao, N. Santos, S. Gomes, B. Silva, G. Caires,
A. Drumond Freitas, D. Pereira (Funchal, PT)
Percutaneous coronary revascularization reduces risk of acute renal failure when compared to coronary P5378 TUESDAY – MORNING
artery bypass graft: a meta-analysis of 8 studies and 257980 patients.
– G. Quadri, C. Moretti, F. D’Ascenzo, P. Omede’, A. Montefusco, G. Frati, M. Mancone, T. Palmerini,
G. Biondi Zoccai, F. Gaita (Turin, Rome and Bologna, IT)
Routine SYNTAX scoring correctly identifies suitability for PCI in high-risk surgical patients. P5379
– L. Tin, J. Sarma, A. Mozid, W. Yafi, M. Buch, E. Abdelaal, S. Chowdhary, H. Contractor (Manchester, UK)
Impact of albuminuria on contrast-induced acute kidney injury and in-hospital adverse cardiac events in P5380
patients who underwent emergency coronary intervention.
– A. Kunimura, T. Uetani, M. Takeshita, S. Okumura, N. Shinoda, K. Harada, B. Kato, H. Ishii, T. Amano,
T. Murohara (Nagoya, JP)
Impact of lipoprotein(a) on long-term major cardiovascular events in patients with chronic kidney disease P5381
after percutaneous coronary intervention.
– H. Konishi, K. Miyauchi, R. Naito, S. Tsuboi, M. Ogita, T. Dohi, T. Kasai, H. Tamura, S. Okazaki, H. Daida
(Tokyo, JP)
The validation of CHA2DS2-VASc-CKD2 score for risk stratification in patients with coronary heart P5382
disease undergoing PCI without known atrial fibrillation.
– H. Hioki, T. Miura, Y. Miyashita, H. Motoki, K. Shimada, M. Kobayashi, S. Ebisawa, J. Koyama, U. Ikeda
(Matsumoto and Nagano, JP)
Genetic variation in ADAMTS7 is associated with severity of coronary artery disease. P5383
– K. Chan, R.S. Patel, X. Pu, F.L. Ng, S. Hayek, R.N. Poston, A. Quyyumi, S. Ye (London, UK; Atlanta, US)
335
Background characteristics, treatment and long-term prognosis in patients with significant coronary P5384
artery stenosis classified as type 1 or type 2 myocardial infarction. Data from SWEDEHEART registry.
Copeptin, a marker of vasopressin, predicts coronary artery disease, cardiovascular and total mortality. P5385
– I. Tasevska, S. Enhorning, P. Nilsson, O. Melander (Malmö, SE)
Proprotein convertase subtilisin-kexin type 9 as a biomarker for the development and severity of coronary P5386
artery disease in general population.
– S. Li, R.-X. Xu, Y. Zhang, Y.-L. Guo, C.-G. Zhu, N.-X. Wu, P. Qing, G. Liu, Q. Dong, J.J. Li (Beijing, CN)
CORONARY ARTERY DISEASE AND COMORBIDITIES VI

A clinical conundrum: is nitrate still safe and effective in coronary artery spasm when combined with P5387
myocardial bridge?
Thyroid function and proprotein convertase subtilisin/kexin type 9 levels in euthyroid subjects with P5388
– S. Li, R.-X. Xu, Y.-L. Guo, Y. Zhang, C.-G. Zhu, J. Sun, J.J. Li (Beijing, CN)
Impact of uric acid and cystatin c on long-term clinical outcomes in patients undergoing percutaneous P5389
coronary intervention with drug-eluting stents.
– I.J. Choi, M.-H. Jung, S.M. Seo, M.-J. Kim, D.I. Shin, D.S. Jeon (Incheon, KR)
Do patients with acute coronary syndromes without conventional risk factors have a better prognosis? P5390
– P. Magalhaes, S. Leao, F. Cordeiro, P. Mateus, S. Carvalho, J.I. Moreira (Vila-Real, PT)
Impact of anemia at admission in a one year prognostic of patients with acute coronary syndromes. P5391
– B. Saldanha Santos, D. Severino, D. Durao, M. Leal (Santarem, PT)
Predictive value of routine cardiovascular screening for myocardial ischemia in kidney transplantation P5392
candidates: a single center prospective study (MONICARD study group).
– C. Bergerot, C. Ronzat, T. Bejan-Angoulvant, F. Ivanes, E. Morelon, L. Badet, X. Andre-Fouet, L. Juillard,
M. Ovize, D. Angoulvant (Lyon and Tours, FR)
Major bleeding in acute myocardial infarction: population characterization, predictors and impact in P5393
prognosis.
– B. Picarra, A.R. Santos, A.F. Damasio, D. Neves, J. Carvalho, J. Aguiar (Évora and Lisbon, PT)
Impact of Triglyceride Levels on cardiovascular event in T-SPARCLE registry in Taiwan. P5394
– C.Y. Chen, S.Y. Chuang, C.C. Fang, L.C. Huang, I.C. Hsieh, W.H. Pan, H.I. Yeh, C.C. Wu, W.H. Yin,
J.W. Chen (Taipei, Miaoli, Tainan and Tao-yuan, TW)
Impact of new-onset dyslipidemia on coronary artery spasm as assessed by acetylcholine provocation P5395
test.
– S.H. Park, S.W. Rha, B.G. Choi, J.-B. Seo, U. Jeon, W.-Y. Shin, D.K. Jin, C.G. Park, H.S. Seo, D.J. Oh
(Cheonan and Seoul, KR)
Association of progression or regression of coronary artery atherosclerosis with long-term prognosis. P5396
– S. Kufner, G. Ndrepepa, R. Iijima, S. Braun, R.A. Byrne, J. Sorges, S. Schulz-Schuepke, K.L. Laugwitz,
H. Schunkert, A. Kastrati (Munich, DE; Tokyo, JP)
CORONARY ARTERY DISEASE AND COMORBIDITIES VII

Prognostic value of automatically measured ST-segment deviation in patients undergoing exercise ECG. P5397
– C. Puelacher, T. Reichlin, R. Abaecherli, N. Schaerli, G. Pretre, U. Honegger, M. Wagener, T. Nestelberger,
M. Zellweger, C. Mueller (Basel, CH)
Premature myocardial infarction is strongly associated with increased levels of remnant cholesterol. P5398
– G. Goliasch, F. Wiesbauer, H. Blessberger, S. Demyanets, J. Wojta, K. Huber, G. Maurer, M. Schillinger,
W. Speidl (Vienna, AT)
Type 1 or type 2 myocardial infarction in patients without significant coronary artery disease - do we P5399
choose clinical type by chance? Data from the SWEDEHEART registry.
Type 2 myocardial infarction - does the presence of stenosis matter? Data from the SWEDEHEART P5400
registry.
The epicardial adipose tissue is related with coronary spasm as well as coronary aterosclerosis in female P5401
patients presented with chest pain: from the KoRean wOmenS chest pain rEgistry (koROSE).
– M.N. Kim, H.L. Kim, S.M. Park, M.S. Shin, M.A. Kim, W.J. Shim (Seoul and Incheon, KR)
Characteristics of coronary artery ectasia in patients with ST-segment elevated myocardial infarction. P5402
– A. Kuwayama, K. Kadota, Y. Hyodo, D. Hasegawa, T. Tada, S. Habara, H. Tanaka, Y. Fuku, T. Goto,
Is chronic obstructive pulmonary disease a predictor of poor one-year outcome after myocardial P5403
infarction?
– O. Polikutina, Y. Slepynina, E. Bazdyrev, O. Barbarash (Kemerovo, RU)
The cardiovascular disease risk factor profile in a young woman (under the age of 45) with acute P5404
coronary syndrome (ACS).
– M. Beckowski, L. Polonski, M. Gierlotka, T. Zdrojewski, W. Drygas, J. Karwowski, I. Kowalik, H. Szwed
(Warsaw and Zabrze, PL)
Breast arterial calcification as an independent predictor of coronary atherosclerotic disease in a female P5405
cohort of African descent.
– M. Renker, S. Baumann, U.J. Schoepf, D. Newallo, O. Doerr, J. Rixe, H. Moellmann, H. Nef, C. Hamm
(Giessen, Mannheim and Bad Nauheim, DE; Charleston, US)
336
Relation between coronary arterial lesion location and major adverse cardiac events 6- months after an P5406
– J.C. Duarte Rodrigues, A.R. Godinho, P. Dias, R. Almeida, M. Viana, O. Laszczynska, C. Araujo, I. Moreira,
M.J. Maciel, A. Azevedo (Porto and Vila-Real, PT)
ROLE OF ECHO-IMAGING IN ISCHAEMIC HEART DISEASE

Echocardiography, contractile reserve and magnetic resonance to predict left ventricular remodelling. P5407
– S. Rodero, M. Mutuberria, J. Rodriguez-Palomares, M. Terricabras, L. Gutierrez, G. Teixido, L. Galian,
T. Gonzalez-Alujas, A. Evangelista, D. Garcia-Dorado (Barcelona, ES)
Prediction of adverse events after ST segment-elevation myocardial infarction by imaging techniques. P5408
– S. Rodero, M. Mutuberria, J. Rodriguez-Palomares, M. Terricabras, L. Gutierrez, G. Teixido, L. Galian,
T. Gonzalez-Alujas, A. Evangelista, D. Garcia-Dorado (Barcelona, ES)
Assessment of post-systolic shortening and early systolic lengthening by 2D speckle-tracking is useful to P5409
detect cad in patients with suspected NSTE-ACS.
– T. Caspar, H. Samet, L. Jesel, H. Petit-Eisenmann, A. Trinh, S. Talha, A. Schultz, O. Morel, P. Ohlmann
(Strasbourg, FR)
How frequent are signs of left ventricular dysfunction in acute myocardial infarction patients with normal P5410
ejection fraction? Impact of the latest chamber quantification recommendations.
– T. Baron, C. Christersson, K. Johansson, F.A. Flachskampf (Uppsala, SE)
Arterial stiffness and arterial-ventricular matching in patients after myocardial infarction. P5411
– F.Q. Huang, R.S. Tan, T.T. Le, L. Zhong (Singapore, SG)
New 3D echo-derived morphometric criteria for discriminating between ischemic and non-ischemic P5412
cardiomyopathy.
– S. Schwartzenberg, M.D. Handschumacher, X. Zeng, T.C. Tan, J.W. Hung (Petah Tikva, IL; Boston, US)
Excellent discrimination ability of resting multilayer longitudinal strain using two-dimensional speckle P5413
tracking echocardiography for myocardial infarction and ischemic segments.
– T. Nishi, N. Funabashi, K. Ozawa, M. Takahara, H. Takaoka, Y. Fujimoto, Y. Kobayashi (Chiba, JP)
Quantification of regional left ventricular function in patients with coronary artery disease by P5414
layer-specific strain.
– J.-L. Chen, Z.-L. Zhao, Q. Zhou, H.-N. Song, B. Hu, X. Yao, J.-J. Zhu, P. Zhu (Wuhan, CN)
Routine manual thrombus aspiration has no impact on left ventricular remodeling: the echocardiographic P5415
substudy of the randomized physiologic assessment of thrombus aspiration in patients with ST-segment
elevation myocardial infarction
– D. Orlic, M. Tesic, D. Trifunovic, B. Vujisic-Tesic, D. Milasinovic, M. Borovic, B. Belelsin, D. Sobic-Saranovic,
S. Stojkovic, M. Ostojic (Belgrade, RS)
Left ventricular global longitudinal strain rate is associated with changes in myocardial redox state in P5416
patients with ischaemic heart disease.
– G. Sangha, A. Antonopoulos, R. Upton, L. Herdman, M. Margaritis, A. Tarun, M. Petrou, G. Krasopoulos,
K.M. Channon, C. Antoniades (Oxford, UK)
Prognostic assessment of myocardial viability after acute myocardial infarction: a clinical follow-up study P5417
by speckle tracking.
– B. Hu, Q. Zhou, J.-L. Chen, H.-N. Song, R.-Q. Guo (Wuhan, CN)
CARDIAC ECHO-IMAGING IN SYSTEMIC DISEASES
Greater improvement of coronary artery function, left ventricular deformation and twisting by IL12/23 P5418
compared to TNF-a inhibition in psoriasis.
– I. Ikonomidis, G. Makavos, E. Papadavid, M. Varoudi, I. Andreadou, K. Gravanis, N. Liarakos, G. Pavlidis,
D. Rigopoulos, J. Lekakis (Athens, GR)
Effect of liver transplant on the progression of cardiomyopathy in familial amyloid polyneuropathy. P5419
– T. Guimaraes, N. Cortez-Dias, A.R.G. Francisco, G.L. Silva, R. Placido, S. Goncalves, A.G. Almeida,
I. Conceicao, F.J. Pinto, C. Azevedo Coutinho (Lisbon, PT)
TUESDAY – MORNING
Subclinical abnormalities of two-dimensional speckle tracking echocardiography associate with early P5420
peripheral vascular disease in patients with chronic kidney disease.
– S. Sulemane, V. Panoulas, P. Nihoyannopoulos (London, UK)
The effect of different treatment strategies on left ventricular myocardial deformation parameters in P5421
patients with chronic renal failure.
– U. Yildirim, O. Gulel, A. Eksi, M. Dilek, S. Demircan, M. Sahin (Samsun and Istanbul, TR)
The impact of liver transplantation on myocardial function in patients with familial amyloid P5422
polyneuropathy.
– R. Placido, N. Cortez-Dias, T. Guimaraes, M. Nobre E Menezes, G. Lima Da Silva, I. Conceicao,
S. Goncalves, A.R. Francisco, F. Pinto, C. Azevedo Coutinho (Lisbon, PT)
Causes and consequences of longitudinal left ventricular dysfunction assessed by 2D strain P5423
echocardiography in patients with cardiac amyloidosis.
– J. Ternacle, D. Bodez, A. Guellich, S. Rappeneau, P. Lim, N. Benhaiem, V. Plante-Bordeneuve, J.-F. Deux,
J.-L. Dubois-Rande, T. Damy (Créteil, FR)
Relationship between inflammation and timing markers of LV rotation and untwist in psoriatic arthritis - a P5424
study of the mechanisms of early myocardial dysfunction in systemic diseases.
– Q. Shang, L.S. Tam, J.E. Sanderson, E.K.M. Li, C.M. Yu (Hong Kong, HK)
Diagnostic accuracy of global longitudinal strain by echocardiography for detecting cardiac involvement P5425
in patients with extra-cardiac sarcoidosis.
– P. Patel, Z. Popovic, D. Culver, R. Brunken, B. Tamarappoo (Cleveland, US)
337
The usefulness of left atrial volume index and left ventricular mass index in determining subclinical P5426
cardiac involvement in patients with early-stage sarcoidosis.
– H. Ayhan, H.A. Kasapkara, E. Bilen, B. Duran Karaduman, A. Senturk, M.B. Ozen, T. Durmaz, T. Keles,
E. Bozkurt (Ankara, TR)
ASSESSMENT OF LEFT VENTRICULAR FUNCTION BY SPECKLE TRACKING ECHOCARDIOGRAPHY

2D speckle tracking-derived left ventricle global longitudinal strain: is it useful to discriminate left P5427
ventricular dysfunction stages?
– M. Oliveira-Santos, R. Martins, R. Baptista, R. Ramalho, A. Barbosa, N. Ribeiro, A. Oliveira, G. Castro,
M. Pego (Coimbra, PT)
Relationship among left ventricular twist, torsion and contractility in hypertensive patients: one-beat P5428
real-time three-dimensional speckle tracking echocardiography study.
– S. Minatoguchi, M. Kawasaki, R. Tanaka, T. Watanabe, K. Ono, M. Nagaya, M. Ishiguro, T. Noda, H. Houle,
S. Minatoguchi (Gifu, JP; Los Angeles, US)
Left ventricular mechanics: novel tools to evaluate function and dyssynchrony in controls and cardiac P5429
resynchronization therapy candidates.
– E. Galli, M. Fournet, B. Polin, C. Leclercq, E. Samset, P. Mabo, E. Donal (Rennes, FR)
Less is more: three dimensional strain may not add much. P5430
– K. Negishi, H. Yang, Y. Wang, M. Nolan, M. Saito, T. Negishi, T. Marwick (Hobart, AU)
Early detection of myocardial injury by layer-specific strain imaging. P5431
– C. Yu, T.G. Zhu, Q. Ding, W.Y. Jin, P.H. Wu, X. Li, D.Y. Liu (Beijing, CN)
The Association between Early Stage Renal Insufficiency, Subclinical Left Ventricular Systolic Dysfunction P5432
and Torsion in Asymptomatic Subjects.
– K.T. Sung, W.R. Lan, Y.H. Lai, C.I. Lo, T.C. Hung, J.Y. Kuo, J.Y. Hou, H.I. Yeh, C.L. Hung (Taipei, TW)
Do deformation patterns reveal the underlying pathophysiology in hearts with thick walls? P5433
– E. Pagourelias, J. Van Cleemput, J. Bogaert, G. Vovas, J. Duchenne, L. Van Aelst, M. Delforge, J.U. Voigt
(Leuven, BE)
Automated quantification of global left ventricular performance in patients with cardiac contractility P5434
modulation by speckle tracking imaging.
– X.X. Luo, F. Fang, Q. Zhang, Z. Ma, S.F. Gan, C.M. Yu (Hong Kong, HK)
Apical variant Tako-tsubo is associated with persistent myocardial strain dysfunction. P5435
– K. Schwarz, J. Srinivasan, M. Bruce, C.J. Neil, C. Scally, J.D. Horowitz, M.P. Frenneaux, D.K. Dawson
(Aberdeen, UK; Adelaide, AU)
Angiotensinogen gene M235T and T174M polymorphisms in systolic heart failure: changes of the left P5436
ventricular strain during six-month spironolactone therapy.
– R. Dankowski, W. Sacharczuk, A. Nowicka, A. Baszko, J. Grabia-Zaprutko, A. Szyszka (Poznan, PL)
Early detection of chemotherapy induced biventricular cardiac dysfunction after bone marrow P5437
transplantation by speckle tracking echocardiography.
– G. Makavos, P. Psarogiannakopoulos, I. Ikonomidis, P. Tsirigotis, J. Parissis, I. Paraskevaidis, J. Lekakis
(Athens, GR)
Assessment of left ventricular dyssynchrony and prediction of response to cardiac resynchronization P5438
therapy: a new three-dimensionnal echocardiography integral-based indicator of longitudinal strain.
– M. Fournet, A. Bernard, E. Galli, C. Leclercq, P. Mabo, J.C. Daubert, E. Donal (Rennes, FR)
MISCELLANEOUS
Alterations of phasic left atrial strain in patients with pre-clinical diastolic dysfunction: 2D speckle P5439
tracking echocardiography-derived results from the BEFRI-echo study.
– A. Brecht, S. Oertelt-Prigione, V. Regitz-Zagrosek, G. Baumann, F. Knebel, V. Stangl (Berlin, DE)
Subclinical lV systolic dysfunction in patients with chronic obstructive pulmonary disease. P5440
– B. Cengiz, S. Kamat, S. Yurdakul, S.T. Sahin, A. Sarper, P. Yildiz, S. Aytekin (Istanbul, TR)
Subclinic left ventricular dysfunction on echocardiography predicts long-term adverse events. P5441
– W.Q. Lin, L.W. Tan, T.C. Yeo, K.K. Poh (Singapore, SG)
Left ventricular flow redirection towards the outflow tract: a marker for atrio-ventricular delay P5442
optimization.
– D. Rodriguez Munoz, C. Lozano Granero, A. Carbonell San Roman, J.L. Moya Mur, C. Fernandez-Golfin,
E. Casas Rojo, A. Garcia Martin, S. Fernandez Santos, J. Moreno Planas, J.L. Zamorano Gomez (Madrid,
ES)
Disturbed flow transit in heart failure with a history of decompensation. P5443
– L. Takahashi, T. Uejima, M. Goto, H. Sawada, T. Yamashita (Toda and Tokyo, JP)
CELL THERAPY AND BIOENGINEERING

Post-infarct administration of multilineage-differentiating stress-enduring (Muse) cells regenerates P5444
cardiomyocytes and microvessels and improves cardiac function and remodeling in rabbits.
– Y. Yamada, S. Minatoguchi, K. Higashi, H. Kanamori, M. Kawasaki, K. Nishigaki, A. Mikami, S. Wakao,
M. Dezawa, S. Minatoguchi (Gifu and Sendai, JP)
A novel cardiac bioprosthesis for myocardial repair. P5445
– I. Perea Gil, C. Prat-Vidal, C. Galvez-Monton, S. Roura, A. Llucia-Valldeperas, C. Soler-Botija,
A. Bayes-Genis (Badalona, ES)
338
Survival, migration and benefits of human cardiac progenitor cell seeded-collagen patches applied on P5446
failing right ventricle: preliminary results in a large animal model.
– V. Lambert, A. Hodzic, M. Coblence, M. Ly, E. Le Bret, E. Gouadon, M. Humbert, P. Jourdon, M. Puceat,
C. Rucker-Martin (Le Plessis-Robinson and Marseille, FR)
Effects of cardiac stem cells in myocardial infarction; meta-analysis of preclinical studies. P5447
– P.P.M. Zwetsloot, A.M.D. Vegh, S.J. Jansen Of Lorkeers, G.P.J. Van Hout, G.L. Currie, E.S. Sena,
M.J. Goumans, P.A. Doevendans, S.A.J. Chamuleau, J.P.G. Sluijter (Utrecht and Leiden, NL; Edinburgh,
UK)
First-in-man experience with transendocardial injections of bone marrow-derived mesenchymal stem P5448
cells in idiopathic dilated cardiomyopathy. Results of the pilot phase of the MYOCYTE trial.
– R. Sanz Ruiz, A. Casado, M.E. Fernandez, J. Anguita Velasco, E. Perez-David, J.C. Alonso Farto, J. Elizaga
Corrales, F. Atienza, F. Fernandez-Aviles (Madrid, ES)
Endothelial derivatives of human pluripotent stem cells show antiplatelet effects in 3D culture -steps P5449
towards vascular tissue engineering.
– E. Gara, B. Merkely, J. Skopal, M. Polos, I. Hartyanszky, S.E. Harding, G. Foldes (Budapest, HU; London,
UK)
CARDIOVASCULAR PATHOLOGY AND STEM CELLS

Erythropoietin promotes cardiac autonomic dysfunction and does not modify end diastolic pressure in a P5450
myocardial infarction model in rats.
– O. Albuquerque, L.E. Souza, K.B. Scapini, C. Mostarda, F.M. Consolim-Colombo, M.C. Irigoyen (São Paulo
and São Luis, BR)
Single-centre experience with 3D printing cardiac anatomy: feasibility and controversies. P5451
– G. Biglino, C. Capelli, J. Wray, L.K. Leaver, A. Jones, A.M. Taylor, S. Schievano (London, UK)
Insights into the anatomical sites of acute left atrial appendage reconnection after successful electrical P5452
isolation.
– S. Panikker, R. Virmani, F. Kolodgie, J. Jarman, L. Mantziari, S.K. Haldar, J.P. Foran, V. Markides, T. Wong
(London, UK; Gaithersburg, US)
Central donepezil infusion prevents progression of cardiac remodeling and dysfunction in chronic heart P5453
failure rats with extensive myocardial infarction.
– M. Li, C. Zheng, T. Kawada, M. Inagaki, K. Uemura, T. Shishido, M. Sugimachi (Osaka, JP)
Isolation, characterization and bio-grafting of perivascular progenitor cells from myocardial specimens of P5454
paediatric patients undergoing palliative surgical repair of congenital heart defects.
– E. Avolio, I. Rodriguez-Arabaolaza, H.L. Spencer, V.V. Alvino, F. Riu, G. Mangialardi, S.C. Slater,
M. Ghorbel, M. Caputo, P. Madeddu (Bristol, UK)
Exosome secreted miR-27a-3p and miR543 are critical modulator of PDI activity in cardiac stem cells P5455
during hypoxia.
– D. D’Amario, M. Manchi, A. Siracusano, A. Severino, C. Mandolini, F. Cannata, P.G. Bruno, A.M. Leone,
M. Massetti, F. Crea (Rome, IT)
Creating new trans-species types of myocytes by forced fusion between cardiomyocytes and fibroblasts P5456
to counteract arrhythmias: breaking boundaries with muscular mixtures.
– S.F. Askar, E.C.A. Nyns, M.C. Engels, M.J. Schalij, W. Jangsangthong, Z. Neshati, A.A.F. De Vries,
D.A. Pijnappels (Leiden, NL)
c-kit+ CSC-derived cardiomyocytes exhibit the typical transcriptional gene blueprint of adult P5457
cardiomyocytes.
– M. Scalise, I. Aquila, C. Vicinanza, F. Marino, F. Cristiano, E. Cianflone, P. Veltri, B. Nadal-Ginard,
G.M. Ellison, D. Torella (Catanzaro, IT; London, UK)
Circulating monocytes control myocardial regeneration in neonatal heart. P5458
– T. Konfino, N. Landa, T. Ben-Mordechai, J. Leor (Tel Hashomer, IL)
The Cre / Lox P fate mapping study on cardiac progenitor cells revealed its embryonic origin with its P5459
intrinsic methodological limitation validated by single cell qRT-PCR.
– M. Harada, M. Noseda, M. Schneider (London, UK)
TUESDAY – MORNING
Proteomic analysis of canine failing hearts induced by rapid pacing: evidence for the elevation of the P5460
protein levels related to either mitochondrial dysfunction or acute phase response signaling.
– H. Fukuda, K.D. Min, H. Asanuma, S. Ito, K. Shindo, M. Imazu, T. Tomonaga, N. Minamino, M. Asakura,
M. Kitakaze (Osaka, Kyoto and Ibaraki, JP)
CARDIOVASCULAR PATHOLOGY AND EMBRYOLOGY

Wilms tumor-1 expression in cardiac endothelial cells. P5461
– S.N. Duim, K. Kurakula, M.J. Goumans, B.P.T. Kruithof (Leiden, NL)
Physiopathology of the ubiquitin ligase E3, PDZRN3, in the development of dilated cardiomyopathies. P5462
– M. Pernot, L. Cetran, M. Han Yee Yu, B. Jaspard-Vinassa, T. Couffinhal, C. Duplaa (Bordeaux, FR)
Reduced number of active cardiac mitochondria in a rat model for long-term kidney disease. P5463
– E. Hertzberg-Bigelman, M. Entin-Meer, G. Aharon-Hananel, A. Saada, R. Levy, L. Cohen, Z. Rozenbaum,
G. Keren (Tel Aviv and Jerusalem, IL)
Inhibition of aortic valve calcification by local delivery of zoledronic acid. An experimental study. P5464
– A. Synetos, K. Toutouzas, M. Drakopoulou, K. Stathogiannis, G. Latsios, C. Agrogiannis,
C. Anagnostopoulos, E. Patsouris, D. Cokkinos, D. Tousoulis (Athens, GR; New York, US)
Intraleaflet haemorrhages induce anti-inflammatory and osteoclastic cell phenotypes and are associated P5465
with osteogenic metaplasia in stenotic aortic valves.
– G.J. Lis, U. Czubek, E. Jasek, J. Nessler, J. Sadowski, J.A. Litwin (Krakow, PL)
339
Imaging mass spectrometry with focus microwave treatment reveals heterogeneity in directional glucose P5466
fluxes in and around ischemic myocardium.
– Y. Katsumata, Y. Sugiura, M. Sano, M. Kajimura, K. Fukuda, M. Suematsu (Tokyo, JP)
Heterogeneity of patterns and distribution of myocardial fibrosis in end-stage hypertrophic P5467
cardiomyopathy (ES-HCM) undergoing heart transplant: a morphometric analysis of 24 explanted hearts.
– G. Galati, O. Leone, E. Biagini, F. Pasquale, F. Mingardi, F. Grigioni, C. Rapezzi (Bologna, IT)
Proliferating myofibroblasts contribute to extracellular matrix remodeling in a porcine model of ischemic P5468
cardiomyopathy.
– C.K. Nagaraju, P. Claus, E. Dries, K. Vermeulen, K.R. Sipido, R.B. Driesen (Leuven, BE)
Toll-like receptor 7 is involved in adverse ventricle remodeling after myocardial infarction. P5469
– J.W. Wang, X. Wang, C.S. Lam, F. Vernooij, L. Timmers, D.P. De Kleijn (Singapore, SG; Utrecht, NL)
PEAR1: a novel link between IgE-mediated allergy and cardiovascular disease. P5470
– C. Vandenbriele, Y. Sun, A. Kauskot, P. Verhamme, M. Hoylaerts, G. Wright (Leuven, BE; Cambridge, UK)
Aging impairs cardiac Akt activity leading to myocardial sarcopenia. P5471
– H.K. Kawase, Y. Kureishi Bando, M.A. Aoyama, X.C. Cheng, K.N. Nishimura, T.M. Mitsui, T.M. Murohara
(Nagoya and Obu, JP)
Genetic cardiomyopathy overlaps can modify phenotypic features in dilated cardiomyopathy patients - a P5472
comprehensive next-generation sequencing (NGS) study.
– E. Kayvanpour, J. Haas, F. Sedaghat-Hamedani, A. Waldenstrom, L. Monserrat, P.H. Charron, P. Elliott,
E. Arbustini, B. Meder, H.A. Katus (Heidelberg, DE; Umeå, SE; A Coruña, ES; Paris, FR; London, UK;
Pavia, IT)
Valvular heart disease and pulmonary hypertension in fawn-hooded rats: the role of 5HT2B receptors. P5473
– S. Abid, C.M. Tissot, F. Wan, A. Houssaini, G. Czibik, D. Sawaki, E. Marcos, M. Hamon, G. Derumeaux,
S. Adnot (Créteil and Paris, FR)
Scaling systolic volume to body surface area and its influence in the diagnosis of low-flow/low-gradient P5474
aortic stenosis.
– I. Iglesias Garriz, J. Vara Manso, C. Garrote Coloma, J. Lastra Galan, F. Corral Fernandez, M. Pinedo Gago,
M.A. Rodriguez Garcia, F. Fernandez Vazquez (Leon, ES)
Transcatheter aortic valve implant vs surgical aortic valve replacement in low- to intermediate risk P5475
patients: a Meta-analysis.
– K. Y.-K. Wong, T. Malik, V. Allgar (Hull and York, UK)
High implantation is a new parameter that affects the outcome of patients that undergo transcatheter P5476
aortic valve implantation with self-expandable bioprosthesis.
– M. Vavuranakis, M. Kariori, V. Voudris, G. Siasos, K. Kalogeras, D. Vrachatis, S. Thomopoulou, M. Lavda,
C. Moldovan, D. Tousoulis (Athens, GR)
External validation and decision curve analysis of EuroSCORE 2, STS and German AV score in the P5477
selection of high-risk patients with aortic stenosis to TAVI.
– M.R.N. Pontes, A. Rosler, J. Fraportti, G. Constantin, P. Nectoux, E.A. Lucio, V. Lima, M.C. Sales,
J.D. Frota Filho, F.A. Lucchese (Porto Alegre, BR)
Aortic prosthesis-patient mismatch halters regression of secondary mitral regurgitation after isolated P5478
aortic valve replacement: 6-year follow-up analysis.
– E. Angeloni, G. Melina, P. Pibarot, S. Refice, F. Capuano, A. Roscitano, C. Comito, R. Sinatra (Rome, IT)
Study of mitral valve prolapse and chronic anxiety in patients with breast cancer. P5479
– A.S. Ammar, I.A. Elsherbiny, T.A. Nagib, A.G. Eraky, A.S. Gamal, M.A.S. Ammar (Zagazig, EG)
Prediciton of systemic vascular resistance non-invasively in patients with moderate-severe mitral P5480
regurgitation with a formula taking inspiration from pulmonary hypertension guideline.
– C.E. Caglayan, M. Gok, A.I. Celik, A. Cureoglu, O.S. Deveci, A. Deniz, M. Tangalay, R.E. Akilli, M. Kanadasi,
A. Usal (Adana, TR)
Papillary muscle free strain in patients with degenerative and functional mitral regurgitation. P5481
– A. Kilicgedik, G. Kahveci, C.Y. Karabay, S. Demir, S.C. Efe, A.S. Gurbuz, E. Acar, M.E. Durakoglugil,
M.F. Yilmaz, C. Kirma (Istanbul, TR)
The impact of arterial load on left ventricular performance in severe mitral stenosis. P5482
– A.I. Nagy, A.I. Venkateshvaran, S. Sola, S.C. Govind, L. Lund, R. Winter, B. Merkely, A.I. Manouras
(Budapest, HU; Bangalore, IN; Stockholm, SE)

The type of surgical indication determines patients’ prognosis in infective endocarditis. P5483
– C. Ferrera Duran, I. Vilacosta, C. Fernandez, C. Olmos, J. Lopez, C. Sarria, D. Vivas, A. Freitas-Ferraz,
C. Sanchez-Enrique, J.A. San Roman (Madrid and Valladolid, ES)
Why do we need dedicated tools to quantitate the tricuspid annulus by 3D transthoracic P5484
echocardiography?
– D. Muraru, K. Addetia, C. Jenei, F. Veronesi, V. Mor-Avi, M. Yamat, L. Weinert, R.M. Lang, S. Iliceto,
L.P. Badano (Padua and Bologna, IT; Chicago, US; Debrecen, HU)
First-in-human of a transcatheter tricuspid valve repair in a severely regurgitant tricuspid valve patient. P5485
– J. Schofer, K. Bijuklic, C. Tiburtius, L. Hansen, R. Hahn (Hamburg, DE; New York, US)
In vivo tissue-engineered, autologous, valved conduit “Biovalve” with robust wall tissues. P5486
– M. Funayama, M. Furukoshi, T. Moriwaki, Y. Nakayama (Osaka, JP)
340
Atrioventricular conduction disturbance after transcatheter aortic valve implantation: incidence and P5487
predictive factors.
– A.L. Lefoulon, L.J. Jesel, H.M. Marzak, O.M. Morel, P. Ohlmann (Strasbourg, FR)
Changes of implanted prosthetic valve stent morphology during transcatheter aortic valve implantation P5488
with a ballon-expandable valve.
– K. Mahara, K. Kishiki, M. Ota, Y. Izumi, R. Fukumoto, K. Naito, T. Tobaru, S. Takanashi, M. Takayama
(Tokyo, JP)
Comparison of feasibility and efficacy of transcatheter aortic valve implantation in patients aged 75 years P5489
and older versus patients less than 75 years of age.
– T. Arai, B. Chevalier, T. Hovasse, M. Romano, P. Garot, T. Unterseeh, H. Benamer, E. Bouvier,
M.C. Morice, T. Lefevre (Massy, FR)
Feasibility and safety of early discharge after transfemoral transcatheter valve implantation with P5490
balloon-expandable prosthesis: a prospective study.
– G. Cellier, E. Durand, S. El Hatimi, C. Tron, A. Cribier, H. Eltchaninoff (Rouen, FR)
Prevalence and classification of mitral regurgitation in TAVI population. P5491
– I. Rosa, S. Miyazaki, M. Barletta, S. Stella, A. Chieffo, M. Montorfano, A. Latib, A. Margonato, A. Colombo,
Prediction of mortality after transcatheter aortic valve replacement: developement of a novel risk score. P5492
– A. Lauten, C. Hamm, F.W. Mohr, H.R. Figulla (Jena, Bad Nauheim and Leipzig, DE)
CARDIOMYOPATHIES
Sex-correlatad differences in a population affected by hypertrophic cardiomyopathy referred to a single P5493

italian regional center.
– C. De Rosa, S. Bongioanni, T. Forni, M. Borghese, S. Luceri, B. Mabritto, A. Pizzuti, M.R. Conte (Turin, IT)
Clinical usefulness of next generation sequencing techniques analysis in hypertrophic cardiomyopathy. P5494
– E. Zatarain, E. Villacorta-Arguelles, M.A. Espinosa-Castro, I. Mendez-Fernandez, A. Maroto-Aramendi,
M.E. Vazquez-Alvarez, R. Alvarez-Garcia-Rodes, C. Medrano-Lopez, R. Yotti-Alvarez,
F. Fernandez-Aviles-Diaz (Madrid, ES)
Prevalence and clinical significance of life threatening arrhythmias in takotsubo cardiomyopathy. P5495
– I.E. Eitel, T.S. Stiermaier, C.E. Eitel, S.D. Desch, G.S. Schuler, H.T. Thiele (Lübeck and Leipzig, DE)
Multiple gene sequencing reveals striking genetic diversity in patients with dilated cardiomyopathy. P5496
– B. Andersson, M. Dalin, P. Engstrom, M. Bergo, T. Gilljam, M. Schaufelberger (Gothenburg and Stockholm,
SE)
Prevalence of fabry disease in patients with hypertrophic cardiomyopathy: preliminary results of a P5497
multicenter nationwide screening study.
– O. Azevedo, N. Marques, L. Reis, L. Lopes, E. Correia, K. Domingues, J. Almeida, C. Lourenco, B. Picarra
(Guimaraes, Faro, Coimbra, Almada, Viseu, Santarem, Vila Nova de Gaia, Penafiel and Évora, PT)
Long term results in a geographical cohort of hypertrophic obstructive cardiomyopathy: P5498
Pacemaker-therapy has comparative survival and a lower need for re-operations than surgical myectomy.
– D. Javidgonbadi, N.J. Abdon, I. Ostman-Smith (Gothenburg and Trollhättan, SE)
Diagnostic utility of whole exome sequencing for the elucidation of genetic architecture in familial dilated P5499
cardiomyopathy (DCM): examination of a representative Czech cohort with recent-onset DCM.
– M. Kubanek, A. Krebsova, L. Piherova, V. Stranecky, N. Ptakova, M. Macek, M. Macek, V. Melenovsky,
S. Kmoch, J. Kautzner (Prague, CZ)
Assessment of systolic and diastolic function in systemic light chain amyloidosis: an echocardiographic P5500
and cardiac magnetic resonance study.
– C. Boulogne, D. Mohty, T. Damy, J. Magne, S. Martin, M.P. Boncoeur, V. Aboyans, A. Jaccard (Limoges
and Créteil, FR)
FOXO3a deficiency protects from pathogen-induced myocarditis in mice and men. P5501
– C. Skurk, M. Loebel, A. Jenke, S. Pinkert, H. Fechner, H.P. Schultheiss, W. Poller, C. Scheibenbogen,
U. Landmesser (Berlin, DE) TUESDAY – MORNING
The impact of atrial fibrillation on a large population with hypertrophic cardiomyopathy. P5502
– T. Zegkos, D. Parcharidou, G.K. Efthimiadis, H. Karvounis (Thessaloniki, GR)
PULMONARY CIRCULATION, IMAGING, OTHER I
Under-developed bronchial arteries in patients with chronic thromboembolic pulmonary hypertension: a P5503
risk factor for hemoptysis associated with balloon pulmonary angioplasty.
– M. Takei, M. Kataoka, T. Kawakami, M. Kimura, Y. Yamada, M. Yamada, M. Zinzaki, K. Fukuda (Tokyo, JP)
Components of elastic lamina from endothelial cells and smooth muscle cells of pulmonary arteries. P5504
– H. Maruyama, S. Sakai, C. Dewachter, A. Belhaj, B. Rondelet, M. Remmelink, J.L. Vachiery, K. Aonuma,
R. Naeije, L. Dewachter (Moriya and Tsukuba, JP; Brussels, BE)
Non-invasive assessment of effect of exercise on Pulmonary artery systolic pressure in healthy subjects. P5505
– A.A. Khan (Newcastle-upon-Tyne, AU)
Inhibitory effects of TIR/BB-loop mimetic AS-1 on proliferation of pulmonary artery smooth muscle cells P5506
from patients with pulmonary arterial hypertension.
– K. Nakamura, Y. Saito, S. Akagi, T. Sarashina, M. Sakaguchi, T. Oto, H. Ito (Okayama, JP)
Accuracy of echocardiography to evaluate pulmonary vascular and right ventricular function during P5507
exercise.
– G. Claessen, A. La Gerche, F. Schnell, T. Petit, S. Dymarkowski, J.U. Voigt, R. Willems, P. Claus,
M. Delcroix, H. Heidbuchel (Leuven and Hasselt, BE)
341
Serum amyloid A is elevated in chronic thromboembolic pulmonary hypertension. P5508

– R. Sadushi-Kolici, I.A. Tilea, I.M. Lang (Vienna, AT)
The effect of prostacyclin analogues on right heart function is abolished by right heart failure. P5509
– S. Holmboe, A. Andersen, J. Johnsen, J.M. Nielsen, R. Noerregaard, H.E. Boetker, L.H. Clapp,
J.E. Nielsen-Kudsk (Aarhus, DK; London, UK)
Effects of Trimetazidine on patients with chronic obstructive pulmonary disease and pulmonary P5510
hypertension.
– S.J. Oh, S.J. Yoon, D.W. Jeon, J.Y. Yang, C.H.O. Dk (Goyang, KR)
Right ventricular function assessed by 2D speckle-tracking echocardiography in pulmonary hypertension. P5511
Relation with cardio-pulmonary exercise testing.
– M.B. Rehman, L.S. Howard, J.S.R. Gibbs, P. Nihoyannopoulos (London, UK)
The cardioprotective effect of soluble guanosine monophosphate stimulation is abolished in the P5512
hypertrophic and failing right ventricle.
– A. Andersen, J.A. Povlsen, J.A. Johnson, H.E. Boetker, J.E. Nielsen-Kudsk (Aarhus, DK)

Non-invasive multi-modality imaging evaluation of pulmonary arterial elastance in patients with P5513
– C. Venner, O. Huttin, R. Aslam, D. Mandry, P.Y. Marie, F. Chabot, A. Chaouat, Y. Juilliere, C. Selton-Suty
(Vandoeuvre-lès-Nancy, FR)
Prevalence and prognostic significance of CT criteria for pulmonary veno-occlusive disease in systemic P5514
sclerosis-associated pulmonary hypertension.
– M.J. Connolly, M. Ahmed, S. Abdullah, B. Schreiber, C. Handler, C. Denton, J. Haddock, J.G. Coghlan
(London, UK)
Comparison of intravascular optical frequency domain imaging with intravascular ultrasound in balloon P5515
pulmonary angioplasty for the patients with chronic thromboembolic pulmonary hypertension.
– N. Ikeda, S. Kubota, T. Okazaki, H. Hara, Y. Hiroi (Tokyo, JP)
Involvement of thrombin in vascular remodeling in chronic thromboembolic pulmonary hypertension. P5516
– A. Ogawa, H. Matsubara (Okayama, JP)
Pulmonary hypertension connection formula provides a more realistic eight-year survival estimates than P5517
national institute of health and French registry equations.
– C. Kaymaz, O. Akbal, N. Poci, S. Turkday, S. Ozturk, M. Kalamanoglu Balci, T. Aktemur, F. Yilmaz,
H.C. Tokgoz, N. Ozdemir (Istanbul, TR)
Pulmonary arterial capacitance in heart failure with preserved and reduced ejection fraction complicated P5518
by pulmonary hypertension.
– R. Dragu, D. Aronson (Haifa, IL)
The use of the diastolic pressure gradient in the diagnosis of group 2 pulmonary hypertension can P5519
identify patients at increased risk for adverse events.
– M. Gostimir, R. Davies, G. Chandy, D. Stewart, V. Contreras Domingues, R. Dunne, C. Pugliese,
L. Mielniczuk (Ottawa, CA)
Reduction in NT-proBNP and its correlation with survival in patients with CTEPH treated with riociguat: P5520
2-year results from the CHEST-2 long-term extension study.
– M.M. Hoeper, M. Halank, Z.-C. Jing, N.H. Kim, C. Neurohr, H. Wilkens, S. Nikkho, A. Fritsch, H.-A. Ghofrani
(Hannover, Dresden, Munich, Homburg, Berlin, Wuppertal and Giessen, DE; Beijing, CN; San Diego, US)
Left main coronary artery extrinsic compression by enlarged pulmonary artery in patients with pulmonary P5521
arterial hypertension.
– N. Galie’, F. Saia, A. Manes, G. Dall’ara, E. Monti, M. Palazzini, C. Marrozzini, V. Russo, M. Zompatori,
A. Marzocchi (Bologna, IT)
RV free wall strain adds significantly to predicting functional capacity in PAH. P5522
– L. Wright, N. Dwyer, T. Marwick (Hobart, AU)
The diastolic pressure gradient and the cardiorespiratory profile during exercise in pulmonary P5523
hypertension due to left heart disease.
– S. Caravita, G.M. Di Marco, G. Deboeck, A. Faini, L. Novelli, J.L. Vachiery (Brussels, BE; Milan, IT)
Hemodynamic effect of initial combination therapy as compared to initial monotherapy in pulmonary P5524
arterial hypertension: a single centre blinded evaluation of patients enrolled in the AMBITION study.
– C. Bachetti, A. Manes, F. Dardi, M. Palazzini, G. Mazzanti, A. Rinaldi, A. Albini, E. Gotti, E. Monti, N. Galie’
(Bologna, IT)
PULMONARY CIRCULATION, IMAGING, OTHER II
Resistance, compliance, and the time constant of the pulmonary circulation at exercise. P5525
– S. Wright, S. Esfandiari, J.M. Goodman, S. Mak (Toronto, CA)
Non-invasive evaluation of right atrial morphology and function in patients with and without pulmonary P5526
– M. D’Alto, A. D’Andrea, G. Scognamiglio, R. Badagliacca, G. Di Salvo, E. Romeo, P. Argiento, C.D. Vizza,
G. Valentini, M.G. Russo (Naples and Rome, IT; Riyadh, SA)
Evaluation of right atrial function using speckle tracking strain in patients with pulmonary hypertension. P5527
– Y. Fukuda, H. Tanaka, Y. Motoji, K. Ryo, H. Sano, T. Sawa, Y. Mochizuki, K. Matsumoto, N. Emoto,
K. Hirata (Kobe, JP)
The glucagon-like peptide-1 receptor agonist improves hypoxia induced pulmonary hypertension in mice P5528
model.
– T. Kimura, K. Tajiri, K. Kyo, N. Murakoshi, S. Sakai, K. Aonuma (Tsukuba, JP)
342
2D speckle tracking analysis of right atrium in patients with pulmonary hypertension. P5529
– M. D’Alto, D. Di Salvo, R. Badagliacca, G. Scognamiglio, E. Romeo, P. Argiento, A. D’Andrea, A. Correra,
C.D. Vizza, M.G. Russo (Naples and Rome, IT; Riyadh, SA)
Right ventricular function in patients with systemic sclerosis without pulmonary arterial hypertension. P5530
– L. Gargani, F. Ferrara, S. Guiducci, O. Vriz, R. Sicari, M. Matucci Cerinic, E. Picano, E. Bossone (Pisa,
Salerno and Florence, IT; Astana, KZ)
Assessment of systemic and pulmonary arterial remodeling in women with systemic sclerosis. P5531
– K. Irzyk, P. Bienias, Z. Rymarczyk, Z. Bartoszewicz, M. Siwicka, M. Bielecki, A. Karpinska,
I. Dudzik-Niewiadomska, P. Pruszczyk, M. Ciurzynski (Warsaw, PL)
Follow-up of the pulmonary right-to-left shunt with transthoracic contrast echocardiography in patients P5532
with hereditary haemorrhagic telangiectasia.
– V.M.M. Vorselaars, S. Velthuis, R.J. Snijder, C.J.J. Westermann, J.-A. Vos, J.J. Mager, M.C. Post
(Nieuwegein, NL)
The availability of dual-energy computed tomography for the optimal diagnosis and treatment in patients P5533
with chronic thromboembolic pulmonary hypertension.
– H. Shimokawahara, S. Ijyuin, K. Hiramine, K. Higashi, H. Tanaka, N. Nuruki, M. Sonoda (Kagoshima, JP)
Clinical impact of treatment of atrial fibrillation in patients with pulmonary hypertension. P5534
– S. Havranek, D. Ambroz, Z. Fingrova, P. Jansa, R. Votavova, J. Lindner, J. Kunstyr, A. Linhart (Prague, CZ)
CARDIOVASCULAR RISK: PREMATURE AGEING AND ELDERLY

Accelerated atherosclerosis in systemic lupus erythematosus patients with secondary antiphospholpid P5535
syndrome.
– A. Djokovic, L. Stojanovich, B. Todic (Belgrade, RS)
Advanced atherosclerosis in rheumatoid arthritis: the role of von willebrand factor activity. P5536
– G. Ristic, V. Subota, T. Lepic, D. Stanisavljevic, B. Glisic, A.D. Ristic, M. Petronijevic, D. Stefanovic
(Belgrade, RS)
Evaluation of early cardiovascular involvement in young patients with psoriatic arthritis. P5537
– P. Ozdowska, R. Dabrowski, P. Gluszko, I. Kowalik, R. Rupinski, K. Sikorska-Siudek, B. Kwiatkowska,
H. Szwed (Warsaw, PL)
Association of insulin resistance and subclinical atherosclerosis in patients with rheumatoid arthritis. P5538
– G. Ristic, V. Subota, T. Lepic, D. Stanisavljevic, A.D. Ristic, D. Stefanovic (Belgrade, RS)
Testosterone deprivation accelerates cardiac dysfunction and cardiac mitochondrial impairments in P5539
obese-insulin resistant rats.
– W. Pongkan, H. Pintana, S. Sivasinprasan, N. Apaijai, S. Kumfu, T. Jaiwongkam, S. Chattipakorn,
N. Chattipakorn (Chiang Mai, TH)
Low testosterone and high pulse pressure are complementary predictors of cardiovascular events in P5540
erectile dysfunction patients.
– N. Ioakeimidis, C. Vlachopoulos, A. Angelis, P. Pietri, D. Terentes-Printzios, P. Xaplanteris, M. Abdelrasoul,
I. Gourgouli, C. Georgakopoulos, D. Tousoulis (Athens, GR)
Association between endogenous serum testosterone concentrations and aortic pressures and pulse P5541
wave amplification indices in erectile dysfunction patients.
– M. Abdelrasoul, C. Vlachopoulos, N. Ioakeimidis, D. Terentes-Printzios, A. Angelis, P. Xaplanteris,
I. Gourgouli, C. Georgakopoulos, P. Pietri, C. Stefanadis (Athens, GR)
Impact of ages on fibrinogen levels and its relationship with coronary artery disease: a single-centre P5542
study.
– G. Di Giovine, M. Verdoia, A. Schaffer, L. Barbieri, P. Marino, H. Suryapranata, G. De Luca (Novara, IT;
Nijmegen, NL)
The prognostic values of hypoalbuminemia in patients with ST-segment elevation myocardial infarction. P5543
– V. Boasi, M. Vercellino, D. Perri, C. Tacchi, F.A. Sanchez, S. Suppo, S. Cattunar, G. Mascelli (Sanremo, IT)
3-year health related quality-of-life outcomes after percutaneous coronary intervention in elderly patients. P5544
– B.P.Y. Yan, L.L. Chan, V.W.Y. Lee, C.M. Yu, C. Reid (Hong Kong, HK; Melbourne, AU) TUESDAY – MORNING
Decreased six-minute walk distance at hospital discharge is an independent predictor for poor P5545
instrumental activities of daily living after discharge in elderly patients with chronic heart failure.
– K. Nozaki, T. Masuda, K. Kamiya, N. Hamazaki, R. Matsuzawa, S. Tanaka, E. Maekawa, J. Ako
(Sagamihara, JP)
Unexpected senile cardiac amyloid in 5% of severe aortic stenosis patients undergoing surgery. P5546
– T. Treibel, M. Fontana, J.A. Gilbertson, K.B. Boniface, S.K. White, T. Bampouri, L. Warren, M.T. Ashworth,
P.N. Hawkins, J.C. Moon (London, UK)
PHARMACOTHERAPY AND ELECTROPHYSIOLOGY ISSUES IN THE ELDERLY

Vitamin K supplementation inhibits cardiovascular calcification in a murine model of chronic kidney P5547
disease.
– D. Scheiber, V. Veulemans, P. Horn, C. Chatrou, S. Potthoff, L. Schurgers, M. Kelm, R. Westenfeld
(Düsseldorf, DE; Maastricht, NL)
The association between antihypertensive drug use, mortality, and hospital admissions related to P5548
medication in community dwelling elderly of 80 year and older: a retrospective cohort study.
– C. Van Nyendaal, S.A. De Boer, J. Talsma, J.D. Lefrandt, G.J. Izaks, D.J. Mulder (Groningen, NL)
Antiplatelet therapy in the very elderly: should tolerability of therapy after percutaneous coronary P5549
intervention guide patient and device selection?
– M. Allan, S. Ong, S. Roy, P. Gonski, M. Pitney (Sydney, AU)
343
New oral anticoagulants: perioperative bridging therapy versus no bridging therapy. P5550
– H. Omran, R. Bauersachs, F. Goss, C. Hammerstingl (Bonn, Darmstadt and Munich, DE)
Long-term effect of antihypertensive drugs on the risk of new onset osteoporotic fractures in the elderly - P5551
A population-based longitudinal cohort study.
– G.P. Jong, H.Y. Chen, Y.S. Liou (Taichung, TW)
The dynamics of velocity parameters of cardiac electrical activity in healthy males aged 1 to 64 years. P5552
– S.Y.U. Levashov, A.S. Gorbunova, O.A. Levashova, E.G. Volkova (Chelyabinsk, RU)
Electrophysiological study is required for the prognosis evaluation of preexcitation syndrome in patients P5553
aged 60 and over.
– B. Brembilla-Perrot, A. Olivier, J.M. Sellal, V. Manenti, T. Villemin, D. Beurrier, C. De Chillou, N. Girerd
(Vandoeuvre-lès-Nancy, FR)
Prevalence and prognosis of Brugada electrocardiogram patterns in an elderly Han Chinese population: a P5554
nation-wide community-based study (HALST cohort).
– J.M. Juang, C.Y. Chen, Y.H. Chen, I.C. Wu, C.C. Hsu, L.N. Chen, F.C. Tang, C.C. Wang, F.T. Chiang,
C. Hsiung (Taipei, Zhunan, Changhua and Hualien, TW)
The natural history of multifocal atrial rhythms in elderly outpatients. Prospective data from the ’Ikaria P5555
study’.
– G. Lazaros, C. Chrysohoou, E. Oikonomou, D. Tsiachris, S. Mazaris, E. Venieri, K. Zisimos, D. Tousoulis,
C. Pitsavos, C. Stefanadis (Athens, GR)
Prognosis of the elderly patients after implantation of bradycardia pacemaker. P5556
– T. Yamaguchi, T. Miyamoto, K. Kawahatsu, R. Miyazaki, N. Hara, T. Umemoto, Y. Yamauchi, T. Obayashi,
M. Isobe (Tokyo, JP)
Osteopontin-deficient mice are protected against age-related myocardial dysfunction, structural P5557
remodelling and senescence.
– G. Czibik, D. Sawaki, F. Wan, J. Ternacle, M. Breau, A. Houssaini, S. Abid, L. Ernande, S. Adnot,
G. Derumeaux (Créteil, FR)
Increased expression of the aging related splice variant progerin in patients with cardiomyopathy. P5558
– S.K. Ghadge, M. Messner, G. Poelzl, W.M. Franz, M.M. Zaruba (Innsbruck, AT)
CARDIOVASCULAR MORTALITY IN ELDERLY

Heart failure mortality in the elderly in Brazil: time trend analysis from 1996 to 2012. P5559
– E. Pitthan, V. Hirakata, J.N. Barbisan (Porto Alegre, BR)
Trend in mortality rates from acute coronary syndrome in octogenarian patients during the period P5560
2000-2006 compared to 2008-2013.
– M. Shechter, I. Goldenberg, S. Matetzky (Tel Hashomer, IL)
Four-year (2009-2013) all cause and cardiovascular disease mortality in older adults and its determinants. P5561
– C. Chrysohoou, J. Skoumas, G. Lazaros, E. Venieri, K. Katte, M. Kariori, E. Oikonomou, D. Tousoulis,
C. Pitsavos, C. Stefanadis (Athens, GR)
Identifying the last year of life in patients presenting with acute coronary syndrome: a multicentre P5562
prospective study (FATE-ACS study).
– C.M. Moretti, J.I. Iqbal, S.M. Murray, M.B. Bertaina, Y.P. Parviz, S.F. Fenning, G.Q. Quadri,
F.D.A. D’Ascenzo, F.G. Gaita, M.D. Denvir (Turin, IT; Sheffield and Edinburgh, UK)
Factors, associated with in-hospital mortality of acute myocardial infarction: results from the P5563
single-center registry in Ukraine.
– K.O. Mikhaliev, D.D. Diachuk, M.Y.U. Kolomoiets, A.M. Kravchenko, O.O. Sopko, I.M. Simak (Kiev, UA)
Residual lesion in left anterior descending artery is associated with 3-year mortality in super-elderly P5564
patients with acute coronary syndrome.
– S. Higuchi, Y. Kabeya, K. Matsushita, H. Kohsho, H. Ishiguro, T. Inami, H. Taguchi, T. Yamagishi,
Y. Shigeta, H. Yoshino (Tokyo, JP)
Predicting clinical outcomes in elderly patients with acute myocardial infarction undergoing primary P5565
– M. Hermans, D.C. Eindhoven, J.J.M. Otto, L.A.M. Van Winden, G.J. De Grooth, M. Muller, M.J. Schalij
(Leiden, NL)
Performance of Euroscore II compared to additive and logistic Euroscore in predicting hospital and P5566
midterm mortality, ICU and hospital lenght of stay in octagenarians undergoing cardiac operation.
– M. Rahman, N. Kostoulas, Y. Ahmed, I. Toumpoulis, P. Kumar, S. Ashraf (Swansea, UK; Athens, GR)
Laboratory tests combined into a frailty index predict mortality and cardiovascular events in hypertensive P5567
older adults.
– R. Peters, N. Beckett, J. Warwick, K. Rockwood, A. Mitnitski, S. Howlett, C. Bulpitt (London and Coventry,
UK; Halifax, CA)
Incidence and prognosis of incident disability in older patients hospitalized for acute cardiac conditions. P5568
– F.J. Noriega, M.T. Vidan, E. Sanchez, J.A. Serra, F. Fernandez-Aviles, H. Bueno (Madrid, ES)
Outcome of acute coronary syndrome octogenarian patients in Israel. P5569
– M. Shechter, I. Goldenberg, S. Matetzky (Tel Hashomer, IL)
AGEING: COGNITIVE, VASCULAR AND AUTONOMIC IMPAIRMENT

Central aortic reservoir-wave analysis predicted 20-year all-cause and cardiovascular mortalities P5570
independently of wave reflection and arterial stiffness: a community-based study.
– H.M. Cheng, S.Y. Chuang, S.H. Sung, H.A. Spurgeon, C.T. Ting, S.S. Najjar, E.G. Lakatta, F.C.P. Yin,
P. Chou, C.H. Chen (Taipei, Miaoli County and Taichung, TW; Baltimore and St. Louis, US)
344
Predictors of aortic pulse wave velocity in the very elderly with severe aortic stenosis. P5571
– K. El Chilali, H. Farouk, M. Abdelhafez, T. Neumann, S. Alotibi, D. Wendt, Z. Ashour, K. Sorour, R. Erbel,
P. Kahlert (Essen, DE; Cairo and Assiut, EG)
Cardiovascular risk factors over the adult life course: associations with carotid intima-media thickness P5572
and carotid-femoral pulse wave velocity in older British men.
– V. Kapetanakis, K.E. Smith, O. Papacosta, E.A. Ellins, L.T. Lennon, C.G. Owen, A.R. Rudnicka,
J.P. Halcox, S.G. Wannamethee, P.H. Whincup (London and Swansea, UK)
Incidence of carotid plaque components: a 4-year follow-up study using serial magnetic resonance P5573
imaging.
– L. Pletsch Borba, M. Selwaness, A. Van Der Lugt, A. Hofman, O. Franco Duran, M. Vernooij (Rotterdam, NL)
Ankle-brachial Index: an ubiquitary available marker of cognitive impairment in low-income countries- the P5574
EPIDEMCA study.
– I. Desormais, V. Aboyans, M. Guerchet, B. Bandzouzi, P. Mbelesso, B. Marin, J.F. Dartigues, P.M. Preux,
P. Lacroix (Limoges and Bordeaux, FR; London, UK; Brazzaville, CG; Bangui, CF)
Cognitive aging and the incidence of cardiovascular events and diabetes: a meta-analysis of the HPS, P5575
SEARCH and HPS2-THRIVE studies.
– S. Parish, A. Offer, R. Clarke, D. Bennett, L. Bowman, R. Bulbulia, R. Haynes, M. Landray, J. Armitage,
R. Collins (Oxford, UK)
A combined cognitive-exercise training improves endothelial function in patients with mild cognitive P5576
impairment: the train the brain study.
– R.M. Bruno, F. Stea, L. Ghiadoni, S. Taddei, L. Maffei, N. Berardi, L. Volpi, L. Gargani, E. Picano, R. Sicari
(Pisa, IT)
Extent and characteristics of atherosclerotic plaques and their relation to cerebral grey matter atrophy in P5577
asymptomatic patients with non-obstructive carotid lesions.
– E. Ammirati, M. Magnoni, R. Messina, N. Anzalone, F. Besana, P. Spagnolo, O.E. Rimoldi, A. Falini,
M. Filippi, P.G. Camici (Milan, IT)
Cognitive impairment predicts future cardiac events in elderly patients with heart failure. P5578
– T. Okumura, K. Kobayashi, N. Watanabe, N. Kano, H. Mori, K. Fukaya, A. Sawamura, Y. Bando,
S. Yamada, T. Murohara (Nagoya, JP)
Skeletal muscle atrophy is associated with presymptomatic hippocampal atrophy in elderly patients with P5579
heart failure.
– N. Kakutani, A. Fukushima, R. Nakamura, S. Mori, T. Tsunemaru, T. Oikawa, R. Ishimoto, M. Katayose,
I. Yoshida (Obihiro and Sapporo, JP)
Impaired orthostatic blood pressure stabilization is highly prevalent and a novel risk factor for P5580
unexplained falls in older adults: Findings from a prospective national cohort study.
– C. Finucane, C.W. Fan, K. Richardson, O. Donoghue, M. O’Connell, G. Savva, S. Jansen, H. Cronin,
R.A. Kenny (Dublin, IE; Norwich, UK; Amsterdam, NL)
Age and outcome of head-up tilt table testing in syncope patients. P5581
– A. Shafiee, S. Sadeghian, R. Noormand, G. Davoodi, A. Yaminisharif (Tehran, IR)
ASSESSING CARDIOVASCULAR RISK AND INCIDENCE ACROSS THE LIFESPAN

Avoidable deaths from cardiovascular diseases: 40-year follow-up of 19,000 London Civil Servants. P5582
– R. Clarke, J. Emberson, D. Leon, M. Marmot, M. Shipley (Oxford and London, UK)
Correlation of ankle brachial index measurement: all the techniques are valid? P5583
– G.O. Perea, M. Corneli, G. De Bono, F. Belcastro, R. Ronderos (Buenos Aires, AR)
Phytate (IP6) and age-related cardiovascular calcification. P5584
– M.L. Panelo, R. Prieto, F. Grases, C. Fernandez-Palomeque (Palma de Mallorca, ES)
Temporal trends in the prevalence of ischaemic heart disease in Catalonia. P5585
– S. Sans Menendez (Barcelona, ES)
Is the extent of coronary arterial plaque associated with non-coronary vascular outcomes in P5586
asymptomatic type 2 diabetics? A prospective CT angiography based 7 year outcomes study. TUESDAY – MORNING
The prevalence of cardiovascular events and short-term mortality increase in the elderly with stable P5587
coronary artery disease and hospitalization for acute lower respiratory tract infection.
– L.U.O. Luo, L.M. Luo (Beijing, CN)
Association between dynamic penile peak systolic velocity and major adverse cardiovascular events in P5588
men with arterial hypertension.
– N. Ioakeimidis, C. Vlachopoulos, A. Angelis, A. Samentzas, K. Rokkas, D. Terentes-Printzios, P. Pietri,
K. Aznaouridis, G. Lazaros, D. Tousoulis (Athens, GR)
Decreasing incidence of cardio-vascular events or deaths in CAD patient cohorts 2004-2011. Results from P5589
the disease management program (DMP) for coronary artery disease (CAD).
– B. Hagen, S. Groos, J. Kretschmann, A. Weber, L. Altenhofen (Cologne, DE)
Association of polymorphisms of FURIN and ZPR1 with metabolic syndrome in Japanese individuals. P5590
– H. Horibe, C. Ueyama, T. Kondo, T. Fujimaki, M. Oguri, K. Kato, M. Arai, S. Watanabe, T. Murohara,
Y. Yamada (Tajimi, Inabe, Nagoya, Gifu and Tsu, JP)
Design and recruitment of the ROBINSCA trial: screening for cardiovascular disease. P5591
– H.J. De Koning, C.M. Van Der Aalst, M.A. Van Aerde, R. Ijkema, R. Van Bruggen, M. Oudkerk (Rotterdam,
Apeldoorn and Groningen, NL)
Prevalence of abnormal glucose regulation 7 years after a ST-elevation myocardial infarction in patients P5592
without known diabetes at baseline: results of repeated oral glucose tolerance testing.
– E.C. Knudsen, I.S. Seljeflot, J. Eritsland, A. Mangschau, H. Arnesen, G.Ø. Andersen (Oslo, NO)
345
Association of genetic variants of the alpha-kinase 1 gene with type 2 diabetes mellitus in a longitudinal P5593
population-based genetic epidemiological study.
– M. Oguri, T. Fujimaki, H. Horibe, K. Kato, T. Murohara, K. Matsui, I. Takeuchi, Y. Yamada (Nagoya, Inabe,
Tajimi and Tsu, JP)
STROKE
Endovascular Treatment in Ischemic Stroke: A Meta-analysis of 11 Randomized Trials with Trial P5594
Sequential Analysis.
– I.H. Tanboga, S. Topcu, E. Aksakal, S. Sevimli (Erzurum, TR)
Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect P5595
of anticoagulation and its timing. The RAF study.
– M. Paciaroni, G. Agnelli, C. Becattini (Perugia, IT)
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. P5596
– C. Benn Christiansen, J. Pallisgaard, T.A. Gerds, J.B. Olesen, M.E. Joergensen, A.K. Nume, N. Carlson,
G. Gislason, C. Torp-Pedersen (Aalborg and Copenhagen, DK)
Thrombectomy for acute ischemic stroke: retrieval of larger thrombi is associated with improved P5597
neurological recovery.
– A.S.A. Autar, D. Beumer, R. Ganpat, O. Berkhemer, W. Van Zwam, R. Van Oostenbrugge, C. Majoie, M. De
Maat, D.W.J. Dippel, H.M.M. Van Beusekom (Rotterdam, Maastricht and Amsterdam, NL)
Stroke, major bleeding and mortality in newly diagnosed atrial fibrillation with moderate-to-severe P5598
chronic kidney disease: results from GARFIELD-AF.
– S. Goto, D. Atar, J.-P. Bassand, K.A.A. Fox, S.Z. Goldhaber, F. Misselwitz, S. Oh, A.G.G. Turpie,
F. Verheugt, A.K. Kakkar (Kanagawa, JP; Oslo, NO; Besançon, FR; Edinburgh and London, UK; Boston,
US; Berlin, DE; Seoul, KR; Hamilton, CA; Nijmegen, NL)
A preclinical study of honeycomb microporous covered stents for the treatment of large wide-necked P5599
cerebral aneurysms.
– Y. Nakayama, T. Satow, M. Funayama, M. Furukoshi, T. Moriwaki, D. Ishii, M. Hayashi, E. Hamano,
T. Tajikawa, J.C. Takahashi (Suita and Osaka, JP)
Usual blood pressure and risk of vascular dementia. P5600
– C.A. Emdin, S.G. Anderson, G. Salimi-Khorshidi, M. Woodward, K. Rahimi (Oxford, UK)
Atrial fibrillation is associated with stroke in veteran endurance athletes. P5601
– M. Myrstad, M. Aaronaes, A.H. Ranhoff (Oslo, NO)
Progression from paroxysmal to sustained atrial fibrillation as an increased risk of stroke or systemic P5602
embolism: The Fushimi AF Registry.
– H. Ogawa, D. Takagi, M. Ishii, M. Iguchi, M. Esato, Y.H. Chun, H. Wada, K. Hasegawa, M. Abe, M. Akao
(Kyoto, JP)
Insertable cardiac monitors for detection of atrial fibrillation in patients with embolic stroke of P5603
undetermined source (ESUS) selected by risk factors.
– N. Goetz, S. Poli, F. Haertig, A. Bauer, M. Duckheim, C. Eick, J. Schreieck, M. Gawaz, U. Ziemann,
C.S. Meyer-Zurn (Tübingen, DE)
Under reporting of intracranial haemorrhage associated with antiplatelet and anticoagulant use to the P5604
health products regulatory authority versus referrals to a national neurosurgery centre.
– S. Cuddy, E. Ennis, R. Collis, S. Matiullah, E. O’Mahony, D. Foley, D. O’Brien, R. Sheahan (Dublin, IE)
Spontaneous echo contrast is associated with increased risk for cardioembolic events a metaanalysis. P5605
– J.D. Ramos, J.A. Aherrera, L. Chiong, E.W. Timbol, F.E. Punzalan (Manila, PH)
Discontinuation of oral anticoagulation agents in patients with atrial fibrillation and concomitant risks of P5606
stroke and bleeding using therapy approach guided by insertable cardiac monitors.
– B.K. Kantharia, M.U. Farooq, D.A.N. Mascarenhas (Houston and Easton, US)
The role of functional characteristics in symptomatic carotid artery prediction in ischemic stroke. P5607
– G. Benetos, K. Toutouzas, M. Drakopoulou, C. Deligianni, I. Koutagiar, A. Synetos, K. Spengos, E. Tsiamis,
E. Siores, D. Tousoulis (Athens, GR; Bolton, UK)
Pre-event CHA2DS2-VASc score and severity of acute stroke in patients with atrial fibrillation: findings P5608
from the RAF study.
– M. Paciaroni, G. Agnelli, C. Becattini, M. Acciarresi (Perugia, IT)
Carotid atherosclerosis and the risk for ischemic stroke in patients with atrial fibrillation on oral P5609
anticoagulant treatment.
– C. Becattini, A. Sembolini, G. Manina, F. Dentali, G. Camporese, C. Tonello, G. Agnelli (Perugia, Varese and
Padua, IT)
Association of polymorphisms of TOMM40 and SLC22A4 with ischemic stroke. P5610
– H. Horibe, Y. Yamase, T. Kondo, T. Fujimaki, M. Oguri, K. Kato, M. Arai, S. Watanabe, T. Murohara,
Y. Yamada (Tajimi, Inabe, Nagoya, Gifu and Tsu, JP)
Frequent atrial ectopic activity and risk of recurrent cryptogenic ischemic stroke and transient ischemic P5611
attack.
– J.R. Siles Rubio, A. Ramirez Moreno, M. Noureddine, M. Saguer, R. Bravo-Marques, E. Zambrano-Medina,
A. Valle-Alberca, A. Milan-Pinilla, L. Inigo-Garcia, J. Munoz-Bellido (Estepona and Marbella, ES)
Does the left atrial appendage morphology correlate with stroke risk in patients with sinus rhythm? P5612
– M. Komar, W. Plazak, B. Sobien, L. Tomkiewicz-Pajak, M. Olszowska, P. Podolec (Krakow, PL)
Predictors of stroke after aortic valve replacement with or without concurrent coronary artery bypass P5613
grafting.
– T.K.M. Wang, T. Ramanathan, D.H. Choi, P. Ruygrok (Auckland, NZ)
346
Neuroprotective effect of sitagliptin after ischemic stroke in type 2 diabetic patients: a nationwide cohort P5614
study.
– T.H. Chen, D.Y. Chen, S.H. Wang (Taipei, TW)
Silent neuronal ischemias after elective percutaneous coronary intervention. P5615
– H. Goksuluk, S. Gulec, O.U. Ozcan, M. Gerede, V.K. Vurgun, N. Ozyuncu, C. Erol (Ankara, TR)
CAROTID DISEASE
Carotid artery stenting prior to the cardiac surgery - a hybrid treatment strategy in the extended P5616
TARGET-CAS study population.
– K. Dzierwa, P. Pieniazek, L. Tekieli, T. Przewlocki, J. Piatek, J. Konstanty-Kalandyk, M. Trystula,
M. Wojcik-Pedziwiatr, P. Podolec, K. Zmudka (Krakow, PL)
Long-term outcome of patients after carotid artery stenting depending on patient age. P5617
– J. Ledwoch, S. Staubach, M. Segerer, H. Mudra (Munich, DE)
The clinical relevance of myocardial injury after carotid endarterectomy. P5618
– R.B. Grobben, J.E.P. Vrijenhoek, H.M. Nathoe, J.A.R. Van Waes, H.M. Den Ruijter, L.M. Peelen, W.A. Van
Klei, G.J. De Borst (Utrecht, NL)
Patients with carotid artery stenosis and recent cerebral ischemic event are less likely to have a P5619
well-developed cerebral collateral pathways, which should prompt early carotid intervention.
– R. Badacz, A. Kablak-Ziembicka, I. Karch, A. Roslawiecka, D. Rzeznik, P. Pieniazek, M. Trystula, L. Tekieli,
K. Zmudka, T. Przewlocki (Krakow, PL)
Hypertension and age-specific burden of carotid atherosclerosis in China: results from 25,000 individuals P5620
in the China Kadoorie biobank study.
– R. Clarke, L. Li, H. Du, O. Kurmi, Y. Guo, Z. Bian, M. Arnold, R. Collins, S. Parish, Z. Chen (Oxford, UK;
Beijing, CN)
Ultrasound assessment of carotid plaque echogenicity response to statin therapy: a systematic review P5621
and meta-analysis.
– P. Ibrahimi, F. Jashari, G. Bajraktari, P. Wester, M.Y. Henein (Umeå, SE)
Fibrin clot properties are linked to the symptomatic vs. asymptomatic status of atherosclerotic carotid P5622
artery stenosis.
– P. Musialek, A. Mazurek, L. Tekieli, W. Dabrowski, A. Lesniak-Sobelga, A. Kablak-Ziembicka, P. Pieniazek,
W. Tracz, A. Undas, P. Podolec (Krakow, PL)
Progression of atherosclerotic carotid plaque in hypertensive patients: the Campania-Salute Network. P5623
– E. Stabile, R. Izzo, G. Esposito, E. Barbato, M.-A. Losi, V. Trimarco, B. Trimarco, N. De Luca, G. De Simone
(Naples, IT)
Investigating the mechanism of action of statins in carotid plaque stability in patients undergoing P5624
endarterectomy.
– F. Sigala, D. Karageorgiadi, P. Efentakis, S.I. Bibli, D. Farmakis, E.K. Iliodromitis, I. Andreadou (Athens, GR)
Carotid artery stenting is safe and effective in patients with restenosis after carotid endarterectomy: data P5625
from a real-world single center.
– S. Staubach, J. Ledwoch, M. Segerer, H. Strohm, H. Mudra (Munich, DE)
A prospective, multicenter study on the safety and efficacy of a novel mesh covered stent in patients with P5626
carotid artery stenosis:.
– J. Schofer, K. Bijuklic, P. Musialek, R. Kolvenbach, H. Sievert (Hamburg, Düsseldorf and Frankfurt am Main,
DE; Krakow, PL)
Carotid arteries ipsilateral to cerebral ischemia exhibit higher temperatures in patients with ischemic P5627
stroke.
– G. Benetos, K. Toutouzas, M. Drakopoulou, C. Deligianni, I. Koutagiar, A. Synetos, K. Spengos, E. Tsiamis,
E. Siores, D. Tousoulis (Athens, GR; Bolton, UK)
CORONARY SURGERY
Sex specific trends in 4-year survival in 94 328 patients who underwent a first isolated coronary artery P5628
TUESDAY – MORNING
bypass graft procedure 1987-2006.
– S. Nielsen, L. Bjorck, A. Jeppsson, K.W. Giang, A. Rosengren (Gothenburg, SE)
Current off-pump coronary artery bypass grafting with multiple skeletonized arterial conduits can P5629
improve clinical outcome for diabetic patients.
– T. Suzuki, T. Asai, T. Kinoshita (Otsu, JP)
Effect of warfarin use in patients with new-onset atrial tachyarrhythmia after isolated coronary artery P5630
bypass graft.
– K.W. Hwang, G.B. Nam, C.H. Kwon, W.S. Lee, Y.G. Kim, H.O. Choi, J. Kim, K.J. Choi, Y.H. Kim (Yansan,
Seoul, Ulsan and Bucheon, KR)
Coronary artery bypass graft surgery in acute coronary syndrome: when to operate? P5631
– A.I. Azevedo, A. Albuquerque, A. Dias, L. Vouga, V. Gama Ribeiro (Porto, PT)
Role of HDL-C in patients undergoing coronary artery bypass grafting. P5632
– E. Angeloni, F. Paneni, S. Refice, C. Comito, G. Melina, R. Sinatra (Rome, IT; Stockholm, SE)
Should bilateral internal thoracic artery grafting be used in patients with left main disease? P5633
– N. Nesher, D. Loberman, D. Pevni, R. Mhor, A. Kramer, Y. Paz, G. Uretzki, Y. Ben-Gal (Tel Aviv, IL)
Do diabetic patients benefit from bilateral internal mammary artery grafting? P5634
– F.-A. Saraiva, N. Vilas-Boas, M.J. Amorim, P.C. Silva, T.B. Azevedo, R.J. Cerqueira, A.C. Pinho-Gomes,
A.P. Lourenco, P. Pinho, A. Leite-Moreira (Porto, PT)
347
BIMA versus SIMA in coronary artery bypass grafting surgery long-term survival: retrospective cohort P5635
with propensity matched analysis.
– F.-A. Saraiva, N.M. Vilas-Boas, M.J. Amorim, P.C. Silva, T.B. Azevedo, R.J. Cerqueira, A.C.P. Gomes,
A.P. Lourenco, P. Pinho, A. Leite-Moreira (Porto, PT)
An event driven myocardial infarction definition using troponins after coronary artery bypass surgery in P5636
the coronary trial.
– E.P. Belley-Cote, A. Lamy, J. Vincent, P. Kavsak, Y. Ou, M. Zhang, P.J. Devereaux, R.P. Whitlock
(Hamilton, CA)
Usefulness of the logistic clinical syntax score in prediction saphaneous vein graft failure in patients P5637
undergoing coronary artery bypass grafting.
– D. Ozturk, O. Celik, H.A. Cakmak, S. Aslan, F. Akin, I. Bakir (Istanbul, TR)
Does metformin exhibit liver protective properties in diabetic patients undergoing CABG? P5638
– R. Nazer, M. Abalhassan, D. Shamma, H. Altaradi, F. Alayoubi, A. Alsaddique, M. Fouda, T. Kashour
(Riyadh, SA)
The anemia conundrum in cardiac surgery: does it enhance risk assessment? P5639
– L.S. De Santo, G.P. Romano, S. De Notaris, M. Mango, L. Savarese, F. Iorio, M. Miele, F. Numis,
S.M. Caparrotti (Foggia, Naples and Mercogliano, IT)
Validation of STS and EuroSCORE 2 for risk prediction in off-pump coronary artery bypass graft surgery P5640
(CABG).
– M.R.N. Pontes, A. Rosler, J. Fraportti, G. Constantin, P. Nectoux, E.A. Lucio, V. Lima, M.C. Sales,
J.D. Frota Filho, F.A. Lucchese (Porto Alegre, BR)
Female gender is an independent predictor of survival in coronary artery bypass surgery: a single centre P5641
experience.
– N. Vilas Boas, F.-A. Saraiva, M.J. Amorim, P. Cidade Silva, T. Azevedo, R. Cerqueira, A. Pinho-Gomes,
A. Lourenco, P. Pinho, A. Leite-Moreira (Porto, PT)
Impact of gender on long-term outcomes following surgical versus interventional revascularization. P5642
– P. Kurlansky, M. Herbert, S. Prince, M. Mack (New York and Dallas, US)
Reduced benefit of delayed coronary artery bypass graft surgery after acute coronary syndromes. P5643
– J.F. Carmo, J. Ferreira, L. Raposo, M.S. Almeida, M. Trabulo, C. Aguiar, A. Tralhao, M. Abecasis,
J.P. Neves, M. Mendes (Lisbon, PT)
Sleep apnea is associated with new-onset atrial fibrillation after coronary artery bypass grafting: Results P5644
from SABOT study.
– L.P. Zhao, T. Kofidis, T.W. Lim, S.P. Chan, T.H. Ong, H.C. Tan, C.-H. Lee (Singapore, SG)
Hospital-Acquired Pneumonia Increases Risk Of Mediastinitis After Cardiac Surgery. P5645
– J.E. Barrios Baqueiro, T. Machain Choreno, E. Bucio-Reta, H. Rodriguez Zanella, F. Baranda Tovar (Mexico
City, MX)
Comparison of quality of life among patients with multivessel coronary artery disease treated with CABG P5646
or hybrid coronary revascularization.
– K. Gierlaszynska, M. Gasior, R. Pudlo, I. Jaworska, A. Kurek, M. Gierlotka, M. Hawranek, M. Tajstra,
M. Zembala, M. Zembala (Zabrze and Katowice, PL)
Aorto-coronary bypass graft outcomes predicted by the distal vessel quality score: optimization of P5647
revascularization strategy.
– H.D. Cubero, I.J. Amat Santos, D. Diez, P.E. Elpidio, C. Cortes, J. Castrodeza, J. Tobar, L. Vera, A. Di
Stefano, A. San Roman (Valladolid, ES)
Sleep apnoea screening in patients scheduled for coronary artery bypass surgery. P5648
– L.P. Zhao, T. Kofidis, S.P. Chan, T.H. Ong, T.C. Yeo, H.C. Tan, C.-H. Lee (Singapore, SG)
The forgotten variable of shear stress in saphenous venous graft disease: whole blood viscosity. P5649
– E.H. Ozcan Cetin, M.S. Cetin, O. Ozeke, H.L. Kisacik, D. Aras, S. Topaloglu, A. Temizhan, S. Aydogdu
(Ankara, TR)
Feasibility of platelet function point-of-care test in ticagrelor or clopidogrel-treated patients undergoing P5650
coronary artery bypass graft surgery.
– C.F. Barrera-Ramirez, L.R. Pineda-Pompa, M.A. Camacho-Garcia, A. Carranza-Rebollar, E. Uresti-Flores,
R. Campo-Aguirre, J.A. Tovar-Maldonado, R. Valdes-Castro (Saltillo, MX)
COMORBIDITIES
Additive positive effect of the reversion of depression and physical capacity improvement on the P5651
sympathovagal balance in the course of home-based telerehabilitation in heart failure patients.
– E. Piotrowicz, W. Piotrowski, M. Stepnowska, R. Piotrowicz (Warsaw, PL)
Value of renal vascular Doppler sonography in management of cardiorenal syndrome type 1. P5652
– O.U. Ozcan, D. Kumbasar, S. Gulec, V.O. Baris, H. Goksuluk, N. Ozyuncu, C. Tulunay Kaya, C. Erol
(Ankara, TR)
The reverse remodeling of left atrium in patients after renal transplantation - the value of left atrium P5653
volume index.
– T. Zapolski, J. Furmaga, A. Jaroszynski, S. Rudzki, A. Wysokinski (Lublin, PL)
Cardiac involvement in hemoglobin SC disease compared to homozygous sickle-cell anemia. P5654
– P. Guedeney, A. Ceccaldi, K. Stankovic Stojanovic, F. Laveau, M. Duprey, A. Cohen, R. Isnard, F. Lionnet,
N. Hammoudi (Paris, FR)
Lack of association between central chemosensitivity and disease severity in optimally treated patients P5655
with mild heart failure.
– B. Paleczny, M. Olesinska, A. Siennicka, P. Niewinski, E.A. Jankowska, B. Ponikowska, W. Banasiak,
S. Von Haehling, S.D. Anker, P. Ponikowski (Wroclaw, PL; Göttingen, DE)
348
Pulmonary hypertension due to left heart disease: comparison between transpulmonary pressure P5656
gradient and diastolic pulmonary vascular pressure gradient.
– T. Ibe, H. Wada, K. Sakakura, T. Nakamura, N. Ikeda, Y. Sugawara, T. Mitsuhashi, J. Ako, H. Fujita,
S. Momomura (Saitama and Sagamihara, JP)
Serial changes in red blood cell volume during transition of heart failure status: a reflection of cellular P5657
hydration status?
– H. Kataoka (Oita, JP)
Anemia and (combined) hematinic factors deficiency in heart failure. P5658
– M.B. Araujo, I. Araujo, F. Marques, P. Moniz, P. Pereira, R. Costa, P. Sena, C. Fonseca (Lisbon, PT)
Effects of functional tricuspid regurgitation and right ventricular dysfunction on renal function in patients P5659
with heart failure and left ventricular dysfuncytion.
– C. Marini, I. Rosa, S. Miyazaki, S. Stella, F. Ancona, A. Fisicaro, M. Oppizzi, A. Cappelletti, A. Margonato,
Chronic kidney disease and community-acquired acute kidney injury are associated with cardio-hepatic P5660
syndrome in patients with decompensated heart failure.
– A. Soloveva, S. Villevalde, Z. Kobalava (Moscow, RU)
Sleep-disordered breathing is of high prevalence in patients with acute cardiac decompensation. P5661
– H. Fox, T. Bitter, D. Horstkotte, O. Oldenburg (Bad Oeynhausen, DE)
Improvement of left ventricular function by unloading the rat hearts of diabetic cardiomyopathy. P5662
– Z. Meng, G. Liu, H. Zheng, Y. Yang (Shijiazhuang and Beijing, CN)
THERAPY
Effects of beta-blocker therapy on hs-CRP levels in elderly patients with ischemic and non-ischemic P5663
heart failure: results from the CIBIS-ELD trail.
– H.D. Duengen, E. Isenovic, B. Putnikovic, P. Milicevic, S. Radenovic, E. Tahirovic, G. Loncar, M. Fritschka,
T. Trippel, F. Edelmann (Berlin, DE; Belgrade, RS)
The effects of Baduanjin exercise on fatigue and quality of life in patients with heart failure. P5664
– A.-F. Chiou, D.-M. Chen, J.-C. Tsai, W.-C. Yu, H.-F. Hung (Taipei, TW)
Three-year experience of the left sided radiofrequency ablation in patients with long-standing persistent P5665
atrial fibrillation and rheumatic mitral valve disease.
– G.M. Turganbayeva, T.D. Lesbekov, E.M. Kuatbayev, N. Smagulov, D.Z.H. Suigenbayev (Astana, KZ)
Improvement of symptoms and quality of life with ivabradine, in patients with heart failure and left P5666
ventricular systolic dysfunction. The OPTIMIZE QOL study.
– H. Karvounis, V. Grammatikou, E. Kallistratos, S. Adamopoulos (Thessaloniki and Athens, GR)
Guidelines implementation in different populations - summarizing from CIBIS ELD and CIBIS ELD 24 P5667
Months FUP studies.
– S. Apostolovic, D. Stanojevic, R. Jankovic-Tomasevic, S. Salinger-Martinovic, D. Djordjevic-Radojkovic,
M. Pavlovic, E. Tahirovic, H.D. Dungen (Nis̆, RS; Berlin, DE)
First clinical experience with ONO-4232, a healthy volunteer study of a novel lusitropic agent for acutely P5668
– C. Ward, V. Jamieson, T. Nabata, J. Sharpe, Y. Hashimoto, K. Dozono, I. Gussak (London, UK)
Family focused approach to improve heart failure care in Lebanon quality (family) intervention: P5669
randomized controlled trial for implementing an education family session.
– H. Deek, P.J. Newton, S.C. Inglis, S. Noureddine, P.S. Macdonald, P.M. Davidson (Sydney, AU; Baltimore,
US)
Audit and clinical service evaluation for acute heart failure patients dying within 48 hours of admission. P5670
– A. D’Silva, S. Bains, S. Liu, L.J. Anderson (London, UK)
Chronic vagus nerve stimulation improves baroreflex sensitivity assessed by heart rate turbulence in P5671
heart failure patients.
– I. Libbus, B.D. Nearing, B. Amurthur, B.H. Kenknight, R.L. Verrier (Houston and Boston, US)
The effects of temperature and air pollution on heart failure incidence and readmissions: is beta-blocker P5672 TUESDAY – MORNING
protective?
– Q. Huynh, F. Johnston, C.L. Blizzard, T.H. Marwick, K. Negishi (Hobart, AU)
Impact of evaluation of left ventricular dys-synchrony and scar burden upon outcome of cardiac P5673
– W. Ahmed, W. Samy, N. Behairy, O. Tayeh, A. Hassan (Cairo, EG)
IMAGING IN HEART FAILURE MANAGEMENT

The Kruppel like factor 15 rs9838915 single nucleotide polymorphism is associated with left ventricular P5674
hypertrophy and heart failure in patients with type 2 diabetes.
– S.K. Patel, B. Wai, P.M. Srivastava, L.M. Burrell (Melbourne, AU)
Echocardiographic myocardial strain during left ventricular assist device support. P5675
– M.A.R. Noor, S. Rahman Haley, C.T. Bowles, N.R. Banner (London, UK)
Depressive symptomatology accompanies impaired ventricular diastolic function, detected by Doppler P5676
imaging, in patients with chronic systolic heart failure.
– C. Chrysohoou, J. Kotroyiannis, G. Metallinos, C. Pitsavos, D. Tousoulis (Athens, GR)
Scar burden and mechanical dyssynchrony assessment with SPECT-myocardial perfusion imaging as a P5677
potential tool to predict responsiveness to cardiac resynchronization therapy.
– S.M. Leite, E. Martins, T. Vieira, M.J. Campelo, J. Rodrigues, S. Amorim, B. Moura, J.S. Cardoso,
J. Pereira, M.J. Maciel (Porto, PT)
349
Relationship between transmural myocardial mechanic and acute heart failure in STEMI patients treated P5678
with primary percutaneous coronary intervention.
– D. Trifunovic, G. Krljanac, L. Savic, M. Asanin, M. Srdic, R. Lasica, N. Zlatic, L.J. Jovanovic, M. Petrovic,
I. Mrdovic (Belgrade, RS)
Stress cardiomyopathy - 10 years’ experience at a tertiary care hospital. P5679
– G. Neves Pestana, M. Vasconcelos, R. Pinto, M. Tavares-Silva, V. Ribeiro, P.B. Almeida, M.J. Maciel (Porto,
PT)
Asymmetric dimethylarginine (ADMA) in the pericardial fluid may contribute to the development of P5680
cardiac hypertrophy.
– A. Koller, Z. Nemeth, S. Szabados, B. Biri, S. Keki, A. Cziraki (Budapest, Valhalla, Pécs and Debrecen, HU)
Heart failure awareness is being increased in HF patients: TREAT-HF cohorts. P5681
– H. Kaya, B. Yagmur, B. Acar, M. Demir, K. Karauzum, G. Acar, A. Celik, M. Ege, I. Sari, M.B. Yilmaz (Sivas,
Izmir, Ankara, Kocaeli, Kahramanmaras, Mersin and Istanbul, TR)
Impact of sociodemographic and clinical risk factors on hospitalisation rates among ambulatory patients P5682
with heart failure and preserved ejection fraction.
– V. Georgiopoulou, G. Burkman, T. Lebeis, K. Farooq, R. Al-Anbari, M. Yazdani, L. Papadimitriou, A. Smith,
J. Butler, A. Kalogeropoulos (Atlanta and Stony Brook, US)
Systemic hypertension and heart failure: insight from different left ventricular ejection fraction. P5683
– A. Iorio, C. Di Nora, E. Zambon, S. Poli, C. Mazzone, D. Radini, L. Tarantini, G. Sinagra, G. Cioffi, A. Di
Lenarda (Trieste, Belluno and Trento, IT)
EPIDEMIOLOGY & MANAGEMENT IN HEART FAILURE
Proposed diagnostic algorithm for patients with heart failure and sleep disordered breathing. P5684
– I. Araujo, F. Marques, M. Araujo, P. Pereira, P. Moniz, F. Ferreira, S. Marques, S. Andre, L. Campos,
C. Fonseca (Lisbon, PT)
Heart failure patients in Germany: mortality and morbidity in a claims database analysis. P5685
– C. Bakogiannis, F. Calado, J. Walker, S. Hupfer, S. Klebs, R. Handrock (Nuremberg and Berlin, DE; Basel,
CH)
Acute heart failure management at a secondary hospital in Spain: current situation and opportunities for P5686
improvement based on the best available evidence.
– L. Molina Blazquez, R. Mata, J. Pais, J. Gorriz, R. Casado, A. Rodriguez-Chaverri, L. Goicolea, A. Fraile,
V. Hernandez, J. Saavedra (Getafe and Mostoles, ES)
Clinical characteristics and profile of heart failure subjects attending a specialized cardiac clinic in P5687
south-western Nigeria.
– A. Akintunde, A.M. Akinlade (Osogbo, NG)
High prevalence of asymptomatic left ventricular dysfunction despite excellent risk factor control in a P5688
diabetic cohort.
– S. James, J. Gallagher, C. Kenny, D.F. Waterhouse, J. Mc Cambridge, T. Murphy, E. O’Connell,
M. Ledwidge, V. Harkins, K. Mc Donald (Dublin, IE)
Peripartum cardiomyopathy in the gulf region; from the gulf CARE study. P5689
– A.M.F. Salam, K. Sulaiman, J. Al-Suwaidi, K. Alhabib, W. Almahmeed, M. Al Jarallah, A. Al-Motarreb,
H. Amin, M. Johnson, J.W. Roos-Hesselink (Doha, QA; Muscat, OM; Riyadh, SA; Abu Dhabi, AE; Kuwait
City, KW; Sana’a, YE; Bahrain, BH; London, UK; Amsterdam, NL)
Nation and gender effects on quality of life changes in patients with heart failure: results from the P5690
CIBIS-ELD trial.
– H.D. Duengen, E. Tahirovic, C. Zelenak, T. Trippel, M. Fritschka, M. Lainscak, F. Edelmann, G. Loncar,
C. Herrmann-Lingen (Berlin and Göttingen, DE; Golnik, SI; Belgrade, RS)
Seasonal variation in patient backgrounds and in-hospital outcomes of Takotsubo cardiomyopathy: a P5691
retrospective cohort study.
– T. Isogai, H. Yasunaga, H. Matsui, H. Tanaka, K. Fushimi (Tokyo, JP)
Identification of Climatic Condition Associated with the Onset of Acute Heart Failure Syndrome. P5692
– T. Taniguchi, M. Ariyoshi, D. Irie, K. Miyagawa, H. Takata (Yosano-cho, JP)
PROGNOSTIC MARKERS IN HEART FAILURE

Increased heart rate at hospital discharge augments 1-year rehospitalization rates, but does not affect P5693
two and three year rehospitalization rates in heart failure patients.
– U. Yuksek, F. Akin (Kastamonu, TR)
Clinical profile and prognosis of the combination of diabetes mellitus and heart failure in ambulatory P5694
patients.
– M. Vives-Borras, A. Ferrero-Gregori, J. Alvarez-Garcia, M.T. Puig, R. Vazquez, J. Delgado,
D.A. Pascual-Figal, L. Alonso-Pulpon, J.R. Gonzalez-Juanatey, J. Cinca (Barcelona, Cadiz, Madrid, Murcia
and Santiago de Compostela, ES)
The prevalence of sleep-disordered breathing and the predictors of the increased apnea-hypopnea index P5695
in patients with chronic heart failure.
– V. Sliziuk, N. Ebner, J. Kube, S. Elsner, L. Steinbeck, T. Bekfani, A. Sandek, W. Doehner, S.D. Anker,
S. Von Haehling (Berlin and Göttingen, DE)
Predictors of cytolisis in patients with acute decompensated heart failure. P5696
– A. Soloveva, S. Villevalde, Z. Kobalava (Moscow, RU)
350
Predictors of heart failure in patients with diabetes mellitus: insights from an observational study over 20 P5697
years.
– A. El-Menyar, S. Mohammad, E. Ahmed, M. Gomaa, A.A. Gehani, N. Asaad, R. Singh, H. Albinali, J. Al
Suwaidi (Doha, QA)
Investigation of incidence, etiology, prognosis, and predictors of ischemic stroke during hospitalization P5698
for congestive heart failure.
– Y. Hamatani, M. Iguchi, M. Nakamura, R. Ohtani, Y. Yamashita, M. Hamatani, M. Abe, M. Akao (Kyoto, JP)
Left bundle branch block by Strauss criteria predicts outcome of cardiac resynchronisation therapy. P5699
– Y.T. Tan, D. Wan, K. Al-Lawati, S. Lim (Birmingham, UK)
Relationship between galectin 3, myocardial function and 24 hours urinary albuminuria excretion in P5700
systolic heart failure.
– F. Gaborit, H. Bosselmann, C. Kistorp, K. Iversen, T. Kumler, F. Gustafsson, J.P. Gotze, G. Soletormos,
N. Toender, M. Schou (Herlev, Hillerod and Copenhagen, DK)
Prognostic impact of syncope in patients hospitalized with heart failure: insights from the Gulf CARE P5701
registry.
– A. Siaidawi, J. Al Suwaidi, K. Kadhim, I. Ibrahim, W. Wael, R. Ridha, A. Ahmed, N.I.D.A.L. Nidal,
H.A.I.T.H.A. Haitham, A.M.A.R. Sallam (Doha, QA; Muscat, OM; Riyadh, SA; Abu Dhabi, AE; Kuwait City,
KW; Sana’a, YE; Bahrain, BH)
Aberrant brain functional connectivity in patients with heart failure. P5702
– R. Kumar, B. Park, J.A. Palomares, G.C. Fonarow, M.A. Woo (Los Angeles, US)
HYPERTENSION HAEMODYNAMICS
Long-term mortality in patients admitted with hypertensive crisis. P5703

– G. Weisz, N. Smilowitz (Jerusalem, IL; New York, US)
One-point carotid wave intensity in newly diagnosed never treated hypertensive patients. P5704
– O. Vriz, C. Driussi, K. Loboz, J. Jaroch, E. Bossone, F. Antonini-Canterin, P. Palatini (San Daniele del Friuli,
Salerno, Pordenone and Padua, IT; Wroclaw, PL)
Abnormal aortic and coronary function is associated with reduced endothelial glycocalyx thickness in P5705
hypertensives.
– I. Ikonomidis, A. Voumvourakis, H. Triantafyllidi, G. Pavlidis, P. Trivilou, M. Varoudi, D. Vlastos, A. Schinas,
J. Lekakis (Athens, GR)
Renal artery anatomy as a new risk factor for resistant hypertension? P5706
– N. Avdonina, M.I. Chashkina, I.V. Emelyanov, E.V. Fominykh, N.V. Gagarina, A.V. Rodionov, N.E. Zvartau,
A.V. Sulimov, A.O. Konradi (St. Petersburg and Moscow, RU)
Ankle-brachial index and brachial-ankle pulse wave velocity jointed to predict mortality in a community P5707
study.
– S.-Y. Chuang, S.-H. Sung, H.-M. Cheng, P.-F. Hsu, P. Chou, C.-H. Chen (Miaoli County and Taipei, TW)
Impact of myocardial deformation on exercise tolerance in patients with arterial hypertension. P5708
– E. Nesukay, V. Kovalenko, N. Polenova, I. Titov, O. Danylenko (Kiev, UA)
Echocardiographic assessment of longitudinal and radial left ventricular systolic function in hypertensive P5709
patients.
– M.L. Muiesan, M. Salvetti, A. Paini, F. Bertacchini, C. Agabiti Rosei, G. Maruelli, R. Germano, E. Colonetti,
A. Comaglio, E. Agabiti Rosei (Brescia, IT)
Testosterone levels in hypertensive patients with vascular organ damage. P5710
– N. Ioakeimidis, C. Vlachopoulos, P. Pietri, D. Terentes-Printzios, A. Angelis, E. Paschalidis, M. Abdelrasoul,
I. Gourgouli, C. Georgakopoulos, D. Tousoulis (Athens, GR)
Oscillometric mean arterial pressure-derived, not systolic pressure-derived, central blood pressure better P5711
discriminates cardiac structural abnormalities.
– K. Negishi, H. Yang, Y. Wang, M. Nolan, M. Saito, T. Negishi, J. Sharman, T. Marwick (Hobart, AU)
Renal resistive index in resistant hypertension: a case-control study. P5712
– A.M. Maresca, C. Mongiardi, L. Robustelli Test, S. Moretti, M. Agostinis, N. Tandurella, A. Bertolini, TUESDAY – MORNING
G.V. Gaudio, A.M. Grandi, L. Guasti (Varese and Somma Lombardo, IT)
Low systolic blood pressure is associated with increased mortality in patients with myocardial injury. P5713
– L. Sarkisian, L. Saaby, N. Jangaard, S. Hosbond, A. Diederichsen, K. Thygesen, H. Mickley (Odense and
Aarhus, DK)
New diagnostic tool for masked hypertension; impaired sleep quality. P5714
– F.H. Erdem, U. Cakir, O. Yildirim, A. Alcelik, I. Donmez, T.C. Tuman, S.O. Caglar, A. Erdem, M. Yazici (Bolu,
TR)
351
TUESDAY 1 SEPTEMBER 2015 – LUNCH TIME SESSIONS

EUROPEAN CARDIOVASCULAR RESEARCH AND INNOVATION – EU FUNDING AND Special Session
NETWORKING OPPORTUNITIES
Chairperson(s): V. Dambrauskaite (Brussels, BE); F. Van de Werf (Leuven, BE)
12:45 European Union’s programme for investment in research and innovation Horizon 2020 – 5715
Opportunities for cardiovascular researchers and business - Innovative Medicines Initiative.
– K. Berkouk (Brussels, BE)
13:00 The role of the Scientific Panel for Health in fostering knowledge sharing and effective 5716
collaboration in Europe.
– K.R. Sipido (Leuven, BE)
13:10 Coordination of national and regional programmes for research in the area cardiovascular 5717
research – CVD ERA-NET.
– C. Steingen (Bonn, DE)
13:20 European Research Council: a personal experience in obtaining funding. 5718
– T. Eschenhagen (Hamburg, DE)
13:30 Discussion. 5719

WOMEN TRANSFORMING LEADERSHIP PROGRAMME: ENABLING WOMEN CAREERS IN Special Session
CARDIOLOGY
Chairperson(s): B. Casadei (Oxford, UK)
12:45 Enabling women’s careers in cardiology. 5720
– K. Bishop (Oxford, UK)
12:45–13:45 | Kiev - Village 3

OPTIMAL BLOOD PRESSURE (BP) CONTROL AND CARDIOVASCULAR (CV) OUTCOMES – Satellite Symposium
HAVE WE REACHED THEM YET?
Chairperson(s): T. Unger (Maastricht, NL)
12:45 Welcome & introduction - Optimal Blood Pressure (BP) control and Cardiovascular (CV) outcomes 5721
– Have we reached them yet?
12:48 Reducing blood pressure – Optimising results for individual patients. 5722
13:04 Adherence to antihypertensive medication – Is there room for improvement? 5723
13:19 Cardiovascular risk reduction – Are there meaningful differences? 5724
13:34 Panel discussion - Optimal Blood Pressure (BP) control and Cardiovascular (CV) outcomes – Have 5725
we reached them yet?
– J. Wang (Shanghai, CN), T. Unger (Maastricht, NL), M. Brown (Cambridge, UK)
13:41 Summary & close - Optimal Blood Pressure (BP) control and Cardiovascular (CV) outcomes – 5726
Have we reached them yet?
352

PATIENT-CENTERED APPROACH WHEN MULTIPLE EBAC Accredited Educational Programme
CARDIOVASCULAR RISKS COEXIST
Organised by Athens Medical School. Course Director: Charalambos Vlachopoulos
Chairperson(s): C. Vlachopoulos (Athens, GR); B. Williams (London, UK)
12:45 Introduction - Patient-centered approach when multiple cardiovascular risks coexist. 5727
12:48 How to achieve treatment goals in patients with multiple cardiovascular risk factors? 5728
13:03 New practical solution for hypertensive patients with dyslipidemia. 5729
13:18 New synergistic strategy for patients with coronary artery disease. 5730
13:33 Discussion - Patient-centered approach when multiple cardiovascular risks coexist. 5731
– C. Vlachopoulos (Athens, GR), B. Williams (London, UK), R. Ferrari (Cona, IT)
13:43 Conclusion - Patient-centered approach when multiple cardiovascular risks coexist. 5732

CARDIAC RHYTHM MANAGEMENT 2015: LINQING DIAGNOSIS TO THERAPY Satellite Symposium
Chairperson(s): J.H. Svendsen (Copenhagen, DK); T. Lewalter (Munich, DE)
12:45 Introduction - Cardiac rhythm management 2015: linqing diagnosis to therapy. 5733
– T. Lewalter (Munich, DE)
12:50 How to identify which syncope patients will benefit from pacemakers? 5734
– N.J. Linker (Middlesbrough, UK)
13:05 A new era of pacing: transcatheter implantation of a miniaturized intracardiac capsule. 5735
– L.V.A. Boersma (Nieuwegein, NL)
13:20 How to detect atrial fibrillation in patients at risk for stroke? 5736
– T. Sanna (Rome, IT)
13:35 Pacing therapies to prevent atrial fibrillation. 5737
13:50 Dynamic left ventricular pacing to reduce atrial fibrillation in heart failure patients. 5738
– S. Winter (Cologne, DE)
14:05 Conclusions - Cardiac rhythm management 2015: linqing diagnosis to therapy. 5739
– J.H. Svendsen (Copenhagen, DK)

INNOVATIONS FOR TREATING PATIENTS WITH ARRHYTHMIAS Satellite Symposium
TUESDAY – LUNCH TIME

Sponsored by Boston Scientific
Chairperson(s): J. Brugada Terradellas (Barcelona, ES); F. Leyva-Leon (Sutton Coldfield, UK)
12:45 The precise localisation of critical isthmuses and foci using a novel high resolution 3D mapping 5740
system.
– T. Wong (London, UK)
13:05 Which patients are indicated to resynchronisation therapy? How to maximise the clinical benefit? 5741
– A. Auricchio (Lugano, CH)
13:25 The era of the subcutaneous defibrillator for sudden cardiac death prevention: how to select 5742
patients?
353

PCSK9 INHIBITION: AN IMPORTANT STEP FORWARD IN TREATING DYSLIPIDEMIA IN Satellite Symposium
HIGH-RISK PATIENTS
Sponsored by Amgen
Chairperson(s): E. Stroes (Amsterdam, NL)
12:45 Welcome and introduction - PCSK9 inhibition: an important step forward in treating dyslipidaemia 5743
in high-risk patients.
12:50 PCSK9 inhibition: the road to effective management of high-risk patients. 5744
– J. Chapman (Paris, FR)
13:10 Paving the way to a better future for high-risk patients. 5745
13:40 Closing remarks - PCSK9 inhibition: an important step forward in treating dyslipidemia in 5746
high-risk patients.
Tuesday 1 September, 15:45–16:15 in Holland Park (The Hub)!

PREVENTION OF ATHEROTHROMBOTIC EVENTS: WHAT’S THE NEW EVIDENCE? Satellite Symposium
Sponsored by MSD
Chairperson(s): P.G. Steg (Paris, FR); D.A. Morrow (Boston, US)
12:45 Opening by the chairs - Prevention of atherothrombotic events: what’s the new evidence? 5747
– P.G. Steg (Paris, FR), D.A. Morrow (Boston, US)
12:50 Atherothrombotic disease: lessons from real life (post Myocardial Infarction (MI)). 5748
13:00 Protease Activated Receptor-1 (PAR-1) antagonist: emerging evidence for a novel pathway. 5749
13:15 PAR-1 antagonist: what do clinical trials teach us? 5750
– D.A. Morrow (Boston, US)
13:30 Putting secondary prevention of atherothrombotic events into perspective. 5751
– G.M. De Ferrari (Pavia, IT)
13:30 Panel discussion & Q&A - Prevention of atherothrombotic events: what’s the new evidence? 5752
– P.G. Steg (Paris, FR), D.A. Morrow (Boston, US), J.A.C. Morais (Leiria, PT), G.M. De Ferrari (Pavia, IT)
13:40 Closing - Prevention of atherothrombotic events: what’s the new evidence? 5753
– P.G. Steg (Paris, FR), D.A. Morrow (Boston, US)
Tuesday 1 September, 15:45–16:15 in Green Park (The Hub)!
12:45–13:45 | Tunis - Village 7

CLINICAL DECISION MAKING IN ELECTROPHYSIOLOGY/ARRHYTHMIAS Satellite Symposium
Organised by EPIC Alliance, supported by an unrestricted educational grant form BIOTRONIK
Chairperson(s): C. Linde (Stockholm, SE); S. Ernst (London, UK)
12:45 PVI should be offered to heart failure patients with persistent AF - presentation. 5754
– M. Chung (Cleveland, US)
12:55 PVI should be offered to heart failure patients with persistent AF - discussion. 5755
– S. Ernst (London, UK)
13:00 Safety of MRI with pacemakers and implantable cardiac defibrillators - presentation. 5756
– U. Birgersdotter-Green (La Jolla, US)
13:10 Safety of MRI with pacemakers and implantable cardiac defibrillators - discussion. 5757
– J. Poole (Seattle, US)
13:15 Asymptomatic AF on pacemaker interrogation: how to manage and when to start anticoagulants - 5758
presentation.
– K. Chia (Brisbane, AU)
13:25 Asymptomatic AF on pacemaker interrogation: how to manage and when to start anticoagulants - 5759
discussion.
13:30 “QRS duration is more important than QRS morphology when choosing the optimal candidate 5760
for CRT.”
– V. Kutyifa (Rochester, US), A. Garlitski (New York, US)
354

ANTICOAGULATION AND NON-VALVULAR ATRIAL FIBRILATION (NVAF)... THE PAPER, Satellite Symposium
THE PRACTICE, THE PATIENT
Chairperson(s): A. Kakkar (London, UK)
12:45 Welcome - Anticoagulation and Non-Valvular Atrial Fibrilation (NVAF)... The paper, the practice, 5762
the patient.
12:50 Interactive patient cases. 5763
– M. Antz (Oldenburg, DE), P. Verhamme (Leuven, BE)
13:40 Summary and close - Anticoagulation and Non-Valvular Atrial Fibrilation (NVAF)... The paper, the 5764
practice, the patient.
13:00–13:45 | Oslo - Village 6

CHALLENGE THE EXPERTS: BEST PRACTICE AND FUTURE PERSPECTIVES FOR Satellite Symposium
RESIDUAL RISK MANAGEMENT
Sponsored by Lilly
Chairperson(s): N.R. Poulter (London, UK)
13:00 Remaining cardiovascular risk: targeting LDL-C. 5765
– S.J. Nicholls (Adelaide, AU)
13:15 Remaining cardiovascular risk: going beyond LDL-C. 5766
– N. Sattar (Glasgow, UK)
13:30 Ask the experts: question and answers. 5767
– N.R. Poulter (London, UK)
TUESDAY – LUNCH TIME
355
TUESDAY 1 SEPTEMBER 2015 – AFTERNOON SESSIONS

ESC GUIDELINES – PERICARDIAL DISEASES Main Session
Chairperson(s): Y. Adler (Rannana, IL); P. Charron (Paris, FR)
14:00 Etiologies and diagnostic work-up. 5768
– A. Brucato (Bergamo, IT)
14:22 Integrated cardiovascular imaging. 5769
– P. Gueret (Créteil, FR)
14:45 Therapeutic management of main pericardial syndroms. 5770
– M. Imazio (Turin, IT)
15:07 Interventional pericardiology and surgery. 5771

CLINICAL TRIAL UPDATE III – PHARMACOLOGY & THERAPY Clinical Trial Update
Chairperson(s): B. Casadei (Oxford, UK); S. Agewall (Oslo, NO)
14:00 Efficacy and safety of the PCSK9 monoclonal antibody alirocumab vs placebo in 1254 patients 5772
with heterozygous familial hypercholesterolaemia (HeFH): analyses up to 78 weeks from four
ODYSSEY trials.
14:15 Everolimus-eluting stents versus bare-metal stents in ST-segment elevation myocardial infarction. 5773
Five-year results of the EXAMINATION trial.
– M. Sabate Tenas (Barcelona, ES)
14:30 Incidence of new onset diabetes in the IMPROVE-IT trial: does adding ezetimibe to simvastatin 5774
increase risk compared to simvastatin alone?
– M. Blazing (Durham, US)
14:45 Effect of age and gender on efficacy and tolerability of beta-blockers in heart failure: an individual 5775
patient meta-analysis from the beta-blockers in heart failure collaborative group.
– D. Kotecha (Birmingham, UK)
15:00 Adenylate cyclase type 6 gene transfer for clinical congestive heart failure. 5776
– H.K. Hammond (La Jolla, US)
15:15 Five-year follow-up in a randomised comparison of catheter ablation and antiarrhythmic drug 5777
therapy as first-line treatment in paroxysmal atrial fibrillation.
– J.C. Nielsen (Aarhus N, DK)

ESC REGISTRIES Special Session
Organised by EURObservational Research Programme
Chairperson(s): R. Ferrari (Cona, IT); F.J. Pinto (Lisbon, PT)
14:00 Introduction and presentation of EurObservational Research Programme (EORP). 5778
14:10 Presentation of the main results of the 1-year outcome of the Long Term Heart Failure registry. 5779
– M.G. Crespo-Leiro (La Coruña, ES)
14:30 Presentation of the main results of the pilot phase of the Cardiomyopathy registry. 5780
14:45 Presentation of the main results of the pilot phase of the Chronic Ischemic Cardiovascular 5781
Disease.
15:00 Cardiac Oncology Toxicity Registry in Breast Cancer patient: rationale, study design, and 5782
methodology (EACVI/HFA COT registry).
15:10 Main results of the European Lead Extraction ConTRolled Registry (ELECTRa). 5783
356

DEEP DIVE INTO PERCUTANEOUS VALVULAR INTERVENTION Rapid Fire Abstract
Chairperson(s): H.I. Ragy (Cairo, EG); M. Haude (Neuss, DE)
14:00 Percutaneous annuloplasty for mitral valve repair: multicentre trial report. 5784
– A. Vahanian, G. Nickenig, A. Colombo, O. Alfieri, S. Baldus, K.H. Kuck, F. Maisano (Paris, FR; Bonn,
Cologne and Hamburg, DE; Milan, IT; Zurich, CH)
14:09 Predictors of left ventricular reverse remodeling and outcome in heart failure patients with severe 5785
mitral regurgitation treated with the MitraClip.
– M.J. Claeys, J. Bartunek, B. Paelinck, P. Debonnaire, G. Saad, D. De Bock, M. Penicka, P. Coussement,
C. Van De Heyning, M. Vanderheyden (Antwerp, Aalst, Brugge and Liège, BE)
14:18 Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing 5786
transcatheter aortic valve implantation. A subanalysis of the SOURCE XT prospective multicentre
registry.
– G. Tarantini, M. Mojoli, F. Saia, T. Lefevre, T. Walther, S. Windecker, O. Wendler, M. Napodano,
A. Vahanian, I. Merioua (Padua and Bologna, IT; Massy and Paris, FR; Bad Nauheim, DE; Berne and Nyon,
CH; London, UK)
14:27 Mitraclip therapy in the setting of advanced heart failure with severe functional mitral 5787
regurgitation: pre-operative evaluation and implications in patients selection.
– D. Stolfo, A. De Luca, G. Morea, E. Fabris, M. Merlo, G. Vitrella, B. Pinamonti, A. Salvi, G. Sinagra (Trieste,
IT)
14:36 Mortality in transfemoral transcatheter aortic valve implantation: impact of ejection fraction. 5788
– G.M. Stachel, N. Mangner, F.J. Woitek, R. Hoellriegel, S. Haussig, F. Schlotter, D. Holzhey, F.W. Mohr,
G.C. Schuler, A. Linke (Leipzig, DE)
14:45 Geometry of the aortoventricular annulus as a predictor of pacemaker implantation following 5789
– M.B. Barkagan, Y. Topilsky, A. Steinvil, G. Aviram, A. Finkelstein, S. Banai, G. Keren, H. Shmilovich (Tel
Aviv, IL)
14:54 5-years outcomes after transcatheter aortic valve implantation with the CoreValve prosthesis. 5790
– E. Munoz-Garcia, M. Munoz-Garcia, A.J. Munoz Garcia, M.F. Jimenez-Navarro, A.J. Dominguez-Franco,
ES)
15:03 Transfemoral aortic valve implantation of edwards sapien 3 without predilatation. 5791
– W. Kim, F. Praz, J. Blumenstein, C. Liebetrau, L. Gaede, T. Walther, H. Nef, C. Hamm, S. Windecker,
H. Moellmann (Bad Nauheim and Giessen, DE; Berne, CH)
15:12 Alterations of the platelet pool in the early period after transcatheter aortic valve implantation or 5792
surgical valve replacement in patients with aortic stenosis.
– C. Stratz, T. Nuhrenberg, F. Pawlitschek, S. Leggewie, H.J. Buettner, M. Siepe, C. Keyl, F.J. Neumann,
D. Trenk (Bad Krozingen, DE)
15:21 First-in-human complete filter-based cerebral embolic protection with transcatheter aortic valve 5793
implantation.
– L. Van Gils, M.E.I. Schipper, P.P.T. De Jaegere, N.M. Van Mieghem (Rotterdam, NL)

NOTHING IS AS IT SEEMS IN INTERVENTIONAL CARDIOLOGY Clinical Cases
Chairperson(s): F. Romeo (Rome, IT); I. Nunez-Gil (Madrid, ES)
14:00 Management of a patient with preserved ejection fraction heart failure with an interatrial shunt 5794
device. TUESDAY – AFTERNOON
– T.F. Pasley (Auckland, NZ)
14:12 An unusual cause of right heart failure and syncope. 5795
– S.K. Vijay (Lucknow, IN)
14:25 Pulmonary valve perforation with coronary hardware, a definitive management for membranous 5796
pulmonary atresia and intact ventricular septum.
– P. Barwad (Chandigarh, IN)
14:38 A cardiac masquerade - an unusual myocardial infarction. 5797
– T. Moon (London, UK)
14:51 Kounis syndrome: a rare case of ST elevation acute myocardial infarction (STEMI) from 5798
anaphylactic reaction to bee sting complicated by thrombolysis with streptokinase.
– D. Karthikesan (Alor Setar, MY)
15:04 Extrinsic compression of the left coronary artery by neoplastic tissue: a case report. 5799
– F. Fiorelli (Pisa, IT)
15:17 Unblocking the unknown - a journey through a hidden, anomalous and occluded left anterior 5800
descending artery of a 23 years old male with acute anterior ST elevation myocardial infarction.
– M. Mokbel (Bucharest, RO)
357

ECHO-IMAGING PREDICTORS OF CARDIOVASCULAR OUTCOME Rapid Fire Abstract
Chairperson(s): R.E. Dulgheru (Liège, BE); K.K. Poh (Singapore, SG)
14:00 Mechanics and prognostic value of left and right ventricular dysfunction in patients with systemic 5801
sclerosis.
– M. Saito, L. Wright, K. Negishi, N. Dwyer, T. Marwick (Hobart, AU)
14:09 Long-term prognostic value of the Doppler derived ejection intraventricular pressure gradient in 5802
patients with dilated cardiomyopathy.
– A. Gonzalez-Mansilla, R. Yotti, C. Perez Del Villar, Y. Benito, P. Martinez-Legazpi, A. Barrio, R. Prieto,
T. Mombiela, F. Fernandez-Aviles, J. Bermejo (Madrid, ES)
14:18 Echocardiographic deformation analysis for the prediction of atrial fibrillation and stroke 5803
development after ST-elevation myocardial infarction treated with primary percutaneous coronary
intervention.
– F.J. Olsen, S. Haahr-Pedersen, J.S. Jensen, T. Biering-Sorensen (Hellerup, DK)
14:27 Diastolic dysfunction and adverse diastolic remodelling as predictors of infarct scar and 5804
cardiovascular events following acute myocardial infarction.
– T.L. Nguyen, J. Phan, J. Hogan, L. Hee, C. Juergens, R. Rajaratnam, H. Dimitri, J. French, D. Richards,
L. Thomas (Liverpool and Sydney, AU)
14:36 Reversible abnormal right ventricular function at follow-up is associated with better survival in 5805
patients with chronic systolic heart failure.
– A. Simioniuc, M.C. Scali, L. Gargani, C. Cucco, E. Carluccio, S. Ghio, A. Rossi, P.L. Temporelli, F.L. Dini,
M. Marzilli (Pisa, Perugia, Pavia, Verona and Veruno, IT)
14:45 Novel echocardiographic and clinical score predicts 3-year mortality in coronary care unit 5806
patients.
– P. Gaba, N. Naksuk, C. Thongprayoon, V. Herasevich, C. Bruce, S. Kapa, S. Asirvatham (Rochester, US)
14:54 Left ventricular contractile reserve as a new prognostic factor in systemic sclerosis patients? 5807
– C. Cadeddu Dessalvi, S. Palmas, G. Giau, M. Deidda, R. Piras, A.M. Settembrini, F. Nonne, M.N. Mura,
P.E. Manconi, G. Mercuro (Monserrato, IT)
15:03 Better prognostic values of longitudinal strain of sub-epicardial myocardium in hypertension. 5808
– W.-C. Tsai, W.-H. Lee, Y.-W. Liu, L.-T. Yang (Tainan, TW)
15:12 Predictive value of local prolonged electro-mechanical interval by echocardiography in the 5809
concealed stage of arrhythmogenic right ventricular dysplasia/cardiomyopathy.
– A.J. Teske, T.P. Mast, J.F. Van Der Heijden, P. Loh, M.J. Cramer, P.A. Doevendans, R.N. Hauer (Utrecht,
NL)
15:21 Right ventricular function assessed by 2D longitudinal strain independently predicts mortality in 5810
chronic heart failure patients.
– G. Citarelli, M. Iacoviello, V. Antoncecchi, F. Monitillo, M. Leone, A. Doronzo, C. Rizzo, M.S. Lattarulo,
A. Puzzovivo, M.M. Ciccone (Bari and Pordenone, IT)
358

HOT TOPICS ON STEMI Rapid Fire Abstract
Chairperson(s): E. Omerovic (Gothenburg, SE); A. MacIsaac (Melbourne, AU)
14:00 Comparison of hospital variation in acute myocardial infarction care and outcome between 5811 (W)
Sweden and the United Kingdom. (withdrawn)
– S.-C. Chung, J. Sundstrom, C.P. Gale, S. James, J. Deanfield, L. Wallentin, A. Timmis, T. Jernberg,
H. Hemingway (London and Leeds, UK; Uppsala and Stockholm, SE)
14:09 Impact of oral beta-blocker therapy on long-term mortality in ST-segment elevation myocardial 5812 (W)
infarction with preserved systolic fraction: a meta-analysis of observational studies. (withdrawn)
– N. Misumida, Y. Kanei (New York, US)
14:18 Impact of acute infarct-related artery patency before PCI on 30 day outcomes in patients with 5813
ST-segment elevation myocardial infarction treated with primary PCI in the EUROMAX trial.
– D. Dudek, T. Rakowski, A.W. Van’t Hof, J. Ten Berg, L. Soulat, U. Zeymer, F. Lapostolle, D. Bernstein,
E.N. Deliargyris, P.G. Steg (Krakow, PL; Zwolle and Nieuwegein, NL; Chateauroux and Paris, FR;
Ludwigshafen am Rhein, DE; Parsippany, US)
14:27 In-hospital prognosis of eltderly patients undergoing primary angioplasty: results of a national 5814
multicenter registry.
– I. Cruz, H. Pereira, H. Pereira, R. Cale, R. Cale, B. Stuart, B. Stuart, D. Caldeira, D. Caldeira, G. Morgado,
G. Morgado, C. Gomes, C. Gomes, C. Martins, C. Martins, H. Vinhas, H. Vinhas (Almada, PT)
14:36 Effect of pre-hospital ticagrelor in STEMI patients in the first 24 hours after primary PCI: The 5815 (W)
ATLANTIC-H24 analysis. (withdrawn)
– G. Montalescot, A.W. Van ’T Hof, L. Bolognese, W.J. Cantor, J.-P. Collet, K. Huber, M. Janzon,
F. Lapostolle, U. Zeymer, C.W. Hamm (Paris and Bobigny, FR; Zwolle, NL; Arezzo, IT; Newmarket, CA;
Vienna, AT; Linköping, SE; Ludwigshafen am Rhein and Bad Nauheim, DE)
14:45 Nyctohemeral variations in hour of STEMI onset in relation with time to first call. The e-MUST 5816
registry.
– H. Lefort, Y. Lambert, A. Loyeau, J.Y. Letarnec, F.X. Laborne, G. Le Bail, S. Bataille, N. Danchin (Paris,
Versailles, Melun, Corbeil-Essonnes and Garches, FR)
14:54 Culprit vessel versus multivessel intervention at the time of primary percutaneous coronary 5817
intervention for patients with multivessel disease: insights from the British Columbia Cardiac
Registry.
– M.B. Iqbal, I.J. Nadra, D. Ayers, A. Fung, E. Aymong, A.W. Chan, S. Hodge, A. Della Siega, S.D. Robinson
(Victoria, Vancouver and Kelowna, CA)
15:03 ST-segment elevation myocardial infarctions in younger patients: is there a specific risk profile? 5818
– A. Fach, L. Mata Marin, S. Buenger, H. Wienbergen, E. Fiehn, S. Seide, J. Schmucker, R. Hambrecht
(Bremen, DE)
15:12 In-hospital outcome in octogenarians with acute coronary syndrome undergoing invasive 5819
coronary procedures.
– B. Ricci, E. Cenko, Z. Vasiljevic, M. Dorobantu, D. Trninic, B. Knezevic, D. Milicic, O. Manfrini, L. Badimon,
R. Bugiardini (Bologna, IT; Belgrade, RS; Bucharest, RO; Banja Luka, BA; Podgorica, ME; Zagreb, HR;
Barcelona, ES)
15:21 Impact in the prognosis of the utilization of thrombectomy devices in primary angioplasty in 5820
patients with ST-elevation acute myocardial infarction.
– B. Picarra, A.R. Santos, A.F. Damasio, D. Neves, J. Carvalho, J. Aguiar (Évora and Lisbon, PT)
14:00–15:30 | Rabat - Village 1

NEXT-GENERATION CARDIOVASCULAR PHENOTYPING FOR OMIC DISCOVERY Meet the Experts
TUESDAY – AFTERNOON
Chairperson(s): A. Grace (Cambridge, UK); C. Macrae (Boston, US)
14:00 Next-generation cardiovascular phenotyping for OMIC discovery - Introduction to the session. 5821
– A. Grace (Cambridge, UK)
14:05 21st century phenotyping in population based research. 5822
14:15 21st century phenotyping in population based research - Panel discussion and questions from the 5823
audience.
– J.D. Pearson (London, UK), R.E. Collins (Oxford, UK), J. Schulz-Menger (Berlin, DE), H. Runz (Boston, US)
14:30 Phenomics in hospital based bio-banks. 5824
– H. Runz (Boston, US)
14:40 Phenomics in hospital based bio-banks - Panel discussion and questions from the audience. 5825
14:55 High precision phenotyping by cardiac MRI. 5826
– J. Schulz-Menger (Berlin, DE)
15:05 High precision phenotyping by cardiac MRI - Panel discussion and questions from the audience. 5827
15:20 Next-generation cardiovascular phenotyping for OMIC discovery - Take home message. 5828
– C. Macrae (Boston, US)
359

HARNESSING CYCLIC GMP SIGNALLING FOR CARDIOVASCULAR PROTECTION Meet the Experts
Chairperson(s): J. Bauersachs (Hannover, DE); C.S.P. Lam (Singapore, SG)
14:00 Harnessing cyclic GMP signaling for cardiovascular protection - Introduction to the session. 5829
14:05 New insight from sGC (GUCY1A3) deletion and apo-sGC mice. 5830
– P. Brouckaert (Ghent, BE)
14:15 New insights from sGC (GUCY1A3) deletion and apo-sGC mice - Panel discussion and questions 5831
from the audience.
– P. Brouckaert (Ghent, BE), J.L. Balligand (Brussels, BE), H. Schmidt (Maastricht, NL), K. Channon
(Oxford, UK), S. Janssens (Leuven, BE)
14:30 cGMP in cardiac remodelling. 5832
– J.L. Balligand (Brussels, BE)
14:40 cGMP in cardiac remodelling - Panel discussion and questions from the audience. 5833
14:55 Pharmacologic modulators. 5834
– H. Schmidt (Maastricht, NL)
15:05 Pharmacologic modulators - Panel discussion and questions from the audience. 5835
15:20 Harnessing cyclic GMP signaling for cardiovascular protection - Take home message. 5836
– C.S.P. Lam (Singapore, SG)

STROKE AND RISK IN ATRIAL FIBRILLATION: WHAT DO THE GUIDELINES SAY? Guidelines in Daily Practice
Chairperson(s): I.C. Van Gelder (Groningen, NL); A.J. Camm (London, UK)
14:00 My patient has a CHA2DS2-VASc score 1 - Do I have to anticoagulate? 5837
14:15 My patient has a CHA2DS2-VASc score 1 - Do I have to anticoagulate? What do the Guidelines 5838
say?
– I. Savelieva (London, UK)
14:30 My patient has a CHA2DS2-VASc score 1 - Do I have to anticoagulate? Panel discussion on how 5839
– C. Torp-Pedersen (Aalborg, DK), S. Goto (Isehara, JP)
14:40 My patient has a CHA2DS2-VASc score 1 - Do I have to anticoagulate? Conclusion and take home 5840
message.
– I.C. Van Gelder (Groningen, NL)
14:45 An ederly hypertensive patient with AF: how best to assess and balance risk of hemorrhage and 5841
stroke?
– A. Sarkozy (Edegem, BE)
stroke? What do the Guidelines say?
stroke? Panel discussion on how to implement the Guidelines.
– P. Kirchhof (Birmingham, UK), A.W. Hoes (Utrecht, NL)
stroke? Conclusion and take home message.
360

VASCULAR REMODELLING IN AGEING AND DISEASE Advances in Science
Chairperson(s): N. Smart (Oxford, UK); G. Vilahur Garcia (Barcelona, ES)
14:00 State of the Art in vascular remodelling in ageing and disease. 5845
– J. Hall (Minneapolis, US)
14:20 Insulin receptor substrate 2 (IRS2) overexpression in vascular smooth muscle cells (VSMC) blunts 5846
neointima formation in mice.
– A. Markl, N. Blank, K. Krysztofiak, E. Berghausen, M. Vantler, S. Rosenkranz (Ingolstadt and Cologne, DE)
14:37 Hnrnpa1 is a critical regulator in vascular smooth muscle cell functions and neointima 5847
hyperplasia.
– Q. Chen, G. Wen, Y. Huang, L. Luong, J. Zhu, L. Zhang, Q. Xiao (Hangzhou, CN; London, UK)
14:54 Selective inhibition of the histone lysine methyltransferase G9a preserves differentiation and 5848
inhibits calcification in vascular smooth muscle cells.
– F. Kahles, J. Marx, A. Makowska, M. Lehrke, N. Marx, H.M. Findeisen (Aachen and Münster, DE)
15:11 Future direction for research in vascular remodelling in ageing and disease. 5849
– M.R. Bennett (Cambridge, UK)

IMPORTANT DRUG INTERACTIONS: WHAT THE CARDIOLOGIST SHOULD KNOW Symposium
Chairperson(s): K.P. Kjeldsen (Copenhagen, DK); L.M. Ruilope (Madrid, ES)
14:00 Magnitude of the problem. 5850
– M.A. Alonso Garcia (London, UK)
14:22 Heart failure polypharmacy. 5851
14:45 Antithrombotics and anticoagulants. 5852
– S. Wassmann (Munich, DE)
15:07 Statins. 5853
– H. Drexel (Feldkirch, AT)

MANAGEMENT AND RISK STRATIFICATION OF ASYMPTOMATIC PATIENTS WITH INHERITED Symposium
ARRHYTHMIC SYNDROMES
Chairperson(s): D. Corrado (Padua, IT); J. Brugada Terradellas (Barcelona, ES)
14:00 Long QT syndrome. 5854
14:22 Brugada syndrome. 5855
– V. Probst (Nantes, FR)
– H. Bundgaard (Copenhagen, DK)
15:07 Asymptomatic patient with ARVC. 5857
– T. Wichter (Osnabrück, DE)

ATRIAL FIBRILLATION AND HEART FAILURE – CHICKEN OR THE EGG? Case-based Symposium
Chairperson(s): R. Schilling (London, UK); J.L. Lopez-Sendon (Madrid, ES)
14:00 Patient with recent onset of heart failure and atrial fibrillation. 5858
– C. Tondo (Milan, IT)
14:15 Patient with recent onset of heart failure and atrial fibrillation - Panel discussion and questions 5859
from the audience.
– S. Ernst (London, UK), T.J.R. De Potter (Aalst, BE), C. Tondo (Milan, IT)
14:30 Patient with chronic heart failure and atrial fibrillation. 5860
14:45 Patient with chronic heart failure and atrial fibrillation - Panel discussion and questions from the 5861
audience.
– S. Ernst (London, UK), T.J.R. De Potter (Aalst, BE), L. Mont (Barcelona, ES)
15:00 How to manage atrial fibrillation in heart failure? State of the Art lecture. 5862
361

CARDIAC IMAGING IN DIASTOLIC DYSFUNCTION Symposium
Chairperson(s): F. Alpendurada (London, UK); J.-L. Vanoverschelde (Brussels, BE)
14:00 Diagnostic evaluation and prognosis by echo: less is more. 5863
– F. Flachskampf (Uppsala, SE)
14:22 Nuclear cardiology: a less known role. 5864
– A. Gimelli (Pisa, IT)
14:45 The added value of CMR: diagnosis and prognosis. 5865
– C. De Luigi (., CH)
15:07 Heart failure with preserved ejection fraction: the role of imaging. 5866
– Z. Vered (Zerifin, IL)

HOT TOPICS IN CAROTID ARTERY DISEASE Symposium
Chairperson(s): M. Brodmann (Graz, AT); J. Lekakis (Haidari and Athens, GR)
14:00 Carotid intima-media thickness: end of the story? 5867
14:22 Should we screen asymptomatic carotid artery disease? 5868
– S. Kedev (Skopje, MK)
14:45 Asymptomatic carotid artery disease: who is at high risk? 5869
– S. Kownator (Thionville, FR)
15:07 Revascularisation in asymptomatic carotid artery stenosis: when and how? 5870
14:00–15:30 | Oslo - Village 6

2015 ESC GUIDELINES ON NSTE-ACS: IMPLEMENTATION IN DAILY PRACTICE Guidelines in Daily Practice
Chairperson(s): C.E. Mueller (Basel, CH); C. Patrono (Rome, IT)
14:00 2015 ESC guidelines on NSTE-ACS: implementation in daily practice - Introduction to the session. 5871
14:11 A case of NSTEMI at intermediate risk: when to transfer to a cath-lab center and how-long to 5872
monitor.
– M. Al Asnaj (Jeddah, SA)
monitor - What do the Guidelines say?
monitor - Panel discussion on how to implement the Guidelines.
– R.F. Storey (Sheffield, UK), M. Al Asnaj (Jeddah, SA)
14:45 A case of a NSTEMI patient scheduled for coronary angiography in two days: what about 5875
antiplatelet treatment?
antiplatelet treatment? - What do the Guidelines say?
– D. Chew (Adelaide, AU)
antiplatelet treatment? - Panel discussion on how to implement the Guidelines.
– F.J. Neumann (Bad Krozingen, DE), D. Chew (Adelaide, AU)
15:07 2015 ESC guidelines on NSTE-ACS: implementation in daily practice - Conclusion and take home 5878
message.
– C. Patrono (Rome, IT)

UNDERSTANDING THE FEMALE HEART Symposium
Chairperson(s): K. Schenck-Gustafsson (Stockholm, SE); P. Collins (London, UK)
14:00 Preeclampsia predicts future heart disease. 5879
– A.H.E.M. Maas (Nijmegen, NL)
14:22 Microvascular angina: from myth to reality. 5880
– J.C. Kaski (London, UK)
14:45 Non-obstructive coronary artery disease in women: mind the future. 5881
– E. Prescott (Copenhagen, DK)
15:07 Myocardial ageing in women: silent killer. 5882
362
14:00–15:30 | Tunis - Village 7

IMPROVING CARDIOPULMONARY RESUSCITATION Advances in Science
Chairperson(s): N. Nikolaou (Athens, GR); J. Poess (Lübeck, DE)
14:00 State of the Art in cardiopulmonary resuscitation. 5883
– M. Tubaro (Rome, IT)
14:20 FirstAED emergency dispatch, global positioning of first responders with distinct roles - a solution 5884
to reduce response times and ensuring early defibrillation on a bridge connected island area.
– F.L. Henriksen, H. Schakow, M.L. Larsen (Odense and Aalborg, DK)
14:37 Clinical comparison of off-hours versus regular hours extracorporeal cardiopulmonary 5885
resuscitation for cardiac arrest.
– T. Kawashima, H. Uehara, S. Chiba, K. Yamashita, C. Nago, K. Nakamura, N. Miyagi, M. Shimajiri,
T. Kuniyoshi, M. Isobe (Urasoe and Tokyo, JP)
14:54 Predictive value of neuron-specific enolase for clinical outcome in cardiac arrest survivors 5886
depends on the time of sample collection: results of a prospective study.
– D. Vondrakova, P. Ostadal, A. Kruger, M. Janotka, P. Neuzil (Prague, CZ)
15:11 Future direction for research on cardiopulmonary resuscitation. 5887

CHALLENGES IN THE TREATMENT OF MITRAL DISEASE Symposium
ESC and the American Heart Association
Chairperson(s): E.M. Antman (Boston, US); L.A. Pierard (Liège, BE)
14:00 Preoperative imaging: what the surgeon needs to know. 5888
– J.-L. Monin (Créteil, FR)
14:22 When to repair, replace or leave alone? 5889
– T.J. Gardner (Newark, US)
14:45 Functional MR: a cardiologists perspective. 5890
– R. Bonow (Chicago, US)
15:07 ESC and AHA/ACC Guidelines: a critical appraisal. 5891
– J.J. Bax (Leiden, NL)

COMPLEX ENDOCARDITIS Case-based Symposium
Chairperson(s): R.J.C. Hall (Holt, UK); C. Muneretto (Brescia, IT)
14:00 An endocarditis with neurologic complication. 5892
14:15 An endocarditis with neurologic complication - Panel discussion and questions from the 5893
audience.
– M. De Bonis (Milan, IT), J.F. Obadia (Lyon-Bron, FR), B.D. Prendergast (London, UK), P. Tornos Mas
(Barcelona, ES)
14:30 A recurrent endocarditis in a patient with 2 prosthetic valves? 5894
– J.F. Obadia (Lyon-Bron, FR)
14:45 A recurrent endocarditis in a patient with 2 prosthetic valves? - Panel discussion and questions 5895
from the audience.
– J.F. Obadia (Lyon-Bron, FR), B.D. Prendergast (London, UK), M. De Bonis (Milan, IT), P. Tornos Mas
(Barcelona, ES)
15:00 Complex endocarditis - State of the Art lecture. 5896
363

THE CHALLENGE OF INFLAMMATORY CARDIOMYOPATHIES Advances in Science
Chairperson(s): M. Böhm (Homburg, DE); A. Angelini (Padua, IT)
14:00 State of the Art in endomyocardial biopsy markers of inflammation and myocyte damage. 5897
– K. Klingel (Tübingen, DE)
14:20 High number of CD45RO positive cells in endomyocardial biopsies is associated with increased 5898
mortality of patients with Inflammatory Cardiomyopathy.
– D. Lassner, U. Kuhl, M. Rohde, F. Escher, C. Tschope, H.-P. Schultheiss (Berlin, DE)
14:37 T2 mapping increases diagnostic accuracy in patients with clinically suspected acute myocarditis 5899
- A prospective, endomyocardial biopsy controlled study.
– F. Boenner, M. Spieker, B. Stanske, S.M. Haberkorn, C. Jacoby, B. Schnackenburg, P. Reinecke,
M. Neizel-Wittke, M. Kelm, R. Westenfeld (Düsseldorf, DE; Best, NL)
14:54 Long-term arrhythmic prognosis in patients with biopsy-proven myocarditis, studied by cardiac 5900
magnetic resonance imaging and electroanatomic mapping.
– I. Coviello, M.L. Narducci, D. D’Amario, R. Mollo, I. Battipaglia, S. Bartoletti, G.L. Bencardino, F. Perna,
G. Pelargonio, F. Crea (Rome, IT)
15:11 Future direction for research in inflammatory cardiomyopathy. 5901
– U. Eriksson (Wetzikon, CH)
14:00–15:30 | Bern - Village 9

NON-CODING RNAS IN HEART FAILURE Advances in Science
Chairperson(s): G. Condorelli (Rozzano, IT); M. Mayr (London, UK)
14:00 State of the Art in non-coding RNAs. 5902
– T. Pedrazzini (Lausanne, CH)
14:20 A crucial role of miR-195 in pressure overload-mediated cardiac remodeling. 5903
– S. Wang, C. Yang, J. Jia, J. Wu, J. Yuan, G. Zhang, H. Gong, A. Sun, J. Ge, Y. Zou (Shanghai, CN)
14:37 Transcoronary gradient of circulating microRNAs in heart failure. 5904
– O. De Filippo, A. Rapacciuolo, C. Gareri, J. Sabatino, G. Maresca, A. Agresta, A. Curcio, C. Carella,
C. Indolfi, S. De Rosa (Naples and Catanzaro, IT)
14:54 MiR-21 and miR-133 levels in peripheral blood mononuclear cells in patients with heart failure 5905
with preserved ejection fraction.
– M. Marketou, J. Kontaraki, F. Parthenakis, E. Zacharis, H. Nakou, S. Maragkoudakis, K. Roufas, J. Logakis,
D. Vougia, P. Vardas (Heraklion, GR)
15:11 Future direction for research in non-coding RNAs. 5906
– T. Thum (Hannover, DE)

MYOCARDITIS Meet the Experts
Chairperson(s): D. Brito (Lisbon, PT); C. Tschoepe (Berlin, DE)
14:00 Myocarditis - Introduction to the session. 5907
– D. Brito (Lisbon, PT)
14:05 A case of difficult diagnosis. 5908
– A.L.P. Caforio (Padua, IT)
14:15 A case of difficult diagnosis - Panel discussion and questions from the audience. 5909
– A.L.P. Caforio (Padua, IT), C. Fonseca (Oeiras, PT), S.B. Felix (Greifswald, DE), T.A. McDonagh (London,
UK), C. Tschoepe (Berlin, DE)
14:30 A case of difficult therapy. 5910
– A. Frustaci (Rome, IT)
14:40 A case of difficult therapy - Panel discussion and questions from the audience. 5911
– A. Frustaci (Rome, IT), C. Fonseca (Oeiras, PT), S.B. Felix (Greifswald, DE), T.A. McDonagh (London, UK),
C. Tschoepe (Berlin, DE)
14:55 Myocarditis - State of the Art lecture. 5912
– S. Heymans (Maastricht, NL)
15:25 Myocarditis - Take home message. 5913
364

NEW INSIGHTS IN DEVICE THERAPY Rapid Fire Abstract
Chairperson(s): R. Hatala (Bratislava, SK); B. Merkely (Budapest, HU)
14:00 Feasibility, safety, and acute hemodynamic effect of a new approach for anti-bradycardia pacing: 5914
left ventricular septum pacing by transvenous approach through the inter-ventricular septum.
– M. Mafi Rad, Y. Blaauw, J.G.L.M. Luermans, H.J. Crijns, F.W. Prinzen, K. Vernooy (Maastricht, NL)
14:09 Exercise detection with 3-Axis accelerometer of a total intracardiac leadless pacemaker. 5915
– G.Z. Duray, Z.S. Bari, A. Sztaniszlav, T. Sheldon, P. Ritter, D.W. Reynolds (Budapest, HU; Mounds View
and Oklahoma City, US; Bordeaux, FR)
14:18 Right ventricular lead placement in a pacemaker population: comparison of apical and septal 5916
positions. The right pace study.
– G.L. Botto, G. Maglia, V. Calvi, D. Pecora, R. Calvanese, L.M. Zuccaro, M. Racheli, A. Costa, S. Valsecchi,
C. Muto (Como, Catanzaro, Catania, Brescia, Naples, Rome, Negrar-Verona, Milan and Nola, IT)
14:27 Minimized ventricular pacing delays first onset of AF in pacemaker patients without AF history. 5917
– P. Defaye, S. Boveda, J. Moreno, G. Macaluso, G. Jauvert, M. Burban, J. Noack, E. Garcia Campo,
P.H. Siot, M. Stockburger (Grenoble, Toulouse, Marseille, Paris, Nantes and Clamart, FR; Madrid and Vigo,
ES; Hamburg and Berlin, DE)
14:36 Are DDD/AAI mode switch algorithms worthwhile to prevent unnecessary right ventricular pacing 5918
in sick sinus rhythm patients? Results from a randomized cross-over study.
– E.C.L. Pisano’, V. Calvi, M. Brieda, V. Giudici, D. Orsida, A. Del Rosso, B. Marenna, L. Caccamo, A. Lo
Presti, A. Capucci (Lecce, Catania, Pordenone, Seriate, Gallarate, Empoli, Biella, Rimini, Venice and
Ancona, IT)
14:45 Outcome of epicardial pacing in neonates with isolated congenital complete atrioventricular 5919
block. A bicentric study.
– D. Rahim, C. Marquie, A. Maltret, N. Costedoat-Chalumeau, L. Wissocque, F. Brigadeau,
L. Guedon-Moreau, S. Kacet, D. Klug (Lille and Paris, FR)
14:54 Pacemaker implantation using ultrasound guided axillary vein puncture compared to conventional 5920
techniques.
– S. Hassan, N. Newall, D. Rittoo (Wirral, UK)
15:03 Feasibility and safety of concurrent atrioventricular junctional ablation in patients undergoing a 5921
transcatheter pacemaker implantation: a single-center experience.
– T. Okabe, R. Augostini, R. Weiss, J. Tyler, M. Houmsse, E.G. Daoud, S.J. Kalbfleisch, J.D. Hummel
(Columbus, US)
15:12 Cardiac implantable devices: an invaluable tool for the diagnosis of sleep apnea. 5922
– J.M. Portugues, S. Ribeiro, V. Sanfins, L. Moreira, A. Alves, B. Rodrigues, M.J. Guimaraes, C. Duraes,
D. Ferreira, A. Lourenco (Guimaraes and Braga, PT)
15:21 Persistence of left bundle branch block within periinterventional pacemaker implantation after 5923
– A.C. Geisler, M. Seiffert, N. Gosau, L. Conradi, H. Treede, S. Willems, H. Reichenspurner, B. Hoffmann,
S. Blankenberg, U. Schaefer (Hamburg, DE)
365
their research within 3 minutes and then address questions
from the Chairpersons and Audience.

VENTRICULAR ARRHYTHMIAS: STRATIFICATION AND TREATMENT Moderated Posters
Chairperson(s): L. Szumowski (Warsaw, PL); D. Osmonov (Bishkek, KG)
15:30 Real World Experience with Wearable Cardiac Defibrillators. P5924
– W.J. Hucker, J.S. Leyton-Mange, N. Mihatov, W.R. Reynolds, C.M. Albert, S.A. Lubitz, D.J. Milan (Boston,
US)
15:38 Lack of an additional prognostic value of programmed electrical stimulation for risk stratification P5925
in Brugada patients without previous cardiac arrest: J-IVFS study.
– M. Takagi, Y. Sekiguchi, Y. Yokoyama, N. Aihara, M. Hiraoka, K. Aonuma (Osaka, Tsukuba, Tokyo, Suita
and Toride, JP)
15:47 Critical progressive activation delay after premature stimulation is associated with polymorphic P5926
ventricular tachycardia in nonischemic cardiomyopathy: results from the Leiden NICM Study.
– J. Venlet, S.R.D. Piers, S.F.A. Askar, G.F.L. Kapel, M. De Riva Silva, H.M. Siebelink, M.J. Schalij,
D. Pijnappels, K. Zeppenfeld (Leiden, NL)
15:55 PainFree SST trial: T-wave oversensing algorithm performance. P5927
– M. Brown, A. Auricchio, E.J. Schloss, T. Kurita, A. Meijer, L.D. Sterns, B. Gerritse, K.A. Ellenbogen (Mounds
View, Cincinnati and Richmond, US; Lugano, CH; Osaka, JP; Eindhoven and Maastricht, NL; Victoria, CA)
16:04 Arrhythmia treatment and survival of patients wearing the cardioverter defibrillator vest. P5928
– V. Johnson, R. Chasan, C. Veltmann, D. Duncker, M. Arnold, J. Sperzel, D. Erkapic, C.W. Hamm,
J. Schmitt (Giessen, Hannover, Erlangen and Bad Nauheim, DE)
16:12 Prevalence and significance of electroanatomical and ultrastructural abnormalities in patients P5929
with Brugada syndrome.
– S. Grotti, M. Pieroni, P. Notarstefano, R. Guida, T. Rio, A. Camporeale, A. Fraticelli, A. Oliva, L. Bolognese
(Arezzo and Rome, IT)
16:21 Reproducibility of repetitive T-wave alternans measurements in the EUTrigTreat study. P5930
– B. Vandenberk, C. Rover, M. Vos, T. Friede, P. Flevari, M. Zabel, R. Willems (Leuven, BE; Göttingen, DE;
Utrecht, NL; Athens, GR)

REPERFUSION OF STEMI Moderated Posters
Chairperson(s): R.M. Mathew (Cochin, IN); V. Velchev (Sofia, BG)
15:30 Cardiogenic shock in elderly patients with acute myocardial infarction. The FAST-MI programme. P5931
– N. Aissaoui, E. Puymirat, Y. Juilliere, S. Cattan, F. Schiele, J. Ferrieres, T. Simon, N. Danchin (Paris, Nancy,
Le Raincy-Montfermeil, Besançon and Toulouse, FR)
15:38 Reperfusion in elderly patients with acute ST-elevation myocardial infarction: results from the P5932
RENAU-RESURCOR STEMI network.
– J. Turk, M. Fourny, G. Debaty, J. Labarere, M. Rata, K. Yayehd, A. Ispas, G. Deschanel, M. Latappy,
L. Belle (Chambery, Grenoble and Annecy, FR; Lomé, TG)
15:47 Management of young STEMI patient with mono truncular coronary artery occlusion based on P5933
minimum intravascular material implantation and guided by optical coherence tomography.
– N.C. Combaret, N.B.C. Barber-Chamoux, G.S. Souteyrand, G.M. Malcles, R.T. Tresorier, P.M. Motreff
(Clermont-Ferrand, FR)
15:55 Prognostic significance of the culprit vessel in patients with ST-segment elevation myocardial P5934
infarction treated with primary coronary intervention.
– A. Janosi, D. Simkovits, A. Poth, A. Zorandi, P. Ofner (Budapest, HU)
16:04 Benefit of thrombaspiration for patients admitted with ST-elevation myocardial infarctions on P5935
post-interventional coronary flow, extension of myocardial infarction and mortality.
– J. Schmucker, A. Fach, H. Wienbergen, R. Zabrocki, L. Mata Marin, S. Buenger, E. Fiehn, R. Hambrecht
(Bremen, DE)
16:12 Circadian variation of intracoronary thrombus aspiration efficacy in patients with ST-segment P5936
elevation myocardial infarction undergoing primary percutaneous coronary intervention.
– S. Fournier, S. Hugelshofer, S. Degrauwe, P. Marques-Vidal, D. Radovanovic, P. Erne, E. Eeckhout,
O. Muller, J.F. Iglesias (Lausanne, Zurich and Lucerne, CH)
16:21 Association of changes in patients’ characteristics and management with decreasing mortality P5937
rates of men and women with STEMI in Poland from 2005 to 2011.
– L. Zandecki, M. Sadowski, M. Janion, M. Gierlotka, L. Polonski (Kielce and Zabrze, PL)
366

NEW TECHNIQUES AND NEW APPLICATIONS IN ECHOCARDIOGRAPHY Moderated Posters
Chairperson(s): S. Ben Youssef Zouari (Sfax, TN); A. Varga (Szeged, HU)
15:30 A new 2D semi-quantitative echocardiographic tool to detect myocardial scar. P5938
– L. Albertini, P. Faggiano, G. Faden, M. Bianconcini, N. Marziliano, C. Siniscalchi, C. Reverberi, I. Parrini,
M.R. Conte, N. Gaibazzi (Parma, Brescia and Turin, IT)
15:38 Blood-flow propagation in LA by Doppler echocardiography depend on elevation of LA pressure. P5939
– T. Ariyoshi, Y. Wada, S. Okuda, W. Murakami, M. Takeki, A. Fujii, K. Hirayama, N. Tanaka, M. Yano (Ube,
JP)
15:47 Echocardiographic predictors of postoperative atrial fibrillation after high-risk abdominal surgery. P5940
– L. Demirevska, D. Gotchev, I. Daskalov (Sofia, BG)
15:55 Effect of afterload increase on left ventricle mechanical dispersion and electromechanical P5941
window.
– O. Mirea, C. Vallecilla, P. Haemers, J. D’hooge, F.E. Rademakers, P. Claus (Leuven, BE)
16:04 Validation of 2D strain parameters in the diagnosis of acute rejection after heart trasplantation. P5942
– J. Goirigolzarri Artaza, S. Mingo Santos, V. Monivas Palomero, D. Jimenez Sanchez, B. Rivero Arribas,
E. Rodriguez Gonzalez, A. Restrepo Cordoba, M. Gomez Bueno, J. Segovia Cubero (Madrid, ES)
16:12 Right atrial volume - a surrogate marker for estimating right atrial pressure. P5943
– S. Iancovici, A. Deaconu, D. Zamfir, I. Petre, O. Tautu, D. Zaharia, T. Constantinescu, C. Toma, M. Bogdan,
M. Dorobantu (Bucharest, RO)
16:21 Detection of clinically stable myocardial ischaemic segments confirmed by invasive fractional P5944
flow reserve using resting 2D speckle tracking echocardiographic multi-layer strain: 13 months
follow up.
– T. Nishi, N. Funabashi, K. Ozawa, M. Takahara, H. Takaoka, Y. Fujimoto, Y. Kobayashi (Chiba, JP)

ION CHANNEL AND CARDIOMYOPATHY: THE NEGLECTED LINK Moderated Posters
Chairperson(s): L. Crotti (Pavia, IT); P.J. Schwartz (Milan, IT)
15:30 A missense mutation in the transcription factor TBX20 gene causes long QT syndrome. P5945
– A. Barana, M. Matamoros, I. Amoros, M. Perez-Hernandez, M. Nunez, D. Filgueiras-Rama, R. Caballero,
J.L. Lopez-Sendon, J. Tamargo, E. Delpon (Madrid, ES)
15:38 VEGF-B induces a unique electrophysiological phenotype in mouse heart. P5946
– J. Huusko, N. Naumenko, M. Merentie, E. Gurzeler, A. Laine, S. Yla-Herttuala, P. Tavi (Kuopio, FI)
15:47 Heart failure is associated with distinct remodelling of atrial repolarising K2P K+ channels in P5947
patients with atrial fibrillation.
– C. Schmidt, F. Wiedmann, X.B. Zhou, N. Voigt, S. Kallenberger, M. Karck, M. Borggrefe, D. Dobrev,
D. Thomas (Heidelberg, Mannheim and Essen, DE)
15:55 The Na+-Ca2+ exchanger mediates beta-adrenergic increase in heart rate in a beating whole P5948
heart mouse model with NCX overexpression.
– S. Kaese, N. Boegeholz, P. Pauls, D. Dechering, J. Olligs, K. Koelker, S. Badawi, G. Frommeyer, C. Pott,
L. Eckardt (Münster, DE)
16:04 Atrial arrhythmia susceptibilit and electrical remodelling with endurance training in a mouse P5949
model of arrhythmogenic right ventricular cardiomyopathy.
– F. Syeda, A.P. Holmes, E. Vloumidi, M. Kemper, S. Hopkins, T.J. Wright, T.Y. Yu, G.L. Riley, P. Kirchhof,
L. Fabritz (Birmingham, UK)
16:12 Evidence and role of the neuronal sodium channel Nav1.8 in the human failing heart. P5950
– N. Hartmann, N. Dybkova, S. Ahmad, T.H. Fischer, G. Hasenfuss, S. Sossalla (Göttingen, DE) TUESDAY – AFTERNOON
16:21 Inducible ventricular arrhythmias and structural heart disease can be identified by determination P5951
of heart rate turbulence in mice.
– F. Stoeckigt, M. Linhart, R. Andrie, T. Beiert, G. Nickenig, J.W. Schrickel (Bonn, DE)
367

DIFFERENTIATING PULMONARY ARTERIAL HYPERTENSION FROM OTHER PULMONARY Moderated Posters
HYPERTENSION GROUPS
Chairperson(s): G. Giannakoulas (Thessaloniki, GR); S. Rosenkranz (Cologne, DE)
15:30 Combined pre-and postcapillary pulmonary hypertension in chronic heart failure: epidemiology, P5952
right ventricular function and survival.
– M. Gerges, C. Gerges, A.M. Pistritto, M.B. Lang, P. Trip, J. Jakowitsch, T. Binder, I.M. Lang (Vienna, AT;
Catania, IT; Amsterdam, NL)
15:38 Venous remodelling in COPD pulmonary hypertension and idiopathic pulmonary arterial P5953
hypertension.
– K.H. Andersen, C.B. Andersen, F. Gustafsson, J. Carlsen (Copenhagen, DK)
15:47 Impact of atrial contraction on diagnosis of pre- versus post-capillary pulmonary hypertension. P5954
– J. Su, A. Charalampopoulos, U. Simonsen, S. Gibbs, L. Howard (Aarhus, DK; Sheffield and London, UK)
15:55 Differences in the relation between right ventricular function and exercise performance between P5955
pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
– M.B. Rehman, L.S. Howard, L.P. Christiaens, P. Nihoyannopoulos (London, UK; Poitiers, FR)
16:04 Prognostic value of pulmonary blood volume by contrast-enhanced magnetic resonance imaging P5956
in heart failure outpatients.
– F. Ricci, A. Barison, G. Todiere, A. Briatico Vangosa, R. Gaeta, S. Gallina, M. Emdin, R. De Caterina,
G.D. Aquaro (Chieti and Pisa, IT)
16:12 Hereditary pulmonary arterial hypertension related to TBX4 mutations: maybe a benign form of P5957
heritable PAH?
– P. Navas Tejedor, J. Tenorio, C.A. Quezada Loaiza, M. Lopez Meseguer, M.T. Velazquez Martin,
C. Jimenez Lopez Guarch, E. Barrios Garrido, J. Delgado Jimenez, P. Lapunzina Abadia, P. Escribano
Subias (Madrid and Barcelona, ES)
16:21 Novel strategy for catheter interventional treatment of chronic thromboembolic pulmonary P5958
hypertension guided by optical coherence tomography imaging.
– K. Sugimura, T. Aoki, M. Miura, S. Tatebe, N. Yaoita, H. Satoh, K. Satoh, H. Shimokawa (Sendai, JP)

WHAT’S NEXT IN CARDIOVASCULAR RISK PREDICTION? Moderated Posters
Chairperson(s): S.K. Malyutina (Novosibirsk, RU); Y.M.Smulders (Amsterdam, NL)
15:30 Coronary artery calcium (CAC) volume, CAC density, and incident coronary heart disease, stroke, P5959
and all cardiovascular disease events.
– M. Criqui, J.B. Knox, J.O. Denenberg, R.L. McClelland (San Diego and Seattle, US)
15:38 Coronary artery calcification improves risk estimation for coronary events in the general P5960
population with and without statin recommendation according to ESC and AHA/ACC primary
prevention guidelines.
– A.A. Mahabadi, S. Moehlenkamp, N. Lehmann, H. Kaelsch, I. Dykun, N. Pundt, S. Moebus, K.-H. Joeckel,
R. Erbel (Essen and Moers, DE)
15:47 Biomarker-based risk score for prediction of cardiovascular events in stable coronary heart P5961
disease - Experiences from the STABILITY biomarker substudy.
– L.C. Wallentin, J. Lindback, C. Held, C.B. Granger, W. Koenig, R.A.H. Stewart, E. Tarka, R.J. De Winter,
H.D. White, A. Siegbahn (Uppsala, SE; Durham and King of Prussia, US; Munich, DE; Auckland, NZ;
Amsterdam, NL)
15:55 Increase the predictive capacity of coronary risk with a Genetic Score. P5962
– A. Pereira, R. Palma Dos Reis, S. Gomes, R. Rodrigues, A.C. Sousa, A.I. Freitas, E. Henriques,
M. Rodrigues, D. Pereira, M.I. Mendonca (Funchal and Lisbon, PT)
16:04 Changes in the Framingham 10-year risk of cardiovascular disease and the European 10-year risk P5963
of fatal cardiovascular disease in a large untreated urban population.
– N. Mansencal, A. Beauchet, C. Karam, F. De Roquefeuil, C. Rodon, A. Bourez, O. Dubourg
(Boulogne-Billancourt and Nanterre, FR)
16:12 Additional value of a combined genetic score to Framingham risk score. P5964
– A. Pereira, M. Mendonca, S. Gomes, R. Rodrigues, A.C. Sousa, S. Freitas, A.I. Freitas, I. Ornelas,
D. Pereira, R. Palma Dos Reis (Funchal and Lisbon, PT)
16:21 Clinical Impact of Ankle Brachial Index in patients undergoing successful PCI. P5965
– S. Hiramori, Y. Soga, N. Kamioka, T. Miura, S. Shirai, K. Ando (Fukuoka and Matsumoto, JP)
368

ANTI-THROMBOTICS IN CLINICAL PRACTICE Moderated Posters
Chairperson(s): A.I. Fernandez Ortiz (Madrid, ES); D. Capodanno (Catania, IT)
15:30 Treatment with cilostazol reduces major amputation after endovascular therapy in hemodialysis P5966
patients with critical limb ischemia.
– D. Kamoi, H. Ishii, N. Umemoto, T. Sakakibara, T. Aoyama, H. Takahashi, Y. Kumada, T. Murohara
(Nagoya, Toyoake and Gifu, JP)
15:38 Initial experience with idarucizumab in dabigatran-treated patients requiring emergency surgery P5967
or interventon: interim results from the RE-VERSE AD study.
– J.H. Levy, P. Verhamme, F.W. Sellke, P.A. Reilly, R. Dubiel, J. Eikelboom, E. Hylek, J. Kreuzer, J.I. Weitz,
C. Pollack (Durham, Providence, Ridgefield, Boston and Philadelphia, US; Leuven, BE; Hamilton, CA;
Biberach, DE)
15:47 Long-term safety and efficacy of evolocumab in patients with statin intolerance. P5968
– L. Cho, R. Dent, E. Stroes, E.A. Stein, D. Sullivan, C.S. Djedjos, A. Xue, A. Pellacani, R. Rosenson
(Cleveland, Thousand Oaks, Cincinnati and New York, US; Amsterdam, NL; Camperdown, AU)
15:55 The effects of optimal medical therapy on coronary plaque. P5969
– M. Miyagi, T. Mitsui, K. Nomoto, M. Kokubo, A. Shimizu, H. Ishii, T. Murohara, K. Toba (Obu and Nagoya,
JP)
16:04 Medical compliance after acute myocardial infarction in the Netherlands. P5970
– D.C. Eindhoven, M.F. Dietz, D.E. Ikkersheim, M.J. Schalij, C.J.W. Borleffs (Leiden and Amstelveen, NL)
16:12 Fixed-dose (10 mg and 5 mg) versus phenotype-based prasugrel dose to match therapeutic zone P5971
with acute coronary syndrome: the A-MATCH trial.
– Y.H. Jeong, O.J.H. Oh, S.E.S. Shin, Y.H.J. Yoon, S.J. Suh, L.K.H. Lee, L.S.H. Lee, K.J.H. Kim (Jinju,
Changwon, Ulsan, Daegu, Bucheon, Incheon, Cheonan and Yangsan, KR)
16:21 Management of oral anticoagulation in patients undergoing cardiac catheterization. P5972
– C. Hammerstingl, S. Glueck, H. Omran (Bonn and Munich, DE)

MANAGEMENT IN HEART FAILURE: NEW PERSPECTIVES Moderated Posters
Chairperson(s): E. Piotrowicz (Warsaw, PL); F. Oliva (Milan, IT)
15:30 A long-term prognosis of adaptive servo ventilation therapy for patients with heart failure P5973
regardless of the severity of sleep-disordered breathing.
– K. Goto, N. Takama, S. Kasama, R. Funada, H. Sano, Y. Matsuo, M. Sato, M. Obokata, H. Hasegawa,
M. Kurabayashi (Maebashi, JP)
15:38 Influence of angina and revascularization in patients with left ventricular systolic dysfunction and P5974
coronary artery disease: insights from the STICH trial.
– M.E. Jolicoeur, A. Dunning, S. Castelvecchio, R. Dabrowski, M.C. Petrie, P.S. Jhund, J.A. Panza, B. Sun,
R.S. Tan, J.F.G. Cleland (Montreal, CA; Durham, New York and Minneapolis, US; Milan, IT; Warsaw, PL;
Glasgow and London, UK; Singapore, SG)
15:47 Adherence to treatment guidelines and its association with clinical outcomes in chronic heart P5975
failure patients.
– S. Takahashi, K. Shimamoto (Tokyo, JP)
15:55 Clinical outcomes and benefit of ambulatory pulmonary artery pressure monitoring in heart failure P5976
patients according to initial pulmonary artery diastolic pressure.
– A.S. Desai, J. Bauman, W.T. Abraham, P. Adamson, M.R. Costanzo, J.T. Heywood, L.W. Stevenson
(Boston, Atlanta, Columbus, Oklahoma City, Naperville and La Jolla, US)
16:04 The effect of disease management on health-related quality of life and depression symptoms in P5977 TUESDAY – AFTERNOON
patients with heart failure: A randomized controlled trial.
– O. Kalter-Leibovici, D. Freimark, M. Benderly, H. Murad, L. Freedman, A. Ziv, N. Friedman, G. Kaufman,
H. Silber (Ramat Gan, Tel Aviv and Kfar-Saba, IL)
16:12 Obesity is associated with increased risk of heart failure in patients with coronary artery disease. P5978
– A. Azimi, C. Torp-Pedersen, G. Gislason, P. Hansen, L. Koeber, H. Tilsed Hansen, J. Ravkilde, J. Lassen,
L. Jensen, M. Charlot (Aalborg, Hellerup, Copenhagen, Aarhus and Odense, DK)
16:21 Heart failure disease management program and the six months readmission rate. P5979
– S. Tatari, N. Shasha, A. Adhami, R. Osman, A. El-Sayed, H. Tamim, S. Kabbani (Beirut, LB)
369

TREATMENT OF HYPERCHOLESTEROLEMIA. A VISION TO THE FUTURE Moderated Posters
Chairperson(s): A. Badawi (New Cairo City, EG); S. Kale (Pune, IN)
15:30 Sustained treatment effect of alirocumab on Lp(a): pooled analyses from 4,915 patients in ten P5980
phase 3 trials in the ODYSSEY program.
– D. Gaudet, G.F. Watts, J. Robinson, D. Thompson, W. Sasiela, J. Edelberg, M. Louie, F. Raal (Montreal,
CA; Perth, AU; Iowa City, Tarrytown and Bridgewater, US; Johannesburg, ZA)
15:38 Futility of supplementation with Coenzyme Q10 for statin-induced myopathy: an updated (2015) P5981
meta-analysis of randomized controlled trials.
– M. Banach, C. Serban, A. Sahebkar, J. Rysz, P. Muntner, P.P. Toth, S.R. Jones, S.P. Glasser, G.Y.H. Lip,
D.P. Mikhailidis (Lodz, PL; Timisoara, RO; Mashhad, IR; Birmingham, Chicago and Baltimore, US;
Birmingham and London, UK)
15:47 Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on cholesterol P5982
efflux from macrophages in dyslipidemic patients.
– S. Yamashita, S. Ishibashi, H. Arai, E. Araki, K. Yokote, H. Suganami, T. Kodama (Osaka, Tochigi, Obu,
Kumamoto, Chiba and Tokyo, JP)
15:55 K-877, a selective PPAR alpha modulator (SPPARM alpha), ameliorates dyslipidaemia in patients P5983
with well-controlled LDL Cholesterol levels on statin therapy, without increases in serum
creatinine.
– J.J.P. Kastelein, Y. Senko, N. Hounslow, G.K. Hovingh, H.N. Ginsberg (Amsterdam, NL; Wokingham, UK;
New York, US)
16:04 Relationship of body weight and dosing of Evolocumab (EVO) for the treatment of P5984
– E. Mahlof, M. Koren, M. Emery, S. Doshi, T. Liu, R. Somaratne, S. Wasserman, L. Sperling (Atlanta,
Jacksonville and Thousand Oaks, US)
16:12 K-877, a selective PPAR alpha modulator (SPPARM alpha), improves dyslipidaemia in P5985
statin-treated patients with type 2 diabetes mellitus.
– J.J.P. Kastelein, Y. Senko, N. Hounslow, T. Nojima, H. Suganami, G.K. Hovingh, H.N. Ginsberg
(Amsterdam, NL; Wokingham, UK; Tokyo, JP; New York, US)
16:21 Impaired acetylsalicylic acid antiplatelet effects caused by dipyrone (metamizole) comedication P5986
can be prevented by order of intake.
– A. Polzin, V. Erschoff, S. Richter, K. Schror, T. Rassaf, M. Kelm, T. Hohlfeld, T. Zeus (Düsseldorf, DE)

MEET THE GUIDELINES TASK FORCE III – INFECTIVE ENDOCARDITIS & PERICARDIAL Special Session
DISEASES
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); S. Agewall (Oslo, NO)
15:40 Infective endocarditis. 5987
– G. Habib (Marseille, FR), P. Lancellotti (Liège, BE)
15:59 Infective endocarditis - Panel discussion. 5988
– M.J. Antunes (Coimbra, PT), P.A. Erba (Pisa, IT), B. Iung (Paris, FR), U. Snygg-Martin (Gothenburg, SE),
P. Tornos Mas (Barcelona, ES)
16:00 Pericardial diseases. 5989
– Y. Adler (Rannana, IL), P. Charron (Paris, FR)
16:19 Pericardial diseases - Panel discussion. 5990
– L. Badano (Padua, IT), M. Imazio (Turin, IT), B. Maisch (Marburg, DE), B.M. Mayosi (Cape Town, ZA),
A.D. Ristic (Belgrade, RS)

MEET THE TRIALIST VI: PLATFORM Meet the Trialists
Chairperson(s): To be announced
15:40 Outcomes of an FFRCT diagnostic strategy versus usual care in suspected coronary artery 5991
disease: results from the PLATFORM (Prospective LongitudinAl Trial of FFRCT: Outcome and
Resource IMpacts) study.
– P.S. Douglas (Durham, US)

MEET THE TRIALIST V: OPTILINK HF Meet the Trialists
Chairperson(s): K. Swedberg (Gothenburg, SE)
15:40 Effect of implanted device-based impedance monitoring with telemedicine alerts on mortality and 5992
morbidity in heart failure: results from the OptiLink HF study.
370

SECONDARY PREVENTION OF ATHEROTHROMBOTIC EVENTS: Satellite Symposium - Experts on the Spot
TREAT THE PATIENT OR TREAT THE STENT?
Sponsored by MSD
Chairperson(s): G.M. De Ferrari (Pavia, IT)
15:45 Secondary Prevention of Atherothrombotic events: treat the patient or treat the stent? 5993

PCSK9 INHIBITION: AN IMPORTANT STEP FORWARD IN TREATING Satellite Symposium - Experts on the Spot
DYSLIPIDEMIA IN HIGH-RISK PATIENTS
Sponsored by Amgen
Chairperson(s): E. Stroes (Amsterdam, NL); K.K. Ray (London, UK)
15:45 PCSK9 inhibition: an important step forward in treating dyslipidemia in high-risk patients. 5994

HOT LINE VI – CORONARY ARTERY DISEASE Hot Line
Chairperson(s): A. de Paola (São Paulo, BR); K.A.A. Fox (Edinburgh, UK)
16:30 Outcomes of an FFRCT diagnostic strategy versus usual care in suspected coronary artery 5995
disease: results from the PLATFORM (Prospective LongitudinAl Trial of FFRCT: Outcome and
Resource IMpacts) study.
– P.S. Douglas (Durham, US)
16:40 PLATFORM: Discussant review. 5996
– To be announced
16:45 PLATFORM: Panel discussion. 5997
16:48 Everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting 5998
metallic stents in patients with acute myocardial infarction. Results of the ABSORB STEMI TROFI
II trial.
16:58 ABSORB STEMI TROFI II: Discussant review. 5999
17:03 ABSORB STEMI TROFI II: Panel discussion. 6000
17:06 ABSORB Japan: 12-month clinical and 13-month angiographic outcomes from a randomized trial 6001
evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting stent.
– T. Kimura (Kyoto, JP)
17:16 ABSORB: Discussant review. 6002
– S.D. Kristensen (Aarhus N, DK)
17:21 ABSORB: Panel discussion. 6003
17:24 Minimizing Adverse haemorrhagic events by TRansradial access site and systemic 6004
Implementation of angioX (MATRIX Antithrombin).
17:34 MATRIX: Discussant review. 6005
– T. Akasaka (Wakayama, JP)
17:39 MATRIX: Panel discussion. 6006
17:42 Prevention of remodeling of the ventricle after large STEMI.
– U. Zeymer (Ludwigshafen, DE)
6007
17:52 PRESERVATION I: Discussant review. 6008
17:57 PRESERVATION I: Panel discussion. 6009
371

ESC CARDIOLOGY QUIZ Special Session
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); J.L. Gutierrez-Chico (Berlin, DE)
ESC Cardiology Quiz. 6010
Supreme court. 6011
– F. Crea (Rome, IT), U. Rauch (Berlin, DE), P.P.T. De Jaegere (Rotterdam, NL)
Score keepers. 6012
– M.J. Jaguszewski (Berlin, DE), L.-C. Engel (Berlin, DE), C. Schwemmler (Berlin, DE)
Greek team. 6013
– C. Karvounis (Thessaloniki, GR), G. Sianos (Thessaloniki, GR), G. Giannakoulas (Thessaloniki, GR), A. Tzikas
(Thessaloniki, GR), D. Parcharidou (Thessaloniki, GR), V. Kamperidis (Thessaloniki, GR)
Brazilian team. 6014
– M.C. Moreira (Belo Horizonte, BR), A. Rassi Jr (Goiania, BR), W. Mathias Jr (São Paulo, BR),
F.M. Consolim-Colombo (São Paulo, BR), E.L. Figueiredo (Belo Horizonte, BR), C.L. Correia (Salvador, BR)
International team. 6015
– S. Matskeplishvili (Moscow, RU), S. Atar (Nahariya, IL), D. Djordjevic (Niska Banja, RS), M.B. Yilmaz (Sivas,
TR), C. Von Zur Muhlen (Freiburg, DE), T. Steen (Oslo, NO), R.A. Henderson (Nottingham, UK)
Participate in a contest between three renowned centres, competing in a series of questions and tests on
different topics in Cardiology. Actively looking for participation and interaction with the audience.
Education with a bit a fun!

PERCUTANEOUS VERSUS SURGICAL MANAGEMENT OF VALVULAR AORTIC STENOSIS: Rapid Fire Abstract
BOUNDARIES VERSUS OPPORTUNITIES
Chairperson(s): L. Torracca (Ancona, IT); M.A. Rosli (Kuala Lumpur, MY)
16:30 Improved outcomes following TAVI for aortic stenosis in low and intermediate risk vs. high risk 6016
patients: results from a multi-center Israeli TAVI registry.
– I. Barbash, A. Finkelstein, V. Guetta, A. Barsheshet, A. Halkin, A. Assali, Y. Ben Gal, H. Vaknin Assa,
A. Segev, R. Kornowski (Ramat Gan, Tel Aviv and Petah Tikva, IL)
16:39 The longterm outcome of patients after TAVI remains uninfluenced by pacemaker implantation in 6017
case of AV-block third degree.
– C. Marzahn, T. Schau, C. Koban, M. Seifert, M. Neuss, F. Hoelschermann, C. Butter (Bernau bei Berlin, DE)
16:48 Outcomes from surgical para-valvular leak repair versus percutaneous closure. 6018
– M. Hernandez-Enriquez, O. Gomez-Monterrosas, X. Freixa, D. Pereda, D. Fernandez-Rodriguez,
J.F. Encalada, S. Brugaletta, V. Martin-Yuste, M. Masotti, M. Sabate (Barcelona, ES)
16:57 An adapted ACEF score improves prediction of mid- and long-term mortality in patients 6019
undergoing TAVI.
– S. Obeid, J. Vontobel, M. Possner, F. Nietlispach, L. Hoffelner, T.F. Luescher, F.C. Tanner, E.W. Holy
(Zurich, CH)
17:06 Impact of right ventricular dysfunction on short- and long-term mortality following transcatheter 6020
– F. Praz, C.J. O’Sullivan, E. Spitzer, D. Heg, S. Stortecky, T. Pilgrim, C. Huber, B. Meier, S. Windecker,
P. Wenaweser (Berne and Zurich, CH)
17:15 Which is the optimal strategy for patients with severe aortic stenosis and intermediate-high risk 6021
profile? A multicenter propensity-score analysis in 991 consecutive patients.
– C. Muneretto, M. De Bonis, G. Bisleri, O. Alfieri, R. Di Bartolomeo, M. Rambaldini, J.P. Maureira,
F. Laborde, M. Tespili, T. Folliguet (Brescia, Milan, Bologna, Mantova and Seriate, IT; Nancy, Paris and
Vandoeuvre-lès-Nancy, FR)
17:24 Matched comparison of surgical aortic valve replacement versus transcatheter valve implantation 6022
in intermediate to low risk aortic stenosis patients.
– J. Castrodeza, I.J. Amat Santos, M. Blanco, J. Lopez, A. Di Stefano, J. Tobar, C. Cortes, A. Revilla,
I. Gomez, A. San Roman (Valladolid, ES)
17:33 Prognostic effect of permanent pacemaker implantation on mortality after transcatheter aortic 6023
valve replacement.
– J. Engborg, F. Olson, C. Riechel-Sarup, M.T. Lauritsen, O. Gerke, H. Mickley, N. Sandgaard, H. Nissen,
A.C.P. Diederichsen (Odense, DK)
17:42 Impact of small annulus on reverse remodeling of left ventricular hypertrophy and mid-term 6024
outcome following transcatheter aortic valve implantation compared with surgical aortic valve
replacement.
– N. Kamioka, S. Shirai, T. Arita (Kitakyushu and Fukuoka, JP)
17:51 High-sensitivity troponin and diagnosis of myocardial infarction after combined aortic valve 6025
replacement and coronary artery bypass grafting.
– T.K.M. Wang, R. Stewart, D.H. Choi, S. Harmos, G.D. Gamble, T. Ramanathan, H.D. White (Auckland, NZ)
372

GUT MICROBIOTA: NEW PLAYERS IN CARDIOVASCULAR MEDICINE Symposium
Chairperson(s): J. Wojta (Vienna, AT); O. Vedin (Uppsala, SE)
16:30 Gut microbiota in health and disease. 6026
– F. Karlsson (Gothenburg, SE)
16:52 Gut microbiota and obesity: a link to cardiovascular disease? 6027
– To be announced
17:15 The gut microbiome in diabetes: impact on atherosclerosis? 6028
– F.J. Tinahones (Málaga, ES)
17:37 Gut microbiota as a therapeutic target: what is the evidence? 6029
– S. Hazen (Cleveland, US)

TOUCHING THE VALVES: HAZARDOUS GAME Clinical Cases
Chairperson(s): O. Alfieri (Brescia, IT); E.A. Jankowska (Wroclaw, PL)
16:30 Loeffler’s endocarditis secondary to toxocarosis: a unique case of both left and right ventricle 6030
large vegetation.
– L. Filippetti (Nancy, FR)
16:42 Coronary artery and sinus of valsalva aneurysms in idiopathic hyperosinophilic syndrome. 6031
– E. Cambronero Cortinas (Albacete, ES)
16:55 Simultaneous tricuspid valve replacement and cesarean section in a complicated right sided 6032
infective endocarditis of an intravenous drug user gravida.
– A. Ahres (Budapest, HU)
17:08 TAVR embolisation: fishing for a solution. 6033
– M. Lazkani (Phoenix, US)
17:21 Intermittent opening of a mitral valve prosthesis, a rare cause of heart failure. 6034
– E. Pelissero (Ciriè, IT)
17:34 Primary right ventricular sarcoma with tricuspid valve extension - what to do without guidelines? 6035
– M. Tarusi (Targu Mures, RO)
17:47 A complicated trilogy: hypertrophic cardiomyopathy, atrial septal defect and persistent left 6036
superior vena cava together.
– U. Kocabas (Izmir, TR)
373

NOVEL INSIGHTS IS PATHOPHYSIOLOGY Rapid Fire Abstract
Chairperson(s): R.M. Christodorescu (Timisoara, RO); A. Di Lenarda (Trieste, IT)
16:30 Hypotension in patients with acute heart failure: Insights from RELAX-AHF. 6037
– R. Mentz, G.M. Felker, M. Metra, G. Cotter, B.A. Davison, G. Filippatos, P. Ponikowski, M. Qian,
A.A. Voors, J.R. Teerlink (Durham, New York and San Francisco, US; Brescia, IT; Athens, GR; Wroclaw, PL;
Groningen, NL)
16:39 Neutrophil-dependent cardiac post-infarct remodeling in mice is mainly mediated by 6038
myeloperoxidase.
– J. Konradi, M. Maass, A. Klinke, M. Mollenhauer, T. Rudolph, V. Rudolph, S. Baldus (Cologne, DE)
16:48 Circulating microRNAs in experimental model of heart failure with preserved ejection fraction: 6039
effects of high-intensity exercise training.
– A.M.O. Berre, G.J. Justo Da Silva, J.B.N. Moreira, V. Adams, U. Wisloff, N. Rolim (Trondheim, NO; Leipzig,
DE)
16:57 The association between platelet/lymphocyte ratio (PLR) and coronary artery disease severity in 6040
asymptomatic low ejection fraction patients.
– F.M. Ucar, B. Acar, E. Gucuk, M. Gul, O. Er, S. Aydogdu (Ankara, TR)
17:06 Gremlin-1 expression correlates with cardiac fibrosis and left ventricular dysfunction visualized by 6041
cardiac magnet resonance imaging in non-ischemic heart failure.
– K.A.L. Mueller, I.I. Mueller, S. Vollmer, R. Kandolf, M. Gawaz, T. Geisler, C. Zuern, P. Krumm, U. Kramer
(Tübingen, DE)
17:15 Biomarkers of heart failure in exhaled breath. 6042
– A.A. Bykova, P.H. Y.U. Kopylov, P. S.H. Chomahidze, L.K. Malinovskaya, M.V. Kuznetsova, V.B. Betelin,
A.L. Syrkin (Moscow, RU)
17:24 The novel cardiovascular biomarker secretoneurin predicts mortality and shock in critical ill 6043
patients with infections.
– H. Rosjo, M. Stridsberg, A.H. Ottesen, G. Christensen, V. Petilla, R. Linko, S. Karlsson, T. Varpula,
E. Ruokonen, T. Omland (Lorenskog and Oslo, NO; Uppsala, SE; Helsinki, Tampere and Kuopio, FI)
17:33 Myocardial fibrosis at cardiovascular magnetic resonance predicts left ventricular reverse 6044
remodelling.
– A. Barison, A. Ortalda, G. Todiere, I. Pescetelli, G. Mirizzi, G. Vergaro, G.D. Aquaro, P.G. Masci, C. Passino,
M. Emdin (Pisa, Milan and Chieti, IT)
17:42 Determinants of long-term outcomes in the extremely aged patients hospitalized for acute heart 6045
failure.
– S.H. Sung, D.L. Wang, H.M. Cheng, W.C. Yu, C.H. Chen (Taipei, TW)
17:51 Predictors of insulin resistance in chronic systolic heart failure. 6046
– L. Voronkov, M. Ilnytska, T. Gavrilenko, L. Yakushko, I. Shkurat (Kiev, UA)
16:30–18:00 | Rabat - Village 1

TRANSLATIONAL ASPECTS OF REMOTE ISCHAEMIC CONDITIONING Symposium
ESC and the International Society of Heart Research
Chairperson(s): P. Ferdinandy (Budapest, HU); D. Garcia-Dorado (Barcelona, ES)
16:30 Mechanisms of remote ischaemic conditioning. 6047
– G. Heusch (Essen, DE)
16:52 Are extracellular vesicles mediators of remote conditioning? 6048
– Z. Giricz (Budapest, HU)
17:15 Remote ischaemic conditioning in STEMI. 6049
– F. Prunier (Angers, FR)
17:37 Remote ischaemic conditioning in extracardiac organ injury. 6050

MECHANISMS OF THROMBOSIS Symposium
ESC and the European Association for the Study of Diabetes
Chairperson(s): J.L. Balligand (Brussels, BE); A.C. Newby (Bristol, UK)
16:30 The hyperglycemic memory as a novel therapeutic target. 6051
– J. Waltenberger (Münster, DE)
16:52 Cellular mechanisms involved in thrombus formation. 6052
– C. Dubois (Marseille, FR)
17:15 Molecular mechanisms of vascular dysfunction in type 2 diabetes. 6053
– F. Cosentino (Stockholm, SE)
17:37 Targeting endothelial metabolism to reduce tumour angiogenesis. 6054
– S. Schoors (Leuven, BE)
374

MODULATING CARDIAC HYPERTROPHY Advances in Science
Chairperson(s): A. Koller (Budapest, HU); J.L. Samuel (Paris, FR)
16:30 State of the Art in the control of cardiac hypertrophy. 6055
16:50 PMCA4 ablation in cardiac fibroblasts protects the heart from pathological hypertrophy. 6056
– R. Abouleisa, T.M.A. Mohamed, N. Stafford, M. Zi, S. Prehar, A. Maqsood, F. Baudoin, E.J. Cartwright,
L. Neyses, D. Oceandy (Manchester, UK)
17:07 Genetic ablation of the G-protein coupled receptor 99 (GPR99) increases pressure 6057
overload-induced hypertrophy in mice.
– A. Omede, M. Zi, S. Prehar, A. Maqsood, E. Cartwright, M. Mamas, D. Oceandy (Manchester, UK)
17:24 Urocortin-2 improves right ventricular function in pulmonary arterial hypertension. 6058
– R. Adao, D. Santos-Ribeiro, P. Mendes-Ferreira, C. Maia-Rocha, B.S. Alves, A.F. Leite-Moreira,
C. Bras-Silva (Porto, PT)
17:41 Future direction for research in the control of cardiac hypertrophy. 6059
– B. Crozatier (Chatenay-Malabry, FR)
16:30–18:00 | Kiev - Village 3

HYPERTENSION HIGHLIGHTS IN 2015 Symposium
ESC and the International Society of Hypertension
Chairperson(s): J.D. Pearson (London, UK); M. Volpe (Rome, IT)
16:30 Isoketols - The clue behind T cells and hypertension. 6060
– T.J. Guzik (Glasgow, UK)
16:45 Salt, macrophages and hypertension. 6061
– D. Mueller (Berlin, DE)
17:30 Hypertension - A systems medicine approach. 6062
– C. Delles (Glasgow, UK)
17:45 Hypertension: a forerunner of stroke and dementia. 6063
– A.M. Heagerty (Manchester, UK)

RENAL SYMPATHETIC DENERVATION Advances in Science
Chairperson(s): To be announced; T. Kahan (Stockholm, SE)
16:30 State of the Art in renal denervation. 6064
16:50 Long-term verification of functional and structural renal damage after renal sympathetic 6065
denervation.
– O. Doerr, C. Liebetrau, H. Moellmann, L. Gaede, C. Troidl, J. Wiebe, M. Renker, T. Bauer, C. Hamm, H. Nef
17:07 24 months follow up of the Luebeck and Erlangen RDN registry: RDN improves 24 h peripheral 6066
and central blood pressure as well as 24h-arterial stiffness.
– K.F. Franzen, K. Mortensen, T. Graf, J. Weil, R.M. Schmieder, C. Ott, M. Reppel (Lübeck, Erlangen and
Langsberg, DE)
17:24 Neuropeptide Y as an indicator of successful alterations in sympathetic nervous activity after 6067
renal sympathetic denervation. TUESDAY – AFTERNOON
– O. Doerr, S. Ewen, C. Liebetrau, H. Moellmann, D. Linz, M. Hohl, M. Böhm, C. Hamm, F. Mahfoud, H. Nef
(Giessen, Homburg and Bad Nauheim, DE)
17:41 Future direction for research in renal denervation. 6068
– M. Schlaich (Melbourne, AU)

CARDIAC ARRHYTHMOGENESIS: MECHANISMS, RISK ASSESSMENT AND GENETICS Symposium
Chairperson(s): S. Hatem (Paris, FR), D.O. Arnar (Reykjavik, IS)
16:30 Arrhythmogenic mechanisms: novel insights. 6069
– P.G.A. Volders (Maastricht, NL)
16:52 Genetic markers and sudden cardiac death. 6070
– C. Albert (Boston, US)
17:15 Diurnal variation and arrhythmogenesis. 6071
– V. Kutyifa (Rochester, US)
17:37 Pluripotent stem cells to study electrophysiology and drug response. 6072
– A. Moretti (Munich, DE)
375

TRANSLATIONAL ELECTROPHYSIOLOGY OF ATRIAL FIBRILLATION Advances in Science
Chairperson(s): S. Levy (Marseille, FR); G. Breithardt (Münster, DE)
16:30 State of the Art in pathophysiology in atrial fibrillation. 6073
– S. Nattel (Montreal, CA)
16:50 Serum YKL-40 as a novel marker of left atrial fibrosis assessed by delayed enhancement MRI in 6074
lone atrial fibrillation.
– U. Canpolat, K. Aytemir, H. Yorgun, T. Hazirolan, B. Evranos, L. Sahiner, E.B. Kaya, G. Kabakci, N. Ozer,
A. Oto (Ankara, TR)
17:07 Exercise-induced left atrial hypertension in patients with non-valvular atrial fibrillation: prevalence 6075
and impact on clinical outcome of cathter ablation.
– M. Sramko, V. Melenovsky, D. Wichterle, M. Clemens, P. Peichl, B. Aldhoon, R. Cihak, J. Kautzner (Prague,
CZ)
17:24 Both low and high resting heart rate is associated with an increased risk of incident atrial 6076
fibrillation.
– M.W. Skov, T.N. Bachmann, P.V. Rasmussen, A. Pietersen, C. Graff, L. Koeber, S. Haunsoe,
J.H. Svendsen, A.G. Holst, J.B. Nielsen (Copenhagen and Aalborg, DK)
17:41 Future direction for research in atrial fibrillation. 6077
– H.J.G.M. Crijns (Maastricht, NL)

DIFFICULT DIAGNOSIS AND MANAGEMENT OF INFECTIVE ENDOCARDITIS Case-based Symposium
Chairperson(s): B. Cosyns (Braine-l’Alleud, BE); A. Mahdhaoui (Sousse, TN)
16:30 A case of suspicion of prosthetic valvular endocarditis. 6078
– P.A. Erba (Pisa, IT)
16:45 A case of suspicion of prosthetic valvular endocarditis - Panel discussion and questions from the 6079
audience.
– P.A. Erba (Pisa, IT), U. Snygg-Martin (Gothenburg, SE), P. Lancellotti (Liège, BE)
17:00 A case of neurological complication in infective endocarditis. 6080
– U. Snygg-Martin (Gothenburg, SE)
17:15 A case of neurological complication in infective endocarditis - Panel discussion and questions 6081
from the audience.
– U. Snygg-Martin (Gothenburg, SE), P.A. Erba (Pisa, IT), P. Lancellotti (Liège, BE)
17:30 Difficult diagnosis and management of infective endocarditis - State of the Art lecture. 6082
– M.J. Antunes (Coimbra, PT)

ADVANCES IN SCIENCES: PERIPHERAL CIRCULATION Advances in Science
Chairperson(s): M. Brodmann (Graz, AT); K. Kim (Daegu, KR)
16:30 State of the Art in screening for silent PAD. 6083
– M. Criqui (La Jolla, US)
16:50 Defining the value of the toe-brachial index for normal, mild, moderate and severe PAD. 6084
– M. Matangi, C. Tobin, D. Armstrong, U. Jurt, D. Brouillard (Kingston, CA)
17:07 Burden of subclinical atherosclerosis assessed by carotid and femoral 3D vascular ultrasound: 6085
the PESA (Progression of Early Subclinical Atherosclerosis) study.
– B. Lopez-Melgar, L. Fernandez-Friera, B. Oliva, J.L. Penalvo, V. Martinez, B. Ibanez, A. Mocoroa,
A. Fernandez-Ortiz, L.J. Jimenez-Borreguero, V. Fuster (Madrid, ES)
17:24 Association of ankle brachial index, protein-energy wasting and inflammation status with 6086
cardiovascular mortality in patients on chronic hemodialysis.
– H. Ishii, D. Kamoi, T. Aoyama, N. Umemoto, T. Sakakibara, H. Takahashi, Y. Kumada, T. Murohara
(Nagoya, Toyoake and Kasamatsu, JP)
17:41 Future direction for research: is PAD only a vascular disease? 6087
– L. Mazzolai (Lausanne, CH)
376
16:30–18:00 | Oslo - Village 6

THE HEART TEAM LIVE ON STAGE Case-based Symposium
Chairperson(s): J. Fajadet (Toulouse, FR); P.H. Kolh (Liège, BE)
16:30 A case of coronary artery disease - PCI or CABG. 6088
– P. Agostoni (Utrecht, NL)
16:45 A case of coronary artery disease - PCI or CABG - Panel discussion and questions from the 6089
audience.
– J. Holfeld (Innsbruck, AT), H. Yoshino (Tokyo, JP)
17:00 A case of aortic valve stenosis - TAVI or aortic valve replacement. 6090
– A. Latib (Milan, IT)
17:15 A case of aortic valve stenosis - TAVI or aortic valve replacement - Panel discussion and 6091
– J. Holfeld (Innsbruck, AT), Y. Ozaki (Toyoake, JP)
17:30 Heart team, from inception to evolution - State of the Art lecture. 6092

REVERSIBLE CARDIOMYOPATHIES: WHAT WE KNOW AND WHAT WE DON’T Symposium
Chairperson(s): S. Pankuweit (Marburg, DE); A.L.P. Caforio (Padua, IT)
16:30 Tachycardia induced cardiomyopathy. 6093
16:52 Alcoholic cardiomyopathy. 6094
– P. Garcia-Pavia (Majadahonda, ES)
17:15 Peripartum cardiomyopathy. 6095
– D. Hilfiker-Kleiner (Hannover, DE)
17:37 Myocarditis. 6096

MYOCARDITIS TASK FORCE CRITERIA IN THE REAL WORLD Case-based Symposium
Chairperson(s): A. Keren (Jerusalem, IL); W.J. McKenna (London, UK)
16:30 A patient with myocardial infarction and normal coronary arteries. 6097
– A. Yilmaz (Münster, DE)
16:40 A patient with myocardial infarction and normal coronary arteries - Panel discussion and 6098
– A. Frustaci (Rome, IT), H.P. Schultheiss (Berlin, DE), A. Yilmaz (Münster, DE)
17:00 A patient presenting with dilated cardiomyopathy. 6099
– A. Frustaci (Rome, IT)
17:10 A patient presenting with dilated cardiomyopathy - Panel discussion and questions from the 6100
audience.
– A. Frustaci (Rome, IT), H.P. Schultheiss (Berlin, DE), A. Yilmaz (Münster, DE)
17:30 Myocarditis-bridging the gap from task force criteria to evidence-based therapy - State of the Art 6101
lecture.
– H.P. Schultheiss (Berlin, DE)
IMAGING MODALITIES FOR PULMONARY HYPERTENSION Advances in Science
Chairperson(s): M. Delcroix (Leuven, BE); J.S.R. Gibbs (London, UK)
16:30 State of the Art in MRI of the pulmonary circulation and right ventricle. 6102
– A. Vonk Noordegraaf (Amsterdam, NL)
16:50 A feasible method for non-invasive measurement of pulmonary vascular resistance in pulmonary 6103
arterial hypertension: combined use of transthoracic Doppler-echocardiography and cardiac
magnetic resonanc.
– C. Yan, Z. Xu, J. Jin, J. Lv, Q. Liu, Z. Zhu, K. Pang, Y. Shi, W. Fang, Y. Wang (Beijing, CN)
17:07 Atrial volume and function during exercise in chronic thromboembolic pulmonary hypertension. 6104
– F. Schnell, G. Claessen, A. La Gerche, P. Claus, J. Bogaert, M. Delcroix, F. Carre, H. Heidbuchel (Rennes,
FR; Leuven and Hasselt, BE; Melbourne, AU)
17:24 Association between endothelial function and micro-vascular remodeling measured by 6105
synchrotron radiation pulmonary micro-angiography in pulmonary arterial hypertension.
– C. Tokunaga, S. Fujii, S. Matsushita, K. Hyodo, H. Sakamoto, M. Matsubara, S. Aikawa, Y. Enomoto,
F. Sato, Y. Hiramatsu (Tsukuba, JP)
17:41 Future direction for research in pulmonary circulation imaging. 6106
– K.-F. Kreitner (Mainz, DE)
377

PALLIATION AND END OF LIFE CARE IN HEART FAILURE Symposium
Chairperson(s): J. Riley (London, UK); S.T. Toumanidis (Athens, GR)
16:30 Symptom management in severe ambulatory heart failure. 6107
16:52 Switching off ICDs: legal and practical issues. 6108
17:15 Psychosocial experiences in the context of life-threatening illness: how are these patients 6109
prepared?
– E. Lambrinou (Nicosia, CY)
17:37 End of life: what are the characteristics of the patients and who should care? 6110
– C.E. Angermann (Würzburg, DE)
378
TUESDAY 1 SEPTEMBER 2015 – AFTERNOON POSTERS

BEST POSTERS IN CATHETER ABLATION
Discussant: Best Posters in catheter ablation. P6111

– R. Herrera (Guatemala, GT)
The utility, efficacy and safety of a new rapid high-resolution mapping system in the catheter ablation of P6112
atrial and ventricular arrhythmias in humans.
– L. Mantziari, C. Butcher, A. Kontogeorgis, S. Panikker, K. Roy, V. Markides, T. Wong (London, UK)
Ablation of hemodynamically unstable VT with support of a microaxial pump, early experience. P6113
– T. Dietze, R. Paliege, H.M. Moeller, R. Gradaus, J. Neuzner (Kassel, DE)
The impact of NavX in pediatric arrhythmia ablation on safety, procedure duration and number of RF P6114
lesions. Is it a time to change approach?
– A. Baszko, K. Czyz, A. Lazniak, B. Sprada, A. Bartkowiak-Sniatkowska, W. Bobkowski (Poznan, PL)
Initial international multicenter human experience of a novel epicardial access tuohy needle embedded P6115
with a real time pressure/frequency monitoring to facilitate epicardial access.
– L. Di Biase, J.D. Burkhardt, V. Reddy, P. Neuzil, Z. Csanadi, C. Carbucicchio, A. Dello Russo, C. Tondo,
P. Jais, A. Natale (Austin and New York, US; Prague, CZ; Debrecen, HU; Milan, IT; Bordeaux, FR)
BEST POSTERS IN MEDICAL THERAPY OF STABLE CORONARY ARTERY DISEASE
Discussant: Best posters in medical therapy of stable coronary artery disease. P6116
Impact of long-acting nifedipine on coronary vascular function after drug-eluting stent implantation - The P6117
NOVEL study.
– R. Tsuburaya, J. Takahashi, E. Nozaki, M. Sugi, T. Hiramoto, S. Horiguchi, K. Inoue, T. Goto, A. Kato,
H. Shimokawa (Sendai, Morioka, Iwaki, Oosaki, Yokote, Ookawara and Yamagata, JP)
Atorvastatin downregulates in vivo the immediate-early response gene EGR1 in patients with acute P6118
coronary syndromes.
– C. Zara, A. Severino, D. Flego, S. Ucci, F. Trotta, D. Pedicino, A.F. Giglio, L.M. Biasucci, G. Liuzzo, F. Crea
(Rome, IT)
Differential benefit of statin in secondary prevention of acute myocardial infarction according to the level P6119
of triglyceride and high-density lipoprotein cholesterol.
– M.H. Jeong, K.H. Kim, Y. Ahn, C.J. Kim, M.C. Cho, Y.J. Kim (Gwangju, Seoul, Cheongju and Daegu, KR)
Achievement of dual LDL-C (<70 mg/dL) and hs-CRP (<2 mg/L) goals more frequent with addition of P6120
ezetimibe and associated with better outcomes in IMPROVE-IT.
– E.A. Bohula May, R.P. Giugliano, C.P. Cannon, S.A. Murphy, J. Zhou, M.A. Blazing, J.A. White,
A.M. Tershakovec, T.A. Musliner, E. Braunwald (Boston, Durham and Kenilworth, US)
BEST POSTERS IN ADVANCES IN ECHOCARDIOGRAPHY
Discussant: Best posters in advances in echocardiography. P6121

– G. Restrepo (Medellin, CO) TUESDAY – AFTERNOON
Quantification of longitudinal and radial motion of the right ventricle using 3D echocardiography: P6122
technical aspects and clinical relevance in heart transplant patients.
– A. Kovacs, Z. Toser, A. Assabiny, A. Kosztin, S. Braun, E. Nemeth, K. Racz, P. Takacs, B. Sax, B. Merkely
(Budapest, HU)
Right ventricular post systolic shortening using speckle-tracking echocardiography associated with P6123
prognosis in patients with pulmonary artery hypertension.
– K. Sakata, K. Matsushita, Y. Uesugi, A. Isaka, T. Minamishima, T. Satoh, H. Yoshino (Tokyo, JP)
The contribution of pressure recovery and three-dimensional imaging on echocardiographic evaluation of P6124
severe aortic stenosis for TAVI.
– W. Kong, E. Tay, J. Yip, T.C. Yeo, R. Wong, K.K. Poh (Singapore, SG)
Left atrial appendage thrombus in patients with atrial fibrillation before pulmonary vein isolation: P6125
discrepancy between tee and cardiac CT.
– M. Takano, M. Izumo, K. Minami, K. Yoneyama, K. Kida, K. Suzuki, T. Harada, Y. Akashi (Kawasaki, JP)
379
BEST POSTERS IN VASCULAR SIGNAL TRANSDUCTION
Discussant: Best posters in vascular signal transduction. P6126

– E. Lutgens (Amsterdam, NL)
Role of perivascular T cell dependent inflammation in the regulation of vascular dysfunction in human P6127
atherosclerosis.
– K. Urbanski, D. Ludew, G. Filip, M. Filip, R. Nosalski, A. Sagan, T. Mikolajczyk, B. Kapelak, T.J. Guzik
(Krakow, PL)
STAT3 in vascular smooth muscle cells protects aorta from dissection. P6128
– S. Hirakata, H. Aoki, M. Nishihara, S. Ohno, A. Furusho, N. Nishida, S. Ito, M. Hayashi, H. Tanaka,
High Density Lipoproteins exert pro-inflammatory effects on macrophages via passive cholesterol P6129
depletion and PKC-dependent NF-kB/STAT1 activation.
– M. Donners, E.P.C. Van Der Vorst, K. Theodorou, M.A. Hoeksema, P. Goossens, S.W. Tas, M. Van Eck,
K.-A. Rye, M.P.J. De Winther, E.A.L. Biessen (Maastricht, Amsterdam and Leiden, NL; Marseille, FR;
Sydney, AU)
Gp130 inhibitor reduces inflammation and reverses pulmonary arterial remodeling of P6130
monocrotaline-induced pulmonary arterial hypertension.
– Z.W. Huang, Z.H. Liu, Q. Luo, Z.H. Zhao, Q. Zhao, Y.G. Zheng, Q.Y. Xi (Beijing, CN)
BEST POSTERS IN RHEUMATIC HEART DISEASE
Discussant: Best posters in rheumatic heart disease. P6131

– M. Sobhy (Alexandria, EG)
Prevalence of rheumatic heart disease in north Madagascar: an echocardiographic screening. P6132

– C.M. Campanale, A. Nusca, S. Mega, S. Di Maria, F. Marullo, G. Mottini, M. Ciccozzi, G. Di Sciascio (Rome,
IT)
Prevalence of clinically silent and manifest rheumatic heart disease among children in Nepal. P6133
– N.R. Shrestha, R. Mahto, P. Karki, K. Gurung, M. Rothenbuehler, K. Agrawal, P. Urban, N. Pandey,
P. Jueni, T.M. Pilgrim (Biratnagar and Dharan, NP; Berne and Geneva, CH)
Echocardiographic screening for rheumatic heart disease using the WHF criteria among 16,329 P6134
asymptomatic school children from 4 sites in India.
– A. Saxena, S. Ramakrishnan, R. Thangjam, S. Kulkarni, A. Desai, A.K. Jaques E Costa, R. Sukhramwala
(New Delhi, Imphal, Mumbai and Goa, IN)
Echocardiographic screening among schoolchildren in Peru: prevalence of rheumatic heart disease P6135
according to different definitions and incidental findings.
– E. Spitzer, J. Mercado, F. Islas, M. Rothenbuehler, R. Kurmann, F. Zuercher, P. Kraehenmann, P. Juni,
P. Torres, T. Pilgrim (Berne, CH; Arequipa, PE; Madrid, ES)
BEST POSTERS IN CARDIOVASCULAR PREVENTION: INTERVENTIONS AND OUTCOMES
Discussant: Best posters in cardiovascular prevention: interventions and outcomes. P6136

– M. Volpe (Rome, IT)
Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: The Fushimi AF Registry. P6137
– Y. Yamashita, Y. Hamatani, M. Esato, Y. Chun, H. Itoh, M. Nishimura, H. Wada, K. Hasegawa, M. Abe,
M. Akao (Kyoto, JP)
Mortality in takotsubo syndrome is similar to mortality in myocardial infarction - a report from the P6138
SWEDEHEART registry.
– B. Redfors, R. Vedad, O. Angeras, T. Ramunddal, P. Peturrson, I. Haraldsson, C. Dworeck, J. Odenstedt,
P. Albertsson, E. Omerovic (Gothenburg, SE)
Effect of monitoring warfarin treatment of patients by single versus multiple physicians on time in P6139
therapeutic range (TTR) and treatment associated complications: Multicenter prospective cohort study.
– L. Dinc Asarcikli, O. Beton, T. Sen, E. Gucuk Ipek, H. Kafes, A. Temizhan, B. Yilmaz (Ankara, Kutahya,
Kayseri and Sivas, TR)
Predictive Value of the SAMe-TTR2R2 to predict quality of oral anticoagulation in atrial fibrillation: a P6140
prospective validation in the multicentre Spanish observational registry fantasiia.
– F. Marin, V. Roldan-Schilling, V. Bertomeu-Gonzalez, A. Cequier, J. Muniz, I. Roldan,
V. Bertomeu-Martinez, L. Badimon, G.Y.H. Lip, M. Anguita (Murcia, Alicante, Barcelona, A Coruña, Madrid
and Córdoba, ES; Birmingham, UK)
BEST POSTERS IN CIRCULATORY ASSIST AND OTHER
Discussant: Best posters in circulatory assist and other. P6141

– N. Kucher (Berne, CH)
Impact of preoperative pulmonary hypertension and right ventricular dysfunction on cardiorenal P6142
interaction after left ventricular assist device implantation.
– S. Keymel, S. Bueter, D. Saeed, U. Boeken, C. Heiss, A. Lichtenberg, M. Kelm, R. Westenfeld (Düsseldorf,
DE)
380
Is tricuspid annuloplasty really unnecessary at pulmonary endarterectomy for chronic thromboembolic P6143
pulmonary hypertension?
– K. Minatoya, H. Sasaki, H. Tanaka, T. Itonaga, Y. Seike, T. Oda, Y. Inoue, J. Kobayashi, H. Ogino (Osaka
and Tokyo, JP)
Dramatic improvements in the thrombotic burden and right heart hemodynamics with P6144
ultrasound-facilitated thrombolysis in patients with pulmonary embolism at high risk or intermediate-high
risk.
– C. Kaymaz, O. Akbal, S. Ozturk, F. Yilmaz, S. Turkday, N. Poci, A. Hakgor, M. Demirel, T. Aktemur,
N. Ozdemir (Istanbul, TR)
The efficacy and safety of novel hemostasis technique: ultrasound-guided thrombin injection with P6145
ballooning.
– H. Takimura, T. Muramatsu, R. Tsukahara, Y. Ito, T. Sakai, K. Hirano, M. Yamawaki, M. Araki,
N. Kobayashi, Y. Sakamoto (Yokohama, JP)
BEST POSTERS IN PROGNOSIS
Discussant: Best posters in prognosis. P6146

– C.E. Angermann (Würzburg, DE)
Impact of non-cardiac comorbidity on mortality and morbidity in a predominantly elderly heart failure P6147
population among different heart failure phenotypes.
– A. Iorio, M. Senni, S. Poli, E. Zambon, G. Barbati, G. Faganello, G. Sinagra, L. Tarantini, G. Cioffi, A. Di
Lenarda (Trieste, Bergamo, Belluno and Trento, IT)
Nocturnal desaturation: a predictor of outcome in heart failure with reduced ejection fraction. P6148
– B. Gellen, F. Canoui-Poitrine, L. Boyer, A. Le Thuaut, A. Covali-Noroc, J.L. Dubois-Rande, L. Hittinger,
S. Adnot, S. Bastuji-Garin, T. Damy (Créteil, FR)
Midregional pro-Adrenomedullin.Performance and risk stratification in patients with decompensated P6149
systolic heart failure.
– C. Morbach, A. Marx, M. Kaspar, G. Gueder, S. Brenner, D. Berliner, S. Stoerk, J. Vollert, G. Ertl,
C. Angermann (Würzburg, Hannover and Henningsdorf, DE)
BEST POSTERS IN HYPERTENSION TREATMENT
Discussant: Best posters in hypertension treatment. P6150

– R. Touyz (Glasgow, UK)
Circulating endothelial progenitor cells in patients with essential hypertension. P6151

– E. Karelkina, O. Irtyuga, V. Moroshkin, O. Moiseeva (St. Petersburg, RU)
TAK-085 is superior to eicosapentaenoic acid in ameliorating salt-sensitive hypertension in rats. P6152
– D. Sueta, H. Ogawa, S. Kim-Mitsuyama (Kumamoto, JP)
Amlodipine alone compared to amlodipine + acetylsalicylic acid on inflammation and endothelial damage P6153
markers in hypertensive patients.
– P. Maffioli, A.F.G. Cicero, D. Romano, A. D’Angelo, G. Derosa (Pavia and Bologna, IT)
381

NEW INSIGHTS IN ARRHYTHMIAS: MECHANISMS AND TREATMENT

The combined effects of ranolazine and low dose dronedarone on atrial vs. ventricular electrophysiology; P6154
a novel therapeutic hope?
– N. Hartmann, F. Mason, I. Braun, N. Voigt, T.H. Fischer, G. Hasenfuss, S. Sossalla (Göttingen and Essen,
DE)
Digoxin use is associated with higher mortality among patients with atrial fibrillation with and without P6155
heart failure: insights from the ARISTOTLE trial.
– R. Rordorf, G.M. De Ferrari, D. Wojdyla, R. De Caterina, L. Thomas, C.B. Granger, S. Leonardi,
J.H. Alexander, L. Wallentin, R.D. Lopes (Pavia and Chieti, IT; Durham, US; Uppsala, SE)
Effects of combination therapy with nifekalant and mexiletine on electrical storm. P6156
– S. Otuki, K. Hasegawa, H. Watanabe, N. Yagihara, K. Iijima, A. Sato, D. Izumi, H. Furushima, M. Chinushi,
T. Minamino (Niigata, JP)
The changing landscape of oral anti-arrhythmic prescriptions for atrial fibrillation in England: 1998-2014. P6157
– H.C. Patel, C. Hayward, K. Patel, S.D. Rosen, A.R. Lyon, C. Di Mario, S.Y. Ahsan (London, UK)
Effective suppression of atrial fibrillation by the antihistaminic agent antazoline: first experimental P6158
insights into a novel antiarrhythmic agent.
– G. Frommeyer, M. Schmidt, P. Milberg, L. Eckardt (Münster, DE)
Selective late sodium current inhibition abolishes torsades de pointes arrhythmias in the chronic P6159
atrioventricular block dog model by reducing repolarization and spatial dispersion of repolarization.
– A. Bossu, M.J.C. Houtman, V.M.F. Meijborg, R. Varkevisser, H.D.M. Beekman, J.M.T. De Bakker,
M.A.G. Van Der Heyden, S. Rajamani, L. Belardinelli, M.A. Vos (Utrecht and Amsterdam, NL; Foster City,
US)
Genetic analysis of desmosomal gene mutations in Han Chinese patients with ARVC. P6160
– D. Wang, X.J. Zhou, H.W. Chen, K.J. Cao, M.L. Chen, B. Yang (Nanjing, CN)
Genotype/phenotype relationship in a large cohort of long QT syndrome patients. P6161
– V. Probst, J.B. Gourraud, P. Mabo, D. Babuty, S. Bezieau, F. Sacher, S. Le Scouarnec, J.J. Schott, H. Le
Marec, F. Kyndt (Nantes, Rennes, Tours and Bordeaux-Pessac, FR)
Single nucleotide polymorphisms discriminates between symptomatic and asymptomatic LQTS2 patients: P6162
A DNA-based patient classification.
– A. Mehta, C.J.A. Ramachandra, M. Mura, L. Crotti, P.J. Schwartz, M. Gnecchi, W. Shim (Singapore, SG;
Pavia and Milan, IT)
Sustained QTc shortening by GS-6615 in patients with LQT3. P6163
– W. Zareba, S. Rosero, D. Zeng, A.J. Moss, J.P. Couderc, B. Layug, L. Belardinelli (Rochester and Foster
City, US)
Inflammation in ARVC: new pathophysiological insights. P6164
– E. Morel, R. Donate, D. Bauer, A. Mejat, P. Chevalier (Lyon, FR)
Genomewide expression profiling of micro-RNA in atrial fibrillation. P6165
– N. Cortez-Dias, M. Costa, R. Carvalho, A. Magalhaes, C. Calisto, X. Galego, J. Sousa, A. Nobre, F.J. Pinto,
F. Enguita (Lisbon, PT)
ARRHYTHMIAS AND CARDIOMYOPATHIES

Lamin A/C gene mutations underlie Arrhythmogenic Cardiomyopathy with atrio-ventricular block. P6166
– I. Rigato, E. Lazzarini, M. Cason, B. Bauce, E. Carturan, G. Thiene, C. Basso, K. Pilichou (Padua, IT)
Progression of cardiac arrhythmia in familial amyloidotic polyneuropathy, portuguese type, after liver P6167
transplant.
– M.J. Sousa, B. Brochado, I. Silveira, P. Rodrigues, M. Santos, S. Santos, J. Silveira, T. Coelho, H. Reis,
S. Torres (Porto, PT)
Characteristics of supra- and ventricular arrhythmias in 94 patients with genetically proven myotonic P6168
muscular dystrophy and no clinically overt cardiac dysfunction.
– P. Bienias, M. Ciurzynski, A. Lusakowska, Z. Rymarczyk, K. Irzyk, K. Kurnicka, B. Lichodziejewska,
A. Kostera-Pruszczyk, A. Kaminska, P. Pruszczyk (Warsaw, PL)
Phenotype-genotype correlation of Lamin (LMNA A/C) associated dilated cardiomyopathy. P6169
– T. Vaikhanskaya, L.N. Sivitskaya, N.G. Danilenko, T.V. Kurushka, I.V. Sidorenko, O.G. Davydenko (Minsk,
BY)
Cardiac magnetic resonance and arrhythmic risk stratification of cardiomyopathy associated with lamin P6170
A/C mutations: results from a 5 year study.
– G. Peretto, S. Sala, S. Benedetti, C. Di Resta, M. Ferrari, P. Della Bella (Milan, IT)
Cardiac hypertrophy is associated with mutations in SCN5A gene. P6171
– A.G. Shestak, S.L. Dzemeshkevich, E.V. Zaklyazminskaya (Moscow, RU)
Association of genetic variants with atrial fibrillation in Japanese individuals. P6172
– K. Kato, T. Fujimaki, M. Oguri, H. Horibe, M. Arai, T. Noda, S. Watanabe, T. Murohara, Y. Yamada (Nagoya,
Inabe, Tajimi, Gifu and Tsu, JP)
382
Transcriptional profile and functional analysis of aged atrial fibrillation. P6173

– Y. Yao, R. Bai, X. Du, J.Z. Dong, C.S. Ma (Beijing, CN)
Exercise-induced changes in Brugada ECG. P6174
– P. Carvalho, A. Previti, G.P. Varalda, L. Colombatti, R. Pozzi (Orbassano, IT)
Spatial reproducibility of complex fractionated atrial electrograms depending on the direction and P6175
configuration of bipolar electrodes: a patient specific in-silico left atrial modeling study.
– J.S. Song, M. Hwang, Y.S. Lee, J.K. Lee, C. Li, B. Jeoung, M.H. Lee, E.B. Shim, H.N. Pak (Seoul and
Chuncheon, KR)
PITX2 and atrial fibrillation: from palpitations to methylation. P6176
– R. Donate Puertas, S. Rome, E. Morel, J. Claude, P. Chevalier (Lyon, FR)
LED flash-induced termination of anatomical reentry in optogenetically modified transverse rat ventricular P6177
tissue slices.
– M. Watanabe, I. Feola, A.S. Teplenin, M.J. Schalij, K. Zeppenfeld, D.L. Ypey, A.A.F. De Vries,
D.A. Pijnappels (Leiden, NL)
ATRIAL FIBRILLATION: BASIC MECHANISMS
Increased cellular inflammation and chemotactic activity of epicardial adipose tissue in atrial fibrillation. P6178
– P. Haemers, W. Heggermont, P. Holemans, S. Hatem, R. Willems (Leuven, BE; Paris, FR)
Profibrotic and inflammatory atrial remodeling of zucker diabetic fatty rats is aggravated by rapid pacing. P6179
– A. Bukowska, R.K. Chilukoti, C. Wolke, U. Lendeckel, A. Goette (Magdeburg, Greifswald and Paderborn,
DE)
Inhibitions of late sodium current and calmodulin kinase II terminate atrial fibrillation induced by P6180
isoproterenol.
– L. Ren, S.H. Huang, Q.M. Yang, X.H. Wei, P.K. He, L. Wu (Beijing, CN)
Pro-inflammatory skewing of inflammatory to regulatory T lymphocyte ratio in atrial fibrillation. P6181
– I.E. Dumitriu, S. Dinkla, R. Mehta, G. Barkey, J.C. Kaski, A.J. Camm (London, UK)
Tissue expression levels of miRNAs associated with fibrosis in patients with paroxysmal and persistent P6182
– N.W.E. Van Den Berg, W.R. Berger, A. Jongejan, I. Van Der Made, A.H.G. Driessen, W.J. Van Boven,
Y.M. Pinto, J.R. De Groot (Amsterdam, NL)
Atrial fibrillation altered hepatic gene expression profiles in human and rat model. P6183
– N. Kanamori, T. Kato, T. Yaegashi, S. Usui, H. Furusho, S. Takashima, H. Murai, S. Kaneko, M. Takamura
(Kanazawa, JP)
Differential expression of microRNAs associated with electrical remodeling in left atrial tissue of patients P6184
with paroxysmal versus persistent atrial fibrillation.
– W. Berger, N.W.E. Van Den Berg, A. Jongejan, I. Van Der Made, A.H.G. Driessen, W.J. Van Boven,
Y. Pinto, J.R. De Groot (Amsterdam, NL)
Effect of idarucizumab on bleeding time associated with dabigatran in combination with antiplatelet P6185
agents aspirin, clopidogrel and ticagrelor in a rat tail bleeding model.
– J. Van Ryn, J. Schurer, A. Goss, M. Kink-Eiband (Biberach, DE; Ridgefield, US)
Exploration of the function of class I HDACs and class IIa HDACs in experimental atrial fibrillation. P6186
– D. Zhang, X. Hu, M. Wiersma, F. Hoogstra-Berends, M. Esteban, G. Deniz, S. Durdu, R. Akar, R. Henning,
B.J.J.M. Brundel (Groningen, NL; Guangzhou, CN; Ankara, TR)
Association of C34T AMP deaminase 1 gene polymorphism with permanent atrial fibrillation in patients P6187
with chronic heart failure.
– N. Farre, C. Enjuanes, J. Comin-Colet, S. Ruiz, P. Moliner-Borja, B.A. Perez, D. Bueno, D. Bas,
R. Olivero-Soldevila, B. Benito (Barcelona, ES)
Increased platelet toll- like receptor- 2 and 4 expression in atrial fibrillation. P6188
– K.M. Gurses, D. Kocyigit, M.U. Yalcin, H. Canpinar, B. Evranos, L. Tokgozoglu, M.A. Oto, D. Guc, N. Ozer,
Novel HSP-inducing compounds restoring cardiomyocyte function in atrial fibrillation.
– D. Van Marion, X. Hu, E. Lanters, M. Wiersma, F. Hoogstra-Berends, N. De Groot, R. Henning,
P6189
B.J.J.M. Brundel (Groningen and Rotterdam, NL)
ANTICOAGULATION AND ATRIAL FIBRILLATION I
Mediterranean diet does not affect anticoagulation quality in non-valvular atrial fibrillation. P6190
– D. Pastori, P. Pignatelli, T. Bucci, T. Vicario, G. Tanzilli, S. Bartimoccia, C. Nocella, R. Carnevale, F. Violi
(Rome, IT)
Economic analysis of rivaroxaban and vitamin K antagonists in cardioversion for atrial fibrilation in Spain. P6191
– F. Atienza Fernandez, R. Graefenhain De Codes, D. Rubio-Rodriguez, C. Rubio-Terres (Madrid and
Barcelona, ES)
Patient profile of oral anticoagulation (OAC) use in people with non-valvular atrial fibrillation (NVAF): P6192
Findings from REACT-AF 2 study in UK primary care data.
– H. Benhaddi, M. Johnson, A. Maguire, S.L. Collings, D. Evans, D. Budd (Rueil-Malmaison, FR; London, UK)
Similar performance of HASBLED, CHADS2 and CHA2DS2-VASc scores in bleeding risk prediction: do we P6193
need a bleeding score?
– D. Poli, E. Antonucci (Florence, IT)
CCP survey about management of thromboembolic events in atrial fibrillation prevention. P6194
– R. Asteggiano, M. Guenoun, G. Baron Esquivias, D. Richter (Turin, IT; Marseille, FR; Sevilla, ES; Athens, GR)
383
Effect of renal function on the cost-effectiveness of high-dose edoxaban compared to adjusted-dose P6195
warfarin for stroke prevention in non-valvular atrial fibrillation patients.
– E.S. Mearns, C.I. Coleman (Hartford and Storrs, US)
Validation of the SAMe-TT2R2 score in a nationwide, unselected population of nonvalvular atrial P6196
fibrillation patients on vitamin K antagonists.
– M. Ruiz Ortiz, V. Bertomeu, A. Cequier, F. Marin, M. Anguita (Córdoba, Alicante, Barcelona and Murcia, ES)
Clinical and demographic characteristics according to dosage among non-valvular atrial fibrillation P6197
patients newly initiated on novel oral anticoagulants.
– C. Masseria, I. Lin, J. Mardekian, M. Frean, H. Phatak, S. Kamble, Y. Ravee, Y. Abdulsattar, W. Petkun,
G.Y.H. Lip (New York, Waltham and Princeton, US; Birmingham, UK)
Guideline adherence to anticoagulation for atrial fibrillation: a study in indigenous and non-indigenous P6198
Australians.
– C.X. Wong, S.W. Lee, S. Gan, R. Mahajan, R.K. Pathak, A.G. Brooks, K.C. Roberts-Thomson, A. Brown,
D.H. Lau, P. Sanders (Adelaide, AU)
Inadequacy of oral anticoagulation is a crucial factor for development of dementia in patients with P6199
permanent atrial fibrillation.
– R. Petroni, M. Di Mauro, L. Pezzi, R. Magnano, A. Petroni, S. Romano, M. Penco (L’Aquila and Avezzano,
IT)
Hemostasis POC tests are affected by dabigatran, rivaroxaban and apixaban treatments in patients with P6200
– R. Paniccia, R. Marcucci, R. Priora, A. Alessandrello Liotta, D. Poli, G. Lembo, Y. Ahmed, C. Fanciullacci,
M. Pazzi, R. Abbate (Florence, IT)
Dabigatran and rivaroxaban have different risk factors for bleeding in atrial fibrillation patients. P6201
– M. Nishino, N. Okamoto, A. Tanaka, N. Mori, T. Yoshimura, N. Makino, Y. Egami, R. Shutta, J. Tanouchi
(Sakai and Osaka, JP)
ANTICOAGULATION AND ATRIAL FIBRILLATION II

Management of anticoagulation in patients with non-valvular atrial fibrillation in general practice in UK: P6202
Evolution and characteristics of patients not treated with antithrombotic therapy.
– L. Lacoin, E. Ridha, C. Lefevre, S. McGuigan, S. Ramagopalan, A. Jenkins, D. Evans, I. Minns, J. Halcox
(London, Tadworth and Swansea, UK; Paris, FR)
Safety and efficacy of the direct factor Xa inhibitor rivaroxaban for peri-procedural anticoagulation in P6203
catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
– M. Vamos, J. Erath, S.H. Hohnloser (Frankfurt am Main, DE)
Dabigatran plasma concentration measurement in patients with atrial fibrillation: is it helpful for choosing P6204
the optimal dose?
– A. Pipilis, S. Makrygiannis, G. Anagnostou, S. Kaliambakos, K. Papadopoulos, G. Tsakonas, M. Traki,
T. Kostelidou (Athens, GR)
Ability of bleeding risk scores for stratification of bleeding events in elderly patients with atrial fibrillation. P6205
– L. Fauchier, A. Banerjee, I. Lagrenade, N. Clementy, A. Bernard, D. Angoulvant, D. Babuty, G.Y.H. Lip
(Tours, FR; Birmingham, UK)
Differences in clinical outcome of patients with paroxysmal and sustained atrial fibrillation under oral P6206
anticoagulation therapy - results from the thrombEVAL study.
– J. Prochaska, T. Knoepfler, S. Gobel, K. Keller, M. Coldewey, C. Bickel, H. Ten Cate, T. Rostock,
T. Munzel, P.S. Wild (Mainz and Koblenz, DE; Maastricht, NL)
Direct acting oral anticoagulants are more effective than Vitamin-K-antagonists for the resolution of P6207
established left atrial thrombi in patients with atrial fibrillation.
– C. Hammerstingl, R. Schueler, G. Nickenig, M. Weber, M. Lambers (Bonn, DE)
Stroke and bleeding risk-associated use of antithrombotic therapies for stroke prevention in atrial P6208
fibrillation in routine clinical practice: the BALKAN-AF Survey.
– T.S. Potpara, G.A. Dan, E. Trendafilova, V. Paparisto, Z. Kusljugic, M.M. Polovina, R. Musetescu,
S. Manola, L.J. Music, G.Y.H. Lip (Belgrade, RS; Bucharest and Craiova, RO; Sofia, BG; Tirana, AL; Tuzla,
BA; Zagreb, HR; Podgorica, ME; Birmingham, UK)
Predictors of LAA thrombi in patients with atrial fibrillation and low CHA2DS2-VASc score. P6209
– S. Nedios, T. Seewoester, S. Koutalas, J. Kornej, S. Rolf, A. Arya, P. Sommer, D. Husser, G. Hindricks,
A. Bollmann (Leipzig, DE)
Treatment consistency across levels of baseline renal function with rivaroxaban compared with warfarin: P6210
insights from ROCKET AF.
– S.M. Lindner, C.B. Fordyce, A.S. Hellkamp, Y. Lokhnygina, J.P. Piccini, G. Breithardt, K.W. Mahaffey,
D.E. Singer, R.C. Becker, M.R. Patel (Durham, Stanford, Boston and Cincinnati, US; Münster, DE)
ANTICOAGULATION AND ATRIAL FIBRILLATION III

Early assessment of bleeding-related hospital readmissions among nonvalvular atrial fibrillation patients P6211
treated with the new oral anticoagulants using an electronic medical record database in the US.
– S. Deitelzweig, A. Bruno, J. Trocio, N. Tate, K. Gupta, J. Lin, M. Lingohr-Smith (New Orleans, Plainsboro,
New York and Green Brook, US)
Characteristics of patients initiating oral anticoagulant therapy for management of non-valvular atrial P6212
fibrillation (NVAF).
– C. Masseria, I. Lin, J. Mardekian, M. Frean, H. Phatak, S. Kamble, S. Unniachan, W. Petkun, Y. Abdulsattar,
G.Y.H. Lip (New York, Waltham and Princeton, US; Birmingham, UK)
384
Temporal trends in thromboembolism and bleeding in patients with non-valvular atrial fibrillation between P6213
1996 and 2011.
– P.W. Hansen, G. Gislason, C. Torp-Pedersen, C. Andersson (Copenhagen, Aalborg and Hellerup, DK)
Antithrombotic management in patients with atrial fibrillation undergoing stent implantation: what is the P6214
impact of the ESC guidelines adherence?
– L. Fauchier, Y. Ancedy, C. Lecoq, C. Saint Etienne, F. Ivanes, D. Babuty, D. Angoulvant, G.Y.H. Lip (Tours,
FR; Birmingham, UK)
Real-world bleeding risk among non-valvular atrial fibrillation (NVAF) patients prescribed apixaban, P6215
dabigatran, rivaroxaban and warfarin: analysis of electronic health records.
– I. Lin, C. Masseria, J. Mardekian, M. Frean, H. Phatak, S. Kamble, Y. Abdulsattar, W. Petkun, J. Menzin,
G.Y.H. Lip (Waltham, New York and Princeton, US; Birmingham, UK)
Real-life use of non-vitamin K antagonist oral anticoagulants in comparison with vitamin K antagonists P6216
for non-valvular atrial fibrillation: data from a prospective cohort.
– M. Giustozzi, M.C. Vedovati, F. Cianella, P. Verdecchia, M. Verso, S. Conti, E. Filippucci, E. Marchesini,
G. Agnelli, C. Becattini (Perugia, Assisi, Spoleto and Foligno, IT)
Real world comparison of major bleeding risk among non-valvular atrial fibrillation patients newly P6217
initiated on apixaban, dabigatran, rivaroxaban or warfarin.
– G.Y.H. Lip, X. Pan, S. Kamble, H. Kawabata, J. Mardekian, C. Masseria, A. Bruno, H. Phatak (Birmingham,
UK; Princeton and New York, US)
Higher amounts of heparin use with oral factor Xa-Inhibitor compared to oral vitamin K antagonist and P6218
thrombin-inhibitor during ablation procedure for atrial fibrillation.
– T. Kinoshita, T. Fujino, H. Koike, K. Kitahara, H. Yuzawa, T. Suzuki, H. Sato, S. Fukunaga, K. Kobayashi,
T. Ikeda (Tokyo, JP)
Management of anticoagulation in patients with non-valvular atrial fibrillation in general practice in UK: P6219
Evolution and characteristics of patients treated with antiplatelet therapy alone.
– E. Ridha, L. Lacoin, R. Donaldson, C. Lefevre, S. Ramagopalan, A. Jenkins, D. Evans, I. Minns, J. Halcox
(London, Tadworth and Swansea, UK; Paris, FR)
ANGINA PECTORIS STABLE I

Long-term cost-effectiveness of diagnostic tests for assessing stable chest pain. P6220
– C.A. Polanczyk, S.F. Stella, L.E.P. Rohde, E.G. Bertoldi (Porto Alegre and Pelotas, BR)
High-sensitive troponin T as a predictor of short-term outcome in coronary artery disease patients with P6221
glucose metabolism disorder, ARTEMIS study.
– S. Lepojarvi, O.-P. Piira, A.M. Kiviniemi, J. Miettinen, O. Ukkola, M.P. Tulppo, H.V. Huikuri, M.J. Junttila
(Oulu, FI)
Diagnostic significance of duration of myocardial early systolic lengthening in patients with stable P6222
– M. Minamisawa, J. Koyama, T. Miura, T. Saigusa, S. Ebisawa, H. Motoki, A. Okada, A. Izawa, U. Ikeda
(Matsumoto, JP)
High-frequency QRS analysis compared to conventional ST-segment analysis in a large series of patients P6223
with chest pain and normal ECG managed with the propensity score matching for cardiovascular risk.
– A. Conti, S. Bianchi, C. Grifoni, F. Trausi, S. Bigiarini, D. Lazzeretti, E. Angeli, A. Covelli, A.M. Lencioni,
R. Bonini (Massa-Carrara and Florence, IT)
Relationship between 24 hour pulse pressure dipping and cardiovascular risk assessment in patients with P6224
CHD.
– M. Wirtwein, D. Jarosz, E. Trybala, D. Jarosz, M. Gruchala, W. Sobiczewski (Gdansk and Chojnice, PL)
In-plaque microchannel volume as a quantitative surrogate marker of plaque vulnerability: study with 3D P6225
optical coherence tomography and color-coded intravascular ultrasound.
– T. Nishida, T. Hiro, T. Takayama, T. Kougo, K. Iida, M. Sudo, D. Fukamachi, Y. Okumura, Y. Higuchi,
A. Hirayama (Tokyo, JP)
Ranolazine added to standard-of-care treatment in the management of stable angina: cost-effectiveness
analysis from the United Kingdom perspective.
P6226
– C.G. Kohn, N. Freemantle, C. Coleman (Hartford and Storrs, US; London, UK)
Four-year clinical outcome of drug-eluting stent following rotational atherectomy for heavily calcified P6227
lesions.
– H. Jinnouchi, S. Kuramitsu, Y. Kobayashi, S. Shinichi, K. Ando, M. Nobuyoshi (Kitakyushu, JP)
Modifiable risk factors associated with mild cognitive impairment in patients with stable coronary heart P6228
disease in the STABILITY trial.
– R.A.H. Stewart, P.W. Armstrong, K. Chiswell, E. Hagstrom, C. Held, S. Krug-Gourley, C.M. Ryan,
A. Stebbins, L. Wallentin, H.D. White (Auckland, NZ; Edmonton, CA; Durham, King of Prussia and
Pittsburgh, US; Uppsala, SE)
Effect of ivabradine on heart rate variability in patients with stable coronary artery disease. P6229
– A. Zupan Meznar, M. Lainscak, I. Zupan, J. Poles, G. Rosano, D. Kovacic (Celje, Ljubljana and Topolsica,
SI; London, UK)
Circulating high-sensitivity cardiac troponin T is a strong predictor of coronary atherosclerotic burden P6230
independently from the presence of inducible ischemia.
– C. Caselli, C. Prontera, M.A. De Graaf, R. Ragusa, V. Lorenzoni, D. Rovai, S. Del Ry, A.J. Scholte,
A. Clerico, D. Neglia (Pisa, IT; Leiden, NL)
385
ANGINA PECTORIS STABLE II

Occurrence and in-hospital mortality of vasospastic angina pectoris in Finland. P6231
– V. Kyto, J. Sipila, P. Rautava (Turku, FI)
Increased level of circulating glutamate and cystine in patients with coronary artery spasm. P6232
– K. Fujibayashi, Y. Kawai, W. Fujita, S. Takano, T. Takamura, M. Watanabe, K. Tanabe, M. Wakasa,
M. Kitayama, K. Kajinami (Uchinada, JP)
The predictive value of stress echocardiography. A real life study from a tertiary center. P6233
– A. Papachristidis, D. Roper, D. Casar Demarco, I. Tsironis, K. Alfakih, M.J. Monaghan (London, UK)
Clinical efficacy of a device to narrow the coronary sinus for the treatment of refractory angina a single P6234
center real-world experience.
– P. Agostoni (Utrecht, NL)
Nationwide trends in revascularization in patients referred to coronary angiography for stable angina. P6235
– C. Ozcan, M.L. Hansen, G.H. Gislason (Hellerup and Copenhagen, DK)
Comparison of NICE and ESC risk scores for diagnosing stable coronary artery disease; is there a P6236
real-world consensus? A tertiary centre experience.
– D. Cassar Demarco, A. Papachristidis, D. Roper, I. Tsironis, M.J. Monaghan, K. Alfakih (London, UK)
Angiographic Gensini score predicts coronary plaque burden and components assessed by P6237
iMap-intravascular ultrasound in patients with stable angina pectoris.
– S. Koga, S. Ikeda, T. Nakata, T. Katayama, Y. Koide, H. Kawano, K. Maemura (Nagasaki, JP)
Impact of moderate vasomotor response to acetylcholine provocation test on long-term prognosis. P6238
– M. Hoshino, T. Yonetsu, M. Suzuki, A. Matsumura, Y. Hashimoto (Kamogawa, JP)
Ultrasensitive troponin assay predicts cardiac stress and diastolic function. P6239
– S. Svedlund, H. Westergren, M. Lagerstrom Fermer, K. Wahlander, L.M. Gan (Gothenburg and Mölndal, SE)
ANGINA PECTORIS STABLE III
Comparison of coronary artery disease consortium 1, 2 and duke clinical score to predict obstructive P6240
coronary disease by coronary angiography.
– J.G. Almeida, P. Fonseca, T. Dias, R. Lopes, N. Ferreira, N. Bettencourt, J. Ribeiro, V. Gama (Porto, PT)
Translating clinical trial results into clinical practice for patients with diabetes and multivessel coronary P6241
artery disease in British Columbia: A population-based study.
– K. Ramanathan, J. Abel, J.E. Park, A. Fung, D. Wong, A. Dellla-Siega, G. Fradet, L. Ding, C.M. Taylor,
M.E. Farkouh (Vancouver, Victoria and Toronto, CA)
Assessment of the relationship between serum visfatin levels and presence and extension of the coronary P6242
slow flow phenomenon.
– H.A. Cakmak, S. Aslan, A.A. Yalcin, I.F. Akturk, B. Yalcin, F. Uzun, D. Ozturk, M. Erturk, M. Gul (Rize and
Istanbul, TR)
Inflammatory mediators TIMP-1 and MMP-8 as prognostic markers for mortality in cardiac patients and P6243
TIMP-1 as indication of a vulnerable coronary plaque.
– P. Vesterinen, M.T. Nieminen, T. Tervahartiala, T. Sorsa, P. Pussinen, J. Sinisalo (Helsinki, FI)
Incremental value of B-type natriuretic peptide for detection and risk reclassification of obstructive P6244
coronary artery disease on computed tomography angiography.
– M. Kawabe, A. Sato, T. Hoshi, E. Masae, Y. Ikuo, K. Aonuma (Tsukuba and Moriya, JP)
Ivabradine reduces post-ischemic stunning in patients with exercise-inducible ischemia assessed by P6245
longitudinal strain.
– P.G. Camici, F. Maranta, L. Tondi, E. Agricola, A. Margonato, O. Rimoldi (Milan and Segrate, IT)
Prevalence and prognostic significance of preprocedural high-sensitivity cardiac troponin elevation P6246
among patients with stable coronary artery disease undergoing percutaneous coronary intervention.
– L. Raber, T. Zanchin, D. Heg, K.C. Koskinas, C. Moro, B. Meier, P. Juni, S. Windecker (Berne, CH)
Poor performance of guidelines endorsed CAD prediction tool results in overdiagnosis of CAD risk in P6247
patients investigated for chest pain. A single centre experience in a large cohort of patients.
– S. Thiru, A. Reaney, S. Saltissi, A. Chenzbraun (Liverpool, UK)
Soluble vascular endothelial growth factor receptor-1 levels in serum collected from arterial catheter P6248
sheath are inversely associated with cardiovascular events in combination with the SYNTAX score.
– M. Ishii, H. Wada, M. Akao, S. Ura, A. Yamada, M. Abe, N. Masunaga, T. Unoki, D. Takagi, K. Hasegawa
(Kyoto, JP)
Correlation of rise in high sensitive troponins following positive exercise testing with underling coronary P6249
artery disease.
– A.K. Pradhan, P.R.E.M. Ratan, R. Sethi, V.S. Narain (Lucknow, IN)
INFLAMMATION AND IMMUNITY I

Monocyte chemoattractantprotein-1 (MCP-1) as an independent predictor of coronary artery ectasia. P6250
– J.A. Franco Pelaez, R. Martin Reyes, A.M. Pello Lazaro, A. Acena Navarro, O. Lorenzo Gonzalez, J.L. Martin
Ventura, L. Blanco Colio, J. Farre Muncharaz, J. Ejido De Los Rios, J. Tunon Fernandez (Madrid, ES)
Allergic inflammation is associated with coronary instability and a worse clinical outcome after acute P6251
– C. Calvieri, G. Niccoli, D. Flego, A. Imaeva, V. Sabato, D. Schiavino, G. Liuzzo, F. Crea (Rome, IT; Moscow,
RU; Antwerp, BE)
386
Functional mannan-binding lectin deficiency is not associated with improved outcome in comatose P6252
survivors of out-of-hospital cardiac arrest.
– J. Bro-Jeppesen, J. Kjaergaard, S. Thiel, J.C. Jensenius, M. Wanscher, C. Hassager (Copenhagen and
Aarhus, DK)
Leukocyte characteristics improve prediction of mortality after coronary angiography. P6253
– C.M. Gijsberts, G.H.J.M. Ellenbroek, M. Ten Berg, A. Huisman, W. Van Solinge, F.W. Asselbergs, H.M. Den
Ruijter, G. Pasterkamp, D.P.V. De Kleijn, I.E. Hoefer (Utrecht, NL; Singapore, SG)
Prognostic significance of carotid artery inflammation in patients with coronary artery disease. P6254
– G. Benetos, K. Toutouzas, M. Drakopoulou, F. Mitropoulou, C. Nikolaou, N. Barampoutis, P. Davlouros,
E. Tsiamis, E. Siores, D. Tousoulis (Athens and Patras, GR; Bolton, UK)
Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a). P6255
– K.A. Krychtiuk, S.P. Kastl, S.L. Hofbauer, A. Wonnerth, G. Maurer, K. Huber, E. Dostal, S. Oravec, J. Wojta,
W.S. Speidl (Vienna, AT; Bratislava, SK)
Comparison between change of lipid profiles and on-treatment C-reactive protein in patients treated P6256
statin monotherapies after the first year of onset of acute coronary syndrome.
– M. Ishida, T. Itoh, Y. Ishikawa, R. Sakamoto, K. Komuro, S. Nakajima, T. Mifune, T. Fusazaki, M. Nakamura,
Y. Morino (Morioka, JP)
Association of platelet-to-lymphocyte ratio with severity and complexity of coronary artery disease in P6257
patients with acute coronary syndromes.
– A. Kurtul, S.N. Murat, M. Yarlioglues, M. Duran, G. Ergun, S.K. Acikgoz, M.B. Demircelik, M. Cetin,
H.A. Kasapkara, E. Ornek (Ankara, TR)
Elevated antiendothelial antibodies are associated with improved survival in patients undergoing P6258
coronary angiography.
– N. Teodorovich, M. Jonas, G. Gandelman, J. George (Rehovot, IL)
INFLAMMATION AND IMMUNITY II
Plasma chemerin is elevated in type 2 diabetes, is associated with impaired kidney function and is P6259
predictive for cardiovascular events.
– A. Leiherer, A. Muendlein, P. Rein, K. Geiger, P. Fraunberger, H. Drexel, C.H. Saely (Feldkirch, AT;
Philadelphia, US)
Recombinant human placental growth factor 2 treatment for ischemic cardiomyopathy in atherosclerotic P6260
mice.
– M. Wu, M. Swinnen, E. Caluwe, H. Gillijns, N. Vanden Driessche, P. Pokreisz, S. Janssens (Leuven, BE)
Galectin-2 polarizes macrophages into an non-arteriogenic phenotype. P6261
– M. Hollander, C. Yildrim, A. Van Der Laan, D.Y.S. Vogel, J.M. Baggen, T. Van Der Pouw-Kraan,
A.J.G. Horrevoets, N. Van Royen (Amsterdam, NL)
Prevalence at computed coronary tomography of non-calcified plaques in asymptomatic hiv patients P6262
treated with haart: a meta-analysis.
– F. Ballocca, F. D’Ascenzo, E. Cerrato, W. Grosso Marra, P. Omede, M. Cannillo, D. Garabello, G. Biondi
Zoccai, C. Moretti, F. Gaita (Turin and Rome, IT)
Cooperative effect of palmitic acid and minimally oxidized LDL on macrophage activation via P6263
MAPK-dependent manner.
– S.J. Ann, S. Park, S.M. Kang, S.-H. Lee (Seoul, KR)
Inflammatory markers MMP-8 and TIMP-1 identify vulnerable coronary artery plaque in acute cardiac P6264
situation.
– M.T. Nieminen, O. Parkkonen, P. Vesterinen, T. Tervahartiala, T. Sorsa, P.J. Pussinen, J. Sinisalo (Helsinki,
FI)
Similarities in impairment of endothelial glycocalyx between psoriasis and coronary artery disease: the P6265
role of oxidative stress and inflammation.
– I. Ikonomidis, G. Makavos, I. Andreadou, K. Gravanis, M. Varoudi, H. Triantafyllidi, E. Papadavid,
D. Rigopoulos, G. Pavlidis, J. Lekakis (Athens, GR)
Respiratory infection following acute myocardial infarction is an independent predictor of in-hospital P6266
cardiovascular mortality.
– C. Quina-Rodrigues, A. Gaspar, G. Abreu, C. Arantes, J. Martins, C. Galvao Braga, C. Vieira, M.A. Pereira,
P. Azevedo, J. Marques (Braga, PT)
Evaluation of neutrophil/lymphocyte and platelet/lymphocyte ratios in the extent of coronary artery P6267
calcification among clinically stable patients.
– C.V. Serrano Jr, C.L. Garzillo, E.G. Lima, R.L.O. Costa, F.H. Rached, S.F. Oliveira, C.H. Nomura,
W.A. Hueb, D. Favarato, R. Kalil-Filho (São Paulo, BR)
Role of macrophage migration inhibitory factor (MIF) and its endogenous inhibitor Gremlin-1 in P6268
intracoronary thrombi of patients with acute myocardial infarction.
– K.A.L. Mueller, A. Hermann, C. Chakkalakal, L. Streib, M. Rauer, M. Gawaz, T. Geisler, I.I. Mueller
(Tübingen, DE)
Three-year results of stenting of bifurcation stenoses of the left main coronary artery: data of P6269
intravascular ultrasound study.
– Z. Shugushev, D. Maximkin (Moscow, RU)
ANGINA PECTORIS STABLE IV

The effect of ivabradine on silent ambulatory myocardial ischemia. P6270
– W. Kadro, M. Turkmani, H. Rahim, G. Pietro, C. Rigali, M. Read (Damascus, SY)
387
Different vasoreactivity of left internal thoracic artery bypass grafts and left anterior descending coronary P6271
arteries to acetylcholine in patients with stable angina and no relevant stenosis.
– P.E. Ong, G. Pirozzolo, A. Athanasiadis, S. Hill, H. Mahrholdt, T. Schaeufele, U. Sechtem (Stuttgart, DE)
Associations of ankle-brachial index with the severity and characteristics of coronary atherosclerosis in P6272
patients with stable angina pectoris: assessment by Gensini score, IVUS, and OCT.
– S. Koga, S. Ikeda, T. Nakata, T. Katayama, Y. Koide, H. Kawano, K. Maemura (Nagasaki, JP)
Fractional flow reserve after percutaneous coronary intervention was strongly associated with better P6273
long-term clinical outcome in stable coronary artery disease.
– H. Shibata, K. Okada, Y. Doi, M. Ogawa, Y. Kijima, T. Masano, R. Nagoshi, A. Kozuki, J. Shite (Osaka and
Suita, JP)
Association of platelet to lymphocyte ratio with inflammation and severity of coronary atherosclerosis in P6274
patients with stable coronary artery disease: a single center large scale study.
– M. Akboga, C. Yayla, U. Canpolat, F. Ozcan, O. Ozeke, S. Topaloglu, D. Aras (Ankara, TR)
The acute and chronic effects of ivabradine on the parameters of central aortic pressure in patients with P6275
stable coronary artery disease.
– Y.M. Lopatin, V.A. Uskova (Volgograd, RU)
Efficacy of everolimus-eluting stent implantation in patients with small coronary (<2.5 mm) arteries: P6276
outcomes of 4-year clinical follow-up.
– H. Yano, M. Ishikawa, S. Horinaka, T. Ishimitsu (Tochigi, JP)
Ivabradine reduces symptoms and improves quality of life in patients with stable angina and diabetes P6277
mellitus.
– J. Zarifis, V. Grammatikou, E. Kallistratos, A. Katsivas (Thessaloniki and Athens, GR)
Percutaneous coronary intervention for restenosis with stent fracture after drug-eluting stent P6278
implantation compared between first and new drug-eluting stents.
– K. Iwasaki, K. Kadota, S. Otsuru, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto,
Blood bioactive sphingolipids and activity of sphingomyelinases in patients with multivessel coronary P6279
artery disease.
– M. Knapp, A. Lisowska, M. Baranowski, P. Zabielski, R. Sawicki, A. Krajewska, W.J. Musial (Bialystok, PL)
ANGINA PECTORIS STABLE V

Effect of allopurinol on serum uric acid and platelet aggregation in patients with essential arterial P6280
hypertension.
– A. Campeanu, A.S. Hodorogea, V. Uscatescu, I.T. Nanea (Bucharest, RO)
The Difference between Ergonovine and Acetylcholine in the Changes of Reactive Oxygen Metabolites P6281
during Intracoronary Spasm Provocation Test in Patients with Vasospastic Angina.
– T. Kiyooka, H. Suzuki, T. Moroboshi, H. Takahashi, N. Natsumeda, H. Tanaka, Y. Ikari (Oiso and Isehara,
JP)
Impact of diabetes mellitus for angiographical mid-term outcome in new generation drug eluting stent. P6282
– M. Habara, K. Nasu, M. Terashima, Y. Kinoshita, E. Tsuchikane, T. Matsubara, T. Suzuki (Toyohashi, JP)
Dose-dependent effect of aspirin on the level of sphingolipids in human blood. P6283
– M. Knapp, A. Lisowska, M. Baranowski, R. Sawicki, W.J. Musial, A. Chabowski (Bialystok, PL)
Mechanisms of ischemic preconditioning in coronary artery disease by arterial compliance and heart rate P6284
variability.
– A.S. Sherbakova, Y. Safina, N.S. Zagidullin, A.R. Dunaeva, T.N. Haphyzov, R.H. Zulkarneev, S.Z. Zagidullin
(Ufa, RU)
Prolonged chest symptoms in patients with vasospastic angina: what does this mean? P6285
– H. Teragawa, Y. Fujii, Y. Uchimura, T. Ueda (Hiroshima, JP)
Comparison between plain old balloon angioplasty and drug-eluting stent implantation for the treatment P6286
of stent fracture.
– S. Mitomo, T.N. Naganuma, K.T. Takagi, S.N. Nakamura (Chiba, JP)
Long-term clinical outcome of angiotensin-converting enzyme inhibitor versus angiotensin II receptor P6287
blocker in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
– S. Lim, H.Y. Kim, C.S. Park, Y.S. Koh, H.J. Park, B.J. Kim, K. Chang, W.S. Chung, M.H. Jeong,
K.B. Seung (Seoul and Gwangju, KR)
Association of neutrophils to lymphocytes ratio, carotid atherosclerosis, and coronary artery disease in P6288
– K.I. Cho, B.H. Kim, H.S. Kim, J.H. Heo (Busan and Pusan, KR)
Single-night ventilation therapy for sleep disordered breathing is associated with a decrease in P6289
inflammatory markers in patients with heart diseases.
– J. Spiesshoefer, H. Schmalgemeier, A. Tueroff, H. Fox, T. Bitter, D. Horstkotte, O. Oldenburg (Bad
Oeynhausen, DE)
ADJUNCTIVE MEDICAL THERAPY

Characterization of cardiovascular endpoints, impact of event adjudication and effects of darapladib in P6290
the STABILITY trial.
– C. Held, H.D. White, R.A.H. Stewart, R. Davies, S.H. Sampson, K. Chiswell, U. Boden, K.W. Mahaffey,
L. Wallentin (Uppsala, SE; Auckland, NZ; King of Prussia, Durham and Stanford, US)
Heart rate reduction by ivabradine for improvement of endhotelial function in patients with coronary P6291
artery disease: the randomized open-label RIVENDEL study.
– F. Mangiacapra, I. Colaiori, E. Ricottini, F. Balducci, A. Creta, C. Demartini, G. Di Sciascio (Rome, IT)
388
ECHO-VENTRICULAR FUNCTION AND MYOCARDIAL DISEASE

Determinants of electrocardiographic parameters for the left ventricular mass index on P6292
echocardiography.
– M. Okano, T. Kato, M. Inoko (Osaka, JP)
Left atrial ejection force as a quantitaive measure of left ventricular diastolic dysfunction measured by P6293
Doppler echocardiography.
– M.S. Saber Hafez, M.I. Ahmed, S.S. Raafat Naguib, A.M. Abou Bakr El Missiri (Cairo, EG)
The Association between Semi-quantitative Microalbuminuria, Altered Cardiac Geometry, Diastology and P6294
Contractile Mechanics in Asymptomatic Individuals.
– K.T. Sung, Y.H. Lai, C.I. Lo, W.R. Lan, T.C. Hung, J.Y. Kuo, J.Y. Hou, H.I. Yeh, C.L. Hung (Taipei, TW)
Tissue mitral annular displacement - a novel technique for rapid quantitative assessment of global left P6295
ventricular systolic function based on speckle tracking algorithm.
– K. Wdowiak-Okrojek, B. Michalski, J.D. Kasprzak, P. Lipiec (Lodz, PL)
The prevalence of transient apical hypertrophy during recovery phase of takotsubo cardiomyopathy. P6296
– G. Hashimoto, M. Suzuki, H. Yoshikawa, T. Otsuka, K. Makino, Y. Isekame, H. Hara, M. Moroi,
M. Nakamura, K. Sugi (Tokyo, JP)
Wasted myocardial work in left ventricular dyssynchrony: a preliminary report of a novel principle to P6297
predict response to cardiac resynchronization therapy.
– J. Vecera, M. Penicka, M. Eriksen, K. Russell, J. Bartunek, M. Vanderheyden, O.A. Smiseth (Oslo, NO;
Aalst, BE)
Myocardial stiffness as an important determinant of early systolic lengthening and post-systolic P6298
shortening.
– K. Masuda, T. Asanuma, D. Sakurai, M. Oka, K. Kotani, E. Iwagami, S. Nakatani (Suita and Osaka, JP)
ECHO-IMAGING EVALUATION OF THE RIGHT VENTRICLE
Validation of right ventricular volume derived from 3-dimensional speckle tracking echocardiography: P6299
application for adult congenital heart disease.
– T. Ishizu, Y. Seo, M. Yamamoto, H. Horigome, Y. Kawakami, K. Aonuma (Tsukuba, JP)
Pseudonormal right ventricular filling pattern reflects left ventricular systolic dysfunction and remodeling. P6300
– M. Oikawa, A. Kobayashi, H. Yamauchi, S. Suzuki, A. Yoshihisa, K. Nakazato, H. Suzuki, S. Saitoh,
Y. Takeishi (Fukushima, JP)
Impact of an expedition to 8000m peak on the right heart - the echocardiographic assessment of right P6301
ventricle structure, performance and mechanics after exposure to extreme altitude.
– M. Kurdziel, K. Gierlaszynska, A. Kazik, J. Waclawski, G. Pytel, A. Kurek, M. Gasior (Zabrze, PL)
Pre-operative right ventricular function predicts clinical outcome after prophylactic tricuspid ring P6302
implantation.
– A. Watt, P. Lindqvist, H. Jashari, A. Holmgren, M. Henein (Umeå, SE)
Improvement of biventricular myocardial function in patients with cirrhosis following liver transplantation. P6303
– Y. Chen, Z. Zhen, J.H. Liu, H.F. Tse, K.H. Yiu (Hong Kong, HK)
Right ventricular fractional area change obtained in different echocardiographic views. Comparison with P6304
right ventricular ejection fraction by cardiac magnetic resonance imaging.
– R. Takemoto, H. Oe, N. Watanabe, Y. Ohno, Y. Sakatani, T. Kimura, T. Miyoshi, K. Nakamura, H. Morita,
Effect of CPAP therapy on right ventricular function by speckle tracking strain echocardiography in P6305
obstructive sleep apnea.
– C.Y. Yung, J. Chan, A. Yamada, H.C. Fan, Y.K. Lau, K. Chan (Hong Kong, CN; Gold Coast, AU)
Right ventricular regional volume and systolic function in patients before and after percutaneous closure P6306
of atrial septal defect assessed by three-dimensional echocardiography.
– D.H. Kong, X.H. Shu, H.H. Yao, L.L. Dong, X.U.E. Gong, J.B. Ge (Shanghai, CN)
Differentiation of early arrhythmogenic right ventricular cardiomyopathy from right ventricular outflow P6307
tract ventricular tachycardia.
– J. Saberniak, I.S. Leren, T.F. Haland, N.E. Hasselberg, R. Borgquist, T. Edvardsen, K.H. Haugaa (Oslo, NO;
Lund, SE)
Assessment of right atrial and ventricular function by strain and strain rate imaging in patients with single P6308
ventricular physiology after cardiac progenitor cell therapy.
– D. Ousaka, S. Ishigami, T. Goto, S. Ohtuki, S. Kasahara, S. Sano, H. Oh (Okayama, JP)
MISCELLANEOUS
Pressure-volume relationship in the stress-echo lab: does (left ventricular end-diastolic) size matter? P6309
– T. Bombardini, S. Salvadori, M.F. Costantino, E. Picano (Pisa and Potenza, IT; Astana, KZ)
New echocardiographic parameters in the diagnosis of heart failure with preserved ejection fraction. P6310
– M. Spinarova, J. Meluzin, H. Podrouzkova, R. Stepanova, L. Spinarova (Brno, CZ)
Improvements in ventriculo-arterial coupling and myocardial energetics under dobutamine stress are P6311
important determinants of cardiovascular outcome in patients with dilated cardiomyopathy.
– K. Matsumoto, H. Tanaka, Y. Motoji, J. Ooka, H. Toki, T. Sawa, Y. Mochizuki, K. Ryo, K.-I. Hirata (Kobe, JP)
Association of periodontitis with subclinical myocardial dysfunction in patients with diabetes. P6312
– Z. Zhen, Y. Chen, J.H. Liu, I. Lai, L.J. Jin, K.H. Yiu (Hong Kong, HK)
Subclinical myocardial dysfunction detected by two-dimensional and three-dimensional speckle tracking P6313
echocardiography in asymptomatic type 1 diabetic patients.
– A. Ringle, A. Dornhorst, D. Dawson, M. Rehman, C. Ruisanchez, P. Nihoyannopoulos (London, UK)
389
The superior value of quadripolar versus bipolar left ventricular leads for cardiac resynchronisation P6314
therapy: a cost effective analysis in a UK registry.
– J.M. Behar, J. Bostock, H.M.S. Chin, S. Fearn, S. Claridge, T. Jackson, J. Webb, E. Sammut, M. Sohal,
C.A. Rinaldi (London, UK)
Reduced-dose dual-source coronary computed tomography angiography (CCTA): is raw-data-based P6315
iterative reconstruction able to maintain diagnostic confidence?
– F. Pontana, I. Castellano, T.F. Ismail, N. Gartland, M.B. Rubens, E.D. Nicol (Lille, FR; London, UK)
Submillisievert computed tomography with model-based iterative reconstruction before pulmonary veins P6316
radiofrequency catheter ablation of atrial fibrillation: impact on radiation exposure and outcome.
– G. Pontone, D. Andreini, A.I. Annoni, M. Petulla’, E. Russo, E. Innocenti, M. Guglielmo, S. Mushtaq,
C. Tondo, M. Pepi (Milan, IT)
Is CT verified vulnerable coronary plaque really prone to rupture in itself? P6317
– T. Kodama, T. Kondo, S. Fujimoto, M. Kondo (Tokyo and Takasaki, JP)
Diagnostic performance of computed tomography perfusion in coronary artery disease. P6318
– H. Ito, S. Motoyama, M. Sarai, H. Kawai, Y. Nagahara, K. Takada, M. Okumura, H. Naruse, J. Ishii, Y. Ozaki
(Toyoake, JP)
Novel imaging method for real time cardiac computed tomography and coronary angiography image P6319
registration as a tool for chronic total occlusion intervention.
– F. Yamanaka, T. Ochiai, Y. Tanaka, M. Murakami, J. Matsumi, S. Takahashi, T. Akasaka, S. Tanaka,
S. Saito (Kamakura, JP)
Distribution and predictors of direct costs of acute heart failure in Greece: a social security system P6320
perspective.
– P. Stafylas, J. Parissis, V. Aletras, A. Mavrodi, S. Chatzopoulos, K. Tsarouhas, A. Karavidas, J. Lekakis,
G. Filippatos (Thessaloniki, Athens and Karditsa, GR)
Growth and geographical variation in the use of cardiac imaging in Australia may reflect ineffective P6321
utilisation.
– R. Fonseca, P. Otahal, N. Wiggins, T.H. Marwick (Hobart, AU)
Coronary artery calcification, left atrial, and left ventricular size measured from non-contrast cardiac CT P6322
predict incident heart failure hospitalization in the general population.
– I. Dykun, N. Lehmann, I. Noellen, H. Kaelsch, M.H. Geisel, S. Moehlenkamp, S. Moebus, K.-H. Joeckel,
R. Erbel, A.A. Mahabadi (Essen and Moers, DE)
Cost evaluation and comparison of three decision strategies for cardiac revascularization: results of the P6323
suspected CAD protocol of the European CMR registry.
– K. Moschetti, S.E. Petersen, G. Pilz, R.Y. Kwong, M. Lombardi, G. Korosoglou, A.C. Van Rossum,
O. Bruder, H. Mahrholdt, J. Schwitter (Lausanne, CH; London, UK; Munich, Heidelberg, Essen and
Stuttgart, DE; Boston, US; San Donato Milanese, IT; Amsterdam, NL)
Long-term clinical impact of coronary CT angiography in patients with recent acute-onset chest pain. P6324
– J.J. Linde, J.D. Hove, M. Soergaard, H. Kelbaek, G.B. Jensen, J.T. Kuhl, L. Hindsoe, L. Koeber,
W.B. Nielsen, K.F. Kofoed (Hvidovre, Copenhagen and Roskilde, DK)
Is there a structural basis for vasovagal syncope? Cardiac functions in patients with vasovagal syncope. P6325
– E. Alpaslan, E. Ozpelit, S. Tas, M.E. Ozpelit, B. Unal, H. Dursun, O. Badak, B. Akdeniz (Izmir, TR)
Improvement of ventricular contraction and dyssynchrony in patients with idiopathic ventricular P6326
arrhythmias undergoing catheter ablation.
– J.-N. Liao, F.P. Chung, Y.J. Lin, S.A. Chen (Taipei, TW)
The role of quality improvement approach on reducing systematic errors in echocardiographic P6327
hemodynamic parameters assessment.
– Z. Fanari, U. Choudhry, S. Hammami, V. Reddy, W.S. Weintraub, E. Marshall (Newark, US)
ISCHAEMIA AND CARDIOPROTECTION
Cardioprotection is impaired in cardiomyocyte specific TNF-deficient mice. P6328

– T. Adam, L. Lacerda, N. Hadebe, N.H. Davies, K. Sliwa, S. Lecour (Cape Town, ZA)
Delta-opioid stimulation abolishes beneficial effect of ischemic preconditioning and postconditioning in P6329
human myocardium in vitro.
– M. Kunecki, T. Roleder, J. Biernat, W. Plazak, P. Podolec, M.A. Deja, K.S. Golba (Krakow and Katowice, PL)
Suppression of Bim by microRNA-19a protected cardiomyocytes against hypoxia induced apoptosis via P6330
autophagy activation.
– Y.H. Gao, J.Y. Qian, J.F. Xu, M.Q. Fu, Y. Xia, Y.Z. Zou, J.B. Ge (Shanghai, CN)
Hypoxia/reoxygenation could shift microRNA-150 from inhibition to activation of MEK4 expression in P6331
H9c2 cardiomyocytes.
– C.H. Yeh, H.J. Chien, W.C. Wang, T.P. Chen (Keelung, TW)
Effect of remote ischemic preconditioning on extracellular vesicles in patients with acute ST-elevation P6332
– N. Ryazankina, M. Vagida, J.-C. Grivel, A. Arakelyan, V. Manchurov, O. Ivanova, A. Lebedeva, A. Shpektor,
L. Margolis, E. Vasilieva (Moscow, RU; Bethesda, US)
Mechanical stretch induces apoptosis regulator trb3 in cultured cardiomyocytes and volume-overloaded P6333
heart.
– K.G. Shyu, W.P. Cheng, B.W. Wang (Taipei, TW)
Role of Two-pore channels in cardiac autophagy. P6334
– V. Garcia-Rua, S. Feijoo-Bandin, D. Rodriguez-Penas, A. Mosquera-Leal, M. Portoles, E. Rosello-Lleti,
M. Rivera, J.R. Gonzalez-Juanatey, F. Lago (Santiago de Compostela and Valencia, ES)
390
Biological pacemaker created by HCN4-overexpressing mouse embryonic stem Cell-derived P6335

cardiomyocytes.
– K. Nakamura, Y. Saito, S. Hiroki, H. Morita, H. Ito (Okayama, JP)
Relationship of cardiac IL33/ST2 system with natriuretic pepride system and inflammation in an P6336
experimental model of obesity.
– R. Ragusa, M. Cabiati, P. Iozzo, A. D’Amico, S. Del Ry, C. Caselli (Pisa, IT)
IL-33/ST2 in angiogenesis and limb ischemia in mice. P6337
– M. Besnier, M. Meloni, A. Caporali, A.H. Baker, A. Miller, C. Emanueli (Bristol and Glasgow, UK)
Statin therapy modulates epicardial adipose tissue inflammatory status. P6338
– V. Parisi, G. Rengo, V. D’Esposito, G. Ferro, A. Bevilacqua, A. Caruso, G. Grimaldi, P. Formisano,
D. Leosco, N. Ferrara (Naples and Maddaloni, IT)
Alprostadil treatment is associated with up-regulation of hypoxia-inducible factor 1s subunit HIF1alpha in P6339
monocytes from patients with sustained peripheral ischemia.
– L. Heger, M. Kerber, C. Weis, M. Mauler, M. Mohr, D. Stallmann, C. Bode, C. Hehrlein, I. Ahrens (Freiburg,
DE)
CARDIAC HYPERTROPHY AND GROWTH FACTORS

MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac P6340
troponin I-interacting kinase.
– Y.S. Wang, J. Zhou, K. Hong, X.S. Cheng, Y.G. Li (Shanghai and Nanchang, CN)
The heparan sulphate proteoglycan glypican-6 is increased in experimental and clinical heart failure and P6341
might play a role in cardiac fibrosis through PDGF-BB signalling.
– A.O. Melleby, M.E. Strand, K.M. Herum, B. Skrbic, C.P. Dahl, I. Sjaastad, A.E. Fiane, J. Filmus,
G. Christensen, I.G. Lunde (Oslo, NO; Toronto, CA)
MicroRNA-378 suppresses myocardial fibrosis through a paracrine mechanism at the early stage of P6342
cardiac hypertrophy following mechanical stress.
– J. Yuan, H.B. Liu, L. Zhang, W. Gao, Y. Ye, Z.W. Ding, S. Hung, L. Kang, Y.Z. Zou (Shanghai, CN)
TMEM43 mutation induces massive fibrosis and heart failure: a new mouse model to unravel therapeutic P6343
targets.
– L. Padron-Barthe, R. San Jose, M. Villalba, J. Gomez-Salinero, J. Larrasa, F. Martinez, E. Gonzalez Lopez,
P. Garcia-Pavia, E. Lara-Pezzi (Madrid, ES)
Pre-operative growth differentiation factor 15 (GDF-15) as a novel biomarker of acute kidney injury after P6344
cardiac bypass surgery.
– A. Kahli, C. Guenancia, C. Girard, C. Vergely, O. Bouchot (Dijon, FR)
Cardiac ampk alpha 1 promotes ap-1 activity via pkc - zeta. P6345
– J.G.J. Voelkl, I. Alesutan, U. Primessnig, S. Mia, M. Feger, T. Castor, R. Viereck, F. Stoeckigt, O. Borst,
F. Lang (Tübingen, Berlin and Bonn, DE)
Pathological hypertrophy stimulation generates mitochondrial dysfunction and induces the expression of P6346
the mitochondrial motor protein Kif5B.
– H.H.W. Sillje, W. Tigchelaar, A.M. De Jong, W.H. Van Gilst, R.A. De Boer (Groningen, NL)
Selective cathepsin K inhibition ameliorates left ventricular hypertrophy and diastolic dysfunction. P6347
– S.-P. Lee, S. Lee, S.-A. Kang, H.-K. Kim, Y.-J. Kim, D.-W. Sohn (Seoul, KR)
Adiponectin attenuates adverse cardiac remodeling following cardiac injury by up-regulating matrix P6348
metalloproteinase 9 expression.
– R. Schur, A. Jenke, M. Grueger, L. Holzhauser, K. Savvatis, U. Landmesser, C. Skurk (Berlin, DE; New
York, US)
ION CHANNELS AND ELECTROPHYSIOLOGY
Nos1AP alters QTc intervals upon overexpression in mice. P6349

– T. Williams, D. Oppelt, P.A. Arias-Loza, M. Abesser, J. Schmitt, K. Schuh, O. Ritter (Würzburg, DE)
Cardiac sodium channel mutation associated with epinephrine-induced QT prolongation and sinus node P6350
dysfunction.
– J. Chen, T. Makiyama, Y. Wuriyanghai, S. Ohno, T. Ueyama, A. Shimizu, M. Horie, T. Kimura (Kyoto, Shiga
and Ube, JP)
Abnormal expression of cardiac ion channels-associated genes in lamin A/C-related P6351
cardiomyopathy-specific induced pluripotent stem cell derived cardiomyocytes.
– S. Nishiuchi, T. Makiyama, K. Sasaki, Y. Kohjitani, S. Ohno, Y. Yoshida, T. Doi, S. Shizuta, M. Horie,
T. Kimura (Kyoto and Otsu, JP)
PITX2c deficiency augments anti-arrhythmic effects of sodium channel blockers: results in a mouse P6352
model and validation in a simulation study of the human atrium.
– F. Syeda, T.Y. Yu, A.P. Holmes, F. Jousset, J. Kucera, S. Rohr, G.L. Riley, S.P. Tull, L. Fabritz, P. Kirchhof
(Birmingham, UK; Berne, CH)
Enhanced fast-inactivated state stability of cardiac sodium channels by a novel voltage sensor SCN5A P6353
mutation R1632C as a cause of multiple electrophysiological phenotypes.
– T. Nakajima, Y. Kaneko, A. Saito, M. Ota, T. Iijima, M. Kurabayashi (Maebashi, JP)
Do major ion channels of pacemaker clock also play a role in atrioventricular nodal conduction in young P6354
and aged rats?
– Y. Saeed, I. Temple, Z. Borbas, A. Atkinson, J. Yanni, M. Boyett, C.J. Garratt, H. Dobrzynski (Manchester,
UK)
391
Nitrated fatty acids suppress fibroblast differentiation and oxidative stress in a murine model of P6355
AngII-induced atrial fibrillation.
– T.K. Rudolph, T. Ravekes, A. Klinke, K. Friedrichs, M. Mollenhauer, M. Pekarova, L. Kubala, S. Baldus,
V. Rudolph (Cologne, DE; Brno, CZ)
Cardiac electromechanical heterogeneity as a physiological state - an effort to tie up loose ends from P6356
electrophysiology, protein analysis, mechanical MRI and computational modelling.
– F.F. Dressler, I. Bodi, M. Menza, S. Perez-Feliz, M. Zehender, C. Bode, J.E. Schneider, J.C. Behrends,
G. Seemann, K.E. Odening (Freiburg and Karlsruhe, DE; Oxford, UK)
The role of pitx2c in generating regional action potential gradients in the murine left atrium. P6357
– A.P. Holmes, T.Y. Yu, F. Syeda, S. Kuhlman, N.A. Brown, L. Fabritz, P. Kirchhof (Birmingham and London,
UK)
Transmural 2D living cardiac tissue slice model for investigating spatial heterogeneity of intracellular P6358
calcium handling in the heart.
– Q. Wen, K. Gandhi, J. Wu, R. Capel, H.B. Ni, P. Camelliti, H. Zhang, G. Faggian, D. Terrar, M. Lei (Wuhan,
CN; Verona, IT; Oxford, Manchester and Surrey, UK)
Deletion of PDK1 causes cardiac sodium current reduction in mice. P6359
– Z.L. Han, Y. Jiang, Y.Q. Yang, X.H. Li, Z.Z. Yang, K.J. Cao, D. Wang (Nanjing, CN)
Cardiac transcription factor MEF2C controls cardiac sodium channel gene SCN5A expression. P6360
– A. Zhou, N. Jiang, L. Patel, G. Shi, A. Xie, H. Liu, M. Liu, E.M. Jeong, S.C. Dudley (Providence, US)
Linagliptin, a dpp-4 inhibitor, suppresses the electrical remodeling and myocardial injury in rats. P6361
– N. Ishizue, S. Niwano, T. Igarashi, T. Fujiishi, T. Hashikata, J. Kishihara, M. Murakami, H. Fukaya,
H. Niwano, J. Ako (Sagamihara and Machida, JP)

Impact of new echocardiographic scoring system for predicting procedural outcome of percutaneous P6362
trasmitral valvuloplasty in patients with rheumatic mitral stenosis.
– S.J. Ha, I.J. Cho, C.Y. Shim, S.K. Ryu, H.J. Chang, G.R. Hong, J.W. Ha, N. Chung (Seoul, KR)
Noninvasive estimation of left ventricular filling pressure in patients with mitral regurgitation: a speckle P6363
tracking echocardiography study.
– Y. Kawase, M. Kawasaki, R. Tanaka, R. Kitsukuri, R. Otake, M. Okubo, K. Tsuchiya, S. Tomita, H. Matsuo,
Long-term follow-up after percutaneous mitral valve repair using the mitraclip system. P6364
– A. Attinger, A.H. Frangieh, J. Yoon, C. Gruner, J. Vontobel, R. Corti, T.F. Luescher, F. Ruschitzka,
F. Maisano, O. Gaemperli (Zurich, CH)
Predictors of exercise capacity in asymptomatic patients with significant primary mitral regurgitation P6365
undergoing stress echocardiography.
– K. Patel, P. Naji, T. Barr, L. Rodriguez, R.A. Grimm, B.P. Griffin, M.Y. Desai (Cleveland, US)
Left ventricular function analysis with 2D and 3D speckle tracking in secondary mitral regurgitation P6366
treated with transcatheter mitral valve repair with the MitraClip system.
– R. Schueler, P. Lang, M. Eiden, M. Weber, C. Oeztuerk, N. Werner, G. Nickenig, C. Hammerstingl (Bonn,
DE)
Predictors of long term outcome post surgical treatment of ischemic mitral regurgitation - results from P6367
Polish multicenter registry - PIMAR.
– T. Kukulski, A. Kubicius, M. Gierlotka, T. Niklewski, R. Przybylski, B. Winter, K. Mokrzycki, J. Bak,
M. Zembala, Z. Kalarus (Zabrze, Cieszyn, Wroclaw, Szczecin and Rzeszow, PL)
Mitral valve prolapse: crosstalk between human valve endothelial and interstitial cells. P6368
– P. Poggio, P. Songia, V. Myasoyedova, A. Parolari, F. Alamanni, E. Tremoli (Milan and San Donato
Milanese, IT)
Is left ventricular systolic dysfunction a prognostic determinant of patients undergoing mitraclip? P6369
– H. Kaneko, M. Neuss, T. Schau, A. Isotani, J. Weissenborn, M. Schoepp, M. Seifert, C. Butter (Bernau bei
Berlin, DE)
Long-term outcome and change of right ventricular function in patients with LVEF <25% after P6370
MitraClip-implantation: comparison between left ventricular dysfunction alone and biventricular
dysfunction.
– A. Isotani, T. Schau, M. Neuss, M. Schoepp, C. Butter (Bernau bei Berlin, DE)
Infective endocarditis: absence of microbiological diagnosis is an independent risk factor for inhospital P6371
mortality.
– M. Martinez-Selles, P. Diez-Villanueva, J.M. Reguera, A. Moreno Rodriguez, M.J. Alonso Socas,
F.J. Martinez Marcos, M. Marin (Madrid and Spain, ES)

Incidence, predictors and impact on prognosis of estimated systolic pulmonary artery pressure and its P6372
improvement after transcatheter aortic valve implantation; a multicenter registry.
– F. Giordana, C. Moretti, M. D’Amico, P. Presbitero, P. Agostoni, G. Tarantini, C. Tamburino, G. Biondi
Zoccai, S. Marra, F. Gaita (Turin, Rozzano, Padua, Catania and Rome, IT; Utrecht, NL)
Pulmonary hypertension and transcatheter aortic valve implantation in patients with severe aortic P6373
stenosis: prevalence, prognosis, and evolution.
– B. Glinel Mortreuil, E. Durand, C. Tron, N. Bouhzam, S. El Hatimi, A. Cribier, H. Eltchaninoff, F. Bauer
(Rouen, FR)
392
Modified surgical cutdown as access route for transfemoral transcatheter valve implantation (TAVI): Early P6374
and long-term results in 100 consecutive patients.
– M.B. Arnold, R. Feyrer, M. Kondruweit, S. Loders, S. Jung, M. Weyand, S. Achenbach (Erlangen, DE)
Impact of chronic lung disease on outcome in patients undergoing transcatheter aortic valve P6375
replacement.
– L. Testa, A. Latib, F. De Marco, M. De Carlo, A.S. Petronio, F. Ettori, C. Fiorina, C. Tamburino, N. Brambilla,
F. Bedogni (Milan, Pisa, Brescia and Catania, IT)
Abnormal gas diffusion in aortic stenosis: the link between left and right heart. P6376
– F. Bandera, G. Generati, V. Labate, V. Donghi, M. Pellegrino, F. Carbone, E. Alfonzetti, M. Guazzi (San
Donato Milanese, IT)
Comparison of stroke rate between the balloon expandable Edwards Sapien valve and the P6377
self-expandable Corevalve for transcatheter aortic valve replacement.
– S. Fateh-Moghadam, A. Prinz, M. Gawaz, W. Bocksch (Berlin and Tübingen, DE)
In-hospital results of transfemoral TAVI: Analysis of the French national database. P6378
– P. Candolfi, D. Jackson, G. Goodall (Nyon, CH)
Comparison of Transcatheter Aortic Valve Replacement Approach on Early and Late Mortality Among P6379
Severe Aortic Stenosis Patients.
– E. Koifman, S. Kiramijyan, M. Magalhaes, R. Didier, S. Negi, J. Gai, R. Torguson, A. Pichard, L. Satler,
Unsupervised network analysis of genome wide association study data identifies the epidermal growth P6380
factor receptor as the most connected hub in aortic valve calcification.
– S. Coffey, B.D. Prendergast, M.J.A. Williams, G.T. Jones (Oxford, UK; Dunedin, NZ)
Prognostic impact of electrocardiographic abnormalities in patients with severe aortic stenosis. P6381
– T. Taniguchi, H. Shiomi, M. Kosuge, T. Morimoto, M. Nishiga, K. Nakatsuma, T. Sasa, N. Saito, T. Kimura
(Kyoto, Yokohama and Hyogo, JP)

Differences in the diagnostic ability and analysis of 18F-FDG-PET/CT-Angiography in infective P6382
endocarditis between prosthetic valves and intracardiac devices.
– M.N. Pizzi, A. Roque, N. Fernandez-Hidalgo, H. Cuellar-Calabria, M.T. Gonzalez-Alujas, G. Oristrell,
J. Rodriguez-Palomares, D. Garcia-Dorado, S. Aguade-Bruix, P. Tornos (Barcelona, ES)
A positive 18F-FDG PET/CT on admission predicts new embolic events but not mortality in patients with P6383
infective endocarditis.
– E. Ravis, L. Tessonnier, S. Hubert, C. Lavoute, L. Saby, E. Salaun, J.P. Casalta, S. Camilleri, J. Haentjens,
G. Habib (Marseille, FR)
The role of aortic valve velocity and stroke volume index in predicting the outcomes of severe aortic P6384
stenosis with preserved ejection fraction in elderly.
– Z. Fanari, D. Barmpouletos, S. Hammami, B. Hammami, W.S. Weintraub, E. Marshall (Newark, US)
Atorvastatin diminishes gene expression of tumor necrosis factor-alpha in left atrial appendage but not P6385
interferon-gamma and interleukin-4 in rheumatic heart disease.
– A. Fadhilah, A.U. Rahajoe, M. Kasim, N. Hersunarti, D. Hanafy, E. Listianingsih, A. Santoso, A. Soesanto
(Jakarta, ID)
Thrombolysis in elderly patients with prosthetic heart valve thrombosis. P6386
– S. Gunduz, M. Yesin, M. Kalcik, S. Karakoyun, M.O. Gursoy, Z. Bayram, A.C. Aykan, M.A. Astarcioglu,
M. Biteker, M. Ozkan (Istanbul, TR)
Preprocedural hemodynamics improve the discriminatory value of the aortic regurgitation index in P6387
patients undergoing transcatheter aortic valve implantation.
– J.M. Sinning, M. Vasa-Nicotera, D.T. Chin, A. Sedaghat, M. Weber, C. Hammerstingl, J. Kovac, E. Grube,
N. Werner, G. Nickenig (Bonn, DE; Leicester, UK)
Influence of nutrinional status on survival after transfemoral transcatheter aortic valve implantation. P6388
– M.S. Van Mourik, E.M.A. Wiegerinck, K.T.H. Koch, J. Baan Jr, M.M. Vis (Amsterdam, NL)
Impact of paravalvular leak on mitral regurgitation change after transcatheter aortic valve replacement P6389
for aortic stenosis and its prognostic implications.
– F. Ancona, S. Miyazaki, M. Spartera, C. Marini, I. Rosa, A. Latib, M. Montorfano, A. Margonato,
A. Colombo, E. Agricola (Milan, IT)
Three-year outcomes of transcatheter aortic valve implantation in patients with STS score less than or P6390
equal to 7%: a comparative analysis between different risk strata from the ADVANCE study.
– M. Barbanti, U. Gerckens, S. Bleiziffer, J. Bosmans, P. Wenaweser, S. Brecker, C. Tamburino, A. Linke
(Catania, IT; Bonn, Munich and Leipzig, DE; Antwerp, BE; Berne, CH; London, UK)
Temporal trends in procedural death after transcatheter aortic valve implantation. P6391
– Z. Terzian, D. Himbert, B. Iung, C. Bouleti, E. Brochet, M. Urena-Alcazar, W. Ghodbane, J.-P. Depoix,
P. Nataf, A. Vahanian (Paris, FR)
CARDIOMYOPATHIES
Cardiac extracellular volume quantified by cardiac magnetic resonance reflects degree of cardiac and P6392
neurological involvement in familial transthyretin amyloidosis.
– M. Gallego Delgado, E. Gonzalez-Lopez, F. Munoz Beamud, J. Buades, L. Galan, J.L. Munoz Blanco,
J. Sanchez Gonzalez, B. Ibanez, J. G Mirelis, P. Garcia-Pavia (Madrid, Huelva and Palma de Mallorca, ES)
393
Late gadolinium enhancement on cardiac magnetic resonance for the prediction of non-sustained P6393
ventricular tachycardia in patients with hypertrophic cardiomyopathy.
– J.G. Almeida, N. Marques, I. Cruz, E. Correia, L. Teles, C. Lourenco, R. Faria, P. Magalhaes, K. Domingues,
O. Azevedo (Porto, Faro, Almada, Viseu, Coimbra, Penafiel, Famalicão, Vila-Real, Santarem and Guimaraes,
PT)
Myocarditis: cardiac magnetic resonance findings in follow-up. P6394
– F. Melao, T. Pinho, M. Vasconcelos, E. Martins, A. Madureira, I. Ramos, F. Macedo, M.J. Maciel (Porto, PT)
Differential cytokine profiling in chagasic patients treated with amiodarone and stratified with Lown and P6395
NYHA classifications.
– H.O. Rodriguez Angulo, I. Mendoza, J. Marques, M. Villegas, A. Mijares, N. Girones, M. Fresno (Caracas,
VE; Ciudad Real and Madrid, ES)
Effects of paediatric human immunodeficiency virus infection on electrical conduction of the heart. P6396
– N.S. Idris, M.M.H. Cheung, D.E. Grobbee, D. Burgner, N. Kurniati, M.M. Djer, C.S.P.M. Uiterwaal (Jakarta,
ID; Melbourne, AU; Utrecht, NL)
Abnormal Q-wave in anterior wall but not in inferior wall on surface ECG is marker for cardiac death in P6397
long-term follow-up of subjects with chronic Chagas disease.
– P.R. Benchimol Barbosa, B.R. Tura, A.C.L. Benchimol Barbosa, E.C. Barbosa, J. Barbosa-Filho (Rio de
Janeiro and Niterói, BR)
Electrocardiographic criteria and outcome in patients with arrhythmogenic right ventricular P6398
cardiomyopathy.
– S. Peters (Salzgitter, DE)
Exercise capacity in hypertrophic cardiomyopathy; predictors and effect of treatment with losartan. P6399
– A. Axelsson, K. Iversen, N. Vejlstrup, L. Langhoff, A. Thomsen, O. Havndrup, K.F. Kofoed, M.K. Jensen,
H. Bundgaard (Copenhagen and Roskilde, DK)
Obstruction in asymmetric hypertrophic cardiomyopathy: a multicentre study. P6400
– C.E. Correia, I. Cruz, L. Teles, M. Oliveira, J. Almeida, C. Lourenco, R. Faria, S. Leao, K. Domingues,
N. Marques (Viseu, Almada, Coimbra, Guimaraes, Vila Nova de Gaia, Penafiel, Vila Nova de Famalicao,
Vila-Real, Santarem and Faro, PT)
Inheritance of left ventricular deformation: the BUDAPEST Twins study. P6401
– A. Kovacs, A.A. Molnar, A.D. Tarnoki, D.L. Tarnoki, L. Littvay, A. Apor, T. Horvath, P. Maurovich-Horvat,
G. Jermendy, B. Merkely (Budapest, HU)
ACUTE PULMONARY EMBOLISM

Right-sided heart thrombus in the patients with atrial fibrillation and acute pulmonary embolism: impact P6402
on in-hospital prognosis.
– P. Kukla, G. Koracevic, W.F. Mc Intyre, D. Kutlesic-Kurtovic, K. Fijorek, E. Mirek-Bryniarska, E. Krupa,
L. Bryniarski, P. Pruszczyk, A. Baranchuk (Gorlice, Krakow, Kraków, Tarnów and Warsaw, PL; Nis̆, RS;
Winnipeg and Kingston, CA)
Predictive value of TDI assessment of right ventricular function in patients with acute pulmonary P6403
embolism.
– R. Petkov, Y. Yamakova (Sofia, BG)
Computed-tomography-findings of inferior vena cava perforation after inferior vena cava filter P6404
deployment and its prognosis.
– T. Kodama, H. Nishikawa, S. Ishiwata, M. Ohno (Tokyo, JP)
Patient selection in outpatient and short-stay treatment in pulmonary embolism - comparison of different P6405
criteria (PESI, sPESI, Hestia and RVD on CT) in relation to ESC 2014 guidelines.
– T.A. Meinander, M. Huttunen, M. Lintu, V.-P. Harjola, P. Mustonen (Jyväskylä and Helsinki, FI)
Usefullness of right ventricular rate pressure product to assess right ventricular dysfunction and mortality P6406
in acute hemodynamically stable pulmonary embolism.
– M.S. Cetin, E.H. Ozcan Cetin, Y. Akin, S. Kuyumcu, F. Arisoy, A. Temizhan, S. Topaloglu, D. Aras,
H.L. Kisacik, S. Aydogdu (Ankara, TR)
Course of vascular obstruction after pulmonary embolism as assessed by ventilation-perfusion lung scan P6407
follow-up.
– R. Chopard, B. Genet, M. Chatot, M. Badoz, B. Bonnet, M.F. Seronde, F. Schiele, N. Meneveau
(Besançon, FR)
Effect of atrial fibrillation on the in-hospital prognosis of patients with acute pulmonary embolism. P6408
– P. Kukla, G. Koracevic, W.F. Mc Intyre, V. Atanaskovic, K. Fijorek, E. Mirek-Bryniarska, M. Jastrzebski,
L. Bryniarski, P. Pruszczyk, A. Baranchuk (Gorlice, Krakow, Kraków and Warsaw, PL; Nis̆, RS; Winnipeg
and Kingston, CA)
Comparisson of rivaroxaban and vitamin K antagonists anticoagulant therapy after thrombolysis in P6409
patients with intermediate and high risk pulmonary embolism.
– S. Obradovic, B. Dzudovic, S. Vukotic, D. Vranes, B. Subotic, G. Koracevic, N. Antonijevic (Belgrade and
Nis̆, RS)
Identification of normotensive patients with pulmonary embolism at high risk of adverse clinical outcome: P6410
comparison of two clinical scores.
– S. Vanni, D. Jimenez, P. Nazerian, C. Gigli, G. Pepe, B. Paladini, F. Ermini, C. Caviglioli, F. Morello,
S. Grifoni (Florence and Turin, IT; Madrid, ES)
Filter thrombosis in patients with venous thromboembolism undergoing a temporary inferior vena cava P6411
filter insertion.
– K. Tsukahara, K. Hashiba, T. Ebina, K. Hibi, N. Iwahashi, N. Maejima, E. Akiyama, K. Kimura, S. Umemura
(Yokohama, JP)
394

Depression and anxiety in adult Filipinos with congenital heart disease using the validated Filipino version P6412
of the Hospital Anxiety and Depression Score (HADS).
– J. Aherrera, L. Abrahan, G.Z. Racaza, C.Q. Train, R. Jara (Manila, PH)
Survival Prospects and Circumstance of Death in Contemporary Adult Patients with Congenital Heart P6413
Disease: The Shifting Focus of Mortality from the Perioperative Period to Long-Term Complications.
– A. Kempny, G.P. Diller, R. Alonso-Gonzalez, L. Swan, A. Uebing, W. Li, S.J. Wort, K. Dimopoulos,
M.A. Gatzoulis (London, UK)
How Doppler echocardiographic follow-up of aortic coarctation can be improved - a novel approach for P6414
the determination of pressure gradient using a refined equation.
– J. Stehli, F.C. Tanner, M. Zuber, M. Greutmann, R. Jenni (Zurich, CH)
Anomalous connections or the coronary arteries: a prospective observational cohort of 472 adults. The P6415
ANOCOR Registry.
– P. Aubry, X. Halna Du Fretay, P. Dupouy, G. Leurent, M. Godin, L. Belle, P. Couppie, P. Ou, J.-P. Laissy,
J.-M. Juliard (Paris, Suresnes, Antony, Rennes, Rouen, Metz-Tessy and Haguenau, FR)
Uncertainties in insurances for adults with congenital heart disease. P6416
– M.A. Sluman, S. Apers, B.J. Bouma, J.P. Van Melle, C.H. Peels, M.C. Post, W.M. Waskowsky, P. Moons,
B.J.M. Mulder (Amsterdam, Groningen, Eindhoven, Nieuwegein and Zwolle, NL; Leuven, BE)
Multivariable mortality risk stratification in adult patients with eisenmenger syndrome. P6417
– A. Kempny, K. Dimopoulos, R. Alonso-Gonzalez, L. Swan, W. Li, K. Szostek, A. Uebing, G.P. Diller,
S.J. Wort, M.A. Gatzoulis (London, UK; Krakow, PL)
Release of growth-differentiation factor 15 and associations with cardiac function in adults with P6418
congenital heart disease.
– J.A. Eindhoven, A.E. Van Den Bosch, R.M. Oemrawsingh, V.J. Baggen, I. Kardys, J.A.A.E. Cuypers,
M. Witsenburg, J.W. Roos-Hesselink, E. Boersma (Rotterdam, NL)
Long-term outcome of patients with ventricular septal defect: results from a national registry. P6419
– C. Gabriels, J. De Backer, A. Pasquet, B. Paelinck, M. Morissens, W. Budts (Leuven, Ghent, Brussels and
Antwerp, BE)
The advisability of atrial septal defect closure in patients older than 60 years. P6420
– D. Zverev, A. Pavlov, V. Gurev, T. Tatarinova, T. Makushkina (St. Petersburg, RU)
Anticoagulation in adults with congenital heart disease and atrial arrhythmias. A report from a regional P6421
registry of congenital heart disease (RACCA).
– F.J. Guerrero Marquez, M.J. Rodriguez Puras, C. Fernandez Vivancos, R. Garcia Orta, J. Cano Nieto,
V. Cuenca, J. Robledo, A. Manovel, M. Romero, P. Gallego Garcia De Vinuesa (Seville, Sevilla, Granada,
Málaga, Huelva and Córdoba, ES)
RISK REDUCTION – CLINICAL ASPECTS

Metabolic syndrome given by different definitions and ten year (2001-2011) cardiovascular disease P6422
incidence in Greece; the ATTICA Study.
– C.M. Kastorini, D.B. Panagiotakos, E. Georgousopoulou, V. Metaxa, C. Chrysohoou, P.E. Puddu,
J. Skoumas, D. Tousoulis, C. Pitsavos, C. Stefanadis (Athens, GR; Rome, IT)
Risk factors for cardiovascular and cerebrovascular diseases among 4,752 adult hypertensive subjects in P6423
the primary care setting in Guangdong province, China: a 5-year longitudinal analysis.
– H.H.X. Wang, J.J. Wang, D.Y. Zhang, J. Tang, D.R. Yu, L.C. Li, X. Huang, X.J. Lai, M.C.S. Wong,
S.M. Griffiths (Shatin, HK; Guangzhou, CN)
Periodontitis - independent contributor to risk of myocardial infarction - a report from the PAROKRANK P6424
study.
– L.A.R.S. Ryden, K. Buhlin, U. De Faire, A. Gustafsson, B. Kjellstrom, B. Lindahl, A. Norhammar, A. Nygren,
E. Svenungsson, B. Klinge (Stockholm and Uppsala, SE)
NT-proBNP as a predictor of calcified coronary atherosclerosis progression. P6425
– L.E. Pastormerlo, S. Maffei, D. Della Latta, V. Chubuchny, C. Giampietro, C. Susini, S. Berti, C. Passino,
M. Emdin, D. Chiappino (Pisa and Massa, IT)
Impact of delay to reperfusion on infarct size and clinical outcomes in patients with ST-segment P6426
– C. Granda Nistal, B. Rubio Alonso, A. Jurado Roman, S. Mayordomo Gomez, J. Garcia Tejada, E.P. Garcia
Martin, E. Gomez Mariscal, M.T. Velazquez Martin, F. Hernandez Hernandez, A. Albarran Gonzalez-Trevilla
(Madrid and Ciudad Real, ES)
Consistent reductions in atherogenic lipid parameters with the PCSK9 inhibitor alirocumab in patients not P6427
receiving background statin.
– M.-R. Taskinen, C.P. Cannon, D. Thompson, D.A. Gipe, M.T. Baccara-Dinet, E.M. Roth (Helsinki, FI;
Boston, Tarrytown and Cincinnati, US; Montpellier, FR)
Cardio- and reno-protective effect of remote ischemic preconditioning in patients undergoing P6428
percutaneous coronary intervention. A prospective, non-randomized controlled trial.
– A.K.M. Hassan, H. Shams-Eddin, M.H.M. Abdel-Rahim, H.A. Abd El-Hafeez (Assiut, EG)
Prognostic value of coronary CT imaging in high-risk patients without symptoms of coronary artery P6429
disease.
– A. Dedic, C.J. Roos, M.A. De Graaf, V. Delgado, A.J.H.A. Scholte, E.J.G. Sijbrands, E. Boersma,
K. Nieman, J.J. Bax, P.J. De Feyter (Rotterdam and Leiden, NL)
Carotid intima-media thickness and aortic stiffness index are increased in normal healthy subjects with P6430
parental history of diabetes mellitus.
– M. Ghaleb, Z. Ashour, M. Abd Elghany, A. El Damaty (Cairo, EG)
395
Predictive and protective values of high-density lipoprotein cholesterol for cardiovascular events in P6431
statin-treated patients with acute myocardial infarction.
– J.S. Park, K.S. Cha, J.H. Choi, B. Kim, H.W. Lee, J.H. Oh, J.H. Choi, H.C. Lee, T.J. Hong, M.H. Jeong
(Busan and Gwangju, KR)
The efficacy of ischemic preconditioning for prevention of contrast medium-induced acute kidney injury. P6432
– T. Iwaki (Yokohama, JP)
Long-term anti-hypertensive treatment with amlodipine/perindopril results in lower carotid IMT at 3.5 P6433
years than with atenolol/bendroflumethiazide.
– D.M. Thompson, A. Hughes, A. Stanton, J. Mayet, S. Thom (London, UK; Dublin, IE)
UPCOMING RISK FACTORS

Prevalence and determinants of exercise oscillatory ventilation in a population at cardiovascular risk P6434
enrolled in the EUROEX trial.
– M. Pellegrino, G. Generati, F. Bandera, V. Labate, F. Carbone, E. Alfonzetti, M. Guazzi (San Donato
Milanese, IT)
New indexes of cardiovascular risk: relationship between epicardial and pericardial fat thickness. P6435
– R. Petroni, M. Di Mauro, S. Bencivenga, S. Romano, M. Penco (L’Aquila, IT)
Simultaneously measured inter-arm & inter-leg systolic blood pressure differences and cardiovascular P6436
risk stratification: A systemic review and meta-analysis.
– S. Singh, A. Sethi, M. Singh, N. Grewal, S. Khosla (Chicago, US)
Surgical and pharmacological reassignment influence on transsexuals cardiovascular risk profile. P6437
– M.M. Ciccone, G. Loverro, O. Todarello, C. Bettocchi, A. Zito, G. Ricci, S. Carbonara, F. Cortese,
M. Gesualdo, P. Scicchitano (Bari, IT)
The mediating effect of adherence to Mediterranean diet on the association between fibrinogen and P6438
10-year cardiovascular disease risk: Results Of The 10-year Follow-up of the ATTICA study (2002-2012).
– E. Georgousopoulou, C. Pitsavos, D.B. Panagiotakos, C. Chrysohoou, I. Skoumas, A. Laskaris,
Living alone and depressive symptoms are associated with major cardiovascular events in patients with P6439
chronic coronary heart disease.
– E. Hagstrom, F. Nordlund, R.A. Harrington, J. Lopez-Sendon, J. Soffer, A. Stebbins, R.A.H. Stewart,
L. Wallentin, H.D. White, C. Held (Uppsala, SE; Stanford, King of Prussia and Durham, US; Madrid, ES;
Auckland, NZ)
Marital status is associated with a prevalence of metabolic syndrome in men based on the 2013 Korean P6440
National Health Examination and Nutrition Survey.
– B.H. Kim, K.I. Cho (Pusan and Busan, KR)
The role of uric acid as early marker carotid atherosclerosis in subjects without cardiovascular disease. P6441
– S. Kostic, I. Tasic, D. Djordjevic, D. Mijalkovic, I. Nikolic Pavlovic (Niska Banja and Nis̆, RS)
Relation between parameters of arterial stiffness and endothelial function among patients with and P6442
without severe periodontal disease.
– L.N. Nicolosi De Cortese, J.J. Rudzinski, P.G. Lewin, P.A. Rodriguez, M.C. Rubio (Buenos Aires, AR)
High protein intake supplementation to compensate changes in ventricular repolarization due to 21-days P6443
of bedridden immobilization.
– E.G. Caiani, A. Martin-Yebra, J. Bolea, A. Auricchio, E. Pueyo, P. Vaida (Milan, IT; Zaragoza, ES; Lugano,
CH; Bordeaux, FR)
Trajectories of body mass index before the diagnosis of cardiovascular disease. P6444
– K. Dhana, J. Van Rosmalen, D. Vistisen, M.A. Ikram, A. Hofman, O.H. Franco, M. Kavousi (Rotterdam, NL;
Gentofte, DK)
Statin is associated with lower incidence of deep vein thrombosis confirmed by CT angiography in P6445
patients undergoing total knee replacement arthroplasty.
– S.H. Jo, S.A. Kim, H.S. Kim, S.J. Han, W.J. Park (Anyang and Gyeonggi-Do, KR)
INTERVENTIONS IN PRIMARY AND SECONDARY PREVENTION

A critical appraisal of safety and efficacy of statins for primary prevention in HIV patients. P6446
– S. Gili, E. Lonni, F. D’Ascenzo, M. Cannillo, F. Ballocca, A. Calcagno, S. Bonora, C. Moretti, W. Grosso
Marra, F. Gaita (Turin, IT)
Correlations between subclinical cardiovascular disease and periodontal disease. P6447
– S.I. Dumitrescu, L. Chiriac, M. Vicol, S. Stanciu, I.M. Geru, A. Girleanu, S.R. Geru, A.M. Vintila, I. Tintoiu,
H. Barbu (Bucharest, RO)
One-year follow-up from the CUT-IT trial: A randomized trial comparing a low energy diet with aerobic P6448
exercise in overweight individuals with coronary artery disease.
– A. Jurs, L.R. Pedersen, R.H. Olsen, S.B. Haugaard, E. Prescott (Copenhagen, DK)
Effects of resveratrol and caloric restriction on serum levels of norepinephrine in healthy subjects. P6449
– A.P. Mansur, A. Roggerio, M.F.S. Goes, J.Y. Takada, S.D. Avakian, C.M.C. Strunz (São Paulo, BR)
Impact of cardiovascular risk factors management on long-term all-cause and cardiovascular mortality: P6450
an observational study.
– E. Berard, V. Bongard, D. Arveiler, J. Dallongeville, A. Wagner, P. Amouyel, B. Hass, D. Cottel, J. Ferrieres,
J.B. Ruidavets (Toulouse, Strasbourg and Lille, FR)
Effect of multidisciplinary educational programs delivered to scholar children on cardiovascular risk P6451
profile of their relatives- systematic review and meta-analysis.
– C. Baena, B. Linnemkamp, L.C. Guarita-Souza, A. Minamihara, C.E.A. Fujisawa, D.H. Sato, J.R. Faria-Neto
(Curitiba, BR)
396
Patients’ understanding of chronic antithrombotic therapy in the era of direct oral anticoagulant therapy. P6452
– F. Leclercq, D. Vandenberghe, M. Viala, D. Belardi, G. Cayla, D. Delseny, R. Gervasoni, F. Roubille,
A. Agullo, J.C. Macia (Montpellier, FR)
Predictors of permanent work disability in patients under 50 years old undergoing percutaneous coronary P6453
intervention.
– J. Gunn, T.O. Kiviniemi, F. Biancari, K.E.J. Airaksinen (Turku and Oulu, FI)
Adults with congenital heart disease: individualized structured patient education to improve patients’ P6454
knowledge on infective endocarditis.
– C. Thomet, M. Hadorn, S. Schmidt, K. Wustmann, M. Schwerzmann (Berne, CH)
Visualization of coronary artery calcification: influence on preventive therapy and lifestyle modification in P6455
patients with a new diagnosis of coronary artery disease.
– R. Elmose Mols, J. Moeller Jensen, N.P. Sand, C. Fuglesang Christensen, D. Bagdat, P. Vedsted,
H.E. Boetker, L. Huche Nielsen, B.L. Noergaard (Aarhus, Esbjerg and Vejle, DK)
Closing the treatment gap: coaching patients on achieving cardiovascular health (COACH). P6456
– C.F. Ski, M.J. Vale, V. Chalmers, G. Bennett, K. McFarlane, M.V. Jelinek, I. Scott, D.R. Thompson
(Melbourne and Brisbane, AU)
Women’s awareness, perceptions and knowledge of heart disease - three country comparison. P6457
– N. Walker, C. Lawes, V. Parag, A. Rolleston, R.N. Doughty (Auckland, NZ)
Usefulness of carotid ultrasonography for prevention of cerebral infarction. P6458
– T. Tomaru (Sakura, JP)
SURVEILLANCE OF RISK FACTORS AND INTERVENTIONS
Management of overweight and obesity in patients with coronary heart disease across Europe: results P6459
from EUROASPIRE IV survey.
– K. Kotseva, D. De Bacquer, C. Jennings, D. Wood (London, UK; Ghent, BE)
Secular changes in cardiovascular risk factors of 50-year-old men over a period of 50 years. The study of P6460
men born 1913, 1923, 1933, 1943, 1953 and 1963.
– Y. Zhong, A. Rosengren, L. Welin, K. Caidahl, M. Fu, Z. Mandalenakis, P.-O. Hansson (Beijing, CN;
Gothenburg, SE)
The burden of cardiovascular diseases in Europe - results of the global burden of disease study 2013. P6461
– G.A. Roth, G. Saade, M. Naghavi, M. Fourozanfar, A.H. Mokdad, T. Vos, C.J.L. Murray (Seattle, US; Beirut,
LB)
Trends in clinical profile, medical treatment and risk factors control in patients with stable coronary heart P6462
disease in Spain between 2006 and 2014.
– A. Cordero, E. Galve, H. Bueno, L. Facila, A. Cerquier, E. Alegria, V. Bertomeu-Martinez,
J.R. Gonzalez-Juanatey (Alicante, Barcelona, Madrid, Valencia, San Sebastian and Santiago de
Compostela, ES)
Prevalence, recognition and treatment of atherosclerotic cardiovascular disease in Korea: from 2002 to P6463
2010 Korea Health Insurance Sample Cohort Database (KHISCDB).
– M.K. Chon, J.S. Kim, S.Y. Lee, J.M. Hwang, S.H. Lee, K.W. Hwang, J.H. Kim, K.J. Chun (Yangsan, KR)
Treatment withdrawals and their implications on the success of cardiovascular outcome studies. P6464
– M. Abt, J. Brumm, D. Kallend, D. Kaufman, H. Mundl, G.G. Schwarz, R.S. Wright (Basel, CH; South San
Francisco, Denver and Rochester, US)
Estimating the reduction in 10-year atherosclerotic cardiovascular disease risk with statin therapy: a P6465
VOYAGER meta-analysis.
– M.K. Palmer, S.J. Nicholls, P. Lundman, P.J. Barter, B.W. Karlson (Manchester, UK; Adelaide and Sydney,
AU; Stockholm and Mölndal, SE)
Muscle related complaints, serious adverse events vents and drug discontinuations in 17,706 subjects P6466
randomized to simvastatin or ezetimibe/simvastatin in the IMPROVE-IT study.
– M.A.B. Blazing, R.P.G. Giugliano, S.D.W. Wiviott, J.A.W. White, J.A.D. Delemos, D.K.M. McGuire,
B.S.L. Lewis, A.M.T. Tershakovec, T.A.M. Mussliner, E.B. Braunwald (Durham, Boston, Dallas and
Kenilworth, US; Haifa, IL)
Influence of medical follow-up on the quality of preventive therapy and ACS outcomes, according to P6467
registry data.
– S. Martsevich, I. Balashov, N. Kutishenko, M. Ginzburg (Moscow, RU)
Long term adherence to evidence-based cardioprotective medications after acute myocardial infarction P6468
and its impact on mortality.
– H. Hamood, R. Hamood, R. Almog (Haifa, IL)
Coaching care model in patients with high cardiovascular risk: lessons from the EuroASPIRE database. P6469
– S.L. Mosteoru, K. Kotseva, O.C. Iancu, L. Gaita, R. Pleava, A. Dumitrescu, G. Mut-Vitcu, D. Gaita,
S. Mancas, D. Wood (Timisoara, RO; London, UK)
Impact of PPI treatment on gastrointestinal bleeding associated with NSAID use among post-myocardial P6470
infarction patients on antithrombotic therapy - A nationwide study.
– A.M. Schjerning Olsen, J. Lindhardsen, G. Gislason, P. McGettigan, M. Hlatky, L. Koeber,
C. Torp-Pedersen, M. Lamberts (Hellerup, Copenhagen and Aalborg, DK; London, UK; Stanford, US)
DIET AND EXERCISE: PREVENTION BEGINS HERE
Randomized study of 30 days of resveratrol and caloric restriction on serum levels of sirtuin-1 in healthy P6471
subjects.
– A.P. Mansur, A. Roggerio, M.F.S. Goes, J.Y. Takada, S.D. Avakian, C.M.C. Strunz (São Paulo, BR)
397
Can we LEARN to be effective in reducing obesity-related cardiovascular risk in women? Conventional vs P6472
internet-based program administration: interim analysis.
– C. Ball, K. Carter, S.S. Abdelmoneim, J. Bauman, R. Huang, R. Mankad, S. Iftikhar, C. Yeung,
F. Lopez-Jimenez, S.L. Mulvagh (Rochester, US)
J-shaped curve relationship of daily salt excretion and electrocardiographic left ventricular hypertrophy in P6473
first-visit outpatients.
– F. Takahashi, N. Hasebe, N. Sato (Rumoi and Asahikawa, JP)
Plasma levels of c-type natriuretic peptide in normal, overweight and obese young population. P6474
– S. Del Ry, M. Cabiati, V. Bianchi, L. Caponi, M. Maltinti, C. Caselli, B. Marchi, E. Randazzo, G. Federico
(Pisa, IT)
Real-time longitudinal monitoring of patients diet, exercise and weight loss has substantial positive P6475
effects on metabolic syndrome parameters.
– K.A. Walsh, A. Sheppard, S. Egan, N.S. Colwell (Waterford, Cork and Clonmel, IE)
Increased consumption of fat and carbohydrates is associated with severe coronary artery disease. P6476
– G. Siasos, E. Kokkou, E. Georgousopoulou, E. Oikonomou, T. Psaltopoulou, K. Mourouzis,
M. Zaromytidou, S. Tsalamandris, E. Dimitropoulos, D. Tousoulis (Athens, GR)
Aerobic high-intensity exercise training improves coronary flow reserve velocity and endothelial function P6477
in individuals with chest pain and normal coronary angiogram.
– A.I. Larsen, T. Valborgland, J. Vegsundvag, K. Isaksen, M. Skadberg, M. Gaballa, P.S. Munk (Stavanger
and Ålesund, NO)
Acute effects of energy drink consumption on endothelial function. P6478
– J. Akhundova, C. Tulunay Kaya, D.M. Gerede, O.U. Ozcan, H. Goksluk, V.K. Vurgun, N. Ozyuncu, C. Erol
(Ankara, TR)
Previous exercise training improves the lipid profile and the autonomic modulation in a model of P6479
menopause.
– R.K.P. Palma, C.P.S. Santos, M.R.H.D. Dutra, N.B. Bernardes, A.B.L. Lopes, K.D.A. De Angelis,
C.M. Malfitano (São Paulo, BR)
Natural antioxidant ice-cream improves vascular function and exercise performance in healthy subjects. P6480
– D. Francomano, M. Manco, V. Sanguigni (Rome, IT)
Does statin therpy unfavourably influence healthy lifestyle? The results of the lipidogram survey. P6481
– M. Banach, M. Tomaszewski, T. Tomasik, D.M. Mikhailidis, A. Windak, P. Muntner, K.K. Ray, G.K. Hovingh,
A. Slezak, J. Jozwiak (Lodz, Krakow and Czestochowa, PL; Leicester and London, UK; Birmingham, US;
Amsterdam, NL)
MITRAL SURGERY
Unfractionated vs. low-molecular weight heparin immediately after heart valve surgery. P6482
– D. Dinic, P. Otasevic, P. Milojevic, D. Nezic, B. Djukanovic, A.N. Neskovic (Belgrade, RS)
Conventional mitral surgery in patients with left ventricular dysfunction: a single centre experience. P6483
– L. Botta, B. De Chiara, T. Colombo, F. Musca, O. Belli, A. Costetti, A. Moreo, C. Giannattasio, C. Russo,
C. Taglieri (Milan, IT)
Effects of concomitant MAZE procedure in patients with functional mitral regurgitation undergoing P6484
isolated mitral valve annuloplasty using the HeartPort technique.
– M. Kotrc, J. Bartunek, M. Vanderheyden, F. Van Praet, M. Penicka (Aalst, BE)
Do we bring down long-term survival in patients with severe ischemic mitral regurgitation when replace P6485
mitral valve: propensity-matched analysis?
– V. Shumavets, A. Shket, I. Andraloits, S. Kurganovich, I. Grinchuk, N. Semenova, Y. Ostrovski (Minsk, BY)
OPTIMISING TECHNIQUES AND OUTCOME AFTER CARDIAC SURGERY
Should Ross procedure be considered a feasible alternative for adult patients who require AVR? Single P6486
centre 357 patients long-terms outcome, clinical and echocardiographic study.
– V. Pergola, G. Di Salvo, B. Fadel, M. Aladmawi, M. Alshahid, M. Alamri, Z. Bulbul, Z. Issa, B. Alsoufi,
Z. Alhalees (Riyadh, SA)
Systemic inflammation and oxidative stress contribute to acute kidney injury after transcatheter aortic P6487
valve implantation.
– R. Dworakowski, A. Navaratnatajah, A. Bhan, E. Alcock, T. Dew, M. Monaghan, R. Sherwood, A. Shah,
O. Wendler, P. MacCarthy (London, UK)
A tailor made valve surgery with a novel autologous bioprosthesis. P6488
– Y. Takewa, Y. Nakayama, H. Sumikura, N. Naito, K. Kanda, T. Tajikawa, T. Tanaka, E. Tatsumi (Osaka,
Kyoto and Aichi, JP)
Conventional aortic valve replacement in medium/high risk patients. P6489
– P. Marques Correia, G.F. Coutinho, M.J. Antunes (Coimbra, PT)
Ross operation: is it possible to identify the ideal candidate? P6490
– M. Ruiz Ortiz, M. Delgado, D. Mesa, E. Duran, C. Ferreiro, J. Sanchez, J. Casares, C. Merino, P. Alados,
J. Suarez De Lezo (Córdoba, ES)
Impact of small annulus on valve hemodynamic and mid-term outcome following transcatheter aortic P6491
valve implantation compared with surgical aortic valve replacement.
– N. Kamioka, S. Shirai, T. Arita (Kitakyushu and Fukuoka, JP)
Type 2 diabetes and prosthesis-patient mismatch are associated with faster structural valve degeneration P6492
in bioprosthetic aortic valves.
– S. Ruiz Bustillo, A.B. Perez, M. Ble Gimeno, M. Gomez Perez, H. Tizon Marcos, L. Molina Ferragut,
J. Bruguera Cortada, A. Fernandez Gasalla, D. Bueno Lopez, M. Cladellas Capdevila (Barcelona, ES)
398
ROBOTIC SURGERY
Minimally invazive transcatheter ventricular restoration (TCVR). P6493
– P. Neuzil, I. Skalsky, T. Mraz, M. Mates, A. Kruger, T. Martinca, S. Cerny, K. Kopriva, P. Ostadal, J. Petru
(Prague, CZ)
AORTA, PERIPHERAL ARTERIAL AND VENOUS SURGERY

Bypass surgery versus endovascular therapy in chronic hemodialysis patients with critical limb ischemia P6494
due to infra-inguinal disease.
– Y. Kumada, H. Ishii, T. Aoyama, D. Kamoi, T. Sakakibara, N. Umemoto, H. Takahashi, T. Murohara
(Kasamatsu, Nagoya and Toyoake, JP)
Assessment of aortic dissection risk in Marfan syndrome patients by analysis of aortic viscoelastic P6495
properties.
– A. Pini, A. Grillo, S. Marelli, L. Gao, L. Salvi, P. Salvi, G. Trifiro, M. Viecca, R. Carretta, G. Parati (Milan,
Trieste and Rho, IT; Beijing, CN)
Demonstration of the mechanisms of aortic regurgitation in type a aortic dissection by real time 3D P6496
transesophageal echocardiography.
– Z.H. Gou, Y. He, X. Gu, Y.E. Zhang (Beijing, CN)
Aortic insufficiency indicated higher risk for progressive ascending aorta dilatation and adverse aortic P6497
events in bicuspid aortic valve disease after isolated aortic valve replacement.
– Y.S. Wang, B.T. Wu, L.L. Dong, X.H. Shu (Shanghai, CN)
Bicuspid aortopathy: does it really exist? An histological study. P6498
– V. Canadas, I. Vilacosta, E. Rodriguez, C. Fernandez, C. Macaya (Madrid, ES)
Thrombogenic state after vascular surgery and perioperative cardiovascular events. P6499
– D. Calderaro, A.F. Pastana, T.R.F. Rocha, F.A. Justo, D.M. Gualandro, P.C. Yu, M.G. Matheus,
E.A. D’Amico, B. Caramelli (São Paulo, BR)
Screening for abdominal aortic aneurysm during echocardiographic examination in high risk patients. P6500
– A. Bouferrouk, S. Boutamine, A. Bedjaoui, C. Belhadi, A. Mekkarnia (Algiers, DZ)
Role of matrix metalloproteinase single nucleotide polymorphisms in thoracic aortic aneurysm P6501
development.
– N. Gavriliuk, V. Uspenskiy, O. Irtyuga, T. Druzhkova, O. Moiseeva (St. Petersburg, RU)
Influence of the false lumen status on acute type A aortic dissection without urgent surgical repair. P6502
– A. Tanaka, H. Ishii, S. Suzuki, T. Ota, H. Oshima, A. Usui, T. Murohara (Nagoya, JP)
Carbon dioxide-aided angiography decreases contrast volume and prevents kidney injury in peripheral P6503
vascular interventions.
– E. Stegemann, R. Sansone, C. Tegtmeier, N.Y. Bimpong-Buta, B. Stegemann, R. Westenfeld, M. Kelm,
C. Heiss (Düsseldorf, DE)
Increased pulse wave velocity indicates presence of coronary artery disease in patients with abdominal P6504
aortic aneurysms.
– I. Ikonomidis, D.P.E. Kadoglou, J. Papadakis, K. Moulakakis, G. Pavlidis, H. Triantafyllidi, C.D. Liapis,
J. Lekakis (Athens, GR)
Impact of one-stage systematic endovascular treatment for multilevel (femoropopliteal and below the P6505
knee) lesions in patients with critical limb ischemia.
– S. Tohoku, Y. Soga, Y. Tomoi, K. Ichihashi, K. Ando (Kitakyushu, JP)
Central blood pressure correlates with size of abdominal aortic aneurysm. P6506
– L. Artyszuk, I. Nawrocka, I. Machaj, M. Kaczynska, P. Abramczyk (Warsaw, PL)
CIRCULATORY ASSIST AND OTHER
Acute proteolysis of Von Willebrand factor at initiation of continuous-flow left ventricular assist devices. P6507
– A. Rauch, E. Van Belle, C. Caron, F. Vincent, C. Hurt, G. Schurtz, C. Delhaye, F. Juthier, A. Vincentelli,
S. Susen (Lille, FR)
Structural and functional echocardiographic responses to left ventricular assist device implantation: P6508
focus on the right ventricle.
– K. Bhatt, R. Al-Anbari, V. Georgiopoulou, A. Morris, J. Butler, A. Smith, D. Vega, A. Kalogeropoulos (Atlanta
and Stony Brook, US)
Management of oesophageal fistulae after transcatheter or intraoperative radiofrequency ablation for P6509
atrial fibrillation - a single center experience over 15 years.
– M. Luehr, P. Sommer, M. Zachaeus, M. Misfeld, U. Halm, S. Leinung, M. Gutberlet, F.W. Mohr,
G. Hindricks (Leipzig, DE)
The utility of CHA2DS2-Vasc and HAS-BLED scores as predictor of thromboembolic and bleeding risk P6510
after left ventricular assist device implantation.
– S. Nalbantgil, H.S. Kemal, S. Ertugay, P. Ozturk, C. Engin, T. Yagdi, M. Ozbaran (Izmir, TR)
Comparison of radiation exposure between vascular approach sites in diagnostic coronary angiography P6511
and interventional procedures in a contemporary time period analysis.
– H.W. Lee, K.S. Cha, J.H. Choi, B.W. Kim, D.S. Lee, J.S. Park, J.H. Oh, J.H. Choi, H.C. Lee, T.J. Hong
(Busan, KR)
Cardiac resynchronization therapy can be a rescue therapy for inotrope-dependent patients with P6512
advanced heart failure?
– T. Imamura, K. Kinugawa, D. Nitta, T. Inaba, H. Maki, M. Hatano, I. Komuro (Tokyo, JP)
399
Right ventricular function improves through pump speed optimization in patients on long-term left P6513
ventricular assist devices.
– L.E. Couperus, V. Delgado, H.F. Verwey, L.F. Tops, M.J.H. Khidir, M. Palmen, R.J.M. Klautz, M.J. Schalij,
S.L.M.A. Beeres (Leiden, NL)
A novel right heart assist device- the perkat (percutoneous catheter pump technology) sytem. P6514
– D. Kretzschmar, A. Lauten, R. Reich, J. Pfeifer, P. Patzer, H.R. Figulla, M. Ferrari (Jena and Wiesbaden, DE)
RESTENOSIS
Efficacy of drug eluting balloons for patients with in-stent restenosis: a meta-analysis of 8 randomized P6515
controlled trails.
– W. Liu, G.S. Gao, Z.Y.J. Zhou (Beijing, CN)
Treatment of drug-eluting stents in-stent restenosis with paclitaxel-coated balloon angioplasty: insights P6516
from the French real-world prospective GARO registry.
– V. Auffret, J. Berland, P. Barragan, M. Waliszewski, L. Bonello, N. Delarche, A. Furber, F. Albert, D. Carrie,
M. Bedossa (Rennes, Rouen, Ollioules, Marseille, Pau, Angers, Chartres and Toulouse, FR; Melsungen, DE)
Results of percutaneous coronary intervention of stent restenosis lesions with sequent please paclitaxel P6517
eluting balloon catheter at a very long-term follow-up.
– A. Jurado Roman, I. Sanchez Perez, F. Lozano Ruiz-Poveda, N. Pinilla Echeverri, M.T. Lopez Lluva,
J. Piqueras Flores, A. Moreno Arciniegas, J. Benitez Peyrat, M. Marina Breysse (Ciudad Real, ES)
Efficacy of a novel paclitaxel-eluting balloon in reducing in-stent restenosis in a porcine model. P6518
– L. Shen, J.S. Yin, Y.Z. Wu, Z.F. Yao, J.H. Chen, M. Ji, C. Chen, J. Lv, J.B. Ge (Shanghai, CN)
The incidence and risk factors of late catch up phenomenon after second generation des deployment. P6519
– T. Tokuda, T. Muramatsu, R. Tsukahara, Y. Ito, H. Ishimori, K. Hirano, M. Nakano (Yokohama, JP)
Incidence and predictors of late catch-up phenomenon after second generation drug-eluting stent P6520
implantation.
– M. Ohya, K. Kadota, T. Tada, S. Otsuru, D. Hasegawa, S. Habara, H. Tanaka, Y. Fuku, T. Goto, K. Mitsudo
(Kurashiki, JP)
Three-year clinical outcomes after treatment of drug-eluting Stent restenosis with paclitaxel-eluting P6521
balloon vs. everolimus-eluting stent.
– M. Almalla, S. Reith, F. Vogt, N. Marx, J. Schroeder (Aachen, DE)
Incidence and distribution of thin high signals detected by optical coherence tomography in patients P6522
treated with paclitaxel-coated balloon.
– H. Kawashima, N. Suzuki, H. Nakaya, M. Mitsui, N. Hosogoe, Y. Watanabe, S. Ishikawa, H. Kyono,
N. Yokoyama, K. Kozuma (Tokyo, JP)
Estimation value of prediction plasma osteopontin levels in patients undergoing percutaneous coronary P6523
intervention.
– K. Yilmaz, U.A. Bal, E. Karacaglar, K. Okyay, A. Aydinalp, A. Yildirir, H. Muderrisoglu (Ankara, TR)
Long-term results of treatment of in-stent restenosis in aortocoronary saphenous vein grafts with P6524
paclitaxel-eluting balloon and paclitaxel eluting stent.
– M. Almalla, F. Vogt, N. Marx (Aachen, DE)
Percutaneous coronary intervention for restenosis with stent fracture after drug-eluting stent P6525
implantation for de novo vs. in-stent restenosis lesions.
– S. Otsuru, K. Kadota, Y. Hyodo, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto,
Clinical outcome after successful implantation of drug eluting and bare metal stents in large coronary P6526
arteries.
– J.R. Siles Rubio, A. Ramirez Moreno, J. Munoz-Bellido, L. Inigo-Garcia, A. Valle-Alberca,
M. Pombo-Jimenez, R. Bravo-Marques, A. Milan-Pinilla, E. Zambrano-Medina, M. Noureddine (Estepona
and Marbella, ES)
Morphological and circulatory markers of the in-stent restenosis: matching and relevance. P6527
– L. Ciobanu, M. Popovici, S. Costin, V. Cobet, I. Popovici, V. Ivanov, C. Dumanschi, M. Lazu, L. Semionov
(Chisinau, MD)
The level of plasma myeloperoxidase predicts rate of drug-eluting stent restenosis. P6528
– F. Byazrova, V. Buza, V. Lopukhova, K. Zykov, V. Masenko, A. Samko, Y.U. Karpov (Moscow, RU)
Incidence of in-stent restenosis over 13 years - a study based on a national registry. P6529
– G. Abreu, C. Braga, C. Arantes, J. Martins, C. Rodrigues, P. Azevedo, M. Alvares Pereira, J. Marques
(Braga and Lisbon, PT)
Bifurcation angle between left main trunk and left anterior descending artery is independently related to P6530
restenosis after stent implantation for proximal left anterior descending artery disease.
– T. Konishi, T. Yamamoto, N. Funayama, D. Hotta, K. Kikuchi (Sapporo, JP)
Difference of the development of restenosis with respect to time for various drug-eluting stents. P6531
– K. Tanaga, Y. Nakamura, Y. Iwata, T. Inoue, A. Miyazaki (Chiba, JP)
The optimal strategy for in-stent restenosis at the right coronary artery ostial lesion after stent P6532
implantation.
– S. Otsuru, K. Kadota, Y. Hyodo, D. Hasegawa, S. Habara, T. Tada, H. Tanaka, Y. Fuku, T. Goto,
Is bare-metal stent sill useful for improving outcomes of percutaneous coronary intervention? From the P6533
FU-Registry.
– K. Gondo, A. Ike, K. Shirai, H. Nishikawa, K. Mori, K. Saku (Fukuoka, JP)
Two-year restenosis rate and its predictors after femoropopliteal drug-eluting stenting. P6534
– K. Nanto, O. Iida, S. Okamoto, T. Ishihara, T. Shiraki, T. Tsujimura, S. Okuno, K. Yanaka, M. Uematsu
(Amagasaki, JP)
400
In-stent neoatherosclerosis can be a possible mechanism of the impaired flow after re-percutaneous P6535
coronary intervention for the in-stent restenosis.
– H. Koiwaya, N. Watanabe, N. Kuriyama, T. Kimura, T. Nakama, M. Furugen, K. Ashikaga, T. Ueno,
Y. Fukumoto, Y. Shibata (Miyazaki and Fukuoka, JP)
PROGNOSIS I
Usefulness of geriatric nutritional risk index for assessing the nutritional status and its prognostic impact P6536
in elderly patients with acute heart failure.
– Y. Honda, T. Nagai, Y. Sugano, T. Shibata, Y. Asaumi, T. Noguchi, K. Kusano, H. Ogawa, S. Yasuda,
T. Anzai (Osaka, JP)
The prognostic value of the transtubular potassium gradient in patients with acute decompensated heart P6537
failure.
– T. Sakaguchi, K. Shinouchi, H. Miura, K. Miyazaki, M. Koide, H. Abe, M. Date, Y. Koretsune, H. Kusuoka,
Y. Yasumura (Osaka, JP)
Left ventricular global longitudinal displacement assessed by tissue Doppler imaging is the strongest P6538
echocardiographic predictor of all-cause mortality in patients with heart failure.
– M. Sengelov, P.J. Jorgensen, N.E. Bruun, F.J. Olsen, T. Fritz-Hansen, J.S. Jensen, T. Biering-Sorensen
(Gentofte, DK)
Recent trends in the prevalence, management and clinical outcomes of patients with symptomatic P6539
chronic heart failure in Japan - A report from the CHART studies.
– R. Ushigome, Y. Sakata, S. Miyata, M. Miura, S. Tadaki, K. Sato, T. Yamauchi, T. Onose, K. Tsuji,
Quantification of fibrosis in left ventricular endomyocardial biopsy can be a valuable tool to estimate P6540
prognosis and individualize therapy in heart failure patients.
– E. Kayvanpour, F. Sedaghat-Hamedani, T.D. Li, N. Grabe, B. Lahrmann, H.A. Katus, B. Meder (Heidelberg,
DE)
A useful risk assessment tool of malnutrition and its prognostic impact in patients with acute heart P6541
failure.
– N. Iwakami, T. Nagai, Y. Sugano, T. Shibata, Y. Asaumi, T. Noguchi, K. Kusano, H. Ogawa, S. Yasuda,
Association of compromised right ventricular function with reduced exercise tolerance predicts survival P6542
in patients with chronic heart failure.
– C. Cucco, A.B. Scardovi, G.G. Galeotti, A. Simioniuc, M.C. Scali, S. Ghio, A. Rossi, P.L. Temporelli,
M. Marzilli, F.L. Dini (Pisa, Rome, Pavia, Verona and Veruno, IT)
Advanced age affects outcomes with LVAD support. P6543
– S.A. Smith, B.C. Lee, S. Emani (Columbus, US)
Prognostic impacts of new onset atrial fibrillation in patients with chronic heart failure: an interim P6544
analysis of the CHART-2 study.
– T. Yamauchi, Y. Sakata, S. Miyata, M. Miura, S. Tadaki, R. Ushigome, K. Sato, T. Onose, K. Tsuji,
Determinants and prognostic significance of delirium in patients with acute heart failure. P6545
– S. Honda, T. Nagai, Y. Sugano, T. Shibata, Y. Asaumi, T. Noguchi, K. Kusano, H. Ogawa, S. Yasuda,
Mortality after hospitalization for heart failure: a Slovenian national database analysis 2004 to 2012. P6546
– M. Lainscak, D. Omersa, I. Erzen, J. Farkas (Celje and Ljubljana, SI)
Apolipoprotein J but not high-density lipoprotein is an independent predictor of mortality in patients with P6547
advanced heart failure.
– B. Richter, L. Koller, M. Brekalo, G. Zorn, K. Huber, G. Maurer, R. Pacher, J. Wojta, M. Huelsmann,
A. Niessner (Vienna, AT)
PROGNOSIS II TUESDAY – AFTERNOON

Pericardial effusion is a marker of increased mortality in thalassemia major patients. P6548
– A. Meloni, P. Toia, M.G. Neri, S. Renne, G. Valeri, V. Positano, R. Renni, R. Mattei, C. Salvatori, A. Pepe
(Pisa, Palermo, Lamezia Terme, Ancona, Casarano and Adria, IT)
Outcomes in patients with probable cardiac sarcoidosis in comparison with definite cardiac sarcoidosis. P6549
– Y. Takaya, K. Nakamura, H. Ito (Okayama, JP)
Prevalence and impact of coronary artery disease in patients with takotsubo cardiomyopathy. P6550
– J. Diekmann, M. Jaguszewski, J.R. Ghadri, V.L. Cammann, D.R. Bataiosu, C. Neumann, V. Geyer,
L.C. Napp, T.F. Luescher, C. Templin (Zurich, CH; Hannover, DE)
YKL-40 In chronic heart failure: Analysis from the controlled rosuvastatin multinational trial in heart P6551
failure (CORONA).
– F.K. Arain, L. Gullestad, S.H. Nymo, J. Kjekshus, J.G. Cleland, J. Wikstrand, J.J. McMurray, P. Aukrust,
T. Ueland (Oslo, NO; Hull and Glasgow, UK; Gothenburg, SE)
Clinical utility of combined platelet count and neutrophil-to-lymphocyte ratio in predicting cardiovascular P6552
outcome in patients with chronic heart failure.
– M. Mohan, M. Levin, J. Singh, A.M. Choy, A.D. Struthers, C.C. Lang (Dundee, UK)
Incidence and predictors of new-onset heart failure in patients with atrial fibrillation: the fushimi af P6553
registry.
– M. Iguchi, H. Ogawa, N. Masunaga, M. Ishii, M. Esato, Y. Chun, H. Wada, K. Hasegawa, M. Abe, M. Akao
(Kyoto, JP)
401
Additional prognostic impact of sequential organ failure assessment on 30-day mortality in acute heart P6554
failure.
– T. Yagyu, T. Nakagawa (Osaka, JP)
Growth differentiation factor 15 (GDF-15) is a strong predictor of outcome in heart failure patients with P6555
anaemia-results from the RED-HF study.
– T. Ueland, L. Gullestad, J. Young, M. Pfeffer, K. Swedberg, J.J.V. McMurray, R. Diaz, A. Desai, I. Anand,
P. Aukrust (Oslo, NO; Cleveland, Boston and Minneapolis, US; Gothenburg, SE; Glasgow, UK; Rosario, AR)
Usefulness of child-turcotte-pugh score for predicting death in patients with acute decompensated heart P6556
failure.
– R. Zhang, J. Zhang, Y. Zhang, Y. Huang, Q. Zhou, T. An (Beijing, CN)
Factors predicting mortality after transcatheter aortic valve implantation in patients with severe aortic P6557
stenosis with the corevalve prosthesis.
– E. Munoz-Garcia, M. Munoz-Garcia, A.J. Munoz Garcia, M.F. Jimenez-Navarro, A.J. Dominguez-Franco,
ES)
PROGNOSIS III
Prognostic impact of fat volume in men versus women with acute decompensated heart failure. P6558
– T. Yamada, Y. Furukawa, S. Tamaki, Y. Iwasaki, M. Kawasaki, A. Kikuchi, T. Kondo, M. Ishimi, T. Ozaki,
M. Fukunami (Osaka, JP)
Worsening heart failure in acute decompensated heart failure admissions: In-hospital and post discharge P6559
impact on prognosis.
– P. Klin, C. Zambrano, L. Varela Falcon, F. Zeppa, A. Bilbao, E. Giordanino, F. Klein (Buenos Aires, AR)
Prognosis and predictive factors for normalization of left ventricular ejection fraction in dilated P6560
cardiomyopathy.
– I. Ruiz-Zamora, J. Rodriguez-Capitan, M.L. Ruiz-Reina, J.J. Gomez-Doblas, L. Morcillo-Hidalgo,
A.J. Munoz-Garcia, E. De Teresa-Galvan, J.M. Garcia-Pinilla (Calahorra, El Ejido, Granada and Málaga, ES)
Age, clinical characteristics and outcomes for patients hospitalized with acute heart failure: insights from P6561
the Gulf aCute heArt failuRe rEgistry (Gulf CARE).
– E. Ahmed, K. Sulaiman, J. Al-Suwaidi, N. Asaad, R. Singh, K. Alhabib, A. Alsheikh, M. Al-Jarallah,
H. Alfaleh, M. Yaccoub (Doha, QA; Muscat, OM; Riyadh, SA; Abu Dhabi, AE; Kuwait, KW)
Troponin I by new ultrasensitive single molecule array technology: the determinants and prognostic role P6562
in chronic systolic heart failure.
– V. Melenovsky, J. Benes, M. Kotrc, M.J. Conrad, D. Wilson, J. Kautzner, P. Jarolim (Prague, CZ; Boston
and Lexington, US)
Different prognostic factors according to left ventricular systolic function in patients with acute P6563
– S.H. Kim, H.L. Kim, M.S. Im, H.L. Lee, J.B. Seo, W.Y. Chung, J.H. Zo, M.A. Kim (Seoul, KR)
Characteristics and outcome of patients admitted to hospital with heart failure according to the severity P6564
of peripheral oedema in the national (England & Wales) heart failure audit.
– A. Shoaib, J. John, S. Gupta, M. Nasir, M.N. Attar, K. Wong, H. Dargie, T. McDonagh, A.L. Clark,
J.G.F. Cleland (Hull, York, Glasgow and London, UK)
Determinants of shock and mortality in Takotsubo cardiomyopathy: a cohort study. P6565
– C.-R. Chong, J. Stansbourough, B. Raman, T.H. Nguyen, C.J. Neil, J.D. Horowitz (Adelaide, AU)
Atrial fibrillation in acute heart failure: A secondary analysis of the ALARM-HF registry. P6566
– P. Simitsis, J. Parissis, D.T. Farmakis, I. Ikonomidis, V. Bistola, A. Xanthopoulos, G. Filippatos, A. Mebazaa,
J. Lekakis, F. Follath (Athens, GR; Paris, FR; Zurich, CH)
Echo and natriuretic peptide guided therapy in chronic systolic heart failure: a propensity score analysis P6567
from an observational study of 1,137 patients.
– A. Simioniuc, E. Carluccio, M.C. Scali, L. Gargani, C. Cucco, S. Ghio, A. Rossi, P.L. Temporelli, M. Marzilli,
F.L. Dini (Pisa, Perugia, Pavia, Verona and Veruno, IT)
PROGNOSIS V
Outcomes prediction in heart failure by measures of heart rate variability dynamics. P6568
– S. Srivastava, A. Eleuteri, R. Dawson, M. Fisher, M. Elt, R. Laflin, R.M. Cubbon, M.T. Kearney, A.C. Fisher,
D. Groves (Liverpool and Leeds, UK)
Increase in ultra-sensitive troponin I is associated with poor prognosis in patients with acute heart failure. P6569
– R. Zymlinski, M. Sokolski, J. Biegus, P. Siwolowski, E.A. Jankowska, J. Todd, R. Yerramilli, J. Estis,
W. Banasiak, P. Ponikowski (Wroclaw, PL; Alameda, US)
Sleep-disordered breathing are associated with impaired cardiac sympathetic innervation and P6570
incrementally predict prognosis in heart failure patients.
– O. Scala, S.F. Paolillo, T.P. Pellegrino, R.F. Formisano, G.R. Rengo, A.S. Starace, F.D.M. De Michele,
D.L. Leosco, A.C. Cuocolo, P.P.F. Perrone Filardi (Naples, IT)
Multi-parametric cardiac magnetic resonance for prediction of cardiac complications in thalassemia P6571
intermedia: a prospective multicenter study.
– N. Giunta, A. Meloni, P. Giuliano, P. Terrazzino, M.G. Neri, C. Gerardi, N. Romano, V. Positano,
C. Salvatori, A. Pepe (Palermo, Pisa, Sciacca and Reggio Emilia, IT)
Role of endogenous hydrogen sulfide synthesis enzymes gene variants in the 5-year prognosis of P6572
patients with ischemic cardiomyopathy related chronic heart failure in Chinese Han population.
– L. Ren, X.Y. Liu, Q. Guo, X.H. Chen, Y.H. Jia, J.L. Pu, S. Zhang (Beijing, CN)
402
The role of GDF-15, a marker of fibrosis, in cardiogenic shock. P6573

– M. Hongisto, V.-P. Harjola, A. Mebazaa, L. Kober, A. Sionis, J. Silva Cardoso, K. Pulkki, J. Lassus (Helsinki
and Kuopio, FI; Paris, FR; Copenhagen, DK; Barcelona, ES; Porto, PT)
The use of different methods for the selection of patients with non-ischemic cardiomyopathy for cardiac P6574
– D. Lebedev, S.V. Popov, S.N. Krivolapov, G. Savenkova, S. Minin, M.V. Zlobina (Tomsk, RU)
Prognostic predictors in a population-based cohort study of outpatients across different heart failure P6575
phenotypes.
– S. Poli, A. Iorio, C. Di Nora, E. Zambon, M. Russo, G. Barbati, L. Tarantini, G. Cioffi, G. Sinagra, A. Di
Lenarda (Trieste, Belluno and Trento, IT)
Severe hyponatremia and in-hospital deterioration of sodium is associated with increased mortality in P6576
patients admitted with acute heart failure.
– D.Y. Lu, H.M. Cheng, W.C. Yu, C.H. Chen, S.H. Sung (Taipei, TW)
Comparison of usefulness of coronary SYNTAX score in patients with prior heart failure with preserved P6577
ejection fraction versus with reduced ejection fraction: a sub-analysis of shinano registry.
– M. Minamisawa, T. Miura, H. Motoki, H. Hioki, N. Hashizume, N. Abe, S. Ebisawa, A. Izawa, J. Koyama,
U. Ikeda (Matsumoto, JP)
PROGNOSIS IV
The relationship between glucose variability and in-hospital mortality in patients with acute heart failure P6578
syndrome: data from the Korean Acute Heart Failure (KorAHF) registry.
– J. Oh, S.M. Kang, E.S. Jeon, J.J. Kim, S.H. Baek, M.C. Cho, S.C. Chae, D.J. Choi, B.S. Yoo, B.H. Oh
(Seoul, Cheongju, Daegu, Seongnam and Wonju, KR)
Prognostic value of NT-proBNP in heart failure with preserved versus reduced ejection fraction (From the P6579
Korean Heart Failure [KorHF] registry).
– S.H. Kang, J. Park, D.J. Choi, C.H. Yoon, I.Y. Oh, S.M. Kang, B.S. Yoo, E.S. Jeon, J.J. Kim, B.H. Oh
(Seongnam, Seoul and Wonju, KR)
Which patient with left ventricular ejection fraction ≤40% and when die during 3 years after discharge P6580
home from acute myocardial infarction - analysis of joined PL-ACS and AMI-PL registries.
– M. Gasior, M. Gierlotka, B. Wojtyniak, M. Wysocki, P. Hoffman, G. Opolski, K. Chlebus, M. Zembala,
L. Polonski, T. Zdrojewski (Zabrze, Warsaw and Gdansk, PL)
Right ventricle deformation, systolic function and pressure overload which one the key prognosticator in P6581
outpatients with systolic heart failure.
– L. Sargento, S. Longo, N. Lousada, R. Palma-Reis (Lisbon, PT)
KIM-1 and NAG: new predictors for long-term progression of chronic kidney disease in patients with P6582
heart failure.
– C. Jungbauer, S. Stadler, L.S. Maier, A. Luchner (Regensburg, DE)
Impact of diabetes mellitus on acute heart failure. P6583
– H.Y. Lee, C.W.S. Choe, L.S.E. Lee, C.H.J. Cho, O.B.H. Oh (Seoul, KR)
Heart failure epidemiology: a population-based analysis of 88,195 patients. P6584
– N. Farre, E. Vela, M. Cleries, M. Bustins, C. Enjuanes, P. Moliner, S. Ruiz, J.M. Verdu-Rotellar,
J. Comin-Colet (Barcelona, ES)
Left atrial emptying function predicts long-term outcome in HFpEF patients. P6585
– G. Bajraktari, I. Bytyci, A. Ahmeti, P. Ibrahimi, A. Poniku, E. Haliti, A. Batalli, M.Y. Henein (Prishtina, XK;
Umeå, SE)
Serum relaxin as a prognostic biomarker in acute heart failure. P6586
– M. Pintalhao, P. Castro-Chaves, F. Vasques-Novoa, F. Goncalves, R. Fontes-Carvalho, P. Lourenco,
A. Leite-Moreira, P. Bettencourt (Porto, PT)
Additive effect of reduced left ventricle ejection fraction and functional status at discharge home from P6587
acute myocardial infarction on 3-year rehospitalizations due to heart failure and mortality.
– M. Gierlotka, M. Gasior, M. Hawranek, T. Tajstra, M. Ostrega, B. Hudzik, P. Rozentryt, A. Lekston,
M. Zembala, L. Polonski (Zabrze, PL)
TREATMENT OF HYPERTENSION II
Nine-year target systolic blood pressure less than 120 mmHg for more than 65 aged hypertension P6588
patients with chronic renal disease.
– X. Zeng, X.H. Zeng, X.J. Zeng, Y.Y. Li, J.Y. Xie, Z.H. Liu (Chengdu and Shenzhen, CN)
Effect of metformin on ventricular remodeling in patients with primary hypertension and type 2 diabetes P6589
mellitus.
– W. Zhao, Y.Y. Wu, Y.Y. Zhang, W.Y.Y. Gao (Beijing, CN)
Randomized study to determine the effect of unmonitored diet and exercise education on blood pressure P6590
(the LSM study).
– C.J. Lee, J.-C. Youn, S.-H. Lee, S. Park, S.-M. Kang, D. Choi, Y. Jang (Seoul, KR)
Influence of fixed-dose combination perindopril/amlodipin on target organ damage in patients with P6591
– G. Radchenko, L.O. Mushtenko, Y.U. Sirenko, O. Snitzarenko, S. Potashev, S. Kushnir, O. Yarinkina (Kiev,
UA)
Prevalence, treatment and control of hypertension in middle-aged Mexican adults. P6592
– L. Gnatiuc, J. Alegre-Diaz, W. Herrington, M. Lopez Cervantes, R. Peto, R. Collins, R. Tapia-Conyer,
J. Emberson, P. Kuri-Morales (Oxford, UK; Mexico City, MX)
403
Use of blood pressure salt sensitivity determination to optimize anti-hypertensive therapy in patients with P6593
complicated arterial hypertension.
– A. Babkin, N.V. Golovko, M.M. Romanova, L.A. Stepanova, O.N. Zolotarev (Voronezh, RU)
Evaluation of β-thalassemia minor on metabolic profile in patients with newly diagnosed hypertension. P6594
– K.M. Lampropoulos, A. Triantafyllou, E. Triantafyllou, P. Karkalousos, G. Vyssoylis, E. Kapranoy, K. Kappos
(Athens, GR)
Serum uric acid and the risk of development of hypertension in the urban population. P6595
– O. Podpalova (Vitebsk, BY)
Association of urinary sodium excretion with blood pressure and cardiovascular clinical events in South P6596
America: The PURE study.
– P.L. Lamelas, A. Mente, M. O’Donnell, S. Rangarajan, R. Diaz, F. Lanas, P. Lopez Jarammillo, A. Avezum,
K. Teo, S. Yusuf (Hamilton, CA; Rosario, AR; Temuco, CL; São Paulo, BR)
The association between urinary sodium to potassium ratio and blood pressure by salt consumption P6597
level: the Takahata study.
– A. Hirayama, T. Konta, R. Kawasaki, T. Watanabe, A. Hozawa, T. Kayama, I. Kubota (Yamagata and
Sendai, JP)
Low testosterone levels and increased intima media thickness: importance of lipid profile in hypertensive P6598
men.
– N. Ioakeimidis, C. Vlachopoulos, P. Pietri, M. Abdelrasoul, I. Gourgouli, C. Georgakopoulos,
D. Terentes-Printzios, D. Tsekoura, G. Lazaros, D. Tousoulis (Athens, GR)
Relationships between periodontal disease and hypertension and vascular dysfunction - importance of P6599
immunosenescent CD8+ T cells.
– M. Czesnikiewicz-Guzik, G. Osmenda, T. Mikolajczyk, J. Maciag, P. Matusik, M. Drozdz, D. Nowakowski,
M. Filip, G. Wilk, T.J. Guzik (Krakow, PL)
404
WEDNESDAY
2 SEPTEMBER
Attend the online event on

WEDNESDAY
Join ESC Experts to see how recent developments will affect your daily practice
Save the date now to watch the one hour online event
WEDNESDAY 2 SEPTEMBER 2015 – MORNING SESSIONS

BASIC SCIENCE HIGHLIGHTS Highlight Session
Chairperson(s): L. Badimon (Barcelona, ES); G.A. Derumeaux (Créteil, FR)
08:30 Development and cell-based new therapies: stem cells and genes. 6600
– A. Bayes Genis (Badalona, ES)
08:45 Integrative cardiovascular pathophysiology. 6601
– C. De Wit (Lübeck, DE)
09:00 Cardiac function. 6602
– J.L. Balligand (Brussels, BE)
09:15 Ischaemic heart disease. 6603
09:30 Atherosclerosis and remodeling. 6604
– J. Tunon Fernandez (Madrid, ES)
09:45 Inflammation and immunomodulation. 6605
– A.C. Newby (Bristol, UK)

HOT ISSUES IN THE CARDIOMYOPATHIES Rapid Fire Abstract
Chairperson(s): S.B. Felix (Greifswald, DE); C. Rapezzi (Bologna, IT)
08:30 Prediction of thromboembolic (TE) risk in patients with hypertrophic cardiomyopathy (HCM 6606
Risk-CVA).
– O.P. Guttmann, P. Elliott (London, UK)
08:39 A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in 6607
patients with hypertrophic cardiomyopathy.
– M. Liebregts, P.A. Vriesendorp, B.K. Mahmoodi, A.F.L. Schinkel, M. Michels, J.M. Ten Berg (Nieuwegein
and Rotterdam, NL)
08:48 Randomised trial of combination cytokine and adult autologous bone marrow progenitor cell 6608
administration in patients with non-ischaemic dilated cardiomyopathy - the regenerate-dcm
randomized phase II.
– S. Hamshere, S. Arnous, T. Choudhury, F.A. Choudry, D. Jones, S. Agrawal, J. Martin, A. Mathur (London,
UK)
08:57 Long-term prognosis according to different aetiologies in an adult population of patients with 6609
– S. Rosmini, C. O’Mahony, E. Biagini, N. Ruozi, L. Lopes, A. Pantazis, M. Tome-Esteban, W. McKenna,
C. Rapezzi, P.M. Elliott (London, UK; Bologna, IT)
09:06 Comparison of two models estimating sudden cardiac death risk in hypertrophic cardiomyopathy. 6610
Impact on primary prevention practice.
– P. Rubis, B. Biernacka-Fijalkowska, S. Wisniowska-Smialek, L. Khachatryan, A. Karabinowska, P. Faltyn,
E. Dzwiecka, A. Lesniak-Sobelga, M. Kostkiewicz, P. Podolec (Krakow, PL)
09:15 Predictors of atrial fibrillation in hypertrophic cardiomyopathy (HCM Risk-AF). 6611
– O.P. Guttmann, P. Elliott (London, UK)
09:24 Utility of qualitative and quantitative evaluation of viral nucleic acids in cardiac biopsy and blood 6612
samples in patients with suspected myocarditis/ inflammatory cardiomyopathy.
– A. Pawlak, M. Przybylkowski, A.M. Nasierowska-Guttmejer, K.E. Gil, M. Durlik, R.J. Gil (Warsaw, PL)
09:33 Morphological features in Noncompaction Cardiomyopathy - Data from the German NCCM 6613
Registry (ALKK).
– B.J. Gerecke, C. Stoellberger, M. Bradaczek, C.H. Mueller, D. Nothnagel, R. Engberding (Peine, Wolfsburg,
Lüneburg and Ludwigsburg, DE; Vienna, AT)
09:42 Expression of stromal cell-derived factor 1 in endomyocardial biopsies of patients with suspected 6614
myocarditis predicts mortality.
– C.S. Meyer-Zurn, B. Walker, D. Rath, P. Seizer, T. Geisler, R. Kandolf, F. Lang, K. Klingel, M. Gawaz,
O. Borst (Tübingen, DE)
09:51 Parvovirus B19 nucleic acids copy number do not determine structural changes in cardiac tissue 6615
from patients with cardiac viral infection.
– A. Pawlak, M. Frontczak-Baniewicz, M. Przybylkowski, K. Labus, R.J. Gil (Warsaw, PL)
406

INVASIVE IMAGING AND FUNCTIONAL ASSESSMENT FOR PLAQUE VULNERABILITY AND Rapid Fire Abstract
CLINICAL OUTCOMES
Chairperson(s): U. Limbruno (Grosseto, IT); A. Maehara (New York, US)
08:30 Using pressure wire to assess discrepancies between cardiac catheterization and 6616
echocardiography assessement of severe aortic stenosis, impact on clinical outcomes.
– Z. Fanari, J. Thapa, K. Persad, S. Hammami, M. Kostal, E. Marshall, A. Doorey (Newark, US)
08:39 Randomized study comparing the impact of FFR measurement in patients with intermediate 6617
coronary stenoses allocated by angiography to conservative versus interventional treatment -
SPECTRUM trial.
– G.L. Figueiredo, G.B. Marin, A.V. Badran, G.C. Novaes, D.C. Lemos, I.M. Lago, J.L. Haddad,
M.O. Lima-Filho, P.A. Lemos-Neto, J.A. Marin-Neto (Ribeirao Preto and São Paulo, BR)
08:48 Relationship between atherosclerotic plaque components on optical coherence tomography and 6618
chronic kidney disease in patients with coronary artery disease.
– T. Sugiyama, S. Kimura, Y. Yamakami, K. Kojima, Y. Sagawa, H. Ohtani, K. Hishikari, H. Hikita,
08:57 Impact of intravascular imaging guidance in high-risk percutaneous coronary intervention: 6619
propensity adjusted analysis.
– J. Chandrasekhar, S. Roy, M. Aquino, J. Kovacic, A. Kini, P. Moreno, P. Krishnan, G. Dangas, S. Sharma,
R. Mehran (New York, US)
09:06 FFR risk continuum for target vessel failure: a FAME 2 trial subanalysis. 6620
– E. Barbato, G. Toth, N.P. Johnson, N.H.J. Pijls, W. Fearon, P. Tonino, N. Curzen, Z. Piroth, P. Juni, B. De
Bruyne (Aalst, BE; Houston and Stanford, US; Eindhoven, NL; Southampton, UK; Budapest, HU; Berne,
CH)
09:15 First clinical and intracoronary evaluation of indocyanine green for targeted intravascular 6621
near-infrared fluorescence imaging of high-risk atherosclerotic plaques.
– J.W. Verjans, E.A. Osborn, G.J. Ughi, A.P. Antoniadis, M.I. Papafaklis, P. Libby, P.H. Stone, R.P. Cambria,
G.J. Tearney, F.A. Jaffer (Utrecht, NL; Boston, US)
09:24 Mechanisms of stent thrombosis analyzed by optical coherence tomography: insights from the 6622
national PESTO French registry.
– G. Souteyrand, N. Amabile, L. Mangin, G. Cayla, G. Finet, N. Meneveau, G. Range, P. Barnay, C. Trouillet,
P. Motreff (Clermont-Ferrand, Paris, Annecy, Nîmes, Lyon, Besançon, Chartres, Avignon and La Rochelle,
FR)
09:33 A novel optical coherence tomography system for detection of a lipid-rich plaque. 6623
– A. Shimokado, T. Kubo, A. Taruya, T. Nishiguchi, Y. Matsuo, Y. Ino, T. Hozumi, A. Tanaka, T. Akasaka
(Wakayama, JP)
09:42 Incidence, clinical presentation, and predictors of early-onset neoatherosclerosis after 6624
drug-eluting stent implantation.
– C.K. Kim, B.K. Kim, S.Y. Lee, D.H. Shin, J.S. Kim, Y.G. Ko, D.H. Choi, Y.S. Jang, M.K. Hong (Seoul, KR)
09:51 Comparison between non-invasive coronary flow reserve, instantaneous wave-free ratio, and 6625
fractional flow reserve, to assess the functional significance of LAD stenosis of intermediate
severity.
– P. Meimoun, D. Ardourel, J. Clerc, A. Luycx-Bore, F. Elmkies, S. Martis, H. Zemir, J. Boulanger
(Compiegne, FR)
WEDNESDAY – MORNING
407

CARDIOPULMONARY RESUSCITATION Rapid Fire Abstract
Chairperson(s): C. Spaulding (Suresnes, FR); C.H. Hassager (Copenhagen, DK)
08:30 Implementation of a medical emergency team leads to a reduction in cardiac arrest calls and 6626
enhanced patient care in the critically ill.
– S. Hassan, A. Patel, H. Kirk, A. Ullah, T. Hamid (Wirral, UK)
08:39 Bystander cardiopulmonary resuscitation associated with lower risk of nursing home admission 6627
and anoxic brain damage in out-of-hospital cardiac arrest survivors.
– K. Kragholm, M. Wissenberg, R.N. Mortensen, F. Lippert, G. Gislason, L. Kober, K. Fonager, S.E. Jensen,
C. Torp-Pedersen, B.S. Rasmussen (Aalborg, Gentofte and Copenhagen, DK)
08:48 Relationship between electrocardiographic changes and neurologic outcomes in patients treated 6628
with multidisciplinary therapy after out-of-hospital ventricular fibrillation cardiac arrest: SAVE-J
Study.
– T. Nakashima, Y. Tahara, S. Yasuda, N. Morimura, K. Nagao, Y. Asai, H. Yokota, M. Hase, T. Atsumi,
T. Sakamoto (Osaka, Yokohama, Tokyo, Sapporo and Kobe, JP)
08:57 Characteristics of regional cerebral oxygen saturation levels in patients who experience 6629
out-of-hospital cardiac arrest with or without return of spontaneous circulation.
– K. Nishiyama, N. Ito, T. Orita, M. Abe, H. Yasuda, Y. Honma, H. Arimoto, M. Tokura, K. Hayashida,
K. Nagao (Kyoto, Kawasaki, Yokohama, Musashino, Tokyo, Osaka and Tochigi, JP)
09:06 Effectiveness of extracorporeal life support for patients with cardiogenic shock due to intractable 6630
arrhythmic storm.
– S. Le Pennec-Prigent, R.P. Martins, C. Chabanne, B. Lelong, J.C. Daubert, C. Leclercq, P. Mabo,
E. Flecher (Rennes, FR)
09:15 Outcome predictors in cardiopulmonary resuscitation facilitated by extracorporeal membrane 6631
oxygenation.
– C. Jung, K. Janssen, M. Kaluza, G. Fuernau, T.C. Poerner, M. Fritzenwanger, R. Pfeifer, H.R. Figulla (Jena
and Leipzig, DE)
09:24 Well-trained emergency life-saving technicians improve rates of return of spontaneous circulation 6632
and neurologic survival after out-of-hospital cardiac arrest.
– T. Uechi, S. Shibata, T. Tsukada, T. Kobayashi, H. Miyauchi, T. Tokutsu, Y. Sano, M. Arai, T. Tsunoda,
T. Matsuda (Tokyo, JP)
09:33 Does the temperature influence on the moment of awakening in patients treated with therapeutic 6633
hypothermia after cardiac arrest?
– I. Ponz De Antonio, E. Lopez De Sa, D. Gemma, O. Gonzalez, J. Caro, Z. Blazquez, J.L. Lopez Sendon
(Madrid, ES)
09:42 In-hospital and mid-term outcome in resuscitated patients after out-of-hospital cardiac arrest 6634
complicating acute myocardial infarction (analysis from MIE ACS registry in Japan).
– J. Masuda, N. Kumagai, T. Seko, K. Dohi, T. Tanigawa, Y. Saito, T. Kitamura, A. Kawasaki, K. Makino,
M. Itou (Tsu and Mie, JP)
09:51 Pre-hospital cardiac arrest survivors sent for emergency angiography: who is more likely to 6635
experience an acute myocardial infarction?
– F. Zeyons, L. Jesel, O. Morel, H. Kremer, N. Messas, S. Hess, U. Crimizade, P. Ohlmann (Strasbourg, FR)
408

PROGNOSIS Rapid Fire Abstract
Chairperson(s): K. McDonald (Dublin, IE); F. Braunschweig (Stockholm, SE)
08:30 Nocturnal hypoxemic burden: time of hypoxemia represents a robust and independent predictor 6636
of death in chronic heart failure and reduced ejection fraction.
– O. Oldenburg, B. Wellmann, H. Fox, T. Bitter, U. Thiem, A. Buchholz, D. Horstkotte, K. Wegscheider (Bad
Oeynhausen, Bochum and Hamburg, DE)
08:39 Prognostic impact of kidney disease in heart failure - A study of 47,716 heart failure patients in 6637
the Swedish heart failure registry.
– I. Lofman, K. Szummer, I. Hagerman, U. Dahlstrom, L.H. Lund, T. Jernberg (Stockholm and Linköping, SE)
08:48 A Low baseline hsTnT value in acute heart failure identifies patients at very low risk for 180-day 6638
cardiovascular mortality: An analysis from the RELAX-AHF trial.
– P. Pang, M. Metra, M.F. Prescott, P. Ponikowski, J. Kriger, B. Greenberg, G. Filippatos, M. Felker,
B. Davison, J.R. Teerlink (Indianapolis, Hanover, New York, San Diego, Durham and San Francisco, US;
Brescia, IT; Warsaw, PL; Athens, GR)
08:57 Absence of obesity paradox in ambulatory diabetic patients with heart failure. 6639
– E. Zamora, J. Lupon, M. De Antonio, N. Alonso, J. Santesmases, M. Troya, C. Diez-Quevedo, S. Altimir,
M. Boldo, A. Bayes-Genis (Badalona, ES)
09:06 Clinical implications of identifying co-morbid depression on heart failure prognosis in a 6640
community cohort.
– B. Jani, F. Mair, V. Roger, S. Weston, J. Ruoxiang, A. Chamberlain (Glasgow, UK; Rochester, US)
09:15 Long-term temporal patterns of serially measured circulating miR-22-3p and miR-378 are strong 6641
predictors of adverse clinical outcome in patients with chronic heart failure: results from the
Bio-SHiFT.
– N. Van Boven, K.M. Akkerhuis, S.S. Anroedh, A.A. Constantinescu, K. Caliskan, O.C. Manintveld,
D. Rizopoulos, E. Boersma, V.A. Umans, I. Kardys (Alkmaar and Rotterdam, NL)
09:24 Lower mortality but similar rates of heart failure readmission in young adults with heart failure: a 6642
nationwide Danish cohort study.
– S.L. Kristensen, C.M. Wong, U.M. Mogensen, M. Lamberts, P.S. Jhund, M. Petrie, G.H. Gislason,
C. Torp-Pedersen, J.J.V. McMurray, L. Kober (Hellerup, Copenhagen and Aalborg, DK; Glasgow, UK)
09:33 Soluble ST2 is associated with outcome in patients with heart failure and anaemia: results from 6643
the RED-HF study.
– K. Broch, T. Ueland, L. Kou, I.S. Anand, J.J.V. McMurray, A.S. Desai, P. Aukrust, L. Gullestad (Oslo, NO;
Cleveland, Minneapolis and Boston, US; Glasgow, UK)
09:42 Fibroblast growth factor 23 is an independent and specific predictor of mortality in patients with 6644
heart failure and reduced ejection fraction.
– L. Koller, M.E. Kleber, V.M. Brandenburg, G. Goliasch, H. Scharnagl, T.B. Grammer, A. Tomaschitz,
M. Huelsmann, W. Maerz, A. Niessner (Vienna and Graz, AT; Mannheim and Aachen, DE)
09:51 AHEAD score - long-term risc clasification in acute heart failure. 6645
– J. Spinar, J. Parenica, J. Jarkovsky, L. Spinarova, J. Vitovec, A. Mebazaa, E. Gayat, A. Linhart,
P. Widimsky, F. Malek (Brno and Prague, CZ; Paris, FR)
409

CARDIOVASCULAR PREVENTION: WHAT WORKS FOR WHOM? Rapid Fire Abstract
Chairperson(s): E. Prescott (Copenhagen, DK); A. Santoso (Jakarta Barat, ID)
08:30 Long-term effects of a cardiovascular prevention program in primary health care in Sweden. 6646
– G. Journath, N. Hammar, A. Linnersjo, M. Vikstrom, G. Walldius, I. Krakau, P. Lindgren, U. De Faire,
M.-L. Hellenius (Stockholm, SE)
08:39 Stairs instead of elevators at the workplace decreases PCSK9 levels in a healthy population. 6647
– C. Kamani, B. Gencer, F. Monteccuco, D. Courvoisier, N. Vuilleumier, P. Meyer, F. Mach (Geneva, CH)
08:48 Comparative effectiveness of transitional care services in patients discharged from hospital with 6648
heart failure: a meta-analysis.
– H. Van Spall, T. Rahman, O. Mytton, M. Coppens, Q. Ibrahim, S. Connolly (Hamilton, CA; Cambridge, UK)
08:57 Effects of interactive patient support with a smartphone app on drug adherence and lifestyle 6649
changes in myocardial infarction patients.
– C. Varenhorst, J. Bodegard, S. Jerstrom, J. Akesson, H. Brorsson, J. Alfredsson, P. Albertsson,
J.E. Karlsson, N. Johnston (Uppsala, Södertälje, Linköping, Gothenburg and Jönköping, SE)
09:06 Effect of a multi-dimensional secondary prevention program on cardiovascular events in patients 6650
hospitalized with acute coronary syndromes: a multicentric Swiss prospective trial.
– B. Gencer, D. Carballo, R. Auer, D. Nanchen, L. Raeber, C.M. Matter, S. Windecker, T.F. Luescher,
N. Rodondi, F. Mach (Geneva, Lausanne, Berne and Zurich, CH)
09:15 Myocardial function and systemic anti-inflammatory drugs in patients with severe psoriasis: a 6651
prospective echocardiographic study.
– O. Ahlehoff, P.R. Hansen, G.H. Gislason, M. Frydland, L.E. Bryld, H.E. Elming, G.B.E. Jemec (Roskilde,
Hellerup and Copenhagen, DK)
09:24 Change in CHD secondary prevention paradigm: improved medical blood pressure and 6652
hyperlipidaemia control, but increasing prevalence of obesity and diabetes inadequately
controlled by lifestyle changes.
– J. Bruthans, O. Mayer Jr, J. Filipovsky, P. Wohlfahrt, R. Cifkova (Prague and Pilsen, CZ)
09:33 Patterns of statin use and outcomes following myocardial infarction among Medicare 6653
beneficiaries.
– L.D. Colantonio, K.L. Monda, L. Huang, R. Rosenson, S.T. Kent, B. Taylor, P. Muntner, S. Glasser
(Birmingham, Thousand Oaks and New York, US)
09:42 Health outcomes and platelet-aggregation inhibition after acute myocardial infarction in clinical 6654
practice. Findings from the PIPER Study.
– L. Degli Esposti, G. Mosumeci, C. Veronesi, S. Buda (Ravenna and Bergamo, IT)
09:51 Low oxygen concentration is an associated risk of contrast induced nephropathy in patients with 6655
impaired renal function after cardiovascular angiography.
– H. Sekiguchi, Y. Ajiro, Y. Uchida, K. Iwade, N. Tanaka, K. Shimamoto, Y. Tsurumi, M. Kawana, N. Hagiwara
(Yokohama and Tokyo, JP)

ESC CLINICAL PRACTICE GUIDELINES 2015 – HIGHLIGHTS Highlight Session
Chairperson(s): J.L. Zamorano Gomez (Madrid, ES); A.V.C. Vaz Carneiro (Lisbon, PT)
09:00 Pericardial Diseases. 6656
09:12 Ventricular Arrhythmias & Sudden Cardiac Death. 6657
09:24 ESC/ERS Pulmonary Hypertension. 6658
09:36 Infective Endocarditis. 6659
– P. Nihoyannopoulos (London, UK)
09:48 Acute Coronary Syndromes NSTE. 6660
410

ESC CONGRESS HIGHLIGHTS Highlight Session
Chairperson(s): G.A. Derumeaux (Créteil, FR); S.G. Priori (Pavia, IT)
10:30 ESC Congress 2015 Awards. 6661
– G.A. Derumeaux (Créteil, FR)
10:42 Arrhythmias. 6662
10:54 Heart failure and cardiomyopathies. 6663
11:06 Acute coronary syndromes and acute cardiac care. 6664
11:18 Interventional cardiology. 6665
11:30 Hypertension. 6666
11:42 Valvular heart disease and pulmonary circulation. 6667
11:54 Imaging. 6668
12:06 Preventive cardiology. 6669
12:18 Best of ESC presentation. 6670
411
EXTEND YOUR ESC CONGRESS
EXPERIENCE ON
ESC Congress 2015 provides you with

the latest updates in cardiovascular science
Watch the Best of ESC on ESC TV to see how
recent developments will affect your daily
practice
Moderated by
Geneviève A Derumeaux, FESC (FR)
Keith A A Fox, FESC (UK)
International Experts
V Delgado (NL) Imaging
C Linde, FESC (SE) Arrhythmias - Genetics and Basic Science
JJV McMurray, FESC (UK) Heart Failure
M Roffi, FESC (CH) Interventions - Valve Disease
S Sharma, FESC (UK) Cardiovascular Prevention
J Stepinska, FESC (PL) Acute Cardiac Care - Acute Coronary Artery Disease - Thrombosis
B Williams, FESC (UK) Hypertension
SAVE THE DATE NOW

TO WATCH THE 1 HOUR ONLINE EVENT
This programme is supported by AstraZeneca and SERVIER

This programme is accredited by the European Board for Accreditation

in Cardiology (EBAC) and by the European Accreditation
Council in CME (EACCME).
NOTES
413
*ULYs
Advances in Cardiology – The Next Lap

www.apsc2017.com
Hosted by Under the auspices of Supported by Managed by

LIST OF
CHAIRPERSONS
& JUDGES, SPEAKERS
& DISCUSSANTS / AUTHORS
Chairpersons & Judges / Speakers & Discussants / Authors Aak – Ahm
NAME PAGE(S) / PROGRAMME NR(S) NAME PAGE(S) / PROGRAMME NR(S) NAME PAGE(S) / PROGRAMME NR(S)
Aakhus, S. 336, P1404, P1791, P2621, Abola, M.T. P1609 Adjedj, J.A. P3461
P3589, 4048, 4156, P4307, 4960 Abou Bakr El Missiri, A.M. P6293 Adlam, D.A. P817
Aakre, K.M. P528 Aboujalala, S. P2468 Adlan, A.M. P4338
Aarnoudse, A.L.H.J. P1391 Aboul Einen, H. 41, 86 Adlbrecht, C. 4278
Aaroe, J. P2745 Abouleisa, R. 6056 Adlbrecht, C.A. P3454
Aaronaes, M. P5601 Aboyans, V. 147 Adler, Y. 325, 356
Aasa, M. P177 Aboyans, V. 3263, 3264, P4108, 4248, Adler, Y. 918, 5989
Aasum, E. P4531 P4558, 5161, P5500, P5574, 6658 Adnot, S. P2360, P4525, P5473, P5557,
Abaci, A. P4534 Abraham, R. 4913 P6148
Abaci, O. P573, P2714 Abraham, T.P. 4913 Adragao, P. P2394, P4349, P4350, P4380
Abad, J.L. P3554 Abraham, W.T. 82 Adriaenssens, T. P2771
Abad Vicente, J. P167 Abraham, W.T. 148, 1079, 2892, P5976 Adrian Cid Menendez, A. P4419
Abaecherli, R. P2695, P4077, P5397 Abrahan, L. P1609, P6412 Aegerter, P.A. 5089
Abaecherli, R.A. P4101 Abramczyk, P. P6506 Aeschbacher, S. P1706, 1843, P4663
Abalhassan, M. P5638 Abramova, A.A. P500 Afonso Nogueira, M. P2473, P2489, P2502,
Abawi, M. P2624 Abreu, A. 322 P2510
Abbas, M. P647 Abreu, A. 59, P501, P506, 2006, 2008, 2010, Agabiti Rosei, C. P5709
Abbas, U. P4606 P2673, 2937 Agabiti Rosei, E. P5709
Abbate, R. P1496, P2522, P6200 Abreu, G. P545, P3452, 4255, P4993, P5338, Agabiti-Rosei, E. 126, 194
Abd Allah, H. P3404 P5345, P5352, P6266, P6529 Agabiti-Rosei, E. 1878, 1879, 2964
Abd El Rahman, M. P2542 Abreu, J. P867, P4434 Agahari, I. P1343
Abd El Raouf, M. P2542 Abreu, M.M.N. 2953 Agarwal, S. P3774
Abd El-Hafeez, H.A. P6428 Absi, D. P1767 Agathopoulos, S. P3442
Abd Elghany, M. P6430 Abt, M. P6464 Agdauletova, S. P667
Abdel Ghany, M. P679 Abu Assi, E. P2482, P4415 Ageno, W. 261
Abdel Moneim, S.S. P3515 Abu-Assi, E. P2458, P2466, P3113, P3472, Ageno, W. P3619, 4133
Abdel Wahab, A.M.A. P5287 P3474, P4406, P5304 Agewall, S. 356, 370
Abdel-Rahim, M.H.M. P6428 Abu-Romeh, N. P652, P2352 Aggarwal, S.K. P1617
Abdel-Salam, Z. P3081 Abugov, S. 235 Aggelakas, A. P4668
Abdelaal, E. P5379 Abuhav, Y. P4587 Aggelaki, M. P791
Abdelaziz, H. P4708 Abujalala, S. P4069 Aggeli, C. P1342
Abdelhafez, M. P5571 Abumuaileq, R.R. P2458, P2482, P3113 Aggeli, K. P3116, 3253
Abdelhai, A.F. P2628 Acar, B. P5681, 6040 Aggelis, A. P1342, P4118
Abdelhamid, M. P701 Acar, E. P5481 Aggio, S. P2389, P4745, P4758, 4863
Abdellaoui, M. P579 Acar, G. P5681 Agha, H.M. P2542
Abdelmoneim, S. 4887 Acasandrei, A.M. 4157 Agiba, N.A. P2807
Abdelmoneim, S.S. P3508, P6472 Accetta, G. 3278 Agnelli, G. 81
Abdelrasoul, M. P204, P1572, P2574, Acciarresi, M. P5608 Agnelli, G. 3055, 4174, P4675, P5595,
P3116, P3679, P4118, P4668, P5540, Acele, A. P722 P5608, P5609, P6216
P5541, P5710, P6598 Acena Navarro, A. P6250 Agnoletti, G. 2930
Abdelwahab, A.M. P1537 Acevedo, M. P4631 Agostinho, J. P2109
Abdon, N.J. P5498 Achenbach, S. 73, 93, 132 Agostinis, M. P3802, P5712
Abdul-Khaliq, H. P721, 2926 Achenbach, S. P623, 959, 1257, P4479, Agostoni, P. P4701, 6088, P6234, P6372
Abdullah, S. P5514 P4510, P5001, P5028, 5154, 5155, 5156, Agostoni, P.F. P2617
Abdulsattar, Y. 1975, P6197, P6212, P6215 P5231, P6374, 6656 Agrawal, K. P6133
Abe, D. P4466 Acikgoz, S.K. P6257 Agrawal, S. 6608
Abe, H. P1108, P1437, P5003, P6537 Ackermann, H. P459 Agresta, A. 5904
Abe, I. P2415 Ackland, G. P1415 Agricola, E. P2616, P5491, P5659, P6245,
Abe, M. P767, P1357, P3434, P3690, P4121, Acosta, J. P3371 P6389
4290, P4611, P4626, P4635, P4642, Acosta Martinez, J. P1405 Agricola, T. P3418
P5602, P5698, P6137, P6248, P6553, 6629 Adachi, H. P739 Agrogiannis, C. P5464
Abe, N. P6577 Adachi, S. P2648, P2650, P2684 Agrogiannis, G. P2388, P3590
Abecasis, J. P3586, P4349 Adachi, T. P3685 Aguade, S. P610
Abecasis, M. P4350, P5643 Adam, J. P3639 Aguade-Bruix, S. P6382
Abed, H.S. 4053 Adam, M. P2604 Agudo Quilez, P. P3122, P4714
Abel, J. P6241 Adam, T. P6328 Aguiar, C. P5643
Abella, R. P3612 Adami, E. P3538 Aguiar, J. P5393, 5820
Abellard, J. P1124 Adami, P.E. 979 Aguiar Rosa, S. P2473, P2489, P2502,
Abellas Sequeiros, R. P3472 Adamopoulos, S. 40 P2510, P4488
Abellas Sequeiros, R.A. P3474 Adamopoulos, S. P170, P1816, P5666 Aguilar, R. P2554
Abellas-Sequeiros, R.A. P3113 Adams, V. P3639, 5090, 6039 Aguilar-Torres, R. P5243
Abesser, M. P6349 Adamson, P. P4461, P5976 Aguilo, S. P1369
Abhyankar, A. P4713 Adamyan, K.G. P3770, P5286, P5330 Aguinaga, L. P3371
Abi Rafeh, N.N. P3714 Adao, R. 6058 Agullo, A. P6452
Abid, S. P2360, P5473, P5557 Adasme, M. P4631 Aharon-Hananel, G. P5463
Abir-Khalil, S. 260 Adavane, S. P4650, P4982 Aherrera, J. P1609, P6412
Abir-Khalil, S. P3351 Addetia, K. P2545, P2546, P2550, P5484 Aherrera, J.A. P3631, P5605
Abizaid, A. 369 Adhami, A. P5979 Aherrera, J.A.M. 3948
Ablasser, K. 2244 Adijiang, A. P1580 Ahlehoff, O. 3942, 6651
Ablonskyte-Dudoniene, R. P1594 Adjedj, J. P1364, P2729, P2767 Ahluwalia, A. P1569
Abnousi, F. P4105 Ahmad, M. P3795
416
Chairpersons & Judges / Speakers & Discussants / Authors Ahm – Ale
Ahmad, S. P5950 Akashi, T. 1083 Al-Khalili, F. P1512, 3279, P4067

Ahmad, Y. P1714 Akashi, Y. P5372, P6125 Al-Lammee, R. P1714
Ahmed, A. P182, P2702, 4912, P5701 Akazawa, H. 4189 Al-Lammee, R.A. 4932
Ahmed, E. P5697, P6561 Akbal, O. P5517, P6144 Al-Lawati, K. P4757, P5699
Ahmed, M. P5514 Akboga, M. P4533, P4534, P4577, 5210, Al-Mallah, M. 210
Ahmed, M.I. P6293 P6274 Al-Mallah, M. P182, P2702, 4912
Ahmed, N. P617, P1519, P1522, 4024, 4055, Akbulak, R. Ö. P3414 Al-Mohammad, A. P3765
P4078, 4293, P5226 Akbulak, R.Ö. P3393 Al-Motarreb, A. P5689
Ahmed, S. 2343 Akbulak, R.O. P4362 Al-Suwaidi, J. P5689, P6561
Ahmed, W. P5673 Akcay, M. 237 Alabas, O.A. P171, P176, P770, P1102,
Ahmed, Y. P5566, P6200 Akchurin, R.S. 236 1196, 2914, 4261
Ahmeti, A. P4727, P6585 Akdag, S. P2535, P2847 Aladmawi, M. P6486
Ahn, H.S. 4153 Akdeniz, B. P6325 Alados, P. P6490
Ahn, J.-H. P1780 Akdis, A.C. P1390 Alam, S.R. P2127
Ahn, J. P1525 Akdis, D. P1390 Alamanni, F. P6368
Ahn, J.H. P3703, P4363 Akerstrom, F. P3369 Alameemi, O. P4716
Ahn, J.W. P863 Akesson, J. 6649 Alamri, M. P6486
Ahn, M.S. P5334 Akgun, T. P2514 Alayoubi, F. P5638
Ahn, S.G. P5334 Akhmedov, A. P1115 Alayoubi, S. P1418
Ahn, T.-H. P1502 Akhundova, J. P6478 Albarran, A. P2759
Ahn, T.H. P784 Akilli, R.E. P5480 Albarran Gonzalez-Trevilla, A. P4710,
Ahn, Y.-K. P1495, P1502, P2735 Akin, F. P5637, P5693 P6426
Ahn, Y. P821, P824, P3787, P4471, P4726, Akin, Y. P4561, P6406 Albenque, J.P. P4358
P6119 Akinlade, A.M. P5687 Alber, H. P584
Ahn, Y.G. P3732 Akintunde, A. P5687 Alberca, P.M. P2557
Ahn, Y.K. P2486, P3768, P4616, P4633, Akita, K. P4087 Alberola, A. P475
P4697 Akiyama, A. P1567 Albers - Akkers, M.T.H. P4678
Ahrens, I. P6339 Akiyama, D. 4052 Albert, C. 6070
Ahres, A. 6032 Akiyama, E. P885, P6411 Albert, C.M. P5924
Ahsan, A.J. P3318 Akiyama, T. P4784 Albert, F. P6516
Ahsan, S. P494 Akkaya, E. P3364, P3391, P4367, P4368 Albert, R. P2759
Ahsan, S.Y. P6157 Akkerhuis, J.M. 2101 Albertario, A. P1557
Aiba, T. P417, P480, P487, P2448, P4377 Akkerhuis, K.M. 6641 Alberti, G. P756, P3627
Aidonidis, I. P5309 Ako, E. P1617 Albertini, L. P5938
Aigner, E. P4644 Ako, E.A. P5328 Alberto Darte, J. P2372
Aihara, K. P2803 Ako, J. P505, P655, P1422, P2672, P2696, Albertsen, A.E. P5277, P5310
Aihara, N. P5925 P2719, P3742, P5545, P5656, P6361 Albertsen, I.E. P5308
Aikawa, E. P1589, P2591 Akodad, M. P3451 Albertsson, P. 278, P3435, P6138, 6649
Aikawa, M. P2591 Akoumianakis, I. 1834, P2595 Albiach, C. P2128
Aikawa, S. 6105 Aksakal, A. P542 Albinali, H. P5697
Ailawadi, G. 5215 Aksakal, E. P838, P1741, P3695, P5594 Albini, A. 4182, P5524
Aillerie, V. P1810 Aksoy, O. P825 Alboji, A. P1484
Aimo, A. P1366 Aksu, F. P3450 Alboni, P. 251
Ainla, T. 1198 Aksu, U. P838, P1741, P3695 Albrecht, A. P1726, P2377
Ainslie, M.P. P619, P2432 Aktemur, T. P5517, P6144 Albuquerque, A. P5631
Airaksinen, J. P197, P4061 Aktoz, M. P2534 Albuquerque, I.M. P3643
Airaksinen, K.E.J. P6453 Akturk, I.F. P2519, P4104, P6242 Albuquerque, O. P5450
Aissaoui, N. 2328, 2332, P4991, 5089, Akyol, A. P2535, P2847 Alburquerque-Bejar, J.J. 1088
P5931 Al Alfarhan, H. P4315 Albus, C. 2954, 3963
Aissou, L. P2815 Al Amri, I. P2607 Alcalde Martinez, V. 34
Aizawa, Y. P3419, P4361 Al Asnaj, M. 5872, 5874 Alcelik, A. P5714
Ajani, A.E. P4302 Al Jarallah, M. P5689 Alcock, E. P6487
Ajiro, Y. P4611, 6655 Al Mahmeed, W. P1681 Aldaydamony, M. P814
Ajmone Marsan, N. P2543, P2607, P4089 Al Mousa, E. P4475 Aldhoon, B. 956, 6075
Akabane, T. P890 Al Musaad, A. 78 Aldous, S. 127, P3483
Akagi, S. P5506 Al Namat, R. P5037 Alegre-Diaz, J. P6592
Akagi, T. P3607, P4503 Al Oufi, S. P2663 Alegret, J.M. P3332
Akanuma, H. 961 Al Qahtani, A. P4069 Alegria, E. P6462
Akao, M. P767, P1357, P3110, P3690, Al Raisi, S. P3734 Alehagen, U. P3744, P5268
P4121, P4611, P4626, P4635, P4642, Al Sifri, S.N. P1681 Aleksandrov, M.V. P3628
P5602, P5698, P6137, P6248, P6553 Al Suwaidi, J. P3542, P5697, P5701 Aleksov Ahtarovski, K. P554
Akar, I. P2416 Al Suwaidi, J.M. P4069 Alemayehu, M. P652, P2352
Akar, R. P6186 Al’aref, S. 1197 Alessandrello Liotta, A. P6200
Akasaka, H. P5288 Al-Aidarous, S. P1418 Alessandri, N. P2443
Akasaka, K. P2449 Al-Anbari, R. P5682, P6508 Alessandrini, H. P4563, P4564
Akasaka, T. 123, 139 Al-Attar, N. P3323 Alesutan, I. P2587, P6345
Akasaka, T. P583, P811, P1728, P1736, Al-Daccak, R. P3554 Aletras, V. P6320
P1745, P2746, 3945, 4929, 6005, P6319, Al-Hussaini, A. P817 Alexander, J. 2032
6623 Al-Hussainy, N. P3747 Alexander, J.H. 1973, 1974, 4203, 4979,
Akasheh, B.F. P5325 Al-Janabi, F. P4709 P6155
Akasheva, D. 1837 Al-Jarallah, M. P6561
417
Chairpersons & Judges / Speakers & Discussants / Authors Ale – Ana
Alexander, S. 20 Almeida-Gutierrez, E. P5360 Alvarez-Garcia-Rodes, R. P5494

Alexander, S. 1 Almelor, L.G. 1199 Alvarez-Ortega, C.A. P853, 4049
Alexandrakis, M. P1481 Almendro Delia, M. P1622 Alvero-Cruz, J.R. P4662
Alexandru, D. P4571 Almeria, C. P1107, P1593, P2548, P2549, Alves, A. 5922
Alexeyeva, N. 3051 P3520, P3573, P5243 Alves, A.C. P2529
Alexis-Fardini, S. P1544 Almog, R. P6468 Alves, B.S. 6058
Alexopoulos, D. P1469, P1478, P1479 Almudarra, S. 1196, 2914, P4327 Alves, C. P592
Alfakhouri, A. P678 Alnabti, A. P2468, P4716 Alves, C.M.R. P4410, P4455
Alfakih, K. 2968, P6233, P6236 Alogna, A. P3471, P3492 Alves, M. P506
Alfakouri, A. P3570 Alomar Serrallach, X. P4996 Alves, M.J.N.N. P198, P700, 2944
Alfaleh, H. P6561 Alonso, A.A. P3714 Alves, P. P768
Alfieri, O. 27, 40, 373 Alonso, C. 323 Alvino, V.V. P5454
Alfieri, O. 140, 1916, 5784, 6021 Alonso, F. P3665 Aly, M.F.A. P2569
Alfonso, F. P818, P836, P2554 Alonso, J.J. P1394 Alzoubi, B. P3570
Alfonso Manterola, F. 139, 308 Alonso, N. 6639 Alzueta, J. P167, P475, P478
Alfonso Manterola, F. 254, 4258 Alonso -Montes, C. P3591 Amabile, N. P3344, 6622
Alfonzetti, E. P750, P886, P2618, P4744, Alonso Farto, J.C. P5448 Amado, J.M. P2526
P4750, P6376, P6434 Alonso Garcia, D. P1623 Amann, M. P809
Alfredsson, J. P551, 1953, 6649 Alonso Garcia, M.A. 23, 303 Amano, A. 2210
Alghamdi, M.A. P4703 Alonso Garcia, M.A. 79, 5850 Amano, H. P1482, P1504, P4512
Alhabib, K. P5689, P6561 Alonso Gonzalez, R. 1300 Amano, M. P1607, P2664
Alhaddad, I. P4475 Alonso Pulpon, L. P1768 Amano, T. 139
Alhaddad, I.A. P5325 Alonso Salinas, G. 5091 Amano, T. P1134, P1744, 2228, P5380
Alhaideri, H. P3323 Alonso Socas, M.J. P6371 Amanullah, M. 202
Alhalees, Z. P6486 Alonso Tello, A. 962 Amara, W. 104
Alhede, C. 957 Alonso-Briales, J.H. P4584, P5337, 5790, Amarenco, P. 211
Ali, A. 1986 P6557 Amarenco, P. P766, 2073, 3260
Ali, D. 1857, P4071 Alonso-Gonzalez, R. P723, P6413, P6417 Amat Santos, I.J. P3637, P5647, 6022
Ali, J. P762, 5124 Alonso-Pulpon, L. P1123, P3755, P5694 Amati, S. P3672
Ali, S. P776 Alos, B. P5014 Amato, V.L. P1671
Alieva, A. P735 Alotaibi, A. P207 Amaya, N. P3400, P3422
Alimohammadi, A. P4545 Alotibi, S. P5571 Ambalath, S. P4679
Alings, M. 3820 Alpaslan, E. P6325 Ambegaonkar, B. P1675, P1680, P1681
Aliot, E. P164, P3530, P4296 Alpendurada, F. 362 Ambegaonkar, B.M. 69, P1654
Aljizeeri, A. 4912 Alpendurada, F. 1986, 4228, 4229, 4231, Ambrosio, G. P1513, P4404, P4456
Alkmim, M.B. P621 4233, 4235 Ambrosio, M.T. P2121
Alla, F. P676 Alper, A.T. P5275 Ambroso, D. P495
Allaart, C.P. P178 Alpert, J.S. 1162 Ambroz, D. P5534
Allaire, E. 5164 Alqahtani, A. P2468, P4716 Ameri, P. P3328, P3550
Allan, A. P4703 Alsaddique, A. P5638 Amin, A.E.H. 3932
Allan, M. P5549 Alscher, D. 4054 Amin, H. P5689
Allanore, Y. P687 Alshahid, M. P6486 Amin, M. 295
Allen, B.G. P4520 Alsheikh, A. P6561 Amin, N. P2356
Allessie, M. P3388 Alsoufi, B. P6486 Amit, G. P2405
Allessie, M.A. P4392 Alsuwaidi, J. P2468, P4716 Amit, U. P3548, P3555
Allgar, V. P2801, P5475 Altaf, F. P1477 Amitay, Y. P731
Allison, T. P4102 Altameemi, O. P2468 Amiya, E. P5042
Allison, T.G. P4557 Altaradi, H. P5638 Amiya, R. P1438
Almaas, V.M. 4960 Altarev, S. P4443 Ammar, A.S. P5479
Almagor, Y. P794 Altay, A. P4607 Ammar, M.A.S. P5479
Almahmeed, W. P5689 Altenhofen, L. P5589 Ammar, S. P4365
Almalla, M. P6521, P6524 Altieri, P. P3328, P3550 Ammendola, E. P504, P2400
Almeida, A.G. P2552, P3601, P5419 Altimir, S. P752, 6639 Ammirati, A. P2397
Almeida, A.M.G. 323 Altinier, A. P3646 Ammirati, E. P3603, 3936, P5577
Almeida, A.M.G. P1121 Altintas, S. P4623, P5228 Amodeo, A. P4601
Almeida, C. P618, P4995 Altintas Aykan, D. P3620 Amorim, I.R.P. 2944
Almeida, D.R. P5032 Altiok, E. 3175, P3725, P4449, P4462 Amorim, M.J. P4464, P5634, P5635, P5641
Almeida, I. P209, P2472, P3473, P5346 Altiparmak, I.H. P3466 Amorim, S. P5677
Almeida, J. P1605, P1626, P1627, P4062, Altunkas, F. P2416 Amoros, I. P5945
P4995, P5497, P6400 Alvares Pereira, M. 4255, P6529 Amoroso, V. P854
Almeida, J.G. P6240, P6393 Alvares Pereira Pereira, M. P5352 Amosova, K.M. P3762, P3779
Almeida, L.K.R. P1787, P2822 Alvarez, C. P4550 Amouyel, P. P1358, P6450
Almeida, M. P3586 Alvarez, N. P1636 Amri, I. A.L. P2543
Almeida, M.A. P829, 1200 Alvarez Alvarez, B. P2458, P2494 Amundsen, B. 336
Almeida, M.S. P5643 Alvarez Calderon, M. P2757 Amunts, K. P2357
Almeida, N. P618 Alvarez Castro, E. P432 Amurthur, B. P3775, P5671
Almeida, P.B. P5679 Alvarez Garcia, J. 161 Amzulescu, M. P3504
Almeida, R. P1668, P5367, P5406 Alvarez Lopez, M. P1410 An, Q. P2805
Almeida, S. 103, P1118, P3618 Alvarez Ortega, C. P3632 An, T. P6556
Almeida Morais, L. P501 Alvarez-Alvarez, B. P3113 Anagnostopoulos, A. P4571
Almeida-Coelho, J. P1814, 1853 Alvarez-Garcia, J. P3755, P5694
418
Chairpersons & Judges / Speakers & Discussants / Authors Ana – Ara
Anagnostopoulos, C. P3590, P5464 Andrica, F. P1676 Antonelli, B. P5358

Anagnostopoulos, C.D. P612 Andrie, R. P663, 1216, P1417, P5951 Antoniades, C. 20
Anagnostou, G. P6204 Andrikou, E. 2232, 2265, 4869, 4874 Antoniades, C. P898, P1458, 1834, P2575,
Anan, H. P3434 Andronache, M. P164 P2595, P3115, P3803, P5000, P5416
Anand, A. P4461 Andronic, A.A. P2806 Antoniades, L. P1624, P2641, P2643
Anand, I. P6555 Androshchuk, V. P1738 Antoniadis, A. 1841
Anand, I.S. 6643 Androulakis, A. P4671 Antoniadis, A.P. 6621
Anantharam, B. P2562 Androulakis, E. P644, P660, P898, P3803, Antonijevic, N. P6409
Anastasakis, A. P1624, P2641, P2643, 4032, P5368 Antonini-Canterin, F. P5704
4036 Androulakis, N. P1481 Antoniou, S. P765
Anastasiadis, G. P4666 Androulaks, A. 4871 Antoniucci, C. P582
Anastasiou, M. P455, P2725 Andrukhova, O. P3460 Antoniucci, D. P1094, P1496
Anavekar, N.S. 4237 Andrzejewska, R. P1616 Antonopoulos, A. P2595, P4088, P5000,
Ancedy, Y. P6214 Aneman, A. P3470 P5416
Anceschi, A. P1590 Ang, A.S. P831 Antonopoulos, A.S. 1834
Ancona, F. P5659, P6389 Ang, J.J. P588 Antonov, A. P2784
Andersen, A. P5509, P5512 Ang, R. P1415 Antonucci, E. P6193
Andersen, C.B. P5953 Angchaisuksiri, P. 3278 Antoons, G. 206
Andersen, G.O. P3489 Angeli, E. P179, P5290, P6223 Antoons, G. P3769
Andersen, G.Ø. P422, P5592 Angelidis, C. P2154 Antov, S. P2531
Andersen, H.R. P3723 Angelin, B. P2133 Antovic, J. P4067
Andersen, K. 3301, P5306 Angelini, A. 124, 364 Antunes, C. P1506
Andersen, K.H. P3624, P5953 Angelini, A. P1350, P1788, 5194 Antunes, M.J. 156
Andersen, M.J. P1792 Angelini, G. P1557 Antunes, M.J. 1264, 2209, P4578, P5252,
Andersen, P.S. P3108 Angelini, G.D. P2155 5988, 6082, P6489
Anderson, J.L. P3356, P4376 Angelis, A. P2699, P3116, P4331, P5540, Antunes, P. P5252
Anderson, L.J. P5670 P5541, P5588, P5710 Antz, M. 138
Anderson, R. P2742 Angeloni, E. P3490, P3579, P4317, P5241, Antz, M. 5763
Anderson, R.D. P215 P5478, P5632 Anusis, J. P1380
Anderson, S.G. P744, P813, P3683, P5322, Angelucci, E. P2716 Anzai, T. P881, P883, P2800, 3305, P4761,
P5600 Angeras, O. 278, P3435, 4972, P6138 P4763, P5354, P6536, P6541, P6545
Andersson, B. P1152, P4782, P5496 Angermann, C. P1669, P6149 Anzalone, N. P5577
Andersson, C. P6213 Angermann, C.E. 27 Anzawa, R. P2353
Andersson, U. 1974, 2032 Angermann, C.E. 3296, 3298, 3300, 6110, Anzini, M. P686, P1347
Andion, R. 962 P6146 Aoki, H. 2337, 2338, P6128
Andion Ogando, R. P3673 Angiolillo, D.J. P3318 Aoki, J. P2374
Ando, K. P1136, P2491, P2747, P2749, Angoulvant, D. 309 Aoki, S. P1744
P3439, P3440, P3701, P3702, P5965, Angoulvant, D. 950, 1970, P4985, P4991, Aoki, T. P3549, P5958
P6227, P6505 P5267, P5313, P5392, P6205, P6214 Aonuma, K. P1371, P1399, P3083, P3360,
Ando, K.A. P1137 Anguera, I. P476 P3498, 4052, P4116, P4402, P4466,
Ando, Y. P4753 Anguera Camos, I. P1444 P5504, P5528, P5925, P6244, P6299
Andoh, K. P515 Anguita, M. P4576, P6140, P6196 Aonuma, T. P220
Andonov, S. P2713 Anguita, M.A.S. P2442 Aoyama, A. P2672, P2719
Andrade, J. P2751 Anguita Velasco, J. P5448 Aoyama, D. P3422
Andrade, J.P. P2717 Anker, A. P3558 Aoyama, M. P1558
Andrade, M. P3586 Anker, S.D. 156, 254 Aoyama, M.A. P4542, P5471
Andrade, M.J. P4349 Anker, S.D. P887, 1319, P1789, 2329, Aoyama, R. P1737
Andraka, L. P832 P2786, P2796, 3293, P3793, 3850, 3851, Aoyama, T. P3753, P4109, P5966, 6086,
Andraloits, I. P6485 4854, P5256, P5655, P5695 P6494
Andre, F. P194 Ankou, B. P1385 Apaijai, N. P3781, P5539
Andre, S. P5684 Ankri, R. P1587 Apers, S. P6416
Andre-Fouet, X. P5392 Ann, S.J. P6263 Apiyasawat, S. P2419
Andrea Lopez Lopez, A. P4419 Annemans, L. P2463, 3031 Apor, A. 4856, P6401
Andreadou, I. 1089, P2499, P3082, P3084, Annoni, A. P4997, P5233 Apostolovic, S. 5105, P5667
P3441, P5418, P5624, P6265 Annoni, A.I. P6316 Appadurai, V. P1603
Andreassen, A.K. 2894 Annzai, H. P3764 Appelbaum, S. P4607, P4661, P5016, P5369
Andreassi, M.G. P5020 Anousakis-Vlachochristou, N. P3582 Appelman, Y. 94
Andreata, F. P4086 Anroedh, S.S. 6641 Appelman, Y. 368, P590, 1287, P1746
Andreev, A. P3779 Ansalone, G. P2390 Appelman, Y.E.A. P531
Andreini, D. P1092, 4051, 4056, P4997, Ansell, J. P3076 Appert, A. P840
P5233, P6316 Anselme, F. P3583 Aprile, A. P2741
Andreini, D.A. 2102 Anselmino, M. P1406, P3394 Aquaro, G.D. P5956, 6044
Andreis, A. P5353 Anstey, C.M. P1603 Aquila, I. P1554, P2547, P3560, P3561,
Andreotti, F. 121, 1945, 3033, 4127, 5174 Antal, D. 2229 P3563, P5457
Andreou, C. P791 Antignac, M. P3134, P3135 Aquino, M. P807, P1510, P2762, P3717,
Andres, M. P1622 Antlanger, M. P1808 P4695, P4699, P5375, 6619
Andreu, D. P1405 Antman, E.M. 148, 363 Arabi, A. P2468, P4716
Andreu Cayuelas, J.M. P4403 Antoine, C. P3516 Arabi, A.R. P4069
Andriani, M. P5353 Antonakis, V. 4867, 4869 Arac, M. P457
Andrianopoulos, N. P4302 Antonakopoulos, A. P791 Arad, M. 4034, 4036
Andriantoro, H. P558 Antoncecchi, V. 5810 Aradi, D. 1043
419
Chairpersons & Judges / Speakers & Discussants / Authors Ara – Att
Arafa, S. P2468, P4716 Arkhipova, N. P3647 Asgar, A. P717

Arafa, S.O. P4069 Arkolaki, E. P5329 Ashfield, K. P477
Aragiannis, D. 4869 Armitage, J. 91 Ashida, K. P2408
Arai, A.E. P1520 Armitage, J. P4613, P5575 Ashikaga, K. P3691, P6535
Arai, H. P5982 Armstrong, D. 6084 Ashour, Z. P5571, P6430
Arai, M. P5590, P5610, P6172, 6632 Armstrong, P.W. P6228 Ashraf, S. P5566
Arai, T. P1615, P5010, P5489 Arnar, D.O. 375 Ashton, V. P1675, P1680, P1681
Arain, F.K. P6551 Arnar, D.O. 299 Ashworth, M.T. P5546
Arakawa, T. P2368 Arnesen, H. P422, P1574, P3489, P5592 Asin Guillen, J.M. P3673
Arakelyan, A. P6332 Arnold, M. P637, P5620, P5928 Asirvatham, S. 5806
Araki, E. P5982 Arnold, M.B. P6374 Asirvatham, S.J. P1377, P3324, P4984,
Araki, M. P789, P1361, P1362, P1715, Arnous, S. 6608 5093
P1718, P1719, P1720, P2733, P4492, Arnson, Y. P5318 Askar, S.F. P5456
P4718, P6145 Arntz, H.R. P3487 Askar, S.F.A. P5926
Aranega, A. P1425 Aro, A.L. P2346 Asker, M. P2535, P2847
Arangalage, D. 1984 Aroca, A. P3615 Aslam, R. P5513
Arantes, C. P545, P3452, 4255, P4993, Aroca Peinado, A. P2143, P3608 Aslam, S.H. P717
P5338, P5345, P5352, P6266, P6529 Arokiaraj, M.A.R.K. P2753 Aslan, S. P5637, P6242
Arao, M. P870 Aronson, D. P447, P1140, P1790, P5518 Aslanidou, L. P185, P186
Aras, D. P1459, P1460, P2118, P2490, Aros, F. P4662 Asmar, R. 33, 153, 241
P3699, P4533, P4534, P4562, P5271, Arouny, B. P2425 Asmar, R. 3837, 3840, 3842
P5649, P6274, P6406 Arpino, G. P858 Asmi, M. P850
Aras, R. P215 Arra, C. P859 Asonuma, H. P4486
Arashi, H. P4694 Arrebola, A. P4712 Aspelund, T. 299
Araujo, C. P1668, P3668, P5367, P5406 Arrer, A. P3558 Aspromonte, N. P1664, P3743
Araujo, I. P5658, P5684 Arribas Ynsaurriaga, F. P3486 Asrress, K.A. P669
Araujo, M. P5684 Arruda-Olson, A. 4887 Asrress, K.N. 4931
Araujo, M.B. P5658 Arsenault, B. P201, P766 Assabiny, A. P1794, P1795, P4097, P6122
Araujo, V. P1407 Arslan, S. P573, P2714 Assaidi, A. P2501
Arbelo, E. 209 Arslan, U. P542 Assali, A. 1981, P5013, 6016
Arbelo, E. P472, P1434, 3056 Arstila, T.P. P3098 Assali, A.A. P2731
Arbustini, E. P1631, 2053, P5472 Arteaga, C.B. P2838 Assali, A.R. P3698
Arceluz, M. P3420 Artero, S. 964 Assante Di Panzillo, E. P3739
Archbold, A. P2740 Arthur, H.M. P2810 Assayag, P. P4548
Ardeleanu, E. P5043 Artman, B. P2407 Asselbergs, F.W. P1702, P6253
Arden, C. 3 Artyszuk, L. P6506 Assmann, A. P1589
Arderiu, G. 54 Aruta, P. P702, P2539, P2545, P2546, P2560, Assous, B. P842
Ardito, C. P3403 P3532, P3571 Astarcioglu, M.A. P4319, P6386
Ardourel, D. 6625 Arutyunov, G.P. P2796 Asteggiano, R. P865, 983, 985, 987, 1927,
Arena, G. P3399, P3403, P3411 Arvandi, M. P464 3817, 3818, P6194
Arenal, A. P2410 Arveiler, D. P1358, P1703, P6450 Astin, F. 45, P774
Arentz, T. P2829 Arvidsson, P.M. P4755 Astolfo, A. P185, P186
Arevalo, L.C. 4976 Arya, A. P516, P3392, P3415, P6209 Atanaskovic, V. P6408
Arfsten, H. P3454 Aryan, N.M.K. P4373 Atar, D. 74, 207, 247
Argacha, J.-F. 4195 Arzt, M. 358, P3128 Atar, D. 80, 82, 938, P1513, 1929, 2069,
Argiento, P. P4546, P4553, P5526, P5529 Asaad, N. P5697, P6561 P4404, P5598
Arheden, H. P507, P1754, P2665, 4057, Asada, Y. P2380 Atar, S. 6015
P4755 Asadi, Y. P3500 Ates, A.H. P542
Arias, M.A. P3369 Asai, T. P5629 Athanasiadis, A. P3093, P6271
Arias Valdes, E.M. P3673 Asai, Y. 6628 Athanasiadis, E. P612
Arias-Loza, P.A. P6349 Asakura, M. P5460 Athanasiou, D. P2689, P4312
Arici, M. P1678 Asami, T. 2107 Athanassopoulos, G. 1023, P1340
Arieti, M. P2741 Asanin, M. P446, P580, P630, P827, P830, Atherton, J. 4047
Arif, S. P3613 P2518, P5678 Atherton, J.J. P3349
Arima, R. P1727, P1731 Asano, T. P815, P3685 Atianzar, K.C. P3714
Arimoto, H. 6629 Asanoi, H. P5025 Atienza, F. P2410, P5448
Arimoto, T. P851, P1660, P3533 Asanuma, H. P5460 Atienza Fernandez, F. P6191
Arimura, T. 1083 Asanuma, R. P759 Atkinson, A. P6354
Ariotti, S. P1499 Asanuma, T. 3169, 3172, P6298 Atkinson, D. P1612, P4579
Arisha, M.M. P4357 Asarcikli, L.D. P3760 Atmaca, Y. P3677
Arisi, I. P2362 Asaumi, Y. P881, 3305, P4761, P4763, Atrey, A. P2724
Ariskina, O. P5349 P6536, P6541, P6545 Atsma, D.E. P2126
Arisoy, A. P2416 Ascedu, F. P1573 Atsuchi, N. P1727, P1731
Arisoy, F. P6406 Asch, F. P3593 Atsuchi, Y. P1727, P1731
Aristizabal, C. P4576 Aschauer, S. P1786, P1808, P2129, 2212 Atsumi, T. 6628
Arita, T. 6024, P6491 Aschieri, D. P2406 Atsumi, W. P1127
Arita, Y. P839 Ascione, L. P3505 Attali, V. 5077
Ariti, C. P582, 2913, P3342, P3717 Ascione, R. P3505 Attanasio, M. P2522
Ariyoshi, M. P5692 Asdonk, T. P664 Attanasio, P. P1093, P3079, P4385
Ariyoshi, T. P5939 Asensio-Lopez, M.C. P2813 Attar, M.N. P6564
Asfour, B. P4605
420
Chairpersons & Judges / Speakers & Discussants / Authors Att – Bal
Attinger, A. P6364 Azevedo Coutinho, C. P2428, P3804, Bae, M.H. P2462, P4724
Atzinger, A. P5231 P5419, P5422 Baechler, T. P1575
Atzler, D. P2572, P3623, P4661, P5022 Azevedo Coutinho, M.C. P598, P1122, Baehr, F. 1851
Au-Yeung, K.Y. P1150 P2636 Baek, S.H. P3778, P3787, P4110, P4726,
Aubert, J.-F. P4530 Azimi, A. P5978 P6578
Aubry, P. P6415 Azizi, M. P1147 Baena, C. P6451
Audonnet, M. P1509, P4417 Azizi, S. P2373 Baeriswyl, G. P2378
Auer, R. P1691, 6650 Aznag, H. P5343 Baessler, A. 2230
Auffret, V. P6516 Aznaouridis, K. P1572, P2574, P3116, Baeza, F. P3730
Auger, C. P647 P3806, P5588 Bafakis, I. 2265
Auger, D. P5364 Azzam, A. P1790 Baganha, F. P5006
Augostini, R. 5921 Baaj, S. P5043 Bagdat, D. P6455
Augstein, A. P662 Baaken, M. P1372 Baggen, J.M. P6261
Auguadro, C. P1149 Baan, J. 1840 Baggen, V.J. P6418
Augustine, D. P4420 Baan Jr, J. 364, P6388 Baggiano, A. 4051, 4056, P4997, P5233
Aujesky, D. P5007 Baba, K. P435, 4058 Baghdady, Y.B. P5287
Aukrust, P. 336, P5257, P6551, P6555, 6643 Baba, Y. P1619, P4592 Bagyura, Z. 2105
Auquier, N. P3583 Babadjanov, B. P5376 Bah, A. P4061
Auricchio, A. 204 Babaliaros, V. P1604 Bahit, M.C. 1973
Auricchio, A. P1334, P2439, 5741, P5927, Babalis, D. P526 Bahrami, T. P4390
P6443 Babat, N. P2535 Bahrmann, A. 959
Autar, A.S.A. P1456, P5597 Babatseva Vagena, I. P4671, 4871 Bahrmann, P. 959
Avakian, S.D. P6449, P6471 Babenko, A.Y. P5236 Bai, R. P5266, P6173
Avanzas, P. P5248 Babenko, A.Y.U. P2576 Bai, R.O.N.G. P5274
Avdonina, N. P900, P5706 Baber, U. P807, 4000, P4326, P4328, P4699 Bai, Y. P2817
Averina, V. P2805 Babich, P. P1770 Baicus, C. P849, P1630
Avezum, A. P1671, P6596 Babkin, A. P6593 Baig, F. P5321
Avgeropoulou, A. P4671, 4871 Babu-Narayan, S. P428, P3366 Bailey, K. 4887
Avila, P. 968 Babu-Narayan, S.V. P2142 Bailey, K.R. P5018
Aviram, G. 5789 Babuty, D. 950, 1970, P4985, P5267, P5313, Bailleul, C.B. 5089
Aviram-Paz, M. P2785 P6161, P6205, P6214 Bains, S. P5670
Avishai-Eliner, S. P1806 Baccara-Dinet, M.T. P6427 Baiocchi, C. P504
Avolio, E. P3566, P5454 Bacchi, E. 2016 Bair, T.L. P3356, P4376
Avouac, J. P687 Bacchi Reggiani, M.L. P4456 Bairey Merz, N.C. 279
Avran, A. P4701 Baccillieri, S. P495 Bajaj, H. P760
Avunduk, S. 943 Bachetti, C. 4182, P5524 Bajoria, R. P5328
Awad, M. P4301 Bachmann, A. P1786, P2129, 2212 Bajraktari, G. P4727, P5255, P5621, P6585
Awad, O. P2564 Bachmann, T.N. 6076 Bak, J. P6367
Awamleh Garcia, P. P1394 Bachorzewska-Gajewska, H. P5293 Baker, A.H. P6337
Axelsson, A. P2827, P6399 Back, M. 91 Baker, N. P670, P1599
Ayala, H.D. P3637 Backs, J. 917 Baker, W. P1759
Ayaori, M. P2720 Backus, B.E. P590 Bakhoum, S. P729, P901, P1785
Ayaz, A. P2519 Backx, F.J.G. P2371 Bakhru, S. 4971
Aydin, S. P1459, P1460 Badacz, R. P638, 2022, P5619 Bakir, I. P5637
Aydinalp, A. P6523 Badagliacca, R. P5526, P5529 Bakker, J. P695
Aydogdu, S. P1459, P1460, P2118, P2490, Badak, O. P6325 Bakker-De Boo, M. P437
P3699, P4561, P4562, 5210, P5271, Badalica-Petrescu, M. P4706 Bakkestroem, R. P1792
P5649, 6040, P6406 Badano, L. 25 Bakloul, M. P4595
Ayers, D. 2907, 5817 Badano, L. 14, 5990 Bakogiannis, C. P5685
Ayesta Lopez, A. P1505 Badano, L.P. P702, P2539, P2541, P2545, Bakos, Z. P507
Ayguc, B. P2416 P2546, P2550, P2559, P2560, P2806, Bakris, G. P1148, P1799, 1877, 1878
Ayhan, H. P488, P5426 P3532, P3571, P5484 Baksi, A.J. P866
Aykan, A.C. P3620, P4319, P6386 Badawi, A. 151, 370 Bal, U.A. P6523
Aymong, E. P2727, P2736, 2907, 5817 Badawi, S. P5948 Balabagno, M.M. P1609
Aytekin, S. 34 Badenco, N. P714, P2429, P3588 Balaji, H.P. P1684
Aytekin, S. P5440 Bader, T.R. 4866 Balashov, I. P6467
Aytemir, K. 1839, P4379, P4690, 6074, Badet, L. P5392 Balbarini, A. P3458
P6188 Badia, S. P2554 Balbay, Y. 35
Ayub-Ferreira, S.M. P1787, P2822 Badimon, L. 76, 124, 406 Balcells Iranzo, J. 161
Azar, R. P1681 Badimon, L. P561, P594, P1128, P1445, Balci, A. P713
Azencot, M. P203, P205, 3995, 4886, P5586 P1586, P2130, P2601, 3952, 4287, 4291, Baldazzi, F. P2485
Azevedo, A. P758, P1668, P3130, P3668, P4422, P4524, P4698, 5086, 5819, P6140 Balde, D.M. P3134
P5367, P5406 Badings, E. P4071 Baldi, J.C. P1775
Azevedo, A.I. P5631 Badings, E.A. 1857 Baldin, B. P840
Azevedo, O. P1626, P1627, P4062, P5497, Badmaeva, M. P5339 Baldini, K. P466
P6393 Badosa Marce, N. P1125 Balducci, F. P6291
Azevedo, P. P545, P3452, 4255, P5338, Badoz, M. P1733, P6407 Baldus, S. P1104, P1591, 2335, P3622,
P5345, P5352, P6266, P6529 Badran, A.V. 6617 P4074, 4191, 5784, 6038, P6355
Azevedo, T. P5641 Bae, I.H. P2756 Balea, M.I. P2454
Azevedo, T.B. P5634, P5635 Bae, J.H. P2508 Balia, C. P3087
Bae, J.W. P2816, P4474 Balicer, R. P1652, P5276, P5318
421
Chairpersons & Judges / Speakers & Discussants / Authors Bal – Bat
Baligh, E. P4653 Barbarash, O.L. P2520 Barres, C. P4357

Balistreri, F. P3785 Barbarossa, A. P4554 Barreto, G. P1671
Balkau, B. P756 Barbash, I. 6016 Barrett, M. P4580
Balkay, L. P3577 Barbati, G. P522, P686, P691, P1621, P4399, Barretti, P. P2704
Ball, C. P3515, P6472 P5297, P6147, P6575 Barriales Villa, R. P1623
Ballantyne, C.M. 125, 298 Barbato, E. P1364, P1468, P1729, P2729, Barrio, A. P4569, 5802
Ballantyne, C.M. P1679, 1864, 1868, 4786, P2767, 4023, P4325, P4715, P5623, 6620 Barrios, V. P1554
4789 Barbato, E.B. P3461 Barrios Baqueiro, J.E. P5645
Balligand, J.-L. 4190 Barber, K.R. P792 Barrios Garrido, E. P4550, P5957
Balligand, J.L. 124, 249, 374 Barber, T. P4617 Barrios Garrido, M.E. P2652
Balligand, J.L. 5831, 5832, 5833, 5835, Barber-Chamoux, N.B.C. P5933 Barron, D. P1647
6602 Barbero, U. P1748 Barros, C. P5259
Ballocca, F. P6262, P6446 Barbetseas, J. P4666 Barroso, P. P2790
Balse, E. 4186 Barbic, D. 156 Barry, S. P1374
Baltabaeva, A. P4505 Barbier, P. P3527 Barry, T. P3734
Balteau, M. P2363 Barbieri, A. P3508 Barsheshet, A. 1981, P5013, 6016
Balzer, J. 1887 Barbieri, L. P1480, P1501, P2117, P3119, Barskova, T. P4669
Balzi, D. P2522 P5542 Barsness, G.B. P4444
Bampouri, T. P5546 Barbisan, J.N. P5559 Barsotti, M.C. P3447
Banach, J. P4739 Barbosa, A. P5427 Barsukevich, V. P3736
Banach, M. P1450, P1584, P1676, 2229, Barbosa, A.H.P. P4455 Barter, P.J. 298
P5981, P6481 Barbosa, E.C. P6397 Barter, P.J. 4789, P6465
Banaei-Bouchareb, L. P544, P3663 Barbosa, M. 141, 198 Barthel, P. P1539, P4638
Banai, S. P3584, 5789 Barbosa, M. P2679 Barthelemy, O. 363, P2429
Banasiak, W. P841, P889, P1789, 3308, Barbosa, T.S. P1787, P2822 Bartimoccia, S. P6190
P3430, P3758, P5655, P6569 Barbosa, V.A. P3643 Bartko, P. P1381
Banaszewski, M. P880, P3491, P4768 Barbosa-Filho, J. P6397 Bartkowiak-Sniatkowska, A. P6114
Bancone, C. P2630 Barboza, C.A. 1998 Bartoletti, S. 5900
Bandera, F. P750, P886, P2618, P4744, Barbu, H. P6447 Bartolini, D. 1202, P2523, P4412
P4750, P6376, P6434 Barc, J. P485 Barton, P.J.R. 3072
Bando, Y. P5578 Barchet, W. P664 Bartoszewicz, Z. P5531
Bandzouzi, B. P5574 Barchielli, A. P2522 Bartunek, J. P1364, P1468, P2614, P2767,
Baneras Rius, J. P2507 Barcin, C. P3379 4023, 5785, P6297, P6484
Banerjee, A. P712, 1970, P6205 Bard, R.L. P3340 Bartus, K. 3010, P3741
Banerjee, A.K. 32 Bardhaj, G. P3425 Bartykowszki, A. 2105, 2234, P4496
Bang, C.N. P4094 Bardy, G. P840, 3235, 3237 Barwad, P. 5796
Bangalore, S. 204 Barekatain, A. 5094 Barwari, T. P1472
Bangalore, S. 1861, 1862, 2880 Baretti, R. P562 Barysheva, N. 2100
Bangert, A. P3606 Bari, Z.S. 5915 Baryshnikova, E. 2208
Banke, A. P5033 Baricevic, Z. P2824 Barywani, S. P3716
Bankowski, T. P2110 Barile, L. 1081 Barywani, S.B. P5265
Banks, H. P464 Baris, V.O. P5652 Bas, D. P3077, P6187
Banner, N. P1772 Barisione, C. P3328 Baselice, A. P2765, P2782
Banner, N.R. P5675 Barison, A. P5956, 6044 Bash, L. P2785
Bannon, P.G. P2660, 2931 Baritussio, A. P1534, P4078, P4420, P4460 Bashir, J. P463
Banovic, M. P630, 4288 Barka, E. P3442 Basile, E. P5027
Banya, W. P526 Barkagan, M.B. 5789 Basit, S. P711
Banzato, A. P871 Barkey, G. P6181 Bassand, J.-P. 43
Bapat, V. P1592 Barletta, M. P2616, P5491 Bassand, J.-P. 391, 397, P1513, 3999,
Baptista, R. P1796, P2470, P3493, P4333, Barmpouletos, D. P6384 P5598
P4764, P5427 Barna, O. 208, 306 Basso, C. 30, 96, 267, 321
Baptista, S.B. P768 Barnason, S. P3655 Basso, C. P690, 3281, P3536, P6166
Barabach, S. P1539 Barnay, C. 104 Basso, V. P2794
Barabash, I. P4999 Barnay, P. 6622 Bastante, T. P1622
Baracca, E. P2389, P4745, P4758, 4863 Barnes, P.J. 2254 Basterra, N. P478
Barak, L. P3584 Barnes, S. P3767 Bastos Fernandez, G. P2751
Barallat, J. P2811, 4277, 4279 Baron, T. P5373, P5384, P5399, P5400, Bastuji-Garin, S. P6148
Barallobre-Barreiro, J. P4082 P5410 Baszak, J. P2411
Barampoutis, N. P1469, P6254 Baron Esquivias, G. 983, 985, 987, P2344, Baszko, A. 1261, P3376, P5436, P6114
Baran, J. P4388 3816, 3818, 4903, P6194 Bataille, S. P534, P1338, P4445, 5816
Barana, A. P5945 Barone, L. P4522 Bataiosu, D.R. P6550
Baranchuk, A. P3404, P6402, P6408 Barr, C.S. P4299 Batalli, A. P6585
Baranda, F.M. 2068 Barr, T. P6365 Batalov, R.E. P2450
Baranda Tovar, F. P5645 Barra, G. 3943 Bates, R. 4887
Baranova, E. 152 Barrabes, J. P538 Bath, P. 4894
Baranova, E. P735, P2384, 3941, P5339 Barrabes, J.A. P818, P835, P836 Batin, P.D. P1102, 1196, P4994
Baranowski, M. P6279, P6283 Barrabes Riu, J.A. P2507 Batista, M.C. 2209
Barasch, E. P4571 Barragan, P. P6516 Batkai, S. P530
Barba, I. 1088 Barragan-Garcia, R. P641 Battaglia, A. P3394
Barbanti, M. P6390 Barral Varela, A. P3591 Battelli, N. P860
Barbarash, O. P3338, P3647, P5403 Barrera-Ramirez, C.F. P5650 Battermann, S. P1734
422
Chairpersons & Judges / Speakers & Discussants / Authors Bat – Ben
Battipaglia, I. 5900 Becattini, C. P3617, 4174, P4675, P5595, Bellando Randone, S. P4669
Battista, R. 2013 P5608, P5609, P6216 Bellasi, A. 4028
Battistoni, I. P3437 Becher, P.M. P2164 Belle, L. P579, P796, P2147, P5932, P6415
Batyraliev, T. 2916 Becher, U. P663 Bellei, N. P5032
Bauce, B. 323 Bechlioulis, A. P765 Bellemain-Appaix, A. 4938, 4940
Bauce, B. P690, P3536, P6166 Becker, D. P614, P3709, P4099 Belley-Cote, E. P207
Baud, L. P4525 Becker, M.-M. P4449, P4462 Belley-Cote, E.P. P2152, P5636
Baudet, M. P842 Becker, M. 3175, P3725 Belli, E. P1650, P4602
Bauditz, J. P887 Becker, R.C. P172, P4398, P6210 Belli, O. P6483
Baudoin, F. 6056 Becker, T. P1618 Belli, R. P4588
Baudry, G. 2103 Beckett, N. 5078, P5567 Belloch, V. P1690
Bauer, A. P1536, P4079, P5603 Beckmann, B.M. P1400 Bellotti, S. 1202, P2523, P4412
Bauer, D. P6164 Beckmann, Y. P705 Bellu, R. 351
Bauer, F. P6373 Beckowski, M. P547, P2525, P5291, P5404 Belohlavek, J. 3301
Bauer, R. 3066, P3537 Becova, B. P1414 Beloin, C. P1640
Bauer, T. P837, P2386, P3120, P3137, Bedanova, H. P3114 Beloqui, O. P1778
P4487, P4499, P5028, 6065 Bedjaoui, A. P6500 Beltrama, V. 4051, 4056
Bauer, U.M.M. P721, P724, 2926 Bednar, F. P565 Beltrami, A.P. P3566
Bauer, W. P3599 Bedogni, F. P2617, P3592, P6375 Beltrami, M. P514
Bauersachs, J. 360 Bedossa, M. P6516 Beltran-Debon, R. P3332
Bauersachs, J. P724, P884, 1233, 1850, Beecher, S. P2348 Beltukov, P. P1826
2328, 2332, P2590, P2791, 2928, P3455, Beek, A. P2497 Belyaeva, O. P5339
P3610, 4281, 5829, 6107 Beek, A.M. P426 Bemtgen, X. 1956
Bauersachs, R. P5550 Beek, A.M.B. P2569 Ben Gal, Y. 6016
Bauerschmitz, P. P2138 Beekman, H.D.M. P6159 Ben Massoud, M. P533, P5356
Bauloye, C. 4195 Beer, A. P1556 Ben Messoud, M. P2615
Baum, C. P2572, P4332, P5022 Beer, J.C. P1696, P3080 Ben Said, R. P850
Baum, H. P528 Beer, J.H. P1115, P5007 Ben Salem, H. P4693
Bauman, J. P5976, P6472 Beeres, S.L.M.A. P2126, P3794, P6513 Ben Youssef Zouari, S. 367
Baumann, G. P5439 Beeri, R. 136, 137, 139, 3194 Ben-Gal, T. 1981
Baumann, K. 1959, 1960 Begaj, I. P712 Ben-Gal, Y. P5633
Baumann, S. P5405 Beganton, F. 1320, P1382, P4073 Ben-Haim, S. P428
Baumbach, A. 1201, 2288, P2840, 3182, Begue, C. P1631 Ben-Mordechai, T. P3548, P5458
P4078, P4420, P5226 Behaghel, A. P2434 Benamer, H. P1615, P5010, P5489
Baumert, J. 4205 Behairy, M. P4656 Bencardino, G.L. 5900
Baumgartner, H. 260, 310 Behairy, N. P5673 Benchimol Barbosa, A.C.L. P6397
Baumgartner, H. 143, P684, P721, P724, Behar, J.M. P518, P6314 Benchimol Barbosa, P.R. P2681, P6397
2075, P2138, 2310, 2311, 2312, 2314, Behar, N. P2434 Bencivenga, S. P6435
2316, 2926, 3037, 4950, P5015 Beheiry, S. 955, P3417 Benderly, M. P4654, P5977
Baumgartner-Parzer, S. P572 Behr, E. 1848 Bendig, G. 162
Bauml, M. P3091 Behr, E.R. P1629, P4373 Benedetti, S. 2015, P6170
Bauters, C. P1124, P1492 Behradfar, E. P1411 Benes, J. P4762, P6562
Bax, J.J. 89, 152, 318 Behrends, J.C. P6356 Benetos, G. P612, P785, P2388, P3590,
Bax, J.J. P2543, P2607, 3809, P4089, P4482, Behrens, I. P711 P4106, P5607, P5627, P6254
5891, P6429 Behrens, S. P562, P837, 1203 Benezet Mazuecos, J. 953, P1440
Baxter, P. P4327 Beiert, T. 1216, P5951 Bengel, F.M. 109
Baxter, P.B. 4269 Beigel, R. P1565 Benhaddi, H. P5292, P6192
Baxter, P.D. P4994 Beinart, R. 207 Benhaiem, N. P5423
Baycan, O.F. P4104 Beissel, J. 4907 Benichou, M. P3365
Bayes Genis, A. P2811, 4192, 6600 Bejan-Angoulvant, T. P5392 Benit, E. P2730
Bayes-Genis, A. P752, P1139, P1586, Bekers, O. P4615 Benitez, J.M. P3122
P2580, P2790, P3350, P3546, P3553, Bekfani, T. P887, P5695 Benitez Peyrat, J. P3718, P4714, P6517
4277, 4279, P5445, 6639 Bekkers, S.C.A.M. P4458 Benito, B. 952, P3077, P5301, P6187
Baykan, A.O. P722 Bel, A. P3574 Benito, Y. 5802
Baykaner, T. P1550, P3386, P4378 Bel, E.H. 152 Benito Gonzalez, T.F. 5100
Bayraktar, F. 5210 Beladan, C.C. P1630 Benke, K. P3709
Bayram, Z. P6386 Belardi, D. P3451, P6452 Benkner, A. P4736
Bayrasheva, V. P2576 Belardinelli, L. P6159, P6163 Benn Christiansen, C. P5284, P5596
Bayrasheva, V.K. P5236 Belardinelli, R. 2012, P2705 Bennett, A. P3789
Bays, H.E. P1679 Belcastro, F. P5583 Bennett, D. P1359, P1700, P2688, 5123,
Baz Alonso, J.A. P2751 Belelsin, B. P5415 P5575
Bazan, R. P2704 Belen Alvarez Alvarez, B. P4419 Bennett, G. P6456
Bazdyrev, E. P3338, P5403 Beleslin, B. 41, P609, P1716, P2567, 4292 Bennett, K. 1856
Bazhenova, E. P5339 Belhadi, C. P6500 Bennett, M.R. 5849
Bazin, P. P2504 Belhaj, A. P5504 Bennett, P. P4738
Beanlands, R. 4873 Belke, D.D. P3539 Benouda, L. P2815
Beauchet, A. P5963 Bell, J. P4401 Benova, T. P1414
Beaulieu, M. P5364 Bell, M.R. P3324 Bensahi, I. P2501
Beauloye, C. P2363 Bell, R.M. 1087, P3444, P5328 Bental, T. P3698
Beauverger, P. 3310 Bella, J.N. P4117 Bental, T.B. P2731
Bellamkonda, V.R. 4237 Bento, D. P2526
423
Chairpersons & Judges / Speakers & Discussants / Authors Ben – Bin
Bentz, K. P3093 Bernstein, D. P1505, P4992, 5813 Bezrodniy, A. P3779

Bentzon, J.F. P665 Berous, M. 4169 Bezrodnyi, A.B. P3762
Benussi, B. P5242, P5244 Berra, K. 192 Bezzera, H.B. P4329
Benvenuti, L.A. P1787, P2822 Berra, K. 20 Bhagat, P. P709, P4081
Benyounes, N. P4982 Berre, A.M.O. 6039 Bhagwat, A. 203
Benyoussef, S. 4006, 4008, 4010 Berrebi, A.J. 326 Bhalshankar, J. P3102
Benz, D. P4481 Berrera, M. 2242 Bhamra-Ariza, P. P4469
Benz, D.C. P611 Berrino, L. 1852 Bhan, A. P6487
Beppu, S. P2453, P3434 Berruezo, A. P1405, P3371 Bhardwaj, A. 2024
Berard, E. P6450 Berry, B. P3117 Bharucha, T. P4597
Berardi, N. P5576 Berry, C. P617, P1519, P1522, 4024, 4055, Bhaskaran, A. P4352
Berardi, R. P860 4293, 4294 Bhat, G. P4773
Berbner, A. P4516 Berry, N. P2700, 4047 Bhatt, D. P1148
Berdeaux, A. 309 Berta, B. 945 Bhatt, D.L. P1497, 3032, P3317, P3318,
Bereta, J. 1833 Bertacchini, F. P5709 P3503, 4002, P4105
Berezin, A. P1368, P4723 Bertaglia, E. P2390, 4860, P5222 Bhatt, K. P6508
Berezina, T. P4723 Bertagnolli, M. 5082 Bhowruth, D.J. P658
Berg, S.K. 2939, P3654 Bertaina, M.B. P3118, P5562 Bhupali, A. P4713
Berg, S.K.B. 2938 Bertel, O. P532 Bhupinder, S. P3793
Bergamasco, L. P1406 Bertelli, L. P3508 Biagetti, M. 4961
Bergau, L. P165 Bertelsen, L. P622 Biagi, M. P2682
Berge, E. P4404 Berteotti, M. P4634 Biagini, E. 85
Berge, K.E. P418 Berthelot, E. P4548 Biagini, E. 158, P2640, P5467, 6609
Bergemann, T.A. P3313 Berti, S. 32 Biagioni, C. 2060, P2728, P3573
Berger, F. P718 Berti, S. 114, P206, P4414, P4478, P6425 Bialkowski, J. P3729
Berger, R. P1752 Bertini, M. P503 Bian, W. P2817
Berger, R.M.F. 2310, 2312, 2313, 2314, Bertoldi, E.G. P6220 Bian, Z. P637, P1359, P1700, P2688, P4652,
2316 Bertolin, F. 2935 5123, P5620
Berger, S. P1706 Bertolini, A. P5712 Biancari, F. P2156, P6453
Berger, W. P6184 Bertolini, A.M. P3802 Bianchi, R.M. P5365
Berger, W.R. P6182 Bertolotti, A. P1767 Bianchi, S. P179, P5290, P6223
Bergerot, C. P5392 Bertomeu, V. P6196 Bianchi, V. P6474
Bergfeldt, L. P2403, P4063, P4782 Bertomeu-Gonzalez, V. P2788, P6140 Bianciardi, P. P2586
Berghausen, E. 2335, 5846 Bertomeu-Martinez, V. P571, P2788, Bianconcini, M. P5938
Bergin, P. P1811 P5348, P6140, P6462 Biasucci, L.M. P1483, 3944, P6118
Bergler-Klein, J. 258 Bertram, H. 2928 Biava, L. P208
Bergler-Klein, J.C. P530 Bertrand, L. 76 Bibli, S.I. 1089, P3084, P3441, P5624
Berglund, E. P2655 Bertrand, L. P2363 Bickel, C. 1978, P4074, 4977, P6206
Bergman, G. 1197 Bertrand, M.E. 150, 303 Bidoli, E. 4149
Bergmann, M. P3733 Bertsch, T. 959 Bieganski, S. P709, P4081
Bergmeijer - For The International Berul, C. 1014, 1015 Biegus, J. P889, 3308, P6569
Clopidogrel Pharmacogenomics Berwanger, O. P2717, 5071 Bielecki, M. P5531
Consortium Investigators, T.O. P1490 Besana, F. P5577 Bielinski, S.J. P1653
Bergo, M. P5496 Besnier, M. P6337 Biener, M. P5340
Bergsland, J. P3462 Besola, L. 351, P4568 Bienias, P. P5531, P6168
Berisha, G. P4727 Besseling, J. P2146 Biere, L. P4417
Berkhemer, O. P5597 Bessell, E. P1356 Bierhuizen, M.F.A. P4115
Berkouk, K. 5715 Betbout, F. P533, P2615, P5356 Biering-Sorensen, T. P844, 5803, P6538
Berkovich, O. P5339 Betelin, V.B. 6042 Biermann, B. P2149
Berkowitsch, A. P2620, P3364, P3391, Bethencourt, A. P1110 Biernacka, E.K. P471, P482
P4367, P4368 Beton, O. P3760, P6139 Biernacka-Fijalkowska, B. 6610
Berkowitsch, A.B. P567 Bettencourt, B. P1761 Biernat, J. P2447, P6329
Berkowitz, S.D. 2031, P4398 Bettencourt, N. P618, P1530, P4490, P4995, Biesbroek, P.S. P531
Berland, J. P6516 P6240 Bieseviciene, M. P636
Berliner, D. P6149 Bettencourt, P. P2813, P3130, P3350, Biessen, E.A.L. P665, P6129
Berlinghieri, N. P1555 P6586 Bietenbeck, M. P1532
Berman, D.S. P623, 3996, P4480 Betteridge, D.J. 126 Biffi, M. P503, P504
Berman, L. P1799 Betteridge, D.J. 1870, 1873 Bigiarini, S. P6223
Bermejo, J. P3127, P4569, 5802 Bettocchi, C. P6437 Biglino, G. P5451
Bernal-Sobrino, J.L. P2788 Beumer, D. P5597 Bihry, N. P842
Bernard, A. 950, 1970, P2836, P5267, Beurrier, D. P2418, P2455, P5553 Bijnens, B. P694
P5313, P5438, P6205 Beuscart, R. P621 Bijuklic, K. P673, P1606, P1608, P2608,
Bernard, M. P3135 Bevc, S. P3433 P5485, P5626
Bernardes, A. P511, P2433 Bevilacqua, A. P6338 Bilardo, C.M. P713
Bernardes, L. P3693 Bevilacqua, G. P3458 Bilbao, A. P6559
Bernardes, N.B. P6479 Beyar, R. P447 Bilen, E. P488, P5426
Bernardo, E. P1470, P2119 Beygui, F. 124 Bilici, R. P1688
Bernares, N. P2679 Bezante, G.P. P3328, P3550 Bilinska, Z.T. P3540, P3543
Berndt, A. P5005 Bezerra, H.G. P4707 Bilo, G. P3352
Berndtsson, M. P4067 Bezieau, S. P485, P6161 Bimpong-Buta, N.Y. P6503
Bernlochner, I. P1485 Bin Abdullah, O. P1571
424
Chairpersons & Judges / Speakers & Discussants / Authors Bin – Bon
Bindeman, J. 2108 Bloem - De Vries, L. P4678 Boettcher, M. P1546

Binder, C. 5092 Bloise, R. P4298 Bogaard, H.J. P178
Binder, T. P5952 Blok, I.M. P437, P2658, P2661 Bogaert, J. 5187, P5433, 6104
Binia, A. P896 Blom, D. 4797 Bogard, J. P3554
Biondi Zoccai, G. P5378, P6262, P6372 Blom, N.A. P632, P1551 Bogdan, M. P5943
Bird, J. P4102 Blomster, J. 4295 Bogdan, S.Z. P3762
Birgersdotter-Green, U. 2027, 5756 Blomstrom-Lundqvist, C. 190 Bogers, A. P3388, P4392
Biri, B. P5680 Blomstrom-Lundqvist, C. 920, 2172, 2195, Bogers, A.J.J.C. P715, P2656, P5314
Birkmeier, S. 4054 5759 Boggild, H. P3641
Bis, J. P3446 Blondal, M. 1198 Boggioni, I. P4781
Bisgaard Christensen, S. P3747 Bloomfield, D. P891 Bogossian, H. P3773
Bishop, D. P2690 Blue, L.M.J. 21 Bogunovic, N. P3526
Bishop, K. 5720 Bluem, B. P3523 Bogyi, P. P3348
Bishop, M.J. P1432 Blum, S. P4663 Bohm, A. 1979
Bisleri, G. P2151, P3382, 6021 Blumenstein, J. P2620, P4565, 5791 Böhm, M. 240, 364
Bistola, V. P2459, 3303, P6566 Blumenstein, J.B. 1988, P4687 Böhm, M. 386, P873, P1698, P2160, P2370,
Biteker, M. P6386 Bo, Y. P2746 P2841, P2843, P2846, 3828, P4085, 5057,
Bitigen, A. P2514 Boasi, V. P5543 5992, 6064, 6067
Biton, Y. 2271 Boaz, M. P4587 Bohm, M. P3735
Bittencourt, M.S. 70 Bobin, P. 2283 Bohula May, E.A. P6120
Bitter, T. P2797, P5661, P6289, 6636 Bobkowski, W. P3376, P6114 Boidol, J. P3322
Biyik, I. P2519 Boccanelli, A. 4254 Boileau, C. 270
Bizzotto, E. 351, P4568 Boccara, F. 342, P4647, P4650, P4982 Boiron, P. P3516
Bjoernerheim, R. P3489 Bocchi, E.A. P1787, P2822 Bois, J.P. 4237
Bjorck, L. P2157, P2496, P5628 Bochard-Villanueva, B. P181, P2128 Boivin, V. P3599
Bjorkenheim, A. P4344 Boche, T. P1338 Bojalil, R. P1601
Bjornstad, H. 3195, 3198 Bochenek, M.L. P2158, P2602 Bojti, I. P3468
Blaauw, Y. P5223, 5914 Bochoeyer, A. 3243 Bokhari, F. 1008
Blackburn, E.H.B. 89, 123 Bock, K. P468, P3359 Bokma, J.P. P2137
Blackburn, H. P739 Bocksch, W. P671, P674, P675, P680, 4270, Boldo, M. 6639
Blackburn, Y. P3315 P6377 Boldt, L.H. P1093, P3079, P3428, P4385
Blackman, D.B. 4269 Bockstahler, M. P3605, P3606 Bolea, J. P6443
Blagden, M. P1756 Bode, C. 44, 299 Bolen, M. P613, P2585
Blagojevic, Y. P4669 Bode, C. 408, 413, P1429, P1454, 1956, Boles, U. P3404
Blaha, M.J. P1676 P2125, 3892, 4800, P6339, P6356 Bollini, M. P5244
Blamire, A.M. 2933 Bode, F. 4060 Bollini, S. P3328, P3550
Blanc, J.-J. 2982 Bode, K. 4858 Bollmann, A. P516, P3392, P3415, P6209
Blanchard, D. P4991 Bode, P. P1390 Bolognese, L. 1271, 1273, P1354, P5929
Blanco, I. P2652, P3625 Bodegard, J. 6649 Bolzan, B. 5146
Blanco, M. P2758, P3694, P4676, 6022 Boden, U. P6290 Bom, M.J. P5232
Blanco, R.G. P3076 Bodez, D. P5423 Boman, K. P4093
Blanco, S. P1703 Bodez, D.B. P843 Bomanji, J. P428
Blanco Colio, L. P6250 Bodi, I. P6356 Bombardini, T. P450, P1769, P3509, P3510,
Blanco-Verea, A. P3096 Bodi, V. P1517, P1518, 3252 P6309
Blank, N. 5846 Body, R. 162, 1936 Bombelli, M. P4119
Blankenberg, S. 125, P882, P1591, P2164, Body, S.C. P1589 Bonaca, M. 3918
P2572, 3961, P4332, P4607, P4661, Boe, E. P4754 Bonaca, M.P. 3032, P3317, P3318
P5016, P5022, P5369, 5923 Boeckh-Behrens, T. 2058 Bonanad, C. P1518
Blankenstijn, P.J. 3825 Boeddinghaus, J. 126, 154, 157, 159, P524, Bonanad Lozano, C. 963, P1517, 3252
Blankesteijn, W.M. P3442, P3745 P525, P1097, P1103, P2461, P3481, Bonci, A. P5289
Blankstein, R. P3503 P3484, P4077 Boncoeur, M.P. P5500
Blann, A. P4400 Boeder, N.F. P5028 Bonderman, D. P1786, P1808, P2129, 2212
Blaschke, F. P1093, P3079, P4084, P4385 Boegeholz, N. P5948 Bonello, L. 915, P2504, P6516
Blasetti, F. 4196 Boeger, R.H. P2572, P3623, P4661, P5022 Bonetti, F. P1529
Blaszczyk, R. P2411 Boehmer, F.D. P2589 Bonetti, G. P854
Blauwet, L. P2651 Boehmer, J. P2805 Bonfiglioli, R. P2640
Blazejewski, J. P4739 Boeken, U. P6142 Bongard, V. P758, P1358, P1703, 2023,
Blazing, M. 5774 Boekholdt, S.M. P4594 P6450
Blazing, M.A. 68, P1131, P6120 Boekstegers, P. 349 Bongioanni, S. P5493
Blazing, M.A.B. P6466 Boemicke, T. P1493 Bongiorni, M.G. P1092, P2439, 4845, 5148,
Blazquez, Z. 6633 Boening, A. P4529 5783
Blazquez Bermejo, Z. P2402 Boenner, F. 5899 Bongo, A.S. P2781
Blazquez-Bermejo, Z. 4049 Boergermann, J. P1618, P3526 Bonhoeffer, P. P2141
Ble Gimeno, M. P6492 Boersema, J. P1566 Boniface, K.B. P5546
Bleich, S. P3610 Boersma, E. P1746, P6418, P6429, 6641 Bonifazi, M. P2682
Bleie, O. 32 Boersma, H. 142 Bonini, R. P179, P6223
Bleiziffer, S. P6390 Boersma, L.V.A. 2273, 5735 Bonitta, G. P452
Blessberger, H. P5398 Boetker, H.E. P1336, P1337, P1464, P1498, Bonnefoy-Cudraz, E. 320
Blizzard, C.L. 1844, P5672 P1503, P1546, P2745, 3997, P4508, Bonnefoy-Cudraz, E. 2197, P2504
Block, P. P1604 P5234, P5351, P5359, P5509, P5512, Bonner, W. 2108
Block, S. P2625 P6455 Bonnet, B. P1733, P6407
425
Chairpersons & Judges / Speakers & Discussants / Authors Bon – Bre
Bonnet, D. P1650, P4602, 4952, 4954, 4956 Botto, G.L. 128 Brado, J. P1429
Bonomo, C. P892, P2808, P3788 Botto, G.L. 1908, P2112, 4860, P5222, 5916 Brady, P.A. P3324, 5093
Bonora, S. P6446 Botto, N. P4414, P4478 Braeckman, R.A. P1679
Bonou, M. P4666 Bou-Khalil, M. P1413 Braga, C. P3452, 4255, P4993, P5352,
Bonow, R. 1165, 5890 Bouafia, M.T. 29 P6529
Bonzani, G. P3505 Boucek, T. P3423 Braga, G.P. P2704
Bonzini, M. P3619 Bouchachi, A. P4548 Braga, P. P4490, P4995
Boon, R. 2342 Bouchelouche, K. P4743 Braganca, B. P2809
Boos, C.J. P1603 Bouchot, O. P6344 Bragason, K. 2936
Boraita, A. 978 Boudjemline, Y. P1639, P1640 Bragg, F. P1700
Borbas, Z. P6354 Boueri, Z. P579 Bragos, R. P3553
Bordalo, A. P1121 Bouferrouk, A. P6500 Brahimaj, A. P2594
Bordese, R. 2930 Boughzela, E. P4693 Brailova, N. 1837
Bordun, K. 4152 Bougiakli, M. P765 Brala, D. P1549
Boren, J. P4063 Bougouin, W. P4073 Bramanti, F. P1366
Borer, J.S. 42 Bouhzam, N. P668, P3583, P6373 Brambatti, M. P3078, P3603
Borer, J.S. 388, 994 Bouillet, E. 2014 Brambilla, N. P3592, P6375
Borger, M. P2623 Bouisset, F. P579 Bramlage, P. P3131, P3132, P3353, P3771,
Borger, M.A. 3256 Boukantar, M. 948 P3796
Borges, R.F. P732 Boukens, B. P1432 Branchitta, G. P1092
Borges, S. P4643 Boulanger, J. 6625 Branco, C.F. P4578
Borggrefe, M. P489, P493, P1400, 2173, Boule, S. P3374 Branco, L. P867, P1773, P4434
4031, 4032, 4217, P4591, P5947 Bouleti, C. 2103, P3731, P5014, 5217, 5218, Brand, G. P1561
Borghese, M. P5493 P6391 Brand, T. P1421
Borghi, C. 127, 137, 316 Boulif, B.J. 5212 Brandao, L. P1118
Borghi, C. 1892, 1893, P5263 Boulogne, C. P4558, P5500 Brandenburg, V.M. 6644
Borghini, A. P5020 Bouma, B.J. P437, P473, P716, P2137, Brandes, A. 3277, P4344
Borgna-Pignatti, C. P1529 P2658, P2661, 2927, 2934, 3050, P6416 Brandl, L. P607
Borgquist, R. P507, P2403, 4057, P4755, Bourantas, C. P2752 Brandt, M. 1084
P6307 Bourez, A. P5963 Brans, M.A.D. P4115
Boriani, G. P464, 930, P2115, P2425, P4619, Bourier, F. P4365 Bras-Silva, C. 6058
4865, 5141, 5737 Bourier, F.B. P5295 Brasier, N. P628
Bories, W. P4342 Bourni, E. P857, P1592 Bratlie, M. 336
Borjesson, M. 77 Boursier, M. 104 Braun, D. P3568
Bork, C.S. P4322 Bouslema, K. P704 Braun, I. P6154
Borleffs, C.J.W. P5970 Bouslenko, Z. 2935 Braun, N. 4054
Borodovsky, A. P1761 Boussada, M. P533, P5356 Braun, O.Ö. 4972
Boros, A. P499 Boutamine, S. P6500 Braun, S. P1485, 2284, P5396, P6122
Boros, A.M. P509, P2396 Boutouyrie, P.B. P1658 Braun, S.L. P3405
Borovic, M. P1716, P5415 Bouvaist, H. P579 Braun, S.Z. P1794
Borras, F.E. P2580 Bouvier, E. P1615, P5010, P5489 Braun-Dullaeus, R.C. P2592
Borras, R. P472, P1405, P1434 Bouzas Cruz, N. P2494, P4415 Braunschweig, F. 409
Borrayo-Sanchez, G. P5360 Bouzas-Cruz, N. P4406 Braunschweig, F. P166, 2276
Borrell-Pages, M. P2601 Bouzas-Mosquera, A. P3506, P3507 Braunschweig, T. 4978
Borren, N.M. P1750 Bouzourene, K. P4530 Braunstein, C. P1613
Borsanyi, T. P3348 Boveda, S. P4358, 5917 Braunwald, E. 211
Borschert, M. P3428 Bovenzi, F.M. P1474 Braunwald, E. 68, P1131, P1682, 3032,
Borst, O. P1487, P1494, P1508, 2341, Bowater, S.E. P3613 P3317, P3318, P6120
P2524, P6345, 6614 Bowles, C.T. P5675 Braunwald, E.B. P6466
Bortolotti, U. P3458, P4091 Bowman, L. P5575 Bravo, S. P4541
Bortolotto, L.A. P4785 Boyaci, F. P3620 Bravo Baptista, S. P1506
Bosch, L. 3950 Boyarinova, M. P735 Bravo-Marques, F. P601
Bosch, X. P1518, P3090, P4988 Boyd, H. P711 Bravo-Marques, R. P2381, P2777, P3657,
Bosker, H. P1547 Boyer, L. P6148 P5611, P6526
Bosmann, M. P2602 Boyer-Chatenet, L. P4647, P4650, P4982 Breau, M. P2360, P5557
Bosmans, J. P6390 Boyett, M. P415, P6354 Brecht, A. P5439
Bosmans, J.M. P3581 Boyne, J. 1230 Brecka, D. P1095
Bossard, M. P1706, P4663 Boytsov, S. 1837 Breckenridge, R. 1087
Bosse Pilon, C. P2675 Boytsov, S.A. P3354 Brecker, S. P6390
Bosselmann, H. P5700 Bozbeyoglu, E. P5275 Breda, L. P192
Bossone, E. P5530, P5704 Bozikis, S. P4505 Breithardt, G. 73, 323, 376
Bossu, A. P6159 Bozio, A. 4039 Breithardt, G. 2031, P4398, P5316, P6210
Bostock, J. P6314 Bozkurt, E. P488, P5426 Breithardt, O.A. 248
Botas, J. P4712 Bozo, K. P3348 Breithecker, A.B. P4687
Botelho, A. P209 Brabec, M. P631 Brekalo, M. P6547
Botker, H. 1842 Braber, T. P2371 Brembilla-Perrot, B. P2418, P2455, P3365,
Botker, H.E. 73, P577, P596, 2910, P4998 Brachmann, J. 75 P4599, P4600, P5553
Botnar, R.M. 1027 Brachmann, J. P3385, P3523, P4356, 5140 Bremner, A. P3640
Bots, M.L. P2371 Bracic, T. 2206 Brendel, L.C. P3405
Botta, L. P877, P2382, P3447, P6483 Brada, J. P169 Brennan, A.L. P4302
Botto, G. P2425 Bradaczek, M. 6613 Brenner, C. P607
426
Chairpersons & Judges / Speakers & Discussants / Authors Bre – Bur
Brenner, S. P6149 Broyd, C. P2512 Buch, M. P5379

Bressi, E. 4023 Broyd, C.J. 4930 Buchan, R.J. 3072
Bretelle, C. P2759 Brozovic, I. P572 Buchholz, A. P5316, 6636
Brewer, A. P4531 Brucato, A. P192, P4586, 5768 Buchman, V. P1415
Briand, S. 1954 Bruce, C. 5806 Bucio-Reta, E. P5645
Briand, Y. P5282, P5283 Bruce, M. P5435 Buckova, J. P5247
Briasoulis, A. P644, P660, P2575, P5368 Bruch, L. P1443 Buda, S. 6654
Briatico Vangosa, A. P5956 Bruckert, E. 1223, 1224, 1226 Budaj, A. 4975
Briceno, D. P1489, P3488 Bruder, O. 4229, 4231, 4233, 4234, 4235, Budano, C. P5353
Bridgman, C. P2356, P3630 P5001, P6323 Budd, D. P5292, P6192
Bridson, J.D. P3635 Brudi, P. 69, P1654, P1680, P1681 Budde, T. 1203
Brieda, M. 5918 Bruecher, B. P1379 Buddhari, W. P1684
Brieger, D. 325 Brueck, M. 1203 Buder, O. P4479
Briest, J. P3610 Brueckmann, M. 4980 Budera, P. P4364, P4395
Briffa, T. P3640 Brugada, G. P1640 Budnik, M. P2515
Brigadeau, F. P608, P3374, P3580, 5919 Brugada, J. P472, P1405, P1434, P3371 Budnikova, N.V. P3628
Brignole, M. 307 Brugada, P. P1388 Budoff, M. P4465
Brignole, M. 3977, 4905 Brugada Terradellas, J. 37, 148, 353, Budts, W. 95, 145, 155
Brili, S. P898, P3582, P3803 361 Budts, W. P6419
Brion, M. P3096 Brugada Terradellas, J. 12, 92, 2921 Buechau, M. P3570
Briongos Figuero, S. 5091 Brugada Terradellas, P. 2866, 2951 Buechel, R. P4481
Brisinda, D. P2693 Brugada Terradellas, R. 5118 Buechel, R.R. P611
Bristow, M. P3756 Brugaletta, S. P832, 1205, P1710, P2732, Buenger, S. 5818, P5935
Brito, D. 315, 364 P2780, P4712, 6018 Bueno, D. P6187
Brito, D. P1121, P1631, 3058, 3059, 5907 Brugger, N. P2378, P4098 Bueno, H. 44, 147, 154
Brito, J. P3586 Bruguera, J. P1774, 2213, P3124, P5301 Bueno, H. 407, P818, P836, 2177, 2179,
Brizendine, J. 960 Bruguera Cortada, J. P1125, P6492 2180, P2463, 3031, P4629, 5173, P5568,
Brkovic, V. 4288 Bruheim, K. 1857, P4071 P6462
Bro-Jeppesen, J. P421, P1792, P6252 Bruining, N. 1260 Bueno Lopez, D. P6492
Broch, K. P1404, P2621, P3589, 4048, Bruja, R. P635 Bueter, M. P1575
P4307, 6643 Brumm, J. P6464 Bueter, S. P6142
Brochado, B. P1634, P6167 Brun, F. P1375, P1393 Buettner, H.J. P809, P1493, P3720, 5792
Brochet, E. 198 Brunckhorst, C. P1390, P4590 Buffet, P. P799
Brochet, E. 3245, 3247, 3248, 3249, P3731, Brundel, B. P5314 Bugiardini, R. 95, 271
P4574, P5014, 5217, 5218, P6391 Brundel, B.J.J.M. P6186, P6189 Bugiardini, R. P561, P594, 4287, 4291,
Broczek, K. P5269 Brundler, M.-A. P1636 P4698, 5086, 5819
Brodehl, A. P1636, P3539 Brunekreef, B. 4197 Buglioni, A. 2336, P5018, 5076
Brodie, B.R. 4000 Brunelli, C. P3328, P3550 Buhlert, H. P3653
Brodmann, M. 250, 362, 376 Brunetti, N.D. 39 Buhlin, K. P6424
Brodmann, M. P4103, 4925, 4927 Brunetti, N.D.B. 2102 Buiatti, A. P4365, P5295
Broe, A. P3319 Bruneval, P. 3282 Buiciuc, O. P2553
Broersen, A. P4482 Bruning, T. 2101 Bujaki, C.S. P5023
Brogan, R.A. 1196, 2914 Brunken, R. P5425 Bukowska, A. P6179
Brook, R.D. P3340 Brunna, V. 37 Bulbul, N.G. P705
Brooks, A.G. P6198 Brunner, S. P607 Bulbul, Z. P2663, P6486
Brooks, G. P862 Brunner-La Rocca, H.P. 246 Bulbulia, R. P5575
Brorsson, H. 6649 Brunner-La Rocca, H.P. P1139, 3903, Bulfamante, G. P4734
Brosnan, M. P2683 P4458 Bulkova, V. P3423
Brossa, V. P1781 Bruno, A. 1971, P6211, P6217 Bull, K. P2139
Brossa-Loidi, V. P1123 Bruno, F. P3512 Bull, R. P1603
Brotons, C. 1222 Bruno, M.R. P5020 Buller, H. 3043, 3045
Brouckaert, P. P3084, 5830, 5831, 5833, Bruno, N. P3739 Buller, H.R. P3621
5835 Bruno, P.G. P5455 Bulpitt, C. 5078, P5567
Brough, C.E.P. 72 Bruno, R.M. 4196, P5576 Bulut, A. P722
Brouillard, D. 6084 Bruno, V. P572 Bulut, U. P4104
Broullon, J. P3506, P3507 Brusaferro, S. P2724 Bulzis, G. P4311
Brouwer, M.A. P695, P4678 Bruthans, J. 6652 Bun, S.S. P3412
Brouwer, T.F. P466, P473, P4299 Bruun, L.E. P3108, P3312 Bunch, T. P3356, P4376
Brown, A. P776, P6198 Bruun, N.E. P844, P6538 Bundgaard, H. P711, P2456, P2827, 4959,
Brown, A.D. P1612, P4579 Bryld, L.E. 6651 5856, P6399
Brown, A.S. P709 Bryniarski, K.L. 2022 Bundgaard, H.K. P460
Brown, B. P619, P2432 Bryniarski, L. P6402, P6408 Buno-Soto, A. P853, 4049
Brown, C. P1380 Bryson, G.L. P4393 Buonadonna, A. P871, 4149
Brown, K. 4971 Brzoska, J. P2835 Bura-Riviere, A. 324
Brown, M. 2259, 2261, 2262, 4140, 4212, Brzozowski, W. P2438 Burazor, I. P3651
5722, 5725, P5927 Buades, J. P6392 Burban, M. 5917
Brown, M.L. P168, P4297 Bucci, T. P6190 Burchell, A.E. P2840, P4339, 4875
Brown, N.A. P6357 Bucci, T.B. P5279 Burchielli, S. P3447
Brown, O.I. P1491 Bucciarelli-Ducci, C. 210 Burghardt, A. P2638
Brown, S. P3456 Bucciarelli-Ducci, C. 1019, 2040, 2041, Burgmaier, M. P1563, P1734
Brownlee, J. P4606 3002, P4078, P4420, 4872, 4875, P5226
427
Chairpersons & Judges / Speakers & Discussants / Authors Bur – Can
Burgner, D. 3951, P6396 Cadeddu, M. P578 Cambronero Cortinas, E. P1518, 6031

Burgos, A. P3420 Cadeddu Dessalvi, C. 5807 Cambronero-Sanchez, F. P586, P1098
Burke, M.A. 3065 Cademartini, F. P4465 Cameli, M. P1769, P2682, P4741
Burke, M.C. P4299 Cadena Bonifante, A. P3453 Camelliti, P. P6358
Burkhardt, J.D. 955, P3383, P3396, P3417, Cadenas Menendez, S. P2652 Camenzind, E. P4695
P6115 Caeiro, D. P4995 Camerino, C. P450
Burkman, G. P5682 Caetano, F. P2472, P3473, P5346 Cameron, D. 4275
Burnett, J.C. P1653, P5018, 5076 Caforio, A.L.P. 26, 377 Cameron, J. P1343, P4777
Burnett Jr, J.C. 2336, 4809 Caforio, A.L.P. 4266, 5908, 5909 Camici, G.G. P1115, P5007
Burnier, M. 1002 Caglar, S.O. P5714 Camici, P.G. 253
Buron, M. P5284 Caglayan, C.E. P875, P5480 Camici, P.G. 1289, 1291, 2037, 2039, 2041,
Buron, M.J.D. 1846 Cai, A. P4313 2861, 4878, 4910, P5577, P6245
Burrell, A. 2108 Cai, H.W. P2634 Camilleri, S. P1611, P6383
Burrell, C.J. P2820 Cai, Q.Z. P4306 Camino Lopez, A. 5091
Burrell, L.M. P894, P5674 Caiani, E.G. 1258, P1545, P6443 Camm, A.J. 25, 128, 187, 240, 261,
Burri, H. 72 Caiazzo, G. P2752, P2764 299, 360
Burri, H. 293, 2275 Caico, S.I. P5222 Camm, A.J. 392, P1513, 1898, 1899, 2173,
Bursi, F. P3508 Caidahl, K. P6460 2186, 2878, 2881, 2897, 3278, 3819,
Bursill, C. P1559 Caires, G. P3431, P5377 3822, 4131, P4404, 4802, 4806, 5072,
Burzotta, F. P604, P5027 Caixal, G. P4988 5844, P6181
Busch, M.A. P3610, P3666 Caixeta, A.M. 123 Camm, J.A. P2115
Busch, S.B. P5295 Cakilli, Y. P5275 Cammalleri, V. P1590
Buser, P.T. 81, 83 Cakir, U. P5714 Cammann, V.L. P2791, P6550
Bushinsky, D.A. P1799 Cakmak, H.A. P423, P2535, P2847, P4104, Campagna, M.S. P3791
Buss, S. P194, P2687 P5637, P6242 Campagnolo, P. P3545
Busseuil, D. P1561 Calabrese, A. P5285 Campan, M. P4494
Bussey, C.T. P1142, P1775 Calabrese, D. P3672 Campana, A. P504
Bustamante, M.J. P4631 Calabrese, G. P846 Campana, C. 2207
Bustins, M. P6584 Calabro, P. P5365 Campanale, C.M. P6132
Butcher, C. P3367, P6112 Calabro, R. P5365 Campari, M. P2112
Butcher, J. P3542 Calabro’, P. P1499 Campeanu, A. 5080, P6280
Butler, J. P441, P3785, P5682, P6508 Calado, F. P5685 Campelo, M. P4464
Butnaru, A. P794 Calcagnile, C. P5353 Campelo, M.J. P5677
Butt, M. P2742 Calcagno, A. P6446 Campia, U. P845
Butter, C. 349, 350, P1597, P3572, P3652, Calcagno, S. P846, P847 Campo-Aguirre, R. P5650
P4366, 5216, 6017, P6369, P6370 Caldeira, D. P1118, P3669, 5814 Camporeale, A. P452, P1354, P5929
Butterworth, A. 937 Caldentey, G. P3090, P4988 Camporese, G. P5609
Buys, D. P650 Calder, P.C. 3895, P4740 Camporotondo, R. 1204
Buza, V. P6528 Calderaro, D. P1804, P6499 Campos, D.H.S. P892
Buzas, R. P225 Calderon-Snachez, E. P4528 Campos, I.C. P5251
Buzea, C.A. P849, P2454 Cale, R. P3669, 5814 Campos, L. P5684
Buzzi, S. P4119, P4781 Calella, G. P4628 Canadas, V. P6498
Byazrova, F. P6528 Cali’, G. 3943 Canales-Albendea, M. P853
Bykova, A.A. 6042 Calicchio, F. P866 Canas Da Silva, P. 366
Byrkjeland, R. P1574 Califf, R.M. 990, 3920 Cancedda, R. P3550
Byrne, C.D. P1603 Caligiuri, G. P4086, P5008 Canciello, G. 4900
Byrne, J. P2625, P3726 Calin, A. P1630 Canciello, M. P2112
Byrne, R.A. 116, 117, 118, P1500, P3705, Calin, S.I. P2806 Cancio, S. P4622
P5396 Caliskan, K. 3074, 6641 Candolfi, P. P6378
Byrom, R. P3767 Caliskan, M. P3450 Canepa, M. P3328, P3550
Bytyci, I. P4727, P6585 Calisto, C. 4154, P6165 Cangemi, R.C. P5279
Byun, J.K. 277, P736, P762, P808, P826, Calkins, H. 205 Cannao, P.M. P452
P834, P2766, P2842, P3703, 5124, P5350, Calkins, H. 3145 Cannata, F. P5455
P5355, P5387 Calle Perez, G. P4468 Cannata -Andia, J.B. P3591
Byun, Y.S. P563, P3656 Calli, S. P1688 Cannillo, M. P6262, P6446
Caballero, R. P5945 Calmac, L. P4442 Cannon, C.P. 204, 243, 261
Cabanes, R. P2790 Calo’, L. 2270 Cannon, C.P. 68, P1682, 2222, 2853, 3030,
Cabiati, C.M. P4598 Calore, M. P3536 3143, 3862, 3863, 3867, 3868, P6120,
Cabiati, M. P877, P2382, P4601, P6336, Caluwe, E. P1111, P6260 P6427
P6474 Calvanese, C. P5263 Cannone, V. P1653, P5018
Cable, T. P803 Calvanese, R. 5916 Cano, M.N.C. 2911
Cabrera, S. 952 Calvert, P. P4447 Cano Nieto, J. P6421
Cabrera Gomez, S. P5301 Calvi, V. P2112, 5916, 5918 Canoui-Poitrine, F. P4111, P6148
Cabrera-Bueno, F. P1689 Calvieri, C. P452, P847, P6251 Canova, P. P5285
Cabrera-Fuentes, H.A. P4529 Calvo, P.L. 2930 Canpinar, H. 1839, P4379, P6188
Cabriera, M. P1348 Calvo-Bonacho, E. P1689 Canpolat, U. P3699, 4173, P4533, P4534,
Cacao, R. P2760, P4686 Camacho Freire, S.J. P4468, P4470 P4577, P4690, 5210, 6074, P6274
Caccamo, L. 5918 Camacho-Garcia, M.A. P5650 Cantarini, L. P192
Cacciavillani, L. P1528 Camara, B. P663 Cantinho, G. P598, P2636
Cacela, D. P3693 Cambria, R.P. 6621 Cantinotti, C.M. P4598
Cadeddu, C. P1573 Cambronero, E. 3252 Cantinotti, M. P4601
428
Chairpersons & Judges / Speakers & Discussants / Authors Cao – Cat
Cao, K.J. P6160, P6359 Carlsson, N. 2033 Casado, H. P4488

Cao, X.S. P2833 Carlton, E. P1603, P4463 Casado, R. P5686
Caparrotti, S.M. P2630, P5639 Carluccio, E. 5805, P6567 Casadonte, L. P1708
Capderou, A. 2283 Carmo, J. P1610 Casalli, K.R. 5082
Capdevila, A. P2130, P4524 Carmo, J.F. P5643 Casalta, J.P. P1611, P3105, P6383
Capel, R. P6358 Carmo, P. P2394, P4350, P4380 Casani, L. P2130, P4524
Capelli, C. P5451 Carneiro, L. P1796 Casar Demarco, D. P6233
Capellini, S. P854 Carnevale, R. P6190 Casares, J. P6490
Capello, C. 2928 Carnevale, R.C. P5279 Casas, E. P1554, P3531
Caples, N. P625 Carnevali, A. P1354 Casas Rojo, E. 3173, P5442
Capodanno, D. 84, 369 Carnicelli, V. P3087 Cascinu, S. P860
Capodanno, D. P2768, P5285 Carnicer, R.C. P4517 Casella, I.B. P1804
Capogrosso, C. P4683 Caro, J. P3420, 6633 Casella, M. P3427, P4346
Caponi, D. P3377 Caro-Codon, J. P853 Caselli, C. P877, P2382, P4598, P4601,
Caponi, L. P6474 Caron, A. P621 P6230, P6336, P6474
Caporali, A. P6337 Caron, C. P6507 Caselli, S. 258
Cappato, R. 4803 Caron, H.N. P5035 Casiglia, E. P899
Cappelletti, A. P5659 Carpeggiani, C. P1341 Caso, P. P3505, 3989, 3991, 3992, 3993
Cappelli, G. P3508 Carpenter, A. P4078 Casolo, G. P5289
Cappelli, R. P4675 Carpenter, R.E. P2701 Cason, M. P6166
Cappelli Bigazzi, M. P5365 Carpentier, A. 3294 Caspar, T. P5409
Cappuccio, F.P. 2021 Carpinteiro, L. P511, P2433 Caspers, S. P2357
Capranzano, P. 1046 Carr-White, G. P857, P1530 Caspi, O. P447
Capretti, G. 2013 Carracedo, A. P3096 Cassagneau, R. P4358
Capuano, F. P544, P3490, P3579, P3663, Carranza-Rebollar, A. P5650 Cassandra, M. P3473, P5346
P4317, P5241, P5478 Carraro, M. P4588 Cassano, F. P2682
Capucci, A. P860, P2406, P3078, P4554, Carrasco, F. P4576 Cassar Demarco, D. P6236
5918 Carrasco, F.C.A. P2442 Cassat, C. P4558
Caputo, M. P1334, P1557, P3559, P5454 Carrat, F. 4260 Casselman, F. P1729
Caputo, M.L. P2439 Carratu’, P. P4311 Cassese, S. P3705
Caramelli, B. P1804, P6499 Carre, F. 23, 194 Cassin, M. P1644, P1646, P3335, P5242
Caramori, J.C.T. P2704 Carre, F. 2064, 6104 Castagno, D. P1406, P3394
Caranci, F. P3739 Carreno Jaimes, M. P3453 Castaldi, B. P706
Carapetis, J.R. P1612, P4579 Carreras, F. P745, P2130, P4524 Castel Lavilla, M.A. P1766
Caravelli, G. P899 Carreras Costa, F. P4996 Castellani, C. P1788
Caravelli, P. P2351 Carrero-Roig, J.J. P4304 Castellano, I. P6315
Caravita, S. P5523 Carresi, C. P3560 Castellano, M. 2850
Carballo, D. 6650 Carretta, R. P6495 Castelletti, S. P1632
Carberry, J. P617, P1519 Carrick, D. P617, P1519, 4293 Castelvecchio, S. P452, 2208, 5214, P5974
Carbonara, R. P657, P733, P4311, P4664 Carrick, D.J.A. P1522, 4024, 4055, 4294 Castillo, F.C.B. P2442
Carbonara, S. P657, P4664, P6437 Carrie, D. P6516 Castillo, J.C. P4576
Carbone, F. P750, P886, P2618, P4744, Carriere, C. P4399, P5297 Castillo, J.C.D. P2442
P4750, P6376, P6434 Carrillo, P. P571, P5348 Castillo Bernal, F.J. P4576
Carbonell San Roman, A. P508, P2691, Carrion, C. P1674 Castineira Busto, M. P2494, P4415
3173, P5442 Carrizo, A.G. P2405, P3401 Castineira-Busto, M. P3113, P3474
Carbucicchio, C. P6115 Carrizzo, A. P2121 Castiniera-Busto, M. P4406
Cardenal Piris, R. P4468, P4470 Carro Hevia, A. 962 Castor, T. P2587, P6345
Cardim, N. 4006, 4008, 4010, P4509, 5149, Carta, M.P. P1533 Castrini, A.I. P3790
5150, 5152, 5154, 5156 Carter, K. P6472 Castro, G. P5427
Cardinal, H. P5364 Carter, N. P4299 Castro, M. P3586, P4624
Cardinale, D. 92 Carter, R.E. 5047 Castro, M.C. P829, 1200
Cardinale, D. 5197 Cartigny, G. P3080 Castro, P. P3518
Cardona, M. P1766 Carturan, E. P6166 Castro Alba, M.A. P3612
Cardoso, D.M. P3643 Cartwright, E. 6057 Castro Arias, L. P3486
Cardoso, J.S. P1407, P5677 Cartwright, E.J. 6056 Castro Conde, A. P3632, 4207, 4208, 4210
Cardozo, F.A.M. P1804 Carubelli, V. P3790 Castro-Chaves, P. P5006, P6586
Carella, C. 5904 Caruso, A. P6338 Castro-Ferreira, R. 1853
Carerj, M.L. P3521 Carvalho, A.C. P4410 Castrodeza, J. P5647, 6022
Carerj, S. P634, P3521 Carvalho, A.C.C. P4455 Catalan Sanz, P. P2691
Caria, R. P591 Carvalho, H. P1634 Catalucci, D. 4190
Carigi, S. P2485, P3672 Carvalho, J. P5393, 5820 Catanzariti, D. P3399, P3403, P3411
Cariou, A. 1320, P1382 Carvalho, M.S. P2394 Catanzaro, M. P569
Carli, P. P4073 Carvalho, P. P1406, P6174 Catapano, A.L. P1677
Carlino, F. P1552 Carvalho, R. P2473, P2489, P6165 Catapano, L. 245
Carlino, M. P2761 Carvalho, S. P3457, P4350, P4380, P5390 Catapano, L. 71, 1865, 3884, 4890
Carlsen, J. P3624, P5953 Carver, K. 2005, 2006 Catarzi, S. P5290
Carlson, J. P1375 Carza, L. P450 Catelani, G. P5289
Carlson, N. 951, P5284, P5596 Casabe, J.H. 4961 Catini, C. P2532
Carlsson, J. P552 Casadei, B. 88, 193, 352, 356 Cattafi, G. P3411
Carlsson, M. P507, P1754, P2665, 4057, Casadei, B. P4517 Cattan, S. P5931
P4755 Casado, A. P5448 Cattaneo, M. P4100
429
Chairpersons & Judges / Speakers & Discussants / Authors Cat – Che
Cattinelli, S. P4675 Cesena, F.H. 70 Channon, K.M. 1834, P2595, P4517, P5000,
Cattunar, S. P5543 Cesna, S. P2141 P5416
Cauldwell, M. 144 Cetin, M. P2416, P5335, P6257 Chanoit, G. P3559
Caulfield, M. 4215 Cetin, M.S. P1459, P1460, P2118, P2490, Chao, T.-H. P1466
Cavaco, D. P2394, P4349, P4350, P4380 P3699, P4561, P4562, P5271, P5649, Chao, T.F. 297, 932, P2427, P5273, P5298
Cavada, G. 1854 P6406 Chao, W.T. 1961
Cavalcante, M.A. P2717 Cetinkal, G. P573, P2714 Chaosuwannakit, N. P708
Cavalera, M. P2362 Cetran, L. P5462 Chaouat, A. P5513
Cavallero, E.C. P3118 Ceyhan, K. P2416 Chapman, A. P4461
Cavalli, G. P2545, P2546 Cezar, M.D.M. P892, P3788 Chapman, A.R. P3432
Cavallo, L. P657 Cgojeva, I. P2347 Chapman, J. 91
Cavanagh, J. P1374 Cha, D.-H. P2153, P4513 Chapman, J. 1227, P2146, 5744
Caviezel, S. P2671 Cha, K.S. 371, P819, P1511, P2726, P4424, Charakida, M. P2136
Caviglioli, C. P6410 P6431, P6511 Charalampopoulos, A. P5954
Cavirani, G. P5289 Cha, K.S.C. P1724 Charatkulangkun, O. P1695
Cavusoglu, Y. P1764, P3746, P3776 Cha, T.J. P2414, P5336 Charbonnier, M. P4647, P4650
Cayla, G. 84 Chabanne, C. P4095, 6630 Charchar, F. P2784
Cayla, G. 363, P556, P3344, P4446, P6452, Chabot, F. P5513 Charitakis, E. P5268
6622 Chabowski, A. P6283 Charles, H. P3763
Cayli, M. P722 Chacko, S. P3091 Charles, P. P5009
Cea Soriano, L. P3320 Chacko, S.J. P1521 Charlot, M. P5978
Ceccacci, A. P847 Chae, I.H. P2570 Charlot, M.G. P2120
Ceccaldi, A. P5654 Chae, J.K. P2486, P4426, P4428 Charoensri, N. P613
Cecchetto, A. P2539, P2541, P3532 Chae, S.C. P2462, P2486, P3732, P3768, Charpentier, S. P173
Cecchi, F. 141 P3787, P4110, P4724, P4726, P6578 Charron, P. 141, 356
Cecchi, F. P466, 2078, 2080 Chahal, N.S. P2562 Charron, P. 919, 2085, 4265, 5989
Cecconi, A. P2517 Chai, M. P659 Charron, P.H. P5472
Ceconi, C. 322 Chaimy, T. P4587 Chasan, R. P5928
Cefalu, C. P3527 Chaiteerakij, R. 2211 Chasapi, A. P1478
Celeng, C. 2105, P4496 Chakkalakal, C. P6268 Chase, A. P2742
Celi, A. P3087 Chakraborty, A. P1463 Chashkina, M.I. P5706
Celic, V.C. P4778 Chalikias, G. P4432 Chasnoits, A. P3736
Celik, A. P2416, P5681 Chalmers, V. P6456 Chastre, T. P714, P3588
Celik, A.I. P875, P5480 Chamberlain, A. 6640 Chateau, N. 5079
Celik, I.E. P5335 Chamberlain, A.M. P4984 Chatellier, G.C. 5089
Celik, O. P423, P2519, P5637 Chambers, B. 196, 321 Chatot, M. P1733, P6407
Celik, S. P3620 Chambers, B. 2991 Chatrou, C. P5547
Celikyurt, Y.U. P4347 Chambers, J. P669 Chatterjee, M. P1494, P1508, 2341, P2524
Cellier, G. P668, P5490 Chamodraka, E.F. P906 Chatterjee, R. P5328
Cenarro, A. P1586 Chamova, T. P1352, P4589 Chatterjee, S. P823
Cendrowska-Demkow, I. P4721 Champagne, S. P3516 Chattipakorn, N. P3781, P3786, P4538,
Cengiz, B. P5440 Chamuleau, S.A.J. 1957, P5447 P5539
Cengiz, M. P1828 Chan, A.W. P2727, P2736, 2907, 5817 Chattipakorn, S. P3781, P3786, P4538,
Cenko, E. P561, P594, 4287, 4291, P4698, Chan, J. P6305 P5539
5086, 5819 Chan, K. P2674, P2840, P5383, P6305 Chaturvedi, N. 1849, P2709
Centeno Jimenez, M. P1392 Chan, K.T. 314 Chatzianagnostou, K. P4414
Cepas, P. P2402 Chan, L.L. P5544 Chatzianastasiou, A. 1089
Ceponiene, I. P3514 Chan, P.H. P4765 Chatzigeorgiou, M. P4648
Cequier, A. P551, P761, P818, P1444, Chan, S.P. P5644, P5648 Chatzikyriakou, S. P4432
P6140, P6196 Chan, W.M. P3629 Chatzinikolaou, C. P2711
Cequier-Fillat, A. P546 Chan, Y.H. P738 Chatzistamatiou, E. P898, P3803, P4671,
Ceravolo, G. P2583 Chanchai, T. P4538 4871
Cerda, A. P1579 Chandra, S. P4408 Chatzizisis, Y. 1841
Cerecera, F. 1854, P3665 Chandrachamnong, S. P2419 Chatzopoulos, S. P6320
Cerisano, G.P. P1094 Chandran, S. P3664 Chaudhary, G. P4408
Cermakova, E. P4441 Chandrasekhar, J. P2762, P3717, 6619 Chaudhry, U. P2403, 4057
Cernecka, H. P864 Chandwani, P. P4713 Chauveau, S. P1385, P4357
Cerny, D. 2014 Chandy, G. P5519 Chavez, E. P4527
Cerny, S. P4720, P6493 Chang, C.P. 2205 Chaykovskaya, M. P489, 5097
Cerqueira, R. P5006, P5641 Chang, D. P4370 Chazal, R. 205, 309
Cerqueira, R.J. P5634, P5635 Chang, H.J. P2544, P3585, P6362 Chazard, E. P621
Cerquier, A. P6462 Chang, K. P666, P6287 Chazov, E. P1822
Cerrato, E. P1449, P1748, P6262 Chang, K.C. P5317 Cheang, M.H. P1617
Cerrato, E.C. P3118 Chang, S.-A. P3109 Checinski, L. P1441
Cerrato, N. P1406 Chang, S.A. P4493, P4559 Cheezum, M. 2108
Cervesato, E. P1644, P1646 Chang, S.L. 3949 Chefu, S.G. P2576, P5236
Cervinka, P. P4329, P4707 Chang, T.Y. 297 Cheggour, S. 104
Cervinkova, M.C. P4329 Chang, W.L. P4076 Chemnitz, A. P4344
Cervio, E. 1081 Chang, W.T. P3436 Chen, A. P1145
Cesana, B.M. P854 Channon, K. 10, 5831, 5833, 5835 Chen, C.-H. P5707
Cesare, M.M. P877 Chen, C. P6518
430
Chairpersons & Judges / Speakers & Discussants / Authors Che – Cho
Chen, C.H. P4759, 5075, P5570, 6045, Cheskes, S. P1331 Cho, A. P3454
P6576 Chettibi, M. P551 Cho, C.H.J. P6583
Chen, C.W. 1855 Cheung, B.M.Y. P4659 Cho, D.K. P3799
Chen, C.Y. P5394, P5554 Cheung, C. 156 Cho, E.-J. P3109
Chen, D.-M. P5664 Cheung, C.L. P4659 Cho, E.J. P4559
Chen, D. P4122 Cheung, D. 4152 Cho, G.Y. P2570
Chen, D.Y. P5614 Cheung, M.M.H. 3951, P6396 Cho, H.J. P4771
Chen, H.H. P221 Cheung, Y.F. P719 Cho, I.J. P2544, P3585, P6362
Chen, H.W. P6160 Chevalier, B. 369, P1615, P5010, P5489 Cho, J.-M. P802
Chen, H.Y. P5551 Chevalier, P. P1385, P4357, P6164, P6176 Cho, J.G. P461, P824, P3732, P4471, P4616,
Chen, J.-L. P5414, P5417 Chew, D. P2839, P3630, 4127, 4939, 4940, P4633
Chen, J.-W. 1976, P2131, P4684 5876, 5877 Cho, J.H. P4526, P4696, P4752
Chen, J. P1359, P2113, P2688, P4652, 5123, Chia, K. 5758 Cho, J.R. P4355
P6350 Chiandotto, S. 2013 Cho, J.S. P2848
Chen, J.H. P6518 Chiang, C.E. 5075 Cho, J.Y. P3787, P4726
Chen, J.W. P800, P1819, P5394 Chiang, F.T. P1684, P5554 Cho, K.I. P2414, P5336, P5363, P6288,
Chen, J.Y. P4313 Chiang, Y.T. 1855 P6440
Chen, K.P. P470 Chiappino, D. P6425 Cho, L. 3858, 3927, P5968
Chen, L. P3667 Chiarella, F. 4254 Cho, M.C. P821, P2486, P2816, P3768,
Chen, L.C. P653 Chiarini, V. P3508 P3787, P4110, P4726, P6119, P6578
Chen, L.H. P2634 Chiba, S. P2692, 5885 Cho, S.-C. P1495
Chen, L.N. P5554 Chieffo, A. 370, 1265, P2616, P2761, P3342, Cho, S.-Y. P2153, P4513
Chen, M.L. P6160 P4699, P5491 Cho, S.W. P820
Chen, N.C. P3436 Chiellini, F. P3447 Cho, Y. P2462, P4724
Chen, P.C. P2116 Chien, H.J. P6331 Cho, Y.K. P445, P4474
Chen, Q. P643, 5847 Chikamori, T. P184, P603 Cho, Y.R. P819
Chen, Q.Y. 1080, P3464 Child, N. P1432 Chodick, G. P2785
Chen, R.Z. P3598, P3602, P4518 Child, N.M. P615 Chodor, P. P5303
Chen, S. P2113 Chilingaryan, A.L. P3770, P5286 Choe, C.W.S. P6583
Chen, S.A. 297, P2427, 3949, P5273, P5298, Chillo, P. P1538 Choe, J.C. 371
P6326 Chilukoti, R.K. P6179 Choe, S.I. P1809
Chen, S.A.C. P4680 Chimed, S. P3469 Choe, W.S. P4771
Chen, S.L.C. P3118 Chimenti, C. P1430 Choe, Y.H. P4493
Chen, S.W. P483 Chimura, M. P1713, P3692 Choen, M. 3032
Chen, T.H. P4990, P5614 Chin, C.W.L. 1986, 1987 Choi, B.G. 277, P736, P762, P808, P812,
Chen, T.P. P6331 Chin, D. P510, P786 P826, P834, P2766, P2779, P2842, P3703,
Chen, W. 2342 Chin, D.T. P6387 5124, P5350, P5355, P5387, P5395
Chen, W.J. P3436 Chin, H.M.S. P6314 Choi, B.J. P1721, P2755
Chen, X. 2335 Chin, J. P1683 Choi, C. 2264
Chen, X.H. P6572 Chin, S.H. P510 Choi, C.U. P808, P812, P826, P2766, P5355,
Chen, Y. P1143, P1412, P1700, P2588, Chin-Dusting, J. P2637 P5387
P4652, 4821, P6303, P6312 Chin-Yee, I. P652 Choi, D. 1239, P1657, P2710, P4682, P6590
Chen, Y.H. P5554 Chinaglia, A. P564, P569 Choi, D.H. P4581, P4651, P5613, 6025, 6624
Chen, Y.J. P4076 Chinen, D. P1737 Choi, D.J. P3768, P4110, P6578, P6579
Chen, Y.L. P1762, P3564 Ching, C.K. 294, P3413 Choi, E.Y. P1638, P3687
Chen, Y.Y. 4059, P4515, P4990 Chinta, S. P4711 Choi, H.O. P5630
Chen, Z. P637, P710, P1346, P1359, P1700, Chinushi, M. P6156 Choi, I.J. P5389
P2688, P3557, P4652, 5123, P5237, P5620 Chiodi, E. P2355 Choi, J.-H. P1757
Chen, Z.W. 4059 Chioncel, O. P3752 Choi, J.H. 371, P1387, P1511, P2401,
Chen, Z.X. P2634 Chiong, L. P5605 P2495, P2544, P2726, P4424, P4472,
Cheng, A.S. P3126 Chiong, L.O. 3948 P4493, P4702, P6431, P6511
Cheng, C.-F. P2132 Chiou, A.-F. P5664 Choi, J.H.C. P1724
Cheng, C.C. P3565 Chiou, K.R. P3565 Choi, J.I. P1525
Cheng, H.-M. P5707 Chiou, S.H. P3565 Choi, J.O. P4493, 5214
Cheng, H.M. P219, P4759, 5075, P5570, Chioza, B.A. P1629 Choi, J.W. P812
6045, P6576 Chirca, A. 4157 Choi, J.Y. P746
Cheng, J. P1746, P3795 Chiriac, L. P6447 Choi, K.J. P1387, P2401, P5630
Cheng, K. P2674 Chiribiri, A. P1530, 4931 Choi, S.-H. P1757
Cheng, S. 3168 Chirmicci, S. P1790 Choi, S.-W. P3768
Cheng, S.M. P1819 Chisari, A. P2768 Choi, S.H. P2495, P4472, P4702
Cheng, W.P. P1568, P6333 Chishiro, T. P1515 Choi, S.I. P904
Cheng, X.C. P5471 Chiswell, K. P6228, P6290 Choi, S.Y. 277, P736, P762, P808, P812,
Cheng, X.S. P6340 Chiti, M. P569 P826, P834, P1721, P2755, P2766, P2779,
Cheniti, G. P2615, P4693 Chiu, C.-C. P574, P2131 P2842, P3703, 5124, P5350, P5355, P5387
Chenot, C.F. 5212 Chiu, S. P3459 Choi, T.Y. P3799
Chenzbraun, A. P6247 Chiva-Blanch, G. P1128 Choi, W.G. P2779
Cherif, M. P1557 Chlebus, K. P549, P6580 Choi, Y.W. P2755
Cherniavsky, A. P2613 Chmielecki, M. P3475 Chomahidze, P. S.H. 6042
Chernogubova, E. P2604 Chmielewski, P. P3540, P3543 Chon, M.K. P6463
Chernyavskaya, T. 234 Chmura, A. P755 Chong, C.-R. P6565
Cherubini, A. P5297 Chniti, G. P533
431
Chairpersons & Judges / Speakers & Discussants / Authors Cho – Cof
Chong, D. P3413 Chubuchny, V. P6425 Cividjian, A. P4357

Chong, D.W.S. P496 Chun, K.J. P6463 Cladellas Capdevila, M. P6492
Chong, M. P2571, P4082 Chun, W.J. 2912 Claessen, G. P2683, P5507, 6104
Choo, E.H. P666 Chun, Y. P4635, P6137, P6553 Claeys, M.J. 1285, 4195, 4792, 5213, 5785,
Chopard, R. P6407 Chun, Y.H. P767, P1357, P4121, P4626, 6008
Chopra, H.K. 23 P4642, P5602 Claggett, B. P213, P214, 3168, 3302, P3756
Choquet, C. 2103 Chung, E.S. P215, 4857 Clapp, B. P669, 4931
Choquet, D. P1670 Chung, F.P. P6326 Clapp, L.H. P5509
Chorin, E. P3584 Chung, H. P1638 Claridge, S. P518, P6314
Chorro, F.J. 963, P1517, P1518, 3252 Chung, I.H. P563 Clark, A.L. 255
Chosa, E. P2380 Chung, J. P1521, P3091 Clark, A.L. 3295, 3296, P3789, P6564
Chou, C.Y. P5317 Chung, J.H. P640 Clark, A.L.C. 2231
Chou, P. P5570, P5707 Chung, J.W. P2508 Clark, D. P619, P2432
Chou, R.H. P800 Chung, M. 5754 Clark, D.J. P4302
Choudhary, F. P3456 Chung, M.L. P440 Clark, R. 4047
Choudhry, U. P2770, P6327 Chung, N. P2544, P6362 Clarke, K. 5112
Choudhury, A. P2742 Chung, N.A.Y. P2662 Clarke, R. P637, 1856, P4613, P4652, P5575,
Choudhury, R. P3387 Chung, N.S. P3585 P5582, P5620
Choudhury, T. P3774, 6608 Chung, W.-J. P200 Clarke, S.C. 34, 205, 324
Choudry, F.A. P1446, 6608 Chung, W.S. P6287 Clarke, S.C. 3163, 3166
Choukroun, J. P3485 Chung, W.Y. P6563 Claude, J. P6176
Choussat, R. P3588 Chung-Lieh, H.U.N.G. 3168 Claus, P. 2282, P5468, P5507, P5941, 6104
Chovanec, M. P4387, P4720 Chuo, C.H. P4521 Clausen, V. P1761
Chow, A.W. P494 Chwyczko, T. P5291 Clavel, M.-A. 134, 135, 137, 139
Chow, K. P3102 Cialdella, P. P5027 Clavel, M.A. 3049
Chow, L.W. P3545 Cianchetti, S. P3087 Clavero, M. P2557
Chowdhary, S. P5379 Cianella, F. P6216 Clavet-Lanthier, M.-E. P4520
Chowdhury, M. 4047 Cianflone, D. P4634 Clays, E. P1663, P4324, P4636
Chowdhury, R.A. P3398 Cianflone, E. P3560, P3561, P5457 Cleemput, I. 105
Chowdhury, T.A. P1569 Ciaramitaro, G. P2112 Cleland, J.F.G. P5974
Choy, A.M. P517, P5321, P6552 Ciborowski, M. P4731 Cleland, J.G. P3789, P6551
Chrabaszcz, M. P3361 Ciccaglioni, A. P2443 Cleland, J.G.F. 242, 326
Christ, G. P2488 Ciccarelli, G. 3943 Cleland, J.G.F. 4963, P6564
Christ, M. 162, 959 Ciccone, M.M. P657, P733, P4311, P4664, Clemens, M. 6075
Christensen, G. P451, 3065, 6043, P6341 5810, P6437 Clement, M. P4086
Christensen, T. 4289 Ciccozzi, M. P6132 Clemente, A. P4478
Christenson, J. 156 Cicero, A. 1891, 1893 Clementy, N. 950, 1970, P4985, P5267,
Christenson, R. 162, P878 Cicero, A.F.G. P6153 P5313, P6205
Christensson, A. P4532 Cicoira, M. P1365 Clemmensen, P. P593, P1546
Christersson, C. 1953, P2655, P3611, Cid, B. 1205, P2732 Clemmensen, T.S. P4743, P4749
P5410 Cid Alvarez, B. P2494, P5248 Clerc, J. 6625
Christia, P. P1489, P3488 Cid Menendez, A. P3113 Clerc, O. P4481
Christiaens, L.P. P5955 Cid-Menendez, A. P3474 Clerfond, G. P4417
Christiansen, E.H. P2745, 3997, P4508, Cidade Silva, P. P5641 Clerico, A. P4598, P6230
P5234 Cierniewski, C. P4722 Cleries, M. P6584
Christiansen, J. 4156 Cifkova, R. 92 Clesham, G.J. P4709
Christodorescu, R. P4706 Cifkova, R. 3969, 3971, 6652 Clifford, A. P2585
Christodorescu, R.M. 374 Cihak, R. 956, 4859, 6075 Clift, P. P1647
Christoph, M. P3389, P3409, P4341, P4359, Cikes, M. P694, P2639, P2824, 4245, 4247 Clift, P.F. P3613
4973, P4983 Cimadevilla, C. 1984, P4574 Climent, V. P616
Christou, A. P2721 Cimaz, R. P192 Climent Paya, V. P1398
Chronaki, C.E. 93 Cimmino, G. 3943 Climent Salarich, M. 1955
Chruszcz-Chrabaszcz, A. P3361 Cinca, J. 161, P1425, P3755, P5694 Cloez, J.L. P4599
Chrysochoou, C. P3116 Cinello, M. P3335 Coats, A.J. P5256
Chrysohoou, C. P727, P730, 2233, P2711, Cinti, L. 158, P4456 Coats, A.J.S. 212
P2721, P2723, P3681, P4331, P4429, Ciobanu, L. P6527 Coats, A.J.S. 1077, 2324
P4648, P5555, P5561, P5676, P6422, Cioffi, G. P4399, P5297, P5683, P6147, Coats, L. 2933
P6438 P6575 Cobb, V. P494
Chrysostomakis, S. P5329 Cioppa, A. P2630 Cobet, V. P6527
Chrzan, I. P5294 Cipolla, A. P2443 Coblence, M. P5446
Chrzanowski, L. 72 Cipolletta, L. P3427, P4389 Cobo Gomez, N. 2940, P3650
Chrzanowski, L. P856 Cipriani, A. P1528 Coca, A. 78, 92, 137
Chu, G.S. P510 Cipriani, M. P3603 Coca, A. 4141, 4896
Chu, Y. P2793 Ciriello, N. P569 Cochrane, L. P3763
Chua, A.P. 2942 Cirillo, M. 2207 Codd, V. P4090
Chua, K. P3413 Cirillo, P. P2481, 3943 Codogno, I. 1984, P4574
Chua, S. P1762, P3564 Cislak, A. P566, P576, P585, P587, P589 Coelho, O. P3648
Chuaiphichai, S. P4517 Citak, S. P1688 Coelho, T. P1634, P6167
Chuang, S.-Y. P5707 Citarelli, G. 5810 Coelho Lima Junior, J.A. P570, P588
Chuang, S.Y. P219, P4759, 5075, P5394, Ciurzynski, M. P755, P5531, P6168 Coffee, N. P2700
P5570 Civeira, F. P1586
432
Chairpersons & Judges / Speakers & Discussants / Authors Cof – Cos
Coffey, S. P1775, P6380 Conceicao, I. P598, P1122, P2636, P3804, Corman, I. P842
Coghlan, J.G. 131 P5419, P5422 Cormier, B. P1615, P5010
Coghlan, J.G. 1938, 1941, P5514 Conceicao, R.D. 70 Cornara, S. 1204
Cognasse, F. 3955 Concin, H. 966 Cornel, J.H. 1324, 4975, P5232
Cohen, A. 123 Condorelli, G. 201, 364 Corneli, M. P5583
Cohen, A. 77, P1453, P4647, P4650, P4982, Condorelli, G. 1955 Cornide, L. 962
P5654 Conen, D. P628, P1706, 1843, 1922, P4663 Coronel, R. P1427, P1432, P2412
Cohen, A.T. 4129 Cong, T. P4370 Corrada, E. P1499
Cohen, D. P3717 Conley, P.B. P3088 Corrado, D. 361
Cohen, D.J. 2913 Connelly, D. P1380 Corrado, D. P690, P1528, P1534, P2682,
Cohen, H.Y. P3548 Conner, D. 3065 P3536, P4460
Cohen, L. P5463 Connolly, M.J. P5514 Corrado, L. P569
Cohen, M. P3317, P4484, P4485 Connolly, S. 245 Corral Fernandez, F. P5474
Cohen, S.S. P5374 Connolly, S. 2, P2425, P2718, 6648 Correia, A. P592, P2464, P2529, P3431,
Cohen Solal, A. P3757 Connolly, S.J. P1389, P2405, 3885, 4852, P4303, P5377
Cohen-Solal, A. 40 4980, 5143 Correia, C.E. P6400
Cohen-Solal, A. P842 Conraads, V. 5213 Correia, C.L. 6014
Cohen-Tenoudji, P.H. P1670 Conrad, M.J. P6562 Correia, E. P4062, P5497, P6393
Cohoon, A.L. P792 Conradi, L. 5923 Correia, L. 190
Coisne, A. P2626 Conrath, C.E. P1427 Correia, P.M. P4578
Cokkinos, D. P3590, P5464 Conrotto, F. P1449, P2617 Correia De Sa, P. P2809
Cokkinos, D.V. 289, P612 Conroy, J.M. P4571 Correra, A. P4546, P4553, P5529
Colaiori, I. P6291 Conroy, R. P4401 Corsi, P. P1094
Colantonio, L.D. 6653 Consoli, A. P2716 Corsini, A. 158, 1224, 1226, P3437, P4456
Coldewey, M. 1978, 4977, P6206 Consolim-Colombo, F. P4785 Cortes, C. P5647, 6022
Coleman, C. P1759, P6226 Consolim-Colombo, F.M. 22 Cortes, M. 953, P1440
Coleman, C.I. P6195 Consolim-Colombo, F.M. P3648, P3658, Cortes Garcia, M. 968
Coles, J. P4297 P5450, 6014 Cortese, F. P657, P733, P6437
Collaku, E. P5285 Constantin, G. P5477, P5640 Cortese-Krott, M. P1372
Collart, P. 4195 Constantine, A. P681, P1543 Cortese-Krott, M.M. 2340
Collas, V.M. P3581 Constantinescu, A.A. P647, 6641 Corteville, B.F.J. P492
Colleran, R. P4068 Constantinescu, T. P5943 Cortez, D. P1375, P1393
Collet, J.-P. 154 Contadini, D. P860 Cortez Dias, N. P511, P598
Collet, J.-P. 324, 363, 1943, 4127, 4936 Conte, E. P4997, P5233 Cortez-Dias, N. P1122, P2109, P2428,
Collet, J.P. P2429, P3588 Conte, G. P1334, P2439 P2433, P2552, P2636, P3804, 4154,
Colli, A. 351, P4568 Conte, L. P4091 P5419, P5422, P6165
Collier, D.J. P2840 Conte, M.R. P865, P5493, P5938 Corti, A. P3087
Collings, S.L. P6192 Conte, S. 3943 Corti, R. P6364
Collins, P. 362 Conti, A. P179, P5290, P6223 Cortijo, J. P2128
Collins, R. P1700, P5575, P5620, P6592 Conti, L. P2558 Cortina, J. P2652
Collins, R.E. 935, 1207, 5822, 5823, 5825, Conti, S. P3427, P4346, P4389, P6216 Corveleyn, A. P3101
5827 Contractor, H. P5379 Cosentino, F. 123, 205
Collinson, J. P1520 Contreras Domingues, V. P5519 Cosentino, F. P218, P725, 1852, 2013,
Collinson, P. P528 Conway, A. P627 P4539, 6053
Collis, R. P5604 Conway, D. P774 Cosentino, N. P786
Collison, D. P2348 Cook, C. P1714 Cosin Sales, J. 1907
Colom Comi, C. P745 Cook, C.M. 4932 Cosin-Sales, J. P1690
Colombatti, L. P6174 Cook, R.F. P1142 Cossio-Aranda, J. P1601
Colombo, A. 370, P1608, P1748, P2608, Cook, S. 1237, P2378, 4183 Costa, A. 5916
P2616, P2761, 2913, 5167, 5168, 5169, Cook, S.A. 199 Costa, F.M. P2394
5171, P5491, 5784, P6389 Cook, S.A. P748, P1562, 3072, P3102, Costa, G.M. P3397, P3418
Colombo, F.M.C. P2717 P3538 Costa, J. P523, P4993
Colombo, T. P6483 Cools, F. P1513, 3278, P4404 Costa, L. 4154
Colonetti, E. P5709 Cooney, M.T. 4206 Costa, M. P209, P2472, P2760, P3473,
Colonna, P. 3244, 3245, 3247, 3249 Cooper, C.J. 3972 P4686, P5346, P6165
Colquhoun, D.M. P4323 Cooper, M. 3950 Costa, P. P3601
Colussi, G. P1347 Coppens, M. 6648 Costa, R. P5658
Colwell, N.S. P6475 Coppini, R. 4824 Costa, R.A.C. P3689
Comaglio, A. P5709 Coppola, C. P859 Costa, R.L.O. P6267
Combaret, N.C. P5933 Coppolino, P. P4683 Costa, S. P1796, P4333, P4764
Combes, A. 329, 330, 331, 333, 2305, 2307 Copponi, G. P1483 Costa Jr, J.R. 2911, P3689
Combes, N. P4358 Coquerel, D. P1112 Costa Jr, R.A.C. 2911
Combes, S. P4358 Corcostegui, L. P3554 Costa Rodrigues, K.E. P3538
Comin Colet, J. P1125 Cordeiro, F. P3457, P5390 Costa Rodrigues, R. P2394
Comin-Colet, J. 27 Corden, B. P748 Costa-Hong, V. P4785
Comin-Colet, J. P1774, 2213, P2796, Corder, R. 4198, 4201 Costantino, M.F. P6309
P3077, P3124, P6187, P6584 Cordero, A. P571, P5348, P6462 Costantino, S. P725, 916, 970, 1852, 2013,
Comito, C. P3490, P3579, P4317, P5241, Cordoba Soriano, J.G. P1622 P4539
P5478, P5632 Cordova, S. P3518 Costanzo, E. P179
Conceicao, G. P1578 Cordts, K. P3623, P5022 Costanzo, M.R. 4965, P5976
Corella, D. 5120 Costanzo, P. P3789
433
Chairpersons & Judges / Speakers & Discussants / Authors Cos – Dal
Coste, P. P4438 Cronin, H. P5580 Cyganek, L. P3552

Costedoat-Chalumeau, N. 5919 Crosato, M. P2400 Cywinski, J. P1119
Costello-Boerrigter, L. P4391 Crosby, A.H. P1629 Czajkowski, M. P2440, 5145
Costes, B. P4111 Cross, H. P1629 Czaplicki, D. 1833
Costetti, A. P6483 Crotti, L. 367 Czarnecka, D. P1823, P3807
Costin, J. 4971 Crotti, L. P6162 Czekaj, A. P2835
Costin, S. P6527 Crowley, J. P2348, P4068 Czerny, M. P3331
Cosyns, B. 376 Crozatier, B. 6059 Czerwinska, K. P3724
Cosyns, B. 307, 2279 Cruden, N.L. P1117 Czesnikiewicz-Guzik, M. P6599
Cottel, D. P6450 Cruz, C. P2140 Czibik, G. P2360, P5473, P5557
Cotter, G. 6037 Cruz, I. P1118, P1626, P1627, 5814, P6393, Czimbalmos, C.S. P614, P4099
Cottin, Y. P799, P1696, P2147, P3080 P6400 Cziraki, A. P5680
Couderc, J.P. P6163 Cruz, P. P2679 Czubek, U. P5465
Couffinhal, T. P5462 Cruz, P.F. P3420 Czuriga, D. 39
Couperus, L.E. P696, P3794, P6513 Cruz Ferreira, R. P1642, P2473, P2502, Czyz, K. P3376, P6114
Couppie, P. P6415 P2510, P4488 D’Agostino, C. 2270
Courand, P.Y. P5009 Cruz-Gonzalez, I. P2772 D’Agostino, R.B. P2144
Courcier, D. P1670 Cruz-Madrigal, K.M. P5360 D’Aiello, F. P4683
Courtz, F. P2631 Crystal, E. P2425 D’Aiuto, F. P658
Courvoisier, D. 6647 Csanadi, Z. P6115 D’Alto, M. 1299, P4546, P4553, P5526,
Coussement, P. 5785 Csecs, I. P614, P4099 P5529
Coutinho, G.F. P6489 Cuadrado, E. 952 D’Amario, D. P5027, P5455, 5900
Coutinho, T. 4873 Cubbon, R.M. P3767, P6568 D’Amico, A. P4601, P6336
Coutts, G. P619 Cubedo, J. P1445, P2130, 3203, P4422, D’Amico, D.A.A. P4598
Covali-Noroc, A. P6148 P4524 D’Amico, E.A. P6499
Covassin, N. P4381 Cubero, H.D. P3637, P5647 D’Amico, M. P2617, P6372
Covelli, A. P179, P5290, P6223 Cubillos-Arango, A. P2128 D’Andrea, A. P3505, 4229, 4230, 4231,
Coviello, I. 5900 Cucchini, U. P702, P2539, P2541, P2559, 4233, 4235, P5526, P5529
Cowburn, P.J. P2398 P2560 D’Angelo, A. P5040, P6153
Cowie, M. 4857 Cuccia, C. 2207 D’Angelo, M. P634, P3521
Cowie, M.R. 387, P526, 1074, 1075, 1209, Cucco, C. P3525, P3527, 5805, P6542, D’Ascenzi, F. P2682
2999, 3834, 3836, 4124, 5063 P6567 D’Ascenzo, F. P1449, P1748, P2617, P5378,
Cox, A. 2968 Cuddy, S. P5604 P6262, P6446
Cox, J. P4613 Cueff, C. P1124 D’Ascenzo, F.D.A. P5562
Cozar-Santiago, P. P181 Cuellar Calabria, H. P3612 D’Esposito, V. P6338
Cozzi, F. P702 Cuellar-Calabria, H. P6382 D’hooge, J. 2282, 2285, P5941
Cracowski, J.-L. P3623 Cuenca, V. P6421 D’Onofrio, A. P2400, 4860, P5222
Cragg, P.A. P1142 Cuenza, L.R.C. P2635 d’Ortho, M.-P. 82
Cramariuc, D. P4093 Cuhadaroglu, C. P1758 d’Ortho, M.-P. 1073
Cramer, G.E. P695 Cui, F.-M. P643 D’Ortho, M.P. 5077
Cramer, H. P777 Cuisset, T. 363 D’Silva, A. 2967, P5670
Cramer, M.J. 5809 Cullen, S. P2139, P2141 D’Souza, R. P1576
Crandall, B.G. P3356, P4376 Culver, D. P5425 Da Silva, G. P2109, P2428, P3601
Craps, S. P1114 Cune, J. P1126 Da’as, S. P3542
Crea, F. 324 Cung, T.T. P4446, 5088 Dabrowski, M. P3724, P5011
Crea, F. P604, P786, 1294, 1296, P1483, Cunha, P. P506, P2673, 2937 Dabrowski, R. P2697, P5291, P5537, P5974
P3512, 3944, 4014, P4522, P5027, P5225, Cunha, P.S. 103 Dabrowski, W. P5622
P5455, 5900, 6011, P6116, P6118, P6251 Cunningham, K. P2718 Dachille, A. P4311
Creager, M.A. 210 Cuocolo, A. P874 Daemen, J. P3733, P4673
Cremer, P. P597, P599, P606 Cuocolo, A.C. P6570 Daemen, M. 253
Cremer Luengos, D. P3625 Cuppen, E. P3538 Daga, S. P1682
Cremers, B. P2843 Cupples, M.E. 194, 208 Dagli, E. 4827
Crespo, J. P1128, P2601 Cupples, M.E. 3217 Dagnelie, P.C. P4458, P4615
Crespo-Leiro, M. P3759 Curcio, A. P1394, 5904 Daha, I. P849
Crespo-Leiro, M.G. 5779 Cureoglu, A. P875, P5480 Dahan, B. P4073
Cresti, A. P2345 Curnis, A. 2270, P2400, P3382, P3399, Dahl, C.P. P6341
Creta, A. P6291 P3403, P3411 Dahl, I. 1325
Cribier, A. 81, 269 Curnutte, J.T. P3088 Dahl, J. P5033
Cribier, A. P2632, 2923, P5490, P6373 Currie, G.L. P5447 Dahlstrom, U. P218, 4282, P5036, 6637
Criel, M. P1114 Curry, P. P3323 Dai, Y. P470
Crijns, H.J. P3078, P4623, P5223, P5228, Curtis, A. 4857 Dai, Z.K. P3751
5914 Curzen, N. 1196, 2914, P4327, 6620 Daiber, A. P656, P667, P2581, P3084
Crijns, H.J.G.M. P3333, P4458, 6077 Cusma-Piccione, M. P634 Daida, H. P2500, P2799, P3675, P3721,
Crimi, G. 1204 Cusma-Piccione, M.C. P3521 P4087, P4477, 5087, P5381
Crimizade, U. 6635 Cuspidi, C. P4119 Daimon, M. 2210, P5042
Criqui, M. P5959, 6083 Cutler, M. P4376 Daisuke, I. P5327
Crisci, M. P5365 Cutler, M.J. P3356 Dakota, I. P558
Crispo, S. P3739 Cuttitta, F. P3785 Dal Lago, P. P3648, P3658
Cristiano, F. P5457 Cuypers, J.A.A.E. P707, P2656, P6418 Dal Torrione, P.L. P5289
Cristol, J.P. P3451, 5088 Cvetkovic, J. P2713, P4423 Dalal, J. 256
Croisille, P. P3594 Cwetsch, A. P1807
434
Chairpersons & Judges / Speakers & Discussants / Authors Dal – De
Dalby, A.J. P1682 Dash, R. P2124 De Boer, R.A. 354, 3073, P4594, P6346
Dalby, M. 29 Daskalakis, A. P2642 De Boer, S. P1746
Dalby, M. P581, 3026, P4505 Daskalopoulos, E.P. P3442, P3745 De Boer, S.A. P183, P5548
Daleffe, E. 4865 Daskalov, I. P5940 De Bonis, M. 80
Dalen, H. P1791, P3674, 4156, P4307 Dasseni, N. P1555 De Bonis, M. 1307, 1308, 4009, 5892, 5893,
Dalgic, Y. P573 Date, M. P1108, P6537 5895, 6021
Dalianis, N. P4666 Datz, C. P4644 De Bono, G. P5583
Dalin, M. P5496 Daubert, J.C. 195 De Borst, G.J. P1755, P5618
Dall’ara, G. P5521 Daubert, J.C. 2268, P2434, P3129, P5220, De Bortoli, M. P3536
Dalla Vecchia, E. P495 P5438, 6630 De Bruin-Bon, R.H.A.C.M. P2658, P2661
Dalla Vecchia, L. P4337 Daugherty, A. P1782 De Bruyne, B. P1364, P1729, P1740, P2729,
Dallaglio, P. P476, P1444 Dauphin, R. P5009 P2767, 4023, 6620
Dallongeville, J. P1358, P6450 Davalos, A. 211 De Bruyne, B.D.B. P3461
Dalmau, M.J. P2772 Davalos, A. 3275 De Buck, S. P3362
Dalmau Gallarza, R. P3632 Davani, S. P1461 De Caralt, T.M. P3090
Dalos, D. P1752, 2212 Davi, G. P2716 De Carlo, M. P1598, P3592, 4924, 4926,
Daly, K. P4068 David, C. P1121, P3601 P6375
Damaas, J.K. 336 Davidson, N. P619, P2432 De Caterina, R. 44, 74, 204, 207
Damasceno, A. P2651 Davidson, N.C. P4740 De Caterina, R. 123, 413, 940, P1348, 3139,
Damasio, A.F. P5393, 5820 Davidson, P.M. P5669 3142, 3854, 4199, 4201, P4414, P5956,
Damato, A. P2121 Davies, J. 4932 P6155
Damatto, F.C. P3788 Davies, J.E. 123, 253 De Chiara, B. P6483
Damatto, R.L. P892, P2808, P3788, P5258 Davies, J.E. 1041, P1714, 3824, P4777, De Chillou, C. P164, P2418, P3365, P4600,
Dambrauskaite, V. 352 4930 P5553
Dambrink, J.H.E. P4453 Davies, J.E.R. P1717, P1725 de Chillou, C. 101
Damman, K. P891, 3301 Davies, L. P2660 De Corte, T. P2627
Damman, P. P1101 Davies, N.H. P6328 De Diego, A. P1369
Damorou, J.M.F. P3135 Davies, R. P5519, P6290 De Faire, U. P6424, 6646
Damy, T. P4111, P5423, P5500, P6148 Davies, S.W. P681, P1543 De Ferrari, G. P1675
Damy, T.D. P843 Davies, W.R. 4027 De Ferrari, G.M. 371
Dan, A.R. P849, P2454 Davison, B. 6638 De Ferrari, G.M. 1204, 5751, 5752, P6155
Dan, G.-A. 37 Davison, B.A. 6037 De Feyter, P.J. P6429
Dan, G.A. P849, P1784, P2454, P4619, Davison, B.J. P2810 De Filippo, O. 5904
P5272, P6208 Davlouros, P. P1469, P1479, P6254 De Filippo, P. P503, P3399
Dan, M.U. P3547 Davoodi, G. P5581 De Geest, B. P1765, P4544
Danad, I. P426, P553 Davy, J.M. P5282, P5283 De Geus, J.C.N. P632, P1551
Danchin, N. 94 Davydenko, O.G. P6169 De Gonzalo Calvo, D. P1586
Danchin, N. P173, P544, P739, P1338, Dawes, T. 1237, 4183 De Graaf, M.A. P4482, P6230, P6429
P1696, P2147, P2463, P2504, 3031, Dawes, T.J.W. P748 De Greef, Y. P3408
P3663, 3876, 3877, 4260, 4262, P4445, Dawoud, F. P2124 De Groot, J.R. P473, P1427, P2426, P6182,
P4629, P4991, 5816, P5931 Dawson, D. P6313 P6184
Danchin, N.D. 5089 Dawson, D.K. P5435 De Groot, N. P6189
Daneels, D. P1388 Dawson, E. P803 De Groot, N.M.S. P715, P3388, P4392,
Danenberg, H. 3194 Dawson, R. P6568 P5314
Dangas, G. P582, P1510, 3005, 4208, 4209, Day, J.D. P3356, P4376 De Groote, P. P1124
4210, 6619 Dayag, A. 1199 De Grooth, G.J. P5565
Daniel, J.-M. 1850 Dayer, M. P2392, 5106 De Haan, F. P724
Daniel, J.M. P2590 De Agustin, A. P2549 De Haan, J. P649
Danielsen, T.K. P416 De Agustin, J.A. P2548, P2557 De Jaegere, P.P.T. 5793, 6011
Danilenko, N.G. P6169 De Agustin Loeches, J.A. P1593 De Jager, S.C.A. 3950
Dankova, M. P1797 De Angelis, K. P2679, 5082 De Jong, A.M. P6346
Dankowski, R. P5436 De Angelis, K.D.A. P6479 De Jong, S. P4115
Dankwardt, S. P2581 De Antonio, M. P752, P1139, 4277, 6639 De Kerchove, L. P3504
Danowski, D. P4494 De Backer, G. 77 De Kleijn, D. 133
Dantas, J.M.M. P2717 De Backer, G. 981, 1220, P2146, 4202, De Kleijn, D. 973
Danylenko, O. P5708 P4636 De Kleijn, D.P. P5469
Danza, M.L. P604 De Backer, J. 4272, P6419 De Kleijn, D.P.V. P6253
Danzi, G.B. P2741, P2765, P2781, P2782 De Backer, T. P2627 De Koning, H.J. P5591
Daoud, E.G. 5921 De Bacquer, D. P1663, P2146, P2724, De La Cruz, E. 968
Darabont, R. P5043 P4324, P4636, P6459 De La Espriella-Juan, R. P2128
Darago, A. P2649 De Bakker, J.M.T. P1427, P4115, P6159 De La Torre, J.M. P1710
Darawsha, W. P1790 De Belder, M. 1196, 2914, P4327 De La Torre Hernandez, J.M. 116, 118,
Dardi, F. 4182, P5524 De Belder, M.B. 4269 119, P832, 1205, P2732, P2757, P4712
Dargie, H. P6564 De Beule, M. P2729 De La Vieja, J.J. 953, P1440
Darius, H. P837, 1203, 4129, P4989 De Bever, J.B. P1151 De Laat, M.W.M. P713
Darko, D. P4484, P4485 De Biase, C. P1468, P4715 De Labriolle, A. P2147
Dart, A. P903, P2637, P4617 De Biase, L. P786 De Las Heras Gala, T. 4205
Dartigues, J.F. P4108, P5574 De Bock, D. 5785 De Lazzari, M. P1528, P1534
Das, M. P4623, P5228 De Boer, K. P178 De Leeuw, P.W. 3968, 3969, 3971
Das, R. P3340 De Boer, M. P2161, 4151 De Lorenzo, C. P859
Das Neves, B. P3573 De Boer, M.J. P559 De Luca, A. 5787
435
Chairpersons & Judges / Speakers & Discussants / Authors De – Del
De Luca, G. P1476, P1480, P1501, P2117, De Vos, L.C. P1566 Del Bene, R. P1769
P3119, P5542 De Vos, T. 4195 Del Carpio, F. P1377
De Luca, L. P1474, 4254 De Vries, A. P2743 Del Franco, A. P1366
De Luca, N. 4870, 4900, P5623 De Vries, A.A.F. P5456, P6177 Del Giorno, G. P3427, P4389
De Luigi, C. 5865 De Vries, A.E. P1548 Del Mar Soto, A. P4301
De Maat, M. P1456, P5597 De Vries, C.J.M. P5239 Del Pozo, R. P2652, P3625
De Man, F.S. P178 De Vries, J.K. P696, P1373 Del Pozo Contreras, R. P4468
De Marchena, E. P4413 De Waard, G. P1717, P1725 Del Prado Diaz, S. P2143
De Marchi, D. P1533 De Waard, G.A. P553, P2497, P2512 Del Rio Lechuga, A. P1440
De Marco, F. P3592, P6375 De Waard, M.C. P2161 Del Rosso, A. 5918
De Marco, M. P4117, 4870, 4900 De Waard, V. 3071, P5239 Del Ry, S. P877, P2382, P4598, P4601,
De Maria, B. P4337 De Waha, S. P2480, P3494 P6230, P6336, P6474
De Maria, G.L. P5027 De Waha, S.D.W. P3094 Del Valle, R. P5248
De Maria, R. P1664, P3743 De Weerd, G. P1423 Del Vecchio, G.C. P1529
De Martino, A. P3458, P4091 De Wijs-Meijler, D.P.M. P3745 Delacruz, P. 2108
De Marvao, A. 1237, 4183 De Windt, L.J. 2945 Delagarde, H. P4417
De Marvao, A.S.M. P748 De Winter, R. P2743 Delahunty, N. P1617
De Meester, C. P3504 De Winter, R.J. 364, P716, P1101, P3738, Delarche, N. P579, P2759, P6516
De Meester, C.H.D.M. 5212 P5961 Delassi, T. P3412
De Melis, M. P2115 De Winther, M.P.J. P6129 Delborg, M. P2655
De Meyer, G.R. 1835 De Wit, C. 4876, 6601 Delbosc, S. P5008
De Michele, F.D.M. P6570 De Zeeuw, D. 1860, 1862 Delcayre, C. P3757
De Miguel Castro, A. P2751 Deaconu, A. P5943 Delcea, C. P849, P2454
De Mol, B.A.J.M. 1840 Deanfield, J. P658, P2136 Delcroix, M. 190, 377
De Natale, M.G. 4174 Deanfield, J.E. 126, 298 Delcroix, M. 1061, 1063, P5507, 6104
De Notaris, S. P5639 Deanfield, J.E. P1102, 1869, 1873, 4261, Deleanu, A. P5043
De Palma, R. P2609, 3943 4795, 4799 Delemos, J.A.D. P6466
de Paola, A. 196, 256, 371 Deaton, C. P777 Deleskog, A. 4972
De Paola, A.A. P5032 Deaton, M.C. 136, 190, 193 Delewi, R. P174, P1507
De Paola, A.A.V. P2717 Deaton, M.C. 56, 2004 Delforge, M. P5433
De Paoli, A. P871, 4149 Deb, P.K. 35 Delfour-Peyrethon, R. P2690
De Pasquale, C. P3630 Debaty, G. P5932 Delgado, A.S. 103
De Pauw, A. 4190 Debelder, M.A. P4994 Delgado, J. P3755, P5694
De Pergola, G. P733 Debney, M.T. P1411, P3398 Delgado, M. P3730, P6490
De Persis, F. P1590 Deboeck, G. P5523 Delgado, M.D. P2442
De Placido, S. P858 Debonnaire, P. 5785 Delgado, R. P3420
De Pooter, J. P492 Debski, G. 2022 Delgado, V. P2543, P2607, 3286, P3794,
De Potter, T.J.R. 251 Decandia, G.F. P578 P4089, 4948, P6429, P6513, 6668
De Potter, T.J.R. 3187, P3425, 4902, 5859, Dechant, M. P1429 Delgado Jimenez, J. P5957
5861 Decher, N. P1421 Delgado Jimenez, J.F. P4550
De Ravel, T. P3101 Dechering, D. P5948 Delgado Ortega, M. P1109
De Riva Silva, M. P1401, P3372, P5926 Decker, P.A. P1653 Delgado Silva, J. P2760, P4686
De Roquefeuil, F. P5963 Deckers, J.W. P1391 Delgado-Montero, A. P5221
De Rosa, C. P5493 Deckers, N. P645, P646 Delhaas, T. P5221
De Rosa, F.D.R. 2102 Dedeilias, P. P2154 Delhaye, C. P3580, P6507
De Rosa, S. 5904 Dedic, A. P6429 Deliargyris, E.N. P1505, P4992, 5813
De Santo, L.S. P2630, P5639 Dedovic, V. P609, P816, P2484, P2567, Deligianni, C. P5607, P5627
De Sensi, F. P2345 P3715, P4433 Deligiannis, A. P2698
De Servi, S. P1474, 4254 Deek, H. P5669 Delile, E. P1112
De Silva, K. 4931 Deev, A.D. P3354 Deljanin Ilic, M. 22
De Silva, R. 6 Defaye, P. P1096, P4386, 5917 Deljanin Ilic, M. P2713, P3634, P3661,
De Simone, A. P5222 Deffge, C. P2592 P4423, P4614
de Simone, G. 124, 250, 302, 307 Defilippi, C. P878 Dell’angela, L. P5242, P5244
De Simone, G. P858, P2481, P4117, 4870, Deftereos, S. P1479, P2154 Dell’oro, R. P1149, P4781
4900, P5623 Degli Esposti, L. 6654 Della Bella, P. 2015, P6170
de Simone, G. 2980 Degrauwe, S. P535, P5936 Della Corte, A. 3052
De Simone, G.G. 1985 Degrieck, I. P1729 Della Latta, D. P4478, P6425
De Smedt, D. P1663, P4324 Deguzman, F. P3088 Della Mattia, A. P3646
De Smet, C. 4190 Deharo, J.-C. 3979, 5144 Della Siega, A. P2727, P2736, 2907, P3117,
De Sousa, J. P511, P2109, P2428, P2433 Dehghan, A. P2594 P3712, 5817
De Souza, F.R. P700, 2944 Dehoux, M. 1984 Dellanna, F. P2134
De Sutter, J. P2627 Deidda, M. P1573, 5807 Dellborg, M. P438, P2654, P2657, P2659,
De Teresa-Galvan, E. P1689, P4584, Deif, B. P3314 2925, P3611, P3614
P5337, 5790, P6557, P6560 Deisenhofer, I. P3405, P4365 Delle-Karth, G. P1752, P2488
De Terline, D. P3135 Deisenhofer, I.D. P5295 Delles, C. 6062
De Torres Alba, F. P684, P2138 Deitelzweig, S. 1971, P6211 Dellla-Siega, A. P6241
De Torres-Alba, F. P5015 Deiuliis, J. 1217 Dello Russo, A. P3427, P4346, P4389,
De Una, D. P1398, 3067 Deja, M.A. 5214, P6329 P6115
De Velasco, J. P2724 Dekany, M. P3348 Delmar, C. P5281
De Vincentis, G. P427, P847 Dekemp, R. 4873 Delmar, M. 4184
De Vito, R. P3377 Dekker, L.R.C. P3313
436
Chairpersons & Judges / Speakers & Discussants / Authors Del – Dik
Delpon, E. P5945 Desperak, P. P566, P576, P585, P587, P589 Di Silvestro, M. P2768
Delrue, L. P1468, P2767 Despres, J.-P. 2000 Di Stefano, A. P5647, 6022
Delseny, D. P6452 Desta, L.A. P2787 Di Stefano, R. P3447, P3458
Deltreuil, M. P4558 Dettori, F. P2112 Di Tano, G. P1664, P3743
Deluigi, C. 255 Deubner, N. P3364, P4367, P4368 Di Tommaso, C. P4741
Deluigi, C. 2929 Deutch, K. P3376 Di Valentino, M. P4100
DeMaria, A. 323 Deutsch, K.D. P3361 Di-Gioia, G. P2771
DeMaria, A. 110 Deux, J.-F. P5423 Diab, M. P3107
Demartini, C. P6291 Devaux, Y. P421, P1408 Diab, R. P4653
Demian, P. P2564 Deveci, O.S. P875, P5480 Diachkov, V.A. P2163
Demicco, D. P201 Devereaux, P.J. P2152, P5636 Diachuk, D.D. P5563
Demicco, D.A. P766 Devereux, R.B. P4117, 4829, 4897 Diana, V. P5365
Demidova, M.M. P2476 Devignes, J. P676 Diao, C. P3539
Demir, M. P5681 Devireddy, C. P1604 Dias, A. P5631
Demir, R. P3644 Devito, F. P4311 Dias, C.C. P2140
Demir, S. P5481 Devlin, G. P2629 Dias, D. 5082
Demirbag, R. P3466 Devlin, G.D. P5034 Dias, D.S. P2679
Demircan, S. P2444, P5421 Devriendt, K. P3101 Dias, P. P1668, P3668, P4519, P5367, P5406
Demircelik, M.B. P5335, P6257 Dew, T. P6487 Dias, R.R. P198
Demirel, M. P6144 Dewachter, C. P5504 Dias, T. P6240
Demirevska, L. P5940 Dewachter, L. P5504 Diaz, I. P4528
Demirtas, C. P4534 Dey, D. P623, 3997, P4510, P4998, P5234 Diaz, J.F. 366, P2732
Demirtas, M. P875 Deyell, M.W. 156 Diaz, R. P6555, P6596
Demkow, M. P4649, P4721 Dezawa, M. P5002, P5444 Diaz Anton, B. P3486
Demoniere, F. P1544, P1670 Dezsi, C.S.A. P5023 Diaz Cuervo, H. P5292
Demyanets, S. P5398 Dhana, K. 276, P741, P749, P6444 Diaz Fernandez, B. P2482
Den Exter, P.L. P3621, 4175 Dharma, S. P558 Diaz Fernandez, J.F. P2759, P4468, P4470
Den Ruijter, H.M. P5618, P6253 Dhillon, A. P1119 Diaz Infante, E. P167
Denaro, C. P3349 Dhillon, P. P4373 Diaz Pelaez, E. P1392
Denchev, S. P1352, P4589 Dhutia, H. P2373, P2680, 2967, 2968 Diaz-Villanueva, P. 962
Dendale, P. 105 Di Bacco, L. P2151 Dib, M. P667
Deneke, T. P3383, P4391 Di Bacco, M. P3313 Dibb, K.M. P4543
Denenberg, J.O. P5959 Di Bartolomeo, R. 6021 Dicarlo, L. P1146, P1150
Deniz, A. P5480 Di Bello, V. P3525, P4091 Dichgans, M. 2058
Deniz, G. P6186 Di Biase, L. 97, 300, 955, 2188, P3383, Dichtl, W. P4491
Denniff, M.J. P4090 P3396, P3417, P6115 Dickfeld, T. P878
Dennis Verano, R. P3453 Di Biase, M.D.B. 2102 Dickinson, K. P1477
Denny, J.C. P5374 Di Clemente, F. P3377 Dickstein, K. 82
Dens, J. 163, P4701 Di Cori, A. P1092 Dickstein, K. 5130
Dent, R. P1677, P5968 Di Donna, P. P3377 Didenko, Y.V. P1818
Dentali, F. P3619, P5609 Di Filippo, S. 1068, 4041, P4595 Didier, R. P4583, P6379
Denton, C. P5514 Di Franco, A. P3512 Diebold, S. P4540
Denvir, M.D. P5562 Di Gaudio, F. P3785 Diederichsen, A. P4465, P5713
Deplagne, A. 104 Di Giamberardino, A.L. P2443 Diederichsen, A.C. P5017
Depoix, J.-P. P6391 Di Gioia, G. P1364, P1468, P1729, P2729, Diederichsen, A.C.P. P4431, P4618, 6023
Dequal, D. P2550 P2767, 4023, P4715 Diego, A. 1205, P2772
Der, G. P1374 Di Gioia, G.D.G. P3461 Diego Iglesias Alvarez, D. P4419
Derda, A. 3205 Di Giovine, G. P1476, P5542 Diehl, J.L.D. 5089
Derosa, G. P5040, P6153 Di Girolamo, E. P3418 Diehl, P. P1454
Derrick, G. P2139 Di Lascio, N. 4196 Dieker, H.J. P695
Derumeaux, G. P2360, P4525, P5473, Di Lenarda, A. 374 Diekmann, J. P2791, P6550
P5557 Di Lenarda, A. P686, P691, P4399, P5297, Diemberger, I. P4619
Derumeaux, G.A. 133, 150, 261, 298, P5683, P6147, P6575 Diener, H.C. 129
406, 411 Di Marco, A. P1444 Diener, H.C. P1488, P1516, 1910, 1913
Derumeaux, G.A. 2215, 6661 Di Marco, G.M. P4546, P4553, P5523 Dieplinger, B. P4767
Desai, A. P6134, P6555 Di Maria, S. P6132 Diercks, D. 3030
Desai, A.S. P213, P3756, P5976, 6643 Di Mario, C. 302 Dietz, A. 1851
Desai, M. P1629 Di Mario, C. P681, P1520, P1543, P2752, Dietz, M.F. P5970
Desai, M.Y. P1119, P3511, P6365 P2764, P3737, 4932, P6157 Dietze, T. P6113
Desch, S. P2387, P2480, P3092, P3494, Di Mauro, M. P6199, P6435 Diez, C. P752
4060, 5090 Di Molfetta, A. P4601 Diez, D. P3637, P5647
Desch, S.D. P3094, P5495 Di Nardo, G. P4546 Diez, E.R. P1414
Deschanel, G. P5932 Di Nora, C. P5683, P6575 Diez, J. P1778
Deseive, S.D.C. 2099 Di Palma, G. P5365 Diez Martinez, J. 2950
Deser, M. P5231 Di Pasquale, G. 4254 Diez-Quevedo, C. P752, 6639
Deshmukh, A. P3373 Di Pasquale, P. P3785 Diez-Villanueva, P. P6371
Deshpande, N.V. 87 Di Resta, C. 2015, P6170 Digiacomo, M. P783
Desmet, W. P1500 Di Salvo, D. P5529 Dihel, L. P5358
Desormais, I. P4108, P5574 Di Salvo, G. P2663, 5186, P5526, P6486 Dijkstra, J. P1553
Desouza, A. P4390 Di Sciascio, G. P6132, P6291 Dikic, M. P609
Di Serafino, L. 4023 Dikici, S.A. P1828
437
Chairpersons & Judges / Speakers & Discussants / Authors Dik – Dre
Dikur, O. P3347 Dobreanu, D. P2135 Dong, J.-Z. P5266, P5274

Dilaveris, P.E. 143 Dobrecky-Mery, I. 3191, 3194 Dong, J.Z. P6173
Dilba, P. 162 Dobrev, D. P5947 Dong, L.L. P6306, P6497
Dilek, M. P5421 Dobric, M. 4292 Dong, Q. P1662, P5229, P5357, P5386
Diletti, R. 115, 116, 118, 2909 Dobrokhod, A. P3805 Dong, Y.X. P4370
Dilic, M. 145 Dobrovolsky, A.B. P456 Donghi, V. P6376
Dilic, M. P594 Dobrowolski, L.C. P3738 Dongzhu, X. P1371
Diller, G.P. 143, 344, P684, P724, 1298, Dobrzynski, H. P415, P6354 Donia, A. P4656
P2138, P2142, 2926, 4952, 4954, 4956, Dobson, L. P1343 Donio, V. P5282, P5283
P5015, P6413, P6417 Doco-Lecompte, T. P676 Donmez, I. P5714
Dilly, M.P. 5218 Doehner, W. 151, 266, 268, P887, 2002, Donnelly, P. 984, 985
Dima, A. P849 P2786, 3265, 3266, P5695 Donners, M. P6129
Dimer, L. P3640 Doejaaren, E. 1324 Donners, M.M.P.C. P665
Dimitri, H. P2516, 5804 Doenst, T. 1982, P3107, P3500 Donoghue, O. P5580
Dimitriadis, K. 2232, 2265, P2670, P2839, Doering, M. P516, P2829, 4858 Donos, N. P658
P2844, 4867, 4869, 4874 Doerler, J. P584 Dookhan, C. P4413
Dimitriadis, Z. P2827, P3526 Doerr, M. P4736 Doorey, A. 6616
Dimitriou, P. P791 Doerr, O. P2386, P2620, P3137, P4487, Dopheide, J.F. P2669
Dimitropoulos, E. P455, P740, P2689, P4499, P4500, P5028, P5405, 6065, 6067 Doppelhammer, M. P1349
P2725, P3680, P4312, P6476 Doerr, O.D. P567 Dore, A. P717
Dimmeler, S. 2342, P3535 Doesch, C. P4591 Dorel, S. P2690
Dimopoulos, K. 325 Doevendans, P.A. P590, P2371, P5223, Dorian, P. P1331, P4987
Dimopoulos, K. P723, P6413, P6417 P5447, 5809 Dorlet, S. P3365
Din, J.N. P2727, P2736 Doevendans, P.A.F.M. P1755, 1957 Dorn, T. P1346
Din, S.S. P496 Dogan, B. P3450 Dornhorst, A. P6313
Dinc Asarcikli, L. P6139 Doh, J.H. 4022 Dorobantu, M. 24, 95, 125
Dincer, I. 240 Doherty, P. 2246, 2939, 5128 Dorobantu, M. P225, P594, P4442, P5043,
Diness, T. P3319 Dohi, K. P1535, 3254, P4114, P4774, 6634 5819, P5943
Dinet, M. P3740 Dohi, K.D. P828 Dorofeykov, V. P1826
Ding, L. P463, P3117, P3712, P6241 Dohi, T. P5381 Doronzo, A. P1644, P1646, P3335, 4168,
Ding, Q. P5431 Dohi, Y. P202, P897, P3111, 4898, P5315 5810
Ding, X. P623 Dohmen, P. P677 Doros, G. P2722
Ding, Y. P1656 Doi, M. P4486 Dorzycki, S. P5293
Ding, Z.P. P689 Doi, T. P6351 Dos Remedios, C. P4738
Ding, Z.W. P6342 Doi, Y. P6273 Dos Santos, M.R. P700, 2944
Dingemanse, J. P2645 Doijiri, T. P4689 Dos Santos, P. P4438
Dini, F. P3527 Doimo, S. P3646 Dos Santos, S. P2558
Dini, F.L. P2351, P3525, P4769, 5805, P6542, Doka, G. P864, P872 Dos Subira, L. P3612
P6567 Doktorova, M. P804 Doshi, S. 2988, P5984
Dinic, D. P6482 Dolci, G. P1602 Doshi, S.N. P4447
Dinkla, S. P6181 Doletsky, A. P3347 Dostal, E. P6255
Dinov, B. P516 Doll, F. P5005 Dote, K. 4256, P4437
Dion, R. 311, 1034, 1036 Dolliner, P. P3744 Doubek, D. P3476
Diop, I.B. P3134, P3135 Dollman, J. P2700 Doughty, R.N. P5034, P6457
Dippel, D.W.J. P5597 Domanovits, H. 1903, 1905 Douglas, P.S. 5991, 5995
Distelmaier, K. 5092 Domei, T. P2747, P2749, P3701, P3702 Douma, R.A. P3621
Distler, J. P687 Domenichini, G. P4373 Dourado, R. P618
Divakara Menon, S.J. P2405 Domian, I.J. P3567 Dovellini, E.V. P1094
Dixen, U. 957 Domienik, J. P755 Downes, K. P1446
Dixon, B. P4398 Domingo, M. P752, P2790, 4277 Doyle, R.T. P1679
Djedjos, C.S. P5968 Domingo Ribas, E. P2507 Doytcheva, P. P1575
Djenic, N. P833 Domingues, K. P1626, P1627, P4062, Dozono, K. P5668
Djer, M.M. P6396 P5497, P6393, P6400 Dragan, S.R. P4706
Djire, B. 960 Dominguez, H. P1571 Dragnev, A. P1822
Djokovic, A. P5535 Dominguez, R.F. P4785 Drago, F. P2397
Djordjevic, B. P4614 Dominguez-Franco, A.J. P4584, P5337, Dragomir-Daescu, D. P2375
Djordjevic, D. 5084, 6015, P6441 5790, P6557 Dragschitz, F. P4545
Djordjevic Dikic, A. 4292 Dominiczak, A.F. 137, 266 Dragu, R. P1140, P5518
Djordjevic-Dikic, A. 40, 2039, P2567 Dommasch, M. P4638 Drakopoulou, M. P785, P1141, P2388,
Djordjevic-Radojkovic, D. P5667 Donal, E. P852, 1023, P2836, P3129, P4095, P3501, P3582, P3590, P4106, P4751,
Djukanovic, B. P6482 P4111, 4915, P5429, P5438 P5464, P5607, P5627, P6254
Dk, C.H.O. P5510 Donaldson, R. P6219 Dratva, J. P2671
Dlask, J. P224 Donataccio, M. P173 Drechsler, C. P4767
Dluzniewski, M. P5280, P5332 Donate, R. P6164 Dreizehnter, L. P1346
Dmitriev, Y.V. P2576, P5236 Donate Puertas, R. P6176 Drenckhahn, J.-D. P4084
Do, B. P3134 Donazzan, L. P3735 Drescher, C. P5256
Doan, H.-L. P3516 Donde, K. P2590 Dressler, F.F. P6356
Dobies, D.R. P792 Dondo, T. 1196 Drexel, H. P1697, P3678, P4473, 5853,
Dobler, F. P3405 Dondo, T.B. P171, P176, P770, P1102, P6259
Dobranici, M. P849 2914, 4261 Drexhage, O.S. P560
Dobras, J. P446, P827, P830
438
Chairpersons & Judges / Speakers & Discussants / Authors Dre – Egg
Dreyer, P. P1666 Dulak, J. 22 Dwyer, J. P4738

Dreyfus, J. 1984 Dulgheru, R.E. 358 Dwyer, N. P5522, 5801
Dreyfuss, C. P4548 Dulgheru, R.E. 3245, 3246, 3247, 3249 Dwyer, T. P1356
Drici, M.-D. P840 Dullaart, R.P.F. P1566 Dybkova, N. P5030, P5950
Dridi, Z. P533, P2615, P5356 Dullaghan, L. 47 Dydula, A. P2653
Dries, E. P5468 Dumanschi, C. P6527 Dyer, B.T. P869
Driesen, R.B. P5468 Dumas, F. 1320, P1382, P4073 Dykun, A. P4107
Driessen, A.H.G. P1427, P6182, P6184 Dumesnil, C. P621 Dykun, I. P5960, P6322
Driessen, R.S. P180, 368 Dumitrescu, A. P6469 Dymarkowski, S. P5507
Driussi, C. P5704 Dumitrescu, D. P3622 Dzemeshkevich, S.L. P6171
Drobni, Z.D. P4630 Dumitrescu, S.I. P6447 Dzielinska, Z. P4649
Droogmans, S. P1388 Dumitriu, I.E. P6181 Dzierwa, K. P5616
Droppa, M. P671, P674, P1484, 4270 Dumo, A. P4484 Dzikowska-Diduc, O. 4179
Drozd, M. P3758 Dunaeva, A.R. P6284 Dzikowska-Diduch, O. P755
Drozdz, J. P2613, P3759, P4722 Dunbar, S. P441, 1228 Dzudie, A. P2651
Drozdz, M. P6599 Duncan, A. P498, P681, P1543 Dzudie Tamdja, A.I. 343
Druelles, P. P2504 Duncker, D. P5928 Dzudovic, B. P833, P6409
Drumond, A. P2464, P4303 Duncker, D.J. P2161, P3745, 4151, 4877 Dzwiecka, E. 6610
Drumond Freitas, A. P592, P3431, P5377 Duncun, A.L. P3559 Dzyak, G.V. P1818
Druzhkova, T. P6501 Dungen, H.D. P5667 Eaddy, M. 1971
Drygas, W. P5404 Dunne, R. P5519 Ebert, D. P3570
Dryzmalski, M. 3310 Dunning, A. P5974 Ebert, M. P2829
Drzewoski, J. P3759 Dunsby, C. P869 Ebina, T. P885, P6411
Drzymalski, M. P1722 Dunselman, P. P895 Ebisawa, S. 961, P4467, P5382, P6222,
Dschietzig, T.B. 3928 Dupas, F. P1338 P6577
Du, H. P637, P1359, P2688, 5123, P5620 Duplaa, C. P5462 Ebner, N. P887, P2786, P5695
Du, X. P5266, P6173 Duplyakov, D. P1436, P1800, P2825, 3941 Ebrille, E. P3377
Du, X.J. P4617 Dupouy, P. P6415 Echahidi, N. P4558
Du Mond, C. P1799 Dupre, M. P4435 Echavarria Pinto, M. 2060, P2728
Duan, X.J. P2793 Dupre, M.E. P1333 Echavarria-Pinto, M. P1717, P1725, P2512,
Duarte, R. P3618 Duprey, M. P5654 4930
Duarte, T. P591 Dupuy, A.M. P3451, 5088 Eckardt, L. P1379, P1431, P3385, P5948,
Duarte Rodrigues, J.C. 35, P4464, P5367, Duraes, C. 5922 P6158
P5406 Durakoglugil, M.E. P5481 Eckel, J. 3220
Dubiel, R. P5967 Duran, E. P6490 Eckel, R.H. 2854, 3144
Dubner, S.J. P1488, P1516 Duran, M. P825, P5335, P6257 Ecken, S. 1082
Duboc, D. 2081, 2082 Duran, O. P467 Eckert, S. P465
Dubois, C. 6052 Duran Hernandez, J.M. P2757 Eckhardt, L. 2988
Dubois-Rande, J.-L. P3516, P4525, P5423 Duran Jimenez, E. P1109 Eckl, R. P3405
Dubois-Rande, J.L. P6148 Duran Karaduman, B. P488, P5426 Eckstein, J. P628
Dubois-Rande, J.L.D.B. P843 Durand, E. P668, P2632, P3583, P5490, Ector, J. P1541, P3362
Dubourg, O. P5963 P6373 Edelberg, J. P5980
Dubowski, K. P482 Durao, D. P5391 Edelmann, F. P1777, P5663, P5690
Dubreuil, O. P579, P3344 Durao, D.D. P2479, P5361 Ederhy, S. P4647, P4650, P4982
Duca, F. P1786, P1808, P2129, 2212 Duray, G. P1389 Edes, I. P2649, P3468
Ducas, R.A. 4194 Duray, G.Z. 5915 Edes, I.F. P3709
Duchenne, J. P5433 Durdu, S. P6186 Edlinger, M. 966
Duckheim, M. P5603 Durier, C. P579 Edner, M. P218, 4282, P5036
Ducreux, C. P4595 Durlik, M. 6612 Edvardsen, T. 79
Ducrocq, G. 2103, 4975 Durmaz, T. P488, P5426 Edvardsen, T. 30, 302, P418, P460, P512,
Dudek, D. 74 Dursun, H. P6325 1024, P1397, P3497, 4959, 4960, P6307
Dudek, D. P555, P1747, 4016, 4017, 4019, Dursun, I. P3620 Edvardsson, N. P4344, 4904
5813 Duru, F. P1390, P4590 Edwards, E. P3102
Dudink, E. P3078 Dusek, J. P3446 Edwards, E.C. 3072
Dudinskaya, E. 1837 Duthoit, G. P714, P2429 Eeckhout, E. 25
Dudley, S.C. P6360 Dutour, A. 3218 Eeckhout, E. P535, P5936
Dudzik-Niewiadomska, I. P5531 Dutra, M.R.H.D. P6479 Eeftinck Schattenkerk, D.W. P3738
Duebner, N. P3391 Dutra-Marques, A.C.B. P700 Eeg-Olofsson, K. P1730, P3343
Duengen, H.D. P5663, P5690 Dutzmann, J. 1850, P2590 Eerenberg, E. P2497
Duerschmied, D. P2125 Duva-Pentiah, A. P2626 Efe, S.C. P5481
Duerwald, S. P1751 Duval, X. 1984 Efe, T. P3760
Duesing, D. P1591 Duytschaever, M. 134 Efentakis, P. P3441, P5624
Duff, C. P528 Duytschaever, M. P3387, P5302 Efimov, I.R. P1411, P1432
Duffy, S.J. P4302 Dvir, D. P3723 Efimova, E. P516
Dufouil, C. 964 Dvirnik, N. P207 Efthimiadis, G.K. P5502
Dufour, R. P1756 Dvorsak, B. P3433 Egami, Y. P2503, P6201
Dugenet, F. P4386 Dweck, M. 108, 255, 1057, 1987 Egan, S. P6475
Duglan, D. P4517 Dweck, M.R. 1986, P2127 Ege, M. P5681
Duhay, F. P2623 Dwivedi, S.K. P4408 Egeberg, A. 3942
Duim, S.N. P5461 Dworakowski, R. P2625, P3726, P6487 Eggebrecht, H. 349
Duimel, H. 4151 Dworeck, C. P177, 278, P3435, P6138
439
Chairpersons & Judges / Speakers & Discussants / Authors Egg – Erg
Egger, M. P4767 El-Sayed, A. P5979 Emery, S.J. P2701

Eggers, K.M. 5074 Elamin, A. P3523 Emig, U. P493
Eggersdorfer, M. 245 Elasfar, A. P868 Emmanuel, S. P4469
Egholm, G. P1336, P1337, P1464, P1498, Elasfar, A.A. P2754 Emmel, E. P1618
P1503, P5351 Elashry, F. P3578 Emmens, J.E. P891
Egito, J.G.T. P5251 Elassal, J.E. P2144 Emmert, M. P3577
Egnaczyk, G. 4857 Elbahaie, H. P3578 Emneus, M. P3319
Egorov, D. P3363, P3368 Elbaz, M. P3523 Emoto, N. P4551, P5527
Egorov, D.F. P4596 Elder, D.H. P517, P3763 Empana, J.P. 964, P1658, P4073
Egstrup, K. P3325 Elder, J.M. P869 Emrich, F.C. P2604
Eguchi, K. P2166 Elefteriades, J. 4247, 4251 Enache, R. P1630
Eguchi, N. P4353, P4384 Eleftheriadou, I. 2232 Encalada, J.F. 6018
Egurbide Arberas, V. P3625 Eleid, M.F. 3049 Ende, G. P662, 1989
Eha, J. 1198 Eleuteri, A. P3635, P6568 Endemann, D. P1722
Ehler, E. P4738 Eleuteri, E. 2935 Endes, S. P2671
Ehlermann, P. P4591 Elfol, A. P701 Endler, G. 4866
Ehret, G. P2558 Elgendy, I.Y. P600 Endo, M. P1745, P2814
Eichhorn, C. P3398 Elhajj, I. P597 Endo, T. P3434
Eichler, S. P3652, P3653 Elia, L. 1955 Endo, T.E. P2509
Eick, C. P5603 Elia, Y. P2136 Enescu, O.A. 4157
Eicken, A. 140, 192 Elias Hernandez, T. P2652 Engberding, R. 6613
Eicken, A. 4951, 4952 Elisaf, M. P1675 Engbers, E.M. P624, P633, P1750
Eickholt, C.E. P4362 Elizaga, J. P538, P4712 Engblom, H. P1754, 4057
Eickholt, C.H. P3414 Elizaga Corrales, J. P5448 Engborg, J. P5017, 6023
Eide, L.S.P. P4566 Elkelany, W. P4708 Engel, L.-C. 6012
Eiden, M. P6366 Ellenbogen, K.A. P5927 Engelhardt, S. 1836, P3769
Eifert Rain, S.J. P3515 Ellenbroek, G.H.J.M. P2783, 3950, P6253 Engels, E.B. P491
Eijgelsheim, M. P1391 Eller, P. P4103 Engels, M.C. P5456
Eikelboom, J. 129 Ellermann, C. P1431 Engelter, S. P628
Eikelboom, J. P207, 1909, 1913, 3821, Ellims, A. P2637, P4617 Engin, C. P6510
P5967 Ellins, E.A. P4776, P5572 Engstroem, T. P554, P822, 4001
Eindhoven, D.C. P5565, P5970 Elliott, A. 1847 Engstrom, G. P4532
Eindhoven, J.A. P707, P6418 Elliott, P. P1628, P5472, 6606, 6611 Engstrom, G.E. 949
Einsenberg, E. P3488 Elliott, P.M. 254 Engstrom, P. P5496
Eiringhaus, J. P2159 Elliott, P.M. 26, 1022, 1023, 2173, 2972, Engstrom, T. 2910
Eisele, L. 2104 3898, 4033, 5109, 5780, 6609 Enguita, F. P6165
Eisen, A. P1652, P1682 Ellis, J.E.E. P2577 Enguita, F.J. P638
Eiskjaer, H. P4743, P4749 Ellison, G.M. P3560, P3561, P3563, P5457 Enhorning, S. P5385
Eisner, D.A. P4543 Elmaghawry, M. P4460 Enina, T.N. P521, P2391
Eitel, C. 4060 Elming, H.E. 6651 Enjuanes, C. P1774, 2213, P3077, P3124,
Eitel, C.E. P5495 Elmkies, F. 6625 P6187, P6584
Eitel, I. P2480, P3092, 3251, P3494, 4060, Elmose Mols, R. P6455 Ennis, E. P5604
5090 Elola, F.J. P2788 Enomoto, S. P1607, P3777
Eitel, I.E. P3094, P5495 Elorz, C. P1477 Enomoto, Y. 6105
Ejido De Los Rios, J. P6250 Elosua, R. P1674, P3098 Enriquez, A. P3404
Ejiri, K. P4547 Elouni, A. P704 Enriquez-Sarano, M. 3049
Ejlersen, J.A. P3522 Elpidio, P.E. P5647 Enseleit, F. P1390, P1812
Ekart, R. P3433 Elsaesser, A. P837, P1488, P1516, P4989, Ensinger, C. P4737
Eken, S. P2604 P5028 Ensminger, S. P1618
Eksi, A. P2444, P5421 Elsaesserr, A. P1471 Entin-Meer, M. P5463
Ekuklu, G. P2534 Elshahawy, O.S. P2754 Er, O. 6040
El Amrani, A. P571, P5348 Elsherbiny, I.A. P5479 Eraky, A.G. P5479
El Asri, C. P4647, P4982 Elsner, S. P2786, P5695 Erath, J. P6203
El Chilali, K. P5571 Elt, M. P6568 Erath, J.W. P459
El Damaty, A. P6430 Eltchaninoff, H. 38, 141 Erba, P.A. 5988, 6078, 6079, 6081
El Haddad, M. P492 Eltchaninoff, H. P173, P668, P2632, P3583, Erbas, G. P457
El Hadidi, A.M.R. P548 4267, 4268, P5490, P6373 Erbay, A. P2444
El Hatimi, S. P668, P5490, P6373 Elvan, A.G. P3401 Erbel, R. 2104, 2250, P2357, 4205, 4247,
El Jamili, M. P3412 Emad, O. P548 4251, P5571, P5960, P6322
El Khoury, G. 4949 Emad Abu-Assi, E. P4419 Erben, R.G. P3460
El Kiky, H. P2542 Emani, S. P6543 Erbs, S. P3639
El Tahlawi, M. P814 Emanueli, C. 1213, P6337 Ercan, E. 2236
El Zambely, L. P2542 Emberson, J. P4321, P4613, P5582, P6592 Erdem, A. P5714
El-Armouche, A. 1851, P2159, P3537, Emdin, C.A. P744, P813, P5322, P5600 Erdem, F.H. P5714
P5030 Emdin, M. 270 Erdine, S.E. 2962, 2963
El-Aroussy, W.A. P1785 Emdin, M. P1366, P3757, P5956, 6044, Erdmann, E. 358, P3128
El-Gamel, M.A. P2629 P6425 Erel, O. P3466
El-Khoury, G. P3504 Emelyanov, I. P900, P1826 Erglis, A. 90
El-Menyar, A. P5697 Emelyanov, I.V. P5706 Erglis, A. P2347
El-Naggar, W. P1537 Emery, M. P5984 Ergun, G. P5335, P6257
440
Chairpersons & Judges / Speakers & Discussants / Authors Erh – Far
Erhayiem, B. P4096 Estensen, M.-E. 141 Fajadet, J. 154, 377

Eriksen, M. P4754, P6297 Estensen, M.-E. 3198 Fajadet, J. 4260
Eriksson, M. P2133 Estis, J. P889, P4663, P6569 Falaschetti, E. 5078
Eriksson, P. P438, P2654, P2657, 2925, Estornell-Erill, J. P181, P2128 Falcao-Pires, I. P1578, P1605, P1814, P5259
P3614 Estruch, R. P1128, 2905 Falconi, E.C. P3420
Eriksson, S.V. P1685 Eteiba, H. P1522, 4055, 4293, 4294 Faletra, F.F. P3519
Eriksson, U. 129, 5901 Ethier, I. P5364 Falini, A. P5577
Eritsland, J. P422, P3489, P5592 Eto, M. P220 Falk, V. 40, 154
Erkapic, D. P5928 Etriby, A.M.K. 3214 Falk, V. P453, P562, P718, P2593, 3007,
Erkens, R. 2340 Ettert, B. P4366 4247, 4251
Erkilet, G. P2578 Ettischer, N. P3595 Fall, C. 4850
Erkus, M.E. P3466 Ettori, F. P3592, P6375 Faller, H. P1669
Erler, N.S. P4609 Eugen-Olsen, J. P4094 Falsini, G. P564
Erlinge, D. 197 Eurlings, L. P3350 Faltado, A. P1609
Erlinge, D. P421, P1408, P2476, 3021, 3271, Evangelista, A. P3096, P5407, P5408 Faltyn, P. 6610
4945, P5373, P5384, P5399, P5400 Evangelista Masip, A. 3285, 4246, 4247, Falukozy, J. P5023
Ermacora, D. P2541, P2559, P2560 5150, 5152, 5153, 5156 Fam, J.M. 2909
Ermini, F. P6410 Evans, D. P5292, P6192, P6202, P6219 Fan, C.K.M. P3629
Ernande, L. 25, 76 Evans, J. 35 Fan, C.W. P5580
Ernande, L. P2360, P5557 Evans, M. P777, P4304 Fan, F. P903, P4122
Erne, P. P532, P535, 965, P5936 Evans, P. 85 Fan, F.L. P4617
Ernst, S. 92, 153, 212, 354 Evans, P. P4310, 5112, 5114, 5116 Fan, H.C. P6305
Ernst, S. 246, P428, P3366, 5755, 5859, Evdokimov, V. P3761 Fan, K. P2674
5861 Evdokimova, A. P3761 Fan, P. 2205
Erol, C. 34 Even, G. P4086 Fan, X.H. P470
Erol, C. P3677, P5366, P5615, P5652, P6478 Everaert, B. 2909 Fanari, Z. 5094, P6327, P6384, 6616
Erol, M.K. P2519 Evertz, R. P5314 Fanciullacci, C. P6200
Ersanli, M. P573, P2714 Evranos, B. P4690, 6074, P6188 Fandino-Vaquero, R. P2466, P3474
Ersboel, M. P1792 Evrard, P. 4195 Fandrich, R. 4152
Erschoff, V. P5986 Evseeva, M.V. P2520 Fanelli, A.L. P5353
Ertekin, E. P1402 Eweda, I. P2564 Fang, C.C. P5394
Ertl, G. 213 Ewen, S. P873, P2843, P3735, 6067 Fang, F. P5434
Ertl, G. P694, P1669, P2639, P3569, P3599, Eyiol, A. 5210 Fang, L. P2637, P4617
P3752, P6149 Eykyn, T. P4531 Fang, W. P1526, 6103
Ertugay, S. P6510 Ezekowitz, J. 2032 Fania, C. P899
Erturk, M. P423, P4104, P6242 Ezekowitz, J.A. 1312 Fanourgiakis, J. P2642
Erzen, I. P6546 Ezekowitz, M.D. 138 Fanta, S. P1635
Esato, M. P767, P1357, P4121, P4626, Ezekowitz, M.D. 3044, 4980 Fantini, F. 4196
P4635, P4642, P5602, P6137, P6553 Fabbri, E. P3672 Farag, A. 947
Escande, W. P3374 Fabbrizzioli, A. P2406 Farag, M. P2407
Escane Duarte, P. 2940, P3650 Faber, L. P2638, P2827, P3526 Farcomeni, A. P427
Escaned, J. 1042, P1717, P1725, P1748, Faber, T. P1423 Farcomeni, A.F. P5279
2060, P2512, P2517, P2728, 3268, 4022, Fabiani, I. P4091 Fares, E. P1785
4879, 4930, 4932 Fabijanovic, D. P2824 Farhan, S. P572, P2488
Escarsega, R. P670, P1599, P3593 Fabre, J. P1670 Faria, R. P618, P1626, P4062, P6393, P6400
Eschen, O. P460, 4959 Fabregat Andres, O. P1622, P2128 Faria-Neto, J.R. P6451
Eschenhagen, T. 265 Fabregat-Andres, O. P181 Farina, A. 4254
Eschenhagen, T. 49, 5718 Fabregues, G.E. 305 Farkas, B. P1795
Escher, F. P1353, P3600, 5898 Fabris, E. P2752, P2764, 5787 Farkas, J. P6546
Escoubet, B. P4086, P5008 Fabritz, L. P1416, 4219, P5949, P6352, Farkas, K. P4665
Escribano, D. P1517, P1518, 3252 P6357 Farkash, R. P794
Escribano, P. P2652, P3625 Facchetti, R. P4119 Farkouh, M. 1948
Escribano Subias, P. P4550, P5957 Fach, A. 3309, 5818, P5935 Farkouh, M.E. 156, P6241
Eser, P. 2929, P4098 Facila, L. P6462 Farkowski, M. P5291
Esfandiari, S. P5525 Facin, M. P4298 Farmakis, D. P758, P3441, P5624
Esler, M. P3735 Fadel, B. P6486 Farmakis, D.T. P2459, P2666, 3303, P3358,
Espinola, N. P1601 Faden, G. P5938 5198, P6566
Espinola-Klein, C. 308 Fadhilah, A. P6385 Farneti, L. P3672
Espinola-Klein, C. 1978, P2669, 4977 Fadl El Mula, F. P1147 Farnier, M. 43
Espinosa, M.A. P4569 Faerber, G. P3107 Farnier, M. 398, P1696, P2147, 3881
Espinosa-Castro, M.A. P1392, P5494 Faganello, G. P5297, P6147 Farooq, K. P5682
Espinoza, A. P3462 Fagerland, M. P422 Farooq, M.U. P5606
Esposito, F. P4298, 4860 Faggian, G. P6358 Farouk, H. P5571
Esposito, G. 1985, P2121, P2481, P4715, Faggiano, P. P4769, P5938 Farouque, O. P894
P5623 Faggioni, M. P1598 Farr, M. 2210
Esposito, M. P4715 Fagon, J.Y.F. 5089 Farrag, A.A.M. P729, P901, P1785
Esposito, R. P858 Fagyas, M. P2649 Farre, A. P1710
Esquirol, Y. P1667, 2023 Fahey, T. 1856 Farre, J. 953, 968, P1440
Esteban, A. P1396 Fahy, G.J. P3406 Farre, N. P1774, 2213, P3124, P6187, P6584
Esteban, M. P6186 Faini, A. P3352, P5263, P5523 Farre Muncharaz, J. P6250
Faita, F. 4196
441
Chairpersons & Judges / Speakers & Discussants / Authors Far – Fil
Farrelly, E. 1971 Fenger, R.V. P2170 Ferraro, G. 2930

Farrero, M. P1766 Fenici, R. P2693 Ferraro, M.R. P2351
Farsky, P.S. P5251 Fenk, S. 2230 Ferrarotti, L. P2561
Farto E Abreu, P. P768, P1506 Fenning, S.F. P5562 Ferreira, A. 4158, P4413
Farzana, S. 2343 Fenoglio, L. P3619 Ferreira, A.M. P4509, P4624
Farzaneh-Far, A. P1521, P3091 Feola, I. P6177 Ferreira, D. 5922
Fassa, A.A. P3731, 5217 Ferdinandy, P. 83, 193, 374 Ferreira, F. P5684
Fassini, G. P3382, P4346, P4389 Ferdinandy, P. P1348, P3326 Ferreira, G.M. P4455
Fassini, G.M. P3427 Ferenc, M. P3720 Ferreira, J. P3648, P3658, P5643
Fateh-Moghadam, S. P671, P674, P675, Ference, B.A. 3864, 3867 Ferreira, J.F. P829
P680, 4270, P6377 Ferenci, T. P1829, P4665 Ferreira, J.M. P2470
Fatkin, D. P4725 Feretou, A. P4671, 4871 Ferreira, L. P4434
Fattore, G. P464 Ferguson, C. P4096 Ferreira, M.L. P2473, P2489
Fauchier, L. 950, 1970, P2836, P3080, Ferlini, A. P1421 Ferreira, N. P618, P4490, P4995, P6240
P4985, P5267, P5313, P6205, P6214 Fernandes, A. P3473, P5346 Ferreira, R. 103, P501, P506, P867, P1773,
Fauconnier, J. 206 Fernandes, D.C. P2808 P2372, P2470, P2489, P2673, 2937, P4434
Faude, O. P2685 Fernandes, F. P198, P700 Ferreira, R.C. P3693
Faurie, B. P4701 Fernandes, R. P2760, P4686 Ferreira, V.M. 144
Faustino, C. P209 Fernandes E Fernandes, J. 314 Ferreira Gonzalez, I. P538, P3608
Faustino, M. P768, P1506, P3397, P3418 Fernandez, A. P1107, 4961 Ferreira Martins, J.D. P1642
Fava, A. 4961 Fernandez, C. P1470, 2318, 2320, P3106, Ferreira-Gonzalez, I. P2507, P3615
Favaloro, L. 4961 P5483, P6498 Ferreirinha, F. P2809
Favaloro, L.E. P1767 Fernandez, F. P546 Ferreiro, C. P6490
Favaloro, R.R. P1767 Fernandez, J. P478, 963, P4576 Ferreiro, J.L. P546, P761
Favarato, D. P6267 Fernandez, M. P4631 Ferreiro Quero, C. P1109
Favre, S. P2586, P3133 Fernandez, M.E. P5448 Ferrer Menduina, Q. P3612
Fawzy, A.M. P4447 Fernandez Cisnal, A. P546 Ferrer-Rebolleda, J. P181
Faxen, J. P2460 Fernandez Del Palacio, M.J. P862 Ferrera, C. P3103, P3104, P3106, P3576,
Fayad, Z.A. 4798 Fernandez Diaz, J.A. 1205 P4575
Fayyad, R. P766 Fernandez Fernandez, X. P1623 Ferrera Duran, C. 2320, P5483
Fayyadh, M. P2663 Fernandez Figueras, M.T. P3546 Ferreri, E. P173
Fazio, S. P5374 Fernandez Gasalla, A. P1125, P6492 Ferrero, A.M. P865
Fearn, S. P6314 Fernandez Golfin, C. P1554 Ferrero, P. P5285
Fearon, W. 4022, 6620 Fernandez Golfin Loban, C. P2547 Ferrero Gregori, A. 161
Fechner, H. P5501 Fernandez Guerrero, J.C. P2759 Ferrero-Gregori, A. P3755, P5694
Fedchenko, M. P3614 Fernandez Lozano, I. P475 Ferri, C. P3340
Fedele, F. P427, P846, P847 Fernandez Ortiz, A. 2060, P2728 Ferrier, R. P1636
Feder, G. P777 Fernandez Ortiz, A.I. 369 Ferrieres, J. 69, P758, P1358, P1654, P1667,
Federici, M. P2362 Fernandez Santos, S. 5091, P5442 P1675, P1680, P1683, P1696, P1703,
Federico, G. P4598, P4601, P6474 Fernandez Vazquez, F. P5474 2023, P2147, P2504, 4260, P4991, P5931,
Federico, V. P2716 Fernandez Vivancos, C. P6421 P6450
Fedorco, M. P1095, P4351 Fernandez-Armenta, J. P1405, P3371 Ferrieres, J.E.A.N. P173
Fedorov, A. P5349 Fernandez-Aviles, F. P538, P1392, P2410, Ferro, G. P6338
Fedorowski, A. 1328 P3127, P3554, P4569, P5448, P5568, 5802 Ferron, M. P1810
Fedrigo, M. P1788 Fernandez-Aviles-Diaz, F. P5494 Fessmann, D. 2230
Feenstra, H. 3071 Fernandez-Friera, L. 6085 Fette, G. P3569
Fefer, F. P4999 Fernandez-Golfin, C. P508, P1396, 1886, Feuchtner, G. P4491
Feger, M. P2587, P6345 P2691, 3173, P3531, 4176, P5442 Feyrer, R. P6374
Fehrendt, S. P4366 Fernandez-Guerrero, J.C. 366 Fiane, A.E. P6341
Feijen, E.A.M. P5035 Fernandez-Hidalgo, N. P6382 Fiarresga, A. P1642, P3693
Feijoo-Bandin, S. P4541, P6334 Fernandez-Lopez, X.A. P5304 Fibbe, W.E. P2126
Feistritzer, H.-J. P4411 Fernandez-Meseguer, A. P1689 Ficheur, G. P621
Feistritzer, H.J. P4416 Fernandez-Ortiz, A. P1470, P2119, P2517, Fiehler, J. 3273
Fejfer, K. P482 P3520, 4930, 6085 Fiehn, E. 5818, P5935
Felblinger, J. P164 Fernandez-Palomeque, C. P1110, P5584 Fieuws, S. P1765
Feldman, D. 1197 Fernandez-Perez, C. P2788 Fife, A. P2625
Feldman, L. P1500 Fernandez-Portales, J. P476 Figiel, L. P2528
Feldman, T. 312, 5215 Fernandez-Rodriguez, D. 6018 Figini, F. 370, P2761
Felekos, I. P1342, P3116 Fernhall, B. 2937 Figueiredo, E.L. P2717, 6014
Felice, F. P3447, P3458 Ferraironi, A. P4769 Figueiredo, G.L. 6617
Feliciano, J. 103, P1773 Ferraiuolo, G. P2794 Figueiredo, L. P4488
Feliu, E. P616 Ferrante, G. P1499 Figulla, H.R. P648, P787, 1980, 1982, P2538,
Feliu-Batlle, J. P853 Ferrara, A. P1364, P2767 3167, P3500, P3719, P3727, P4113,
Felix, C.M. 2909 Ferrara, A.F. P3461 P5005, P5492, P6514, 6631
Felix, S.B. 406 Ferrara, F. P5530 Fijalkowska, A. P3671
Felix, S.B. P4736, 5909, 5911 Ferrara, N. P874, P6338 Fijalkowski, M. P3475
Felker, G.M. 356, 6037 Ferrari, M. 1982, 2015, P6170, P6514 Fijorek, K. P6402, P6408
Felker, M. 6638 Ferrari, R. 140, 242, 356 Fikal, N. P2501
Feltes, G. P2548 Ferrari, R. 3843, 3846, 5730, 5731, 5778 Fikrova, P. P3446
Feneley, M.P. P4725 Ferrari, V. 3255 Filgueiras-Rama, D. P475, P3380, P5945
Feneon, D. P2434 Ferrario, M. 1204 Filimon, S.S. P3659
442
Chairpersons & Judges / Speakers & Discussants / Authors Fil – Fra
Filip, G. P6127 Fleming, S. P4327 Fosboel, E.L. 298, 2033

Filip, M. P6127, P6599 Flessas, D. 4867, 4869 Fosbol, E.L. 1832
Filipiak, K.J. P1616, P3086, P3744, P4572, Fletcher, B. 251 Fossaa, A. P1791
P5270, P5280, P5300 Fletcher, L. P2398 Fossaa, K. P2621, P3589
Filipovsky, J. 6652 Flevari, P. P165, 1326, P5930 Fossaa, S.D. P1791
Filippatos, G. P2459, P2666, P2796, 3303, Flis, A. P3495 Fosse, E. P3462
6037, P6320, P6566, 6638 Floege, J. 4029 Foster, E. 5215
Filippatos, G.S. 96, 242, 311 Floerchinger, B. 3310 Fotakis, S. P2154
Filippatos, G.S. 3150, 3848, 3851 Flore, V. P1364 Fotinos, A. P1487, 2341
Filippetti, L. P3530, 6030 Flore, V.F. P3461 Fouda, M. P5638
Filippi, M. P5577 Flores-Blanco, P.J. P586, P1098, P4403 Foulon, V. P1541
Filippucci, E. P6216 Florescu, M. 4157 Fouraux, M.A. P695
Filis, K. P612 Florian, A.R. P1532 Fournet, M. P2836, P4095, P5429, P5438
Filmus, J. P6341 Floris, R. P578 Fournier, S. P535, 942, P5936
Finco, G. P1573 Flugelman, M.Y. P203, P205, P703, 3995, Fourny, M. P5932
Findeisen, H.M. P4540, 5848 4886, P5586 Fourozanfar, M. P6461
Findlay, I. P1380 Foa’, A. 158 Foussas, S.G. 211
Finet, G. P3594, 6622 Focardi, M. P2682 Fox, D.J. P619, P2432
Finger, S. 1084 Foglia, P. P4100 Fox, H. P2797, P5661, P6289, 6636
Fingrova, Z. P3423, P5534 Foin, N. P2752 Fox, K.A.A. 93, 123, 244, 317, 371
Finkelstein, A. 34 Fokkert, M.J. 1857, P4071 Fox, K.A.A. 395, 1159, 1160, P1513, 2031,
Finkelstein, A. P3584, 5789, 6016 Foldes, G. P5449 3874, 3877, P4398, P4629, 4801, P4994,
Finkelstein, Y. P192 Foldyna, B. P3381 5048, 5050, 5051, P5598
Finn, C. P778 Foley, D. P5604 Fox, K.F. 20, 195
Finne, P. 4911 Folke, F. P4072 Fox, K.F. 2973
Finocchiaro, G. P1621, 1848, 2967 Follacchio, G.A. P427 Fox, K.M. 185, 322
Finucane, C. P5580 Follath, F. P2459, 3303, P6566 Fox, K.M. 2860, 2863
Fioravanti, F. P2693 Folliguet, T. 6021 Fox, R. P1146
Fiorelli, F. P1598, 5799 Folliguet, T.A.F. 4005 Fraccaro, C. 4863
Fiorentini, C. P4997 Fomaneg, C. 1199 Fraccarollo, D. P3610
Fiorentino, F. P2155 Fomin, A. P3552 Fradet, G. P6241
Fiorina, C. P3592, P6375 Fominykh, E.V. P5706 Fraessdorf, M. 4980
Firman, D. P3467 Fonager, K. 6627 Fraga-Silva, R.A. P185, P186
First, E. P203 Fonarow, G. 4857 Fragni, M. P854
Fischer, A. P3605, P3606 Fonarow, G.C. P780, P781, P3076, P5702 Fraile, A. P5686
Fischer, D. P684, P5015 Fonseca, C. P5658, P5684, 5909, 5911 Fraile Sanz, C. P2691
Fischer, F. P840 Fonseca, F.A. P1673 Franaszczyk, M. P3540, P3543
Fischer, J. P516 Fonseca, H. P2372 Francese, G.M. P4371
Fischer, K. 1198 Fonseca, H.A. P1673 Franci, B. P3791
Fischer, M. 2230 Fonseca, P. P618, P4995, P6240 Franciosa, P. P1430
Fischer, T.H. P2159, P5950, P6154 Fonseca, R. P6321 Francis, C. P430
Fischer-Rasokat, U. P4565 Font-Gonzalez, A. P5035 Francis, D. P1714
Fisher, A.C. P6568 Fontana, A. 4163 Francis, L. P619, P2432
Fisher, J.P. P4338 Fontana, M. P5546 Francis, M. P4772
Fisher, M. P3635, P6568 Fontana, V. 1202, P2523, P4412 Francisco, A.R. P598, P1121, P1122, P2552,
Fisher, R. P2629 Fontes, M.S.C. P4115 P2636, P5422
Fisicaro, A. P5659 Fontes Carvalho, R. 303 Francisco, A.R.G. P3804, P5419
Fiszer, R. P3729 Fontes Carvalho, R. 1194, 2974 Franco, D. P1425, 2239, P4715
Fitchett, D. 1872, 1873 Fontes Sousa, A.P. P2809 Franco, F. P1796, P4333, P4764
Fito, M. P4662 Fontes-Carvalho, R. P3130, P6586 Franco, J.A. 968
Fitzgerald, K. P1761 Fontoura, D. P1578 Franco, L. P4675
Fitzmaurice, D. 396 Foo, D. P831 Franco, N. P1423, P2485
Fitzsimons, D. 125 Foppa, M. 307 Franco, O.H. 276, P741, P747, P749, P1391,
Fitzsimons, D. 228 Foran, J.P. P3395, P3741, P5452 P2594, P4609, P5021, P6444
Fitzsimons, S. P5034 Forastiere, F. 4196 Franco, R.J.S. P2704
Fiuza, M. P3601, 4154 Ford, G.A. 2933 Franco Diez, E. P508
Fixler, D. P1587 Ford, K. P3460 Franco Duran, O. P5573
Flaa, A. 3224 Fordyce, C.B. P6210 Franco Pelaez, J.A. P1710, P6250
Flachskampf, F. 210 Forfar, J.C. P3609 Francomano, D. P6480
Flachskampf, F. 3245, 3247, 3249, 3250, Forkmann, M. P3389, P3409, P4341, P4359, Francuz, P. P4476, P5303
5863 P4983 Frangieh, A.H. P6364
Flachskampf, F.A. P5410 Forleo, G. 2270, P2390 Frank, H. 325
Flack, J. P1148 Formigli, D. P1474 Frank, M. P1812
Flaherty, G. P2718 Formisano, P. P6338 Frank, R. P2429, P3588
Flamm, S. P613, P2585 Formisano, R. P874 Franken, R. 3071, P5239
Flammer, A.J. P1812 Formisano, R.F. P6570 Frankenstein, L. P2687
Flather, M.D. P526 Forni, T. P5493 Franklin, B. 1960, P2676
Flecher, E. P4095, 6630 Forsberg, T. P4081 Franks, T. 3162
Fleg, J. P3756 Forster, T. P1772 Frantellizzi, V. P427, P847
Flego, D. 3944, P4522, P6118, P6251 Forsyth, P. P2826 Frantz, S. 249
Fortner, P. P194 Frantz, S. 131
443
Chairpersons & Judges / Speakers & Discussants / Authors Fra – Gab
Frantzen, A. P4566 Fritz, J. 966 Fuku, Y. P1504, P1514, P2622, P2738,

Franz, M. P648, 1980, 1982, P3107, P5005 Fritz-Hansen, T. P844, P6538 P2739, P2748, P2774, P3345, P3688,
Franz, W.-M. P607, P1556 Fritzenwanger, M. P648, 6631 P3713, P5402, P6278, P6520, P6525,
Franz, W.M. P1349, P4411, P4416, P5558 Fritzer-Szekeres, M.F.S. P2677 P6532
Franzen, K.F. 6066 Froehlich, G.M. 4269 Fukuchi, K. P4112
Franzetti, I. P5040 Froekiaer, J. P4743 Fukuda, D. P431, P642
Franzini, M. P3087 Frohn - Mulder, I.M.E. P1120 Fukuda, H. P5460
Franzone, A. 362 Fromentin, S. 104 Fukuda, K. P3123, P3419, P3477, 4180,
Fraportti, J. P5477, P5640 Frommeyer, G. P1379, P1431, P5948, P4336, P4361, P5466, P5503
Fras, Z. 36 P6158 Fukuda, M. 2243
Fras, Z. 5126 Frontczak-Baniewicz, M. 6615 Fukuda, Y. P5527
Fraser, A.G. 247 Frontini, M. P1446 Fukui, K. P4674, P4677
Fraser, A.G. 3925 Frost, L. P5277 Fukui, S. P2366, P2368
Frati, G. P5378 Frota Filho, J.D. P5477, P5640 Fukui, T. P3334
Fraticelli, A. P1354, P5929 Frustaci, A. P1430, 5910, 5911, 6098, 6099, Fukumitsu, M. P4784
Fraunberger, P. P6259 6100 Fukumoto, R. P3334, P5488
Frea, S. P3394 Frutos, A. P571, P5348 Fukumoto, Y. 2337, 2338, P3691, P5249,
Frean, M. P6197, P6212, P6215 Frutuoso, C. P1407 P6128, P6535
Frederiksen, K. P5281 Frydland, M. P1408, 6651 Fukunaga, K. P1727, P1731
Freedman, L. P5977 Fryer, M. P4704 Fukunaga, M.F. P1712
Freedman, S.B. P4981, P5320 Frykman, V. P5324 Fukunaga, S. P6218
Freeman, C.I. P2398 Frynas, K. P856 Fukunami, M. P1378, P1437, P4760, P6558
Freeman, L.J. 5109 Fryzek, J.P. P5374 Fukuoka, Y. P2551, P3400, P4309
Freeman, M. P894, P4302 Fu, F. P3443 Fukushima, A. P5579
Freeman, P. P1738 Fu, H. P4348 Fukushima, K. P2409
Freemantle, N. P6226 Fu, M. P3716, P5265, P6460 Fukushima, N. P1793
Frei, M. 1201 Fu, M.Q. P4515, P6330 Fukushima, S. P2610, P3544
Freidin, M.B. P430 Fu, X.H. 1054 Fukuyama, M. P1386
Freimark, D. P5977 Fucharoen, S. P3786 Fukuyama, N. P603
Freitas, A. P1506 Fuchs, C.S. P1131 Fukuzawa, S. P801
Freitas, A.I. P5962, P5964 Fuentes-Castillo, L. P546 Fumagalli, S. P514
Freitas, C. P4621, P4625, P4645 Fuernau, G. P2480, P3494, 5090, 6631 Fumiaki, F. P2598
Freitas, P. P1610 Fuglesang Christensen, C. P6455 Funabashi, N. P3528, P4501, 5211, P5413,
Freitas, P.F. P829, 1200 Fujibayashi, K. P6232 P5944
Freitas, S. P4643, P4646, P5964 Fujii, A. P4354, P5939 Funada, A. 1321, P1332, P1384
Freitas Coutinho, G.F. P4578 Fujii, H. P490, P751 Funada, R. P5973
Freitas-Ferraz, A. 2318, P3106, P5483 Fujii, K. P1712, P1739, P1743, P2775, P3407 Funasako, M. P626
Freixa, X. P206, P2780, 6018 Fujii, S. P515, P1514, P2449, P4483, P4547, Funayama, A. P851
French, J. P2516, 5804 6105 Funayama, M. P5486, P5599
French, P.M.W. P869 Fujii, Y. P1386, P5041, P6285 Funayama, N. P6530
Frenneaux, M.P. P5435 Fujiishi, T. P6361 Funck, R. P3597
Frenz, P. 1854 Fujimaki, T. P5590, P5593, P5610, P6172 Funck-Brentano, C. 92
Frerker, C. P682, P685, P4563, P4564 Fujimoto, N. P1535, P4114, P4774 Fung, A. P2727, P2736, 2907, 5817, P6241
Frese, K.S.F. P3100 Fujimoto, S. P6317 Furber, A. P4417, P6516
Fresno, M. P6395 Fujimoto, T. P1779 Furmaga, J. P5653
Fressart, V. P714 Fujimoto, Y. P3636, P3797, P4353, P4384, Furman-Niedziejko, A. P5294
Frestad, D. 4289 P5413, P5944 Furudono, S. P876, P2475, P4451
Fresz, T. P4688 Fujino, A. P1743 Furugen, M. P3691, P6535
Frey, F.F. P4101 Fujino, M. P5354 Furuhashi, M. P1582
Frey, M.K. P1455 Fujino, N. P693, P698 Furukawa, Y. P1378, P2491, P5249, P6558
Frey, N. P1751 Fujino, T. P6218 Furukoshi, M. P5004, P5486, P5599
Freylikhman, O. 3051 Fujino, Y. 4286 Furushima, H. P6156
Freynhofer, M.K. P572 Fujioka, D. P2563 Furusho, A. 2337, 2338, P6128
Friberg, H. P421, P1408, P3470 Fujisawa, C.E.A. P6451 Furusho, H. P6183
Frick, M. 3175, P3725 Fujisawa, M. P5262 Furuyama, F. P2720
Fridlund, B. P4566 Fujisawa, T. P1117 Fusaro, M. P3705
Friebel, J. P3575 Fujita, H. P5656 Fusazaki, T. P6256
Friede, T. P165, P5930 Fujita, M. P1760, P2404, 3170, P4498, P5326 Fusco, D. P758
Friedman, N. P5977 Fujita, W. P6232 Fuseya, T. P1582
Friedman, P.A. P4381 Fujito, T. P2556 Fushimi, K. P5691
Friedrich, G. P4491 Fujiu, K. P5042 Fusini, L. P3527
Friedrich, M.G. 2043, 2045 Fujiwara, M. P1134 Fuso, L. P865
Friedrichs, J. P662 Fukai, T. P4732 Fuster, V. 185, 266
Friedrichs, K. P6355 Fukamachi, D. P6225 Fuster, V. 995, 997, 999, 1218, 2851, 2924,
Frieman, M. 1217 Fukaya, H. P1422, P6361 4211, 6085
Frigerio, M. P3603 Fukaya, K. P5578 Fynn, S.P. 231
Frigiola, A. P2139 Fukazawa, R. 4290 G Mirelis, J. P6392
Friou, E. P3485 Fuks, K.B. 3229 Gaba, P. 5093, 5806
Frisso, G. P1351 Gaballa, M. P6477
Fritsch, A. 4181, P5520 Gabbarini, F. P3377
Fritschka, M. P5663, P5690
444
Chairpersons & Judges / Speakers & Discussants / Authors Gab – Gar
Gabinsky, J. P2376, P2734 Gallagher, S.M. P3711 Garbi, M. 251

Gaborit, F. P5700 Gallego, P. P2652 Garbi, M. 2993, 2995, 2997
Gabriel, D. P1453 Gallego Delgado, M. P1123, P6392 Garcia, A. P651, 968
Gabrielli, L. P3518 Gallego Garcia De Vinuesa, P. P3608, Garcia, D. P1398, 3067
Gabriels, C. P6419 P6421 Garcia, E. P167, P1107, P3520, P3573
Gabrysiak, A. 160, P3480 Gallego-G De Vinuesa, P. P3615 Garcia, J. 365, P3704
Gaburro, A. P1419 Gallet, R. P3516 Garcia, M. P3488, P3515
Gac, P. P3112 Galletta, F. P859 Garcia, M.I. P3479
Gach, O. P2730 Galli, D. P854 Garcia, P.E. P3103
Gackowska, L. P4739 Galli, E. P4095, P5429, P5438 Garcia, S. P1446
Gacon, J. P638 Gallina, S. P5956 Garcia Acuna, J.M. P2458, P2482, P4415
Gaede, L. P2386, P3137, P4565, 5791, 6065 Gallinghouse, J. 955 Garcia Camarero, T. P832, P2757
Gaede, L.G. P567, 1988 Gallini, C. P179 Garcia Campo, E. 5917
Gaede, L.S.E. P2620 Gallino, A. P4100 Garcia De Frutos, P. P1781
Gaemperli, O. 30, 313 Gallino, A.F. 324 Garcia De La Villa, B. 962
Gaemperli, O. P611, 1253, 1254, 2278, Galmiche, L.G. P1640 Garcia Del Blanco, B. P818, P835, P836,
P6364, 6660 Galrinho, A. P867, P1773, P4434 P2759
Gaertner, C. P1419 Galuszka, O.M. P3502 Garcia Del Saz, E. P5262
Gaestel, M. P4520 Galvao Braga, C. P6266 Garcia Fernandez, A. P616, P1398
Gaeta, R. P5956 Galve, E. P610, P1631, P6462 Garcia Fernandez, M.A. 2089, P2345,
Gafoor, S. P206, P3741 Galvez, J. P4622 P2548
Gagarina, N.V. P5706 Galvez-Monton, C. P2580, P3546, P3553, Garcia Granja, P.E. P3576, P4575
Gaggin, H. P1139 P5445 Garcia Hamilton, D. P2143, P3615
Gagliardi, C. P2640 Galvin, I.F. P1775 Garcia Hernandez, F.J. P3625
Gago, P. P2526 Gama, V. P4490, P4995, P6240 Garcia Martin, A. P2547, P3531, P5442
Gago-Diaz, M. P3096 Gama Ribeiro, V. P618, P5631 Garcia Martin, E.P. P4710, P6426
Gai, J. P670, P1599, P3593, P4583, P6379 Gamal, A.S. P5479 Garcia Orta, R. P6421
Gaibazzi, N. P5938 Gaman, S.A. 2100 Garcia Pinilla, J.M. P1689
Gaine, S. P2365 Gamberini, M.R. P1529 Garcia Porrero, E. 2006, 2008, 2010
Gaio, G. P4683 Gambert, S. P1461 Garcia Rodriguez, L.A. P3320
Gaiolla, P.S.A. P3788 Gambetta, E. P3617 Garcia Saenz, J.A. P2557
Gaita, D. 136 Gambino, G. P874 Garcia Santos-Gallego, C. 1993
Gaita, D. 265, 267, 2959, 3966, P6469 Gamble, G.D. P4651, P5034, 6025 Garcia Tejada, J. P4710, P6426
Gaita, F. P1406, P1449, P1748, P2617, Gammelsrud, L. P512 Garcia Zamora, S. P2421
P3377, P3394, P4588, P5378, P6262, Gamra, H. P533, P2615, P5356 Garcia-Acuna, J.M. P2466, P3113, P3472,
P6372, P6446 Gan, L.-M. 4295 P3474
Gaita, F.G. P3118, P5562 Gan, L.M. P1152, P3129, P6239 Garcia-Alberola, A. P4403
Gaita, L. P6469 Gan, S. P6198 Garcia-Alvarez, A. P1766
Gajek, J. P1441, P1442, P2110 Gan, S.F. P5434 Garcia-Aranda Dominguez, B. 5101
Gal, P. P3401 Gancarczyk, U. P1641 Garcia-Blas, S. 963
Gala, S. 2930 Gandelman, G. P6258 Garcia-Carrilero, M. P571, P5348
Galagoudza, M. 4893 Gandhi, K. P6358 Garcia-Del-Blanco, B. P538
Galan, A. P1139, P2811, 4277, 4279 Gandjbakhch, E. P714, 908, P2429 Garcia-Dorado, D. 123, 208, 298, 374
Galan, L. P6392 Gandra, S.R. P1677 Garcia-Dorado, D. P538, P818, P835, P836,
Galan, M. P1369 Ganesan, A. P2356 1088, 2066, P2507, P4529, 4790, P5407,
Galanakos, S. P2670, 4867 Gang, Y. P4373 P5408, P6382
Galaska, R. P3475 Gangl, C. P1752 Garcia-Dorado Garcia, D. P3612
Galasso, G. P2481 Ganpat, R. P5597 Garcia-Elias, A. P3077, P3124
Galat, A. P843 Ganyukov, V. P2773 Garcia-Fernandez, D.J. P3369
Galati, G. P5467 Gao, E. P3465 Garcia-Fernandez, M.A. P1593, P2549,
Galcera-Jornet, E. P616 Gao, F. P1113, 1831, P2712, P3459 P5243
Galderisi, M. P858, 2277, P2481 Gao, G.S. P6515 Garcia-Garcia, H. 369, P1746, P2730
Galderisi, M.A. 1985 Gao, H. P4652 Garcia-Garcia, H.M. 80
Gale, C. P4327 Gao, L. P6495 Garcia-Garcia, H.M. 1026, P1553, P1584,
Gale, C.P. P171, P176, P770, P1102, 1196, Gao, L.J. P4370 4933
2914, 4261, P4994 Gao, M. P463 Garcia-Gonzalez, P. P181, P2128
Galego, X. P6165 Gao, R. P2730 Garcia-Granja, P.E. P3104, P3637
Galema, T.W. 2101 Gao, R.L. P3697 Garcia-Grcia, H.M. P5026
Galeotti, G.G. P4769, P6542 Gao, W. 337, 1215, 1958, P6342 Garcia-Margallo, M.T. P1689
Galian, L. P5407, P5408 Gao, W.Y.Y. P6589 Garcia-Mendez, R.C. P5360
Galie, N. 131, 241, 247 Gao, X.J. P2521, P4407 Garcia-Narbon, A. P586, P1098
Galie, N. 922, 1940, 2174, P2364, P2365, Gao, Y.H. P6330 Garcia-Navarro, E. P862
3829, 3832, 3833, 4181 Gapelyuk, A. P1549 Garcia-Pavia, P. 85
Galie’, N. 4182, P5521, P5524 Gara, E. P5449 Garcia-Pavia, P. P1123, 4930, 6094, P6343,
Galiuto, L. P604 Garabello, D. P6262 P6392
Galizio, N. 4961 Garaeva, I. P1557 Garcia-Picart, J. 161
Galkina, O.V. P5362 Garakani, A. P3567 Garcia-Piney, E. P467
Galkova, K. P2647 Garascia, A. P3603 Garcia-Pinilla, J.M. P6560
Gallagher, J. P5688 Garbade, J. P516 Garcia-Rua, V. P4541, P6334
Gallagher, M.M. P4373 Garberoglio, L. P3394 Garcia-Seara, J. P5304
Gardner, R. P2805
445
Chairpersons & Judges / Speakers & Discussants / Authors Gar – Gia
Gardner, T.J. 5889 Gayat, E. 6645 Gerckens, U. P1141, P3501, P6390

Gareri, C. 5904 Gaye, B.G. P1658 Gerdes, C. 195
Garg, S. P813 Gayoso, C. P1398, 3067 Gerdes, C. 2269
Gargani, L. P620, P4669, P5530, P5576, Gayretli Yayla, K. 5210 Gerds, T.A. P5305, P5596
5805, P6567 Gaziano, M. 934 Gerdts, E. 2979, 3198, P4093, 4900
Gargioli, C. P2573 Ge, J. 81 Gerecke, B.J. 6613
Gargiulo, G. 1985 Ge, J. 337, 1215, 1958, P2817, 5166, 5167, Gerede, D.M. P6478
Garikipati, N. P3384 5169, 5171, 5903 Gerede, M. P3677, P5615
Garkavaya, T. P427 Ge, J.B. P483, P2833, P3598, P3602, 4059, Gergel, J. P1797
Garlitski, A. 5760 P4515, P4585, P6306, P6330, P6518 Gerges, C. P1455, 4866, P5952
Garot, P. P5010, P5489 Ge, P. P1412 Gerges, M. P1455, P5952
Garrahy, P. P4704 Gebhardt, J. P4638 Gerhardt, M. 2335
Garratt, C.J. 21 Geelen, P. P3425 Gerke, O. P4431, P4618, P5017, 6023
Garratt, C.J. P6354 Geerlings, M.I. P5246 Germain, S. 4162
Garratt, K. 2856 Gehani, A. P2468, P4716 Germano, R. P5709
Garrote Coloma, C. P5474 Gehani, A.A. P4069, P5697 Gerosa, G. 351, P4568
Gartland, N. P6315 Gehle, P. P718, P2593 Gerritse, B. P5927
Garton-Smith, J. P3640 Gehmlich, K. P1416 Gersak, B. P3421
Garweg, C. P1541, P3362 Gehrkens, R. P673 Gersh, B. P3076, P4705
Gary, R.A. P441 Geidel, S. P4563 Gersh, B.J. 88
Gary, T. P4103 Geier, C.G. P3100 Gersh, B.J. 1035, 1037, 1158, P4984
Garza, D. P1799 Geiger, J. P1429 Gershlick, A.H. 2219, P2530, P2778
Garzillo, C.L. P6267 Geiger, K. P6259 Gerth, A. P5316
Gasche, Y. P3470 Geisel, H. 4205 Geru, I.M. P6447
Gashaw, H. P430 Geisel, M.H. P6322 Geru, S.R. P6447
Gasior, M. P541, P547, P549, P566, P576, Geisen, U. P1454 Gerull, B. P1636, P3539
P585, P587, P589, P699, P2471, P2506, Geisler, A.C. 5923 Gervasoni, R. P4446, 5088, P6452
P2525, P2789, P5646, P6301, P6580, Geisler, T. P671, P675, P680, P1484, P1487, Gestal Romani, S. P2494
P6587 P1494, P1508, P2524, 4270, 6041, P6268, Gesualdo, M. P657, P733, P4664, P6437
Gasior, P. P589, P1747 6614 Geuns, R. P1746
Gasior, Z. P1747, P2837, P4641 Geissler, P. P2669 Geyer, V. P6550
Gaspar, A. P545, P5338, P5345, P6266 Gelbrich, G. P1669, P5311 Geyik, B. P2534
Gaspar, T. P3381, P3389, P3409, P4341, Geleris, P. P2698 Ghabashi, A.E. P4703
P4359, P4983 Gellen, B. P4525, P6148 Ghadge, S. P4737
Gaspar Lopes Francisco, A.R. P2109, Geller, L. P499, P509, P2396, P2399 Ghadge, S.K. P1349, P5558
P2428, P3601 Geller, L.A. P3075, 4856 Ghadri, J.R. P2791, P6550
Gasparini, G. 4865 Gelsomino, S. P4371 Ghaleb, M. P6430
Gasparini, M. P2115, P2400, 2984, 4222, Gemma, D. 6633 Ghaleb, S. P4606
4224, 4226, 4865 Gencer, B. P1691, 6647, 6650 Ghaleh, B. 124, 146
Gasparovic, H. P2824 Generati, G. P750, P886, P2618, P4744, Ghannem, M. P2675
Gassdorf, F. P787 P4750, P6376, P6434 Gharacholou, S.M. P1377
Gassdorf, J. P3719 Genet, B. P6407 Ghasemzadeh, N. P4301
Gast, M. 3069, P3535 Geng, Y.J. P1348 Ghatak, A. P4413
Gaston, A.T. P4086, P5008 Genovese, S. 317 Gheban, D. P2135
Gatehouse, P. P1520 Genovese, S. 5055, 5056 Gheorghe, L. P4470
Gati, S. 61, 62, 63, 65 Genser, B. P4767 Gheorghe, L.L. P4468
Gatsiou, A. 2342 Gensini, G.F. P1496, P2522 Gheorghiade, M. 199
Gatti, G. P5242, P5244 Genuino, M.N. P689 Ghetti, L. P450
Gatto, F. P1608, P2608 Georgakopoulos, A. P612 Ghiadoni, L. P733, P5576
Gatto, I. P1560 Georgakopoulos, C. P3116, P5540, P5541, Ghiciuc, C. P5037
Gatto, M.C. P846 P5710, P6598 Ghigo, J.M. P1640
Gattorno, M. P4586 George, J. P6258 Ghio, S. P4769, 5805, P6542, P6567
Gatzoulis, M.A. P723, P2142, P6413, P6417 George, O.K. P210 Ghodbane, G. P3731
Gaudet, D. P5980 George, P. 127, P3483 Ghodbane, W. P6391
Gaudio, C. P2443, P3789 George, P.V. P210 Ghodhbane, W. 5218
Gaudio, G.V. P3802, P5712 George, S. 972, P4447 Ghofrani, A.G. P4687
Gaudron, P.D. P694 Georger, F. 104 Ghofrani, H.-A. 4181, P5520
Gaur, S. 3997, P4508, P4998, P5234 Georges, J.L. P796 Ghofrani, H.A. P2365
Gautel, M. P3562 Georgiakaki, M. P3358 Gholami, K.H. P2715
Gauthier, C. P1810 Georgiopoulos, G. 2233, P4429 Ghorayeb, N. 91
Gautier, S. P1813 Georgiopoulou, V. P5682, P6508 Ghorbel, M. P5454
Gavara, J. P1517 Georgousopoulou, E. P727, 2233, P2711, Ghorbel, M.T. P1557, P3559
Gavina, C. P1605, 5179 P2721, P2723, P3681, P4648, P6422, Ghosh, S.M. P1569
Gavras, H. P1481 P6438, P6476 Ghosh Dastidar, A. P4078, P4420, 4872,
Gavras, I. P1481 Gepstein, L. 51 4875, P5226
Gavrilenko, T. P1770, 6046 Gerardi, C. P6571 Ghotbi, A.A. 4289
Gavriliuk, N. P6501 Gerbaud, E. P4438 Ghouse, J. P1433
Gawaz, M. P671, P674, P675, P680, P1484, Gerber, B.L.M. 138 Giacca, M. P1347, 2948
P1487, P1494, P1508, 2341, P2524, 4270, Gerber, B.L.M. P1659, 2035, P2354 Giacchi, G. P2768
P4347, P5603, 6041, P6268, P6377, 6614 Gerber, G.B. 5212 Gialafos, E. 3253
Gawlik, I. 2022 Gerber, R.T. P1477 Giamberti, A. 1012, 1013, 2074
446
Chairpersons & Judges / Speakers & Discussants / Authors Gia – Gol
Giammaria, M. 2270, P2390 Gimeno, F. 366, P3637 Glaudemans, A.W.J.M. P183

Giampietro, C. P6425 Gimeno Blanes, J.R. 212 Glikson, M. 207
Giang, K.W. P2157, P5628 Gimeno De Carlos, F. 1205 Glikson, M. P1389, 2983
Giannakoulas, G. 368 Gimeno-Orna, J.A. P2813 Glinel Mortreuil, B. P6373
Giannakoulas, G. 6013 Gin-Sing, W. P2646 Glinka, M. P5332
Giannaris, V.G. P2584 Ginghina, C. P1630 Glisenti, F. P1555
Giannattasio, C. P6483 Ginsberg, H.N. P5983, P5985 Glisic, B. P5536
Giannini, C. P1598 Ginzburg, M. P6467 Glisic, M. P580, P2484
Giannini, I. P2406 Giordana, F. P6372 Gloanec, M. P544, P3663
Giannitsi, S. P765 Giordanino, E. P6559 Gloekler, S. P1723
Giannitsis, E. 26 Giordano, A. P604 Glotzer, T.V. P2115
Giannitsis, E. 125, 162, 1937, P2687, P3605, Giorgi, B. P1528, P1534 Glowacki, J. P699
P5340 Giorgi, M. P208 Glozier, N. P4323
Giannoglou, G. 1841 Giorgini, P. P3340 Glueck, S. P5972
Giannoni, A. P1366 Giovannone, E.D. P3561 Gluhova, V. P1436, P1800
Giannopoulos, A. 1841 Gipe, D.A. P6427 Gluszek, S. P1693
Giannopoulos, G. P2154 Giral, H. P2582 Gluszko, P. P5537
Giannuzzi, P. 2935 Giraldo, A. P862 Gluud, C. P3654
Giardinelli, F. P4311, P4664 Girard, C. P6344 Gluud, C.G. 2938
Giardini, A. P1664, P2139 Girardey, M. P845 Gnatiuc, L. P4321, P6592
Giarretta, I. P1560 Girerd, N. P557, P2418, P2455, P3365, Gnecchi, M. 1204, P6162
Giau, G. P1573, 5807 P4357, P4600, P5553 Gobbo, M. P686, P1621
Gibbs, J.S.R. 299, 325, 377 Girerd, X. 5079 Gobel, S. 1978, 4977, P6206
Gibbs, J.S.R. 3905, 3907, 3909, 4813, Giri, J. P823 Goda, A. P1801, P4300
4816, P5511 Giricz, Z. 6048 Godbehere, P. P1146
Gibbs, S. P2646, 4183, P5954 Girleanu, A. P6447 Godfrey, R. P2589
Giblett, D. P2392 Girones, N. P6395 Godin, M. P668, P2632, P6415
Gibson, C. 4804 Gislarson, G.H. P3641 Godinho, A.R. P1407, P5406
Gibson, C.M. P1497, P3342, 4002 Gislasen, G.H. 1972 Godoy, H.L. P5032
Gibson, I. P2718 Gislason, G. 1329, 1832, 1846, P3319, Godschalk, T.C. P1500
Gick, M. P809, P1493, P3720 P3747, 3942, P4072, 4283, 4284, P5033, Goebel, B. P648, P787, 1982, P2538, 3167,
Gielen, S. 124, 194 P5284, P5596, P5978, P6213, P6470, 6627 P3500, P3727
Gielen, S. 2226 Gislason, G.H. 298, P462, P474, 951, 2033, Goebel, G. P4411
Giepmans, W. P4496 P2120, P3108, 3277, P3312, 4976, P6235, Goedel, A. P1346
Gierlaszynska, K. P5646, P6301 6642, 6651 Goehring, S. P1726, P2377
Gierlotka, M. P539, P541, P547, P549, P566, Gisslinger, H. 4278 Goehringer, F. P676
P576, P585, P589, P2471, P2506, P2525, Gitsioudis, G. 1841 Goeing, O. P1549
P2789, P5404, P5646, P5937, P6367, Gitt, A. P3120 Goes, M.F.S. P6449, P6471
P6580, P6587 Gitt, A.K. 69, P550, P1654, P1675, P1680, Goessling, W. P1131
Gierula, J. P3767 P1681, P3131, P3132, P3771, 3865, 3867, Goesswald, A. P3666
Giesecke, P. P5324 P4629 Goette, A. 3140, 3142, P6179
Gigli, C. P3617, P6410 Gittenberger-De Groot, A.C. 1065, 3050 Goetz, M. P1722
Gigli, M. P522, P691, P1621 Giubertoni, A. P2561 Goetz, N. P5603
Giglio, A.F. P6118 Giudici, V. 5918 Gogiraju, R. P2158
Gijsberts, C.M. P6253 Giuffre, M. P1636 Gohlke-Baerwolf, C. 27
Gikas, E. P3082 Giugliano, R.P. 68, P217, P1131, 1896, Gohlke-Barwolf, C. P4093
Gil, K.E. 6612 1898, 1947, P6120 Gohya, M. P5323
Gil, R.G. P3449, P3686 Giugliano, R.P.G. P6466 Goicolea, L. P5686
Gil, R.J. P555, 6612, 6615 Giuliano, A. P3352 Goirigolzarri Artaza, J. P1768, P4308,
Gil, V. P768 Giuliano, P. P6571 P5942
Gil, V.M. P1506 Giunta, N. P6571 Goitein, O. P4999
Gilard, M. 1059, 4017, 4019 Giurgea, G.A. P530 Gok, M. P5480
Gilbert, R. P2820 Giurlani, L. P1094 Gokalp, G. P457
Gilbertson, J.A. P5546 Giusca, S. P194 Gokdeniz, T. P3620
Gilham, D. P1585 Giustetto, C. P1406 Gokoz-Dogu, G. P855
Gili, S. P3394, P6446 Giusti, B. P1496 Goksluk, H. P6478
Gill, F. P2373 Giustino, G. P807, 2913, P3342, 4000, Goksuluk, H. P3677, P5366, P5615, P5652
Gill, J. P1432 P4326, P4328, P4695, P4699 Goktekin, O. 93
Gill, P.S. P226, P1783 Giustozzi, M. P6216 Golba, K. P2613
Gill-David, S. P760 Giverts, I. P3347 Golba, K.S. P2447, P6329
Gillam, L.D. 95 Givertz, M.M. P891 Gold, M.R. 4221, 4222
Gillam, L.D. 1309, 3035 Gizurarson, S. P4063 Goldacre, M.J. P3609
Gillebert, T.C. 124, 137 Gjergo, H. P5272 Goldacre, R. P3609
Gillebert, T.C. 4135 Gjesdal, O. P4754 Goldenberg, I. P731, 2271, P2474, 4204,
Gillijns, H. P1111, P6260 Gkizas, V. P1469 P4632, P5560, P5569
Gillis, M.A. P4520 Gkouziouta, A. P170, P1816 Goldhaber, S.Z. 130, 148
Gilljam, T. P460, 4959, P5496 Gkranias, N. P658 Goldhaber, S.Z. 393, 1061, 1063, 1064,
Gilon, D. 135 Glanzmann, M. P1115 1928, 1931, 2182, P4404, P5598
Gilthorpe, M.S. P1102, P4994 Glasnov, T. 2206 Goldstein, P. 26
Gilyarevsky, S. 3941 Glasser, S. 6653 Goldstein, P. P4991
Gimelli, A. 4916, 5864 Glasser, S.P. P5981 Golenischa, V. P3736
447
Chairpersons & Judges / Speakers & Discussants / Authors Gol – Gra
Goliasch, G. P530, 4278, 5092, P5398, 6644 Gong, X.P. P2568 Gorenek, B. 37, 96
Golino, P. 3943 Gong, X.U.E. P6306 Gorham, J. 3065
Golinska Grzybala, K. P5294 Gonna, H. P4373 Gori, A.M. P1496, P2522
Golmard, J.L. P1631 Gonon, A.T. P3085 Gori, M. 3302
Gologanu, D. P2454 Gonski, P. P5549 Gori, T. P2669, P4107
Golovchiner, G. P5013 Gonzalez, A. P1554, P2402 Gormley, A.J. P3545
Golovko, N.V. P6593 Gonzalez, A.E. P3380 Gormsen, L.C. P4508
Golovner, M. P2457 Gonzalez, B. P2790 Gorodetski, B. P453
Golubic, K. P5278 Gonzalez, K. 2087, P2823 Gorog, D.A. P2407
Gomaa, M. P5697 Gonzalez, O. 6633 Gorriz, J. P5686
Gomes, A.C. P1118, 4158 Gonzalez, T. P4719 Gorst-Rasmussen, A. 359, P1666, 1830
Gomes, A.C.P. P5635 Gonzalez, W. P1489, P3488 Gorter, T.M. P4594
Gomes, C. 5814 Gonzalez Correa, M.J. P3650 Gosau, N. 5923
Gomes, M.J. P892, P2808, P3788 Gonzalez Fernandez, O. P195, P3632 Gosden, T. P1453
Gomes, R. S.M. P2571 Gonzalez Ferreiro, R. P2458, P4415 Gosh, B. 1197
Gomes, S. P592, P2464, P2529, P3431, Gonzalez Garcia, A. P2143, P3608 Goshev, E. P5272
P4303, P4621, P4625, P4643, P4645, Gonzalez Gomez, A. P2547 Gosling, O.E. P2392
P4646, P5377, P5962, P5964 Gonzalez Juanatey, J.R. 141, 149, Gospodinova, M. P1352, P4589
Gomes, T.N. P3643 326 Goss, A. P6185
Gomes Serrao, M. P592, P3431, P5377 Gonzalez Juanatey, J.R. P2458, P2494, Goss, F. P5550
Gomez, F. P3366 P4415 Gosselink, M. P4453
Gomez, I. P3576, P3637, P4575, 6022 Gonzalez Lopez, E. P6343 Gosteev, A. P1822
Gomez Bueno, M. P1768, P4308, P5942 Gonzalez Miqueo, A. P1778 Gostimir, M. P5519
Gomez De Diego, J.J. P1593, P2548, Gonzalez Salvado, V. P2458, P2482 Gotchev, D. P5940
P2549, P2557 Gonzalez Sucarrats, S. P1622 Gotleib, S. P794
Gomez de Diego, J.J. 2891 Gonzalez Vasserot, M. P3380 Goto, E. P2533
Gomez Doblas, J.J. 962 Gonzalez-Alujas, M.T. P6382 Goto, H. P2451
Gomez Hospital, J.A. P832, 1205, P4712 Gonzalez-Alujas, T. P5407, P5408 Goto, I. 2339
Gomez Jaume, A. P4712 Gonzalez-Cambeiro, M.C. P3474 Goto, K. P603, P5973
Gomez Juanatey, A. P472 Gonzalez-Fernandez, O. P853, 4049 Goto, M. P3749, P3754, P5443
Gomez Mariscal, E. P6426 Gonzalez-Ferreiro, R. P2466, P3113, Goto, S. 390, P1452, P1570, 1973, 3278,
Gomez Menchero, A.E. P4468, P4470 P3472, P4406 P5598, 5839
Gomez Perez, M. P6492 Gonzalez-Garcia, A. P3615 Goto, T. P435, P1504, P1514, P1817, P2622,
Gomez Sanchez, M.A. 95 Gonzalez-Gomez, A. P1396, P3531 P2707, P2738, P2739, P2748, P2774,
Gomez-Doblas, J.J. P1394, P1689, 1925, Gonzalez-Juanatey, J.R. P432, P651, P3345, P3688, P3713, 4058, P5402,
P4584, P5337, 5790, P6557, P6560 P2466, P2482, P3113, P3472, P3474, P6117, P6278, P6308, P6520, P6525,
Gomez-Gracia, E. P4662 P3755, P4406, P4541, P5304, P5694, P6532
Gomez-Hospital, J.A. P546, P761 P6334, P6462 Goto, Y. P629, 1321, P1332, P1384, P1535,
Gomez-Juanatey, A. P1434 Gonzalez-Lopez, E. P6392 P2368, P5354
Gomez-Lara, J. P761 Gonzalez-Mansilla, A. P3127, 5802 Gotschy, A. P4590
Gomez-Lara, J.L. P546 Gonzalez-Molina Espinar, M. P2792 Gotsman, I. P1806
Gomez-Molina, M. P586, P1098 Gonzalez-Robledo, G. P1774, 2213, P3124 Gotte, M. P5314
Gomez-Monterrosas, O. P2780, 6018 Gonzalez-Salvado, V. P4406, P5304 Gotte, M.J.W. 308
Gomez-Salinero, J. P6343 Gonzalez-Zuelgaray, J. P2421, 3241 Gotti, A. P2573
Gommans, D.H.F. P695 Gonzalo, N. 2060, P2728, P2732, 4930 Gotti, E. 4182, P5524
Goncalves, A. 3168, P3503 Gonzalo Lopez, N. 1267 Gotze, J.P. P5700
Goncalves, D. P2372 Gonzini, L. P564, P569, 4254 Gou, Z.H. P6496
Goncalves, F. P2470, P3493, P6586 Good, N. 1843 Gouadon, E. 2283, P5446
Goncalves, H. P4995 Goodall, A.H. P1500, P2778 Goublaire, C. P4574
Goncalves, I. 39, 249 Goodall, G. P6378 Goudevenos, J.A. 156
Goncalves, I. P175 Goodman, J.M. P5525 Goudot, F.X. P2815
Goncalves, I.S. P2109 Goodman, S. P551 Gouliopoulos, N. P740, P1116, P1577,
Goncalves, L. P2472, P2760, P3473, P4686, Goodman, S.G. 4979 P3680, P4312
P5346 Goodyer, J. P776 Goumans, M.J. 1957, P5447, P5461
Goncalves, L.M. 124, 248 Goossens, M. P4111 Gourgouli, I. P1572, P3679, P4118, P5540,
Goncalves, L.M. 1179 Goossens, P. P6129 P5541, P5710, P6598
Goncalves, M. P2809 Gopal, A.S. P2536 Gouriet, F. P3105
Goncalves, N. P1578, P2372 Gopalakrishnan, B. P653 Gourine, A.V. P1415
Goncalves, P. P4509 Gopalamurugan, A.B. P1477 Gourraud, J.B. P485, P1409, P6161
Goncalves, P.A. P4624 Gor, A.K. P2847 Govind, S.C. P5482
Goncalves, P.G. P829 Gorbach, A.V. P5362 Goy, J.J. P2378
Goncalves, R.S. P2704 Gorbunova, A. P1692 Goyal, V. 4152
Goncalves, S. P527, P591, P2552, P5419, Gorbunova, A.S. P5552 Grabe, N. P6540
P5422 Gorcsan, J. 192 Grabenwoeger, M. 4250, 4251
Goncalves Rodrigues, P. P5259 Gorcsan, J. 1951, P5221 Graber, M. P2596
Goncalvesova, E. P4770 Gorcyca, K. P1683 Grabherr, A. P1810
Goncharik, D. P3736 Gorda, I.I. P3762, P3779 Grabia-Zaprutko, J. P5436
Gondo, K. P6533 Gordeeva, M.S. P1540, P1542 Grabowski, M. P1091, P2438, P2445, 5147
Gong, H. P3557, P4369, 5903 Gorelik, J. 264 Grace, A. 359
Gong, X. P483 Gorelik, J. P4519 Grace, A. 5821
Gracia-Rodenas, M.R. P2811, P2813
448
Chairpersons & Judges / Speakers & Discussants / Authors Gra – Gum
Gracida, M. P546, P761 Grifoni, C. P5290, P6223 Guan, K. P3552, P3562

Gracik, T. P3340 Grifoni, E. P1496 Guan, T.R. P779
Gradaus, R. P6113 Grifoni, S. P2532, P3617, P6410 Guaricci, A.I. 2102, 4051, 4056
Graefenhain De Codes, R. P6191 Grigioni, F. P5467 Guarini, G. P3525
Graeni, C. P611, P4481 Grigolo, I.H. P5254 Guarita-Souza, L.C. P6451
Graf, T. 6066 Grigorian-Shamagian, L. P651 Guarner-Lans, V. P641
Graff, C. 6076 Grigoryan, S. P5330 Guarracino, F. P1598
Graham, D. P2583 Grillo, A. P6495 Guasti, L. P3802, P5712
Graham, I.M. 265 Grimaldi, G. P6338 Guazzarotti, F. P4554
Graham, I.M. 982, 983 Grimby, G. 2966 Guazzarotti, F.G. P2705
Gramley, F. P3390, P3416 Grimm, G. P584 Guazzi, M. P750, P886, 2247, P2618, P4744,
Gramlich, M. P4347 Grimm, K. 126, 154, 159, P524, P525, P595, P4750, P6376, P6434
Grammatikou, V. P5666, P6277 P1097, P1103, P3484 Guc, D. 1839, P4379, P6188
Grammer, T.B. 6644 Grimm, M. P2596 Gucuk, E. 6040
Grana, A. 3067 Grimm, R.A. P3511, P6365 Gucuk Ipek, E. P6139
Granda Nistal, C. P4710, P6426 Grinchuk, I. P6485 Gudjoncik, A. P3080
Grande, C. P1430 Grineva, E.N. P2576, P5236 Gudnason, T.G. 81
Grande, E. P4399 Griva, M. P4705 Gudnason, V. 299
Grandi, A.M. P3802, P5712 Grivel, J.-C. P6332 Guedeney, P. P5654
Granger, C. P4435 Grivenco, A.A. P3659 Gueder, G. P6149
Granger, C.B. P1333, 1973, 1974, 1977, Grobbee, D.E. 23, 91 Guedes, J. P2526
2032, 4203, P5961, P6155 Grobbee, D.E. 986, 987, P1755, P2371, Guedj, K. P4086, P5008
Granich, V. P3805 3951, P6396 Guedon-Moreau, L. P3374, 5919
Grant, P.J. 322 Grobben, R.B. P1755, P5618 Gueffet, J.P. P1124, P4111
Grant, P.J. 3870, 3872 Groch, L. P4705 Guellich, A. P5423
Grapsa, J. 3183 Grochowska, M. P4739 Guellich, A.G. P843
Grarup, N. P1433 Grodzicki, T. P5269 Guenancia, C. P6344
Gras, D. 153 Groenberg, T. P4061 Guenoun, M. 79, 130
Grases, F. P5584 Groenink, M. 3071, P5239 Guenoun, M. 1016, 3814, 3818, P6194
Grassi, G. P1149, P4119, P4781 Grofkova, H. P1095, P4351 Guenther, A. P3107
Graupner, C. P1394 Groos, S. P5589 Guenther, M. 1323
Gravanis, K. P5418, P6265 Grooteman, M.P.C. P5364 Guerchet, M. P4108, P5574
Gravino, R. P1351 Groschel, K. P5311 Gueret, P. P4465, P4991, 5769
Graw, S. P1375, P1393 Gross, L. P607 Guergelcheva, V. P1352, P4589
Gray, A. P3432 Gross, M. P3502 Guerola Segura, R. 2940
Gray, C.D. P2127 Gross, U.M. P3600 Guerra, F. P860, P2406, P3078, P4554
Grayburn, P.A. P2613, 5215 Grossenbacher, R. P1709 Guerra, G. P4621, P4625, P4643, P4645,
Greaves, D. 313 Grosseto, D. P2485, P3672 P4646
Greaves, K. P1603, P4463 Grossmann, B. P675, 4270 Guerreiro, S. P1610, P4349
Green, A. P3319 Grosso, M. 4971 Guerrero Marquez, F.J. P6421
Green, D. P803 Grosso Marra, W. P3394, P6262, P6446 Guerrero-Perez, E. P586, P1098
Green, L. P3594 Grothoff, M. P3381 Guerrini, F. P2345
Greenberg, B. 6638 Grotti, S. P1354, P5929 Guetta, V. P4999, 6016
Greenberg, B.H. 5060 Grottke, O. 4978 Guevara, E. 4961
Greenberg, G. P2731 Grove, E.L. 38, 212 Guglielmo, M. P3527, 4051, 4056, P5233,
Greenhalgh, J. P774 Grove, T. P2718 P6316
Greenlaw, N. P2826 Groves, D. P6568 Guha, K. P498
Greenway, S.C. P1636 Groves, D.G. P3635 Guida, R. P1354, P5929
Greenwood, J. 5157 Grozdic, I. P609 Guidalotti, P.L. P2640
Greenwood, J.P. P2530, P4096, P4570 Grube, E. P1141, P1596, P2631, P2633, Guidet, B.D. 5089
Gregori, D. P4568 P3501, P4573, P6387 Guiducci, S. P4669, P5530
Gregori, G. P564 Grube, K. P4736 Guijarro, D. P1810
Greiss, H. P3364, P3391, P4367, P4368 Grubisic, M. P463 Guillon, B. P1733
Grekas, T. P2721 Gruchala, M. P757, P3475, P6224 Guimaraes, M.J. 5922
Grekhov, E. 3051 Grueger, M. P4083, P6348 Guimaraes, T. P598, P1122, P2109, P2428,
Grenier, C. P544, P3663 Gruen, K. P5005 P2636, P3601, P3804, P5419, P5422
Grett, M. P497 Grufman, H. P175 Guizoni, D.M. P5258
Greulich, S. 4054 Grunau, B. 156 Gujoncik, A. P799
Greutmann, M. 143, 2927, P6414 Grundeken, M. 369, P2743 Gul, I. P3620
Greve, A. P1520 Grundeken, M.J.D. 364 Gul, M. P423, 6040, P6242
Grewal, N. P6436 Grundmann, S. 1956 Gulayin, P.E. P2421
Gribaa, R. P4693 Gruner, C. P6364 Gulec, S. P5366, P5615, P5652
Griebenow, R. 89 Gruzdeva, O.V. P2520 Gulel, O. P5421
Grieger, A.G. P3633 Grygier, M. P4572 Guleri, A. P677
Griendling, K. P2583 Grymyr, O.J. P3462 Gulizia, M. 4254
Grieten, L. 163 Gu, H.Y. P5253 Gulizia, M.M. P1474, P4371
Griffin, B. 4819 Gu, X. P697, P1645, P1648, P6496 Gullestad, L. 336, P1404, P2621, P3589,
Griffin, B.P. P3511, P6365 Guagliumi, G. 93, 211 P6551, P6555, 6643
Griffith, A. 2244 Guagliumi, G. P1500 Gulya, M. P5224
Griffith, K.E. 21 Guagnano, M.T. P2716 Gummert, J. P3526, P5005
Griffiths, S.M. P3629, P6423 Gualandro, D.M. P1804, P6499 Gummert, J.F. P1618
449
Chairpersons & Judges / Speakers & Discussants / Authors Gum – Ham
Gumrukcuoglu, H.A. P2535, P2847 Ha, J.-W. 267 Hajas, A. P1794, P1795, P4097
Gunawardene, M. P3393 Ha, J.W. P2544, P3585, P6362 Hajek, P. 250
Gunbatar, H. P2535 Ha, S.J. P6362 Hajjar, R.J. 4968
Gundlund, A. 298, 1832 Haahr-Pedersen, S. 5803 Hakgor, A. P6144
Gunduz, S. P4319, P6386 Haake, H. P3597 Hakimzadeh, N. P2715
Gunebakmaz, O. P3466 Haaland, T. P512 Hakkarainen, H. P2597
Guney, M.C. P488 Haapaniemi, A. P2346 Hakkinen, U. P758
Gunn, J. P197, P6453 Haapaniemi, E. P2346 Hakui, H. P4760
Gunn, J.M. P2156 Haas, J. P5472 Haladyn, J.K. P4704
Gunning, M. P2625 Haas, J.H. P3100 Haland, T.F. P418, P1397, P3497, 4960,
Gunturiz, C. P571, P5348 Haas, S. 394, 3278 P6307
Guo, L.Z. P819 Haaverstad, R. P4566 Halank, M. P5520
Guo, Q. P6572 Habara, M. P2746, P3708, P3722, P4608, Halawa, S.R. P4703
Guo, R.-Q. P2555, P5417 P6282 Halbach, M. 4191
Guo, X. 337, 1958, P2413, P3378 Habara, S. P1504, P1514, P2622, P2738, Halbfass, P. P4356, P4391
Guo, Y.-L. P1662, P5229, P5357, P5386, P2739, P2748, P2774, P3345, P3688, Halcox, J. P6202, P6219
P5388 P3713, P5402, P6278, P6520, P6525, Halcox, J.P. P4776, P5572
Guo, Y. P637, 928, P1700, P2688, P4652, P6532 Haldar, S.K. P3395, P4390, P5452
5123, P5620 Habbal, R. P2501 Hale, A. P4517
Guo, Y.U. P1359 Haberka, M. P4641 Halestrap, A.P. 4942
Gupta, K. 1971, P6211 Haberkorn, S.M. 5899 Haliti, E. P4727, P6585
Gupta, M. P760 Habib, A.K.M.A. P223, 2343, P5261 Halkin, A. 6016
Gupta, R.C. P848, 3307, P3783 Habib, G. 302 Hall, J. 199, 201
Gupta, S. 1851, P4318, P6564 Habib, G. 924, P1611, P3105, 5987, P6383 Hall, J. 5845
Gupta, S.K. P4082 Habib, M. P447, P1140 Hall, J.A. 1176
Gur, M. P722 Habib, N. P737 Hall, R. 142, 143, P1402, P2160
Gurbuz, A.S. P5481 Habibi, H. P2662 Hall, R.J.C. 363
Gurdogan, M. P4104 Hachulla, E. P687 Hall, R.J.C. 5109
Gurev, V. P211, P6420 Hacke, C. P2703 Halle, M. 2888
Gurgenyan, S. P3792 Hackl, G. P4103 Halliday, C. P1585
Gurgun, A. P2795 Hadamitzky, M. 2099 Halm, U. P6509
Gurgun, C. P2795 Haddad, H. P2613 Halmai, L. P1772
Gurgus, D. P5043 Haddad, J.L. 6617 Halna Du Fretay, X. P6415
Gurlertop, H.Y. P2534 Haddock, J. P5514 Halnon, N.J. P442
Gurses, H.N. P3644 Haddour, N. P4647, P4650 Halon, D.A. P203, P205, 3995, 4886, P5586
Gurses, K.M. 1839, P4379, P6188 Hadebe, N. P6328 Halperin, J. 148
Gursoy, M.O. P4319, P6386 Hadley, R.H. P1151 Halperin, J. P1488, 2182
Gurung, K. P6133 Hadorn, M. P6454 Halperin, J.L. P1516
Gurzeler, E. P5946 Haemers, P. P5941, P6178 Halsey, J. P4321
Gurzun, M. P1630 Haentjens, J. P6383 Halvorsen, P.S. P3462
Gussak, I. P5668 Haentze, K. P4113 Halvorsen, S. 23, 123, 311
Gustafsson, A. P737, P6424 Haerer, W. P1726, P2377 Halvorsen, S. 72, P422, 2032, 2070
Gustafsson, F. P1792, P3624, 4283, 4284, Haertig, F. P5603 Hama, Y. P4353, P4384
P5033, P5700, P5953 Haertle, M. P2590 Hamad, N.M. P5325
Gustiene, O. P594, 5086 Haeusler, K.G. P5316 Hamada, S. 3175, P4449, P4462
Gutberlet, M. P3381, P6509 Hafner, F. P4103 Hamadanchi, A. 1982, P2538, 3167
Guterbaum, T.J. P1571 Hafstad, A. P4531 Hamano, E. P5599
Guth, S. P3095 Hage, C. P3129 Hamaoka, K. P4604
Guth, S.G. P4687 Hagege, A. P3574 Hamasaki, T. P1515
Gutierrez, E. P4569 Hagege, A.A. 156 Hamatani, M. P5698
Gutierrez, G. P4576 Hagege, A.A. P214, P1613, 2333, P4111 Hamatani, Y. P1357, P4626, P5698, P6137
Gutierrez, H. P2732 Hagen, B. P5589 Hamazaki, N. P1567, P2696, P5545
Gutierrez, J.A. 4002 Hagerman, I. 6637 Hambraeus, K. P5373, P5384, P5399,
Gutierrez, L. P2421, P5407, P5408 Haghikia, A. P884 P5400
Gutierrez, M. P2130, P4524 Hagiwara, N. P1637, P4552, P4694, 6655 Hambrecht, R. 3309, 5818, P5935
Gutierrez-Chico, J.L. 372 Hagstrom, E. 4979, P6228, P6439 Hamdan, A. P4999
Gutierrez-Chico, J.L. P787 Hahalis, G. P1469, P1479 Hamdanchi, A. P3500
Gutleben, K.J. P465, P4383 Hahn, J.-Y. P1757 Hamdani, N. 1853, P5259
Gutterman, D. P493 Hahn, J.Y. P2495, 2912, P4472, P4702 Hamdy, A.M. P2807
Guttman, O. P1628 Hahn, R. P5485 Hamed, K. P677
Guttmann, O.P. 6606, 6611 Hai, J.J. P4765 Hamid, S.A. P2832
Gutu, C. P1784 Haider, A. P2722 Hamid, T. 6626
Guzik, P. 25 Haider, K.S. P2722 Hamilton, M. P1453
Guzik, T. 2022 Haig, C. P617, P1519, P1522, 4024, 4055, Hamilton, M.C.K. 4872, 4875
Guzik, T.J. 6060, P6127, P6599 4294 Hamilton Garcia, D. P3608
Guzman, J.C. P3314 Hailan, A. P2742 Hamm, C. 125, 1980, P2386, P2620, P3095,
Gwon, H.-C. P1757 Haim, M. P1652, 3192, 3193, P5276, P5318 P3120, P3137, P4500, P4565, P5405,
Gwon, H.C. P2495, P4472, P4702 Haissaguerre, M. 1964, 1965 P5492, 5791, 6065, 6067
Gyllenhammar, T. P1754 Haitham, H.A.I.T.H.A. P5701 Hamm, C.H. P567, 1988, P4687
Gyongyosi, M. P530, P3577 Haj Yahia, S. P3323 Hamm, C.W. 150, 195, 244
450
Chairpersons & Judges / Speakers & Discussants / Authors Ham – Hau
Hamm, C.W. P556, P1497, P3391, 3877, Hanssen, H. P2685 Hasegawa, D. P1504, P2622, P2738, P2739,
3878, 3923, 4002, P4367, P4368, P4487, Hansson, G.I. P4658 P2748, P2774, P3345, P3713, P5402,
P4499, P4992, P5028, 5049, 5050, P5928 Hansson, G.K. P1589, 3199 P6278, P6520, P6525, P6532
Hamm, W. P1536, P4079 Hansson, N.C. P3723 Hasegawa, H. P3748, P5973
Hammache, N. P3530 Hansson, P.-O. P438, P2657, 2966, P6460 Hasegawa, K. P1357, P3110, P3400, P3422,
Hammami, B. P6384 Hantula, A. 1322 P3690, P4121, P4611, P4626, P4635,
Hammami, S. 5094, P6327, P6384, 6616 Hanzawa, H. P1583 P4642, P5602, P6137, P6156, P6248,
Hammar, N. 6646 Hao, H. P1743 P6553
Hammer, F. P4767 Hao, I. P2380 Hasegawa, M. P726
Hammerer-Lercher, A. P528 Hao, J. 5096 Hasegawa, Y. P5327
Hammerman, H. P447, P1140 Hao, K. P1707 Haselbach, T. P673
Hammerschmidt, R. P2593 Haphyzov, T.N. P6284 Hasenfuss, G. 310
Hammerstingl, C. P893, P1596, P2633, Happonen, J.M. P1649 Hasenfuss, G. P165, 911, P1777, P2159,
P4986, P5550, P5972, P6207, P6366, Hara, H. P199, P505, P3764, P4409, P5515, 3291, P3552, 4177, 4178, 4179, P5950,
P6387 P6296 6055, P6154
Hammett, C.J. P556 Hara, K. P536, P2804, P5029 Hashiba, K. P6411
Hammond, H.K. 5776 Hara, M. P2503 Hashiguchi, N. P1439, P1686, P1687, P2423
Hammoudeh, A. P4475 Hara, N. P5556 Hashikata, T. P655, P6361
Hammoudeh, A.J. P5325 Hara, T. P642 Hashimoto, A. P2556, P5288
Hammoudi, N. P5654 Harada, D. P5025 Hashimoto, G. P3499, P6296
Hamon, M. P1492, P1505, P5473 Harada, K. 2228, P5380 Hashimoto, K. 4290
Hamood, H. P6468 Harada, M. 961, P4512, P5459 Hashimoto, R. P642
Hamood, R. P6468 Harada, T. P2353, P5372, P6125 Hashimoto, S. P487, P2448
Hamouda, S. P1670 Haraldsson, I. 278, P6138 Hashimoto, T. P655, P815
Hamshere, S. P692, P3774, 6608 Harari, E. P1587 Hashimoto, Y. P420, P1798, P3784, 4290,
Hamza, M.T. P4656 Harata, S. P788, P5333 P5668, P6238
Hamzaoui, S. P704 Harbalioglu, H. P722 Hashimoto-Kataoka, T. P839
Han, D. P2710 Harbaoui, B. P5009 Hashizume, N. P6577
Han, I.S. P2726, P4424 Harburn, J.J. P2375 Hasoba, H. P3578
Han, J.C. P1645, P1648 Harcombe, A. P3456 Hass, B. P1703, P6450
Han, S. P200 Harders, G.E. 2336, 5076 Hassager, C. 155, P421, P1408, P1792,
Han, S.H. P784 Hardikar, A.A. P4502 P3470, P3496, P3654, P6252
Han, S.J. P6445 Hardin, J. P5374 Hassager, C.H. 39, 408
Han, S.W. P445, P3768 Harding, I. P3444 Hassager, C.H. 93, 334, 2298, 5887
Han, W. P1428 Harding, S.E. 190 Hassan, A. P5673
Han, Y.M. P779 Harding, S.E. P869, P5449 Hassan, A.K.M. P6428
Han, Z.L. P6359 Hare, D.L. 2956 Hassan, M. P548
Han Yee Yu, M. P5462 Harfoush, B. P4301 Hassan, S. 5920, 6626
Hanafy, D. P6385 Harimura, Y. P3498 Hassanein, A. P1463
Hancu, N. 31 Harjola, V.-P. 146, P880, P3491, P4768, Hasselberg, N.E. P418, 4960, P6307
Hancu, N. 270, 272 P6405, P6573 Hassell, M.E.C.J. P174, P1507
Handler, C. P5514 Harjola, V.P. P4457, P4748 Hasselwander, O. P1126
Handley, A.J. 2062 Harkema, J.R. P653 Hassine, M. P533, P2615, P5356
Handrock, R. P5685 Harkess, M. P2819 Hassoba, H.M. P2628
Handschuh, S. P3460 Harkins, V. P5688 Hastrup Svendsen, J. P166, P622
Handschumacher, M.D. P5412 Harmos, S. 6025 Hasun, M. P584
Hanif, H. P207 Harms, H.J. P178, P180 Hasvold, L.P. P2467, P3319, P3662
Hanna, M. 1973, 1974, 2032 Harms, M.P.M. P1373 Hasvold, P. 4972
Hanninen, H. 4911 Harnath, A. P3652 Hatakeyama, K. P2380
Hannu, H.K. P2819 Harnek, J. P177 Hatakeyama, S. P4694
Hanon, C. P2690 Haroon, N. P4653 Hatala, R. 92, 365
Hanon, O. 5129 Harrington, R.A. P1497, 4002, P4105, 4979, Hatano, M. P4567, P4640, P6512
Hanratty, C. P4701 P6439 Hatazawa, J. P3544
Hansen, C.M. P4072, P4435 Hart, C. P5019 Hatem, E. P3620
Hansen, D.R.M.J. 2918 Hart, E.C. P2840, P4339 Hatem, S. 30, 193, 375
Hansen, J. P460 Hartikainen, J. P4061, 5052 Hatem, S. 3221, P6178
Hansen, J.H. 4959 Hartley, A. P1411 Hattge Jr, S.P. P732
Hansen, L. P673, P1606, P1608, P5485 Hartman, E. P3733 Hattori, H. P1637
Hansen, M.L. 951, 1832, 1972, 3277, P6235 Hartmann, G. P664 Hatziefthimiou, A. P5309
Hansen, P. P5978 Hartmann, N. P5950, P6154 Hatzis, G. P644, P660, P1458, P3115, P4088,
Hansen, P.B. P519, P2395 Hartmann, S. P3329 P5368
Hansen, P.R. P2120, 3942, 6651 Hartwig, V. P4669 Haude, M. 38, 357
Hansen, P.S. 957 Hartyanszky, I. P5449 Haude, M. 44
Hansen, P.W. P6213 Haruna, T. P626 Haudek, S.B. 1210
Hansen, S.I. P593 Harunari, T. P4466 Hauer, R.N. 5809
Hansen, S.M. P4072 Harvey, A. P2583 Haugaa, K.H. 21, 207
Hansen, T.B. 22 Hasagawa, K. P767 Haugaa, K.H. P416, P418, P460, 1325,
Hansen, T.B. P775, 2939 Hasbak, P. 4289 P1397, P3497, 4959, 4960, 5150, 5151,
Hansen, T.M. P4436 Hasdai, D. P1652, P2474, 3194 5152, 5154, 5156, P6307
Hansky, B. 83 Hase, M. 6628 Haugaard, S.B. P6448
Hanson, B. P415, P1432 Hasebe, N. P2449, P6473
451
Chairpersons & Judges / Speakers & Discussants / Authors Hau – Heu
Haugan, K. P622 Heckmann, M. P3537 Henriksson, M. P3662

Haun, C. P4605 Heckmann, M.B. 3066 Henriques, E. P4621, P4625, P4645, P5962
Haunsoe, S. 6076 Hecksteden, A. P2370 Henriques, J. P177
Haupt, L. P3552 Hedberg, P.O. P753 Henriques, J.P.S. 364
Hauptmann, F. P4986 Heddle, W. P3630 Henriques-Coelho, T. P2372
Hauptmann, K.E. P837 Hedman, M. P3099 Henry, R.M. P4615
Hausding, M. P667 Hedstrom, M. P2659 Henry, T. P3717
Hausenloy, D.J. 83 Hee, L. P2516, 5804 Hensey, M. P625
Hausenloy, D.J. 3844, P4529, 4791, 6050 Heeger, C.H. P3733 Henzel, J. P4721
Hausleiter, J. 2099, P3568, P4479, P5001 Heg, D. 362, P3448, 6020, P6246 Heo, J.H. P2414, P5336, P5363, P6288
Haussig, S. P683, P1600, 2319, 5788 Hegbom, K. 2943 Her, S.H. P2848
Hautala, A.J. P2708 Heger, L. P6339 Herasevich, V. P3324, 5806
Hauw-Berlemont, C.H.B. 5089 Heggermont, W. P1765, P6178 Herbert, M. P5642
Haverich, A. P2623 Hehrlein, C. P6339 Herdman, L. 1834, P2595, P5000, P5416
Haverkamp, W. P1093, P3079, P3428, Heiberg, E. P507, P2665, 4057, P4755 Herijgers, P. P1111
P4385, 5206, 5208, 6108 Heidbuchel, H. 194, 317 Herlitz, J. P3435
Havndrup, O. P6399 Heidbuchel, H. 1245, 1895, 1898, P2683, Herman, D. P4364
Havranek, S. P3423, P3424, P5534 3893, P5507, 6104 Hermann, A. P6268
Hawkey, S. P5321 Heidenreich, P. 360 Hermann, T.S. P1571
Hawkins, N.M. P463, 1977 Heidrich, F.M. P3570 Hermans, K.C.M. P3745
Hawkins, P.N. P5546 Heine, T. 4858 Hermans, M. P560, P5565
Hawranek, M. P541, P566, P576, P585, Heineke, J. P4082 Hermans, M.P. P1675
P587, P589, P2506, P2789, P5646, P6587 Heinemann, D. P2387 Hermes, B.M. P3643
Hawryluk, L. P1524 Heinemann, S. P550 Hermida, J.S. P2553
Hay, E. P4999 Heinig, M. P3538 Hermiller, J.B. 2913
Hayakawa, S. P433 Heinsen, L. P3325 Hernandez, E. P4719
Hayakawa, Y. P905 Heintzelmann, S.B. P1503 Hernandez, F. 366, P2732, P4712
Hayama, Y. P5312 Heinz, G. P3454, 5092 Hernandez, J. P467, P476, P1434
Hayama, Y.H. P4603 Heinzel, F.R. 2206, P3769, P5319 Hernandez, J.M. P5248
Hayashi, A. P2694 Heiss, C. P1372, P2134, P2578, P6142, Hernandez, V. P5686
Hayashi, F. P4112, P4409 P6503 Hernandez Hernandez, F. P4710, P6426
Hayashi, H. P202, P1386, P3111, P5315 Heissenhuber, F. P4080 Hernandez Leiva, E. P3453
Hayashi, K. P693, P698, P1420, P1437 Helantera, I. 4911 Hernandez Mejia, B. P641
Hayashi, M. P513, 2337, 2338, P3701, Helbing, T. 1956 Hernandez Ojeda, J. P472
P5599, P6128 Helbing, W.A. P707, P2656 Hernandez-Enriquez, M. 6018
Hayashi, T. P2599 Held, C. 1973, 4203, 4975, P5961, P6228, Hernandez-Garcia, J.M. P4584, P5337,
Hayashi, Y. P3327, P4506, P4535, P4537, P6290, P6439 5790, P6557
P4733 Helft, G. 3159 Hernandez-Madrid, A. P508, 3173
Hayashida, A. P2769 Hell, M. P623, P4510 Hero, C. P1730, P3343
Hayashida, K. 6629 Hellberg, S.E. P425 Herold, J. P2592
Hayek, S. P4301, P5383 Hellenius, M.-L. 6646 Herouvim, E. P4331
Hayes, C. P772 Hellenkamp, K. 4178 Herraiz, A. P1425
Hayes, S. P623 Hellkamp, A.S. 2031, P4398, P6210 Herrera, R. P6111
Hayiroglu, M.I. P5275 Hellmich, M. P3622 Herrera-Alarcon, V. P641
Haynes, R. P5575 Hellstrom Angerud, K. P552 Herrington, W. P6592
Hayward, C. P2819, P3737, P6157 Hellwig, D. P3735 Herrmann, J.H. P4444
Hayward, C.S. P4725 Helm, P. P721, P724, 2926 Herrmann, S. P694, P2639, P3569
Hayward, M. P415 Helmark, C. P775 Herrmann-Lingen, C. P5690
Hazaimeh, L. P4475 Helqvist, S. P822, P2827, 4001 Hersi, A. 1006
Hazarapetyan, L.G. P5330 Helve, S. 4911 Hersunarti, N. P6385
Hazelwood, T. 3162 Hemingway, H. P777, P1102, P4994, 5182 Hertzberg-Bigelman, E. P5463
Hazen, S. 6029 Hemradj, V. P559, P4453 Herum, K.M. P6341
Hazirolan, T. 6074 Henaine, R. P4595 Hervas, A. P1517
Hazukova, R. P4441 Henderson, D.J. 151 Herzog, B.A. P611
He, B. 1838, P3465 Henderson, R.A. 4, 5109, 6015 Hescheler, J. 4191
He, C. P1467 Hendgen-Cotta, U. 1082 Heseltine, P. 129
He, J. 4181 Hendgen-Cotta, U.B. P2134 Heseltine, P. 1920, 1923
He, P.K. P6180 Hendrie, D. P3640 Hess, E.P. 4237
He, Y.-M. P643 Hendriks, J.M.L. P5277 Hess, K.A. 2226
He, Y. P697, P1645, P1648, P2583, P6496 Hendry, C. P2727, P2736 Hess, S. P845, 6635
He, Y.A.H. P5237 Henein, M. P2682, P4741, P6302 Hesselink, T. P4394, P4396
He, Y.H. P710 Henein, M.Y. P4465, P4727, P5621, P6585 Hesselstrand, R. P1754
He, Z.Q. P2493 Heng, E.L. P2142 Hessling, G. 1010, 1011, P3405, P4365
Heagerty, A.M. 319 Hengel, C. P2784 Hessling, G.H. P5295
Heagerty, A.M. 6063 Hengstenberg, C. P1631, P4092 Hetzel, G.R. P2134
Heald, A.H. P3683 Heninburg, A.M.H. P2577 Heusch, G. 135
Healey, J. P2425 Hennigs, J.K. P2604 Heusch, G. P3445, 4218, 6047
Healey, J.S. P1389, P2405 Henning, B.J. P3563 Heuschen, C.B.B.C.M. P716
Heaney, D. 2917 Henning, R. P6186, P6189 Heuser, A. P4084
Heck, P. 22 Henriksen, F.L. 5884 Heuser, R. P2577
Heck, R. P2538, 3167 Henriksen, P.A. P2127 Heuten, H. P650
452
Chairpersons & Judges / Speakers & Discussants / Authors Hey – Hol
Heymans, S. 5912 Hirano, K. P1132, P1133, P2733, P3706, Hodge, S. P2727, P2736, 2907, 5817
Heywood, J.T. P5976 P4492, P4718, P6145, P6519 Hodges, G. P4094
Hiasa, G. P536, P2804, P5029 Hirano, K.H. P1137 Hodkinson, E.C. P477
Hiatt, W.R.H. P5279 Hirano, M. P790 Hodorogea, A.S. 5080, P6280
Hibender, S. P5239 Hirano, T. 3169, P4677 Hodwin, B. 1836
Hibi, K. P885, P1745, P4674, P6411 Hirao, K. P3360, P5323 Hodzic, A. 2283, P5446
Hickey, A. P3349 Hirao, T. P3360 Hoebers, L. P177
Hida, S. P184, P603 Hiraoka, K. P4336 Hoefer, I. 76, 136, 157, 266, 321
Hidalgo, A. P2130, P4524 Hiraoka, M. P5925 Hoefer, I. 1956, 5110
Hidden Lucet, F. 267 Hirashiki, A. P2648, P2650, P2684 Hoefer, I.E. P2783, 3950, P6253
Hidden Lucet, F. 4227 Hirata, A. P1438 Hoefsten, D.E. 4001
Hidden-Lucet, F. P714, P3588 Hirata, K.-I. P6311 Hoegh, V. P5281
Hiebert, B. 4194 Hirata, K. P583, P1728, P1736, P4551, P5527 Hoeher, M. P4340
Higaki, A. P536, P2804, P5029 Hirata, K.I. P1363 Hoejberg, S. P622
Higaki, J. 3172, P4354, P4507 Hirata, M. P1579 Hoek, G. P3336
Higashi, K. P5002, P5444, P5533 Hirata, R.D.C. P1579 Hoeksema, M.A. P6129
Higashi, Y. P1760 Hirata, Y. P431 Hoekstra, T. P1805
Higashikuni, Y. P431 Hiraya, D. 4052 Hoell, A. P3769
Higashimori, A. P1134 Hirayama, A. P1127, P1383, P6225, P6597 Hoellriegel, R. P683, 2319, 5788
Higashiyama, A. P742 Hirayama, K. P5939 Hoelschermann, F. 6017
Higgins, M.K. P441 Hiremath, S. 271 Hoen, B. 202
Higuchi, K. P839 Hirjikaka, S. P760 Hoendermis, E.S. P437, P2661
Higuchi, S. P5564 Hiro, T. P6225 Hoeper, M.M. 2175, P2365, P2367, 3831,
Higuchi, T. P605 Hiroe, M. P3083 3910, 4181, P5520
Higuchi, Y. P6225 Hirohata, A. P2769 Hoerer, J. 2076
Hiippala, A. P1649 Hiroi, Y. P199, P5515 Hoerstrup, S. P3577
Hijazi, Z. 1974, 2032, 4203 Hiroki, S. P6335 Hoes, A. P2724
Hiki, M. P2799 Hiromasa, T. P2747, P2749, P3439, P3440 Hoes, A.W. 5843
Hikita, H. P1735, P1753, P4514, 6618 Hirosa, T. P3777 Hof, A.W.J. P4071
Hilbert, S. P3381 Hirose, K. P184 Hof Van ’T, A.W.J. P4453
Hildebrandt, H. P3445 Hirose, M. P3748 Hofbauer, S.L. P6255
Hildebrandt, P. P5033 Hirose, T. P2830 Hofer, S. P1663, P4324
Hildick-Smith, D.H.S. 4269 Hirota, S. P1743 Hoffelner, L. 6019
Hilfiker-Kleiner, D. 72, 303 Hirota, T. P1619, P4592 Hoffman, G. P2585
Hilfiker-Kleiner, D. P884, P2359, P3610, Hirota, Y. 3306 Hoffman, P. P471, P6580
4190, 6095 Hirowatari, Y. P1707 Hoffmann, B. 5923
Hilgendorf, I. 1956 Hirsch, A. P174, P1101, P1507 Hoffmann, B.A. P3393, P3414
Hilker, M. P4092 Hisatome, I. P1426 Hoffmann, B.H. P4362
Hill, S. P3093, P6271 Hisazaki, K. P3400, P3422 Hoffmann, E. 186
Hill, T.J. P3655 Hishikari, K. P1735, P1753, P4514, 6618 Hoffmann, E. 112, P3385
Hillege, H. 3919 Hitaka, Y. P1452 Hoffmann, R. 105, 3175, P3725, P4449
Hillege, H.L. P1805 Hitrata, K. 3945 Hofland, J. P3388
Hillinger, P. P524, P529, P595, P1097, Hittinger, L. P6148 Hofma, S. P2730
P1099, P1100, P1103, P2461, P3481 Hittinger, L.H. P843 Hofman, A. 276, P741, P747, P749, P1391,
Himbert, D. P3731, 4268, P5014, 5217, Hjalmarson, A. P895 P2594, P4609, P5021, P5573, P6444
5218, P6391 Hjalmarsson, C. P4782 Hofman-Bang, C. P2787
Himeno, H. P2814 Hjelm, H. P2467, P3662 Hofmann-Bowman, M. P1782
Himi, T. P4353, P4384 Hjelmfors, L. P443 Hofner, B. 959
Himmelmann, A. P172, 3030, 4975 Hladunewich, M. P1576 Hogan, J. 5804
Himmrich, E. P468, P3359 Hlatky, M. P6470 Hogan, L. P4704
Himpfen, H. P2357 Hlawaty, M. P720 Hogg, P. 53
Hin, H. P4613 Hlinomaz, O. P4705 Hohl, M. P873, 6067
Hindricks, G. 90, 246 Ho, H.H. P831 Hohlfeld, T. P5986
Hindricks, G. 100, 96, 98, 247, P516, 957, Ho, K.L. P3413 Hohnloser, S.H. 186, 205
1011, 1013, 1015, 2173, 2189, P2829, Ho, L.A.M. 160, P3480 Hohnloser, S.H. P459, P1389, 1974, 2032,
P3381, P3392, P3415, 3900, 3903, 4858, Ho, S.Y. 325 2869, 3145, 3887, P6203
4964, P6209, P6509 Ho, S.Y. P2142, 3289 Hoijer, J. P5324
Hindsoe, L. P6324 Hoashi, T. 2932 Hoiseth, A.D. P2383
Hingorani, A. P658 Hobbs, R. P606 Hojen, A.A. P1666
Hinkel, R. P3097 Hobohm, L. 4177 Hojs, R. P3433
Hinojar, R. P1396, P1554, P3531 Hochadel, M. P837, 1203, P1471, P3120, Hokimoto, S. P811, P1339
Hinrichs, S. P2164 3309, P3385, P4989 Holbova, R. P3548
Hioki, H. P4467, P5382, P6577 Hochhauser, E. P3555 Holda, J.P. P187, P188, P190
Hippisley-Cox, J. 266 Hochholzer, W. P809, P1493 Holda, M.K. P187, P188, P190
Hirakata, S. 2337, 2338, P6128 Hochleitner, M. 966 Holemans, P. P6178
Hirakata, V. P5559 Hochman, J.S. 155 Holfeld, J. P2596, 6089, 6091
Hirakawa, A.H. 5081 Hod, H. P1565 Hollander, M. P6261
Hiramatsu, Y. 6105 Hodakovska, E.V. P3762 Hollander, M.R. P553, P2497, P2512
Hiramine, K. P5533 Hodatsu, A. P693, P698 Hollema, N. P5035
Hiramori, S. P1136, P5965 Hodge, D.O. P221 Hollenbach, S.J. P3088
Hiramoto, T. P6117
453
Chairpersons & Judges / Speakers & Discussants / Authors Hol – Hui
Hollingsworth, K.G. 2933 Horn, J. P3470 Hsieh, M.-Y. P4684

Holloway, C.J. P4469 Horn, P. P1372, P2578, P5547 Hsin, H.T. P773
Holm, J. 82 Horne, R. P2820 Hsiung, C. P5554
Holm, N.R. P1546 Horowitz, J.D. P5435, P6565 Hsu, C.-Y. 1976, P2131
Holm, P.J. 4955, 4956 Horrevoets, A.J.G. P6261 Hsu, C.C. P5554
Holmboe, S. P5509 Horrigan, M. P894 Hsu, C.Y. P800
Holmen, J.H. P4444 Horstkotte, D. P465, P1618, P2149, P2638, Hsu, J.H. P3751
Holmen, O.L. P3674 P2797, P3526, P4383, P5661, P6289, 6636 Hsu, L.Y. P1520
Holmes, A.P. P5949, P6352, P6357 Hortom, R. P3417 Hsu, P.-F. P5707
Holmes, D. P207 Horton, J. P1761 Hsu, P.F. P219
Holmes, M.V. P1702 Horton, R. P3396 Hsu, W.H. P3469
Holmgren, A. P6302 Horvath, T. 2234, P4630, P6401 Htun, P. P671, P674, P680
Holmqvist, L. P4782 Hosako, S. P2599 Hu, B. P2555, P5414, P5417
Holmstrom, M. P1523 Hosbond, S. P4431, P4618, P5713 Hu, D. 69, P3567
Holmvang, L. P554, P822, 3022, 4001 Hoshen, M. P1652, P5276, P5318 Hu, F.B. 4200, 4201
Holopherne-Doran, D. P3559 Hoshi, T. P1371, 4052, P6244 Hu, J.Q. P4369
Holst, A.G. 6076 Hoshide, S. P2166, P2167, P3352 Hu, K. P694, P2639, P3569
Holt, J. P774 Hoshina, K. P1582 Hu, S.S. P1643, P5253
Holtermann, A. P4636 Hoshino, K. 3254 Hu, T. P4984
Holy, E.W. P1614, 6019 Hoshino, M. P420, P6238 Hu, W.S. P2668
Holz, L. P3595 Hoshizaki, H. P2533 Hu, X. P6186, P6189
Holzamer, A. P4092 Hoskote, A. P2139 Hu, Y. P896, P4680
Holzhauser, L. P4083, P6348 Hosoda, J. P515 Hua, W. P470
Holzhey, D. P683, P1600, 1983, 2319, 5788 Hosogi, S. P4309 Huang, C.C. P800
Homma, S. 2210, 2323 Hosogi, Y. P2551 Huang, C.H. P3436
Honda, S. P6545 Hosogoe, N. P6522 Huang, F.Q. P1763, P4747, P5411
Honda, Y. P3696, P3707, P4763, P4766, Hossain, O.F.S. 2343 Huang, J. P2793
P6536 Hossein-Foucher, C. P608 Huang, J.W. P2116
Honegger, U. P2695, P4612, P5397 Hostalek, U. P1823 Huang, L. 6653
Hong, B.K. P1638, P3687 Hotta, D. P6530 Huang, L.C. P5394
Hong, G.R. P2544, P3585, P5296, P6362 Hou, J.Y. P888, 2227, P3534, P4076, P5432, Huang, P.-H. 1976, P2131, P4684
Hong, K. P6340 P6294 Huang, P.S. P800
Hong, M.K. 6624 Hou, X. P1412, P1465, P1473 Huang, R. P6472
Hong, S.P. P746 Hou, Z.X. P2712 Huang, S.H. P6180
Hong, T.J. 371, P1511, P2726, P4424, Houben, R. P5302 Huang, W.C. P3565
P6431, P6511 Houck, C.A. P715 Huang, X. P6423
Hong, T.J.H. P1724 Houghton, R.J. P3635 Huang, Y. 4181, P4369, 5847, P6556
Hong, Y.-J. P1495, P1502, P2735 Houle, H. P5428 Huang, Z.G. P2493
Hong, Y.J. P824, P4471 Houmsse, M. 5921 Huang, Z.W. P6130
Hongisto, M. P6573 Hounslow, N. P5983, P5985 Huart, V. 1984
Honickel, M. 4978 Houssaini, A. P2360, P4525, P5473, P5557 Hubauer, U. 2230
Honma, M. P1651 Houtman, M.J.C. P6159 Huber, C. 6020
Honma, Y. 6629 Houyel, L. P1650, 4038 Huber, C.H. 1030, 1032
Hood, C. P4405 Hovasse, T. P1615, P5010, P5489 Huber, K. 38, 263
Hood, M. 2988 Hovath-Puho, E. 1842 Huber, K. 122, 125, P572, 2295, P2488,
Hood, S. P1522, 4024, 4293 Hovdenes, J. P3470 3280, P5398, P6255, P6547, 6664
Hoog, M. P4397 Hove, J.D. P6324 Huber-Schoenauer, U. P4644
Hoogstra-Berends, F. P6186, P6189 Hove-Madsen, L. P1425 Hubert, S. P1611, P3105, P6383
Hookana, E. 1322 Hovinga - De Boer, M.C. P183 Hubner, N. P1562, P3538
Hope, S.A. P4777 Hovingh, G.K. P1677, P2146, P5983, P5985, Huche Nielsen, L. P5359, P6455
Hopf, K. P4066 P6481 Hucker, W.J. P5924
Hopkins, J. P2770 Howard, L. P2646, 2875, 4183, P5954 Huczek, Z. P1616, P4572
Hopkins, S. P5949 Howard, L.S. P5511, P5955 Hudsmith, L.E. P3613
Hopp, E. P2621, P3589, 4960 Howe, A. P3097 Hudzik, B. P699, P6587
Hoppe, U.C. P3558 Howlett, S. P5567 Hue, L. P2363
Horack, M. 69, P1654, P1680, P1681 Hoye, A. P1491 Hueb, W.A. P6267
Horcsik, D. 2105 Hoylaerts, M. P1114, P5470 Huelsmann, M. 4278, P6547, 6644
Horcsik, D.V. 2234 Hoyme, M. P3500 Huemer, M. P1093, P3079, P4385
Hori, Y. P2409 Hozawa, A. P6597 Huerta, A. P1778
Horibe, H. P5590, P5593, P5610, P6172 Hozawa, K. 4286 Huet, O. P649
Horie, M. P1386, P2491, P6350, P6351 Hozumi, T. P583, P1728, P1736, 3945, 6623 Hufthammer, K.O. P4566
Horigome, H. 1327, P6299 Hraska, V. P4605 Hugelshofer, S. P535, P5936
Horiguchi, A. P505 Hricak, V. P1797 Hugenholtz, P.G. 265
Horiguchi, S. P6117 Hristov, G. P3605 Hughes, A. P6433
Horimatsu, T. P1739, P2775 Hryniewiecki, T. P5011 Hughes, A.D. 1849, P2709, P4777
Horimatsu, T.H. P1712 Hrynkiewicz-Szymanska, A. P5280 Hughes, G. P1142, P1775
Horinaka, S. P6276 Hsia, C. P652 Hughes, K. P2373
Horio, Y. P3782 Hsia, T.Y. P2141 Hughes, S. P496
Horiuchi, Y. P815 Hsiao, L.C. P5317 Huguet, F. P3096
Horke, S. P2602 Hsiao, Y.W. 3949 Hui, R.T. P2588
Horman, S. 974, P2363 Hsieh, I.C. P5394 Huikuri, H. P3098
454
Chairpersons & Judges / Speakers & Discussants / Authors Hui – Ima
Huikuri, H.V. 1322, P1376, P2708, P3125, Hwang, J.-Y. P1780 Iida, K. P6225
4908, P6221 Hwang, J.K. P2495, P4472 Iida, M.I. 5081
Huisman, A. P6253 Hwang, J.M. P6463 Iida, N. P4116
Huisman, M.C. P180 Hwang, J.W. P4559 Iida, O. P1135, P2404, 3170, P4498, P5326,
Huisman, M.V. 931, P1488, P1516, P3621, Hwang, J.Y. P863 P6534
4175, 4179, P4316 Hwang, K. P1825 Iida, O.I. P1137
Hullin, R. P861 Hwang, K.K. P2816 Iijima, K. P6156
Hulsbergen-Zwarts, M.S. 2934 Hwang, K.W. P5630, P6463 Iijima, R. P3764, P4409, P5396
Humbert, M. 247 Hwang, M. P6175 Iijima, T. P6353
Humbert, M. 923, 2174, P3623, P4548, Hwang, S.-J. P1780 Iitsuka, K. P1426
P5446 Hyafil, F. 2058 Ijiri, Y. P2599
Huml, M. P1588 Hyde, E. P518 Ijkema, R. P5591
Hummel, J.D. 5921 Hylek, E. 140, 245 Ijsselmuiden, A. P2743
Hung, C.-L. P888, P4076 Hylek, E. 3889, P5967 Ijyuin, S. P5533
Hung, C.L. 2227, P3534, P5432, P6294 Hyler, S. P3462 Ikai, Y. P2446
Hung, H.-F. P5664 Hynes, B. P4068 Ikama, M.S. P3134
Hung, J. 38 Hyodo, E. P3089 Ikari, Y. 259
Hung, J. 135 Hyodo, K. 6105 Ikari, Y. P6281
Hung, J.W. P5412 Hyodo, M. P2747, P2749, P3701, P3702 Ike, A. P6533
Hung, S. P6342 Hyodo, Y. P2622, P2774, P5402, P6525, Ikebe, Y. P2415
Hung, T.C. P888, 2227, P3534, P5432, P6532 Ikeda, K. P4604
P6294 Hytoenen, J. P4084 Ikeda, M. P1694
Hung, Y.J. P1819 Iacobazzi, D. P1557, P3559 Ikeda, N. P199, P5515, P5656
Hunger, T. P464 Iacono, C. P4683 Ikeda, S. P6237, P6272
Hunink, M.G.M. P4623 Iacoviello, M. 5810 Ikeda, T. P1482, P3549, P4512, P6218
Hunt, J. 20 Iakobishvili, Z. P1652, P2474 Ikeda, U. 961, P4467, P5382, P6222, P6577
Huntgeburth, M. P1104 Iakovou, I. P582 Ikeda, Y. P3742
Huntjens, P.R. P5221 Iancovici, S. P5943 Ikegami, M. P2353
Huntley, B.K. 2336 Iancu, O.C. P6469 Ikegami, R. P4535
Hunuzelmann, N. P3622 Iannaccone, A. P4502, 4868 Ikegami, Y. P4361
Hunzelmann, N. P687 Iannone, A. 1202, P2523, P4412 Ikehara, N. P2707
Huo, Y. 200 Ibanez, B. 6085, P6392 Ikehara, S. P2686
Huo, Y. P779, P3389, P3409, P4122, P4341, Ibarra, A. P1126 Ikeno, F. P2124
P4359, P4983 Ibe, T. P5656 Ikenouchi, T. P4783
Huo Yung Kai, S. P1358, 2023 Iborra Cuevas, C. P3486 Ikewaki, K. P2720
Hupfer, S. P5685 Ibrahim, I. P5701 Ikkersheim, D.E. P5970
Hur, S.H. P445, P3732, P4474 Ibrahim, K. 1989, 4973 Ikonomidis, I. P639, P654, P2459, P2499,
Hurel, S. P658 Ibrahim, Q. 6648 P2666, 3174, 3262, 3264, 3266, 3303,
Hurst, N. P2645 Ibrahim, R. P717 P3513, P5347, P5418, P5437, P5705,
Hurt, C. P6507 Ibrahimi, P. P4727, P5621, P6585 P6265, P6504, P6566
Husada, W. P3097 Ibrahimov, F. 94 Ikram, M.A. 276, P741, P6444
Husche, C. P1698 Ichibori, Y. P1793 Ikuno, T. P3549
Huscher, D. P2367 Ichihashi, K. P6505 Ikuo, Y. P6244
Husebye, T. P3489 Ichikawa, H. 2932 Ilardi, F. P858, P2121
Husemoen, L.L. P2170 Ichikawa, K. P4783 Ilic, S. P2713, P3634, P3661, P4423, P4614
Husic, M. P3325 Ichikawa, M. P1386, P1742 Iliceto, S. P690, P702, P1528, P1534, P2539,
Hussain, W. P3395, P4390 Ichikawa, S. P801 P2541, P2546, P2550, P2559, P2560,
Hussaini, A. P625 Ichikawa, Y. P4774 P3532, P3571, P4460, P5484
Husse, B. P1349 Ichiki, H. P4065, P4375 Iliesiu, A.M. 5080
Husse, B.E. P4737 Ichiki, T. 2336 Iliodromitis, E. P2499
Hussein, G. P2542 Idris, N.S. 3951, P6396 Iliodromitis, E.K. P3082, P3084, P3441,
Hussein, Y. P2542 Iemmi, A. P3451 P5624
Husser, D. P6209 Iernici, A. P2454 Iliopoulos, D.C. P672
Husser, O. P4092 Iesaka, Y. P4511, P5323 Iliou, M.-C. P2675
Husted, S. 325, 3030, 3277, 4975 Ifrim, R. P1544 Illindala, U. P2124
Hutchings, D.C. P3683 Iftikhar, S. P6472 Ilnytska, M. P1770, 6046
Huth Ruwald, A.C. P462, P474 Igarashi, M. P1399, P4402 Im, M.S. P6563
Huttin, O. P557, P676, P3530, P5513 Igarashi, T. P801, P1422, P6361 Im, S.I. P2414
Huttunen, M. P6405 Igarashi, Y. P184 Im, Y.H. P1809
Hutyra, M. P540 Iglesias, D. P2466 Imaeva, A. P6251
Huusko, J. P3099, P5946 Iglesias, J.A. 953, P1440 Imahashi, M. P2449
Huynh, Q. 1844, P5672 Iglesias, J.F. P535, 965, P5936 Imaizumi, S. P764, P1452, 2059, P4655
Hveem, K. P3674 Iglesias Alvarez, D. P2482 Imamura, H. P3482
Hwan, J. 1987 Iglesias Garriz, I. P5474 Imamura, T. P4567, P4640, P6512
Hwang, B.H. P666 Iglesias-Alvarez, D. P3472 Imanaka, K. P1743, P3083
Hwang, C. P783 Igual, B. P1690, P4775 Imanaka, T. P1739, P2775
Hwang, D. P806 Iguchi, M. P767, P4121, P4642, P5602, Imanaka, T.I. P1712
Hwang, G.S. P1721 P5698, P6553 Imanalieva, G. P193
Hwang, H.-J. P802 Ihlemann, N. P1571, P3496 Imanishi, T. P2487
Hwang, J.-W. P1757, P3109 Ihm, S.H. P666, P2848 Imazio, M. P192, P4586, P4588, 5189, 5770,
Ihori, H. P5227 5990
455
Chairpersons & Judges / Speakers & Discussants / Authors Ima – Iwa
Imazu, M. P5460 Isaksen, K. P602, P6477 Ispas, A. P796, P5932

Imbert-Bismut, F. P1631 Isaksson, R.M. P552 Ispas, A.F. 3933
Imhof, K. P2685 Isaza Restrepo, D. P3453 Isper, L. P1787, P2822
Imperiale, A. P845 Isbilen, B. P3450 Israel, A. 4204
Inaba, S. P3360 Isbister, J. P793 Israel, C.W. 909, 3236, 3238, 3242
Inaba, T. P6512 Isekame, Y. P3499, P6296 Issa, V.S. P1787, P2822
Inada, T. P4112 Isenovic, E. P5663 Issa, Z. P2663, P6486
Inagaki, J. P734 Isermann, B. P2592 Isshiki, T. P515
Inagaki, M. P801, P5453 Ishak, K.J. P4397 Itaya, H. P2802
Inagaki, Y. P1637 Ishak, M. 1857, P4071 Itchhaporria, D. P2762
Inagawa, K. P4361 Ishaq, L. P1413 Ito, E. P3544
Inagawa, T. P3748 Ishibashi, K. P417, P4377 Ito, H. P505, P907, P1386, P1403, P1776,
Inami, T. P5564 Ishibashi, S. P3638, P5982 P2537, P2605, P3529, P3607, P4112,
Inamo, A. P1544 Ishibashi, Y. 369, 2909 P4483, P4486, P4495, P4503, P4547,
Inamo, J. P1544, P1670 Ishida, A. P5262 P4728, P5238, P5506, P6304, P6318,
Inazu, A. P1655, P1661, P1699, P1701, Ishida, K. P3400 P6335, P6549
P1704, P2150 Ishida, M. P1535, P2603, P4774, P6256 Ito, H.I. P3780, P4660
Indelicato, S. P3785 Ishida, T. P2603 Ito, K. P790, P2353, P4753
Indolfi, C. P2764, P3560, 5904 Ishigami, M. P3549 Ito, M. P433, P1535, 2339, 3254, P4114,
Indriani, S. P3467 Ishigami, S. P435, P1817, 4058, P6308 P4774
Infante De Oliveira, E. P2552 Ishigami, T.I. P2509 Ito, M.I. P828
Inglis, S.C. P783, P5669 Ishiguro, H. 4286, P5564 Ito, N. P3434, 6629
Ingwersen, G. P775 Ishiguro, M. P2540, P2830, P4779, P5428 Ito, S. 2337, 2338, 4237, P5460, P6128
Inigo-Garcia, L. P601, P2381, P2777, P3657, Ishihara, M. P1739, P1743, P2775 Ito, Y. P1132, P1133, P2733, P3706, P4402,
P5611, P6526 Ishihara, M.I. P1712 P4492, P4718, P6145, P6519
Iniguez Romo, A. P2751 Ishihara, T. 3170, P5326, P6534 Itoh, C. P2694
Innocente, R. P871 Ishii, D. P5599 Itoh, H. P6137
Innocenti, E. P6316 Ishii, H. P726, P788, P1672, 2228, P3753, Itoh, T. 338, P6256
Ino, Y. P583, P1728, P1736, 3945, 6623 P4109, P5333, P5380, P5966, P5969, Itonaga, T. P6143
Inohara, T. P1801, P3477 6086, P6494, P6502 Itou, M. 6634
Inoko, M. P626, P2818, P6292 Ishii, J. P6318 Itti, E.I. P843
Inokuchi, Y. P1570 Ishii, M. P767, P1339, P3690, P4121, P4635, Iudice, G. P1366
Inomata, T. P3742 P4642, P5602, P6248, P6553 Iudina, Y. P900
Inoue, H. P890, P1108, P5025, P5227 Ishikawa, M. P6276 Iung, B. 1058, 2103, 3288, P3731, 4831,
Inoue, K. P1570, 3172, P3410, P4354, Ishikawa, S. P6522 P5014, 5217, 5218, 5988, P6391
P4507, 5087, P6117 Ishikawa, T. P515 Iuti, K. P5025
Inoue, M. P2814 Ishikawa, T.I. P2509 Ivanac Vranesic, I. P5278
Inoue, T. P6531 Ishikawa, Y. P6256 Ivanes, F. P5392, P6214
Inoue, Y. P6143 Ishimi, M. P1378, P4760, P6558 Ivanitskiy, E.A. P3375
Insabato, L. 3943 Ishimitsu, T. P6276 Ivanov, V. P6527
Inserte, J. 1088 Ishimori, H. P1132, P1133, P2733, P3706, Ivanova, A.N. P2576, P5236
Inui, K. P1737 P6519 Ivanova, O. P3684, P6332
Inzucchi, S. 1871, 1873 Ishimoto, R. P5579 Ivanovic, B.I. P4778
Ioakeimidis, N. P204, 967, P1572, P2574, Ishimura, H. P603 Ivern Diaz, I. P1125
P2699, P3679, P3806, P4118, P5540, Ishimura, M. P1439, P1686, P1687, P2423 Iversen, K. P593, P5700, P6399
P5541, P5588, P5710, P6598 Ishimura, S. P1582 Iversen, M. P3624
Ioakimidis, N. P3116 Ishise, H. P5025 Ivynian, S.E. P783
Ioanes, D. P177 Ishiwata, S. P6404 Iwade, K. 6655
Ionov, M. P900 Ishizu, T. P3498, P4116, P6299 Iwagami, E. P6298
Ionova, J.I. P5362 Ishizue, N. P1422, P6361 Iwahashi, N. P885, P6411
Ioppolo, A. P634 Ishizuka, N. P3670 Iwai, R. P5004
Iori, M. P504 Isihara, T. P2404, P4498 Iwakami, N. 3305, P4761, P6541
Iorio, A. P5683, P6147, P6575 Isik, T. P1741, P3695 Iwakawa, N. P1744
Iorio, F. P5639 Iskratsch, T. P4738 Iwaki, T. P6432
Iozzo, P. P6336 Islam, M.M. 2343 Iwakura, K. P3407
Ipek, E.G. P3760 Islam, T. 1851 Iwama, A. 4189
Iqbal, A. P5024 Islas, F. P1107, P2548, P2549, P2557, P3520, Iwama, M. P2830
Iqbal, J.I. P5562 P6135 Iwama, T. P4466
Iqbal, M.B. P581, P2727, P2736, 2907, 5817 Ismaeel, H. P597 Iwamura, T. P3089
Iranian, M. P2828 Ismail, A. P3314 Iwao, H. P4523, P4549
Irazola, V.E. P2421 Ismail, N. P548 Iwaoka, M. P3638
Irazusta, J. P3632 Ismail, T.F. P3710, P6315 Iwasa, M. P905
Iriart, X. P3740, P4504 Isnard, R. P1631, P5654 Iwasaki, K. P6278
Irie, D. P5692 Iso, H. P2686 Iwasaki, Y. P513, P1134, P1378, P4760,
Irigoyen, M.C. P2679, P3648, P3658, 5082, Isobe, M. P420, P1362, P1711, P1715, P6558
P5450 P1720, P1735, P1749, P1753, P5556, Iwashima, I. P223
Iriki, Y. P4065, P4375 5885, 6618 Iwashima, Y. P5261
Irtyuga, O. P4555, P6151, P6501 Isoda, K. P3675, P3721, P4087, P4477 Iwata, A. P764, 2059, P4655
Irzyk, K. P5531, P6168 Isogai, T. P688, P1633, P5691 Iwata, H. P2591
Isagawa, T. P5003 Isotani, A. 350, P3572, 5216, P6369, P6370 Iwata, Y. P4689, P6531
Isaka, A. P6123 Iwatsuka, R. P420
456
Chairpersons & Judges / Speakers & Discussants / Authors Iwa – Jeo
Iwaya, S. P3330 Jalal, Z. P1639, P1640, P1650, P3740, Jarolim, P. P4762, P6562
Izaks, G.J. P5548 P4504, P4602 Jarosz, D. P757, P6224
Izar, M.C. P1673 Jalalian, R. P2828 Jaroszynski, A. P5653
Izawa, A. P6222, P6577 Jalique, J.R. P2635 Jarrah, M. P4475
Izgi, C. 202 James, S. 405, 1268, P5688 Jaruvongvanich, V. 2211
Izhaki, A. P4587 James, S.K. P172, 3030 Jaschke, W. P4491
Izumi, C. P1607, P2664, P5312 Jamieson, V. P5668 Jasek, E. P5465
Izumi, D. P6156 Jamil, H.A. P3767 Jashari, F. P5621
Izumi, T. P626, P3742 Jamme, M. P3105 Jashari, H. P6302
Izumi, Y. P1801, P2599, P3334, P4549, Janabi, H. P4475 Jasiewicz, M. P4731
P5488 Janas, J. P4649 Jaskowski, M. P2528
Izumo, M. P5372, P6125 Jang, E.J. P2756 Jaspard-Vinassa, B. P5462
Izzo, R. P4117, P4715, 4870, 4900, P5623 Jang, J.-S. P2478, P2498, P2737, P4700 Jaspers, L. P747, P4609
Jaarsma, T. 125, 190 Jang, J.K. P820 Jaspers Focks, J. P4678
Jaarsma, T. P443, P782, P1548, P1665, Jang, S.Y. P2462, P4724 Jassal, D. 4152
P1805, 3296, 3298, 3300 Jang, W.-J. P1757 Jastroch, M. P4084
Jabara, R. P1806 Jang, W. P4474 Jastrzebski, J. P5011
Jabbour, A. P2819, P4725 Jang, W.J. P2495 Jastrzebski, M. 4862, P6408
Jaber, S. 202 Jang, Y. P1657, P6590 Jastrzebski, T. P2527
Jaber, S. P5260 Jang, Y.S. P1684, 6624 Jatho, A. P3329
Jaber, W. 300 Jangaard, N. P4431, P4618, P5713 Jaukovic, M. 4288
Jaber, W. P597, P599, P606, 4817 Jangsangthong, W. P5456 Jauvert, G. 5917
Jablkowska-Gorecka, K. P2515 Jani, B. P1374, 6640 Javidgonbadi, D. P5498
Jablonowski, R. 4057 Janiak, P. 3310 Javorsky, G. P3349
Jabre, P. P4073 Janicijevic, A. P816 Jawad Ul Qamar, M. P2435
Jaccard, A. P5500 Janion, M. P448, P539, P1091, P2438, Jaworska, I. P5646
Jachczyk, J. P3652 P2445, P2789, 5147, P5937 Jazwiec, P. P3112
Jachec, W. P1091, P2438, P2445, 5147 Janion-Sadowska, A. P3121 Jeanjean, M. P1659
Jackson, D. P6378 Jankovic-Tomasevic, R. P5667 Jedrzejczyk-Patej, E. P3322, P4075, P4476,
Jackson, E.A. P3340 Jankowska, E. P3759 4861, P5303
Jackson, R.T. P4620 Jankowska, E.A. 36, 270, 373 Jeemon, P. 2024
Jackson, T. P518, P6314 Jankowska, E.A. 153, P841, P889, 1315, Jeevarethinam, A. P4484, P4485
Jackuliak, P. 1979 P1789, P2786, 3189, 3308, P3430, P3758, Jegaden, O. P5009
Jacob, S. P758 3934, P5655, P6569 Jeger, R. 3915
Jacobi, F. P761 Jankowski, P. P3671 Jeger, R.V. P5375
Jacobs, D. P739 Janosi, A. P5934 Jegier, A. P1693
Jacobs, N. P4085 Janotka, M. P169, P3476, P4387, P4720, Jehlicka, P. P1588, P3476, P5247
Jacobs, V. P3356, P4376 5886 Jeilan, M. P510
Jacobsen, P. P2609 Janowiec, K. P3495 Jelakovic, B. P4667
Jacobson, S.H. P4304 Jansa, P. P5534 Jelinek, M.V. P6456
Jacoby, C. 5899 Jansen, E.K. P4316 Jellinghaus, S. P662
Jacon, P. P1096, P4386 Jansen, F. 1952, 1959, 1960 Jemec, G.B.E. 6651
Jadczyk, T. P2837 Jansen, M. P2497 Jenei, C. P2545, P2546, P2550, P5484
Jae, S.Y. P2676, P2798 Jansen, R.W.M.M. 1324 Jenei, C.S. P5023
Jaeger, B. P2488 Jansen, S. P5580 Jenei, Z. P2396
Jaeger, C. 159 Jansen Of Lorkeers, S.J. P5447 Jenke, A. P4083, P5501, P6348
Jaeger, J. P896 Jansky, P. P1513 Jenkins, A. P1559, P6202, P6219
Jaeger-Beitinger, M. P5231 Jansova, H. 4859 Jenkins, D. 2893
Jaffe, M. 4885 Janssen, K. 6631 Jenkins, P.J. P4489
Jaffer, F.A. 6621 Janssen, M. P1547 Jenni, R. P6414
Jagdeep, S. P517, P4772 Janssens, L. P543 Jennings, C. P2724, P6459
Jager, P.L. P624, P633 Janssens, S. 265 Jennings, C.S. 125, 192
Jaguszewski, M. P6550 Janssens, S. P1111, P1114, P1345, P3554, Jennings, C.S. 230, 262, P439
Jaguszewski, M.J. 6012 P3752, 4151, 5831, 5833, 5835, P6260 Jensen, G.B. P6324
Jahangard-Rafsanjani, Z. P2715 Jansson, C. P782 Jensen, H.K. P460, 2269, 4959
Jahangiri, M. P4082 Jansweijer, J.A. 3070, 3073 Jensen, J.M. 2269, 3997, P4508, P4998,
Jahns, R. P605, P3599 Jantti, T. P880, P4768 P5234, P5359
Jahns, V. P605 Januszewicz, A. 4213 Jensen, J.S. P844, 957, 5803, P6538
Jain, A.K. P2840 Januzzi, J. 1314 Jensen, K. P2687
Jain, S. P4713 Januzzi, J.L. P1139 Jensen, L. P5978
Jais, P. P6115 Janzon, M. P551, P2467, P3662 Jensen, L.O. P1336, P1337, P1464, P1498,
Jais, X. P4548 Jaques E Costa, A.K. P6134 P1503, P2745, P5351
Jaiwongkam, T. P5539 Jara, R. P6412 Jensen, M. P2827
Jakim, P. P4735 Jarai, Z. P4665 Jensen, M.K. P6399
Jakl, M. P4707 Jarcho, J. 191 Jensen, S.E. P1464, P1498, 6627
Jakl, M.J. P4329 Jarcho, J. 5045 Jensen, S.M. P2403
Jakob, P. P2582, P3448 Jariwala, N. P1521, P3091 Jensen, U. P177
Jakobsen, C. 951 Jarkovsky, J. P1095, P4351, 6645 Jensenius, J.C. P6252
Jakobsen, M.U. P4322 Jarman, J. P4390, P5452 Jenuwein, T. P4539
Jakobsson, L. P2810 Jarman, J.W.E. P3395 Jeon, D.S. P5389
Jakowitsch, J. P5952 Jaroch, J. P5704 Jeon, D.W. P5510
457
Chairpersons & Judges / Speakers & Discussants / Authors Jeo – Jun
Jeon, E.S. P3768, P3778, P3787, P4110, Jin, C.N. P2612 Jones, G.T. P6380
P4726, P6578, P6579 Jin, D.K. P5395 Jones, J. P2718, P2724
Jeon, H.K. 4153 Jin, E.-S. P802 Jones, M.I. P2141
Jeon, U. P5395 Jin, H.-Y. P2478, P2498, P2737, P4700 Jones, P. P4299
Jeong, E.M. P6360 Jin, H.Y. P4697 Jones, P.P. P1775
Jeong, J.O. P2755, 2912 Jin, J. 6103 Jones, S. P2709
Jeong, M.-H. P1495, P1502, P2735 Jin, L.J. P6312 Jones, S.R. P1676, P5981
Jeong, M.H. P821, P824, P2486, P2756, Jin, W.Y. P5431 Jong, G.P. P5551
P3732, P4428, P4471, P4616, P4633, Jin, Y. P1147, P2810 Jongbloed, M.R.M. 3050
P4697, P6119, P6287, P6431 Jing, Z.-C. P5520 Jongejan, A. P6182, P6184
Jeong, S.W. P2169 Jinga, D. 4157 Jonkaitiene, R. P636
Jeong, Y.H. P1475, P5971 Jinno, N. P883 Jons, C. P462, P474
Jeoung, B. P6175 Jinno, Y. P1744 Jonsson, A. P4372
Jeppesen, J. P4094 Jinnouchi, H. P2749, P3439, P3440, P6227 Joo, S. P1825
Jeppesen, J.L. P2170 Jirak, P. P584 Joosen, I.A. P4623
Jeppsson, A. P2157, P4063, P4658, 4846, Jirous, S. P804 Jopling, C. 2238
P5628 Jk, R.Y.U. P746 Jorat, V. P4298
Jepson, N. P793 Jo, H.J. P640 Jorbenadze, R. P671, P674
Jeremy, R.W. P2660, 2931, P4742 Jo, S.H. P6445 Jordaens, L. 96
Jermendy, A. 2105 Jo, U. P1387, P2401 Jordan, C. P502
Jermendy, A.L. 2234, P4496 Jodkowska, M. P3671 Jorgensen, P.G. P844
Jermendy, G. 2234, P4630, P6401 Joeckel, K.-H. P2357, P5960, P6322 Jorgensen, P.J. P6538
Jernberg, T. P2460, P2467, P2496, P2787, Joeckel, K.H. 2104, 4205 Jose Ramon Gonzalez-Juanatey, J.R.
P3662, P4304, 5183, P5373, P5384, Joens, C. 957 P4419
P5399, P5400, 6637 Joergensen, E. P822 Joseph, G. P210
Jerstrom, S. 6649 Joergensen, M.E. P5596 Josephson, M.E. P2417
Jesel, L. P647, P845, P5409, 6635 Joergensen, O.D. P462, P474 Joshi, A. P692
Jesel, L.J. P5487 Jogia, P. P2629 Jost, D. P4073
Jeske, O. P3455 Joh, J.A. P2802 Joung, B. P4355, P4440
Jesmin, S. P223, 2343, P5261 Johannessen, A. 957 Joung, B.Y. P484, P3337, P4064, P4497,
Jessup, M. 299 Johannsen, S.S. P2572 P5296
Jessup, M. 3059, 3061, 3063, 4807, 4811, Johansen, J.B. P462, P474 Jourdon, P. P5446
4966 Johansen, K. P775 Journath, G. 6646
Jesus, E. P4455 Johansson, B. P2655, P2659 Jousset, F. P6352
Jesus, I. P2526 Johansson, I. P5036 Joustra, R. P4678
Jesus, J. 2335 Johansson, J. P1585 Jouven, X. 266
Jha, S.R. P2819 Johansson, K. P5410 Jouven, X. P534, 1320, P1382, P1409,
Jhund, P. P214 Johansson, P. P1548 P1613, 2952, P3134, P3135, P4073
Jhund, P.S. 1977, P2826, P5974, 6642 John, D. 2342 Jouven, X.J. P1658
Ji, M. P6518 John, J. P6564 Jovanovic, I. P2567
Ji, Q.W. P659 John, S. 3072, P3102 Jovanovic, L.J. P5678
Jia, J. P3557, P4122, 5903 Johnsen, J. P5509 Joy, E. P3315
Jia, Y. P4081 Johnsen, S.P. 3277, P5277 Jozwiak, J. P6481
Jia, Y.H. P3357, P6572 Johnson, J.A. P5512 Jr, I.G. P4455
Jiang, C.-X. P5274 Johnson, J.W. P168, P4297 Juan-Babot, O. P2601
Jiang, L. 5184 Johnson, L.J. 949 Juang, J.M. P5554
Jiang, N. P6360 Johnson, M. P5689, P6192 Jueni, P. P6133
Jiang, Q.X. P2493 Johnson, M.R. 142, 143, P1402 Juergens, C. P2516, 5804
Jiang, X.F. P3464 Johnson, N.P. 6620 Juhlin, T. P1395
Jiang, X.J. P4692 Johnson, N.P.J. P3461 Juhlin, T.J. 949
Jiang, Y. P6359 Johnson, R. P777 Juillard, L. 2197, P5392
Jiao, S. P3327, P4535, P4733 Johnson, T. P4420, P5226 Juilliere, Y. 125
Jimenez, D. 2874, 3039, 3041, 4176, P6410 Johnson, V. P5928 Juilliere, Y. P676, P3530, P5513, P5931
Jimenez, R.M. P1394 Johnston, F. 1844, P5672 Jujo, K. P4689, P4694
Jimenez Diaz, V.A. P2751 Johnston, N. 6649 Jukema, J.W. 1867
Jimenez Jaimez, J. P1410 Joho, S. P890 Jularic, M. P3414
Jimenez Lopez Guarch, C. P5957 Jokhadar, M. 145 Jularic, M.J. P4362
Jimenez Mena, M. 5091 Jokinen, E.V.O. 82, 140, 254 Julia Maciel, M. P2140
Jimenez Nacher, J.J. P1396, P1554, Jolicoeur, M.E. P5974 Juliano, R. P1679
P2547, P3531 Jollis, J. P4435 Juliard, J.-M. P4445, P6415
Jimenez Navarro, M.F. P5248 Jollis, J.G. P1333 Julien, C. P4357
Jimenez Sanchez, D. P1768, P4308, P5942 Jolly, K. 1229 Jung, B.A. P1429
Jimenez Valero, S. P195 Jonas, M. P6258 Jung, C. P648, P787, P2538, 3167, P3500,
Jimenez-Borreguero, L.J. 6085 Jonauskiene, I. P3514 P3558, P5005, 6631
Jimenez-Candil, J. P467, P476 Jondeau, G. 4274 Jung, F. P4084
Jimenez-Nacher, J.J. 4176 Joner, M. 139 Jung, H.-S. P2478
Jimenez-Navarro, M. P1689, P4662 Joner, M. 1266 Jung, I.H. P3656
Jimenez-Navarro, M.F. P4584, P5337, Jones, A. 3225, P5451 Jung, L.Y. P4426
5790, P6557 Jones, D. P2740, 6608 Jung, M.-H. P5389
Jimenez-Quevedo, P. P2517, P3573 Jones, D.A. P581, P3711, P3774 Jung, S. P6374
Jin, C.D. P819 Jones, D.G. P4390
458
Chairpersons & Judges / Speakers & Discussants / Authors Jun – Kan
Jung, Y.H. P1780 Kahol, K. 2024 Kam, K.K. P2612

Jungbauer, C. P4730, P6582 Kahveci, G. P5481 Kamada, Y. P1567, P2672, P2719
Junger, C. 4977 Kahya Eren, N. P705 Kamakura, S. P480, P487, P2448, P4377
Jungmann, A. 3066, P3537 Kai, H. P5249 Kamal, H.M. P2628, P3578
Juni, P. 259 Kaibara, S. P4451 Kamani, C. 6647
Juni, P. 362, P1691, P5026, P6135, P6246, Kaida, T. P505 Kamat, S. P5440
6620 Kaikita, K. P811, P1339 Kambara, T. P433
Junien, C. 257 Kaikkonen, L. P2162 Kambaxis, M. P2721
Junttila, J. 1322 Kain, D. P3548, P3555 Kamble, S. 1975, P4397, P6197, P6212,
Junttila, M.J. P2708, P6221 Kaiser, C.A. 2220 P6215, P6217
Jurado Roman, A. P3122, P3718, P4710, Kaitani, K. P1607, 2184, 2185, P2664, P5312 Kameda, R. P655
P4714, P6426, P6517 Kaitozis, O. P2388, P4751 Kamekawa, D. P1567, P2672
Jurdziak, M. P3112 Kajii, E. P220 Kameyama, T. P5025, P5227
Juricic, S. P2484 Kajimura, M. P5466 Kamihata, H. P4691
Jurin, H. P2824 Kajinami, K. P6232 Kamijima, R. P5372
Jurk, K. P2581 Kajiya, K. P734 Kamimukai, T. 3169
Jurkevicius, R. P1594 Kajiya, T. P1727, P1731 Kamimura, Y. P2648, P2650, P2684
Jurkko, R. P3491 Kajiyama, T. P1439, P1686, P1687, P2423 Kaminska, A. P6168
Jurkovitz, C. P2770 Kakarla, J. 2933 Kaminski, K. P1451, 1833, P2812
Jurs, A. P6448 Kakino, T. 1083 Kaminski, K.A. P4731, P4735
Jurt, U. 6084 Kakkar, A. 43, 245, 355 Kamioka, N. P5965, 6024, P6491
Justo, F.A. P6499 Kakkar, A. 389, 1932, 3890, 3894, 5762, Kamisago, M. 4290
Justo Da Silva, G.J. 6039 5764 Kamishima, K. P4694
Juthier, F. P2626, P6507 Kakkar, A.K. P1513, 3278, P4404, P5598 Kamiya, A. P4784
Juul, N. P5284 Kakuta, T. P789, P1361, P1362, P1711, Kamiya, H. P1672
Kaab, S. P1400, 2988 P1715, P1719, P1720, P1749, P4511 Kamiya, H.K. 5081
Kaabachi, N. P850 Kakutani, N. P5579 Kamiya, K. P2696, P2719, P5545
Kaasalainen, T. P1523 Kala, P. P4707 Kamke, W. P3652
Kabakci, G. 6074 Kala, P.K. P4329 Kammerlander, A. P1786, P1808, P2129
Kabbani, S. P5979 Kalaeva, V.V. P2520 Kammerlander, A.A. 2212
Kabeya, Y. P5564 Kalamanoglu Balci, M. P5517 Kamniski, S. P3653
Kablak-Ziembicka, A. P638, P4685, P5619, Kalampogias, A. P4088 Kamoi, D. P726, P3753, P4109, P5966, 6086,
P5622 Kalarus, Z. 266 P6494
Kabul, H.K. P3379 Kalarus, Z. P549, P2471, P3322, P4075, Kamp, O.K. P2569
Kabutoya, T. P2167 P4476, P4619, 4861, 4864, P5303, P6367 Kamper, A.L. 2033
Kacem, S. P4693 Kalashnikov, V. P3684 Kamperidis, V. P2543, P2607, P4089, 6013
Kacet, S. P3374, 5919 Kalaska, B. P1451, 1833 Kamphuisen, P.W. P183, P3621, 4174
Kachenoura, N. 257 Kalayci, A. P2514 Kampman, M.A.M. P713
Kacmaz Basoglu, O. P2795 Kalaycioglu, E. P3620 Kampouromiti, G. P4432
Kaczkowski, R. P2447 Kalbfleisch, S.J. 5921 Kanacri, A. P3518
Kaczmarska, E. P4649 Kalcik, M. P4319, P6386 Kanadasi, M. P5480
Kaczynska, M. P6506 Kale, S. 370 Kanaeda, T. P1687
Kaddach, S. P1659 Kalejs, O. P2347 Kanagala, P. P3126
Kadhim, K. P5701 Kalender, E. P1459, P1460, P4562 Kanagaratnam, P. 24, P3398
Kadirvelu, A. 3304 Kaleschke, G. P684, P2138, P5015 Kanagasabapathy, C. 5079
Kadmon, E. P5013 Kalia, N. P2579 Kanai, M. P1779
Kadoglou, D.P.E. P6504 Kaliambakos, S. P6204 Kanaji, T. 3306
Kadoglou, N. P1632, P5347 Kalil, R. P1705 Kanaji, Y. P789, P1361, P1362, P1711,
Kadota, K. P1504, P1514, P2491, P2622, Kalil-Filho, R. P6267 P1715, P1719, P1720, P1749, P4511
P2738, P2739, P2748, P2774, P3345, Kalinin, V. P489 Kanamori, H. P905, P5002, P5444
P3688, P3713, P5402, P6278, P6520, Kalkan, A.K. P423, P4104 Kanamori, N. P6183
P6525, P6532 Kalkan, G.Y. P722 Kanasseril, M. P709, P4081
Kadowaki, S. P4766 Kalkman, D.N. P1101 Kanazawa, H. 4180
Kadro, W. P6270 Kallenberger, S. P5947 Kanazawa, T. P2748, P3713
Kaeberich, A. 4178 Kallend, D. P1761, P6464 Kanda, K. P6488
Kaelsch, H. 2104, P5960, P6322 Kallergis, E. P2642 Kanda, M. P3551, 4189
Kaempfner, D. P468, P3359 Kallikazaros, I. P898, 2265, P3803, P4671, Kanda, T. P2404, 3170, P4498, P5326
Kaese, S. P1379, P1431, P5948 4871 Kandil, H.I. 260
Kaess, B. P4365 Kallinikou, Z. P2378 Kandolf, R. P3595, 6041, 6614
Kaess, B.K. P5295 Kallistratos, E. P5666, P6277 Kandolin, R. P1620
Kaess, B.M. P3405 Kallistratos, M.S. P906, P4123 Kandzari, D. P807, P2762
Kafes, H. P3760, P6139 Kalman, J. P1424 Kane, C. P4519
Kagawa, E. 4256, P4437 Kalogerakis, D. P170 Kane, G. P4102, P4557
Kagawa, Y. P4506 Kalogeras, K. P4582, P5476 Kane, G.C. 4237
Kagiyama, N. P1798, P2769, P3784 Kalogeropoulos, A. P2740, P5682, P6508 Kaneko, H. P1597, P3572, P6369
Kagizaki, K. 2932 Kalos, T. P2670 Kaneko, K. P2803
Kahan, T. 195, 204, 375 Kalpak, O. P2531 Kaneko, M. P4466
Kahl, K.G. P3610 Kalter-Leibovici, O. P4654, P5977 Kaneko, N. P4689
Kahlert, P. P3445, P5571 Kaltoft, A.K. 3997, P4436, P4508, P5234 Kaneko, S. P6183
Kahles, F. P4540, 5848 Kalusche, D. P2829 Kaneko, Y. P1420, P6353
Kahli, A. P6344 Kaluza, M. 6631
459
Chairpersons & Judges / Speakers & Discussants / Authors Kan – Kau
Kanellopoulos, A. 4156 Karasek, D. P4739 Kaspar, M. P6149

Kanemura, N. P433 Karasek, J. P4439 Kasprzak, J.D. P856, P2528, P2566, P2653,
Kanfi, Y. P3548 Karatas, O.F. P1828 P3524, 4238, P4448, P4670, P4722, P6295
Kang, D. P1825 Karauzum, K. P5681 Kasprzak, J.D.K. 2266
Kang, D.H. P640 Karavidas, A. P2666, P3358, P6320 Kassahun, H. P1756
Kang, J.H. P2145 Karavolias, G. P1816 Kassem, H. P2834
Kang, L. P6342 Karayakali, M. P2416 Kast, J. P1390
Kang, M.K. P863, P4355 Karaye, K.M. P2651 Kaste, M. P2346
Kang, S.-A. P6347 Karbach, S. P656, 1084 Kastelein, J.J.P. 185, 298
Kang, S.-M. P1657, P6590 Karbarz, D.K. P3361 Kastelein, J.J.P. P201, 399, 1154, P2146,
Kang, S.H. P820, P6579 Karben, Z. 2916 3860, 4795, 4799, 4891, 5772, P5983,
Kang, S.J. P3314 Karch, I. P638, P5619 P5985
Kang, S.M. 1239, P2710, P3778, P3787, Karcher, J. P550 Kastellanos, S. P1342
P4110, P4726, P6263, P6578, P6579 Karcher, J.C. 1203 Kastl, S.P. P6255
Kang, S.W. P640 Karck, M. P5947 Kastner, J. P1752
Kang, W.C. P784, P4682 Kardami, E. 4152 Kastorini, C.M. P3681, P6422
Kang, Y. P2833 Kardos, A. P1772 Kastrati, A. 150
Kanic, V. P3433 Kardys, I. P6418, 6641 Kastrati, A. P1485, 3023, 3025, 3027, P3568,
Kanic, Z. P3433 Kareli, D. P4432 P3705, P4092, P4699, P5396
Kanjanahattakij, N. P1695 Karelkina, E. P6151 Kastrup, J. 4289
Kanjanavanit, R. 5219 Karetnikova, V. P4443 Katada, J. P5039
Kanmori, M. P1727 Karetnikova, V.N. P2520 Katagiri, T. P1672
Kano, N. P5578 Karhunen, P.J. P3098 Kataiwa, H. P2487
Kano, S. P3700 Karimova, A. 5083 Katan, O. 3049
Kanonidis, I. 87 Kario, K. 282, 284, 285, 286, P1148, P2166, Kataoka, H. P5657
Kanoupakis, E. P2642, P5329 P2167 Kataoka, M. 4180, P5503
Kanovsky, J. P4707 Kariori, M. P730, P4582, P5476, P5561 Kataoka, S. P4694
Kanovsky, J.K. P4329 Karjalainen, P. P4748 Kataoka, T. P1779
Kansara, P. P2770 Karjalainen, P.P. P197 Katare, R. P3566
Kanski, M. P507, P1754, P4755 Karjalainen, V.P. P4457 Katayama, T. P3638, P6237, P6272
Kanters, J.K. P1433 Karkalousos, P. P6594 Katayose, M. P5579
Kantharia, B.K. P5606 Karki, P. P6133 Kathiresan, S. P1704, 4796
Kanyal, R. P681, P1543 Karlson, B.W. P6465 Katholing, A. P4981, P5320
Kanzaki, H. P2800 Karlsson, F. 6026 Katikireddy, C. P1815
Kanzaki, S. 2932 Karlsson, J.E. 6649 Kato, A. P6117
Kapa, S. P3324, P3373, 5093, 5806 Karlsson, L. P4372 Kato, B. 2228, P5380
Kapel, G.F.L. P1401, P3372, P5926 Karlsson, S. 6043 Kato, H. P1514
Kapelak, B. P6127 Karolko, B. P2469 Kato, K. P1386, P5590, P5593, P5610, P6172
Kapeliovich, M. P447 Karolyi, L. P3426, P4343, P4345 Kato, M. P1426, P1567, P2706, 4256, P4437
Kapetanakis, S. P857, P1592 Karolyi, M. 2105, P4496 Kato, N. 77
Kapetanakis, V. P5572 Karonova, T. P4555 Kato, N. P1548, P4552
Kapl, M. 2244, P5319 Karpenko, Y. P500 Kato, R. P2599
Kappel, B.A. P2362 Karpettas, N. P575 Kato, T. P626, 2243, P2799, P2803, P2818,
Kappert, K. P3622 Karpinska, A. P5531 P6183, P6292
Kappetein, A.P. 135, 137, 138, 139 Karpinski, G. P5300 Katoh, H. P2453, P3345
Kappos, K. P6594 Karpov, Y.U. P6528 Katoh, Y. P1134, P3777
Kapranoy, E. P6594 Karter, A. 4885 Katou, K. P1737
Kaprio, J. 1845 Karthikesan, D. 5798 Katritsis, D.G. P3386, P4378, 4862
Kaptsiukh, T.M. P520 Karvounis, C. 6013 Katsanos, S. P2607
Kapusta, P. P2606, P3587 Karvounis, H. P206, P5502, P5666 Katsaras, D. 1326
Kar, S. 129 Karwowski, J. P547, P2525, P5404 Katsivas, A. P6277
Kar, S. 1914, 1919, 3008, 5215 Kasacka, I. P1451 Katsube, Y. 4290
Kara, K. 2104 Kasahara, M. P2694 Katsumata, T. P2599
Kara, T. P4381 Kasahara, S. P435, P1817, 4058, P6308 Katsumata, Y. P3419, P5466
Karabay, C.Y. P2514, P5481 Kasai, T. P2799, P3721, P4477, P5381 Katsuumi, G. P3327, P4314, P4535, P4537,
Karabinowska, A. 6610 Kasama, S. P5973 P4733
Karacaglar, E. P6523 Kasapkara, H.A. P488, P5426, P6257 Katsytadze, I. P3779
Karadzic, A. P580 Kaseno, K. P3400, P3422 Katsytadze, I.Y. P3762
Karageorgiadi, D. P5624 Kashimura, S. P3419 Katsyuba, M. P4443
Karagiannis, A. P2698 Kashiwagi, Y. P2353 Katte, K. P730, P5561
Karakas, M. P4607, P5016, P5369 Kashiwase, K. P1438 Katus, H. P3605, P3606
Karakoyun, S. P4319, P6386 Kashiyama, K. P1718 Katus, H.A. 130
Karaliute, R. P636 Kashour, T. P5638 Katus, H.A. P172, P194, 1841, P2687, 3066,
Karam, C. P5963 Kashtalap, V. P4421 P3537, P4591, 5178, 5180, P5340, P5472,
Karam, N. P534, 1320, P1382 Kasiakogias, A. 2232, 2265, P2839, P2844, P6540
Karaman, K. P2416 4874 Katus, H.A.K. P3100
Karamanou, A. P906, P4123 Kasim, M. P2424, P6385 Kaudewitz, D. P1472
Karamfiloff, K. P3449, P3686 Kaski, J.C. 322 Kaufman, D. P6464
Karanasos, A. P3733, P4673 Kaski, J.C. P1603, 5880, P6181 Kaufman, G. P5977
Kararigas, G. 4151 Kasner, M. 2205, P3502 Kaufmann, B. P4481
Karasek, A. P1807 Kaufmann, J. 1854
460
Chairpersons & Judges / Speakers & Discussants / Authors Kau – Kho
Kaufmann, P. P4481 Kazakova, E. P4555 Kerber, S. P837, P1471

Kaufmann, P.A. 142 Kazatani, Y. P536, P2804, P5029 Keren, A. 254, 377
Kaufmann, P.A. P611, P1614, 4914 Kazemisaeed, A. P2431 Keren, A. P1806, 4037
Kaufmann, U.P. 191, 266 Kazik, A. P6301 Keren, G. P3584, P5463, 5789
Kauhanen, J. P2798 Kazmi, S. 2231 Kerimli, N. P3677
Kausik, R. 86 Ke, M.W. P3565 Kerins, C. P2718
Kauskot, A. P1114, P5470 Keane, D. P3406 Kerins, M. 249
Kautzky-Willer, A. P572 Kearney, L.C. P3767 Kerkar, P. P4681
Kautzner, J. 89, 303 Kearney, M.T. P3767, P6568 Kerkhove, D. P1388
Kautzner, J. 956, 2274, 3231, 3233, P4762, Keating, B.J. P1702 Kermer, P. P5311
4859, P5499, 6075, P6562 Keavney, B. 2933 Kerneis, C. P5014
Kavanagh, D. P2579 Kececioglu, D. P721, 2926 Kerneis, M. 363
Kaviratne, A. 2108 Kechagias, V. P4113 Kerr, A. P4405
Kavousi, M. 276, P741, P747, P749, P4609, Kecskes, K. P614 Kertesz, I. P3577
P5021, P6444 Kedev, S. P561, P2531, 4287, 4291, P4698, Kerzner, R. 5094
Kavsak, P. P2152, P5636 5868 Kesaniemi, Y.A. P3125, P4093
Kawabata, H. P6217 Kedhi, E. P4453 Keskin, B. P2795
Kawabata, K. P2563 Kee, F. P1667 Kessler, E. P2675
Kawabata, M. P5323 Keech, A. P1559, P2660 Kessler, T. P4092
Kawabe, M. P6244 Kefala, A. 4869 Kettering, K. P3390, P3416
Kawada, T. 2210, P4756, P4784, P5453 Keijzers, M. P4316 Kettner, J. 4835
Kawahatsu, K. P5556 Keilberg, P. P2355 Keweloh, B. P1443
Kawai, H. P1564, P1713, P3692, P6318 Keki, S. P5680 Key, D. P2709
Kawai, T. P3710 Kelbaek, H. P554, P822, 1201, 2910, 4001, Key, T. P1359, 5123
Kawai, Y. P6232 P6324 Keyl, C. 5792
Kawakami, H. P4354 Kelepesis, G. P4666 Keymel, S. P6142
Kawakami, J. P2599 Keles, N. P3450 Khachatryan, L. 6610
Kawakami, R. P1743 Keles, N.N. P3450 Khader, Y. P4475
Kawakami, S. P487, P2448 Keles, T. P488, P5426 Khader, Y.S. P5325
Kawakami, T. 4180, P5503 Keles, T.K. 4173 Khafaga, M. 2244
Kawakami, Y. P6299 Kelion, A. P5000 Khafi, S. P2828
Kawamoto, H. 370, P2761 Kellar, P. P793 Khairy, P. 40
Kawamukai, M. P2556 Kelleher, C.C. 966 Khairy, P. P717
Kawamura, A. P734, P3123, P3544 Kellens, S. 163 Khairy, T. P4708
Kawamura, T. P3544 Keller, A.K. P3100 Khalaf, S. P597
Kawamura, Y. P2449 Keller, J. P169 Khaled, S. P4708
Kawana, M. P3670, 6655 Keller, K. 1978, 4977, P6206 Khalid, F. P182
Kawanishi, H. P1672 Keller, S. P1115 Khalid, U. 3942
Kawano, H. P6237, P6272 Keller, T. 2342, P4074, P5022 Khalilulin, T. P1813
Kawano, S. P223, 2343, P5261 Kellermayer, D. P1144, 2284, P2667, P2678, Khallou-Laschet, J. P4086
Kawano, Y. P5261 P4536 Khambata, R.S. P1569
Kawasaki, A. 6634 Kellokumpu-Lehtinen, P. P3517 Khambhati, B. P4717
Kawasaki, M. P905, P1378, P2451, P2540, Kelloniemi, A. P2162 Khan, A. P223
P2830, P4779, P5002, P5428, P5444, Kelly, D. P2398 Khan, A.A. P5505
P6363, P6558 Kelly, D.J. P2530 Khan, F. P494, 4868
Kawasaki, R. P6597 Kelly, R. 151 Khan, F.Z. 2028
Kawase, H.K. P1558, P4542, P5471 Kelm, M. 1082, P1372, P2134, 2340, P2578, Khan, I. P1683
Kawase, T. P4506 P5547, 5899, P5986, P6142, P6503 Khan, J.N. P2530, P3126
Kawase, Y. P3700, P6363 Keltai, M. P1513 Khan, S. P2832
Kawashima, H. P6522 Kem, D.C. 1328 Khan, S.Q. P4447
Kawashima, T. P2692, 5885 Kemal, H.S. P6510 Khan, T. P658, P2136
Kawashiri, M. P693, P1420, P1655, P1661, Kemper, M. P5949 Khanna, A. P1119
P1699, P1701, P1704, P2150 Kempf, T. P882, 2226, P2633 Kharabish, A. P2542
Kawata, Y. P536, P2804, P5029 Kempny, A. P723, P6413, P6417 Kharabsheh, H. P4475
Kawatoh, M. P3549 Kemps, H.M.C. P3645 Kharlamov, A. P2376, P2734
Kawauchi, K. P1127 Kenknight, B.H. P3775, P5671 Khaschevskaya, D. P3541
Kawecki, D. 160, P3480 Kennedy, L.M. P1395 Khatri, B. P1815
Kaya, A. P838, P1741, P3695, P5275 Kennergren, C.E.H. 83, 323 Khattar, R.S. P866
Kaya, C.T. P3677 Kennon, S. P3723 Khatun, T. P223
Kaya, E.B. 1839, 4170, P4690, 6074 Kenny, C. P2821, P5688 Khaw, K.T. 2218
Kaya, H. P5681 Kenny, R.A. 251 Khayata, M. P4301
Kaya, Z. P3466, P3605, P3606 Kenny, R.A. 1856, P5580 Khedr, E. P4656
Kayaert, P. 4195, P4701 Kent, S.T. 6653 Khedri, M. P4304
Kayama, T. P6597 Kentta, T. P1376 Kherad, B. P3428
Kayamori, H. P4314, P4535, P4537 Kentta, T.V. P2708 Khidir, M.J.H. P6513
Kayani, G. P4404 Keogh, A.M. P4725 Khin, E. P1562
Kayikcioglu, M. 145 Keong, C.C. P5240 Khlynin, M.S. P2450
Kaymaz, C. 4171, 4172, P5517, P6144 Kepez, A.K. 4173 Khokhar, K.B. P2629
Kayvanpour, E. P2687, P5472, P6540 Kepka, C. P4649 Khokhlunov, S. P1436
Kayvanpour, E.K. P3100 Keramida, K.K. P2584, P4560 Kholmovski, E.K. P1151
Kazakov, A. P873, P2160 Kerber, M. P6339 Khosla, S. P6436
461
Chairpersons & Judges / Speakers & Discussants / Authors Khr – Kit
Khripun, A.V. P2492 Kim, I.C. P4474 Kimura, T. P444, P515, P1371, P1486,
Khurana, S. P2356 Kim, I.S. P3337 P1745, P2491, P2762, 2908, P3083,
Kichler, A. P4082 Kim, J.-H. P1495 P3419, P3529, P3691, P4361, P5249,
Kida, K. P3742, P6125 Kim, J. P1387, 2264, P2401, P5630 P5528, 6001, P6304, P6350, P6351,
Kido, T. P4507 Kim, J.B. 277, P736, P812, P834, P2842, P6381, P6535
Kiechl, S. P1472 P5350 Kimura, T.K. P2465
Kiefte-De Jong, J.C. P2594, P4609 Kim, J.H. P824, P2462, P2508, P3799, Kimura, Y. P480, P5262
Kienemund, J. P5319 P4471, P4639, P4724, P6463 Kindermann, I. P873, P2843, P2846
Kienzle, R.P. P3720 Kim, J.J. P3768, P3778, P3787, P4110, Kinderyte, M. P3514
Kiernan, T. P1675 P4726, P6578, P6579 Kindya, B. P1604
Kietadisorn, R. 4151 Kim, J.S. P461, P6463, 6624 King, E. P1559
Kietselaer, B.L. P4623, P5228 Kim, J.S.K. P1724 Kingdom, J. P1576
Kietselaer, B.L.J.H. P3333, P4458 Kim, J.Y. P461, P821, P1638, P3687, P3799, Kini, A. P1510, 2913, 6619
Kihara, Y. P2603, 4256, P4437 P4064, P4355, P4497, P5334 Kink-Eiband, M. P6185
Kijima, Y. P1742, P6273 Kim, K. 376 Kinnaird, T. P2742
Kijlstra, J.D. P3567 Kim, K. P1825 Kinoshita, D. P4766
Kik, C. P3388, P4392 Kim, K.B. P4474 Kinoshita, M. P536, P2804, P5029
Kikas, P. P4432 Kim, K.C. P640 Kinoshita, O. P4567, P4640
Kikuchi, A. P1378, P6558 Kim, K.H. P2644, P3787, P4697, P4726, Kinoshita, T. P5629, P6218
Kikuchi, K. P6530 P6119 Kinoshita, Y. P3708, P3722, P4608, P6282
Kikuchi, N. P1637, 1995 Kim, K.J. P806, 2912 Kintis, K. 2232, 2265
Kikuchi, S. P2707 Kim, K.J.H. P1475, P5971 Kinugasa, Y. P2706
Kilger, J. P5231 Kim, K.S. P746, P904 Kinugawa, K. P1548, P4567, P4640, P6512
Kilias, A. P674 Kim, K.T. 4153 Kinutani, H. P1363, P4551
Kilic, D. P2752 Kim, L. 1197 Kioka, H. P1793
Kilic, H.K. P457 Kim, M.-J. P5389 Kioufis, S. P455
Kilic, I.D. P2764 Kim, M. P1825 Kiraijyan, S. P670
Kilic, S. P1505 Kim, M.A. P5401, P6563 Kiramijyan, S. P1599, P3593, P4583, P6379
Kilicgedik, A. P4319, P5481 Kim, M.G. P4682 Kirby, A.C. P4323
Kilickiran Avci, B. P1828 Kim, M.H. P819 Kircher, S. P3392
Killian, J. P4984 Kim, M.N. P5401 Kirchhof, P. 74
Kiluk, I. P3616 Kim, N.H. P5520 Kirchhof, P. 97, 98, P1416, 1897, 1898,
Kim, B. 371, P1511, P6431 Kim, N.K. P2462, P4724 2173, 2868, 3891, 5109, P5316, 5843,
Kim, B.H. P5363, P6288, P6440 Kim, S.-H. P1502, P2153, P4513 P5949, P6352, P6357
Kim, B.J. P2145, P6287 Kim, S.A. P6445 Kirchmair, E. P2596
Kim, B.K. P746, 6624 Kim, S.G. P904, P1809 Kirchmair, R. P1556
Kim, B.O. P563, P3656 Kim, S.H. P461, 2003, P2779, P3778, P6563 Kirienko, A.I. P456
Kim, B.S. P2145 Kim, S.M. P2816 Kirigaya, J. P2814
Kim, B.W. P2726, P4424, P6511 Kim, S.S. P820, P4428, P4616, P4633 Kirk, H. 6626
Kim, B.W.K. P1724 Kim, S.Y. P3799 Kirkby, N.S. P430
Kim, C.-J. P802 Kim, T.H. P484, P5296 Kirkfeldt, R. 2029
Kim, C. P3656 Kim, T.S. P2848 Kirma, C. P2514, P5481
Kim, C.H. P2570 Kim, W.-J. P2153, P4513 Kirsch, C.M. P3735
Kim, C.J. P821, P2486, P2848, P6119 Kim, W. P3095, P4526, P4696, P4752, 5791 Kirschfink, A. 3175
Kim, C.K. 6624 Kim, W.H. P2755, P4426 Kirtane, A.J. 4000, P4326, P4328
Kim, C.S. P3337 Kim, W.J. P640 Kisacik, H. P2490
Kim, C.Y. P2462, P4724 Kim, W.K. 1980, 1988, P2620, P4565 Kisacik, H.L. P1460, P2118, P3699, P5649,
Kim, D.-H. P802 Kim, Y.-J. P1495, P1502, P6347 P6406
Kim, D.-K. P2478, P2498, P2737, P4700 Kim, Y.A. P1146, P1150 Kiserud, C.E. 4048, P4307
Kim, D.-S. P2478, P2498, P2737, P4700 Kim, Y.D. P819 Kishi, H. P734
Kim, D. P1825, P3585 Kim, Y.G. P5630 Kishi, M. P537, P2511
Kim, D.H. P1525, P2477, P3703, P4363 Kim, Y.H. P461, P1387, P1525, P2401, Kishihara, J. P1422, P6361
Kim, D.I. P4697 P4363, P5630 Kishiki, K. P3334, P5488
Kim, D.K. P4697 Kim, Y.J. P821, P2486, P2508, P3732, Kishima, H. P2408
Kim, D.W. P2816 P4497, P6119 Kishk, Y. P679
Kim, E.-K. P3109 Kim, Y.K. P2508 Kislyak, O. P3798
Kim, E. 2264 Kim, Y.N. P445 Kiss, A. P3085
Kim, E.J. P736, P808, P826, P2766, P2842, Kim, Y.R. P1387, P2401 Kiss, O. P614, P4099
P5350, P5355, P5387 Kim, Y.S. P2508, P4426 Kiss, R.G. 146
Kim, E.K. P2495, P4493, P4702 Kim-Mitsuyama, S. P6152 Kiss, R.G. P3348
Kim, E.M. P666 Kimata, A. P4402 Kistorp, C. P5700
Kim, H.-K. P1495, P1502, P6347 Kimenai, D.M. P4615 Kita, T. P5249
Kim, H.-S. P1495 Kimura, H. 961, P4467 Kitagawa, K. P1535, P1744, 3254, P4774
Kim, H.K. P824, P2644, P3732, P4428, Kimura, K. P885, P1821, 2210, P2814, P6411 Kitagawa, M. P1718
P4471 Kimura, K.K. P2509 Kitahara, K. P6218
Kim, H.L. P5401, P6563 Kimura, M. P3670, P5503 Kitakaze, M. P2500, 5114, 5116, P5460
Kim, H.S. P445, P806, P1511, P2414, P2755, Kimura, S. P1735, P1753, P4514, 6618 Kitamura, F. P5039
2912, P4428, P4474, P4695, P4696, Kitamura, K. P2380
P5336, P5363, P6288, P6445 Kitamura, T. 6634
Kim, H.Y. P4493, P6287 Kitamura, T.K. P828
Kim, I.-J. P2153, P4513 Kitano, I. P1135
462
Chairpersons & Judges / Speakers & Discussants / Authors Kit – Kok
Kitaoka, H. P1619, P4592 Kmoch, S. P5499 Koch, E.M.W. P1823

Kitas, G.D. P4338 Kmonicek, P. P3476 Koch, F. P4383
Kitasato, L. P655 Knaapen, P. P178, P180, 368, P426, P553, Koch, K. P2743
Kitayama, M. P6232 P2512, P4701 Koch, K.T. 364, 1840
Kitsiou, A.N. 93 Knapp, M. P6279, P6283 Koch, K.T.H. P6388
Kitsiou, A.N. 1250 Knebel, F. P5439 Kochanowski, J. P2515
Kitsukuri, R. P6363 Knechtelsdorfer, K. P2129 Kocher, A. P2623
Kittel, F. P4636 Knezevic, B. P561, P594, 4287, 4291, Kochergin, N. P2773
Kitterer, D. 4054 P4698, 5086, 5819 Kochiadakis, G. P1481, P5371
Kitzman, D.W. 3168 Knezl, V. P1414 Kochiadakis, G.E. P3355, 4899
Kiviniemi, A.M. P2708, P6221 Knight, B. 2988 Kochman, J. P1616, P3086, P4572, P5011
Kiviniemi, T. P2156 Knobeloch, J. P628 Koci, J. P4441
Kiviniemi, T.O. P197, P6453 Knoepfler, T. P6206 Kocic, G. P3634, P3661, P4614
Kivisto, S. P1523 Knol, R.J.J. P5232 Kockova, R. 4835
Kivity, S. 4204 Knollema, S. P624, P633 Kocyigit, D. 1839, P4379, P6188
Kiyokuni, M. P2509 Knopp, H. 4858 Koczwara, B. 4047
Kiyooka, T. P6281 Knops, P. P4392 Kodama, A. P3708, P3722
Kizana, E. P4352 Knops, R.E. P466, P473, P2426, P4299 Kodama, T. P5982, P6317, P6404
Kjaer, A. 4289 Knorr, M. P656, 1084 Kodoth, V.N. P477
Kjaergaard, J. 155, P421, P1408, P3470, Knot, J. P565 Koeber, L. 298, P554, P622, 4001, P5033,
P6252 Knowles, J.W. P766 P5978, 6076, P6324, P6470
Kjekshus, J. P895, P6551 Knox, J.B. P5959 Koehler, F. 4280
Kjeldsen, K.P. 37, 361 Knudsen, E.C. P5592 Koehncke, C.K. P1419
Kjeldsen, S. P1147 Knudsen, L. P4436 Koelker, K. P5948
Kjeldsen, S.E. 85, 87, 2267 Knuuti, J. P425 Koell, B. P1808, 2212
Kjellstrom, B. P737, P6424 Knuuti, J.M. 252 Koenig, W. 43
Klaeboe, L.G. P3497 Knuuti, J.M. 305, P424 Koenig, W. 402, 4205, 4883, P5961
Klank-Szafran, M.K. P3361 Knyshov, G. P1635 Koenig-Gorsleben, M. P3402
Klarich, K.W. 2211 Ko, C. P2674 Koenraadt, W.M.C. 3050
Klauser, A. P4491 Ko, D.T. P1331 Koepsell, H. P2363
Klautz, R.J. P2543 Ko, J.K. P4426 Koerber, B. P4383
Klautz, R.J.M. P3794, P6513 Ko, Y. P1604 Koerten, M.-A. P721, P724, 2926
Kleber, M.E. 6644 Ko, Y.G. P4682, 6624 Koese, N. P5005
Klebs, S. P5685 Koabayashi, Y. 5211 Kofflard, M.J.M. P695
Kleemann, T. P469, P3385 Koba, S. P2598, P2720 Kofidis, T. P5644, P5648
Kleijn, S.A.K. P2569 Kobalava, Z. P1802, P5660, P5696 Kofler, T. P1706, P4663
Klein, F. P4439, P6559 Koban, C. 6017 Kofoed, K.F. 1901, P6324, P6399
Klein, H. 2271 Kobara, Y. P3748 Koga, S. P6237, P6272
Klein, H.U. 1244, 4862 Kobayashi, A. P6300 Kogias, Y. P4418, P4430, P4450
Klein, I. 290 Kobayashi, H. 961 Koh, J.-S. P1780
Kleinbongard, P. P3445 Kobayashi, J. P6143 Koh, J.S. P863
Kleinrok, A. P2513, P2527 Kobayashi, K. P5578, P6218 Koh, K. P200, 2001
Kleinschnitz, C. 2341 Kobayashi, M. 961, P4467, P5382 Koh, K.K. P784
Kleiter, M. P3460 Kobayashi, M.K. P754 Koh, M. P1331
Klempfner, R. P4632 Kobayashi, N. P1132, P1133, P3706, P3764, Koh, Y.S. P6287
Kleophas, W. P2134 P4492, P4718, P6145 Kohjitani, Y. P6351
Klersy, C. P2439, P3646 Kobayashi, S. P734, P2148, 2243 Kohl, P. 1212
Klettas, D. P1105 Kobayashi, T. 961, 6632 Kohli, P. P201, P766
Kleveland, O. 336 Kobayashi, Y. 302 Kohn, C.G. P6226
Klich-Raczka, A. P5269 Kobayashi, Y. P1136, P1360, P1439, P1686, Kohn, M. P2159
Klimas, J. P864, P872, P2647 P1687, P2165, P2168, P2423, P2598, Kohno, K. P4486
Klimek-Piotrowska, W. P187, P188, P190 P2720, P2749, P3439, P3440, P3528, Kohno, R. P1437
Klimes, D. P1095 P3551, P3636, P3748, P3797, 4189, Kohsaka, S. P3123, P3477
Klin, P. P6559 P4501, P4689, P5413, P5944, P6227 Kohsho, H. P5564
Kline, J. 1060, 3917 Kober, L. 155, P1792, 2910, P3641, P4072, Koichi, I. P3407
Klinge, B. P6424 4283, 4284, P6573, 6627, 6642 Koide, M. P1108, P6537
Klingel, K. 26 Kober, L.V. P3654 Koide, Y. P6237, P6272
Klingel, K. 340, P3595, 5897, 6614 Kobr, J. P1588 Koifman, E. P1599, P3593, P4583, P6379
Klingenberg, R. P2582, P3448 Kobylecka, M. P3086 Koike, H. P6218
Klinke, A. 4191, 6038, P6355 Kobylyak, V. P798 Koivuniemi, R. P1523
Klis, M. P1442, P2110 Kobza, R.K. P4101 Koiwaya, H. P3691, P6535
Klok, F.A. P3621, 4175, 4179 Koc, M. P722 Koizumi, J. P1694
Klompstra, L. P782 Koca, E. P1688 Kojima, K. P1735, P1753, P4514, 6618
Kloppe, A. P493, P3773 Kocabas, U. 6036 Kojima, S. P811
Klos-Szadryn, A. P5280, P5332 Kocaoglu, I. P542 Kojima, T. P5042
Klosinska, M. P4722 Kocas, B. P573 Kojodjojo, P. P2430
Kloth, J. 4167 Kocas, B.B. P2714 Kok, B. P4115
Klug, D. P608, P3374, P3580, 5919 Kocas, C. P573, P2714 Kok, M. P5228
Klug, G. P4411, P4416 Koch, A. 1850, P4540 Kok, W.E. P3350
Klutstein, M. P794 Koch, C. P3131, P3132, P3771 Kok, W.E.M. P5035
Klutt, B. P4113 Koch, E. 5079 Kok, W.K. P2496
463
Chairpersons & Judges / Speakers & Discussants / Authors Kok – Kov
Kokkou, E. P1116, P6476 Konishi, T. P6530 Kostareva, A. 3051

Kokubo, M. P1827, P3800, P5969 Konka, M. P471, P482 Kostek, O. P3450
Kokubo, Y. P742 Konno, T. P693, P698, P1694 Kostelidou, T. P6204
Kokubu, N. P5288 Kono, S. P2750 Kostenko, V. P5349
Kolb, C. P4365 Kono, T. P4507 Kostenuik, P.J. P3460
Kolbitsch, T. P628 Kononenko, I. P3684 Koster, R.W. 2063
Kolesnik, E. 2244 Konrad, T. P468, P3359 Kostera-Pruszczyk, A. P6168
Kolesnyk, M.Y. P1818 Konradi, A. 265 Kostic, J. 4292
Kolettis, T.M. P3442 Konradi, A. 282, 284, 286, P735, P900, 3941 Kostic, S. P3660, 5084, P6441
Kolev, K. P1457 Konradi, A.O. P1826, P5706 Kostin, S. P4529
Kolh, P.H. 197, 377 Konradi, J. 6038 Kostis, J.B. 1238
Kolh, P.H. 3028, 3262, 3264, 3266 Konsola, T. P740, P3680 Kostis, W.J. 1238
Kolios, M. 33 Konstantinides, S. P2602, 4174, 4176, Kostkiewicz, M. 6610
Koller, A. 123, 136, 375 4177, 4178, 4179, P4432 Kostner, K.M. P1676
Koller, A. P2349, 4291, P5680 Konstantinides, S.V. 81, 186, 261 Kostopoulos, V.K. P2584, P4560
Koller, L. P6547, 6644 Konstantinides, S.V. 2876, 4133, 5193 Kostopoulou, A. P170
Kollia, C. P740 Konstantinidis, D. P4671, 4871 Kostoulas, N. P5566
Kolliakova, N. P1635 Konstanty-Kalandyk, J. P5616 Kostov, J. P2531
Kolm, P. P2770 Konstas, C. P4113 Kostrubiec, M. 4179
Kolodgie, F. P5452 Konta, T. P6597 Kosuge, M. P885, P6381
Kolodzinska, A. P2441 Kontaraki, J. P1481, P5371, 5905 Kosugi, M. P2453
Kolokathis, A.M. P4582 Kontaraki, J.E. P3355, 4899 Koszegi, Z.S. P3468, P5023
Kolomoiets, M.Y.U. P5563 Kontogeorgis, A. P3367, P6112 Kosztin, A. P523, P1794, P1795, P6122
Kolossvary, E. P4665 Kontonika, M. P3442 Kotani, K. P1676, P6298
Kolossvary, M. 2105, P4630 Kontsevaya, A. P1824, 3941 Kotani, Y. P1515
Koloverou, E. P2723 Kontula, K. P1649 Kotecha, D. 1946, 5775
Kolvenbach, R. P5626 Koo, B.K. P806, 2912, 4022 Kothari, S. P4711
Komajda, M. 42 Kooner, J.S. P2562 Kotkowski, M. P5270, P5280, P5300
Komajda, M. 384, P1631, 2326, 2331, 5061, Koopmann, M.K. P1151 Kotlyar, E. P4725
5781 Kopec, G. P436 Kotovskaya, Y. P1802, 3941
Komaki, H. P905 Koponen, M. P1649 Kotrc, M. P2614, P4762, P6484, P6562
Komancsek, A. P1429 Kopp, M. P2581 Kotroyiannis, J. P5676
Komar, M. P436, P720, P1641, P5612 Kopriva, K. P3476, P6493 Kotseva, K. 1219, P1663, P2146, P2724,
Komatsu, I. P3685 Kopylov, P.H. Y.U. 6042 P4324, 5069, P6459, P6469
Komatsu, T. P5331 Koracevic, G. P6402, P6408, P6409 Kottkamp, H. 200
Komi, R. P1651 Korbmacher, B. 5053 Kottmaier, M.K. P5295
Komiyama, M. P3110 Kordalis, A. 2232, 2265, P4429 Kottmann, T. P2149
Komiyama, N. P2409 Koren, M. P1756, P5984 Kou, L. 6643
Komocsi, A. P687 Koren-Morag, N. P1565 Kouakam, C. P3374
Komori, K.N. 5081 Koretsune, Y. P1108, 3278, P4404, P6537 Kouchi, I. P3777
Kompa, A.R. P3750, P4521 Korja, M. 1845 Koudounis, P. P1342
Komukai, K. P2487, 3945 Kornej, J. P6209 Kougo, T. P6225
Komuro, I. 144, 261 Kornowski, R. 253 Kouidi, E. P2698
Komuro, I. P2503, P3551, 4189, P5003, Kornowski, R. P1587, P1740, 1981, P2474, Koukouzeli, A. P906, P4123
P5042, P6512 P3698, P5013, 6016 Koulaouzidis, G. P4489
Komuro, K. P6256 Kornowski, R.K. P2731 Koulouris, N. P4331
Kondal, D. 2024 Korosoglou, G. P194, 1841, P4479, P5001, Koulouris, S. P2744
Kondo, H. P1607, P2415, P2664, P5312 P6323 Kouraki, K. P469
Kondo, M. P4336, P6317 Korpi, K. P1523 Kouranos, V. 3253
Kondo, N. P3551 Korshoj, M. P4636 Kourea, K. P654
Kondo, T. P1378, P1426, P2648, P2650, Kort, R. P1547 Kouremenos, N. P906, P4123
P2684, P5590, P5610, P6317, P6558 Kortelainen, M.-L. 1322 Kouris, N.K. P2584, P4560
Kondo, Y. P1686, P1687 Korzeniec, E. P1807 Kouritas, V.K. P2154
Kondou, N. 4189 Kosacka, U. P3616 Kourkouti, P. P2575
Kondruweit, M. P6374 Kosaka, S. P1801 Koussa, D. P3580
Kone, B.C. 4214 Koschinski, A. 2242 Koutagiar, I. P612, P785, P4106, P5607,
Konen, K. P4999 Kose, S. P3379 P5627
Konfino, T. P5458 Koshiyama, M. P5307 Koutalas, S. P6209
Kong, D.H. P6306 Koshkina, D. P879 Koutlianos, N. P2698
Kong, W. P6124 Koshy, A. P1811 Koutouzis, M. P791
Kongnakorn, T. P4987 Kosiborod, M. P3772, P3793 Koutsogiannis, N. P1478, P1479
Kongoji, K. P5372 Kosinska, J. P3543 Kouvari, M. P4418, P4430
Kongsgaard, E. P512, P1404, P4754 Kosior, D.A. P1595 Kouzu, H. 1086, P2350
Koniari, I. P1478 Kosiuk, J. P3392 Kovac, J. P6387
Konieczynski, J. 2022 Koskinas, K.C. P5026, P6246 Kovacic, D. P6229
Konings, T.C. P715 Kosmalski, M. P3759 Kovacic, J. P1510, 6619
Konishi, A. P1363 Kosowski, M. P3430 Kovacik, F. P540
Konishi, H. P3721, P4477, P5381 Kossmann, S. P656, 1084 Kovacs, A. 345, P523, P1457, P1794, P1795,
Konishi, K.K. P828 Kostadima, M. P1446 2284, P2678, P4097, P6122, P6401
Konishi, M. P885, P5256 Kostakou, P.K. P4560 Kovalenko, E. P3761
Konishi, S. P4360 Kostal, M. 6616 Kovalenko, V. P5708
464
Chairpersons & Judges / Speakers & Discussants / Authors Kov – Kun
Kovalova, M. P2347 Kremer, L.C.M. P5035 Kube, J. P2786, P5695

Kovamees, O. P2133 Kremmin, J. P2593 Kubicius, A. P6367
Kovanen, P.T. P3098 Kremzer, A. P1368, P4723 Kubis, H.P. P3642
Kovats, L. P4665 Krenek, P. P864, P872, P2647 Kubo, M. P1403, P3607
Kovats, T. P4665 Krenn, L. P1752 Kubo, T. P583, P1619, P1728, P1736, P2746,
Kovoor, P. P3734, P4352 Krenning, B. 2101 3945, P4592, 6623
Kowal, R. P568 Krenz, T. 2340 Kubota, A. P3748
Kowalczyk, J. P4075, P4476, P5303 Kretov, E. P2358, P3370 Kubota, I. P851, P1660, P3533, P4766,
Kowalczyk, P. P1807 Kretowski, A. P4731 P6597
Kowalewski, C. P4080 Kretschmann, J. P5589 Kubota, S. P5515
Kowalik, I. P547, P2525, P2697, P5291, Kretzschmar, D. P6514 Kubota, T. P2451
P5404, P5537 Kreuchwig, F. P3538 Kubota, Y. P1737
Kowalski, O. P3322, P4075, 4861, 4864 Kreutz, R. 409, 413 Kucera, J. P6352
Kowara, M.K. P1616 Kreuzer, J. 4980, P5967 Kucher, N. P6141
Kowey, P.R. P3076 Kreuzhuber, M. P3392 Kuciej, A. P5332
Kowlessur, S. P3627 Krieger, D. 211 Kuck, K.-H. 34
Kownator, S. 5869 Krieger, D. 3267, 5142 Kuck, K.-H. 1007, 2865, 2900, 3188, P3741,
Koyama, J. P5382, P6222, P6577 Krieger, K. P1443 P4563, P4564
Koyama, K. P5003 Kriger, J. 6638 Kuck, K. P3385
Koyama, T. P2446 Krinochkin, D.V. P521, P2391 Kuck, K.H. P682, P685, 5784
Koyama, Y. P3407, P4483, P4486, P4495 Krishnan, P. P1510, 6619 Kucukoglu, M.S. 263
Kozan, O. P1764, P3746, P3776 Kristensen, J. 2269 Kucukoglu, S. P1764, P3746, P3776
Kozanitou, M. P644, P660, P5368 Kristensen, K.E. 1846, 4284 Kudaiberdiev, T. P193
Kozarevic, N. P609 Kristensen, S. P5031 Kuder, J. 3032, P3318
Koziej, M. P187, P188, P190 Kristensen, S.D. 324 Kuehl, U. 3069
Koziel, M. P4075, P4476 Kristensen, S.D. P1464, P1498, P1503, Kuehl, U.K. P1353
Kozierkiewicz, A. P549 P2745, 4826, 6002 Kuehne, M. P479, P628
Kozminsky, A.N. P3354 Kristensen, S.L. 4283, 6642 Kuenzli, N. P2671
Kozuki, A. P6273 Kritharis, E.P. P672 Kufner, S. P3705, P5396
Kozuma, K. 191 Krittanawong, C. 2211, P3324 Kuge, Y. P1583
Kozuma, K. P1745, P2746, P6522 Krivolapov, S.N. P2450, P6574 Kugiyama, K. P2563
Kraai, I.H. P1805 Krljanac, G. P5678 Kuhl, J.T. P6324
Kraaier, K. P715 Kroeller-Schoen, S. P667 Kuhl, U. P3600, 5898
Kraak, R.P. 364 Kroepil, P. P2578 Kuhlman, S. P6357
Kraal, J.J. P3645 Kroft, L.J. P4482 Kuhn, J. P2361
Krabatsch, T. P453 Krogmann, A. P664 Kuijpers, J.M. 2934
Krackhardt, F. P3428 Krogmann, A.O. P661 Kuiper, J. 3201
Kraehe, M. P3652 Krolicki, L. P3086 Kuiper, K.K.J. P4566
Kraehenmann, P. P6135 Kroll, L.E. P3666 Kuiper, M. P421, P1408
Kraenkel, N. 1954, P2582 Krombach, G.K. P4687 Kuiperi, C. P3101
Kragholm, K. P1333, P4435, 6627 Kromhout, D. P739 Kukla, P. P6402, P6408
Kragholm Soerensen, K. 1329 Krommydas, A. P857, P1592 Kukulski, T. 154
Kraja, B. P2594 Kronborg, M.B. 2269 Kukulski, T. P5011, 5214, P6367
Krajewska, A. P6279 Kropotkin, E. P3375 Kukuy, O. P3569
Krakau, I. 6646 Krstacic, G. 93 Kulakowski, P. 200
Krakor, R. P3382 Krstacic, G. P3321 Kulakowski, P. P4388
Krakowska, M. P856 Kruchina, T. P3363, P3368 Kulikovskikh, Y. P2492
Kralovec, S. P4720 Krucoff, M.W. P582 Kulikowski, E. P1585
Kramarz, E. P2452 Krug-Gourley, S. P6228 Kulkarni, S. P6134
Kramer, A. P5633 Kruger, A. P3476, 5886, P6493 Kumada, M. P220
Kramer, B. P694, P2639 Kruithof, B.P.T. P5461 Kumada, Y. P726, P4109, P5966, 6086,
Kramer, C.M. 2340 Kruk, M. P4649 P6494
Kramer, U. 6041 Krum, H. P3750, P4521 Kumagai, K. P2436, P2533, P3410, P5299
Kramer, V. P4631 Krumm, P. P2524, 6041 Kumagai, M. P790
Krams, R. P5235 Krummen, D.E. P1550, P3386, P4378 Kumagai, N. P4114, 6634
Krane, V. P4767 Krupa, E. P6402 Kumagai, Y. P3742
Krapf, L. P3516 Krychtiuk, K.A. 263 Kumar, A. P3744
Krasopoulos, G. P2595, P5416 Krychtiuk, K.A. P6255 Kumar, P. P4408, P4713, P5566
Krasuski, R.A. P3795 Kryczka, K. P4649 Kumar, R. P442, P780, P781, P5702
Kratzer, A. P2582 Krykunov, O. P1635 Kumarathurai, P. P5305
Krause, K. P673, P1606 Krysztofiak, K. 5846 Kumarathurai, P.K. 949
Krause, L. 2340 Kryze, L. 4859 Kumarswamy, R. P530
Kravchenko, A.M. P5563 Krzeminska-Pakula, M. P4448, P4722 Kumasaka, R. P2368
Kravchuk, B. P1635 Krzesiak-Lodyga, A. P1807 Kumbasar, D. P5652
Krawczyk, K. P3495 Krzysztofik, J. P3430 Kume, T. P1798, P3784
Krebsova, A. 4835, P5499 Krzysztofik, J.M. P841 Kumfu, S. P3786, P4538, P5539
Kreidel, F. P682, P685, P4563, P4564 Ku, H.-C. P2132 Kumler, T. P5700
Kreitner, K.-F. 6106 Kuatbayev, E.M. P5665 Kummann, M. P4491
Kremastinos, D.T. 212 Kubala, L. P6355 Kunadian, V. P570, P588, 4934, 4936, 5185
Kremastinos, D.T.H. P3441 Kubala, M. P2553 Kunecki, M. P6329
Kremer, H. 6635 Kubanek, M. P5499 Kunicki, P. P4649
465
Chairpersons & Judges / Speakers & Discussants / Authors Kun – Lam
Kunimura, A. 2228, P5380 Kuschyk, J. P493, P4591 Lacoin, L. P5292, P6202, P6219
Kunishige, M. P2453 Kushnir, S. P3805, P6591 Lacour, P. P1093
Kunishima, T. P4674 Kusljugic, Z. 316 Lacquaniti, M.L. P2705
Kuniss, M. P3364, P3391, P4367, P4368 Kusljugic, Z. P5272, P6208 Lacroix, D. P608, P3374, P3580
Kuniyoshi, T. P2692, 5885 Kusmierczyk, M. P3540, P3543 Lacroix, P. P5574
Kuno, A. 1086, P2350, P3782 Kusmierski, K. P2441 Lacroix, P.M. P4108
Kuno, T. P3123 Kuss, O. P1618 Ladeiras-Lopes, R. P3130, P4490
Kunstyr, J. P5247, P5534 Kuster, N. P3451, 5088 Ladenvall, P. 2966
Kunszt, G. 336, P1791 Kusuoka, H. P1108, P6537 Ladhani, S. 2024
Kunugita, F. P5331 Kutarski, A. P1091, P2438, P2440, P2445, Ladouceur, M. P1650, 2927, P4602
Kuo, J.Y. P888, 2227, P3534, P4076, P5432, 5145, 5147 Laerum Sibilitz, K. P3654
P6294 Kutishenko, N. P6467 Lafitte, B. P796
Kupari, M. P1523, P1620 Kutlesic-Kurtovic, D. P6402 Laflamme, M. P3504
Kupatt, C. P3097, 4160 Kutlu Karadag, M. P3801 Laflin, R. P6568
Kupczynska, K. P4448 Kutsuzawa, D. P5299 Lagarto, J. P869
Kupec, A. P4707 Kutyifa, V. 21 Lagarto, V. P1634
Kupec, A.K. P4329 Kutyifa, V. P523, 2271, 4223, 4224, 4862, Lagerqvist, B. P1730, P3343
Kuperstein, R. P4632 5760, 6071 Lagerstrom Fermer, M. P6239
Kurabayashi, M. P212, P1420, P2803, Kuusisto, J. 1021, 1023 Lagioia, R. P733
P3728, P4753, P5973, P6353 Kuwahara, T. P2451, P4353, P4384 Lagiou, F. P2670, 4867
Kurakula, K. P5461 Kuwata, S. P5372 Lago, F. P4541, P6334
Kuramitsu, S. P2747, P2749, P3440, P3701, Kuwayama, A. P1514, P5402 Lago, I.M. 6617
P3702, P6227 Kuyumcu, S. P4561, 5210, P5271, P6406 Lagrenade, I. 1970, P6205
Kuramitu, S. P3439 Kuzmiski, B. 2244 Laguna, P. P1545
Kurata, M. P1456 Kuznetsov, V.A. P521, P2391 Laherran Rodriguez, E. P3673
Kurbatov, V. P2358 Kuznetsova, M.V. 6042 Lahiri, A. P4484, P4485
Kurchakova, E. P3541 Kvaloy, J.T. P5257 Lahrmann, B. P6540
Kurdziel, M. P6301 Kvasnak, M.K. P4329 Lahrmann, C. P661, P664
Kureishi Bando, Y. P1558, P4542, 5081, Kwak, C.H. P1780 Lai, C.L. P2122, P2845
P5471 Kwan, J.U.N. P2477 Lai, C.T.M. P719
Kurek, A. P5646, P6301 Kwan, M.W.M. P3629 Lai, F. P4570
Kurganovich, S. P6485 Kwasiborski, P.J. P1807 Lai, G. P578
Kuri-Morales, P. P6592 Kwiatkowska, B. P5537 Lai, I. P6312
Kurian, B. P841, P3758 Kwiecinski, W. P3574 Lai, X.J. P6423
Kurian, D. 2915 Kwon, C.H. P1387, P2401, P5630 Lai, Y.H. 2227, P3534, P5432, P6294
Kuribara, J. P5231 Kwon, H.M. P1638, P3687, P4355 Laine, A. P5946
Kurien, R. P4613 Kwon, K.H. P640 Laine, M. P1523, 4911
Kurilenko, T.A. P1540, P1542 Kwon, S.W. P1638 Lainscak, M. 150, 3297, 3298, 4050, P5690,
Kurita, N. 4286 Kwon, Y.S. P4639 P6229, P6546
Kurita, T. P1686, P1687, 3254, P5927 Kwong, R.Y. P6323 Laissy, J.-P. P6415
Kuriyama, N. P3691, P6535 Kwoun, S.W. P2477 Laissy, J.P. 2103
Kurl, S. P2676, P2798 Kyhl, K. 2910 Laitinen, P. P528
Kurlansky, P. P5642 Kyhl Kristensen, K. P554 Lakatos, B. P4097
Kurmann, R. P6135 Kyndt, F. P485, P1409, P6161 Lakatta, E.G. P5570
Kurmi, O. P5620 Kyo, K. P5528 Lakkireddy, D. 955, P3383, P3396, P3417
Kurniati, N. 3951, P6396 Kyo, S. P4567, P4640 Lalani, G. P1550
Kurnicka, K. P755, P6168 Kyono, H. P6522 Lalic, K. P3682
Kuro-O, M. P2587 Kyriakides, Z.S. P791 Lalic, N.M. P3682
Kurobe, M. P876, P2475, P4451 Kyriazopoulos, K. P2670 Lam, C.S. P5469
Kuroda, M. P1363 Kyto, V. P6231 Lam, C.S.P. 241, 360
Kurogi, S. P2380 L’Abbate, A. P4669 Lam, C.S.P. 3836, 5836
Kuroiwa, N. P801 L’Huillier, I. P799 Lamaury Bardet, B. 5079
Kuroki, K. P1399 La Gerche, A. 61, 63, 64, 65, P2683, 2969, Lamb, H.J. P2126
Kuroki, N. P4466 P5507, 6104 Lambers, M. P6207
Kurosaki, K. 2932 La Greca, C. 2207 Lambers Heersprink, H.J. P183
Kurosawa, K. P4753 La Manna, A. P2768 Lambert, G. 4787
Kurozumi, A. P4483 La Meir, M. P4371 Lambert, V. 2283, P4602, P5446
Kurozumi, M. P1130 La Rosa, C. P503 Lambert, Y. P534, P1338, P4445, 5816
Kurpesa, M. P2653 Laakkonen, J.P. P2597 Lamberts, M. 951, P5284, P6470, 6642
Kurt, M. P838, P1741, P3695 Laali, M. P3588 Lamberts, R.R. P1142, P1775
Kurtul, A. P825, P5335, P6257 Labarere, J. P5932 Lambiase, P. P494, 4242, 5742, 6093
Kurucz, R. P3600 Labate, V. P750, P886, P2618, P4744, Lambiase, P.D. P415, P4299
Kurup, R. P4352 P4750, P6376, P6434 Lambrechtsen, J. P3325, P5017
Kurushka, T.V. P520, P6169 Laborde, F. 6021 Lambrinou, E. 6109
Kurzawski, J. P448, P3121 Laborie, G. P5267 Lameira, R. P3479
Kurzidim, K. P4080 Laborne, F.X. 5816 Lamelas, P. P2405, P3401
Kusano, K. P417, P480, P487, P881, P2448, Labus, K. 6615 Lamelas, P.L. P6596
P2800, 3305, P4763, P5354, P6536, Lacerda, L. P6328 Lamendola, P. P3512
P6541, P6545 Lackner, K. 4977 Lamerz, J. P5340
Kusano, K.F. P4377, P4761 Lackner, K.J. 1978, P4074, P4607, P5016, Lamhaut, L. 1320, P1382, P4445
P5369 Lammert, F. P2160
466
Chairpersons & Judges / Speakers & Discussants / Authors Lam – Leb
Lammertsma, A.A. P178, P180, 368, P426 Lara-Pezzi, E. P6343 Lauten, A. 1980, 1982, P2538, 3167, P3500,
Lammintausta, O. 4911 Larbi, T. P704 P5492, P6514
Lampert, T. P3666 Larman, M. P1710 Lauterbach, M. 1978
Lampropoulos, K. P672 Laroche, C. P4619 Lautsch, D. 69, P1654, P1675
Lampropoulos, K.M. P6594 Laronga, G. P2716 Lauzier, B. P1810
Lamy, A. P2152, P5636 Larrasa, J. P6343 Lavall, D. P4085
Lan, W.R. P888, P3534, P5432, P6294 Larsen, A.I. P602, 3198, P5257, P6477 Lavda, M. P4582, P5476
Lanas, F. P6596 Larsen, B. P5305 Laveau, F. P5654
Lancaster, R.E. P4096 Larsen, B.S. 949 Laven, J.S.E. P747, P4609, P5021
Lancefield, T. P894 Larsen, M.L. 5884 Lavers, T. P709
Lancellotti, P. 302 Larsen, T.B. 359, P1666, 1830, P5308 Lavi, B. 4204
Lancellotti, P. 925, 3034, 5782, 5987, 6079, Larson, N.B. P1653 Lavi, I. P1740
6081 Larsson, P.G. 1325 Lavi, R. P2352
Landa, N. P3555, P5458 Larstorp, A.C. P1147 Lavi, S. P652, P2352
Landi, P. P1341 Lasica, R. P4425, P4452, P5678 Lavieren, M.A. P1507
Landmesser, U. 1262, P1463, P1549, 1954, Laskar, M. P4558 Lavin, P.T. P3772, P3793
P2582, P2600, 3069, P3448, P3487, Laskaris, A. P6438 Lavoute, C. P1611, P3105, P6383
P3502, P3535, P3575, P4083, P5501, Laskey, R. P201, P766 Lavrut, T. P840
P6348 Lassen, J. P5978 Lavu, D. P3664
Landmesser, U.L.F. 2214 Lassen, J.F. P556, P822, P2745, 3997, Lawes, C. P6457
Landolina, M. P502, P2400, 4865 P4436, P4508, P4998, P5234 Lawo, T. P493
Landray, M. P5575 Lassner, D. P3600, 5898 Lawrence, J. P4987
Lane, D.A. P1666, P5308 Lassner, D.L. P1353 Lax, J.A. 3053
Lang, C.C. P517, P3763, P4772, P5321, Lassus, J. P880, P3491, P4768, P6573 Lay, M. P4613
P6552 Lassus, J.O. P4457, P4748 Layland, J. 4024, 4293, 4294
Lang, F. P1487, 2341, P2587, P6345, 6614 Lastra Galan, J. P5474 Layug, B. P6163
Lang, I. P1752, P2365 Laszczynska, O. P1668, P3668, P5367, Lazam, S. 5212
Lang, I.M. 190, 198, 246 P5406 Lazarev, P.O. P3762
Lang, I.M. P1455, 2175, 3904, 3908, P4545, Laszlo, C. P687 Lazaris, E. P791
4866, 5092, P5508, P5952 Latappy, M. P5932 Lazaro, L.L. P689
Lang, M. P3352 Latcu, D.G. P3412 Lazaro Rivera, C. P2547, 3173
Lang, M.B. P5952 Latib, A. 370, P1608, P2608, P2616, P2761, Lazaros, G. P730, 1834, P4429, P4586,
Lang, P. P6366 P3592, P5491, 6090, P6375, P6389 P4588, P5555, P5561, P5588, P6598
Lang, R. P2550 Latsios, G. P644, P785, P898, P1141, P2388, Lazkani, M. 6033
Lang, R.M. 127 P3115, P3501, P3582, P3803, P4106, Lazniak, A. P3376, P6114
Lang, R.M. 1888, P2545, P2546, P5484 P4751, P5368, P5464 Lazoryshynets, V. P1635
Lang, S. P4647, P4650, P4982 Lattarulo, M.S. 5810 Lazoura, O. 958
Lang, V. P2164 Lattuca, B. P3451, P4446 Lazovic, M. P3651
Langbein, A. P3426, P4343, P4345 Latus, J. 4054 Lazu, M. P6527
Langdon, T. P4461 Latz, E. 1960 Lazzara, R. 2987
Lange, M. 106, 4191 Lau, C.P. P738 Lazzarini, E. P3328, P3550, P6166
Lange, N. P1419 Lau, D. 1847 Lazzarini, V. P3790
Langer, C. P1751 Lau, D.H. P4374, P6198 Lazzeretti, D. P179, P5290, P6223
Langhauser, F. 2341 Lau, K.K. P738 Le, T.T. P1763, P4747, P5411
Langhoff, L. P6399 Lau, Y.C. P4400 Le Bail, G. 5816
Langleben, D. 4181, 4815 Lau, Y.K. P6305 Le Bret, E. P5446
Langley, S. P2571 Lau-Walker, M. P2646 Le Brun, F.O. P2365
Langley Evans, S. 4848 Lauf, J. P2592 Le Helloco, A. P2434
Langlois, M. P528 Laufer, G. P2623 Le Heuzey, J.-Y. 92
Langsjoen, E.C. P2383 Laufs, U. 243 Le Heuzey, J.-Y. 1249, P1513, 2034, 4844
Laniado, M. P4494 Laufs, U. P1698, P2160, P2370, P2843, Le Jemtel, T.H. P3714
Lanitis, T. P4397, P4987 3862, 3867, 3868, P4085 Le Marec, H. P485, P6161
Lanjewar, C. P4681 Laugaudin, G. 5088 Le Pennec-Prigent, S. 6630
Lankeit, M. P2602, 4174, 4176, 4177, 4178, Laughery, J. P2770 Le Saux, C. P4525
4179 Laugwitz, K.-L. P1485 Le Scouarnec, S. P485, P1409, P6161
Lankes, S. P3137 Laugwitz, K.L. P1346, P3705, P4638, P5396 Le Thuaut, A. P6148
Lantelme, P. P5009 Laukkanen, J. P2676 Le Tourneau, T. P1124
Lanters, E. P6189 Laukkanen, J.A. P2798 Leach, A. P3635
Lanz, H. 4971 Laulicht, B. 4971 Leal, C. P4488
Lanza, D. P2389, P4745, P4758, 4863 Launer, L.J. 299 Leal, M. P5391
Lanza, G.A. P3512, P4522 Laur, O. P3363, P3368 Leal, P. P1506
Lanzillo, T. P569 Laurent, S. 147 Leao, S. P1626, P1627, P3457, P4333,
Lapidus, N. 4260 Laurent, S. 1876, 1878 P4764, P5390, P6400
Lapinskas, T. P3514 Lauria, C. P3512 Leaver, L.K. P5451
Lapostolle, F. P534, P556, P1338, P4445, Laurinavicius, A.G. 70 Lebeaux, D.L. P1640
5813 Laurindo, F.R.M. P2808 Lebedev, D. P1423, P2393, P5224, P6574
Lapp, H. P4391 Laurito, M. P4522 Lebedev, D.S. P4596
Lappas, G. P438, P2654, P2657, 2925, Lauritsen, M.T. 6023 Lebedeva, A. P6332
P3614 Laut, K. P171, P176 Lebedeva, V. P2393
Lapunzina Abadia, P. P4550, P5957 Lautamaki, A.K. P2156 Lebeis, T. P5682
Lara Padron, A. P2652 Leber, A. P4479, P5001
467
Chairpersons & Judges / Speakers & Discussants / Authors Leb – Lep
Leber, R.L. P4101 Lee, S.-C. P3109 Leite, S. P1578

Lebherz, C. P665, P4540 Lee, S.-H. P1657, P1757, P6263, P6590 Leite, S.M. P5677
Lebioda, K. P1585 Lee, S.-H.W.A. P1757 Leite Moreira, A.M. P1814, 1853
Lebreiro, A. P2140 Lee, S.-P. P6347 Leite-Moreira, A. 149
Lebreton, G. P2429 Lee, S. P1825, 2264, P3097, P4426, P6347 Leite-Moreira, A. P1605, P2372, P5634,
Lecce, L. P1559 Lee, S.C. P2495, P4493, P4559 P5635, P5641, P6586
Leccisotti, L. P604 Lee, S.E. P4064, P4771 Leite-Moreira, A.F. P1578, P1814, 1853,
Leclercq, C. 92, 153 Lee, S.H. P824, 1239, P2145, P2710, P4471, P3130, P5006, P5259, 6058
Leclercq, C. 292, P502, P2434, P2836, P4472, P5334, P6463 Leiter, L. 1881
4225, 4226, P5429, P5438, 6630 Lee, S.K. 277 Lejnieks, A. P2347
Leclercq, F. P3451, P4446, 5088, P6452 Lee, S.L. 2210 Lekakis, J. 362
Lecompte, T. P676 Lee, S.R. P4426 Lekakis, J. 355, P639, P654, 1326, P2459,
Lecoq, C. P4985, P6214 Lee, S.W. P6198 P2499, P2666, 3174, 3303, P3513, P5347,
Lecour, S. P4529, P6328 Lee, S.Y. P2816, P3799, P6463, 6624 P5418, P5437, P5705, P6265, P6320,
Lederer, D. P4644 Lee, T. P789, P1361, P1362, P1711, P1715, P6504, P6566
Ledinko, M. P3570 P1719, P1720, P1749, P4511 Lekawanvijit, S. P3781
Ledwidge, M. P5688 Lee, V.W.Y. P5544 Lekston, A. P541, P566, P576, P585, P587,
Ledwoch, J. P5617, P5625 Lee, W.-H. P4780, 5808 P589, P699, P2506, P2789, P6587
Lee, A.P. P2612 Lee, W.S. P1387, P2401, P5630 Lele, S.S. 5090
Lee, B.C. P6543 Lee, Y.-C. P5292 Lelong, B. 6630
Lee, B.K. P1638, P3687 Lee, Y.-M. P2478, P2498 Lemaire, A. P4595
Lee, C.-H. P5644, P5648 Lee, Y.B. P2169 Lemarie, J. P557
Lee, C.H. 2942 Lee, Y.S. P746, P6175 Lembo, G. P6200
Lee, C.J. P1657, 3277, P6590 Leebe, I. P2411 Lembo, M. P858, 4870
Lee, C.L.S. P3629 Leebeek, F. P1456 Lemesle, G. P1492
Lee, C.W. P746, P2755 Leem, C.H. P2169 Lemke, B. P3773
Lee, D. 156 Leemasawat, K. 5219 Lemkes, J.S. 368
Lee, D.H. P2757 Leenders, P. P645, P646 Lemmens, K. 1835
Lee, D.I. P1525, P4363 Leeson, P. 3841 Lemoine, M. P3414
Lee, D.R. P2752 Lefebvre, F. 2283 Lemoine, S. P557
Lee, D.S. P6511 Lefevre, C. P5292, P6202, P6219 Lemos, D.C. 6617
Lee, D.Z.J. P1477 Lefevre, T. P1615, 4268, P5010, P5489, 5786 Lemos-Neto, P.A. 6617
Lee, E.T. P4117 Lefevre, T.L. P3118 Len, K. P2653
Lee, G.-Y. P3109 Lefkowitz, M. P213, 3302 Lenarczyk, R. P3322, P4075, P4476, 4861,
Lee, G. P1424, P2646, P4612 Lefkowitz, M.P. 3301 4864, P5303
Lee, H.C. 371, P484, P1511, P2726, P4424, Lefort, H. 5816 Lencioni, A.M. P179, P6223
P6431, P6511 Lefoulon, A.L. P5487 Lendeckel, U. 208
Lee, H.C.L. P1724 Lefrandt, J.D. P183, P1566, P5548 Lendeckel, U. P6179
Lee, H.J. P4497 Leftheriotis, D. 1326 Lener, D. P1556
Lee, H.L. P6563 Leger, D. 5077 Leng, S. P4747
Lee, H.O. P3703 Leggewie, S. P1493, 5792 Lennie, T.A. P440
Lee, H.T. P904 Legrand, V. P1468 Lennon, L.T. P4776, P5572
Lee, H.W. 371, P1511, P2726, P4424, Leguerrier, A. P4095 Lennon, R.L. P4444
P6431, P6511 Legutko, J. P555 Lenoir, G. P1338
Lee, H.W.L. P1724 Lehachi, S. P2611 Lente, C. P4449, P4462
Lee, H.Y. P563, P3656, P4771, P6583 Lehar, F. P4705 Lenz, C. P1443
Lee, J.-H. P2816 Lehmann, N. P5960, P6322 Lenzen, M. P1746
Lee, J.-Y. P1657 Lehmann, T. P3107 Leo, L.A. P3519
Lee, J. 2264, P4610 Lehnart, S.E. P416, 3931 Leon, A.R. P4299
Lee, J.B. P746 Lehner, S. P607 Leon, D. P4719, P5582
Lee, J.H. P2462, P4724 Lehrke, M. P665, P4540, 5848 Leon, M.B. 313, 315, P807, P2771, 3926,
Lee, J.J. 277, P736, P5350 Lehto, J. P197 4271
Lee, J.K. P2116, P6175 Lehto, M. P2346 Leon, M.M. P5037
Lee, J.M. P806, 2912, 4022 Lehtonen, J. P1620, 4911 Leon-Gonzalez, A.J. P647
Lee, J.S. P5296 Lei, M. P6358 Leonardi, S. 252
Lee, J.W. P5334 Lei, Y. P1589 Leonardi, S. P1474, P4105, P6155
Lee, J.Y. P2145, P4682 Leiballi, E. P3335 Leone, A.M. P604, P5027, P5455
Lee, K.H. P784, P4526, P4616, P4633 Leibetseder, V. 4866 Leone, M. 5810
Lee, K.K. P4461 Leibowitz, M. P1652, P5318 Leone, O. P5467
Lee, L.K.H. P1475, P5971 Leiherer, A. P1697, P3678, P4473, P6259 Leonelli, V. P3335
Lee, L.S.E. P6583 Leimkuehler, P.J. P2631 Leong, D.P. 4053
Lee, L.S.H. P1475, P5971 Leiner, T. P1755 Leoni, L. P3399, P3403, P3411
Lee, M.D. P2477 Leinung, S. P6509 Leontyev, S. P1600
Lee, M.F. 1961 Leipold, R. P1453 Leonzio, L. P3418
Lee, M.H. P461, P484, P3337, P4064, P4355, Leipsic, J. P3723, P4998 Leor, J. P3548, P3555, 4969, P5458
P4440, P4497, P5296, P6175 Leipsic, J.A. 3997, P5234 Leosco, D. P874, P6338
Lee, M.J. P2477 Leirgul, E. P711 Leosco, D.L. P6570
Lee, M.M. P2508, P3768 Leirisalo-Repo, M. P1523 Leosdottir, M. P743, P771, P2162, 2936
Lee, M.Y. P461 Leisch, M. P3558 Lepic, T. P5536, P5538
Lee, N.H. P4355 Leischik, R. P2385 Lepojarvi, S. P2708, P6221
Lee, R. P3741 Leite, F. P5252
468
Chairpersons & Judges / Speakers & Discussants / Authors Lep – Lin
Leppaenen, O. 2335, P4084 Leyva-Leon, F. 304, 353 Liga, R. P611, P4481

Leppert, J. P753 Leyva-Leon, F. 4222, 4224, 4226 Ligero, C. P3332
Lepretre, P.M. P2690 Li, C. P2634, P6175 Ligges, U. P3353, P3796
Leprince, P. 39 Li, E.K.M. P5424 Lighezan, D. P225, P5043
Leprince, P. 327, P2429 Li, G. P1428 Lighezan, R. P5043
Lerakis, S. P1604 Li, H. 1328, P1526 Ligtenberg, E. P2783
Lercher, P. P502 Li, J. P1113, P4122 Ligthart, J. P3733, P4673
Leren, I.S. P1397, P3497, 4960, P6307 Li, J.J. P1662, P5229, P5357, P5386, P5388 Lilja, M. P756
Lerma, E. P3772 Li, L. P637, P1359, P1526, P1700, P2688, Liljenback, H. P425
Lerman, A. 4021, P4381 P2793, P4652, 5123, P5620 Lilli, A. P2112
Leroux, L. P4438 Li, L.C. P6423 Lilliu, M. P3603
Leroy, J. 2283 Li, L.W. P4313 Lillo-Castellano, J.M. P475
Leroyer, S. 969 Li, L.Y.X. P5341 Lim, D.S. 5215
Lesage, F. P4520 Li, M. P5453 Lim, E. P3413
Lesauskaite, V. P636 Li, M.H. P3598, P3602, P4518 Lim, H.S. P1721, P4757
Lesbekov, T.D. P5665 Li, S. P1662, P5357, P5386, P5388 Lim, K.S. P2756
Lesevic, H. P3568 Li, S.J. P1643 Lim, P. P3413, P3516, P5423
Leshem-Lev, D. P1587 Li, S.W.L. P738 Lim, P.B. 232
Leshnower, B. P1604 Li, T.D. P6540 Lim, R. P4704
Lesiak, M. P4572 Li, W. P2521, P4407, P6413, P6417 Lim, S.-W. P2153, P4513
Lesniak-Sobelga, A. P5622, 6610 Li, X.-L. P5229 Lim, S. P5699, P6287
Lesny, P. P4770 Li, X. P5431 Lim, S.Q. P3102
Lestuzzi, C. P871, 3284, 4149 Li, X.H. P6359 Lim, T.W. P2430, 3278, P4352, P5644
Leta, R. P745 Li, Y.-H. P1466 Lim, Y.-M. P2153, P4513
Leta Petracca, R. P4996 Li, Y. P3557 Lim, Y.H. P904
Letarnec, J.Y. 5816 Li, Y.G. P6340 Lima, A.R.R. P892, P2808, P3788, P5258
Letavernier, E. P4525 Li, Y.H. P2568 Lima, E.G. P6267
Lethor, J.P. P4599, P4600 Li, Y.J. P2634 Lima, L.M. P1705
Lettino, M. 81, 154 Li, Y.Y. P6588 Lima, V. P5477, P5640
Lettino, M. 17, 3186 Li, Z. 1215, P4585 Lima Da Silva, G. P511, P2433, P5422
Leu, H.-B. 1976, P2131 Li, Z.A. P5237 Lima Silva, G. P1121
Leu, H.B. P800 Li Mura, I.E.A. P3536 Lima-Filho, M.O. 6617
Leu, S. P1762, P3564 Liakhotska, A.V. P902 Limacher, A. P5007
Leucht, A. P4516 Lian, Q. P3459 Liman, J. P5311
Leurent, G. P6415 Liang, C. P2493 Limbourg, T. P4479, P5001
Lev, E. 3194 Liang, D.H. P4081 Limbruno, U. 407
Lev, E.I. P1587 Liang, H.Y. P3469 Limbruno, U.L. P3118
Lev, E.L. P2731 Liang, X. P3443, P3459 Limeres, J. P818, P835, P836
Levashov, S.Y.U. P1692, P5552 Liang, Y.J. P4348 Limeres Freire, J. P610
Levashova, O.A. P5552 Liang, Y.X. P483 Limite, L.R. P4634
Levenson, B. P1726, P2377 Liao, D.N. P4369 Limongelli, G. P192, P1351, 4264
Lever, H. P1629 Liao, J.-N. P2427, P5273, P6326 Limoni, C. P4100
Lever, H.M. P1119 Liao, M.T. P2122, 5125 Limpens, J. P473
Levesque, R. P5364 Liao, S. P3459 Lin, H. P2132
Levi, A. P3698 Liao, S.Y. P1145 Lin, I. P6197, P6212, P6215
Levi, E.I. P3698 Liao, X.Y. P779 Lin, J. P6211
Levi, Y.L. P4382 Liapis, C.D. P6504 Lin, L.S.K. P5341
Levin, D. P4772, P5321 Liarakos, N. P2499, P5418 Lin, L.Y. P2116, 5125
Levin, M. P6552 Liatakis, I. P2844 Lin, S.-J. P574, 1976, P2131, P4684
Levin-Kotler, L. P3548, P3555 Liaudet, L. 1211 Lin, S.J. P800
Levine, R.A. P1381 Libbus, I. P3775, P5671 Lin, T.T. P2122, P2845, 5125
Levitan, E. P3667 Libby, P. 242, 305 Lin, W.Q. P5441
Levorato, D. P1092 Libby, P. 339, P1589, P2591, 3852, 6621 Lin, W.W. 1961
Levy, J.H. P5967 Liberska, A. P3322, P4075, 4861 Lin, Y.H. P2116
Levy, R. P5463 Libis, R. P2825 Lin, Y.J. P6326
Levy, S. 376 Libugan, B. P3435 Linares, J.A. P4712
Levya, F. 4857 Lichodziejewska, B. P755, P6168 Linares Vicence, J.A. P1622
Lew, K.S. P3464 Lichtenauer, M. P648, P3558 Lindahl, B. 130
Lewalter, T. 353 Lichtenberg, A. P6142 Lindahl, B. P419, P2460, P5373, P5384,
Lewalter, T. P2115, P3385, 5733 Lidegaard, M. P4636 P5399, P5400, P6424
Lewandowska, A. P1451 Lidon Corbi, R.M. P2507 Lindal, S. P5257
Lewin, P.G. P6442 Liebe, V. P4591 Lindback, J. P172, 4203, P5961
Lewington, S. P4321 Liebetrau, C. P567, 1988, P2386, P2620, Lindbohm, J.V. 1845
Lewis, A.B. P442 P3095, P3137, P4487, P4499, P4565, Linde, C. 137, 195, 354
Lewis, B.S. P203, P205, 3995, 4886, P5586 P4687, 5791, 6065, 6067 Linde, C. 16, P3129, 4857, 5200, 5202, 6662
Lewis, B.S.L. P6466 Liebregts, M. 6607 Linde, J.J. P6324
Lewis, E.F. 3153, P3756 Liefhebber, A. P4458 Lindgren, P. 6646
Lewis, M.J. P2701 Liehn, E.A. P4529 Lindhardsen, J. P6470
Leyh, D. P3599 Liem, A. 2101 Lindhardt, T.B. 1832, 1972
Leyton-Mange, J.S. P5924 Liew, R. P895 Lindholm, D. P172
Lindner, A. 1983
469
Chairpersons & Judges / Speakers & Discussants / Authors Lin – Lop
Lindner, D. P2164 Liu, D.Y. P5431 Lokhnygina, Y. P4398, P6210

Lindner, J. P5534 Liu, G. P1662, P5357, P5386, P5662 Lokki, M. P3098
Lindner, S.M. P6210 Liu, H. 337, 1215, 1958, P6360 Loko, G. P1544
Lindqvist, P. P6302 Liu, H.B. P6342 Loktionova, E. P3647
Lindsay, A. 958 Liu, H.N. P5253 Loli, A. P2831
Lindsay, A.C. P681, P1543 Liu, J. P3756, 4885 Lombardi, C. P3352, P3790
Lindsay, M. P1522, 4055, 4294 Liu, J.H. P1143, P6303, P6312 Lombardi, F. P4734, P5358
Lindschou, J. P3654 Liu, L. P643, P4987 Lombardi, M. P452, P6323
Lindschou, J.L. 2938 Liu, L.S. P779 Lonborg, J. 2910
Lindstrom, C. P1512, 3279 Liu, M. P3551, P6360 Loncar, G. P5663, P5690
Lingohr-Smith, M. P6211 Liu, P.-Y. P1466 London, B. P1385
Linhart, A. 246, 269 Liu, Q. 6103 Long, D.-Y. P5266, P5274
Linhart, A. 2083, 2084, 3899, P5534, 6645 Liu, S. 4194, P5670 Long, D. P2634
Linhart, M. P1417, P5951 Liu, S.W. P483 Long, Q. P4505
Linke, A. P683, P1600, 1983, 2319, P3639, Liu, T. P5984 Long, W.R. P4994
5788, P6390 Liu, W. P3438, P5341, P6515 Longhi, S. P2640
Linke, W. P3552, P5259 Liu, X.-H. P5274 Longo, G. P2768
Linke, W.A. 1853, 3065 Liu, X. P2413, P3352, P3378 Longo, S. P6581
Linker, N.J. 23, 5734 Liu, X.L. 1831 Longobardo, L. P3521
Linko, R. P451, 6043 Liu, X.W. P1645 Lonnebakken, M.T. P2621, P4093, 4900
Linneberg, A. P1433, P2170 Liu, X.Y. P6572 Lonni, E. P6446
Linnemkamp, B. P6451 Liu, Y.-W. P4780, 5808 Loo, B. P795
Linnersjo, A. 6646 Liu, Y. P903, P1145 Loo, G. 2942
Lino, G. P209 Liu, Y.Y. P659 Looi, J.L. P2612
Lintu, M. P6405 Liu, Z. P1428, P3357 Lopatin, Y.M. 82
Linz, D. P873, P2843, 6067 Liu, Z.G. P4369 Lopatin, Y.M. P3766, 3941, P6275
Linzbach, S. P459 Liu, Z.H. P6130, P6588 Lopatowska, P. P5293
Lionetti, V. P877, 1081, P2382 Liu, Z.M. P470 Lopes, A.B.L. P6479
Lionnet, F. P5654 Liuba, I. P4372 Lopes, H. P4785
Liou, K. P793 Liuba, P. P2665 Lopes, L. P4062, P5497, 6609
Liou, Y.S. P5551 Liuzzo, G. 3944, P6118, P6251 Lopes, R. P6240
Lip, G. Y.H. P5298 Livingston, M. 2961 Lopes, R.D. 1973, 1974, 2032, P4105, 4979,
Lip, G. 359 Ljubas-Macek, J. P2824 P6155
Lip, G.Y. 1830, P4626, P5273 Ljubojevic, S. 248 Lopez, B. P1778, P3127
Lip, G.Y.H. 186, 205, 260 Ljubojevic, S. 2244, 4187 Lopez, J. 2318, 2320, P3103, P3104, P3106,
Lip, G.Y.H. P226, 412, 413, 929, 950, P1450, Llach, A. P1425 P3576, P3637, P5483, 6022
P1488, P1516, P1666, P1783, 1832, 1911, Lleshi, A. 4149 Lopez, L. P1781
1970, 1975, 2192, 2867, 2870, 2872, Llobet, G.B. P1804 Lopez, M. 968
3146, 3276, 4129, P4338, P4400, P4619, Llorente-Cortes, V. P1586, 3202 Lopez, T. P3090, P4988
P4622, P4985, P4987, P5267, P5272, Llucia-Valldeperas, A. P3546, P3553, P5445 Lopez Aguilera, J. P2114
P5284, P5308, 5842, P5981, P6140, Lo, C.I. P888, P3534, P5432, P6294 Lopez Cervantes, M. P6592
P6197, P6205, P6208, P6212, P6214, Lo Bello, G. P3649 Lopez De Sa, E. 6633
P6215, P6217, 6657 Lo Presti, A. 5918 Lopez De Sa Y Areses, E.A. 5132
Lip, G.Y.H.L. P5279 Lobban, T. 4132 Lopez Diaz, J. P4575
Lipari Dinardi, L.F. P1787, P2822 Lobenwein, D. P2596 Lopez Fernandez, T. 198
Lipiec, P. P856, P2566, P3524, 4238, P4448, Loberman, D. P5633 Lopez Fernandez, T. 1234
P6295 Lobo, J.L. 4176 Lopez Jarammillo, P. P6596
Lippert, F. P4072, 6627 Lobo, M. 1003 Lopez Jimenez, E.A. P3486
Lippert, F.K. 155 Lobo, M.D. P2840 Lopez Lluva, M.T. P3122, P3718, P4714,
Liptak, B. P1414 Lobo, R. P3479 P6517
Lipworth, L. P5374 Loboz, K. P5704 Lopez Lopez, A. P2458, P2482, P2494,
Lis, A. P3430 Locatelli, A. P2390 P4415
Lis, G.J. P5465 Locorotondo, G. P604 Lopez Meseguer, M. P3625, P4550, P5957
Lisewski, U.L. P1419 Loders, S. P6374 Lopez Otero, D. P2494, P5248
Lishmanov, Y. P5224 Loebel, M. P3535, P5501 Lopez Palop, R. P832, 1205, P1710, P2732,
Lisi, M. P4741 Loeffelhardt, N. P809, P1493 P2759
Lisii, D.M. P3659 Loeffler, I. P2589 Lopez Reyes, R. P3625
Lisik, W. P755 Loegstrup, B.B. P4743, P4749 Lopez Rosetti, M. P1767
Lisowska, A. P2812, P4731, P4735, P6279, Loenborg, J. P554, P822 Lopez Sendon, J.L. P195, P3420, P3632,
P6283 Loeper, F. 2931, P4742 6633
Lissoni, F. P503 Lofman, I. 6637 Lopez Suarez, A. P4470
Listianingsih, E. P6385 Logakis, J. P1481, P5371, 5905 Lopez-Cuenca, A.A. P586, P1098
Litherland, C. 4000, P4326, P4328 Logander, E. P552 Lopez-Fernandez, S. P2792
Litschauer, B.L. P2677 Logeart, D. 28 Lopez-Fernandez, T. P853, 4049
Littarru, G.P. P3744 Logeart, D. P842, P4111 Lopez-Jimenez, F. P1377, P6472
Little, W.C. 4044 Loh, J.K. P3413, 5098 Lopez-Lereu, M.P. P1517, P1518, 3252
Littnerova, S. P224 Loh, P. 5809 Lopez-Lopez, A. P2466, P3474, P4406,
Littvay, L. P4630, P6401 Lohse, M.J. P3599 P5304
Litwin, J.A. P5465 Loirat, A. P2434 Lopez-Melgar, B. 6085
Liu, C.P. P3565 Lokhandwala, T. 1971 Lopez-Otero, D. P651
Liu, D. P694, P2639
470
Chairpersons & Judges / Speakers & Discussants / Authors Lop – Mac
Lopez-Palop, R. 366, P571, 962, P5348 Luchner, A. P4730, P6582 Ly, M. P1650, 2283, P5446
Lopez-Pineda, A. P2788 Luciani, G. P3739 Lyall, G.K. P4096
Lopez-Sendon, J. P3752, P6439 Lucio, E.A. P5477, P5640 Lyasnikova, E. P2393, P2825
Lopez-Sendon, J.L. 187, 270, 361 Lucron, H. P1670 Lyen, S.M. 4875
Lopez-Sendon, J.L. P853, 1075, 2879, Ludew, D. P6127 Lygate, C. P4517
2882, 2976, 3157, 4049, P5945 Ludman, P. 2914, P4327 Lynas, P. P4489
Lopukhova, V. P6528 Ludman, P.F. P813, 1196, P4447 Lyngbakken, M.N. P2383, P3674
Lorenzini, M. 158, P2640, P4456 Ludman, P.L. 4269 Lyon, A.R. P866, P869, 1232, P1411, P3398,
Lorenzo, M.J. P4569 Ludwig, A. P665 P3737, P6157
Lorenzo, N. P2554 Ludwig, S.E. P4113 Lyons, J. P2124
Lorenzo Gonzalez, O. P6250 Ludwik, B.L. P3361 Lythgoe, M.F. P1415
Lorenzon, A. P3536 Luehr, M. P6509 M’rad, S. P704
Lorenzoni, V. P6230 Luermans, J.G.L.M. 5914 Ma, C.-S. P5266, P5274
Loreto, G. P4664 Luers, C. P1777 Ma, C.S. 209
Lorgis, L. P799, P3080 Luescher, T.F. P1115, P1390, P1575, 1954, Ma, C.S. P1488, P1516, P6173
Loriot, A. 4190 P2582, P2791, P3448, P4092, P5007, Ma, J. P2413, P3378
Lorusso, R. P4371 6019, P6364, P6550, 6650 Ma, S.P. P779
Losa, S. P2573 Luesebrink, E. P661 Ma, X. P903, 1838, P3465
Losi, M.-A. P5623 Luetjohann, D. P1698 Ma, Y.C. P5237
Losi, M.A. 1985, 2972, 4900 Lugli, R. P3508 Ma, Y.L. P1467
Losurdo, P. P686, P1621 Luister, A. P1698 Ma, Z. P5434
Lotan, C. P1806 Lukas, M.A. P1682 Maack, C. 2322
Lottonen-Raikaslehto, L. P3099 Lukiyanov, M. P3354 Maas, A.H.E.M. 275, 5879
Lou, Y. 4059, P4515 Luknar, M. P4770 Maass, M. 4191, 6038
Louca, L. P1816 Lumens, J. P5221 Mabire, J.P. P2675
Louch, W. 3178 Lumley, M. P669, 4931 Mabo, P. 72
Loughrey, C. 3929 Lumme, J. P3125 Mabo, P. 100, 99, P1409, P2434, P2836,
Lougiakis, N. P3082 Lunati, M. 153 3901, 3903, P4095, 5205, 5207, P5429,
Louie, A.E.A. P780 Lunati, M. P502, P3399, 4865, 4904 P5438, 5837, P6161, 6630
Louie, M. P5980 Lund, L. P5482 Mabritto, B. P5493
Lourenco, A. P5641, 5922 Lund, L.H. P218, P3129, 6637 Mabuchi, H. P1655, P1661, P1699, P1701,
Lourenco, A.P. P1578, P1814, 1853, P5634, Lund, M. P5034 P1704, P2150
P5635 Lund, M.B. 4048 Mac Neill, B.D. P4068
Lourenco, C. P1627, P4062, P5497, P6393, Lundbye-Christensen, S. P4322, P5281 Macaluso, G. 5917
P6400 Lunde, I.G. 3065, P6341 Macaya, C. P1107, P1470, P1593, 2060,
Lourenco, P. P6586 Lundman, P. P6465 P2119, P2549, P2728, P3520, 4930,
Lousada, N. P6581 Lundqvist, A. P4658 P5243, P6498
Lousinha, A. 103 Luo, E. 1987 Maccarone, M.T. P2716
Louw, R. P3362 Luo, F. P1145 MacCarthy, P. P2625, P3726, P6487
Loverro, G. P6437 Luo, F.B. P2634 MacCarthy, P.M.C. 4269
Lovibond, S. P2784 Luo, L.M. P5587 Maccherini, M. P1769, P4741
Lovic, D. 5084 Luo, L.U.O. P5587 Macchi, S. P1533
Lovic, M. 5084 Luo, Q. P6130 Macdonald, P. P2819
Lowe, M. P494 Luo, X.X. P5434 Macdonald, P.S. P4725, P5669
Lowrie, R. P2826 Luong, L. 5847 MacDonald, T.M. 195
Lowry, J. P3767 Lupi, A. P2781 MacDonald, T.M. 2259, 3156
Loyeau, A. P1338, P4445, 5816 Lupi, L. P1555 Macedo, A.F. P4401
Lozano, I. P1710, P4719 Lupo, U. P3785 Macedo, F. P3604, P6394
Lozano Granero, C. P508, 3173, P5442 Lupon, J. P752, P1139, P2790, P2811, 4277, Maceira Gonzalez, A.M. P1690, P4775
Lozano Ruiz-Poveda, F. P3122, P3718, 4279, 6639 Macek, M. P5499
P4714, P6517 Lupon Roses, J. 91 Macey, N. P1146
Lozekoot, P. P4371 Lupusoru, C.E. P5037 MacFadyen, R.J. P2784
Lozova, T.A. P4427 Lurz, P. P2387, P2480 MacFarlane, P. P621
Lu, D.Y. P6576 Lusakowska, A. P6168 MacGillivray, T.J. P2127
Lu, G. P3088 Luscher, T.F. 88, 185, 242, 316 Mach, F. P1691, P3448, 6647, 6650
Lu, H. P716, P2743 Luscher, T.F. 913, 1153, P1449, P1691, Mach, L. P3114
Lu, W.L. P4369 1852, 2859, 3856, 5046, 5139 Machado, F.P. P4509
Lu, Z. P3339, P5038 Lutale, J. P1538 Machado, M.N. P5254
Luan, S. P697 Lutgens, E. 256, P6126 Machado, V.A. P1673
Lubbers, M.M. 2101 Lutgers, H.L. P183 Machado Leite, S. P5367
Lubimceva, T. P2393 Lutman, C. P3335 Machain Choreno, T. P5645
Lubinski, A. P166 Luttun, A. P1111, P1114 Machaj, I. P6506
Lubitz, S.A. P1381, P5924 Lutz, S. P3329 Machhada, A. P1415
Lubos, E. 349, P1591 Lutz, T.A. P1575 Machi, J.F. P2679
Luca’, F. P4371 Luukkaala, T. P3517 Machino, T. P1371, P1399, P3498
Lucarelli, C. P208 Lux, A. P1144, 2284, P2667, P2678 Machino-Ohtsuka, T. P4116
Lucas, J. 4858 Luycx-Bore, A. 6625 Macia, J.C. P3451, P4446, 5088, P6452
Lucchese, F.A. P5477, P5640 Lv, J. 6103, P6518 Maciag, A. P2441, P5291
Lucci, D. P1474 Lv, Y. P1428 Maciag, J. P6599
Luccia, N. P1804 Lwakatare, J. P1538 Maciejewski, T. P3671
Luceri, S. P5493
471
Chairpersons & Judges / Speakers & Discussants / Authors Mac – Man
Maciel, M.J. P1407, P1668, P3604, P3668, Maggioni, A. P3759 Majid, E. P1397
P4464, P5367, P5406, P5677, P5679, Maggioni, A.P. 32, 37, 73, 90 Majocchi, B. P4346
P6394 Maggioni, A.P. P3752, P4619, 5073 Majoie, C. P5597
MacIsaac, A. 264, 359 Maglia, G. P2112, 5916 Majoor-Krakauer, D.F. 3074
MacIsaac, A. P3316 Magliano, D. P756, P3627 Major-Pedersen, A.T. P1571
MacIver, D.H. 4872 Magnani, G. 3032, P3317 Majoros, Z.S. P3348
Mack, M. 310, 4947, 5215, P5642 Magnano, R. P6199 Majstorovic, A.M. P4778
Macrae, C. 359 Magne, J. 2996, 2997, P4558, P5500 Mak, J.K.C. P1416
Macrae, C. P1562, 3960, 5828 Magnin-Poull, I. P164 Mak, S. P5525
Macrini, M. P1590 Magnoni, M. P4634, P5577 Makarawate, P. P708
Macron, L. 1934 Magnussen, C.G. P1356 Makavos, G. P5418, P5437, P6265
Madaric, J. P3556 Magnusson, A. P2659 Makhmatova, T. P900
Madaricova, T. P3556 Magnusson, M. P4532 Maki, H. P4567, P6512
Maddaloni, D. P2355 Magoutis, N. P2666 Makimoto, H. P5042
Maddalozzo, A. P2541, P2550, P2559, Magri, G.L. P3739 Makino, K. P202, P3111, P3499, P5315,
P3532 Magrini, F. P4734 P6296, 6634
Madeddu, G. P4628 Magro, M. 1201 Makino, N. P2503, P6201
Madeddu, P. P2573, P3545, P3566, P5454 Maguire, A. P6192 Makita, T. P4112
Madeira, H. 2080, 2082, 2084 Maguire, G.P. P1612, P4579 Makiyama, T. P6350, P6351
Madeira, M. P209, P2472, P3473, P5346 Mahabadi, A.-A. P2357 Makkiya, M. P3488
Madeira, S. P1610, P2394, P3586, P4509, Mahabadi, A. 4205 Makowska, A. 5848
P4624 Mahabadi, A.A. 2104, P5960, P6322 Makowski, K. P2452
Madeira, S.M. 1200 Mahadevan, D. P2356 Makrygiannis, D. P4432
Madelaire, C. 4283, 4284 Mahaffey, K.W. P1497, 2031, P3076, 4002, Makrygiannis, S. P6204
Madhavan, M. P4984 P4105, P4398, P6210, P6290 Makushkina, T. P211, P6420
Madias, J.E. P2406 Mahajan, R. 1847, P4374, P6198 Malacrida, M. P504, 4860, P5222
Madiot, H. P579, P796 Mahanonda, R. P1695 Malafaia, F. P1671
Madonna, R. 22 Mahara, K. P1801, P3334, P5488 Malagoli, A. P2619
Madonna, R. P1348 Mahdhaoui, A. 376 Malaiapan, Y. P2839
Madrid, A.H. 2173 Mahendiran, T. P2392 Malcles, G.M. P5933
Madrid-Miller, M.A. P5360 Maheshwari, V. 5094 Malcolmson, J.W. P692
Madsen, M. P1336, P1337, P1464, P1498, Mahfoud, F. 86, 88, P873, 1004, 2289, Maldonado, G.A.M. 2911, P3689
P1503, P2745, P5351 P2841, P2843, P2846, P3735, 3823, 6067 Malek, F. 6645
Madsen, T.L.S.M. 2938 Mahgoub, D. P2542 Malekzadeh Milani, S. P1639
Madssen, E. 2943 Mahia, P. P1593, P2549, P3520, P5243 Malevannyi, M.V. P2492
Madureira, A. P3604, P6394 Mahjoub, M. P533, P2615, P5356 Malfitano, C.M. P6479
Mady, C. P198, P700, 2944 Mahlof, E. P5984 Malhotra, A. P2373, P2680, 2967
Maechler, H. P3471, P3492 Mahmoodi, B.K. 6607 Mali, W.P.T.M. P5246
Maeda, D. 2108 Mahmoud, A. P600 Malik, A. P1477
Maeda, M. P3089 Mahmud, F. P2136 Malik, M. 1005, 2026
Maeda, T. 1321, P1332, P1384 Mahnkopf, C. P4356 Malik, N. P1500, P2778
Maegdefessel, L. P2604, 2947 Mahoney, D. 3049 Malik, T. P5475
Maehara, A. 407 Mahoney, E. P4773 Malikova, E. P2647
Maejima, N. P885, P6411 Mahrholdt, H. P3093, 4054, P6271, P6323 Malinovskaya, L.K. 6042
Maekawa, E. P2696, P2719, P5545 Mahrous, A. P617, P1519 Malinowski, J. P3088
Maekawa, J. P801 Mahto, R. P6133 Malkin, C.M. 4269
Maekawa, Y. P688, P1633, P3123 Mai, W.Y. P4313 Mallamaci, F. P1149
Maemura, K. P876, P2475, P4451, P6237, Maia, L.N. P5254 Mallat, Z. 976
P6272 Maia-Rocha, C. 6058 Mallender, C. P4376
Maeng, M. P1336, P1337, P1464, P1498, Maier, A. P2125 Malloggi, L. P2351
P1503, P2745, P5351 Maier, B. P562, P4070 Malmstrom, R.E. P4067
Maenosono, R. P4065, P4375 Maier, L. P1722, 2230, P4730 Malodiya, A. P2832
Maeremans, J. P4701 Maier, L.S. 151 Malta Hansen, C. P1333
Maerz, W. P4767, 6644 Maier, L.S. 1851, P2159, 3310, P3552, Maltinti, M. P6474
Maessen, J.G. P4371 P4330, P6582 Maltret, A. 5919
Maestri, R. P1664 Maigrat, C.H. P676 Maly, M. P565
Maestrini, V. 2968 Mainar, L. 963 Malyshev, M. P5349
Maffe’, S. 4860 Mainar, V. P2759 Malyszko, J. P5293
Maffei, L. P5576 Maio, E. P1590 Malyutina, S.K. 368
Maffei, S. P6425 Maiolino, P. P859 Mamas, M. 6057
Maffioli, P. P5040, P6153 Maiorana, A. P3640 Mamic, P. 360
Mafi Rad, M. P5223, 5914 Mair, F. P1374, 6640 Mammaev, S. 5083
Magalhaes, A. P511, P2109, P2433, 4154, Mair, F.S. P2826 Man, S.H. P510
P6165 Mair, J. P4411, P4416 Manabe, I. P5003
Magalhaes, M. P670, P1599, P3593, P4583, Maisano, F. 352, 3036, 3812, 5784, P6364 Manapat, N.C. P2635
P6379 Maisch, B. P3597, 5990 Mancas, S. P6469
Magalhaes, P. P3457, P4062, P5390, P6393 Maisel, A. 353 Manchanda, S. P1370
Magda, L.S. 4157 Maiseyeu, A. P653 Manchi, M. 3944, P5455
Mager, J.J. P5532 Majani, G. P1664 Manchurov, V. P6332
Maggi, D. P5289 Majeed, A. P1512, 3279 Mancia, G. 241, 305, 316
472
Chairpersons & Judges / Speakers & Discussants / Authors Man – Mar
Mancia, G. P1149, P2841, P2846, 3827, Manzano Fernandez, S. P586, P1098 Marina Breysse, M. P3718, P4714, P6517
P4119, 4138, P4781 Manzano-Fernandez, S. P4403 Marina Breysse, M.T. P3122
Mancini, D. 2210 Manzi, M.-V. 4870 Marina-Breysse, M. P475
Manco, M. P6480 Manzoli, L. P3397 Marinato, M.M. P1528, P1534
Mancone, M. P846, P847, P5378 Mao, C.T. P4990 Marinelli, M. P4669
Manconi, P.E. P1573, 5807 Maor, E. 4204 Maring, J.A. 1957
Mancusi, C. 4900 Mappa, L. P657 Marinheiro, R. P591
Mancuso, T. P3560, P3561 Maqsood, A. 6056, 6057 Marinho, B. P1605
Manczuk, M. P222 Maques, N. P4062 Marinho Da Silva, A. P4764
Mandal, S. 4152 Mar, G.Y. P3565 Marinho-Da-Silva, A. P4333
Mandalenakis, Z. P438, P2654, P2657, Maragkoudakis, S. P3355, 4899, 5905 Marini, C. P2616, P5659, P6389
2925, 2966, P3614, P6460 Maragoudakis, F. P5371 Marini, D. 2930
Mandoli, G.E. P3525 Marakos, P. P3082 Marini, M. P1664, P3437, P3743
Mandolini, C. P1483, P5455 Marandi, T. 1198 Marino, F. P3560, P3561, P3563, P4741,
Mandry, D. P164, P557, P5513 Maranta, F. P6245 P5457
Manenti, V. P2418, P2455, P3365, P4599, Maras, P. P3646 Marino, P. P1476, P1480, P1501, P2117,
P4600, P5553 Marber, M. P669, 4931 P2561, P3119, P5542
Manerba, A. P1555 Marcano, A.L. P761 Marino, V. P4346
Manes, A. 4182, P5521, P5524 Marcantoni, L. P2389, P4745, P4758, 4863 Marinou, K. P4337
Manfrini, O. P561, P594, 4287, 4291, P4698, Marcantoni, M. P1560 Marinou, M. P654
5086, 5819 Marcelis, C.L.M. P695 Marinskis, G. 3987
Manganaro, R. P634, P3521 Marchei, M. P1590 Marjamaa, A. P1649
Manghat, N.E. 4872, 4875 Marchesini, E. P6216 Marjanovic, M. P446, P830
Mangiacapra, F. 4023, P6291 Marchesini, M. P860 Mark, B. P1462
Mangialardi, G. P3566, P5454 Marchewka, J. 2022 Marketou, M. P1481, P5371, 5905
Mangieri, A. 370 Marchi, B. P6474 Marketou, M.E. P3355, 4899
Mangili, L.C. P1705 Marcinkiewicz Siemion, M. P2812 Markides, V. P2407, P3367, P3395, P4390,
Mangin, L. P796, P3344, 6622 Marcinkiewicz-Siemion, M. P4731, P4735 P5452, P6112
Mangner, N. P212, P683, P1600, 1983, Marco, J. 74 Markiewicz, W. P447
2319, P3639, P3728, 5788 Marco, J. P3120 Markl, A. 5846
Mango, M. P5639 Marco Navarro, E. P1125 Marmelo, B. P1627
Mangoni, L. P1423 Marcolino, M.S. P621 Marmot, M. P5582
Mangschau, A. P5592 Marcon, F. P2455, P4599, P4600 Marosi, C. 4278
Mangum, S. P4105 Marcondes-Braga, F.G. P1804 Maroto, L. 2318, 2320
Manhem, K. P4782 Marconi, M. P2485 Maroto-Aramendi, A. P5494
Maniatis, K. P2725 Marcos, E. P4525, P5473 Marquart, L. P3349
Manina, G. P4675, P5609 Marcos-Alberca, P. P1107, P2548, P3520, Marques, F. P5658, P5684
Manintveld, O.C. 6641 P5243 Marques, H. P4488, P4509, P4624
Maniotis, C. P791 Marcotte, F. P717 Marques, J. P545, P2823, P3452, 4255,
Manivarmane, R. P866 Marcucci, R. P1496, P2522, P6200 P4993, P5338, P5345, P5352, P6266,
Manka, M. 2230 Marculescu, R.M. P2677 P6395, P6529
Manka, R. P4590 Mardekian, J. 1975, P6197, P6212, P6215, Marques, J.S. P3601
Mankad, R. P6472 P6217 Marques, K.M. P1507
Mann, I. P2126 Mardikar, H.M. 41, 312 Marques, M. P4380
Mannhalter, C. 4866 Marechaux, S. P2836 Marques, N. P1626, P1627, P2526, P5497,
Manning, S. P772 Maredia, N. P615 P6393, P6400
Manninger-Wuenscher, M. P3471, P3492 Marelli, S. P6495 Marques, P. P511, P2428, P2433
Mannsverk, J. P5024 Marenna, B. 5918 Marques, S. P5684
Manola, S. P6208 Maresca, A.M. P3802, P5712 Marques Correia, P. 2209, P6489
Manolis, A.J. 127 Maresca, G. 5904 Marques Rodrigues, J.A. 2086
Manolis, A.J. P906, 1889, 1890, 1893, Margalho, S. P2760, P4686 Marques-Vidal, P. P535, P5936
P4123 Margaritis, M. 1834, P2595, P5416 Marquie, C. P608, P3374, 5919
Manolis, A.S. 310 Marginean, A. P2135 Marquie, J.-C. 2023
Manolis, A.S. P2744 Margolis, L. P6332 Marra, S. P208, P2617, P5353, P6372
Manolopoulos, V.G. 1089 Margonato, A. P2616, P5491, P5659, P6245, Marrouche, N.M. P1151
Manotheepan, R. P416 P6389 Marrozzini, C. P5521
Manouras, A.I. P5482 Margulescu, A.D. P635 Marrugat, J. P758
Manovel, A. P6421 Mariani, J.A. P1811 Marsal Mora, J.R. P2507
Manrodt, C. 4857 Marie, P.-Y. P164 Marsh, A.M. P4570
Mansencal, N. 1282, 1284, 1286, P5963 Marie, P.Y. P557, P5513 Marshall, A. P1477
Mansinho, H. 4158 Marijon, E. P534, 1320, P1382, P1409, Marshall, E. P6327, P6384, 6616
Mansur, A.P. P6449, P6471 P1613, P3134, 3982, 3984, P4073 Marshall, K. P774
Mantas, Y. P4418, P4430, P4450 Marin, B. P5574 Marshall, M. P4405
Mantovani, F. P3508, P3515 Marin, F. P1528, P1534, P4403, P4622, Marshner, S.L. P4323
Mantzaraki, V. P2666 P6140, P6196 Marstrand, P. P2456
Mantziari, L. P498, P3367, P3395, P5452, Marin, G.B. 6617 Marta, L. P4509
P6112 Marin, M. P6371 Martens, K. P3539
Mantzouratou, P. P3442 Marin Atucha, N. P862 Martensson, J. P443
Manuaba, I. P5262 Marin-Neto, J.A. 6617 Marti, G. P2732
Manyine Siket, I. P2649 Marina, N. P1415 Marti, M.T. P3546
Manzan, E. 351, P4568
473
Chairpersons & Judges / Speakers & Discussants / Authors Mar – Mat
Marti Aguasca, G. P2507 Martins, J. P3452, 4255, P5352, P6266, Mastrokostopoulos, A. P1141, P3582,
Marti-Almor, J. 952, P3077, P5301 P6529 P4751
Martikainen, M. 1322 Martins, M.V.R.S. P3479 Mastromanolis, E. P3441
Martin, A. P476, P1622, P2119, P4386 Martins, R. P4333, P4764, P5427 Masuda, H. P3439, P3440
Martin, A.M. P1096 Martins, R.P. P2434, 4906, 6630 Masuda, J. 6634
Martin, B. P2671 Martis, S. 6625 Masuda, J.M. P828
Martin, C.A. 3935 Martsevich, S. P6467 Masuda, K. P1399, 3169, 3172, P6298
Martin, D. P861 Martsevich, S.Y.U. P3354 Masuda, M. P2404, 3170, P4360, P4498,
Martin, D.F. P5254 Maruelli, G. P5709 P5326
Martin, F. P2772 Marullo, F. P6132 Masuda, S. P3544
Martin, J. P1446, P1811, P2784, P3774, 6608 Maruo, K. P1514 Masuda, T. P1567, P2672, P2696, P2719,
Martin, L.C. P2704 Maruo, T. P2622 P5545
Martin, M.L. 968 Maruta, S. 3946 Masumoto, H. P3549
Martin, M.P. P3483 Maruyama, H. P5504 Masunaga, N. P767, P3690, P4121, P4635,
Martin, P. 365, P797, P2758, P2763, P3704 Marwan, M. 1255, 1256, P4479, P4510, P4642, P6248, P6553
Martin, R.P. 326 P5231 Masuta, E. P698
Martin, S. P1676, P5500 Marwick, T. P3676, P4746, 4868, P5430, Masuyama, T. 84
Martin, V. P4988 P5522, P5711, 5801 Masuyama, T. P1739, P1743, P2408, P2775
Martin Antoran, J.M. P3673 Marwick, T.H. 107, 1017, 1019, 1844, 4155, Mata, R. P5686
Martin Asenjo, R. P3486 P4502, 5196, P5672, P6321 Mata Marin, L. 5818, P5935
Martin Fernandez, M. P3591 Marx, A. P6149 Matamoros, M. P5945
Martin Garcia, A.C. P1470 Marx, J. 5848 Matangi, M. 6084
Martin Lorenzo, P. P4676 Marx, N. 127 Matas, M. P472
Martin Reyes, R. P1710, P6250 Marx, N. P645, P646, P1563, P1734, 1880, Matcham, F. P2625
Martin Ventura, J.L. P6250 1883, P2362, 3175, P3725, P4449, P4462, Mateescu, A. P1630
Martin-Moreiras, J. P2772 P4540, 5848, P6521, P6524 Matei, L.L. P2806
Martin-Urda, A. P1674 Marzahn, C. 6017 Mateo-Martinez, A. P4403
Martin-Yebra, A. P1545, P6443 Marzak, H. P845 Mateova, R. P3556
Martin-Yuste, V. P1445, P2780, 6018 Marzak, H.M. P5487 Mates, M. P3476, P6493
Martina, S. P899 Marziliano, N. P5938 Matetzky, S. P1565, P2474, P5560, P5569
Martinaios, A. P4123 Marzilli, M. 242 Mateus, P. P3457, P5390
Martinca, T. P6493 Marzilli, M. P2351, P3525, 3847, 5805, Matheus, M.G. P6499
Martinek, M. P3383 P6542, P6567 Mathew, R.M. 366
Martinelli, V. P1347 Marzoa-Rivas, R. P1123 Mathias Jr, W. 1181, 1183, 1184, 1185,
Martineos, A. P906 Marzocchi, A. P2617, P2640, P5521 1187, 3000, 6014
Martinez, A. 315 Masae, E. P6244 Mathur, A. P1446, P2740, P3711, P3774,
Martinez, C. P4981, P5320 Masahide, T. P4409 6608
Martinez, D.L.M. P2577 Masai, T. P4495 Matia Frances, R. P508
Martinez, F. 288, P4775, P6343 Masaki, T. P839 Matic, D. P446, P827, P830, P2518
Martinez, J. P478 Masano, T. P6273 Matic, G. P4425, P4452
Martinez, J.B. P167, P478 Masaoka, Y. P4506 Matiullah, S. P5604
Martinez, J.P. P1545 Masarone, D. P1351 Matmurotov, Q. P5376
Martinez, M.W. P4580 Mascarenhas, D.A.N. P5606 Matoba, T. P3482
Martinez, P.F. P2808, P5258 Mascelli, G. P5543 Matoga, M. P5294
Martinez, R. P571 Mascellino, M.T. P2443 Matos, A. P1796
Martinez, V. 6085 Mascherbauer, J. P1786, P1808, P2129, Matos, L.A.P. P2717
Martinez Abellan, R. P5348 2212 Matos, P. P1796
Martinez De Ilarduya, O. 3067 Masci, P.G. 6044 Matshela, M.R. P196
Martinez Garcia, F. P2652 Maseli, A. P4663 Matskeplishvili, S. 248, 302
Martinez Hernandez, H.J. P641 Maselli, D. P2573 Matskeplishvili, S. 6015
Martinez Marcos, F.J. P6371 Masenko, V. P879, P6528 Matsubara, H. P4547, P5516
Martinez Martinez, E. P1589 Masi, S. 76 Matsubara, M. 6105
Martinez Martinez, J.G. P1398 Masip, J. 3060, 3061 Matsubara, T. P4608, P6282
Martinez-Arias, L. P3591 Maske, U.E. P3610 Matsubayashi, K. P5262
Martinez-Bujidos, M. P1586 Maslowsky, F. P3649 Matsuda, H. P1760, P2694, P3702
Martinez-Ferrer, J.B. P475 Mason, F. P5030, P6154 Matsuda, J. P789, P1361, P1362, P1711,
Martinez-Gomez, A. P2466 Masopustova, A. P1588 P1715, P1719, P1720, P1749, P4511
Martinez-Gonzalez, J. P1369 Masotti, L. 4174, P4675 Matsuda, M. P4611
Martinez-Gonzalez, M.A. P4662 Masotti, M. P2780, P4988, 6018 Matsuda, S. P4732
Martinez-Legazpi, P. P3127, P4569, 5802 Massaro, R. P2390 Matsuda, T. 6632
Martinez-Micaelo, N. P3332 Massberg, S. 249 Matsuda, Y. P420, P2404, P4498
Martinez-Sande, L. P5304 Massberg, S. 335, P607, P1500, 2099, Matsudo, Y. P4353, P4384
Martinez-Selles, M. 962, P6371 P3568 Matsue, Y. P891, P1798, P3784
Martini, A. P192, P4586 Masseria, C. 1975, P4397, P6197, P6212, Matsui, H. P5691
Martinis, G.F. P2554 P6215, P6217 Matsui, K. P5593
Martinka, P. P1367 Massetti, M. P5455 Matsumi, J. P6319
Martins, C. 5814 Massey, R. P2621, P3589, 4156 Matsumoto, C. P1821
Martins, E. P3604, P5677, P6394 Massimi, I. P1483 Matsumoto, H. P2799
Martins, F.A. P5251 Mast, T.P. 5809 Matsumoto, I. P1130
Martins, H. P2470 Mastoris, I. P582, P1510, P5375 Matsumoto, K. P5527, P6311
Mastroianni, C.M. P2443 Matsumoto, N. P1452
474
Chairpersons & Judges / Speakers & Discussants / Authors Mat – Meh
Matsumoto, Y. P790, P1707, P4336 Mayer Jr, O. 6652 McFarlane, K. P6456

Matsumura, A. P420, P1798, P3784, P6238 Mayet, J. P6433 McGavigan, A. 29
Matsunaga, A. P1452 Mayo, M. P1799 McGavigan, A. P3630
Matsuo, H. P1760, P3700, P6363 Mayordomo Gomez, S. P4710, P6426 McGettigan, P. P6470
Matsuo, K. P433 Mayosi, B.M. 5990 McGhie, J.S. P707
Matsuo, Y. P212, P583, P1728, P1736, Mayr, A. P4411, P4416 McGraw, S. P1521
P3728, P3754, 3945, P5973, 6623 Mayr, M. 193, 364 McGuigan, S. P6202
Matsuoka, J. 5087 Mayr, M. P1472, P2571, P4082, P4531, McGuire, D.K.M. P6466
Matsusaki, N. P1779 5111, 5112, 5114, 5116 McInnes, G.T. 187
Matsushita, K. P5564, P6123 Mayranpaa, M.I. P3098 McInnes, G.T. 2884, 2887
Matsushita, S. 6105 Mazaris, S. P730, P5555 McIntyre, B. 4875
Matsuura, H. P417 Mazet-Guillaume, B. P3485 McIntyre, R. P1380
Matsuura, K. P3551 Mazhar, J. P2356 McKeag, N. P477
Matsuzak, M. P4732 Mazighi, M. 3274 McKee, G. 35
Matsuzawa, R. P2696, P5545 Mazij, M.M. P3361 McKee, G. 227, P778
Matta, M.G. P2421 Mazuelos, F. P797, P2763, P3694, P3704, McKendrick, J. P1677
Mattei, R. P6548 P3730 McKenna, W. 6609
Matter, C.M. P1575, P1691, P3448, P5026, Mazuelos, M. 365 McKenna, W.J. 269, 377
6650 Mazuelos Bellido, F. P2114 McKenna, W.J. 28, P1624, P1632, P2641,
Mattesini, A. P2752, P2764 Mazur, G. P3112 4958
Matteucci, M. P877, 1081 Mazur, J. P3671 McKenzie, D. P2392
Matthijs, G. P3101 Mazur, P. P2606, P3587 McKeown, P.P. 27
Mattina, A. 5079 Mazurek, A. P5622 McKinlay, S. P3756
Mattsson, E. P3611 Mazurek, M. P3322, P4075, 4861, P5303 McLaughlin, K. P1576
Mattsson, N. P5305 Mazurek, T. P3086, 3219 McLaughlin, V. P2365
Mattsson Hulten, L. P4658 Mazzaccara, C. P1351 Mcloughlin, E. P2136
Matubara, K. P769 Mazzanti, A. P4298 McManus, R. 282, 284, 286
Matucci Cerinic, M. P4669, P5530 Mazzanti, C.M. P4091 McMurray, J. P217, P895
Matusik, P. P6599 Mazzanti, G. 4182, P5524 McMurray, J.J. P6551
Matyar, S. P875 Mazzanti, M. P1552 McMurray, J.J.V. 41, 147, 299
Matyas, C. P1144, 2284, P2667, P2678, Mazzarotto, F. 3072 McMurray, J.J.V. P213, P214, 372, 375,
P4536 Mazzolai, L. P4530, 5191, 6087 376, 377, 1071, 1168, 1977, P2826, 2901,
Maues, H.P. P5251 Mazzone, A. P4414, P4478 3301, 3810, 4810, 4812, P5031, P6555,
Mauler, M. P2125, P6339 Mazzone, C. P4399, P5297, P5683 6642, 6643
Maupain, C. P714, P2429, P3588 Mazzotta, E. P4628 McNair, P. 1197
Maurea, C. P859 Mbanze, I. P2651 McNally, B. P1333, P4435
Maurea, N. P859 Mbelesso, P. P4108, P5574 McNitt, S. P523, 2271
Maureira, J.P. 6021 Mc Alindon, E. 201 McSpadden, L. P502
Maureira, P. P676 Mc Cambridge, J. P5688 Mead, A. P2718
Maurer, G. 89 Mc Carron, C. P4401 Mead, H. 2988
Maurer, G. P530, P2488, P2613, 2993, 2995, Mc Donald, K. P2821, P5688 Mean, M. P5007
2997, 5092, P5398, P6255, P6547 Mc Intyre, W.F. P6402, P6408 Mearns, E.S. P6195
Maurer, H.H. P2843 Mc Murray, J. 3302 Mebazaa, A. 96, 199, 270
Maurer, L. P532 McAdam, J. P4570 Mebazaa, A. P880, P2459, 3057, 3303,
Maurer, M.J. 3049 McAlindon, E. P4420 P3793, P4768, P6566, P6573, 6645
Mauri, L. 406, 1275, 1277, 2178, 2179, 2903, McAllister, D. P4461 Mechmeche, R. P850
3916 McAllister, D.A. P3432 Mechri, I. P2615
Maurin, V. P4438 McArthur, T. P4489 Mecteau, M. P1561
Maurizi, N. P466 McBride, H. P1413 Medani, S. P625
Maurovich-Horvat, P. 2105, 2234, P4496, McCann, G.M.C. P817 Meddeb, Z. P704
P4630, P6401 McCann, G.P. P2530, P3126, P4570 Medeiros-Domingo, A. P1390
Maurovich-Horvath, P. P3075 McCarthy, A. 4047 Meder, B. P2687, P5472, P6540
Maury, P. 1011, 1013, 1015 McCarthy, R.A. P2398 Meder, B.M. P3100
Mavilio, M. P2362 McClelland, R.L. P5959 Medina, A. 365, P794, P797, P2758, P2763,
Mavrakis, H. P2642 McColl, I. P4441 P3694, P3704, P4676
Mavrodi, A. P6320 McConnachie, A. P5019 Medina, J. P2463, 3031
Mavrogeni, S. 2037, 2039, 2041, 3253 McConnell, M. P2124 Medrano-Lopez, C. P5494
Mavromatis, K. P1604 McCord, J. 162 Medvedeva, E.A. P2163
Mawatari, E. P4467 McCullough, P.A. P3791 Meerkin, D. P794
Maximkin, D. P6269 McCully, K.K. 960 Meex, S.J.R. P3333, P4615
May, H.T. P3356, P4376 McCully, R. P4102, 4887 Mega, S. P6132
May, L.T. P4521 McDiarmid, A.K. P4096 Meghani, A. P2680
May, O. P3522 McDonagh, J. P783 Megias, A. P1396
Maya, Y. P605 McDonagh, T. P6564 Mehilli, J. 1276, 1278, 2226, 3003, P3705,
Mayer, E. P2602, P3095, 4814 McDonagh, T.A. 5909, 5911 4940
Mayer, E.M. P4687 McDonald, K. 409 Mehmedbegovic, Z. P446, P580, P609,
Mayer, J. P3389, P3409, P4341, P4359, McDonald, T. 2261 P816, P827, P830, P2484, P2518, P2567,
P4983 McEneaney, D.J. P477 P3715, P4433, 5105
Mayer, K. P1485 McEntegart, M. P617, P1519, 4024, 4055, Mehran, R. P582, P807, P1510, P2762, 2913,
Mayer, M. P4530 4294 2976, P3342, P3717, 4000, 4148, P4326,
McEwan, A. P3734 P4328, P4695, P4699, P4992, P5375, 6619
475
Chairpersons & Judges / Speakers & Discussants / Authors Meh – Mic
Mehta, A. P6162 Menditto, A. P860 Meschisi, M. P3521

Mehta, L. P2762 Mendonca, L. P5006 Mesquita, E.T. P3479
Mehta, R. P6181 Mendonca, M. P5964 Mesquita, J. P1610
Meier, B. 25 Mendonca, M.I. P4621, P4625, P4643, Messaoudi, Y. P4693
Meier, B. P206, 939, 6020, P6246 P4645, P4646, P5962 Messas, E. 308
Meier, T. P2160 Mendoza, C. P4413 Messas, E. P3574
Meijboom, E.J. 4849 Mendoza, I. 2088, P2823, P6395 Messas, N. P647, P845, 6635
Meijboom, F.J. P2137, P2656, 2934, P5223 Menegus, M. P3488 Messig, M. P201
Meijborg, V.M.F. P2412, P6159 Menet, A. P2836 Messika-Zeitoun, D. 95
Meijer, A. P5927 Meneveau, N. 198 Messika-Zeitoun, D. 133, 1305, 1984,
Meijs, J. P696 Meneveau, N. 1061, 1062, 1063, P1461, P4574
Meimoun, P. 6625 P1733, P3344, P4629, P6407, 6622 Messina, R. P5577
Meinander, T.A. P6405 Menezes, M. P3804, 4154 Messner, M. P1349, P4737, P5558
Meine, M. P5223 Menezes, M.N. P598, P1121, P1122, P2109, Messroghli, D. P189
Meinert Larsen, T. 3212 P2428, P2636, P3601 Mestroni, L. P1375, P1393
Meireles, A.V. P3479 Meng, X.M. P3697 Metallinos, G. P5676
Meisinger, C. P758, 4205 Meng, Y. P903 Metaxa, V. P2711, P6422
Mejat, A. P6164 Meng, Z. P5662 Metra, M. 240
Mejia, H. P1593 Mengden, T. P3353, P3796 Metra, M. 147, P891, 3064, P3350, P3790,
Mejia-Renteria, H. 2060 Menghini, R. P2362 3808, 6037, 6638
Mekkarnia, A. P6500 Menicanti, L. P452, 2208 Metrich, M. P861
Melander, O. 1328, P1395, P2162, P4532, Menken-Negroiu, R.F.M. P2569 Metton, O. P4595
P5385 Menon, A. P3455 Metzger, D.C. P4328
Melandri, G. 158, P3437, P4456 Menon, V. 300 Metzler, B. P4411, P4416
Melao, F. P1668, P3604, P3668, P6394 Menon, V. 3870, 3872 Meun, C. P747, P4609
Melbye, M. P711 Menotti, A. P739 Meune, C. P687, P2815
Melenovsky, V. P4762, P5499, 6075, P6562 Menozzi, M. P2485 Meurice, J. P608
Melgaard, L. 359, 1830 Mente, A. P6596 Meurice, J.C. 5077
Melgar Gonzalez, I. P2410 Mentias, A. P599, P606 Meuwissen, M. P1388
Melgares Moreno, R. P1410 Menting, M.E. P707, P2656 Mewton, N. P3594
Melgares-Moreno, R. P2792 Mentz, R. 6037 Meyer, A.M. 1988
Melica, B. P4490 Menza, M. P1429, P6356 Meyer, C. P4540, P5042
Melina, G. P3490, P3579, P4317, P5241, Menzin, J. P6215 Meyer, C.H. P3414
P5478, P5632 Merai, I. P1802 Meyer, C.M. P4362
Melissopoulou, M. P4574 Meras Colunga, P. P3632 Meyer, G. 5190
Melleby, A.O. P6341 Merati, E. P3382 Meyer, K. 1836
Mellert, F. P1596, P4573 Mercadal, G.R. P689 Meyer, M. P1454
Mello, S. P3669 Mercado, J. P6135 Meyer, M.R. P2843
Mellor, D. 2231 Merchan, S. P2772 Meyer, P. 6647
Mellor, G. 1848, P2680 Merchant, F.M. P4297 Meyer, R. P1417
Mellwig, K.-P. P2149 Mercier, L.A. P717 Meyer, T. P2370
Melnikov, N.N. P2391 Mercuri, A. P5020 Meyer-Zurn, C.S. P5603, 6614
Melnychenko, N.V. P3762 Mercuri, M. 4971 Meynet, I. P208
Melo, D.T.P. P198, P700 Mercuro, G. P1573, 5807 Meza, Y. P2823
Melo, E.S. P1804 Meredith, I.T. P4777 Mhor, R. P5633
Melo, X. 2937 Meredith, M. 1847 Mi, C.J. P2712
Meloni, A. P1529, P1531, P1533, P2355, Mereles, D. P194, P2687 Mi, X.N. P2588
P6548, P6571 Merentie, M. P3099, P5946 Mia, S. P2587, P6345
Meloni, L. P578 Merghani, A. 2968 Miake, J. P1426
Meloni, M. P3566, P6337 Mergia, E. 2340 Miao, D.D. P4370
Meltzer, A. P2678 Merino, C. P6490 Miao, K. P3102
Meluzin, J. P6310 Merino, J.L. 1246, 1248, P3380, P3420 Miasnikov, G.V. P486
Melz, C. P3570 Merioua, I. 5786 Miatello, R.M. P1414
Memmi, M. P4298 Merkely, B. 78, 248, 260, 267, 365 Micard, E. P557
Memo, G. P4671, 4871 Merkely, B. P166, P491, P499, P509, P523, Michael, K. P3404
Mena Latorre, J.M. P1392 P556, P614, P1144, P1457, P1794, P1795, Michaelsson, E. P3129
Menafoglio, A. P4100 2105, 2234, 2284, P2396, P2399, P2667, Michalak, E. P3540, P3543
Menardi, E. P503, P2390 P2678, P2805, P3075, P3709, P4097, Michalek, P. 1979
Menasche, P. 311 P4099, 4220, P4496, P4536, P4557, Michalis, L.K. P765, 1178
Menazza, S. 259 P4630, 4856, P5449, P5482, P6122, P6401 Michalopoulou, M. P4418
Mendelsohn, F. P215 Merkin, M. 241 Michalski, B. P2566, P6295
Mendes, M. 136 Merkulova, I.N. 2100 Michalski, B.W. P4448
Mendes, M. 1282, 1284, 1286, P1610, 2011, Merkus, D. P3745 Micheau, A. P4446
P3586, P4349, P5643 Merlet, N. P1561 Michel, J.B. P568, P5008
Mendes, M.M. P829, 1200 Merlo, M. P522, P686, P691, P1621, 5787 Michel, S. 3309
Mendes, P. P1796 Merola, A. P723 Michelakakis, N. P3358
Mendes-Ferreira, P. 6058 Merono Duenas, O. P1125 Michelena, H. 3049, 3287
Mendez, I. P2554 Merval, R. P3757 Michelongona, A. P4751
Mendez Fernandez, I. 36 Mesa, D. P3730, P4576, P6490 Michels, M. P695, P1120, 3074, 6607
Mendez-Fernandez, I. P1392, P5494 Mesa, D.M. P2442 Michelsen, M.M. 4289
Mendi, M. P4577 Mesa Rubio, D. P1109 Michelucci, A. P1094
476
Chairpersons & Judges / Speakers & Discussants / Authors Mic – Miy
Micheu, M. P4442 Millaire, A. P1124 Mishra, S. 261

Michie, S. 4828 Millar, L. P2680 Miskowiec, D. P2653
Michishita, I. P4674, P4677 Miller, A. P6337 Misselwitz, F. P5598
Michurova, M. P3684 Miller, C. P619, P2432 Missere, M. P1531
Mickley, H. P4431, P4465, P4618, P5017, Miller, F.A. 5214 Missiou, A. 1841
P5713, 6023 Miller, L.W. P215 Mistrik, M. P3556
Mico Valls, C. P862 Milli, M. P1664, P3743 Miszalski-Jamnka, K. P699
Middeldorp, M. P4374 Mills, N.L. P1117, P3432, P4461 Mita, T. P1582
Middeldorp, S. 5192 Milo, M. P4522 Mital, S. 346
Middeldrop, M.E. 1847 Milojevic, P. P6482 Mitarai, M. P734
Midttun, Ø. P4657 Milovanovic, I. P4423 Mitarai, T. P5372
Mielczarek, A.J. P3524 Mimoso, J. P2526 Mitchell, A. P1117
Miele, M. P5639 Min, D. P2153, P4513 Mitchell, J. P4595
Mielniczuk, L. 4873, P5519 Min, J.K. 3996, P4480 Mitchell, J.A. P430
Miettinen, J. P6221 Min, K.D. P5460 Miteva, K. P4544
Mifune, T. P6256 Min, P.K. P1638 Mitic, V. P2713, P3634, P4423, P4614
Miglioranza, M.H. P2545, P2559, P2560, Min, X. P2113 Mitnitski, A. 5078, P5567
P3532, P3571 Minakata, K. P3549 Mitomo, S. P6286
Migliore, F. P4460 Minakata, Y. 4180 Mitov, V. 5105
Miguel Gutierrez, A. P4710 Minalga, E.M. P1151 Mitrega, K. 4864
Mihaescu, R. P1450 Miname, M.H. P1705 Mitro, P. P1435
Mihaila, S. P2539, P2559, P2560, P2806, Minami, K. P876, P2436, P2475, P4451, Mitropoulou, F. P6254
P3571 P5299, P6125 Mitrovic, P. P4425, P4452
Mihalache-Avram, T. P1561 Minami, Y. P4694 Mitsouras, D. 1841
Mihalcea, D.J. 4157 Minamiguchi, H. P4360 Mitsudo, K. P1504, P1514, P2622, P2738,
Mihaltan, F. 2255 Minamihara, A. P6451 P2739, P2748, P2774, P3345, P3688,
Mihatov, N. P5924 Minamino, N. P5460 P3713, P5402, P6278, P6520, P6525,
Mii, S. P1135 Minamino, T. P3327, P4314, P4535, P4537, P6532
Mijalkovic, D. P6441 P4733, P5327, P6156 Mitsuhashi, H. P3685
Mijares, A. P6395 Minamisawa, M. P6222, P6577 Mitsuhashi, T. P5656
Mijic, D. P3773 Minamishima, T. P6123 Mitsuhashi, T.M. P2509
Mijic, N. P4425 Minana, G. 4279 Mitsui, M. P6522
Mikami, A. P5002, P5444 Minatoguchi, S. P905, P2451, P2540, Mitsui, T. P1827, P3800, P5969
Mikhail, G. 1283 P2830, P4779, P5002, P5428, P5444, Mitsui, T.M. P1558, P4542, P5471
Mikhail, G.W. P807, P5375 P6363 Mitsutake, Y. P2124
Mikhailidis, D.M. P6481 Minatoya, K. P6143 Mittal, N.V. P3567
Mikhailidis, D.P. 144 Minden, H.-H. P3402 Mittal, S. P3384
Mikhailidis, D.P. P1450, P1584, 2229, P5981 Mine, T. P2408 Mittal, T.K. P4505
Mikhaliev, K.O. P5563 Mingardi, F. P5467 Mitu, F. P5037
Mikhaylov, E. 3938 Mingels, A.M.A. P4458, P4623 Mitu, O. P5037
Mikhed, Y. P667, P2581 Mingo Santos, S. P1768, P4308, P5942 Miura, H. P1108, P6537
Miki, K.M. P1712 Minin, S. P6574 Miura, M. P2483, P5958, P6539, P6544
Miki, T. 1086, P2350, P5288 Minns, I. P6202, P6219 Miura, S. P764, 2059, P3749, P3754, P4556,
Miklasz, P. P4731 Minossi, V. P732 P4655
Mikolajczyk, T. P6127, P6599 Mintz, G. 1838 Miura, T. 961, 1086, P1582, P2350, P2556,
Mikulicic, F. P611, P4481 Minutello, R. 1197 P3782, P4467, P5288, P5382, P5965,
Mikulska, A. P1807 Minwegen, D. P656 P6222, P6577
Milan, D.J. P1381, P5924 Miolo, G.M. P871 Miwa, H. P2540, P4779
Milan-Pinilla, A. P601, P2381, P2777, P3657, Miquerol, L. 4159 Miyachi, H. P2483
P5611, P6526 Mirabel, M. P1613, P3135 Miyagawa, K. P5692
Milandri, A. P2640 Mirabet Perez, S. P1781 Miyagawa, M. P603
Milanesi, O. P706 Miracapillo, G. P2345 Miyagawa, S. P2610, P3544
Milani, E. P3649 Miranda, B. P818, P836 Miyagi, M. P1827, P2706, P3800, P5969
Milano, E.G. P1602 Miranda, F. 366 Miyagi, N. P2692, 5885
Milano, G. P2586, P3133 Miranda, R. P1118 Miyahara, S. P4114
Milasinovic, D. P446, P580, P609, P816, Miranda Barrio, B. P835 Miyake, K. P2622
P827, P830, P1716, P2484, P2518, P2567, Miranda-Silva, D. P5259 Miyake, M. P1607, P2664
P3715, 4292, P4433, P5415 Mircoli, L. P5358 Miyake, Y. P2769
Milberg, P. P1379, P1431, P6158 Mirea, O. 2282, P5941 Miyamoto, K. P480, P4377
Milesi, G. P1555 Mirek-Bryniarska, E. P6402, P6408 Miyamoto, S. P626
Milewski, R. P3616 Mirica, C. P2614 Miyamoto, T. P851, P1660, P3533, P5556
Milic, N. P3682 Mirizzi, G. P1366, 6044 Miyamoto, Y. P417, P742
Milicevic, P. P5663 Miro, J. P717 Miyamura, A. P1727, P1731
Milicic, D. 212, 269 Miro-Casas, E. 1088 Miyashita, Y. 961, P4467, P5382
Milicic, D. 149, P561, P2824, 4287, 4291, Mironkov, B. P1813 Miyata, A. P2818
P4698, 5086, 5177, P5278, 5819 Mironova, S. P900 Miyata, M. P4065, P4375
Miliou, A. P644, P660, P1116, P1458, P3115, Mirsadraee, S. P2127 Miyata, S. P1570, P6539, P6544
P4088, P5368 Misaki, A. P1130 Miyata, T. P1760
Miljoen, H. P4342 Misaki, M. P4402 Miyauchi, H. 6632
Milkas, A. 4867 Misaki, T. P5227 Miyauchi, K. P2483, P3675, P3721, P4477,
Milkas, T. 4874 Misfeld, M. P6509 P5381
477
Chairpersons & Judges / Speakers & Discussants / Authors Miy – Mor
Miyauchi, Y. P513, P3410 Mohamed Fereig Hamed, H. P2807 Monasterio, V. P1545

Miyazaki, A. P6531 Mohammad, I. P814 Monda, K. P5374
Miyazaki, K. P6537 Mohammad, S. P5697 Monda, K.L. P3667, 6653
Miyazaki, R. P5556 Mohan, M. P517, P3763, P4772, P5321, Monda, V. P3505
Miyazaki, S. P2616, P5491, P5659, P6389 P6552 Mondillo, S. P2682, P4741
Miyazaki, T. 370, P2761, P3675 Mohanty, P. 955, P3383, P3396, P3417 Monedero Campo, J. P2757
Miyazawa, A. P1745 Mohanty, S. 955, P3383, P3396, P3417 Mongeon, F.P. P717
Miyazawa, K. P1439, P1686, P1687, P2423 Mohee, K. P3315 Mongiardi, C. P3802, P5712
Miyoshi, T. P536, P907, P1776, P2537, Mohgadamnia, A. P2828 Mongillo, M. 9
P2605, P2804, P3529, P4483, P4486, Mohiaddin, R. P3737 Monguio-Tortajada, M. P2580
P4495, P4503, P5029, P5238, P6304 Mohiddin, S.A. P692 Monin, J.-L. 212
Mizariene, V. P636, P1594 Mohideen, M.R. P5370 Monin, J.-L. 1181, 1183, 1185, 1186, 1187,
Mizukami, Y. P2453 Moholdt, T. 2943 5888
Mizukoshi, K. P5372 Mohr, F. P2623, 4268 Monitillo, F. 5810
Mizuno, A. P1801 Mohr, F.W. P683, P1600, 1983, 2319, Moniuszko, M. P2812
Mizuno, H. P4360 P5492, 5788, P6509 Monivas Palomero, V. P1768, P4308,
Mizuno, M. P815, P2350 Mohr, M. P6339 P5942
Mizusawa, M. P4514 Mohri, M. P3482 Moniz, P. P5658, P5684
Mlayeh, D. P533, P5356 Mohty, D. P4558, P5500 Monji, A.H. P1558
Mlodawska, E. P5293 Mohyi, P. 3307 Monk, L. P1333, P4435
Mlotek, M. 104 Moiduddin, N. P2663 Monmeneu, J.V. P1517, P1518, 3252
Mlynarska, A. P2447 Moimas, S. P1347 Monserrat, L. 2970, 3067, 5112, 5113,
Mlynarski, A. P2835 Moir, S. P1343 5114, 5116, P5472
Mlynarski, R. P2447 Moiseeva, O. 3051, P3541, P4555, P6151, Monserrat Iglesias, L. P1398, P1623
Moat, N.E. P681, P1543 P6501 Mont, L. 100, 96, 98, P472, P1330, P1405,
Moat, N.M. 4269 Mojcher, A. P2591 P1434, P3371, 4917, 5860, 5861
Mocarzel, K. P3479 Mojoli, M. 5786 Montagnier, C. 104
Moccetti, T. 1081, P1334, P2439, P3519 Mok, K.H. P831 Montaigne, D. P2626
Mochida, T. P2563 Mok, R.Y. P3629 Montalescot, G. 363, P551, P556, P1462
Mochizuki, A. P2556 Mokbel, M. 5800 Montalescot, G.M. 185
Mochizuki, T. P603, P4507 Mokdad, A.H. P6461 Montalescot, G.M. 1167, 2176, 2191, 2855,
Mochizuki, Y. P5527, P6311 Mokrejs, J. P5247 2858, 2871, 3914
Mochmann, H.-C. P3487 Mokrzycki, K. P2613, P6367 Montanaro, C. P723
Mockel, M. 125 Molano Casimiro, F.J. 2940, P3650 Montange, D. P1461
Mocoroa, A. 6085 Molatta, S. P4383 Montani, D. P4548
Mocumbi, A.O. P2651 Moldovan, C. P4582, P5476 Montant, M.P. 5212
Modaffari, P. P865 Molenaar, M.M.D. P4394, P4396 Monteagudo, M. P832
Modena, M.G. P3508 Molhoek, S.G. P5314 Monteccuco, F. 6647
Moebius-Winkler, S. P3639 Molina, C.E. 258, 4823 Montefusco, A. P1449, P1748, P5378
Moebus, S. 2104, P2357, 4205, P5960, Molina, E. 366 Monteiro, A. P3693, P4434
P6322 Molina Blazquez, L. P5686 Monteiro, A.V. P867, P1773
Moeckel, M. 28 Molina Ferragut, L. P6492 Monteiro, C. P1506
Moehlenkamp, S. P5960, P6322 Molina-Jimenez, M. P2792 Monteiro, D. P618
Moeller, D. P5310 Molinaro, S. P4414 Monteiro, P. P2470, P3493
Moeller, D.S. P5277 Moliner, P. P6584 Monteiro, S. P2470, P3493
Moeller, H.M. P6113 Moliner-Borja, P. P1774, 2213, P3124, Montes De Oca, R. P2554
Moeller, J. P5033 P6187 Monteyrol, P.J. 5077
Moeller, V. P4366 Moliterno, D. P3717 Montezano, A.C. P2583
Moeller Jensen, J. P6455 Molkentin, J.P. P1812 Monti, E. 4182, P5521, P5524
Moellmann, H. 1980, 2224, 2225, P2386, Mollace, V. P3560 Montisci, R. P578
P2620, P3095, P3120, P3137, P4334, Mollenhauer, M. 6038, P6355 Montorfano, M. 370, P2616, P2761, P5491,
P4487, P4499, P4500, P4565, P5028, Moller, J.E. P1792 P6389
P5405, 5791, 6065, 6067 Mollnau, H. P468, P3359 Montoy, M. P5009
Moellmann, H.M. P567, 1988, P4687 Mollo, R. 5900 Montserrat, L. P1123
Moellmann, J. P646, P4540 Molnar, A.A. P6401 Monzo, L. P3789
Moellmann, S. P4500, P4565 Molnar, F. P5023 Moon, G. P1150
Moenning, E. P5310 Molnar, L. P499, P509, P2396, P2399, 4856 Moon, J.-Y. P2153, P4513
Moens, A.L. 4151 Molotski, N. P3548 Moon, J. 25, 2968, 5150, 5152, 5154
Moffet, H. 4885 Moltrasio, M. P3382, P3427, P4346, P4389 Moon, J.C. P5546
Mogabgab, O. P3714 Molvin, J. P4532 Moon, T. 5797
Mogensen, H.M. P5277 Molz, S. P5369 Mooney, M.A. 18
Mogensen, J. 310 Mombiela, T. 5802 Moons, P. 1855, P6416
Mogensen, J. 4035, 4036 Momcilovic, D. P1596 Moore, J.P. P3642
Mogensen, U.M. 6642 Momiyama, Y. P4361 Moore, X.-L. P2637
Mogielnicki, A. P1451, 1833 Momomura, S. P5656 Moore, X.L. P4617
Moguchaya, E. P735 Monaca, C. 5077 Moos, V. P3575
Mohamed, E.A. P3542 Monaco, C. 207, 257 Mor-Avi, V. P5484
Mohamed, M.O. P1647 Monaghan, M. P1105, P6487 Mora, G. P4337
Mohamed, S. P5328 Monaghan, M.J. 127 Mora Pardo, J.A. P3650
Mohamed, T.M.A. 6056 Monaghan, M.J. 1884, P3726, 3987, 3989, Moraca, A.M. P2705
3990, 3991, 3993, P6233, P6236 Moraes, P.I.M. P4410, P4455
478
Chairpersons & Judges / Speakers & Discussants / Authors Mor – Mud
Moraes-Silva, I.C. P2679 Morii, E. P3544 Moser, J. P3393, P3414

Morais, C. P768, P1506 Morii, J. P1452 Moser, J.B. P3737
Morais, J.A.C. 72, 123, 249 Morillo, C.A. P2405, P3314, P3401, 5066 Moser, J.M. P4362
Morais, J.A.C. 2072, 3029, 5749, 5752 Morimoto, C. P1150 Moser, M. P1454, 1956
Morais, L. P506, P2673 Morimoto, T. P1486, P2491, 2908, P5342, Moshiri, S. P2741, P2765, P2781, P2782
Moraleda, J.M. P862 P6381 Mosmann, C.P. 2235
Morales-Rull, J.L. P2813 Morimura, N. 6628 Mosna, F. P5247
Morandi, F. 2207 Morin, L. 5077 Mosquera-Leal, A. P4541, P6334
Morani, G. P2400, 4865, 5146 Morinaga, T. P2749, P3439, P3440 Moss, A.J. P523, 2271, P6163
Morath, T. P1485 Morini, M. P4298 Mostafa, A.E. P2564, P4656
Morawiec, B. 160, P3480 Morinigo, J. P467, P476 Mostarda, C. P5450
Morawski, S. P3322, P4075 Morino, Y. 338, P1745, P5331, P6256 Mosteoru, S. P1584
Morbach, C. P6149 Moris, C. P3591, P5248 Mosteoru, S.L. P6469
Morcillo-Hidalgo, L. P6560 Morishima, I. P2446 Mosterd, A. P2371
Morcov, L.G. P3659 Morishita, M. P3340 Mosumeci, G. 6654
Morea, G. 5787 Morishita, T. P3400 Moszczynska-Stulin, J. P1441, P1442,
Moreira, A.C.M. 2911, P3689 Morissens, M. P6419 P2110
Moreira, D.A. P1626 Morita, H. P1403, P2537, P2605, P3529, Mota Carmo, M. P501, P506, P867, P1773,
Moreira, I. P1668, P5367, P5406 P3607, P4495, P4728, P6304, P6335 P2673
Moreira, J.B.N. 6039 Morita, H.M. P3780, P4660 Motohiro, M. P4691
Moreira, J.I. P3457, P3668, P5390 Morita, N. P3410 Motoji, Y. P5527, P6311
Moreira, L. 5922 Morita, T. P1378 Motoki, H. P4467, P5382, P6222, P6577
Moreira, L.P. P5032 Morita, Y. P1527, P2446 Motoki, K. P4728
Moreira, M.C. 89 Moritz, M. P2125 Motovska, Z. P565, P804
Moreira, M.C. 6014 Moriuchi, K. P2800 Motoyama, S. P6318
Moreira, N. P2470 Moriwaki, T. P5004, P5486, P5599 Motreff, P. 269
Morel, E. P1385, P6164, P6176 Morley, C. P3315 Motreff, P. 3270, P3344, 4260, 6622
Morel, O. P647, P845, P5409, 6635 Morner, S. P1631 Motreff, P.M. P5933
Morel, O.M. P5487 Moro, C. P6246 Motro, M. P2796
Morell, S. P2128 Moroboshi, T. P6281 Mottini, G. P6132
Morelli, M. P860 Moroi, M. P223, P3499, P3764, P5261, Mottonen, M. P3125
Morello, F. P2532, P6410 P6296 Mottram, P.M. P1343
Morello, M. P3394 Morosato, M. P3377, 5146 Motwani, M. 3996, P4480
Morelon, E. P5392 Moroshkin, V. P6151 Motz, I. P664
Morenate, M.C. P2758, P3694, P3730 Morosin, M. P3335, P5242, P5244 Mouchawar, G. P2113
Morenate Navio, M.C. P1109 Morr, C. P2823 Mouden, M. P624, P633
Moreno, A.C. P4410 Morr, I. P2823 Moukbel, Y.C. P892
Moreno, F. P2557 Morrice, K. P3425 Moulakakis, K. P6504
Moreno, J. P1107, P2557, 5917 Morris, A. P6508 Moulin Zinsch, A. P2455
Moreno, P. P1510, 6619 Morris, D.A. P3079 Moulin-Zinsch, A. P4599, P4600
Moreno, R. P195 Morris, G. P1424 Moumneh, T. P3485
Moreno Arciniegas, A. P3122, P3718, Morris, J. P803 Moura, B. P5677
P4714, P6517 Morrison, G. P3573 Mourad, G. P1665
Moreno Planas, J. P508, 3173, P5442 Morrison, L.J. P1331 Mourad, J.-J. 380
Moreno Rodriguez, A. P6371 Morrone, D. P3458 Mourali, M. 87
Moreno-Weidmann, Z. 159 Morrow, D.A. 354 Mourali, M.S. P850
Moreno-Yanguela, M. 4049 Morrow, D.A. 5747, 5750, 5752, 5753 Mouridsen, M.R. P5305
Moreo, A. P6483 Morshuis, M.J.G. 329, 331, 332, 333 Mourouzis, K. P455, P740, P1116, P1577,
Moretti, A. P1346, 6072 Mortensen, J. P3522 P2689, P2725, P4312, P6476
Moretti, C. P1449, P1748, P5378, P6262, Mortensen, K. 6066 Mousinho, M.C.C. P5251
P6372, P6446 Mortensen, L.S. P5277 Moussalem, N. 87
Moretti, C.M. P3118, P5562 Mortensen, P.T. 2269 Moustafa, A. P745
Moretti, S. P3802, P5712 Mortensen, R.N. P3641, 6627 Moustafa, A.H. 161
Morgado, F. P2394 Mortensen, S.A. P3744 Moustafa, F. P2542
Morgado, F.B. P4349 Mortier, P. P2729 Moustakas, G. P4671, 4871
Morgado, G. P1118, 5814 Morton, A.C. P774, P1472 Moya I Mitjans, A. 998, 3980
Morgado Polavieja, J. P4470 Morvan, M. P4086 Moya Mur, J.L. P508, P2547, 3173, P5442
Morgan, C. 140 Morvan, Y. P2675 Moyles, C. P3315
Morgan, G. P1385 Mos, I.C.M. P3621 Mozenska, O. P1595
Morgante, E. P1430 Mos, L. P899 Mozid, A. P3774, P5379
Mori, C. P2796 Mosack, V. P3655 Mraz, T. P6493
Mori, H. P5578 Mosakowska, M. P5269 Mrdovic, I. P5678
Mori, K. P6533 Moscarella, E. P1499 Mrkonjic, I. P580, P2484
Mori, N. P6201 Moschandreas, J. P739 Mrochek, A. P3736
Mori, S. P4492, P4718, P5579 Moschetti, K. P6323 Mu, Y. P2568
Mori, T.M. P828 Moschos, M. P1577, P3680 Muccioli, G. P2363
Mori Junco, R.A. P3632 Moschovitis, A. P5026 Muderrisoglu, H. P6523
Moribayashi, K. P3089 Moschovitis, G. P4100 Mudge, A. P3349
Morice, M.C. 93 Moscicki, R. P616 Mudra, H. P837, P5617, P5625
Morice, M.C. 13, P1615, P5010, P5375, Moscoso Costa, F. P4350, P4380 Mudroch, M. P169
P5489 Moser, D.K. P440
479
Chairpersons & Judges / Speakers & Discussants / Authors Mue – Nag
Muegge, A. P3773 Munoz Guijosa, C.H. P1781 Musameh, M.D. P4090

Mueller, A.-M. P3605, P3606 Munoz Navarro, A.J. P5248 Musat, D. P3384
Mueller, A. P4638 Munoz-Bellido, J. P601, P2381, P2777, Musca, F. P6483
Mueller, C. 125, 126, 154, 157, 159, 162, P3657, P5611, P6526 Muscariello, R. P858
P524, P525, P529, P595, P1097, P1099, Munoz-Garcia, A.J. P6560 Muschiol, G. P4510
P1100, P1103, P2695, P3481, P3484, Munoz-Garcia, E. P4584, P5337, 5790, Muscoli, S. 74, 150
P4077, P4454, P4459, P4612, 5085, P5397 P6557 Muscoli, S. P1590, 3934
Mueller, C.E. 314, 362 Munoz-Garcia, M. P4584, P5337, 5790, Musetescu, R. P6208
Mueller, C.E. 128, 1935, 1942, 4127, 5181, P6557 Mushtaq, S. 4051, 4056, P4997, P5233,
5871 Munoz-Guijosa, C. P1425 P6316
Mueller, C.H. 6613 Munster, A.B. P2571 Mushtaq, S.M. 2102
Mueller, D. P4084, 6061 Muntner, P. P1450, P3667, P5981, P6481, Mushtenko, L.O. P1820, P6591
Mueller, H. P2558 6653 Musial, W.J. P2812, P4731, P4735, P5293,
Mueller, I. P3596 Munzel, T. P882, 1978, 2252, P2572, 3228, P6279, P6283
Mueller, I.I. 6041, P6268 P4074, P4107, P4332, P4607, 4977, Musialek, P. P4685, P5622, P5626
Mueller, K. P1484, P1494, P1508 P5016, P6206 Music, L.J. P5272, P6208
Mueller, K.A.L. 6041, P6268 Muo, C.H. P5317 Muslin, A.J. 3310
Mueller, M.F. P2582 Mura, M. P1573, P6162 Musliner, T.A. 68, P1131, P6120
Mueller, N. P2589 Mura, M.N. 5807 Mussliner, T.A.M. P6466
Mueller, O.J. 3066, P3537 Murad, H. P5977 Mustafina, O.E. P5264
Mueller, P. P4391 Murai, H. P6183 Musters, P. 2101
Mueller, T. P4767 Murai, K. P1737 Mustonen, P. P6405
Mueller, U. P2387, P3639 Murai, S. 4898 Mustroph, J. 1851
Mueller, U.A. P2589 Murai, T. P789, P1361, P1362, P1711, P1715, Musumeci, G. P5285
Mueller-Ehmsen, J. 4191 P1719, P1720, P1749, P4511 Mut-Vitcu, G. P6469
Mueller-Hennessen, M. P5340 Murakami, K. P2591 Muthurangu, V. 4830, 4901
Muendlein, A. P1697, P3678, P4473, P6259 Murakami, M. P1422, P6319, P6361 Muto, C. P2112, 5916
Muenzel, T. P468, P550, P656, P667, 1084, Murakami, N. P5288 Mutuberria, M. P818, P835, P836, P5407,
P2581, P2602, P2669, P3359, 4177, Murakami, T. P688, P1633, P4783 P5408
P4661, P5369 Murakami, W. P5939 Muzzarelli, S. P3519
Muenzer, P. P1487, 2341 Murakawa, K. P769 My, L. P564
Muessigbrodt, A. 4858 Murakawa, Y. P3410 Myasoyedova, V. P6368
Muggenthaler, M. P1629 Murakoshi, N. P1371, P5528 Myc, J. P3741
Muhlestein, J.B. P3356 Muramatsu, T. P1132, P1133, P1745, Mygind, N.D. 4289
Muiesan, M.L. P5709 P2733, P3706, P3710, P4492, P4718, Myhre, P. P451
Muk, B. P3348 P6145, P6519 Mylotte, D. P4068
Muka, T. P747, P2594, P4609, P5021 Muranaka, A. P2556 Myrstad, M. P5601
Mukete, B.N. P3714 Muranishi, H. P1138 Mysuta, M. 4961
Mukherjee, D. P823 Muraoka, Y. P1718 Mytton, O. 6648
Mukhopadhyay, B.N. 5090 Muraru, D. P702, 1306, 1308, P2539, P2541, N’guetta, R. P3134
Mulcahy, D. P795 P2545, P2546, P2550, P2559, P2560, Nabata, T. P5668
Mulder, B.J. P2137, 3050 P2806, P3532, P3571, P5484 Nabauer, M. P5316
Mulder, B.J.M. 27, 40, 312 Murat, S.N. P825, P5335, P6257 Nabeebaccus, A. P4531
Mulder, B.J.M. P437, P473, P713, P716, Murata, A. P2799 Naber, C. 156, 196
P2658, P2661, 2927, 2934, 3071, P5239, Murata, M. 4180 Nabih, M.A. P2807
P6416 Murata, T. P2533, P4732 Nabti, A.R. P4069
Mulder, D.J. P183, P1566, P5548 Muratsubaki, S. 1086, P5288 Naccarato, A.G. P3458, P4091
Mullen, M.J. P1617 Murbraech, K. 4048, P4307 Nachiappan, A. P3398
Mullens, E. 5077 Murday, V. P1380 Nadal, J. P2681
Muller, A. P1539 Muriel, M. P794 Nadal-Ginard, B. P3560, P3561, P3563,
Muller, M. P5246, P5565 Murin, J. P887 P5457
Muller, O. 160, P535, P1691, P3480, P5936 Murin, P. P1435 Nademanee, K. P1427
Muller, O.M. P3461 Murohara, T. 253 Nader, K. P4358
Mulpuru, S. P3373 Murohara, T. P433, P726, P788, P1672, Nader, N. P679
Mulvagh, S.L. P3515, P6472 P1744, P1827, 2228, P2648, P2650, Nadra, I.J. P2727, P2736, 2907, P3117,
Muminov, I. P1813 P2684, P3710, P3753, P4109, P5333, P3712, 5817
Mun, H.S. P4355 P5380, P5578, P5590, P5593, P5610, Naegele, M. P1812
Munawar, M. P1684 P5966, P5969, 6086, P6172, P6494, P6502 Naeije, R. P4546, P4553, P5504
Mundl, H. P6464 Murohara, T.M. P1558, P4542, 5081, P5471 Naerr, G. P3678, P4473
Muneretto, C. 363 Murphy, C.M. 1856 Naftali-Shani, N. P3555
Muneretto, C. P2151, P3382, 6021 Murphy, J.G. P4557 Nagahara, Y. P6318
Munhoz, G. P5251 Murphy, J.G.M. P4444 Nagai, R. 313
Muniz, J. P1394, P6140 Murphy, S. 3032 Nagai, R. P5003
Munk, K. P577, P596 Murphy, S.A. 68, P6120 Nagai, T. P881, 3305, P3551, 4189, P4354,
Munk, P.S. P602, P5257, P6477 Murphy, S.M. P3317 P4761, P4763, P6536, P6541, P6545
Munns, A. P3349 Murphy, T. P5688 Nagano, N. P5288
Munoz Beamud, F. P6392 Murray, C.J.L. P6461 Nagano, T. P2818
Munoz Blanco, J.L. P6392 Murray, S.M. P5562 Naganuma, T. P1748, 4286
Munoz Garcia, A.J. P4584, P5337, 5790, Murrow, J. 960 Naganuma, T.N. P6286
P6557 Muruato-Ontiveros, E. P641 Nagao, K. P688, P1127, P1383, P1633,
Murzilli, R. P3519 P2483, P3434, P3482, P4112, 6628, 6629
480
Chairpersons & Judges / Speakers & Discussants / Authors Nag – Nei
Nagaraju, C.K. P5468 Nakanishi, N. P2366, P2368 Nasser, R. 5213

Nagase, S. P1403, P3607, P4728 Nakano, A. P2500 Nassif, M. P716, P2743
Nagase, S.N. P3780, P4660 Nakano, M. P1132, P1133, P1687, P2733, Nasu, K. P3708, P3722, P4608, P6282
Nagashima, M. 1327 P3706, P4336, P4492, P5299, P6519 Nasu, T. 338
Nagata, Y. P698, P1452 Nakano, Y. P2648, P2650, P2684, 4256, Naszydlowska, E. P1693
Nagaura, T. P3089 P4437 Nataf, P. P3731, P5014, 5217, 5218, P6391
Nagaya, M. P2540, P5428 Nakao, M. P4694 Natale, A. 955, P3383, P3396, P3417, P6115
Nagel, C. P1767 Nakao, Y.M. P742 Nathoe, H.M. P590, P1755, P2371, P5246,
Nagel, E. P1530, 2048, 2050, 3959 Nakaoka, Y. P839 P5618
Nagel, F. P4545 Nakashima, H. P876, P2475, P4451 Natorska, J. P2606, P3587
Nagel, G. 966 Nakashima, M. P815 Natsuaki, M. P1486
Naghavi, M. P6461 Nakashima, T. P2451, 6628 Natsumeda, N. P6281
Nagib, T.A. P5479 Nakata, T. 3254, P6237, P6272 Nattel, S. 6073
Nago, C. P2692, 5885 Nakatani, S. 267 Naumenko, N. P5946
Nagoshi, R. P6273 Nakatani, S. 369, 3169, 3172, P6298 Nava, F. P3617
Nagoshi, T. P2353 Nakatsu-Goto, Y. 1321, P1332, P1384 Navar-Boggan, A.M. P2144
Nagot, N. P4446 Nakatsuma, K. P2491, P6381 Navaratnatajah, A. P6487
Nagy, A.I. P1457, P5482 Nakaya, H. P6522 Navarrete, C. P4631
Nagy, E. P1589, P4688 Nakayama, A. P3754 Navarro, F. P1710
Nagy, V.K. P499, P3075, 4856 Nakayama, K. P4551 Navarro Cuartero, J. P4712
Nah, D.Y. P2508 Nakayama, N. P1745 Navarro Penalver, M. P2811
Nahrendorf, M. 3853 Nakayama, T. P3434, P3636, P3797 Navas Tejedor, P. P4550, P5957
Naik, R. P1146 Nakayama, Y. P5004, P5486, P5599, P6488 Naves, M. P3591
Nair, D. P4484, P4485 Nakazato, K. P6300 Nawaito, S.A. P4520
Nair, T. 75 Nakazone, M.A. P5254 Nawata, K. P4567, P4640
Naito, A.T. 4189 Nakmura, M. P4409 Nawrocka, I. P6506
Naito, K. P5488 Nakou, H. 5905 Naydenko, N.V. P500
Naito, N. P6488 Naksuk, N. 2211, P3324, 5093, 5806 Naydenov, R. P3370
Naito, R. P3721, P4477, P5381 Nalbantgil, S. P6510 Nazer, R. P5638
Naito, S. P2436, P2533, P3410, P5299 Nalliah, C.J. P4352 Nazerian, P. P2532, P3617, P6410
Naji, P. P6365 Nam, C.W. P445, 4022, P4474 Nazir, S.A. P2530, P3126
Najib, M. P2831 Nam, G.B. P1387, P2401, P5630 Nazli, C. P705
Najjar, S.S. P5570 Namba, S. P655 Nazzal, C. 1854, P3665
Najm, H.K. 38, 146 Namdar, M. 3897 Nchimi, A. 139, 308
Naka, K.K. P765, 4919, 4921 Namgung, J. P3799 Ndamba Bandzouzi, B. P4108
Nakagawa, H. P3387 Namino, F. P4065, P4375 Ndjessan, J.J. P1096, P4386
Nakagawa, K. P1403, P3607, P4728 Nammas, W. P3081 Ndrepepa, G. P5396
Nakagawa, K.N. P3780, P4660 Nanasato, M. 5081 Nearing, B. P1376
Nakagawa, M. P2415 Nanayakkara, S. P1811 Nearing, B.D. P3775, P5671
Nakagawa, T. P6554 Nanba, T. P1130 Nectoux, P. P5477, P5640
Nakagawa, Y. P1607, P2491, P2664, P5312 Nanchen, D. P1691, 6650 Nedeljkovic, I. 42, 4288
Nakagomi, A. P2165, P2168 Nanea, I.T. 5080, P6280 Nedeljkovic, M. 321
Nakahara, M. P1727 Nanto, K. P2404, 3170, P4498, P5326, Nedeljkovic, M. P1716, 4292
Nakahashi, H. P2814 P6534 Nederend, I. P632, P1551
Nakajima, I. P4377, P5354 Naono, S. P629 Nedio, M. P1506
Nakajima, M. P1760 Napankangas, J. P2162 Nedios, S. P3392, P6209
Nakajima, S. P6256 Napodano, M. 5786 Nedoshivin, A.O. 22
Nakajima, T. P1420, P6353 Napolitano, C. P4298 Neely, D. P588
Nakama, T. P3691, P6535 Napp, L.C. P2791, P3455, P6550 Neely, M.L. 4979
Nakamori, S. P1535, 3254, P4114, P4774 Narain, R. P2373, P2680, 2968 Nef, H. P2386, P2620, P3120, P3137, P4500,
Nakamoto, K. P1793 Narain, V.S. P4408, P6249 P4565, P5405, 5791, 6065, 6067
Nakamura, J. P2563 Narayan, O. P4777 Nef, H.M. 2226, P3095, P4487, P4499,
Nakamura, K. P907, P1776, P2436, P2533, Narayan, S.M. P1550, P3386, P4378 P5028
P2537, P2563, P2605, P2692, P2800, Nardai, S. P3709 Nef, H.N. P567, 1988
P3422, P3529, P3607, P4483, P4486, Nardin, M. P1476, P1480, P2117 Neffati, E. P4693
P4495, P4728, P5238, P5299, P5506, Narducci, M.L. P504, 5900 Negi, P. 2024
5885, P6304, P6335, P6549 Narduzzi, S. 4196 Negi, S. P4583, P6379
Nakamura, K.N. P3780, P4660 Naritomi, H. P1760 Negishi, K. 1844, P3123, P3676, P4746,
Nakamura, M. 203 Narula, J. 1025, 2057 P4753, 4868, P5430, P5672, P5711, 5801
Nakamura, M. 338, P1651, P2148, P2380, Narumi, T. P4766 Negishi, T. P5430, P5711
2857, P3499, P3764, P5331, P5698, Naruse, H. P6318 Neglia, D. 252, 307
P6256, P6296 Narusov, O. P879 Neglia, D. 5159, P6230
Nakamura, M.N. P2802 Narusov, O.Y. P4593 Neglia, L. P1644, P1646, P3335
Nakamura, R. P5579 Nasario-Junior, O. P2681 Negm, H. P3523
Nakamura, S. P1737, 4286 Nascimento, A. P2679, 5082 Negoita, M. P1148
Nakamura, S.N. P6286 Nash, P. P4068 Negrao, C.E. P198, P700, 2944
Nakamura, T. P1567, P2563, P2610, P4783, Nasibullin, T.R. P5264 Negru, A.G. 5095
P5656 Nasierowska-Guttmejer, A.M. 6612 Neil, C.J. P5435, P6565
Nakamura, Y. P220, P4523, P4549, P6531 Nasir, M. P6564 Neiva, J. P3618
Nakane, E. P626 Nasman, P. P737, P5036 Neiva-Silva, L. 2235
Nakanishi, M. P2368 Nasonova, S. P879 Neiva-Sousa, M. 1853
481
Chairpersons & Judges / Speakers & Discussants / Authors Nei – Nis
Neizel-Wittke, M. 2226, 5899 Newby, A.C. 257, 374 Niemann, C. 4177

Nejedly, M. P5247 Newby, A.C. 6605 Niemann, K. P3325
Nekolla, S.G. 2058 Newby, D. 1987 Niemann, M. P1614, P4590
Nel, K. P1603 Newby, D.E. P1117, P2127, 2253, P3432, Niemeijer, M.N. P1391
Nelemans, P.J. P4623, P5228 4146, P4461 Nieminen, M.S. P1376, 2299, 2301
Nelson, A.J. 4053 Newman, C. P4613 Nieminen, M.T. P3429, P3478, P6243,
Nelson, C.P. P4090 Newman, D. P2425 P6264
Nelson, D. P1333, P4435 Newton, J. P2392 Nieminen, T. 257
Nemec, P. P3114 Newton, P. P2819 Nieminen, T. P1536, P3491, 4911
Nemes, A. P1772 Newton, P.J. P783, P5669 Niespialowska-Steuden, M. P2407
Nemeth, B.T. P1144, 2284, P2667, P2678, Neyses, L. 6056 Niessner, A. 5092, 5131, 5132, 5134, P6547,
P4536 Nezic, D. P6482 6644
Nemeth, E. P6122 Ng, B. P793 Nietlispach, F. P1614, 6019
Nemeth, Z. P5680 Ng, C.H. P3117, P3712 Nieto, R. 4176
Nencioni, A. P2532 Ng, F.L. P5383 Nieuwhof, K. 3073
Nentwich, K. P4391 Ng, F.S. P1411, P3398 Nieuwlaat, R. P3078
Neoh, S.W. P795 Ng, G.A. P510 Niewinski, P. P1789, P5655
Neovius, M. P5306 Ng, J. P2674 Niezen, A. 2101
Nepper-Christensen, L. P554 Ng, L.L. P3126 Nightingale, A. P4078, P4420, P5226
Neri, M.G. P1529, P1531, P1533, P2355, Ng, M. P1559 Nightingale, A.K. P2840, P4339, 4872, 4875
P6548, P6571 Ng, M.K. 4022 Niglio, T. P2481
Neri, T. P3087 Ngernsritrakul, T. P2419 Nigro, P. P4734
Nerlekar, N. 4293 Ngo, A.T. P3496 Nihoyannopoulos, P. 2896, 5109, P5420,
Neroutsos, G. P3358 Ngow, H.A. P762, 5124 P5511, P5955, P6313, 6659
Neselioglu, S. P3466 Nguyen, B.L. P2443 Niida, T. P789, P1361, P1362, P1711, P1715,
Neshati, Z. P5456 Nguyen, C. P2136, P2429, P3588 P1719, P1720, P1749, P4511
Nesher, N. P5633 Nguyen, T.H. P6565 Niikura, H. P3764
Neskovic, A.N. 124, 267 Nguyen, T.L. P2516, 5804 Niinuma, H. P3685
Neskovic, A.N. P6482 Nguyen, V. 1984, P4574 Niizuma, S. P1127
Nessel, C.C. 2031 Nguyen, V.Q. P3714 Nijjer, S. P1714, 4932
Nessler, J. P2505, P3495, P5294, P5465 Ni, H.B. P6358 Nijjer, S.S. P1717, P1725
Nestel, P.J. P4323 Nicastro, I. P4091 Nijveldt, R. P174, P531, P1507
Nestelberger, T. 126, 157, 159, P595, Niccoli, G. P604, P786, 4025, P6251 Nikkho, S. 4181, P5520
P4459, P5397 Nicholls, S.J. 3859, 5765, P6465 Nikkinen, M. P4061
Nesti, M. P514 Nichols, Z. P627 Niklewski, T. P6367
Nesukay, E. P5708 Nickenig, G. 205 Nikoghosyan, K. P3792
Nesvetov, V. 4150 Nickenig, G. P661, P663, P664, P893, 1216, Nikolaev, V.O. P1421
Netiazhenko, N.V. P902 P1417, P1596, 1952, 1959, 1960, 1980, Nikolaou, C. P6254
Netiazhenko, V.Z. P902 P2631, P2633, 3146, P4573, P4986, 5784, Nikolaou, N. 140, 363
Neto, M. P2464, P2529, P4303 P5951, P6207, P6366, P6387 Nikolaou, N. 2173
Neubauer, S. P1772, P3609, P5000 Nicol, E. 958, P3395 Nikolic Pavlovic, I. P6441
Neudorfer, I. P2125 Nicol, E.D. P6315 Nikolopoulou, L. P2670
Neumann, B. P5319 Nicola, P. P5043 Nikolsky, E. 3194
Neumann, C. P6550 Nicoletti, A. P4086 Nikos, W. 1980
Neumann, F.J. 309 Nicoletti, A.T. P5008 Nilsson, G. P753
Neumann, F.J. P809, 1053, P1493, P1500, Nicolino, A. P2741, P2765, P2781, P2782 Nilsson, J. P175, 3200
P3720, P4326, P4328, 4941, 5792, 5875, Nicoll, R. P4465 Nilsson, K.R. 960
5877 Nicolosi, G.L. P1644, P1646, P5242, P5244 Nilsson, P. P4532, P5385
Neumann, S.B. P4339 Nicolosi De Cortese, L.N. P6442 Nilsson, P.M. P743, P771
Neumann, T. P3364, P3391, P4367, P5571 Nicolson, W.B. P510 Nilsson, P.N. 949
Neumann, T.H. P4368 Nidal, N.I.D.A.L. P5701 Ninet, J. P4595
Neunteufl, T. P1752 Niebauer, J. 193 Ning, M. P5274
Neupane, B. P207 Niebauer, J. 3214, 3216 Ning, X.N. P1113
Neurohr, C. P5520 Niederer, S. P518 Ninkina, N. P1415
Neuss, M. 350, P1597, P3572, 5216, 6017, Niederseer, D. P4644 Ninkovic, O. P3715
P6369, P6370 Nielsen, B.J. P3641 Ninomiya, R. P420
Neuzil, P. 21, 29 Nielsen, J.B. P1433, 6076 Niraula, S. 4152
Neuzil, P. P169, 1241, 2988, P3476, P4387, Nielsen, J.C. 95, 96, 296, P462, P474, P519, Nishi, T. P5413, P5944
P4720, 5886, P6115, P6493 957, 2269, P2395, 2904, 5777 Nishi, Y. P3685
Neuzner, J. P1389, P6113 Nielsen, J.M. P5509 Nishida, G. P1671
Neves, D. P2728, P5393, 5820 Nielsen, M.L. P743, P771 Nishida, H. P1108
Neves, D.C.H.S. 2060 Nielsen, N.-E. P2655 Nishida, J. P2556, P5288
Neves, I. P3804 Nielsen, N. P421, P1408, P3470 Nishida, N. 2337, 2338, P6128
Neves, J. P1610, P3586 Nielsen, O.W. P3752, P5305 Nishida, T. P6225
Neves, J.P. P5643 Nielsen, P.B. 933 Nishiga, M. P6381
Neves, J.S. 1853 Nielsen, R. P5310 Nishigaki, K. P905, P2451, P5002, P5444
Neves Pestana, G. P5679 Nielsen, S. P2157, P2496, P5628 Nishigami, K.N. 5081
Nevmerzhytska, L. P1635 Nielsen, W.B. P6324 Nishiguchi, T. P1728, P1736, 3945, 6623
New, G. P4302 Nielsen-Kudsk, J.E. P5509, P5512 Nishihara, M. 2337, 2338, P6128
Newall, N. 5920 Nieman, K. 1019, 1251, 1252, 2101, P4623, Nishihata, Y. P3685
Newallo, D. P5405 5158, P6429 Nishii, N. P1403, P2537, P3607, P4728
482
Chairpersons & Judges / Speakers & Discussants / Authors Nis – Oba
Nishii, N.N. P3780, P4660 Nojima, T. P5985 Ntouskou, M. 3253

Nishikawa, H. P6404, P6533 Nolan, J.P. 2065 Nube, M.J. P5364
Nishikawa, T. P5354 Nolan, M. P3676, P4746, P5430, P5711 Nucci, C. P1354
Nishimiya, K. P790, P1707 Nolan, M.T. 4155 Nuche Berenguer, J. P3486
Nishimoto, S. P431 Nolan, R. P2700 Nuehrenberg, T. P3720
Nishimura, H.K. P1558 Noma, S. P3123 Nuhrenberg, T. P809, 5792
Nishimura, K. P4354, P4507 Nombela, L. P2728, P3573 Numasawa, Y. P3123
Nishimura, K.N. P5471 Nombela-Franco, L. P2517, P3520 Nume, A. 1329
Nishimura, M. P1739, P2775, P6137 Nomoto, K. P1827, P3800, P5969 Nume, A.K. P3312, P5596
Nishimura, M.N. P1712 Nomura, A. P1637, P1704 Numis, F. P5639
Nishimura, S. 2243, P2664 Nomura, C.H. P6267 Nunes, A.R. P4410
Nishino, M. P2503, P6201 Nonne, F. 5807 Nunez, E. 963
Nishino, S. P4707 Nonnini, S. P3603 Nunez, J. 963, P2811, 3252, P4092, 4279
Nishiuchi, S. P6351 Nonogi, H. P1383 Nunez, M. P5945
Nishiyama, K. P3434, 6629 Nonomura, M. P5227 Nunez, R. P2790
Nishiyama, N. P3419, P4361 Noohi Bezanjani, F. 255 Nunez-Garrido, E. P641
Nishiyama, S. P851, P3533 Noor, M.A.R. P5675 Nunez-Gil, I. 357
Nishiyama, T. P3419, P4361 Noor, S.L.R. P5258 Nunez-Gil, I. P1470, P1622, P2119
Nishizaki, M. P490, P751, P5323 Noormand, R. P5581 Nunez-Gil, I.J. P2517
Nishizaki, Y. P815, 5087 Norata, G.D. P4634 Nunohiro, T. P876, P2475, P4451
Nishizawa, K. P2350 Nordbeck, P. P2639, 3068 Nuotio, I. P4061
Nissen, H. 6023 Nordestgaard, B.G. 1866 Nuruki, N. P5533
Nissen, S.E. 243 Nordio, A. P1347 Nusca, A. P6132
Nissen, S.E. 3857, 3861, 3924 Nordlund, F. P6439 Nuti, R. P3791
Nissen Bonde, A. 2033 Norekval, T.M. 77 Nuyens, D. P3101
Nissinen, A. P739 Norekval, T.M. P4566 Nybo, M. P4431, P4618, P5017
Nitsche, K. P787, P3719 Norell, M.S. 205 Nyenhuis, J. P2113
Nitta, D. P6512 Norell, M.S. 3162, 3164 Nygaard, O.K. P1656
Nitta, J. P5323 Norgaard, B.L. 2269, P3723, 3997, P4508, Nygard, O.K. P4657
Nitti, C. P4675 P4998, P5234, P5359 Nygard, S. P451
Niwano, H. P1422, P6361 Norhammar, A. P737, P1730, P3343, P5036, Nygren, A. P1411, P6424
Niwano, S. P505, P1422, P6361 P6424 Nyktari, E. 1986
Nixdorff, U. 152 Noriega, F.J. P5568 Nylander, S. P1469
Nizard, J. P714 Noris Mora, M. P3612 Nyman, C. P3503
Njerve, I.U. P1574 Norman, M. P4373 Nymo, S.H. P6551
Nkomo, V. P4557 Noronha, M. P4717 Nyns, E.C.A. P5456
Nkomo, V.T. P1377 Norscini, G. 158, P3437, P4456 Nyolczas, N. P3348
Noack, J. 5917 Nosalski, R. P6127 O’Brien, D. P5604
Noad, R.L. P477 Noseda, M. P5459 O’Brien, E. P1580
Noaman, A. P3432 Notara, V. P4418, P4430, P4450 O’Brien, E.R. 1997
Nobre, A. 258 Notarstefano, P. P1354, P5929 O’Brien, J. P4617
Nobre, A. P6165 Nothnagel, D. 6613 O’Callaghan, C. P795
Nobre E Menezes, M. P2552, P5422 Noto, T. P5025 O’Carroll, G. P2821
Nobre Menezes, M. P511, P2433 Nouamou, I. P2501 O’Connell, E. P2821, P5688
Nobuyoshi, M. P515, P1136, P2747, P3439, Noureddine, M. P2381, P2777, P3657, O’Connell, M. P5580
P3440, P6227 P5611, P6526 O’Connor, C. 1318, 3835, 3836
Noc, M. 154 Noureddine, S. P5669 O’Donnell, D. P502
Nocella, C. P6190 Noutsias, M. P1625, P4113 O’Donnell, M. P6596
Nochioka, K. 3168 Novaes, G.C. 6617 O’Donoghue, M.L. P1682, P3317
Noda, M. P4783 Novakovic, A. P580, P816, P3715, P4425, O’Dwyer, E.J. P4469
Noda, T. P480, P2540, P2830, P4377, P4779, P4452 O’Gara, P. 247
P5428, P6172 Novelli, L. P5523 O’Gara, P. P4580, 4946
Noda, Y. P2605 Novelli, V. P4298 O’Hanlon, R. P2821
Nodari, S. P854, P1555 Noventa, F. P2389, P4745, P4758 O’Keeffe, M. P3444
Node, K. 78 Nover, I. P2385 O’Kennedy, N. 3896
Node, K. 993, P5342 Novichkova, E.A. P3628 O’Mahoney, C. P1628
Noel, B. P1613 Novik, G. P3363, P3368 O’Mahony, C. P692, 6609
Noelker, G. P4383 Novoa, J. 365, P2763 O’Mahony, E. P5604
Noellen, I. P6322 Novoa Medina, J. P4676 O’Meara, E. 1313
Noera, G. P450 Nowak, R.M. 162 O’Neil, A. P4323
Noergaard, B.L. P519, P2395, P6455 Nowakowska, M. P1451, 1833 O’Neill, D. 4847
Noerregaard, R. P5509 Nowakowska, M.A. P856 O’Neill, S. P4740
Nogales-Romo, M.T. P2549, P5243 Nowakowski, D. P6599 O’Regan, D. 1237, 4183
Nogami, A. P1371, P1399, P3410 Nowalany-Kozielska, E. 160, P3480 O’Regan, D.P. P748
Noguchi, T. P881, P1527, P2800, 3305, Nowicka, A. P5436 O’Sullivan, C.J. 6020
P4761, P4763, P5354, P6536, P6541, Noye, M.K. P1775 O’Sullivan, J.J. 2933
P6545 Nozaki, E. P6117 Oba, Y. P2166
Nogue, E. P4446 Nozaki, K. P2696, P2719, P5545 Obadia, J.F. 252
Nogueira, M. P1773 Nozoe, M. P3463 Obadia, J.F. 2197, P3594, 4011, 5893,
Nohara, A. P1655, P1661, P1699, P1701, Nozue, T. P4674, P4677 5894, 5895
P1704, P2150 Ntertimani, M. P727 Obata, J. P2563
483
Chairpersons & Judges / Speakers & Discussants / Authors Oba – Old
Obayashi, T. P5556 Oginosawa, Y. P1437 Oikonomidis, D. P791

Obedinsky, A. P2358 Ogita, M. P3721, P4477, P5381 Oikonomidou, L. P654
Obeid, S. 6019 Ogo, T. P2366, P2368 Oikonomou, E. P455, P740, P1116, P1458,
Obel, O.A. P168 Ogura, K. P1426 P1577, P2575, P2689, P2725, P3115,
Obenhuber, T. 2058 Ogura, M. P2672, P2719 P3680, P4088, P4312, P5555, P5561,
Oblacinska, A. P3671 Oguri, M. P1672, P5590, P5593, P5610, P6476
Obokata, M. P4753, P5973 P6172 Ois, A. 952
Obradovic, S. P833, 5105, P6409 Oguz, A. P3450 Ojeda, F. P5022
Obrebska, J. P4476 Oh, B-H. 136 Ojeda, F.M. P4332
Obrenovic-Kircanski, B. P3682 Oh, B.H. P3778, P3787, P4110, P4726, Ojeda, J. P3665
Ocaranza, R. P4415 P4771, P6578, P6579 Ojeda, S. 365, P797, P2758, P2763, P3694,
Ocaranza Sanchez, R. P2494 Oh, D.-J. P1502 P3704, P4676
Ocaranza-Sanchez, R. P651, P3472 Oh, D. 2264 Ojeda Pineda, S. P2114
Oceandy, D. 6056, 6057 Oh, D.J. 277, P736, P762, P808, P812, P826, Ojrzanowski, M. 2266
Ocek, A.H. P825, P5335 P834, P2766, P2779, P2842, P3703, 5124, Oka, M. P6298
Ochala, A. P555, P1747, P2837, P4572 P5350, P5355, P5387, P5395 Oka, T. P3407
Ochiai, T. P6319 Oh, H. P435, 4058, P6308 Okabe, T. 5921
Ochiumi, Y. P3708, P3722 Oh, I.Y. P6579 Okada, A. P881, P6222
Ochoa, J.P. P1398, P1623, 3067, 4961 Oh, J.-H. P1724 Okada, D.R. P3503
Ochodnicky, P. P864 Oh, J. 1239, P4110, P6578 Okada, H. 2339
Ochs, A. P194 Oh, J.H. 371, P1511, P2726, P4424, P6431, Okada, I. P1548
Octavia, Y. P2161, 4151 P6511 Okada, K. P6273
Oda, H. P734 Oh, J.K. 4237, P4493, 5214 Okada, M. P1438
Oda, N. 4256, P4437 Oh, O.B.H. P6583 Okada, S. P2165, P2168
Oda, T. 2243, P6143 Oh, O.J.H. P1475, P5971 Okada, T. P1694, 3169
Odaira, M. P1821 Oh, P. P200, P1677 Okado, T. P202, P3111, P5315
Odaka, Y. P1707 Oh, P.C. P784, P4682 Okafor, O. P2407
Oddershede, G.D. P5277 Oh, S. P1145, 3278, P5598 Okamoto, C. P905
Odening, K.E. P1429, P6356 Oh, S.J. P5510 Okamoto, N. P6201
Odenstedt, J. 278, P3435, P6138 Oh, Y.S. P461 Okamoto, R. 2339
Odgaard, A. P5277 Ohara, K. P5227 Okamoto, S. P2404, 3170, P4498, P5326,
Odille, F. P164 Ohara, M. P2769 P6534
Odland, H. P512 Ohara, Y. P2551, P4309 Okamura, A. P3407
Odumusi, K. P4606 Ohashi, K. P433 Okamura, H. P480, P4377
Oduncu, V. P838, P2514, P3695 Ohde, S. P3685 Okano, M. P626, P2818, P6292
Oe, H. P907, P1776, P2537, P3529, P3607, Ohe, H. P1437 Okayama, H. P536, P2804, P5029
P4503, P6304 Ohe, T. P2769 Okayama, M. P220
Oeff, M. P5316 Ohishi, M. P4065, P4375 Okazaki, O. P5261
Oehman, J. P4457, P4748 Ohkubo, T. 4290 Okazaki, S. P3675, P3721, P4477, P5381
Oei, F. P3388 Ohlmann, P. P647, P845, P5409, P5487, Okazaki, T. P5515
Oelze, M. P656, P667, P2581 6635 Oketani, N. P4065, P4375
Oemrawsingh, R.M. P6418 Ohlsson, M.A. P1395 Okimoto, T. P4506
Oertelt-Prigione, S. P5439 Ohman, M. 4147 Okino, S. P801
Oettl, R. P3605, P3606 Ohno, K. 1086 Okisheva, E. P4637
Oevrehus, K.A. 3997, P4998, P5234 Ohno, M. P6404 Okishige, K. P3360, P5323
Oezbek, C. P1608, P2608 Ohno, S. P1386, 2337, 2338, P6128, P6350, Okkonen, M. P451
Oeztuerk, C. P893, P6366 P6351 Okon, T.H. P2387
Offer, A. P5575 Ohno, Y. P907, P1776, P2537, P3529, Okoshi, K. P892, P2808, P3788, P5258
Offredo, L. 1320 P4503, P6304 Okoshi, M.P. P892, P2808, P3788, P5258
Ofner, P. P5934 Ohota, M. P3710 Oksuz, F. P825, P4577
Ogano, M. P513 Ohrvik, C.J.O. P753 Okubo, M. P6363
Oganov, R. P1675 Ohsawa, K. P4495 Okubo, R. P1482, P4512
Ogasawara, M. 1086 Ohta, K. P1420 Okuda, J. P3777
Ogata, H. 1327 Ohta, M. P5307 Okuda, S. 2243, P5939
Ogawa, A. P4547, P5516 Ohtani, H. P1735, P1753, 6618 Okui, H. P4065, P4375
Ogawa, H. 143 Ohtani, R. P5698 Okumiya, K. P5262
Ogawa, H. P487, P767, P811, P881, P883, Ohtani, T. P839, P1793, P4360 Okumura, K. 209
P1339, P1357, P1527, P2366, P2448, Ohte, N. P202, P897, P2707, P3111, 4898, Okumura, K. P3410
P2800, 3305, 4013, P4121, 4134, P4626, P5315 Okumura, M. P3710, P6318
P4635, P4642, P4761, P4763, P5354, Ohtomo, K. P5323 Okumura, S. 2228, P5380
P5602, P6152, P6536, P6541, P6545, Ohtsuki, H. P4694 Okumura, T. P2684, P5578
P6553 Ohtsuki, S. P435, P1817, 4058 Okumura, Y. P6225
Ogawa, M. P1452, P6273 Ohtuki, S. P6308 Okuno, S. P6534
Ogawa, S. 4290 Ohukainen, P. P2162 Okura, H. P1779, P1798, P2776, P3784
Ogawa, T. P4753 Ohya, M. P2738, P6520 Okura, T. P4354, P4507
Ogbonnaya, A. 1971 Ohya, Y. P5262 Okuyama, M. P435, 4058
Oghumu, S. 1217 Ohyama, K. P790 Okuyama, Y. P4360
Ogihara, Y. 2339 Oikarinen, L. P1376 Okyay, K. P6523
Ogimoto, A. P4354, P4507 Oikawa, A. P3566 Olah, A. P1144, 2284, P2667, P2678, P4536
Ogino, H. P6143 Oikawa, M. P3330, P6300 Oldenburg, O. 358, P2797, P3128, P5661,
Oikawa, T. P5579 P6289, 6636
484
Chairpersons & Judges / Speakers & Discussants / Authors Old – Ott
Oldenburg, R.A. P1120 Omori, T. P1535, 3254, P4774 Ortega-Pozzi, A. P1470

Oldenordkamp, L. P466 Omran, H. P206, P5550, P5972 Ortiz, J.L.M. P2751
Oldgren, J. 4980 Omura, T.O. P828 Ortiz, J.T. P1518, P3090, P4988
Oldridge, N. P1663, P4324 Onciul, S. P2539, P2541 Ortiz, M. 3067
Oldroyd, K. 4022 Onda, T. 5087 Ortiz Bautista, C. P3576, P4575
Oldroyd, K.G. P617, P1519, P1522, 4024, Ondrakova, M. P565 Ortiz Genga, M. P1623
4055, 4293, 4294 Ondrus, T. P2614 Ortiz Saez, A. P2751
Oleichuk, E. P3368 Ong, P.E. 36 Ortiz-Bautista, C. P3103
Olesen, J.B. 298, 1832, 1972, 2033, 4976, Ong, P.E. P3093, 4012, P6271 Orvin, K. P5013
P5284, P5596 Ong, P.J.L. P831 Orwat, S. 143, P684, P2138, P5015
Olesen, K.K.W. P1336, P1337, P1464, Ong, S. P5549 Osada, J. P1369
P2745, P5351 Ong, S.G. P3577 Osadnik, T. P2506
Olesen, M.S. P1433 Ong, T.H. P5644, P5648 Osawa, K. P907, P4483, P4503
Olesen, S.P. P1433 Ongen, Z. P1828 Osborn, E.A. 6621
Olesinska, M. P1789, P5655 Ongun, A. P5366 Osby, U.O. P1685
Oleszczak, K. P2411 Onishi, N. P5312 Osei Bonsu, K. 3304
Olien, L. 4194 Onishi, Y. P4674, P4677 Oseroff, O. 209
Oliva, A. P2443, P5929 Ono, K. P2830, P4779, P5428 Oshima, H. P6502
Oliva, B. 6085 Ono, M. P417, P4567, P4640 Oshima, S. P2436, P2533
Oliva, F. 369 Ono, T. P907, P1776, P3764 Osipova, I. P5349
Oliva, F. P3603 Onoda, T. P1651 Ositani, K. P5025
Olivares, R. P3420 Onodera, M. P1651 Osman, R. P5979
Olivari, Z. P564, P569, P1474, 4254 Onodera, S. P3638 Osmancik, P. P4364, P4395
Olivecrona, G. P177 Onose, T. P6539, P6544 Osmenda, G. P6599
Oliveira, A. P5427 Onuma, Y. 369, P2730, 2909 Osmonov, D. 366
Oliveira, H. P2760, P4686 Ooi, S. P793 Osokina, A.V. P2520
Oliveira, L. P2673 Ooka, J. P6311 Ossei-Gerning, N. P1738, P2742
Oliveira, M. 103, P501, P506, P2673, 2937, Oosterhuis, J. P4742 Osswald, S. 126, 154, 157, P479, P524,
P6400 Ootsuka, Y. P4483 P525, P529, P595, P1097, P1099, P1100,
Oliveira, M.G.L. P5254 Opara, M. 160, P3480 P1103, P2461, P3481, P3484, P4077,
Oliveira, S.F. P6267 Oparil, S. P1148 P4454, P4459, P4612, 5085
Oliveira-Jr, S.A. P5258 Opdahl, A. 29 Ostadal, P. P3476, P4439, 5886, P6493
Oliveira-Santos, M. P4333, P5427 Opitz, C.F. P2367 Ostenfeld, E. P507
Oliver, J. 22 Opolski, G. P549, P1091, P1616, P2438, Ostensson, B. P507
Oliver, J.M. P2402, P3380 P2445, P2471, P2515, P3086, P3759, Ostermann, K. P1625
Oliver, L. P3105 P4572, 5147, P5270, P5280, P5300, P6580 Ostlund, O. 4203
Oliver Ruiz, J.M. P2143, P3608, P3615 Oppelt, D. 3068, P6349 Ostman-Smith, I. P5498
Olivero-Soldevila, R. P1774, 2213, P3124, Oppizzi, M. P5659 Osto, E. P1575
P6187 Oprescu, N. P4442 Ostojic, M. P1716, P5415
Olivier, A. P2418, P2455, P3365, P4599, Oqueli, E. P2784 Ostojic, M.C. P630, P739, P3682
P4600, P5553 Oravec, S. P6255 Ostrega, M. P6587
Olivier, C.B. P1454 Orbach, A. P703 Ostrovski, Y. P6485
Olivieri, C. P3739 Orban, M. P1485, P3114, P3568 Osue, T. P1363
Olivotti, L. P2765, P2782 Orban, M.W. P3568 Osugi, N. P788, P5333
Olivotto, I. P466, 4030, 4032, 4962 Ordonez, A. P4528 Osztheimer, I. P509, P2399, P3075
Olligs, J. P5948 Ordonez, J. P1781 Ota, M. P3334, P5488, P6353
Olmos, C. 2318, 2320, P3103, P3104, Ordonez-Llanos, J. P1586 Ota, S. P2487
P3106, P3520, P3576, P4575, P5483 Orellana, L. P4631 Ota, S.O. P828
Olsen, F.J. P844, 5803, P6538 Oreziak, A. P2441 Ota, T. P5333, P6502
Olsen, M.H. 306 Origasa, H. P1760 Otaegui, I. P538
Olsen, M.H. P743, P771, 3973 Orihara, Y. P3407 Otahal, P. P6321
Olsen, R.H. P6448 Orii, M. P583 Otake, H. P1363
Olson, F. P5017, 6023 Orini, M. P415 Otake, R. P6363
Olson, K.J. 4237 Oristrell, G. P610, P6382 Otaki, Y. P184, P851, P1660
Olsson, E.O. P1685 Orita, T. 6629 Otani, H. P4514
Olszowska, M. P436, P720, P1641, P5612 Orlandi, C. P3515 Otasevic, P. P6482
Olympios, C.D.O. P2584, P4560 Orlandi, M. P658 Oteri, A. P634
Omarov, A. 2916 Orlic, D. P609, P630, P1716, P4433, 5102, Otero, S. P3737
Omede, A. 6057 P5415 Oto, A. 134
Omede, P. P6262 Orlov, A. P735 Oto, A. 6074
Omede, P.O. P3118 Orme, J. P2831 Oto, M.A. 1839, P4379, P6188
Omede’, P. P1449, P5378 Ornek, E. P5335, P6257 Oto, T. P5506
Omer, M. 4887 Ornelas, I. P4646, P5964 Otomo, F. P2814
Omerovic, E. 94, 359 Orofino, S. P1573 Otsuji, Y. P1437, P1718
Omerovic, E. P177, 278, P895, 1280, P1335, Orriols, M. P1369 Otsuka, M. P4506
P3435, P4063, P6138 Orsida, D. 5918 Otsuka, T. P3499, P6296
Omersa, D. P6546 Orsini, E. P2351 Otsuki, S. P2780
Omiya, K. P2694 Ortalda, A. 6044 Otsuru, S. P1504, P2622, P2738, P2748,
Omland, T. P451, 1316, P2383, P3497, Ortega, A. P1410, P2119 P2774, P3713, P6278, P6520, P6525,
P3674, 6043 Ortega, J. P2838 P6532
Omori, A. P1582 Ott, C. 6066
485
Chairpersons & Judges / Speakers & Discussants / Authors Ott – Pap
Ott, I. P3405, P3568 Ozturk, U. P2420 Palmer, M.K. P6465

Ottaviani, J. P2134 Ozveren, O. P2514 Palmerini, T. P5378
Ottaviani, O. P2532 Ozyuncu, N. P5615, P5652, P6478 Palmieri, R. P2397
Ottervanger, J.P. P559, P624, P633, P1750, Pace Napoleone, C. 2930 Palmiero, G. P3505
P4453 Pacher, R. 4278, P6547 Palomares, J.A. P5702
Ottesen, A.H. P451, 6043 Pacho, C. P2790 Palomino Doza, A.J. P1398
Otto, C.M. 1056, 3048 Pachon, M. P3369 Palomino Doza, J. P1623, 3067
Otto, J.J.M. P5565 Paci, A.M. P569 Palomo, J. P1123
Otto, S. P787, P2538, 3167, P3500, P3719, Paci, C. P1533 Pals, G. 3071
P3727 Paciaroni, M. P5595, P5608 Paluzie, G. P1674
Otto, T. P4343, P4345 Pacileo, G. P1351 Pambrun, T. P4358
Otuki, S. P5327, P6156 Packer, D. P3373 Pamidimukkala, V. P4711, P4717
Ou, P. 2103, P3731, P5014, 5217, 5218, Packer, D.L. 186 Pan, C.Z. P2833, P4585
P6415 Packer, M. P213, P214, 1317, 3301, 3302, Pan, J.-P. P574
Ou, Y. P2152, P5636 4144, P5031 Pan, J. P1428
Ouali, S. P4693 Packham, D. P3772 Pan, M. 365, P3704, P3730, P4676
Ouarrak, T. 349, P3131, P3132, P3771 Padeletti, L. P514, P2425, P3399, P3403, Pan, M.P. P2442
Ouchi, N. P433 P3411, 4860 Pan, S. P1428
Oudijk, M.A. P713 Padley, S. 958, P3737 Pan, W.H. P5394
Oudit, G. 130 Padmanabhan, D. P3373 Pan, X. P6217
Oudkerk, M. P5591 Padrao, A.I. P2372 Pan Alvarez Ossorio, M. P1109
Ouhlous, M. 2101, P4673 Padro, T. P1445, P4422 Pan Alvarez-Osorio, M. P797, P2114,
Ousaka, D. P435, P1817, 4058, P6308 Padron Encalada, R. P3591 P2758, P2763, P3694
Ouwehand, W.H. P1446 Padron-Barthe, L. P6343 Panagiotakos, D. P2711, P2721
Ouzan, E. P1604 Paelinck, B. 5785, P6419 Panagiotakos, D.B. P727, 2233, P2641,
Overhus, K. P4465 Pagan, L.U. P2808, P3788, P5258 P2723, P3681, P4418, P4430, P4450,
Overvad, K. P4322, P5281 Pagano, B. P1531 P4648, P6422, P6438
Overvad, T.F. P5308 Pagano, G. P874 Panagopoulou, V. P1342, P2154
Ovize, M. 123, 298 Page, M. P3504 Panajotu, A. P4496
Ovize, M. 1173, 1990, 4793, P5392 Pagnotta, P. P1499 Panchenko, E.P. P456
Ovsianas, J. P1594 Pagoni, S. P4123 Pancholia, A.K. 263
Owan, O.T. P1151 Pagourelias, E. P5433 Pandey, N. P6133
Owen, C.G. P5572 Paini, A. P5709 Pandolfini, L. P514
Owens, P. P625 Paintmayer, L. P607 Pandya, B. P2141
Oxnard, D. P1380 Pais, J. P5686 Panelo, M.L. P1110, P5584
Oyen, N. P711 Paiva, L. P209, P2760, P4686 Paneni, F. P725, 1852, 2013, P4539, P5632
Ozaki, S. P3499 Pajitnev, D. P4368 Pang, K. 6103
Ozaki, T. P4760, P6558 Pajitnev, D.E. P4367 Pang, P. 6638
Ozaki, Y. 308 Pak, H.N. P484, P3337, P4064, P4355, Paniccia, R. P1496, P2522, P6200
Ozaki, Y. 2054, P3710, 6091, P6318 P4440, P4497, P5296, P6175 Panikker, S. P3367, P3395, P3741, P5452,
Ozanne, S. 4851 Palacios Rubio, J. P2517 P6112
Ozawa, K. P3528, P4501, 5211, P5413, Paladin, A. P4452 Panikker, S.K. P4390
P5944 Paladini, B. P6410 Panknin, C. 2340
Ozawa, M. P5331 Palaiodimos, L. P639, P2499, 3174 Pankratz, F. 1956
Ozbaran, M. P6510 Palapies, L. P4074 Pankuweit, S. 39, 377
Ozcan, C. P6235 Palatini, P. P899, P5704 Pankuweit, S. P3597
Ozcan, E.E. P3075, 4856 Palazon, O. P3332 Pannier, B.P. P1658
Ozcan, F. P4577, P5271, P6274 Palazzi, G. P2355 Panoulas, V. P5420
Ozcan, O.U. P3677, P5366, P5615, P5652, Palazzini, M. 4182, P5521, P5524 Pansieri, M. 4260
P6478 Palazzuoli, A. P3791, P4078 Pantazis, A. P1632, 2080, 2082, 2084, 6609
Ozcan Cetin, E.H. P1459, P1460, P2118, Palazzuoli, A.P. P3118 Pantos, C. P3442
P2490, P3699, P4561, P4562, P5271, Paleczny, B. P1789, P5655 Pantos, I. P3386, P4378
P5649, P6406 Palermo, C. P2559 Panza, J.A. P5974
Ozdemir, H.M. 4173 Palevski, D. P3548, P3555 Panzenboeck, A. P4545, 4866
Ozdemir, N. P5517, P6144 Palfy, J.A. 968 Panzer, S. P1455
Ozdowska, P. P5537 Palhares, D. P621 Panzini, I. P3672
Ozeke, O. P1460, P2118, P2490, P3699, Paliege, R. P6113 Paolillo, S.F. P6570
P4533, P4562, P5649, P6274 Palka, I. P5294 Paonessa, K. P2765, P2782
Ozen, M. P1828 Palladini, G. 2208 Papachristidis, A. P3726, P6233, P6236
Ozen, M.B. P5426 Palladino, M.T. P4683 Papacosta, O. P4776, P5019, P5572
Ozer, N. 238, 1839, P4379, P4690, 6074, Pallantza, Z. P644, P660, P5368 Papadakis, I. P654
P6188 Pallisgaard, J. 1972, P5596 Papadakis, J. P5347, P6504
Ozkalayci, F. P2534 Pallisgaard, J.L. 1832, 3277, 4976 Papadakis, M. 258
Ozkan, M. P4319, P6386 Palma, R.K.P. P6479 Papadakis, M. 60, 61, 63, 65, 1848, P2373,
Ozkor, M. P1617 Palma Dos Reis, R. P4621, P4625, P4643, P2680, 2967
Ozpelit, E. 2236, P6325 P4646, P5962, P5964 Papadavid, E. P5418, P6265
Ozpelit, M.E. 2236, P6325 Palma-Reis, R. P6581 Papademetriou, M. P2139
Ozturk, D. P423, P2519, P5637, P6242 Palmas, S. P1573, 5807 Papademetriou, V. P2839, P2844
Ozturk, O. P2420 Palmas, W. P1653 Papadimitriou, L. P3681, P5682
Ozturk, P. P6510 Palmas Dos Reis, R. P4645 Papadopoulos, C. 3174, P3513
Ozturk, S. P2534, P5517, P6144 Palmen, M. P3794, P6513
486
Chairpersons & Judges / Speakers & Discussants / Authors Pap – Paw
Papadopoulos, D. P4666 Park, H.S. P445, P2462, P4724 Pascual-Figal, D.A. P3755, P5694
Papadopoulos, K. P6204 Park, H.W. P4616, P4633 Pascuzzo, G. P1590
Papafaklis, M.I. 6621 Park, J. P806, P1825, P4497, P4639, P6579 Pasley, T.F. 5794
Papageorgiou, N. P644, P660, P898, P1458, Park, J.B. P484 Pasotti, E. P3519
P3115, P3803, P4088, P5368 Park, J.C. P824, P4471, P4616, P4633 Pasquale, F. P5467
Papaioannou, S. P644, P898, P1458, Park, J.E. P6241 Pasquet, A. P3504, P6419
P3115, P3803, P4088, P5368 Park, J.H. P445 Pasquet, A.A. 190
Papaioannou, T. P4582 Park, J.J. P2570 Pasquet, A.A. 135, 137, 139
Papakonstantinou, P. P5329 Park, J.K. P484, P904, P2756, P4064 Pasquet, P.A. 5212
Papalois, A. P3442, P3590 Park, J.R. P863, P1780 Passarelli, C. P1421
Papamichael, N.D. P4597 Park, J.S. 371, P819, P1511, P1721, P2726, Passino, C. P1366, P3757, 6044, P6425
Papanagnou, G. P4430, P4450 P3799, P4424, P6431, P6511 Pastana, A.F. P6499
Papanikolaou, A. P2388, P4106, 4874 Park, J.S.P. P1724 Pasterkamp, G. 1214, P2783, 3950, P6253
Papaoikonomou, S. P1458 Park, J.W. P206 Pastor Pueyo, P. P2691
Papapetropoulos, A. 1089, P3082, P3084 Park, J.Y. P812, 5093 Pastor Torres, L. 2940, P3650
Paparisto, V. P5272, P6208 Park, K.-H. P1495, P1502, P2735 Pastor-Perez, F.J. P4403
Papataxiarchis, E. P4450 Park, K.I. P819 Pastore, G. P2389, P4745, P4758, 4863
Papathanassiou, K. P765 Park, K.S. P2477 Pastore, J. P215
Papavassiliu, T. P4591 Park, K.W. 2912 Pastori, D. P5279, P6190
Paperini, L. P1092 Park, M.W. P2848 Pastormerlo, L.E. P6425
Papingiotis, G. 3303 Park, S.-J. P3109 Pastushyna, A.I. P902
Papp, Z. P2649 Park, S.-W. P3109 Patel, A. 6626
Pappalardo, A. P5242, P5244 Park, S. 1239, P1657, 2264, P2710, P6263, Patel, A.N. P215
Pappalardo, F. 2290, 2291, 2293 P6590 Patel, H.C. P3737, P6157
Pappone, C. P502 Park, S.D. P2477 Patel, K. 2968, P3511, P6157, P6365
Paques, M. 5079 Park, S.H. P5395 Patel, L. P6360
Paquette, M. P1516 Park, S.J. P4493, P4559 Patel, M. 1039, P4066
Paradela-Dobarro, B. P432 Park, S.M. P5401 Patel, M.R. 2031, P4398, P6210
Paradossi, U. P4414 Park, S.W. P1525, P4363, P4493, P4559 Patel, N. 4857
Parag, V. P6457 Park, T.H. P819 Patel, N.N. P2155
Paraggio, L. P5027 Park, W.J. P6445 Patel, P. P5425
Parapid, B. P173, P739, P3682 Park, Y.M. P784 Patel, P.M. P1418
Parasa, R. P3456 Park, Y.W. P746 Patel, R.S. P5383
Paraskevaidis, I. P3513, P5437 Parker, J. P1576 Patel, S. 1834
Paraskevaidis, J. 3174, P5347 Parker, J.D. 27 Patel, S.K. P894, P5674
Paraskevopoulos, T. P1577, P3680 Parker, J.D. P4107 Paterna, S. P3785
Parati, G. 36, 42, 209 Parker, K.H. P4777 Pathak, R.K. 1847, P4374, P6198
Parati, G. 287, 382, 383, P3352, 3837, 3842, Parker, M. P4709 Pathan, R. P677
P5263, P6495 Parkkonen, O. P3429, P6264 Pathik, B. P1424, P2356, P3630
Parcharidou, D. P5502, 6013 Parks, T. P1613 Pathirana, C. P5370
Pareek, M. P743, P771 Parma, R. P4572 Paton, J.F.R. P2840, P4335, P4338, P4339
Pareek, N. P681 Parmon, E.V. P1540, P1542 Paton, J.R.F. 4872
Paren, P. 4282 Parodi, G. 143 Patricio, L. P3693
Parenica, J. 6645 Parodi, G. 323, P1469, P1496 Patricio, L.M. 3214, 3215, 3216
Pariggiano, I. P5365 Parolari, A. P6368 Patrono, C. 132, 362
Parik, R. P878 Parolini, M. P3743 Patrono, C. 927, 4126, 5878
Parikh, J.D. 2933 Parra Fuertes, J.J. P3486 Patsch, W. P4644
Parikh, N. P4713 Parravicini, U. 4860 Patsilinakos, S. P1479
Parish, S. P637, P5575, P5620 Parreira, L. P4350, P4380 Patsouris, E. P5464
Parisi, V. P874, P6338 Parrinello, G. P3785 Patzer, P. P6514
Parissis, J. P880, P2459, P2666, 3303, Parrington, J. P4541 Paul-Clark, M. P430
P3513, P4768, P5437, P6320, P6566 Parrini, I. P865, P5938 Pauls, P. P5948
Parissis, J.T. 3062, 3063 Parruti, G. P4628 Paulus, W.J. 4042
Park, B. P5702 Parthenakis, F. 5905 Pauschinger, M. 3309
Park, C.-B. P802 Parthenakis, F.I. P3355, 4899 Pauvaday, V. P3627
Park, C. 2264 Partyka, L. P2837 Pavel, P. P4720
Park, C.G. 277, P736, P762, P808, P826, Parviainen, V. P3099 Pavelescu, A. P4553
P834, P2766, P2842, P3703, 5124, P5350, Parviz, Y. P652 Pavesi, C. 1204
P5355, P5387, P5395 Parviz, Y.P. P5562 Pavitt, C. 958
Park, C.H. P4497, P4682 Parwani, A. P1093 Pavlidis, A.N. P2740
Park, C.M. 1849 Parwani, A.S. P3079, P3428, P4385 Pavlidis, G. P639, P654, P2499, 3174,
Park, C.S. P6287 Pasaoglu, H. P4534 P5347, P5418, P5705, P6265, P6504
Park, D.S. P2756 Pascalau, L. P4706 Pavlov, A. P211, P6420
Park, E.H. P666 Paschalaki, K. 2256 Pavlovic, D. P2114, P4676
Park, G.M. P2848 Paschalidis, E. P1572, P2574, P3679, Pavlovic, M. 5105, P5667
Park, H.-Y. P802 P3806, P4118, P5710 Pavlovic, R. P3634, P3661
Park, H. P824, P3732, P4471 Pascual, D. 4279 Pavlovic, V. P827, P830, P2518, P4433
Park, H.B. P3799 Pascual Calleja, I. P5248 Pavo, N. P530, 4278
Park, H.C. P904 Pascual Figal, D. P2811 Pavon, N. P4527
Park, H.E. P666 Pascual Figal, D.A. P2813 Pavy, B. P2675
Park, H.J. P4428, P6287 Pascual Izco, M. 5091 Pawlak, A. 6612, 6615
487
Chairpersons & Judges / Speakers & Discussants / Authors Paw – Per
Pawlak, D. P1451, 1833 Pellicano, M. P1364, P1729, P1740, P2729, Pereverseva, K.G. P3354
Pawlitschek, F. 5792 P2767, 4023 Perez, A. P3077
Pawlowski, T. P555 Pellicano, M.P. P3461 Perez, A.B. P6492
Paya, A. P1517, P1518, 3252 Pelliccia, A. 152, 318 Perez, B.A. P1125, P6187
Paya-Serrano, R. P181 Pelliccia, A. 66 Perez, F. P167
Paydas, S. P875 Pellicori, P. P3789 Perez, L. P167, P478
Paykova, A.V. P3628 Pellikka, P. P4102, 4887 Perez, P.P. 953, P1440
Payne, A.P. P1151 Pellikka, P.A. 3049 Perez, X. 2915
Paz, Y. P5633 Pellizzari, A. P5289 Perez De Isla, L. P1107, P1593, P2548,
Pazdernik, M. 81, 320 Pello Lazaro, A.M. P6250 P2549, P2557, P3520, 3986, 3987, 3989,
Pazdernik, M. 1192, 3937 Peluso, D. P702, P2559, P2560, P3532 3991, 3993, P5243
Paziuc, A. P796 Pemberton, C.J. P4610 Perez De Prado, A. P832, 1205
Pazmanova, T. P1797 Pemberton, C.P. P567 Perez Del Villar, C. P3127, P4569, 5802
Pazzi, M. P6200 Pemberton, J. P763 Perez Martinez, M.T. P2811
Pchelina, S. P5339 Pena, A. 4289 Perez Vizcayno, M.J. P2728
Peace, A. 4023 Pena, M.L. P1623 Perez Vyzcaino, M.J. 2060
Peacock, W.F. P3772, P4066 Pena Duque, M.A. 140 Perez-Alvarez, L. P475
Pearman, C.M. P4543 Pena Pena, M.L. P1398, 3067 Perez-Calvo, J.I. P2813
Pearson, D.A. P1333, P4435 Pena-Gil, C. P3472, P4406 Perez-Cebey, L. P3506, P3507
Pearson, I. P4327 Penafiel, J. 4277 Perez-David, E. P5448
Pearson, J.D. 72, 262, 375 Penaloza, A. P3485 Perez-Feliz, S. P6356
Pearson, J.D. 5823, 5825, 5827 Penalvo, J.L. 6085 Perez-Hernandez, M. P5945
Pecora, D. P2112, 2207, P5222, 5916 Pencina, M.J. P2144 Perez-Martinez, M.T. P2813, 4279
Pecoraro, R. P3335 Penco, M. P2794, P6199, P6435 Perez-Perez, A. P745
Peczek, L. P4448 Penela, D. P1405, P3371 Perez-Rodon, J. P610
Pedersen, E.K.R. P1656 Penicka, M. P2614, 5785, P6297, P6484 Perez-Torres, I. P641
Pedersen, E.R. P4657 Penkalla, A. P453 Perez-Villa, F. P1123, P1766
Pedersen, F. 4001 Penn, M. P215 Perez-Vizcayno, M.J. P2517
Pedersen, J.B. P1503 Pennell, D.J. 304, P1520, 1986, P2142 Perge, P. P499, P509, P2396
Pedersen, L. P577 Pennestri’, F. P3512 Pergola, V. P6486
Pedersen, L.R. P6448 Pentara, I. P1478, P1479 Perian, M. P2135
Pedersen, O. P1433 Pepe, A. P1529, P1531, P1533, P2355, Perier, M.C.P. P1658
Pedersen, T.R. P4093 P6548, P6571 Perin, E. P1348
Pedicino, D. 3944, P6118 Pepe, G. P6410 Perin, F. P1410
Pedrazzini, G. 965 Pepi, M. 4051, 4056, P4997, P5233, P6316 Perisic, Z. 22
Pedrazzini, T. 5902 Pepi, M.P. 2102 Perk, J. 77, 124, 302
Pedretti, R.F. P3649 Pepi, P. P5222 Perk, J. 15, 988
Pedrinelli, R. P3087 Pepin, J.L. 1075, 1077 Perkiomaki, J. 1322, P3125
Pedrotti, P. 201 Peppa, M. P2666 Perkiomaki, J.S. P2708
Pedrotti, P. P3603 Pepper, J.R. P430 Perlini, S. 2208
Peebles, C. P2530 Pequignot, R. 964 Perna, F. 5900
Peek, M. 2919 Pera-Rojas, C. P2381 Perna, G.P. P3437, P4554
Peek, N. P3645 Peradejordi, M. P1767 Perna, G.P.P. P2705
Peelen, L.M. P1755, P5618 Perazzolo Marra, M. P690, P1528, P1534, Pernat, A. P3421
Peels, C.H. P6416 P4460 Pernick, Y. P3642
Peeraphadit, T. 2211 Perdiguero, P. P467 Pernigotti, A. P5358
Peeraphatdit, T. 5093 Perea, G.O. P5583 Pernot, M. P3574, P5462
Peeters, F.E.C.M. P3333 Perea, R.J. P3090 Pernow, J. P648, P2133, P3085
Pego, M. P2470, P3493, P4333, P4764, Perea Gil, I. P2580, P5445 Perola, M. P3098
P5427 Perea-Gil, I. P3546, P3553 Perolo, P. P5358
Peichl, P. 956, 6075 Pereda, D. 6018 Perperis, A. P1478
Peinado, R. P2402, P3380 Pereira, A. P2529, P4621, P4625, P4643, Perperoglou, A. 1986
Peinkofer, G. 4191 P4645, P4646, P5962, P5964 Perpinia, A. P3358
Pejkov, H. P2531 Pereira, D. P592, P2464, P2529, P3431, Perrea, D. P2575
Pekarova, M. P6355 P4303, P4621, P4625, P4643, P4645, Perrey, S. P2690
Pekel, N. 2236 P4646, P5377, P5962, P5964 Perri, D. P5543
Pelargonio, G. 5900 Pereira, E. P3669 Perrino, C. 1985, P2121
Pelissero, E. 6034 Pereira, H. P1118, P3669, 4158, 5814 Perrone Filardi, P. P874
Pelizzoni, V. P2406 Pereira, J. P5677 Perrone Filardi, P.P.F. P6570
Pella, D. P3744 Pereira, M. P545, P4993, P5338, P5345 Perrone-Filardi, P. P217, P218
Pellacani, A. P5968 Pereira, M.A. P6266 Perrotta, M.E. P5290
Pellanda, L.C. P732, 2235 Pereira, P. P5658, P5684 Perrucci, G.L. P4734
Pellegrin, M. P4530 Pereira, S.B. P2717 Persad, K. 6616
Pellegrini, M. P3791 Pereira, S.N. P3643 Pershukov, I. 2916
Pellegrino, G. 3943 Pereira, T.V. P1787, P2822 Persson, C. 2966
Pellegrino, M. P750, P886, P2618, P4744, Pereira Da Silva, T. P1773, P3693 Persson, H. P2787
P4750, P6376, P6434 Pereira Silva, T. P2473, P4488 Persson, M. P4532
Pellegrino, T. P874 Perelshtein, O.P. P4632 Persu, A. P1147
Pellegrino, T.P. P6570 Perera, D. P669, P2740, 4931 Pertosa, G. P4664
Pellek, M. P2645 Peres, K. 964 Peruga, J.P. P4670
Peretto, G. 2015, P4634, P6170
488
Chairpersons & Judges / Speakers & Discussants / Authors Per – Pir
Peruga, J.Z. P4670 Phatak, H. 1975, P4397, P4987, P6197, Pignatelli, P.P. P5279
Pervez, M.O. P2383 P6212, P6215, P6217 Pigrim, T. 362
Pescetelli, I. 6044 Phatarpekar, A. P4681 Piherova, L. P5499
Petakov, A. P816 Phatharacharukul, P. 2211 Pihkala, J. 2309, 2310, 2312, 2314, 2316
Peteiro, J. P3506, P3507 Philip, S. P1679 Piira, O.-P. P2708, P6221
Petelina, T.I. P521 Philipp, R. 4194 Pijls, N.H.J. 1949, 6620
Peter, A. P2649 Philipsen, T.E. P3581 Pijnappels, D. P5926
Peter, K. P2125 Phlips, T. P3387 Pijnappels, D.A. P5456, P6177
Peternelli, D.G. P4410, P4455 Phrommintikul, A. 5219 Pijuan Domenech, A. P3612
Peters, A. 3223, 4205 Piatek, J. P5616 Pike, N.A. P442
Peters, N.S. P869, P1411, P1418, P3398 Piatek, K. P187, P188, P190 Pilat, E. P2447
Peters, R. 5078, P5567 Piatkowski, R. P2515 Pilato, E. P1769
Peters, S. P6398 Piazza, N. 3006 Pilgrim, T. 6020, P6135
Petersen, A. P3108 Piazza, R. P1644, P1646, P3335, P5242 Pilgrim, T.M. P6133
Petersen, H.H. P462, P474 Pibalyart, S. P4672 Pilichou, K. P690, P6166
Petersen, S.E. 2280, 4229, 4231, 4232, Pibarot, P. 81 Pilichowska, E. P4388
4233, 4235, P6323 Pibarot, P. 2992, 2993, P5478 Pilleri, A. P564
Peterson, E. 148 Picano, E. 38 Pilz, G. 1933, P6323
Peterson, E. 1882, 2181, 3259 Picano, E. P450, P620, P1341, P1769, Pilz, M. 350
Peterson, E.D. 298, P2144, P3076 P3509, P3510, P3525, P5020, P5530, Pimenta, R. 103
Petilla, V. 6043 P5576, P6309 Pina, I. 374, 376, 377
Petillo, F. P4571 Picard, W. P4438 Pinamonti, B. P522, P686, P1621, P5242,
Petit, T. P1111, P5507 Picardi, E. P569, P4588 P5244, 5787
Petit-Eisenmann, H. P5409 Picariello, C. P2389, P4745, P4758, 4863 Pinar, E. 366
Petitalot, V. P4558 Picarra, B. P1626, P1627, P5393, P5497, Pine, P.R. P3088
Petiteau, P.Y. P579 5820 Pineda, V. P538
Petkov, R. P6403 Picchi, A. P2345 Pineda-Pompa, L.R. P5650
Petkun, W. 1975, P6197, P6212, P6215 Piccini, J.P. 298, 2031, P3076, P4297, Pinedo Gago, M. P5474
Peto, R. P1700, P4652, P6592 P4398, P6210 Pingel, S. P2631, P4573
Petousis, S. P5371 Piccinino, C. P2561 Pingitore, A. 291
Petraco, R. P1714, P1717, P1725, 4932 Piccoli, A.B. 2235 Pinho, P. P1605, P4464, P5634, P5635,
Petre, I. P5943 Piccolo, E. P860 P5641
Petretto, E. P1562 Piccolo, R. 362 Pinho, T. P2140, P3604, P6394
Petrie, M. P1522, 2094, 2095, 2097, 4024, Pichard, A. P670, P1599, P3593, P4583, Pinho-Gomes, A. P5641
4293, 6642 P6379 Pinho-Gomes, A.C. P5634
Petrie, M.C. P5974 Pichler, G. P4775 Pini, A. P6495
Petroni, A. P6199 Pickering, J.W. 127, P3483, P4610 Pinilla, N. P3122
Petroni, R. P6199, P6435 Picoi, M.L.E. P3458 Pinilla Echevarri, N. P3718
Petronijevic, M. P5536 Picon Heras, R. 2940, P3650 Pinilla Echeverri, N. P3401, P4714, P6517
Petronio, A.S. 25 Pie Raventos, S. P3612 Pinkert, S. P5501
Petronio, A.S. 1281, P1598, P3592, P6375 Piechaud, J.F. P1639 Pintalhao, M. P6586
Petrosillo, N. P677 Piek, J. P669, P1717, P1725 Pintana, H. P5539
Petrosova, V. 5083 Piek, J.J. P174, 364, P1507, P1708, 1840 Pinto, F. P1642, P2552, 4154, P5422
Petrou, M. P2595, P5416 Pieles, G. P3559 Pinto, F.J. 88, 133, 150, 196, 247,
Petrov, I. 86 Pieles, G.E. 1900 298, 309, 356
Petrov, L. P1348 Pieniazek, P. P4685, P5616, P5619, P5622 Pinto, F.J. P511, P598, P1121, P1122, 2017,
Petrovic, D. P2713, P4423 Piepenburg, S.M. P1669 P2428, P2433, P2636, P3601, P3669,
Petrovic, M. P630, P5678 Pieper, P.G. P713, P2137, 2934, 2971 P3804, P5419, P6165
Petru, J. P169, P4387, P4720, P6493 Piepoli, M.F. 1069, 2889, P4320 Pinto, R. 2937, P5679
Pettersson, G. P606 Pierard, L.A. 363 Pinto, Y. 310
Pettersson, K. P425 Pierard, L.A. 309, 1302, 1304, 1924, 2993, Pinto, Y. P3350, 4263, P6184
Pettila, V. P451 2995, 2997 Pinto, Y.M. 3070, 3073, P5239, P6182
Petulla’, M. P6316 Pieroni, M. P1354, P5929 Pinto Teixeira, P. P867, P1773
Peturrson, P. 278, P6138 Pierre, B. P5313 Pinto-Teixeira, P. P4434
Petursson, P. P3435 Pierre-Louis, B. 2915 Pinyosamosorn, K. P1732
Petychev, P. P3425 Piers, S.R.D. P1401, P3372, P5926 Piorkowski, C. P3381, P3389, P3409,
Petzold, M. P3716 Piersigilli, A. P185, P186 P4341, P4359, P4983
Pevni, D. P5633 Pieske, B. 203 Piot, C. 1293, 1295
Pezzi, L. P6199 Pieske, B. P718, P1777, 2206, P3079, Piotrowicz, E. 369
Pfaffenberger, S. P2129 P3428, P3471, P3492, P3769, 4045, Piotrowicz, E. P5651
Pfeffer, M. 5138, P6555 P4385, P5319 Piotrowicz, R. P5651
Pfeffer, M.A. 1977, P3756 Pietersen, A. 6076 Piotrowski, W. P5651
Pfeifer, J. P6514 Pietila, M.J. 256 Piovaccari, G. P2485, P3672
Pfeifer, P. 1960 Pietri, P. P204, 967, P1572, P2574, P2699, Piovano, E. P865
Pfeifer, R. 6631 P3679, P3806, P4118, P4668, P5540, Piper, C. P677
Pfisterer, M. P1139 P5541, P5588, P5710, P6598 Pipilis, A. P6204
Pfluecke, C. 1989, 4973 Pietro, G. P6270 Piqueras, J. P3122
Phadke, M. P4681 Pigatto, E. P702 Piqueras Flores, J. P3718, P4714, P6517
Pham, T.H. P1349 Pigearias, B. 5077 Piras, A.M. P3447
Phan, J. P2516, 5804 Pignatelli, P. P6190 Piras, R. 5807
Pires-Morais, G. P4490
489
Chairpersons & Judges / Speakers & Discussants / Authors Pir – Por
Pirinen, J.R.R. P2346 Pocock, S. P582, P2463, 2913, 3031, Polo Lopez, L. P2143, P3608
Piriou, N. P1810 P3342, P3717 Polo-Lopez, L. P3615
Pirisi, R. P578 Pocock, S.J. 74, 76, 78, P2796, 4855, 5137 Poloczek, S. P4070
Piroth, Z. 6620 Podczeck-Schweighofer, A. P2488 Polokova, L. P4705
Pirozzolo, G. P3093, P6271 Podesser, B. P4545 Poloni, G. P3536
Pisano’, E.C.L. 5918 Podewski, E. P884, 2928 Polonski, L. P539, P547, P549, P585, P587,
Pischke, S. P3462 Podoleanu, C. P3311 P589, P2471, P2506, P2525, P2789,
Piscopo, G. P859 Podolec, J. P720 P3759, P5404, P5937, P6580, P6587
Pistritto, A.M. P5952 Podolec, N. 2022 Polonsky, B. 2271
Pitaraki, E. P4648 Podolec, P. P436, P638, P720, P1641, Polos, M. P5449
Pitcher, A. P3609 P4685, P5612, P5616, P5622, P6329, 6610 Polovina, M. P5272
Pitic, D. P4442 Podolecki, T. P3322, P4476, 4861, P5303 Polovina, M.M. P6208
Pitney, M. P5549 Podpalova, O. P6595 Poltavskaya, M. P3347
Pitrolo, L. P1531 Podrouzkova, H. P6310 Polvani, G.L. P3382
Pitsavos, C. P727, 2233, P2711, P2721, Poelzl, G. P4737, P5558 Polyatykina, T.S. P3628
P2723, P3681, P4331, P4418, P4430, Poerner, T.C. P787, P2538, 3167, P3500, Polzin, A. P5986
P4450, P4648, P5555, P5561, P5676, P3719, P3727, 6631 Pombo-Jimenez, M. P2777, P3657, P6526
P6422, P6438 Poesch, A. P4736 Pomero, F. P3619, P4675
Pitt, B. P1799, 2330, P3756 Poess, J. 133, 363 Pomeshkina, S. P3647
Pittarello, D. 351 Poess, J. 1048, 1049, 1050, P3092, P3494, Pompilio, G. P2586, P3133, P4734
Pitthan, E. P5559 3937, 4249, 4251 Poncelas, M. 1088
Pittrow, D. P2367 Poess, J.P. P3094 Pongetti, G. P2406
Piva, T. P3437 Poggio, P. P6368 Pongkan, W. P5539
Pivackova, L. P872 Poggio, R. P2421 Ponikowska, B. P1789, P5655
Pivetta, A. P522, P686 Poh, K.K. 358 Ponikowski, P. 141
Pivovarova, L. P5349 Poh, K.K. P1684, P5441, P6124 Ponikowski, P. 387, P841, P889, 1076,
Pizon, T. P3807 Poh, R. 2942 1077, P1789, P2796, 3308, P3430, P3758,
Pizzi, C. P3397, P3418 Pohanka, A. P4067 P3759, 3849, 3851, 4285, 4808, P5655,
Pizzi, M.N. P610, P6382 Pohl, M. P3389, P3409, P4341, P4359, P4983 6037, P6569, 6638
Pizzini, P. P1149 Poirier, N. P717 Poniku, A. P4727, P6585
Pizzuti, A. P5493 Poitz, D. 4973 Poninska, J.K. P3540
Placidi, S. P2397 Poitz, D.M. P662 Pons, G. P745
Placido, R. P598, P1121, P1122, P2109, Pokorney, S.D. P3076 Pons Llado, G. P4996
P2428, P2552, P2636, P3804, P5419, Pokreisz, P. P6260 Pons-Llado, G. P2130, P4524
P5422 Pokrovskaya, M. 1837 Pontana, F. P6315
Placzkiewicz, D. P2527 Pokrovsky, A.V. 34 Pontes, M.R.N. P5477, P5640
Placzkiewicz, D.T. P2513 Pokushalov, E. P2358, P3313, P3370 Pontone, G. 130, 313
Plana, J.C. 3054 Pola, R. P1560 Pontone, G. 4051, 4056, P4997, P5233,
Plana, N. P1674 Polach, J. P4439 P6316
Planinc, I. P2824 Polanczyk, C.A. P6220 Pontone, G.P. 2102
Plank, F. P4491 Polasek, R. P4439 Pontuch, P. P1797
Plante-Bordeneuve, V. P5423 Polavarapu, A. P4711, P4717 Ponz De Antonio, I. P195, 6633
Plashchinskaya, L. P3736 Polavarapu, N. P4711, P4717 Poole, J. 1242, 5757
Plat, J. P1698 Polavarapu, R.S. P4711, P4717 Poole, S. 3211
Platek, A.E. P5270, P5280, P5300, P5332 Polenova, N. P5708 Poon, K.L. P1421
Platonov, P. P1375 Poles, J. P6229 Pop, N. P2815
Platonov, P.G. P460, P2403, P2476, 4959 Poleszak, K. P2411 Popescu, B.A. 153, 210, 252
Platzek, I. P4494 Poletti, A. P5244 Popescu, B.A. P1630, 4004
Plazak, W. P5612, P6329 Polewczyk, A. P1091, P2438, P2440, P2445, Popescu, M.I. P4619
Pleava, R. P6469 5145, 5147 Popescu, R.A. P849, P2454
Plein, S. 197 Polewczyk, A.M. P2440 Popov, S.V. P2450, P6574
Plein, S. 306, P4096, 4931 Polewczyk, M. P2440, 5145 Popovic, D. P630, 4288
Pleskot, M. P4441 Polgar, P. P5023 Popovic, Z. P5425
Pless, H. P3523 Polge, A.S. P1124, P2626 Popovic, Z.B. 4236
Pletsch Borba, L. P5573 Poli, D. P6193, P6200 Popovici, I. P6527
Plewka, M. P4670 Poli, M. P2794 Popovici, M. P6527
Plewka, M.P. 2266 Poli, S. P4399, P5297, P5603, P5683, P6147, Popp, R.L. 1962, 1963
Plichart, M.P. P1658 P6575 Poppas, A. 198
Pllaha, E. 4166 Poli, V. 132 Poppas, A. 5064
Plock, G. P4070 Polikutina, O. P3338, P4443, P5403 Poppe, K.K. P4620
Ploederl, M. P4644 Polilli, E. P4628 Poppert, H. 2058
Plonska-Gosciniak, E. 139 Polin, B. P5429 Porcellini, S. P3399, P3403, P3411
Ploski, R. P3540, P3543 Polischuk, S. P3805 Poreba, R. P3112
Pluess, M. P4738 Polk, D. 3962 Porizka, M. P5247
Plummer, C.J. 262 Pollack, C. 148 Porretta, A.P. P4100
Pluta, S. 4864 Pollack, C. 1912, 2183, 3030, P5967 Porro, R. P475
Pluymaekers, N. P192 Pollack, S. P4571 Porta, A. P4337
Poci, D. P4344 Pollak, A. P3540 Porta, D. 4196
Poci, N. P5517, P6144 Poller, W. 3069, P3535, P5501 Porter, J. P5328
Pociask, E. P1747 Poller, W.C. P1353 Porter, K.E. 20
Pollock, J. P878 Porthan, K. P1376
490
Chairpersons & Judges / Speakers & Discussants / Authors Por – Puz
Portillo, A.K. 4176 Pravkina, E.A. P3354 Pruszkowska, P. P3322, 4861

Porto, I. P604 Praz, F. P1723, 5791, 6020 Pryds, K. P596
Portoles, M. P4541, P6334 Precek, J. P540 Przewlocka-Kosmala, M. P2469
Portugal, G. 103, P501, P506, P867, P1773, Pregowska-Chwala, B. P4721 Przewlocki, T. P436, P638, P720, P1641,
P2673, P4434 Pregowski, J. P4649 2022, P4685, P5616, P5619
Portugal, J.C. P1396, P3531 Prehar, S. 6056, 6057 Przybylkowski, M. 6612, 6615
Portugues, J.M. 5922 Preissner, K. 975, 3954, 6603 Przybylska, K. P4476
Posch, L. P804 Preissner, K.T. P4529 Przybylska-Siedlecka, K. P4075, 4861
Positano, V. P1529, P1531, P1533, P2355, Premecz, S. 4152 Przybylski, A. P471, P2441
P6548, P6571 Preminger, M.W. P3384 Przybylski, R. P2613, P6367
Poslednik, K. P471 Prendergast, B.D. 321 Przyklenk, K. 1174
Pospisilik, A.J. P4539 Prendergast, B.D. 1926, 2317, 5893, 5895, Przywara-Chowaniec, B. 160, P3480
Possner, M. P1614, P4481, 6019 P6380 Psaltopoulou, T. P6476
Post, H. P3471, P3492, 4944 Pres, D. P541, P585, P2506 Psarogiannakopoulos, P. P5437
Post, J.A. P2783 Presbitero, P. P208, P1499, P2617, P6372 Ptakova, N. P5499
Post, M.C. P2137, P5532, P6416 Prescott, E. 73, 410 Ptaszynska Kopczynska, K. P2812
Posterma, P.G. P2412 Prescott, E. 2248, 4289, 5881, P6448 Ptaszynska-Kopczynska, K. P4731, P4735
Poston, R.N. P5383 Prescott, M.F. P214, 6638 Pu, J. 1838, P3465
Potapov, E. P453 Pretre, G. P2695, P4612, P5397 Pu, J.L. P470, P6572
Potashev, S. P1770, P6591 Pretre, R. 2077 Pu, X. P5383
Potelle, C. P3580 Preux, P.M. P4108, P5574 Pua, C.J. P3102
Potemski, P. P856 Previti, A. P6174 Puca, A. P1560
Potena, L. P1769 Prevolnik Rupel, V. P464 Pucci, A. P2382, P3447
Potenza, A. 1204 Preziosi, P. P1531, P1533 Pucciarelli, A. P2630
Potenza, D. P503, 2270 Pribe-Wolferts, R.P.W. P3100 Puceat, M. P5446
Poth, A. P5934 Pribetich, M. P3649 Puche, C.M. P4403
Potluri, R. P3664 Pribojova, J. P3556 Puchol, A. P3369
Potpara, T. 323 Price, M.J. 4002 Puddu, P.E. P3681, P6422
Potpara, T. P5272 Price, S. 133 Pudil, R. P1771
Potpara, T.S. P6208 Price, S. 1177, 2300, 2302, 5109 Pudlo, R. P5646
Pott, C. P5948 Pries, A.R. 208, 305, 321 Puelacher, C. 126, 154, 159, P524, P525,
Pottegaard, A. P3319 Pries, A.R. 941, 5117 P529, P1097, P1099, P1100, P1103,
Potter, C.M. P430 Prieto, D. 2209 P2461, P2695, P3481, P3484, P4454,
Potthoff, S. P5547 Prieto, R. P5584, 5802 P4612, 5085, P5397
Pottle, A. P772, P776 Primak, G. P3805 Puente-Lanzarote, J.J. P2813
Pouleur, A.-C.P. 5212 Primessnig, U. 2206, P3769, P6345 Puentes Chiachio, M. P1109
Pouli, N. P3082 Prince, S. P5642 Puerto, A. P3103
Poulimenos, L.E. P906, P4123 Prinz, A. 4270, P6377 Pueyo, E. P6443
Pouliot, P. P4520 Prinzen, F.W. P491, P2389, P4745, P4758, Puga-Martinez, M. P2792
Poulsen, M.K. P442 4863, P5221, P5223, 5914 Puggia, I. P691
Poulsen, S.H. 2269, P3522, P4743, P4749 Prioli, M.A. P1602 Pugliese, C. P5519
Poulsen, T.S. P4431, P4618 Prior, D. 5214 Pugliese, F. P3723, 4918
Poulter, N.R. 355 Prior, D.L. P2683 Pugliese, N.R. P4091
Poulter, N.R. 1875, 1878, 5767 Priora, R. P2522, P6200 Puig, M.T. P3755, P5694
Poveda, P. P3077 Priori, S.G. 190, 411 Pulatov, U. P5376
Povlsen, J.A. P5512 Priori, S.G. 921, 2172, 2899, P4298, 5854 Pulcinelli, F. P1483
Pozios, I. 4913 Prisecaru, R. P3408 Pulkki, K. P528, P880, P4768, P6573
Pozzi, A. 1977 Privorotsky, V. P211 Puls, M. 349
Pozzi, M. P3594 Priyantoro, S. P2424 Pundt, N. 2104, P2357, P5960
Pozzi, R. P1406, P6174 Probst, V. P485, P1409, 5855, P6161 Punjabi, P. 4007
Prabhakaran, D. 2024 Probst-Hensch, N. 1843, P2671, 5121 Puntmann, V. P1396
Pracon, R. P4649, P4721 Probyn, J.E. P774 Puntrello, C. P4371
Pradhan, A. P4408 Prochaska, J. 1978, 4977, P6206 Punzalan, F.E. P1609, P3631, P5605
Pradhan, A.K. P6249 Prochnau, D. P787 Punzi, L. P702
Prado, N.J. P1414 Prochownik, P. P1641 Puppe, F. P3569
Prado, R. P1705 Proclemer, A. 4865 Purerfellner, H. P3313
Prajapati, J. P4711, P4713, P4717 Prohaszka, Z. P2396 Puricel, S. P535, P2378
Prakash, K. P2680 Proniak, M. P3430 Purty, A. 2024
Prakken, N.H.J. P2371 Prontera, C. P6230 Puska, P. 265
Pranevicius, R. P1594 Prosperi, M. P2397 Pussinen, P. P3478, P6243
Prappa, E. P2643 Protasov, V. P879 Pussinen, P.J. P3429, P6264
Prasad, S.K. P1520, 1986, 3072 Protonotarios, A. P1624, P2641, P2643 Putaala, J. P2346
Prat, A. P2626 Protty, M. P1738 Putnikovic, B. P5663
Prat, S. P3090 Providencia, R. P4358 Puttini, S. P3133
Prat, V. P1810 Providencia, R.A. P494 Putzu, P. P3789
Prat-Vidal, C. P3546, P3553, P5445 Prud’homme, M. P3757 Puymirat, E. P173, P1696, P2147, P2504,
Prati, F. 79 Prugger, C. 964 3023, 3025, 3027, 4260, P4629, P4991,
Prati, F. 2055 Prugger, C.P. P1658 P5931
Pratikhya, P. P3088 Prunier, F. P3485, P4417, 6049 Puymirat, E.P. 5089
Prats, J. P1497, P4105 Pruszczyk, P. P755, 4174, 4179, P5531, Puzniak, M. P2513, P2527
Pravenec, M. P1562, P3538 P6168, P6402, P6408 Puzzovivo, A. 5810
491
Chairpersons & Judges / Speakers & Discussants / Authors Pyk – Ras
Pyka, L. P566, P587, P589, P2506 Rademakers, T. P665 Raman, B. P2356, P6565
Pykhtina, V. 1837 Radenovic, S. P5663 Ramanathan, K. 156, P6241
Pylypchuk, R.D. P4620 Raderer, M. 4278 Ramanathan, T. P763, P4581, P4651,
Pyrgakis, V. P2666, P3346, P3358 Radini, D. P5683 P5613, 6025
Pytel, G. P6301 Radjenovic, A. P617, P1519, P1522, 4024, Ramani, F. P522, P691
Pytkowski, M. P5291 4055, 4294 Ramazanov, J. 2916
Pyun, W.B. P2124 Radke, R. P684, P5015 Rambaldini, M. 6021
Pyxaras, S. P2729, P2771 Radosavljevic-Radovanovic, M. P580, Ramdjan, T.T.K. P5314
Qaderdan, K. P4992 5103, 5104 Ramires, F.J.A. P198
Qaqa, Z. P4475 Radovanovic, D. P532, P535, 965, P5936 Ramirez Moreno, A. P601, P2381, P2777,
Qi, J. P3562 Radovanovic, M. P4425, P4452 P3657, P5611, P6526
Qian, J. P2817 Radovanovic, N. P4425, P4452 Ramis, M. P1110
Qian, J.Y. 4059, P4515, P6330 Radovits, T. P1144, 2284, P2667, P2678, Rammos, C. P2134
Qian, M. 6037 P4097, P4536 Ramos, F.R.S. P3626
Qian, P. P3734, P4352 Radsak, M.P. P2669 Ramos, I. P3604, P6394
Qian, Z. P1412 Radu, E. 4157 Ramos, J.D. P3631, P5605
Qin, X. P4122 Radu, M. 2056, 3269 Ramos, J.D.R. 3948
Qin, Y. P5344 Radu, M.D. P1553 Ramos, P. 952, P5301
Qing, P. P5229, P5386 Radu-Loghin, C. 302 Ramos, R. P2760, P3693, P4488, P4686
Qiu, F. P1331 Radzikowska, U. P2812 Rampazzo, A. P690, P3536
Qiu, W. P570, P588 Rae, A. P1380 Ramunddal, T. P177, 278, P3435, P6138
Quadri, G. P1449, P5378 Raeber, L. 1201, P5026, 6650 Ramuschkat, M. P4661
Quadri, G.Q. P5562 Rael, M. P4397 Ramzy, A.M. P4468, P4470
Quah, K.H. P831 Raemmler, C. P4343, P4345 Rana, J. 4885
Quaranta, V. P4311 Rafael, A. P1381 Randall, T. P4738
Quaresma, A. P209 Rafie, I. P2468, P4069, P4716 Randazzo, E. P6474
Quarti, F. P4119, P4781 Rafnsson, A. P648 Randhawa, M. P1119
Quattrocchi, S. P634 Ragab, A.M. P1537 Rangarajan, S. P6596
Quenum, S. P2553 Raglianti, V. P1366 Rangarajan, V. P1521, P3091
Querci, F. P5040 Ragonesi, P.D. P5040 Range, G. 363, P3344, 6622
Querejeta, R. P1778 Ragusa, R. P4601, P6230, P6336 Rangel, I. P1407
Quesada Ocete, B. P468, P3359 Ragusa, R.R. P4598 Ranhoff, A. P4566
Quezada, C.A. P3625 Ragy, H.I. 357 Ranhoff, A.H. P5601
Quezada Loaiza, C.A. P4550, P5957 Rahajoe, A.U. P6385 Rankin, A. P1380
Quick, S. 1323, 1989, P4494, 4973 Raheem, A. P4711, P4717 Rankin, J. P3640
Quina-Rodrigues, C. P3452, 4255, P5006, Rahim, D. 5919 Ranucci, M. 3258
P5352, P6266 Rahim, H. P6270 Rao, A. P496
Quinones, M.A. 953, P1440 Rahimi, K. P744, P813, P3683, P5322, P5600 Rao, L. P2634
Quintavalle, M. 1955 Rahman, A. P223, 2343 Rao, S. P4469
Quintin, L. P4357 Rahman, E. P2770 Rao, S.V. P558
Quiroga, A. 4961 Rahman, M. P5566 Rao, V. 5214
Quiroga, X. P610 Rahman, M.A. P5261 Rao, X. P653, 1217
Quiros, A. 2060, P2512, P2728, 4930 Rahman, T. 6648 Raoult, D. P3105
Qureshi, N. P3398 Rahman Haley, S. P4505, P5675 Rapacciuolo, A. P2481, 4860, 5904
Qureshi, W. P182, P2702, P2770 Raijmakers, P.G. 368, P426 Rapakoulias, P. P4331
Quyyumi, A. P4301, P5383 Raijmakers, P.G.H.M. P180 Rapezzi, C. 406
Qvist, I. P5277 Raimondo, C. P3377 Rapezzi, C. 158, 2079, 2080, P2640, P3437,
R-Borlado, L. P3554 Rainer, P.P. 4165 P4456, P5467, 6609
Raafat Naguib, S.S. P6293 Raineri, C. P1664, P3743 Raphael, C.E. 946, P1520, 1986
Raaijmakers, R. P4496 Rajagopalan, S. P653, 1217 Raposeiras Roubin, S. P2458, P2482,
Raal, F. P1756, P5980 Rajah, K. P2784 P4415
Raatikainen, P. 957, P3517 Rajamani, K. P1559 Raposeiras-Roubin, S. P432, P2466,
Raaz, U. P2604 Rajamani, S. P6159 P3113, P3472, P3474, P4406, P5304
Rabacal, C. P3618 Rajan, S. P4072 Raposo, L. P5643
Rabago, G. P1778 Rajani, R. P857, P1592 Rappel, W.J. P1550
Rabani, V. P1461 Rajapurkar, M.M. 5090 Rappeneau, S. P5423
Rabczenko, D. P1595 Rajaratnam, R. P2516, 5804 Rappeneau, S.R. P843
Rabe, K.F. P4332 Rajendran, S. P2356 Rapti, A. 3253
Raber, L. P1553, P6246 Rajic, D. P4425, P4452 Rascanu, N.L. P5037
Rabi, Y. P1652, P5276 Raju, H. 980 Rashid, T. P4708
Racaza, G.Z. P6412 Rajwani, A. P615 Rasmusen, H.K. 77
Rached, F.H. P6267 Rajzer, M. P3807 Rasmusen, H.K. P2369
Racheli, M. 5916 Rakhit, R. P4484, P4485 Rasmussen, B.S. 6627
Raciti, M. P620 Rakowski, T. 5813 Rasmussen, F. P5306
Racugno, P. P1517, 3252 Ralston, J. 3967 Rasmussen, H.S. P3772, P3793
Racz, I. P3468 Ramachandra, C.J.A. P6162 Rasmussen, L.H. P1666, 1830, P4619,
Racz, K. P6122 Ramagopalan, S. P6202, P6219 P5308
Rada Bucheli, F. P3453 Ramaiola, I. P1445 Rasmussen, P.V. 6076
Radchenko, G. P1820, P6591 Ramakrishnan, S. P6134 Rasmussen, T.B.R. 2938
Rademakers, F.E. 251 Ramalho, A. P4764 Rassaf, T. 1082, P2134, P5986
Rademakers, F.E. 1164, 2282, P5941 Ramalho, R. P4333, P5427 Rassi, D. P2701
492
Chairpersons & Judges / Speakers & Discussants / Authors Ras – Ric
Rassi, L. P527, P591 Refice, S. P3490, P3579, P4317, P5241, Rentsch, K. 159
Rassi Jr, A. 6014 P5478, P5632 Renzi, N. P5290
Rat, J. 362 Reganit, P.F. P1609 Repassos, E. 1326
Rata, M. P796, P5932 Regar, E. P1456, P1746, 2909, P3733, P4673 Repetto, A. 1204
Ratan, P.R.E.M. P6249 Regeer, M. P2607, P4089 Repossini, A. P2151
Ratcliffe, L.E. P4339 Regeer, M.V. P2543 Reppel, M. 6066
Ratcliffe, L.E.K. 4875 Reges, O. P1652, P5276, P5318 Resta, O. P4311
Rateri, D. P1782 Reggi, S. P4410 Restaino, G. P1529, P1533
Rath, D. P1484, P1487, P1494, P1508, Regitz-Zagrosek, V. 46, 260, 2978, P5439, Restrepo, G. P6121
P2524, 6614 5882 Restrepo, J. P2402
Rathod, K.S. P581, P3711 Regoli, F. P1334, P2439 Restrepo Cordoba, A. P1768, P4308,
Rathore, S. P803 Reguenga, C. P5006 P5942
Ratto, R. P1767 Reguera, J.M. P6371 Retwinski, A. P3759
Rauch, A. P6507 Rehman, M. P6313 Reutelingsperger, C. P1563
Rauch, B. 2006, 2008, 2010 Rehman, M.B. P5511, P5955 Reutelingsperger, C.P. P645, P646
Rauch, U. P1463, 2214, P2600, 6011 Reiber, J.H.C. P2771 Reverberi, C. P5938
Rauer, M. P6268 Reibis, R. P3653 Reverdin, S. P2558
Rauhalammi, S.M. P617, P1519 Reich, R. P6514 Revilla, A. 6022
Raunsoe, J. P1571 Reichek, N. P2536, P4571 Revishvili, A.S. 3939, 3940
Rautava, P. P6231 Reichenspurner, H. 5923 Rewiuk, K. P5269
Rava’, L. P2397 Reichlin, T. 126, 154, 157, P525, P529, P595, Rexhaj, E. 2014
Ravassa, S. P1778 P1100, P1103, 1921, P2461, P2695, Reyes, G. P2554
Ravee, Y. P6197 P3481, P3484, P4077, P4459, 5085, P5397 Reynolds, D. P2426
Ravekes, T. P6355 Reichmuth, L. P4505 Reynolds, D.W. 5915
Ravis, E. P1611, P6383 Reid, A.B. P619, P2432 Reynolds, W.R. P5924
Ravizzoni Dartora, D. 5082 Reid, C. P5544 Rezacova, M. P4441
Ravkilde, J. P2745, P5978 Reid, C.M. P4302 Rezek, M. P4705
Ravn-Fischer, A. 278 Reidpath, D.D. 3304 Rha, S. 2264
Ray, K. P2146 Reifart, N. P1726, P2377 Rha, S.W. 277, P736, P762, P808, P812,
Ray, K.K. 125, 185, 317, 371 Reilly, C.M. P441 P826, P834, P2486, P2755, P2766, P2779,
Ray, K.K. 401, P1584, 1858, 1859, 1862, Reilly, P. 4980 P2842, 2912, P3703, 5124, P5350, P5355,
1863, 2852, 5054, 5056, 5745, P6481 Reilly, P.A. P5967 P5387, P5395
Ray, S. P4093 Rein, P. P1697, P3678, P4473, P6259 Rheaume, E. P1561
Raya, A. 48, P3546 Reinecke, H. P684, P5015 Rhee, G.J. P3656
Razavi, R. P518, P1530 Reinecke, P. 5899 Rhee, K.J. P563
Rea, D. P859 Reiner, M.F. P1115, P5007 Rhee, K.S. P4426
Read, M. P6270 Reiner, Z. 306 Rhee, M.Y. P2169, P2508, P3799
Reaney, A. P6247 Reiner, Z. P2146, 3880 Rhew, J.Y. P4526, P4696, P4752
Reaven, G. P766 Reinierse, M.T. P180 Rho, T.H. P461
Rebelo, A. P545, P4993, P5338, P5345 Reinke, F. P5015 Riahi, L. P3408
Rebelo da silva, N. 2955 Reinstadler, S. P3092, P4416 Riahi, S. P462, P474, P5281
Rebillard, L. P4445 Reinstadler, S.J. P4411 Rial Baston, V. P3632
Rebonato, M. P1602 Reinthaler, M. P1617, P3502 Rials, S. P2805
Rebuffo, E.M. P865 Reis, H. P1634, P6167 Ribas, S.C. P2405
Rebuzzi, A.G. P5027 Reis, L. P209, P5497 Ribeiras, R. P3586, P4349
Recalde, A. P4517 Reis Pires Martins, J. P545, P4993, P5338, Ribeiro, A. P768
Rechova, A. P4439 P5345 Ribeiro, A.L. P621
Reczuch, K. P3430 Reiss, I.K. P3745 Ribeiro, J. P618, P6240
Redberg, R. 86 Reith, S. P1563, P1734, P6521 Ribeiro, N. P5427
Reddy, V. 1243, 2194, 3138, P6115, P6327 Rekik, H. P1096, P4386 Ribeiro, S. 5922
Redfearn, D. P3404 Reklaitiene, R. P3627 Ribeiro, V. P1668, P3604, P3668, P5679
Redfern, J. P3640 Rekovets, O. P3805 Ribera Sole, A. P2507
Redfors, B. 278, P3435, P4063, P6138 Remadi, F. P4693 Ricard, C. P796
Redgrave, R.E. P2810 Remah, H.A. P2754 Ricchiuto, P. P2591
Redon, C. 2108 Remenyi, B. P1612, P4579 Ricci, B. P561, P594, 4287, 4291, P4698,
Redon, J. 152 Remme, C.A. 4185 5819
Redon, J. 2963, P4775 Remme, E.W. P4754 Ricci, F. P5956
Redon, R. P485, P1409 Remmelink, M. P5504 Ricci, G. P657, P4664, P6437
Redondo Dieguez, A. P2458, P2482, Remond, M.G.W. P1612, P4579 Ricci, R. P4769, 4865, 5086
P4415, P4419 Ren, D. 4059 Ricciardi, D. 2270
Redondo-Dieguez, A. P3472 Ren, D.Y. P4515 Riccio, G. P859
Redpath, C. P1413 Ren, L. P6180, P6572 Richard, C. P799
Redpath, C.J. P4393 Rengo, G. P874, P6338 Richard, V. P1112
Redwood, M. 5 Rengo, G.R. P6570 Richard-Jourjon, V. P3485
Redwood, S. P669, 4931 Renker, M. P4487, P4499, P4500, P5405, Richards, A.M. 127, 1080, P3464, P3483
Reed, D. P430 6065 Richards, A.M.R. P567
Reefat, E. P786 Renne, S. P6548 Richards, D. P2516, 5804
Reekers, J.A. P3738 Renner, A. P5005 Richards, M. P4610, P5034
Reents, T.R. P4365, P5295 Renner, S. P3097 Richardson, J. P4401
Reffo, E. P706 Renni, R. P6548 Richardson, J.D. P615, 4053
Renou, P. P3740 Richardson, K. P5580
493
Chairpersons & Judges / Speakers & Discussants / Authors Ric – Rog
Richardson, M. P2626 Ritsinger, V. P1730, P3343 Rodrigues, A. P4490

Richter, B. 4973, P6547 Ritter, O. P2361, 3068, P4516, P6349 Rodrigues, B. 5922
Richter, D. P6194 Ritter, P. P2426, 3230, 3232, 5915 Rodrigues, C. P545, P4993, P5338, P5345,
Richter, D.J. 3815, 3818, 5178, 5180 Rittoo, D. P449, 5920 P6529
Richter, S. P516, P2829, P3392, P3415, Riu, F. P3566, P5454 Rodrigues, F.B. P5254
4858, P5986 Riva, S. P3427, P4346, P4389 Rodrigues, I. P501
Rickli, H. 26 Rivas, D. P1561 Rodrigues, J. P1605, P4078, P4420, P5226,
Ricottini, E. P6291 Rivas, M.B. P3479 P5677
Ridha, E. P6202, P6219 Rivera, M. P4541, P6334 Rodrigues, J.C.L. 4872, 4875
Ridha, R. P5701 Rivera Juarez, A.R. P2410 Rodrigues, M. P3431, P5962
Ridker, P.M. 400, 3855 Rivera-Lopez, R. P2792 Rodrigues, P. P1634, P6167
Ridocci-Soriano, F. P181, P2128 Rivero Arribas, B. P1768, P4308, P5942 Rodrigues, R. P527, P591, P592, P1610,
Riechel-Sarup, C. 6023 Rivetti, L. P634 P2464, P2529, P3431, P4303, P4464,
Riedmaier, P. P1471 Rixe, J. P3095, P4487, P4499, P4500, P5001, P4621, P4624, P4625, P4643, P4645,
Rief, P. P4103 P5405 P4646, P5377, P5962, P5964
Rieger, G. P1423 Rizas, K.D. P1536, P4079 Rodrigues, R.R. 1200
Riegger, J. 1996 Riziq-Yousef Abumuaileq, R. P4406, Rodrigues, T. P2809
Riehle, J. P1751 P5304 Rodrigues Neto, M. P592, P3431, P5377
Rienks, R. P2371 Rizk, A.F.R. P548 Rodriguez, A. P475, P478
Riezebos, R.K. P437 Rizk, J. P2455 Rodriguez, C. P1369, P2632
Rifai, R. P4548 Rizopoulos, D. 6641 Rodriguez, E. P6498
Riffel, J. P194 Rizzo, C. 5810 Rodriguez, F. P1444
Rigali, C. P6270 Rizzo, M. 2229 Rodriguez, I. P3591
Rigatelli, G.R. P3449, P3686 Rizzoni, D. 3976 Rodriguez, J. P610, P3090, P4988
Rigato, I. P690, P3536, P6166 Roa Garrido, J. P4468, P4470 Rodriguez, L. P3511, P6365
Rigby, A. 2231 Robalo Martins, S. P2552 Rodriguez, L.L. 206
Righini, F.M. P4741 Robbers, L. P174, P1507 Rodriguez, M. P2790
Rigo, F. 1252, 1254, 1256 Robbers, L.F. P2497 Rodriguez, M.M. P1410
Rigolin, V. 84 Robbers, L.F.H.J. P426 Rodriguez, P.A. P6442
Rigopoulos, A.G. 2080, 2082, 2084 Robbers, L.F.R. P2569 Rodriguez, Z. P1107
Rigopoulos, D. P5418, P6265 Roberts, K. P1612, P4579 Rodriguez Angulo, H.O. P6395
Rijnbeek, P.R. P1391 Roberts, L. P4302 Rodriguez Anton, D. P1125
Rijndertse, M. P1746 Roberts, L.R. 2211 Rodriguez Capitan, J. P1689, P4662
Rijnierse, M.T. P178 Roberts, M.J.D. P477 Rodriguez Diego, S. 944
Riley, G.L. P5949, P6352 Roberts, W.T. P3117, P3712 Rodriguez Garcia, M.A. P5474
Riley, J. 378 Roberts-Thomson, K.C. P4374, P6198 Rodriguez Gonzalez, E. P1768, P4308,
Rim, S.J. P1638, P3687 Robertson, A. P1569, 3950 P5942
Rimbas, R.C. P2806, 4157 Robertson, T. P1150 Rodriguez Munoz, D. P508, 3173, P5442
Rimoldi, O. P6245 Robertus, J.L. 1848 Rodriguez Palomares, J.F. 144
Rimoldi, O.E. P5577 Robic, B. P3421 Rodriguez Puras, M.J. P6421
Rimoldi, S.F. 2014 Robinson, J. P1756, P5980 Rodriguez Zanella, H. P5645
Rinaldi, A. 4182, P5524 Robinson, P.N. P718 Rodriguez-Arabaolaza, I. P3566, P5454
Rinaldi, C.A. P518, P1432, P6314 Robinson, S.D. P2727, P2736, 2907, P3117, Rodriguez-Borja, E. 963
Rinaldi, M.J. 4000, P4326 P3712, 5817 Rodriguez-Campelo, A. 952
Rincon, L.M. P1396, P1554, P3531 Robledo, J. P6421 Rodriguez-Capitan, J. P6560
Rincon Diaz, L.M. P2547, P2691 Robson, J. 34 Rodriguez-Chaverri, A. P5686
Ringel, M. 1206 Robustelli Test, L. P3802, P5712 Rodriguez-Collado, J. P2772
Ringle, A. P2626, P6313 Robyns, T. P3101 Rodriguez-Costoya, I. P1774, 2213, P3124
Ringquist, S. 1323 Rocca, B. 80, 123 Rodriguez-Fraga, O. 4049
Ringwald, G. P1726, P2377 Rocco, E. P1555 Rodriguez-Padial, L. P2788, P3369
Rinne, S. P1421 Rocha, T.R.F. P6499 Rodriguez-Palomares, J. P538, P5407,
Rinvenuto, N. P427 Rocha Almeida, A. P3618 P5408, P6382
Rio, P. P867, P2473, P2489, P4434 Rocha Lopes, L. P1118, 4158 Rodriguez-Penas, D. P4541, P6334
Rio, T. P1354, P5929 Rocha Rodrigues, G.M. P829, 1200 Rodriguez-Sinovas, A. 1088
Rios, C. P2790 Rocha-Gonacalves, F. P1605 Rodriguez-Torres, D. P2792
Rioufol, G. 1288, 1290, P3594 Rochitte, C.E. 1180, 1181, 1183, 1185, Rodriguez-Zavala, J. P4527
Ripoli, A. P4478 1187, P1705, 3001 Rodrigus, I.E. P3581
Ripoll, C. P1690 Rocio Gonzalez Ferreiro, R. P4419 Roeger, S. P493, P4591
Risch, L. P1706, 1843, P4663 Rockwood, K. 5078, P5567 Roehnert, K. P2387
Risch, M. P1706, 1843, P4663 Rodeheffer, R.J. P5018 Roepke, T.K. P1419
Risoe, C. 31 Roder, D. 4047 Roesch, S. P1532
Risom, S.S. 2938 Rodero, S. P5407, P5408 Roever, C. P165
Rispler, S. P1140 Rodgers, D. P494 Roffi, M. 132
Ristic, A. P630, 4288 Rodionov, A.V. P5706 Roffi, M. 926, 3927, 4126, 5176, 5870, 6665
Ristic, A.D. 31 Rodnenkov, O. P1822 Roger, V. 6640
Ristic, A.D. P2518, 3283, 5188, P5536, Rodon, C. P5963 Roger, V.L. P4984
P5538, 5771, 5990 Rodondi, N. P1691, P3448, P5007, 6650 Rogers, P. P776
Ristic, G. P5536, P5538 Rodrigo, J. P1107 Roggenbuck, U. P2357
Ritsatos, C. P1624, P2641, P2643 Rodrigo, J.L. P1593, P2548, P2549, P5243 Roggerio, A. P6449, P6471
Ritschel, V.N. P422 Rodrigo, S.F. P2126 Rognaas, L. P4436
Ritsema Van Eck, H.J. P2412
494
Chairpersons & Judges / Speakers & Discussants / Authors Rog – Rud
Rognoni, A. P2781 Roohani, S. P667 Rotger, F. P1110

Roh, G.S. P863 Roolvink, V. P4453 Roth, A. P2457
Roh, S.Y. P1525, P4363 Roos, C.J. P6429 Roth, C. P1752, 5092
Rohan, S. 4872 Roos, M. P4391 Roth, E.M. P6427
Rohanek, P. P1095 Roos, S.T. P531 Roth, G.A. P6461
Rohde, L.E.P. P6220 Roos-Hesselink, J.W. 141 Rothenbuehler, M. P6133, P6135
Rohde, M. 3069, P3600, 5898 Roos-Hesselink, J.W. 142, 143, P707, Rotheram, N. P4401
Rohr, P. 5082 P713, P715, 1301, P1402, P2656, 4953, Rothman, K.J. P1488, P1516
Rohr, S. P6352 4954, P5689, P6418 Rotival, M. P1562
Roig, E. P1394, P1781 Roper, D. P3726, P6233, P6236 Rottstaedt, F.A. 1323
Roitelman, J. P4587 Roque, A. P6382 Roubille, F. P1561, P3451, P4446, 5088,
Roithinger, F.X. P584 Roque, J. 952 P6452
Roivainen, A. P425 Rordorf, R. P502, P2439, 4865, P6155 Rouet, P. 3958
Rojas, I. P4527 Rosa, I. P651, P2616, P5491, P5659, P6389 Roufas, K. P1481, P2642, P5371, 5905
Rokkas, K. P5588 Rosa, J. P1147 Rougin, A. P447
Rokyta, R. P631, P804 Rosano, G. P6229 Roul, D. P1810
Rolandi, M.C. 1840 Rosano, G.M.C. 78 Rouleau, J. P213, 3302
Rolando, C. P1406 Rosano, G.M.C. P217, 1000, 1235, 2327, Rouleau, J.L. P214, 3301, P5031
Roldan, F.J. 2067, P4527 3299, 3300 Roura, G. P546, P761
Roldan, I. P6140 Rosati, F. P3382 Roura, S. P2580, P3546, P3553, P5445
Roldan, V. P4403 Rosca, M. P1630 Rousse, N. P2626
Roldan-Schilling, V. P4622, P6140 Roscitano, A. P3490, P3579, P4317, P5241, Roussin, R. P1650
Roleder, T. P6329 P5478 Rousso, B. P493
Roleder, T.M. P1747, P2837 Rosell-Ferrer, J. P3553 Roussos, D. 4867, 4874
Rolf, A. P3095, P4487, P4499, P4500 Rosello-Lleti, E. P6334 Rovai, D. P6230
Rolf, S. P3392, P3415, P6209 Rosen, S.D. P866, P3737, P6157 Rover, C. P5930
Rolim, N. 6039 Rosenbaum, A.N. 5093 Rowland, E. P494
Rolleston, A. P6457 Rosenbaum, D. 5079 Rowland, S. P2783
Rollo, R. P564 Rosenblad, A. P753 Roy, I. P478
Romaguera, R. P761 Rosenfeldt, F. P3744 Roy, K. P3366, P3367, P6112
Roman, M.J. P4117 Rosengren, A. 36 Roy, P.M. P3485
Romanenko, T. P1824 Rosengren, A. P438, P2157, P2496, P2654, Roy, S. P1510, P5549, 6619
Romano, D. P6153 P2657, 2925, P3614, 4282, P5628, P6460 Rozado Castano, J. P3591
Romano, G.P. P5639 Rosenhek, R. 130, 198 Rozec, B. P1810
Romano, M. 4268, P5489 Rosenhek, R. 1303, 1304, 4026, 6667 Rozenbaum, Z. P5463
Romano, N. P6571 Rosenkranz, S. 246, 368 Rozenman, Y. 34
Romano, S. P1521, P3091, P6199, P6435 Rosenkranz, S. 2335, P2367, P3622, 3906, Rozenman, Y. P4587
Romanov, A. 248 5846 Rozentryt, P. P6587
Romanov, A. P3370 Rosenqvist, M. P5324 Rrapaj, E. P2406
Romanova, M.M. P6593 Rosenschein, U. P481 Ruano, S. P4484
Romanovic, R. P833 Rosenson, R. P5968, 6653 Rubartelli, P. 1202, P2523, P4412
Rome, S. P6176 Rosenson, R.E. P1677 Rubbiani, E. P3508
Romeo, E. P4546, P4553, P5526, P5529 Rosenson, R.S. P3667 Rubeau, T. P4449, P4462
Romeo, F. 357 Rosenthal, E. 79 Rubenfire, M. P3340
Romeo, F. P1590 Rosenthal, E. 1009 Rubens, M. 958
Romeo, G. P702, P2539, P2541, P2545, Rosenthal, M. P4484, P4485 Rubens, M.B. P6315
P2550, P2560, P3532 Rosero, S. P6163 Rubin, L.J. P2365
Romeo, M.A. P1529 Rosillo, S. P195, P853, 4049 Rubin Gimenez, M. P4459
Romero, A.M. 968 Rosinus, N.S. P2602 Rubini, M. P4077
Romero, J.C. P2601 Rosjo, H. P451, P2383, P3497, P3674, 6043 Rubini Gimenez, M. 126, 154, 157, P524,
Romero, M. 365, P797, P2758, P2763, Roslawiecka, A. P4685, P5619 P525, P529, P595, P1097, P1099, P1100,
P3694, P3704, P6421 Rosler, A. P5477, P5640 P1103, P2461, P3481, P3484, P4454, 5085
Romero Moreno, M. P2114 Rosli, M.A. 372 Rubino, M. P1351
Romero Reyes, M.J. 2940, P3650 Rosmini, S. 2968, 6609 Rubinshtein, R. P203, P205, 244, 3995,
Romero Roldan, J. P167 Ross, D.L. P4352 P5586
Romero-Villafane, S. P2780 Ross, H. 96 Rubinstein, A.L. P2421
Rommel, K.-P. P2387 Ross, S. P512 Rubio, C. P2772
Rommel, K. P3092 Rossaint, R. 4978 Rubio, J.M. 953, P1440
Romo, E.R. P2442 Rossello, X. 1087 Rubio, M.C. P6442
Ronckers, C.M. P5035 Rossetti, L. P1602 Rubio Alonso, B. P4710, P6426
Ronco, C. P1788, P3791 Rossi, A. P3723, P4769, 5805, P6542, P6567 Rubio-Rodriguez, D. P6191
Roncon, L. P2389, P4745, P4758, 4863 Rossi, L. P2619 Rubio-Terres, C. P6191
Roncon-Albuquerque Jr, R. P5006 Rossington, J. P1491 Rubis, P. 6610
Rondan Murillo, J. P4719 Rossini, R. P5285 Rublee, D. P1453
Rondelet, B. P5504 Rossmann, H. 4178 Rubrech, J. P2669
Ronderos, R. P5583 Rosso, J.R. P843 Rubulis, A. P2403
Rondon, E. 2944 Rosso, R. P2781, P4382 Rucker-Martin, C. 2283, P5446
Roney, C.H. P3398 Rostagno, C. P4371 Rudenko, K. P1635
Ronkainen, K. P2798 Rostock, T. P468, P3359, P6206 Rudenko, Y.U. P3779
Ronquist-Nii, Y. P4067 Rota, C. 4051, 4056 Rudic, B. P489, 1193, P1400, P4591
Ronzat, C. P5392 Rotar, O. P735 Rudnicka, A.R. P5572
495
Chairpersons & Judges / Speakers & Discussants / Authors Rud – Sak
Rudolph, T. 6038 Rutigliano, S. P2741 Sacharczuk, W. P5436

Rudolph, T.K. 2223, P6355 Rutsch, W. P4070 Sacher, F. P1409, 3981, 3982, 3984, P6161
Rudolph, V. P1104, P1591, 6038, P6355 Rutschow, S. P3502 Sacherer, M. P2587
Rudzinski, J.J. P6442 Ruttmann, E. 966 Sade, L.E. 138
Rudzki, S. P5653 Rutz, T. 2927 Sade, L.E. 239, 2037, 2041, 2042
Rueckert, D. P748, 1237, 4183 Ruud, E. 4156 Sadee, A.S.J.M. P437
Ruedebusch, J. P4736 Ruuhijarvi, K. P4061 Sadeghian, S. P5581
Ruff, C.T. 410, 413, 2030, 3141, 3142 Ruwald, M.H. 1329, P3312 Sadjadieh, G. 4001
Ruga, O.R. P2705 Ruygrok, P. P4581, P4651, P5613 Sadoshima, J. 1992
Ruhrberg, C. 4161 Ruzek, L. P4381 Sadoul, N. P164, P557, P3530
Ruidaverts, J.-B. P1703 Ruzgyte, E. P3514 Sadowski, J. P2606, P3587, P5465
Ruidavets, J.-B. P1667, 2023 Ruzic Medvescek, N. P3421 Sadowski, M. P448, P539, P1447, P1448,
Ruidavets, J.B. P758, P1358, P6450 Ruzsa, Z. P3709 P3121, P5937
Ruilope, L.M. 319, 361 Ryan, C.M. P6228 Sadredini, M. P416
Ruilope, L.M. 283 Ryazankina, N. P6332 Sadushi-Kolici, R. P5508
Ruisanchez, C. P6313 Rybak, K. P1423 Saeed, D. P6142
Ruiter, J.H. 1324 Rychkov, A.Y. P521 Saeed, Y. P6354
Ruiz, M. P4576 Rychlak, R. P5294 Saeki, H. 2107
Ruiz, M.R.O. P2442 Rychta, E. P2411 Saeki, M. P4779
Ruiz, S. P1554, P1774, 2213, P3124, P3531, Ryckx, N. P2378 Saely, C.H. P1697, P3678, P4473, P6259
P6187, P6584 Ryczek, R. P1807 Saemann, M. P1808
Ruiz, V. 963 Ryden, L. 152, 264, P737, 1221, P5036, Saenen, J.B. P4342
Ruiz Bustillo, S. P1125, P6492 5122 Saez, C. P3103, P3104
Ruiz Cantador, J. P2143, P2402, P3608 Ryden, L.A.R.S. P6424 Safina, Y. P6284
Ruiz Ortiz, M. P1109, P3730, P6196, P6490 Rydzanicz, M. P3540 Safiullina, A.A. P4593
Ruiz-Cano, M.J. P1123 Rye, K.-A. P6129 Safstrom, K. P4372
Ruiz-Cantador, J. P3380, P3615 Rymarczyk, Z. P755, P5531, P6168 Sagan, A. P6127
Ruiz-Meana, M. 135 Rymuza, B. P1616 Sagawa, Y. P1735, P1753, P4514, 6618
Ruiz-Meana, M. 1088, P4529 Rymuza, H. P2697 Sagie, A. 1981, P3698
Ruiz-Reina, M.L. P6560 Ryngach, E.A. P1542 Saguer, M. P5611
Ruiz-Zamora, I. P6560 Rynkiewicz, A. P3475 Saguner, A.M. P1390, P4590
Rumbinaite, E. P3514 Ryo, K. P5527, P6311 Saha, S.K. P2536
Rumoroso, J.R. P832, P2732 Rysa, J. P2162 Sahebkar, A. P1450, P1584, P1676, 2229,
Rundqvist, B. P1152 Rysz, J. P1450, P1584, 2229, P5981 P5981
Runov, A. P3541 Ryu, K.H. P3768 Sahin, D.Y. P722
Runz, H. 5823, 5824, 5825, 5827 Ryu, S.K. P812, P6362 Sahin, M. P2444, P5421
Ruocco, G. P3791 Rzayeva, N. P4332 Sahin, O. P875
Ruokonen, E. 6043 Rzeznik, D. P4685, P5619 Sahin, S.T. P5440
Ruoxiang, J. 6640 Sa, C. P527, P591 Sahinarslan, A. P457, P4534
Ruozi, N. 6609 Saaby, L. P4431, P4618, P5713 Sahiner, L. 6074
Rupar, M.R. P3660 Saad, F. P2722 Sahiner, M.L. P4690
Ruparelia, N. 370, P2761 Saad, G. 5785 Sai, E. P3675
Ruperti Repilado, J. P1706 Saada, A. P5463 Saia, F. 319, 321, P2640, P5521, 5786
Rupinski, R. P5537 Saadatmand, A.R. P2159 Said, K. P701
Ruppert, M. P1144, P2667, P4536 Saade, G. P6461 Said, S. P493
Rupprecht, L. 3310 Saager, L. P1119 Saigo, S. P2814
Rusak, M. P2812 Saam, T. 2058 Saigusa, T. P6222
Ruscazio, M. P578 Saar, A. 1198 Saint Etienne, C. P6214
Ruschitzka, F. 156, 240 Saavedra, J. P5686 Saint-Andre, C. P4438
Ruschitzka, F. 1072, 1171, P1812, P2796, Saavedra, R. P3518 Sainz, J.C. P1689
3190, 3813, P6364, 6663 Saba, S. P5221 Sainz Laso, F. P2757
Ruscio, M. P899 Sabate, M. P1445, P2780, P4988, 6018 Saita, T. P1739, P1743, P2775
Rusinaru, D. P2771 Sabate, X. P1444 Saita, T.S. P1712
Ruskoaho, H. P2162 Sabate Tenas, M. 5773 Saito, A. P6353
Russell, K. P6297 Sabatine, M. 3875, 3877, 5136 Saito, D. P1482
Russhard, P. P4709 Sabatine, M.S. 3032, P3317, P3318 Saito, K. P2449
Russo, C. P6483 Sabatino, J. 5904 Saito, M. P3676, P4746, 4868, P5430,
Russo, C.F. P3603 Sabato, V. P6251 P5711, 5801
Russo, E. P6316 Sabbah, H.N. 213 Saito, N. P6381
Russo, F. 3073 Sabbah, H.N. P848, 3307, P3783 Saito, S. P2415, P2610, P6319
Russo, G. P1664, P3512, P3743, P4399, Saber Hafez, M.S. P6293 Saito, T. P453
P4522 Saberniak, J. P418, P1397, 4960, P6307 Saito, Y. P2563, P2746, P3636, P3797,
Russo, M. P6575 Sabharwal, N. P5000 P5238, P5506, P6335, 6634
Russo, M.A. P1430 Sabia, R. P3752 Saitoh, D. P4512
Russo, M.G. P1351, P4546, P4553, P4683, Sabielny, R. P685 Saitoh, S. P3330, P6300
P5365, P5526, P5529 Sable, C. P709 Saitoh, T. P184
Russo, V. P5521 Sablin, A.V. P3762 Sajadieh, A. P5305
Rusu, S. P5037 Sabry, A.M. P4656 Sajadieh, A.S. 949
Rutherford, L. P5321 Saby, L. P1611, P3105, P6383 Sakaguchi, M. P5506
Rutherford, M. 4261 Sacha, J. P1539 Sakaguchi, T. P6537
Rutherford, M.J. 2914 Sacha, K. P1539 Sakai, C. P2603
496
Chairpersons & Judges / Speakers & Discussants / Authors Sak – San
Sakai, S. P3083, 4052, P5504, P5528 Saltzberg, M.T. P2832 Sanchez-Fernandez, G. P3506, P3507
Sakai, T. P1651, P4492, P6145 Salukhe, T. P4390 Sanchez-Galian, M.J. P586, P1098
Sakakibara, M. P1744 Salvador, O. P2402, P3380, P3420 Sanchez-Jurado, R. P181
Sakakibara, T. P3753, P4109, P5966, 6086, Salvadori, S. P3509, P6309 Sanchez-Martinez, M. P586, P1098
P6494 Salvatella, N. P832 Sanchez-Mas, J. P2813, 4279
Sakakura, K. P5656 Salvatore, F. P1351 Sanchez-Recalde, A. P3615
Sakamoto, H. P4503, 6105 Salvatori, C. P1531, P6548, P6571 Sanchez-Sendin, D. 962
Sakamoto, K. P811, P1339 Salvatori, E. P5289 Sanchis, J. 963, 1205, 4279
Sakamoto, N. P2449 Salvatori, V. P3617 Sancho Jaldon, M. P4468, P4470
Sakamoto, R. P6256 Salvetti, M. P5709 Sand, N.P. P5017, P6455
Sakamoto, S. P2380 Salvi, A. 5787 Sand, N.P.R. P5359
Sakamoto, T. P1583, 6628 Salvi, L. P6495 Sandberg, C. P2659
Sakamoto, Y. P1779, P4718, P6145 Salvi, N. P427, P847 Sandek, A. 361, P887, P2786, P5695
Sakata, K. P688, P693, P1633, P1651, Salvi, P. P6495 Sanders, P. 1847, P4374, P6198
P2148, P6123 Salzberg, S. 113, 3009 Sanders, P.H. P3313
Sakata, R. P3549 Salzwedel, A. P3652, P3653 Sanders, P.S. 1247
Sakata, Y. P839, P1793, P2503, P4360, Samaja, M. P2586, P3133 Sanders-Van Wijk, S. P1139
P6539, P6544 Samani, N.J. P4090 Sanderson, J.E. P5424
Sakatani, Y. P2537, P6304 Samani, N.S. P817 Sandgaard, N. 6023
Sakaue, H. P431 Samaniego, B. P4719 Sandhaus, T. 1982
Sakne, S. P2347 Samardzic, J. 197 Sandhu, G.S. P2375, P4444
Sakr, G. P597 Samardzic, J. P2824 Sandhu, M.S. P4713
Saku, K. P764, 1083, P1383, P1452, 2059, Samba, H. P4108 Sandri, M. P212, P3728
P3749, P3754, P4655, 4843, P6533 Sambola, A. P835 Sandrini, C. P1602
Sakuma, H. P1535, 3254, P4774 Sambola Ayala, A. P818, P836 Sandstrom, T. P2496
Sakuragi, S. P4486 Samedli, S. P3379 Saner, H. 31
Sakurai, D. 3172, P6298 Samentzas, A. P2699, P5588 Saner, H. 102, P5376
Sakurai, R. P810 Samer, E. P3735 Sanfins, V. 5922
Sakurai, T. P3800 Samet, H. P5409 Sang, C.-H. P5274
Sala, S. 2015, P6170 Samko, A. P6528 Sangalli, E. P2573
Saladini, F. P899 Sammut, E. P518, P1530, P6314 Sangaralingham, S.J. 2336, P5018, 5076
Salah, K. P3350 Samniah, N. P481 Sangha, G. P5416
Salah Eldin, H. P2834 Samniang, B. P4538 Sanghvi, J. 2024
Salam, A.M.F. P1402, P5689 Sampaio, F. P4490, P4995 Sanguigni, V. P6480
Salama, M.I. P2628 Sampson, M. P4373 Sani, M.U. P2651
Salama, M.S. P1151 Sampson, S.H. P6290 Sanidas, E. P3501, P4666
Salama, S. P701 Samset, E. P5429 Sanmartin Fernandez, M. 5091
Salamova, L.A. P521 Samson, R. P3714 Sanna, F. 1834, P2595
Salas-Salvado, J. P4662 Samstad, S.O. 3198 Sanna, T. 5736
Salascheva, T.G. P1820 Samuel, J.L. 375 Sannino, A. 1985
Salaun, E. P1611, P3105, P6383 Samuel, J.L. P3757 Sano, F. P4112
Salazar, A. P4631 Samura, T. P4723 Sano, H. P5527, P5973
Salazar, J. P1123, P1690 Samy, W. P5673 Sano, M. P5466
Salazar, L. P1579 San Antonio, R. P3090 Sano, S. P435, P1817, 4058, P6308
Saldanha Santos, B. P5391 San Damaso, E. P2680 Sano, Y. 6632
Saleh, A. P4475 San Jose, G. P1778 Sans, J. P4422
Saleh, A.M. P3523, 4164 San Jose, R. P6343 Sans Menendez, S. P5585
Saleh, N. P1730, P3343 San Roman, A. P3637, P5647, 6022 Sansone, R. P1372, P6503
Saleh, Q.A. P3714 San Roman, J.A. 2318, 2320, P3103, Santa Clara, H. P501, P2673
Salem, M.A. P729, P901 P3104, P3106, P3576, P4575, P5483 Santa-Clara, H. P506, 2937
Salem, M.A.S. P5287 San Roman Calvar, J.A. P3673 Santamaria, M. P504, P2439, P5222
Salem, V.C. 2944 San-Roman, A. P538 Santangeli, P. P3396
Salemi, V.C. P700 Sanchez, B. P2410, P3553 Santarelli, A. P2485
Salemi, V.M.C. P198 Sanchez, E. P5568 Santarelli, E. P5289
Salemme, L. P2630 Sanchez, F.A. P5543 Santer, D. P4545
Salerno, S. P3352 Sanchez, J. 955, P3383, P3396, P3417, Santesmases, J. P752, 4277, 6639
Sales, M.C. P5477, P5640 P6490 Santiago, E. P1766
Salgado, A. P3452, P5338 Sanchez, P. P3371 Santilli, F. P2716, P4628
Salgado, R. P650, P3369 Sanchez, P.L. P467, P476, P2772, P4569 Santini, F. P5263
Salido Tahoces, L. P2547 Sanchez, R. P1683 Santini, L. 2270, P2390
Salih, H. P4358 Sanchez, R.J. P2144 Santini, M. P2115
Salih, M. P1489, P3488 Sanchez Fernandez, J.J. P1109 Santisteban, M. P3730
Salim, H.M. P642 Sanchez Gonzalez, J. P6392 Santisteban Sanchez De Puerta, M.
Salimi-Khorshidi, G. P5322, P5600 Sanchez Mas, J. P2811 P2114
Salinger-Martinovic, S. P5667 Sanchez Perez, I. P3122, P3718, P4714, Santoni, T. P3447
Sallam, A.M.A.R. P5701 P6517 Santoro, C. P858, P2481
Sallo, Z. 4856 Sanchez Recalde, A. P1710, P2143, P2402, Santoro, D. P2485, P3672
Salmas, J. P3389, P3409, P4341, P4359, P3380, P3608 Santoro, G. P4683
P4983 Sanchez-Borque, P. 953, P1440 Santos, A. P835, P836
Salomaa, V. P1376, 1845 Sanchez-Enrique, C. 2320, P2517, P3104, Santos, A.R. P5393, 5820
Saltissi, S. P6247 P3106, P5483 Santos, B.S. P2479, P5361
497
Chairpersons & Judges / Speakers & Discussants / Authors San – Sch
Santos, C.P.S. P6479 Sashida, G. 4189 Sbrana, S. P4478

Santos, E.V.S. P4410 Sasiela, W. P5980 Sbrojavacca, R. P4675
Santos, F. P3648, P3658 Sastroasmoro, S. 3951 Scacciatella, P. P208
Santos, J.G. P4785 Sata, M. P431, P642 Scaglione, M. P3377, P3394
Santos, L. P2552, 4154, P4490 Sathananthan, J. P4405 Scala, O. P6570
Santos, M. P1610, P1634, P4764, P6167 Satler, L. P670, P1599, P3593, P4583, P6379 Scales, D.C. P1331
Santos, M.S. P829, 1200 Sato, A. P1371, P3083, 4052, P4466, P5327, Scalese, M. P4414
Santos, N. P592, P2529, P5377 P6156, P6244 Scali, M.C. P3509, P3525, P3527, 5805,
Santos, P. P4350, P4380 Sato, D.H. P6451 P6542, P6567
Santos, P.G. P2394 Sato, F. 6105 Scalise, M. P3561, P3563, P5457
Santos, R. P4488 Sato, H. P2540, P6218 Scalise, V. P3087
Santos, R.A. 5082 Sato, K. P1339, P1651, 3306, P3498, P6539, Scally, C. P5435
Santos, R.D. 70, P1705 P6544 Scalone, G. P786, P2780
Santos, S. P6167 Sato, M. P5973 Scammells, P. P4521
Santos, T.D. P3643 Sato, N. P505, P2449, P3742, P6473 Scapini, K.B. P3648, P3658, P5450
Santos, V. P501, P506, P2673, 2937 Sato, S. 1327 Scappaticci, M. P3739
Santos, W. P2526 Sato, T. P4537 Scardovi, A.B. P4769, P6542
Santos-Ribeiro, D. 6058 Sato, Y. P4114, P4760 Scarlatescu, A. P4442
Santoso, A. 259, 410 Satoh, A. P1422 Scarparo, P. P427, P847
Santoso, A. P3467, P6385 Satoh, H. P5958 Scarrott, A. 3162
Santucci, L.M. P2397 Satoh, K. P4336, P5958 Scatena, C. P3458, P4091
Sanz Ruiz, R. P3554, P5448 Satoh, M. 338 Schach, C. P1722
Saoudi, N. P3412 Satoh, T. P6123 Schade, A. P4391
Sapir, B. P4654 Satoh, Y. P5331 Schaechinger, V. 1203, 4268
Saponjski, J. P3682 Satoshi, Y. P883 Schaefer, A. P3455
Saporito, D. P503 Satoskar, A.R. 1217 Schaefer, K. P2158, P2602
Sapoval, M. P1147 Satow, T. P5599 Schaefer, U. P682, P685, P1591, P4563,
Saraf, S. P4408 Sattar, N. P1374, 2959, 4884, P5019, 5766 P4564, 5923
Sarafov, S. P4589 Saukko, P. P425 Schaefers, H.J. P1698
Sarai, M. P6318 Saunamaki, K. P822 Schaeffeler, E. P1484, P1487
Saraiva, F.-A. P5634, P5635, P5641 Sause, A. P2385 Schaeffer, B. P3393, P3414
Saraiva, F. P2751 Sauter, M. P3595 Schaeffer, B.S. P4362
Saraiva, M. 4154, P4488 Savage, G. P1150 Schaer, B.A. P479
Saran, R.K. P4408 Savarese, G. P217, P218, P1115 Schaerli, N. P2695, P4612, P5397
Sarano, M. P4557 Savarese, L. P5639 Schaeufele, T. P3093, P6271
Sarashina, T. P5506 Savchenko, A. P3736 Schafer, S. P3538
Saraste, A. 30 Savelieva, I. 5838 Schaffer, A. P1476, P1480, P2117, P5542
Saraste, A. 303, P425, 1028 Savenkova, G. P6574 Schaffner, E. P2671
Saravanan, P. P4740 Savic, L. P5678 Schakow, H. 5884
Saravi, M. P2828 Savinova, I. P4729 Schalij, M.J. P560, P696, P1401, P2126,
Saraya, M. P2834 Savioli, G. P3527 P2543, 3050, P3372, P3794, P5456,
Sarayani, A. P2715 Savonitto, S. 4254 P5565, P5926, P5970, P6177, P6513
Sardar, P. P823 Savoure, A. P3583 Scharfe, F. P3426, P4343, P4345
Sargento, L. P6581 Savva, G. P5580 Scharfe, M. P166
Sargsyan, D. 1238 Savvatis, K. 2205, 2214, P3127, P3596, Scharnagl, H. P5319, 6644
Sari, I. P5681 P4083, P6348 Schartum-Hansen, H. P1656
Saric, S. P2713, P3634, P4423, P4614 Sawa, T. P5527, P6311 Schatten, H. 1216
Saric, T. 4191 Sawa, Y. 146 Schatton, M. P2149
Saricopur, A. P855 Sawa, Y. P1793, P2610, P3544 Schau, T. 350, P1597, P3402, P3572, 5216,
Sarikamis, C. P2519 Sawada, H. P5443 6017, P6369, P6370
Sarikas, A. 1836 Sawada, T. P1564 Schaubroeck, H. P2627
Sarkin, A.I. 341 Sawaki, D. P2360, P5473, P5557 Schaufelberger, M. 4282, P5496
Sarkisian, L. P4431, P4618, P5713 Sawaki, D.S. 72 Scheffel, P. P3107
Sarkozy, A. 3240, P4342, 5841 Sawamura, A. P5578 Scheibenbogen, C. P3535, P5501
Sarma, J. P5379 Sawano, M. P3123, P3477 Scheiber, D. P5547
Sarper, A. P5440 Sawhney, J.P.S. P1684 Schellinger, I.N. P2604
Sarria, C. 2318, 2320, P3104, P3106, P3576, Sawhney, P. P681, P1543 Schellong, S. 3046
P5483 Sawicki, R. P6279, P6283 Schenck-Gustafsson, K. 362
Sartori, C. P1476, 2014 Sax, B. P1794, P1795, P4097, P6122 Scherbak, M. 4150
Sartori, S. P582, P807, P2762, 2913, P3342, Saxena, A. P6134 Scherbakov, N. P887
P3717, P4695, P4699, P5375 Saxena, M. P2840 Schermer, E.E. P5239
Sarubbi, B. P4546, P4553, P4683 Saxena, P. P1775 Scherptong, R.W.C. P696
Sarwar Hossain, O. P223 Saxena, S. P4713 Scherr, D. 1969
Sarzani, R. P5018 Sayago Silva, I. P4308 Scherrer, U. 2014
Sarzi Braga, S. P3649 Sayeed, R. P5000 Scherrer-Crosbie, M. 75, 301
Sasa, T. P6381 Sayegh, A.L. P700, 2944 Scherzer, S. P1752
Sasaki, H. P6143 Sayegh, A.L.C. P198 Schewel, D. P682, P685
Sasaki, K. P6351 Sayer, J. P4613 Schewel, J. P682, P685
Sasaki, R. P2449 Saygi, S. 2236 Schiano Lomoriello, V. P858
Sasaki, S. P3533, 4237, 4256, P4437 Sazonova, S. P5224 Schiattarella, G.G. 1985, P2121
Sasaki, T. P2436, P2533, P5299 Sbarra, P.L. P5353 Schiavino, D. P6251
498
Chairpersons & Judges / Speakers & Discussants / Authors Sch – Sci
Schiedat, F. P3773 Schmiegelow, M. 4284 Schroeter, H. P2134

Schieffer, B. P1458, P3115, P3455, P4088 Schmiegelow, M.D. P3108 Schroeter, M.R. P2158
Schiele, F. P1696, P1733, 1904, 1906, Schmitt, J. P5928, P6349 Schror, K. P5986
P2147, P2504, P3663, 4260, P4629, Schmitt, M. P619, P2432 Schrutka, L. 5092
P4991, P5931, P6407 Schmitto, J.D. 2291, 2293, 2294 Schubert, H. P5005
Schiele, T.M. 155 Schmitz, C. P2623 Schuehlen, H. P562, P1471, P4070
Schienkiewitz, A. P3666 Schmucker, J. 5818, P5935 Schueler, R. P893, P1596, P2631, P4986,
Schievano, S. P5451 Schnabel, R.B. P882, P2572, P4332, P4661, P6207, P6366
Schijman, A. P1767 P5022, P5369 Schuh, K. P6349
Schikora, M. P3652 Schnackenburg, B. 5899 Schuhbaeck, A. P4510, P5231
Schillaci, G. 147 Schneck, F. P4500 Schuhmacher, S. P1471
Schillaci, G. 3839 Schneck, F.K. P4487, P4499 Schuler, D. P1372
Schilling, R. 128, 361 Schneider, D.G. P3626 Schuler, G. P212, P683, P1600, 1983, 2319,
Schilling, R. 1908, 2864, 3886, 5862 Schneider, H. P4617 P2387, P2480, P3494, P3639, P3728, 5090
Schillinger, M. P5398 Schneider, I.J.C. P3626 Schuler, G.C. 5788
Schillinger, S.S. 1988 Schneider, J.C. P3626 Schuler, G.S. P5495
Schillinger, W. P206, 349 Schneider, J.E. P6356 Schulman, S. 3279
Schimpf, R. P489 Schneider, M. P5459 Schulte, C. P5016, P5369
Schinas, A. P5705 Schneider, M.B. P4605 Schulte, P.J. 3030, 4975
Schindler, A. 2058 Schneider, S. P550, P4479 Schulten, H.M. P2589
Schindler, C. P2671 Schneider, T. P3575 Schultes, D. P4340
Schindler, R.F. P1421 Schnell, A. P4707 Schultheiss, H.-P. 2214, P3600, 5898
Schindler, T.H. 3017, 3019 Schnell, F. P2836, 3184, P5507, 6104 Schultheiss, H. 3069, P3535
Schini-Kerth, V.B. P647 Schnorbach, S. P3622 Schultheiss, H.P. 1181, 1182, 1183, 1185,
Schinkel, A.F.L. P1120, 6607 Schoeller, R. P562 1187, P1353, P1625, P5501, 6098, 6100,
Schinkel, A.F.M. 3074 Schoen, T. 1843 6101
Schiopu, A. P175 Schoenberger, J. 3068 Schultz, A. P5409
Schipper, M.E.I. 5793 Schoene, K. P3415 Schulz-Menger, J. 5823, 5825, 5826, 5827
Schirdewan, A. P1549 Schoenemann-Lund, M. P593 Schulz-Schuepke, S. P5396
Schirmer, H. 2025, P5024 Schoenenberger, A.W. 965 Schulz-Schupke, S. P1485
Schjerning Olsen, A.M. 1972, P6470 Schoener, L. 1989, 4973 Schulze, P.C. 2210
Schlaich, M. 6068 Schoenleitner, P. P3769 Schulze-Bahr, E. P1400
Schlattmann, P. P4113 Schoepf, U.J. P5405 Schumacher, B.M. P550
Schlegelmilch, I. P224 Schoepp, M. 350, P1597, P3572, 5216, Schunck, W.-H. P4084
Schlensak, C. 2926 P6369, P6370 Schunkert, H. P1485, P3568, P4092, P5396
Schlett, C.L. 936 Schofer, J. P673, P1606, P1608, P2608, Schupke, S. 2221
Schliamser, J. P703 P5485, P5626 Schur, R. P4083, P6348
Schloss, E.J. P5927 Schoinas, A. P639 Schurer, J. P6185
Schlotmann, N. P3597 Scholte, A.J. 3071, P4482, P6230 Schurgers, L. P1563, P2578, P5547
Schlotter, F. P683, 1983, 2319, 5788 Scholte, A.J.H.A. 142 Schurgers, L.J. P645, P646
Schlueter, K.D. P4529 Scholte, A.J.H.A. 3050, 3998, P5230, P6429 Schurtz, G. P1492, P6507
Schlueter, M. P4563, P4564 Scholte, M. P2743 Schuster, P. P4085
Schmalgemeier, H. P6289 Scholten, M.F. P4394, P4396 Schuuring, M.J. P2658, P2661
Schmermund, A. P4465, P4479, P5001 Scholtz, S. P1618, P2827, P3526 Schwab, D.M. P3537
Schmid, C. 3310 Scholtz, W. P1618, P3526 Schwab, M. P1484, P1487, P1508
Schmid, J.-P. 152, 208 Schoors, D. 4195 Schwagten, B. P3408
Schmid, J.J.S. P4101 Schoors, S. 6054 Schwaiger, M. 2058
Schmid, J.P. 2929, P3654 Schoos, M. P593 Schwalbe, H. 2342
Schmid, R.S. P4101 Schott, H.F. P1698 Schwartz, B.S. P2577
Schmidkonz, C. P5231 Schott, J.J. P485, P1409, P6161 Schwartz, P.J. 367
Schmidt, A. P3769 Schotten, J. P4316 Schwartz, P.J. P6162
Schmidt, C. P5947 Schotten, U. 208 Schwartz, R.S. P2577
Schmidt, E.B. P4322 Schou, M. 951, 4283, 4284, P5033, P5700 Schwartzenberg, S. P5412
Schmidt, G. P166, P1539, P4079, P4638 Schouffoer, A.A. P696 Schwarz, G.G. P6464
Schmidt, H. 5831, 5833, 5834, 5835 Schrage, M.O. P1443 Schwarz, K. P5435
Schmidt, M. P577, 1842, P5359, P6158 Schram, M.T. P4615 Schwarzl, M. P3471, P3492
Schmidt, M.R. P577, P596 Schreiber, B. P5514 Schwedhelm, E. P2572, P3623, P4661,
Schmidt, R. 143 Schreiber, C. P3558 P5022
Schmidt, S. P6454 Schreiber, D. P3393, P3414 Schwemmler, C. 6012
Schmidt, S.E. P1546 Schreiber, D.S. P4362 Schwerzmann, M. 2310, 2312, 2314, 2315,
Schmidt, T. P682, P685 Schreiber, W. P2488 2316, 2927, 2929, P6454
Schmidt-Trucksaess, A. 1843, P2671 Schreieck, J. P4347, P5603 Schwierzek, K. P2581
Schmidt-Trucksass, A. P2685 Schrickel, J. P663, 1216 Schwitter, J. 38
Schmidtke, J. 321 Schrickel, J.W. P1417, P4986, P5951 Schwitter, J. P6323
Schmied, C. 23 Schrijvers, D.M. 1835 Schwung, J. 4177, 4178
Schmied, C.S. P4101 Schroeder, J. 3175, P3725, P4449, P4462, Sciarra, L. P3403, P3411
Schmieder, R. P3771 P6521 Sciarretta, S. 971
Schmieder, R.E. 126 Schroeder, R. 3066 Scibisz, A. P1616
Schmieder, R.E. 1874, 1878, 2018, 2263, Schroeder, S. 1252, 1254, 1256, P4479, Scicchitano, P. P657, P733, P4664, P6437
P3131, P3132, 3826, 3975 P5001 Scislo, P. P1616, P4572
Schmieder, R.M. 6066 Schroen, B. P3535, 3956
499
Chairpersons & Judges / Speakers & Discussants / Authors Sco – Sha
Scognamiglio, G. 2927, P4553, P4683, Seifert, R. P1656, P4657 Separovic Hanzevacki, J. 206
P5526, P5529 Seiffert, M. 5923 Sepp, D. 2058
Scopelliti, F. P1430 Seike, Y. P6143 Sepp, R. P4688
Scorodumova, E. P5349 Seiler, C. P1709, P1723 Sepsi, M. P2115
Scott, C. 4887 Seitz, S. P194 Sepulveda, P. P3518
Scott, C.G. P1653, P5018 Seixo, F. P527, P591 Seravalle, G. P1149, P4119, P4781
Scott, G.S. P1377 Seizer, P. P4347, 6614 Serban, C. P1450, P1584, P1676, 2229,
Scott, I. P6456 Sejersted, O.M. P416 P3752, P5981
Scott, J.S. 4269 Seker, T. P722 Serban, R.C. P2135
Scott, M. P4580 Sekhri, N. P692 Serdoz, R. P2764
Scott, R.A.D. 3922 Sekigawa, M. P3360 Serenelli, M. P4554
Scotton, C. P1421 Sekiguchi, H. P3670, 6655 Sergeeva, E.G. P5362
Scowcroft, A. P4401 Sekiguchi, Y. P1399, P5925 Sergeevichev, D. P3370
Scridon, A. P2135 Sekine, A. P417 Sergio Raposeiras Roubin, S. P4419
Scrimieri, P. P564 Sekiya, K. 2107 Sergovia, J. 4930
Scrutinio, D. P733 Sekkali, B. 4190 Serizawa, N. P1637, P4552
Scudeller, L. P3646 Seko, T. 6634 Seronde, M.F. P6407
Searle, J. 125 Selejan, S.R. P873 Serov, V. P4729
Sebbag, L. 2197 Seliger, S. P878 Serova, D. P4729
Sebedio, J.L. P1358 Seljeflot, I. P422, P1574, P3489, 4881 Serpi, R. P2162
Sebekova, K. P3556 Seljeflot, I.S. P5592 Serra, A. 161
Secchi, F. P452 Sellal, J.M. P2418, P2455, P3365, P4599, Serra, J.A. P5568
Secen, O. P3801 P4600, P5553 Serra, S.A. P1425
Sechtem, U. 34 Selle, A. 1982 Serra-Majem, L. P4662
Sechtem, U. 1018, 1019, P1532, 2038, Sellke, F. 3257 Serrano, G. P2557
2039, 2975, P3093, 4054, P6271 Sellke, F.W. P5967 Serrano, J. P1394
Sedaghat, A. P2631, P2633, P4573, P4986, Selmi, W. P4504 Serrano Jr, C.V. P6267
P6387 Selton-Suty, C. P557, P676, P3530, 4006, Serruys, P.W.J.C. 324
Sedaghat-Hamedani, F. P2687, P5472, 4008, 4010, P4111, P5513 Serruys, P.W.J.C. 362, 369, P1553, P1584,
P6540 Selvakumar, K. 156 2061, P2730, P2752, P4695, 5172, 5998,
Sedaghat-Hamedani, F.S.H. P3100 Selvanayagam, J. P3630 6092
Sedding, D. 1850 Selvanayagam, J.B. P2356 Servatius, H. P3393
Sedding, D.G. P2590 Selwaness, M. P5573 Sesana, M. P2741
Sederholm Lawesson, S. P551, P552 Semba, H. P5003 Sestito, A. P3512
Sediva, L. P4387, P4720 Sembolini, A. P5609 Seta, Y. P2803
Sedlacek, K. 4835, 4859 Semenova, N. P3736, P6485 Sethi, A. P6436
See, O. P2419 Semionov, L. P6527 Sethi, R. P4408, P6249
See, V. P878 Semmler, V. P4365 Sethia, B. P2142
Seeber, V. 4177 Semple, S. P2127 Settembrini, A.M. 5807
Seegers, J. P5311 Sen, S. P1714, P1725, 4932 Settergren, M. P2609
Seelaender, S. P1777 Sen, S.S. P1717 Seung, K.B. P2486, P6287
Seemann, G. P6356 Sen, T. P3760, P6139 Seven, E. P2170
Seewoester, T. P6209 Sena, E.S. P5447 Sevenster, M. P4081
Seferovic, P. 31, 212 Sena, P. P5658 Severi, S. P2345
Seferovic, P. 2325 Senatore, G. 2270, P3403 Severino, A. 3944, P5455, P6118
Seferovic, P.M. P2518 Sengelov, M. P844, P6538 Severino, D. P5391
Segal, O. P494 Senges, J. 349, 3309, P3385, P5001 Severino, D.J. P2479, P5361
Segerer, M. P5617, P5625 Sengupta, P.P. 2281 Severino, P. P846, P847
Segers, P. P185, P186 Senior, R. P866, P1603, P2562, 3012, 3014 Sevilla, J.C. P1674
Segev, A. 243, P4999, 6016 Senko, Y. P5983, P5985 Sevilla, T. P3103, P3576, P4575
Segev, S. 4204 Senni, M. 357, 1915, 3302, P5285, P6147 Sevimli, S. P838, P1741, P3695, P5594
Seggewiss, H. P2638 Senol, H. P855 Seyfarth, M. P575, P2385
Segiet, A. P1595 Senoo, T. P4691 Sferrazza Papa, G.F. P3617
Segovia, E. P4719 Sente, T. 1999 Sfikakis, P.P. 3253
Segovia Cubero, J. P1768, P3625, P4308, Senturk, A. P488, P5426 Sfirakis, P. P1816
P5942 Seo, G.W. P4697 Shaban, A. P4656
Segreti, L. P1092, P2439 Seo, H. 2264 Shabanova, M.S. 2100
Seguchi, O. P2500 Seo, H.S. 277, P736, P762, P808, P812, Shabilla, M.A.S. P2577
Segura, J. P797, P2758, P2763, P3704 P826, P834, P2766, P2842, P3703, 5124, Shacham, Y. P2457
Segura De La Cal, T. P2691, 5091 P5350, P5355, P5387, P5395 Shafi, N. P1815
Segura Saint-Gerons, J. P2114 Seo, J.-B. P5395 Shafie Ammar, A. P814
Segura-Heras, J.V. P2788 Seo, J.-S. P2478, P2498, P2737, P4700 Shafiee, A. P2431, P5581
Segurini, C. P4997, P5233 Seo, J.B. P6563 Shah, A. P4301, P6487
Sehnert, W. P3353, P3796 Seo, K.W. P1721 Shah, A.M. 3168, P4531
Seide, S. 5818 Seo, M. P4760 Shah, A.S. P3432, P4461
Seidl, V. P4545 Seo, S.M. P5389 Shah, B.N. P2562
Seidlmayer, L.K. P2361, P4516 Seo, Y. P3498, P4116, P6299 Shah, C.S. P2778
Seidman, C.E. 3065 Seol, S.H. P4697 Shah, D. 24
Seidman, J.G. 3065 Seong, I.W. P3732 Shah, D. 94
Seifert, M. 350, P1597, P3572, P4366, 6017, Seow, S.C. P2430 Shah, M. 1971
P6369 Shah, P.B. P3503
500
Chairpersons & Judges / Speakers & Discussants / Authors Sha – Shu
Shah, R. P1139, 2031 Shevchenko, O. P1813 Shin, H.-C. P2478, P2498, P2737, P4700
Shakeri, H. 1835 Sheyin, O. 2915 Shin, J. P215, P3117, P3712
Shakir, S. P206 Shi, C. P1580 Shin, J.H. P904, P1721, P1809
Shalaeva, A. P5376 Shi, D.M. P659 Shin, M.S. P5401
Shalaeva, E. P5376 Shi, G. P5374, P6360 Shin, S.E.S. P1475, P5971
Shalev, V. P2785 Shi, J. P4585 Shin, S.H. P2477
Shamma, D. P5638 Shi, V. P213, P5031 Shin, W.-Y. P5395
Shams-Eddin, H. P6428 Shi, W. P748, 1237, 4183 Shinagawa, H. P3742
Shang, M.-S. P5266 Shi, W.M. P710 Shindo, K. P5460
Shang, Q. P5424 Shi, Y. P1561, P4520, 6103 Shinichi, S. P6227
Shanmuganathan, S.K. P2589 Shi, Z. P3443 Shinke, T. P1363, P2746, P4551
Shantsila, A. P226, P1783 Shiba, C. P184 Shinkura, Y. P4551
Shantsila, E. P226, P1783 Shibagaki, Y. P3742 Shinlapawittayatorn, K. P4538
Shao, S. P895 Shibata, H. P6273 Shinoda, N. 2228, P5380
Shao, Y. P4063 Shibata, R. P433 Shinohara, T. P2415
Shapira, Y. 242, 1981, P3698 Shibata, S. 6632 Shinouchi, K. P1108, P6537
Sharif, D. P481 Shibata, T. 3305, P4761, P4763, P6536, Shinozaki, K. P629
Sharif, F. P4068 P6541, P6545 Shinozaki, T. P4611
Sharif, Y. P481 Shibata, Y. P788, P3691, P5333, P6535 Shiode, N. P4506
Shariya, M.A. 2100 Shibuya, M. P1739, P1743, P2775 Shiojima, I. P769, P4691
Sharma, A. P649, P2784, P4408 Shibuya, M.S. P1712 Shiomi, H. P1486, P2491, 2908, P6381
Sharma, R. P498, 3253 Shiga, T. P1637, P4552 Shiomi, H.S. P2465
Sharma, S. 21 Shigematsu, H. P1760 Shiomi, Y. P3422
Sharma, S. 977, P1510, P1629, 1848, 2249, Shigemi, S. 2107 Shiono, Y. P583
P2373, P2680, 2965, 2967, 2968, P3324, Shigeta, Y. P5564 Shiozawa, T. P3675
5093, 6619, 6669 Shigyo, H. P2366 Shipley, M. P5582
Sharma, V. P168 Shih, S.C. P4076 Shirai, K. P6533
Sharman, J. P5711 Shiina, K. P759, P1821 Shirai, M. P883
Sharon, O. P2785 Shiina, K.S. P754 Shirai, S. P1383, P2747, P2749, P3439,
Sharpe, J. P5668 Shim, A. 4238 P3440, P3701, P3702, P5965, 6024, P6491
Shasha, N. P5979 Shim, C.Y. P2544, P5296, P6362 Shiraishi, I. 2932
Shatalov, I. P2576, P5236 Shim, E.B. P6175 Shiraishi, Y. P1801, P3477
Shattock, M. 3180 Shim, H.B. P640 Shirakawa, T. P2686
Shauer, A. P1806 Shim, J. P1525 Shiraki, T. P1135, 3170, P5326, P6534
Shaul, A.A. P5013 Shim, J.M. P4363 Shiratori, Y. P2780
Shaviv, E. P4999 Shim, J.Y. P3585 Shirayoshi, Y. P1426
Shaw, J.E. P756, P3627 Shim, W. P6162 Shirey-Rice, J. P5374
Shaw, L.J. 2036, 2037, 3994, 5160 Shim, W.J. P5401 Shirodaria, C. P5000
Shaw, S. P2819 Shimabukuro, M. P431, P642 Shishido, T. P851, P1660, P3533, P4766,
Shawl, F. P3342 Shimada, K. P3675, P4467, P4523, P4549, P4784, P5453
Shchedrina, A. P4593 P5382 Shishkina, N. P3779
Shcherbakova, N. 5099 Shimada, S. P3110 Shite, J. P2746, P6273
Shchukin, Y.V. P2163 Shimajiri, M. P2692, 5885 Shivalkar, B. P650, 3011, 3013
She, L. P2613, 5214 Shimamoto, K. P3670, P5975, 6655 Shizuta, S. P515, P6351
Shea, J.S. P1151 Shimamura, H. P3638 Shket, A. P6485
Sheahan, R. P5604 Shimano, M. P1672 Shkolnik, E. 4150
Shechter, A. P1565 Shimatsu, A. P3110 Shkolnik, L. 4150
Shechter, M. 85 Shimazu, S. P2648 Shkurat, I. 6046
Shechter, M. P731, P1565, P5560, P5569 Shimbo, Y. P788, P5333 Shlezinger, M. P731
Shehata, A.S.H. P5287 Shimizu, A. P1827, P3800, P5969, P6350 Shlomo, N. P2474
Sheikh, S. P760 Shimizu, I. P3327, P4314, P4535, P4537, Shlyakhto, E. P2825
Sheldon, T. 5915 P4733 Shlyakhto, E.V. 34, 124, 209
Shelley, E. 1856 Shimizu, K. P5042 Shlyakhto, E.V. P1540, P1542, 4895
Shemyakin, A. P2133 Shimizu, M. P490, P751, P1694 Shmelkova, E. P4729
Shen, H. 1831 Shimizu, R. P1567, P2672 Shmilovich, H. 5789
Shen, L. P6518 Shimizu, S. P4784, P5299 Shoaib, A. P6564
Sheng, S. 3030 Shimizu, W. P417, P513, P870, P1737 Shoda, M. P3410
Sheppard, A. P6475 Shimizu, Y. P1583 Shoji, M. P2598, P2720
Sheppard, M. 1848 Shimohama, T. P655 Shoji, T. P2165, P2168, P3636
Sheppard, M.N. 212 Shimojo, N. 2343, P5261 Shook, D. P3503
Sheppard, M.N. 1310 Shimokado, A. 6623 Shore, D.F. P2142
Sherbakova, A.S. P6284 Shimokawa, H. P790, P1707, 4015, P4336, Shpektor, A. P6332
Sheridan, P. 2988 P5958, P6117, P6539, P6544 Shrader, P. P3076
Sherrah, A.G. P2660 Shimokawahara, H. P5533 Shrestha, M. P2623
Sherwood, R. P6487 Shimoshige, S. P2556 Shrestha, N.R. P6133
Shestak, A. P489 Shimouchi, A. P883 Shu, C.W. P3565
Shestak, A.G. P6171 Shin, D.H. 6624 Shu, X.H. P483, P2833, P4585, P6306,
Shestakova, M. 1837 Shin, D.I. P5389 P6497
Sheta, H. P3325 Shin, E.C. 1239 Shu, Y.M. 1855
Sheu, J.J. P1762, P3564 Shin, E.K. P784, P4682 Shugushev, Z. P6269
Shevchenko, A. P1813 Shin, E.S. 4022 Shukevich, D. P2773
501
Chairpersons & Judges / Speakers & Discussants / Authors Shu – Sko
Shumavets, V. P6485 Silva Cunha, P. P501 Singh, J. P502, 2272, 2985, P6552
Shun-Shin, M. P1714 Silva Jr, O.L. P5254 Singh, J.P. P491
Shur, V. P2376 Silva-Cardoso, J. 203 Singh, K.Y. P3714
Shurrab, M. P2425 Silvain, J. 197 Singh, M. P1815, P6436
Shuster, J.B. P600 Silvain, J. 363, 2071, P2504 Singh, N. P1765, P4544
Shutov, A. P4729 Silveira, I. P1634, P6167 Singh, P. P2812, P4381
Shutta, R. P2503, P6201 Silveira, J. P6167 Singh, R. P5697, P6561
Shuvy, M. P1331 Silver, K.H. P215 Singh, S. P2159, P2591, P6436
Shvilkin, A. P2417, P2422 Silver, M. P4297 Singhal, P. P5226
Shwammenthal, E. P4999 Silversides, C. 145 Sinhal, A. P2839, P3630
Shyu, K.G. P1568, P6333 Silvestre, J.-S. 50 Sinisalo, J. P3098, P3429, P3478, 4911,
Siaidawi, A. P5701 Silvetti, M.S. P2397 P6243, P6264
Sianos, G. P2607, 6013 Silvola, J.M. P425 Siniscalchi, C. P5938
Siasos, G. P455, P660, P740, P1116, P1458, Sim, D.-S. P1495, P1502 Sinkiewicz, W. P4739
P1577, P2575, P2689, P2725, P3680, Sim, D.S. P824, P2486, P2756, P3732, P4471 Sinkovec, M. P3421
P4088, P4312, P4582, P5476, P6476 Sim, K.-H. 37, 73 Sinnaeve, P. 4195
Siasou, G. P1577, P3680 Sim, W.J. P831 Sinnecker, D. P1346, P4638
Sibbing, D. 320 Simak, I.M. P5563 Sinner, M.F. 2949
Sibbing, D. 1044, P1485 Simantirakis, E. 304 Sinning, C.R. P882, P4332
Sibilitz, K.L. 2939 Simantirakis, E. P5329 Sinning, J.M. P1596, 1980, P2631, P2633,
Sibilitz, K.L.S. 2938 Simard, E. P627 P4573, P6387
Sibon, L. P3740 Sime, I. P2347 Sionis, A. P880, P1622, P1781, P3491,
Sicari, R. 197, 253 Simek, J. P3423, P3424 P4422, P4768, P6573
Sicari, R. P620, P1341, 2049, 2051, 4196, Simeone, P.G. P2716 Siontis, K.C. 4862
P5020, P5530, P5576 Simes, J. P4323 Siores, E. P785, P4106, P5607, P5627,
Sichrovsky, T. P3384 Simioniuc, A. P3525, P3527, P4769, 5805, P6254
Sichting, L. 1989 P6542, P6567 Siostrzonek, P. P584
Sicignano, N. P4066 Simitsis, P. P2459, 3303, P6566 Siot, P.H. 5917
Siciliano, M. P1534, P4460 Simkova, I. 27 Sipahi, I. P1758
Siddiqui, S. P510 Simkovits, D. P5934 Sipido, K.R. 35, 123, 316
Sideris, S. P3582 Simon, A. P1761 Sipido, K.R. 2241, P5468, 5716
Sidharta, P.N. P2645 Simon, C. P1358 Sipila, J. P6231
Sidi, Y. 4204 Simon, J.N. P4517 Sips, P. P1562
Sidi Aly, A. P3134 Simon, T. P173, P1696, P2147, P2504, 4260, Siracusano, A. P5455
Sidorenko, B. 2916 P4629, P4991, P5931 Sirenko, Y.U. P3805, P6591
Sidorenko, I.V. P520, P6169 Simonato, M. P3723 Sirker, A. P2740
Sidorenko, P. P3805 Simoncelli, U. 2207 Sirnes, P.A. 983, 985, 987
Siebelink, H.M. P2126, 3050, P5926 Simoncini, E.L. P854 Siromakha, S. P1635
Sieber, C. 959 Simoncioni, M.C. P3790 Sison, J. 2886
Siebes, M. P669, P1708 Simonneau, G. 2175, P2365, P4548 Sison, S. P2113
Siegbahn, A. 249, 306 Simonotto, J.D. P1418 Siswanto, B.B. P558
Siegbahn, A. 52, P172, 1953, 1974, 3953, Simonovic, D. P3634, P3661, P4614 Sitar, J. P4705
4203, P5961 Simonsen, U. P5954 Sitbon, O. 264
Siegismund, C.S. P3600 Simonyi, G. P1829 Sitbon, O. 1939, P2365, P4548
Siennicka, A. P1789, P5655 Simoons, M.L. 132 Sitges, M. P3090
Siepe, M. 5792 Simor, T. P4099 Sitnikova, M. P2825
Sieswerda, G.T.J. 2927 Simpson, C. P3404 Sitzy, J. P3389, P3409, P4359
Sievert, H. P3741, P5626 Simpson, I.A. 150, 325 Siu, C.W. P738, P4765
Sigala, F. P5624 Simrick, S.L. P1421 Siudak, Z. P555
Sigala, S. P854 Sims, D. P3488 Sivasinprasan, S. P5539
Sigurdsson, S. 299 Sinagra, G. P522, P691, P1347, P3646, Siverina, A. P5349
Sijbrands, E.J.G. P6429 P4399, P5242, P5244, P5297, P5683, Sivitskaya, L.N. P6169
Sikorska-Siudek, K. P5537 5787, P6147, P6575 Siwicka, M. P5531
Silber, H. P5977 Sinagra, G.F. P686, P1621 Siwolowski, P. P889, 3308, P6569
Silber, S. 362 Sinatra, R. P3490, P3579, P4317, P5241, Six, A.J. P590
Siles Rubio, J.R. P601, P2381, P2777, P5478, P5632 Sjaastad, I. P416, P6341
P3657, P5611, P6526 Sinclair, H. P570, P588 Sjoberg, P. P2665
Siliste, C. P635 Sindet-Pedersen, C. 4976 Sjoquist, P.O. P3085
Siller-Matula, J.M. 1045 Sing-Gupta, V. P848 Skaardal, R. P512
Sillje, H.H.W. P6346 Singal, P.K. 4152 Skadberg, M. P6477
Silva, A.F. P2372 Singbal, Y. P4704 Skala, T. P1095, P4351
Silva, B. P592, P2464, P2529, P3431, P4303, Singer, D. P2115 Skalsky, I. P4720, P6493
P5377 Singer, D.E. 2031, P6210 Skeppholm, M. P4067
Silva, D. P2526, 4154 Singh, A. P896, P3503, P4570 Ski, C.F. P6456
Silva, G.L. P598, P1122, P2636, P3804, Singh, A.S. P3126 Skjoeth, F. P5308
P5419 Singh, B. P3772 Skoczynski, P. P1442, P2110
Silva, J.C. P4464 Singh, D. P2430 Skoda, J. P4387, P4720
Silva, P.C. P5634, P5635 Singh, H. 1197 Skoglund, K. 2925
Silva, T. P1642 Singh, I. P1146 Skopal, J. P5449
Silva, V.R.O. P2704 Singh, J. 137 Skoric, B. P2824, 3024
Silva Cardoso, J. P2140, P6573
502
Chairpersons & Judges / Speakers & Discussants / Authors Sko – Sou
Skoularigis, I. P5309 Smits, P.C. P4695 Solomon, S. 32

Skoumas, I. P727, 2233, P2723, P4648, Smolen, A. P2411 Solomon, S. P213, P214, 3151, 4043, 4853
P6438 Smolis-Bak, E. P2697 Solomon, S.D. 1977, 3168, 3301, 3302,
Skoumas, J. P730, P2711, P2721, P3681, Smolka, C. 1956 P3503, P3756, P5031
P5561, P6422 Smolka, G. P1747, P2837 Solomonica, A. P1790
Skourlis, N. P2711, P2723 Smulders, M.W. P4458 Soloschenko, A.V. P3762
Skov, L. 3942 Smulders, Y.M. 368 Soloveva, A. P5660, P5696
Skov, M.W. 6076 Smulders, Y.M. 58 Soma, K. P5003
Skov, R.L. P3108 Smyth, Y. P2348, P4068 Somaratne, R. P5984
Skowerski, M. P1747, P2837 Snijder, R.J. P5532 Somaschini, A. 1204
Skrbic, B. P6341 Snitzarenko, O. P6591 Somers, V.K. P4381
Skroblin, P. P1472, P2571 Snygg-Martin, U. 4834, 5988, 6079, 6080, Sommer, A. P519, 2269, P2395
Skrzypek-Wanha, J. P2835 6081 Sommer, P. P516, P3381, P3392, P3415,
Skulstad, H. P3462, P4754 Soar, S. P3765 P6209, P6509
Skurk, C. 3069, P3535, P4083, P5501, P6348 Soares, A. P4350, P4380 Son, J.H. P746
Skvortsov, A. P879 Soares, C. P3693 Sondergaard, L. P3496
Skvortsov, A.A. P4593 Soares, F. P2470, P2751 Sone, T. P2446
Skytta, T. P3517 Soares, R. 2937 Song, H.-N. P2555, P5414, P5417
Slabe-Erker, R. P464 Soares-Dos-Reis, R. P5006 Song, J.S. P6175
Slagman, A. 125 Sobhy, M. 135, 266 Song, L. P805, P2521
Slama, M. P4111 Sobhy, M. P1681, P6131 Song, L.F. P2793
Slapikas, R. P3514 Sobic-Saranovic, D. P609, P1716, P5415 Song, P.S. P4697, P4702
Slart, R.H.J. P183 Sobiczewski, W. P757, P6224 Song, S.K. P4426
Slater, S.C. P5454 Sobien, B. P436, P720, P1641, P5612 Song, S.L. P4407
Slavic, S. P3460 Sobkowicz, B. P3616 Song, Y.-B. P1757
Slawuta, A. P1441, P1442, P2110 Sochaj, A. P2411 Song, Y.B. P2495, P4472, P4702
Sledz, J. P3376 Sochett, E. P2136 Song, Y.N. 4059, P4515
Sledz, J.S. P3361 Soderberg, S. P756, P3627 Songia, P. P6368
Slegtenhorst, M.A. 3074 Soegaard, R. 2939 Soni, P.N. P1679
Slepynina, Y. P3338, P4443, P5403 Soeholm, H. 155 Sonne, C. P3568
Slezak, A. P6481 Soeki, T. P431, P642 Sonnenschein, S. P468, P3359
Slezak, P. 1979 Soerensen, H.T. P1336, P1337, P1464, Sonoda, K. P1386
Slim, M. P4693 P1498, P1503, P5351 Sonoda, M. P5533
Slingerland, R.J. 1857, P4071 Soergaard, M. P6324 Sonoda, S. P1718
Sliwa, K. P2651, P6328 Soesanto, A. P6385 Sopko, O.O. P5563
Sliwa-Hahnle, K. 39 Soesanto, A.M. P3467 Soranna, D. P3352
Sliwa-Hahnle, K. 2095, 2096, 2097, 2098 Soffer, J. P6439 Sorbets, E. P2815
Sliziuk, V. P2786, P5695 Soflai Sohee, S. 158, P3437, P4456 Sorbo, A.R. P2693
Slomka, P. P623, 3996, P4480 Soga, Y. P1135, P1136, P1137, P1138, Sordelli, C. P3505
Slonka, G. P541 P2747, P2749, P3701, P3702, P5965, Sorensen, E.E. P1666
Sloth, A.D. P577, P596 P6505 Sorensen, H.T. P577, 1842, P5359
Sluijter, J.P.G. 133 Sohael, F. P223 Sorensen, M.H. P5017
Sluijter, J.P.G. 1957, P5447 Sohaib, S.M.A. 20 Sorensson, P. P2655
Sluman, M.A. P6416 Sohal, M. P518, P6314 Sorgato, A. 2207
Slusarczyk, P. P5269 Sohn, D.-W. P6347 Sorges, J. P5396
Slusser, J.P. P221 Sohn, I.S. P802 Soria, R. 2014
Smagulov, N. P5665 Sohns, C. P165 Soriano-Gabarro, M. P3320
Smalcelj, A. P5278 Sokal, A. 4861, 4864 Sorour, K. P5571
Smani, T. P4528 Sokolis, D.P. P672 Sorour, S. P729, P901
Smars, P.A. 4237 Sokolov, M. P798 Sorsa, T. P3429, P3478, P6243, P6264
Smart, N. 72, 303, 361 Sokolov, Y. P798 Sorysz, D. P5011
Smart, N. 2237 Sokolowska, E. P1451, 1833 Sosalla, S. P2164
Smecca, I.M. P1474 Sokolski, M. P889, 3308, P3430, P6569 Sosnowski, M. P2447, P2835
Smedegaard, L. P2120, 3942 Sola, D. P2561 Sosnytska, T.V. P486
Smeekes, M. P560 Sola, S. P5482 Sosnytskyy, V.N. P486
Smilowitz, N. P5703 Solari, M. P2682 Sossalla, S. 248, 302
Smirnova, O. P3684 Solaro, R. P3447 Sossalla, S. P2159, P3552, P5030, P5950,
Smiseth, O.A. 254 Solaz, E. P4775 P6154
Smiseth, O.A. P4754, 5201, 5203, P6297 Solbiati, A. 4051, 4056 Sota, T. P2706
Smit, A.J. P1566 Soldati, E. P1092 Sotiriou, P. P2698
Smith, A. P415, P5682, P6508 Soldatova, A.M. P521, P2391 Soto, M.E. P641
Smith, A.J. P3563 Solecki, K. 5088 Sotonyi, P. P1457
Smith, D. P2742 Soler, C. P1674 Soucek, F. P4381
Smith, E.J. P2740 Soler-Botija, C. P3546, P3553, P5445 Soucek, M. P3114
Smith, G.C. P2142 Soletormos, G. P5700 Soufen, H. P4410
Smith, J. P3640 Solheim, S. P1574 Souissi, Z. P3374
Smith, K.E. P4776, P5572 Solik, P. P4770 Soukoulis, V. 3065
Smith, K.J. P1356 Sollaku, S. P427 Soulat, L. P1505, 5813
Smith, L.A. P2398 Sollie-Szarynska, K.M. P713 Soulat-Dufour, L. P4647, P4650, P4982
Smith, S. 4193 Solntsev, V. P735 Sourij, H. 2244
Smith, S.A. P6543
503
Chairpersons & Judges / Speakers & Discussants / Authors Sou – Ste
Sousa, A.C. P4621, P4625, P4643, P4645, Springer, J. 255 Starodubova, A. P3798
P4646, P5962, P5964 Springer, J. 5199, P5256 Startari, L. P840
Sousa, A.G.M.R.S. 2911, P3689 Sprynger, M.G. 79 Stasek, J. P3446
Sousa, J. P6165 Spurgeon, H.A. P5570 Stasiak, M. P4722
Sousa, J.E.S. 2911, P3689 Spurny, P. P1435 Stasinaki, A. P2689, P4312
Sousa, J.M.A. P4410, P4455 Spyridopoulos, I. 137 Stasinos, V. P3513
Sousa, L. P1642, P3693 Spyrou, G. P612 Stasiv, Y. P1799
Sousa, M.J. P1634, P6167 Squire, I. P5031 Stathogiannis, K. P785, P1141, P3501,
Sousa, P. P4358 Squire, I.B. P770, P2379, P3126 P3590, P4751, P5464
Sousa Uva, M. 210, 309 Squizzato, A. P3619 Statkiewicz-Barabach, G. P1539
Sousa Uva, M. 3023, 3025, 3027, 4937 Sramko, M. 6075 Staubach, S. P5617, P5625
Souteyrand, G. P3344, 6622 Srankova, J. P864, P872 Staudenmayer, K. 360
Souteyrand, G.S. P5933 Srdic, M. P5678 Stauffer, J.-C. P532
Souza, F.R. P198 Sredniawa, B. P2789, P4476 Stauffer, J.C. P2378
Souza, L.E. P5450 Sriharan, M. 958 Stavrakis, S. 2987
Souza, S.B. P3648 Srinivasan, J. P5435 Stavrou, K. P1478
Soylu, K. P2444 Sritara, P. P458, P1695, P2419, P4627, Stawinski, P. P3543
Soyoral, Y. P2847 P4672 Stazi, A. P4522
Sozio, F. P4628 Srivaratharajah, K. 4873 Stazka, J. P2440, 5145
Sozzi, F. P5358 Srivastava, P.M. P5674 Stea, F. P5576
Spaak, J. P2787, P4304 Srivastava, S. P6568 Stebbins, A. P6228, P6439
Spaan, J.A.E. P1708 Sriwattanakomen, R. P2422 Stec, S. P3361, P3376, P4388
Spacek, R.S. P4329 Stabile, E. 1985, P2481, P2630, P4715, Steck, H. P1709
Spadotto, V. P2539, P3532 4870, 5162, P5623 Steen, D.L. P1682, P1683
Spagnolo, P. P5577 Stabile, G. P503, P2400, 4860, P5222 Steen, T. 3198, 6015
Spahiu, K. P728 Stabryla-Deska, J. 4864 Steendijk, P. P3471, P3492
Spahiu Eduard, E.S. P728 Stachel, G. P683, P1600, 1983, 2319 Steer, P. 144
Spallarossa, P. P3328, P3550 Stachel, G.M. 5788 Stefanadis, C. P727, P730, 2233, P2388,
Spallek, B. P1419 Stachura, M. P1807 P2711, P2721, P2723, P3679, P3681,
Sparla, S. P4741 Stadler, S. P4730, P6582 P4118, P4648, 4869, P5541, P5555,
Spartera, M. P6389 Stadlmayr, A. P4644 P5561, P6422, P6438
Spaulding, C. 140, 408 Stadnyuk, L.A. P486 Stefanini, G. P2762
Spaulding, C. P534, 1269, 1320, P1382, Staempfli, R. 2929 Stefanini, G.G. P807, 1263, P4695, P4699,
4257 Staempfli, S.F. P1614 P5375
Spaziani, D. P1149, P2390 Staerk, L. 1832, 1972, 2033 Stefanovic, B. P4425, P4452
Spazzapan, S. P871, 4149 Staessen, J. P1147, 1236 Stefanovic, D. P5536, P5538
Speidl, W. P5398 Stafford, N. 6056 Stefanovic, N. P649
Speidl, W.S. P6255 Stafoggia, M. 2251 Stefansdottir, H. 299
Speiser, U. 1323, P4494 Stafylas, P. P6320 Stefansson, K. 1208
Spencer, H.L. P3566, P5454 Stahle, M. P425 Stefenelli, T. P2488
Spencer, K. P709, P4081 Stahlman, M. P4063 Steffel, J. 74, 76, 78, 411, 413
Spencer, S. 262 Stahrenberg, R. P5311 Steffens, D. P1463, P3575
Spengos, K. 268 Stalikas, D. P2744 Steffens, S. 35
Spengos, K. P5607, P5627 Stalinska, K. 1833 Steffens, S. P429
Sperling, L. 322 Stallmann, D. P6339 Steffensen, F.H. P5017, P5359
Sperling, L. 271, 273, 2960, 2961, P5984 Stallmeyer, B. P1400 Steffensen, R. P593
Sperzel, J. P3364, P4367, P5928 Stamboul, K. P799, P3080 Steg, G. P173, 2103, 3032, P3717
Spezzacatene, A. P1375, P1393 Stamenkovic, B. 5084 Steg, P.G. 44, 80, 354
Spieker, M. 5899 Stammet, P. P421, P1408 Steg, P.G. P172, 403, P582, 1270, 1272,
Spiess, N. P5282, P5283 Stampanoni, M.F.M. P185, P186 P1497, P1505, 1930, 2862, 3030, 3154,
Spiesshoefer, J. P498, P6289 Stanciu, S. P6447 P3317, P3318, 4002, 4003, 4975, P4992,
Spikowski, L.S. P3361 Standl, E. 2958, 2959 P5375, 5747, 5748, 5752, 5753, 5813
Spillmann, F. P3127, P4544 Stanescu, C.M. P1784 Stegemann, B. P6503
Spin, J.M. P2604 Stang, A. 2104 Stegemann, E. P6503
Spinar, J. P880, P1682, P3491, P4768, 6645 Stangl, V. P5439 Steger, A. P4638
Spinarova, L. P6310, 6645 Stanisavljevic, D. P5536, P5538 Stehli, J. P6414
Spinarova, M. P6310 Stanisz-Kempa, J. P4641 Stehouwer, C.D. P4615
Spinetti, G. P2573 Stankovic, G. P446, P580, P816, P827, Steidl, A. P459
Spirito, P. 4032, 4036 P830, P1716, P2484, P2518, P2567, Steigen, T. P5024
Spiroski, I. P2531 P3715, P4433 Steigen, T.K. 21
Spitzer, E. 1201, 6020, P6135 Stankovic, S. P528 Stein, E. 2902
Spitzer, S.G. P3426, P4343, P4345 Stankovic Stojanovic, K. P5654 Stein, E.A. P5968
Sponder, M. P2677 Stanojevic, D. P5667 Stein, S. P3095
Sponholz, C. P3107 Stansbourough, J. P6565 Steinbeck, G. 24
Sprada, B. P6114 Stanske, B. 5899 Steinbeck, G. P5316
Spratt, J. P4701 Stanton, A. P6433 Steinbeck, L. P2786, P5695
Spriersterbach, H. P3577 Stanzl, U. P1556 Steinberg, J.S. P3384
Spriet, I. P1541 Starace, A.S. P6570 Steinborn, F. P4391
Sprigings, D. P4090 Starling, I. P3479 Steinbruchel, D. P3496
Springall, M. P1601 Starling, R.C. P5031 Steiner, S. 4971
Starobinska, E.I. P1381
504
Chairpersons & Judges / Speakers & Discussants / Authors Ste – Suk
Steingen, C. 5717 Stojakovic, T. P5319 Stuck, A.E. 965

Steinhubl, S. P627 Stojanovich, L. P5535 Stuckey, T. P3342
Steinke, E. P3655 Stojkovic, S. 321 Stuckey, T.D. P4326
Steinmetz, M. P664 Stojkovic, S. P1716, P3682, 4292, P5415 Stueflotten, W. P2621, P3589
Steinsiek, A.L. P3405 Stokke, M.K. P416 Stuetz, B. P662
Steinvil, A. P3584, 5789 Stoklosa, T. 4868 Stugaard, M. 3169
Stella, P.R. P531 Stolfo, D. P522, P686, P691, P1621, 5787 Stuijfzand, W. 368
Stella, S. P5491, P5659 Stoller, M. P1709, P1723 Stuijfzand, W.J. P180
Stella, S.F. P6220 Stone, G.W. 1029, 1031, 1170, P1497, Stumpf, T. 1952
Stellin, G. P706 4000, 4002, P4326, P4328, P4695, P4992, Stundl, A. P2631, P4573
Stellos, K. 2342 P5375, 5999 Sturiale, C. P1560
Stender, S. 3210 Stone, P.H. 6621 Su, J. P5954
Stengaard, C. P4436 Stopczynska, I. P3475 Su, W.J. 1855
Stepanova, L.A. P6593 Storey, R. 3032 Su, Y.G. P483
Stepanova, R. P6310 Storey, R.F. 22, 152 Suades, R. P1128
Stepanova, V. P5339 Storey, R.F. 404, P556, P1472, P1497, Suades Soler, R. 4882
Stepanovic, J. P2567, 4292, 5105 P3317, P3318, 4127, 4880, 4975, 5873, Suarez De Lezo, J. P797, P3704, P3730,
Stephen Fry, S.E.F. P2577 5874 P4576, P6490
Stepien, E. P638 Storozhakov, G. P3798 Suarez De Lezo, J.S.L. P2442
Stepinska, J. 192 Storsten, P. P4754 Suarez De Lezo Cruz Conde, J. P1109,
Stepinska, J. 3031, P3724 Stortecky, S. 6020 P2114, P4676
Stepnowska, M. P5651 Storti, S. P4478 Suarez De Lezo Cruz-Conde, J. 365,
Steptoe, A. 3222 Storti, S.S. P4598 P2758, P2763, P3694, P3704
Stergiopulos, N. P185, P186 Stowasser, M. 2258, 2259, 2261 Suarez De Lezo Herreros De Tejada, J.
Stergiouli, I. P4418 Strachan, F. P3432, P4461 365, P2758, P2763, P3694, P3730, P4676
Steriotis, A.K. 2967 Strack, C. 2230 Suarez De Lezo Herreros De Tejada, J.R.
Sterlinski, M. P2441 Straessler, E. 1954 P2114
Stern, S. P1453 Straka, Z. P4364, P4395 Suarez De Lezo Jr, J. P797
Sterns, L.D. P4297, P5927 Strametz-Juranek, J.S.J. P2677 Suberbielle, C. P3554
Sterz, F. P3454 Strand, E. P4657 Subirana Domenech, M.T. P3612
Stetina, R. P3446 Strand, M.E. P6341 Subota, V. P5536, P5538
Steurer, G. P3744 Strand, S. P2581 Subotic, B. P6409
Steven, D. P3393 Stranecky, V. P5499 Suda, M. P3327, P4314, P4535, P4537,
Steven, S. P667, P2581, P3084 Strange, J. P4420, P5226 P4733
Stevenhagen, Y.J. P4394, P4396 Strasberg, B. P5013 Suda, S. P2799
Stevens, M.M. P3545 Strasser, R.H. P662, P678, 1323, 1989, Sudano, I. P1812
Stevens, R.J. P4620 P3570, P4494, 4973 Sudo, M. P6225
Stevens, S.R. 4979 Stratz, C. P809, P1493, 5792 Sudo, Y. P420
Stevenson, L.W. P5976 Straub, S. P3097 Sudre, A. P3580
Stevlik, J. 1979 Strauss, M. P469 Suematsu, M. P5466
Stevove, M. 1979 Strauss, S. P3487 Suematsu, Y. P3749, P3754
Stewart, D. P5519 Stravopodis, P. P4418, P4430, P4450 Sueta, D. P6152
Stewart, M.J. P615 Strazhesko, I. 1837 Suganami, H. P5982, P5985
Stewart, R. 1849, 6025 Streckfuss-Boemeke, K. P3552 Sugano, A. P3498
Stewart, R.A.H. 4203, P4323, P5961, Streib, L. P6268 Sugano, T.S. P2509
P6228, P6290, P6439 Strelnieks, A. P2347 Sugano, Y. P881, P883, 3305, P4761,
Stewart, S. 991, 1950 Strelnikov, A. P3370 P4763, P6536, P6541, P6545
Sticchi, A. P2761 Stricker, B.H. P1391 Sugawara, H. P2350
Sticherling, C. P166, P479 Stridsberg, M. P451, 6043 Sugawara, Y. P5656
Sticozzi, C. P2619 Stringa, N. P2594 Sugi, K. P3499, P3764, P4409, P6296
Stienen, S. P3350 Stringuetta-Belik, F. P2704 Sugi, M. P6117
Stiermaier, T.H. P2387 Strisciuglio, T. P1468, P4715 Sugihara, S. P2706
Stiermaier, T.S. P5495 Stroecker, C. P664 Sugimachi, M. P480, P487, P2448, P4756,
Stiller, B. P1429 Stroes, E. 354, 371 P4784, P5453
Stimpfle, F. P1484 Stroes, E. 1224, 1225, 1226, P1677, P1756, Sugimura, K. P5958
Stirrat, C. P2127 5743, 5746, P5968 Sugito, Y. P2803
Stirrup, J.E. 128 Strohm, H. P5625 Sugiura, A. 5211
Stirtan, W.G. P1679 Strohmaier, S. 966 Sugiura, E. P4114
Stivala, S. P1115, P5007 Strojek, M. P5280, P5332 Sugiura, T. P202, P897, P1619, P3111, 4898,
Stockburger, M. P4070, 5917 Stromberg, A. 33, 213, 322 P5315
Stocker, E.M. P4737 Stromberg, A. P443, 1231, P1548, P1665 Sugiura, Y. P5466
Stockman, B. P1729, P2614 Stromberg, K. P2426 Sugiyama, H. P5238
Stockman, D. P3408 Stroobandt, R. P492 Sugiyama, K. P4552
Stoeckigt, F. P1417, P5951, P6345 Stroux, A. 3069 Sugiyama, T. P1735, P1753, P2700, P4514,
Stoeckl, G. P1367 Strucksberg, K.H. 3066 6618
Stoehr, R. P645, P646, P2362 Struijk, J.J. P1546 Sugiyama- Kato, T. 2210
Stoellberger, C. 6613 Strunk, G. 4278 Suh, S.J. P1475, P5971
Stoerk, S. P694, P1367, P1669, P2639, Strunz, C.M.C. P6449, P6471 Suh, S.Y. P784
P3569, P3599, P4767, P6149 Struthers, A.D. P6552 Suhai, F. P614, P4099
Stoickov, M. P2713, P4423 Stuart, B. P1118, 5814 Suigenbayev, D.Z.H. P5665
Stoickov, V. P2713, P3661, P4423 Stuber, M. P861, 1841 Sukhinina, T.S. 2100
505
Chairpersons & Judges / Speakers & Discussants / Authors Suk – Tag
Sukhramwala, R. P6134 Suzuki, A. P1637, P1694 Szabo, L. P1144, P1457, 2284, P2667,
Sukmawan, R. P558 Suzuki, C. P4604 P2678, P4536
Sulaiman, K. P5689, P6561 Suzuki, H. P4336, P6281, P6300 Szabo, Z. P2162
Suleiman, I. 4912 Suzuki, J. P4354, P4507 Szczerba, E. P3671
Suleiman, M. P4381 Suzuki, K. P1737, P4466, P6125 Szczubialka, K. P1451, 1833
Sulemane, S. P5420 Suzuki, K.S. P1137 Sze, S. 2231, P2801, P4489
Suleymanoglu, M. P4577, 5210 Suzuki, M. P1798, P2483, P3499, P3784, Szegedi, N. P2399, P3075
Sulimov, A.V. P5706 P4611, P6238, P6296 Szelenyi, Z.S. P1795
Sulimov, V. P4637 Suzuki, N. P2533, P2746, 4290, P6522 Szeplaki, G. P499, P509, P2396, P2399,
Sullivan, D. P1756, P5968 Suzuki, S. P788, P5333, P6300, P6502 P3075, P4097, 4856
Sullivan, T. P4374 Suzuki, T. P1637, P2814, P3700, P3708, Szepligeti, S. 1842
Sultan, A. P3393 P3722, P4552, P4608, P5629, P6218, Szilagyi, S.Z. P499, P509, P2399, P3075,
Sultana, S.N. 2343 P6282 4856
Suman-Horduna, I. P3366 Suzuki, Y. P3700 Szili-Torok, T. P479
Sumian, M. P1611 Svardsudd, K. 2966 Szilveszter, B. 2105, P3709, P4496
Sumikura, H. P6488 Svedberg, L. P4344 Szkodzinski, J. P699
Sumitomo, N. 1327 Svedlund, S. P1152, 4295, P6239 Szkutnik, M. P3729
Sumiyoshi, A. P1739, P2775 Svendsen, J.H. 353 Szoelloesi, G.A. P4391
Sumiyoshi, M. 5087 Svendsen, J.H. P460, 4959, 5739, 6076 Szostek, K. P6417
Sumiyoshi, T. P3334 Svendsen, J.H.S. 2938 Szpakowicz, A. P4731, P4735
Sun, A. 1215, 5903 Svendsen, M.T. P3641 Szpakowski, E. P3540
Sun, B. P5974 Svensson, A. P460, 4959 Sztaniszlav, A. 5915
Sun, C. P1428 Svensson, A.M. P1730, P3343 Szuba, A. P222
Sun, J. P5229, P5388 Svensson, L. 4820 Szummer, K. P2460, P4304, 6637
Sun, J.P. P2612 Svenungsson, E. P6424 Szumowski, L. 366
Sun, L. P697, P1648 Sveric, K.M. P678, P3570 Szumowski, L. P471
Sun, M.M. P2833 Svezia, B. P877, P2382 Szwed, H. P547, P2441, P2525, P2697,
Sun, M.T. P4374 Svingen, G.F.T. P1656, P4657 P5291, P5404, P5537
Sun, Q. P653, P3378 Sviridenko, V. P3347 Szymanska, A. P5332
Sun, S. P168 Svobodova, D. P1797 Szymanski, F.M. P5270, P5280, P5300,
Sun, X. P1562 Swahn, E. 124 P5332
Sun, Y. P2793, P4370, P4407, P5470 Swahn, E. P551, P552 Szymanski, J. P575, P2385
Suna, J. P3349 Swaminathan, R. 1197 Szymanski, P. P5011
Sunaga, A. P2404, P4498, P5326 Swan, H. P1649 Szymanski, R. 160
Sunagawa, K. 1083 Swan, L. 254 Szymczyk, E. P856, P2566, P4448
Sunbul, E.A. P1688 Swan, L. 144, P723, 4040, P6413, P6417 Szymczyk, K. P2566
Sunbul, M. P1688 Swanson, J. P3503 Szymkiewicz, F.S.J. 1323
Sunderkamp, C. P1104 Swedberg, K. 96, 370 Szyszka, A. P5436
Sunderland, T. P4401 Swedberg, K. P213, P214, 1977, 3301, Tabaraie, T. P2600
Sundstrom, J. P2460, P5306 3302, P5031, 5058, P6555 Tabata, N. P811
Sung, K.C. P2145 Sweeney, M. P1585 Tabbalat, R.A. P5325
Sung, K.T. P888, 2227, P3534, P5432, Sweeney, R. P2805 Tabord, A. P628, P1706
P6294 Swenne, C.A. P696 Taborsky, M. 312, 320
Sung, P.H. P1762, P3564 Swerdlow, D.I. P1702 Taborsky, M. P540, P1095, P4351
Sung, S.-H. P5707 Swiatkowski, A. P5303 Tacchi, C. P5543
Sung, S.H. P219, P4759, P5570, 6045, Swim, M. P3559 Tachibana, A. P2124
P6576 Swinnen, M. 4151, P6260 Tachibana, E. P1383, P3482
Sung, S.S. 5075 Swoboda, P.P. P4096 Tachibana, M. P4483, P4486, P4495, P4503
Suppo, S. P5543 Sy, R. P1684 Tachibana, T. 2107
Surakka, I. P2346 Sychenko, Y.O. P3779 Tacke, F. P4540
Suran, M.C.B. P635 Sydo, N. P614, P4099, P4557 Tada, H. P693, P1655, P1661, P1699, P1701,
Surdo, N.C. 2242 Syeda, F. P1416, P5949, P6352, P6357 P1704, P2150, P3400, P3422
Suri, R.M. 3049 Sykora, J. P1588 Tada, T. P1504, P2738, P2739, P2748,
Surkova, E.A. P2163 Symeonidis, D. P4432 P2774, P3345, P3705, P3713, P5402,
Suryapranata, H. P559, P1476, P1480, Synetos, A. P785, P1141, P2388, P3115, P6278, P6520, P6525, P6532
P1501, P2117, P3119, P4453, P5542 P3501, P3582, P3590, P4106, P4751, Tadaki, S. P6539, P6544
Susana, A. P1528 P5464, P5607, P5627 Taddei, A. P4414
Susen, S. P6507 Syrkin, A. P3347 Taddei, C. P1366
Susini, C. P4478, P6425 Syrkin, A.L. 6042 Taddei, S. 153
Suter, T.M. 262, 325 Syrris, P. P1624, P1632, P2641 Taddei, S. P725, P4539, P5576
Sutherland, G.R. 2216 Syrseloudis, D. 2232, 4874 Tadic, M. P4778
Sutherland, J. P1761 Syska, P. P2441, P5291 Tadokoro, H. P3748
Sutton, M. 989 Syska-Suminska, J. P5280, P5332 Taeib, J. 104
Sutton, R. 1328, 3978 Sysuenkova, E. P1436, P1800 Tafer, N. P3740
Suvan, J. P658 Szabados, S. P5680 Tafflet, M. P534, P1613
Suvisaari, J. P528 Szabo, B. P3348 Tafti, H.A. P2431
Suwa, S. 5087 Szabo, G. P4536 Tagarakis, G.I. P2152
Suwalski, P. 196 Szabo, G.T. P3468 Taggart, M.J. P2810
Suwannasom, P. 369, P2730 Szabo, G.Y. P3709 Taggart, P. 268
Suzjuki, H. 1327 Szabo, K. 4243 Taggart, P. P415, P1432
Suzuka, Y. 2107
506
Chairpersons & Judges / Speakers & Discussants / Authors Tag – Tar
Taghavi Azar Sharabiani, M. P2155 Takata, Y. P759 Tan, W.A. P689

Taghji, P. P3387 Takata, Y.T. P754 Tan, Y.T. P4757, P5699
Taglieri, C. 2935, P6483 Takatsuki, S. P3419, P4361 Tanabe, J. P513
Taguchi, E.T. 5081 Takaya, T. P1363 Tanabe, K. P3341, P6232
Taguchi, H. P5564 Takaya, Y. P3607, P4503, P6549 Tanabe, N. P4501
Taha, S. P1748 Takayama, M. P688, P1383, P1633, P2483, Tanabe, S. P1570
Tahara, S. 4286 P5488 Tanabe, Y. P5372
Tahara, Y. 6628 Takayama, S. P202, P3111, P5315 Tanaga, K. P6531
Tahin, T. P499, P509, P3075 Takayama, T. P6225 Tanaka, A. P583, P1728, P1736, 3945,
Tahirovic, E. P5663, P5667, P5690 Takayama, Y. P788, P5333 P6201, P6502, 6623
Tahk, S.J. P1721, P2755 Takeda, N. P5003 Tanaka, F. P1651, P2148
Tai, B.C. 2942 Takei, M. P5503 Tanaka, H. P1504, P1514, 2337, P2483,
Taibo, M. P2554 Takeishi, Y. P3330, P6300 P2738, P2739, P2748, P2774, P3345,
Tajes, H. P3332 Takeki, M. P5939 P3688, P3713, P5402, P5527, P5533,
Tajes, M. P3077 Takemoto, R. P3529, P6304 P5691, P6128, P6143, P6278, P6281,
Tajikawa, T. P5599, P6488 Takenaka, M. P1744 P6311, P6520, P6525, P6532
Tajiri, K. P3083, P5528 Takeshima, T. P220 Tanaka, K. P431, P1651, P3407, P4707
Tajstra, M. P541, P576, P585, P587, P2506, Takeshita, K. P2650, P2684 Tanaka, K.T. P4329
P2789, P5646 Takeshita, M. 2228, P5380 Tanaka, M. P1582, P4112
Tajstra, T. P6587 Takeshita, S. P876, P2475, P4451 Tanaka, N. P184, P3407, P5939, 6655
Takacs, P. P1794, P1795, P6122 Takeuchi, I. P5593 Tanaka, R. P2540, P2830, P4779, P5428,
Takada, J.Y. P6449, P6471 Takeuchi, M. P4677 P6363
Takada, K. P6318 Takewa, Y. P6488 Tanaka, S. P1567, P2672, P2696, P2719,
Takagawa, J. P5025 Takeyasu, N. P4402 P5545, P6319
Takagi, D. P1357, P3690, P4611, P5602, Takimura, H. P4718, P6145 Tanaka, T. P202, P417, P811, P1339, P2353,
P6248 Takizawa, T. P1570 P3111, 3169, P5315, P6488
Takagi, K.T. P6286 Takombe, J.L. P3135 Tanaka, Y. P1420, P6319
Takagi, M. P5925 Talavera, J. P862 Tanboga, I.H. P838, P1741, P3695, P5594
Takagi, S. P3123 Talavera, P. P1394 Tanck, M.W. 3070
Takagi, Y. P1130 Talha, S. P5409 Tande, P.M. 3196, 3197, 3198
Takahara, M. P1135, P5413, P5944 Talib, A. P2449 Tandurella, N. P3802, P5712
Takahara, M.T. P1137 Talsma, J. P5548 Tang, A. 4857
Takahashi, A. P1735, P1753, P4514, 6618 Tam, J.W. 4194 Tang, F.C. P5554
Takahashi, F. P6473 Tam, L.S. P5424 Tang, H. P4348
Takahashi, H. P726, P851, P1363, P1660, Tamada, M. 338 Tang, H.C. P689
P2353, P2409, P3533, P3710, P3753, Tamaki, K. P5307 Tang, J. P6423
P4109, P5966, 6086, P6281, P6494 Tamaki, N. P1583 Tang, M. P470
Takahashi, J. P790, P1707, P6117 Tamaki, S. P1378, P4760, P6558 Tang, R.-B. P5266, P5274
Takahashi, J.C. P5599 Tamaki, Y. P1607 Tang, X.F. P1467, P3697
Takahashi, K. 338 Tamakoshi, A. P2686 Tang, X.R. P4407
Takahashi, L. P5443 Tamarappoo, B. P5425 Tang, Y. P2793
Takahashi, M. P1437, 3306 Tamargo, J. P5945 Tangalay, M. P5480
Takahashi, N. P629, P2415, P4112 Tamargo, J.L. 24 Tanganelli, V. P5251
Takahashi, O. P815 Tamargo, J.L. P454, 3930 Tange, S. P1420
Takahashi, S. P2148, P3529, P3675, P5039, Tamaru, H. P1739, P2775 Tanglay, Y. P4612
P5975, P6319 Tamaru, H.T. P1712 Tani, S. P1127, P1383
Takahashi, T. P536, P3551, 4189, P4766, Tamayo, S. P4066 Tanigawa, T. 6634
P5029 Tamburino, C. 196 Taniguchi, H. P1134, P3777
Takahashi, Y. 338, P3110, P3670, P5323 Tamburino, C. 2092, P2768, P3592, P6372, Taniguchi, T. P5692, P6381
Takai, F. P3549 P6375, P6390 Taniguchi, Y. P4551
Takai, M. P2694 Tamekiyo, M. P4506 Tanik, V.O. P5275
Takaki, H. P480, P487, P2368, P2448 Tamim, H. P5979 Tanimoto, K. P4361
Takama, N. P2803, P5973 Tamimi, O. P4069 Tanimoto, Y. P3419
Takami, H. P1718 Tamion, F. P1112 Tanimura, M. P4114
Takamura, M. P6183 Tamita, K. P3089 Tanioka, K. P1619, P4592
Takamura, T. P6232 Tammadoni, A. P2828 Taniwaki, M. P1553, P5026
Takanashi, S. P3334, P5488 Tamosiunas, A. P3627 Tanjararak, P. P458
Takano, H. P1737, P3748 Tamura, A. P629 Tanner, F.C. P1614, P4590, 6019, P6414
Takano, M. P6125 Tamura, H. P3675, P3721, P4477, P5381 Tanno, K. P2148
Takano, S. P6232 Tamura, T. P1607, P2664 Tanno, M. 1086, P2350, P5288
Takano, T. P5327 Tamuta, T. P1515 Tanouchi, J. P2503, P6201
Takaoka, H. P3528, P4501, 5211, P5413, Tan, B.Y. P3413 Tanter, M. P3574
P5944 Tan, H. 4216 Tanzilli, G. P6190
Takaoka, J. P1727, P1731 Tan, H.C. 324 Tao, L. P2712
Takasaki, A.T. P828 Tan, H.C. 5165, P5644, P5648 Tapia-Conyer, R. P6592
Takase, H. P202, P897, P3111, 4898, P5315 Tan, H.L. P1427 Tar, B. P5023
Takashima, S. P6183 Tan, L.W. P5441 Tarantini, G. P2617, 5786, P6372
Takasugi, M. P2451 Tan, M.C. P831 Tarantini, L. P4399, P5297, P5683, P6147,
Takasugi, N. P2451 Tan, R.S. P1763, P4747, P5411, P5974 P6575
Takata, H. P5692 Tan, S. P3088 Tarasco, E. P1575
Takata, K. 2059, P4655 Tan, T.C. P5412 Tarcza, Z.S. P1794
507
Chairpersons & Judges / Speakers & Discussants / Authors Tar – Thi
Tardif, J.-C. 4788 Teerlink, J.R. P891, 3059, 3061, 3063, 6037, Terentes-Printzios, D. P204, 967, P1572,
Tardif, J.C. P1561, P4520 6638 P2574, P2699, P3679, P3806, P4118,
Targonska, S. P2440, 5145 Tefft, B.J. P2375 P4668, P5540, P5541, P5588, P5710,
Tarhbalouti, R.T. P5343 Tefik, N. P2514 P6598
Tarifa, C. P1425 Tegtmeier, C. P6503 Tereschenko, S. P879
Tarka, E. P5961 Teh, A.W. P4302 Tereschenko, S.N. P4593
Tarkin, J. 4932 Teiger, E. 196 Terkelsen, C.J. P822, P4436
Tarnoki, A.D. 2234, P4630, P6401 Teiger, E. P3516 Ternacle, J. P2360, P3516, P5423, P5557
Tarnoki, D.L. 2234, P4630, P6401 Teixeira, R. P209, P4062 Terracciano, C. M.N. P4519
Tarnowska, A. P4721 Teixeira, T. P4350, P4380 Terracciano, C. 151
Tarro Genta, F. 2935 Teixido, G. P3096, P5407, P5408 Terracciano, C.M. P1418
Tartaglione, D. P5365 Tejedor, A. P2410 Terrar, D. P6358
Tartaro, A. P2716 Tejedor, P. P2757 Terrazzino, P. P6571
Tartuferi, L. P871, 4149 Tejeida, S. P4527 Terricabras, M. P5407, P5408
Tarui, S. P435, 4058 Tejelbenet, C. P850 Terrizzi, A. P634
Tarun, A. P5416 Tekieli, L. P5616, P5619, P5622 Tershakovec, A.J. 68
Tarusi, M. 6035 Tekkesin, A.I. P5275 Tershakovec, A.M. P1131, P6120
Taruya, A. P1728, P1736, 6623 Teles, L. P1626, P1627, P3473, P5346, Tershakovec, A.M.T. P6466
Tarvasmaki, T. P3491 P6393, P6400 Teruel, L. P761
Tas, S. P6325 Teles, R. P3586 Tervahartiala, T. P3429, P3478, P6243,
Tas, S.W. P6129 Teles, R.T. P829, 1200 P6264
Tasbakan, M.S. P2795 Telishevska, M. P4365 Terzi, A. P1688
Tasevska, I. P5385 Telishveska, M.T. P5295 Terzian, Z. P6391
Tashiro, M. P4336 Tello De Meneses, R. P3486 Terzic, A. 4970
Tasic, I. 5084, P6441 Temirsultanova, T.H. P3766 Terzis, G. P2689, P4312
Taskin, A. P3466 Temizhan, A. P1459, P1764, P2490, P3746, Terzopoulos, D. P623
Taskinen, M.-R. 4889, P6427 P3760, P3776, P4561, P4562, P5649, Teschler, H. 358, P3128
Tatami, Y. P788, P5333 P6139, P6406 Teshima, Y. P2415
Tatari, S. P5979 Temple, I. P6354 Tesic, M. P609, P816, P1716, P2484, P2567,
Tatarinova, T. P211, 3051, P6420 Templin, C. P1449, P2791, P4092, P6550 4292, P4433, P5415
Tatarsky, B. P3363 Temporelli, P.L. P4769, 5805, P6542, P6567 Teske, A.J. 5809
Tate, N. 1971, P6211 Ten Berg, J. 5813 Tesorio, T. P2630
Tatebe, S. P4336, P5958 Ten Berg, J.M. 326, P556, 914, P1500, Tespili, M. P2151, 6021
Tateishi, E. P1527 P1505, 1857, P4071, P4992, 6607 Tessonnier, L. P1611, P6383
Tateishi, K. P4466 Ten Berg, M. P6253 Testa, L. P3592, P6375
Tateno, S. 1327 Ten Cate, H. P6206 Teunissen, P.F. P426, P553, P2497, P2512
Tatlisumak, T. P2346 Ten Freyhaus, H. P1104, P3622 Teutsch, C. P1488
Tatsumi, E. P6488 Ten Haaf, M.E. P1746 Teuwen, C. P5314
Tatsumi, F. P3670 Ten Harkel, A.D.J. P632, P1551 Teuwen, C.P. P715
Tatsumi, K. P4501 ten Hoedt, R. 3921 Tezgah, E. 2104
Tatu, A.M. P873 Ten Sande, J.N. P1427, P4594 Thabet, S. P4708
Tatu-Chitoiu, G.P. 2961, 2963 Tendera, M. 268 Thakkar, A. P4711, P4717
Tauboll, E. 1325 Tendera, M. P2837, 5070 Thakkar, K. P4711, P4717
Tauchi, N. 1327 Tendl, K.A. P3454 Thambo, J.B. P3740, P4504
Tautu, O. P225, P5943 Tengiz, I. 2236 Thamilarasan, M. P1119
Tavares Aguiar, M.T. 302 Tennakoon, L. 360 Than, M. 127, P4610
Tavares Aguiar, M.T. 3883 Tenorio, J. P4550, P5957 Thangjam, R. P6134
Tavares-Silva, M. P5679 Tentolouris, N. P740 Thapa, J. 6616
Tavazzi, L. P4619 Tentzeris, I. P572 The, S.H.K. P1423
Tavernier, R. P3387, P5302 Teo, K. P6596 Thebaut, J.F. P3663
Tavi, P. P5946 Teo, W.S. P3413 Theil Have, C. P1433
Tavil, Y. P4534 Teodorovich, N. P6258 Theilade, J. P2456
Tay, E. P6124 Teoh, X. P570 Theis, C. 245, P468, P3359
Tay, H.Y. 2942 Tepekoylu, C. P2596 Theiss, H. P607
Tayal, B. P5221 Teplenin, A.S. P6177 Themistoclakis, S. 312
Tayal, U. 3072 Tepper, P. 1975 Theocharis, P. P4597
Tayeh, O. P5673 Ter Bekke, R.M.A. P3497 Theodorakis, G. P170
Taylor, A. P2637 Ter Maaten, J.M. P891 Theodorou, K. P665, P6129
Taylor, A.M. P5451 Terada, K. P2446 Theres, H. P562, P4070
Taylor, B. 6653 Teragawa, H. P6285 Theuns, D.A. P4299
Taylor, C.M. 156, P6241 Teragawa, H.T. P5041 Theuns, D.A.M.J. P479, P1388
Taylor, D. P1348 Teramoto, R. P693, P698 Theurl, M. P1556
Taylor, K.D. P1653 Teramoto, T. P3700 Thiagalingam, A. P3734
Taylor, R.S. 2007, 2008, P3654 Terashima, M. P3708, P3722, P4608, P4674, Thibault, H. 2197
Tazi, N.T. P5343 P6282 Thiebaut, P.A. P1112
Tchabi, Y. P3134 Terashima, S. P3110 Thiel, S. P6252
Te Rijdt, W.P. P4594 Terashita, D. P1363 Thiele, H. 79
Tearney, G.J. 6621 Tercedor, L. P3371 Thiele, H. 1020, P1462, 1967, 2304, 2306,
Teberino, M.A. P1348 Tercedor Sanchez, L. P1410 P2480, 3059, 3061, 3063, P3092, P3494,
Tebloev, K. P3761 Terekhin, S. P3684 4060, 5090
Thiele, H.T. P3094, P5495
508
Chairpersons & Judges / Speakers & Discussants / Authors Thi – Tor
Thielman, M. 4268 Timar, R. P1355 Tokmaji, G. 3050

Thielsen, T. P682, P685, P4563, P4564 Timasheva, Y. P5264 Tokodi, M. P1794, P1795
Thiem, U. 6636 Timbol, E.W. 3948, P5605 Tokuda, H. 4180
Thiene, G. 212 Timerman, S. 24 Tokuda, T. P2733, P3089, P6519
Thiene, G. P690, P1788, P6166 Timm, M. P5231 Tokunaga, C. 6105
Thienemann, F. P2651 Timmer, J.R. P624, P633 Tokura, M. 6629
Thijs, L. 5078 Timmer, S.A.J. P426 Tokutsu, T. 6632
Thilen, M. P3611 Timmermans, F. P492 Tolbod, L.P. P4743
Thilen, U. P2655, P3611 Timmermans, J. P695, 3071 Toldo, S. 3206
Thim, T. P1336, P1337, P1464, P1498, Timmers, L. P531, P5469 Toli, E. P2154
P1503, P5351 Timmis, A. P777 Tolonen, J. P880, P4768
Thiru, S. P6247 Timmis, A.D. P1102, 4261, P4994 Tolosana, J.M. P472, P1434
Thiruthalil, S. P776 Timoteo, A. P4434 Tolppanen, H.E.V. P3491
Thode, J. P593 Timoteo, A.T. P867, P2473, P2489, P2502, Tolsma, R. P4071
Thollet, A. P485 P2510 Tolsma, R.T. 1857
Thom, S. P6433 Tin, L. P5379 Toma, C. P5943
Thomas, C. P2690 Tinahones, F.J. 6028 Tomaru, T. 315
Thomas, D. 3902, 3903, P5947 Ting, C.T. P5570 Tomaru, T. P6458
Thomas, F.T. P1658 Ting, Q.P. P1145 Tomaschitz, A. 6644
Thomas, G.N. 3209 Tinker, A. P1415 Tomasevic, M.V. 43
Thomas, L. P2516, 5804, P6155 Tintoiu, I. P6447 Tomasi, C. P504
Thomas, M.R. P3318 Tippaporn, B. P1417 Tomasi, L. 5146
Thomas, S. P3734, P5000 Tirado, G. P1470, P2119, 2318, P3106, Tomasik, T. P6481
Thomas, S.P. P4352 P5243 Tomaszewska-Kiecana, M. P5332
Thomassen, A.L.L. P3333 Tiroch, K. P575, P2385, P3705 Tomaszewski, A. P2438
Thomet, C. 2929, P6454 Tisserand, A. P4599 Tomaszewski, M. 33
Thomopoulos, C. P2844 Tissier, R. 4943 Tomaszewski, M. P6481
Thomopoulou, S. P5476 Tissing, W.J.E. P5035 Tomaszuk-Kazberuk, A. P5293
Thompson, D. P5980, P6427 Tissot, C.M. P5473 Tomcsanyi, J. P4688
Thompson, D.M. P6433 Titaeva, E.V. P456 Tome, M. P1628
Thompson, D.R. P6456 Titov, I. P5708 Tome-Esteban, M. 6609
Thompson, E. P2724 Tiyerili, V. P663, 1216 Tomei, M. P5289
Thompson, V.S. P210 Tizon Marcos, H. P6492 Tomita, S. P3754, P6363
Thomsen, A. P6399 Tjeerdsma, G. P1423 Tomiyama, H. P1821
Thomsen, C. P622 Tjessem, K.H. P1791 Tomkiewicz-Pajak, L. P436, P720, P1641,
Thomsen, J.H. 155 Tjong, F.V.Y. P2426 P5612
Thomson, H. P4617 Tkacheva, O. 1837 Tomlins, H. P2571
Thon-Gutschi, E. P5319 Tkaczyszyn, M. P3758 Tomoi, Y. P1136, P6505
Thongprayoon, C. 2211, P3324, 5093, 5806 To, A.H.M. P719 Tomomatsu, T. P2446
Thorne, S. 347, P712 Toba, K. P3800, P5969 Tomonaga, T. P5460
Thorne, S.A. P3613 Tobar, J. P5647, 6022 Tomson, J. P4613
Thourani, V. P1604 Tobaru, T. P5488 Tondi, L. P6245
Thum, T. P530, 3957, P4082, 5906 Tobin, C. 6084 Tondo, C. P3382, P3399, P3403, P3411,
Thune, J.J. P2456 Tobisawa, T. 1086, P2350 P3427, P4346, P4389, 5858, 5859, P6115,
Thuresson, M. P2467, P3662, 4972 Tobler, D. 143, 2927 P6316
Thurston, S. P1146 Tocchetti, C.G. P3328 Tonello, C. P5609
Thygesen, K. 314, 324 Toda, H. P3780, P4660 Tonet, E. P522
Thygesen, K. 4020, P4431, P4618, P5713 Toda, K. P1793, P2610 Tongers, J. P3455
Thygesen, L.C. 2939, P3654 Toda, M. P1482, P4512 Tonino, P. 6620
Thyregod, H.G.H. P3496 Todarello, O. P6437 Tonkin, A.M. P4323
Tian, H. P903 Todaro, M.C. P3521 Tontodonati, M. P4628
Tiano, L.T. P2705 Todd, J. P889, P4663, P6569 Toole, R.S. P2536
Tibazarwa, K. P2651 Todd, M. P4105 Topaloglu, S. P1459, P1460, P2118, P2490,
Tiburtius, C. P5485 Todic, B. P5535 P3699, P4533, P4562, P5271, P5649,
Ticali, P.F. P2532 Todica, A. P607 P6274, P6406
Tideman, P. P3630 Todiere, G. P5956, 6044 Topcu, S. P838, P1741, P3695, P5594
Tidu, M. 2935 Toender, N. P5700 Topilsky, Y. 5789
Tigas, S. P765 Toft, E. P1546 Toplisek, J. P3421
Tigchelaar, W. P6346 Toger, J. P4755 Toprak, C. P4319
Tighe, M. P4489 Togni, M. P2378 Tops, L.F. P3794, P6513
Tijssen, J. P3350 Tohoku, S. P6505 Torbas, O. P3805
Tijssen, J.G. P1101 Tohyama, S. P4674, P4677 Torbica, A. P464
Tijssen, J.G.P. P174, 364 Toia, P. P6548 Torbicki, A. 325
Tikkanen, J.T. P1376 Tojo, T. P655 Torbicki, A. 2296, 3038, 3040, 3911, 4181,
Tilea, I.A. P5508 Tokgoz, H.C. P5517 4825
Tilemanbetova, K. P193 Tokgozoglu, L. 124, 250, 263, 306 Torella, D. P3560, P3561, P3563, P5457
Tilemann, L. P3537 Tokgozoglu, L. 1839, P4379, P6188 Torguson, R. P670, P1599, P3593, P4583,
Tillin, T. 1849, P2709 Toki, H. P6311 P6379
Tilsed Hansen, H. P5978 Tokimasa, S. P3636 Torigoe, K. P629
Tilsted, H.H. 4001 Tokioka, K. P4495 Torlasco, C. P5263
Tilz, R. P3741, 3982, 3983, 3984 Tornos, P. P6382
509
Chairpersons & Judges / Speakers & Discussants / Authors Tor – Tsi
Tornos Mas, P. 198, 253 Trachsel, L.D. P4098 Trocio, J. P6211

Tornos Mas, P. 4832, 5893, 5895, 5988 Tracz, W. P5622 Troidl, C. P2386, P3137, 6065
Torok, M. P1144, P2667, P4536 Traeder, F. 5090 Troidl, C.T. P567
Torp-Pedersen, C. 307, 322 Trafford, A. P2432, P4740 Troise, G. 2207
Torp-Pedersen, C. 298, 951, 1329, 1832, Trafford, A.W. P4543 Troitskaya, E. P1802
1972, P3108, 3277, P3312, P3641, P3747, Tragante, V. P1702 Tron, C. P668, P2632, P3583, P5490, P6373
P4072, 4283, 4284, 4909, P5033, P5284, Train, C.Q. P6412 Trotta, F. 3944, P6118
P5596, 5839, P5978, P6213, P6470, 6627, Traish, A. P2722 Troughton, R. 127, P3483, P5034
6642 Traki, M. P6204 Troughton, R.W. P4610
Torp-Pedersen, C.T. P1571 Tralhao, A. P1610, P4509, P4624, P5643 Trouillet, C. P3344, 6622
Torracca, L. 372 Tralhao, A.T. P829 Trovato, M. 2929
Torre, T. 1081 Trambaiolo, P. P2794 Trovik, T. P5024
Torres, D. P3785 Tranberg, T. P4436 Troya, M. P752, 6639
Torres, P. P6135 Trancart, M. P5282, P5283 Trukshina, M. P2393, P2825
Torres, S. P1634, P6167 Trani, C. P5027 Trumpp, A. P2669
Torring, O. P5324 Trantalis, G. P4751 Truszkowska, G. P3543
Torrini, F. P4522 Trapp, S. P1415 Trybala, E. P757, P6224
Toser, Z. P6122 Trappe, H.-J. P497 Trystula, M. P4685, P5616, P5619
Tosi, D. P4734 Tratsiakovich, Y. P3085 Trzcinski, P. P2528
Tosu, A.R. P2535, P2847 Traulle, S. P2553 Trzebiatowska-Krzynska, A. P3611
Toteja, G. 2024 Trausi, F. P5290, P6223 Trzos, E. P2653
Toth, A. P614, P2649, P4097, P4099 Trautner, S. P4436 Tsai, J.-C. P5664
Toth, G. P1729, P2767, 6620 Treede, H. 5923 Tsai, J.P. P4076
Toth, G.G. P2729, P2771, 3181 Trefil, L. P1588 Tsai, M.S. P3436
Toth, G.T. P3461 Treibel, T. P5546 Tsai, T.H. P1762, P3564
Toth, P.P. 67, P1676, 3866, 3867, P5981 Treiman, M. P554, 2910 Tsai, W.-C. P1466, P4780, 5808
Toti, F. P647 Trembovetska, O. P1635 Tsai, Y.N. 3949
Touloupaki, M. P2642 Tremoli, E. P6368 Tsakonas, G. P6204
Toumanidis, S.T. 378 Trencsenyi, G. P3577 Tsalamandris, S. P455, P660, P1577,
Toumpas, S. P3082 Trendafilova, E. P5272, P6208 P2689, P2725, P6476
Toumpoulis, I. P5566 Trenk, D. P809, P1493, 5792 Tsanaxidis, N. P5309
Toure, I. P3135 Trenson, S. P1111 Tsang, H.K. P3635
Tournev, I. P1352, P4589 Trento, A. 5215 Tsang, M.Y.C. 5214
Tousoulis, D. 325 Treptau, J. P3455 Tsang, V. P2141
Tousoulis, D. P204, P455, P612, P644, P660, Treshkur, T.V. P1540, P1542 Tsao, P.S. P2604
P727, P730, P740, P785, P898, 967, Treskes, R.W. P696 Tsaregorodtsev, D. P4637
P1116, P1141, P1342, P1458, P1572, Tresorier, R.T. P5933 Tsarouhas, K. P6320
P1577, P1624, 1834, P2154, 2232, 2233, Tretina, M. P3114 Tsatsopoulou, A. P1624, P2641, P2643
2265, P2388, P2574, P2575, P2595, Trevethan, S. P1601 Tsatsoulis, A. P765
P2641, P2643, P2670, P2689, P2699, Triantafyllidi, H. P639, P654, P2499, 3174, Tschirner, A. P5256
P2711, P2721, P2723, P2725, P2839, P5705, P6265, P6504 Tschoepe, C. 364
P2844, P3115, P3116, P3501, P3582, Triantafyllou, A. P6594 Tschoepe, C. 8, P1353, P1367, 2044, 2046,
P3590, P3679, P3680, P3681, P3803, Triantafyllou, E. P6594 P3127, P3596, P4544, 5909, 5911, 5913,
P3806, P4088, P4106, P4118, P4312, Tribulova, N. P1414 6096
P4331, P4429, P4582, P4586, P4588, Triedman, J.K. P5314 Tschoepe, C.P. 2205
P4648, P4668, P4751, 4867, 4869, 4874, Trifiro, G. P6495 Tschoepe, D. P3131, P3132, P3771
P5368, P5464, P5476, P5540, P5555, Trifunovic, D. 4288, P5415, P5678 Tschope, C. P3600, 5898
P5561, P5588, P5607, P5627, P5676, Trifunovic, Z. 4292 Tse, H. P3459
P5710, P6254, P6422, P6438, P6476, Triggiani, M. P854, P1555 Tse, H.F. P738, P1143, P1145, P4765, P6303
P6598 Trigo Pereira, C. P1642 Tsekoura, D. P6598
Toutouzas, K. P612, P785, P1141, 2090, Trikas, A. P2699 Tseluyko, V. P4427
P2388, P3501, P3582, P3590, P4106, Trillo, R. 80 Tseng, C.H. P5317
P4751, P5464, P5607, P5627, P6254 Trillo Nouche, R. P2494 Tseng, C.J. P3565
Touyz, R. 306 Trillo-Nouche, R. P5248 Tseng, S.-Y. P1466
Touyz, R. P6150 Trimarco, B. P217, 1240, P1468, P1729, Tseng, T.-L. P2132
Touyz, R.M. P2583 P2121, P2481, P4715, 4870, P5623 Tseng, W.K. P1819
Touzery, C. P1696, P3080 Trimarco, V. P2121, 4870, 4900, P5623 Tsiachris, D. 2232, 2265, P2844, P4331,
Tovar-Maldonado, J.A. P5650 Trinh, A. P845, P5409 P4429, 4867, 4869, P5555
Townend, J.N. P4447 Trip, P. P5952 Tsiamis, E. P785, P3582, P4106, P5607,
Townsend, M. P5226 Tripepi, G. P1149 P5627, P6254
Townsend, R. P1148 Triposkiadis, F. P5309 Tsigalou, C. P4432
Toyoda, F. P417 Triposkiadis, F.K. 27 Tsigkas, G. P1469, P1479
Toyofuku, M. P1515 Trippel, T. P5663, P5690 Tsigoulis, M. P760
Toyoshi, H. P2451 Tritakis, V. P5347 Tsioufis, C. P898, 2020, 2232, 2265, P2670,
Toyoshima, Y. P3407 Trivedi, C. 955, P3383, P3396, P3417 P2839, P2844, P3803, P4429, 4867, 4869,
Toyota, T. P1486 Trivella, M.G. P4598, P4601, P4669 4874
Tozzetti, C. P2532 Trivilou, P. P639, 3174, P5347, P5705 Tsioulpas, C. P4741
Trabulo, M. P5643 Trivisonno, A. P3739 Tsipis, A. P170
Trachanas, C. P4671, 4871 Trmarco, B. 1985 Tsirigotis, P. P5437
Trachet, B. P185, P186 Trninic, D. P561, 4287, P4698, 5086, 5819 Tsironis, I. P6233, P6236
Trachsel, L. 2929 Trochu, J.N. P1124 Tsitsinakis, G. P4331
510
Chairpersons & Judges / Speakers & Discussants / Authors Tso – Ure
Tsompanaki, E. P4450 Tupiec, J. P645, P646 Uematsu, M. P1135, P2404, P2563, 3170,
Tsougos, E. P654 Tura, B.R. P6397 P4360, P4498, P5326, P6534
Tsoukanas, K. P906 Turak, O. P4533, P4577 Uemura, H. P2142
Tsubata, H. P1564 Turan, O.E. P542 Uemura, K. P4756, P5453
Tsuboi, H. P2446 Turan, T. P3620 Uemura, S. P2746
Tsuboi, S. P3721, P4477, P5381 Turchi, S. P5020 Ueno, K. P1438
Tsuburaya, R. P6117 Turganbayeva, G.M. P5665 Ueno, T. P3691, P6535
Tsuchihashi, K. P2556 Turi, V. P4706 Ueoka, A. P1403, P2537
Tsuchikane, E. P3700, P3708, P3722, Turinay, Z.S. P488 Ueshima, D. P4689
P4608, P6282 Turk, J. P5932 Uesugi, Y. P6123
Tsuchiya, K. P6363 Turkday, S. P5517, P6144 Uetani, T. 2228, P4354, P4507, P5380
Tsuda, E. P4603 Turkkan, C. P5275 Ueyama, C. P5590
Tsuda, T. P693, P1420, P2832 Turkmani, M. P6270 Ueyama, T. P6350
Tsuda, Y. P1718, P2551, P4309 Turkyilmaz, E. P2514 Ughi, G.J. P2771, 6621
Tsugu, T. 4180 Turner, L. P2660 Uher, T. 1979
Tsui, C. P2674 Turowski, P. 7 Uhlemann, M. P3639
Tsuji, A. P2366, P2368 Turpie, A.G.G. 186 Uhm, J.S. P484, P3337, P4064, P4355,
Tsuji, K. P6539, P6544 Turpie, A.G.G. 396, 2873, 2877, P4404, P4440, P4497, P5296
Tsuji, T. P3638 P5598 Uiterwaal, C.S.P.M. 3951, P6396
Tsuji, Y. P2446 Turrini, P. P495 Uitterdijk, A. P3745
Tsujii, N.T. P4603 Tuset, L. P1690, P4775 Uitterlinden, A.G. P1391
Tsujikawa, L. P1585 Tutarel, O. P724, 2928 Ukena, C. P2843, P3735
Tsujimoto, S. P4691 Tuzcu, E.M. 4818 Ukkola, O. P2708, P3125, P6221
Tsujimoto, T. P1515 Twerenbold, R. 126, 154, 157, 159, P524, Ukkonen, H.J. 190, 307
Tsujimura, T. P6534 P525, P529, P595, P1097, P1099, P1100, Ukkonen, H.J. 1019
Tsujimura, Y. P3434 P1103, P2461, P2695, P3481, P3484, Ulc, I. P631
Tsujita, K. P811, P1339 P4077, P4454, P4459, 5085 Ullah, A. 6626
Tsujita, Y. P3482 Twomey, D. P4374 Ullah, S. 4047
Tsukada, T. 6632 Tybjerg, A.J. P3641 Ullrich, J. P3599
Tsukahara, K. P885, P6411 Tyden, P. 2936 Ulman, J. P565
Tsukahara, R. P1132, P1133, P2733, P3706, Tyler, J. 5921 Ulmer, H. 966
P4492, P6145, P6519 Tympas, K. P654 Ulus, T. P3379
Tsukamoto, Y. P1793 Tynelius, P. P5306 Umana Mallarino, J.P. P3453
Tsunemaru, T. P5579 Tyson, C. P1333, P4435 Umans, V.A. 6641
Tsunoda, T. 6632 Tzanis, G. P4666 Umans, V.A.W.M. P560, P4316
Tsuruda, T. P2380 Tzanoglou, D. P4430 Umar, F. P1647
Tsurumi, Y. 6655 Tzelepis, G.E. 3253 Umeda, H. P3710
Tsuruta, H. 4180 Tziakas, D. P4432 Umemoto, N. P3753, P4109, P5966, 6086,
Tsutsumi, M. P4718 Tzikas, A. P206, 6013 P6494
Tsvetkova, E. P1581 Tzikas, S. P4074 Umemoto, S. P734, P4732
Tsyganov, A. P489 Tzivoni, D. P794 Umemoto, T. P4689, P5556
Tu, A. P4416 Tzortzis, S. 3174, P5347 Umemura, J. P3334
Tu, S. P2771 Tzourio, C. 964 Umemura, S. P515, P2814, P4691, P6411
Tual-Chalot, S. P2810 Ubaid, S. 3162 Umemura, S.U. P2509
Tuan, T.C. P2427 Ucar, F.M. 6040 Umezawa, S. P4674, P4677
Tubaro, M. 26, 268 Ucci, S. 3944, P6118 Unal, B. P6325
Tubaro, M. 1968, P4629, 5883 Uchida, K. P603 Undas, A. P1447, P1448, P1450, P2505,
Tuburaya, R. P1707 Uchida, S. 2342 P2606, P3587, P5622
Tuccillo, B. P1474 Uchida, T. P3777 Underwood, S.R. 323
Tudisca, C. P2355 Uchida, Y. P876, P2475, P4451, 6655 Underwood, S.R. 1252, 1254, 1256
Tueller, D. 1201, P1723 Uchimura, Y. P6285 Ungar, A. 995, 997, 999
Tueroff, A. P2797, P6289 Uchmanowicz, I. 33 Unger, P. 2994, 2995
Tuinenburg, A.E. P165 Udagawa, N. P2380 Unger, T. 352
Tuininga, Y. P1547 Uddin, M. P2742 Unger, T. 1001, 5721, 5724, 5725, 5726
Tukkie, R. P1547 Udell, J. 3913 Unlu, M. P3379
Tulintseva, T.E. P1540, P1542 Uebing, A. P723, P6413, P6417 Unlu, S. P457
Tull, S.P. P6352 Uechi, T. 6632 Unniachan, S. P6212
Tulppo, M.P. P2708, P6221 Ueda, A. P3366 Unoki, T. P3434, P3690, P4611, P4635,
Tulumen, E. P489, P1400, P4591 Ueda, J. P2366 P6248
Tulunay Kaya, C. P5652, P6478 Ueda, M. P1439, P1686, P1687, P2423 Unterseeh, T. P5010, P5489
Tuman, T.C. P5714 Ueda, S. P5342 Upex, A. P3559
Tumasyan, L.R. P3770, P5286 Ueda, T. P688, P1633, P6285 Uppal, H. P3664
Tundo, F. P4346, P4389 Ueda, T.U. P5041 Upton, M. P5019
Tunnicilff, P. P2819 Ueda, Y. P1438 Upton, R. P5416
Tunon Fernandez, J. P6250, 6604 Uehara, H. P2692, 5885 Ura, S. P3110, P3690, P6248
Tunyan, L.G. P3770, P5286 Uehara, Y. P3749, P3754 Ural, D. 4173
Tuohinen, S. P3517 Uejima, T. P5443 Urban, K. 4191
Tuomilehto, J. 260 Ueki, Y. P3482 Urban, P. P6133
Tuomilehto, J. 3148, 4888 Ueland, P.M. P1656, P4657 Urbano Pagan, L. P892
Tuomilehto, J.E. P756, P3627 Ueland, T. 336, P6551, P6555, 6643 Urbanski, K. P6127
Urena, M. P3731, P5014, 5217, 5218
511
Chairpersons & Judges / Speakers & Discussants / Authors Ure – Van
Urena-Alcazar, M. P6391 Valente, B. 103 Van Der Geest, R.J. P2126

Uresti-Flores, E. P5650 Valente, M. P1788 Van Der Graaf, Y. P590, P5246
Uretzki, G. P5633 Valente, S. P564, P2522 Van Der Gucht, A.V.D.G. P843
Urheim, S. P2621, P3589 Valenti, A. P192 Van Der Heide, E. P3733, P4673
Urias, E.G. P2838 Valenti, R. P1094, P1496, P2741 Van Der Heijden, J.F. 5809
Uribarri, A. P2772 Valentini, G. P687, P5526 Van Der Heyden, M.A.G. P6159
Ursini, T. P4628 Valentino, G. P4631 van der Horst, I.C.C. 1966
Ursoniu, S. P1450, P1584, 2229 Valentova, M. P887 Van Der Kallen, C.J.H. P4615
Usal, A. P5480 Valeri, G. P1531, P6548 Van Der Kley, F. P2607
Uscatescu, V. P6280 Valeron, D. P3694, P4676 Van Der Laan, A. P6261
Ushakova, S.E. P3628 Valgimigli, M. P1456, P1499, 1944, 2287, Van Der Lely, S. P1706
Ushigome, R. P6539, P6544 4127, P4699, 4935, 4936, 6004 Van Der Linde, D. P2660, 2931, P4742
Ushijima, R. P890 Valina, C. P809, P1493 Van Der Linden, N. P3333
Ushinohama, H. 1327 Valina, C.M. P3720 Van Der Lugt, A. P5573
Uskov, I. P2171 Valle-Alberca, A. P601, P2381, P2777, Van Der Made, I. P5239, P6182, P6184
Uskova, V.A. P6275 P3657, P5611, P6526 Van Der Meer, M.G. P590
Usmiani, T. P5353 Valle-Munoz, A. P181 Van Der Meer, P. P891, P3567
Uspenskiy, V. 233, P6501 Vallecilla, C. 2282, P5941 Van Der Pal, H.J.H. P5035
Ussia, G.P. P1590 Vallely, M. P2660, 2931 Van Der Pals, J. 4057
Ustun, E.E. P5366 Valles, E. 952, P3077, P5301 Van Der Pouw-Kraan, T. P6261
Usui, A. P6502 Vallone, A. P2355 Van Der Veen, P.H. P5246
Usui, E. P789, P1361, P1362, P1711, P1715, Valls-Lacalle, L. 1088 van der Velde, E.T. 25
P1719, P1720, P4511 Valocik, G. P1435 van der Velde, E.T. 1259
Usui, H. P1749 Valsangiacomo Buechel, E.R. 1066, 4273 Van Der Voort, P.H. P715
Usui, M. P4783 Valsecchi, O. P5285 Van Der Vorst, E.P.C. P665, P6129
Usui, S. P6183 Valsecchi, S. 5916 Van Der Vynckt, C. P4647, P4650, P4982
Usui, Y. P759 Valuckiene, Z. P1594 Van Der Wal, A.C. 251
Usui, Y.S. P754 Valverde, I. P4719 Van Der Wal, M.H.L. 91
Utens, E.M.W.J. P2656 Valzania, C. P464 Van Der Wal, M.H.L. P443
Uthamaraj, S. P2375 Vamos, M. P459, P1389, P6203 Van Der Wall, S.J. P4316
Utili, R. P677 Van ’T Hof, A. P4992 Van Der Zant, F.M. P5232
Utsunomiya, M. P4689 Van ’T Hof, A.W. P556 Van Der Zee, P.M. P5232
Uygur, B. P4104 Van ’T Hof, A.W.J. P1505, P1750, 1857 Van Der Zwaag, P.A. P4594
Uznanska-Loch, B. P2653 Van Aelst, L. P5433 Van Dessel, P.F. P4594
Uzui, H. P3400, P3422 Van Aerde, M.A. P5591 Van Dessel, P.F.H.M. P1427
Uzuka, H. P790 Van Assche, L. 5213 Van Deursen, C.J.M. P491
Uzun, F. P2519, P4104, P6242 Van Belle, E. 1040, 3016, 3018, P6507 Van Dieijen-Visser, M.P. P4458, P4615
Uzun, H. P1828 Van Belle, E.R.I.C. 363 Van Dijk, A.P. P2137
Uzun, O. P2701 Van Beusekom, H. P1456 Van Dijk, A.P.J. P437, P2658, P2661
Vaccarino, V. P4301 Van Beusekom, H.M.M. P5597 Van Domburg, R.T. P2656
Vaccher, E. 4149 Van Boven, N. 6641 Van Dooren, S. P1388
Vachiery, J.L. 3830, 3912, P5504, P5523 Van Boven, W.J. P6182, P6184 Van Dorpel, M. P4742
Vaclavik, J. P224 Van Bruggen, R. P5591 Van Dyck, M. P3504
Vadini, F. P4628 Van Brussel, P.M. P3738 Van Eck, M. P6129
Vado, A. P2400 Van Buul, J.D. P665 Van Eenennaam, F. 1857, P4071
Vafaie, M. 125, P5340 Van Buuren, F. P2149, P2638, P2827 Van Eijl, S. P1569
Vagany, D. P3348 Van Camp, G. 196 Van Es, J. P3621
Vaggelli, L. P179 Van Camp, G. P1388, 2998 Van Es, N. P3621
Vagida, M. P6332 Van Campen, J.S. P178 Van Gelder, I.C. 360
Vagnarelli, F. 158, P3437, P4456 Van Cleemput, J. P1765, P3101, P5433 Van Gelder, I.C. 1246, 1248, 5840
Vago, H. P614, P4097, P4099 Van Craenenbroeck, E. 57, 5213 Van Geuns, R.J.M. 2909
Vahanian, A. 89, 129 van de Borne, P. 209 Van Gils, L. 5793
Vahanian, A. 348, 1918, 1984, 2093, 2103, Van De Heyning, C. 5785 Van Gilst, W.H. P6346
2286, P3731, 3811, P4574, P5014, 5217, Van De Heyning, C.M. P3581 Van Gorselen, E.O.F. 2934
5218, 5784, 5786, P6391 Van De Hoef, T.P. P1717, P1725, 1840 Van Grootel, R.W.J. P707
Vaida, P. P6443 Van de Werf, F. 191, 262, 352 Van Haelst, P.L. P4594
Vaidean, G. P222 Van De Werf, F. P543, P2463, 3031 Van Hagen, I.M. 142, 143, P1402
Vaikhanskaya, T. P520, P6169 Van de Werf, F. 1157, 3147, 4128 Van Heeswijk, R. P861
Vaile, J. P3630 Van Deel, E.D. P2161 Van Herck, J.L. 4253
Vaknin Assa, H. P5013, 6016 Van Den Akker-Van Marle, M.E. P3645 Van Herck, K. P4636
Vaknin Assa, H.V. P2731 Van Den Berg, M. 3071 Van Hoeyweghen, R. P5302
Vaknin-Assa, H. 1981, P3698 Van Den Berg, M.E. P1391 Van Hout, G.P.J. 3950, P5447
Valachovicova, M. P3556 Van Den Berg, M.P. 3073, P4594 Van Hove, C.R. 1835
Valatsou, A. P2575 Van Den Berg, N.W.E. P6182, P6184 Van Kesteren, F. 1840
Valborgland, T. P602, P5257, P6477 Van Den Born, B.J.H. P3738 Van Klei, W.A. P1755, P5618
Valbuena-Lopez, S. P853, 4049 Van Den Bosch, A.E. P707, P2656, P6418 Van Kranenburg, M. P4673
Valcovici, M. P4706 Van Den Bosch, B. P1541 Van Laar, M. P171, P176, P770, P1102,
Valdes, M. P586, P1098, P4403, P4622 Van Den Heuvel, P. P3408 1196, 2914, 4261
Valdes-Castro, R. P5650 van den Hoff, M. 2240 Van Leeuwen, M.A. 368
Valdovinos, P. P3332 Van Der Aalst, C.M. P5591 Van Lierde, J. 163
Vale, M.J. P6456 Van Der Does, L. P4392 Van Linthout, S. 2205, P3596, P4544
512
Chairpersons & Judges / Speakers & Discussants / Authors Van – Ver
Van Malderen, S.C.H. P1388 Vanerio, G. P2437 Vavrincova, D. P2647

Van Marion, D. P6189 Vanerven, L. P1389 Vavrinec, P. P2647
Van Melle, J.P. P6416 Vanhaecke, J. P1765 Vavuranakis, M. P455, P4582, P5476
Van Mieghem, N. P3733, P4673 Vanhaverbeke, M. P543, P1111 Vaz Carneiro, A.V.C. 410
Van Mieghem, N.M. 5793 Vanhees, L.E.M. 2009, 2010 Vazquez, G. P1674
Van Mieghem, N.M.D.A. 2909 Vanmechelen, M. 163 Vazquez, R. P3755, P5694
van Mieghem, N.M.D.A. 318, 320 Vannan, M. 37, 154, 308 Vazquez-Alvarez, M.E. P5494
Van Mourik, M.S. P6388 Vanni, S. P2532, P3617, 4174, P6410 Vazquez-Rodriguez, J.M. P3506, P3507
van Nieuwenhoven, F.A. 90 Vanniyasingam, T. P3314 Vd Hulle, T. P3621
Van Nyendaal, C. P5548 Vanoverschelde, J.-L. 362 Vd Woestijne, P. P4392
Van Oostenbrugge, R. P5597 Vanoverschelde, J.-L. 1885 Vecchiato, C. P5358
Van Opstal, J.M. P715, P4394, P4396 Vanoverschelde, J.L. P1659, P2363, P3504 Vecchierini, M.F. 5077
Van Praet, F. P1729, P2614, P6484 Vanoverschelde, J.L.V.O. 5212 Vecchione, C. P2121
Van Ramshorst, J. P2126 Vant Hof, A. P551 Vecera, J. P6297
Van Riel, A.C.M.J. P437, P2658, P2661 Vantler, M. 2335, 5846 Vedad, R. P6138
Van Rijen, H.V.M. P4115 Vanwalleghem, S. P796 Vedin, O. 373
Van Rooij, E. 2946 Vara Manso, J. P5474 Vedovati, M.C. 4174, P6216
Van Roon, A.M. P183 Varabyova, Y. P464 Vedsted, P. P6455
Van Rosendael, A. P4482 Varalda, G.P. P6174 Veerasamy, M. P570, P588
Van Rosendael, P. P2607 Varanasi, S.S. P510 Vega, A. P2402, P3380
Van Rosendael, P.J. P2543, P4089 Vardas, P. P1481, P2642, P5329, P5371, Vega, B. P4719
Van Rosmalen, J. P6444 5905 Vega, D. P6508
Van Rossum, A.C. P174, P180, 368, P426, Vardas, P.E. 124, 209, 250 Vega, J. P3518
P531, P1507, P6323 Vardas, P.E. P3355, 4899 Vegas, J.M. P4719
Van Royen, N. 368, P426, P531, P553, Varela Falcon, L. P6559 Vegh, A.M.D. P5447
P1717, P1725, P2497, P2512, P6261 Varenhorst, C. P172, 6649 Vegh, E.M. P491
Van Ryn, J. P6185 Varesio, L. P3550 Veglio, F. 2259, 2260, 2261
Van Slegtenhorst, M.A. P1120 Varga, A. 367 Vegsundvag, J. P6477
Van Solinge, W. P6253 Varga, I. P4770 Vehmeijer, J.T. P473
Van Solinge, W.W. 3950 Varga, P. P1630 Veiga Fernandez, G. P2757
Van Spaendonck, K.Y. 3070, 3073 Vargas, K.G. P5021 Vejlstrup, N. P554, P622, P822, P2456,
Van Spall, H. 6648 Vargas, M.A.O. P3626 2910, P6399
Van Steenbergen, A. P2363 Vargas-Barron, J. P4527 Vekov, T. P4705
Van Suijlen, J.D. P4615 Varghese, M.J. P210 Vela, E. P6584
Van T Sant, J. P5223 Varkevisser, R. P6159 Velasco-Lajo, T. P601
Van Timmeren, J.E. P180 Varlan, G. 4150 Velazquez Martin, M.T. P4550, P4710,
Van Tintelen, J.P. 3070, 3073 Varlet, E. P714 P5957, P6426
Van Tulder, R. P3454 Varnous, S. 2291, 2292, 2293 Velcea, A. P2806
van Veldhuisen, D.J. 40, 241 Varona, S. P1369 Velchev, V. 366
Van Veldhuisen, D.J. P713, P2796 Varoudi, M. P639, P2499, P5418, P5705, Velez, P. P651
van Veldhuisen, D.J. 2173, 2898, 3836 P6265 Velkoska, E. P894
Van Velzen, H.G. P1120 Varpula, T. 6043 Velmurugan, S. P1569
Van Vessem, M.E. P3794 Vasa-Nicotera, M. P2633, P4573, P6387 Velthuis, B.K. P531, P2371
Van Vugt, S.P.G. P4678 Vaschilko, A. P3805 Velthuis, S. P5532
Van Waes, J.A.R. P1755, P5618 Vasconcelos, M. P1407, P3604, P4464, Veltmann, C. P1400, P5928
Van Waning, J.I. 3074 P5679, P6394 Veltri, P. P5457
Van Wijk, M.C.A. P4115 Vasichkina, E.S. P4596 Vencloviene, J. P3514
Van Wijngaarden, S.E. P2543 Vasileiou, P. P4586, P4588 Venetsanos, D. P551
Van Winden, L.A.M. P5565 Vasilieva, E. P735, P900, P6332 Venieri, E. P730, P5555, P5561
Van Workum, S. P5228 Vasiljevic, Z. P561, P594, 4287, 4291, Venkateshvaran, A.I. P5482
Van Zwam, W. P5597 P4425, P4452, P4698, 5086, 5819 Venlet, J. P1401, P3372, P5926
Van’t Hof, A.W. 5813 Vaskelyte, J.J. P636, P3514 Venn, A. P1356
Vancrayenest, V.D. 5212 Vasko, P. P804 Venner, C. P5513
Vancura, V. P631, 4859 Vasques-Novoa, F. P2372, P5006, P6586 Venneri, L. P866
Vandael, E. P1541 Vassalli, G. 1081, P3133 Ventila, M. P3491
Vande Kerckhove, B. P2627 Vassanelli, C. P1602, 5146 Ventura-Clapier, R.F. 35, 90, 123
Vandecasteele, G. 2283 Vassanelli, F. P1405 Venturi, P. P3672
Vandekerckhove, Y. P3387, P5302 Vassilev, D.V. P3449, P3686 Venuraju, S. P4484, P4485
Vanden Driessche, N. P1111, P6260 Vassilikos, V. P2698, P4074 Venuti, A. P2693
Vandenberghe, D. P6452 Vassiliou, V. 1986 Vera, L. P3637, P5647
Vandenberghe, J. P1541 Vassilopoulos, D. P4586 Verabraecken, J. P650
Vandenberk, B. P1541, P5930 Vastarella, R. P1351 Verardo, R. P1430
Vandenbriele, C. P1114, P5470 Vaswani, A. P3432 Verbeek, P.R. P1331
Vanderbeck, B. P166 Vasyuk, Y. 4150 Verberne, H.J. P3738
Vanderheyden, M. P1364, P1468, P2614, Vataman, E.B. P3659 Verbrugge, F.H. 163
5785, P6297, P6484 Vathesatogkit, P. P458, P1695, P4627, Vercellino, M. P5543
Vandersmissen, I. P1114 P4672 Verdecchia, P. 281, P6216
Vandervoort, P. 163 Vatinian, S. P3792 Verdejo-Paris, J. P1601
Vandijck, D. 105 Vaturi, M. P3698 Verderber, J. P3471, P3492
Vanek, J. P4707 Vaugrenard, T. P3530 Verdiani, V. P3350
Vanek, T. P5247 Vautrin, E. P3344
513
Chairpersons & Judges / Speakers & Discussants / Authors Ver – Vol
Verdoia, M. P1476, P1480, P1501, P2117, Vidan, M.T. P5568 Vinhas, H. 5814
P3119, P5542 Videbaek, L. P5033 Vinnicombe, Z. P2373
Verdu-Rotellar, J.M. P1774, 2213, P6584 Videm, V. 2943 Vinogradova, I. P3363, P3368
Verdugo, M. P2792 Vidorreta, S. P1434 Vinolas, X. P167, P478, P1389
Verdun, F. P2378 Viecca, M. P6495 Vinther, M. P462, P474
Vered, Z. 37 Vieira, C. P545, P2548, P3452, 4255, P5345, Vintila, A.M. P6447
Vered, Z. P3642, 5866 P5352, P6266 Violeta Gonzalez Salvado, V. P4419
Vergaro, G. P3757, 6044 Vieira, T. P5677 Violi, F. P6190
Vergely, C. P6344 Viel, E. P871, 4149 Violi, F.V. P5279
Verges, B. P2675 Viereck, R. P2587, P6345 Virani, F. P1477
Vergis, K. P4123 Viethen, T. P3622 Virani, S.A. 1977
Vergnat, M. P4602 Viezelis, M. P3514 Virdis, A. P725, P4539
Verhage, V. 1957 Vigliano, C. P1767 Virdone, S. P871, 4149
Verhamme, P. 148 Vigmond, E. P1411 Virmani, R. P5452
Verhamme, P. P1114, 2183, P5470, 5763, Vigorito, C. 5127 Virot, P. P4558
P5967 Viigimaa, M. 250 Virtanen, M. P3517
Verheugt, F. P5598 Viitasalo, M. P1376 Virtanen, V. P3517
Verheugt, F.W.A. P4678 Vijay, S.K. 5795 Virzi, M.G. P1788
Verheyen, F.K. 4151 Vikmane, M. P2347 Vis, M.M. 364, 1840, P6388
Verhoeff, B.J. P1708 Vikstrom, M. 6646 Vischer, A. 1047, 1048, 1050, P1632
Verjans, J.W. 6621 Vila, J. 4277 Viskin, S.V. P4382
Verlato, R. P495, P3399, P3411 Vila Sala, M. P546 Visseren, F.L.J. P5246
Verma, P. P4713 Vilacosta, I. P1470, P2119, 2318, 2320, Vistisen, D. 276, P6444
Vermeulen, K. P5468 2321, P3103, P3104, P3106, P3576, Vitali Serdoz, L. P4356
Vermeulen, K.M. P1805 P4575, 4833, P5483, 5896, P6498 Vitorino, S. P3669
Vermeulen, T. 5213 Vilades, D. P745 Vitovec, J. 6645
Vernardos, M. P2642 Vilades Medel, D. P4996 Vitrella, G. 5787
Vernis, J.M. P3332 Vilaeti, A.D. P3442 Vittori, C. P5285
Vernooij, F. P5469 Vilahur, G. P2130, P4524 Vittorini, M. P2532, P3617
Vernooij, M. P5573 Vilahur Garcia, G. 262, 311, 361 Vivanco, F. 5112, 5114, 5115, 5116
Vernooy, K. P491, P5223, 5914 Vilahur Garcia, G. 1991 Vivas, D. P1470, P2119, 2318, 2320, P3104,
Veronesi, C. 6654 Vilaiwatanakorn, K. P4627 P5483
Veronesi, F. P2545, P2546, P2550, P5484 Vilardosa, U. 1088 Vives Borras, M. 161
Verrier, R.L. P1376, P3775, P5671 Vilas Boas, N. P5641 Vives-Borras, M. P3755, P5694
Versaci, F. P3739 Vilas-Boas, N. P5634 Vizza, C.D. P5526, P5529
Verschuren, F. 162 Vilas-Boas, N.M. P5635 Vlachopoulos, C. 353
Verschuren, M. 208 Vilaseca, M. P1674 Vlachopoulos, C. P204, 967, P1572, P2574,
Verseckaite, R. P636 Vilchez-Tschischke, J.P. P2517 P2699, P3116, P3679, P3806, P4118,
Verso, M. P6216 Viliani, D. P1593 P4429, P4668, 4920, 4922, P5540, P5541,
Versteeg, H. 55 Villa, A. P1530 P5588, P5710, 5729, 5731, 5732, 5867,
Verveniotis, A. P1116 Villa, C. P1555 P6598
Vervuurt, J. P4458 Villa, G. P2646, P2741 Vlachopoulou, E. P3098
Verwey, H.F. P3794, P6513 Villablanca Spinetto, P. P1489, P3488 Vlagouli, V. P1624, P2641, P2643
Verzijl, A. P3745 Villacorta Arguelles, E. P1392 Vlasica Carlos, J.A. 213
Vescovo, G. P1788 Villacorta-Arguelles, E. P5494 Vlassopoulou, N. P1478
Veselka, J. 4842 Villalba, M. P6343 Vlastos, D. 3174, P5347, P5705
Veselova, T.N. 2100 Villalobos, I. P2823 Vliegen, H.W. P696, P2137, 2934, 3050,
Vesterinen, P. P3429, P3478, P6243, P6264 Villamena, F. P653 4179
Vettel, C. P3537 Villani, G.Q. 315 Vloumidi, E. P1416, P5949
Vettor, G. P3427, P4389 Villani, G.Q. P2406, P2619 Voelker, U. P4736
Vettori, S. P687 Villano, A. P3512, P4522 Voelker, W. P3569
Veulemans, V. P5547 Villanueva, E. P797 Voelkl, J.G.J. P2587, P6345
Veyrier, M. P4595 Villegas, M. P6395 Voelz, S. P1152
Viala, M. P6452 Villejoubert, O. P5313 Voesch, S. P671
Viallon, M. P3594 Villemain, O. P1640, P1650, P3574, P4602 Vogel, B. P572, 2226
Viana, M. P1668, P3668, P5406 Villemin, T. P2418, P2455, P3365, P4599, Vogel, D.Y.S. P6261
Viana Tejedor, A. 3185 P4600, P5553 Vogely, H.C. P1755
Viani, S. P1092 Villevalde, S. P5660, P5696 Vogiatzi, C. P1469, P1478, P1479
Viart, G. P668, P3583 Villines, T. 2108 Vogiatzi, G. P2575
Vicario, T. P6190 Villuendas, R. P478 Vogiatzis, I. P4331
Vicario, T.V. P5279 Vincent, A. 4053 Vogt, F. P6521, P6524
Vicaut, E.R.I.C. 363 Vincent, F. P6507 Vogt, L. P3738
Vicente, M.S. P3643 Vincent, J. P2152, P2418, P5636 Vogt, P. P3448
Vicente, V. P4622 Vincentelli, A. P2626, P6507 Voigt, J.U. 2895, P4305, P5433, P5507
Vicinanza, C. P3561, P5457 Vincze, T. P2649 Voigt, N. 3177, P5947, P6154
Vicol, M. P6447 Vindis, D. P804 Voilliot, D. P164, P3530
Vicuna, R. 143 Viner, R. P4082 Volders, P.G.A. 264
Viczenczova, C. P1414 Vinereanu, D. P635, 1973, P2806, P3571, Volders, P.G.A. 6069
Vida, V.L. P706 4157 Volkov, D.E. P500
Vidal Perez, R.C. 207 Vingron, M. P3538 Volkova, E.G. P5552
Vidal Perez, R.C. 1195 Vinh, P.N. P1684
514
Chairpersons & Judges / Speakers & Discussants / Authors Vol – Wan
Vollan, G. 207 Vranckx, P. 253, 268 Walker, D.M. P1477

Voller, H. 3213, 3216, P3652, P3653, P5245 Vranckx, P. 328, 329, 331, 333 Walker, F. 310
Vollert, J. 125, P6149 Vranes, D. P6409 Walker, F. 141, P2139, P2141, 4957
Vollmer, S. 6041 Vriend, J.W.J. P715, P5314 Walker, J. P5685
Vollrath, M. P3433 Vriesendorp, P.A. 6607 Walker, J.M. P5328
Volpato, V. P4997, P5233 Vrijenhoek, J.E.P. P5618 Walker, N. P6457
Volpe, M. 250, 306, 375 Vrijsen, K.R. 1957 Walker, S. P3432
Volpe, M. 381, P725, P786, 1852, 2013, Vrinst, C. P650 Wall, S. P652, P2352
P4539, P6136 Vrints, C. P4342, 5213 Wallace, J. 127, P3483
Volpi, L. P5576 Vrints, C.J. P3581 Walldius, G. 6646
Volschan, A. P3479 Vrints, C.J.M. 72, 268 Wallenborn, J. P3569
von Allmen, R.S. 3261, 3262, 5163 Vrints, C.J.M. 1048, 1050, 1051, 2922, 4252 Wallenhorst, C. P4981, P5320
Von Arx, R. 2014 Vriz, O. P899, P5530, P5704 Wallentin, L. P172, 1973, 1974, 2032, 3030,
Von Bardeleben, R.S. 349, 1917, 2091, Vrolix, M. 163 4203, 4975, 4979, 4980, P6155, P6228,
3987, 3988, 3989, 3991, 3993 Vrsalovic, M. P4667 P6290, P6439
Von Birgelen, C. P2730 Vucur, K. P4667 Wallentin, L.C. 2906, 3160, 5132, 5134,
Von Der Ahe, H. P1379 Vuilleumier, N. 6647 5135, P5961
Von Elverfeldt, D. P2125 Vujisic-Tesic, B. P630, 4288, 5105, P5415 Wallmueller, C. P3454
Von Gunten, S. P479 Vukajlovic, D. P4080 Wallner, M. 20, 190
Von Haehling, S. 40 Vukcevic, V. P446, P580, P630, P827, P830, Wallner, M. 2244
Von Haehling, S. P887, 1078, P1789, 1201, P2484, P2518, P3682, P3715, P4433 Walmsley, J. P5221
P2786, 4046, P5655, P5695 Vukotic, S. P6409 Walravens, A.S. P1111
Von Klemperer, K.L. 144 Vulev, I. P3556 Walsh, A.M. P2718
Von Kodolitsch, Y. 270 Vullo, V. P2443 Walsh, K.A. P3406, P6475
Von Kodolitsch, Y. 5119 Vuorio, T. P2597 Walsh, R. P2348, 3072, P3102
Von Lewinski, D. P584, 2244 Vurgun, V.K. P5615, P6478 Walsh, S. P4701
Von Lueder, T. P3750 Vymazal, J. P169 Waltenberger, J. P2589, 6051
Von Lueder, T.G. 996 Vyssoulis, G. P204, P4668 Walters, T. P1424
Von Schacky, C. P5007 Vyssoylis, G. P6594 Walther, C. P4500
Von Scheidt, W. 3309 Waagstein, F. P895 Walther, T. 314, 316, P2620, P2623, 4268,
Von Segesser, L.K. P2586, P3133 Wachtell, K. 2981, P4094 P4565, 5786, 5791
Von Zur Muehlen, C. P2125 Wachter, R. P1777, 4178, P5311 Walther, T.W. 1988
Von Zur Muhlen, C. 6015 Waclawski, J. P6301 Walton, R.D. P1432
Vonbank, A. P1697, P3678, P4473 Wada, H. P767, P1357, P3110, P3690, Walzer, M. P1443
Vondrakova, D. P3476, 5886 P4121, P4611, P4626, P4635, P4642, Wan, D. P4757, P5699
Vonk, A.B.A. P4316 P5602, P5656, P6137, P6248, P6553 Wan, F. P2360, P4525, P5473, P5557
Vonk Noordegraaf, A. 6102 Wada, M. P4377 Wan, S.-H. P221
Vonk-Noordegraaf, A. P178 Wada, Y. P4377, P5939 Wanezaki, M. P3533
Vono, R. P2573 Wadell, K. P2659 Wang, A. 5215
Vonsky, M. P3541 Wael, W. P5701 Wang, A.Y. P3436
Vontobel, J. P611, P1614, P4481, 6019, Waessnig, N.K. 1323 Wang, A.Y.M. P4306
P6364 Wagener, M. 157, P524, P525, P595, P1097, Wang, B.H. P3750, P4521
Voors, A.A. 385, P891, 1070, 4276, 6037 P1099, P1100, P2461, P2695, P3481, Wang, B.W. P1568, P6333
Vorlat, A. 5213 P3484, P4459, P4612, 5085, P5397 Wang, C.C. P5554
Vormbrock, J. P684, P2138, P5015 Wagner, A. P1358, P1703, P6450 Wang, C.H. P3436
Vorobyev, A.N. P3354 Wagner, A.J. P1131 Wang, C.L. P2845
Vorobyeva, N.M. P456 Wagner, C. P2587 Wang, D. P6160, P6359
Voronkov, L. P1770, 6046 Wagner, H. P2476 Wang, D.L. 6045
Voros, S. 2234 Wagner, M. P2592 Wang, H. P3748
Vorpahl, M. P2385 Wagner, S. P1722, 1851, 3310, P3552 Wang, H.H.X. P3629, P6423
Vorpahl, M.M. P575 Wahlander, K. P6239 Wang, H.Y. P2793
Vorselaars, V.M.M. P5532 Wahlers, T. P2623 Wang, J. 137
Vos, G.J.A. P4992 Wai, B. P5674 Wang, J. P1389, P1428, P1467, 2885, 3226,
Vos, J.-A. P5532 Waintraub, X. P714, P3588 P3697, P4652, 5723, 5725
Vos, M. P5930 Wajih, S. P1681 Wang, J.J. P3629, P6423
Vos, M.A. P165, P6159 Wajon, E.M.C.J. P437 Wang, J.W. P5469
Vos, M.A.D. P4115 Wakami, K. P2707 Wang, J.Y. P710, P5237
Vos, T. P6461 Wakao, S. P5002, P5444 Wang, K.Y. 1961
Voskuil, M. P531 Wakasa, M. P6232 Wang, L. P3340
Voss, S. P2386, P3137 Wake, M. P5003 Wang, L.W. P4725
Votavova, R. P5534 Wakimoto, H. 3065 Wang, M. P1562
Voudris, V. P5476 Waksman, R. P670, P1599, P3593, P4583, Wang, P. P3464
Vouga, L. P5631 P6379 Wang, P.J. P1550
Vougia, D. P5371, 5905 Waksmann, R. 2913 Wang, P.P.W. 1080
Vouhe, P. P1650, P4602 Wakula, P. P3769, P5319 Wang, Q. P1386
Voukouti, E. P3358 Waldenstrom, A. P5472 Wang, Q.Z. P2793
Voumvourakis, A. P5705 Waldeyer, C. P4607 Wang, S. 5903
Vovas, G. P5433 Walfridsson, H. 957, P4372, P5268 Wang, S.H. P5614
Vozhdaeva, Z. P1436, P1800 Walfridsson, U. P4372 Wang, T.K.M. P763, P4405, P4581, P4651,
Vrachatis, D. P4582, P5476 Waliszewski, M. P6516 P5613, 6025
Vrakas, S. P906, P4123 Walker, B. P1487, 2341, 6614
515
Chairpersons & Judges / Speakers & Discussants / Authors Wan – Wie
Wang, W. P3443 Wdowiak-Okrojek, K. P856, 4238, P6295 Wenaweser, P. P1723, 3004, 6020, P6390
Wang, W.C. P6331 Webb, G.D. 155, 192 Wendelboe Nielsen, O.W. 949
Wang, W.T. 5075 Webb, G.D. P434 Wendler, O. 269
Wang, X. 3069, P3535, P5469 Webb, J. P518, P3723, P6314 Wendler, O. 1304, 1308, P2625, P3726,
Wang, X.G. P3602 Webb, T.R. 2890 5786, P6487
Wang, Y.-J. P2555 Weber, A. P5589 Wendt, D. P5571
Wang, Y. P1412, P2159, P3676, 4155, Weber, C. 76, 91 Wenner, J.B. P4393
P4407, P4746, P5344, P5430, P5711, 6103 Weber, M. P893, P1596, P2631, P4573, Wenzel, D. 2928
Wang, Y.N. P710 P6207, P6366, P6387 Wenzel, P. 1084
Wang, Y.S. P6340, P6497 Weber, S. P4340 Werner, C. P662, P2370
Wang, Y.X. P2588 Weber-Krueger, M. P5311 Werner, G.F. P2717
Wang, Z.J. 1831 Wedel, H. P895 Werner, G.S. 4822
Wanha, W. P1747, P2837 Weeke, P. P1433 Werner, N. P1596, 1952, 1959, 1960, 2257,
Wann, S.R. P3565 Weerackody, R. P2740 P2633, P4573, P4986, P6366, P6387
Wannamethee, G. P5019 Weevers, A. P2743 Werner, R.A. P605
Wannamethee, S.G. P4776, P5572 Wegner, C. P584 Wernly, B. P3558
Wanner, C. P4767 Wegscheider, K. 358, P3128, P3653, 3836, West, R.J. P1146
Wanner, M. P2671 P5316, 6636 West, R.M. P4994
Wanscher, M. 155, P3470, P6252 Wei, S.P. P4076 West, T.M. P2115
Ward, C. P5668 Wei, W.-Q. P5374 Westaby, S. 912
Wardle, F. P2571 Wei, X. P4348 Westenfeld, R. P1372, P2578, P5547, 5899,
Ware, J.S. 3072, P3102 Wei, X.H. P6180 P6142, P6503
Warisawa, T. 4286 Weichet, J. P169 Wester, P. P5621
Warnberg, J. P4662 Weidemann, F. P694, P2639, P3569 Westergren, H. 4295, P6239
Warnert, E.A. P4339 Weidenbach, M. 2340 Westerlund, J. P782
Warren, L. P5546 Weidinger, F. 252 Westermann, C.J.J. P5532
Warrings, B. P1669 Weidinger, F. P584, 1055, P2488, P3120 Westermann, D. P882, 1161, P1353, P2164,
Warwick, J. 5078, P5567 Weigt, K. P3575 P4607, P5016
Washio, T. P2500 Weik, P. P1454 Westhoff-Bleck, M. 2928, P3610
Wasiak, S. P1585 Weil, J. P2846, 6066 Weston, S. 6640
Wasilewski, J. P566, P576, P585, P587, Weiland, T. P682 Weston, S.A. P4984
P589 Weinberg, H. P5318 Weyand, M. P6374
Waskowsky, W.M. P6416 Weinberg, J. P709 Weytjens, C. P1388
Wasser, K. P5311 Weinert, L. P5484 Wheeler, P. P3765
Wasserman, S. P1756, P5984 Weinert, S. P2592 Whelan, C. 259
Wassilew, K. P189, P2593 Weingaertner, O. P1698 Whincup, P.H. P4776, P5572
Wassmann, S. 5852 Weinmann, T. P3426, P4343, P4345 White, A. P1612, 1987, P4579
Waszkiewicz, E. P4735 Weinstein, R. P1150 White, D. P2637
Watabe, T. P1437, P3544 Weintraub, W.S. 992, P2770, 5094, P6327, White, H.D. P1497, 4002, 4203, P4323,
Watanabe, E. P3670 P6384 P5961, 6025, P6228, P6290, P6439
Watanabe, H. P2465, P5327, P6156 Weir, M. P1799 White, J.A. 68, P1131, P6120
Watanabe, I. P1482, P4512 Weis, C. P6339 White, J.A.W. P6466
Watanabe, K. 2107 Weisheit, S. P2590 White, P.J. P4521
Watanabe, M. P742, P1401, 4290, P6177, Weiss, C. P3605 White, S. P1761
P6232 Weiss, J.P. P3356, P4376 White, S.K. P5546
Watanabe, M.W. P754 Weiss, R. 2988, P4299, 5921 Whiteman, M. 1089
Watanabe, N. P2537, P3529, P3691, P4503, Weiss, S. P2770 Whitlock, R. P207
P5578, P6304, P6535 Weiss, T.W. 22, 200, 306 Whitlock, R.P. P2152, P5636
Watanabe, S. P2540, P2694, P4783, P5590, Weiss, T.W. 379 Whittaker, D. P2625
P5610, P6172 Weissenborn, J. 350, P1597, P3572, P6369 Whittington, H. P4517
Watanabe, T. P742, P851, P1660, P3533, Weisser, B. P2703 Wi, J. P4440
P4766, P5428, P6597 Weissman, N.J. 5215 Wiberg, S.C. P593
Watanabe, Y. P1582, P6522 Weisz, G. P794, P3342, 4000, P4328, P4699, Wichter, T. 96
Waterhouse, D. P2821 P5703 Wichter, T. 5857
Waterhouse, D.F. P5688 Weithauser, A. 2214, P2600 Wichterle, D. P631, 956, P3424, 4859, 6075
Waterhouse, H. 20 Weitz, J. 128 Wickramatilake, C.M. P5370
Waters, D.D. P201, P766 Weitz, J. 1894, 1898, 3888 Widder, J. 2928
Watkin, R. 5107, 5108 Weitz, J.I. P5967 Widera, C. P2633
Watkins, H. 21 Weitzman, D. P2785 Widimsky, J. P1147
Watkins, L. P2820 Wejner-Mik, P. P856, 4238 Widimsky, P. 90, 303
Watkins, S. 4055, 4293, 4294 Welin, L. P6460 Widimsky, P. P565, 3272, P4705, 6645
Watkinson, O. P1628 Weller, T.J. P3750 Wiebe, J. P2386, P5028, 6065
Watremez, C. P3504 Wellmann, B. 358, P2797, P3128, 6636 Wiecek, A. 253
Watson, G. 4183 Wellnhofer, E. P718 Wiecek, A. P5269
Watt, A. P6302 Wells, A.U. 3253 Wiedemann, S. P678, P3570
Watt, G. P5019 Welsh, P. P5019 Wiedenroth, C.W. P4687
Watts, G.F. P5980 Welstand, J. 19 Wiederhold, B. P627
Wauters, A. 4195 Welz, A. P1596 Wiederhold, M. P627
Wauters, K. P650 Wen, G. 5847 Wiedmann, F. P5947
Waweru, C. P2426 Wen, M.H. P1819 Wieffer, H. P1677
Wen, Q. P6358
516
Chairpersons & Judges / Speakers & Discussants / Authors Wie – Wu,
Wieg, S. P3727 Windecker, S. 362, P807, 965, 1201, P1553, Wolpert, C. P414, P1400, 2986
Wiegerinck, E.M.A. 1840, P6388 P1691, P1723, P3448, P5026, 5786, 5791, Wolterbeek, R. P4316
Wiemer, M. P1751 6020, P6246, 6650 Won, K.B. P445
Wienbergen, H. 3309, 5818, P5935 Windhausen, F. P1101 Wong, C.M. 6642
Wieneke, H. 3207 Windle, J. P2718 Wong, C.X. P4374, P6198
Wiersma, M. P6186, P6189 Windorfer, B. P3487 Wong, D. P6241
Wierucki, L. P2471 Winkel, P.W. 2938 Wong, J. P2530
Wierzbowska-Drabik, K. P3524 Winkler, S. P212, 2920, P3728 Wong, J.I. P1763, P4747
Wiesbauer, F. P5398 Winter, B. P6367 Wong, K. Y.-K. P5475
Wiesinger, M. P2129 Winter, L. 3066, P3610 Wong, K. P6564
Wiggins, N. P6321 Winter, M.-P. P4545 Wong, K.Y.K. 2231, P2801, P4489
Wijers, S. P166 Winter, M.M. P2137 Wong, M. P2674
Wijeysundera, H.C. P1331 Winter, M.P. 5092 Wong, M.C.S. P3629, P6423
Wijngaard, P. P1761 Winter, R. P2609, P5482 Wong, N. P1585
Wijns, W. 1156, P1364, P1468, P2729, Winter, S. P1508, 5738 Wong, N.D. 151, 194
P2762, P2767, P2771, 4023 Winther, S. P1546 Wong, N.D. 2957
Wiklo, K. P2653 Winther-Jensen, M. P3470 Wong, P. P2752
Wiklund, O. 4892 Winwood, R. 245 Wong, R. P6124
Wikstrand, J. P895, P6551 Wirtwein, M. P757, P6224 Wong, S.C. 1197
Wilck, N. P1419 Wise, M. P421 Wong, S.J. P719
Wilczek, J. P2447 Wise, M.P. P1408 Wong, S.W. P831
Wilczek, K. P541, P2789 Wise, R.G. P4339 Wong, T. 958, P3367, P3395, P3741, P4390,
Wilczynska-Golonka, M. P5294 Wiseth, R. 336, 2943 P5452, 5740, P6112
Wild, P. 4977 Wisloff, U. 2943, 6039 Wongcharoen, W. P1732
Wild, P.S. P882, 1978, P2572, P4332, P4607, Wisniewski, P. 2108 Wongjaikam, S. P3786
P4661, P5016, P5369, P6206 Wisniowska-Smialek, S. 6610 Wonnerth, A. P6255
Wildberger, J.E. P4623, P5228 Wissenberg, M. P4072, 6627 Woo, E. P2599
Wilde, A.A. 3070 Wissocque, L. 5919 Woo, J.S. P4526, P4696, P4752
Wilde, A.A.M. 195 Witberg, G. 1981 Woo, M.A. P442, P780, P781, P5702
Wilde, A.A.M. P1427, P2412, 3073, 3985 Witberg, G.W. P2474 Woo, S.I. P2477
Wilde, J. P1600, 1983 Witkowski, A. P3724, 4017, 4019 Wood, A. 2849
Wildi, K. 154, 159, P524, P525, P529, P595, Witkowski, M. P1463, 2214, P2600, P2812, Wood, D. P2146, P2724, P6459, P6469
P1097, P1099, P1103, P2461, P3481, P4735 Wood, D.A. 91, 150, 250
P3484, P4077, P4454, 5085 Witsch, T. P2125 Wood, D.A. 2217
Wildi, K.S. 126, 157, P1100, P4459 Witsenburg, M. P707, P2656, P6418 Wood, M.E. 1089
Wilhelm, K. P2819 Witt, J. P673, P1606 Woodhead, A. P763
Wilhelm, M. 2929, P4098 Witte, K.K. P3767 Woodward, M. P744, P813, P3683, P5322,
Wilhelmsen, L. 2966 Wittert, G.A. 4053 P5600
Wilimski, R. P1616, P3086, P4572 Witzenbichler, B. 4000, P4326, P4328 Wort, S.J. P6413, P6417
Wilk, G. P6599 Witzenhausen, J. P5311 Worthley, M. P2839
Wilkens, H. P5520 Wiviott, S.D. 68, P1131 Worthley, S. P2839
Wilkins, M. 4183 Wiviott, S.D.W. P6466 Worthley, S.G. 4053
Wilkolek, P. P436, P720, P1641 Wiwatworapan, W. P2419 Woudstra, P. P1101
Willeit, K. P1472 Wizner, B. P5269 Woynarowska, B. P3671
Willeit, P. P1472 Wodnar, R. P3558 Wozniak, J. P5291
Willems, A.M. P2627 Woehrle, H. 358, P3128, 3836 Wozniak, O. P471, P482
Willems, R. P165, P1541, P3101, P3362, Woestijne, P. P3388 Wragg, A. P581, P2740, P3711
P5507, P5930, P6178 Wohlfahrt, J. P711 Wray, J. P5451
Willems, S. P3385, P3393, P3414, 5923 Wohlfahrt, P. 6652 Wright, D.J. P496
Willems, S.W. P4362 Wohlmuth, P. P4564 Wright, G. P5470
Willems, T.P. P4594 Woitek, F. P683, P1600, 1983 Wright, J. P774, P803
Willerson, J.T. P1348 Woitek, F.J. 2319, 5788 Wright, L. P3676, P5522, 5801
Williams, B. 36, 42, 78, 187, 353 Wojakowski, W. P1747, P2835, P2837 Wright, R.S. P4444, P6464
Williams, B. 280, 378, 383, 1155, 2019, Wojcik, M. P2411 Wright, S. P5525
2883, 2887, 3838, 3974, 4137, 4143, Wojcik-Pedziwiatr, M. P5616 Wright, T.J. P5949
5044, 5727, 5728, 5731, 6666 Wojdyla, D. 4979, P6155 Wrobel, K. P2613
Williams, E.D. 1849 Wojdyla, D.M. 1973, P2144 Wu, B.T. P6497
Williams, K.A. 88, 250 Wojta, J. 373 Wu, C.-C. P4684
Williams, M.J.A. P1775, P6380 Wojta, J. P5398, P6255, P6547 Wu, C. 337, 1215, 1958
Williams, R. P669 Wojtera, K. P2515 Wu, C.C. P1819, P5394
Williams, R.P.C. 4931 Wojtkowska, I. 3031 Wu, C.K. P2116
Williams, T. 3068, P6349 Wojtyniak, B. P549, P2471, P6580 Wu, F. P2493
Williamson, R. P2113 Wold, J.F.H. 1324 Wu, I.C. P5554
Willoteaux, S. P4417 Wolf, E. P3097 Wu, J. P2817, 5903, P6358
Wilson, C. P4078 Wolf, G. P2589 Wu, J.C. P3577
Wilson, C.M. P477 Wolf, M. P4342 Wu, J.R. P3751
Wilson, D. P6562 Wolff Gowdak, L.H. 3845 Wu, K.C. 4057
Wilson, M. P2660, 2931, P4105 Wolke, C. P6179 Wu, L. P6180
Wimmer-Greinecker, G. 4268 Wollert, K. P882 Wu, M. P6260
Winchester, D. P600 Wollert, K.C. P2633 Wu, N.-Q. P1662, P5229
Windak, A. P6481 Wu, N.-X. P5386
517
Chairpersons & Judges / Speakers & Discussants / Authors Wu, – Yao
Wu, P.H. P5431 Yahiro, E. P3749, P3754 Yamashita, E. P2533

Wu, T.-C. P2131 Yahyai, A. P1803 Yamashita, J. P184, P2483, P3549
Wu, T.C. P1819 Yajima, S. P2610 Yamashita, K. P2692, 5885
Wu, V.C. P2116 Yakar Tuluce, S. P705 Yamashita, S. P897, P3360, 4898, P5982
Wu, Y.Y. P6589 Yakovleva, M. P489 Yamashita, T. P5443
Wu, Y.Z. P6518 Yaksh, A. P3388, P4392 Yamashita, Y. P1357, P4626, P5698, P6137
Wu, Z.G. P2493 Yakushin, S.S. P3354 Yamat, M. P5484
Wu, Z.S. P2568 Yakushko, L. 6046 Yamauchi, H. P6300
Wunderlich, C. P3389, P3409, P4341, Yalcin, A.A. P2519, P4104, P6242 Yamauchi, K. P4483
P4359, P4983 Yalcin, B. P6242 Yamauchi, M. P2694
Wuriyanghai, Y. P6350 Yalcin, F. 4913 Yamauchi, R.Y. P828
Wurm, R. P3454 Yalcin, H. 4913 Yamauchi, T. P6539, P6544
Wustmann, K. 2929, P6454 Yalcin, M.U. 1839, P4379, P6188 Yamauchi, Y. P3360, P5323, P5556
Wuttge, D. P1754 Yalcin, R. P457, P4534 Yamauchi-Takihara, K. P839
Wuttichaipradit, C. P613, P2585 Yamada, A. P3690, P6248, P6305 Yamaura, G. P1660, P3533
Wutzler, A. P1093, P3079, P4385 Yamada, K. P2706 Yamawake, N. P490, P751
Wykrzykowska, J. P2743 Yamada, M. P5503 Yamawaki, M. P2733, P4492, P4718, P6145
Wykrzykowska, J.J. 364, 5167, 5169, 5170, Yamada, N. P1535, 2339, P4114, P4486, Yamazaki, H. P1570
5171 P4774 Yamazaki, T. P4523, P4549
Wypasek, E. P2606, P3587 Yamada, O.Y. P4603 Yamazoe, M. P1801, P3685
Wysocki, M. P2471, P6580 Yamada, R. P2776 Yameogo, N.V. P799
Wysokinski, A. P2411, P5653 Yamada, S. P1713, P3692, P5578 Yameogo, V. P3080
Xanthopoulos, A. P6566 Yamada, T. P536, P1378, P2804, P4760, Yaminisharif, A. P2431, P5581
Xanthopoulou, I. P1469, P1478, P1479 4908, P5029, P6558 Yamwong, S. P458, P1695, P4627, P4672
Xaplanteris, P. P204, 967, P1572, P2574, Yamada, Y. P905, P5002, P5444, P5503, Yan, B. P1684
P2699, P3806, P4668, P5540, P5541 P5590, P5593, P5610, P6172 Yan, B.P.Y. P5544
Xhepa, E. P3705 Yamagishi, K. P2686 Yan, C. P1526, P3330, 6103
Xhyheri, B. P3418 Yamagishi, M. 318 Yan, H. 3947
Xhyhery, B. P3397 Yamagishi, M. 111, P693, P698, P1420, Yan, L.Y. P1782
Xi, Q.Y. P6130 P1655, P1661, P1694, P1699, P1701, Yanagisawa, Y. P605
Xia, Y. P3596, P6330 P1704, P2150 Yanaka, K. P6534
Xia, Y.L. P4370 Yamagishi, S. P4677 Yang, A. P3772, P3793
Xiao, Q. 5847 Yamagishi, T. P5564 Yang, B. P6160
Xie, A. P6360 Yamaguchi, H. P1727 Yang, C. P3557, 5903
Xie, J.U.N. P3547 Yamaguchi, J. P4552, P4694 Yang, D.H. P2462, P4724
Xie, J.Y. P6588 Yamaguchi, N. P5261 Yang, H.-M. 3208
Xie, Y. P4518 Yamaguchi, O. P1793, P4360 Yang, H. P2634, 2927, P3676, 4155, P4746,
Xie, Y.Q. P3598, P3602 Yamaguchi, S. P1744 P5430, P5711
Xing, W.J. P1113, P2712 Yamaguchi, T. P688, P759, P1633, P2599, Yang, H.B. 4059
Xiong, C.M. 2334 P4523, P4549, P5556 Yang, H.M. P1721
Xiong, J. P2516 Yamaguchi, T.Y. P754 Yang, J.-H. P1757
Xiong, Q. P4400 Yamaguchi, Y. P5299 Yang, J. P1756, 2205, P3085
Xu, B. P2730, P3547, P3697 Yamahina, A. P759 Yang, J.G. P2521, P4407
Xu, H.Y. P2521, P4407 Yamaji, K. P1553, 2908 Yang, J.H. P2495, P4472
Xu, J. P1113 Yamakage, H. P3110 Yang, J.N. 3204
Xu, J.F. 4059, P4515, P6330 Yamakami, Y. P1735, P1753, P4514, 6618 Yang, J.Y. P5510
Xu, R.-X. P5229, P5357, P5386, P5388 Yamakova, Y. P6403 Yang, L.-T. P4780, 5808
Xu, R.L. P4313 Yamamoto, E. P811, P1339 Yang, L. P1113, P1700, P2712
Xu, S. P762, P2842, 5124 Yamamoto, H. P2453 Yang, Q.M. P6180
Xu, X. P4122 Yamamoto, K. P1426, P1798, P2551, Yang, R.C. P3751
Xu, Z. 6103 P2706, P2769, P3784, P4309 Yang, S.J. P2588
Xue, A. P5968 Yamamoto, M. P881, P3498, P3700, P3708, Yang, S.W. 1831
Xue, Y.M. P4585 P3722, P4116, P4353, P4384, P6299 Yang, T.-H. P2478, P2498, P2737, P4700
Xuereb, R.G. P5250 Yamamoto, S. P4674, P4677 Yang, T.H. P4697
Yabe, T. P1482, P4512 Yamamoto, T. P688, P1633, 2243, P2483, Yang, W.-I. P2153, P4513
Yabe-Nishimura, C. P2583 P2491, P6530 Yang, X.S. P2612
Yabu, K. P1567, P2672 Yamamoto, Y. P3463, P4783 Yang, X.U. P1648
Yaccoub, M. P6561 Yamamuro, A. P3089 Yang, Y. P4122, P5662
Yacoub, M. P2468, P3542, P4069, P4716 Yaman, M. P542, P2535, P2847, P3760 Yang, Y.H. P2116
Yadalam, A. P4301 Yamanaka, F. P6319 Yang, Y.J. P805, P2521, P3697, P4407
Yadav, R. 80 Yamanaka, K. P801 Yang, Y.Q. P6359
Yaegashi, T. P6183 Yamane, K. P4506 Yang, Y.Z. P4370
Yafi, W. P5379 Yamane, T. P3410 Yang, Z.Z. P6359
Yagawa, M. P1801 Yamano, T. P583 Yanni, J. P415, P6354
Yagdi, T. P6510 Yamaoka, T. P1135 Yano, H. P6276
Yagi, S. P431, P642 Yamaoka-Tojo, M. P655, P2672, P2719 Yano, M. P764, 2243, P5939
Yagi, T. P1127, P1383 Yamasaki, M. P2483, P3482 Yano, T. 1086, P2350, P5299
Yagihara, N. P5327, P6156 Yamasaki, N. P1619, P4592 Yao, H.H. P6306
Yagmur, B. P5681 Yamase, Y. P5610 Yao, K. 337, 1958
Yagyu, T. P6554 Yamashina, A. P184, P603, P1821 Yao, L. 2205
Yahata, T. P4604 Yamashina, A.Y. P754 Yao, X. P5414
518
Chairpersons & Judges / Speakers & Discussants / Authors Yao – Yur
Yao, Y. P1467, P3697, P6173 Yin, J.S. P6518 Yoshino, H. P5564, 6089, P6123
Yao, Z.F. P6518 Yin, W.H. P1819, P5394 Yoshino, T. P2353
Yaoita, N. P5958 Yin, X. P2571, P4082, P4531 Yoshioka, D. P2610
Yap, J. P1617 Yin, X.M. P4370 Yoshioka, K. P420
Yap, S. P479 Yingchoncharoen, T. P458, P1695, P2419, Yoshioka, R. P2769
Yarinkina, O. P6591 P2585, P4627, P4672 Yoshiyama, M. P2599, P4523, P4549
Yarlioglues, M. P825, P5335, P6257 Yip, G. P2674 Yoshizane, T. P2830, P4779
Yarnell, J. P1667 Yip, H.K. P1762, P3564 Yoshizawa, R. P5331
Yasaka, Y. P1564, P1713, P3692 Yip, J. P6124 Yoshizawa, T. P1422
Yasuda, H. 6629 Yiu, K.H. P738, P1143, P6303, P6312 Yoshizumi, M. P2603
Yasuda, K. P1672 Yla-Herttuala, S. 35 Yost, G. P4773
Yasuda, R. 4180 Yla-Herttuala, S. P2597, P3099, P5946 Yotti, R. P3127, P3554, P3608, P3615,
Yasuda, S. P480, P487, P881, P1527, P2366, Ylae-Herttuala, S. P4084 P4569, 5802
P2368, P2448, P2800, 3305, P4761, Ylitalo, A. P4061 Yotti-Alvarez, R. P1392, P5494
P4763, P5354, P6536, P6541, P6545, 6628 Yndestad, A. P5257 You, L.K. 5075
Yasuda, T. P1452 Yndigegn, T. P175 You, S.C. P3337
Yasui, T. P839 Yodogawa, K. P513 Youn, J.-C. P6590
Yasukatsu, I. P4523 Yokoe, H. P769 Youn, J.C. P2710
Yasukawa, H. 2338 Yokoi, M. P3708, P3722 Youn, T.J. P2570
Yasumura, K. P1108 Yokoi, T. P1744 Youn, Y.J. P5334
Yasumura, Y. P6537 Yokokawa, M. P3422 Young, H.J. 960
Yasunaga, H. P5691 Yokokawa, T. P883 Young, J. P6555
Yatsu, S. P2799 Yokota, H. 6628 Young, J.M. 127, P3483
Yavuzer, H. P1828 Yokota, Y. P2720 Younis, S.E. P2628
Yavuzer, S. P1828 Yokote, K. P5982 Yousef, Z. P3752
Yayehd, K. P5932 Yokoyama, K. P5039 Yousef-Abumuaileq, R.R.Y. P2466
Yayla, C. P4533, P4577, 5210, P6274 Yokoyama, M. P1564, P2487, P4314, P4766 Youssef, A. P679
Yaylali, Y.T. P855 Yokoyama, N. P6522 Youssef, G. P4653
Yazaki, Y. P3764 Yokoyama, S. P1130 Ypey, D.L. P6177
Yazdani, K.O. P2431 Yokoyama, Y. P3685, P5925 Ytsma, T. P560
Yazdani, M. P5682 Yonekura, Y. P2148 Yu, C. P5431
Yazeed, Y. P1537 Yonemoto, N. P1383, P3482 Yu, C.M. 2959, 2961, 2963, 3965, P5424,
Yazici, M. P5714 Yonetsu, T. P6238 P5434, P5544
Ye, S. P5383 Yonetsu, Y. P420 Yu, C.W. P2755, 2912
Ye, Y. P6342 Yoneyama, K. P5372, P6125 Yu, D.R. P6423
Yegin, B. P2847 Yonezawa, T. P2605 Yu, H.T. 1239
Yeh, C.H. P6331 Yong, A.S. 4022 Yu, J. P3542
Yeh, H.I. P888, P1819, 2227, P3534, P4076, Yong, Z.Y. 1840 Yu, P. P4515
P5394, P5432, P6294 Yoo, B.S. P4110, P5334, P6578, P6579 Yu, P.C. P1804, P6499
Yeh, J.L. P3751 Yoon, C.H. P6579 Yu, P.H. P3436
Yeh, R. P823 Yoon, H.J. P445, P4474 Yu, R.-H. P5266, P5274
Yeh, S.-J. 24 Yoon, J. P5334, P6364 Yu, T.Y. P1416, P5949, P6352, P6357
Yehia, A. P481 Yoon, J.Y. P4426 Yu, W.-C. P5664
Yelgec, N.S. P5275 Yoon, M.H. P1721 Yu, W. 337, P1636, 1958
Yellon, D.M. 1087, P3444 Yoon, N.S. P4616, P4633 Yu, W.C. P4759, 6045, P6576
Yeo, T.C. P5441, P5648, P6124 Yoon, S.J. P5510 Yu, X. 1328
Yeo, W.T. P2430 Yoon, Y.E. P2570 Yu, Y. P3598, P3602, P4518
Yerramilli, R. P889, P6569 Yoon, Y.H.J. P1475, P5971 Yu, Y.B.Y. P4680
Yesin, M. P4319, P6386 Yoon, Y.W. P1638, P3687 Yu, Y.I.N.G. P3598, P3602
Yeung, A. P2124 Yorgun, H. P4379, P4690, 6074 Yuan, J. 337, 1215, P1412, P1559, 1958,
Yeung, C. P6472 Yoshida, A. P1637, P4552 5903, P6342
Yigit, Z. P3644 Yoshida, H. P1582 Yuan, J.Q. P1467, P3697
Yigitbasi, M. P718 Yoshida, I. P5579 Yuan, Z. P4066
Yildirim, O. P5714 Yoshida, K. P1798, P2776, P3784, P4402 Yuasa, D. P433
Yildirim, U. P5421 Yoshida, M. P2605, P5238 Yuba, T. P4466
Yildirimturk, O. P5275 Yoshida, R. P2446 Yucel, H. P542
Yildirir, A. 4173, P6523 Yoshida, S. P2610 Yuda, S. P2556
Yildiz, A. P573, P2714 Yoshida, T. P2769, P3083 Yudina, V. P735
Yildiz, G. P2519 Yoshida, Y. P3327, P4314, P4535, P4537, Yue, Y. P903
Yildiz, P. P5440 P4733, P6351 Yuecel, S. P1141, P3501
Yildrim, C. P6261 Yoshihisa, A. P6300 Yuen, D. P649
Yilmaz, A. P1532, 2236, P3093, 6097, 6098, Yoshikawa, H. P1694, P3499, P6296 Yufu, K. P2415
6100 Yoshikawa, T. P688, P1633, P1801 Yuksek, U. P5693
Yilmaz, B. P6139 Yoshikawa, Y. P2610 Yuksel, M. P4533
Yilmaz, F. P5517, P6144 Yoshimura, A. P4065, P4375 Yuksel, S. P2444
Yilmaz, K. P6523 Yoshimura, K. P4732 Yun, H.R. P4559
Yilmaz, M.B. P3760, 4173, P5681, 6015 Yoshimura, M. P2353 Yun, S.C. P3778
Yilmaz, M.F. P5481 Yoshimura, T. P2503, P6201 Yung, C.Y. P6305
Yilmaz, O. P2444 Yoshimuta, T. P1694 Yung, L.T.M. P2820
Yilmaztepe, M. P2534 Yoshinaga, M. 1327 Yuniadi, Y. P2424
Yin, F.C.P. P5570 Yoshinaka, Y. P1570 Yurchenko, A. P2825
519
Chairpersons & Judges / Speakers & Discussants / Authors Yur – Zho
Yurdakul, S. P5440 Zampetaki, A. P1472, P2571 Zeng, X.H. P6588

Yurtdas, M. P855 Zanaboni, J. P2561 Zeng, X.J. P6588
Yuruyen, M. P1828 Zanchin, T. P6246 Zengin, E. P882
Yusen, R.D. 4176 Zandecki, L. P448, P539, P1447, P1448, Zengin, H. P2444
Yusuf, S. 318 P3121, P5937 Zeppa, F. P6559
Yusuf, S. 252, 1977, 3964, 4980, P6596 Zannad, F. 244 Zeppenfeld, K. P1401, P3372, P5926, P6177
Yuyama, R. P769 Zannad, F. 373, 376, 377, 995, 997, 999, Zeren, M. P3644
Yuzawa, H. P6218 3292, P3793, 3869, 3871, 3872, 3873, Zetterstom, A.-K. P2659
Yuzawa, Y. P726 5851 Zeus, T. P2578, P5986
Zabala Diaz, L. P167 Zanni, A. P2619 Zeymer, U. 256
Zabczyk, M. P1447, P1448, P2505 Zanolin, D. P1697, P3678, P4473 Zeymer, U. 120, P837, 1203, P1462, P1471,
Zabel, M. P165, P166, P5930 Zanolla, L. P1602 P1505, P2463, P3120, P4989, 5813, 6007
Zabielski, P. P6279 Zanon, F. P503, 2270, P2389, P2390, P4745, Zeyons, F. 6635
Zaborska, B. P4388 P4758, 4863 Zhang, A. P1428
Zabrocki, R. P5935 Zapolski, T. P5653 Zhang, B. 2059, P3339, P4655, P5038
Zabsonre, P. P3135 Zara, C. 3944, P6118 Zhang, D. P6186
Zabunova, M. P2347 Zaraisky, M.I. P5362 Zhang, D.Y. P6423
Zaccardi, F. P2798 Zareba, V. 2271 Zhang, G. P3557, 5903
Zacchigna, S. P1347 Zareba, W. P523, 4862, P6163 Zhang, H. P415, P1643, P3443, P6358
Zaccolo, M. 2242 Zarifis, J. P6277 Zhang, H.F. P1113
Zacek, J. P169 Zarinabad, N. P1530 Zhang, J. P903, P3789, P4489, P6556
Zachaeus, M. P6509 Zarka, S. 2103 Zhang, J.H. P1467, P3697
Zacharis, E. P5371, 5905 Zaromitidou, M. P740 Zhang, J.L. P1113
Zacharis, E.A. P3355, 4899 Zaromytidou, M. P455, P1116, P1577, Zhang, J.Y. P2493, P4369
Zaciragic, A. P2594 P2575, P2689, P2725, P3680, P4312, Zhang, L. P557, 1958, P2555, 5847, P6342
Zadak, Z. P3446 P6476 Zhang, M. P2152, P4531, P5636
Zafrir, B. P203, P205, P703, 3995, 4886, Zaroui, A. P850 Zhang, P. 1838, P3465
P5586 Zarse, M. P3773 Zhang, Q. P5434
Zagatina, A. P1344, P2565 Zartner, P.A. P4605 Zhang, Q.P. P2634
Zagidullin, N.S. P6284 Zaruba, M.M. P1349, P4737, P5558 Zhang, R. P6556
Zagidullin, S.Z. P6284 Zatarain, E. P5494 Zhang, S. P470, P2410, P2413, P3378,
Zagrebelnyy, A.V. P3354 Zatarain Nicolas, E. P1392 P6572
Zaharia, D. P5943 Zatonska, K. P222 Zhang, S.L. P4370
Zaharijev, S. P816 Zaugg, S. 1201, P5026 Zhang, T. P1643
Zahedi, F. 1994 Zausig, Y. 3310 Zhang, W.L. P2588
Zahedi, R. 2341 Zavadovsky, K. P5224 Zhang, X. P1113
Zahger, D. 2297, 3194, 4017, 4018, 4019 Zavalloni Parenti, D. P208 Zhang, X.H. P779
Zahir, D. 1329, P3312 Zaya, K. P884 Zhang, X.L. P4348
Zahka, K. P1629 Zaykov, I. P3370 Zhang, Y. P779, P903, 1052, P1662, P2712,
Zahn, R. P469, P550, P837, 1203, P1462, Zbinden, R. P1723 P2805, P2817, P3459, P4122, P5357,
P1471, P3385, P4989 Zbozinkova, Z. P224 P5386, P5388, P6556
Zahner, L. P2685 Zdradzinski, M.J. P3795 Zhang, Y.E. P1645, P1648, P6496
Zaizen, H. P629 Zdravkovic, S. 2936 Zhang, Y.Q. 3227
Zajac, M. P1771 Zdrojewski, T. P549, P1693, P2471, P5404, Zhang, Y.Y. P6589
Zakharevich, V. P1813 P6580 Zhang, Y.Z. P4369
Zakirova, A.N. P5264 Zebele, C. P3559 Zhao, H. P2793
Zaklyazminskaya, E.V. P6171 Zecchin, M. P522, P1621 Zhao, J.G. P779
Zaklyazminskaya, H. P489 Zechmeister, C. P3599 Zhao, J.J. 2335
Zalewski, J. P2505, P3495, P5294 Zeebregts, C.J. P1566 Zhao, L.P. P5644, P5648
Zaltsberg, S. P3391, P4368 Zegkos, T. P5502 Zhao, M. P3720
Zaman, J. P777, P3386 Zehender, M. P6356 Zhao, Q. P6130
Zaman, J.A. P4378 Zehetmayer, S. 4866 Zhao, S. P470, P1583
Zaman, J.A.B. P1418, P1550 Zeiher, A.M. 2342, 4967 Zhao, W. P4407, P6589
Zambon, A. 3882 Zeiser, R. 1956 Zhao, X. P4369
Zambon, E. P5683, P6147, P6575 Zeitz, U. P3460 Zhao, X.D. P4747
Zambrano, C. P6559 Zelenak, C. P5690 Zhao, Y. P697, P1583, P1648
Zambrano, T. P1579 Zeller, J. 2230 Zhao, Y.X. P659
Zambrano-Medina, E. P601, P2381, P2777, Zeller, M. P1696, P2147, P3080 Zhao, Z.-L. P5414
P3657, P5611, P6526 Zeller, T. P882, P2572, 3969, 3970, 3971, Zhao, Z.H. P6130
Zamfir, D. P5943 P4074, P4332, P4607, P4661, P5016, Zhao, Z.Y.X. P3438
Zamora, A. P1674 P5022, P5369 Zhen, Z. P1143, P1145, P6303, P6312
Zamora, E. P752, 4277, 6639 Zellweger, M. P2695, P4612, P5397 Zheng, C. P5453
Zamorano, J.J. P1554 Zembala, M. P549, P566, P576, P699, Zheng, H. P5662
Zamorano, J.L. P1396, P3531 P2471, P2506, P2789, P5011, P5646, Zheng, Y. 2334, P3315
Zamorano, P. P4465 P6367, P6580, P6587 Zheng, Y.G. P6130
Zamorano Gomez, J.L. 73, 128, 147, Zemir, H. 6625 Zheng, Z. P5253
245, 260, 370, 372, 410 Zemora, Z. P1806 Zhiduleva, E. P4555
Zamorano Gomez, J.L. P508, 1902, P2547, Zencir, C. P2416 Zhong, J. P653, 1217
P2691, 3173, 3879, 5091, P5442 Zeng, D. P6163 Zhong, L. P1763, P4747, P5411
Zampetaki, A. 157 Zeng, X. P5412, P6588 Zhong, Y. P6460
520
Chairpersons & Judges / Speakers & Discussants / Authors Zho – Zys
Zhong, Y.I. P3339, P5038 Zimmer, S. P661, P664, 1960 Zornoff, L.A.M. P5258
Zhou, A. P6360 Zimmermann, D. P896 Zorzi, A. P690, P1534, P4460
Zhou, B. P3557 Zimmermann, W.-H. 4188 Zotter Tufaro, C. 2212
Zhou, D. 4181 Zimmermann, W.H. P3329 Zotter-Tufaro, C. P1786, P1808, P2129
Zhou, G. 38, P2413, P3378 Zimmet, P. P756, P3627 Zou, J. P1412
Zhou, J. 68, P1682, P6120, P6340 Zimoch, W. P3430 Zou, Y. 337, P903, 1215, 1958, P2817,
Zhou, J.Y.J. P5341 Zindel, C. P1614 P3557, 5903
Zhou, N.W. P483 Zint, K. P1488, P1516 Zou, Y.Z. P3598, P3602, P6330, P6342
Zhou, Q. P1454, P2555, P5414, P5417, Zintl, K. P3523 Zrenner, B. 1203
P6556 Zinzaki, M. P5503 Zuber, M. P1614, P6414
Zhou, X.B. P5947 Zirngast, B. P3471, P3492 Zuberi, Z. P4373
Zhou, X.J. P6160 Zisimos, C. P730 Zublillaga, E. P1778
Zhou, Y. P710, P5237 Zisimos, K. P1116, P1342, P2725, P5555 Zuccaro, L.M. 5916
Zhou, Y.J. P659, 1831 Zitny, B. P1797 Zucchelli, G. P1092
Zhou, Y.L. P4313 Zito, A. P657, P733, P4311, P4664, P6437 Zucchetta, F. 351, P4568
Zhou, Z. P3082, P5253 Zito, C. P634, P3521 Zucchi, R. P3087
Zhou, Z.Y.J. P3438, P6515 Zittermann, A. P1618 Zucco, M. P3521
Zhu, C.-G. P1662, P5229, P5357, P5386, Zitzelsberger, T. P2524 Zueco, J. 366, P2757
P5388 Ziv, A. P5977 Zueco Gil, J.C. P2759
Zhu, D. P1412 Zivkovic, I. P446, P827, P830, P2518, P3715, Zuercher, F. P6135
Zhu, J.-J. P5414 P4433 Zuern, C. 349, 6041
Zhu, J. 337, 5847 Zivkovic, M. P446, P827, P2484, P2567, Zugck, C. P1367
Zhu, P. P5414 P3715, P4433 Zuk, K. P1723
Zhu, T.G. P5431 Zlabinger, K. P3577 Zulkarneev, R.H. P6284
Zhu, Y.X. P4369 Zlatanovic, P. P816 Zumhagen, S. P1400
Zhu, Z. 6103 Zlatic, N. P5678 Zundler, J. P2370
Zhu, Z.F. P3100 Zlobina, M.V. P6574 Zuniga-Munoz, A.M. P641
Zhu, Z.Y. P1145 Zmudka, K. P638, 2022, P4685, P5616, Zupan, I. P6229
Zhuravskaya, N. P1344, P2565 P5619 Zupan Meznar, A. P6229
Zi, M. 6056, 6057 Zo, J.H. P6563 Zvartau, N. P900
Zideman, D. 90 Zoccali, C. P620, P1149 Zvartau, N.E. P5706
Zielinska, T. P5303 Zoccarato, A. P4531 Zverev, D. P211, P6420
Zielinski, C. 4278 Zoga, A. P2499, P3082, P3441 Zverkova Sandstrom, T. P2157
Zielinski, T. P3543 Zoghbi, W.A. 153 Zweiker, D. P3471, P3492
Ziemann, U. P5603 Zografos, T. P791, P3386, P4378, 4862 Zwetsloot, P.P.M. P5447
Zierden, M. 2335 Zola, P. P865 Zwinderman, A.H. P2658, P2661, 3071,
Zijlstra, F. P174, P1456, P1507, 2909, P3733, Zolotarev, O.N. P6593 P5239
P4673 Zolotova, O. P3761 Zwisler, A.D. 2939, P3654
Zile, M. P213, 3301, 3302, P5031 Zombolos, S. P4418, P4430, P4450 Zwisler, A.D.Z. 2938
Zile, M.R. P214 Zompatori, M. P5521 Zykov, K. P6528
Ziliani, F. P3790 Zondag, W. 4175 Zykov, K.A. P4593
Zilles, K. P2357 Zoni Berisso, M. P504 Zymlinski, R. P889, 3308, P6569
Zima, E. P499, P509, P2396, P2399, 4856 Zorandi, A. P5934 Zysko, D. P1441
Zimba, A. P530 Zorin, A. P1822 Zyssman, I. P3642
Zimlichman, R. P4654 Zorn, G. P6547
521
25: Sha
25x25:
25 Shaping
aping the future of global heart health
A GLOBAL INTERACTIVE EVENT TO

PROMOTE CV HEALTH
Uniting cardiovascular disease specialists with other
disciplines to network, share knowledge and build Abstract
innovative solutions for patients and populations submission
AN OUTSTANDING LINE UP OF WORLD opens
15
LEADERS IN HEART HEALTH 14 Sept 20
120 sessions on cardiovascular health and
cardiology practice - including acute coronary
syndromes, heart rhythm disorders, heart failure -
for all health and public health professionals
BEST PRACTICE SHARING

An interactive programme designed to respond
to the needs of professionals - representing
disciplines including cardiology, internal medicine,
general practice, nursing and public health - in their
L]LY`KH`WYHJ[PJLHJYVZZKPɈLYLU[YLZV\YJLZL[[PUNZ
GROUND BREAKING RESEARCH INTO

CARDIOVASCULAR HEALTH
1,000 new abstracts on prevention, diagnosis
and treatment alongside public health and health
systems approaches for cardiovascular and related
diseases
SPOTLIGHT ON LATIN AMERICA AND

SESSIONS IN SPANISH
Exploring the spectrum of CVD in Latin America:
epidemic of atherosclerosis, Chagas’ and rheumatic
heart disease, obesity, tobacco as well as health
systems
A PLATFORM TOWARDS THE 25X25 GOAL

A 25% reduction in premature CVD morbidity and
mortality by 2025
www.worldcardiocongress.org
LIST OF TOPICS
Topic (PROGRAMME NUMBER(S))
3-D echo
P2536, P2538, P2539, P2540, P2541, P2543, P2544, P2545, P2546, P2547, P2548, P2549, P2550, P2555, P2556, P2557, P2558, P2559, P2560,
P2568, P2569, P2570, 3167, 3168, P3530, P3531, P3532, P6122, P6124, P6326
Acute cardiac care in the emergency department

124, 125, 126, 127, 128, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 1047, 1048, 1050, 1051, 1161, 1162, 1163, P1515, P3428, P3429, P3430,
P3431, P3432, P3478, P3479, P3480, P3481, P3482, P3483, P3484, P3485, P3486, 4167, 4169, P4454, P4455, P4456, P4457, P4458, P4459, P4460,
P4461, P4462, P4463
Acute intensive cardiovascular care
1049, 2295, 2296, 2297, 2298, P3437, P3451, P3452, P3453, P3454, P3455, P3456, P3468, P3469, P3470, P3471, P3472, P3473, P3474, P3475,
P3476, P3477, P3488, P3489, P3490, P3491, P3492, P3493, P3494, P3495, 3936, 4163, 4164, 4165, 4168, 4253, 4254, 4255, 4256, 4257, 5074,
5085, 5086, 5087, 5088, 5089, 5090, 5091, 5092, 5093, 5094
Acute nursing care
44, 45, 46, 47, P772, P773, P774, P775, P776, P777
Acute pulmonary embolism
1060, 1061, 1062, 1063, 1064, 2873, 2874, 2875, 2876, 2877, 3038, 3039, 3040, 3041, 3042, 3043, 3044, 3045, 3046, 3047, P3616, P3617, P3618,
P3619, P3620, P3621, 3917, 4174, 4175, 4176, 4177, 4178, 4179, 5190, 5191, 5192, 5193, P6402, P6403, P6404, P6405, P6406, P6407, P6408,
P6409, P6410, P6411
Adjunctive medical therapy
P582, P583, P596, P1510, P1511, 1947, P2122, P2458, P2459, P3467, 3883, P4453, P6116, P6117, P6119, P6120, P6260, P6287, P6289, P6290,
P6291
Adult congenital heart disease
143, 344, 345, 346, 347, P434, P436, P437, P438, P715, P716, P717, P718, P719, P720, P721, P722, P723, P724, 1010, 1012, 1014, 1298, 1300,
P2137, P2140, 2309, 2311, 2313, 2315, 2925, 2927, 2929, 2934, 3048, 3052, P3333, P3607, P3608, P3609, P3610, P3611, P3612, P3613, P3614,
P3615, 4272, 4273, 4274, 4275, 4950, 4951, 4952, 4953, 4954, 4955, 4956, 4957, P6412, P6413, P6414, P6415, P6416, P6417, P6418, P6419,
P6420, P6421
Ambulatory pressure monitoring
280, 281, 282, 283, 284, 285, 286, 287, 1003, P2847, P2848, P3351, P3352, P3353, P3796, P3797, P3798, P3799, P3800, P3801, P3802, P4119
Angina pectoris stable
6, 1039, P1337, P1339, 2859, 2860, 2861, 2862, 2863, 2878, 2879, 2880, 2881, 2882, 3843, 3844, 3845, 3846, 3847, 4146, 4147, 4148, P4300,
P4301, 4934, 4935, 4936, 4937, 4938, 4939, 4940, 4941, 5880, 5881, 5991, 5995, 5996, 5997, P6220, P6221, P6222, P6223, P6224, P6225, P6226,
P6288
Angina pectoris unstable
P1097, P1098, P1103, P1508, 3011, 3012, 3013, 3014, 3015, 3016, 3017, 3018, 3019, 3020, P3438, 4012, 4013, 4014, 4015, 4016, 4017, 4018,
4019, 4020, P4074, P5227, P6231, P6232
Angiogenesis
P429, P431, P1114, P1556, P1557, P1558, P1559, P1560, P1562, 1956, 1957, 1958, 4159, 4160, 4161, 4162, 6605
Antiarrhythmic drugs
5099, P6154, P6155, P6156, P6157, P6158, P6159
Antibradycardia pacing
1241, 1243, P1438, P1439, P1440, P1441, P1442, P1443, P2109, P2110, P2112, P2113, P2114, P2115, 2194, 2195, 2196, P2426, P2427, P2428,
P2429, P2430, P2431, P2432, P2433, P2434, P2435, 3138, 5735, 5756, 5757, 5914, 5915, 5916, 5917, 5918, 5919, 5920, 5921, 5922, 5923
Antithrombotic agents and thrombolysis
P565, P584, P1505, P1512, P1513, P1514, P1516, 1831, 2070, 2071, 2072, 2073, 2906, 4979, 4980
Aorta, peripheral arterial and venous surgery
4245, 4246, 4247, 4248, 4249, 4250, 4251, 4252, 4919, 4920, 4921, 4922, 4923, 4924, 4925, 4926, 4927, 4928, 5161, 5162, 5163, 5164, P6494,
P6495, P6496, P6497, P6498, P6499, P6500, P6501, P6502, P6503, P6504, P6505, P6506
Aortic valve disease
133, 134, 135, 136, P669, P670, P671, P672, P673, P674, P675, 1056, 1057, 1058, 1059, P1589, P1601, P1602, P1603, P1604, P1605, P1606, P1607,
P1608, 1846, 1924, 1925, 1926, 1927, 1980, 1981, 1982, 1983, 1984, 1985, 1986, 1987, 1989, P2606, P2607, P2618, P2619, P2620, P2621, P2622,
P2623, P2624, 3049, 3285, 3286, 3287, 3288, P3331, P3332, P3334, P3335, P3585, P3586, P3587, P3588, P3589, P3590, P3591, P3592, P3593,
P3594, P4089, P4090, P4091, P4092, P4093, P4094, P4095, 4267, 4268, 4269, 4270, 4271, P4316, P4555, P4556, P4557, P4558, P4566, P4567,
P4568, P4569, P4570, P4571, P4572, P4573, P4574, 4817, 4818, 4819, 4820, P5009, P5011, P5473, P5474, P5475, P5476, P5477, P5478, 6031,
P6373, P6374, P6375, P6376, P6377, P6378, P6379, P6380, P6381
Aortic valve interventions
233, 234, 235, 236, P668, P680, P681, P682, P683, P684, P685, P1599, P1600, P1614, P1615, P1616, P1617, P1618, 1840, 1988, P2616, P2617,
P2630, P2631, P2632, P2633, P3580, P3581, P3582, P3583, P3584, P4565, P4581, P4582, P4583, P4584, 4946, 4948, P5010, P5013, P5014, P5015,
P5487, P5488, P5489, P5490, P5491, P5492, 6033, 6090, P6372, P6387, P6388, P6389, P6390, P6391
Aortic valve surgery
3257, 4947, 4949, 6021, 6022, 6023, 6024, 6025, P6486, P6487, P6488, P6489, P6490, P6491, P6492
Atherosclerosis
253, 254, 255, 256, P637, P638, P640, P642, P644, P645, P646, P651, P653, P659, P660, P661, P663, P665, P666, 1214, 1216, 1217, 1218, P1561,
P1563, P1566, P1568, P1570, P1582, P1583, P1584, P1585, P1586, P1587, P1588, 1960, 1961, P2135, 3199, 3200, 3201, 3202, 3837, 3838, 3839,
3840, 3841, 3842, 3862, 3863, 3865, 3867, 3868, 3882, 5727, 5728, 5729, 5730, 5731, 5732
Atrial fibrillation (AF)
22, 23, 24, 296, 297, 298, 299, 300, 389, 390, 391, 392, 393, 394, 395, 396, 397, 408, 409, 410, 411, 412, 413, 928, 929, 930, 931, 932, 933, 950,
951, 952, 953, 957, 958, 1245, 1246, 1247, 1248, 1249, 1832, 1847, 1894, 1895, 1896, 1897, 1898, 1899, 1903, 1904, 1905, 1906, 1907, 1908,
524
1909, 1910, 1911, 1913, 1928, 1929, 1930, 1931, 1932, 1970, 1971, 1972, 1973, 1974, 1975, 1976, 1977, 1978, 1979, 2030, 2031, 2032, 2033,
2034, 2182, 2184, 2185, 2186, 2187, 2191, 2192, 2193, 2867, 2868, 2869, 2870, 2871, 2872, 2981, P3075, P3076, P3077, P3078, P3079, P3080,
P3081, 3139, 3140, 3141, 3142, 3145, 3146, 3819, 3820, 3821, 3822, 3885, 3889, P4061, P4062, P4064, P4065, P4066, P4067, 4129, 4131, 4132,
4216, 4217, 4218, 4219, P4349, P4350, P4351, P4352, P4353, P4354, P4355, P4356, P4357, P4358, P4359, P4360, P4361, P4362, P4363, P4364,
P4403, P4404, P4405, P4406, 4800, 4801, 4802, 4803, 4804, 4805, 4806, P4981, P4982, P4983, P4984, P4985, P4986, P4987, 5052, 5053, 5140,
5141, 5142, 5143, P5265, P5266, P5267, P5268, P5269, P5270, P5271, P5272, P5273, P5274, P5275, P5276, P5277, P5278, P5279, P5280, P5281,
P5320, P5321, P5322, P5323, P5324, P5325, P5326, P5328, P5329, P5330, P5331, P5332, 5733, 5737, 5739, 5758, 5759, 5762, 5763, 5764, 5777,
5858, 5859, 5860, 5861, 5862, 6073, 6074, 6075, 6076, 6077, P6173, P6175, P6176, P6178, P6179, P6180, P6181, P6182, P6183, P6184, P6185,
P6205, P6206, P6207, P6208, P6209, P6210, P6211, P6212, P6213, P6214, P6215, P6216, P6217, P6218, P6219
Automatic implantable cardioverter / defibrillator
36, P164, P166, P167, P168, P169, P170, P459, P460, P461, P462, P463, P464, P465, P466, P467, P468, P469, P470, P471, P472, P473, P474, P475,
P476, P477, P478, P479, 1242, 1244, 2984, 2985, P4296, P4297, P4298, P4299, 4844, P5927
Autonomic nervous system and humoral regulations
3224, P3804, P4335, P4336, P4337, P4338, P4339, P4781, P4782, P4783, P4784, P4785
Basic mechanisms
P2158, P2159, P2160, P2161, P2162, P2163, P2164, P4731, P4732, P4733, P4734, P4735, P4736, P4737, P4738, P4739, P4740, P4741, 5902, 5903,
5904, 5906
Biomarkers
1920, 1921, 1922, 1923, P3674, 4134, 4135, 4136, P4607, P4608, P4609, P4610, P4611, P4612, P4613, P4614, P4615, P4616, P4617, P4618,
P5020, P5021, P5022
Bodyweight
P748, P749, P750, P751, P752, P753, P754, P755, P756, P757, P1357, 3965
CAD and comorbidities

1157, 1289, 1293, P1335, P1336, 1948, P3457, 4130, P4302, P4303, P4304, P4464, P4465, P4466, P4467, P4468, P4469, P4470, P4471, P4472,
P4473, P4474, P4475, P4476, P4477, 5070, P5225, P5228, P5229, P5333, P5334, P5335, P5336, P5337, P5338, P5339, P5340, P5341, P5342,
P5400, P5401, P5402, P5403, P5404, P5405, P5406, 5781, 6050
Cardiac biology and senescence
1210, 1211, 1212, 1213, 1834, 1836, 1999, P3326, P3327, P3328, P3329, P3330, P4542, P4543, 4823, 4824
Cardiac surgery
P449, P452, P453, P1816, 2207, 2208, 2209, 2210, P3794, P3795
Cardiomyopathies
343, P686, P687, P688, P689, P690, P691, P692, P693, P694, P695, P1118, P1119, P1120, P1121, P1122, P1123, P1124, P1350, P1619, P1620,
P1621, P1622, P1623, P1624, P1625, P1626, P1627, P1628, P1629, P1630, P1631, P1632, P1633, P1634, P1635, P1636, P1637, P1638, 2078, 2079,
2080, 2081, 2082, 2083, 2084, 2085, P2634, P2635, P2636, P2637, P2638, P2639, P2640, P2641, P2642, P2643, 3897, 3898, 3899, 4030, 4031,
4032, 4033, 4034, 4035, 4036, 4037, 4263, 4264, 4265, 4266, P4589, P4590, P4591, P4592, P4593, P4594, 4842, 4958, 4959, 4960, 4961, 4962,
P5493, P5494, P5495, P5496, P5497, P5498, P5499, P5500, P5502, 5780, 5898, 6093, 6094, 6095, P6398, P6399, P6400, 6606, 6607, 6608, 6609,
6610, 6611, 6613
Cardiotoxicity of drugs
P853, P854, P855, P856, P857, P858, P859, P860, P861, P862, P863, P864, P865, P866, P867, P868, P869, P870, P871, P872, 3147, 4046, 4047,
4048, 4049, 4050, 4128, 4149, 4150, 4151, 4152, 4153, 4154, 4155, 4156, 4157, 4158, 5058, 5059, P5259, 5782
Cardiovascular anatomy and pathology
P185, P186, P187, P188, P189, P190, P5450, P5451, P5452, P5454, P5462, P5463, P5464, P5465, P5466, P5467, P5468, P5469, 6601
Cardiovascular Magnetic Resonance (CMR)
P613, P614, P615, P616, P617, P618, P619, P622, 1028, P1517, P1518, P1519, P1520, P1521, P1522, P1523, P1524, P1525, P1526, P1527, P1528,
P1529, P1530, P1531, P1532, P1533, P1534, P1535, 2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, P2124, P2125, P2126, P2127,
P2128, P2129, P2354, P2355, P2356, P2357, P2358, P3089, P3090, P3091, P3092, P3093, P3094, P3095, 3248, 3250, 3251, 3252, 3253, 3254,
3255, 3990, 3992, 4051, 4052, 4053, 4054, 4055, 4056, 4057, 4058, 4059, 4060, 4229, 4231, 4233, 4235, 4917, 5865
Cardiovascular prevention: interventions and outcomes
1, 2, 249, 250, 251, 252, 275, 276, 277, 278, 279, P1125, P1126, P1127, P1128, P1130, P1131, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226,
1227, 1858, 1859, 1860, 1861, 1862, 1863, 1889, 1891, 1892, 1893, P2712, P2714, P2715, P2717, P2718, P2719, P2720, P2722, P2724, 2849, 2850,
2851, 2902, 2917, 2918, 2920, 2957, 2958, 2959, 2960, 2961, 2962, 2963, 2964, P3681, 3855, 3895, 3896, 4786, 4787, 4788, 4789, 4790, 4791,
4792, 4793, 4794, 4884, 4885, 4886, 4887, 4888, 5069, 5071, P5583, P5586, P5587, P5588, P5589, P5591, 5765, 5766, 5767, 5772, 5837, 5838,
5839, 5840, 5841, 5842, 5843, 5844, P6136, P6137, P6138, P6139, P6140, P6422, P6423, P6424, P6425, P6426, P6427, P6428, P6429, P6430,
P6469, P6470, P6471, P6472, P6479, P6481, 6646, 6647, 6648, 6649, 6650, 6651, 6652, 6653, 6654, 6655
Cardiovascularărehabilitation: interventions and outcomes
1950, 2935, 2936, 2937, 2938, 2939, 2940, 2942, 2943, 2944, 3213, 3214, 3215, 3216, 3217, P3632, P3633, P3634, P3635, P3639, P3640, P3641,
P3661, P6477
525
Carotid disease
P5616, P5617, P5618, P5619, P5620, P5621, P5622, P5623, P5624, P5625, P5626, P5627, 5867, 5868, 5869, 5870
Catheter ablation
34, 35, 38, 94, 95, 96, 97, 98, 99, 100, 101, 955, 956, 1009, 1011, 1013, 1015, 1016, 2188, 2189, 2190, 2864, 2865, 2866, 2904, P3370, P3371,
P3417, P3418, P3419, P3420, P3421, P3422, P3423, P3424, P3425, P3426, P3427, 3886, 3986, P4340, P4341, P4342, P4343, P4344, P4345, P4346,
P5327, 5740, P6111, P6114, P6115
Chronic nursing care
227, 228, 229, 230, P439, P440, P441, P442, P443, P778, P780, P781, P782, P783, 991, 1228, 1229, 1230, 1231, 1855
Chronic pulmonary hypertension
1299, 1938, 1939, 1940, 1941, 1995, 2174, 2175, P2364, P2365, P2367, P2368, P2644, P2645, P2646, P2647, P2648, P2649, P2650, P2651, P2652,
P2653, 2893, 2894, P3622, P3623, P3624, P3625, 3904, 3905, 3906, 3907, 3908, 3909, 3910, 3911, 3912, 4170, 4171, 4172, 4181, 4182, P4545,
P4546, P4547, P4548, P4549, P4550, 4813, 4814, 4815, 4816, P5513, P5514, P5515, P5516, P5517, P5518, P5519, P5520, P5521, P5522, P5523,
P5524, P5953, P5954, P5957, P5958, 6104
Circulatory assist and other
4166, P6141, P6142, P6143, P6507, P6508, P6509, P6510, P6511, P6512, P6513, P6514
Congenital heart disease imaging
P705, P706, P707, P708, P709, P710, 1066, P2665, 2932, 2933, 3050, 4039
Congenital, foetal heart disease and intervention
P435, P1639, P1640, P1641, P1642, P1643, P1644, P1645, P1646, P1647, P1648, 3051
Coronary surgery
P2151, P2152, P2153, P2154, P2155, P2156, P2157, 3256, 3258, 3259, P5250, P5251, P5252, P5253, P5254, P5628, P5629, P5630, P5631, P5632,
P5633, P5634, P5635, P5636, P5637, P5638, P5639, P5640, P5641, P5642, P5643, P5644, P5645, P5646, P5647, P5648, P5649, P5650
CPR (cardiopulmonary resuscitation)
2062, 2064, 2065, P3433, P3434, P3435, P3436, P3487, P4435, P4436, P4437, P4438, P4439, P4440, P4441, 4843, 5883, 5884, 5885, 5886, 5887,
6626, 6627, 6628, 6629, 6630, 6631, 6632, 6633, 6634, 6635
Developmental biology
8, 2237, 2238, 2239, 2240, 4848, 4849, 4850, 4851, P5461, 6600
Device complications and lead extraction
37, 292, 293, 294, 295, P1091, P1092, P1093, P1094, P1095, P1096, P2436, P2437, P2438, P2439, P2440, P2441, P2442, P2443, P2444, P2445,
P2446, P2447, 3230, 3231, 3232, 3233, 3234, 3235, 3236, 3237, 3238, 3239, 4845, 5144, 5145, 5146, 5147, 5148, 5783
Devices / interventions
Diabetes management
237, 238, 239, 240, P760, P761, P762, P763, P764, 1869, 1870, 1871, 1872, 1873, 1880, 1881, 1882, 1883, 3153, 3869, 3870, 3871, 3872, 3873,
5054, 5055, 5056, 5064, 5065, 5122, 5123, 5124, 5125, 5126
Diabetes, dysglycaemia and metabolic syndrome
P199, P200, P201, P202, P203, P204, P205, P736, P737, P738, P739, P740, P741, P742, P743, P744, P745, P746, P747, P765, P766, P767, P768,
P769, P770, P771, P2713, P2716, P2723, P3675, P3676, P3677, P3678, P3679, P3680, P3682, P3683, P3684, P3685, 4889, 4890, 4891, 4892, P5590,
P5592, P5593
Diastolic dysfunction
P1810, P1814, P1815, P1817, 2205, 2206, 2211, 2212, 2213, 2214, P3124, P3125, P3126, P3127, P3128, P3129, P3130, 5882
Drug therapy, pharmacogenomics
72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 288, 289, 290, 291, P454, P455, P456, P457, P458, 993, 994, 995, 996, 997, 998,
999, 1000, 1232, 1233, 1234, 1235, 3848, 3849, 3850, 3851, 4212, 4213, 4214, 4215, P5037, P5038, P5039, P5040, P5041, P5042, 5131, 5132,
5133, 5134, 5135, 5136, 5850, 5851, 5852, 5853, P5980, P5981, P5982, P5983, P5984, P5985, P5986
e-Cardiology other
P632, 1192, 1193, 1194, 1195, 1258, 1259, 1260, 1261, P1551, 2919, P3321, P4081
ECG, arrhythmia analysis, signal processing
P625, P626, P627, P628, P629, P630, P631, P1536, P1537, P1538, P1539, P1540, P1541, P1542, P1543, P1544, P1545, P1546, P1549, P1550, P3324,
P4077, P4078, P4079
Echo / Doppler, other
P635, P636, P2532, P2533, P2534, P2535, P2537, P2542, P2551, P2552, P2553, P2554, P2561, P2562, P2563, P2564, P2565, P2566, P2567, 3169,
3170, 3172, 3173, 3174, 3175, P3529, P3533, P3534, 4236, 4237, 4238, 4240, P5938, P5939, P5940, P5941, P5942, P5943, P5944, P6121, P6123,
P6125, P6327
Echo-contrast / tissue characterisation
P3516, P3517, P3518, P3519, P6325
Echo-valvular heart disease
1025, 1027, P1104, P1105, P1107, P1108, P1109, P1110, 1887, 2992, 2993, 2996, 2997, 3245, 3246, 3247, 3249, P3496, P3497, P3498, P3499,
P3500, P3501, P3502, P3503, P3504, P3505, P3520, P3521, 3987, 3988, 3989, 3991, 3993, 6079, 6081
Echo-ventricular function and myocardial diseases
1017, 1018, 1019, 1884, 1885, 1886, 1888, 1900, 2281, 2282, 2283, 2284, 2285, 2895, 2896, 2991, 2998, P3526, P3527, P3528, P4305, P4306,
P5442, P5443, 5801, 5802, 5803, 5804, 5805, 5806, 5807, 5808, 5809, 5810, P6292, P6293, P6294, P6295, P6296, P6297, P6298, P6299, P6300,
P6301, P6302, P6303, P6304, P6305, P6306, P6307, P6308, P6309, P6310, P6311, P6312, P6313
526
Elderly and cardiovascular diseases

959, 960, 961, 962, 963, 964, 965, 968, 2255, 5127, 5128, 5129, 5130, P5245, P5246, P5247, P5248, P5249, P5539, P5540, P5541, P5542, P5543,
Electrocardiography / cardioversion / defibrillation
231, 908, 909, P1387, P1406, P1436, P2344, P2345, P2346, P2347, P2348, P2401, P2402, P2403, P2404, P2405, P2406, P2407, P2408, P2409,
P2410, P2411, P2412, P2413, P2414, P2415, P2416, P2417, P2418, P2419, P2420, P2421, P2422, P2423, P2424, P2425, P3379, P4348, P5924
Endocarditis
P676, P677, P1609, P1610, P1611, 2317, 2318, 2319, 2320, 2321, P2625, P2626, P2627, P3103, P3104, P3105, P3106, P3107, P3108, P3109, P3575,
P3576, 3932, P4575, P4576, P4577, 4831, 4832, 4833, 4834, P5483, 5892, 5893, 5894, 5895, 5896, 5987, 5988, 5989, 6030, 6032, P6371, P6382,
P6383
Endothelial function
7, 10, P430, P432, P433, P639, P641, P643, P647, P648, P649, P650, P652, P654, P655, P656, P657, P658, P662, P664, P667, P1111, P1112, P1113,
P1115, P1116, P1117, P1564, P1565, P1567, P1569, P1571, P1572, P1573, P1574, P1575, P1576, P1577, 1954, P2131, P2133, P2134, P2136, P4310,
P4311, P4312, P4313, P4314
Environment and CV diseases
261, 262, 263, 264, 1844, 2000, 2001, 2002, 2003, 2250, 2251, P3336, P3337, P3338, P3339, P3340, P3636, P3637, 3960, 3961, 3962, 3963, 4193,
4194, 4195, 4196, 4197
Epidemiology, lipids
67, 68, 69, 70, 71, 1154, P1651, P1652, P1653, P1654, P1655, P1656, P1657, P1658, P1659, P1660, P1661, P1662, P1673, P1674, P1675, P1676,
P1706, P2144, P2145, P2146, P2147, P2148, P2149, P2150, P4321, P4322, 5774
Excitation-contraction coupling and contractile remodelling
1851, 2241, 2242, 2243, 2244, 2245, 2949, 2950, 2951, 2952, 3177, 3178, 3179, 3180, 3929, P4516, P4517, P4518, P4519
Exercise testing and training
56, 57, 58, 59, 2004, 2006, 2007, 2008, 2009, 2010, 2011, P2666, P2667, P2668, P2669, P2670, P2672, P2673, P2674, P2675, P2678, P2679, P2684,
P2685, P2689, P2690, P2691, P2692, P2693, P2694, P2695, P2696, P2701, P2705, P2706, P2707, P2708, P2709, P2710, 2966, P4102
Genetic aspects of arrhythmias

245, 246, 247, 248, P414, P417, P418, P1385, P1386, P1397, P1398, P1409, P1410, P1421, P1422, P1433, P1434, 2899, 2986, 2987, 2988, 2990,
5854, 5855, 5856, 5857, P6160, P6161, P6162, P6163, P6164, P6165, P6166, P6167, P6168, P6169, P6170, P6171, P6172, P6174, P6177
Genetics and gene therapy
2890, 2945, 2946, 2947, 2948, 3065, 3066, 3067, 3068, 3069, 3070, 3071, 3072, 3073, 3074, P3096, P3097, P3098, P3099, P3100, P3101, P3102,
P3535, P3536, P3537, P3538, P3539, P3540, P3541, P3542, P3543, 3864, 5118, 5119, 5120, 5121, P5472
Grown-up congenital heart disease and surgery
144, 1067, 1068, 1301, 2074, 2075, 2076, 2077, P2138, P2139, P2141, P2142, P2143, 2310, 2312, 2314, 2316, P2654, P2655, P2656, P2657, P2658,
P2659, P2660, P2661, P2662, P2663, P2664, 2926, 2931, 4041
Growth factors, neurohormones and signal transduction-cardiac
9, 3930, P4082, P4083, P4085, P4515, P6341, P6343, P6344, P6345, P6348
Guidelines and implementation in low resource settings
2970, 2971, 2972, 2973, 2974, 2975, 2976, 2977, 4207, 4208, 4209, 4210, 4211, P5043, 5137, 5138, 5139
Haemodynamics, heart and hypertension

1236, 1237, 1238, 1239, 1240, P2165, P2166, P2167, P2168, P2169, P2170, P2171, 2258, 2259, 2260, 2261, 2262, 2979, P3803, 3829, 3830, 3831,
3832, 3833, 3973, 3974, 3975, 3976, P4117, P4118, P4774, P4775, P4776, P4777, P4778, P4779, P4780, 4866, 4867, 4868, 4869, 4870, 4871,
4872, 4873, 4875, 4893, 4897, 4899, 4900, 4901, P5703, P5704, P5705, P5706, P5707, P5708, P5709, P5710, P5711, P5712, P5713, P5714
Health economics and comparative effectiveness research
P6314, P6320, P6321, P6323
Heart failure, other
146, 147, 148, 149, 150, 151, 152, 153, 353, 354, 355, 356, 358, 359, 360, 372, 373, 374, 375, 376, 377, 384, 385, 386, 387, 388, P875, 1026, 1069,
1070, 1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, P1365, P1366, P1367, P1368,
P1807, 2090, 2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330, 2331, 2332, 2333, P2784,
P2824, P2825, P2826, P2827, P2828, P2829, P2830, P2831, P2832, P2833, P2834, P2835, P2836, 3053, 3054, 3057, 3058, 3059, 3060, 3061, 3062,
3063, 3064, 3205, 3222, 3244, 3291, 3292, 3293, 3294, 3295, 3296, 3297, 3298, 3299, 3300, P3772, P3773, P3774, P3775, P3776, P3792, P3793,
3834, 3835, 3836, 4042, 4043, 4044, 4045, P4764, P4773, 4807, 4808, 4809, 4810, 4811, 4812, 4963, 4964, 4965, 4966, 4967, 4968, 4969, 4970,
P5030, P5031, P5032, P5033, P5034, P5035, P5036, 5057, 5058, 5059, 5063, 5064, 5065, 5066, 5067, 5068, 5073, 5196, 5197, 5198, 5199, 5200,
5201, 5202, 5203, 5204, 5205, 5206, 5207, 5208, 5209, P5651, P5652, P5653, P5654, P5655, P5656, P5657, P5658, P5659, P5660, P5661, P5662,
P5701, P5702, 5754, 5755, 5776, 5907, 5908, 5909, 5910, 5911, 5912, 5913, P5973, P5974, P5975, P5976, P5977, P5978, P5979, 5992, 6037,
6038, 6039, 6040, 6041, 6042, 6043, 6044, 6045, 6046, 6107, 6108, 6109, 6110
Hypertension, diet, other
P896, P897, P898, P899, P900, P901, P902, P903, P904, P905, P906, P907, P1374, 2021, 2022, 2023, 2024, 2025, 3226, 3227, 3228, 3229, P3355,
3968, 3970, P4121, P4122, P4123, 4874, 4894, 4898, 6060, 6061, 6062, 6063, P6597, P6598, P6599
Hypertension: regional and ethnic profiles
P220, P221, P222, P223, P224, P225, P226, 2263, 2264, 2265, 2267, P5260, P5261, P5262, P5263, P5264, P6594, P6595, P6596
527
Hypertrophy, cell cycle and apoptosis

258, 259, 260, 6057, P6333, P6340, P6342, P6346, P6347, 6602
Image databases, image data transmission, image analysis

P1552, P3323
Image hardware, image standards, image processing
P1553, P1554, 1933, 1934, P3325, P4080
Imaging for peripheral disease
P4669, P4670, P4671, P4672, P4673, 6083, 6084, 6085, 6087
Infarction acute phase non STEMI
P590, P591, P592, P593, P594, P595, P1099, P1100, P1101, P1102, 1935, 1936, 1937, 1942, 1943, 1944, 1945, 2223, 2224, 2225, P2460, P2461,
P3086, 4126, 4127, 5102, 5103, 5104, 5173, 5174, 5175, 5176, 5177, 5178, 5179, 5180, 5181, P5226
Infarction acute phase STEMI
29, 30, 31, 32, P531, P532, P533, P534, P535, P536, P537, P538, P539, P540, P541, P542, P543, P544, P545, P546, P547, P548, P549, P550, P551,
P552, P553, P554, P555, P556, P557, P558, P559, P560, P561, P562, P563, P564, P577, P578, P579, P580, P581, 1052, 1053, 1054, 1055, 1167,
1168, 1169, 1173, 1174, 1175, 1280, 1281, 1282, 1283, 1284, 1285, 1286, 1287, P1338, 2176, P2472, P2473, P2474, P2475, P2476, P2477, P2478,
P2517, P2518, P2519, P2520, P2521, P2522, P2523, P2524, P2525, P2526, P2527, P2528, P2529, P2530, P2531, 3021, 3022, 3023, 3024, 3025,
3026, 3027, 3028, 3914, P4407, P4408, P4409, P4410, P4411, P4412, P4413, P4414, P4415, P4416, P4442, P4443, P4444, P4445, P4446, P4988,
P4989, P4990, P4991, P4992, P4993, P4994, 5182, 5183, 5184, 5185, 5797, 5798, 5800, 5813, 5814, 5816, 5817, 5818, 5819, 5820, P5931, P5932,
P5933, P5934, P5935, P5936, P5937, 6007, 6008, 6009, 6049
Infectious, parasitic and nutritional diseases
2086, 2087, 2088, 2089, P6395, P6396, P6397
Inflammation and immunity
335, 336, 337, 338, 339, 340, P419, P420, P421, P422, P423, 1839, 3268, 3269, 3270, 3271, 3852, 3853, 3854, 3856, 3942, 3943, 3944, 3945, 3946,
P6266, P6267, P6268
Inflammation, growth factors and signal transduction-vascular
973, 974, 975, 976, 1959, P2580, P2581, P2582, P2594, P2595, P2596, P2597, P2598, P2599, P2605, 3928, P4086, P4087, P4088, P5002, P5006,
P6126, P6129, P6130
Integrative physiology and control mechanisms
916, 917, 1852, 1853, 5110, 5111, 5112, 5113, 5114, 5115, 5116, 5117, P5453, P5460, P5470, P5471, 5829, 5830, 5831, 5832, 5833, 5834, 5835,
5836, 6055, 6056, 6058, 6059
Invasive and functional coronary imaging
P5028, P5029, 6617, 6618, 6619, 6620, 6621, 6622, 6623, 6624
Invasive electrophysiological studies
P1427, P3381, P3388, P3395, P3404, P4347, P5926, P5929, P6112, P6113
Ion channels and electrophysiology
P6355, P6356, P6357, P6358, P6359, P6360, P6361
Ischaemia and protection
1080, 1081, 1082, 1083, 1084, 1086, 1087, 1088, 1089, 1990, 1991, 1992, 1993, 1998, 3956, 3957, 3958, 3959, P4520, P4521, P4522, P4523,
P4524, P4525, P4526, P4527, P4528, P4529, P4530, 4880, 4881, 4882, 4883, 6047, P6328, P6329, P6330, P6331, P6332, P6337, P6339
Ischaemia, experimental studies
2066, 2067, 2068, 2069, P2349, P2350, P2351, P2352, P2353, P3082, P3083, P3084, P3085, 3203, 3206, P3439, P3440, P3441, P3442, P3443,
P3444, P3445, P3446, P3447, P3448, P3449, P3450, P3458, P3459, P3460, P3461, P3462, P3463, P3464, P3465, P3466
Lipids
398, 399, 400, 401, 402, 1215, P1578, P1579, P1580, P1581, 1864, 1865, 1866, 1867, 1868, 1997, P2130, P2132, 2852, 2853, 2854, 3143, 3144,
3857, 3858, 3859, 3860, 3861, 3866, 3879, 3880, 3884, 4795, 4796, 4797, 4798, 4799, 5743, 5744, 5745, 5746, 5994, 6604
Mechanisms of arrhythmias
232, 257, P415, P416, P1411, P1412, P1413, P1414, P1415, P1416, P1417, P1418, P1419, P1420, P1423, P1424, P1425, P1426, P1428, P1429,
P1430, P1431, P1432, 3056, 3223, P3386, P3398, P4063, 6069, 6070, 6071, 6072
Medical aspects of transplantation
P1765, P1766, P1767, P1768, P1769, P1781, P1793, P1794, P1795, P1811, P1812, P1813
Medical treatment
P839, P840, P1756, P1757, P1758, P1759, P1760, P1761, P1762, 3156, 3916, 4002, P4674, P4675, P4676, P4677, P4678, P4679, P4680, 5067,
5068, P5966, P5967, P5968, P5969, P5970, P5971, P5972
Metabolism and metabolic syndromes
2181, P2359, P2360, P2361, P2362, P2363, 3204, 3881, P4531, P4532, P4533, P4534, P4535, P4536, P4537, P4538, P4539, P4540, P4541, 6051,
6052, 6053, 6054, P6336, P6338, 6603
Microcirculation and collaterals
1290, 1291, 1292, 1295, 1296, 1297, P1506, P1507, 1841, 4021, 4022, 4023, 4024, 4025, 4286, 4287, 4288, 4289, 4290, 4291, 4292, 4293, 4294,
4295, P6261
528
Minimally invasive and robotic surgery

P6493
Miscellaneous
11, 12, 13, 14, 15, 16, 17, 25, 26, 27, 28, 352, 912, 913, 918, 919, 920, 921, 922, 923, 924, 925, 927, 934, 935, 936, 937, 938, 939, 940, 941, 1153,
1156, 1158, 1159, 1160, 1176, 1177, 1178, 1179, 1188, 1189, 1190, 1191, 1206, 1207, 1208, 1209, 1310, 1311, 1962, 1963, 1964, 1965, 1966,
1967, 1968, 1969, 2197, 2198, 2199, 2200, 2201, 2202, 2203, 2204, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222, 2226, 2246, 2247, 2248,
2249, 2273, 2274, 2275, 2276, 2278, 2279, 2280, 2286, 2287, 2288, 2289, 2891, 2892, 2921, 2922, 2923, 2924, 3162, 3163, 3164, 3181, 3182,
3183, 3184, 3185, 3186, 3187, 3188, 3189, 3190, 3194, 3198, 3289, 3290, 3808, 3809, 3810, 3811, 3812, 3813, 3941, 4124, 4124, 4125, 4125,
4173, 4825, 4826, 4835, 4836, 4837, 4838, 4839, 4840, 4841, 4852, 4853, 4854, 4855, 4942, 4943, 4944, 4945, 5045, 5046, 5047, 5105, 5106,
5107, 5108, 5109, 5194, 5195, 5715, 5716, 5717, 5718, 5719, 5720, 5778, 6010, 6011, 6012, 6013, 6014, 6015, 6102, 6106, 6656, 6657, 6658,
6659, 6660, 6661, 6662, 6663, 6664, 6665, 6666, 6667, 6668, 6669, 6670
Mitral valve disease
137, 138, 139, 140, 309, 348, 349, 350, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, P1590, P1591, P1592, P1593, P1594, P1595, P1596,
1914, 1915, 1916, 1917, 1918, 1919, P2608, P2609, P2610, P2611, P2612, P2613, 3034, 3035, 3036, 3037, P3568, P3569, P3570, P3571, P3573,
P4559, P4560, P4561, P4562, 5210, 5211, 5212, 5213, 5218, 5219, P5479, P5480, P5481, P5482, 5888, 5889, 5890, 5891, P6362, P6363, P6364,
P6365, P6366, P6368
Mitral valve interventions
351, P1597, P1598, P2614, P2615, P3572, P3574, P4563, P4564, 5214, 5215, 5216, 5217, 6092, P6367, P6369, P6370
Mitral valve surgery
310, 311, 1029, 1030, 1031, 1032, 1033, 1034, 1035, 1036, 1037, 1038, 4004, 4005, 4006, 4007, 4008, 4009, 4010, 4011, P6482, P6483, P6484,
P6485
Morphology, pathology and genetics
P6401
Multimodality / hybrid imaging, other imaging
107, 108, 109, 110, 301, 302, 303, 304, 305, 306, 307, 308, P424, P428, P604, P624, P633, 1020, 1021, 1022, 1023, 1024, 1180, 1181, 1182, 1183,
1184, 1185, 1186, 1187, 1250, 1251, 1252, 1253, 1254, 1255, 1256, 1257, 1901, 1902, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042, 2108,
2277, 2999, 3000, 3001, 3002, 4228, 4230, 4232, 4234, P4503, P4504, P4505, 4915, 5149, 5150, 5151, 5152, 5153, 5154, 5155, 5156, 5157, 5158,
5159, 5160, 5863, 6078, 6080, 6082
Myocardial-pericardial imaging
5186, 5187, 5188, 5189, P6392, P6393, P6394
Myocarditis
129, 130, 131, 132, P1353, P1354, P3595, P3596, P3597, P3598, P3599, P3600, P3601, P3602, P3603, P3604, P3605, P3606, P5501, 5897, 5899,
5900, 5901, 6096, 6097, 6098, 6099, 6100, 6101, 6612, 6614, 6615
Neurohormones
P450, P451, P873, P874, P877, P878, P879, P2379, P2380, P2381, P2382, P2383, P3350, 4276, 4277, 4278, 4279, 4280
Non coronary cardiac interventions
P206, P207, P208, P209, P210, P211, P212, P3723, P3724, P3725, P3726, P3727, P3728, P3729, P3730, P3731, P3732, P4720, P4721, 5794, 5795,
5796, 6016, 6017, 6018, 6019, 6020
Non invasive studies
P165, P480, P481, P482, P483, P484, P485, P486, P487, P488, P489, P490, P1437, P2448, P2449, P2450, P2451, P2452, P2453, P2454, P2455,
P2456, P2457, 5097, P5930
Non-invasive coronary imaging
1266, 1267, 1268, 1269, P1754, P1755, 6625
Nutrition / obesity
265, 266, 267, 268, 269, 270, 271, 272, 273, 274, P725, P726, P727, P728, P729, P730, P731, P732, P733, P734, P735, P758, P759, P1355, P1356,
P1358, P1359, 1843, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234, 2235, 2236, 2252, 2253, P2721, P2725, 2905, 3209, 3210, 3211, 3212,
3218, 3219, 3220, 3221, 4198, 4199, 4200, 4201, P6473, P6474, P6475, P6476, P6478, P6480
Paediatric cardiology, other

1065, P1649, P1650, 2930, 4038, 4040, P4595, P4596, P4597, P4598, P4599, P4600, P4601, P4602, P4603, P4604, P4605, P4606
Pathophysiology and diagnosis
P4110, P4111, P4112, P4113, P4114, P4115, P4116, 5779
Pathophysiology, epidemiology
1890, P4103, P4104, P4105, P4106, P4107, P4108, P4109, P4665, P4666, P4667, P4668, 6086
PCI / stents: devices and technique
362, 363, 364, 365, 366, 368, 369, 370, 371, 943, 944, 946, P2374, P2375, P2376, P2377, P2378, P2726, P2727, P2728, P2729, P2730, P2731,
P2770, P2771, P2772, P2773, P2774, P2775, P2776, P2777, P2778, P2779, P2780, P2781, P2782, 3887, 3933, 4821, 4822, 5165, 5166, 5167, 5168,
5169, 5170, 5171, 5172, 6001, 6002, 6003
PCI: long-term outcome
1842, 1949, 2907, 2908, 2909, 2910, 2911, 2912, 2913, 2914, 2915, 2916, P3341, P3342, P3343, P3344, P3345, P3686, P3687, P3688, P3689,
P3709, P3710, P3711, P3712, P3713, P3714, P3715, P3716, P3717, P3718, P3719, P3720, P3721, P3722
PCI: pre-clinical studies
P789, P790, P2783, 5871, 5872, 5873, 5874, 5875, 5876, 5877, 5878
529
PCI: primary PCI, patient subsets, other

P828, P829, P830, P831, P832, P833, P834, P835, P836, P837, P838, 1196, 1197, 1198, 1199, 1200, 1201, 1202, 1203, 1204, 1205, 3999, 4000,
P4708, P4709, P4710, P4711, P4712, P4713, P4714, P4715, P4716, P4717, P4718, P4719, 4847, 5773, 5799, 5998, 5999, 6000, 6088, 6089, 6091
PCI: procedural complications
115, 116, 117, 118, 119, P444, P445, P446, P447, P448, P791, P792, P793, P794, P795, P796, P797, P798, P799, P800, P801, P802, P803, P804,
942, 945, 947, 948, 2290, 2291, 2292, 2293, 2294, P3117, P3118, P3119, P3120, P3121, P3122, P3123, 6004, 6005, 6006
Percutaneous / endovascular treatment
312, P1132, P1133, P1134, P1135, P1136, P1137, P1138, P3740, P3741, 3919, 3920, 3921, 3922, 3923, 3924, 3925, 3926, 3927, P4681, P4682,
P4683, P4684, P4685, P4686, P4687, P4688, P4689, P4690, P4691, P4692, P4693, P4694, 5784, 5785, 5786, 5787, 5788, 5789, 5790, 5791, 5792,
5793, P6144, P6145
Pericardial and myocardial disease, tumours, other
P192, P193, P194, P195, P196, P197, P198, 341, 342, P696, P697, P698, P699, P700, P701, P702, P703, P704, P1351, P1352, 3281, 3282, 3283,
3284, P4585, P4586, P4587, P4588, 5768, 5769, 5770, 5771, 5990
Peripheral circulation, metabolism and skeletal muscle
P886, P887, P888, P889, 2888, 2889, 3308, P3347, P3788, P5255, P5256, P5257, P5258
Pharmacologic therapy
P213, P214, P215, P217, P218, P219, 1946, P2796, 2901, 3150, 3301, 3302, 3303, 3304, 3305, 3306, 3307, 3309, 3310, P3346, P3348, P3349,
P3786, P3787, 4281, 4282, 4283, 4284, 4285, 5060, 5061, 5061, 5062, 5062, 5775
Physical activity
2005, P2370, P2671, P2676, P2677, P2686, P2687, P2688, P2697, P2698, P2699, P2700, P2702, P2703, P2704, P2711
Physiology, haemodynamics and microcirculation
111, 112, 113, 114, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 1040, 1041, 1042, 1262, 1263, 1264, 1265, 1288, 1294, P1707, P1708, P1709,
P1710, P1711, P1712, P1713, P1714, P1715, P1716, P1717, P1718, P1719, P1720, P1721, P1722, P1723, P1724, P1725, 3003, 3004, 3005, 3006,
4929, 4930, 4931, 4932, 4933, 6616
Platelets and antiplatelets therapy
3, 4, 5, 323, 324, 325, 327, 328, 329, 330, 331, 332, 333, 334, 403, 404, 405, 406, 407, 914, 915, 1043, 1044, 1045, 1046, 1270, 1271, 1272, 1273,
1274, 1275, 1276, 1277, 1278, 1279, P1462, P1463, P1464, P1465, P1466, P1467, P1468, P1469, P1470, P1471, P1472, P1473, P1474, P1475,
P1495, P1496, P1497, P1498, P1499, P1500, P1501, P1502, P1503, P1504, P2116, P2119, P2121, 2177, 2178, 2179, 2180, 2855, 2856, 2857, 2858,
2903, 3029, 3030, 3031, 3032, 3033, 3159, 3160, 3161, P3316, P3317, P3318, P3319, P3320, 3874, 3875, 3876, 3877, 3878, 3913, 3915, 3918,
3955, 4846, 4972, 4973, 4975, 5048, 5049, 5050, 5051, P6280
Positron Emission Tomography (PET)
P178, P180, P183, P425, P426, P605, P606, P607, P608, P612, 4910, 4912, 4913, 4914
Post infarction period
P171, P172, P173, P174, P175, P176, P177, P1509, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306, 2307, 2308, P2462, P2463, P2464, P2465,
P2466, P2467, P2468, P2469, P2470, P2471, 4258, 4260, 4261, 4262, P4417, P4418, P4419, P4420, P4421, P4422, P4423, P4424, P4425, P4426,
P4427, P4428, P4429, P4430, P4431, P4432, P4433, P4434, P4447, P4448, P4449, P4450, P4451, P4452
Pregnancy and heart disease
141, 142, 145, P711, P712, P713, P714, 2928
Prehospital cardiac care
1857, P4068, P4069, P4070, P4071, P4072, P4073
Premature cardiovascular ageing
966, 967, 1835, 2012, 2013, 2014, 2015, 2016, 2254, 2256, 2257, P5535, P5536, P5537, P5538, P5552, P5558, P5570, P5575, 5879
Primary care
18, 19, 20, 21, P779, 3814, 3815, 3816, 3817, 3818
Prognosis
357, 361, P880, P881, 1164, 1165, 1166, 1830, P3789, P3790, P3791, P4722, P4723, P4724, P4725, P4726, P4727, P4728, P4729, P4730, P4759,
P6577, P6578, P6579, P6580, P6581, P6582, P6583, P6584, P6585, P6586, P6587, 6636, 6637, 6638, 6639, 6640, 6641, 6642, 6643, 6644, 6645
Psycho-social, economic, cultural, occupational diseases
P1694, P1695, 1854, 2953, 2954, 2955, 2956, P4320, P4323, P4324
Public health and health policy
992, P3626, P3627, P3628, P3629, P3630, P3631, P3662, P3663, P3664, P3665, P3666, P3667, P3668, P3669, P3670, P3671, P3672, P3673, 3964,
3967
Pulmonary circulation, imaging, other
P2366, 4180, P4551, P4552, P4553, P4554, P5503, P5504, P5505, P5506, P5507, P5508, P5525, P5526, P5527, P5528, P5529, P5530, P5531, P5532,
P5533, P5534, P5956, 6103, 6105
Renal denervation
P3733, P3734, P3735, P3736, P3737, P3738, P3739, 3823, 3824, 3825, 3826, 3827, 3828
530
Restenosis
P6534, P6535
Resynchronisation therapy
39, P491, P492, P493, P494, P495, P496, P497, P498, P499, P500, P501, P502, P503, P504, P505, P506, P507, P508, P509, P510, P511, P512, P513,
P514, P515, P516, P517, P518, P519, P520, P521, P522, P523, 1170, 1171, 1172, P1435, 2026, 2027, 2028, 2029, 2268, 2269, 2270, 2271, 2272,
P2389, P2390, P2391, P2392, P2393, P2394, P2395, P2396, P2397, P2398, P2399, P2400, 2982, 2983, 4220, 4221, 4222, 4223, 4224, 4225, 4226,
4227, 4856, 4857, 4858, 4859, 4860, 4861, 4862, 4863, 4864, 4865, P5220, P5221, P5222, P5223, P5224, 5738, 5741, 5760, 5761
Right ventricular function
4183, P5509, P5510, P5511, P5512, P5952, P5955
Risk scores
981, 982, 983, 984, 985, 986, 987, 988, 4202, 4203, 4204, 4205, 4206, P4619, P4620, P4621, P4622, P4623, P4624, P4625, P4626, P4627, P4628,
P4651, P4652, P5959, P5960, P5961, P5962, P5963, P5964, P5965
Scintigraphy (SPECT)
P179, P181, P182, P184, P427, P597, P598, P599, P600, P601, P602, P603, P609, P610, P611, 4911, 4916, 5864
Sports cardiology
60, 61, 62, 63, 64, 65, 66, 977, 978, 979, 980, 1848, P2369, P2371, P2372, P2373, P2680, P2681, P2682, P2683, 2965, 2967, 2968, 2969, P4096,
P4097, P4098, P4099, P4100, P4101
Stem cells and cell therapy
48, 49, 50, 51, 910, 911, P1345, P1346, P1347, P1348, P1349, 3208, P3544, P3545, P3546, P3547, P3548, P3549, P3550, P3551, P3552, P3553,
P3554, P3555, P3556, P3557, P3558, P3559, P3560, P3561, P3562, P3563, P3564, P3565, P3566, P3567, 4188, 4189, 4190, 4191, 4192, P5444,
P5445, P5446, P5447, P5448, P5449, P5455, P5456, P5457, P5458, P5459
Stress echo
P634, P1340, P1341, P1342, P1343, P1344, P3506, P3507, P3508, P3509, P3510, P3511, P3512, P3513, P3514, P3515, P3522, P3523, P3524, P3525
Stroke
3007, 3008, 3009, 3010, 3225, 3260, 3261, 3262, 3263, 3264, 3265, 3266, 3267, 3272, 3273, 3274, 3275, 4241, 4242, 4243, 4244, 4896, 5072,
P5613, P5614, P5615, 5736, 6048
Sudden death / resuscitation
90, 91, 92, 93, 1005, 1006, 1007, 1008, 1320, 1321, 1322, 1323, P1330, P1331, P1332, P1333, P1334, P1375, P1376, P1377, P1378, P1379, P1380,
3195, 3196, 3197, 3207, 3900, 3901, 3902, 3903, 3981, 3982, 3983, 3984, 3985, 5098, 5742, P5928
Supraventricular arrhythmias (excluding AF)
33, 949, 3240, P3356, P3357, P3358, P3359, P3360, P3361, P3362, P3363, P3364, P3365, P3366, P3367, P3368, P3369, 5095, 5096
Syncope
1324, 1325, 1326, 1327, 1328, 1329, P1444, P3311, P3312, P3313, P3314, P3315, 3977, 3978, 3979, 3980, 4902, 4903, 4904, 4905, 4906, 4907,
4908, 4909, 5100, 5101, 5734
Telemedicine in cardiology
102, 103, 104, 105, 106, P620, P621, P1547, P1548, P1555, P3322, P4075, P4076
Thrombosis and coagulation
120, 121, 122, 123, 326, P1445, P1446, P1447, P1448, P1449, P1450, P1451, P1452, P1453, P1454, P1455, P1456, P1457, P1458, P1459, P1460,
P1461, 1833, 1912, 1996, P2117, P2118, P2120, 2183, 3055, P3087, P3088, 3276, 3277, 3278, 3279, 3280, 3888, 3890, 3891, 3892, 3893, 3894,
3952, 3953, 3954, 4133, 4971, 4976, 4977, 4978, 5747, 5748, 5749, 5750, 5751, 5752, 5753, 5993
Tobacco
1845, P3110, P3111, P3112, P3113, P3114, P3115, P3116, P3638, 3966, 4827, 4828
Treatment of hypertension
378, 379, 380, 381, 382, 383, 1001, 1002, 1004, 1155, P1370, P1371, P1372, P1373, P1818, P1819, P1820, P1821, P1822, P1823, P1824, P1825,
P1826, P1827, P1828, P1829, 1856, 1874, 1875, 1876, 1877, 1878, 1879, 2017, 2018, 2019, 2020, 2266, P2384, P2385, P2386, P2388, 2883, 2884,
2885, 2886, 2887, P3131, P3132, P3133, P3134, P3135, P3137, P3354, P3805, P3806, P3807, 3969, 3971, 3972, 4137, 4138, 4139, 4140, 4141,
4142, 4143, 4144, 4145, 4829, 4830, 4895, 5044, 5075, 5076, 5077, 5078, 5079, 5080, 5081, 5082, 5083, 5084, 5721, 5722, 5723, 5724, 5725,
5726, 6064, 6065, 6066, 6067, 6068, P6150, P6151, P6152, P6153, P6588, P6589, P6590, P6591, P6592, P6593
Valvular imaging
241, 242, 243, 244, P678, P3577, P5484, 6034, 6036, P6384
Valvular other and rheumatic disease
P679, P1612, P1613, P2628, P2629, 2994, 2995, P3578, P3579, 4026, 4027, 4028, 4029, P4315, P4317, P4318, P4319, P4578, P4579, P4580, P5240,
P5241, P5242, P5243, P5244, P5485, P5486, 6035, P6131, P6132, P6133, P6134, P6135, P6385, P6386
Vascular biology, other
52, 53, 54, 55, 969, 970, 971, 972, 1837, 1953, 1955, 2336, 2337, 2338, 2340, 2341, 2342, P2571, P2572, P2573, P2574, P2575, P2576, P2577,
5826, 5827, 5828, 6026, 6027, 6028, 6029, P6127, P6128
Vascular remodelling
1850, 1952, 1994, 2334, 2335, 2339, 2343, P2584, P2585, P2586, P2587, P2588, P2589, P2590, P2591, P2592, P2593, P2604, P4544, 4876, 4877,
4878, 4879, P5003, P5004, P5005, 5845, 5846, 5847, 5848, 5849
531
Ventricular arrhythmias
P1399, P1400, P1401, P1402, P1403, P1404, P1405, 2900, 3191, 3192, 3193, 3241, 3242, 3243, 3935, 3938, 3939, 3940, P5925
Ventricular function / haemodynamics
40, 41, 42, 43, P1139, P1140, P1141, P1142, P1143, P1144, P1145, 1849, 1951, 2978, 2980, P3777, P4330, P4331, P4332, P4333, P4334, P4742,
P4743, P4744, P4745, P4746, P4747, P4748, P4749, P4750, P4751, P4752, P4753, P4754, P4755, P4756, P4757, P4758, 5905
Vulnerable plaque
P784, P785, P786, P787, P788, 1838, 2053, 2054, 2055, 2056, 2057, 2058, 2059, 2060, 2061
X-ray Computed Tomography (CT)

P623, 2099, 2100, 2101, 2102, 2103, 2104, 2105, 2107, 3994, 3995, 3996, 3997, 3998, P4478, P4479, P4480, P4481, P4482, P4483, P4484, P4485,
P4508, P4509, P4510, P4511, P4512, P4513, P4514, 4918, P4995, P4996, P4997, P4998, P4999, P5000, P5001, P5230, P5231, P5232, P5233,
P5234, 5866, P6315, P6316, P6317, P6318, P6319, P6322, P6324
532
NOTES
533
The American
College of Cardiology is
Your Professional Home.
Visit ACC Stand #P640
and discover how ACC can support you
from your training through retirement.
Discounts to ACC.16 in Chicago

Free Access to the JACC Journals
Guidelines, Mobile Apps
& Career Resources
ACC.org/International
©201
©20
©2
© 5,, A Co ege
merican Coll
Ameri
mer e of Cardi
ge olog X1524
ologyy X152
rdiolog 4
LIST OF
ACRONYMS
List of Acronyms / Abbreviations PROGRAMME NUMBER(S)
1STOP One Shot technologies TO Pulmonary vein isolation P3399, P3403,

P3411
3C The Three-City Study 964
AAA Aortic Aneurysmal remodeling by ARB 5081
ACALM Algorithm for Comorbidities, Associations, Length of stay and Mortality P3664
ACCES An alternative model of cardiac rehabilitation for cost effective secondary prev P3640
ADAPT-DES Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents 4000, P4326,
P4328
ADONHERS Project Aged Donor Heart Rescue by Stress Echo Project P1769
AFNET German Atrial Fibrillation competence NETwork registry P5316
AHEAD Acute HEArt failure Database 6645
ALARM-HF Acute Heart Failure Global Registry of Standard Treatment P2459, 3303,
P6566
A-MATCH Fixed-dose versus Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone P1475, P5971
AMI-NCS Asymptomatic Myocardial Injury after Non Cardiac Surgery P1755
AMI-PL Acute Miocardial Infarction in Poland P549, P2471
AMIS Plus Acute Myocardial Infarction in Switzerland P532
ANOCOR ANOmalous connections of the CORonary arteries P6415
ANOX Novel biomarkers related to ANgiogenesin or OXidative stress study P4611
AnPAF Antazoline in rapid cardioversion of Paroxysmal Atrial Fibrillation P5291
ANSWER evaluAtioN of the SafeR mode in patients With a dualchambER pacemaker trial 5917
ANTHEM-HF Autonomic Neural Regulation Therapy to Enhance Myocardial Function in HF P3775, P5671
APACE Advantageous Predictors of Acute Coronary Syndrome Evaluation 126, 157, 159,
P1100, P4459
APPRAISE-2 Apixaban for Prevention of Acute Ischemic Events 2 4979
ARCTIC Assessment by a double Randomization of a Conventional antiplatelet strategy ver 363
ARIC Atherosclerosis Risk in Communities Study 3168
ARISTOTLE Apixaban for Reduction in Stroke and Other Thromboembolic Events in AF 1973, 2032
ARTEMIS Innovation to Reduce Cardiovascular Complications of Diabetes at Intersection P2708, P6221
ARTICLE Anesthesy-ReanimaTIon and Cardiac surgery cardiopulmonary bypass GDF-15 P6344
LEvels
ASTA Arrhythmia-Specific questionnaire in Tachycardia and Arrhythmia P4372
AtheroRemoIVUS The European Collaborative Project on Inflammation and Vascular Wall Remodeling P1746
ATLANTIC Administration of Ticagrelor in the Cath Lab or in the Ambulance for New sT P551, P556
elevation myocardial Infarction to open the Coronary artery study
BASEL VIII Biochemical and electrographic signals for the detection of exercise induced myo P2695, P4612,
P5397
BELFIT Belgian Physical Fitness Study P4636
BEST-D Biochemical Efficacy and Safety Study of Vitamin D P4613
BETTER-HF Benefit of Exercise Training ThErapy and cardiac Resynchronization - HF P2673
BIC-8 Biomarkers in Cardiology 8 125
BJPCI Beijing Percutaneous Coronary Intervention Registry P805
BMF Biomakers and frailty 963
BMPCs Hemotopoietic progenitor cells P2586
BRHS British Regional Heart Study P4776, P5019,
P5572
BRIGHT-CEA The Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque Trial 6621
BRS in CTO Bioresorbable vascular scaffolds in chronic total occlusion P2768
BUDAPEST Twins BUrDen of Atherosclerotic PlaquEs STudy in Twins P6401
CAFE-PIE Coronary Atherosclerosis FEatures for the Prediction of Ischemic Events Study 2102
CAMI China Acute Myocardial Infarction registry P2521
CAP The Clotinab application in high risk ACS undergoing PCI registry P2755
CAPIAS Carotid Plaque Imaging in Acute Stroke 2058
CARDH CARdiovascular and late-life Dementia risk in HIV (CARDH) Study P4628
CARE Coronary Artery Revascularization Evaluation P5642
CAREMI Cardiac stem cells for acute myocardial infarction P3554
CARMAGUE Cardiac Marker Guideline Uptake in Europe P528
CASCADE Longitudinal ChAngeS of CArdiac Structure and Function in Chronic KiDney DisEase P4306
CATCH CArdiac cT in the treatment of acute CHest pain trial P6324
CDAH Childhood Determinants of Adult Health P1356
CESCAS I Southern Cone American Center for Cardiovascular Health P2421
CHAMPION CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in P5976
NYH
CHAMPION Cangrelor vs Standard Therapy to Achieve Optimal Management of Platelet Inhibiti P4105
CHART Studies Chronic Heart Failure Analysis and Registry in the Tohoku District Studies P6539
CHART-2 Chronic Heart Failure Analysis and Registry in the Tohoku District-2 P6544
CIBIS-ELD Cardiac Insufficiency Bisoprolol Study in Elderly P5663, P5690
CIBIS ELD FUP Cardiac Insufficiency Bisoprolol Study in Elderly 24 months follow-up P5667
cIMT Corotid intima-media thickness P5620
CKB China Kadoorie Biobank P1700
536
COACH Coaching patients On Achieving Cardiovascular Health P6456

COMPERA Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary P2367
Hypertension
CONFIRM Registry COronary CT angio evaluatioN For clinical outcomes: an InteRnational Multicenter 3996, P4480
CopenHeartRFA CopenHeart Radio frequency ablation 2938
CopenHeartVR CopenHeart Valve Replacement or Repair Trial P3654
CRAGS Coronary aRtery diseAse in younG adultS P6453
CRAVE Cardiovascular Risk factors Affecting Vascular agE 967, P1572,
P2574, P3806
CREDO-Kyoto Coronary Revascularization Demonstrating Outcome study in Kyoto 2908, P5249
CRESCENT Computed Tomography versus Exercise Testing in Suspected Coronary Artery 2101
Disease trial
CTO Chronic Total Occlusion P819
CUT-IT Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low P6448
Energy Diet
dal-OUTCOMES Efficacy and safety of dalcetrapib in patients with recent ACS P6464
DANAMI-3 The Third DANish Study of Optimal Acute Treatment of Patients with STEMI 4001
DATA-HELP Diagnostic And TherApeutic methods used in patients with systolic HEart failure P841
DDVTCMR Detection and dynamics of ventricular thrombus by CMR after STEMI P1517
DEGS German Health Interview and Examination Survey for Adults P3666
DESIRE Drug-Eluting Stents In the REal world 2911
DIAMOND HFPEF Developing Imaging And plasMa biOmarkers iN Describing HFPEF P3126
DISHA Diet and lifestyle InterventionS for Hypertension risk reduction through AWW 2024
DMP-HF Disease management program - heart failure P5979
DREAM CRT Device left captuRe confirmation through an Electrogram Analysis Model P495
DYSIS Dyslipidemia International Study 69, P1654
DYSIS II Dyslipidemia International Study II P1675, P1680,
P1681, P1684
EA+ EUROACTION PLUS P2724
ECCLIPSE EffeCts of lysine aCetylsaLIcylate comPared to aSpirin on platElet inhibition P2119
ECCLIPSE Prasugrel and Lysine Acetylsalicylate intravenous versus Prasugrel and Aspirin P1470
Echo-BEFRI Berliner Frauen Risikoevaluation P5439
E-ECHOES Ethnic-Echocardiographic Heart of England Screening Study P226
EIPSAP Electrocardiographic identification of posteroseptal accessory pathway location P3379
EMMACE-3 The Evaluation of the Methods and Management of Acute Coronary Events P171, P176
e-MUST Evaluation en Médecine d’Urgence des Strategies Thérapeutiques des infarctus P1338, 5816
END-AF Effect of ColchiciNe on the InciDence of Atrial Fibrillation in OHS Patients P5325
ENGAGE AF - TIMI 48 Effective aNticoaGulation with factor xA next GEneration in Atrial 1896
Fibrillation-Thrombolysis In Myocardial Infarction study 48
EORP-AF EurObservational Research Programme – Atrial Fibrillation P4619
EPICOR Long-tErm follow-uP of antithrombotic management patterns In ACS 3031
EPIDEMCA Epidemiology of Dementia in Central Africa P5574
EPIDEMCA-FU Epidemiology of Dementia in Central Africa – Follow-up P4108
EQUIP-ACS European Quality Improvement Programme for Acute Coronary Syndromes P526
ESTROFA MI+75 Estudio español de stents farmacoactivos en infarto + 75 años P832, 1205, P4712
ESTROFA OCT:BVS-DES Grupo español de estudio de stents farmacoactivos: estudio con OCT de BVS vs P2732
DES
ETiCS Etiology, Titre-Course, and Survival Study P3599
EU-CORE European Cubicin® Outcomes Registry and Experience P677
EUROASPIRE European Survey of Cardiovascular Disease Prevention and Diabetes P1663, P2146,
P4324, P6459,
6652
Euro-CCAD Euro-Calcific Coronary Artery Disease P4465
EURO-CRIPS The EUROpean and Chinese cardiac and renal Remote Ischemic Preconditioning P3118
Study
EUROMAX European Ambulance Acute Coronary Syndrome Angiography trial 5813
EUTRAF The EUropean network for Translational Research in Atrial Fibrillation P6179
EU-TrigTreat European Triggers and Treatment Study P165
EXAMI Exenatide in patients with an acute myocardial infarction P531
EYESHOT EmploYEd antithrombotic therapies in patients with acute coronary Syndromes P1474
HOsp
FALCON Swiss Fontan & Altitude Collaboration Study 2929
FAMILY Family focused Approach to iMprove Heart Failure care In Lebanon QualitY (FAMILY P5669
FAMOUS TRIAGE Fast assessment and management of chest pain without ST-elevation in the pre-hos 1857, P4071
FANS Familial Arrhythmia Network Scotland P1380
FAST-MI French registry of Acute ST-elevation and non-ST elevation Myocardial Infarction P173, P2147,
P2504, 4260,
P4991, P5931
FFR Fractional Flow Reserve P1740
FIB-ES-HCM FIBROSIS END-STAGE HCM P5467
537
FinPPS Finland PostPericardiotomy Syndrome study P197

Fix-CHF-18 Fix-CHF-18 A Randomized Comparison: CCM Delivered from 1 versus 2 leads P493
FMC First Medical Contact study P4070
GABA gamma-aminobutyric acid P4537
GARFIELD-AF Global Anticoagulant Registry in the FIELD-Atrial Fibrillation P1513, 3278,
P4404, P5598
GBD 2013 Global Burden of Disease Study 2013 P6461
GECAME Grupo de Estudio de CArdiotoxicidad por MEdicamentos P853, 4049
GeneCAST Genetics of Calcific Aortic Stenosis P4090
GHS Gutenberg Health Study P882, P2572,
P4332
GLORIA-AF Global Registry on Long-Term Oral Antithrombotic Treatment - Atrial Fibrillation P1488, P1516
GREECS The Greek Study of acute Coronary Syndrome P4418, P4430,
P4450
GRIPHON Prostacyclin (PGI2) Receptor agonist In Pulmonary arterial HypertensiON P2365
GSR Global SYMPLICITY Registry P2841, P2846
Gulf CARE Gulf aCute heArt failuRe rEgistry P5689, P5701,
P6561
HACVD Hypertension Associated Cardiovascular Disease P6433
HALST Healthy Aging Longitudinal Study P5554
HARMONIZE Hyperkalemia Randomized Intervention Multi-dose ZS-9 Maintenance P3772, P3793
HARVEST Hypertension Ambulatory Recording VEnetian STudy P899
HIGHCARE-ALPS High Altitude Cardiovascular Research-Alps P3352
High-STEACS High-sensitivity Troponin in the Evaluation of Acute Coronary Syndrome P4461
HLM Heart Lung Malfunction of other organs HF classification P846
HNRS Heinz Nixdorf Recall Study 2104
HSP27 Heat Shock Protein 27 P1580
HYSR Helsinki Young Stroke Registry P2346
HYVET The HYpertension in the Very Elderly Trial P5567
IANUS ItAliaN cardiologists’ Undetected distress Study- Survey P1664
IBIS-4 Integrated Biomarker Imaging Study P5026
ICPC International Clopidogrel Pharmacogenomics Consortium P1490
I-HAT Ibaraki Hypertension Assessment Trial P1371
IMPLAC IMaging della PLAcca Carotidea P5577
IMPROVE IT IMProved Reduction of Outcomes: Vytorin Efficacy International Trial 68, P1131, P6120,
P6466
INH Interdisciplinary Network Heart Failure P6149
INHERIT INHibition of the renin angiotensin system in hypertrophic cardiomyopathy and th P6399
INSIGHT (R)XT Indications for diagnosis, arrhythmia and monitoring of Reveal (R)XT P1423
InterTAKRegistry International Takotsubo Registry P2791, P6550
IPAH Idiopathic pulmonary arterial hypertension 2339
iPOWER ImProve diagnOsis and treatment of Women with angina pEctoris and micRovessel 4289
disease
iPSCs and CMs Induced pluripotent stem cells and cardiomyocytes P3562
J-CARAF Japanese Catheter Ablation Registry of Atrial Fibrillation P3410
JCD-KiCS Japan Cardiovascular Database-Keio interhospital Cardiovascular Studies P3477
J-HOP Japan Morning Surge Home Blood Pressure Study P2166
JoPCR1 The First Jordanian PCI Registry P4475
J-POP The Japan - Prediction of Neurological Outcomes in Patients Post-cardiac Arrest P3434, 6629
Registry
KAMIR Korea Acute Myocardial Infarction Registry P4697
kArEN Karolinska and Rennes collaborative study about HFpEF P852
KORA Kooperative Gesundheitsforschung im Raum Augsburg 4205
KorAHF Korean Acute Heart Failure P3778, P4110,
P6578
koROSE KoRean wOmenS chest pain rEgistry P5401
K-STAR KAI trial of tolvaptan on HF patients with renal impairment P3742
LEAF LEvosimendan in Acute heart Failure following myocardial infarction P3489
LIPID Long Term Intervention with Pravastatin in Ischemic Disease P4323
LIPIDOGRAM Prevention of coronary heart disease in primary medical care in Poland P6481
LSM Life Style Modification P6590
LUCAS II-CPR LUCAS II-Cardiopulmonary Resuscitation P4439
LURIC Ludwigshafen Risk and Cardiovascular Health Study 6644
MANTRA PAF The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal AF 957
substudy
MARC Measuring Athlete’s Risk of Cardiovascular events P2371
MEF2C Myocyte enhancer factor 2C P6360
MESA Multi-Ethnic Study of Atherosclerosis P5959
MINAP Myocardial Ischemia National Audit Project 4261
538
MIOT Myocardial Iron Overload in Thalassemia P1529, P1531, P1533,

P2355, P6548, P6571
MIR-RLP Myocardial Infarction Registry Rheinland Pfalz P550
MK5 mitogen activated protein kinase-activated protein kinase 5 P4520
Mona Lisa - Nut Monitoring du Risque artériel - Nutrition P1358
MONICARD Monitoring coronary heart disease in dialysis patients P5392
MPP Malmö Preventive Project P743, P771
MultiSENSE Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients P2805
MYOCYTE The MYOCYTE clinical trial of MSC for idiopathic dilated cardiomyopathy P5448
MYOPENT Myocarditis treatment with pentaglobin P3597
NANOM-FIM Plasmonic Nanophotothermic Therapy of Atherosclerosis P2734
NANOM-PCI Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting P2376
NONCAD Non invasive examinations of coronary artery disease P3522
NOTE Non-vitamin K antagonist oral anticoagulants for thromboembolic prevention 2927
NOVEL Nifedipine On coronary Vascular function after drug-ELuting stent implantation P6117
ODACE Oxygen uptake drop during all-out cycling exercise P2690
OPTI-DAPT The OPTImal duration of Dual AntiPlatelet Therapy following drug-eluting stent 2915
OptimEx Optimizing Exercise Training in Prevention and Treatment of DHF 6039
ORBIT-AF Outcomes Registry for Better Informed Treatment of Atrial Fibrillation P3076
ORCADES Mandibular Repositioning Device in the second-line treatment of severe OSA 5077
PAH pulmonary arterial hypertension 1939, 1940, 2334
PainFree SST PainFree SmartShock Technology trial P5927
PAPUCO Pan African Pulmonary Hypertension Cohort (PAPUCO) P2651
PARACHUTE PercutAneous Ventricular RestorAtion in Chronic Heart FailUre PaTiEnts P4334
PARADIGM-HF Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality P213, P214, 3301,
P5031
PARIS Patterns of non-adherence to anti-platelet regimens in stented patients P582, P3717
PAROKRANK PAROdontit och dess relation till KRANsKärlsjukdom P6424
PARTNER EU Placement of AoRTic TraNscathetER Valves Trial (EUrope) 4268
PATA STEMI Physiologic Assessment of Thrombus Aspiration in STEMI patients P609, P1716,
P5415
PEGASUS TIMI 54 Prevention of CV Events in Patients with Prior Heart Attack Using Ticagrelor 3032, P3317
PERKAT PERkutane KATheterpumptechnologie-percutaneous catheter pump technology P6514
PESA Progression of Early Subclinical Atherosclerosis 6085
PIMAR Polish Registry of Ischaemic Mitral Regurgitation P6367
PL-ACS Polish Registry of Acute Coronary Syndromes P2506, P2789,
P6587
PL-ACS & AMI-PL Polish Registry of Acute Coronary Syndromes and AMI in Poland Registry P6580
PLATO Platelet Inhibition and Patient Outcomes P172, 3030
PLTOCMRSTEMI Prediction of long-term major events with CRM after STEMI 3252
POL-TAVI 2013 Polish Transcatheter Aortic Valve Implantation Registry (POL-TAVI) 2013 P5011
PONS The Polish Norwegian Study P222
POP The PostOperative Prognosis study P4425
PORAF Predictors Of Rheumatic Atrial Fibrillation P5287
POST Effects of Postconditioning on Myocardial Reperfusion in Patients with ST-segment P4702
elevation trial
PPS3 Paris Prospective Study III P1658
PRACTICE PRospective Assessment of Cardiovascular risk and Treatment In Canadians of P760
varying Ethnicity Registry
PREDIMED Prevención con Dieta Mediterránea P4662
PRESTIGE Prevention of late stent thrombosis by an interdisciplinary European effort P1500
PRIME The Prospective Epidemiological Study of Myocardial Infarction P1667
PROCEED Progression of coronary atherosclerosis in diabetics: Evaluation of CT coronary P4484, P4485
PROFIL FA Screening campaign of Atrial Fibrillation P5282, P5283
PROMISE protection with adenosine during primary PCI in patients with STEMI P538
PROVE-HF PROgnostic value of pulmonary blood VolumE in Heart Failure P5956
PROWL PRognostic factors for adverse Outcome on the heart transplant Waiting List P4725
PSC Prospective Studies Collaboration P4321
PURE Prospective Urban and Rural Epidemiological study P6596
Q-SYMBIO Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomized, P3744
double-blinded study
Quality HF-DM Cost Effectiveness and Quality of Life in heart failure and diabetes P441
RAID-HF Registry Analysis of Iron Deficiency – Heart Failure 3309
REACT Registry of Clinical Practice in High-risk Cardiovascular Practice P2717
REALISM EVEREST II Real World Expanded Multicenter Study of the MitraClip System 5215
REALITY HF Resting Heart Rate and Real Life Treatment Modality in Outpatients with Left P1764, P3746,
Ventricular Systolic Dysfunction P3776
RED-HF Reduction of Events With Darbepoetin Alfa in Heart Failure Trial P6555
RELAX-AHF Serelaxin for Treatment of Acute Heart Failure 6037, 6638
RELAX-AHF-EU Recombinant human relaxin-2 for treatment of acute heart failure - European Union P3752
539
RE-LY Randomized Evaluation of Long Term Anticoagulation Therapy 4980

REPARA Registry of patients with bioresorbable coronary devices in clinical practice 366
RETAKO REgistro español sobre síndrome de TAKOtsubo P1622
RE-VERSE AD Study of the REVERSal Effects of idarucizumab in patients on Active Dabigatran P5967
RICO observatoiRe des Infarctus de Côte d’Or P3080
RIP-PCI Remote ischemic postconditioning-percutaneous coronary intervention trial P2352
RNAi Therapeutic RNA interfering Therapeutic ALN-PCSSC P1761
RNSCA Registo Nacional de Sindromes Coronarias Agudas P3457, P5390
ROBINSCA Risk Or Benefit IN Screening for CArdiovascular disease P5591
ROBUST Comparison of Biolimus A9 and Everolimus Drug-Eluting Stents in Patients... P4707
ROCKET AF Rivaroxaban Once Daily Oral Direct FXa Inhibition Compared with VKA for 2031, P4398,
Prevention of Stroke and Embolism Trial in Atrial Fibrillation P6210
ROPAC Registry Of Pregnancy And Cardiac disease 142
RUS-HFR RUssian hoSpital Heart Failure Registry P2825
SABOT Sleep apnea and Atrial fibrillation after Bypass OperaTion P5644
SABRE Southall And Brent REvisited 1849
SAPALDIA Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults P2671
SCAD UK, Europe Spontaneous Coronary Artery Dissection P817
SchlaHF-XT SchlaHF-XT Register 358, P3128
SCN5A Sodium channel, voltage gated, type V alpha subunit P6360
SDEC Sudden death expertise center 1320, P1382
SEAS Simvastatin Ezetimibe in Aortic Stenosis P4093, P4094
SEPHAR II Study for the Evaluation of Prevalence of Hypertension and Cardiovascular Risk II P225
SETAM Strategy of Early deTection and Active Management of AF with telecardiology 104
SEVEN Quality assessment of SEVEN cardiovascular drugs in ten African countries P3134, P3135
SHEP Systolic Hypertension in the Elderly Program 1238
SHINANO The Shinshu Prospective Multi-center Analysis for Elderly Patients with Coronary P4467
SICA-HF Studies Investigating Co-morbidities Aggravating Heart Failure P887, P1789,
P5655, P5695
SLOVASeZ II Slovak acute heart failure survey II P4770
SMART-MR Secondary Manifestations of ARTerial disease-Magnetic Resonance Study P5246
SOLID- TIMI 52 Stabilization of Plaque using Darapladib-Thrombolysis in Myocardial Infarction P1682
SoPP Follow-up of Sollentuna Prevention Program 6646
SORT OUT V Scandinavian Organization for Randomized Trials with Clinical Outcome V P2745
SOURCE-XT SAPIEN XT™ Aortic Bioprosthesis Multi-region Outcome Registry 5786
STABILITY STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY P5961, P6228,
P6290, P6439
STICH Surgical Treatment of Ischemic Heart Failure P2613, 5214,
P5974
STOP-HF SDF1 plasmid Treatment fOr Patients with Heart Failure P215
Stopshock Project Hemorrhagic shock treatment with anti-opioid neuropeptide. Stopshock Project P450
SUMMIT Study of HM system Safety and efficacy in cardiac implantable electronic device P470
Super-MIMI Super - Minimalist Immediat Mecanical Intervention P579
SUPPORT A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients with 6649
Myocardial Infarction
Swiss ACS Swiss Acute Coronary Syndrome study P1691
SymTime Symptoms and delay times in ST elevation myocardial infarction P552
SYSTEMA Syncope Study of Unselected Population in Malmö 1328
T2Target Treat to Target P3353, P3796
TARGET-CAS CAS With Patient- and Lesion-Selection of the Neuroprotection and Stent Type P5616
TAS-ELF Tasmanian Study of Echocardiographic detection of Left ventricular dysfunction P3676, 4155
Tema HF 1 Telemonitoring in the management of heart failure 105
THRAPS THRombus Analysis in intra-arterially treated Patients with acute ischemic Strok P5597
thrombEVAL Evaluation of oral anticoagulation therapy 1978, 4977, P6206
TILDA The Irish Longitudinal Study on Ageing 1856, P5580
TNT and IDEAL Treating to New Targets and Incremental Decrease in End Points through Aggressive P201
TNT and SPARCL Treating to New Targets; Stroke Prevention by Aggressive Reduction in Cholesterol P766
TOPCAT Treatment of Preserved Cardiac Function Heart Failure With Aldosterone Antagonis P3756
TRAMI Transcatheter Mitral Valve Interventions registry 349
TRAPID-AMI High sensitivity cardiac Troponin T assay for RAPID rule-out of Acute MI 162
TRITON TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet P2623
InhibitioN
TRIVENT NR Tri-ventricular pacing in non-responders to conventional biventricular pacemaker P510
TTM Target Temperature Management trial P421
VALIDA HTE-DLP Clinical validation of effective treatment hypercholesterolemia CDSS P1674
VHM&PP Vorarlberg Health Monitoring & Promotion Programme 966
VICC Variation in Cardiac Care P777
VIPERS Ventricular Pace Suppression Versus Intrinsic Rhythm Support Study 5918
VISAT VIeillisement SAnte Travail 2023
Whitehall Study Whitehall Study of London Civil Servants P5582
540
WITAVI WIllebrand TAVI P6507

YMCA Young patient with Monotruncular Coronary artery Acute occlusion P5933
YUKAWA-2 Study of LDL-C reduction using PCSK9 Antibody in Japanese Patients with aCVR P5968
ZAHARA Zwangerschap bij Aangeboren HARtAfwijkingen, Pregnancy in CHD P713
541
LIST OF
EXHIBITORS
Exhibitor name (as of 17 June 2015) Hall | Stand Number
Accriva Diagnostics Exhibition | B240

6260 Sequence Drive, San Diego, CA 92121 - United States of America
Tel: +1 858 263 2421 - Fax: +1 858 314 6700
Email: bdoyen@accriva.com - Website: www.accriva.com
Actelion Pharmaceuticals Ltd Exhibition | A400

Gewerbestrasse 16, 4123 Allschwil - Switzerland
Tel: +41 615 656 565 - Fax: +41 615 656 500
Email: ingrid.marti@actelion.com - Website: www.actelion.com
Advanced Cooling Therapy Exhibition | I100

3440 S. Dearborn Street, #215-South, Chicago, IL 60616 - United States of America
Tel: +1 312 805 8701
Email: robin@advancedcoolingtherapy.com - Website: www.advancedcoolingtherapy.com
Advanced Medical Education Exhibition | E730

4 East Central Street #3126, Worcester, MA 01613 - United States of America
Tel: +1 508 614 5413 - Fax: +1 508 519 0789
Email: info@advancedmedicaledu.com - Website: www.advancedmedicaledu.com
Aegerion Pharmaceuticals SARL Exhibition | J100
UB11 1BD Uxbridge - United Kingdom
Tel: +33 682 086 922
Email: scasabianca@aegerion.com
AEPC ESC Plaza | P505

Childrens Heart Center, Skane University Hospital, 221 85 Lund - Sweden
Tel: +46 702 699 626
Email: katarina.hanseus@skane.se
Agfa HealthCare Exhibition | A350
Septestraat 26, 2640 Mortsel - Belgium
Tel: +32 3444 7527
Email: eva.deherdt@agfa.com - Website: www.agfahealthcare.com
Ai Mediq S.A. Exhibition | C620

Rue de la Chapelle 1, L-1325 Luxembourg - Luxembourg
Tel: +352 278 606 97
Email: info@aimediq.com - Website: www.aimediq.com
Albanian Society of Cardiology ESC Plaza | P135

University Hospital Centre Mother Tereza, Dibra Street 370, 1000 Tirana - Albania
Tel: +355 672 058 763 - Fax: +355 422 371 122
Email: enkelejda_tena@hotmail.com
Algerian Society of Cardiology ESC Plaza | P405

B.P.261, Hydra, DZ-16035 Alger - Algeria
Tel: +213 212 329 81 - Fax: +213 212 329 81
Email: eldabajraktari@yahoo.com
American College of Cardiology ESC Plaza | P640

2400 N Street, NW, Washington, DC 20037 - United States of America
Tel: +1 202 375 6484 - Fax: +1 202 375 7000
Email: amccormick@acc.org - Website: www.acc.org
American Heart Association ESC Plaza | P680

7272 Greenville Avenue, Dallas, TX 75231 - United States of America
Tel: +1 214 706 1943 - Fax: +1 214 706 5262
Email: julie.davis@heart.org - Website: www.myamericanheart.org
544
American Society of Echocardiography ESC Plaza | P630

2100 Gateway Centre Blvd, Suite 310, Morrisville, NC 27560 - United States
of America
Tel: +1 919 861 5574
Email: ase@asecho.org - Website: www.asecho.org
Amgen Exhibition | B300 / H970

Dammstrasse 23, 6300 Zug - Switzerland
Email: katerina.vourvouhaki@amgen.com - Website: www.amgen.com
Armenian Cardiologists Association ESC Plaza | P390

Institute of Cardiology, 5 P.Sevak Str., 44 Yerevan - Armenia
Tel: +374 102 886 16 - Fax: +374 102 885 02
Email: zelveian@armeda.am
Arrhythmia Alliance ESC Plaza | P500
PO Box 3697, Stratford Upon Avon, CV37 8YL Warwickshire - United Kingdom
Tel: +44 178 986 7501 - Fax: +44 178 945 0682
Email: info@aa-international.org - Website: www.aa-international.org
Asian Pacific Society of Cardiology Congress ESC Plaza | P545

c/o The Meeting Lab Pte Ltd 695E East Coast Road, 459059 Singapore - Singapore
Tel: +65 673 565 80 - Fax: +65 673 533 08
Email: secretariat@apsc2017.com - Website: www.apsc2017.com
Aspen Europe Exhibition | H760

Aspen Europe GmbH, Montgelasstraß223;e 14, 81679 München - Germany
Email: de_info@aspenpharma.eu - Website: www.aspenpharma.com
Association of Cardiologists of Bosnia and Herzegovina ESC Plaza | P130

Behdzeta Mutevelica 33, BA-71000 Sarajevo - Bosnia and Herzegovina
Tel: +387 623 306 06
Email: ukbih@bih.net.ba - Website: www.ukbih.com
Association of Cardiologists of Kazakhstan ESC Plaza | P205
Aiteke Bi Street 120, 50000 Almaty - Kazakhstan
Tel: +7 727 233 0021 - Fax: +7 727 233 0021
Email: kz-cardio@yandex.kz
AstraZeneca Exhibition | E100 / E150 / E600

2 Kingdom Street, Paddington, W2 6BD London - United Kingdom
Tel: +44 207 604 8000
Email: marianne.weimers@astrazeneca.com - Website: www.astrazeneca.com
AUM Cardiovascular, Inc. Exhibition | I300
1001 Highway 3 S, Northfield, MN 55057 - United States of America
Tel: +1 612 799 2511
Email: matt@aumcardiovascular.com - Website: www.aumcardio.com
Austrian Society of Cardiology ESC Plaza | P290
Dept. of Internal Medicine II, Div. of Cardiology Waehringer Guertel 18-20, 1090 Vienna -
Austria
Tel: +43 140 400 461 40 - Fax: +43 140 400 421 60
Email: edith.tanzl@meduniwien.ac.at
Azerbaijan Society of Cardiology ESC Plaza | P125
Azerbaycan Respublikasi, Nizami Rayonu, Qara-qarayev prospekdi. Bina 70, Blok-1,
M-11, 1010 Baku - Azerbaijan
Tel: +994 559 201 723 - Fax: +994 124 408 270
Email: lamiyaa@gmail.com - Website: www.akc.az
545
Bayer HealthCare Exhibition | C200 / E500

Bayer Pharma AG, 13353 Berlin - Germany
Tel: +49 304 681 111
Website: www.healthcare.bayer.com
Belgian Society of Cardiology ESC Plaza | P250

Rue des Champs-Elysées 63, Elyzeese-Veldenstraat, 1050 Brussel - Belgium
Tel: +32 264 462 32
Email: secretariat@bvc-sbc.be - Website: www.bscardio.be
Belorussian Scientific Society of Cardiologists ESC Plaza | P170
R. Luxemburg Str 110, 220036 Minsk - Belarus
Tel: +375 172 851 466 - Fax: +375 172 851 466
Email: bssc@cardio.by - Website: www.cardio.by
BePATIENT Exhibition | B520

4 Allée Verte, 75003 Paris - France
Tel: +33 1 44 61 52 25
Email: audrey.cohuet@bepatient.com
Biocare Co., Ltd Exhibition | C350

7/F, Block A, Shenzhen Mingyou Industrial Products Exhibition & Procurement
Center, Baoyuan Road, Xixiang Sub-district, Bao’an District, 518102 Shenzhen -
Tel: +86 755 366 153 33 - Fax: +86 755 279 606 43
Email: tammy.li@biocare.com.cn - Website: www.biocare.com.cn
BIOTRONIK Exhibition | H600

Woermannkehre 1, 12359 Berlin - Germany
Tel: +49 306 890 514 21 - Fax: +49 306 890 539 24
Email: inez.von.randow@biotronik.com - Website: www.biotronik.com
Blueprint Genetics Oy Exhibition | E960
Tukholmankatu 8, Biomedicum 2U, 00290 Helsinki - Finland
Tel: +358 402 511 372 - Fax: +358 985 657 17
Email: support@blueprintgenetics.com - Website: www.blueprintgenetics.com
BMS / Pfizer Alliance Exhibition | H100

Pfizer Ltd, Walton Oaks, Dorking Road, KT20 7NS Tadworth - United Kingdom
Tel: +44 796 678 8589
Email: info@pfizer.com - Website: www.pfizer.eu
Boehringer Ingelheim Exhibition | G100 / G300

Binger Strasse 173, 55216 Ingelheim - Germany
Tel: +49 613 2770 - Fax: +49 613 2720
Email: birgit.akerfors@boehringer-ingelheim.com - Website: www.boehringer-ingelheim.com
BPLab Exhibition | B230

Gagarin Avenue 37, 603950 Nizhny Novgorod - Russian Federation
Tel: +7 831 296 1414 - Fax: +7 831 296 1415
Email: 113@bplab.com - Website: www.bplab.com
Brazilian Society of Cardiology ESC Plaza | P540

Av. Marechal Camara 160, 3° Andar, Ed.Lebourget-Centro, 20020-907 Rio de Janeiro -
Brazil
Tel: +55 213 478 2745 / 2747 - Fax: +55 213 478 2755
Email: cientifico@cardiol.br - Website: www.cientifico.cardiol.br
British Cardiovascular Society ESC Plaza | P260
9 Fitzroy Square, W1T5HW London - United Kingdom
Tel: +44 207 380 1928
Email: bertramd@bcs.com
546
British Journal of Cardiac Nursing Exhibition | C801

MA Healthcare, St Judes Church, Dulwich Road, SE24 0PB London - United Kingdom
Tel: +44 207 501 6781
Email: maguire.barry@gmail.com
British Society of Echocardiography Exhibition | B705

Docklands Business Centre 10-16 Tiller Road, E14 8PX London - United Kingdom
Tel: +44 207 345 5185 - Fax: +44 207 345 5186
Email: admin@bsecho.org - Website: www.bsecho.org
Bulgarian Society of Cardiology ESC Plaza | P185

76 James Bourchier Blvd., Office 422, 1407 Sofia - Bulgaria
Tel: +359 884 786 884 - Fax: +359 298 774 77
Email: deltahold@yahoo.com - Website: www.cardiobg.com
Cardio Alex ESC Plaza | P620

2 El Asdekae Street, Garden City Smouha, Alexandria - Egypt
Tel: +203 420 4849
Email: radwa.elfar@icomgroup.org
Cardiological Society of India ESC Plaza | P660

Indian Heart House P-60, C.I.T. Road, Scheme VIIM Kankurgachi, 700054 Kolkata - India
Tel: +91 033 235 563 08 - Fax: +91 033 235 563 08
Email: csi@cal2.vsnl.net.in - Website: www.csi.org.in
Cardiology Society of Serbia ESC Plaza | P175

Koste Todorovica 8, 11000 Belgrade - Serbia
Tel: +381 604 223 340 - Fax: +381 113 981 676
Email: milanned@hotmail.com
Cardiome AG Exhibition | B400
Chamerstr. 176, 6300 Zug - Switzerland
Tel: +49 176 724 720 70 - Fax: +49 880 139 502 17
Email: jpolifka@cardiome.com - Website: www.cardiome.com
CardioSecur Exhibition | H710

60320 Frankfurt am Main - Germany
Email: hofmann@cardiosecur.com - Website: www.cardiosecur.com/de
Cardiostim ESC Plaza | P525
52-54 Quai de Dion Bouton, 92800 Puteaux - France
Tel: +33 1 47 56 24 56 - Fax: +33 1 47 56 24 55
Email: cardiostim@wanadoo.fr - Website: www.cardiostim.com
Cardiovascular Society of India ESC Plaza | P695
301 37/2 Royal Plaza, Tikekar Road Dhantoli, 440012 Nagpur - India
Tel: +91 989 072 8799 - Fax: +91 712 200 0000
Email: sam@promaxevents.in
Carewell Electronics Co., Ltd. Exhibition | C660

1A-2F, Building 29, District B, Tanglang Industrial Zone, Taoyuan Street, Nanshan,
518055 Shenzhen - China, People’s Republic of
Tel: +86 755 861 703 89 ext 8009 - Fax: +86 755 861 703 89
Email: alex.cui@carewell.com.cn
CellAegis Devices Inc Exhibition | D610
139 Mulock Ave, Toronto, ON M6N 1G9 - Canada
Tel: +1 647 722 9601 - Fax: +1 647 722 9553
Email: dnunes@cellaegisdevices.com - Website: www.cellaegis.com
547
Charity Cardiac Risk in the Young (CRY) Exhibition | B702

Unit 1140B, The Axis Centre, Cleeve Road, KT22 7RD Leatherhead - United Kingdom
Tel: +44 173 736 3222 - Fax: +44 173 736 3444
Email: steve@c-r-y.org.uk - Website: www.c-r-y.org.uk
China Qingdao Bright Medical Manufacturing Co Ltd Exhibition | B555

No.1 Tiankang Road, Chengyang District, Shandong, 266107 Qingdao - China,
People’s Republic of
Tel: +86 532 838 135 60 - Fax: +86 532 838 135 60
Email: export@bright-med.com
Chinese Society of Cardiology ESC Plaza | P690

No. 42 Dongsi Xidajie, 100710 Beijing - China, People’s Republic of
Tel: +86 138 104 731 43
Email: 13810473143@139.com
Circle Cardiovascular Imaging Inc. Exhibition | H720
815 8th Ave SW, Suite 250, Calgary, AB T2P 3P2 - Canada
Tel: +1 403 453 2061 - Fax: +1 403 338 1895
Email: jocelyn@circlecvi.com
Covance Exhibition | B260

210 Carnegie Center Drive, Princeton, NJ 08540 - United States of America
Tel: +1 609 452 4440
Email: covance.inc@covance.com - Website: www.covance.com
CPR (cardiopulmonary resuscitation) Workshops Exhibition | A900
European Society of Cardiology (ESC) European Heart House Les Templiers -
2035 Route des Colles CS 80179 Biot, 06903 Sophia Antipolis Cedex - France
Tel: +33 4 92 94 76 00 - Fax: +33 4 92 94 76 01
Email: congress@escardio.org - Website: www.escardio.org
Croatian Cardiac Society ESC Plaza | P120

Clinical Hospital Center Zagreb-Rebro, University Clinic for Cardiovascular Diseases,
Medical School, University of Zagreb, Kispaticeva 12, HR-10 000 Zagreb - Croatia
Tel: +385 123 675 01 - Fax: +385 123 675 12
Email: d.milicic@mail.inet.hr - Website: www.kardio.hr
custo med GmbH Exhibition | B200
85521 Ottobrunn - Germany
Tel: +49 897 109 800 - Fax: +49 897 109 810
Email: info@customed.de - Website: www.customed.de
Cyprus Society of Cardiology ESC Plaza | P395
P.O Box 27031, 1641 Nicosia - Cyprus
Email: cycardio@topkinisis.com - Website: www.cycardio.com
Czech Society of Cardiology ESC Plaza | P215

Pekarska Street 72, 60200 Brno - Czech Republic
Tel: +420 543 213 825
Email: klimova@kardio-cz.cz - Website: www.kardio-cz.cz
Daiichi Sankyo Europe GmbH Exhibition | F100
Zielstattstr 48, 81379 Munich - Germany
Tel: +49 897 8080 - Fax: +49 897 808 551
Email: service@daiichi-sankyo.eu - Website: www.daiichi-sankyo.eu
DailyCare BioMedical Exhibition | C710

7F, No. 1, Ding-An Road, Chungli District, 320 Taoyuan City - Taiwan, ROC
Tel: +886 326 311 68 - Fax: +886 346 278 66
Email: sale@dcbiomed.com - Website: www.dcbiomed.com
548
Defibtech LLC Exhibition | H700

741 Boston Post Road, Suite 201, Guilford„ CT 06437 - United States of America
Tel: +1 203 453 6654 - Fax: +1 203 453 6657
Email: sales@defibtech.com - Website: www.defibtech.com
DocCheck Medical Services GmbH Exhibition | A355
Vogelsanger Str. 66, 50823 Köln - Germany
Tel: +49 221 920 530
Email: frontoffice@antwerpes.de - Website: www.doccheck.com
Dot Medical Ltd Exhibition | J400

Silk Point Queens Avenue, SK10 2BB Macclesfield - United Kingdom
Tel: +44 162 566 8811 - Fax: +44 162 566 8855
Email: irankin@dot-medical.com - Website: www.dot-medical.com
DSM Nutritional Products Ltd Exhibition | C720
P.O. Box 2676, 4002 Basel - Switzerland
Tel: +41 797 887 206
Email: celine.zuber@dsm.com - Website: www.dsm.com
Edan Instruments, Inc. Exhibition | G860
3/F-B, Nanshan Medical Equipments Park, Nanhai Rd 1019, 518067 Nanshan Shenzhen -
Tel: +86 755 268 811 72 - Fax: +86 755 268 983 30
Email: arlene@edan.com.cn - Website: www.edan.com.cn
Edwards Lifesciences Exhibition | B450
Route de l’Etraz 70, 1260 Nyon - Switzerland
Tel: +41 702 203 292
Email: petra_holopirkova@edwards.com
Egyptian Society of Cardiology ESC Plaza | P295

The Egyptian Heart House, 9 Adel Hussein Rostom Street, 12311 Dokki-Giza - Egypt
Tel: +20 233 813 08 - Fax: +20 233 813 09
Email: egyptiancardiology@gmail.com - Website: www.cardioegypt.com
Eli Lilly and Company Limited Exhibition | G400

Lilly Corporate Center, Indianapolis, IN 46285 - United States of America
Tel: +1 317 510 7866
Email: demetrion_stephanie@network.lilly.com - Website: www.lilly.com
Elsevier Exhibition | B530

Radarweg 29, 1043 NX Amsterdam - The Netherlands
Tel: +31 204 853 911
Website: www.elsevier.com
ERCULES Exhibition | C809
Via Roma 10, 10023 Chieri (TO) - Italy
Tel: +39 011 941 1080 - Fax: +39 011 941 2228
Email: info@ercules.it - Website: www.ercules.it
ESAOTE Exhibition | H300
Via di Caciolle 15, 50127 Florence - Italy
Tel: +39 055 422 91 - Fax: +39 055 422 9208
Email: international.sales@esaote.com - Website: www.esaote.com
ESC Global Affairs Meeting Point ESC Plaza | P560
European Society of Cardiology (ESC) European Heart House Les Templiers -
2035 Route des Colles CS 80179 Biot, 06903 Sophia Antipolis Cedex - France
Tel: +33 4 92 94 76 00 - Fax: +33 4 92 94 77 51
Email: internationalaffairs@escardio.org - Website: www.escardio.org
549
European Association for the Study of Diabetes ESC Plaza | P515

Rheindorfer Weg 3, 40591 Düsseldorf - Germany
Tel: +49 211 758 469
Email: mischa.vaneimeren@easd.org - Website: www.easd.org
European Heart Agency of the ESC ESC Plaza | P520

European Society of Cardiology (ESC), European Heart House, Les Templiers,
2035 Route des Colles, CS 80179 Biot, 06903 Sophia Antipolis Cedex - France
Tel: +33 4 92 94 86 85 - Fax: +33 4 92 94 86 69
Email: communications@escardio.org - Website: www.escardio.org
European Heart for Children ESC Plaza | N100

c/o The European Heart House, Les Templiers, 2035 Route des Colles, CS 80179 Biot,
06903 Sophia Antipolis - France
Tel: +39 053 223 7858
Email: info@europeanheartforchildren.org - Website: www.europeanheartforchildren.org
European Society of Cardiology ESC Plaza | P350

European Heart House, Les Templiers, 2035 Route des Colles, CS 80179 Biot,
06903 Sophia Antipolis Cedex - France
Tel: +33 4 92 94 86 85 - Fax: +33 4 92 94 86 69
Ferrer Internacional SA Exhibition | B600

Avda. Diagonal 549, 08015 Barcelona - Spain
Tel: +34 936 003 700 - Fax: +34 936 003 774
Email: nparis@ferrer.com - Website: www.ferrer.com
French Society of Cardiology ESC Plaza | P305

5 Rue des Colonnes du Trône, 75012 Paris - France
Tel: +33 1 43 22 33 33 - Fax: +33 1 43 22 63 61
Email: contact@sfcardio.fr - Website: www.sfcardio.fr
Fresenius Medical Care Exhibition | C610
Else-Kroener-Strasse 1, 61352 Bad Homburg v.d.H. - Germany
Tel: +49 617 260 924 73 - Fax: +49 617 260 921 91
Email: olivera.gligoric-fuerer@fmc-ag.com - Website: www.freseniusmedicalcare.com
FUKUDA DENSHI Exhibition | H961

Tel: +41 613 362 211
Email: sales@fukuda.ch - Website: www.fukuda.com
GE Healthcare Exhibition | H200
Beethovenstr.239, Postfach 110560, 42665 Solingen - Germany
Tel: +49 171 550 9718 - Fax: +49 212 280 228
Email: martina.emde@med.ge.com - Website: www.gehealthcare.com
Genzyme, a Sanofi company Exhibition | A250

Gooimeer 10, 1411 DD Naarden - The Netherlands
Tel: +31 356 912 00 - Fax: +31 356 943 214
Email: info@genzime.com - Website: www.genzime.com
Georgian Society of Cardiology ESC Plaza | P165

3 Chachava Str, GE-0159 Tbilisi - Georgia, Republic of
Tel: +995 322 526 631 - Fax: +995 322 530 632
Email: contact@geosc.ge - Website: www.geosc.ge
German Cardiac Society ESC Plaza | P280

Grafenberger Allee 100, DE-40237 Dusseldorf - Germany
Tel: +49 211 600 6920
Email: info@dgk.org - Website: www.dgk.org
550
Glenmark Pharmaceuticals Ltd Exhibition | A360

Corporate Enclave, B.D Sawant Marg, Chakala, Andheri East, 400099 Mumbai - India
Tel: +91 224 018 9999
Email: deepal.mistry@glenmarkpharma.com
GSK Exhibition | D700

GSK House, Great West Road„ TW8 9GS Brentford - United Kingdom
Tel: +44 208 047 500
Email: robert.g.huxford@gsk.com - Website: www.gsk.com
Health in Code SL Exhibition | E910

Edificio El Fortin, Hospital Maritimo de Oza, As Xubias, s/n, 15006 A Coruna - Spain
Tel: +34 881 600 003 - Fax: +34 981 167 093
Email: angela.bar@healthincode.com - Website: www.healthincode.com
Hellenic Cardiological Society ESC Plaza | P380

Potamianou Street 6, 11528 Athens - Greece
Tel: +30 210 725 8003 - Fax: +30 210 722 6139
Email: geohcs@hcs.gr - Website: www.hcs.gr
History of Cardiology ESC Plaza | N200

European Society of Cardiology (ESC) European Heart House, Les Templiers,
2035 Route des Colles, CS 80179 Biot, 06903 Sophia Antipolis Cedex - France
Tel: +33 4 92 94 76 00 - Fax: +33 4 92 94 76 01
HITACHI Medical Systems Europe Exhibition | E900

Sumpfstrasse 13, 6300 Zug - Switzerland
Tel: +41 417 486 33
Email: e.fischer@hitachi-medical-systems.com - Website: www.hitachi-medical-systems.eu
Hungarian Society of Cardiology ESC Plaza | P105

Chazar Andras utca 19, HU-1146 Budapest - Hungary
Tel: +36 202 857 236 - Fax: +36 146 106 65
Email: tunde.czetenyi@mkardio.hu - Website: www.mkardio.hu
i-cor Exhibition | I200

Im Zukunftspark 1, 74076 Heilbronn - Germany
Tel: +49 713 127 064 25 - Fax: +49 713 127 064 99
Email: vitas.ackermann@xenios-ag.com - Website: www.i-cor.com
Interamerican Society of Cardiology ESC Plaza | P585

Juan Badiano No 1, Col. Seccion XVI, 14080 Mexico City - Mexico
Tel: +52 555 513 5177 - Fax: +52 555 513 5177
Email: soinca@prodigy.net.mx - Website: www.siacardio.com
International Society of Cardiovascular Pharmacotherapy ESC Plaza | P535

Ruelle du Ptit-Gris 1, 1228 Plan-les-Ouates - Switzerland
Tel: +44 208 878 0308 - Fax: +44 704 308 9616
Email: info@iscpcardio.org - Website: www.iscpcardio.org
International Society on Thrombosis and Haemostasis Exhibition | B704

610 Jones Ferry Road, Suite 205, Carrboro, NC 25710 - United States of America
Tel: +1 919 929 3807 - Fax: +1 919 929 3935
Email: hina_ahmed@isth.org
Irish Cardiac Society ESC Plaza | P255

50 Ringsend Road, 4 Dublin - Ireland
Tel: +353 163 469 47 - Fax: +353 166 858 96
Email: bdalton@irishheart.ie - Website: www.irishcardiacsociety.com
551
ISA 2016 - Anitschkow Days, St. Petersburg Exhibition | B706

Na Pankráci 17, 14021 Prague 4 - Czech Republic
Tel: +420 284 001 444 - Fax: +420 284 001 448
Email: isa2016@guarant.cz - Website: www.isa2016.org
Israel Heart Society ESC Plaza | P220

1 Twin Towers, 33 Jabotinsky Str, IL-5251107 Ramat-Gan - Israel
Tel: +972 361 225 77 - Fax: +972 361 225 88
Email: ihs@israel-heart.org.il - Website: www.israel-heart.org.il
Italian Federation of Cardiology ESC Plaza | P245

Cardiovascular and Neurology Department, San Donato Hospital, Via Pietro Nenni 20,
52100 Arezzo - Italy
Tel: +39 575 255 529 - Fax: +39 575 255 524
Email: paola.luciolli@federcardio.it - Website: www.federcardio.it
Itamar Medical Ltd Exhibition | C450

38900 Caesarea - Israel
Tel: +972 461 770 06 - Fax: +972 462 755 98
Email: hjudith@itamar-medical.com
Japanese Circulation Society ESC Plaza | P580

18th Floor, Imperial Hotel Tower, 1-1-1, Uchisaiwai-cho, Chiyodaku, 100-0011 Tokyo -
Japan
Tel: +81 355 010 862 - Fax: +81 355 019 855
Email: international@j-circ.or.jp - Website: www.j-circ.or.jp/english/
Kaneka Pharma Europe N.V. Exhibition | A370

Frankfurter Straße 80-82, 65760 Eschborn - Germany
Tel: +49 619 696 797 16
Email: christina.schulte-huxel@kaneka.de - Website: www.kanekapharma.com
Kosovo Society of Cardiology ESC Plaza | P150

Rrethi i Spitalit, p.n., 10000 Prishtina - Kosovo, Republic of
Tel: +377 458 008 08
Email: ganibajraktari@yahoo.co.uk
Labtech Ltd. Exhibition | E750

4031 Debrecen - Hungary
Tel: +36 523 101 28 - Fax: +36 524 120 23
Email: medical@labtech.hu - Website: www.labtech.hu
Lebanese Society of Cardiology ESC Plaza | P425
Lebanon-Beirut-Lebanese Order of Physician-Tahwitat Furnel Chebak-Cardiology Society
Office-3rd Floor, 11-640 Beirut - Lebanon
Tel: +961 139 7315 - Fax: +961 139 7315
Email: office@lscardio.org - Website: www.lscardio.org
Lev EL Diagnostics of Heart Diseases Exhibition | J200

6099000 Kibbutz Shefayim - Israel
Tel: +972 526 674 097
Email: mel@levhm.com
Libyan Cardiac Society ESC Plaza | P415
Tripoli - Libya
Tel: +218 928 293 351
Email: khalidellafi@yahoo.com - Website: www.LCS.org
Lithuanian Society of Cardiology ESC Plaza | P480

Santariskiu Str. 2, LT-08661 Vilnius - Lithuania
Tel: +370 523 652 16 - Fax: +370 523 652 10
Email: mrnsks@yahoo.com - Website: www.lcs.lt
552
Littmann / 3M Health Care Exhibition | L100

Carl-Schurz-Strasse 1, 41453 Neuss - Germany
Tel: +49 213 114 4305 - Fax: +49 213 114 4443
Email: aeming@mmm.com - Website: www.littmann.co.uk
Luxembourg Society of Cardiology ESC Plaza | P400

Fondation INCCI, 2A Rue Nicolas-Ernest-Barble, 1210 Luxembourg - Luxembourg
Tel: +352 262 551 21 - Fax: +352 262 550 19
Email: secretariat@slcardio.lu - Website: www.slcardio.lu
Macedonian FYR Society of Cardiology ESC Plaza | P155
Vodnjanska, No 17, 1000 Skopje - Macedonia, The Former Yugoslav Republic of
Tel: +389 703 871 53 - Fax: +389 231 341 64
Email: esrbinovska@yahoo.com
Maltese Cardiac Society ESC Plaza | P145

Mater Dei Hospital, Cardiac Laboratory, Birkirkara Bypass, MSD 2090 Msida - Malta
Tel: +356 994 441 31 - Fax: +356 213 135 48
Email: mcs@maltamed.eu - Website: www.maltime.com
Maltron International Ltd Exhibition | I500
20 Sirdar Road, SS6 7XF Rayleigh - United Kingdom
Tel: +44 126 877 8251 - Fax: +44 126 874 5176
Email: maltron@msn.com - Website: www.maltronint.com
McKesson Imaging & Workflow Solutions Exhibition | B275
3 The Exchange, Brent Cross Gardens, NW4 3RJ London - United Kingdom
Tel: +44 782 523 0595
Email: katrina.sheridan@mckesson.co.uk - Website: www.mckessonimaging.co.uk
MediMatic Exhibition | E800

Viale Cembrano 4C, 16148 Genova (GE) - Italy
Tel: +39 010 307 1634 - Fax: +39 010 307 4548
Email: info@medimatic.com - Website: www.medimatic.com
Medis Medical Imaging Systems Exhibition | G800
Schuttersveld 9, 2nd & 3rd floor, 2316XG Leiden - The Netherlands
Tel: +31 715 223 244 - Fax: +31 715 215 617
Email: info@medis.nl - Website: www.medis.nl
Meditek Ltd Exhibition | B500
27,16ya Parkovaya Str., 105484 Moscow - Russian Federation
Tel: +7 495 662 5703 - Fax: +7 495 662 5703
Email: shatalova@astrocard-meditek.ru - Website: www.astrocard-meditek.com
Medley Farmaceutica Exhibition | B550
Avenida Portugal, 1100 Itaqui, 06696-060 Itapevi - Brazil
Tel: +55 192 117 8550
Email: bruna.dallaqua@medley.com.br
Medscape Cardiology Exhibition | C500

825 8th Avenue, 11th Floor, New York, NY 10019 - United States of America
Tel: +1 514 891 0052 - Fax: +1 514 931 5362
Email: rbrodeur@x-po.ca - Website: www.medscape.com/cardiology
Medtronic Exhibition | F400

Route du Molliau 31, 1311 Tolochenaz - Switzerland
Tel: +41 218 027 000
Email: christine.dettwiler@medtronic.com - Website: www.medtronic.eu
553
Mexican Society of Cardiology ESC Plaza | P595

Juan Badiano No. 1, Col. Seccion XVI, 14080 Mexico City - Mexico
Tel: +52 555 655 7694 - Fax: +52 555 573 2111
Email: smcardiologia@prodigy.net.mx - Website: www.smcardiologia.org
Microlife AG Exhibition | E720

Espenstrasse 139, 9443 Widnau (SG) - Switzerland
Tel: +41 717 277 041
Email: andrea.mazenauer@microlife.ch - Website: www.microlife.com
MIDES GmbH Exhibition | G850
Weinholdstraße 33, 8010 Graz - Austria
Tel: +43 316 426 500 10 - Fax: +43 316 426 5003
Email: petra.kamper@mides.com - Website: www.mides.com
Mindray Exhibition | H960

Mindray Building, Keji 12th Road South, High-tech Industrial Park, Nanshan,
518057 Shenzhen - China, People’s Republic of
Tel: +86 755 818 875 07 - Fax: +86 755 265 825 00
Email: alisa.brguo@mindray.com - Website: www.mindray.com
Moroccan Society of Cardiology ESC Plaza | P410

Service de Cardiologie A, 5ème étage CHU Ibn Sina, 10000 Rabat - Morocco
Tel: +212 537 671 549
Email: marocsmc@gmail.com - Website: www.smcmaroc.org
Mortara Instrument Inc Exhibition | G900

7865 N. 86th Street, Milwaukee, WI 53224 - United States of America
Tel: +1 414 354 1600 - Fax: +1 414 354 1600
Email: cynthia.cruz@mortara.com - Website: www.mortara.com
MSD Exhibition | A500

2000 Galloping Hill Road, Kenilworth, NJ 07033 - United States of America
Tel: +1 908 423 1000
Email: cynthia_sucro@merck.com - Website: www.msd.com
Mylan Exhibition | F200

Hegenheimermattweg 127, 4123 Allschwil - Switzerland
Tel: +41 614 870 391
Email: sabah.abibes@abbott.com
Netherlands Society of Cardiology ESC Plaza | P270
Postbus 19192, 3501 DD Utrecht - The Netherlands
Tel: +31 302 345 000 - Fax: +31 302 345 002
Email: bureau@nvvc.nl - Website: www.nvvc.nl
NeuroVive Pharmaceutical AB Exhibition | B540
Medicon Village, Scheelevagen 2, SE-22381 Lund - Sweden
Tel: +46 702 996 264
Email: mikael.bronnegard@neurovive.com - Website: www.neurovive.com
Norav Medical GmbH Exhibition | C300

Otto-von-Guericke-Ring 10, D-65205 Wiesbaden - Germany
Tel: +49 612 270 5240 - Fax: +49 612 270 52414
Email: info@norav.com - Website: www.norav.com
NorthEast Monitoring Inc Exhibition | H730
141 Parker Street, Suite #111, Maynard, MA 01754 - United States of America
Tel: +1 978 461 3992 - Fax: +1 978 461 5991
Email: swinick@nemon.com - Website: www.NEMon.com
554
Novartis Pharma AG Exhibition | D200

Forum 1, Novartis Campus, 4056 Basel - Switzerland
Tel: +41 613 241 11
Email: karen.ash@novartis.com - Website: www.novartis.com
Osaka University & JMC Corporation Exhibition | B270
2-2, Yamadaoka, Suita, 565-0871 Osaka - Japan
Tel: +81 668 793 638 - Fax: +81 668 793 634
Email: okayama@cardiology.med.osaka-u.ac.jp - Website: www.jmc-rp.co.jp/heartroid
Oxford University Press Exhibition | B801

Great Clarendon Street, Ox2 6DP Oxford - United Kingdom
Email: medicine.books.uk@oup.com - Website: www.oup.com
PCR ESC Plaza | P600

31015 Toulouse Cedex 6 - France
Tel: +33 5 34 45 12 30 - Fax: +33 5 361 420 09
Email: cpereira@europa-organisation.com
Pfizer Exhibition | D800 / D850

235 East 42nd Street, New York, NY 10017 - United States of America
Tel: +1 484 865 4093
Email: jeff.carson@pfizer.com
Philips Healthcare Exhibition | G200

Veenpluis 4-6, 5684 PC Best - The Netherlands
Tel: +31 427 835 96
Email: healthcare@philips.com - Website: www.healthcare.philips.com
Physicians’ Academy for Cardiovascular Education Exhibition | B410

P.O. Box 916, 2003 RX Haarlem - The Netherlands
Tel: +31 235 317 357 - Fax: +31 235 317 271
Email: onno.kaagman@medconinternational.com - Website: www.pace-cme.org
Polish Cardiac Society ESC Plaza | P200

Stawki Str 3A/1, 00-193 Warsaw - Poland
Tel: +48 228 871 856 - Fax: +48 228 871 858
Email: beatal@ptkardio.pl
Portola Pharmaceuticals Inc Exhibition | B515

270 E. Grand Avenue, South San Francisco, CA 94080 - United States of America
Tel: +1 650 246 7000
Email: ngrozdic@nscigroup.com - Website: www.portola.com
Portuguese Society of Cardiology ESC Plaza | P100

Campo Grande 28, 13rd floor, 1700-093 Lisbon - Portugal
Tel: +351 217 970 685 - Fax: +351 217 931 095
Email: secretariado@spc.pt - Website: www.spc.pt
PRS Neoscan Exhibition | H780

10 Rue du Docteur Pravaz, 69110 Sainte Foy les Lyon - France
Tel: +33 4 72 32 26 26 - Fax: +33 4 72 32 26 55
Email: lpralus@prsfrance.com - Website: www.prsfrance.com
Radcliffe Cardiology Exhibition | C810

7/8 Woodlands Farm, Spring Lane, Cookham Dean, SL6 9PN Maidenhead - United
Kingdom
Tel: +44 207 193 5381
Email: david.ramsey@radcliffecardiology.com - Website: www.radcliffecardiology.com
555
Randox Laboratories Exhibition | D650

55 Diamond Road, BT29 4QY Crumlin - United Kingdom
Tel: +44 289 442 2413 - Fax: +44 289 445 2912
Email: marketing@randox.com - Website: www.randox.com
ResMed Exhibition | H950

292 Allée Jacques Monod, 69800 St Priest - France
Tel: +33 4 26 10 03 38 - Fax: +33 4 26 10 03 00
Email: perrine.fily@resmed.fr
Roche Diagnostics International Ltd Exhibition | D500

Forrenstrasse 2, 6343 Rotkreuz - Switzerland
Tel: +41 795 398 222
Email: patricia.lhopital@roche.com - Website: www.roche.com
Romanian Society of Cardiology ESC Plaza | P300

63 Avrig, Department 2, 21578 Bucarest - Romania
Tel: +40 212 505 086 - Fax: +40 212 500 100
Email: office@cardioportal.ro - Website: www.cardioportal.ro
Russian Society of Cardiology ESC Plaza | P190

Akkuratova str. 2, 197341 Saint-Petersburg - Russian Federation
Tel: +7 812 702 3716 - Fax: +7 812 702 3716
Email: info@scardio.ru - Website: www.scardio.ru
SADS UK Exhibition | B700
Suite 6 Churchill House Horndon Park, Station Rd, West Horndon, Essex, CM13
3XD Brentwood - United Kingdom
Tel: +44 127 781 1215
Email: john.sadsuk@btconnect.com - Website: www.sadsuk.org
SAGE Publications Ltd Exhibition | B802

1 Oliver’s Yard, 55 City Road, EC1Y 1SP London - United Kingdom
Tel: +44 207 324 8500 - Fax: +44 207 324 8600
Email: market@sagepub.co.uk - Website: www.sagepub.co.uk
San Marino Society of Cardiology ESC Plaza | P240

c/o Studio Legale e, Notarile Lonfernini Anna Maria, Piazza M. Tini 12, 47891 Dogana -
San Marino, Republic of
Tel: +378 054 999 4320 - Fax: +378 054 999 4371
Email: info@progettocuore.sm - Website: www.ssc.sm
Sanofi Regeneron Exhibition | A100

54, Av. La Boétie, 75008 Paris - France
Tel: +33 1 53 77 40 00
Email: elizabeth.baxter@sanofi.com - Website: www.en.sanofi.com
Sanofi Regeneron Patient Advocacy Connection Exhibition | A200
777 Old Saw Mill River Road, Tarrytown, NY 10591 - United States of America
Tel: +1 914 847 7000
Email: arleen.goldenberg@regeneron.com - Website: www.regeneron.com
Saudi Heart Association ESC Plaza | P670

Saudi Heart Association Headquarters 6th floor, Amaztower, King Fahad Road,
11461 Riyadh Ksa - Saudi Arabia
Tel: +966 920 000 742 - ext 102 - Fax: +966 125 207 18
Email: admin.2@sha.org.sa
Schiller AG Exhibition | A300

Altgasse 68, 6341 Baar - Switzerland
Tel: +41 417 664 205 - Fax: +41 417 610 880
Email: lotti.deringer@schiller.ch
556
Schwarzer Cardiotek GmbH Exhibition | H900

Im Zukunftspark 3, 74076 Heilbronn - Germany
Tel: +49 713 127 745 14 - Fax: +49 713 127 745 90
Email: christine.noske@schwarzer.net - Website: www.schwarzercardiotek.com
ScottCare Corporation Exhibition | C400
4791 W. 150th Street, Cleveland, OH 44135 - United States of America
Tel: +1 800 243 9412 - Fax: +1 216 267 6129
Email: info@scottcare.com - Website: www.scottcare.com
SERVIER Exhibition | B100 / C100 / D100
50 Rue Carnot, 92284 Suresnes Cedex - France
Tel: +33 1 55 72 76 31 - Fax: +33 1 55 72 52 95
Email: pascal.visentin@fr.netgrs.com
Shire Exhibition | H750

Shire International GmbH, Zählerweg 10, 6300 Zug - Switzerland
Tel: +41 412 884 029
Email: cloiselle@shire.com - Website: www.shire.com
Siemens Healthcare GmbH Exhibition | G700
Henkestr.127, D-91052 Erlangen - Germany
Tel: +49 913 184 4494 - Fax: +49 913 184 4001
Email: heike.b.roeder@siemens.com - Website: www.healthcare.siemens.com
Singulex Exhibition | J500
1701 Harbor Bay Parkway, Suite 200, San Francisco, CA 94502 - United States of
America
Tel: +1 510 995 4612
Email: n.ritz@singulex.com - Website: www.singulex.com
Slovak Society of Cardiology ESC Plaza | P195

Bárdosova 2A, 831 01 Bratislava 37 - Slovak Republic
Tel: +421 905 822 087 - Fax: +421 254 7912 10
Email: ssc@cardiology.sk - Website: www.cardiology.sk
Slovenian Society of Cardiology ESC Plaza | P160

Stukljeva Cesta 48, SI-1000 Ljubljana - Slovenia
Tel: +386 143 421 00 - Fax: +386 143 421 01
Email: sasa.radelj@sicardio.org - Website: www.sicardio.org
SOMNOmedics GmbH Exhibition | A450

Am Sonnenstuhl 63, 97236 Randersacker - Germany
Email: jh@somnomedics.de - Website: www.somnomedics.eu
South African Heart Association ESC Plaza | P665

PO Box 19062, 7505 Tygerberg - South Africa
Tel: +27 219 318 210 - Fax: +27 219 318 210
Email: erika@saheart.org - Website: www.saheart.org
Spanish Society of Cardiology ESC Plaza | P230

Nuestra Senora de Guadalupe, 5-7, ES-28028 Madrid - Spain
Tel: +34 618 772 491 - Fax: +34 917 242 371
Email: slegendre@secardiologia.es - Website: www.secardiologia.es
St. Jude Medical Exhibition | D550

The Corporate Village Da Vincilaan 11, Box F1, 1935 Zaventem - Belgium
Tel: +32 277 468 12
Email: aparmentier@sjm.com - Website: www.sjmprofessional.com
557
STORZ MEDICAL AG Exhibition | B220

Lohstampfestrasse 8, 8274 Tägerwilen - Switzerland
Tel: +41 716 774 545 - Fax: +41 716 774 505
Email: info@storzmedical.com - Website: www.storzmedical.com
Sunshine Heart Exhibition | B510
12988 Valley View Road, Eden Prairie, MN 55344 - United States of America
Tel: +1 952 388 6046 - Fax: +1 952 224 0181
Email: katherine.pearce@sunshineheart.com
Swiss Society of Cardiology ESC Plaza | P420

Schwarztorstrasse 18, 3007 Bern - Switzerland
Tel: +41 763 244 413 - Fax: +41 313 888 098
Email: marjam.ruediger@swisscardio.ch - Website: www.swisscardio.ch
Takeda Pharmaceuticals International GmbH Exhibition | H500

Thurgauerstrasse 130, 8152 Glattpark-Opfikon (Zurich) - Switzerland
Tel: +44 782 459 2266
Email: nigel.glover@takeda.com - Website: www.takeda.com
The Great Wall International Congress of Cardiology (GW-ICC) ESC Plaza | P555
11# Xizhimen S. Ave, 100044 Beijing - China, People’s Republic of
Tel: +86 108 838 1733 - ext 8009
Email: secretariat@gw-icc.org - Website: www.gw-icc.org
The Jama Network Exhibition | C802

330 N. Wabash Avenue, Suite 39300, Chicago, IL 60611 - United States of America
Tel: +1 312 464 5000 - Fax: +1 312 464 2580
Email: sales@jamanetwork.com - Website: www.jamanetwork.com
The Lancet Exhibition | B545

125 London Wall, EC2Y 5AS London - United Kingdom
Tel: +44 207 424 4200
Email: marketing@lancet.com - Website: www.thelancet.com
THE MENARINI GROUP Exhibition | F500

1611 Luxembourg - Luxembourg
Tel: +39 055 568 01 - Fax: +390 555 680 484
Email: enanni@menarini.it
The New England Journal of Medicine Exhibition | C807
860 Winter Street, Waltham, MA 02451 - United States of America
Tel: +1 800 843 6356 - Fax: +1 800 893 0413
Email: lchase@mms.org - Website: www.nejmgroup.org
Thrombosis Research Institute Exhibition | H400

Emmanuel Kaye Building Manresa Road, SW3 6LR London - United Kingdom
Tel: +44 207 351 8348
Email: irieba@tri-london.ac.uk - Website: www.tri-london.ac.uk
TomTec Imaging Systems GmbH Exhibition | G810
Edisonstrasse 6, 85716 Unterschleissheim - Germany
Tel: +49 89 32175 518 - Fax: +49 89 32175 750
Email: hklein@tomtec.de - Website: www.tomtec.de
Toshiba Medical Systems Exhibition | G500
Zilverstraat 1, 2718 RP Zoetermeer - The Netherlands
Tel: +31 793 689 222 - Fax: +31 793 689 444
Email: info@tmse.nl - Website: www.toshiba-medical.eu
558
Tunisian Society of Cardiology and Cardio-Vascular Surgery ESC Plaza | P180

Maison du Coeur, Rue du Lac Huron, Residence Les Pergolas, Apt. 201, Les Berges
du Lac, 1053 Tunis - Tunisia
Tel: +216 983 023 21 - Fax: +216 718 746 64
Email: r.chettaoui@planet.tn
Turkish Society of Cardiology ESC Plaza | P110

Bahcelievler, Yenibosna, Cobancesme Sanayi Cd. Nish Istanbul Blok A, Flat 8,
34196 Istanbul - Turkey
Tel: +90 212 221 1730 - Fax: +90 212 221 1754
Email: aunver@tkd.org.tr
UEMS Cardiology Section ESC Plaza | P510

51467 Bergish Gladbach - Germany
Tel: +49 221 169 986 22 - Fax: +49 221 200 000 00
Email: office@uems-cardio.eu - Website: www.uems-cardio.eu
Ukrainian Association of Cardiology ESC Plaza | P140
5, Narodnogo Opolchenia Str, UA-03680 Kiev - Ukraine
Tel: +380 442 756 622 - Fax: +380 442 751 633
Email: s.kozhukhov@i.ua - Website: www.strazhesko.org.ua
United Therapeutics Europe Ltd Exhibition | C600

Unither House, Curfew Bell Road, KT16 9FG Chertsey - United Kingdom
Tel: +44 193 257 3800
Email: abirtley@unither.com - Website: www.unither.com
Vales and Hills Biomedical Tech.Ltd Exhibition | B250

Bldg 46-1 BDA International Business Park, 100176 Beijing - China, People’s Republic of
Tel: +86 106 785 6941 - Fax: +86 106 785 6343
Email: cathyfeib@vhmedical.com - Website: www.vhecg.com
Vasomedical Inc Exhibition | A480

180 Linden Avenue, Westbury, NY 11590 - United States of America
Tel: +1 516 997 4600 - Fax: +1 516 997 2299
Email: info@vasosolutions.com - Website: www.vasosolutions.com
VectraCor Inc. Exhibition | I400
785 Totowa Road, Suite 100, Totowa, NJ 07512 - United States of America
Tel: +1 973 904 0444
Email: mvanlaar@vectracor.com - Website: www.vectracor.com
Wiley Exhibition | B800
9600 Garsington Road, OX4 2DQ Oxford - United Kingdom
Tel: +44 186 577 6868
Email: customer@wiley.com
Wisepress Online Bookshop Ltd Exhibition | B701

25 High Path, SW19 2JL London - United Kingdom
Tel: +44 208 715 1812 - Fax: +44 208 715 1722
Email: bookshop@wisepress.com - Website: www.wisepress.com
Wolters Kluwer Health Exhibition | C800

Two Commerce Sq, 2001 Market Street, Philadelphia, PA 19103 - United States of America
Tel: +1 215 521 830
Email: joey-rose.jester@wolterskluwer.com - Website: www.lww.com
World Heart Federation ESC Plaza | P675

32 Rue de Malatrex, 1201 Geneva - Switzerland
Tel: +41 228 070 32
Email: sarah.ramsey@worldheart.org
559
ZEUS Scientific Exhibition | D630

P.O. Box 38, Raritan, NJ 08869 - United States of America
Tel: +1 908 526 3744
Email: info@accucardia.com - Website: www.accucardia.com
ZOLL Medical Corporation Exhibition | D600
ZOLL CMS GmbH, Emil Hoffmann Str 13, 50996 Koeln - Germany
Tel: +49 223 687 874 68 - Fax: +49 223 700 0000
Email: vvonbeauvais@zoll.com - Website: www.zoll.com
560
NOTES
561
Expect BIG Things
REGISTER TODAY
BIG Science. BIG Names. BIG Clinical Content. BIG Technology. BIG Networking.
Stay on the cutting edge of cardiovascular science and

clinical practice by attending AHA’s Scientific Sessions 2015,
Nov. 7-11, in Orlando, Florida.
5 PROGRAMMING for 30 different areas of interest

5 5 DAYS of comprehensive, unparalleled education
5 MORE THAN 5,000 PRESENTATIONS from the world’s
leaders in cardiovascular science
5 200 EXHIBITORS showcasing the latest cardiovascular
technology and resources
5 A TRULY GLOBAL PERSPECTIVE with 18,000 cardiovascular
professionals in attendance from more than 100 countries
KEY DATES
WEDNESDAY, SEPT. 9 WEDNESDAY, OCT. 7
Deadline for early Deadline for advance
registration rates registration rates
WEDNESDAY, SEPT. 10 SATURDAY-WEDNESDAY,

Advance Registration rates apply NOV. 7-11
Scientific Sessions 2015 in
Orlando, Florida
Photos ©2014 AHA/Todd Buchanan
Register today at: scientificsessions.org

#AHA15
For information on how to exhibit and sponsor at

AHA’s Scientific Sessions 2015 visit www.exhibitatsessions.org.
LIST OF
COUNTRY CODES
ALPHABETICAL LIST REFERRING TO THE LIST ESTABLISHED BY THE UNITED NATIONS ORGANIZATION
AF Afghanistan FJ Fiji
AL Albania FI Finland
DZ Algeria FYR Former Yugoslav Republic
AS American Samoa FR France
AD Andorra GF French Guiana
AO Angola PF French Polynesia
AI Anguilla GA Gabon
AQ Antarctica GM Gambia
AG Antigua and Barbuda GE Georgia, Republic of
AR Argentina DE Germany
AM Armenia GH Ghana
AW Aruba GI Gibraltar
AU Australia GR Greece
AT Austria GL Greenland
AZ Azerbaijan GD Grenada
BS Bahamas GP Guadeloupe
BH Bahrain GU Guam
BD Bangladesh GT Guatemala
BB Barbados GN Guinea
BY Belarus GW Guinea-Bissau
BE Belgium GY Guyana
BZ Belize HT Haiti
BJ Benin HM Heard And Mc Donald Islands
BM Bermuda HN Honduras
BT Bhutan HK Hong Kong SAR, People’s Republic of China
BO Bolivia HU Hungary
BA Bosnia and Herzegovina IS Iceland
BW Botswana IN India
BV Bouvet Island ID Indonesia
BR Brazil IR Iran (Islamic Republic of)
IO British indian Ocean Territory IQ Iraq
BN Brunei Darussalam IE Ireland
BG Bulgaria IL Israel
BF Burkina Faso IT Italy
BI Burundi JM Jamaica
KH Cambodia JP Japan
CM Cameroon JO Jordan
CA Canada KZ Kazakhstan
CV Cape Verde KE Kenya
KY Cayman Islands KI Kiribati
CF Central African Republic KP Korea, Democratic People’s Republic Of
TD Chad KR Korea, Republic of
CL Chile XK Kosovo, Republic of
CN China, People’s Republic of KW Kuwait
CX Christmas Island KG Kyrgyzstan
CC Cocos (Keeling) Islands LA Lao People’s Democratic Republic
CO Colombia LV Latvia
KM Comoros LB Lebanon
CG Congo LS Lesotho
CK Cook Islands LR Liberia
CR Costa Rica LY Libya
CI Côte d’Ivoire LI Liechtenstein
HR Croatia LT Lithuania
CU Cuba LU Luxembourg
CY Cyprus MO Macau SAR, People’s Republic of China
CZ Czech Republic MK Macedonia, The Former Yugoslav Republic of
ZR Democratic Republic of Congo MG Madagascar
DK Denmark MW Malawi
DJ Djibouti MY Malaysia
DM Dominica (Commonwealth of Dominica) MV Maldives
DO Dominican Republic ML Mali
TP East Timor MT Malta
EC Ecuador MH Marshall Islands
EG Egypt MQ Martinique
SV El Salvador MR Mauritania
GQ Equatorial Guinea MU Mauritius
ER Eritrea YT Mayotte
EE Estonia MX Mexico
ET Ethiopia FM Micronesia (Federated States of)
FK Falkland Islands (Malvinas) MD Moldova, Republic of
FO Faroe Islands MC Monaco
564
ALPHABETICAL LIST REFERRING TO THE LIST ESTABLISHED BY THE UNITED NATIONS ORGANIZATION
MN Mongolia SK Slovak Republic

ME Montenegro SI Slovenia
MS Monteserrat SB Solomon Islands
MA Morocco SO Somalia
MZ Mozambique ZA South Africa
MM Myanmar GS South Georgia And The South Sandwich Islands
NA Namibia ES Spain
NR Nauru LK Sri Lanka
NP Nepal SH St. Helena
NL Netherlands PM St. Pierre And Miquelon
AN Netherlands Antilles SD Sudan
NC New Caledonia SR Suriname
NZ New Zealand SJ Svalbard And Jan Mayen Islands
NI Nicaragua SZ Swaziland
NE Niger SE Sweden
NG Nigeria CH Switzerland
NU Niue SY Syrian Arab Republic
NF Norfolk Island TW Taiwan, ROC
MP Northern Mariana Islands TJ Tajikistan
NO Norway TZ Tanzania, United Republic of
OM Oman TH Thailand
PK Pakistan TG Togo
PW Palau TK Tokelau
PS Palestine Territories TO Tonga
PA Panama TT Trinidad & Tobago
PG Papua New Guinea TN Tunisia
PY Paraguay TR Turkey
PE Peru TM Turkmenistan
PH Philippines TC Turks & Caicos Islands
PN Pitcairn TV Tuvalu
PL Poland UG Uganda
PT Portugal UA Ukraine
PR Puerto Rico AE United Arab Emirates
QA Qatar GB United Kingdom
RE Reunion UM United States Minor Outlying Islands
RO Romania US United States of America
RU Russian Federation UY Uruguay
RW Rwanda UZ Uzbekistan
KN Saint Kitts & Nevis VU Vanuatu
LC Saint Lucia VA Vatican City State (Holy See)
VC Saint Vincent & the Grenadines VE Venezuela
SM San Marino, Republic of VN Viet Nam
ST Sao Tome and Principe VG Virgin Islands (British)
SA Saudi Arabia VI Virgin Islands (U.S.)
SN Senegal WF Wallis and Futuna Islands
RS Serbia EH Western Samoa
SC Seychelles YE Yemen
SL Sierra Leone ZM Zambia
SG Singapore ZW Zimbabwe
565
be globalċ be oneċ
oneworld is proud to be the

official airline alliance of the
ESC Congress ĂĀāĆċ
The oneworld network covers

almost āČĀĀĀ destinations in
more than āĆĀ countriesČ so we
can get you anywhere you
need to beċ
Learn more at oneworldċcom
an alliance of the world's leading airlines working as oneċ
airberlin American Airlines British Airways Cathay Pacific Finnair Iberia Japan Airlines LAN
TAM Malaysia Airlines Qantas Qatar Airways Royal Jordanian SĈ Airlines SriLankan Airlines
oneworld benefits are available only to passengers on scheduled flights that are both marketed and operated by a oneworld member airline
(marketed means that there must be a oneworld member airlineĚs flight number on your ticket)ċ For information on oneworldČ visit
wwwċoneworldċcomċ airberlinČ American AirlinesČ British AirwaysČ Cathay PacificČ FinnairČ IberiaČ Japan AirlinesČ LANČ Malaysia AirlinesČ QantasČ Qatar
AirwaysČ Royal JordanianČ SĈ AirlinesČ SriLankan AirlinesČ TAM Airlines and oneworld are trademarks of their respective companiesċ TAM Airlines
(Paraguay) is currently not a part of oneworldċ
NOTES
567
27 – 31 August
Where the world of

cardiology comes together
27 – 31 August
Where the world of

FDUGLRORJ\FRPHVWRJHWKHU
7KHZRUOG·VODUJHVWDQGPRVWLQÁXHQWLDOFDUGLRYDVFXODUHYHQWZLWK
RYHUH[SHUWVHVVLRQVDQGDEVWUDFWVFRQWULEXWLQJWRJOREDO
DZDUHQHVVRIWKHODWHVWFOLQLFDOWULDOVDQGEUHDNWKURXJKGLVFRYHULHV
Abstract submission: Mid December 2015 – 14 February 2016

ZZZHVFDUGLRRUJ(6&
(XURSHDQ6RFLHW\ HVFFRQJUHVV HVFDUGLRGRWRUJ

RI&DUGLRORJ\
Prince Regent
DLR Station
ENTRANCE
(EAST)
MAIN
ESC MEETING
ROOMS
REGISTRATION
ESC HQ
Satellite Symposium
Basic Science
Coach Parking
SSC
Arrhythmias, Pacing, Resynchronisation
Nursing, Ageing
Industry
Management priorities and clinical
i
Hypertension, Pharma
Most scientific sessions, except satellite symposia, are arranged by topics in themed villages
Interventions, Peripheral Circulation, Stroke, Surgery
VILLAGE 1
outcomes in post-acute coronary syndrome
MAIN AUDITORIUM
LONDON
(ACS) patients with type 2 diabetes (T2D)
VILLAGE 2
ESC PLAZA
Imaging, e-Technology
Delegate
Monday 31 August 2015; 12:45–13:45
Lounge
VILLAGE 3
Room: Oslo – Village 6
Workshops
VILLAGE 4
CPR
EXHIBITION
Chair:
2015
app
ESC
Taxi station
VILLAGE 5
Professor Faiez Zannad, Université de Lorraine and CHU, Vandoeuvre-lès-Nancy, France

Speakers:
Professor Peter Grant, University of Leeds and Leeds Teaching Hospitals Trust, Leeds, UK
i
VILLAGE 6
Medical Care
Dr Venugopal Menon, Cleveland Clinic, Cleveland, USA
THE HUB
Hyde
Park
VILLAGE 7
Agenda
Cloakroom & Left Luggage

VILLAGE 8
Time Presentation Speaker(s)
12:45–12:50 Welcome Faiez Zannad

EXHIBITION
VILLAGE 9
12:50–13:15 Management perspectives for the Venugopal Menon &

Information Point
post-ACS T2D patient: Peter Grant

PRESS
cardiologist vs diabetologist
i
Recording studio
13:15–13:40 Safety profile of DPP-4 inhibitors in All speakers, facilitated

post-ACS T2D patients: a debate by Faiez Zannad
ESC Fellows & VIP Lounge
i
POSTER AREA
Agora
13:40–13:45 Conclusions and close Faiez Zannad

ACCESS WITH
BADGE ONLY
MAIN AUDITORIUM
St James Park
POSTER AREA
Regents Park
Holland Park
Victoria Park
Green Park
Hyde Park
THE HUB
London
ESC Mobile App desk

Agora
Satellite Symposium − Takeda Booth

Speaker Service Centre
Experts-on-the-Spot Please also visit the Takeda Exhibition Booth for

Join the interactive Experts-on-the-Spot more information on our products. Location H500 in
2014
app
ESC
session entitled ‘Seeking improved the exhibition hall from 12:30 on Saturday 29 August
clinical outcomes in post-acute coronary
ESC Congress 365 desk
to 18:00 on Tuesday 1 September

syndrome (ACS) patients with type 2
San Marino
The Hague
Stockholm
VILLAGE 1
VILLAGE 2
VILLAGE 3
VILLAGE 4
VILLAGE 5
VILLAGE 6
VILLAGE 7
VILLAGE 8
VILLAGE 9
diabetes (T2D)’ on Tuesday 1 September

Damascus
Bucharest
Bratislava
Ljubljana
Belgrade
Chisinau
Moscow
Warsaw
ESC Stand
Madrid
Ankara
Algiers
Lisbon
Tirana
Rabat
Tunis
Bern
Oslo
Kiev
in Victoria Park (The Hub); 10:15–10:45 Job code: GLO/ALO/2015-00063 Date of preparation: June 2015
ESC Advert_170x240mm_01CB.indd 1 17/06/2015 10:27

NOW LICENSED
EUROPEAN SOCIETY OF CARDIOLOGY - ESC Congress 2015 - London

29 August – 2 September
Visit us at stand F100

Now licensed for:
Prevention of stroke and systemic embolism in adult patients with nonvalvular
atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart
failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient
ischaemic attack (TIA).
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE),

and prevention of recurrent DVT and PE in adults.
Prescribers are recommended to consult the summary of product characteristics before prescribing LIXIANA.
Information about LIXIANA, including adverse reactions, precautions, contra-indications and method of use Final Programme
can be found at Lixiana.co.uk
Adverse events should be reported. Reporting forms and information

can be found at www.mhra.gov.uk/yellowcard. Adverse events
should also be reported to Daiichi Sankyo UK Medical Information
Legal classification: POM MA holder: Daiichi Sankyo Europe GmbH, Zielstattstrasse on 0800 028 5122, medinfo@daiichi-sankyo.co.uk
48, 81379 Munich, Germany. Job bag number: EDX/15/0074 Date of prep: July 2015.
www.lixiana.co.uk
220xxxxxx LXA UK ESC (UK) FP v10.indd 1 02/06/2015 12:01

Document PDF

Загружено:

Сведения о документе

Оригинальное название

Авторское право

Доступные форматы

Поделиться этим документом

Поделиться или встроить документ

Параметры публикации

Этот документ был вам полезен?

Это неприемлемый материал?

Авторское право:

Доступные форматы

Document PDF

Загружено:

Авторское право:

Доступные форматы

NOW LICENSED

EUROPEAN SOCIETY OF CARDIOLOGY - ESC Congress 2015 - London

Visit us at stand F100

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE),

Adverse events should be reported. Reporting forms and information

220xxxxxx LXA UK ESC (UK) FP v10.indd 1 02/06/2015 12:01

Interventions, Peripheral Circulation, Stroke, Surgery

(ACS) patients with type 2 diabetes (T2D)

Professor Faiez Zannad, Université de Lorraine and CHU, Vandoeuvre-lès-Nancy, France

Cloakroom & Left Luggage

Time Presentation Speaker(s)

12:45–12:50 Welcome Faiez Zannad

12:50–13:15 Management perspectives for the Venugopal Menon &

post-ACS T2D patient: Peter Grant

13:15–13:40 Safety profile of DPP-4 inhibitors in All speakers, facilitated

13:40–13:45 Conclusions and close Faiez Zannad

ESC Mobile App desk

Satellite Symposium − Takeda Booth

Experts-on-the-Spot Please also visit the Takeda Exhibition Booth for

to 18:00 on Tuesday 1 September

diabetes (T2D)’ on Tuesday 1 September

ESC Advert_170x240mm_01CB.indd 1 17/06/2015 10:27

Outstanding and interactive: we continue to have an outstanding number of abstract

Exciting: the spotlight of ESC Congress is “Environment and the Heart”.

The Inaugural Session on Saturday 29 August is a key introduction to the congress.

Fausto Pinto, FESC Geneviève Derumeaux, FESC

and all ESC Members of the Congress

J F Pinto, FESC (Lisbon, PT)

VILLAGE 1 – BASIC SCIENCE

VILLAGE 2 – PREVENTION - REHABILITATION

VILLAGE 3 – HYPERTENSION - PHARMA

VILLAGE 4 – ARRHYTHMIAS - PACING - RESYNCHRONISATION

VILLAGE 5 – CARDIAC IMAGING - E-TECHNOLOGY

VILLAGE 6 – INTERVENTIONS - PERIPHERAL CIRCULATION -

VILLAGE 7 – ISCHAEMIA - CORONARY ARTERY DISEASE -

VILLAGE 9 – HEART FAILURE -

WITH SPECIAL THANKS TO OUR AD HOC MEMBERS

ESC SCIENTISTS OF TOMORROW NUCLEUS

GUIDELINES FOR INDUSTRY PARTICIPATION COMMITTEE

ESC PRESS COMMITTEE

Th e Eu rop ean Society of Cardiol og y, yo ur C o mmuni ty G9

Gen er a l I n formation G37

S ci en t i fi c Prog ramme G53

G uid elines in Da ily Practice ............................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . G6 7

S ci en t i fi c Prog ramme by Day and by V i l l age 1

Hands-On Tutorials .................................. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3

CONNECT WITH ESC TODAY

The administration of the European Society of Cardiology (ESC) is conducted by a Board

Ex-Ofﬁcio Voting Members

H Bueno, FESC, Spain President Acute Cardiovascular Care Association

L Badimon, FESC, Spain Representative Council on Basic Cardiovascular Science

N Clarke, United Kingdom Advisor and Management Group Member

I Bardinet, France Chief Executive Officer of the ESC

Tuesday 1 September 2015, 10:00 - 11:00

Welcome address F Pinto, FESC, ESC President, 2014 – 2016

Report from the Vice President on Global Affairs

Report from the Vice President on National Affairs,

Report from the Vice President on Scientiﬁc Affairs,

Not yet a member? Join us today!

FIND OUT WHAT THE ESC CAN DO FOR YOU

Make sure to visit us for a sneak preview

° Save 100 Euros on the registration fee (applies to

° Create your own personalised poster to take back

Access membership directory

Get voting rights